



Cochrane
Library

Cochrane Database of Systematic Reviews

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA) (Review)

Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA

Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA.
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012437.
DOI: [10.1002/14651858.CD012437](https://doi.org/10.1002/14651858.CD012437).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	5
OBJECTIVES	6
METHODS	6
Figure 1.	8
RESULTS	10
Figure 2.	11
Figure 3.	14
Figure 4.	15
Figure 5.	16
Figure 6.	17
Figure 7.	18
Figure 8.	19
Figure 9.	19
Figure 10.	20
Figure 11.	21
Figure 12.	21
Figure 13.	22
Figure 14.	23
Figure 15.	24
Figure 16.	25
Figure 17.	26
Figure 18.	27
Figure 19.	28
Figure 20.	29
Figure 21.	29
Figure 22.	30
Figure 23.	32
Figure 24.	33
DISCUSSION	36
AUTHORS' CONCLUSIONS	39
ACKNOWLEDGEMENTS	40
REFERENCES	41
ADDITIONAL TABLES	58
APPENDICES	114
WHAT'S NEW	597
HISTORY	597
CONTRIBUTIONS OF AUTHORS	598
DECLARATIONS OF INTEREST	598
SOURCES OF SUPPORT	598
NOTES	598
INDEX TERMS	599

[Overview of Reviews]

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)

Jasvinder A Singh¹, Alomgir Hossain², Elizabeth Tanjong Ghogomu³, Amy S Mudano⁴, Peter Tugwell^{5a}, George A Wells^{6b}

¹Department of Medicine, Birmingham VA Medical Center, Birmingham, AL, USA. ²Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Canada. ³Bruyère Research Institute, University of Ottawa, Ottawa, Canada. ⁴Department of Medicine - Rheumatology, University of Alabama at Birmingham, Birmingham, USA. ⁵Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada. ⁶Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

^aJoint senior author. ^bJoint senior author

Contact address: Jasvinder A Singh, Department of Medicine, Birmingham VA Medical Center, Faculty Office Tower 805B, 510 20th Street South, Birmingham, AL, 35294, USA. jasvinder.md@gmail.com.

Editorial group: Cochrane Musculoskeletal Group

Publication status and date: New, published in Issue 11, 2016.

Citation: Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). *Cochrane Database of Systematic Reviews* 2016, Issue 11. Art. No.: CD012437. DOI: [10.1002/14651858.CD012437](https://doi.org/10.1002/14651858.CD012437).

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced).

Objectives

To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced.

Methods

We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL; *The Cochrane Library* 2015, Issue 6, June), MEDLINE (via OVID 1946 to June 2015), and Embase (via OVID 1947 to June 2015). Article selection, data extraction and risk of bias and GRADE assessments were done in duplicate. We calculated direct estimates with 95% confidence intervals (CI) using standard meta-analysis. We used a Bayesian mixed treatment comparisons (MTC) approach for NMA estimates with 95% credible intervals (CrI). We converted odds ratios (OR) to risk ratios (RR) for ease of understanding. We calculated absolute measures as risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB).

Main results

This update includes 40 new RCTs for a total of 46 RCTs, of which 41 studies with 14,049 participants provided data. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients).

Monotherapy versus placebo

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA) (Review)

1

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Based on moderate-quality direct evidence, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in American College of Rheumatology score (ACR50) and physical function, as measured by the Health Assessment Questionnaire (HAQ) versus placebo. RR was 4.68 for ACR50 (95% CI, 2.93 to 7.48); absolute benefit RD 23% (95% CI, 18% to 29%); and NNTB = 5 (95% CI, 3 to 8). The mean difference (MD) was -0.32 for HAQ (95% CI, -0.42 to -0.23; a negative sign represents greater HAQ improvement); absolute benefit of -10.7% (95% CI, -14% to -7.7%); and NNTB = 4 (95% CI, 3 to 5). Direct and NMA estimates for TNF biologic, non-TNF biologic or tofacitinib monotherapy showed similar results for ACR50, downgraded to moderate-quality evidence. Direct and NMA estimates for TNF biologic, anakinra or tofacitinib monotherapy showed a similar results for HAQ versus placebo with mostly moderate quality evidence.

Based on moderate-quality direct evidence, biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of disease remission versus placebo with RR 1.12 (95% CI 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%; NNTB = 10 (95% CI, 8 to 21)).

Based on low-quality direct evidence, results for biologic monotherapy for withdrawals due to adverse events and serious adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase. The direct estimate for TNF monotherapy for withdrawals due to adverse events showed a clinically meaningful and statistically significant result with RR 2.02 (95% CI, 1.08 to 3.78), absolute benefit RD 3% (95% CI, 1% to 4%), based on moderate-quality evidence. The NMA estimates for TNF biologic, non-TNF biologic, anakinra, or tofacitinib monotherapy for withdrawals due to adverse events and for serious adverse events were all inconclusive and downgraded to low-quality evidence.

Monotherapy versus active comparator (MTX/other DMARDs)

Based on direct evidence of moderate quality, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in ACR50 and HAQ scores versus MTX/other DMARDs with a RR of 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26) and a mean difference in HAQ of -0.27 (95% CI, -0.40 to -0.14); absolute benefit of -9% (95% CI, -13.3% to -4.7%), NNTB = 2 (95% CI, 2 to 4). Direct and NMA estimates for TNF monotherapy and NMA estimate for non-TNF biologic monotherapy for ACR50 showed similar results, based on moderate-quality evidence. Direct and NMA estimates for non-TNF biologic monotherapy, but not TNF monotherapy, showed similar HAQ improvements, based on mostly moderate-quality evidence.

There were no statistically significant or clinically meaningful differences for direct estimates of biologic monotherapy versus active comparator for RA disease remission. NMA estimates showed a statistically significant and clinically meaningful difference versus active comparator for TNF monotherapy (absolute improvement 7% (95% CI, 2% to 14%)) and non-TNF monotherapy (absolute improvement 19% (95% CI, 7% to 36%)), both downgraded to moderate quality.

Based on moderate-quality direct evidence from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD -4.34 (95% CI, -7.56 to -1.12), though the absolute reduction was small, -0.97% (95% CI, -1.69% to -0.25%). We are not sure of the clinical relevance of this reduction.

Direct and NMA evidence (downgraded to low quality), showed inconclusive results for withdrawals due to adverse events, serious adverse events and cancer, with wide confidence intervals encompassing the null effect and evidence of an important increase.

Authors' conclusions

Based mostly on RCTs of six to 12-month duration in people with RA who had previously experienced and failed treatment with MTX/other DMARDs, biologic monotherapy improved ACR50, function and RA remission rates compared to placebo or MTX/other DMARDs.

Radiographic progression was reduced versus active comparator, although the clinical significance was unclear.

Results were inconclusive for whether biologic monotherapy was associated with an increased risk of withdrawals due to adverse events, serious adverse events or cancer, versus placebo (no data on cancer) or MTX/other DMARDs.

PLAIN LANGUAGE SUMMARY

Biologics or tofacitinib alone for people with rheumatoid arthritis who had not improved with traditional disease-modifying anti-rheumatic drugs

In people with rheumatoid arthritis (RA), the immune system, which normally fights infection, attacks the joint lining making joints inflamed, swollen, stiff and painful. We looked for trials of biologics (large molecules administered by injection) or tofacitinib (small molecules given by mouth) in people with RA.

The review shows that in people with RA compared to salt water (placebo) or traditional drugs such as MTX/other DMARDs, biologic monotherapy (without MTX/other DMARDs) improves or probably improves signs and symptoms of RA (tender or swollen joints), function and chances of RA remission (disappearance of symptoms). Compared to salt water (placebo) or MTX/other DMARDs, biologic monotherapy

may increase slightly or make no difference to the number of serious adverse events and withdrawals due to adverse events. In the short-term evidence summarised here, biologic monotherapy does not increase the risk of cancer compared to MTX/other DMARDs.

Best estimate of what happens to people with RA taking biologic monotherapy

Monotherapy versus placebo

RA Symptoms

29 people out of 100 on biologic monotherapy experienced improvement compared to 6 people out of 100 who were on placebo, that is 23 more people out of 100 (23% absolute improvement).

Function improvement by Health Assessment Questionnaire

People who took biologic monotherapy rated that their function improved by 0.46 points on a scale of 0 to 3 compared to 0.14 points by people who took placebo, that is 0.32 points more (11% absolute improvement).

Remission

95 people out of 100 had disappearance of all symptoms of their RA compared to 85 people out of 100 who were on placebo, that is 10 more people out of 100 (10% absolute improvement).

Progression of disease damage as measured on X-rays (on a scale of 0 to 448)

No studies provided data on this comparison.

Withdrawal from study due to adverse events

52 people out of 1000 who took biologic monotherapy withdrew from the study compared to 32 people out of 1000 who were on placebo, that is 20 more people out of 1000 (2% more withdrawals).

Serious Adverse Events

92 people out of 1000 who took biologic monotherapy had serious adverse events (most commonly infections) compared to 72 people out of 1000 who were on placebo, that is 20 more people out of 1000 (2% more withdrawals).

Cancer

No studies provided data on this comparison.

Monotherapy versus other traditional drugs (MTX/other DMARDs)

RA Symptoms

42 people out of 100 who were on biologic monotherapy experienced improvement compared to 29 people out of 100 who were on MTX/other DMARDs, that is 13 more people out of 100 (13% absolute improvement).

Function improvement by Health Assessment Questionnaire

People who took biologic monotherapy rated that their function improved by 0.43 points compared to people who took MTX/other DMARDs, whose function improved by 0.16 points on a scale of 0 to 3, that is 0.27 points (9% absolute improvement).

Remission

21 people out of 100 had disappearance of all symptoms of their RA compared to 15 people out of 100 who were on MTX/other DMARDs, that is 6 more people out of 100 (6% absolute improvement).

Progression of disease damage as measured on X-rays (on a scale of 0 to 448)

The damage to joints of people on biologic monotherapy was 1.6 points compared to 5.9 points for people who took MTX/other DMARDs, that is 4.3 points lower (-0.97% absolute improvement).

Withdrawal from study due to adverse events

80 people out of 1000 who took biologic monotherapy withdrew from the study compared to 70 people out of 1000 who were on MTX/other DMARDs, that is 10 more people out of 1000 (1% more withdrawals).

Serious Adverse Events

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA) (Review)

3

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79 people out of 1000 who took biologic monotherapy had serious adverse events compared to 49 people out of 1000 who were on MTX/other DMARDs, that is 30 more people out of 1000 (3% more withdrawals).

Cancer

The same number of people (1 out of 1000) who took biologic monotherapy compared to those on MTX/other DMARDs had cancer. However, we are cautious about this estimate as there were few events of cancer.

BACKGROUND

Description of the condition

Rheumatoid arthritis (RA), the most common form of autoimmune arthritis, affects 0.5% to 1.0% of the general population (Kvien 2004). RA is characterized by inflammation of the synovial lining of the joints, tendons and periarticular structures (Lee 2001). The impact of RA on health-related quality of life (HRQoL) is significant (Kvien 2005; Lubeck 2004). Long-standing RA can lead to disability characterized by severe functional limitation (Odegard 2005; Yelin 2007).

In addition to the non-steroidal anti-inflammatory drugs (NSAIDs) that provide symptomatic relief, many disease-modifying anti-rheumatic drugs (DMARDs) are available for the treatment of RA. These include glucocorticoids, traditional DMARDs such as methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine etc. (referred to as DMARDs from here on), biologic DMARDs (referred to as biologics from here on) or oral synthetic molecules such as tofacitinib. The use of DMARDs leads to an improvement in pain and functioning for people with RA as well as more long-term outcomes such as reduced radiographic progression (Finckh 2006; Pincus 2002) and disability (Cash 1994; Strand 2008).

Traditional DMARDs, including methotrexate (MTX), are usually the first choice treatment for people with RA (Smolen 2014a; Singh 2012). When traditional DMARDs (including MTX) have failed either due to being ineffective (i.e. inadequate responders (DMARD-IR/MTX-IR); primary or secondary efficacy failure usually) (Tugwell 2000) or because of associated side/adverse effects, treatment options include other traditional DMARDs, biologics or tofacitinib (Smolen 2014a; Singh 2012). This patient population is the focus of this review and will be referred to as MTX/other DMARD-experienced, indicating that treatment with MTX, or one or more traditional DMARDs (including but not limited to sulfasalazine, hydroxychloroquine, leflunomide etc.), was unsuccessful.

Description of the interventions

There are two types of therapy, biologics and small molecules.

Biologics

Use of biologics leads to improvements in pain and function in people not responding to, or intolerant to traditional DMARDs including MTX. While biologics appear to have fewer side effects and greater success in slowing structural joint destruction than MTX, higher cost and concern for longer-term harms are important considerations. Biologics include the following.

1. Tumor necrosis factor (TNF) inhibitors (Scott 2006): infliximab (Remicade, approved 1998 in the USA) (FDA 1999), etanercept (Enbrel, approved 1998) (FDA 1998), adalimumab (Humira, approved 2002) (FDA 2002), certolizumab pegol (Cimzia, approved 2008) (FDA 2008d), golimumab (Simponi, approved 2009) (FDA 2008a).
2. Anti-CD28 therapy: abatacept (Orencia, approved 2005) (FDA 2005; FDA 2008b).
3. Anti-IL1 therapy: anakinra (Kineret, approved 2001) (FDA 2001).
4. Anti-B-cell therapy: rituximab (Rituxan/MabThera, approved 1997 for lymphoma and 2006 for RA) (Drugs 2006).

5. Anti-IL 6 therapy: tocilizumab (Actemra, approved 2010) (FDA 2010).

Small molecule synthetic drug, tofacitinib

Tofacitinib (Xeljanz) (FDA 2012), has also been approved in the USA. The indications for use of biologics and tofacitinib differ slightly between countries.

How the intervention might work

The mechanism of action of the biologics is summarized in the individual Cochrane systematic reviews. In brief, the systemic and joint inflammation in RA is mediated by activation of T-cells (Cope 2008), B-cells, macrophages (Szekanecz 2007) and other immune cells (Woolley 2003). These interactions lead to expression of chemokines, metalloproteinases and inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and various interleukins (IL) (Brennan 2008; Choy 2001). Interaction of lymphocytes and inflammatory cytokines with host cells such as fibroblasts, osteoclasts and chondrocytes leads to bone and cartilage destruction, a hallmark of RA (Brennan 2008; Connell 2006). It is possible that, due to different contributions of these cytokines and processes to the disease expression, the use of therapy targeting one cytokine may be more efficacious or safer than therapy targeting other mechanisms. As briefly mentioned in [Description of the interventions](#), the mechanism of action differs between the biologics (TNF-alpha versus interleukin-1 versus interleukin-6 versus B-cells versus T-cell co-stimulatory molecule).

Small molecule synthetic drug tofacitinib works by a targeted inhibition of several Janus Kinase (JAK) protein isoforms, especially JAK3 and JAK1; JAK proteins integrate signals from many cytokines (Ghoreschi 2009). JAKs phosphorylate the signal transducers and activators of transcription (STATs) to modulate gene expression (O'Sullivan 2007). The use of tofacitinib is associated with reduced synovial mRNA expression of matrix metalloproteinase (MMP) -1 and MMP-3 and chemokines CCL2, CXCL10 and CXCL13, which have been associated with joint inflammation (Boyle 2015).

Why it is important to do this overview

Treatment guidelines published recently (Saag 2008; Singh 2012; Singh 2016a; Smolen 2014a) as well as consensus statements (Furst 2008; Furst 2010; Furst 2012) have summarized guidance based on previous systematic reviews. Several new trials have been published since the publication of these guidelines. Our previous overview of biologics for RA was performed in 2009 and is ready for an update. The previous overview did not include an NMA, and included all patients with RA, regardless of previous experience of MTX/other DMARDs or biologic/s. Due to clinical relevance and feasibility of presenting all information together, we made an a priori decision to examine the use of biologics or tofacitinib in four separate RA populations, namely:

1. MTX/other DMARD-naive;
2. MTX/other DMARD-experienced (biologics or tofacitinib used concomitantly with MTX/other DMARD) (Singh 2016);
3. MTX/other DMARD-experienced (biologics or tofacitinib used as monotherapy); and
4. Biologic-experienced.

The other RA populations will be reported in separate Cochrane Reviews. This review will focus on people with RA whose treatment with MTX/other DMARDs (subset of the second category) had failed, and who were switched to biologic or tofacitinib monotherapy (without MTX/other DMARDs).

The Cochrane Systematic Reviews for biologics and tofacitinib in RA have been published in The Cochrane Library, and show that these medications are associated with improved outcomes in RA, compared to placebo/MTX/other DMARDs (Blumenauer 2002; Lethaby 2013; Lopez-Olivo 2013; Lopez-Olivo 2015; Maxwell 2009; Mertens 2009; Navarro-Sarabia 2005; Ruiz Garcia 2014; Singh 2010a; Singh 2010b). Each existing Cochrane systematic review assessed one biologic at a time. Patients, clinicians and policy-makers need to know if there are any important differences between biologics in terms of important benefits and harms. Such data can be provided by head-to-head comparison studies of biologics; however, such studies are few to date (Gabay 2013a; Schiff 2008; Weinblatt 2013a). In the absence of a large evidence base from head-to-head biologic comparator studies, indirect comparisons can best demonstrate any differences between biologics (Kristensen 2007; Kristensen 2011). There is guidance for using a common comparator to make an indirect comparison (Song 2003).

Our network meta-analysis (NMA) and review differs from the usual review, such that it is not intended to examine only one intervention for RA but aims to systematically review and simultaneously compare the existing randomized trials of biologics or small molecule tofacitinib for RA (Becker 2011; Puhan 2014). Our NMA uses both direct and indirect evidence for making these comparisons.

OBJECTIVES

To determine the comparative benefits and harms of biologic monotherapy or tofacitinib (oral small molecule drug) monotherapy in adults with RA previously treated unsuccessfully with MTX/other DMARDs (MTX/other DMARD-experienced).

Monotherapy indicates that biologic or tofacitinib was used without MTX and other traditional DMARDs. These people with RA are often using glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs), or both, and other non-pharmacologic treatments (occupational therapy, physical therapy, yoga, exercise, Tai Chi etc.), and therefore biologic monotherapy does not exclude the use of these adjunctive therapies.

METHODS

Criteria for considering reviews for inclusion

Randomized controlled trials (RCTs) of biologics or tofacitinib for people with RA previously treated unsuccessfully with MTX/other DMARDs (MTX/other DMARD-experienced).

Search methods for identification of reviews

For the 2015 update, we searched for individual RCTs rather than for systematic reviews as was done in the original review. A Cochrane Information Specialist (TR) conducted a search to identify the individual studies in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL; *The Cochrane Library* 2015, Issue 6), MEDLINE (via OVID 1946 to June 2015), and Embase (via OVID 1947 to June 2015). We considered the 31 studies included in

the 2009 version for this review that included people with RA who were incomplete responders to MTX/other DMARDs.

Types of studies

For the 2015 update, we included all nine biologics and the oral small molecule tofacitinib approved for the treatment of RA. We included studies with any dose of biologic or tofacitinib, expanded from studies with only standard-dose biologic considered in the original 2009 review. RCTs were included in this review, if they had clinically relevant outcomes and included people whose treatment with MTX/other DMARDs had failed.

Although all doses were considered, we defined the standard doses of biologics as for the 2009 version, and included definitions for the newer biologics and tofacitinib, as follows.

1. Abatacept intravenous: every four weeks intravenously at 500 mg dose in people weighing under 60 kg, 750 mg in people 60 kg to 100 kg, and 1000 mg in people weighing over 100 kg, after the initial dosing regimen of baseline, two- and four-week infusions.
2. Abatacept subcutaneous: 125 mg subcutaneous weekly.
3. Adalimumab: 40 mg subcutaneous every two weeks.
4. Anakinra: 100 mg subcutaneous every day.
5. Certolizumab pegol: 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week (for maintenance dosing, 400 mg every four weeks could be considered).
6. Etanercept: 25 mg subcutaneous twice weekly or 50 mg subcutaneous once weekly.
7. Golimumab: 50 mg administered by subcutaneous injection once a month.
8. Infliximab: 3 mg/kg intravenous every eight weeks after initial dosing at 0, 2 and 6 weeks.
9. Rituximab: two 1000 mg intravenous doses two weeks apart.
10. Tocilizumab intravenous: starting dose is 4 mg per kg every four weeks followed by an increase to 8 mg per kg every four weeks based on clinical response.
11. Tocilizumab subcutaneous: 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response for people weighing less than 100 kg and 162 mg administered subcutaneously every week for people weighing 100 kg or over.
12. Tofacitinib: 5 mg orally twice a day.

Types of participants

Adults, 18 years or older, with RA meeting the 1987 American College of Rheumatology (ACR) classification criteria for RA (Arnett 1988) or the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA (Aletaha 2010), who were MTX/other DMARD-experienced, i.e., whose treatment with MTX/other DMARDs had failed due to any reason including incomplete response, intolerance or adverse events to MTX/other DMARDs.

Types of interventions

Biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) or tofacitinib used alone that is, monotherapy (used without MTX and other traditional DMARDs), compared to placebo plus traditional DMARDs (including methotrexate (MTX)) or combinations of DMARDs or placebo alone or to biologics.

Types of outcome measures

Primary/major outcomes

1. American College of Rheumatology score (ACR50) defined as 50% improvement in both tender and swollen joint counts and 50% improvement in at least three of the following five variables: patient global assessment, physician global assessment, pain score, disability as measured by validated measures such as Health Assessment Questionnaire (HAQ) score, and acute phase reactant (Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP) (Chung 2006; Felson 1995). ACR50 was chosen, as clinical and statistical evidence supports this as one of the preferred endpoints for contemporary RA clinical trials (Ghogomu 2014).
2. RA disease remission defined as Disease Activity Score (DAS) less than 1.6 or DAS28 less than 2.6 (Fransen 2005; Prevoo 1996).
3. Function measured by HAQ score or modified HAQ calculated as score changes (Fries 1980; Pincus 1983) and the proportion achieving minimal clinically important difference on HAQ ≤ 0.22 (Wells 1993).
4. Radiographic progression, as measured by Larsen/Sharp/modified Sharp scores (Larsen 1977; Sharp 1971; Van der Heijde 1989).
5. Withdrawals due to adverse events (Ioannidis 2004)
6. Serious adverse events (SAEs) (Ioannidis 2004)
7. Cancer

Since RCTs are limited in their ability to assess long-term safety, as rare or delayed effects will not be detected, we also searched the US Food and Drug Administration (FDA) web site for labels and warnings. We also searched other regulatory agencies' web sites from Canada (Health Canada) and Europe (European Medicines Agency, EMA) to summarize warnings related to included medications under study.

Data collection and analysis

Selection of reviews

For the 2015 update, we only included RCTs, not systematic reviews. We conducted a search of the databases from inception to June 2015 (one update to February 2014 and a second one to June 2015). We had previously included all completed/updated/available Cochrane systematic reviews of biologics for RA for the 2009 version (that included all studies to 2009), if they had been completed and submitted for review or updated by 30 May 2009, or both.


As noted earlier, for reasons of clinical relevance and feasibility, we separated the original 2009 review according to three patient populations for this 2015 update, based on the previous drug exposure/experience:

1. MTX/other DMARD-naive;
2. MTX/other DMARD-experienced (biologics or tofacitinib used concomitantly with MTX/other DMARD) (Singh 2016);
3. MTX/other DMARD-experienced (biologics or tofacitinib used as monotherapy); and
4. Biologic-experienced/failed.

NMAs and systematic reviews focusing on MTX/other DMARD-naive and biologic-experienced (i.e. biologic-failure) patient populations will be published shortly. For MTX/other DMARD-experienced, we carried out analyses separately for biologic + MTX/other DMARDs and for biologic monotherapy. This review focuses on findings for biologic monotherapy, that is, no concomitant MTX/other DMARDs, in people who were MTX/other DMARD-experienced.

Two authors (JS/GW and SN/TC) reviewed the results of the search (titles and abstracts), and obtained the full text of articles identified as relevant for this update. The PRISMA flow chart for study selection is provided in Figure 1 (Liberati 2009).

Figure 1. PRISMA study flow diagram



Data extraction and management

For this systematic review and NMA, we abstracted only studies including people with RA who were MTX-experienced or DMARD-experienced and were treated with biologic or tofacitinib monotherapy. Two review authors (JS and GW for the original review; SN and TC for the update) independently extracted data from the reviews into a Microsoft Excel® spreadsheet for the 2015 update. Two abstractors independently abstracted additional data for all doses of biologics (SN, JS) for RCTs abstracted for the 2009 original overview, since the original review only included standard doses of biologics. TC double-checked data for accuracy. Disagreements were resolved by discussion with JS (or GW, as appropriate). We contacted/emailed authors of RCTs where data were missing or methods were unclear, followed by reminder emails.

Assessment of methodological quality of included reviews

Two review authors in three teams (SN/JS; TC/JS; JS/NS) independently evaluated the methodological quality of the included studies, as well as overall quality of evidence for each of the seven outcomes using GRADE, as summarized below.

Risk of Bias of included trials: Study quality

We assessed the study quality using the Cochrane risk of bias tool (TC/JS/NS/SN) and two abstractors independently assessed the following risk of bias criteria for each included trial: random sequence generation, allocation concealment, presence of blinding (participants, personnel, and outcome assessors) in the studies, incomplete outcome data, and selective outcome reporting (Higgins 2011). The risk of bias was assessed as recommended: low risk, high risk, or unclear risk (i.e. either lack of information or uncertainty over the potential for bias). Disagreements were resolved by discussion between the review authors.

Quality of evidence

Two review authors (AM and JS) independently assessed the overall quality of the evidence for each outcome using the GRADE approach for both direct and NMA estimates (Guyatt 2008; Puhan 2014). The GRADE approach improves reliability in comparison to intuitive judgments about the certainty of a body of evidence (Mustafa 2013). The GRADE system specifies four levels of quality of evidence:

1. high quality for randomized trials; or double-upgraded observational studies;
2. moderate quality for downgraded randomized trials; or upgraded observational studies;
3. low quality for double-downgraded randomized trials; or observational studies; and
4. very low quality for triple-downgraded randomized trials; or downgraded observational studies; or case series/case reports.

Randomized trial evidence could be downgraded by one or two levels depending on the presence of five factors:

1. serious (-1) or very serious (-2) limitation to study quality;
2. important inconsistency (-1);
3. some (-1) or major (-2) uncertainty about directness;
4. imprecise or sparse data (-1);
5. high probability of reporting bias (-1).

Data synthesis

Statistical analyses

We performed the main analyses considering factors including the route of biologic (intravenous versus subcutaneous) and dose (low dose (LD), standard dose (SD) and high dose (HD)) as important variables/characteristics that could potentially impact benefits and harms of the medications. We also performed pre-specified analyses for several subgroups to assess the impact of RA type on outcomes (early versus established versus late) and trial duration (less than six months versus six months or more).

We analyzed MTX- and other DMARD-experienced patients together for this systematic review and NMA, since these are usually defined as a single category in most trials and MTX is a DMARD. We compared biologic and tofacitinib monotherapy to placebo; and biologic and tofacitinib monotherapy to MTX/DMARD.

Network meta-analysis methods (includes direct and indirect estimates)

We conducted NMAs using a Bayesian mixed treatment comparison (MTC) approach to determine the comparative effectiveness of treatments. WinBUGS statistical software for Bayesian analysis (Spiegelhalter 2003), was used for effecting the NMAs. We assessed the model fit based on deviance information criterion (DIC) and the comparison of residual deviance (Spiegelhalter 2003) and assessed model convergence based on trace plots and the Brooks-Gelman-Rubin statistic (Spiegelhalter 2003). We used the continuity correction approach for zero event cells to make non-zero cells where needed. We calculated the corresponding 95% credible intervals (CrI) using Markov Chain Monte Carlo (MCMC) simulation approach with at least 20,000 or more iterations, as needed. We used informative priors for the variance parameters (Turner 2012), and vague priors for the basic parameters. We compared deviance and DIC statistics in fitted consistency and inconsistency models, and examined inconsistency plots to evaluate inconsistency (i.e. a conflict between direct and indirect evidence) (Dias 2011). We chose between the random-effects model and the fixed-effects model for each comparison based on the assessment of the DIC statistics and comparison of residual deviance to number of unconstrained data points; in each case we chose and presented the model with the better fit. We used the continuity correction approach for handling zero event cells. We evaluated heterogeneity for the indirect comparison analyses using τ^2 , which quantifies heterogeneity based on the variance resulting from the interaction between study and treatment (Deeks 2011).

For dichotomous outcomes (i.e. the number of participants achieving more than 50% symptomatic improvement (ACR50) and withdrawal due to adverse events), we performed the meta-analysis by combining trials of various drugs versus placebo to obtain mutually independent estimates using odds ratios (OR) as effect measures. For data on serious adverse events or cancer, we anticipated that events would be rare (Bradburn 2007; Sweeting 2004). In order to handle these expected sparse data, we applied an empirical Bayes (treatment arm-based) approach (Salanti 2008).

Traditional meta-analysis methods

We also considered traditional meta-analyses for assessing the comparative effectiveness of treatments. We used Review Manager 5 (RevMan) (Revman 2014) to conduct the NMA and traditional meta-analysis respectively. Heterogeneity, a common

issue encountered while performing meta-analysis (Higgins 2002; Thompson 1999) was quantified using the I^2 statistic (Higgins 2003). In all the forest plots presenting effect measure data per treatment for direct comparisons, we applied the random-effects model as the conservative default option (DerSimonian 2007).

Overall

We considered P values less than 0.05 and 95% CIs or 95% CrIs that did not include 1 to be statistically significant.

We estimated the number needed to treat for an additional beneficial or harmful outcome, with 95% CIs, by using the derived OR comparing treatment to control, and considering the overall event rate in the comparator group as a proxy for the community baseline event rate. This method enabled direct translation into clinical practice (Osiri 2003), using Visual Rx with the overall (pooled) number of responders within the available studies as proxy for the expected rate of responders in a given RA population (Cates 2009).

Since clinicians may find it easier to interpret relative risks (RR) compared to odds ratios (OR), we converted the OR obtained from the NMA into RR for the 'Summary of findings' table, the Abstract and the Plain language summary (PLS). The NMA produces OR, which are presented in most of the tables and the text of the results section.

AK and AH performed data analyses under the supervision of GW.

Sub-group analyses/planned comparisons

Our main analysis focused on comparing the biologics versus comparator (placebo; active comparator) and tofacitinib versus comparator with regard to benefits and harms. In addition, we specified a priori that we would calculate overall OR for the following.

1. Overall biologic versus placebo, and overall biologic versus active comparator (MTX/other DMARDs)
2. Type of medication (by mechanism): TNF inhibitors (etanercept (ETN), adalimumab (ADA), certolizumab pegol (CERT), golimumab (GOLI), infliximab (INF)) versus nonTNF-inhibitors (abatacept (ABA), rituximab (RITUX), tocilizumab (TOCI),) versus

anakinra (ANA) versus tofacitinib (TOFA): We decided a priori to separate anakinra and tofacitinib and keep the other three non-TNF biologics together due to a low prevalence of use of anakinra in RA (Saag 2008; Zhang 2016), a different mechanism of action and route for tofacitinib versus biologics (oral versus parenteral), a similar categorization of these agents in widely-used treatment guidelines from the ACR (Singh 2012; Singh 2016a), and to keep this review consistent with other recently published Cochrane Reviews, meta-analyses and NMAs (Singh 2016).

3. Type of biologic (antibody versus receptor): medications targeting TNF receptor (etanercept (ETN)) versus monoclonal antibodies against TNF (adalimumab, certolizumab, golimumab, infliximab) versus non-TNF (abatacept, rituximab, tocilizumab) versus anakinra versus tofacitinib
4. Dose: high-dose (HD) versus standard-dose (SD) versus low-dose (LD) biologic


We also pre-specified and performed the following subgroup analyses.

1. Trial duration: short duration (six months or less), intermediate duration (six to 12 months) or long duration (longer than 12 months).
2. RA disease duration: early RA (mean/median duration of less than two years) (Boers 2001), established RA (mean/median duration two to 10 years) or late RA (mean/median duration more than 10 years) (Barlow 1999).

RESULTS

The number of included studies increased dramatically for this 2015 update due to advances in the treatment for RA in the last six years with the availability of new biologic drugs, and the accompanying trials. Our update encompassed the original 31 RCTs from the 2009 review that included people with prior MTX/other DMARD-failure, as well as all eligible new RCTs published since 2009. An example of an evidence network diagram is provided in Figure 2 for cancer. Our analyses were much more detailed than the original 2009 review, given the advances in analytic methods allowing us to interpret the data.

Figure 2. Network diagram for cancer: biologic monotherapy



Created with NodeXL (<http://nodexl.codeplex.com>)

We described only the updated results in this review, rather than pointing out similarities and differences between the 2015 and 2009 versions, preferring the ease of readability over comprehensiveness (which would have lengthened this review). As described earlier, we divided the 2015 update into four reviews, based on prior drug experience, due to clinical relevance and feasibility. Results are easier to follow, interpret and discuss when presented by patient populations based on the prior drug experience.

Description of included reviews

Note: this update uses individual studies, not reviews, as the basis of all analyses.

The overall study selection process for this 2015 update is shown in [Figure 1](#). For the 2015 update, we identified a total of 46 studies from 8,771 titles (including six of the 31 RCTs from the seven Cochrane Reviews in the original 2009 version), which had monotherapy arms for people with RA whose treatment with MTX or DMARDs had failed. Five studies ([MacIsaac 2014](#); [Moreland 2012](#); [Ohta 2014](#); [Pavelka 2009](#); [Van Riel 2008](#)) did not provide data. Reasons for exclusion of studies that we reviewed as full text are provided in [Table 1](#). Of the 41 RCTs providing usable data ([Table 2](#)), 66% (27/41) were less than six months in duration, 19% (8/41) lasted between six months and 12 months, and 15% (6/41) were longer than 12 months. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients).

Methodological quality of included reviews

Note: this update uses individual studies, not reviews, as the basis of all analyses. Two reviewers abstracted study characteristics from the published reports of the individual trials for the 2015 update.

Risk of bias of included trials

Detailed risk of bias assessment for each of the 46 trials, including the reasons for each judgment, are available at the Cochrane Musculoskeletal Group web site ([Risk of Bias Assessment A](#) and [Risk of Bias Assessment B](#)).

Allocation sequence generation and concealment (selection bias)

All trials were described as randomized, however only 17 (37%) reported adequate sequence generation and were assessed as low risk while 29 (63%) did not describe the method used and were assessed as unclear risk.

Allocation concealment was assessed as low risk in 17 (37%) trials, and unclear in 29 (63%) trials.

Blinding (performance and detection bias)

A total of 19 (41%) trials were judged at low risk of performance bias and 18 (39%) at unclear risk of bias. In nine trials (20%), participants were not blinded and these trials were at high risk of performance bias.

We assessed low risk of detection bias in 17 (37%) trials, high risk of detection bias in nine (20%) and unclear risk in 20 (43%) trials.

Incomplete outcome data (attrition bias)

Most trials (22 trials; 48%) were judged at high risk of attrition bias because more than 20% of participants dropped out. Twenty (43%) trials had low risk of attrition bias and 4 (9%) trials were unclear risk.

Selective reporting (reporting bias)

Four trials (9%) had a protocol and were judged as low risk of selective reporting. One trial (2%) was at high risk of selective reporting and 41 trials (89%) were judged as unclear risk since the study protocols were not available and we did not have enough information in the study report to assess selective reporting.

Other potential sources of bias

We assessed studies for major baseline imbalance; 39 (85%) trials had low risk of bias, five (11%) had high risk of bias and two (4%) trials had unclear risk of bias.

Study characteristics are provided in [Table 2](#) for the 41 included studies with 14,049 participants with usable data available for analysis.

Quality of evidence

The overall quality of the evidence for each outcome using the GRADE approach for both direct and NMA estimates was assessed, which is detailed for each outcome in the Summary of Findings tables ([Table 3](#); [Table 4](#)) and in the section below (Summary of findings' tables under the section, [Effects of interventions](#)).

Effect of interventions

We extracted all relevant RCT data for the seven pre-specified outcomes, ACR50, HAQ, RA disease remission, radiographic progression, withdrawals due to adverse events, serious adverse events (SAEs) and cancer. We carried out analyses and comparisons when possible.

In comparison to the original 2009 version, the 2015 update has several new key aspects.

1. Instead of six biologics, we included all nine biologics and the oral small molecule, tofacitinib in this review.
2. We included cancer and serious adverse events as outcomes, which were limited to seven outcomes, as per CMSG guidance.
3. We included all doses of biologics and the oral small molecule, tofacitinib and analyzed by dose.
4. We analyzed outcomes by whether MTX/other DMARDs were used concomitantly or not. The current review focuses on biologic monotherapy and a separate published review focuses on biologic with MTX/other DMARDs in people whose treatment with MTX/other DMARDs has failed ([Singh 2016](#)).
5. We used a Bayesian approach rather than a frequentist approach for analyses and reported odds ratios (ORs) and 95% credible intervals (CrI).
6. We examined the main results for prior MTX/other DMARD/biologic-experienced participants divided into three categories and each was considered in a separate review (MTX-naïve, MTX/other DMARD-experienced, biologic-experienced). The current review is focused on examining the benefits and harms of biologic monotherapy in a RA patient population for whom treatment with MTX or other DMARDs has failed.

7. We combined TNF-biologics and non-TNF biologics for comprehensiveness in the 'Summary of findings' table, Abstract and the beginning of each outcome, but we have presented the results separately for each TNF- and non-TNF biologic, by dose and route, in the main comparisons in the results section, so that readers can evaluate these comparisons.

How to navigate this Review

This 2015 update presents several pre-specified estimates and comparisons. We followed the following principles while describing results to keep this review as clear and comprehensive as possible.

1. Firstly we have presented the overall OR for the entire group of biologics from direct comparison of biologic versus placebo followed by biologic versus active comparator.
2. This was followed by pre-specified three sets of comparisons (e.g. TNF versus non-TNF versus anakinra versus tofacitinib), based on the NMA.
3. In the three sets of comparative analyses (type of biologic; type of medication; biologic dose), only the last set of ORs compared the biologic by dose; other analyses prior to the dose analysis, included all doses and provided comparison by a different characteristic of interest, (e.g. the type of biologic).
4. This section was followed by the main analyses, where we have presented NMA results, for each individual biologic, in every dose, compared to other biologics or itself in a different dose regimen. We carried out these main analyses separately for three groups, MTX-naïve, MTX/other DMARD-experienced, biologic-experienced. This review only discusses the monotherapy portion of the MTX/other DMARD-experienced.
5. This was followed by two pre-specified subgroup analyses by NMA, based on the trial duration and RA disease duration, to assess whether the results varied by these two pre-specified characteristics.
6. When not specified, the biologic or tofacitinib was used in standard doses (details under "Types of studies" section above). We specified high-dose (HD) and low-dose (LD) in every instance that a dose other than standard dose was used. For biologics that are approved for only one route of administration (i.e. intravenous or subcutaneous), we did not specify the route when discussing results. When we mention a drug without specifying the route, it implies that we considered only the approved route for the drug, namely: subcutaneous route for adalimumab, anakinra, certolizumab pegol, etanercept and golimumab; intravenous route for infliximab and rituximab; and oral for small molecule, tofacitinib. There were two exceptions to this. Firstly, since only two biologics are approved for both subcutaneous and intravenous use (tocilizumab and abatacept), we specified one of these two routes when describing results for these two medications; and secondly, some data exist on different, non-approved routes for some of the other biologics that were initially tested, but not approved by the regulatory agencies, and we have presented these data. The remaining seven biologics were only approved for one route of administration.
7. Due to our attempt to keep the narrative short, we have summarized the clinically meaningful and/or statistically significant results in the text; and we have commented on the clinical significance of these results. We have provided the entire comparison in the appendices for interested readers. The

full network was previously published in the Cochrane Review on Biologic + MTX/other DMARDs in patients who previously failed MTX/other DMARDs (Singh 2016). This network included both biologic + MTX/other DMARDs and biologic monotherapy treatment arms. Therefore, the appendices presented in this review are the same as those presented as appendices in the companion NMA on the MTX/other DMARD-experienced population that assessed biologic + MTX/other DMARDs (Singh 2016). They are presented here again to make it easier for the reader to find the data on biologic monotherapy within this systematic review. This review discusses the biologic monotherapy comparisons, and the previous review focused on biologic + MTX/other DMARDs combination therapy comparisons (Singh 2016).

'Summary of findings' tables

The first 'Summary of findings' table (Table 3) presents both the estimates from direct comparison of biologic monotherapy versus placebo and the NMA estimates, alongside the quality of evidence, in people whose previous treatment with MTX/other DMARDs failed. We provide absolute risk difference as well as relative difference (converted from OR in the NMA to relative risk for ease of interpretation for clinicians) for each estimate. Since cancer is a rare outcome, Peto's odds ratio is the most appropriate statistic, and can be viewed as relative risk (RR). We noted that direct estimates were consistent with NMA estimates for all seven outcomes. The second 'Summary of findings' table (Table 4) presents the results for biologic monotherapy versus active comparator (MTX/other DMARDs). Monotherapy refers to the use of biologic or tofacitinib without MTX/other DMARDs; participants may be using NSAIDs, corticosteroids and other non-pharmacological interventions).

Monotherapy versus placebo

Compared to placebo, biologic monotherapy was associated with clinically meaningful and statistically significant improvement in ACR50, function as measured by the Health Assessment Questionnaire (HAQ) score and RA disease remission, all with moderate quality evidence (Table 3). Results for withdrawals due to adverse events and serious adverse events were mostly inconclusive, with wide CIs that included the null effect and an important increase, based on low-quality evidence for direct and NMA estimates. Results for the TNF biologic, non-TNF biologic, anakinra, and tofacitinib monotherapy were similar to that of the main groups for all outcomes versus placebo (with the exception of the TNF monotherapy subgroup for withdrawals due to adverse events, which showed a clinically meaningful and statistically significant difference), with similar quality of evidence ratings. No studies were included in the placebo-only analysis for radiographic progression and cancer outcomes.

Monotherapy versus active comparator

Our findings were similar when we compared biologic monotherapy to active comparators (MTX/other DMARDs) (Table 4) although RRs for biologic monotherapy versus these comparators for ACR50 were somewhat lower, and the effect on RA disease remission was no longer significant. Data on radiographic progression (scale 0 to 448) versus active comparator showed a significant, but small, absolute reduction (0.97%) and therefore we were not sure of the clinical relevance of this reduction. There were inconclusive results for the risk of withdrawals due to adverse events, serious adverse events, and cancer with biologics, with

wide CIs that included the null effect and an important increase, based on low-quality evidence. The results for the TNF and the non-TNF biologic subgroups were similar and the quality of evidence for all outcomes versus active comparator was moderate to low. There were no anakinra or tofacitinib studies.

Number needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome

We derived the NNTB and NNTH values by comparing biologic monotherapy to comparator. The comparator was MTX or another DMARD for most of the studies. Only 39% (16 of the 41 studies), used placebo (PL) as the comparator: 39% (11 of the 28 studies) for ACR50; 45% (nine of the 20 studies) for HAQ; 10% (one of the 10 studies) for remission; 0% for radiographic progression; 41% (nine of the 22 studies) for serious adverse events; 41% (11 of the 27 studies) for withdrawals due to adverse events; and 0% for cancer. We derived the control event rates used from the control/comparator arms.

Monotherapy versus placebo

Based on direct estimates, the NNTB for biologic monotherapy versus placebo (Table 3) was 5 (95% CI, 3 to 8) for ACR50, 4 (95% CI, 3 to 5) for a meaningful improvement in HAQ score, and 10 (95% CI, 8 to 21) for RA remission. The harms outcomes that were included in the placebo-only analysis (withdrawals and SAEs) were not significant and therefore we did not calculate NNTH.

Monotherapy versus active comparator

When compared to MTX/other DMARDs (Table 4), NNTBs for ACR50 were slightly higher at 7 (95% CI, 4 to 26) and were lower for HAQ

at 2 (95% CI, 2 to 4). Radiographic progression showed a significant result and an NNTB of 9 (95% CI, 5 to 35) based on one study. Estimates for remission and the safety outcomes (withdrawals due to adverse events, SAEs, and cancer) were not significant and therefore we did not calculate any NNTBs or NNTHs.

Primary/major benefit outcome: ACR50


The network presented for all 7 outcomes included both biologic monotherapy (current review and NMA) and biologic used concomitantly with MTX/DMARDs, recently published (Singh 2016). Seventy-nine studies with 30,229 participants, who did not previously respond to treatment with MTX/other DMARDs, reported data on ACR50. Of these, 60 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 25 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).

A list of all abbreviations used in tables/appendices is provided in Appendix 1.

Monotherapy versus placebo

Biologic monotherapy was associated with clinically meaningful and statistically significantly higher ACR50 rate versus placebo with over a six-fold increase in the odds of improved ACR50, OR 6.39 (95% CI, 3.76 to 10.85), and with I² of 58% denoting moderate heterogeneity in standard meta-analyses (nine studies; Figure 3).

Figure 3. ACR50: biologic monotherapy vs placebo




The overall OR (95% CrI) of ACR50 by the type of medication, type of biologic (including mechanism of TNF antibody versus receptor) and the dose using the NMA were as follows.

1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to TNF biologic monotherapy, the odds (95% CrI) of achieving ACR50, were not clinically meaningfully or statistically significantly different for non-TNF biologic monotherapy, OR 2.73 (95%

- CrI, 0.81 to 10.56) or tofacitinib monotherapy, OR 1.08 (95% CrI, 0.44 to 3.02) (Table 5).
2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to monoclonal TNF antibody monotherapy, etanercept monotherapy, OR 0.54 (95% CrI, 0.19 to 1.58), non-TNF monotherapy OR, 2.25 (95% CrI, 0.65 to 9.25) or tofacitinib monotherapy, OR 0.88 (95% CrI, 0.35 to 2.56), were not clinically meaningfully or statistically significantly different (Table 6).
 3. By dose: SD versus HD versus LD
 - a. In placebo comparator analysis, compared to SD biologic monotherapy, LD and HD biologic monotherapy were not associated with differences in odds of ACR50, with OR 0.74 (95% CrI, 0.39 to 1.51) and 1.36 (95% CrI, 0.80 to 2.38) respectively (Table 7).
- Direct estimates for ACR50 by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to placebo (Figure 4).

Figure 4. ACR50: biologic monotherapy vs placebo by drug group




Monotherapy versus active comparator

Biologic monotherapy was associated with clinically meaningful and statistically significant improvement in ACR50 versus MTX/

other DMARDs, nearly a two-fold increase in the odds of improved ACR50 (OR 1.94; 95% CI, 1.20 to 3.15), and with I² of 88% denoting considerable heterogeneity in standard meta-analyses (ten studies; Figure 5).

Figure 5. ACR50: biologic monotherapy vs MTX/DMARD



The overall OR (95% CrI) of ACR50 by the type of medication, type of biologic (including mechanism of TNF antibody versus receptor) and the dose, using the NMA, were as follows.


1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to TNF biologic monotherapy, the odds (95% CrI) of achieving ACR50, were not clinically meaningfully or statistically significantly different for non-TNF biologic monotherapy, OR 1.39 (95% CrI, 0.79 to 2.41) (Table 8).
2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to monoclonal TNF antibody monotherapy, etanercept monotherapy, OR 1.27 (95% CrI, 0.60 to 2.74) and non-TNF monotherapy 1.59

(95% CrI, 0.81 to 3.13) were not clinically meaningfully or statistically significantly different (Table 9).

3. By dose: SD versus HD versus LD
 - a. In active comparator analysis, compared to SD biologic monotherapy, HD biologic monotherapy was not associated with a statistically significant difference in odds of ACR50 with OR 1.35 (95% CrI, 0.93 to 1.96), but LD biologic monotherapy showed statistically significantly lower odds of ACR50 with OR 0.52 (95% CrI, 0.31 to 0.85). LD biologic monotherapy also showed statistically significantly lower odds of ACR50 when compared to HD biologic monotherapy with OR 0.39 (95% CrI, 0.22 to 0.66) (Table 10).

Direct estimates for ACR50 by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to MTX/DMARD (Figure 6).

Figure 6. ACR50: biologic monotherapy vs MTX/DMARD by drug group



Main analyses for MTX/other DMARD-experienced participants using the NMA

Seventy-nine RCTs (38 two-arm, 33 three-arm, 6 four-arm, 1 five-arm and 1 seven-arm trials) with 30,229 participants provided data for all dose analyses (Appendix 2), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.

Monotherapy versus placebo

All nine biologics, in LD, SD or HD, were superior to placebo in achieving ACR50; exceptions were SD rituximab intravenous alone and LD tocilizumab intravenous alone.

Monotherapy versus active comparator

Compared to MTX, we noted the following:

1. only SD etanercept was superior, with OR 1.91, but others were similar;
2. only LD tocilizumab intravenous was inferior, with OR 0.18, but others were similar;
3. most HD biologic monotherapy regimens were superior.

Compared to DMARDs, we noted the following:

1. most SD biologic monotherapy regimens were superior, with ORs 2.6 to 10.2;
2. most LD biologic monotherapy regimens were superior, with ORs ranging from 3.5 to 4.0; and
3. all HD biologic monotherapy regimens were superior, with ORs ranging from 4.9 to 14.6.

We found several other clinically and statistically significant differences (Appendix 2), namely that:

1. high doses of most biologic monotherapy regimens were often more effective in achieving ACR50 compared to standard doses of that biologic as well as standard doses of other biologics;
2. low doses of most biologic monotherapy regimens were often less effective in achieving ACR50 compared to standard dose of biologics (same or other biologic) and compared to SD tofacitinib monotherapy.

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

Compared to placebo, all biologic and tofacitinib monotherapy comparators in SD and HD, were associated with higher OR of ACR50, ranging from 3.77 to 14.79. In general, HD biologic monotherapy was associated with higher OR of ACR50 compared to SD (24,984 participants, 60 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 3).

Late RA (disease duration more than 10 years)

Compared to LD biologic monotherapy, LD biologic + MTX was associated with higher OR of ACR50, ranging from 4.5 to 7.9 (3481 participants, 12 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 4).

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

Compared to MTX, most (but not all) biologic monotherapy (LD, SD or HD) was associated with similar odds of ACR50; exceptions included SD etanercept, SD and HD golimumab and HD abatacept, associated with ORs ranging from 2.67 to 5.45 (24,122 participants, 66 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 5).

Trial duration, six to 12 months

Compared to MTX, most (but not all) biologic monotherapy (LD, SD, or HD) was associated with similar odds of ACR50 (3209 participants, six trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 6).

Trial duration, more than 12 months

There were not enough data to perform NMA.


Primary/major efficacy outcome: HAQ

Forty-eight studies with 16,355 participants whose treatment with MTX/other DMARDs had failed previously, reported data on HAQ scores. Of these, 35 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 16 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).

Monotherapy versus placebo

The use of biologic monotherapy was associated with clinically meaningful and statistically significant improvement in HAQ scores versus placebo, with a mean difference (MD) of -0.32 (95% CI, -0.42 to -0.23) based on results with considerable heterogeneity, with an I² of 70% in standard meta-analyses (seven studies; Figure 7).

Figure 7. HAQ: biologic monotherapy vs placebo



The HAQ improvements by the type of medication, type of biologic and the biologic dose were as follows using the NMA.


1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to TNF biologic monotherapy, the HAQ scores were not clinically meaningfully or statistically significantly different for tofacitinib monotherapy, MD -0.05 (95% CrI, -0.38 to 0.24) or anakinra monotherapy, 0.09 (95% CrI, -0.32 to 0.49) (Table 11).
2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to TNF biologic monotherapy, HAQ scores were not clinically

meaningfully or statistically significantly different for etanercept monotherapy, MD 0.18 (95% CI, -0.24 to 0.55), anakinra monotherapy, MD 0.14 (95% CrI, -0.30 to 0.53) or tofacitinib monotherapy, MD -0.01 (95% CrI, -0.35 to 0.28) (Table 12).

3. By dose: SD versus HD versus LD
 - a. In placebo comparator analysis, compared to SD biologic monotherapy, LD and HD biologic monotherapy were not associated with statistically significant differences in HAQ scores, MD was -0.10 (95% CrI, -0.25 to 0.04) and 0.01 (95% CrI, -0.14 to 0.15) (Table 13)

Direct estimates for HAQ by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to placebo (Figure 8).

Figure 8. HAQ: biologic monotherapy vs placebo by drug group




Monotherapy versus active comparator

The use of biologic monotherapy was associated with clinically meaningful and statistically significant improvement in HAQ scores

versus MTX/other DMARDs, with a MD of -0.27 (95% CI, -0.40 to -0.14) based on results with considerable heterogeneity, with I² of 91% in standard meta-analyses (six studies; Figure 9).

Figure 9. HAQ: biologic monotherapy vs MTX/DMARD



The HAQ improvements by the type of medication, type of biologic and the biologic dose were as follows using the NMA.


1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to TNF biologic monotherapy, the HAQ scores were not clinically meaningful or statistically significantly different for non-TNF biologic monotherapy, MD -0.14 (95% CrI, -0.52 to 0.23) (Table 14).

2. Type of biologic, monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to TNF biologic receptor monotherapy (etanercept) and monoclonal TNF antibody therapy, the HAQ scores were not statistically significantly different for non-TNF biologic monotherapy, MD of MD -0.01 (95% CrI, -0.39 to 0.38) and -0.23 (95% CrI, -0.78 to 0.32), respectively (Table 15).

3. By dose, SD versus HD versus LD:
 a. In active comparator analysis, compared to SD biologic monotherapy, HD biologic monotherapy was not associated with statistically significant differences in HAQ scores, MD -0.03 (95% CrI, -0.34 to 0.28) (Table 16).

Direct estimates for HAQ by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to MTX/DMARD (Figure 10).

Figure 10. HAQ: biologic monotherapy vs MTX/DMARD by drug group



Main analyses using the NMA

Forty-eight studies (25 two-arm, 15 three-arm and 8 four-arm trials), with 16,355 participants provided HAQ data in DMARD-experienced participants (Appendix 7), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.

Monotherapy versus placebo

Compared to placebo, the following treatments were associated with statistically significantly and clinically meaningfully better HAQ scores (reduction) with the following MDs: SD adalimumab, -0.29; SD tofacitinib, -0.40; LD adalimumab, -0.32; HD tofacitinib, -0.52; and HD adalimumab -0.43.

Monotherapy versus active comparator

Compared to MTX, HD biologic monotherapy was associated with statistically significantly and clinically meaningfully better HAQ scores (reduction), and key examples were HD tocilizumab, MD -0.32 and HD tofacitinib, MD -0.56. Compared to MTX, SD biologic monotherapy regimens were not associated with any significant difference in HAQ improvement, except SD etanercept, MD -0.38. LD biologic monotherapy did not differ from MTX significantly.

Compared to DMARDs, SD etanercept, MD -0.38 and HD tofacitinib, MD -0.56 were associated with statistically significantly and clinically meaningfully greater improvements in HAQ scores. LD biologic did not differ statistically significantly from DMARDs.

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

Compared to MTX or DMARD, only SD etanercept monotherapy was associated with statistically significantly and clinically meaningfully more significant improvements of HAQ scores with a MD of -0.38 (95% CI, -0.69 to -0.07) and MD -0.38 (95% CI, -0.74 to -0.01), respectively. All other biologic monotherapy regimens had no significant differences in HAQ improvements compared to MTX. None of the biologic monotherapy regimens were superior to MTX + DMARD regimens (39 trials (22 two-arm, 11 three-arm and 6 four-arm trials), 14,018 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 8).

Late RA (disease duration more than 10 years)

Compared to MTX, SD rituximab was associated with more significant improvements of HAQ scores: MD -0.44 (95% CI, -0.70 to -0.18), and this was the only monotherapy comparison to MTX available (seven trials (1 two-arm, 4 three-arm and 2 four-arm trials), with 2084 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 9).

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

Compared to placebo, the following were associated with statistically significantly and clinically meaningfully greater improvements in HAQ scores with the following MDs: SD etanercept, -0.31; SD tofacitinib, -0.39; SD certolizumab, -0.36; LD adalimumab, -0.32; HD tofacitinib, -0.51; and HD adalimumab, -0.44 (42 trials (23 two-arm, 11 three-arm and 8 four-arm trials), with 13,213 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 10).

Trial duration, six to 12 months

There were not enough data to perform NMA.

Trial duration, more than 12 months

There were not enough data to perform NMA.

Primary/major efficacy outcome: remission


Thirty studies with 14,125 participants, whose treatment with MTX/other DMARDs had failed, reported data on RA disease remission. Of these, 28 studies included at least one arm with participants

on a biologic with concomitant MTX/other DMARDs (most often the comparator was MTX; published as a separate review) and six studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).

Monotherapy versus placebo

Participants receiving biologic monotherapy had higher OR of remission versus placebo at 3.73 (95% CI, 1.59 to 8.74, no I²; based on one study) in standard meta-analyses (Figure 11). This was both clinically meaningful and statistically significant, but was based on only one study.

Figure 11. Remission: biologic monotherapy vs placebo




Since there was only one study comparing biologic monotherapy versus placebo, no analyses could be performed for the type of biologic.

statistically significant with OR of 1.65 (95% CI, 0.98 to 2.80, I²= 42% showing moderate heterogeneity) in standard meta-analyses (four studies; Figure 12).

Monotherapy versus active comparator

Participants receiving biologic monotherapy had higher OR of remission versus MTX/other DMARDs, but this result was not

Figure 12. Remission: biologic monotherapy vs MTX/DMARD




The overall odds (95% CrI) of RA disease remission by the type of medication, type of biologic and the dose using the NMA were as follows. We performed these analyses only for studies of biologic monotherapy versus MTX/DMARD.

1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib (Table 17)
 - a. Compared to TNF biologic, non-TNF biologic was not associated with any statistically significant differences in RA remission, OR 2.17 (95% CrI, 0.94 to 4.93).

2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib (Table 18)
 - a. Compared to monoclonal TNF antibody biologic, etanercept was not associated with any statistically significant differences in remission rates, OR 2.21 (95% CrI, 0.87 to 5.47), but non-TNF biologic was associated with a statistically significantly higher rate of remission OR 2.12 (95% CrI, 1.02 to 4.43). Compared to etanercept, non-TNF biologic was not associated with any statistically significant differences in remission rates, OR 2.23 (95% CrI, 0.86 to 5.92).
 3. By dose: SD versus HD versus LD (Table 19)
 - a. Compared to SD, HD biologic monotherapy was associated with statistically significantly higher OR of remission, 2.17 (95% CrI, 1.12 to 4.19); LD biologic monotherapy was not clinically meaningfully or statistically significantly different than SD biologic monotherapy, OR 1.46 (95% CrI, 0.52 to 4.11) or HD biologic monotherapy, OR 0.67 (95% CrI, 0.22 to 2.10).
- Direct estimates for remission by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both, are shown in Figure 13.

Figure 13. Remission: biologic monotherapy vs MTX/DMARD by drug group



Main analyses using the NMA

Thirty studies (17 two-arm, 11 three-arm, 1 four-arm and 1 five-arm trials), with 14,125 participants provided data for MTX/other DMARD-experienced participants for remission (Appendix 11), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.

Monotherapy versus active comparator

Compared to MTX/other DMARDs, HD biologic monotherapy regimens (tocilizumab, golimumab) were associated with two to three times the OR of remission, which was statistically significant. Compared to MTX, the ORs of remission were similar for most SD and LD biologic monotherapy regimens.

High-dose biologic (higher remission) versus standard- or LD biologic

In general, compared to SD or LD biologic monotherapy, most HD biologic monotherapy was associated with higher rates of remission. Compared to SD adalimumab, HD tocilizumab intravenous was associated with statistically significantly higher OR of RA disease remission: 5.81 (95% CrI, 1.78 to 19.48).

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

Compared to MTX, most HD biologic monotherapy (tocilizumab, golimumab) was associated with two times higher OR of remission, which was statistically significant. Compared to MTX + DMARD, HD biologic monotherapy was associated with 7 to 10 times higher OR of remission (statistically significant), but SD or LD biologic monotherapy were associated with similar OR (13,479 participants, 29 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 12).

Late RA (disease duration more than 10 years)

There were not enough data to perform NMA.

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

We created two networks, one with 9626 participants and 20 trials (Appendix 13) and the other with 1392 participants and five trials (Appendix 14).

Compared to SD adalimumab subcutaneous, HD tocilizumab IV was associated with 5.9 times odds of remission, which was statistically significant. We observed a higher OR with HD tocilizumab or golimumab, as described above.

Trial duration, six to 12 months

There were not enough data to perform NMA.

Trial duration, more than 12 months

There were not enough data to perform NMA.

Primary/major efficacy outcome: radiographic progression

Eight studies with 3267 participants, whose treatment with MTX/other DMARDS had failed, reported data on radiographic progression. Of these, all eight studies included at least one

arm with participants on a biologic with concomitant MTX/other DMARDS (most often MTX; published as a separate review) and only one study had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).


Monotherapy versus placebo

There were no data available for biologic monotherapy versus placebo.

Monotherapy versus active comparator

The one included study showed that the use of SD etanercept monotherapy (one of the TNF biologics) was statistically significantly associated with less radiographic progression compared to MTX with a MD of -4.34 (95% CI, -7.56 to -1.12) modified Sharp units in standard meta-analyses (Figure 14); whether this difference is clinically meaningful or not is unclear.

Figure 14. Radiographic progression: biologic monotherapy vs MTX/DMARD



Since there was only one study available, no estimates could be derived by the type of medication, type of biologic and biologic dose.

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

There were not enough data to perform NMA.

Late RA (disease duration longer than 10 years)

There were not enough data to perform NMA.

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

There were not enough data to perform NMA.

Trial duration, six to 12 months

There were not enough data to perform NMA.

Trial duration, more than 12 months

There were not enough data to perform NMA.


Primary/major safety outcome: Withdrawals due to adverse events (WdAE)

Seventy studies with 29,062 participants reported withdrawals due to AEs. Of these, 52 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDS (most often MTX; published as a separate review) and 23 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).

Monotherapy versus placebo

The use of biologic monotherapy was associated with no statistically significant increase in the likelihood of withdrawals due to AEs versus placebo, with an OR of 1.70 (95% CI, 0.98 to 2.95) and with I² of 15%, denoting low heterogeneity in standard meta-analyses (nine studies; Figure 15).

Figure 15. Withdrawals due to Adverse Events: biologic monotherapy vs placebo



The overall odds (95% CrI) of withdrawals due to AEs by the type of medication, type of biologic and the dose using the NMA were as follows.


1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to TNF biologic monotherapy, non-TNF biologic monotherapy was associated with statistically significantly and clinically meaningfully lower OR of withdrawals due to AEs, OR 0.10 (95% CrI, 0.01 to 0.67), but anakinra monotherapy, OR 0.75 (95% CrI, 0.22 to 2.76) or tofacitinib monotherapy were not, 0.55 (95% CrI, 0.12 to 2.89) (Table 20).
2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to monoclonal TNF antibody monotherapy, there were no significant differences in the OR of withdrawals due to AEs with

etanercept monotherapy, OR 0.71 (95% CrI, 0.17 to 3.51), tofacitinib monotherapy, OR 0.48 (95% CrI, 0.10 to 2.78) or anakinra monotherapy, OR 0.69 (95% CrI, 0.18 to 2.78). Non-TNF biologic monotherapy, OR 0.09 (95% CrI, 0.01 to 0.63), was associated with statistically significantly lower odds compared to monoclonal TNF antibody monotherapy (Table 21).

3. By dose: SD versus HD versus LD
 - a. In placebo comparator analysis, compared to SD biologic monotherapy, LD or HD biologic monotherapy were not associated with a difference in OR of withdrawals due to AEs, OR 0.62 (95% CrI, 0.22 to 1.63) and 0.84 (95% CrI, 0.31 to 2.19), respectively (Table 22)

Direct estimates for withdrawals due to AEs by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to placebo (Figure 16).

Figure 16. Withdrawals due to Adverse Events: biologic monotherapy vs placebo by drug group




Monotherapy versus active comparator

Biologic monotherapy was associated with no statistically significant increase in the likelihood of withdrawals due to AEs

versus MTX/other DMARDs with an OR of 1.09 (95% CI, 0.67 to 1.79; nine studies) and with I² of 62%, denoting moderate heterogeneity in standard meta-analyses (Figure 17).

Figure 17. Withdrawals due to Adverse Events: biologic monotherapy vs MTX/DMARD



The overall odds (95% CrI) of withdrawals due to AEs by the type of medication, type of biologic and the dose using the NMA were as follows.


1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to TNF biologic monotherapy, non-TNF biologic monotherapy was not associated with any statistically significant differences in the odds of withdrawals due to AEs: OR 1.08 (95% CrI, 0.60 to 1.94) (Table 23).
2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to monoclonal TNF antibody monotherapy, there was no statistically significant difference in odds of withdrawals due to AEs with etanercept monotherapy, OR 0.88 (95% CrI, 0.38 to 1.96). When compared to etanercept monotherapy, non-

TNF monotherapy was not associated with a statistically significant difference in odds, OR 1.42 (95% CrI, 0.66 to 3.13) (Table 24).

3. By dose: SD versus HD versus LD
 - a. In active comparator analysis, compared to SD biologic monotherapy, LD or HD biologic monotherapy were not associated with a statistically significant difference in odds of withdrawals due to AEs, OR 0.74 (95% CrI, 0.44 to 1.25) and 1.00 (95% CrI, 0.55 to 1.79), respectively. Likewise, when compared to HD biologic monotherapy, LD biologic monotherapy showed no statistically significant difference, OR 0.74 (95% CrI, 0.37 to 1.51) (Table 25).

Direct estimates for withdrawals due to AEs by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both are shown for comparison to MTX/other DMARDs and were similar to the results above (Figure 18).

Figure 18. Withdrawals due to Adverse Events: biologic monotherapy vs MTX/DMARD by drug group



Main analyses using the NMA

Seventy studies (42 two-arm, 20 three-arm, 7 four-arm and 1 seven-arm trials), with 29,062 participants provided data for all dose analyses (Appendix 15), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.

Monotherapy versus active comparator

We noted no significant increase in the odds of withdrawals due to AEs with biologic monotherapy in any dose, compared to MTX or DMARDs.

Adalimumab and infliximab comparisons

Compared to SD adalimumab + MTX or SD infliximab + MTX, LD adalimumab and HD adalimumab monotherapy showed statistically significantly lower OR of withdrawals ranging from 0.12 to 0.40. Compared to LD adalimumab monotherapy, most HD biologics + MTX as well as tofacitinib + MTX were associated with statistically significantly higher OR of withdrawals, 4.59 to 7.41. Compared to HD adalimumab monotherapy, most HD biologics + MTX as well as tofacitinib + MTX were associated with statistically significantly higher OR of withdrawals due to AEs, OR 4.33 to 7.26.

Compared to SD certolizumab + MTX, we found that LD adalimumab and HD adalimumab monotherapy were associated with statistically significantly lower odds of withdrawals due to AEs, OR 0.17.

Compared to SD tofacitinib + MTX, LD etanercept, LD adalimumab and HD adalimumab monotherapy were associated with statistically significantly lower OR of withdrawals due to AEs, 0.12 to 0.40.

Compared to SD abatacept + MTX, we found that HD tofacitinib monotherapy was associated with statistically significantly higher OR of withdrawals due to AEs, 2.82 to 3.86.

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

Compared to placebo, most SD, LD, and HD biologics were not associated with any differences in the odds of withdrawals due to AEs, except SD and LD etanercept monotherapy, which were associated with statistically significantly higher OR ranging from 4.38 to 4.75. Compared to DMARDs alone, we noted no statistically significant increase in the OR of withdrawals due to AEs with biologic monotherapy (any dose), with minor exceptions (48 trials (30 two-arm, 13 three-arm, and 5 four-arm trials), with 20,301 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 16).

Compared to SD biologic monotherapy, SD or HD biologics + MTX, were associated with statistically significantly higher OR of withdrawals due to AEs, ranging from 4.10 to 16.2. Compared to HD biologic monotherapy, HD biologics + MTX were associated with statistically significantly higher OR of withdrawals due to AEs, ranging from 4.35 to 18.0.

Late RA (disease duration more than 10 years)

Compared to SD etanercept, SD rituximab and SD rituximab + MTX were each associated with statistically significantly higher OR of

withdrawals due to AEs of 26.6 and 7.4, respectively (nine trials (4 two-arm, 4 three-arm and 1 four-arm trials), with 3276 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 17).

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

Compared to SD adalimumab subcutaneous monotherapy, LD adalimumab subcutaneous monotherapy was associated with statistically significantly lower OR of 0.34 (52 trials, 20,850 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 18).

Trial duration, six to 12 months

We noted no significant differences between treatments (seven trials, 3279 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 19).

Trial duration, more than 12 months

There were not enough data to perform NMA.


Primary/major safety outcome: serious adverse events (SAEs)

Sixty-one studies with 28,661 participants reported serious adverse events (SAEs). Of these, 46 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 19 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).

Monotherapy versus placebo

The use of biologic monotherapy was not associated with statistically significantly higher OR of SAEs versus placebo, 1.25 (95% CI, 0.70 to 2.25; six studies), and with I² of 45%, denoting moderate heterogeneity in standard meta-analyses (Figure 19).

Figure 19. Serious Adverse Events: biologic monotherapy vs placebo



The overall odds (95% CrI) of SAEs differed by the type of biologic and the dose as follows:

1. Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to TNF biologic, the OR of SAEs were not clinically meaningfully or statistically significantly different with tofacitinib monotherapy at 0.37 (95% CrI, 0.13 to 1.06) (Table 26).
2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In placebo comparator analysis, compared to monoclonal antibody monotherapy, the OR of SAEs were not clinically meaningfully or statistically significantly different with etanercept monotherapy at 1.25 (95% CrI, 0.14 to 12.92) or


tofacitinib monotherapy at 0.38 (95% CrI, 0.12 to 1.11) (Table 27).

3. By dose: SD versus HD versus LD
 - a. In placebo comparator analysis, compared to SD biologic monotherapy, the odds of SAEs were not clinically meaningfully or statistically significantly different with HD or LD biologic monotherapy, OR 0.48 (95% CrI, 0.15 to 1.44) and 0.80 (95% CrI, 0.28 to 2.36), respectively (Table 28).

Inconsistency was noted for several of these analyses.

Direct estimates for SAEs by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra and/or tofacitinib, are shown for comparison to placebo (Figure 20).

Figure 20. Serious Adverse Events: biologic monotherapy vs placebo by drug group




Monotherapy versus active comparator

The use of biologic monotherapy was not associated with statistically significantly higher OR of SAEs versus MTX/other

DMARDs, 1.54 (95% CI, 0.94 to 2.51; seven studies), and with I² of 30%, denoting moderate heterogeneity in standard meta-analyses (Figure 21).

Figure 21. Serious Adverse Events: biologic monotherapy vs MTX/DMARD



The overall odds (95% CrI) of SAEs differed by the type of biologic and the biologic dose as follows, based on NMA.

- Type of medication: TNF biologic versus non-TNF biologic versus anakinra versus tofacitinib
 - In active comparator analysis, compared to TNF monotherapy, non-TNF monotherapy showed no statistically significant difference in odds of SAEs, OR 1.00 (95% CrI, 0.63 to 1.57) (Table 29).


2. Type of biologic: monoclonal TNF antibody versus TNF receptor versus non-TNF versus anakinra versus tofacitinib
 - a. In active comparator analysis, compared to etanercept monotherapy, the OR of SAEs were not clinically meaningfully or statistically significantly different for TNF monoclonal antibody monotherapy, 1.42 (95% CrI, 0.70 to 2.97), or non-TNF monotherapy, 0.77 (95% CrI, 0.38 to 1.46) (Table 30).
3. By dose: SD versus HD versus LD
 - a. In active comparator analysis, compared to SD biologic monotherapy, the odds of SAEs were not statistically significantly different with HD or LD biologic monotherapy,

OR 1.00 (95% CrI, 0.55 to 1.79) and 0.74 (95% CrI, 0.44 to 1.25), respectively. Compared to HD monotherapy, LD monotherapy also did not show any statistically significant difference, OR 0.74 (95% CrI, 0.37 to 1.51) (Table 31).

Inconsistency was noted for several of these analyses.

Direct estimates for SAEs by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra and/or tofacitinib, are shown for comparison to MTX/other DMARDs (Figure 22).

Figure 22. Serious Adverse Events: biologic monotherapy vs MTX/DMARD by drug group



Main analyses using the NMA

Sixty-one RCTs (38 two-arm, 16 three-arm, 6 four-arm, and one 5-arm trials), with 28,661 participants provided data for all dose analyses for SAEs (Appendix 20), including biologic + MTX/other DMARD combinations or biologic monotherapy arms. Main findings are summarized in the section below.

Monotherapy versus placebo

None of the treatments were significantly different from placebo, except SD certolizumab and LD golimumab intravenous monotherapy, which were associated with 4.67 times and 6.90 times odds of SAEs (Appendix 20). In general, golimumab and certolizumab monotherapy were associated with higher OR and abatacept and adalimumab monotherapy with lower odds of SAEs compared to other biologic or tofacitinib monotherapy.

Monotherapy versus active comparator

MTX/other DMARD comparisons (lower odds)

Compared to MTX, none of the comparators were clinically or statistically significant different. Compared to DMARDs, some SD biologic monotherapy treatments were associated with

statistically significantly higher OR of SAEs, two-times and higher. Compared to MTX + DMARD combination, we found that LD golimumab intravenous monotherapy was associated with statistically significantly higher OR of SAEs, 8.93.

Tofacitinib comparisons

Compared to SD tofacitinib monotherapy, several biologic + MTX as well as tofacitinib + MTX combinations were associated with statistically significantly higher OR of SAEs, ranging from 5.42 to 11.17.

Golimumab comparisons (higher odds)

LD golimumab intravenous monotherapy was associated with statistically significantly higher OR of SAEs compared to several treatments:

1. SD adalimumab monotherapy, 6.29;
2. SD tofacitinib monotherapy, 18.17;
3. SD golimumab intravenous monotherapy, 4.58 times;
4. SD rituximab monotherapy, 12.36 times;
5. SD infliximab + MTX, 5.64;

6. SD adalimumab subcutaneous + MTX, 5.68;
7. SD abatacept + MTX, 6.30;
8. SD abatacept intravenous + DMARD, 10.09;
9. SD adalimumab subcutaneous + DMARD, 16.15
10. SD anakinra + DMARD, 11.02;
11. SD certolizumab + DMARD, 16.49;
12. LD adalimumab monotherapy, 10.84; and
13. LD etanercept monotherapy, 6.83.

Several treatments were associated with statistically significantly lower odds of SAEs compared to LD golimumab intravenous monotherapy: HD tofacitinib monotherapy, OR 0.08 and HD adalimumab monotherapy, 0.14. HD golimumab subcutaneous + MTX was associated with higher OR of SAEs compared to HD tofacitinib monotherapy, 7.54.

Certolizumab comparisons (higher odds)

HD certolizumab subcutaneous + MTX was associated with statistically significantly higher OR of SAEs compared to LD etanercept monotherapy, 3.95. Several treatments were associated with statistically significantly lower OR of SAEs compared to SD certolizumab subcutaneous monotherapy including: LD adalimumab monotherapy, OR 0.14; and HD tofacitinib monotherapy, OR 0.11.

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

Compared to DMARD + placebo, most biologics in SD monotherapy regimens were not associated with any statistically significant differences in the OR of SAEs, except SD certolizumab pegol, which was associated with a three-fold higher OR of SAEs (statistically significant). Compared to SD tofacitinib, several biologics + MTX combinations were associated with statistically significantly higher OR of SAEs, ranging from 5.7 to 24.1, as well as tofacitinib + MTX, OR 12.3, with wide confidence intervals (50 trials, 22,022 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 21).

Late RA (disease duration more than 10 years)

There were no statistically significant differences (four trials (1 two-arm, 2 three-arm and 1 four-arm trials), with 1390 participants,

including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 22).

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

We created two networks, one with 23 studies and 11,146 participants (Appendix 23) and the other with 26 trials and 12,263 participants (Appendix 24). In the first network, compared to SD and HD biologic monotherapy, MTX + DMARD or biologic combination therapy were not associated with statistically significantly lower OR of SAEs with minor exceptions.

Compared to SD and HD biologic monotherapy, MTX alone/biologic combination therapy was not associated with statistically significantly lower OR of SAEs with minor exceptions.

Trial duration, six to 12 months

We noted no statistically significant differences between biologic monotherapy and other comparators (six trials (1 two-arm and 5 three-arm trials), with 2277 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 25).

Trial duration, more than 12 months

There were not enough data to perform NMA.

Primary/major safety outcome: cancer

Twenty-four studies with 10,843 participants reported data on cancer. Of these, 19 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and seven studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).


Monotherapy versus placebo

There were no data available for the comparison of biologic monotherapy to placebo.

Monotherapy versus active comparator

The use of biologic monotherapy was associated with no statistically and clinically significant increase in the odds of cancer, versus MTX/DMARD in participants with RA (six studies), Peto's OR 1.40 (95% CI, 0.67 to 2.93), and with I^2 of 18% in standard meta-analyses (Figure 23), denoting little heterogeneity.

Figure 23. Cancer: biologic monotherapy vs MTX/DMARD




The overall odds (95% CrI) of cancer by the type of medication, type of biologic and the dose for biologic versus MTX/DMARD, based on NMA, were as follows.

1. Type of medication (Table 32)
 - a. Compared to TNF inhibitors, the OR of cancer with non-TNF biologic were not clinically meaningfully or statistically significantly different at 0.95 (95% CrI, 0.22 to 4.35).
2. Type of biologic: receptor versus antibody (Table 33)
 - a. Compared to etanercept monotherapy, neither monoclonal TNF antibody monotherapy nor non-TNF biologic monotherapy, were associated with any significant differences in the odds of cancer, OR 0.91 (95% CrI, 0.06 to 13.28) and 0.91 (95% CrI, 0.17 to 5.40), respectively.
3. By dose (Table 34):
 - a. Compared to SD biologic, the odds of cancer were not clinically meaningfully or statistically significantly different with HD biologic, OR 0.97 (95% CrI, 0.22 to 4.53) and LD biologic, OR 0.46 (95% CrI, 0.10 to 1.68). Compared to HD biologic, LD biologic was not associated with statistically significant differences in the odds of cancer, OR 0.47 (95% CrI, 0.06 to 3.15).

Direct estimates for cancer by the type of biologic, that is, TNF biologic versus non-TNF biologic versus anakinra or tofacitinib, or both are shown in Figure 24.

Figure 24. Cancer: biologic monotherapy vs MTX/DMARD by drug group



Main analyses using the NMA

24 RCTs (16 two-arm and 8 three-arm trials), with 10,843 participants provided data for all dose analyses (Appendix 26), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.

Monotherapy versus active comparator

Compared to DMARD, SD etanercept was associated with 13.86-times higher OR of cancer. Compared to SD etanercept, SD etanercept + DMARD and SD abatacept IV + DMARD were associated with lower OR of cancer, odds of 0.06 and 0.07 respectively.

Subgroup analyses by early versus established versus late RA using the NMA

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA

Established RA (disease duration two to 10 years)

No statistically significant differences in cancer rates were noted between treatments (13 trials, 5853 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 27).

Late RA (disease duration more than 10 years)

There were not enough data to perform NMA.

Subgroup analyses by trial duration using the NMA

Trial duration, less than six months

No statistically significant differences in cancer rates were noted between treatments (eight trials, 3895 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 28).

Trial duration, six to 12 months

There were not enough data to perform NMA.

Trial duration, more than 12 months

There were not enough data to perform NMA.

Summary of safety warnings from regulatory agencies

Evidence from RCTs is limited in informing participants and physicians regarding uncommon or rare adverse events. In the section below, we summarize warnings related to biologics from the FDA, EMA and Health Canada, the regulatory agencies in the USA, Europe and Canada, respectively. This section is similar to the warnings section in the companion review for biologic +MTX/other DMARDs (Singh 2016).

Abatacept

No recent warnings have been issued with regard to abatacept. On the product label of abatacept, the FDA warns against known safety implications reporting, "In controlled clinical trials, participants receiving concomitant abatacept and TNF antagonist therapy experienced more infections (63%) and serious infections (4.4%) compared to participants treated with only TNF antagonists (43% and 0.8%, respectively). Concurrent administration of a TNF antagonist with abatacept has been associated with an increased risk of serious infections and no statistically significant additional benefit over use of the TNF antagonists alone" (FDA 2007). Furthermore, the FDA reports that, "rare occurrences of anaphylaxis or anaphylactoid reactions have been observed in two of 2,688 participants treated with abatacept in clinical trials" (FDA 2007). Trials have also shown that, "COPD participants treated with abatacept developed adverse events more frequently than those treated with placebo, including COPD exacerbations, cough, rhonchi, and dyspnea" (FDA 2007).

The effects of abatacept on pregnant women, children, and the development of malignancies is "not yet fully understood" (FDA 2007). The European Medicines Agency (EMA) reports adverse reactions in people treated with abatacept, ranking the occurrences of such reactions as very common ($\leq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); and very rare ($< 1/10,000$). EMA 2009a reports that increase in blood pressure, abnormal liver function test (transaminases increased) and headaches are very common adverse reactions. Dizziness, cough, rash including dermatitis, diarrhea, nausea, dyspepsia, abdominal pain, lower respiratory tract infection (including bronchitis), urinary tract infection, herpes simplex, upper respiratory tract infection, hypertension, flushing, fatigue and asthenia are common (EMA 2009a). Overall, "the most commonly reported adverse events (occurring in 10% or more of patients) were headaches, upper respiratory tract infection, nasopharyngitis, and nausea. The adverse events most commonly resulting in clinical intervention were due to infection" (FDA 2007).

Adalimumab

The updated 2008 FDA label for adalimumab reports, "Serious infections, sepsis, tuberculosis and cases of opportunistic infections, including fatalities, have been reported with the use of TNF blocking agents including Humira® (adalimumab)" (FDA 2008a). "Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and septicaemia. Hospitalization or fatal outcomes associated with infections have been reported" (EMA 2009b). Furthermore, hepatitis B reactivation has been shown to be associated with adalimumab treatment (Health Canada 2006). The FDA reports, "As observed with other TNF blocking agents, tuberculosis associated with the administration of Humira® in clinical trials has been reported" (FDA 2008a).

In rare instances, adalimumab has been associated with, "new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease including multiple sclerosis" (EMA 2009b). Furthermore, "In the controlled portions of clinical trials of some TNF-blocking agents, including Humira, more cases of malignancies have been observed among patients receiving those TNF blockers compared to control patients" (FDA 2008a).

"Some of these hepatosplenic T-cell lymphomas have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for Crohn's disease". Thus, the risk of the development of hepatosplenic T-cell lymphoma cannot be excluded for patients treated with adalimumab (EMA 2009b). Though the causal relationship of hematological reactions and the use of adalimumab remain unclear as of 2008, the FDA label states, "Rare reports of pancytopenia including aplastic anemia have been reported with TNF blocking agents". Furthermore, the FDA reports "Treatment with Humira® (adalimumab) may result in the formation of autoantibodies and rarely in the development of a lupus-like syndrome" (FDA 2008a).

Anakinra

Anakinra leads to an increased rate of infections (2%) versus placebo (less than 1%). Following the EMA standard of classification of frequency of the occurrence of "undesirable effects" mentioned above, neutropenia and serious infection requiring hospitalizations were common (between 1/10 and 1/100) and headaches and

injection site reactions were very common occurring in 1/10 or more patients treated with anakinra (EMA 2004). "A... clinical trial sponsored by Amgen Inc. showed a higher incidence of serious infection and of neutropenia in anakinra and etanercept combination group than patients receiving Enbrel (etanercept) alone and higher than observed in previous trials where Kineret (anakinra) was used alone (EMA 2003), therefore, the use of etanercept and anakinra is not recommended as it leads to safety complications". Furthermore, the FDA reports in its most recent report on anakinra that "Hypersensitivity reactions associated with Kineret (anakinra) administration are rare" (FDA 2001). Moreover, the FDA reports the effects of anakinra on the hematologic conditions of patients stating that, "In placebo-controlled studies with Kineret® (anakinra), treatment was associated with small reductions in the mean values for total white blood count, platelets, and absolute neutrophil count (ANC), and a small increase in the mean eosinophil differential percentage" (FDA 2001). With regard to the development of malignancies for people treated with anakinra, trials show that, "among 5300 RA patients treated with Kineret (anakinra) clinical trials for a mean of 15 months (approximately 6400 patient years of treatment), lymphomas were observed for a rate of 0.12 cases per 100 patient years. This is 3.6 fold higher than the rate of lymphomas expected in the general population, based on the National Cancer Institutes Surveillance Epidemiology and End Results (SEER) database" (FDA 2001).

Etanercept

In the post-marketing reports of etanercept, "Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with Enbrel® (etanercept)" (FDA 2008c). Furthermore, "Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel® than with TNF-blocking monoclonal antibodies. Nonetheless, post-marketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel® (etanercept). Patients receiving Enbrel® should be monitored closely for signs and symptoms of active tuberculosis. The possibility of tuberculosis should be considered, especially in patients who have travelled to countries with a high prevalence of tuberculosis or had close contact with a person with active tuberculosis. All patients treated with Enbrel® should have a thorough history taken prior to initiating therapy" (FDA 2008c). This finding is also stated in an important health warning issued by Health Canada in 2006 (Health Canada 2006).

Furthermore, etanercept has been associated with the risk of histoplasmosis and other invasive fungal infections. Health Canada 2009 states, "...although no histoplasmosis infections were reported among 17,696 patients from the United States and Canada who were treated with Enbrel®, in 38 clinical trials and four cohort studies involving all authorized indications, post marketing cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel®." The FDA also outlines the risk of nervous system complications stating, "nervous system complications such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes have occurred in rare cases" (FDA 2008c).

Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with Enbrel® (etanercept) (FDA 2008c). The FDA reports on the risk of malignancies for patients on etanercept treatment, stating

"Patients have been observed in clinical trials with Enbrel® for over five years. Among 4462 rheumatoid arthritis patients treated with Enbrel® in clinical trials for a mean of 27 months (approximately 10,000 patient-years of therapy), lymphomas were observed for a rate of 0.09 cases per 100 patient-years. This is 3-fold higher than the rate of lymphomas expected in the general population based on the Surveillance, Epidemiology, and End Results Database. Rare reports of pancytopenia including aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel®" (FDA 2008c). The FDA also reports, "Treatment with Enbrel® may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome or autoimmune hepatitis which may resolve following withdrawal of Enbrel®" (FDA 2008c).

The use of etanercept has also been associated with the relapse of hepatitis B (Health Canada 2006).

Infliximab

In its recent revised report on infliximab, the EMA reports on the risk of infusion reactions and hypersensitivity, stating, "An infusion-related reaction was defined in clinical studies as any adverse event occurring during an infusion or within 1 to 2 hours after an infusion. In clinical studies, approximately 20% of infliximab-treated patients compared with approximately 10% of placebo-treated patients experienced an infusion-related effect. Approximately 3% of patients discontinued treatment due to infusion reactions" (EMA 2009a). Infliximab is also associated with the relapse of hepatitis B as reported by Health Canada in 2006 (Health Canada 2006). "Opportunistic infections have been reported in patients treated with infliximab, suggesting that host defence against infection is compromised. It should be noted that suppression of TNF-alpha may also mask symptoms of infection such as fever." There is also a possible association between infliximab and heptosplenix T-Cell lymphoma in pediatric and young adult patients with Crohn's disease (Health Canada 2006b).

"In a study designed to evaluate Remicade® (infliximab) in congestive heart failure (CHF), 150 patients with moderate to severe (NYHA class II-intravenous) CHF were treated with three infusions of Remicade 5 mg/kg, or placebo over six weeks. Higher incidences of mortality and hospitalization for worsening heart failure were seen in those patients treated with Remicade®, especially have treated with the higher dose of 10 mg/kg. At present 7 out of 101 patients treated with Remicade® have died compared to no deaths among 49 patients on placebo" (EMA 2001). In a May 2009 revision of the Remicade label, the FDA warns, "Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving TNF- blocking agents. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most commonly reported. Patients have frequently presented with disseminated rather than localized disease, and are often taking concomitant immunosuppressants such as methotrexate or corticosteroids with Remicade®" (FDA 2009). In an investigation of neurological events, EMA reports "Infliximab and other agents that inhibit TNF-alpha have been associated in rare cases with optic neuritis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis,

and peripheral demyelinating disorders, including Guillain-Barré syndrome" (EMA 2009a).

The increased risk of developing lymphoma is also reported. An FDA archived report from October 2004 on infliximab safety alerts notifies that

"During the controlled portions of REMICADE trials in patients with moderately to severely active rheumatoid arthritis and Crohn's disease, 1 patient developed lymphoma among 1389 REMICADE-treated patients versus 0 among 483 control patients (median duration of follow-up 1.1 years)." "In the controlled and open-label portions of these clinical trials of REMICADE, 3 patients developed lymphomas (1 patient with rheumatoid arthritis and 2 patients with Crohn's disease) among 2410 patients (median duration of follow-up 1.1 years)." "As a result of this evaluation, a warning concerning malignancy has been added to the labelling for all therapeutic agents that block TNF." (FDA 2004).

Another evidence of infliximab associated with lymphoma states that "In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared with control patients... In the combined clinical trial population for rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and plaque psoriasis, lymphomas were observed for a rate of 0.10 cases per 100 patient-years of follow-up, which is approximately 4-fold higher than expected in the general population. Patients with Crohn's disease, rheumatoid arthritis or plaque psoriasis, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy" (EMA 2009a).

TNF-blockers as a group

In 2008, the FDA issued a safety alert regarding anti-TNF biologics, which stated that the risk of pulmonary and disseminated histoplasmosis, coccidioidomycosis, blastomycosis and other opportunistic infections were not consistently recognized in patients taking tumor necrosis factor-alpha blockers (TNF blockers including etanercept, adalimumab, infliximab or certolizumab), which resulted in the delay of proper antifungal treatment and at times led to death (FDA 2008b). The FDA reviewed 240 reports of histoplasmosis, an infection caused by the fungus *Histoplasma capsulatum*, in patients being treated with Enbrel, Humira, or Remicade. The majority of the reports involved people in the Ohio River and Mississippi River valleys (the fungus is commonly found in those areas). In at least 21 of the reports, histoplasmosis was initially not recognized by healthcare professionals, and antifungal treatment was delayed. Twelve of those patients died. The FDA recommended that for patients at risk of histoplasmosis and other invasive fungal infections, clinicians should consider empiric antifungal treatment until the pathogen(s) are identified.

Rituximab

While no reviews exist for rituximab in the EMA web site and Health Canada's reviews are outdated, the FDA provides its most recent safety information for Rituxan® (rituximab) from 2009. Rituxan was found to be associated with progressive multifocal leukoencephalopathy. FDA and Genetech notified, "A third case

of progressive multifocal leukoencephalopathy (PML) has been reported in a patient with rheumatoid arthritis treated with Rituxan." In view of this event, Genentech has advised physicians to have high index of suspicion for PML stated as "Physicians should consider PML in any patient being treated with Rituxan who presents with new onset neurologic manifestations. Consultation with a neurologist, brain MRI, and lumbar puncture should be considered as clinically indicated. In patients who develop PML, Rituxan should be discontinued." (FDA 2009a). Another event associated with Rituxan was notified in a FDA label from 2008. In this label, the possible safety complications of Rituxan® use included "tumor lysis syndrome which necessitates clinicians to administer prophylaxis and monitor patients renal function, hepatitis B reactivation with fulminant hepatitis, which can sometimes [be] fatal and the risk of progressive multifocal leukoencephalopathy" (Drugs 2006).

FDA and Genentech informed healthcare professionals of important emerging safety information about Rituxan®. "Two patients died after being treated with Rituxan® for systemic lupus erythematosus (SLE). Rituxan® is approved for the above indication and is prescribed off-label for other serious diseases and conditions such as SLE. The cause of death was progressive multifocal leukoencephalopathy, a viral infection of the brain (that is caused by reactivated JC virus which is present in about 80% of adults" (FDA 2006). Further risks include "cardiac arrhythmias and angina", which can be life threatening, and "bowel obstruction and perforation" (FDA 2008c). Health Canada 2006 also provided warnings of bowel obstruction and perforation, "Reports of abdominal pain, bowel obstruction, and perforation, in some cases leading to death, have been observed in patients receiving Rituxan®. The majority of reports, including all deaths, have occurred in patients receiving Rituxan in combination with chemotherapy for NHL ((non-Hodgkin's Lymphoma)) indication. A causal relationship has not been established".

Tofacitinib

The FDA issued a Risk Evaluation and Mitigation Strategy (REMS) document, a modification in February 2015 to the original 11/2012 document, highlighting the known concerns with tofacitinib, instructing the pharmaceutical company to send information to physicians and pharmacists regarding the risk of serious infections, malignancies, decreases in peripheral lymphocyte counts, neutrophil counts, hemoglobin, and increases in lipid parameters in peripheral blood with XELJANZ (tofacitinib) (FDA 2015).

DISCUSSION

Summary of main results

Monotherapy versus placebo

ACR50

Biologic monotherapy was associated with a clinically meaningful and statistically significant improvement in ACR50 versus placebo, RR 4.68 (95% CI, 2.93 to 7.48); absolute benefit 23% (95% CI, 18% to 29%), NNTB = 5 (95% CI, 3 to 8), based on direct evidence of moderate quality (downgraded for inconsistency).

NMA estimates for TNF biologic monotherapy and non-TNF biologic monotherapy groups showed similar results to the direct

estimates for active comparators and placebo comparisons with slightly wider confidence intervals, and all were downgraded to moderate-quality evidence for indirectness. Specifically, in direct comparisons, TNF and non-TNF monotherapy were associated with RR of 4.13 (95% CI, 2.51 to 6.80) and 8.23 (95% CI, 3.44 to 19.65) of ACR50 versus placebo; respective RRs from NMA were 4.40 (95% CrI, 3.02 to 6.68) and 8.20 (95% CrI, 4.06 to 14.89), all based on moderate-quality evidence. In direct comparison with moderate-quality evidence downgraded for imprecision, tofacitinib monotherapy showed clinically meaningful and statistically significant improvement in ACR50 versus placebo with RR of 4.09 (95% CI, 1.94 to 8.61) and similar NMA estimate of 4.63 (95% CrI, 2.60 to 8.83) with moderate-quality evidence, downgraded for indirectness.

Most HD biologic monotherapy regimens were often more effective in achieving ACR50 compared to SD biologic monotherapy (same or other biologics).

With respect to the type of biologics, TNF biologics did not differ from non-TNF biologics or tofacitinib in the ACR50 rates.

Function assessed by Health Assessment Questionnaire (HAQ)

Biologic monotherapy was associated with clinically meaningful and statistically significant improvement in function as measured by HAQ (0 to 3 scale, higher = worse function) score improvement versus placebo, with a MD of -0.32 (95% CI, -0.42 to -0.23); absolute benefit of -10.7% (95% CI, -14% to -7.7%), NNTB = 4 (95% CI, 3 to 5), based on moderate-quality direct evidence (downgraded for inconsistency).

Direct and NMA estimates for TNF biologic monotherapy and tofacitinib monotherapy showed a clinically meaningful and similar statistically significant MD versus placebo, based on moderate-quality evidence. Anakinra monotherapy showed clinically meaningful and statistically significant improvement in direct comparison (MD -0.23 (95% CI, -0.33 to -0.14)) , based on moderate-quality evidence, but this effect was not significant in NMA based on low-quality evidence.

Remission

Biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of participants achieving remission in RA versus placebo ((disease activity score (DAS) < 1.6 or DAS28 < 2.6) with RR 1.12 (95% CI, 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%); NNTB = 10 (95% CI, 8 to 21), based on moderate-quality direct evidence (downgraded for imprecision).

We did not perform NMA analysis versus placebo since there was only one study with a placebo comparator.

Radiographic Progression

No data were available for radiographic progression for monotherapy vs. placebo.

Withdrawals due to adverse events (WdAE)

Results for withdrawals due to AE were inconclusive when compared to placebo, with wide confidence intervals encompassing the null effect and evidence of an important

increase, based on low-quality direct evidence (downgraded for imprecision and inconsistency).

Direct and NMA estimates for TNF biologic monotherapy versus placebo showed a clinically meaningful and statistically significant result, with RR 2.02 (95% CI, 1.08 to 3.78) for direct comparison and RR 2.09 (95% CrI, 1.14 to 4.04) for NMA, both with an absolute difference of 3%. Non-TNF biologic monotherapy (versus placebo), anakinra monotherapy (versus placebo), and tofacitinib monotherapy (versus placebo) comparisons were inconclusive and downgraded to low quality for both imprecision and indirectness.

Serious adverse events (SAE)

Results for SAE were inconclusive, with wide confidence intervals that included the null effect and the evidence of an important increase when compared to placebo, based on low-quality direct evidence (downgraded for serious imprecision).

The NMA estimates for TNF biologic monotherapy (versus placebo) and tofacitinib monotherapy (versus placebo) also included the null effect and the evidence of an important increase, downgraded to low quality, for concerns about imprecision and indirectness.

Cancer

No data were available for cancer for monotherapy vs. placebo.

Monotherapy versus active comparator (MTX/other DMARDs)

ACR50

Biologic monotherapy was associated with a clinically meaningful and statistically significant improvement in ACR50 when compared to active comparator (MTX/other DMARDs), RR 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26).

In direct comparisons, TNF biologic monotherapy showed a statistically significant improvement with RR of 1.43 (95% CI, 1.06 to 1.93) versus MTX/other DMARDs; but non-TNF monotherapy was not significant (RR: 1.57 (95% CI, 0.67 to 3.68)). Both respective RRs from NMA did show a clinically meaningful and statistically significant result; 1.75 (95% CrI, 1.30 to 2.31) for TNF biologic monotherapy and 2.24 (95% CrI 1.55 to 3.10) for non-TNF biologic monotherapy, all based on moderate-quality evidence.

Function assessed by HAQ

Biologic monotherapy was associated with clinically meaningful and statistically significant improvement in function as measured by HAQ (0 to 3 scale, higher = worse function) score improvement versus active comparator (MTX/other DMARDs) with a MD of -0.27 (95% CI, -0.40 to -0.14); absolute benefit of -9% (95% CI, -13.3% to -4.7%), NNTB = 2 (95% CI, 2 to 4), based on moderate-quality evidence.

Non-TNF biologic monotherapy showed a clinically meaningful and statistically significant MD for direct and NMA estimates versus the active comparator group (MTX/other DMARDs), where as TNF biologic monotherapy did not show a clinically meaningful and statistically significant MD for direct and NMA estimates versus the active comparator. All group analyses were downgraded to moderate- or low-quality evidence.

We noted no differences in HAQ scores by the type of biologic (TNF versus non-TNF biologics) or receptor versus antibody TNF-biologic.

Remission

There were no clinically meaningful and statistically significant direct estimates for biologic monotherapy versus the active comparator group.

NMA estimates showed a significant difference versus active comparator for TNF biologic monotherapy, absolute improvement 7% (95% CI, 2% to 14%) and non-TNF biologic monotherapy, absolute improvement 19% (95% CrI, 7% to 36%). These were downgraded to moderate-quality for concerns about indirectness.

Radiographic Progression

Based on moderate-quality direct evidence (downgraded for inconsistency) from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD -4.34 (95% CI, -7.56 to -1.12), though the absolute reduction was small, -0.97% (95% CI -1.69% to -0.25%). We are not sure of the clinical relevance of this reduction.

Withdrawals due to adverse events

Results for withdrawals due to AEs were inconclusive when compared to the active comparator, with wide confidence intervals encompassing the null effect and evidence of an important increase, based on low-quality direct evidence (downgraded to low level for imprecision and inconsistency).

The NMA estimates for TNF biologic monotherapy (versus active comparator) and non-TNF biologic monotherapy (versus active comparator) also included null effect and the evidence of an important increase, both downgraded to low quality for both imprecision and indirectness.

Serious adverse events

Results for SAEs were inconclusive, with wide confidence intervals that included the null effect and the evidence of an important increase when compared to the active comparator, based on low-quality direct evidence (downgraded for serious imprecision).

The NMA estimates for TNF biologic monotherapy (versus active comparator) and non-TNF biologic monotherapy (versus active comparator) also included null effect and the evidence of an important increase, downgraded to low and very low quality respectively, for concerns about imprecision and indirectness.

Cancer

Based on low-quality direct evidence (downgraded for serious imprecision), results for all cancer comparisons were inconclusive, with wide confidence intervals.

With respect to the type of biologics, TNF biologics did not differ from non-TNF biologics in the risk of cancer. Also, the odds of cancer did not differ between SD, HD and LD biologic monotherapy.

Overall completeness and applicability of evidence

This review is up to date to 2015. In addition to the traditional meta-analysis showing direct comparisons of biologic versus placebo

and biologic versus active comparator, our review provides NMA estimates for various categories and doses of biologics compared to each other. The NMA comparisons incorporate both direct and indirect comparisons of biologics/tofacitinib to each other and to MTX/other traditional DMARDs. Since trials with direct comparisons of biologics to each other are few, this study provides evidence comparing biologic monotherapy to placebo and to MTX/other traditional DMARDs.

Quality of the evidence

For this update, the quality of included trials was reasonably good. We noted poor reporting of the conduct of the included trials, with only 37% of included trials reporting adequate sequence generation and 37% of trials judged to be at low risk for allocation concealment. Selective reporting bias could not be assessed since for several (89%) trials, as we could not find published protocols.

The overall quality of the evidence for most outcomes was assessed using GRADE as per the recommendation from Cochrane (Schünemann 2011) and was downgraded to moderate due to limitations in the study designs of the included studies, inconsistency of effect or indirectness, with few head-to-head comparisons. In some cases, such as withdrawals due to adverse events and cancer, the level of evidence was low (very low in one instance). For serious adverse events, the level of evidence was moderate for direct comparison and low for NMA. The quality of evidence reflects the extent to which we are confident that an estimate of the effect is correct. The outcomes for this review were selected following the recommendations of the Outcome Measures in Rheumatology (OMERACT) group, as being relevant to people with RA.

Potential biases in the overview process

Our review has several limitations, as noted below.

1. Lack of reporting of many important outcomes from RCTs (cancer) and the lack of measurement for some outcome (radiographic scores, etc.) limited our ability to analyze them in detail.
2. Our NMA combines the available direct and indirect evidence, including the few head-to-head comparisons of benefit and harms (e.g. Gabay 2013a; Schiff 2008; Weinblatt 2013a etc.) of various biologic monotherapy regimens or tofacitinib monotherapy in people with RA. In the absence of direct comparisons, our approach using NMA provides useful information and comparisons. However, most interpretations are likely based on indirect comparisons.
3. RCTs included in this review and NMA differed in socio-demographic characteristics, prior failed therapy, concomitant use of DMARDs, biologic dose, mean RA disease duration, and trial duration. To address this limitation, we analyzed data by previous DMARD/biologic history (MTX-naive, MTX/other DMARD-experienced, and biologic-experienced), in four separate reviews- this current review focused on the benefits and harms of biologic monotherapy in MTX/other DMARD-experienced population. We also carefully considered and analyzed data by dose (SD, HD, LD) and the type of biologic and also specified a priori and performed subgroup analyses by the duration of RA (early, established, late; might indicate disease severity/impact over time) and by trial duration (less than six

months, six to 12 months and more than 12 months), a surrogate of the duration of biologic exposure.

4. Subgroup analyses presented in this study are subject to type II error, that is, we likely missed some significant results, by chance, due to lower number of studies and patients. Therefore, these results must be interpreted with caution.
5. Some studies presented data on safety for all doses of the biologic together, not just the recommended dose and in some cases presented data for the entire study duration, including the open-label phase. This limited our ability to get the data for the randomized phase or by dose, and we were unable to use these data.
6. Some studies allowed continuation of DMARDs such as methotrexate in a proportion of the participants, but not all. As an example, 78% of patients in an abatacept study continued on methotrexate (Weinblatt 2006). Such studies make the placebo group heterogeneous compared to other studies, where participants are usually randomized to biologic versus placebo or biologic + placebo versus methotrexate + placebo .
7. There is also a possibility of type I error, due to multiple comparisons. Up to five differences per 100 comparisons may be due to chance. Due to limited data for most outcomes, short trial duration and rarity of harms outcomes, our main concern with most of these analyses is Type-II error, that is, missing an important difference due to small number of events, not Type-I error. In the main analyses, we likely missed some significant differences due to short trial duration and/or rarity of outcome leading to type II error. More trial data and data from observational studies would allow meaningful comparisons and increase our confidence in these findings.
8. Some odds ratios and relative risks may look slightly different from each other numerically, but not statistically. These can be challenging to interpret. One must be careful in interpreting these results and should focus on the 95% confidence interval to make a judgement of whether the result indicates a clinically meaningful increase in benefits or harms.

Agreements and disagreements with other studies or reviews

We performed a comprehensive NMA and systematic review, accounting for potential factors that differ between trials and trial arms such as prior DMARD/biologic exposure and concomitant MTX/other DMARD use. Therefore, direct comparison of results to most published NMAs is not possible, particularly those that have not stratified participants by these important characteristics. The use of Bayesian methods and the inclusion of several more studies than included in the previous reviews/overviews, explain some differences when compared to earlier studies, as expected. Additionally, our review includes nine biologics and tofacitinib, while most previous reviews have focused on anti-TNF biologics.

In a systematic review for European League Against Rheumatism (EULAR) guidelines for RA in 2010, biologic monotherapy was as effective as traditional DMARD therapy and was inferior to biologic + DMARD combination for both patient-reported outcomes and radiographic progression (Nam 2010). The systematic review included 51 full papers and 57 abstracts. One of these observations was confirmed in our systematic review, namely that biologic monotherapy was inferior to biologic + MTX/DMARD. In contrast to the previous systematic review, our findings for biologic

monotherapy were different for ACR50 and HAQ. We found that biologic monotherapy was associated with significantly higher ACR50 and improvement in function, but no difference in RA disease remission versus MTX/other DMARDs. Our study advances knowledge compared to this previous systematic review, by performing an NMA and providing additional analyses by dose and trial duration.

In a meta-analysis of 14 eligible studies of licensed-dose etanercept, adalimumab, and tocilizumab monotherapy, biologics were significantly better than placebo in improving ACR 20/50/70 outcomes, and biologic combination therapy was better than biologic monotherapy (Orme 2012). Similarly we found that biologic monotherapy was better than placebo for ACR50, functional improvement on HAQ and RA disease remission. Our study also adds to the current knowledge by showing that withdrawals due to adverse events and serious adverse events were not clinically meaningfully or statistically significantly different between biologics and placebo.

In a meta-analysis of RCTs of anti-TNF biologics for RA (Alonso-Ruiz 2008), compared to control treatment, the relative risk of achieving ACR50 for biologic monotherapy versus MTX was 1.3 (95% CI 1.1 to 1.5). We found that biologic monotherapy was more effective versus active comparator (MTX/other DMARDs) with RR of 1.54 (95% CI 1.14 to 2.08) and versus placebo, RR 4.68 (95% CI 2.93 to 7.48); however, as described above, when compared to MTX, biologic monotherapy in standard doses was similar in efficacy for ACR50 and HAQ improvement, but high-dose biologic was superior to MTX for both ACR50 and HAQ improvement.

In a systematic review of four biologics for RA, TNF-inhibitors were similar to each other in benefit, and seemed to be better than anakinra for ACR20, but not ACR50 (Gartlehner 2006), when all biologic arms were combined regardless of monotherapy or combination with DMARDs/MTX. Our study shows that for several outcomes, TNF inhibitor monotherapy was similar to non-TNF monotherapy regimens, thus extending the observation to a larger group of non-TNF biologics, now with far more data available.

Kristensen 2007 examined ACR50 in people with established RA after one year of therapy. Based on three trials, one each for etanercept, infliximab and adalimumab, they estimated the NNTB to be 8 (5 to 38) people for infliximab, 4 (3 to 6) for etanercept and 4 (3 to 6) for adalimumab. Our NNTB estimates for achieving ACR50 were very similar to this previous study ranging from 5 to 8.

In a meta-analysis of serious adverse events that combined all patient populations (MTX/DMARD-naïve, MTX/DMARD-failure) and biologic use (monotherapy and use with concomitant MTX/other DMARDs), biologics at recommended doses were not associated with any increase in the risk of serious adverse events (Leombruno 2008). Fewer trials were available previously as compared to our study. In our study, we had a similar finding for both comparison of biologic to placebo and biologic to MTX/other DMARDs, based on evidence that was low quality due to imprecision and indirectness or due to serious imprecision.

Several meta-analyses could not be compared to our study since they focused on biologic combination therapy with MTX/other DMARDs or discontinuation rates (Desai 2012), but not biologic monotherapy; or included only early RA trials with no prior failure of MTX/other DMARDs (Thompson 2011). Other systematic reviews

and meta-analyses addressed patient populations different than those in the current review, namely: Lee 2008 focused on comparison of biologic + MTX versus MTX; monotherapy was not analyzed separately than biologic + DMARD/MTX (Bongartz 2006; Bongartz 2009; Nixon 2007). For example, Nixon 2007 performed indirect comparisons of TNF-inhibitors and anakinra for RA including RCTs with both standard approved doses as well as RCTs with non-standardized doses. Similar to our study, they found that ACR50 was similar between various TNF-biologics, with odds ratios (95% CI) as follows: infliximab/etanercept, 0.98 (0.45 to 1.93); adalimumab/etanercept, 0.94 (0.51 to 1.62); and adalimumab/infliximab, 0.96 (0.48 to 1.90). However, this previous study (Nixon 2007) did not distinguish between biologic monotherapy and biologic + MTX/other DMARD arms.

Donahue 2008 performed a qualitative synthesis (and where meta-analyses provided quantitative analysis) of RCTs, observational studies and meta-analyses of traditional and biologics for RA. They reported that TNFi biologic monotherapy was better than MTX for radiographic improvement, but did not differ in ACR50 rates. We confirmed the finding related to greater statistically significantly better improvement in radiographic progression with biologic monotherapy versus MTX/other DMARDs, but are not sure whether this is clinically meaningful or not. In addition, only one study provided these data. We also found that biologic monotherapy improved ACR50 and HAQ scores in a clinically meaningful and statistically significant way. However, we only included all RCTs to date, not observational data.

An NMA, Lopez-Olivo 2012, concluded that biologics were not associated with a higher risk of cancer compared to DMARDs or placebo. Our findings are similar to this earlier analysis. However, we caution that data in both the previous publication and our systematic review and NMA are based on few short-term RCTs. A much longer follow-up and larger evidence base is needed to make such conclusions, which could be achieved with large post-marketing surveillance studies or registry data, or both.

AUTHORS' CONCLUSIONS

Implications for practice

Biologic monotherapy improved RA signs and symptoms (ACR50), physical function and disease remission compared to placebo. There were no data on radiographic progression. We noted inconclusive results for withdrawals due to adverse events, serious adverse events and cancer with biologic monotherapy versus placebo, with wide confidence intervals.

Biologic monotherapy improved RA signs and symptoms (ACR50), physical function and radiographic progression compared to active comparator (MTX/other DMARDs). There were no significant differences in RA remission. We noted inconclusive results for withdrawals due to adverse events, serious adverse events and cancer with biologic monotherapy versus active comparator, with wide confidence intervals.

We provided both direct and NMA comparisons (includes indirect and direct comparison data) of data for biologic or tofacitinib monotherapy versus placebo or versus comparator (MTX/other DMARDs) in people with RA previously unsuccessfully treated with MTX/other DMARDs. We realize that our NMA relies a lot on indirect evidence, since direct comparator trials are few. The finding

of a great concordance between direct and NMA estimates, as shown in the SOF tables, confirms the validity of the approach using NMA for performing these analyses and their robustness. In the relative absence of direct head-to-head comparator trials of biologics in people with RA, patients and healthcare providers face a dilemma when selecting biologics or tofacitinib, for people whose treatment with traditional MTX or other DMARDs has failed. Our NMA now provides these comparisons and estimates for biologic or tofacitinib monotherapy in such people. Our NMA also advances evidence-based medicine by making several observations comparing biologic monotherapy in various doses (standard, low and high) to each other, as well to comparators, and by comparing various groups of drugs, namely TNF versus non-TNF versus tofacitinib versus anakinra. More comparative effectiveness data are needed to better understand comparative benefits and harms of biologic or tofacitinib monotherapy.

Implications for research

More RCTs of direct head-to-head comparisons of biologics and head-to-head comparisons of biologics and tofacitinib in people with RA are needed, which can add new knowledge regarding their comparative benefits and harms. There are

several clinical situations where we need these data, including various disease stages (early, established and late RA), functional limitation levels (mild, moderate and severe limitation) and prior treatments (traditional DMARD-failure versus MTX-failure versus both). Observational studies and registry data can provide additional invaluable insights into harms/side effects of biologics that are uncommon or rare and usually require large sample sizes and longer follow-up, such as cancer, neurological adverse events and others. Although such studies provide real world data, one must carefully consider channeling bias, confounding bias and other study design limitations in data interpretation from observational studies.

ACKNOWLEDGEMENTS

We acknowledge the valuable contributions of Dr. Buchbinder from the Monash University, Malvern, Australia and Dr. Suarez-Almazor and Ms. Lopez-Olivo from the MD Anderson cancer center, Houston, Texas, USA for their contributions to the original 2009 version of this review. We thank Shahrzad Noorbalooshi and Tyler Cullis (SN, TC) at the Boston University for contributing to abstract/title review and data abstraction; Tamara Rader of University of Ottawa for performing the searches.

REFERENCES

References to included reviews

Boyle 2015

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. *Ann Rheum Dis* 2015;**74**:1311-6.

Bresnihan 1998

Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 1998;**41**:2196-204.

Burmester 2014

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). *Ann Rheum Dis* 2014;**73**:69-74.

Combe 2009

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Ann Rheum Dis* 2009;**68**:1146-52.

Coombs 2010

Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis* 2010;**69**:413-6.

Dougados 2013

Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis* 2013;**72**:43-50.

Doyle 2013

Doyle MK, Rahman MU, Frederick B, Birbara CA, De Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. *Rheumatology (Oxford)* 2013;**52**:1214-9.

Edwards 2004

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004;**350**:2572-81.

Fleischmann 2012a

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med* 2012;**367**:495-507.

Fleischmann 2012b

Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum* 2012;**64**:617-29.

Gabay 2013b

Gabay C, Emery P, Van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013;**381**:1541-50.

Genovese 2002

Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum* 2002;**46**:1443-50.

Hobbs 2015

Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. *Springerplus* 2015;**4**:113.

Huizinga 2015

Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. *Ann Rheum Dis* 2015;**74**:35-43.

Jobanputra 2012

Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. *BMJ Open* 2012;**2**(6):e001395.

Johnsen 2006

Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. *J Rheumatol* 2006;**33**:659-64.

Jones 2010

Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe

rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis* 2010;**69**:88-96.

Kameda 2010

Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. *Mod Rheumatol* 2010;**20**:531-8.

Keystone 2009

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis* 2009;**68**:789-96.

Kremer 2009

Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. *Arthritis Rheum* 2009;**60**:1895-905.

Kremer 2010

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2010;**62**:917-28.

Kremer 2013

Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2013;**159**:253-61.

Maclsaac 2014

Maclsaac KD, Baumgartner R, Kang J, Loboda A, Peterfy C, DiCarlo J, et al. Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients. *PLoS One* 2014;**9**(12):e113937.

Maini 2006

Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum* 2006;**54**:2817-29.

Mathias 2000

Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. *Clin Ther* 2000;**22**:128-39.

Miyasaka 2008

Miyasaka N, Investigators CS. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Mod Rheumatol* 2008;**18**:252-62.

Moreland 1999

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 1999;**130**:478-86.

Moreland 2012

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis and Rheumatism* 2012;**64**(9):2824-35.

Nishimoto 2004

Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2004;**50**(6):1761-9.

Nishimoto 2007

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. *Annals of the Rheumatic Diseases* 2007;**66**(9):1162-7.

Ohta 2014

Ohta S, Tsuru T, Terao K, Mogi S, Suzuki M, Shono E, et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). *Journal of Clinical Pharmacology* 2014 Jan;**54**(1):109-19.

Pavelka 2009

Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. *Annals of the Rheumatic Diseases* 2009;**68**(8):1285-9.

Pope 2014

Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. *Ann Rheum Dis* 2014;**73**:2144-51.

Strand 2006

Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course

of rituximab: improvements in physical function over 2 years. *Rheumatology (Oxford)* 2006;**45**:1505-13.

Tada 2012

Tada M, Koike T, Okano T, Sugioka Y, Wakitani S, Fukushima K, et al. Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. *Rheumatology (Oxford)* 2012;**51**:2164-9.

Takeuchi 2013a

Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. *Mod Rheumatol* 2013;**23**:226-35.

Takeuchi 2013b

Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. *Mod Rheumatol* 2013;**23**:623-33.

Takeuchi 2013c

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. *Ann Rheum Dis* 2013;**72**:1488-95.

Van de Putte 2003

Van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, Van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Ann Rheum Dis* 2003;**62**:1168-77.

Van de Putte 2004

Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis* 2004;**63**:508-16.

Van der Heijde 2006

Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis and Rheumatism* 2006;**54**:1063-74.

Van der Heijde 2007

Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination

etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 2007;**56**:3928-39.

Van Riel 2006

Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. *Ann Rheum Dis* 2006;**65**:1478-83.

Van Riel 2008

Van Riel PL, Freundlich B, MacPeck D, Pedersen R, Foehl JR, Singh A. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. *Annals of the Rheumatic Diseases* 2008;**67**(8):1104-10.

Yamamoto 2014a

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. *Mod Rheumatol* 2014;**24**:715-24.

Østergaard 2015

Østergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, et al. MRI assessment of early response to certolizumabpegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. *Annals of the Rheumatic Diseases* 2015;**74**:1156-63. [DOI]

References to excluded reviews

Abe 2006

Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *The Journal of Rheumatology* 2006;**33**:37-44.

Axelsen 2015

Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, et al. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. *Annals of the Rheumatic Diseases* 2015;**74**:867-75.

Bae 2013

Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. *BMC Musculoskeletal Disorders* 2013;**14**:13.

Bathon 2000

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *New England Journal of Medicine* 2000;**343**(22):1586-93.

Bejarano 2008

Bejarano V, Quinn MA, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. *Arthritis and Rheumatism* 2008;**59**(10):1467-74.

Bingham 2015

Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). *Annals of the Rheumatic Diseases* 2015;**74**(5):818-22.

Bonafede 2015

Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. *Arthritis Care and Research (Hoboken)* 2015;**67**(12):1656-63.

Breedveld 2006

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis and Rheumatism* 2006;**54**:26-37.

Burmester 2013

Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet* 2013;**381**(9865):451-60.

Burmester 2015

Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Annals of the Rheumatic Diseases* 2015;**74**(6):1037-44.

Chen 2009

Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. *Journal of the Formosan Medical Association* 2009;**108**:310-9.

Cheng 2014

Cheng T, Wang M, Chen Z, Eisenberg RA, Zhang Y, Zou Y, et al. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese. *Chinese Medical Journal* 2014;**127**(16):2894-9.

Choy 2012

Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. *Rheumatology* 2012;**51**:1226-34.

Cohen 2002

Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatology* 2002;**46**:614-24.

Cohen 2003

Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. *Journal of Rheumatology* 2003;**30**(3):523-8.

Cohen 2004

Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. *Annals of the Rheumatic Diseases* 2004;**63**:1062-8.

Cohen 2006

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis and Rheumatism* 2006;**54**(9):2793-806.

Combe 2006

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. *Annals of the Rheumatic Diseases* 2006;**65**:1357-62.

Conaghan 2013

Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. *Annals of the Rheumatic Diseases* 2013;**72**:1287-94.

Conaghan 2014

Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, DiCarlo J, et al. The effects of tocilizumab on osteitis, synovitis and

erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. *Annals of the Rheumatic Diseases* 2014;**73**(5):810-6.

Detert 2013

Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. *Annals of the Rheumatic Diseases* 2013;**72**:844-50.

Dougados 2014

Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. *Annals of the Rheumatic Diseases* 2014;**73**(5):803-9.

Durez 2004

Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Arthritis and Rheumatism* 2004;**63**:1069-74.

Durez 2007

Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. *Arthritis and Rheumatism* 2007;**56**(12):3919-27.

Emery 2006

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis and Rheumatology* 2006;**54**:1390-400.

Emery 2008

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet* 2008;**372**:375-82.

Emery 2010

Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). *Annals of the Rheumatic Diseases* 2010;**69**:1629-35.

Emery 2014a

Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. *New England Journal of Medicine* 2014;**371**(19):1781-92.

Emery 2014b

Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. *Clinical Rheumatology* 2014;**33**(9):1239-46.

Eriksson 2015

Eriksson JK, Karlsson JA, Bratt J, Petersson IF, Van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. *Annals of the Rheumatic Disease* 2015;**74**(6):1094-101.

Fleischmann 2003

Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. *Arthritis and Rheumatology* 2003;**48**:927-34.

Fleischmann 2009

Fleischmann R, Vencovsky J, Van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Annals of the Rheumatic Diseases* 2009;**68**:805-11.

Fleischmann 2013

Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, et al. 2-year results from the Ample (Abatacept versus adalimumab comparison in biologic-naïve RA patients with background Methotrexate) trial: changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis. *Arthritis and Rheumatism* 2013;**65**(Suppl 10):S577.

Fleischmann 2014

Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A. 2-year results from the Ample (abatacept versus adalimumab comparison in biologic-naïve RA patients with background methotrexate) trial: changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis. *Arthritis and Rheumatism* 2014;**65**(Suppl 10):424.

Furst 2003

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of

Adalimumab in Rheumatoid Arthritis). *Journal of Rheumatology* 2003;**30**:2563-71.

Furst 2007

Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. *Annals of the Rheumatic Diseases* 2007;**66**(7):893-9.

Furst 2015

Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijckens K, et al. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. *Arthritis Care and Research (Hoboken)* 2015;**67**(2):151-60. [DOI]

Gashi 2014

Gashi AA, Rexhepi S, Berisha I, Kryeziu A, Ismaili J, Krasniqi G. Treatment of rheumatoid arthritis with biologic DMARDs (rituximab and etanercept). *Medical Archives* 2014;**68**(1):51-3.

Genovese 2004

Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. *Arthritis and Rheumatology* 2004;**50**:1412-9.

Genovese 2005

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *New England Journal of Medicine* 2005;**353**(11):1114-23.

Genovese 2008

Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis and Rheumatology* 2008;**58**:2968-80.

Genovese 2011

Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb non-inferiority study in patients with an inadequate response to methotrexate. *Arthritis and Rheumatology* 2011;**63**:2854-64.

Genovese 2014

Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. *Annals of the Rheumatic Diseases* 2014;**73**(9):1607-15.

Gherge 2014

Gherge AM, Ramiro S, Landewé R, Mihai C, Van der Heide D. THU0229 association of radiographic damage with physical function in patients with rheumatoid arthritis – results from the

RAPID1 Trial. *Annals of the Rheumatic Diseases* 2014;**73**(Suppl 2):261.

Goekoop-Ruiterman 2007

Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Annals of Internal Medicine* 2007;**146**:406-15.

Haraoui 2014

Haraoui B, Thorne JC, Keystone EC, Poulin-Costello M, Trottier E, Vieira A, et al. Clinical and radiographic outcomes with etanercept and etanercept and methotrexate in patients with rheumatoid arthritis: two-year results from the Canadian Methotrexate And Etanercept Outcome Study (CAMEO). *Arthritis and Rheumatism* 2014;**65**(Suppl 10):1464.

Heimans 2014

Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, Van Oosterhout M, Harbers JB, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. *Annals of the Rheumatic Diseases* 2014;**73**(7):1356-61.

Hørslev-Petersen 2014

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. *Annals of the Rheumatic Diseases* 2014;**73**(4):654-61.

Iannone 2014

Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. *Journal of Rheumatology* 2014;**41**(2):286-92.

Kaine 2011

Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIb ALLOW study). *Annals of the Rheumatic Diseases* 2012;**71**:38-44.

Kameda 2011

Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. *Journal of Rheumatology* 2011;**38**(8):1585-92.

Kavanaugh 2013

Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and

remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. *Annals of the Rheumatic Diseases* 2013;**72**(1):64-71.

Kavanaugh 2014

Kavanaugh A, Mease PJ, Strand V, Purcaru O, Curtis JR. Effect of certolizumab pegol on workplace and household productivity in US patients with rheumatoid arthritis with or without prior anti-tumor necrosis factor exposure: results from the predict study. *Annals of the Rheumatic Diseases* 2014;**73**(Suppl 2):927-8.

Kay 2008

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. *Arthritis and Rheumatism* 2008;**58**(4):964-75.

Kennedy 2014

Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). *Arthritis Research and Therapy* 2014;**16**(5):467.

Keystone 2004a

Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum* 2004;**50**(5):1400-11.

Keystone 2004b

Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatology* 2004;**50**:353-63.

Keystone 2008

Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis and Rheumatism* 2008;**59**(6):785-93.

Keystone 2014

Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. *Journal of Rheumatology* 2014;**41**(2):216-26.

Kim 2007

Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab

administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. *APLAR Journal of Rheumatology* 2007;**10**:9-16.

Kim 2012

Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. *International Journal of Rheumatic Diseases* 2012;**15**(2):188-96.

Kim 2013

Kim J, Ryu H, Yoo DH, Park SH, Song GG, Park W, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. *Journal of Korean Medical Science* 2013;**28**:1716-22.

Kivitz 2014

Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. *Arthritis Care and Research* 2014;**66**:1653-61.

Koroleva 2014a

Koroleva MV, Raskina TA. Effect of rituximab therapy on life quality with rheumatoid arthritis patients. *Osteoporosis International* 2014;**25**:S365-6.

Koroleva 2014b

Koroleva MV, Raskina TA. The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients. *Osteoporosis International* 2014;**25**:S374.

Kremer 2003

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. *New England Journal of Medicine* 2003;**349**:1907-15.

Kremer 2005

Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. *Arthritis and Rheumatology* 2005;**52**:2263-71.

Kremer 2006

Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. *Annals of Internal Medicine* 2006;**144**:865-76.

Kremer 2011

Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis and Rheumatology* 2011;**63**(3):609-21.

Kremer 2012

Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. *Arthritis and Rheumatology* 2012;**64**:970-81.

Kremer 2015

Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. *Arthritis Research & Therapy* 2015;**17**(95):1-11.

Lan 2004

Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. *Journal of the Formosan Medical Association* 2004;**103**:618-23.

Landewé 2015

Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, Van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. *Arthritis Research and Therapy* 2015;**17**:133.

Lipsky 2000

Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. *N Engl J Med* 2000;**343**(22):1594-602.

Lisbona 2008

Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. *Journal of Rheumatology* 2008;**35**(3):394-7.

Lisbona 2010

Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. *Annals of the Rheumatic Diseases* 2010;**69**:1117-22.

Machado 2014

Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. *Journal of Clinical Rheumatology* 2014;**20**:25-33.

Maini 1999

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 1999;**354**(9194):1932-9.

Manders 2015

Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. *Arthritis Research and Therapy* 2015;**17**(1):134.

Mathias 2000a

Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. *Clinical Therapeutics* 2000;**22**(1):128-39.

McInnes 2015

McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Annals of the Rheumatic Diseases* 2015;**74**(4):694-702.

Moreland 2002

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. *Arthritis and Rheumatism* 2002;**46**(6):1470-9.

Nam 2014a

Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study). *Annals of the Rheumatic Diseases* 2014;**73**(1):75-85.

Nam 2014b

Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. *Annals of the Rheumatic Diseases* 2014;**73**(6):1027-36.

Navarro 2014

Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, et al. The 'Switch' study protocol: a randomised controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. *BMC Musculoskeletal Disorders* 2014;**15**:452.

Nishimoto 2009

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Modern Rheumatology* 2009;**19**:12-9.

O'Dell 2013

O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. *New England Journal of Medicine* 2013;**369**:307-18.

Oakley 2014

Oakley S, Esmaili N, Major G, Mathers D, Ratnarajah S, Van der Kallen J, et al. A randomised controlled trial evaluating the effect of humira upon endothelial function in ACPA positive rheumatoid arthritis: an interim analysis. *Arthritis and Rheumatology* 2014;**66**:S211.

Pavelka 2013

Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. *Clinical Rheumatology* 2013;**32**(9):1275-81.

Quinn 2005

Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2005;**52**(1):27-35.

Rantalaiho 2014

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppanen O, Mottonen T, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. *Annals of the Rheumatic Diseases* 2014;**73**(11):1954-61.

Rau 2004

Rau R, Simianer S, Van Riel PL, Van de Putte LB, Krüger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. *Scandinavian Journal of Rheumatology* 2004;**33**(3):145-53.

Rigby 2011

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid

arthritis previously untreated with methotrexate. *Arthritis Care and Research (Hoboken)* 2011;**63**(5):711-20.

Rubbert-Roth 2010

Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). *Rheumatology (Oxford)* 2010;**49**(9):1683-93.

Schiff 2004

Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. *Arthritis and Rheumatism* 2004;**50**(6):1752-60.

Smolen 2008

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;**371**:987-97.

Smolen 2009

Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijckens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Annals of the Rheumatic Diseases* 2009;**68**:797-804.

Smolen 2013a

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. *Lancet* 2013;**381**:918-29.

Smolen 2013b

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. *Lancet* 2013;**381**:918-29.

Smolen 2014b

Smolen JS, Emery P, Fleischmann R, Van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. *Lancet* 2014;**383**(9914):321-32.

Smolen 2015

Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. *Annals of the Rheumatic Diseases* 2015;**74**:843-50.

Sonomoto 2014

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. *Rheumatology (Oxford)* 2014;**53**(5):914-8.

Soubrier 2009

Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology* 2009;**49**:1429-34.

St Clair 2004

St Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis and Rheumatism* 2004;**50**(11):3432-43.

Strand 2012

Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. *Journal of Rheumatology* 2012;**39**(1):63-72.

Tak 2011

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, Van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. *Annals of the Rheumatic Diseases* 2011;**71**(3):351-7.

Tak 2012

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, Van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. *Annals of the Rheumatic Diseases* 2012;**71**:351-7.

Takeuchi 2014

Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. *Annals of the Rheumatic Diseases* 2014;**73**(3):536-43.

Tam 2012

Tam L-S, Shang Q, Li EK, Wang S, Li R-J, Lee K-L, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis - a randomized trial. *The Journal of Rheumatology* 2012;**39**:2267-75.

Tanaka 2011

Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis Care and Research (Hoboken)* 2011;**63**(8):1150-8.

Tanaka 2012

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. *Annals of the Rheumatic Diseases* 2012;**71**:817-24.

Taylor 2004

Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. *Arthritis and Rheumatism* 2004;**50**(4):1107-16.

Taylor 2006

Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis and Rheumatism* 2006;**54**(1):47-53.

Van der Heijde 2013

Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis and Rheumatism* 2013;**65**(3):559-70.

Van der Kooij 2009

Van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Van Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2009;**68**(7):1153-8.

Van Vollenhoven 2009

Van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet* 2009;**374**(9688):459-66.

Van Vollenhoven 2012a

Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *New England Journal of Medicine* 2012;**367**:508-19.

Van Vollenhoven 2012b

Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet* 2012;**379**:1712-20.

Vital 2015

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. *Annals of the Rheumatic Diseases* 2015;**74**:1195-201.

Weinblatt 1999

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *New England Journal of Medicine* 1999;**340**:253-9.

Weinblatt 2003

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis and Rheumatology* 2003;**48**:35-45.

Weinblatt 2006

Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. *Arthritis and Rheumatology* 2006;**54**:2807-16.

Weinblatt 2007

Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. *Annals of the Rheumatic Diseases* 2007;**66**:228-34.

Weinblatt 2008

Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. *Arthritis and Rheumatism* 2008;**58**(7):1921-30.

Weinblatt 2012

Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. *Rheumatology* 2012;**51**:2204-14.

Weinblatt 2013a

Weinblatt ME, Schiff M, Valente R, Van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis Rheum* 2013;**65**(1):28-38.

Weinblatt 2013b

Weinblatt ME, Schiff M, Valente R, Van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis and Rheumatism* 2013;**65**(1):28-38.

Weinblatt 2014

Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. *Annals of the Rheumatic Diseases* 2014;**73**(12):2152-9.

Weisman 2003

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clinical Therapeutics* 2003;**25**:1700-21.

Weisman 2007

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. *Rheumatology* 2007;**46**:1122-5.

Westhovens 2006

Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis and Rheumatology* 2006;**54**:1075-86.

Westhovens 2009

Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. *Annals of the Rheumatic Diseases* 2009;**68**:1870-7.

Westhovens 2014

Westhovens R, Weinblatt ME, Han C, Kim L, Mack M, Lu J, et al. Health-related quality of life of patients with rheumatoid arthritis achieving DAS28 remission, improvement in physical function and no radiographic progression. *Annals of the Rheumatic Diseases* 2014;**73**:479-80.

Yamamoto 2014b

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. *Modern Rheumatology* 2014;**24**(4):552-60.

Yamanaka 2014

Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. *Rheumatology (Oxford)* 2014;**53**(5):904-13.

Yazici 2012

Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. *Annals of the Rheumatic Diseases* 2012;**71**:198-205.

Zhang 2006

Zhang F, Hou Y, Huang F, Wu D, Bao C, Ni L, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. *APLAR Journal of Rheumatology* 2006;**9**:127-30.

Additional references
Aletaha 2010

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;**62**(9):2569-81.

Alonso-Ruiz 2008

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety. *BMC Musculoskeletal Disorders* 2008;**9**:52.

Arnett 1988

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis and Rheumatism* 1988;**31**(3):315-24.

Barlow 1999

Barlow JH, Cullen LA, Rowe IF. Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration). *Patient Education and Counseling* 1999;**38**:195-203.

Becker 2011

Becker LA, Oxman AD. Chapter 22: Overviews of Reviews. In: Higgins JP, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Blumenauer 2002

Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid

arthritis. *Cochrane Database of Systematic Reviews* 2002, Issue 3. [DOI: [10.1002/14651858.CD003785](https://doi.org/10.1002/14651858.CD003785)]

Boers 2001

Boers M. Treatment of early disease. *Rheumatic Diseases Clinics of North America* 2001;**27**:405-14, x.

Bongartz 2006

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006;**295**(19):2275-85.

Bongartz 2009

Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Annals of the Rheumatic Diseases* 2009;**68**(7):1177-83.

Bradburn 2007

Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Statistics in Medicine* 2007;**26**:53-77.

Brennan 2008

Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. *Journal of Clinical Investigation* 2008;**118**(11):3537-45.

Cash 1994

Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. *New England Journal of Medicine* 1994;**330**(19):1368-75.

Cates 2009 [Computer program]

Dr Chris Cates' EBM web site. Available from www.Nntonline.Net/visualrx/. Visual Rx NNT Calculator version 3. Dr Chris Cates' EBM web site. Available from www.Nntonline.Net/visualrx/, Accessed 13 February 2009.

Choy 2001

Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *New England Journal of Medicine* 2001;**344**(12):907-16.

Chung 2006

Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. *Annals of the Rheumatic Diseases* 2006;**65**(12):1602-7.

Connell 2006

Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. *Best Practice and Research Clinical Rheumatology* 2006;**20**(5):865-78.

Cope 2008

Cope AP. T cells in rheumatoid arthritis. *Arthritis Research and Therapy* 2008;**10** Suppl 1:S1.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

DerSimonian 2007

DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemporary Clinical Trials* 2007;**28**(2):105-14.

Desai 2012

Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. *Ann Pharmacother* 2012;**46**(11):1491-505.

Dias 2011

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 1-39 (2011). Available at www.nicedsu.org.uk.

Donahue 2008

Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. *Annals of Internal Medicine* 2008;**148**(2):124-34.

Drugs 2006

Drug Information Online. Drugs.com. FDA Approves First Rheumatoid Arthritis Indication for Rituxan. www.drugs.com/news/fda-approves-first-rheumatoid-arthritis-indication-rituxan-1745.html 03/01/2006.

EMA 2001

European Medicines Agency (EMA). EMA Public Statement on Infliximab (Remicade): Increased incidence of mortality and hospitalization for worsening Congestive Heart Failure. www.emea.europa.eu/pdfs/human/press/pus/325701en.pdf.

EMA 2003

European Medicines Agency (EMA). EMA public statement: Increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept). www.emea.europa.eu/humandocs/PDFs/EPAR/kineret/3163102en.pdf.

EMA 2004

European Medicines Agency (EMA). EPARs for authorized medicinal products for human use: Anakinra: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/kineret/kineret.htm Revision 11, published 27/01/09.

EMA 2009a

European Medicines Agency (EMA). Remicade (infliximab). www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-en.pdf.

EMA 2009b

European Medicines Agency (EMA). EPARs for authorized medicinal products for human use: Humira: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm Revision 15, Published 11/05/09.

FDA 2004

Food, Drug Administration. Safety information. October 2004. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166515.pdf.

FDA 1998

Food, Drug Administration. Etanercept Product Approval Information- Licensing Action 12/2/1998. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm 1998.

FDA 1999

Food, Drug Administration. Remicade® (infliximab) for IV Injection. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107722.pdf 1999.

FDA 2001

Food, Drug Administration. Kineret® (anakinra) Physician packet insert: Kineret® (anakinra) prescribing information. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080650.htm 2001.

FDA 2002

Food, Drug Administration. Package Insert. HUMIRA® (adalimumab). Abbott Laboratories. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm 2002.

FDA 2005

Food, Drug Administration. Patient Information Sheet. Abatacept (marketed as Orencia®). www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/FastTrackApprovalReports/ucm082380.htm 2005.

FDA 2006

Food, Drug Administration. Rituxan® (rituximab). www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150747.htm.

FDA 2007

Food, Drug Administration. Drug details: Orenzia. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

FDA 2008a

Food, Drug Administration. Humira (adalimumab): Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf.

FDA 2008b

Food, Drug Administration. FDA: Manufacturers of TNF-blocker drugs must highlight risk of fungal infections. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116942.htm.

FDA 2008c

Food, Drug Administration. Medication Guide: Enbrel® (etanercept). www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf.

FDA 2008d

Food, Drug Administration. CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008. CDER report. Application number:125160. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM081805.pdf December 31, 2008.

FDA 2009

Food, Drug Administration. Remicade® (infliximab) for IV Injection. www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf.

FDA 2009a

Food, Drug Administration. Safety information. Rituxan (Ritiximab). www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM187792.pdf 2009.

FDA 2010

Food, Drug Administration. CDER report. Application number: L 125276/0.0, December 31, 2010. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals. As of December 31, 2010. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM242677.pdf 2010.

FDA 2012

Food, Drug Administration. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM342733.pdf 2012.

FDA 2015

Food, Drug Administration. Risk Evaluation and Mitigation Strategy (REMS). NDA 203,214 XELJANZ® (TOFACITINIB). www.fda.gov/downloads/Drugs/DrugSafety/

PostmarketDrugSafetyInformationforPatientsandProviders/UCM330290.pdf.

Felson 1995

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis and Rheumatism* 1995;**38**(6):727-35.

Finckh 2006

Finckh A, Liang MH, Van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. *Arthritis and Rheumatism* 2006;**55**(6):86-72.

Fransen 2005

Fransen J, Van Riel PL. The Disease Activity Score and the EULAR response criteria. *Clinical and Experimental Rheumatology* 2005;**23**(5 Suppl 39):S93-9.

Fries 1980

Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis and Rheumatism* 1980;**23**(2):137-45.

Furst 2008

Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of the Rheumatic Diseases* 2008;**67** Suppl 3(Suppl 3):iii2-25.

Furst 2010

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2009. *Annals of the rheumatic diseases* 2010;**69**:Suppl 1:i2-29.

Furst 2012

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011. *Annals of the rheumatic diseases* 2012;**71**(Suppl 2):i2-45.

Gabay 2013a

Gabay C, Emery P, Van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013;**381**(9877):1541-50.

Gartlehner 2006

Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. *The Journal of Rheumatology* 2006;**33**(12):2398-408.

Ghogomu 2014

Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV, et al. Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and meta-analyses. *The Journal of Rheumatology* 2014;**41**(2):194-205.

Ghoreschi 2009

Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. *Immunol Rev* 2009;**228**(1):273-87.

Guyatt 2008

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians?. *BMJ* May 3, 2008;**336**(7651):995-8.

Health Canada 2006

Health Canada. Important Safety Information on anti-TNF α Therapy: Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) - for health professionals. www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2006/anti_tnf_therap_hpc-cps-eng.php.

Health Canada 2006b

Health Canada. Possible association of Remicade (infliximab) with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn's disease - for health professionals. www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2006/remicade_3_hpc-cps-eng.php.

Health Canada 2009

Health Canada. Association of Enbrel (etanercept) with histoplasmosis and other invasive fungal infections - for health professionals. www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2009/enbrel_hpc-cps-eng.php.

Higgins 2002

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**:1539-58.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Ioannidis 2004

Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Annals of Internal Medicine* 2004;**141**(10):781-8.

Kristensen 2011

Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. *Scandinavian Journal of Rheumatology* 2011;**40**(1):1-7.

Kristensen 2007

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to

treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. *Scandinavian Journal of Rheumatology* 2007;**36**:411-7.

Kvien 2004

Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22**(2 Suppl 1):1-12.

Kvien 2005

Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scandinavian Journal of Rheumatology* 2005;**34**(5):333-41.

Larsen 1977

Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. *Acta Radiologica: Diagnosis (Stockholm)* 1977;**4**:481-91.

Lee 2001

Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet* 2001;**358**(9285):903-11.

Lee 2008

Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. *Rheumatology International* 2008;**28**(6):553-9.

Leombruno 2008

Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. *Ann Rheum Dis* 2009;**68**(7):1136-45.

Lethaby 2013

Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2013, Issue 5. [DOI: [10.1002/14651858.CD004525.pub2](https://doi.org/10.1002/14651858.CD004525.pub2)]

Liberati 2009

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Medicine* 2009;**6**:e1000100.

Lopez-Olivo 2012

Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *JAMA* 2012;**308**(9):898-908.

Lopez-Olivo 2013

Lopez-Olivo A, Bavineni M, Suarez-Almazor ME. Tofacitinib for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2013, Issue 4. [DOI: [10.1002/14651858.CD010476](https://doi.org/10.1002/14651858.CD010476)]

Lopez-Olivo 2015

Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2015, Issue 1. [DOI: [10.1002/14651858.CD007356.pub2](https://doi.org/10.1002/14651858.CD007356.pub2)]

Lubeck 2004

Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22**(2 Suppl 1):27-38.

Maxwell 2009

Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: [10.1002/14651858.CD007277.pub2](https://doi.org/10.1002/14651858.CD007277.pub2)]

Mertens 2009

Mertens M, Singh JA. Anakinra for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: [10.1002/14651858.CD005121.pub3](https://doi.org/10.1002/14651858.CD005121.pub3)]

Mustafa 2013

Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. *Journal of Clinical Epidemiology* 2013;**66**(7):736-42.

Nam 2010

Nam JL, Winthrop KL, Van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010;**69**(6):976-86.

Navarro-Sarabia 2005

Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2005, Issue 3. [DOI: [10.1002/14651858.CD005113.pub2](https://doi.org/10.1002/14651858.CD005113.pub2)]

Nixon 2007

Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. *Statistics in Medicine* 2007;**26**(6):1237-54.

Odegard 2005

Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scandinavian Journal of Rheumatology* 2005;**34**(6):441-7.

Orme 2012

Orme ME, Macgilchrist KS, Mitchell S, Spurdin D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. *Biologics: targets & therapy* 2012;**6**:429-64.

Osiri 2003

Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. *Annals of the Rheumatic Diseases* 2003;**62**:316-21.

O'Sullivan 2007

O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. *Mol Immunol* 2007;**44**(10):2497-506.

Pincus 1983

Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis and Rheumatism* 1983;**26**(11):1346-53.

Pincus 2002

Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. *Rheumatology (Oxford)* 2002;**41**(12):1346-56.

Prevoo 1996

Prevoo ML, Van Gestel AM, Van T Hoff MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. *British Journal of Rheumatology* 1996;**35**(11):1101-5.

Puhan 2014

Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;**349**:g5630.

Revman 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ruiz Garcia 2014

Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 9. [DOI: [10.1002/14651858.CD007649.pub3](https://doi.org/10.1002/14651858.CD007649.pub3)]

Saag 2008

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 2008;**59**(6):762-84.

Salanti 2008

Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. *Statistical Methods in Medical Research* 2008;**17**(3):279-301.

Schiff 2008

Schiff M, Keiserman M, Coddling C, Songcharoen S, Berman A, Nayeri S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Annals of the Rheumatic Diseases* 2008;**8**:1096-103.

Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Scott 2006

Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *New England Journal of Medicine* 2006;**355**(7):704-12.

Sharp 1971

Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. *Arthritis and Rheumatism* 1971;**14**(6):706-20.

Shea 2007

Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology* 2007;**7**:10.

Singh 2010a

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2010, Issue 7. [DOI: [10.1002/14651858.CD008331.pub2](https://doi.org/10.1002/14651858.CD008331.pub2)]

Singh 2010b

Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: [10.1002/14651858.CD008341](https://doi.org/10.1002/14651858.CD008341)]

Singh 2012

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2012;**64**(5):625-39.

Singh 2016

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2016, Issue 5. [DOI: [10.1002/14651858.CD012183](https://doi.org/10.1002/14651858.CD012183)]

Singh 2016a

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis and Rheumatology* 2016;**Epub**(68):1-26. [DOI: [10.1002/acr.22783](https://doi.org/10.1002/acr.22783)]

Smolen 2014a

Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 2014;**73**(3):492-509.

Song 2003

Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. *BMJ* 2003;**326**:472.

Spiegelhalter 2003

Spiegelhalter D, Thomas A, Best N. WinBUGS user manual. Version 1.4, January 2003.. MRC Biostat. Unit 2. faculty.washington.edu/jmiamot/p548/spiegelhalter%20winbugs%20user%20manual.pdf. 2003.

Strand 2008

Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. *American Journal of Managed Care* 2008;**14**(4):234-54.

Sweeting 2004

Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Statistics in Medicine* 2004;**23**:1351-75.

Szekanecz 2007

Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. *Current Opinion in Rheumatology* 2007;**19**(3):289-95.

Thompson 1999

Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. *Statistics in Medicine* 1999;**18**(20):2693-708.

Thompson 2011

Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Arthritis Rheum* 2011;**63**(6):1479-85.

Tugwell 2000

Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, et al. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis. *N Engl J Med* 2000;**343**(21):1520-8.

Turner 2012

Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *International Journal of Epidemiology* 2012;**41**(3):818-27.

Van der Heijde 1989

Van der Heijde DM, Van Riel PL, Nuver-Zwart IH, Gribnau FW, Van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. *Lancet* 1989;**1**(8646):1036-8.

Wells 1993

Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with

rheumatoid arthritis: the patient's perspective. *The Journal of Rheumatology* 1993;**20**(3):557-60.

Woolley 2003

Woolley DE. The mast cell in inflammatory arthritis. *New England Journal of Medicine* 2003;**348**(17):1709-11.

Yelin 2007

Yelin E. Work disability in rheumatic diseases. *Current Opinion in Rheumatology* 2007;**19**(2):91-6.

Zhang 2016

Zhang J, Xie F, Yun H, Chen L, Muntner P, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. *Ann Rheum Dis* 2016;**75**(10):1813-18.

ADDITIONAL TABLES
Table 1. Characteristics of excluded studies

Study	Reason for exclusion
Abe 2006	Wrong drug exposure
Axelsen 2015	Duplicate of Horslev 2014
Bae 2013	Wrong drug exposure
Bathon 2000	Duplicate of Genovese 2002
Bejarano 2008	Wrong drug exposure
Bingham 2015	Wrong drug exposure
Bonafede 2015	Not a RCT
Breedveld 2006	Wrong drug exposure
Burmester 2013	Comparing two routes of administration of a biologic
Burmester 2015	Wrong drug exposure
Chen 2009	Wrong drug exposure
Cheng 2014	Conference abstract
Choy 2012	Wrong drug exposure
Cohen 2002	Wrong drug exposure
Cohen 2003	Wrong drug exposure
Cohen 2004	Wrong drug exposure
Cohen 2006	Wrong drug exposure
Combe 2006	Wrong drug exposure

Table 1. Characteristics of excluded studies (Continued)

Conaghan 2013	Wrong drug exposure
Conaghan 2014	Sub-study of Huizinga 2015
Detert 2013	Wrong drug exposure
Dougados 2014	Duplicate of Huizinga 2015
Durez 2004	Wrong drug exposure
Durez 2007	Wrong drug exposure
Emery 2006	Wrong drug exposure
Emery 2008	Wrong drug exposure
Emery 2010	Wrong drug exposure
Emery 2014a	Duplicate
Emery 2014b	Conference abstract
Eriksson 2015	Follow-up at two years of Vollenhoven 2012 NCT00764725
Fleischmann 2003	Wrong drug exposure
Fleischmann 2009	Wrong drug exposure
Fleischmann 2013	Wrong drug exposure
Fleischmann 2014	Conference abstract
Furst 2003	Wrong drug exposure
Furst 2007	Wrong drug exposure
Furst 2015	Open label study
Gashi 2014	Comparing two doses of a biologic
Genovese 2004	Wrong drug exposure
Genovese 2005	Wrong drug exposure
Genovese 2008	Wrong drug exposure
Genovese 2011	Wrong drug exposure
Genovese 2014	Wrong drug exposure
Gherge 2014	Conference abstract
Goekoop-Ruiterman 2007	Wrong drug exposure
Haraoui 2014	Duplicate of Pope 2014

Table 1. Characteristics of excluded studies (Continued)

Heimans 2014	Wrong drug exposure
Hørslev-Petersen 2014	Open label study
Iannone 2014	Open label study
Kaine 2011	Wrong drug exposure
Kameda 2011	Wrong drug exposure
Kavanaugh 2013	Wrong drug exposure
Kavanaugh 2014	Conference abstract
Kay 2008	Wrong drug exposure
Kennedy 2014	Wrong drug exposure
Keystone 2004a	Wrong drug exposure
Keystone 2004b	Wrong drug exposure
Keystone 2008	Wrong drug exposure
Keystone 2014	Conference abstract
Kim 2007	Wrong drug exposure
Kim 2012	Wrong drug exposure
Kim 2013	Wrong drug exposure
Kivitz 2014	Vaccine response study
Koroleva 2014a	Conference abstract
Koroleva 2014b	Conference abstract
Kremer 2003	Wrong drug exposure
Kremer 2005	Wrong drug exposure
Kremer 2006	Wrong drug exposure
Kremer 2011	Wrong drug exposure
Kremer 2012	Wrong drug exposure
Kremer 2015	Cross over study design
Lan 2004	Wrong drug exposure
Landewé 2015	Conference abstract
Lipsky 2000	Wrong drug exposure

Table 1. Characteristics of excluded studies (Continued)

Lisbona 2008	Wrong drug exposure
Lisbona 2010	Wrong drug exposure
Machado 2014	Wrong drug exposure
Maini 1999	Wrong drug exposure
Manders 2015	Participants switched therapy within one year/before completion of study period
Mathias 2000a	Wrong drug exposure
McInnes 2015	Compared lipid levels in those randomized to CZP or PL, in MTX-IR patients
Moreland 2002	Wrong drug exposure
Nam 2014a	Wrong drug exposure
Nam 2014b	Wrong drug exposure
Navarro 2014	Conference abstract
Nishimoto 2009	Wrong drug exposure
O'Dell 2013	Wrong drug exposure
Oakley 2014	Conference abstract
Pavelka 2013	Sub-group analysis of Smolen 2013 NCT00565409
Quinn 2005	Wrong drug exposure
Rantalaiho 2014	Wrong drug exposure
Rau 2004	Wrong drug exposure
Rigby 2011	Duplicate of Tak 2011
Rubbert-Roth 2010	Wrong drug exposure
Schiff 2004	Wrong drug exposure
Schiff 2008	Wrong drug exposure Not in excluded study refs
Smolen 2013b	Wrong drug exposure
Smolen 2008	Wrong drug exposure
Smolen 2009	Wrong drug exposure
Smolen 2013a	Wrong drug exposure
Smolen 2014a	Participants in the control group also received the intervention
Smolen 2015	Wrong drug exposure

Table 1. Characteristics of excluded studies (Continued)

Smolen 2014b	Open label study
Soubrier 2009	Wrong drug exposure
St Clair 2004	Wrong drug exposure
Strand 2012	Wrong drug exposure
Tak 2011	Wrong drug exposure
Tak 2012	Wrong drug exposure
Takeuchi 2014	Wrong drug exposure
Tam 2012	Wrong drug exposure
Tanaka 2011	Wrong drug exposure
Tanaka 2012	Wrong drug exposure
Taylor 2004	Wrong drug exposure
Taylor 2006	Wrong drug exposure
Van der Heidje 2013	Wrong drug exposure
Van der Kooij 2009	Wrong drug exposure
Van Vollenhoven 2009	Wrong drug exposure
Van Vollenhoven 2012a	Duplicate of Van Vollenhoven 2009
Van Vollenhoven 2012b	Wrong drug exposure
Vital 2015	B cell depletion study
Weinblatt 1999	Wrong drug exposure
Weinblatt 2003	Wrong drug exposure
Weinblatt 2006	Wrong drug exposure
Weinblatt 2007	Wrong drug exposure
Weinblatt 2008	Wrong drug exposure
Weinblatt 2012	Wrong drug exposure
Weinblatt 2013a	Wrong drug exposure
Weinblatt 2013b	Wrong drug exposure
Weinblatt 2014	Results at 1 year of Weinblatt 2013b GO-FURTHER trial, NCT00973479
Weisman 2003	Wrong drug exposure

Table 1. Characteristics of excluded studies (Continued)

Weisman 2007	Wrong drug exposure
Westhovens 2006	Wrong drug exposure
Westhovens 2009	Wrong drug exposure
Westhovens 2014	Conference abstract
Yamamoto 2014b	Wrong drug exposure
Yamanaka 2014	Post hoc analysis of Takeuchi 2014
Yazici 2012	Wrong drug exposure
Zhang 2006	Wrong drug exposure

Table 2. Characteristics of 41 studies of biologic monotherapy with usable data

Study name	Year	Biologic(s)	Biologic dose(s)	Number of study arms	Non-biologic comparator	Trial duration	RA duration*	Biologic-naive	Total number of participants
Boyle 2015	2015	Tofacitinib	HD	2	PL	1 month	Late	Yes	27
Bresnihan 1998	1998	Anakinra	SD, LD, HD	4	PL	6 months	Established	Yes	468
Burmester 2014	2014	Tocilizumab (SC v IV)	SD	2	None	6 months	Established	No	1262
Combe 2009	2009	Etanercept	SD	3	DMARD	24 months	Established	No	254
Coombs 2010	2009	Tofacitinib	SD, HD	3	PL	2 months	Established	No	195
Dougados 2013	2013	Tocilizumab (+/- MTX)	HD	2	None	6 months	Established	No	556
Doyle 2013	2013	Golimumab (SC v. IV)	SD	2	None	6 months	N/A	N/A	49
Edwards 2004	2004	Rituximab	SD, LD	4	MTX + PL	12 months	Late	Yes	161
Fleischmann 2012a	2012	Tofacitinib	SD, HD	3	PL	6 months	Established	No	610
Fleischmann 2012b	2012	Adalimumab, Tofacitinib	SD, HD	4	None	6 months	Established	No	226
Gabay 2013b	2013	Adalimumab, Tocilizumab	SD	2	None	6 months	Established	Yes	326
Genovese 2002 (ERA 2yr)	2002	Etanercept	SD, LD	3	MTX + PL	24 months	Late	No	632
Hobbs 2015	2015	Etanercept	SD	2	PL	3 months	Established	No	210
Huizinga 2015	2015	Tocilizumab (+/- MTX)	HD	2	None	24 months	Established	Yes	553
Jobanputra 2012	2013	Adalimumab, Etanercept	SD	2	None	12 months	Established	No	125
Johnsen 2006	2006	Etanercept	SD, HD	2	None	6 months	Late	No	77

Table 2. Characteristics of 41 studies of biologic monotherapy with usable data (Continued)

Jones 2010	2010	Tocilizumab	HD	2	MTX	6 months	Established	Yes	572
Kameda 2010 (JESMR)	2010	Etanercept (+/- MTX)	SD	2	None	6 months	Established	Yes	151
Keystone 2009 (GO-FORWARD)	2009	Golimumab	SD, HD	4	MTX + PL	12 months	Established	No	444
Kremer 2009	2009	Tofacitinib	SD, HD	3	PL	3 months	Established	No	195
Kremer 2010	2010	Golimumab	SD, LD	5	MTX + PL	11 months	Established	No	643
Kremer 2013	2013	Tofacitinib	SD, HD	3	PL	12 months	Established	No	792
Maini 2006 (CHARISMA)	2006	Tocilizumab	SD, LD, HD	7	MTX + PL	5 months	Established	No	359
Mathias 2000	2000	Etanercept	SD	2	DMARD	6 months	Established	No	156
Miyasaka 2008 (CHANGE)	2008	Adalimumab	SD, LD, HD	4	PL	6 months	Established	Yes	352
Moreland 1999	1999	Etanercept	SD, LD	3	PL	6 months	Late	Yes	234
Nishimoto 2004	2004	Tocilizumab	SD, HD	3	PL	3 months	Established	No	162
Nishimoto 2007 (SAMURAI)	2007	Tocilizumab	HD	2	DMARD	12 months	Established	No	306
Østergaard 2015	2015	Certolizumab	SD	2	PL	4 months	Established	No	40
Pope 2014 (CAMEO)	2014	Etanercept (+/- MTX)	SD	2	None	6 months	Established	Yes	205
Strand 2006	2006	Rituximab	SD	4	MTX + PL	24 months	Late	N/A	161
Tada 2012 (PRECEPT)	2012	Etanercept	SD, LD	2	None	12 months	Established	No	70
Takeuchi 2013a	2013	Etanercept	SD, LD	3	MTX + PL	12 months	Established	No	550

Table 2. Characteristics of 41 studies of biologic monotherapy with usable data (Continued)

Takeuchi 2013b	2013	Abatacept	SD, HD	3	PL	6 months	Established	Yes	194
Takeuchi 2013c	2013	Golimumab	SD, HD	3	PL	4 months	Established	N/A	316
Van de Putte 2003	2003	Adalimumab	SD, LD, HD	4	PL	3 months	Established	No	284
Van de Putte 2004	2004	Adalimumab	SD	2	PL	6 months	Late	Yes	223
Van der Heijde 2006 (TEMPO)	2006	Etanercept	SD	3	MTX	24 months	Established	Yes	682
Van der Heijde 2007 (TEMPO)	2007	Etanercept	SD	3	MTX	36 months	Established	Yes	682
Van Riel 2006 (ADORE)	2006	Etanercept (+/- MTX)	SD	2	None	4 months	Established	Yes	315
Yamamoto 2014a	2014b	Certolizumab	SD	2	PL	6 months	Established	Yes	230

*RA Duration: early = 2 years or less; established = > 2-10 years; late = > 10 years

HD - high dose

IV - intravenous

LD - low dose

SC - subcutaneous

SD - standard dose

Table 3. Summary of findings table for biologics vs placebo in MTX/DMARD-experienced people (MTX/DMARD inadequate-responders): only Placebo as a comparator

Comparison	Direct evidence		Network meta-analysis	
	Absolute risk difference, NNTB	Quality of Evidence (GRADE)	Absolute risk difference, NNTB	Quality of evidence (GRADE)
Outcome: ACR50	RR (95% CI)		RR (95% CrI)	

Table 3. Summary of findings table for biologics vs placebo in MTX/DMARD-experienced people (MTX/DMARD inadequate-responders): only Placebo as a comparator (Continued)

All biologics	vs comparator	4.68 (2.93 to 7.48)	23% (18% to 29%), NNTB = 5 (3 to 8)	⊕⊕⊕ moderate (downgraded for inconsistency) ¹	n/a		
TNF biologic	vs comparator	4.13 (2.51 to 6.80)	21% (16% to 26%), NNTB = 5 (3 to 9)	⊕⊕⊕ moderate (downgraded for inconsistency) ²	4.40 [3.02,6.68]	21% (13% to 30%), NNTB = 5 (3 to 8)	⊕⊕⊕ moderate (downgraded for indirectness) ⁴
NonTNF biologic**	vs comparator	8.23 (3.44 to 19.65)	33% (26% to 40%), NNTB = 4 (2 to 8)	⊕⊕⊕ moderate (downgraded for imprecision) ³	8.20 [4.06,14.89]	44% (20% to 70%), NNTB = 3 (2 to 7)	⊕⊕⊕ moderate (downgraded for indirectness) ⁴
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	4.09 [1.94, 8.61]	29% (18% to 40%), NNTB = 4 (2 to 9)	⊕⊕⊕ moderate [downgraded for imprecision] ³	4.63 [2.60,8.83]	22% (10% to 42%), NNTB = 4 (2 to 7)	⊕⊕⊕ moderate [downgraded for indirectness] ⁴
Outcome: Health Assessment Questionnaire (HAQ) score, 0-3 (higher = worse): A measure of function		MD (95% CI)		MD (95% CrI)			
All biologics	vs comparator	-0.32 (-0.42 to -0.23)	-10.7% (-14% to -7.7%), NNTB = 4 (3 to 5)	⊕⊕⊕ moderate (downgraded for inconsistency) ⁵	n/a		
TNF biologic	vs comparator	-0.34 (-0.44 to -0.23)	-11.3% (-14.7% to -7.7%), NNTB = 4 (3 to 5)	⊕⊕⊕ moderate (downgraded for inconsistency) ⁶	-0.33[-0.48,-0.17]	11% (-16% to -5.7%), NNTB = 7 (5 to 13)	⊕⊕⊕ moderate (downgraded for indirectness) ⁴
Non-TNF biologic	vs comparator	no data					
Anakinra	vs comparator	-0.23 (-0.33 to -0.14)	-7.7% (-11% to -4.7%), NNTB = 5 (4 to 9)	⊕⊕⊕ moderate (downgraded for imprecision) ⁷	-0.23[-0.61,0.14]	7.7% (-20.3% to 4.7%), NNTB = n/a	⊕⊕⊕ low (downgraded for indirectness and imprecision) ^{4,9}

Table 3. Summary of findings table for biologics vs placebo in MTX/DMARD-experienced people (MTX/DMARD inadequate-responders): only Placebo as a comparator (Continued)

Tofacitinib	vs comparator	-0.38 [-0.52, -0.25]	-12.7% (-8.3% to -17.3%), NNTB = 4 (3 to 8)	⊕⊕⊕ moderate (downgraded for inconsistency) ⁸	-0.38[-0.65,-0.12]	12.7% (-21.7% to -4%), NNTB = 6 (4 to 18)	⊕⊕⊕ moderate [downgraded for indirectness] ⁴
Outcome: Remission (defined as DAS < 1.6 or DAS28 < 2.6)		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.12 (1.03 to 1.22)	10% (3% to 17%), NNTB = 10 (8 to 21)	⊕⊕⊕ moderate (downgraded for imprecision) ^{3,7}	n/a		
TNF biologic	vs comparator	1.12 (1.03 to 1.22)	10% (3% to 17%), NNTB = 10 (8 to 21)	⊕⊕⊕ moderate (downgraded for imprecision) ^{3,7}			
Non-TNF biologic	vs comparator	no data					
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	no data					
Outcome: Withdrawals due to adverse events		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.65 (0.97 to 2.79)	2% (1% to 4%), NNTH = n/a	⊕⊕⊕ low (downgraded for serious imprecision) ¹⁰	n/a		
TNF biologic	vs comparator	2.02 (1.08 to 3.78)	3% (1% to 4%), NNTH = 40 (16 to 476)	⊕⊕⊕ moderate [downgraded for imprecision] ³	2.09 [1.14,4.04]	3% (0% to 6%), NNTH = 39 (15 to 306)	⊕⊕⊕ moderate (downgraded for indirectness) ⁴
Non-TNF biologic	vs comparator	0.24 (0.05 to 1.29)	-6% (-13% to 2%), NNTH = n/a	⊕⊕⊕ low (downgraded for serious imprecision) ¹⁰	0.22 [0.03,1.29]	-2% (-3% to 1%), NNTH = n/a	⊕⊕⊕ low (downgraded for indirectness and imprecision) ^{4,9}

Table 3. Summary of findings table for biologics vs placebo in MTX/DMARD-experienced people (MTX/DMARD inadequate-responders): only Placebo as a comparator (Continued)

Anakinra	vs comparator	1.53 (0.65 to 3.63)	3% (-2% to 8%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ¹⁰	1.59 [0.59,4.73]	1% (-1% to 9%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for indirectness and imprecision) ^{4,9}
Tofacitinib	vs. comparator	1.17 [0.31, 4.36]	1% (-5% to 6%), NNTH = n/a	⊕⊕⊕⊕ low [downgraded for serious imprecision] ¹⁰	1.19 [0.31,4.96]	0% (-2% to 8%), NNTH = n/a	⊕⊕⊕⊕ low [downgraded for indirectness and imprecision] ^{4,9}
Outcome: Serious adverse events		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.21 (0.71 to 2.07)	2% (-2% to 5%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ¹⁰	n/a		
TNF biologic	vs comparator	1.21 (0.71 to 2.07)	2% (-2% to 5%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ¹⁰	1.25 [0.76,2.19]	1% (-1% to 5%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for indirectness and imprecision) ^{4,9}
Non-TNF biologic	vs comparator	no data					
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	0.44 [0.16, 1.23]	0% (-2% to 3%), NNTH = n/a	⊕⊕⊕⊕ low [downgraded for serious imprecision] ¹⁰	0.48 [0.20,1.17]	-2% (-4% to 1%), NNTH = n/a	⊕⊕⊕⊕ low [downgraded for indirectness and imprecision] ^{4,9}

* No studies for radiographic progression or cancer

** Non-TNF biologic includes abatacept, rituximab, tocilizumab; i.e. all except anakinra, which was considered separately, as specified a priori.

High quality (⊕⊕⊕⊕) - We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality (⊕⊕⊕⊕) - We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality (⊕⊕⊕⊕) - Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low quality (⊕⊕⊕⊕) - We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

n/a = not available

DAS = Disease Activity Score; DMARD = disease-modifying anti-rheumatic drug; MTX = methotrexate; TNF = tumor necrosis factor

Comparator = placebo

The following control event rates were used in NMA calculations: ACR50 = 6.3%, withdrawals = 3.1%

1. I² = 56% - downgraded for inconsistency

2. I² = 58% - downgraded for inconsistency

3. Downgraded for imprecision - few events (< 300)
4. Downgraded for indirectness/intransitivity due to differing patient characteristics (established vs late RA; types of failures); differing biologic doses and co-interventions; and differing comparators
5. $I^2 = 70\%$ - downgraded for inconsistency
6. $I^2 = 67\%$ - downgraded for inconsistency
7. Only one study provided data
8. $I^2 = 77\%$ - downgraded for inconsistency
9. Downgraded for imprecision - 95% CI estimate includes both null effect and appreciable benefit or harm
10. Downgraded twice for serious imprecision - few events (< 300) and 95% CI estimate includes both null effect and appreciable benefit or harm

Table 4. Summary of findings table for biologics vs MTX/DMARD (active comparator) in MTX/DMARD-experienced people

Comparison		Direct evidence		Network meta-analysis		
			Absolute risk difference, NNTB	Quality of evidence	Absolute risk difference, NNTB	Quality of evidence
Outcome: ACR50		RR (95% CI)		RR (95% CrI)		
All biologics	vs comparator	1.54 (1.14 to 2.08)	13% (2% to 23%) to NNTB = 7 (4 to 26)	⊕⊕⊕⊕ moderate (downgraded for inconsistency) ¹	n/a	
TNF biologic	vs comparator	1.43 (1.06 to 1.93)	12% (2% to 22%), NNTB = 8 (4 to 44)	⊕⊕⊕⊕ moderate (downgraded for inconsistency) ²	1.75 (1.30 to 2.31)	9% (4% to 16%), NNTB = 7 (5 to 15) ⊕⊕⊕⊕ moderate (downgraded for indirectness) ⁵
Non-TNF biologic	vs comparator	1.57 (0.67 to 3.68)	14% (-11% to 39%), NNTB = n/a	⊕⊕⊕⊕ low (downgraded for inconsistency and imprecision) ^{3,4}	2.24 (1.55 to 3.10)	15% (7% to 25%), NNTB = 5 (3 to 10) ⊕⊕⊕⊕ moderate (downgraded for indirectness) ⁵
Anakinra	vs comparator	no data				
Tofacitinib	vs comparator	no data				
Outcome: Health Assessment Questionnaire (HAQ) score, 0-3		MD (95% CI)		MD (95% CrI)		

Table 4. Summary of findings table for biologics vs MTX/DMARD (active comparator) in MTX/DMARD-experienced people (Continued)
(higher = worse): a measure of function

All biologics	vs comparator	-0.27 (-0.40 to -0.14)	-9% (-13.3% to -4.7%), NNTB = 2 (2 to 4)	⊕⊕⊕⊕ moderate (downgraded for inconsistency) ⁶	n/a		
TNF biologic	vs comparator	-0.21 (-0.44 to 0.02)	-7% (-14.7% to 0.7%), NNTB = n/a	⊕⊕⊕⊕ moderate (downgraded for inconsistency) ⁷	-0.18(-0.41 to 0.06)	-3% (-13.7 to 2%), NNTB = n/a	⊕⊕⊕⊕ low (downgraded for indirectness and imprecision) ^{4,5}
Non-TNF biologic	vs comparator	-0.33 (-0.51 to -0.16)	-11% (-17% to -5.3%), NNTB = 4 (3 to 10)	⊕⊕⊕⊕ moderate (downgraded for inconsistency) ⁸	-0.32(-0.61 to -0.03)	-10.7% (-20.3.7 to -1%), NNTB = 7 (4 to 73)	⊕⊕⊕⊕ moderate (downgraded for indirectness) ⁵
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	no data					
Outcome: remission (defined as DAS < 1.6 or DAS28 < 2.6)		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.55 (0.94 to 2.53)	6% (2% to 9%), NNTB = n/a	⊕⊕⊕⊕ low (downgraded for imprecision and inconsistency) ^{4,9}	n/a		
TNF biologic	vs comparator	1.50 (0.84 to 2.68)	6% (2% to 9%), NNTB = n/a	⊕⊕⊕⊕ low (downgraded for imprecision and inconsistency) ^{4,10}	1.96 (1.27 to 3.04)	7% (2% to 14%), NNTB = 6 (4 to 19)	⊕⊕⊕⊕ moderate (downgraded for indirectness) ⁵
Non-TNF biologic	vs comparator	2.12 (0.70 to 6.44)	9% (-4% to 22%), NNTB = n/a	⊕⊕⊕⊕ low (downgraded for imprecision and inconsistency) ^{4,11}	3.66 (1.93 to 6.36)	19% (7% to 36%), NNTB = 3 (2 to 7)	⊕⊕⊕⊕ moderate (downgraded for indirectness) ⁵
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	no data					

Table 4. Summary of findings table for biologics vs MTX/DMARD (active comparator) in MTX/DMARD-experienced people (Continued)

Outcome: radiographic progression on Sharp/Van Der Heijde modification (0-448 points)		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	-4.34 (-7.56 to -1.12)	-0.97% (-1.69% to -0.25%), NNTB = 9 (5 to 35)	⊕⊕⊕ moderate ¹²	n/a		
TNF biologic	vs comparator	-4.34 (-7.56 to -1.12)	-0.97% (-1.69% to -0.25%), NNTB = 9 (5 to 35)	⊕⊕⊕ moderate ¹²	-2.35 (-9.12 to 3.49)	-0.52% (-2.04% to 0.78%), NNTB = n/a	⊕⊕⊕ low (downgraded for indirectness and imprecision) ^{4,5}
Non-TNF biologic	vs comparator	no data					
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	no data					
Outcome: withdrawals due to adverse events		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.08 (0.69 to 1.69)	1% (-3% to 4%), NNTH = n/a	⊕⊕⊕ low (downgraded for imprecision and inconsistency) ^{4,13}	n/a		
TNF biologic	vs comparator	0.96 (0.54 to 1.69)	0% (-5% to 5%), NNTH = n/a	⊕⊕⊕ low (downgraded for imprecision and inconsistency) ^{4,14}	1.14 (0.79 to 1.67)	0% (-1% to 2%), NNTH = n/a	⊕⊕⊕ low (downgraded for imprecision and indirectness) ^{4,5}
Non-TNF biologic	vs comparator	1.35 (0.63 to 2.92)	2% (-3% to 7%), NNTH = n/a	⊕⊕⊕ moderate (downgraded for imprecision) ⁴	1.23 (0.75 to 2.02)	1% (-1% to 3%), NNTH = n/a	⊕⊕⊕ low (downgraded for imprecision and indirectness) ^{4,5}
Anakinra	vs comparator	no data					

Table 4. Summary of findings table for biologics vs MTX/DMARD (active comparator) in MTX/DMARD-experienced people (Continued)

Tofacitinib	vs comparator	no data					
Outcome: serious adverse events		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.45 (0.94 to 2.22)	3% (-1% to 6%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ^{4,11}		n/a	
TNF	vs comparator	1.99 (0.78 to 5.09)	4% (-1% to 10%), NNTH = n/a	⊕⊕⊕⊕ very low (downgraded for serious imprecision and inconsistency) ^{4,11,15}		1.21 (0.86 to 1.67) 1% (-1% to 4%), NNTH = n/a ⊕⊕⊕⊕ very low (downgraded for serious imprecision and inconsistency) ^{4,5,11}	
Non-TNF	vs comparator	1.31 (0.84 to 2.05)	1% (-1% to 4%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ^{4,11}		1.20 (0.83 to 1.72) 1% (-1% to 4%), NNTH = n/a ⊕⊕⊕⊕ very low (downgraded for serious imprecision and inconsistency) ^{4,5,11}	
Anakinra	vs comparator	no data					
Tofacitinib	vs comparator	no data					
Outcome: cancer (note: Peto OR used but can interpret as RR due to low event rate)		RR (95% CI)		RR (95% CrI)			
All biologics	vs comparator	1.40 (0.67 to 2.93)	0% (0% to 1%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ^{4,11}		n/a	
TNF	vs comparator	1.44 (0.61 to 3.38)	0% (-1% to 2%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for serious imprecision) ^{4,11}		1.31 (0.63 to 2.98) 0% (0% to 1%), NNTH = n/a	
Non-TNF	vs comparator	1.29 (0.29 to 5.68)	0% (-1% to 1%), NNTH = n/a	⊕⊕⊕⊕ low (downgraded for inconsistency and imprecision) ^{4,16}		1.25 (0.36 to 4.92) 0% (-1% to 3%), NNTH = n/a	

Table 4. Summary of findings table for biologics vs MTX/DMARD (active comparator) in MTX/DMARD-experienced people (Continued)

Anakinra	vs compara- tor	no data
Tofacitinib	vs compara- tor	no data

High quality (⊕⊕⊕⊕) - We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality (⊕⊕⊕⊖) - We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality (⊕⊕⊖⊖) - Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low quality (⊕⊖⊖⊖) - We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

n/a = not available

DAS = Disease Activity Score; DMARD = disease-modifying anti-rheumatic drug; MTX = methotrexate; TNF = tumor necrosis factor

1. $I^2 = 87\%$ - downgraded for inconsistency
2. $I^2 = 81\%$ - downgraded for inconsistency
3. $I^2 = 92\%$ - downgraded for inconsistency
4. Downgraded for imprecision - 95% CI estimate includes both null effect and appreciable benefit or harm
5. Downgraded for indirectness/intransitivity due to differing patient characteristics (established vs late RA; types of failures); differing biologic doses and co-interventions; and differing comparators
6. $I^2 = 91\%$ - downgraded for inconsistency
7. $I^2 = 95\%$ - downgraded for inconsistency
8. $I^2 = 77\%$ - downgraded for inconsistency
9. $I^2 = 50\%$ - downgraded for inconsistency
10. $I^2 = 61\%$ - downgraded for inconsistency
11. Downgraded for imprecision - few events (< 300)
12. Only one study provided data
13. $I^2 = 62\%$ - downgraded for inconsistency
14. $I^2 = 69\%$ - downgraded for inconsistency
15. $I^2 = 58\%$ - downgraded for inconsistency
16. $I^2 = 73\%$ - downgraded for inconsistency

Table 5. ACR50 analysis 2 for the type of medication (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF Inhibitors	Placebo	5.66(3.54,9.68)	4.40(3.02,6.68)	0.21(0.13,0.30)
TOFA		6.07(2.93,15.51)	4.63(2.60,8.83)	0.22(0.10,0.42)
non-TNF		15.53(5.23,55.72)	8.20(4.06,14.89)	0.44(0.20,0.70)
TOFA	TNF Inhibitors	1.08(0.44,3.02)	1.05(0.54,2.10)	0.01(-0.15,0.24)
non-TNF		2.73(0.81,10.56)	1.85(0.86,3.50)	0.23(-0.04,0.52)
non-TNF	TOFA	2.55(0.60,10.69)	1.76(0.72,3.78)	0.21(-0.11,0.52)
Random-effects model	Residual deviance	18.42 vs 9 data-points		
	Deviance information criteria	110.799		
Fixed-effect model	Residual deviance	26.5 vs 9 data-points		
	Deviance information criteria	114.009		
Total participants	2205			
Total studies	9			
2-arm	9			

See Appendix 25 for the list of abbreviations

Table 6. ACR50 analysis 3 for the type of biologic (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Monoclonal antibodies against TNF:	Placebo	6.85(3.92,12.88)	5.05(3.28,8.04)	0.24(0.14,0.37)
TOFA		6.01(2.93,15.13)	4.61(2.60,8.72)	0.22(0.10,0.41)
non-TNF		15.34(5.31,56.88)	8.18(4.12,15.11)	0.44(0.20,0.70)
Medications targeting TNF receptor: etanercept		3.73(1.61,9.36)	3.20(1.55,6.43)	0.13(0.03,0.30)
TOFA	Monoclonal antibodies against TNF	0.88(0.35,2.56)	0.91(0.46,1.87)	-0.03(-0.21,0.20)
non-TNF		2.25(0.65,9.25)	1.62(0.75,3.17)	0.19(-0.09,0.50)

Table 6. ACR50 analysis 3 for the type of biologic (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model (Continued)

Medications targeting TNF receptor: etanercept		0.54(0.19,1.58)	0.63(0.27,1.38)	-0.11(-0.28,0.09)
non-TNF	TOFA	2.55(0.63,11.08)	1.77(0.74,3.83)	0.21(-0.10,0.53)
Medications targeting TNF receptor: etanercept		0.62(0.18,1.94)	0.69(0.27,1.63)	-0.08(-0.31,0.12)
Medications targeting TNF receptor: etanercept	non-TNF	0.24(0.05,0.99)	0.39(0.15,0.99)	-0.30(-0.60,0.00)
Random-effects model	Residual de- viance	26.21 vs 24 data points		
	Deviance infor- mation criteria	146.132		
Fixed-effect model	Residual de- viance	32.92 vs 24 data points		
	Deviance infor- mation criteria	149.36		
Total participants	3,037			
Total studies	12			
2-arm	12			

See Appendix 25 for the list of abbreviations

Table 7. ACR50 analysis 4 by dose (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	Placebo	6.64 (4.22, 11.40)	5.03 (3.46, 7.76)	0.23 (0.16, 0.32)
HD		9.02 (5.14, 17.70)	6.19 (4.02, 10.05)	0.29 (0.19, 0.43)
LD		4.94 (2.50, 11.12)	4.04 (2.28, 7.50)	0.17 (0.08, 0.32)
HD	SD	1.36 (0.80, 2.38)	1.23 (0.86, 1.77)	0.07 (-0.05, 0.19)
LD		0.74 (0.39, 1.51)	0.80 (0.48, 1.33)	-0.06 (-0.17, 0.09)
LD	HD	0.55 (0.26, 1.16)	0.65 (0.38, 1.11)	-0.12 (-0.26, 0.03)
Random-effects model	Residual deviance	27.6 vs 26 data-points		

Table 7. ACR50 analysis 4 by dose (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model *(Continued)*

	Deviance information criteria	155.135
Fixed-effect model	Residual deviance	39.15 vs 26 data-points
	Deviance information criteria	159.022
Total participants	2205	
Total studies	9	
2-arm	3	
3-arm	4	
4-arm	2	

See Appendix 25 for the list of abbreviations

Table 8. ACR50 analysis 2 for the type of medication (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

ACR50 Analysis 2: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
TNF inhibitors	Com-parator: MTX/other DMARD	1.95 (1.36, 2.80)	1.75 (1.30, 2.31)	0.09 (0.04, 0.16)
Non-TNF		2.71 (1.67, 4.33)	2.24 (1.55, 3.10)	0.15 (0.07, 0.25)
TOFA		7.31 (3.46, 15.92)	4.15 (2.66, 5.77)	0.38 (0.20, 0.56)
(MTX or DMARD) + TNF inhibitors		4.13 (3.37, 5.11)	3.00 (2.60, 3.47)	0.24 (0.20, 0.29)
(MTX or DMARD) + non-TNF		3.73 (2.77, 5.02)	2.81 (2.28, 3.41)	0.22 (0.16, 0.29)
(MTX or DMARD) + TOFA		5.58 (2.94, 10.76)	3.60 (2.38, 5.01)	0.31 (0.17, 0.47)
(MTX or DMARD) + ANA		2.82 (1.10, 7.61)	2.31 (1.08, 4.27)	0.16 (0.01, 0.39)
non-TNF	TNF inhibitors	1.39 (0.79, 2.41)	1.28 (0.84, 1.92)	0.06 (-0.04, 0.17)
TOFA		3.76 (1.72, 8.38)	2.37 (1.47, 3.56)	0.29 (0.11, 0.47)
(MTX or DMARD) + TNF inhibitors		2.12 (1.48, 3.06)	1.72 (1.31, 2.29)	0.15 (0.08, 0.21)

Table 8. ACR50 analysis 2 for the type of medication (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model (Continued)

(MTX or DMARD) + non-TNF		1.92 (1.22, 3.01)	1.61 (1.15, 2.25)	0.13 (0.04, 0.21)
(MTX or DMARD) + TOFA		2.87 (1.37, 6.02)	2.06 (1.26, 3.18)	0.22 (0.06, 0.39)
(MTX or DMARD) + ANA		1.45 (0.52, 4.17)	1.33 (0.59, 2.62)	0.07 (-0.10, 0.30)
TOFA	non-TNF	2.70 (1.13, 6.69)	1.84 (1.08, 3.02)	0.23 (0.03, 0.43)
(MTX or DMARD) + TNF inhibitors		1.53 (0.93, 2.56)	1.34 (0.95, 1.98)	0.09 (-0.02, 0.19)
(MTX or DMARD) + non-TNF		1.38 (0.84, 2.28)	1.25 (0.89, 1.82)	0.07 (-0.04, 0.16)
(MTX or DMARD) + TOFA		2.06 (0.94, 4.63)	1.60 (0.96, 2.62)	0.16 (-0.01, 0.34)
(MTX or DMARD) + ANA		1.05 (0.36, 3.15)	1.03 (0.45, 2.12)	0.01 (-0.17, 0.25)
(MTX or DMARD) + TNF inhibitors	TOFA	0.57 (0.26, 1.23)	0.72 (0.51, 1.14)	-0.14 (-0.33, 0.05)
(MTX or DMARD) + non-TNF		0.51 (0.22, 1.14)	0.68 (0.46, 1.09)	-0.16 (-0.36, 0.03)
(MTX or DMARD) + TOFA		0.76 (0.28, 2.07)	0.87 (0.51, 1.50)	-0.07 (-0.30, 0.18)
(MTX or DMARD) + ANA		0.39 (0.11, 1.33)	0.56 (0.25, 1.18)	-0.22 (-0.46, 0.07)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + TNF inhibitors	0.90 (0.64, 1.27)	0.94 (0.74, 1.16)	-0.02 (-0.10, 0.05)
(MTX or DMARD) + TOFA		1.35 (0.69, 2.68)	1.20 (0.78, 1.70)	0.07 (-0.08, 0.24)
(MTX or DMARD) + ANA		0.68 (0.26, 1.87)	0.77 (0.36, 1.44)	-0.08 (-0.24, 0.15)
(MTX or DMARD) + TOFA	(MTX or DMARD) + non-TNF	1.50 (0.74, 3.08)	1.28 (0.82, 1.88)	0.09 (-0.07, 0.27)
(MTX or DMARD) + ANA		0.76 (0.28, 2.13)	0.82 (0.38, 1.57)	-0.06 (-0.23, 0.18)
(MTX or DMARD) + ANA	(MTX or DMARD) + TOFA	0.51 (0.16, 1.64)	0.65 (0.28, 1.34)	-0.15 (-0.38, 0.12)
Random-effects model	Residual deviance	136.3 vs. 9 data-points		
	Deviance information criteria	916.003		
Fixed-effect model	Residual deviance	322 vs. 9 data-points		

Table 8. ACR50 analysis 2 for the type of medication (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model (Continued)

	Deviance informa- tion crite- ria	1058.74
Note:		
Total participants	25,861	
Total studies	65	
2-arm	58	
3-arm	7	

See Appendix 25 for the list of abbreviations

Table 9. ACR50 analysis 3 for the type of biologic (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

ACR50 analysis 3: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
Monoclonal antibodies against TNF	Com- parator: MTX/other DMARD	1.65 (0.91, 2.96)	1.53 (0.92, 2.40)	0.06 (-0.01, 0.17)
Medication targeting TNF receptor: etanercept		2.10 (1.31, 3.44)	1.85 (1.26, 2.67)	0.10 (0.03, 0.20)
Non-TNF		2.62 (1.60, 4.26)	2.20 (1.49, 3.08)	0.14 (0.06, 0.25)
TOFA		6.94 (3.21, 15.43)	4.05 (2.53, 5.71)	0.37 (0.18, 0.56)
(MTX or DMARD) + Monoclonal anti- bodies against TNF		4.23 (3.30, 5.46)	3.05 (2.57, 3.61)	0.25 (0.19, 0.30)
(MTX or DMARD) + non-TNF		3.73 (2.76, 5.06)	2.81 (2.27, 3.43)	0.22 (0.15, 0.29)
(MTX or DMARD) + Medication target- ing TNF receptor: etanercept		3.95 (2.69, 5.95)	2.92 (2.23, 3.76)	0.23 (0.15, 0.33)
(MTX or DMARD) + TOFA		5.60 (2.95, 10.92)	3.61 (2.38, 5.04)	0.31 (0.17, 0.48)
(MTX or DMARD) + ANA		2.82 (1.07, 7.72)	2.31 (1.06, 4.30)	0.16 (0.01, 0.39)
Medication targeting TNF receptor: etanercept	Mono- clonal an- tibodies against TNF	1.27 (0.60, 2.74)	1.21 (0.67, 2.25)	0.04 (-0.09, 0.16)

Table 9. ACR50 analysis 3 for the type of biologic (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model *(Continued)*

Non-TNF		1.59 (0.81, 3.13)	1.43 (0.85, 2.46)	0.08 (-0.04, 0.19)
TOFA		4.22 (1.81, 10.15)	2.62 (1.51, 4.55)	0.30 (0.12, 0.49)
(MTX or DMARD) + Monoclonal anti-bodies against TNF		2.57 (1.41, 4.71)	1.99 (1.27, 3.30)	0.18 (0.07, 0.27)
(MTX or DMARD) + non-TNF		2.27 (1.19, 4.32)	1.84 (1.13, 3.11)	0.15 (0.04, 0.25)
(MTX or DMARD) + Medication targeting TNF receptor: etanercept		2.40 (1.20, 4.93)	1.91 (1.14, 3.35)	0.17 (0.04, 0.29)
(MTX or DMARD) + TOFA		3.39 (1.42, 8.29)	2.35 (1.28, 4.32)	0.25 (0.07, 0.43)
(MTX or DMARD) + ANA		1.71 (0.55, 5.49)	1.51 (0.62, 3.38)	0.09 (-0.09, 0.34)
Non-TNF	Medication targeting TNF receptor: etanercept	1.25 (0.62, 2.45)	1.18 (0.70, 1.97)	0.04 (-0.09, 0.17)
TOFA		3.31 (1.33, 8.33)	2.17 (1.22, 3.65)	0.26 (0.06, 0.47)
(MTX or DMARD) + Monoclonal anti-bodies against TNF		2.02 (1.16, 3.46)	1.64 (1.11, 2.49)	0.14 (0.03, 0.24)
(MTX or DMARD) + non-TNF		1.78 (1.00, 3.12)	1.51 (1.00, 2.33)	0.11 (0.00, 0.22)
(MTX or DMARD) + Medication targeting TNF receptor: etanercept		1.88 (1.17, 3.05)	1.57 (1.11, 2.26)	0.13 (0.03, 0.22)
(MTX or DMARD) + TOFA		2.66 (1.18, 6.02)	1.94 (1.12, 3.24)	0.21 (0.03, 0.39)
(MTX or DMARD) + ANA		1.35 (0.45, 4.07)	1.25 (0.53, 2.59)	0.05 (-0.13, 0.30)
TOFA	non-TNF	2.65 (1.09, 6.67)	1.84 (1.06, 3.06)	0.22 (0.02, 0.43)
(MTX or DMARD) + Monoclonal anti-bodies against TNF		1.61 (0.95, 2.79)	1.39 (0.97, 2.09)	0.10 (-0.01, 0.20)
(MTX or DMARD) + non-TNF		1.42 (0.86, 2.39)	1.28 (0.90, 1.89)	0.07 (-0.03, 0.17)
(MTX or DMARD) + Medication targeting TNF receptor: etanercept		1.51 (0.82, 2.89)	1.33 (0.87, 2.12)	0.09 (-0.04, 0.22)
(MTX or DMARD) + TOFA		2.14 (0.96, 4.90)	1.64 (0.97, 2.74)	0.17 (-0.01, 0.35)
(MTX or DMARD) + ANA		1.08 (0.37, 3.34)	1.06 (0.46, 2.20)	0.01 (-0.17, 0.26)
(MTX or DMARD) + Monoclonal anti-bodies against TNF	TOFA	0.61 (0.27, 1.36)	0.75 (0.52, 1.22)	-0.12 (-0.32, 0.07)
(MTX or DMARD) + non-TNF		0.54 (0.23, 1.23)	0.70 (0.47, 1.15)	-0.15 (-0.35, 0.05)

Table 9. ACR50 analysis 3 for the type of biologic (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model *(Continued)*

(MTX or DMARD) + Medication targeting TNF receptor: etanercept		0.57 (0.24, 1.36)	0.72 (0.47, 1.22)	-0.13 (-0.34, 0.07)
(MTX or DMARD) + TOFA		0.81 (0.29, 2.24)	0.89 (0.52, 1.57)	-0.05 (-0.30, 0.19)
(MTX or DMARD) + ANA		0.41 (0.12, 1.44)	0.58 (0.24, 1.24)	-0.20 (-0.46, 0.09)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + Monoclonal antibodies against TNF	0.88 (0.61, 1.28)	0.92 (0.72, 1.17)	-0.03 (-0.11, 0.06)
(MTX or DMARD) + Medication targeting TNF receptor: etanercept		0.94 (0.59, 1.50)	0.96 (0.70, 1.29)	-0.02 (-0.12, 0.10)
(MTX or DMARD) + TOFA		1.32 (0.66, 2.69)	1.18 (0.76, 1.70)	0.07 (-0.09, 0.24)
(MTX or DMARD) + ANA		0.67 (0.24, 1.89)	0.76 (0.34, 1.44)	-0.09 (-0.25, 0.15)
(MTX or DMARD) + Medication targeting TNF receptor: etanercept	(MTX or DMARD) + non-TNF	1.06 (0.65, 1.76)	1.04 (0.75, 1.44)	0.01 (-0.09, 0.13)
(MTX or DMARD) + TOFA		1.50 (0.74, 3.11)	1.28 (0.81, 1.89)	0.10 (-0.07, 0.27)
(MTX or DMARD) + ANA		0.76 (0.27, 2.17)	0.82 (0.37, 1.58)	-0.06 (-0.23, 0.18)
(MTX or DMARD) + TOFA	(MTX or DMARD) + Medication targeting TNF receptor: etanercept	1.42 (0.66, 3.04)	1.23 (0.77, 1.88)	0.08 (-0.09, 0.27)
(MTX or DMARD) + ANA		0.71 (0.25, 2.08)	0.79 (0.35, 1.55)	-0.07 (-0.26, 0.17)
(MTX or DMARD) + ANA	(MTX or DMARD) + TOFA	0.50 (0.16, 1.66)	0.65 (0.28, 1.35)	-0.15 (-0.38, 0.12)
Random-effects model	Residual deviance	136.2 vs 137 data-points		
	Deviance information criteria	916.929		

Table 9. ACR50 analysis 3 for the type of biologic (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model (Continued)

Fixed-effect model	Residual deviance	319.8 vs 137 data-points
	Deviance information criteria	1058.59
Note:		
Total participants	25,861	
Total studies	65	
2-arm	58	
3-arm	7	

See Appendix 25 for the list of abbreviations

Table 10. ACR50 analysis 4 by dose (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

ACR50 analysis 4: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
SD biologic	Comparator: MTX/ other DMARD	2.30 (1.73, 3.11)	1.99 (1.58, 2.48)	0.12 (0.07, 0.18)
HD biologic		3.12 (2.23, 4.37)	2.48 (1.94, 3.11)	0.18 (0.12, 0.26)
LD biologic		1.20 (0.74, 1.94)	1.17 (0.77, 1.75)	0.02 (-0.03, 0.09)
MTXSD biologic		3.97 (3.37, 4.70)	2.91 (2.59, 3.28)	0.23 (0.20, 0.27)
MTXHD biologic		4.97 (3.89, 6.40)	3.34 (2.85, 3.91)	0.29 (0.23, 0.35)
MTXLD biologic		2.88 (2.20, 3.79)	2.34 (1.91, 2.85)	0.16 (0.11, 0.22)
HD biologic	SD biologic	1.35 (0.93, 1.96)	1.25 (0.95, 1.62)	0.06 (-0.01, 0.14)
LD biologic		0.52 (0.31, 0.85)	0.59 (0.38, 0.88)	-0.10 (-0.17, -0.03)
MTXSD biologic		1.72 (1.28, 2.32)	1.46 (1.18, 1.83)	0.11 (0.05, 0.17)
MTXHD biologic		2.16 (1.51, 3.08)	1.68 (1.32, 2.16)	0.17 (0.09, 0.24)
MTXLD biologic		1.25 (0.86, 1.81)	1.18 (0.90, 1.55)	0.04 (-0.03, 0.11)
LD biologic	HD biologic	0.39 (0.22, 0.66)	0.48 (0.30, 0.73)	-0.16 (-0.24, -0.07)
MTXSD biologic		1.27 (0.90, 1.81)	1.18 (0.93, 1.51)	0.05 (-0.02, 0.12)

Table 10. ACR50 analysis 4 by dose (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model *(Continued)*

MTXHD biologic		1.59 (1.10, 2.33)	1.35 (1.06, 1.75)	0.11 (0.02, 0.19)
MTXLD biologic		0.92 (0.61, 1.40)	0.95 (0.71, 1.27)	-0.02 (-0.10, 0.07)
MTXSD biologic	LD biologic	3.30 (2.04, 5.40)	2.48 (1.67, 3.81)	0.21 (0.14, 0.27)
MTXHD biologic		4.13 (2.47, 7.01)	2.84 (1.89, 4.43)	0.26 (0.18, 0.34)
MTXLD biologic		2.40 (1.42, 4.08)	1.99 (1.31, 3.13)	0.14 (0.06, 0.22)
MTXHD biologic	MTXSD biologic	1.25 (0.97, 1.62)	1.15 (0.98, 1.34)	0.05 (-0.01, 0.11)
MTXLD biologic		0.73 (0.55, 0.95)	0.81 (0.66, 0.97)	-0.07 (-0.12, -0.01)
MTXLD biologic	MTXHD biologic	0.58 (0.41, 0.81)	0.70 (0.56, 0.87)	-0.12 (-0.20, -0.05)
<hr/>				
Random-effects model	Residual deviance	163.8 vs 158 data-points		
	Deviance information criteria	1027.23		
<hr/>				
Fixed-effect model	Residual deviance	335.4 vs 158 data-points		
	Deviance information criteria	1144.83		
<hr/>				
Note:				
Total participants	23,526			
Total studies	61			
2-arm	35			
3-arm	20			
4-arm	4			
5-arm	1			
7-arm	1			

See Appendix 25 for the list of abbreviations

Table 11. HAQ analysis 2 (only placebo comparator trials) for the type of medication: mean difference (MD) for all treatment comparisons - random-effects model

HAQ analysis 2: mean difference (MD) for all treatment comparisons - random-effects model		
Treatment	Reference	MD (95% CrI)
TNF Inhibitors	PL	-0.33(-0.48,-0.17)
TOFA		-0.38(-0.65,-0.12)
ANA		-0.23(-0.61,0.14)
TOFA	TNF Inhibitors	-0.05(-0.38,0.24)
ANA		0.09(-0.32,0.49)
ANA	TOFA	0.15(-0.31,0.61)
Random-Effect Model		
	Total Residual Deviance	18.47 vs 18 data points
	Deviance Information Criteria	-30.822
Fixed-Effect Model		
	Total Residual Deviance	26.58 vs 18 data points
	Deviance Information Criteria	-26.861
Note:		
Total Patients	1855	
Total Studies	9	
2-arm	9	

Table 12. HAQ analysis 3 (only placebo comparator trials) for the type of biologic: mean difference (MD) for all treatment comparisons - random-effects model

Table. HAQ Analysis 3: Mean Difference (MD) for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
Monoclonal antibodies against TNF	Placebo	-0.37(-0.52,-0.18)
TOFA		-0.38(-0.65,-0.13)
ANA		-0.23(-0.61,0.14)
Medications targeting TNF receptor: etanercept		-0.19(-0.54,0.16)
TOFA	Monoclonal antibodies against TNF	-0.01(-0.35,0.28)

Table 12. HAQ analysis 3 (only placebo comparator trials) for the type of biologic: mean difference (MD) for all treatment comparisons - random-effects model *(Continued)*

ANA		0.14(-0.30,0.53)
Medications targeting TNF receptor: etanercept		0.18(-0.24,0.55)
ANA	TOFA	0.14(-0.30,0.61)
Medications targeting TNF receptor: etanercept		0.19(-0.24,0.64)
Medications targeting TNF receptor: etanercept	ANA	0.04(-0.47,0.56)
Random-Effect Model	Total Residual Deviance	18.54 vs 18 data points
	Deviance Information Criteria	-30.977
Fixed-Effect Model	Total Residual Deviance	21.34 vs 18 data points
	Deviance Information Criteria	-31.106
Note:		
Total Patients	1855	
Total Studies	9	
2-arm	9	

Table 13. HAQ analysis 4 by dose (only placebo): mean difference (MD) for all treatment comparisons - random-effects model

THAQ Analysis 4: mean difference (MD) for all treatment comparisons - random-effects model		
Treatment	Reference	MD (95% CrI)
SD biologic	Comparator: placebo	-0.31 (-0.41, -0.20)
HD biologic		-0.30 (-0.44, -0.16)
LD biologic		-0.41 (-0.55, -0.26)
HD biologic	SD biologic	0.01 (-0.14, 0.15)
LD biologic		-0.10 (-0.25, 0.04)
LD biologic	HD biologic	-0.11 (-0.26, 0.04)
Random-effects model	Total residual deviance	20.68 vs 20 data-points
	Deviance information criteria	-41.312

Table 13. HAQ analysis 4 by dose (only placebo): mean difference (MD) for all treatment comparisons - random-effects model (Continued)

Fixed-effect model	Total residual deviance	33.27 vs 20 data-points
	Deviance information criteria	-35.067
Note		
Total studies	7	
2-arm	4	
4-arm	3	

Table 14. HAQ analysis 2 (MTX/other DMARD active comparator) for the type of medication: mean difference (MD) for all treatment comparisons - random-effects model

HAQ analysis 2: mean difference (MD) for all treatment comparisons - random-effects model		
Treatment	Reference	MD (95% CrI)
TNF inhibitors	MTX/other DMARD	-0.18 (-0.41, 0.06)
Non-TNF		-0.32 (-0.61, -0.03)
TOFA		-0.55 (-1.25, 0.14)
(MTX or DMARD) + TNF inhibitors		-0.29 (-0.42, -0.16)
(MTX or DMARD) + non-TNF		-0.22 (-0.43, 0.00)
(MTX or DMARD) + TOFA		-0.44 (-0.98, 0.11)
non-TNF	TNF inhibitors	-0.14 (-0.52, 0.23)
TOFA		-0.37 (-1.03, 0.28)
(MTX or DMARD) + TNF inhibitors		-0.12 (-0.34, 0.11)
(MTX or DMARD) + non-TNF		-0.04 (-0.36, 0.28)
(MTX or DMARD) + TOFA		-0.26 (-0.86, 0.34)
TOFA	non-TNF	-0.23 (-0.98, 0.52)
(MTX or DMARD) + TNF inhibitors		0.03 (-0.29, 0.34)
(MTX or DMARD) + non-TNF		0.10 (-0.21, 0.41)
(MTX or DMARD) + TOFA		-0.12 (-0.73, 0.50)
(MTX or DMARD) + TNF inhibitors	TOFA	0.26 (-0.43, 0.95)
(MTX or DMARD) + non-TNF		0.33 (-0.39, 1.06)

Table 14. HAQ analysis 2 (MTX/other DMARD active comparator) for the type of medication: mean difference (MD) for all treatment comparisons - random-effects model *(Continued)*

(MTX or DMARD) + TOFA		0.11 (-0.77, 1.01)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + TNF inhibitors	0.08 (-0.17, 0.32)
(MTX or DMARD) + TOFA		-0.14 (-0.70, 0.42)
(MTX or DMARD) + TOFA	(MTX or DMARD) + non-TNF	-0.22 (-0.81, 0.37)
Random-effects model	Total residual deviance	76.95 vs 79 data-points
	Deviance information criteria	-172.458
Fixed-effect model	Total residual deviance	533.2 vs 79 data-points
	Deviance information criteria	253.917
Note:		
Total participants	13,017	
Total studies	38	
2-arm	35	
3-arm	3	

Table 15. HAQ analysis 3 (MTX/other DMARD active comparator) for the type of biologic: mean difference (MD) for all treatment comparisons - random-effects model

HAQ analysis 3: mean difference (MD) for all treatment comparisons - random-effects model		
Treatment	Reference	MD (95% CrI)
Monoclonal antibodies against TNF	MTX/other DMARD	-0.09 (-0.57, 0.39)
Medications targeting TNF receptor: etanercept		-0.31 (-0.58, -0.04)
non-TNF: tocilizumab, rituximab, abatacept		-0.32 (-0.59, -0.05)
TOFA		-0.47 (-1.26, 0.33)
(MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab		-0.19 (-0.34, -0.03)
(MTX or DMARD) + medication targeting TNF receptor: etanercept		-0.48 (-0.68, -0.28)
(MTX or DMARD) + non-TNF		-0.22 (-0.42, -0.01)

Table 15. HAQ analysis 3 (MTX/other DMARD active comparator) for the type of biologic: mean difference (MD) for all treatment comparisons - random-effects model *(Continued)*

(MTX or DMARD) + TOFA		-0.44 (-0.95, 0.09)
Medication targeting TNF receptor: etanercept	Monoclonal antibodies against TNF	-0.22 (-0.77, 0.33)
Non-TNF: tocilizumab, rituximab, abatacept		-0.23 (-0.78, 0.32)
TOFA		-0.37 (-1.00, 0.26)
(MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab		-0.09 (-0.57, 0.38)
(MTX or DMARD) + medications targeting TNF receptor: etanercept		-0.38 (-0.90, 0.13)
(MTX or DMARD) + non-TNF		-0.12 (-0.64, 0.39)
(MTX or DMARD) + TOFA		-0.34 (-1.05, 0.36)
Non-TNF: tocilizumab, rituximab, abatacept	Medication targeting TNF receptor: etanercept	-0.01 (-0.39, 0.38)
TOFA		-0.16 (-0.99, 0.69)
(MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab		0.13 (-0.19, 0.44)
(MTX or DMARD) + medication targeting TNF receptor: etanercept		-0.17 (-0.41, 0.08)
(MTX or DMARD) + non-TNF		0.09 (-0.24, 0.43)
(MTX or DMARD) + TOFA		-0.13 (-0.71, 0.46)
TOFA	non-TNF: tocilizumab, rituximab, abatacept	-0.15 (-0.98, 0.69)
(MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab		0.13 (-0.18, 0.45)
(MTX or DMARD) + medication targeting TNF receptor: etanercept		-0.16 (-0.50, 0.18)
(MTX or DMARD) + non-TNF		0.10 (-0.19, 0.40)
(MTX or DMARD) + TOFA		-0.12 (-0.70, 0.47)
(MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab	TOFA	0.28 (-0.52, 1.07)
(MTX or DMARD) + medication targeting TNF receptor: etanercept		-0.01 (-0.83, 0.81)
(MTX or DMARD) + non-TNF		0.25 (-0.57, 1.07)
(MTX or DMARD) + TOFA		0.03 (-0.91, 0.98)

Table 15. HAQ analysis 3 (MTX/other DMARD active comparator) for the type of biologic: mean difference (MD) for all treatment comparisons - random-effects model *(Continued)*

(MTX or DMARD) + medication targeting TNF receptor: etanercept	(MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab	-0.29 (-0.54, -0.04)
(MTX or DMARD) + non-TNF		-0.03 (-0.28, 0.22)
(MTX or DMARD) + TOFA		-0.25 (-0.79, 0.29)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + medication targeting TNF receptor: etanercept	0.26 (-0.02, 0.55)
(MTX or DMARD) + TOFA		0.04 (-0.51, 0.60)
(MTX or DMARD) + TOFA	(MTX or DMARD) + non-TNF	-0.22 (-0.77, 0.34)
Random-effects model	Total residual deviance	77.27 vs 79 data-points
	Deviance information criteria	-172.331
Fixed-effect model	Total residual deviance	414.4 vs 79 data-points
	Deviance Information Criteria	137.144
Note		
Total studies	38	
2-arm	35	
3-arm	3	

Table 16. HAQ analysis 4 by dose (MTX/other DMARD active comparator): mean difference (MD) for all treatment comparisons - random-effects model

HAQ Analysis 4: standardized mean difference (SMD) for all treatment comparisons - random-effects model		
Treatment	Reference	MD (95% CrI)
SD biologic	Comparator: MTX/other DMARD	-0.23 (-0.43, -0.02)
HD biologic		-0.25 (-0.49, -0.01)

Table 16. HAQ analysis 4 by dose (MTX/other DMARD active comparator): mean difference (MD) for all treatment comparisons - random-effects model *(Continued)*

MTX SD biologic		-0.28 (-0.38, -0.18)
MTX HD biologic		-0.28 (-0.43, -0.13)
MTX LD biologic		-0.20 (-0.36, -0.04)
HD biologic	SD biologic	-0.03 (-0.34, 0.28)
MTX SD biologic		-0.05 (-0.25, 0.14)
MTX HD biologic		-0.06 (-0.30, 0.19)
MTX LD biologic		0.03 (-0.22, 0.27)
MTX SD biologic	HD biologic	-0.03 (-0.27, 0.22)
MTX HD biologic		-0.03 (-0.28, 0.23)
MTX LD biologic		0.06 (-0.23, 0.34)
MTX HD biologic	MTX SD biologic	0.00 (-0.16, 0.15)
MTX LD biologic		0.08 (-0.08, 0.25)
MTX LD biologic	MTX HD biologic	0.08 (-0.12, 0.28)
Random-effects model	Total residual deviance	87.32 vs 88 data-points
	Deviance information criteria	-223.589
Fixed-effect model	Total residual deviance	1368 vs 88 data-points
	Deviance information criteria	1014.69
Note		
Total participants		
Total studies	35	
2-arm	21	
3-arm	10	
4-arm	4	

Table 17. Remission analysis 2 (MTX/DMARD active comparator) for the type of medication: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA) (Review)

90

Table 17. Remission analysis 2 (MTX/DMARD active comparator) for the type of medication: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model *(Continued)*

TNF	MTX/other DMARD	2.11 (1.29, 3.54)	1.96 (1.27, 3.04)	0.07 (0.02, 0.14)
Non-TNF		4.59 (2.08, 10.27)	3.66 (1.93, 6.36)	0.19 (0.07, 0.36)
MTX + TNF		4.09 (2.91, 5.93)	3.36 (2.54, 4.50)	0.17 (0.11, 0.23)
MTX + non-TNF		4.71 (3.02, 7.60)	3.73 (2.62, 5.32)	0.19 (0.12, 0.28)
MTX + TOFA		8.15 (1.66, 49.85)	5.40 (1.58, 11.79)	0.31 (0.04, 0.71)
Non-TNF	TNF	2.17 (0.94, 4.93)	1.87 (0.95, 3.38)	0.12 (-0.01, 0.28)
MTX + TNF		1.93 (1.22, 3.09)	1.71 (1.17, 2.56)	0.10 (0.03, 0.16)
MTX + non-TNF		2.23 (1.20, 4.17)	1.90 (1.16, 3.17)	0.12 (0.03, 0.23)
MTX + TOFA		3.85 (0.72, 25.04)	2.74 (0.76, 6.70)	0.24 (-0.04, 0.65)
MTX + TNF	Non-TNF	0.89 (0.40, 2.05)	0.92 (0.53, 1.78)	-0.02 (-0.20, 0.11)
MTX + non-TNF		1.02 (0.48, 2.23)	1.02 (0.61, 1.88)	0.00 (-0.16, 0.13)
MTX + TOFA		1.78 (0.30, 12.74)	1.47 (0.39, 4.02)	0.12 (-0.21, 0.55)
MTX + non-TNF	MTX + TNF	1.15 (0.69, 1.93)	1.11 (0.75, 1.62)	0.03 (-0.07, 0.13)
MTX + TOFA		1.99 (0.39, 12.55)	1.61 (0.46, 3.60)	0.14 (-0.14, 0.56)
MTX + TOFA	MTX + non-TNF	1.73 (0.33, 11.10)	1.45 (0.41, 3.34)	0.12 (-0.17, 0.53)
Random-effects model	Residual deviance	64.66 vs 63 data-points		
	Deviance information criteria	409.045		
Fixed-Effect Model	Residual deviance	134.2 vs 63 data-points		
	Deviance information criteria	459.699		
Note				
Total participants	12668			
Total studies	29			
2-arm	24			
3-arm	5			

Table 18. Remission: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Mono	MTX/other DMARD	2.00 (0.87, 4.70)	1.96 (1.05, 3.56)	0.07 (0.00, 0.17)
Medication targeting TNF receptor: etanercept		4.64 (1.98, 11.03)	1.87 (0.87, 3.76)	0.06 (-0.01, 0.19)
Non-TNF		4.46 (2.86, 7.27)	3.70 (1.85, 6.65)	0.19 (0.06, 0.37)
MTX + Monoclonal antibodies against TNF		4.83 (3.02, 8.00)	3.60 (2.51, 5.22)	0.18 (0.11, 0.27)
MTX + non-TNF		3.64 (1.93, 7.01)	3.82 (2.63, 5.54)	0.19 (0.12, 0.29)
MTX + Medication targeting TNF receptor: etanercept		7.78 (1.53, 50.47)	3.08 (1.81, 5.01)	0.14 (0.06, 0.27)
MTX + TOFA		0.95 (0.31, 2.85)	5.29 (1.47, 11.93)	0.30 (0.03, 0.71)
Medication targeting TNF receptor: etanercept	Monoclonal antibodies against TNF	2.21 (0.87, 5.47)	0.96 (0.36, 2.43)	-0.01 (-0.13, 0.14)
Non-TNF		2.12 (1.02, 4.43)	1.89 (0.89, 3.80)	0.12 (-0.02, 0.29)
MTX + Monoclonal antibodies against TNF		2.30 (1.05, 5.07)	1.84 (1.02, 3.48)	0.11 (0.00, 0.21)
MTX + non-TNF		1.73 (0.66, 4.49)	1.95 (1.04, 3.81)	0.13 (0.01, 0.24)
MTX + Medication targeting TNF receptor: etanercept		3.72 (0.61, 26.89)	1.57 (0.71, 3.45)	0.08 (-0.06, 0.22)
MTX + TOFA		2.32 (0.69, 7.63)	2.68 (0.66, 7.56)	0.23 (-0.06, 0.65)
Non-TNF	Medication targeting TNF receptor: etanercept	2.23 (0.86, 5.92)	1.97 (0.74, 5.14)	0.12 (-0.06, 0.33)
MTX + Monoclonal antibodies against TNF		2.41 (0.92, 6.44)	1.92 (0.89, 4.52)	0.12 (-0.03, 0.23)
MTX + non-TNF		1.82 (0.94, 3.52)	2.03 (0.94, 4.75)	0.13 (-0.01, 0.26)
MTX + Medication targeting TNF receptor: etanercept		3.90 (0.62, 29.66)	1.64 (0.95, 2.95)	0.08 (-0.01, 0.17)
MTX + TOFA		0.96 (0.39, 2.43)	2.79 (0.67, 8.70)	0.23 (-0.06, 0.66)
MTX + Monoclonal antibodies against TNF	Non-TNF	1.04 (0.46, 2.40)	0.97 (0.53, 2.02)	-0.01 (-0.20, 0.14)

Table 18. Remission: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model *(Continued)*

MTX + non-TNF		0.79 (0.27, 2.31)	1.03 (0.59, 2.00)	0.01 (-0.17, 0.14)
MTX + Medication targeting TNF receptor: etanercept		1.69 (0.26, 12.95)	0.83 (0.38, 1.93)	-0.04 (-0.25, 0.14)
MTX + TOFA		1.08 (0.60, 1.93)	1.42 (0.35, 4.18)	0.11 (-0.22, 0.55)
MTX + non-TNF	MTX + Monoclonal antibodies against TNF	0.82 (0.36, 1.79)	1.06 (0.69, 1.62)	0.02 (-0.10, 0.13)
MTX + Medication targeting TNF receptor: etanercept		1.75 (0.32, 11.67)	0.86 (0.45, 1.54)	-0.04 (-0.17, 0.11)
MTX + TOFA		0.75 (0.33, 1.68)	1.47 (0.39, 3.48)	0.12 (-0.17, 0.54)
MTX + Medication targeting TNF receptor: etanercept	MTX + non-TNF	1.61 (0.29, 10.92)	0.81 (0.42, 1.46)	-0.05 (-0.19, 0.10)
MTX + TOFA		2.14 (0.37, 15.21)	1.39 (0.37, 3.32)	0.10 (-0.19, 0.53)
MTX + TOFA	MTX + Medication targeting TNF receptor: etanercept		1.71 (0.44, 4.56)	0.15 (-0.15, 0.58)
Random-effects model	Residual deviance	64.03 vs 63 data-points		
	Deviance information criteria	409.476		
Fixed-effect model	Residual deviance	135.9 vs 63 data-points		
	Deviance information criteria	463.334		
Note				
Total participants	12,668			
Total studies	29			
2-arm	24			
3-arm	5			

Table 19. Remission: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model

Treatment	Refer-ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	MTX/oth-er DMARD	1.90 (1.18, 3.15)	1.78 (1.16, 2.73)	0.06 (0.01, 0.12)
HD		4.14 (2.25, 7.68)	3.34 (2.05, 5.22)	0.18 (0.08, 0.30)
LD		2.79 (1.02, 7.63)	2.45 (1.02, 5.15)	0.11 (0.00, 0.30)
MTX SD		4.15 (3.10, 5.68)	3.35 (2.64, 4.31)	0.18 (0.13, 0.23)
MTX HD		5.82 (3.57, 9.92)	4.27 (2.96, 6.14)	0.25 (0.15, 0.36)
MTX LD		2.26 (1.30, 3.95)	2.07 (1.27, 3.26)	0.08 (0.02, 0.16)
HD	SD	2.17 (1.12, 4.19)	1.87 (1.10, 3.12)	0.12 (0.02, 0.24)
LD		1.46 (0.52, 4.11)	1.38 (0.56, 3.02)	0.05 (-0.07, 0.24)
MTX SD		2.17 (1.38, 3.45)	1.88 (1.29, 2.81)	0.12 (0.05, 0.18)
MTX HD		3.06 (1.65, 5.82)	2.39 (1.47, 3.95)	0.19 (0.08, 0.30)
MTX LD		1.19 (0.60, 2.30)	1.16 (0.65, 2.02)	0.02 (-0.06, 0.11)
LD	HD	0.67 (0.22, 2.10)	0.73 (0.28, 1.72)	-0.07 (-0.23, 0.14)
MTX SD		1.00 (0.54, 1.85)	1.00 (0.65, 1.63)	0.00 (-0.13, 0.10)
MTX HD		1.41 (0.78, 2.62)	1.27 (0.84, 2.03)	0.07 (-0.05, 0.19)
MTX LD		0.55 (0.25, 1.20)	0.62 (0.33, 1.16)	-0.10 (-0.23, 0.03)
MTX SD	LD	1.49 (0.56, 4.06)	1.36 (0.67, 3.27)	0.07 (-0.12, 0.18)
MTX HD		2.09 (0.71, 6.32)	1.74 (0.79, 4.39)	0.13 (-0.07, 0.29)
MTX LD		0.81 (0.28, 2.33)	0.84 (0.38, 2.09)	-0.03 (-0.22, 0.10)
MTX HD	MTX SD	1.40 (0.86, 2.35)	1.27 (0.89, 1.79)	0.07 (-0.03, 0.18)
MTX LD		0.55 (0.31, 0.93)	0.62 (0.38, 0.95)	-0.10 (-0.17, -0.01)
MTX LD	MTX HD	0.39 (0.19, 0.78)	0.48 (0.27, 0.83)	-0.16 (-0.29, -0.04)
Random-effects model	Residual deviance	68.24 vs 68 data-points		
	Deviance information criteria	427.568		

Table 19. Remission: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model *(Continued)*

Fixed-effect model	Residual deviance	137.3 vs 68 data-points
	Deviance information criteria	475.55
Note		
Total participants	11,225	
Total studies	27	
2-arm	16	
3-arm	9	
4-arm	1	
5-arm	1	

Table 20. Withdrawals due to adverse events: analysis 2 (only placebo comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF Inhibitors	Placebo	2.14(1.14,4.27)	2.09(1.14,4.04)	0.03(0.00,0.06)
TOFA		1.20(0.30,5.40)	1.19(0.31,4.96)	0.00(-0.02,0.08)
non-TNF		0.21(0.03,1.30)	0.22(0.03,1.29)	-0.02(-0.03,0.01)
ANA		1.61(0.59,5.16)	1.59(0.59,4.73)	0.01(-0.01,0.09)
TOFA	TNF inhibitors	0.55(0.12,2.89)	0.57(0.13,2.69)	-0.02(-0.06,0.06)
non-TNF		0.10(0.01,0.67)	0.10(0.01,0.68)	-0.04(-0.08,-0.01)
ANA		0.75(0.22,2.76)	0.76(0.23,2.58)	-0.01(-0.05,0.07)
non-TNF	TOFA	0.17(0.01,1.74)	0.18(0.02,1.72)	-0.02(-0.10,0.01)
ANA		1.37(0.22,8.13)	1.35(0.23,7.53)	0.01(-0.07,0.09)
ANA	non-TNF	7.67(0.99,82.01)	7.38(0.99,76.17)	0.03(0.00,0.11)
Random-effects model	Residual deviance	17.25 vs 22 data points		

Table 20. Withdrawals due to adverse events: analysis 2 (only placebo comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model (Continued)

	Deviance information criteria	97.681
Fixed-effect model	Residual deviance	17.32 vs 22 data points
	Deviance information criteria	97.409
Note		
Total Patients	2747	
Total Studies	11	
2-arm	11	

Table 21. Withdrawals due to adverse events: analysis 3 (only placebo comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Monoclonal antibodies against TNF	Placebo	2.38(1.14,5.45)	2.30(1.14,5.05)	0.03(0.00,0.08)
Medications targeting TNF receptor: etanercept		1.71(0.50,6.98)	1.68(0.51,6.23)	0.02(-0.01,0.11)
TOFA		1.16(0.30,5.47)	1.16(0.31,5.03)	0.00(-0.02,0.08)
non-TNF		0.21(0.02,1.32)	0.21(0.02,1.31)	-0.02(-0.03,0.01)
ANA		1.64(0.58,5.40)	1.62(0.59,4.93)	0.01(-0.01,0.09)
Medications targeting TNF receptor: etanercept	Monoclonal antibodies against TNF	0.71(0.17,3.51)	0.72(0.18,3.19)	-0.01(-0.07,0.09)
TOFA		0.48(0.10,2.78)	0.50(0.11,2.61)	-0.03(-0.08,0.06)
non-TNF		0.09(0.01,0.63)	0.09(0.01,0.64)	-0.05(-0.10,-0.01)
ANA		0.69(0.18,2.78)	0.70(0.19,2.60)	-0.02(-0.07,0.07)
TOFA	Medications targeting TNF receptor: etanercept	0.67(0.10,4.91)	0.68(0.10,4.56)	-0.01(-0.11,0.07)
non-TNF		0.12(0.01,1.15)	0.12(0.01,1.15)	-0.03(-0.13,0.00)
ANA		0.96(0.16,5.17)	0.96(0.18,4.79)	0.00(-0.10,0.08)
non-TNF	TOFA	0.18(0.01,1.74)	0.18(0.01,1.72)	-0.02(-0.10,0.01)

Table 21. Withdrawals due to adverse events: analysis 3 (only placebo comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model *(Continued)*

ANA		1.42(0.22,8.73)	1.41(0.24,8.04)	0.01(-0.07,0.09)
ANA	non-TNF	8.08(0.95,91.00)	7.78(0.95,84.53)	0.03(0.00,0.11)
Random-effects model				
	Residual deviance	17.99 vs 22 data points		
	Deviance information criteria	99.313		
Fixed-effect model				
	Residual deviance	18.09 vs 22 data points		
	Deviance information criteria	99.128		
Note				
Total Patients	2747			
Total Studies	11			
2-arm	11			

Table 22. Withdrawals due to adverse events: analysis 4 (only placebo comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD biologic	Comparator: placebo	1.81 (0.83, 3.87)	1.77 (0.84, 3.69)	0.02 (0.00, 0.05)
LD biologic		1.13 (0.39, 2.99)	1.12 (0.40, 2.88)	0.00 (-0.02, 0.04)
HD biologic		1.53 (0.54, 4.00)	1.51 (0.55, 3.79)	0.01 (-0.01, 0.06)
LD biologic	SD biologic	0.62 (0.22, 1.63)	0.63 (0.23, 1.60)	-0.01 (-0.05, 0.02)
HD biologic		0.84 (0.31, 2.19)	0.85 (0.32, 2.11)	-0.01 (-0.04, 0.04)
HD biologic	LD biologic	1.35 (0.44, 4.16)	1.34 (0.46, 3.97)	0.01 (-0.03, 0.05)
Random-effects model				
	Residual deviance	26.76 vs 26 data-points		
	Deviance information criteria	119.734		
Fixed-effect model				
	Residual deviance	33.61 vs 26 data-points		
	Deviance information criteria	120.824		

Table 22. Withdrawals due to adverse events: analysis 4 (only placebo comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model *(Continued)*

Note	
Total studies	9
2-arm	4
3-arm	2
4-arm	3

Table 23. Withdrawals due to adverse events: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
TNF	MTX/other DMARD	1.14 (0.79, 1.70)	1.14 (0.79, 1.67)	0.00 (-0.01, 0.02)
Non-TNF		1.23 (0.75, 2.07)	1.23 (0.75, 2.02)	0.01 (-0.01, 0.03)
(MTX or DMARD) + TNF		1.20 (0.94, 1.54)	1.19 (0.94, 1.52)	0.00 (0.00, 0.01)
(MTX or DMARD) + non-TNF		1.21 (0.87, 1.72)	1.21 (0.87, 1.69)	0.00 (0.00, 0.02)
(MTX or DMARD) + TOFA		1.56 (0.83, 3.01)	1.54 (0.83, 2.87)	0.01 (0.00, 0.05)
Non-TNF	TNF	1.08 (0.60, 1.94)	1.08 (0.61, 1.90)	0.00 (-0.02, 0.02)
(MTX or DMARD) + TNF		1.05 (0.71, 1.53)	1.05 (0.72, 1.51)	0.00 (-0.01, 0.01)
(MTX or DMARD) + non-TNF		1.07 (0.65, 1.73)	1.06 (0.66, 1.70)	0.00 (-0.01, 0.02)
(MTX or DMARD) + TOFA		1.37 (0.65, 2.86)	1.36 (0.66, 2.73)	0.01 (-0.01, 0.05)
(MTX or DMARD) + TNF	non-TNF	0.97 (0.55, 1.69)	0.97 (0.57, 1.67)	0.00 (-0.02, 0.01)
(MTX or DMARD) + non-TNF		0.99 (0.57, 1.68)	0.99 (0.58, 1.65)	0.00 (-0.02, 0.02)
(MTX or DMARD) + TOFA		1.27 (0.56, 2.87)	1.26 (0.57, 2.75)	0.01 (-0.02, 0.05)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + TNF	1.01 (0.69, 1.51)	1.01 (0.69, 1.49)	0.00 (-0.01, 0.01)
(MTX or DMARD) + TOFA		1.30 (0.67, 2.55)	1.29 (0.68, 2.44)	0.01 (-0.01, 0.04)
(MTX or DMARD) + TOFA	(MTX or DMARD) + non-TNF	1.28 (0.62, 2.69)	1.27 (0.63, 2.57)	0.01 (-0.01, 0.05)
Random-effects model	Residual deviance	115.4 vs 117 data-points		

Table 23. Withdrawals due to adverse events: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model (Continued)

	Deviance in-formation cri-teria	612.815
Fixed-effect model	Residual de-viance	148.7 vs 117 data-points
	Deviance In-formation Cri-teria	628.564
Note		
Total participants	23,310	
Total Studies	55	
2-arm	48	
3-arm	7	

Table 24. Withdrawals due to adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
Monoclonal antibodies against TNF	MTX/other DMARD	0.93(0.63,1.43)	0.93(0.64,1.41)	0.00(-0.01,0.01)
Medication targeting TNF receptor: etanercept		0.82(0.38,1.71)	0.82(0.39,1.68)	0.00(-0.02,0.02)
Non-TNF		1.16(0.71,1.90)	1.15(0.72,1.86)	0.00(-0.01,0.02)
MTX + Monoclonal antibodies against TNF		1.53(1.16,2.02)	1.51(1.16,1.97)	0.01(0.00,0.03)
MTX + non-TNF		1.24(0.91,1.70)	1.23(0.91,1.67)	0.01(0.00,0.02)
MTX + TNF		0.73(0.50,1.07)	0.74(0.51,1.07)	-0.01(-0.02,0.00)
MTX + TOFA		1.66(0.93,3.00)	1.63(0.93,2.87)	0.01(0.00,0.05)
TNF	Monoclonal antibodies against TNF	0.88(0.38,1.96)	0.88(0.39,1.92)	0.00(-0.02,0.02)
Non-TNF		1.25(0.66,2.33)	1.24(0.66,2.28)	0.00(-0.01,0.03)
MTX + Monoclonal antibodies against TNF		1.65(0.99,2.66)	1.62(0.99,2.58)	0.01(0.00,0.03)
MTX + non-TNF		1.33(0.79,2.17)	1.32(0.79,2.13)	0.01(-0.01,0.02)

Table 24. Withdrawals due to adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model (Continued)

MTX + Medication targeting TNF receptor: etanercept		0.79(0.50,1.20)	0.79(0.51,1.19)	0.00(-0.02,0.00)
MTX + TOFA		1.78(0.87,3.59)	1.75(0.87,3.42)	0.02(0.00,0.05)
Non-TNF	Medication targeting TNF receptor: etanercept	1.42(0.66,3.13)	1.41(0.67,3.05)	0.01(-0.01,0.03)
MTX + Monoclonal antibodies against TNF		1.87(0.86,4.15)	1.84(0.86,4.02)	0.02(0.00,0.04)
MTX + non-TNF		1.52(0.70,3.40)	1.50(0.70,3.32)	0.01(-0.01,0.03)
MTX + Medication targeting TNF receptor: etanercept		0.90(0.42,1.94)	0.90(0.43,1.91)	0.00(-0.02,0.01)
MTX + TOFA		2.04(0.80,5.39)	2.00(0.80,5.14)	0.02(-0.01,0.06)
MTX + Monoclonal antibodies against TNF	Non-TNF	1.33(0.76,2.28)	1.32(0.77,2.23)	0.01(-0.01,0.03)
MTX + non-TNF		1.07(0.64,1.78)	1.07(0.65,1.76)	0.00(-0.02,0.02)
MTX + Medication targeting TNF receptor: etanercept		0.63(0.34,1.15)	0.64(0.35,1.14)	-0.01(-0.03,0.00)
MTX + TOFA		1.44(0.67,3.09)	1.42(0.67,2.95)	0.01(-0.01,0.05)
MTX + non-TNF	MTX + Monoclonal antibodies against TNF	0.81(0.55,1.19)	0.81(0.56,1.19)	-0.01(-0.02,0.01)
MTX + Medication targeting TNF receptor: etanercept		0.48(0.30,0.76)	0.49(0.31,0.77)	-0.02(-0.04,-0.01)
MTX + TOFA		1.08(0.60,2.02)	1.08(0.61,1.95)	0.00(-0.02,0.04)
MTX + Medication targeting TNF receptor: etanercept	MTX + non-TNF	0.59(0.36,0.96)	0.60(0.37,0.96)	-0.01(-0.03,0.00)
MTX + TOFA		1.34(0.69,2.62)	1.33(0.70,2.51)	0.01(-0.01,0.04)
MTX + TOFA	MTX + Medication targeting TNF receptor: etanercept	2.28(1.14,4.60)	2.22(1.14,4.37)	0.02(0.00,0.06)
Random-effects model	Residual deviance	116.4 vs 117 data-points		

Table 24. Withdrawals due to adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model (Continued)

	Deviance in-formation criteria	610.745
Fixed-effect model	Residual deviance	135 vs 117 data-points
	Deviance in-formation criteria	616.812
Note		
Total participants	23,309	
Total studies	55	
2-arm	48	
3-arm	7	

Table 25. Withdrawals due to adverse events: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
SD biologic	Compara-tor: MTX/ other DMARD	1.16 (0.84, 1.67)	1.16 (0.84, 1.64)	0.00 (0.00, 0.02)
HD biologic		1.17 (0.71, 1.91)	1.17 (0.72, 1.87)	0.00 (-0.01, 0.02)
LD biologic		0.87 (0.52, 1.49)	0.87 (0.52, 1.47)	0.00 (-0.01, 0.01)
MTX SD biologic		1.15 (0.95, 1.41)	1.15 (0.95, 1.39)	0.00 (0.00, 0.01)
MTX HD biologic		1.46 (1.07, 1.99)	1.44 (1.06, 1.95)	0.01 (0.00, 0.03)
MTX LD biologic		1.12 (0.68, 1.79)	1.12 (0.69, 1.76)	0.00 (-0.01, 0.02)
HD biologic	SD biologic	1.00 (0.55, 1.79)	1.00 (0.56, 1.75)	0.00 (-0.02, 0.02)
LD biologic		0.74 (0.44, 1.25)	0.75 (0.45, 1.24)	-0.01 (-0.02, 0.01)
MTX SD biologic		0.99 (0.69, 1.37)	0.99 (0.70, 1.36)	0.00 (-0.01, 0.01)
MTX HD biologic		1.25 (0.80, 1.92)	1.24 (0.80, 1.88)	0.01 (-0.01, 0.02)
MTX LD biologic		0.96 (0.54, 1.64)	0.96 (0.55, 1.62)	0.00 (-0.02, 0.02)
LD biologic	HD biologic	0.74 (0.37, 1.51)	0.75 (0.38, 1.49)	-0.01 (-0.03, 0.01)
MTX SD biologic		0.98 (0.59, 1.66)	0.98 (0.60, 1.64)	0.00 (-0.02, 0.01)

Table 25. Withdrawals due to adverse events: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model *(Continued)*

MTX HD biologic		1.25 (0.74, 2.14)	1.24 (0.75, 2.10)	0.01 (-0.01, 0.02)
MTX LD biologic		0.95 (0.50, 1.86)	0.95 (0.51, 1.83)	0.00 (-0.02, 0.02)
MTX SD biologic	LD biologic	1.33 (0.77, 2.26)	1.32 (0.77, 2.22)	0.01 (-0.01, 0.02)
MTX HD biologic		1.69 (0.92, 3.01)	1.66 (0.92, 2.92)	0.01 (0.00, 0.03)
MTX LD biologic		1.29 (0.64, 2.52)	1.28 (0.65, 2.46)	0.01 (-0.01, 0.03)
MTX HD biologic	MTX SD biologic	1.27 (0.91, 1.76)	1.26 (0.91, 1.72)	0.01 (0.00, 0.02)
MTX LD biologic		0.97 (0.59, 1.55)	0.97 (0.60, 1.53)	0.00 (-0.01, 0.02)
MTX LD biologic	MTX HD biologic	0.77 (0.44, 1.31)	0.77 (0.45, 1.30)	-0.01 (-0.03, 0.01)
Random-effects model	Residual deviance	127.5 vs 130 data-points		
	Deviance information criteria	640.011		
Fixed-effect model	Residual deviance	143.8 vs 130 data-points		
	Deviance information criteria	644.025		
Note				
Total participants	21,395			
Total studies	52			
2-arm	33			
3-arm	15			
4-arm	3			
7-arm	1			

WHERE IS ANALYSIS 2 (PBO), SAE?
Table 26. Serious Adverse Events analysis 2 for the type of medication (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
TNF Inhibitors	Placebo	1.27(0.75,2.29)	1.252(0.7623,2.19)	0.01(-0.01,0.05)

Table 26. Serious Adverse Events analysis 2 for the type of medication (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model (Continued)

TOFA		0.47(0.19,1.18)	0.4828(0.2015,1.172)	-0.02(-0.04,0.01)
TOFA	TNF Inhibitors	0.37(0.13,1.06)	0.3863(0.134,1.055)	-0.03(-0.07,0.00)
Random-Effect Model	Residual Deviance	18.55 vs 18 data points		
	Deviance Information Criteria	92.72		
Fixed-Effect Model	Residual Deviance	21.64 vs 18 data points		
	Deviance Information Criteria	93.944		
Total Patients	3092			
Total Studies	9			
2-arm	9			

Table 27. Serious adverse events: analysis 3 (only placebo comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Monoclonal antibodies against TNF	Placebo	1.25(0.72,2.38)	1.24(0.73,2.27)	0.01(-0.01,0.05)
TOFA		0.47(0.19,1.21)	0.48(0.20,1.20)	-0.02(-0.04,0.01)
Medication targeting TNF receptor: etanercept		1.57(0.20,15.45)	1.54(0.20,10.09)	0.02(-0.04,0.33)
TOFA	Monoclonal antibodies against TNF	0.38(0.12,1.11)	0.39(0.13,1.10)	-0.03(-0.08,0.00)
Medication targeting TNF receptor: etanercept		1.25(0.14,12.92)	1.23(0.15,8.61)	0.01(-0.06,0.33)
Medication targeting TNF receptor: etanercept	TOFA	3.32(0.34,37.78)	3.15(0.35,24.97)	0.04(-0.02,0.35)
Random-effects model	Residual deviance	19.27 vs 18 data points		
	Deviance information criteria	94.334		
Fixed-Effect Model	Residual deviance	22.69 vs 18 data points		

Table 27. Serious adverse events: analysis 3 (only placebo comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model *(Continued)*

	Deviance information criteria	95.962
Note		
Total participants		3092
Total studies		9
2-arm		9

Table 28. Serious adverse events analysis 4 (only placebo trials) by dose: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	Placebo	1.46 (0.71, 3.13)	1.43 (0.73, 2.91)	0.02 (-0.02, 0.07)
HD		0.71 (0.22, 2.15)	0.72 (0.23, 2.05)	-0.01 (-0.04, 0.04)
LD		1.18 (0.41, 3.53)	1.17 (0.43, 3.21)	0.01 (-0.03, 0.09)
HD	SD	0.48 (0.15, 1.44)	0.50 (0.16, 1.40)	-0.03 (-0.08, 0.02)
LD		0.80 (0.28, 2.36)	0.81 (0.30, 2.19)	-0.01 (-0.07, 0.07)
LD	HD	1.66 (0.51, 5.99)	1.62 (0.53, 5.52)	0.02 (-0.03, 0.10)
Random-effects model	Residual deviance	15.97 vs 16 data-points		
	Deviance information criteria	83.893		
Fixed-effect model	Residual deviance	23.26 vs 16 data-points		
	Deviance information criteria	87.741		
Note				
Total participants		1660		
Total studies		6		
2-arm		4		
4-arm		2		

Table 29. Serious adverse events: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
TNF	MTX/other DMARD	1.23 (0.86, 1.74)	1.21 (0.86, 1.67)	0.01 (-0.01, 0.04)
Non-TNF		1.21 (0.82, 1.80)	1.20 (0.83, 1.72)	0.01 (-0.01, 0.04)
MTX + TNF		1.19 (0.98, 1.44)	1.18 (0.98, 1.41)	0.01 (0.00, 0.02)
MTX + non-TNF		1.11 (0.92, 1.35)	1.10 (0.92, 1.33)	0.01 (0.00, 0.02)
MTX + TOFA		1.69 (0.88, 3.34)	1.63 (0.89, 2.98)	0.03 (-0.01, 0.10)
MTX + ANA		1.06 (0.65, 1.80)	1.05 (0.66, 1.73)	0.00 (-0.02, 0.04)
Non-TNF	TNF	1.00 (0.63, 1.57)	1.00 (0.65, 1.52)	0.00 (-0.03, 0.03)
MTX + TNF		0.97 (0.68, 1.40)	0.97 (0.70, 1.37)	0.00 (-0.03, 0.02)
MTX + TNF		0.91 (0.62, 1.32)	0.91 (0.64, 1.30)	-0.01 (-0.03, 0.01)
MTX + TOFA		1.39 (0.66, 2.95)	1.35 (0.68, 2.66)	0.02 (-0.03, 0.09)
MTX + ANA		0.86 (0.47, 1.65)	0.87 (0.49, 1.60)	-0.01 (-0.04, 0.03)
MTX + TNF	Non-TNF	0.97 (0.64, 1.49)	0.98 (0.67, 1.46)	0.00 (-0.03, 0.02)
MTX + TNF		0.91 (0.61, 1.37)	0.91 (0.63, 1.35)	-0.01 (-0.03, 0.02)
MTX + TOFA		1.40 (0.64, 3.02)	1.36 (0.66, 2.73)	0.02 (-0.03, 0.09)
MTX + ANA		0.87 (0.46, 1.69)	0.88 (0.49, 1.63)	-0.01 (-0.04, 0.03)
MTX + TNF	MTX + TNF	0.93 (0.73, 1.20)	0.94 (0.74, 1.18)	0.00 (-0.02, 0.01)
MTX + TOFA		1.43 (0.73, 2.84)	1.39 (0.74, 2.56)	0.02 (-0.02, 0.09)
MTX + ANA		0.89 (0.52, 1.57)	0.90 (0.54, 1.52)	-0.01 (-0.03, 0.03)
MTX + TOFA	MTX + non-TNF	1.53 (0.77, 3.06)	1.48 (0.78, 2.75)	0.03 (-0.01, 0.10)
MTX + ANA		0.96 (0.56, 1.67)	0.96 (0.58, 1.61)	0.00 (-0.03, 0.03)
MTX + ANA	MTX + TOFA	0.63 (0.27, 1.46)	0.65 (0.30, 1.42)	-0.03 (-0.10, 0.02)
Random-effects model	Residual deviance	110.1 vs 104 data-points		
	Deviance information	587.613		

Table 29. Serious adverse events: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model *(Continued)*

	tion criteria	
Fixed-effect model	Residual deviance	136.3 vs 104 data-points
	Deviance information criteria	587.457
Note		
Total participants	22,780	
Total studies	49	
2-arm	43	
3-arm	6	

Table 30. Serious adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD (95% CrI)
Monoclonal antibodies against TNF	MTX/other DMARD	1.08 (0.65, 1.79)	1.07 (0.66, 1.72)	0.00 (-0.02, 0.04)
Medication targeting TNF receptor: etanercept		1.53 (0.90, 2.63)	1.49 (0.91, 2.42)	0.03 (-0.01, 0.07)
Non-TNF		1.17 (0.77, 1.74)	1.16 (0.78, 1.68)	0.01 (-0.01, 0.04)
MTX + Monoclonal antibodies against TNF		1.18 (0.95, 1.46)	1.16 (0.95, 1.43)	0.01 (0.00, 0.02)
MTX + non-TNF		1.07 (0.88, 1.30)	1.06 (0.88, 1.28)	0.00 (-0.01, 0.01)
MTX + Medication targeting TNF receptor: etanercept		1.32 (0.90, 1.98)	1.30 (0.91, 1.89)	0.02 (-0.01, 0.05)
MTX + TOFA		2.02 (1.00, 4.31)	1.92 (1.00, 3.68)	0.05 (0.00, 0.14)
MTX + ANA		1.06 (0.63, 1.83)	1.06 (0.65, 1.75)	0.00 (-0.02, 0.04)
Medication targeting TNF receptor: etanercept	Monoclonal antibodies against TNF	1.42 (0.70, 2.97)	1.38 (0.71, 2.74)	0.02 (-0.02, 0.08)
Non-TNF		1.09 (0.63, 1.83)	1.08 (0.65, 1.77)	0.00 (-0.03, 0.03)

Table 30. Serious adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model *(Continued)*

MTX + Monoclonal antibodies against TNF		1.09 (0.66, 1.85)	1.08 (0.68, 1.79)	0.00 (-0.03, 0.03)
MTX + non-TNF		0.99 (0.59, 1.69)	0.99 (0.61, 1.65)	0.00 (-0.03, 0.02)
MTX + Medication targeting TNF receptor: etanercept		1.23 (0.68, 2.27)	1.22 (0.70, 2.16)	0.01 (-0.03, 0.05)
MTX + TOFA		1.89 (0.80, 4.66)	1.80 (0.81, 4.02)	0.05 (-0.01, 0.14)
MTX + ANA		0.99 (0.48, 2.06)	0.99 (0.50, 1.97)	0.00 (-0.04, 0.04)
Non-TNF	Medication targeting TNF receptor: etanercept	0.77 (0.38, 1.46)	0.78 (0.41, 1.42)	-0.02 (-0.07, 0.02)
MTX + Monoclonal antibodies against TNF		0.77 (0.44, 1.35)	0.78 (0.47, 1.33)	-0.02 (-0.07, 0.02)
MTX + non-TNF		0.70 (0.39, 1.22)	0.72 (0.43, 1.21)	-0.02 (-0.07, 0.01)
MTX + Medication targeting TNF receptor: etanercept		0.87 (0.52, 1.44)	0.88 (0.55, 1.40)	-0.01 (-0.05, 0.02)
MTX + TOFA		1.34 (0.55, 3.26)	1.30 (0.58, 2.86)	0.02 (-0.05, 0.12)
MTX + ANA		0.70 (0.33, 1.47)	0.72 (0.36, 1.43)	-0.02 (-0.08, 0.02)
MTX + Monoclonal antibodies against TNF	Non-TNF	1.00 (0.65, 1.59)	1.00 (0.67, 1.55)	0.00 (-0.03, 0.02)
MTX + non-TNF		0.91 (0.60, 1.41)	0.92 (0.62, 1.38)	-0.01 (-0.03, 0.02)
MTX + Medication targeting TNF receptor: etanercept		1.13 (0.66, 2.01)	1.12 (0.68, 1.92)	0.01 (-0.03, 0.04)
MTX + TOFA		1.74 (0.78, 4.07)	1.66 (0.79, 3.51)	0.04 (-0.02, 0.13)
MTX + ANA		0.91 (0.48, 1.79)	0.92 (0.50, 1.72)	-0.01 (-0.04, 0.04)
MTX + non-TNF	MTX + Monoclonal antibodies against TNF	0.91 (0.69, 1.18)	0.91 (0.71, 1.17)	-0.01 (-0.02, 0.01)
MTX + Medication targeting TNF receptor: etanercept		1.13 (0.73, 1.78)	1.12 (0.74, 1.70)	0.01 (-0.02, 0.04)
MTX + TOFA		1.73 (0.85, 3.71)	1.65 (0.86, 3.19)	0.04 (-0.01, 0.13)

Table 30. Serious adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model *(Continued)*

MTX + ANA		0.91 (0.51, 1.63)	0.91 (0.53, 1.57)	-0.01 (-0.03, 0.03)
MTX + Medication targeting TNF receptor: etanercept	MTX + non-TNF	1.24 (0.81, 1.95)	1.23 (0.82, 1.86)	0.01 (-0.01, 0.04)
MTX + TOFA		1.90 (0.92, 4.13)	1.81 (0.92, 3.54)	0.05 (0.00, 0.14)
MTX + ANA		1.00 (0.58, 1.78)	1.00 (0.59, 1.70)	0.00 (-0.03, 0.04)
MTX + TOFA	MTX + Medication targeting TNF receptor: etanercept	1.53 (0.69, 3.54)	1.47 (0.70, 3.08)	0.03 (-0.03, 0.13)
MTX + ANA		0.80 (0.42, 1.53)	0.82 (0.44, 1.49)	-0.01 (-0.05, 0.03)
MTX + ANA	MTX + TOFA	0.52 (0.21, 1.28)	0.55 (0.24, 1.26)	-0.05 (-0.14, 0.02)
Random-effects model	Residual deviance	109.4 vs 104 data-points		
	Deviance information criteria	588.641		
Fixed-effect model	Residual deviance	115.5 vs 104 data-points		
	Deviance information criteria	588.677		
Note				
Total participants	22,781			
Total studies	49			
2-arm	43			
3-arm	6			

Table 31. Serious adverse events analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
-----------	-----------	--------------	--------------	----------------

Table 31. Serious adverse events analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model *(Continued)*

SD biologic	Com-parator: MTX/other DMARD	1.16 (0.84, 1.67)	1.19 (0.8102, 1.736)	0.01 (-0.01, 0.04)
HD biologic		1.17 (0.71, 1.91)	1.219 (0.825, 1.785)	0.01 (-0.01, 0.04)
LD biologic		0.87 (0.52, 1.49)	1.268 (0.6808, 2.274)	0.01 (-0.02, 0.07)
MTX SD biologic		1.15 (0.95, 1.41)	1.094 (0.9497, 1.264)	0.01 (0.00, 0.01)
MTX LD biologic		1.46 (1.07, 1.99)	1.079 (0.8211, 1.426)	0.00 (-0.01, 0.02)
MTX HD biologic		1.12 (0.68, 1.79)	1.302 (1.014, 1.665)	0.02 (0.00, 0.04)
HD biologic	SD biologic	1.00 (0.55, 1.79)	1.024 (0.596, 1.757)	0.00 (-0.03, 0.04)
LD biologic		0.74 (0.44, 1.25)	1.064 (0.5752, 1.936)	0.00 (-0.03, 0.06)
MTX SD biologic		0.99 (0.69, 1.37)	0.9206 (0.6377, 1.342)	-0.01 (-0.03, 0.02)
MTX LD biologic		1.25 (0.80, 1.92)	0.9079 (0.5811, 1.437)	-0.01 (-0.04, 0.02)
MTX HD biologic		0.96 (0.54, 1.64)	1.095 (0.7013, 1.711)	0.01 (-0.03, 0.03)
LD biologic	HD biologic	0.74 (0.37, 1.51)	1.036 (0.5036, 2.125)	0.00 (-0.04, 0.06)
MTX SD biologic		0.98 (0.59, 1.66)	0.8979 (0.6064, 1.346)	-0.01 (-0.04, 0.02)
MTX LD biologic		1.25 (0.74, 2.14)	0.8826 (0.5705, 1.421)	-0.01 (-0.04, 0.02)
MTX HD biologic		0.95 (0.50, 1.86)	1.068 (0.706, 1.638)	0.00 (-0.03, 0.03)
MTX SD biologic	LD biologic	1.33 (0.77, 2.26)	0.8627 (0.482, 1.6)	-0.01 (-0.06, 0.02)
MTX LD biologic		1.69 (0.92, 3.01)	0.849 (0.4534, 1.658)	-0.01 (-0.07, 0.03)
MTX HD biologic		1.29 (0.64, 2.52)	1.026 (0.5434, 2.002)	0.00 (-0.06, 0.04)
MTX LD biologic	MTX SD biologic	1.27 (0.91, 1.76)	0.9871 (0.7486, 1.299)	0.00 (-0.02, 0.02)
MTX HD biologic		0.97 (0.59, 1.55)	1.191 (0.9129, 1.539)	0.01 (-0.01, 0.03)
MTX HD biologic	MTX LD biologic	0.77 (0.44, 1.31)	1.206 (0.8417, 1.73)	0.01 (-0.01, 0.04)
Random-effects model	Residual deviance	116.9 vs 115 data-points		
	Deviance information criteria	609.119		

Table 31. Serious adverse events analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model *(Continued)*

Fixed-effect model	Residual deviance	120.9 vs. 115 data-points
	Deviance information criteria	608.065
Note		
Total participants	20,677	
Total studies	47	
2-arm	31	
3-arm	12	
4-arm	3	
5-arm	1	

Table 32. Cancer: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF	MTX/other DMARD	1.32 (0.63,3.02)	1.31 (0.63,2.98)	0.00 (0.00,0.01)
Non-TNF		1.25 (0.36,5.05)	1.25 (0.36,4.92)	0.00 (-0.01,0.03)
MTX + TNF		1.21 (0.63,2.40)	1.21 (0.63,2.38)	0.00 (0.00,0.01)
MTX + non-TNF		0.99 (0.58,1.79)	0.99 (0.58,1.78)	0.00 (0.00,0.01)
Non-TNF	TNF	0.95 (0.22,4.35)	0.95 (0.23,4.25)	0.00 (-0.01,0.03)
MTX + TNF		0.91 (0.39,2.16)	0.91 (0.40,2.15)	0.00 (-0.01,0.01)
MTX + non-TNF		0.75 (0.29,1.84)	0.75 (0.30,1.83)	0.00 (-0.01,0.01)
MTX + TNF	Non-TNF	0.97 (0.21,3.77)	0.97 (0.22,3.73)	0.00 (-0.03,0.01)
MTX + non-TNF		0.79 (0.18,3.07)	0.79 (0.18,3.05)	0.00 (-0.03,0.01)
MTX + non-TNF	MTX + TNF	0.83 (0.38,1.71)	0.83 (0.39,1.70)	0.00 (-0.01,0.00)
Random-effects model	Residual deviance	38.11 vs 49 datapoints		
	Deviance information criteria	180.758		
Fixed-effect model	Residual deviance	38.09 vs 49 datapoints		

Table 32. Cancer: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons - random-effects model *(Continued)*

	Deviance information criteria	179.805
Note		
Total participants	9386	
Total studies	23	
2-arm	20	
3-arm	3	

Table 33. Cancer: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Medication targeting TNF receptor: etanercept	MTX/other DMARD	1.43 (0.62, 3.54)	1.43 (0.62, 3.48)	0.00 (0.00, 0.02)
Non-TNF		1.31 (0.31, 5.92)	1.30 (0.32, 5.72)	0.00 (-0.01, 0.04)
Monoclonal antibodies against TNF		1.31 (0.10, 17.94)	1.31 (0.10, 15.86)	0.00 (-0.01, 0.11)
MTX + non-TNF		0.92 (0.52, 1.70)	0.92 (0.52, 1.69)	0.00 (0.00, 0.00)
MTX + Medication targeting TNF receptor: etanercept		1.42 (0.62, 3.52)	1.42 (0.62, 3.46)	0.00 (0.00, 0.02)
MTX + Monoclonal antibodies against TNF		0.93 (0.33, 2.55)	0.93 (0.33, 2.53)	0.00 (-0.01, 0.01)
Non-TNF	Medication targeting TNF receptor: etanercept	0.91 (0.17, 5.40)	0.91 (0.17, 5.22)	0.00 (-0.02, 0.03)
Monoclonal antibodies against TNF		0.91 (0.06, 13.28)	0.91 (0.07, 11.82)	0.00 (-0.02, 0.11)
MTX + non-TNF		0.64 (0.22, 1.80)	0.64 (0.22, 1.79)	0.00 (-0.02, 0.00)
MTX + Medication targeting TNF receptor: etanercept		0.99 (0.39, 2.62)	0.99 (0.39, 2.59)	0.00 (-0.01, 0.01)
MTX + Monoclonal antibodies against TNF		0.65 (0.16, 2.33)	0.65 (0.16, 2.31)	0.00 (-0.02, 0.01)
Monoclonal antibodies against TNF	Non-TNF	0.97 (0.09, 12.11)	0.97 (0.09, 11.11)	0.00 (-0.03, 0.10)
MTX + non-TNF		0.71 (0.14, 3.14)	0.71 (0.15, 3.13)	0.00 (-0.04, 0.01)
MTX + Medication targeting TNF receptor: etanercept		1.09 (0.20, 5.80)	1.09 (0.21, 5.70)	0.00 (-0.03, 0.02)

Table 33. Cancer: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons - random-effects model *(Continued)*

MTX + Monoclonal antibodies against TNF		0.71 (0.11, 4.09)	0.71 (0.12, 4.05)	0.00 (-0.04, 0.01)
MTX + non-TNF	Monoclonal antibodies against TNF	0.70 (0.05, 9.51)	0.71 (0.05, 9.44)	0.00 (-0.12, 0.01)
MTX + Medication targeting TNF receptor: etanercept		1.07 (0.09, 14.19)	1.07 (0.10, 14.03)	0.00 (-0.11, 0.02)
MTX + Monoclonal antibodies against TNF		0.71 (0.04, 11.12)	0.72 (0.05, 11.01)	0.00 (-0.12, 0.01)
MTX + Medication targeting TNF receptor: etanercept	MTX + non-TNF	1.54 (0.56, 4.51)	1.54 (0.56, 4.43)	0.00 (0.00, 0.02)
MTX + Monoclonal antibodies against TNF		1.00 (0.38, 2.62)	1.00 (0.38, 2.60)	0.00 (-0.01, 0.01)
MTX + Monoclonal antibodies against TNF	MTX + Medication targeting TNF receptor: etanercept	0.65 (0.16, 2.42)	0.65 (0.16, 2.40)	0.00 (-0.02, 0.01)
Random-effects model	Residual deviance	39.55 vs 49 datapoints		
	Deviance information criteria	184.079		
Fixed-effect model	Residual deviance	39.64 vs 49 datapoints		
	Deviance information criteria	183.351		
Note				
Total participants	9386			
Total studies	23			
2-arm	20			
3-arm	3			

Table 34. Cancer: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	MTX/other DMARD	1.40 (0.63, 3.00)	1.40 (0.63, 2.96)	0.00 (0.00, 0.01)

Table 34. Cancer: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons - random-effects model *(Continued)*

HD		1.35 (0.35, 5.77)	1.35 (0.35, 5.58)	0.00 (-0.01, 0.03)
LD		0.64 (0.13, 2.33)	0.64 (0.13, 2.31)	0.00 (-0.01, 0.01)
MTX SD		1.05 (0.65, 1.71)	1.05 (0.65, 1.70)	0.00 (0.00, 0.00)
MTX LD		1.37 (0.42, 4.05)	1.36 (0.43, 3.97)	0.00 (-0.01, 0.02)
HD	SD	0.97 (0.22, 4.53)	0.97 (0.23, 4.40)	0.00 (-0.01, 0.03)
LD		0.46 (0.10, 1.68)	0.46 (0.10, 1.67)	-0.01 (-0.02, 0.01)
MTX SD		0.75 (0.34, 1.69)	0.75 (0.35, 1.68)	0.00 (-0.01, 0.00)
MTX LD		0.98 (0.25, 3.60)	0.98 (0.26, 3.53)	0.00 (-0.01, 0.02)
LD	HD	0.47 (0.06, 3.15)	0.47 (0.06, 3.11)	-0.01 (-0.04, 0.01)
MTX SD		0.79 (0.17, 3.14)	0.79 (0.18, 3.12)	0.00 (-0.03, 0.01)
MTX LD		1.02 (0.17, 5.56)	1.02 (0.17, 5.45)	0.00 (-0.03, 0.02)
MTX SD	LD	1.63 (0.42, 8.73)	1.63 (0.43, 8.65)	0.00 (-0.01, 0.01)
MTX LD		2.13 (0.39, 14.46)	2.11 (0.39, 14.17)	0.01 (-0.01, 0.03)
MTX LD	MTX SD	1.31 (0.40, 3.77)	1.30 (0.40, 3.69)	0.00 (-0.01, 0.02)
Random-effects model	Residual deviance	39.23 vs 51 datapoints		
	Deviance information criteria	181.671		
Fixed-effect model	Residual deviance	39.27 vs 51 datapoints		
	Deviance information criteria	180.863		
Note				
Total participants	8740			
Total studies	22			
2-arm	15			
3-arm	7			

APPENDICES

Appendix 1. List of all abbreviations used in appendices and figures

[Insert text]	[Insert text]
TNF	TNF biologic including etanercept, infliximab, certolizumab pegol, golimumab, adalimumab
non-TNF	Non-TNF biologic including abatacept, rituximab or tocilizumab
DMARD	Disease-modifying anti-rheumatic drug
MTX	Methotrexate
PL	Placebo
NMA	Network Meta-Analysis
CI	confidence interval
CrI	Credible interval
OR	Odds ratio
RR	Relative risk
SD	Standard dose
LD	Low dose
HD	High dose
IV	Intravenous (given via a needle into the vein)
SQ or SC	Subcutaneous (given/injected below the skin)
ABA	Abatacept
ADA	Adalimumab
ANA	Anakinra
CERTO	Certolizumab pegol
ETN	Etanercept
GOLI	Golimumab

(Continued)

INF	Infliximab
TOFA	Tofacitinib
TOCI	Tocilizumab
RITUX	Rituximab
Mono	Monoclonal antibody TNF biologic- includes Adalimumab, certolizumab pegol, infliximab and golimumab
TNF receptor	TNF receptor biologic = etanercept
TNF inhibitors	Includes 5 biologics that target TNF: Adalimumab, certolizumab pegol, infliximab, golimumab and etanercept
non-TNF	Includes 5 biologics that target cells/molecules other than TNF: Abatacept, tocilizumab and rituximab
Oral synthetic drug (oral small molecule)	Includes new janus kinase inhibitor oral drug, tofacitinib

Appendix 2. ACR50: main analysis

ACR50 combined: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
PL + MTX/MTX	PL	3.66(1.69,6.81)	3.15(1.62,5.14)	0.13(0.04,0.24)
DMARD/DMARD + PL		0.98(0.37,2.38)	0.98(0.38,2.20)	0.00(-0.04,0.07)
MTX + DMARD		5.57(2.31,13.66)	4.36(2.11,8.02)	0.20(0.07,0.39)
SD ETN SC		6.94(3.38,13.10)	5.09(2.90,7.94)	0.25(0.13,0.38)
SD ADA SC		3.69(2.13,6.72)	3.16(1.98,5.13)	0.13(0.07,0.23)
SD TOFA PO		6.44(3.31,13.07)	4.82(2.87,7.77)	0.23(0.12,0.39)
SD GOLI SC		8.10(3.04,22.03)	5.65(2.70,10.08)	0.28(0.11,0.52)
SD GOLI IV		6.49(2.15,18.77)	4.85(2.00,9.34)	0.23(0.06,0.48)
SD TOCI IV		5.43(2.12,13.52)	4.26(1.97,8.06)	0.20(0.06,0.39)
SD RITUX IV		2.52(0.29,13.36)	2.30(0.30,7.87)	0.08(-0.04,0.39)
SD ABA SC		9.95(2.69,46.12)	6.40(2.43,13.14)	0.33(0.09,0.68)

(Continued)

SD CERTO SC	9.56(3.04,34.80)	6.26(2.70,11.93)	0.32(0.10,0.63)
SD ETN SC + MTX	14.81(6.84,31.08)	8.01(4.78,12.05)	0.43(0.26,0.59)
SD INF IV + MTX	11.26(4.80,24.64)	6.94(3.82,10.64)	0.36(0.19,0.54)
SD ABA IV + MTX	14.62(6.12,33.05)	7.97(4.48,12.16)	0.43(0.23,0.61)
SD ADA SC + MTX	23.24(9.03,57.59)	9.75(5.74,14.38)	0.54(0.32,0.72)
SD CERTO SC + MTX/CER- TO+MTX	21.19(8.18,46.26)	9.46(5.51,13.45)	0.52(0.30,0.69)
SD RITUX IV + MTX	9.14(3.91,21.04)	6.08(3.26,9.92)	0.31(0.14,0.51)
SD TOFA PO + MTX	23.26(9.75,57.30)	9.82(6.11,14.14)	0.54(0.34,0.72)
SD GOLI SC + MTX	23.12(8.75,58.38)	9.79(5.68,14.19)	0.54(0.32,0.72)
SD ABA SC + MTX	18.02(6.44,49.02)	8.78(4.70,13.72)	0.48(0.25,0.68)
SD GOLI IV + MTX	8.64(3.20,22.14)	5.88(2.79,10.06)	0.30(0.12,0.52)
SD ANA SC + MTX	10.68(3.49,30.43)	6.67(3.01,11.55)	0.35(0.13,0.59)
SD TOCI IV + MTX	7.50(2.32,22.43)	5.36(2.13,10.30)	0.27(0.08,0.52)
SD CERTO SC + DMARD	5.17(1.87,14.27)	4.12(1.77,8.03)	0.19(0.05,0.41)
SD ADA SC + DMARD	3.09(0.76,11.16)	2.74(0.78,6.94)	0.11(-0.01,0.35)
SD ETN SC + DMARD	12.68(4.15,38.46)	7.36(3.45,12.62)	0.39(0.16,0.65)
SD TOCI SC + DMARD	4.91(1.24,18.43)	3.95(1.22,9.00)	0.18(0.01,0.48)
LD ADA SC	3.33(1.59,7.53)	2.92(1.53,5.52)	0.12(0.03,0.26)
LD ETN SC	3.51(1.56,7.76)	3.04(1.50,5.60)	0.12(0.03,0.27)
LD GOLI IV	3.85(1.15,12.60)	3.27(1.14,7.53)	0.14(0.01,0.38)
LD TOCI IV	0.65(0.11,2.67)	0.67(0.12,2.43)	-0.02(-0.06,0.08)
LD ADA SC + MTX	16.49(6.28,46.62)	8.42(4.58,13.41)	0.46(0.24,0.68)
LD RITUX IV + MTX	8.07(3.19,18.75)	5.62(2.79,9.50)	0.28(0.12,0.48)
LD ADA IV + MTX	14.69(2.25,82.04)	7.93(2.08,15.00)	0.43(0.07,0.78)
LD ABA IV + MTX	7.85(2.93,21.08)	5.52(2.62,9.82)	0.28(0.10,0.50)
LD ANA SC + MTX	7.33(1.54,32.97)	5.26(1.49,11.70)	0.26(0.03,0.61)
LD CERTO SC + MTX	14.70(4.41,47.72)	7.99(3.58,13.38)	0.43(0.17,0.69)
LD ETN SC + MTX	12.99(4.49,37.72)	7.49(3.65,12.44)	0.40(0.18,0.64)

(Continued)

LD GOLI IV + MTX		7.58(2.45,24.09)	5.38(2.22,10.42)	0.27(0.08,0.54)
LD TOCI IV + MTX		6.08(1.95,18.19)	4.64(1.83,9.22)	0.22(0.05,0.46)
LD TOFA PO + MTX		12.84(2.98,48.04)	7.40(2.66,13.00)	0.39(0.11,0.70)
HD TOCI IV		9.85(4.54,19.49)	6.40(3.64,9.73)	0.33(0.18,0.48)
HD TOFA PO		10.26(5.02,20.82)	6.53(3.97,9.90)	0.34(0.19,0.50)
HD ADA SC		4.69(2.28,10.74)	3.82(2.09,7.00)	0.17(0.07,0.34)
HD ETN SC		7.12(2.81,17.55)	5.19(2.49,9.25)	0.25(0.10,0.47)
HD GOLI SC		9.57(3.90,21.77)	6.26(3.25,10.12)	0.32(0.15,0.52)
HD ABA SC		14.48(3.81,62.31)	7.86(3.20,14.09)	0.42(0.14,0.74)
HD INF IV + MTX		18.36(7.49,43.86)	8.92(5.14,13.22)	0.48(0.28,0.67)
HD TOCI IV + MTX		17.54(7.25,37.88)	8.70(5.10,12.70)	0.47(0.27,0.64)
HD TOFA PO + MTX		18.47(7.83,45.79)	8.90(5.26,13.32)	0.49(0.29,0.68)
HD GOLI SC + MTX		17.77(6.82,47.15)	8.77(4.86,13.44)	0.48(0.26,0.68)
HD CERTO SC + MTX		24.79(10.00,59.86)	10.08(6.17,14.60)	0.56(0.35,0.73)
HD ADA SC + MTX		20.68(6.34,70.20)	9.33(4.67,14.68)	0.51(0.24,0.75)
HD TOCI IV + DMARD		3.61(1.09,11.27)	3.11(1.08,7.06)	0.13(0.01,0.35)
SD ANA SC + SD ETN SC + MTX		9.29(2.84,33.61)	6.10(2.51,11.95)	0.32(0.10,0.62)
SD ANA SC + LD ETN SC + MTX		14.26(4.13,48.43)	7.82(3.39,13.56)	0.42(0.16,0.69)
DMARD/DMARD + PL	PL + MTX/ MTX	0.27(0.12,0.63)	0.31(0.15,0.68)	-0.13(-0.23,-0.05)
MTX + DMARD		1.57(0.88,2.82)	1.41(0.90,2.15)	0.08(-0.02,0.21)
SD ETN SC		1.91(1.28,2.89)	1.63(1.19,2.29)	0.12(0.04,0.20)
SD ADA SC		1.03(0.50,2.31)	1.03(0.58,2.00)	0.00(-0.11,0.13)
SD TOFA PO		1.80(0.72,4.69)	1.56(0.78,3.18)	0.11(-0.06,0.29)
SD GOLI SC		2.27(0.89,6.00)	1.82(0.91,3.47)	0.15(-0.02,0.37)
SD GOLI IV		1.81(0.74,4.28)	1.57(0.78,2.76)	0.10(-0.05,0.31)
SD TOCI IV		1.52(0.69,3.30)	1.38(0.74,2.45)	0.07(-0.06,0.23)
SD RITUX IV		0.71(0.10,3.42)	0.75(0.12,2.35)	-0.05(-0.19,0.24)
SD ABA SC		2.80(0.61,14.74)	2.05(0.67,5.45)	0.20(-0.08,0.57)

(Continued)

SD CERTO SC	2.61(0.70,13.42)	1.99(0.75,5.34)	0.19(-0.06,0.53)
SD ETN SC + MTX	4.16(2.76,6.35)	2.56(1.93,3.64)	0.30(0.19,0.40)
SD INF IV + MTX	3.11(2.05,4.77)	2.19(1.68,2.99)	0.23(0.12,0.34)
SD ABA IV + MTX	4.07(2.66,6.22)	2.53(1.93,3.43)	0.29(0.17,0.41)
SD ADA SC + MTX	6.35(3.76,11.26)	3.10(2.31,4.37)	0.40(0.26,0.54)
SD CERTO SC + MTX/CER- TO+MTX	5.80(3.65,9.41)	2.99(2.25,4.21)	0.38(0.24,0.50)
SD RITUX IV + MTX	2.54(1.53,4.27)	1.95(1.37,2.78)	0.18(0.07,0.31)
SD TOFA PO + MTX	6.49(3.80,11.61)	3.11(2.28,4.56)	0.41(0.26,0.54)
SD GOLI SC + MTX	6.39(3.32,12.48)	3.10(2.14,4.71)	0.40(0.24,0.54)
SD ABA SC + MTX	5.06(2.49,10.03)	2.81(1.88,4.20)	0.35(0.17,0.51)
SD GOLI IV + MTX	2.37(1.22,4.82)	1.87(1.16,2.88)	0.17(0.03,0.34)
SD ANA SC + MTX	2.99(1.27,6.77)	2.14(1.21,3.49)	0.22(0.04,0.42)
SD TOCI IV + MTX	2.10(0.78,5.43)	1.74(0.81,3.13)	0.14(-0.04,0.36)
SD CERTO SC + DMARD	1.45(0.47,4.57)	1.34(0.55,3.01)	0.06(-0.12,0.30)
SD ADA SC + DMARD	0.87(0.26,3.00)	0.89(0.30,2.27)	-0.02(-0.16,0.21)
SD ETN SC + DMARD	3.56(1.36,9.54)	2.37(1.25,4.09)	0.26(0.05,0.49)
SD TOCI SC + DMARD	1.37(0.41,4.84)	1.28(0.47,2.92)	0.05(-0.12,0.33)
LD ADA SC	0.95(0.37,2.61)	0.96(0.44,2.15)	-0.01(-0.14,0.15)
LD ETN SC	0.98(0.50,1.88)	0.98(0.57,1.64)	0.00(-0.10,0.11)
LD GOLI IV	1.08(0.37,2.92)	1.06(0.43,2.13)	0.01(-0.12,0.21)
LD TOCI IV	0.18(0.03,0.66)	0.22(0.04,0.71)	-0.14(-0.25,-0.04)
LD ADA SC + MTX	4.55(2.36,9.09)	2.67(1.83,3.95)	0.32(0.16,0.49)
LD RITUX IV + MTX	2.22(1.29,3.78)	1.78(1.22,2.57)	0.15(0.04,0.29)
LD ADA IV + MTX	4.07(0.70,20.43)	2.52(0.75,4.91)	0.29(-0.05,0.63)
LD ABA IV + MTX	2.19(1.15,4.20)	1.78(1.11,2.65)	0.15(0.02,0.31)
LD ANA SC + MTX	2.01(0.54,8.21)	1.67(0.59,3.74)	0.13(-0.07,0.46)
LD CERTO SC + MTX	4.12(1.67,10.42)	2.54(1.49,4.24)	0.30(0.08,0.52)
LD ETN SC + MTX	3.66(1.61,8.16)	2.40(1.43,3.82)	0.27(0.08,0.47)

(Continued)

LD GOLI IV + MTX		2.13(0.83,5.69)	1.75(0.85,3.06)	0.14(-0.03,0.38)
LD TOCI IV + MTX		1.71(0.63,4.45)	1.50(0.68,2.88)	0.09(-0.07,0.30)
LD TOFA PO + MTX		3.54(1.05,10.97)	2.35(1.05,4.11)	0.26(0.01,0.53)
HD TOCI IV		2.69(1.64,4.53)	2.02(1.42,3.00)	0.19(0.09,0.30)
HD TOFA PO		2.91(1.13,6.96)	2.11(1.09,3.99)	0.21(0.02,0.39)
HD ADA SC		1.31(0.53,3.66)	1.23(0.61,2.74)	0.04(-0.10,0.23)
HD ETN SC		2.00(0.98,4.13)	1.68(0.98,2.69)	0.13(0.00,0.30)
HD GOLI SC		2.66(1.32,5.56)	2.01(1.22,3.29)	0.19(0.05,0.36)
HD ABA SC		3.98(0.87,21.43)	2.48(0.90,6.26)	0.29(-0.02,0.63)
HD INF IV + MTX		5.06(2.95,8.88)	2.80(2.04,4.07)	0.35(0.20,0.48)
HD TOCI IV + MTX		4.85(2.84,8.32)	2.77(1.98,4.06)	0.34(0.20,0.46)
HD TOFA PO + MTX		5.23(2.96,9.43)	2.84(2.08,4.16)	0.35(0.20,0.50)
HD GOLI SC + MTX		4.96(2.55,10.15)	2.78(1.90,4.24)	0.34(0.17,0.51)
HD CERTO SC + MTX		6.96(4.03,12.34)	3.21(2.38,4.77)	0.42(0.28,0.55)
HD ADA SC + MTX		5.77(2.26,15.13)	2.96(1.80,4.72)	0.38(0.15,0.58)
HD TOCI IV + DMARD		0.99(0.37,2.99)	1.00(0.43,2.21)	0.00(-0.13,0.21)
SD ANA SC + SD ETN SC + MTX		2.65(0.91,7.95)	1.99(0.92,3.62)	0.19(-0.01,0.45)
SD ANA SC + LD ETN SC + MTX		3.92(1.35,11.55)	2.48(1.27,4.39)	0.28(0.05,0.53)
MTX + DMARD	DMARD/ DMARD + PL	5.73(2.15,15.44)	4.44(1.92,10.18)	0.20(0.08,0.38)
SD ETN SC		7.00(3.18,16.12)	5.12(2.54,10.99)	0.24(0.15,0.37)
SD ADA SC		3.82(1.49,10.43)	3.24(1.41,8.32)	0.13(0.04,0.23)
SD TOFA PO		6.69(2.23,20.71)	4.95(1.94,13.32)	0.23(0.10,0.39)
SD GOLI SC		8.45(2.52,28.38)	5.74(2.18,14.79)	0.28(0.11,0.51)
SD GOLI IV		6.69(2.03,21.73)	4.90(1.84,12.38)	0.23(0.07,0.47)
SD TOCI IV		5.54(1.99,15.19)	4.30(1.81,10.25)	0.20(0.07,0.38)
SD RITUX IV		2.62(0.35,14.24)	2.37(0.36,9.12)	0.08(-0.04,0.38)
SD ABA SC		10.22(1.96,67.26)	6.42(1.78,21.42)	0.33(0.07,0.68)

(Continued)

SD CERTO SC	9.52(2.41,55.12)	6.21(2.11,20.67)	0.32(0.09,0.64)
SD ETN SC + MTX	15.43(6.09,36.84)	8.16(3.82,17.50)	0.43(0.27,0.58)
SD INF IV + MTX	11.55(4.44,28.43)	6.97(3.19,15.12)	0.36(0.20,0.53)
SD ABA IV + MTX	14.98(5.67,38.74)	8.01(3.80,17.66)	0.42(0.25,0.60)
SD ADA SC + MTX	23.75(8.83,64.04)	9.87(4.67,22.02)	0.54(0.33,0.71)
SD CERTO SC + MTX/CER- TO+MTX	21.40(8.90,54.77)	9.45(4.58,21.00)	0.51(0.32,0.67)
SD RITUX IV + MTX	9.36(3.71,24.79)	6.17(2.85,13.68)	0.31(0.16,0.49)
SD TOFA PO + MTX	24.16(8.45,63.98)	9.85(4.53,22.14)	0.54(0.35,0.71)
SD GOLI SC + MTX	23.37(8.62,68.20)	9.78(4.66,22.22)	0.53(0.34,0.72)
SD ABA SC + MTX	18.79(6.14,55.73)	8.88(3.96,20.29)	0.48(0.26,0.68)
SD GOLI IV + MTX	8.82(3.13,25.00)	5.96(2.52,13.35)	0.29(0.13,0.51)
SD ANA SC + MTX	10.76(3.51,34.96)	6.68(2.78,15.97)	0.35(0.14,0.58)
SD TOCI IV + MTX	7.72(2.37,24.38)	5.42(2.08,13.15)	0.26(0.09,0.50)
SD CERTO SC + DMARD	5.29(2.04,14.40)	4.16(1.83,9.28)	0.19(0.06,0.40)
SD ADA SC + DMARD	3.17(1.27,7.97)	2.78(1.24,5.67)	0.11(0.01,0.32)
SD ETN SC + DMARD	13.15(4.43,40.09)	7.44(3.25,16.84)	0.39(0.18,0.63)
SD TOCI SC + DMARD	5.09(2.05,12.60)	3.99(1.93,7.58)	0.18(0.04,0.43)
LD ADA SC	3.51(1.11,11.39)	3.02(1.10,8.87)	0.12(0.01,0.26)
LD ETN SC	3.57(1.35,9.68)	3.07(1.30,7.43)	0.12(0.03,0.26)
LD GOLI IV	3.95(1.07,14.06)	3.33(1.06,9.32)	0.14(0.01,0.36)
LD TOCI IV	0.66(0.12,3.03)	0.67(0.13,2.77)	-0.02(-0.09,0.08)
LD ADA SC + MTX	17.11(5.62,50.08)	8.52(3.75,19.41)	0.45(0.25,0.66)
LD RITUX IV + MTX	8.19(3.22,20.68)	5.65(2.63,12.55)	0.28(0.13,0.47)
LD ADA IV + MTX	14.37(2.12,93.58)	7.65(1.97,22.26)	0.42(0.06,0.78)
LD ABA IV + MTX	8.07(2.70,22.51)	5.62(2.32,12.95)	0.27(0.11,0.48)
LD ANA SC + MTX	7.55(1.67,34.99)	5.28(1.59,14.89)	0.26(0.04,0.60)
LD CERTO SC + MTX	15.23(4.36,51.01)	8.03(3.36,18.78)	0.43(0.18,0.68)
LD ETN SC + MTX	13.60(4.08,41.18)	7.57(3.08,17.26)	0.40(0.18,0.63)

(Continued)

LD GOLI IV + MTX		7.88(2.31,27.60)	5.58(2.03,13.62)	0.27(0.09,0.53)
LD TOCI IV + MTX		6.21(2.01,20.21)	4.64(1.83,11.75)	0.22(0.06,0.46)
LD TOFA PO + MTX		13.09(3.10,53.35)	7.35(2.61,18.10)	0.39(0.11,0.68)
HD TOCI IV		10.02(4.58,21.22)	6.44(3.23,13.55)	0.32(0.20,0.45)
HD TOFA PO		10.64(3.51,31.38)	6.67(2.69,17.25)	0.34(0.17,0.50)
HD ADA SC		4.92(1.56,16.41)	3.95(1.46,11.38)	0.17(0.05,0.34)
HD ETN SC		7.30(2.73,21.44)	5.23(2.30,12.42)	0.25(0.10,0.47)
HD GOLI SC		9.78(3.41,28.72)	6.38(2.68,15.33)	0.32(0.16,0.52)
HD ABA SC		14.60(3.02,89.72)	7.82(2.52,24.97)	0.42(0.13,0.74)
HD INF IV + MTX		18.86(7.03,48.19)	8.96(4.12,19.83)	0.48(0.29,0.65)
HD TOCI IV + MTX		17.95(7.14,42.71)	8.77(4.14,18.85)	0.47(0.30,0.63)
HD TOFA PO + MTX		19.49(6.68,52.18)	9.08(4.03,20.32)	0.48(0.29,0.67)
HD GOLI SC + MTX		18.31(6.35,54.48)	8.80(3.96,20.53)	0.47(0.27,0.67)
HD CERTO SC + MTX		25.75(9.86,68.31)	10.24(4.85,22.45)	0.56(0.37,0.72)
HD ADA SC + MTX		21.47(6.23,78.69)	9.39(4.00,22.26)	0.51(0.25,0.75)
HD TOCI IV + DMARD		3.74(1.94,6.85)	3.16(1.83,5.11)	0.13(0.04,0.30)
SD ANA SC + SD ETN SC + MTX		9.84(2.56,36.96)	6.33(2.21,15.71)	0.32(0.10,0.60)
SD ANA SC + LD ETN SC + MTX		14.70(3.90,54.42)	7.81(2.97,19.10)	0.42(0.16,0.68)
SD ETN SC	MTX + DMARD	1.23(0.66,2.37)	1.16(0.76,1.91)	0.04(-0.09,0.16)
SD ADA SC		0.67(0.28,1.68)	0.74(0.39,1.50)	-0.07(-0.26,0.08)
SD TOFA PO		1.16(0.39,3.34)	1.11(0.52,2.43)	0.03(-0.19,0.23)
SD GOLI SC		1.46(0.48,4.22)	1.29(0.59,2.64)	0.08(-0.15,0.32)
SD GOLI IV		1.15(0.38,3.37)	1.10(0.48,2.27)	0.03(-0.19,0.26)
SD TOCI IV		0.97(0.38,2.54)	0.98(0.47,1.95)	-0.01(-0.19,0.18)
SD RITUX IV		0.45(0.06,2.33)	0.54(0.08,1.75)	-0.12(-0.33,0.17)
SD ABA SC		1.81(0.36,10.65)	1.48(0.47,4.03)	0.13(-0.19,0.51)
SD CERTO SC		1.71(0.39,8.34)	1.43(0.51,3.69)	0.11(-0.18,0.46)
SD ETN SC + MTX		2.67(1.63,4.24)	1.83(1.30,2.72)	0.22(0.11,0.32)

(Continued)

SD INF IV + MTX	2.00(1.05,3.70)	1.56(1.03,2.49)	0.15(0.01,0.28)
SD ABA IV + MTX	2.61(1.28,5.27)	1.80(1.15,2.99)	0.21(0.06,0.37)
SD ADA SC + MTX	4.11(1.87,9.46)	2.22(1.38,3.82)	0.32(0.14,0.50)
SD CERTO SC + MTX/CER- TO+MTX	3.71(1.76,7.84)	2.13(1.36,3.57)	0.30(0.13,0.46)
SD RITUX IV + MTX	1.62(0.75,3.65)	1.39(0.81,2.43)	0.10(-0.06,0.28)
SD TOFA PO + MTX	4.17(1.85,9.68)	2.22(1.39,3.87)	0.33(0.14,0.50)
SD GOL I SC + MTX	4.13(1.65,9.80)	2.22(1.31,3.91)	0.32(0.12,0.50)
SD ABA SC + MTX	3.24(1.27,8.10)	2.00(1.16,3.54)	0.26(0.05,0.46)
SD GOL I IV + MTX	1.51(0.63,3.81)	1.32(0.73,2.48)	0.08(-0.09,0.29)
SD ANA SC + MTX	1.92(0.67,5.09)	1.53(0.75,2.85)	0.14(-0.08,0.36)
SD TOCI IV + MTX	1.35(0.45,4.09)	1.23(0.55,2.57)	0.06(-0.15,0.30)
SD CERTO SC + DMARD	0.94(0.27,3.22)	0.96(0.37,2.30)	-0.01(-0.25,0.24)
SD ADA SC + DMARD	0.56(0.15,2.14)	0.63(0.20,1.73)	-0.09(-0.30,0.14)
SD ETN SC + DMARD	2.27(0.78,6.68)	1.67(0.85,3.24)	0.18(-0.05,0.43)
SD TOCI SC + DMARD	0.88(0.23,3.44)	0.91(0.31,2.25)	-0.02(-0.25,0.27)
LD ADA SC	0.61(0.21,1.83)	0.68(0.30,1.61)	-0.08(-0.29,0.11)
LD ETN SC	0.62(0.28,1.46)	0.70(0.37,1.36)	-0.08(-0.24,0.06)
LD GOL I IV	0.69(0.21,2.31)	0.75(0.28,1.80)	-0.06(-0.26,0.17)
LD TOCI IV	0.12(0.02,0.51)	0.15(0.03,0.56)	-0.22(-0.40,-0.08)
LD ADA SC + MTX	2.88(1.20,7.42)	1.90(1.13,3.38)	0.24(0.04,0.45)
LD RITUX IV + MTX	1.42(0.65,3.15)	1.27(0.74,2.21)	0.07(-0.09,0.24)
LD ADA IV + MTX	2.62(0.40,15.12)	1.79(0.48,4.13)	0.21(-0.15,0.58)
LD ABA IV + MTX	1.40(0.56,3.39)	1.26(0.67,2.30)	0.07(-0.12,0.26)
LD ANA SC + MTX	1.30(0.30,5.78)	1.20(0.38,2.85)	0.05(-0.19,0.39)
LD CERTO SC + MTX	2.63(0.91,8.27)	1.80(0.94,3.44)	0.22(-0.02,0.47)
LD ETN SC + MTX	2.36(0.92,5.64)	1.70(0.95,2.92)	0.19(-0.02,0.39)
LD GOL I IV + MTX	1.37(0.45,4.14)	1.24(0.54,2.52)	0.06(-0.15,0.30)
LD TOCI IV + MTX	1.09(0.34,3.27)	1.06(0.45,2.25)	0.02(-0.20,0.25)

(Continued)

LD TOFA PO + MTX		2.25(0.57,8.33)	1.66(0.67,3.40)	0.18(-0.10,0.47)
HD TOCI IV		1.74(0.81,3.70)	1.45(0.88,2.56)	0.12(-0.05,0.27)
HD TOFA PO		1.85(0.61,5.04)	1.51(0.73,3.04)	0.13(-0.11,0.34)
HD ADA SC		0.85(0.28,2.57)	0.89(0.40,2.03)	-0.03(-0.24,0.18)
HD ETN SC		1.27(0.53,3.13)	1.18(0.65,2.24)	0.05(-0.13,0.24)
HD GOLI SC		1.70(0.67,4.28)	1.42(0.77,2.71)	0.11(-0.09,0.31)
HD ABA SC		2.57(0.53,14.69)	1.79(0.65,4.51)	0.21(-0.13,0.57)
HD INF IV + MTX		3.24(1.55,7.05)	2.01(1.28,3.40)	0.27(0.10,0.43)
HD TOCI IV + MTX		3.12(1.42,6.58)	1.97(1.22,3.35)	0.26(0.08,0.42)
HD TOFA PO + MTX		3.35(1.44,7.78)	2.04(1.23,3.57)	0.27(0.09,0.46)
HD GOLI SC + MTX		3.20(1.30,7.77)	1.99(1.17,3.54)	0.26(0.06,0.45)
HD CERTO SC + MTX		4.47(1.96,10.26)	2.28(1.43,4.03)	0.34(0.15,0.51)
HD ADA SC + MTX		3.73(1.27,11.82)	2.11(1.15,3.91)	0.30(0.05,0.54)
HD TOCI IV + DMARD		0.65(0.20,2.05)	0.72(0.28,1.69)	-0.07(-0.26,0.15)
SD ANA SC + SD ETN SC + MTX		1.69(0.56,5.21)	1.41(0.65,2.74)	0.11(-0.11,0.38)
SD ANA SC + LD ETN SC + MTX		2.53(0.87,7.62)	1.76(0.91,3.26)	0.20(-0.03,0.45)
SD ADA SC	SD ETN SC	0.54(0.26,1.21)	0.63(0.37,1.15)	-0.11(-0.26,0.03)
SD TOFA PO		0.94(0.39,2.37)	0.96(0.51,1.81)	-0.01(-0.20,0.18)
SD GOLI SC		1.19(0.45,3.22)	1.13(0.57,2.06)	0.04(-0.16,0.27)
SD GOLI IV		0.94(0.35,2.46)	0.96(0.44,1.73)	-0.01(-0.19,0.21)
SD TOCI IV		0.80(0.33,1.87)	0.85(0.42,1.50)	-0.04(-0.21,0.14)
SD RITUX IV		0.37(0.05,1.82)	0.46(0.07,1.45)	-0.16(-0.33,0.14)
SD ABA SC		1.47(0.32,7.50)	1.28(0.44,3.01)	0.09(-0.21,0.46)
SD CERTO SC		1.39(0.37,6.41)	1.24(0.48,2.90)	0.07(-0.20,0.42)
SD ETN SC + MTX		2.17(1.40,3.36)	1.58(1.23,2.08)	0.18(0.08,0.29)
SD INF IV + MTX		1.64(0.92,2.82)	1.36(0.95,1.89)	0.11(-0.02,0.24)
SD ABA IV + MTX		2.12(1.15,3.75)	1.56(1.10,2.16)	0.17(0.03,0.31)
SD ADA SC + MTX		3.31(1.70,6.75)	1.91(1.35,2.69)	0.28(0.12,0.44)

(Continued)

SD CERTO SC + MTX/CER-TO+MTX	3.04(1.63,5.70)	1.84(1.34,2.61)	0.26(0.11,0.41)
SD RITUX IV + MTX	1.32(0.71,2.58)	1.20(0.78,1.80)	0.06(-0.07,0.22)
SD TOFA PO + MTX	3.40(1.68,7.11)	1.93(1.35,2.80)	0.29(0.12,0.45)
SD GOLII SC + MTX	3.32(1.58,7.24)	1.91(1.31,2.84)	0.28(0.10,0.45)
SD ABA SC + MTX	2.64(1.14,5.82)	1.73(1.08,2.55)	0.23(0.03,0.41)
SD GOLII IV + MTX	1.25(0.57,2.80)	1.15(0.67,1.88)	0.05(-0.11,0.24)
SD ANA SC + MTX	1.57(0.61,3.87)	1.34(0.69,2.14)	0.10(-0.10,0.31)
SD TOCI IV + MTX	1.11(0.38,2.98)	1.07(0.48,1.95)	0.02(-0.18,0.25)
SD CERTO SC + DMARD	0.76(0.25,2.22)	0.82(0.35,1.67)	-0.05(-0.25,0.18)
SD ADA SC + DMARD	0.45(0.13,1.55)	0.54(0.19,1.34)	-0.14(-0.30,0.09)
SD ETN SC + DMARD	1.85(0.75,4.62)	1.45(0.83,2.34)	0.14(-0.06,0.36)
SD TOCI SC + DMARD	0.72(0.21,2.47)	0.79(0.29,1.73)	-0.06(-0.25,0.21)
LD ADA SC	0.49(0.19,1.33)	0.59(0.28,1.23)	-0.13(-0.29,0.05)
LD ETN SC	0.51(0.27,0.93)	0.61(0.37,0.95)	-0.12(-0.23,-0.01)
LD GOLII IV	0.57(0.18,1.64)	0.66(0.26,1.38)	-0.10(-0.26,0.10)
LD TOCI IV	0.09(0.02,0.36)	0.13(0.03,0.45)	-0.26(-0.39,-0.14)
LD ADA SC + MTX	2.39(1.11,5.53)	1.65(1.07,2.47)	0.20(0.02,0.40)
LD RITUX IV + MTX	1.17(0.58,2.22)	1.11(0.68,1.66)	0.03(-0.11,0.18)
LD ADA IV + MTX	2.15(0.35,11.91)	1.57(0.44,3.05)	0.18(-0.17,0.53)
LD ABA IV + MTX	1.13(0.52,2.52)	1.09(0.62,1.74)	0.03(-0.12,0.21)
LD ANA SC + MTX	1.07(0.27,4.40)	1.05(0.34,2.22)	0.01(-0.22,0.35)
LD CERTO SC + MTX	2.15(0.78,5.93)	1.57(0.84,2.51)	0.18(-0.05,0.41)
LD ETN SC + MTX	1.92(0.79,4.40)	1.48(0.85,2.26)	0.15(-0.05,0.35)
LD GOLII IV + MTX	1.11(0.40,3.11)	1.07(0.50,1.95)	0.02(-0.17,0.27)
LD TOCI IV + MTX	0.88(0.31,2.38)	0.92(0.40,1.72)	-0.03(-0.21,0.20)
LD TOFA PO + MTX	1.87(0.52,6.29)	1.46(0.61,2.61)	0.14(-0.12,0.42)
HD TOCI IV	1.41(0.79,2.48)	1.25(0.86,1.82)	0.08(-0.05,0.21)
HD TOFA PO	1.52(0.60,3.60)	1.31(0.71,2.27)	0.09(-0.11,0.29)

(Continued)

HD ADA SC		0.69(0.28,1.87)	0.76(0.40,1.56)	-0.07(-0.25,0.13)
HD ETN SC		1.04(0.53,2.06)	1.03(0.63,1.57)	0.01(-0.12,0.17)
HD GOLI SC		1.38(0.63,3.12)	1.23(0.72,2.01)	0.07(-0.10,0.26)
HD ABA SC		2.11(0.46,10.73)	1.56(0.58,3.37)	0.17(-0.16,0.52)
HD INF IV + MTX		2.66(1.38,5.23)	1.74(1.21,2.50)	0.23(0.07,0.38)
HD TOCI IV + MTX		2.51(1.36,4.86)	1.70(1.20,2.49)	0.22(0.07,0.36)
HD TOFA PO + MTX		2.73(1.35,5.74)	1.76(1.21,2.59)	0.23(0.07,0.40)
HD GOLI SC + MTX		2.60(1.22,5.76)	1.72(1.14,2.58)	0.22(0.04,0.41)
HD CERTO SC + MTX		3.63(1.87,7.36)	1.98(1.42,2.86)	0.31(0.14,0.45)
HD ADA SC + MTX		3.03(1.06,8.85)	1.84(1.03,2.87)	0.26(0.01,0.48)
HD TOCI IV + DMARD		0.52(0.19,1.50)	0.62(0.26,1.31)	-0.11(-0.27,0.09)
SD ANA SC + SD ETN SC + MTX		1.36(0.47,4.22)	1.22(0.57,2.16)	0.07(-0.14,0.34)
SD ANA SC + LD ETN SC + MTX		2.05(0.69,5.80)	1.53(0.77,2.52)	0.17(-0.07,0.40)
SD TOFA PO	SD ADA SC	1.73(0.80,3.81)	1.51(0.85,2.66)	0.10(-0.04,0.26)
SD GOLI SC		2.16(0.74,6.48)	1.75(0.78,3.50)	0.15(-0.05,0.39)
SD GOLI IV		1.73(0.54,5.57)	1.51(0.61,3.22)	0.10(-0.09,0.35)
SD TOCI IV		1.46(0.57,3.69)	1.34(0.63,2.60)	0.07(-0.09,0.26)
SD RITUX IV		0.67(0.08,3.59)	0.72(0.09,2.47)	-0.05(-0.20,0.26)
SD ABA SC		2.74(0.62,13.53)	2.03(0.68,4.74)	0.20(-0.07,0.55)
SD CERTO SC		2.59(0.71,10.10)	1.98(0.76,4.10)	0.19(-0.06,0.50)
SD ETN SC + MTX		3.97(1.77,8.94)	2.49(1.47,4.16)	0.29(0.12,0.47)
SD INF IV + MTX		3.00(1.21,7.15)	2.13(1.16,3.72)	0.22(0.04,0.42)
SD ABA IV + MTX		3.88(1.60,9.17)	2.46(1.40,4.19)	0.29(0.09,0.47)
SD ADA SC + MTX		6.24(2.30,15.44)	3.04(1.70,4.99)	0.41(0.17,0.58)
SD CERTO SC + MTX/CER- TO+MTX		5.69(2.20,14.03)	2.92(1.70,4.87)	0.38(0.16,0.56)
SD RITUX IV + MTX		2.46(0.94,5.83)	1.91(0.95,3.29)	0.18(-0.01,0.37)
SD TOFA PO + MTX		6.34(2.41,15.58)	3.06(1.76,4.98)	0.41(0.19,0.59)
SD GOLI SC + MTX		6.17(2.25,17.16)	3.03(1.73,5.10)	0.40(0.17,0.60)

(Continued)

SD ABA SC + MTX	4.84(1.63,13.02)	2.74(1.41,4.62)	0.34(0.10,0.55)
SD GOLI IV + MTX	2.29(0.81,6.37)	1.82(0.85,3.44)	0.16(-0.03,0.39)
SD ANA SC + MTX	2.90(0.91,8.36)	2.10(0.93,3.88)	0.22(-0.02,0.46)
SD TOCI IV + MTX	2.01(0.67,6.11)	1.67(0.72,3.44)	0.13(-0.06,0.39)
SD CERTO SC + DMARD	1.37(0.47,4.26)	1.27(0.53,2.75)	0.05(-0.11,0.29)
SD ADA SC + DMARD	0.83(0.20,3.18)	0.86(0.24,2.33)	-0.03(-0.18,0.22)
SD ETN SC + DMARD	3.42(1.09,10.90)	2.31(1.06,4.23)	0.26(0.01,0.51)
SD TOCI SC + DMARD	1.32(0.33,5.23)	1.25(0.39,3.03)	0.05(-0.14,0.35)
LD ADA SC	0.91(0.44,1.87)	0.92(0.50,1.63)	-0.01(-0.11,0.11)
LD ETN SC	0.94(0.37,2.19)	0.95(0.44,1.85)	-0.01(-0.14,0.14)
LD GOLI IV	1.03(0.29,3.53)	1.03(0.35,2.47)	0.01(-0.15,0.25)
LD TOCI IV	0.18(0.03,0.73)	0.21(0.04,0.76)	-0.15(-0.25,-0.04)
LD ADA SC + MTX	4.38(1.60,12.11)	2.63(1.40,4.53)	0.32(0.10,0.54)
LD RITUX IV + MTX	2.15(0.81,5.17)	1.74(0.85,3.15)	0.15(-0.04,0.34)
LD ADA IV + MTX	3.98(0.57,20.80)	2.50(0.63,4.94)	0.29(-0.08,0.63)
LD ABA IV + MTX	2.09(0.73,5.57)	1.72(0.78,3.24)	0.14(-0.05,0.36)
LD ANA SC + MTX	1.93(0.41,8.78)	1.63(0.47,3.77)	0.12(-0.11,0.47)
LD CERTO SC + MTX	3.97(1.19,13.41)	2.50(1.13,4.56)	0.29(0.03,0.56)
LD ETN SC + MTX	3.49(1.19,10.53)	2.34(1.14,4.20)	0.26(0.03,0.52)
LD GOLI IV + MTX	2.02(0.65,6.88)	1.67(0.71,3.59)	0.13(-0.06,0.41)
LD TOCI IV + MTX	1.63(0.51,4.73)	1.45(0.57,3.02)	0.09(-0.10,0.32)
LD TOFA PO + MTX	3.39(0.77,13.20)	2.30(0.81,4.47)	0.26(-0.04,0.56)
HD TOCI IV	2.61(1.25,5.23)	1.98(1.18,3.19)	0.19(0.04,0.34)
HD TOFA PO	2.75(1.23,5.94)	2.05(1.17,3.40)	0.20(0.04,0.37)
HD ADA SC	1.28(0.63,2.69)	1.21(0.69,2.09)	0.04(-0.07,0.19)
HD ETN SC	1.93(0.72,5.18)	1.63(0.77,3.17)	0.12(-0.05,0.34)
HD GOLI SC	2.56(0.98,6.77)	1.94(0.98,3.62)	0.19(0.00,0.40)
HD ABA SC	3.84(0.91,19.43)	2.44(0.94,5.29)	0.28(-0.02,0.62)

(Continued)

HD INF IV + MTX		4.86(1.92,12.96)	2.74(1.57,4.72)	0.34(0.13,0.55)
HD TOCI IV + MTX		4.65(1.91,10.77)	2.70(1.56,4.51)	0.33(0.13,0.51)
HD TOFA PO + MTX		5.09(1.99,12.40)	2.81(1.58,4.58)	0.35(0.14,0.54)
HD GOLI SC + MTX		4.81(1.72,13.21)	2.73(1.46,4.72)	0.34(0.11,0.55)
HD CERTO SC + MTX		6.80(2.61,16.93)	3.14(1.85,5.20)	0.42(0.20,0.60)
HD ADA SC + MTX		5.60(1.70,19.32)	2.92(1.47,5.02)	0.38(0.10,0.62)
HD TOCI IV + DMARD		0.97(0.30,3.08)	0.98(0.36,2.26)	0.00(-0.15,0.22)
SD ANA SC + SD ETN SC + MTX		2.57(0.75,9.10)	1.94(0.80,3.91)	0.19(-0.05,0.47)
SD ANA SC + LD ETN SC + MTX		3.84(1.10,12.87)	2.46(1.08,4.53)	0.28(0.02,0.55)
SD GOLI SC	SD TOFA PO	1.28(0.39,3.96)	1.18(0.51,2.41)	0.05(-0.19,0.31)
SD GOLI IV		1.00(0.28,3.34)	1.00(0.38,2.20)	0.00(-0.23,0.27)
SD TOCI IV		0.83(0.26,2.48)	0.88(0.37,1.86)	-0.04(-0.25,0.19)
SD RITUX IV		0.39(0.04,2.29)	0.48(0.06,1.74)	-0.15(-0.36,0.17)
SD ABA SC		1.58(0.33,8.35)	1.34(0.44,3.11)	0.10(-0.21,0.48)
SD CERTO SC		1.51(0.38,6.32)	1.31(0.50,2.84)	0.09(-0.19,0.42)
SD ETN SC + MTX		2.31(0.88,6.26)	1.66(0.93,3.01)	0.19(-0.03,0.41)
SD INF IV + MTX		1.72(0.62,4.76)	1.41(0.73,2.69)	0.12(-0.11,0.35)
SD ABA IV + MTX		2.24(0.80,6.24)	1.63(0.86,3.03)	0.19(-0.05,0.41)
SD ADA SC + MTX		3.55(1.17,10.48)	2.01(1.10,3.61)	0.30(0.04,0.52)
SD CERTO SC + MTX/CER- TO+MTX		3.21(1.12,9.16)	1.92(1.07,3.46)	0.28(0.03,0.50)
SD RITUX IV + MTX		1.42(0.46,3.90)	1.26(0.59,2.42)	0.08(-0.16,0.30)
SD TOFA PO + MTX		3.60(1.19,10.34)	2.02(1.11,3.62)	0.30(0.04,0.52)
SD GOLI SC + MTX		3.58(1.17,10.70)	2.01(1.09,3.64)	0.30(0.04,0.52)
SD ABA SC + MTX		2.78(0.88,8.76)	1.81(0.92,3.33)	0.24(-0.03,0.49)
SD GOLI IV + MTX		1.31(0.42,4.18)	1.19(0.54,2.50)	0.06(-0.18,0.32)
SD ANA SC + MTX		1.64(0.51,5.60)	1.36(0.62,2.80)	0.11(-0.14,0.39)
SD TOCI IV + MTX		1.17(0.33,4.14)	1.11(0.44,2.43)	0.03(-0.21,0.32)

(Continued)

SD CERTO SC + DMARD	0.79(0.24,2.75)	0.85(0.35,1.98)	-0.04(-0.26,0.22)
SD ADA SC + DMARD	0.47(0.11,2.03)	0.56(0.16,1.63)	-0.13(-0.33,0.15)
SD ETN SC + DMARD	1.95(0.56,7.17)	1.52(0.68,3.07)	0.15(-0.13,0.44)
SD TOCI SC + DMARD	0.77(0.18,3.11)	0.83(0.25,2.09)	-0.05(-0.28,0.25)
LD ADA SC	0.52(0.20,1.40)	0.61(0.29,1.29)	-0.11(-0.29,0.06)
LD ETN SC	0.54(0.19,1.54)	0.63(0.28,1.37)	-0.11(-0.29,0.08)
LD GOLIV	0.59(0.15,2.28)	0.68(0.22,1.74)	-0.09(-0.31,0.17)
LD TOCI IV	0.10(0.01,0.46)	0.14(0.02,0.53)	-0.25(-0.41,-0.10)
LD ADA SC + MTX	2.57(0.85,8.46)	1.74(0.90,3.31)	0.22(-0.04,0.48)
LD RITUX IV + MTX	1.24(0.40,3.55)	1.16(0.52,2.31)	0.05(-0.18,0.28)
LD ADA IV + MTX	2.27(0.32,14.64)	1.64(0.43,3.55)	0.19(-0.20,0.57)
LD ABA IV + MTX	1.21(0.37,3.79)	1.14(0.50,2.34)	0.04(-0.19,0.30)
LD ANA SC + MTX	1.12(0.22,5.62)	1.08(0.31,2.73)	0.02(-0.25,0.40)
LD CERTO SC + MTX	2.25(0.63,9.29)	1.62(0.73,3.32)	0.19(-0.10,0.50)
LD ETN SC + MTX	2.03(0.62,7.04)	1.55(0.72,3.06)	0.16(-0.10,0.44)
LD GOLIV + MTX	1.17(0.32,4.45)	1.11(0.43,2.48)	0.03(-0.21,0.33)
LD TOCI IV + MTX	0.94(0.26,3.11)	0.96(0.36,2.11)	-0.01(-0.24,0.25)
LD TOFA PO + MTX	1.95(0.43,8.36)	1.52(0.52,3.23)	0.15(-0.16,0.48)
HD TOCI IV	1.49(0.60,3.77)	1.30(0.71,2.41)	0.09(-0.12,0.29)
HD TOFA PO	1.59(0.88,2.79)	1.35(0.92,1.97)	0.10(-0.03,0.23)
HD ADA SC	0.74(0.27,2.01)	0.80(0.38,1.65)	-0.06(-0.25,0.14)
HD ETN SC	1.09(0.37,3.48)	1.06(0.49,2.27)	0.02(-0.19,0.27)
HD GOLIV	1.49(0.49,4.16)	1.30(0.61,2.50)	0.09(-0.15,0.32)
HD ABA SC	2.25(0.47,11.73)	1.63(0.60,3.46)	0.19(-0.15,0.54)
HD INF IV + MTX	2.79(0.94,8.38)	1.80(0.96,3.31)	0.24(-0.01,0.48)
HD TOCI IV + MTX	2.70(1.00,7.10)	1.77(1.00,3.19)	0.23(0.00,0.44)
HD TOFA PO + MTX	2.92(1.00,8.04)	1.84(1.00,3.29)	0.25(0.00,0.47)
HD GOLIV + MTX	2.76(0.89,8.24)	1.80(0.93,3.29)	0.24(-0.03,0.47)

(Continued)

HD CERTO SC + MTX		3.88(1.33,11.44)	2.07(1.18,3.68)	0.32(0.07,0.54)
HD ADA SC + MTX		3.20(0.82,13.02)	1.91(0.88,3.63)	0.27(-0.05,0.56)
HD TOCI IV + DMARD		0.56(0.15,2.04)	0.65(0.22,1.67)	-0.10(-0.31,0.15)
SD ANA SC + SD ETN SC + MTX		1.47(0.37,6.12)	1.29(0.49,2.85)	0.09(-0.19,0.41)
SD ANA SC + LD ETN SC + MTX		2.15(0.57,8.30)	1.59(0.67,3.30)	0.18(-0.12,0.48)
SD GOLI IV	SD GOLI SC	0.79(0.27,2.32)	0.86(0.40,1.74)	-0.05(-0.27,0.18)
SD TOCI IV		0.66(0.21,2.27)	0.75(0.34,1.81)	-0.09(-0.34,0.16)
SD RITUX IV		0.31(0.04,1.82)	0.41(0.06,1.50)	-0.19(-0.45,0.12)
SD ABA SC		1.23(0.23,7.46)	1.14(0.37,3.15)	0.05(-0.31,0.46)
SD CERTO SC		1.17(0.27,5.93)	1.11(0.42,2.89)	0.04(-0.29,0.40)
SD ETN SC + MTX		1.83(0.66,5.08)	1.42(0.80,2.76)	0.14(-0.10,0.36)
SD INF IV + MTX		1.38(0.48,3.74)	1.21(0.65,2.39)	0.07(-0.17,0.29)
SD ABA IV + MTX		1.81(0.63,4.85)	1.40(0.78,2.69)	0.14(-0.11,0.36)
SD ADA SC + MTX		2.82(0.93,8.79)	1.71(0.96,3.35)	0.24(-0.02,0.49)
SD CERTO SC + MTX/CER- TO+MTX		2.60(0.90,7.38)	1.65(0.95,3.25)	0.22(-0.03,0.45)
SD RITUX IV + MTX		1.12(0.38,3.30)	1.07(0.55,2.20)	0.02(-0.22,0.26)
SD TOFA PO + MTX		2.85(0.96,8.93)	1.72(0.98,3.43)	0.25(-0.01,0.49)
SD GOLI SC + MTX		2.81(1.00,8.35)	1.71(1.00,3.33)	0.24(0.00,0.48)
SD ABA SC + MTX		2.22(0.68,7.31)	1.55(0.81,3.11)	0.19(-0.09,0.45)
SD GOLI IV + MTX		1.05(0.36,3.21)	1.03(0.51,2.15)	0.01(-0.23,0.25)
SD ANA SC + MTX		1.31(0.35,4.50)	1.18(0.52,2.57)	0.06(-0.23,0.34)
SD TOCI IV + MTX		0.93(0.24,3.45)	0.96(0.37,2.25)	-0.02(-0.31,0.28)
SD CERTO SC + DMARD		0.64(0.17,2.49)	0.74(0.29,1.85)	-0.09(-0.37,0.19)
SD ADA SC + DMARD		0.37(0.08,1.82)	0.48(0.14,1.52)	-0.17(-0.43,0.12)
SD ETN SC + DMARD		1.57(0.42,6.01)	1.30(0.58,2.82)	0.10(-0.20,0.41)
SD TOCI SC + DMARD		0.61(0.13,2.73)	0.71(0.22,1.87)	-0.10(-0.37,0.21)
LD ADA SC		0.41(0.13,1.46)	0.52(0.23,1.33)	-0.16(-0.42,0.06)

(Continued)

LD ETN SC	0.43(0.14,1.26)	0.54(0.26,1.19)	-0.16(-0.39,0.04)
LD GOLI IV	0.48(0.13,1.70)	0.59(0.22,1.45)	-0.14(-0.38,0.11)
LD TOCI IV	0.08(0.01,0.41)	0.12(0.02,0.49)	-0.30(-0.53,-0.11)
LD ADA SC + MTX	2.00(0.62,6.80)	1.47(0.77,3.04)	0.16(-0.11,0.43)
LD RITUX IV + MTX	0.99(0.32,2.88)	0.99(0.49,2.06)	0.00(-0.26,0.23)
LD ADA IV + MTX	1.79(0.24,12.52)	1.39(0.34,3.44)	0.13(-0.27,0.55)
LD ABA IV + MTX	0.97(0.31,2.94)	0.98(0.46,2.08)	-0.01(-0.27,0.24)
LD ANA SC + MTX	0.91(0.17,4.98)	0.94(0.27,2.51)	-0.02(-0.34,0.36)
LD CERTO SC + MTX	1.81(0.47,7.41)	1.40(0.63,3.14)	0.14(-0.17,0.45)
LD ETN SC + MTX	1.61(0.48,5.33)	1.32(0.64,2.73)	0.11(-0.17,0.38)
LD GOLI IV + MTX	0.94(0.29,3.21)	0.96(0.42,2.09)	-0.01(-0.26,0.27)
LD TOCI IV + MTX	0.74(0.20,2.81)	0.81(0.32,2.03)	-0.06(-0.33,0.22)
LD TOFA PO + MTX	1.58(0.33,6.53)	1.30(0.48,2.88)	0.10(-0.23,0.43)
HD TOCI IV	1.20(0.41,3.21)	1.12(0.60,2.24)	0.04(-0.21,0.25)
HD TOFA PO	1.26(0.41,4.19)	1.15(0.59,2.63)	0.05(-0.22,0.30)
HD ADA SC	0.58(0.18,2.03)	0.69(0.31,1.68)	-0.11(-0.37,0.14)
HD ETN SC	0.87(0.28,2.82)	0.91(0.44,2.00)	-0.03(-0.28,0.23)
HD GOLI SC	1.18(0.48,2.78)	1.10(0.64,1.98)	0.04(-0.17,0.22)
HD ABA SC	1.76(0.34,10.96)	1.38(0.50,3.52)	0.13(-0.25,0.52)
HD INF IV + MTX	2.25(0.72,6.53)	1.56(0.84,3.12)	0.19(-0.08,0.42)
HD TOCI IV + MTX	2.13(0.73,6.30)	1.52(0.85,3.04)	0.18(-0.08,0.41)
HD TOFA PO + MTX	2.28(0.77,7.15)	1.57(0.87,3.11)	0.20(-0.06,0.44)
HD GOLI SC + MTX	2.16(0.72,6.83)	1.52(0.84,3.02)	0.18(-0.08,0.44)
HD CERTO SC + MTX	3.09(1.03,9.34)	1.78(1.01,3.48)	0.27(0.01,0.49)
HD ADA SC + MTX	2.52(0.70,9.68)	1.63(0.81,3.35)	0.22(-0.09,0.51)
HD TOCI IV + DMARD	0.44(0.11,1.76)	0.55(0.20,1.47)	-0.15(-0.41,0.11)
SD ANA SC + SD ETN SC + MTX	1.16(0.27,4.95)	1.10(0.42,2.57)	0.03(-0.28,0.36)
SD ANA SC + LD ETN SC + MTX	1.79(0.40,7.49)	1.38(0.56,3.08)	0.13(-0.20,0.45)

(Continued)

SD TOCI IV	SD GOLI IV	0.83(0.26,2.80)	0.87(0.39,2.13)	-0.04(-0.29,0.19)
SD RITUX IV		0.39(0.05,2.29)	0.48(0.07,1.73)	-0.14(-0.40,0.16)
SD ABA SC		1.63(0.26,9.41)	1.37(0.40,3.98)	0.10(-0.27,0.49)
SD CERTO SC		1.48(0.32,8.09)	1.29(0.46,3.71)	0.09(-0.24,0.44)
SD ETN SC + MTX		2.28(0.88,6.42)	1.64(0.94,3.63)	0.19(-0.03,0.39)
SD INF IV + MTX		1.70(0.67,4.67)	1.40(0.79,2.89)	0.12(-0.10,0.33)
SD ABA IV + MTX		2.24(0.87,6.17)	1.63(0.93,3.39)	0.18(-0.03,0.39)
SD ADA SC + MTX		3.55(1.26,10.41)	1.99(1.12,4.15)	0.29(0.06,0.51)
SD CERTO SC + MTX/CER- TO+MTX		3.21(1.20,8.69)	1.92(1.09,4.00)	0.27(0.04,0.47)
SD RITUX IV + MTX		1.41(0.50,4.00)	1.26(0.65,2.66)	0.07(-0.16,0.28)
SD TOFA PO + MTX		3.55(1.29,10.77)	2.00(1.12,4.38)	0.29(0.06,0.51)
SD GOLI SC + MTX		3.56(1.23,10.36)	1.99(1.11,4.27)	0.29(0.05,0.51)
SD ABA SC + MTX		2.72(0.91,9.50)	1.79(0.94,3.99)	0.23(-0.02,0.49)
SD GOLI IV + MTX		1.31(0.54,3.34)	1.19(0.68,2.33)	0.06(-0.13,0.25)
SD ANA SC + MTX		1.67(0.49,5.35)	1.37(0.64,3.00)	0.11(-0.16,0.36)
SD TOCI IV + MTX		1.19(0.31,4.64)	1.12(0.44,2.77)	0.03(-0.24,0.32)
SD CERTO SC + DMARD		0.79(0.20,3.39)	0.85(0.32,2.40)	-0.04(-0.33,0.24)
SD ADA SC + DMARD		0.48(0.11,2.21)	0.58(0.17,1.78)	-0.12(-0.39,0.15)
SD ETN SC + DMARD		1.96(0.55,7.94)	1.51(0.68,3.70)	0.15(-0.13,0.44)
SD TOCI SC + DMARD		0.79(0.17,3.47)	0.84(0.25,2.36)	-0.04(-0.33,0.26)
LD ADA SC		0.52(0.14,1.85)	0.61(0.25,1.66)	-0.11(-0.38,0.10)
LD ETN SC		0.54(0.19,1.60)	0.63(0.30,1.47)	-0.11(-0.33,0.07)
LD GOLI IV		0.59(0.21,1.72)	0.68(0.29,1.48)	-0.09(-0.29,0.10)
LD TOCI IV		0.10(0.02,0.49)	0.14(0.03,0.56)	-0.25(-0.49,-0.07)
LD ADA SC + MTX		2.49(0.83,7.83)	1.72(0.90,3.79)	0.21(-0.04,0.45)
LD RITUX IV + MTX		1.24(0.43,3.66)	1.16(0.59,2.45)	0.04(-0.19,0.26)
LD ADA IV + MTX		2.30(0.30,14.83)	1.62(0.41,4.17)	0.18(-0.23,0.57)
LD ABA IV + MTX		1.21(0.41,3.57)	1.13(0.56,2.47)	0.04(-0.19,0.26)

(Continued)

LD ANA SC + MTX	1.12(0.23,5.89)	1.07(0.34,2.99)	0.02(-0.27,0.39)
LD CERTO SC + MTX	2.26(0.63,8.62)	1.62(0.75,3.71)	0.18(-0.10,0.47)
LD ETN SC + MTX	2.03(0.63,7.01)	1.53(0.76,3.42)	0.16(-0.10,0.41)
LD GOLI IV + MTX	1.18(0.46,3.15)	1.12(0.57,2.25)	0.03(-0.16,0.25)
LD TOCI IV + MTX	0.94(0.26,3.34)	0.96(0.38,2.39)	-0.01(-0.27,0.25)
LD TOFA PO + MTX	2.02(0.44,8.07)	1.51(0.56,3.52)	0.15(-0.17,0.46)
HD TOCI IV	1.50(0.54,4.28)	1.30(0.71,2.87)	0.09(-0.14,0.29)
HD TOFA PO	1.60(0.48,5.54)	1.36(0.65,3.33)	0.10(-0.17,0.34)
HD ADA SC	0.73(0.21,2.66)	0.80(0.34,2.12)	-0.06(-0.33,0.17)
HD ETN SC	1.09(0.37,3.65)	1.06(0.52,2.44)	0.02(-0.22,0.26)
HD GOLI SC	1.47(0.51,4.28)	1.29(0.67,2.79)	0.08(-0.15,0.30)
HD ABA SC	2.28(0.36,13.60)	1.62(0.52,4.64)	0.18(-0.22,0.56)
HD INF IV + MTX	2.77(1.02,8.60)	1.80(1.01,3.88)	0.23(0.01,0.46)
HD TOCI IV + MTX	2.69(0.97,7.55)	1.78(0.99,3.80)	0.23(-0.01,0.44)
HD TOFA PO + MTX	2.88(1.00,8.48)	1.83(1.00,3.88)	0.24(0.00,0.47)
HD GOLI SC + MTX	2.74(0.95,8.32)	1.78(0.97,3.84)	0.23(-0.01,0.47)
HD CERTO SC + MTX	3.91(1.39,11.12)	2.06(1.18,4.46)	0.31(0.08,0.52)
HD ADA SC + MTX	3.20(0.89,12.30)	1.90(0.93,4.33)	0.26(-0.03,0.54)
HD TOCI IV + DMARD	0.55(0.14,2.36)	0.64(0.23,1.86)	-0.10(-0.36,0.15)
SD ANA SC + SD ETN SC + MTX	1.46(0.38,6.28)	1.28(0.50,3.21)	0.08(-0.21,0.40)
SD ANA SC + LD ETN SC + MTX	2.17(0.55,8.79)	1.59(0.66,3.83)	0.18(-0.13,0.47)
SD RITUX IV	SD TOCI IV 0.45(0.06,2.62)	0.54(0.08,1.98)	-0.12(-0.33,0.20)
SD ABA SC	1.83(0.36,11.86)	1.48(0.46,4.33)	0.13(-0.20,0.53)
SD CERTO SC	1.75(0.41,9.08)	1.45(0.52,3.98)	0.12(-0.18,0.47)
SD ETN SC + MTX	2.71(1.13,6.78)	1.86(1.08,3.65)	0.22(0.03,0.40)
SD INF IV + MTX	2.07(0.83,5.17)	1.60(0.89,3.10)	0.16(-0.04,0.34)
SD ABA IV + MTX	2.66(1.08,6.74)	1.83(1.05,3.55)	0.22(0.02,0.41)
SD ADA SC + MTX	4.19(1.58,11.07)	2.25(1.29,4.30)	0.32(0.11,0.53)

(Continued)

SD CERTO SC + MTX/CER-TO+MTX	3.84(1.57,9.46)	2.17(1.27,4.19)	0.31(0.10,0.49)
SD RITUX IV + MTX	1.67(0.63,4.23)	1.42(0.73,2.79)	0.11(-0.09,0.30)
SD TOFA PO + MTX	4.31(1.65,11.31)	2.27(1.30,4.39)	0.33(0.12,0.52)
SD GOLSI SC + MTX	4.24(1.56,11.54)	2.27(1.29,4.37)	0.33(0.10,0.53)
SD ABA SC + MTX	3.33(1.10,9.34)	2.05(1.06,3.99)	0.27(0.02,0.49)
SD GOLSI IV + MTX	1.58(0.54,4.50)	1.36(0.65,2.81)	0.09(-0.13,0.32)
SD ANA SC + MTX	1.98(0.63,5.86)	1.56(0.72,3.19)	0.14(-0.10,0.39)
SD TOCI IV + MTX	1.40(0.50,3.81)	1.25(0.60,2.54)	0.07(-0.14,0.29)
SD CERTO SC + DMARD	0.95(0.28,3.40)	0.96(0.39,2.42)	-0.01(-0.24,0.24)
SD ADA SC + DMARD	0.56(0.14,2.34)	0.64(0.20,1.82)	-0.09(-0.30,0.16)
SD ETN SC + DMARD	2.36(0.67,8.14)	1.72(0.76,3.69)	0.19(-0.08,0.46)
SD TOCI SC + DMARD	0.90(0.23,3.50)	0.92(0.31,2.34)	-0.02(-0.24,0.26)
LD ADA SC	0.62(0.21,2.00)	0.69(0.30,1.73)	-0.08(-0.28,0.11)
LD ETN SC	0.65(0.24,1.74)	0.71(0.35,1.55)	-0.07(-0.26,0.09)
LD GOLSI IV	0.71(0.18,2.55)	0.77(0.25,1.98)	-0.06(-0.27,0.18)
LD TOCI IV	0.12(0.02,0.49)	0.16(0.03,0.56)	-0.21(-0.39,-0.08)
LD ADA SC + MTX	3.01(1.09,8.51)	1.94(1.06,3.83)	0.25(0.02,0.46)
LD RITUX IV + MTX	1.46(0.56,3.80)	1.29(0.67,2.59)	0.08(-0.12,0.27)
LD ADA IV + MTX	2.72(0.38,15.97)	1.84(0.47,4.52)	0.22(-0.16,0.59)
LD ABA IV + MTX	1.44(0.51,3.84)	1.28(0.61,2.59)	0.07(-0.14,0.29)
LD ANA SC + MTX	1.33(0.29,6.67)	1.21(0.39,3.19)	0.06(-0.21,0.42)
LD CERTO SC + MTX	2.71(0.81,8.99)	1.85(0.86,3.92)	0.22(-0.05,0.48)
LD ETN SC + MTX	2.42(0.75,7.25)	1.74(0.82,3.62)	0.19(-0.06,0.43)
LD GOLSI IV + MTX	1.40(0.40,4.77)	1.27(0.52,2.90)	0.07(-0.18,0.34)
LD TOCI IV + MTX	1.12(0.39,3.10)	1.08(0.49,2.23)	0.02(-0.17,0.24)
LD TOFA PO + MTX	2.34(0.53,9.11)	1.71(0.64,3.72)	0.19(-0.12,0.49)
HD TOCI IV	1.79(0.85,3.71)	1.48(0.91,2.63)	0.12(-0.04,0.26)
HD TOFA PO	1.91(0.63,5.76)	1.53(0.75,3.39)	0.14(-0.10,0.35)

(Continued)

HD ADA SC		0.88(0.29,2.73)	0.91(0.40,2.16)	-0.02(-0.24,0.18)
HD ETN SC		1.29(0.46,4.11)	1.20(0.57,2.74)	0.05(-0.16,0.29)
HD GOLI SC		1.75(0.59,4.93)	1.46(0.71,3.02)	0.12(-0.11,0.33)
HD ABA SC		2.61(0.48,16.78)	1.80(0.61,5.00)	0.21(-0.15,0.59)
HD INF IV + MTX		3.35(1.30,8.69)	2.04(1.17,3.95)	0.27(0.06,0.47)
HD TOCI IV + MTX		3.21(1.43,7.28)	2.00(1.23,3.67)	0.26(0.09,0.43)
HD TOFA PO + MTX		3.44(1.27,9.02)	2.07(1.15,4.09)	0.28(0.06,0.48)
HD GOLI SC + MTX		3.33(1.18,9.47)	2.03(1.10,4.00)	0.27(0.04,0.49)
HD CERTO SC + MTX		4.62(1.78,11.81)	2.33(1.35,4.50)	0.35(0.14,0.54)
HD ADA SC + MTX		3.85(1.10,12.74)	2.16(1.06,4.37)	0.30(0.02,0.55)
HD TOCI IV + DMARD		0.66(0.21,2.26)	0.72(0.28,1.82)	-0.07(-0.27,0.16)
SD ANA SC + SD ETN SC + MTX		1.74(0.48,6.36)	1.46(0.59,3.25)	0.12(-0.14,0.41)
SD ANA SC + LD ETN SC + MTX		2.63(0.69,9.59)	1.82(0.77,3.86)	0.21(-0.08,0.48)
SD ABA SC	SD RITUX IV	4.21(0.44,42.54)	2.76(0.56,19.85)	0.25(-0.16,0.61)
SD CERTO SC		3.74(0.53,50.05)	2.65(0.64,23.72)	0.23(-0.13,0.57)
SD ETN SC + MTX		5.89(1.18,42.29)	3.44(1.09,22.67)	0.34(0.04,0.53)
SD INF IV + MTX		4.43(0.91,31.70)	2.94(0.95,18.79)	0.26(-0.02,0.47)
SD ABA IV + MTX		5.80(1.18,40.44)	3.41(1.10,21.64)	0.33(0.04,0.55)
SD ADA SC + MTX		8.90(1.82,65.79)	4.09(1.35,26.12)	0.43(0.14,0.66)
SD CERTO SC + MTX/CER- TO+MTX		8.30(1.68,59.65)	4.00(1.29,26.59)	0.42(0.12,0.62)
SD RITUX IV + MTX		3.56(0.84,23.14)	2.57(0.90,15.84)	0.22(-0.04,0.42)
SD TOFA PO + MTX		9.40(1.74,68.15)	4.19(1.31,28.09)	0.44(0.13,0.65)
SD GOLI SC + MTX		9.13(1.73,70.86)	4.15(1.30,28.21)	0.44(0.13,0.66)
SD ABA SC + MTX		7.12(1.31,53.91)	3.73(1.18,24.59)	0.37(0.06,0.62)
SD GOLI IV + MTX		3.47(0.62,25.53)	2.49(0.73,16.35)	0.21(-0.10,0.45)
SD ANA SC + MTX		4.30(0.69,35.24)	2.88(0.81,19.26)	0.26(-0.08,0.51)
SD TOCI IV + MTX		3.03(0.48,24.29)	2.31(0.60,15.65)	0.18(-0.15,0.46)

(Continued)

SD CERTO SC + DMARD	2.06(0.34,19.39)	1.77(0.45,13.85)	0.11(-0.22,0.35)
SD ADA SC + DMARD	1.26(0.18,10.65)	1.21(0.25,8.40)	0.03(-0.28,0.27)
SD ETN SC + DMARD	5.13(0.82,40.39)	3.16(0.90,22.15)	0.29(-0.04,0.58)
SD TOCI SC + DMARD	1.96(0.28,17.69)	1.69(0.38,11.57)	0.09(-0.22,0.40)
LD ADA SC	1.34(0.23,11.47)	1.27(0.33,9.14)	0.04(-0.28,0.22)
LD ETN SC	1.39(0.26,10.49)	1.31(0.38,8.58)	0.04(-0.26,0.21)
LD GOLIV	1.55(0.24,12.86)	1.43(0.34,9.67)	0.06(-0.25,0.30)
LD TOCI IV	0.26(0.03,2.85)	0.30(0.04,2.65)	-0.09(-0.40,0.05)
LD ADA SC + MTX	6.43(1.26,49.13)	3.54(1.14,24.27)	0.36(0.05,0.61)
LD RITUX IV + MTX	3.16(0.66,21.59)	2.40(0.77,15.27)	0.19(-0.09,0.39)
LD ADA IV + MTX	5.98(0.47,90.52)	3.31(0.58,25.83)	0.33(-0.13,0.73)
LD ABA IV + MTX	3.14(0.60,22.91)	2.37(0.71,15.40)	0.19(-0.11,0.42)
LD ANA SC + MTX	2.97(0.35,27.99)	2.24(0.47,15.55)	0.17(-0.18,0.53)
LD CERTO SC + MTX	6.02(0.94,48.13)	3.42(0.97,23.32)	0.33(-0.01,0.61)
LD ETN SC + MTX	5.25(0.87,42.64)	3.19(0.92,22.59)	0.30(-0.03,0.56)
LD GOLIV + MTX	3.07(0.50,25.30)	2.31(0.62,16.01)	0.18(-0.14,0.46)
LD TOCI IV + MTX	2.37(0.42,19.76)	1.96(0.53,13.70)	0.13(-0.17,0.41)
LD TOFA PO + MTX	5.16(0.70,44.64)	3.14(0.79,21.06)	0.29(-0.07,0.61)
HD TOCI IV	3.77(0.81,28.69)	2.71(0.88,17.89)	0.23(-0.05,0.42)
HD TOFA PO	4.12(0.70,39.19)	2.85(0.81,21.72)	0.25(-0.08,0.47)
HD ADA SC	1.90(0.32,18.13)	1.67(0.46,13.74)	0.09(-0.22,0.30)
HD ETN SC	2.85(0.49,21.62)	2.25(0.63,14.83)	0.17(-0.15,0.39)
HD GOLIV	3.77(0.70,28.57)	2.68(0.81,18.53)	0.23(-0.08,0.45)
HD ABA SC	6.03(0.63,63.43)	3.37(0.73,24.85)	0.33(-0.10,0.67)
HD INF IV + MTX	7.28(1.39,51.14)	3.77(1.19,23.86)	0.39(0.07,0.60)
HD TOCI IV + MTX	6.83(1.35,52.63)	3.68(1.17,25.31)	0.37(0.07,0.58)
HD TOFA PO + MTX	7.46(1.37,56.14)	3.85(1.18,26.06)	0.39(0.07,0.61)
HD GOLIV + MTX	7.03(1.24,55.18)	3.72(1.12,25.45)	0.38(0.05,0.62)

(Continued)

HD CERTO SC + MTX		10.00(1.95,75.46)	4.32(1.39,30.12)	0.46(0.16,0.67)
HD ADA SC + MTX		8.21(1.51,71.89)	3.95(1.21,26.17)	0.41(0.09,0.69)
HD TOCI IV + DMARD		1.42(0.23,11.64)	1.33(0.32,9.34)	0.05(-0.27,0.27)
SD ANA SC + SD ETN SC + MTX		3.78(0.55,31.04)	2.64(0.68,18.20)	0.22(-0.11,0.54)
SD ANA SC + LD ETN SC + MTX		5.70(0.81,44.18)	3.32(0.88,21.37)	0.32(-0.05,0.62)
SD CERTO SC	SD ABA SC	0.95(0.15,6.00)	0.97(0.34,3.23)	-0.01(-0.43,0.39)
SD ETN SC + MTX		1.47(0.27,6.88)	1.23(0.55,3.54)	0.09(-0.31,0.42)
SD INF IV + MTX		1.12(0.19,5.26)	1.07(0.45,3.10)	0.03(-0.38,0.35)
SD ABA IV + MTX		1.44(0.26,7.18)	1.22(0.52,3.63)	0.09(-0.32,0.42)
SD ADA SC + MTX		2.31(0.39,11.64)	1.50(0.68,4.33)	0.20(-0.22,0.54)
SD CERTO SC + MTX/CER- TO+MTX		2.07(0.36,10.29)	1.45(0.64,4.08)	0.18(-0.24,0.51)
SD RITUX IV + MTX		0.90(0.16,4.50)	0.94(0.37,2.87)	-0.02(-0.42,0.31)
SD TOFA PO + MTX		2.36(0.39,12.22)	1.52(0.68,4.38)	0.20(-0.21,0.54)
SD GOLI SC + MTX		2.32(0.39,11.59)	1.49(0.67,4.31)	0.20(-0.22,0.53)
SD ABA SC + MTX		1.80(0.30,9.81)	1.35(0.58,3.94)	0.14(-0.29,0.50)
SD GOLI IV + MTX		0.86(0.14,4.71)	0.91(0.33,2.85)	-0.03(-0.44,0.32)
SD ANA SC + MTX		1.05(0.16,6.47)	1.03(0.37,3.30)	0.01(-0.42,0.39)
SD TOCI IV + MTX		0.75(0.11,4.27)	0.83(0.28,2.71)	-0.06(-0.48,0.31)
SD CERTO SC + DMARD		0.52(0.08,2.85)	0.64(0.22,2.10)	-0.14(-0.53,0.20)
SD ADA SC + DMARD		0.30(0.04,2.06)	0.43(0.09,1.69)	-0.22(-0.59,0.14)
SD ETN SC + DMARD		1.27(0.19,7.51)	1.14(0.42,3.60)	0.06(-0.37,0.44)
SD TOCI SC + DMARD		0.49(0.06,3.27)	0.62(0.16,2.25)	-0.14(-0.56,0.25)
LD ADA SC		0.34(0.06,1.56)	0.46(0.18,1.42)	-0.21(-0.57,0.07)
LD ETN SC		0.35(0.06,1.72)	0.48(0.18,1.52)	-0.20(-0.57,0.09)
LD GOLI IV		0.38(0.05,2.21)	0.51(0.14,1.80)	-0.19(-0.59,0.15)
LD TOCI IV		0.06(0.01,0.47)	0.10(0.02,0.54)	-0.35(-0.69,-0.08)
LD ADA SC + MTX		1.60(0.27,8.88)	1.29(0.55,3.76)	0.11(-0.31,0.47)
LD RITUX IV + MTX		0.81(0.14,4.00)	0.87(0.33,2.63)	-0.05(-0.44,0.28)

(Continued)

LD ADA IV + MTX		1.49(0.12,14.01)	1.23(0.26,4.12)	0.09(-0.45,0.56)
LD ABA IV + MTX		0.79(0.12,4.23)	0.86(0.30,2.68)	-0.05(-0.46,0.31)
LD ANA SC + MTX		0.72(0.09,6.25)	0.82(0.19,3.03)	-0.07(-0.52,0.40)
LD CERTO SC + MTX		1.44(0.22,9.13)	1.21(0.44,3.75)	0.09(-0.35,0.48)
LD ETN SC + MTX		1.30(0.21,7.28)	1.15(0.45,3.50)	0.06(-0.36,0.42)
LD GOLI IV + MTX		0.75(0.11,4.54)	0.84(0.28,2.79)	-0.06(-0.47,0.32)
LD TOCI IV + MTX		0.60(0.09,3.57)	0.72(0.23,2.38)	-0.11(-0.52,0.26)
LD TOFA PO + MTX		1.25(0.16,9.65)	1.13(0.34,3.72)	0.05(-0.42,0.48)
HD TOCI IV		0.96(0.17,4.48)	0.98(0.41,2.89)	-0.01(-0.41,0.30)
HD TOFA PO		1.02(0.20,4.82)	1.01(0.45,2.95)	0.00(-0.37,0.32)
HD ADA SC		0.47(0.09,2.27)	0.59(0.24,1.83)	-0.16(-0.53,0.15)
HD ETN SC		0.69(0.12,3.76)	0.79(0.30,2.55)	-0.08(-0.46,0.27)
HD GOLI SC		0.96(0.16,4.86)	0.97(0.38,2.96)	-0.01(-0.42,0.33)
HD ABA SC		1.41(0.50,4.38)	1.19(0.67,2.49)	0.08(-0.16,0.33)
HD INF IV + MTX		1.83(0.31,9.05)	1.36(0.59,3.92)	0.14(-0.28,0.48)
HD TOCI IV + MTX		1.75(0.29,8.75)	1.34(0.57,3.87)	0.13(-0.29,0.46)
HD TOFA PO + MTX		1.86(0.31,9.51)	1.38(0.60,3.99)	0.15(-0.28,0.49)
HD GOLI SC + MTX		1.78(0.29,9.95)	1.35(0.57,4.08)	0.14(-0.29,0.48)
HD CERTO SC + MTX		2.46(0.44,13.05)	1.55(0.72,4.43)	0.22(-0.19,0.55)
HD ADA SC + MTX		2.07(0.31,11.93)	1.43(0.57,4.07)	0.17(-0.27,0.54)
HD TOCI IV + DMARD		0.36(0.05,2.15)	0.49(0.13,1.73)	-0.19(-0.59,0.15)
SD ANA SC + SD ETN SC + MTX		0.95(0.14,5.66)	0.97(0.32,2.91)	-0.01(-0.43,0.38)
SD ANA SC + LD ETN SC + MTX		1.40(0.21,8.53)	1.20(0.43,3.59)	0.08(-0.36,0.47)
SD ETN SC + MTX	SD CERTO SC	1.55(0.35,6.31)	1.28(0.58,3.21)	0.10(-0.26,0.41)
SD INF IV + MTX		1.18(0.23,4.70)	1.10(0.45,2.78)	0.04(-0.35,0.33)
SD ABA IV + MTX		1.55(0.28,6.56)	1.28(0.53,3.25)	0.10(-0.30,0.41)
SD ADA SC + MTX		2.43(0.44,10.13)	1.55(0.69,3.86)	0.21(-0.20,0.51)

(Continued)

SD CERTO SC + MTX/CER-TO+MTX	2.25(0.41,9.25)	1.51(0.67,3.78)	0.19(-0.21,0.49)
SD RITUX IV + MTX	0.95(0.19,3.97)	0.97(0.39,2.56)	-0.01(-0.38,0.29)
SD TOFA PO + MTX	2.46(0.45,10.50)	1.56(0.71,3.83)	0.22(-0.19,0.52)
SD GOLII SC + MTX	2.43(0.47,10.61)	1.56(0.72,3.91)	0.21(-0.18,0.51)
SD ABA SC + MTX	1.90(0.35,8.57)	1.40(0.59,3.58)	0.15(-0.25,0.47)
SD GOLII IV + MTX	0.91(0.17,3.93)	0.94(0.35,2.50)	-0.02(-0.41,0.29)
SD ANA SC + MTX	1.13(0.19,5.17)	1.07(0.38,2.87)	0.03(-0.38,0.36)
SD TOCI IV + MTX	0.79(0.14,4.01)	0.86(0.29,2.49)	-0.05(-0.44,0.31)
SD CERTO SC + DMARD	0.54(0.11,2.40)	0.66(0.24,1.83)	-0.13(-0.48,0.18)
SD ADA SC + DMARD	0.33(0.04,1.71)	0.45(0.10,1.48)	-0.20(-0.56,0.10)
SD ETN SC + DMARD	1.34(0.22,6.51)	1.18(0.45,3.07)	0.07(-0.34,0.41)
SD TOCI SC + DMARD	0.54(0.07,2.78)	0.65(0.17,1.93)	-0.13(-0.52,0.21)
LD ADA SC	0.35(0.08,1.39)	0.47(0.20,1.29)	-0.20(-0.52,0.06)
LD ETN SC	0.37(0.08,1.51)	0.49(0.18,1.36)	-0.19(-0.52,0.07)
LD GOLII IV	0.40(0.07,2.05)	0.54(0.16,1.66)	-0.18(-0.52,0.15)
LD TOCI IV	0.07(0.01,0.43)	0.11(0.02,0.51)	-0.34(-0.64,-0.10)
LD ADA SC + MTX	1.71(0.30,7.31)	1.34(0.56,3.27)	0.13(-0.28,0.44)
LD RITUX IV + MTX	0.85(0.15,3.42)	0.90(0.34,2.34)	-0.04(-0.42,0.26)
LD ADA IV + MTX	1.55(0.14,13.76)	1.26(0.27,3.74)	0.10(-0.42,0.56)
LD ABA IV + MTX	0.83(0.15,3.60)	0.89(0.31,2.39)	-0.04(-0.43,0.27)
LD ANA SC + MTX	0.79(0.09,5.35)	0.86(0.20,2.60)	-0.05(-0.47,0.37)
LD CERTO SC + MTX	1.57(0.25,7.88)	1.28(0.47,3.40)	0.11(-0.32,0.46)
LD ETN SC + MTX	1.37(0.24,6.67)	1.20(0.45,3.19)	0.07(-0.33,0.42)
LD GOLII IV + MTX	0.79(0.13,3.92)	0.87(0.29,2.49)	-0.05(-0.44,0.30)
LD TOCI IV + MTX	0.65(0.11,3.09)	0.75(0.24,2.14)	-0.09(-0.47,0.24)
LD TOFA PO + MTX	1.38(0.18,7.25)	1.19(0.37,3.12)	0.07(-0.38,0.44)
HD TOCI IV	1.03(0.22,3.76)	1.02(0.45,2.52)	0.01(-0.36,0.27)
HD TOFA PO	1.06(0.26,4.30)	1.04(0.50,2.66)	0.01(-0.32,0.30)

(Continued)

HD ADA SC		0.49(0.12,2.09)	0.62(0.27,1.69)	-0.15(-0.46,0.14)
HD ETN SC		0.75(0.14,3.26)	0.83(0.31,2.31)	-0.06(-0.44,0.24)
HD GOLI SC		1.01(0.20,4.04)	1.01(0.41,2.60)	0.00(-0.37,0.30)
HD ABA SC		1.49(0.25,9.40)	1.25(0.44,3.33)	0.09(-0.31,0.50)
HD INF IV + MTX		1.89(0.38,7.69)	1.40(0.63,3.47)	0.15(-0.24,0.45)
HD TOCI IV + MTX		1.79(0.38,7.48)	1.37(0.63,3.45)	0.14(-0.23,0.44)
HD TOFA PO + MTX		1.95(0.38,8.22)	1.42(0.63,3.60)	0.16(-0.23,0.47)
HD GOLI SC + MTX		1.87(0.33,8.17)	1.39(0.58,3.65)	0.15(-0.26,0.46)
HD CERTO SC + MTX		2.68(0.51,11.20)	1.61(0.75,4.02)	0.24(-0.15,0.53)
HD ADA SC + MTX		2.17(0.38,11.15)	1.48(0.61,3.82)	0.18(-0.23,0.52)
HD TOCI IV + DMARD		0.38(0.06,1.85)	0.51(0.15,1.56)	-0.18(-0.55,0.12)
SD ANA SC + SD ETN SC + MTX		1.01(0.16,5.44)	1.01(0.34,2.81)	0.00(-0.40,0.38)
SD ANA SC + LD ETN SC + MTX		1.49(0.24,7.93)	1.25(0.44,3.35)	0.09(-0.33,0.47)
SD INF IV + MTX	SD ETN SC + MTX	0.76(0.43,1.28)	0.86(0.60,1.14)	-0.07(-0.20,0.06)
SD ABA IV + MTX		0.98(0.54,1.79)	0.99(0.71,1.33)	0.00(-0.15,0.14)
SD ADA SC + MTX		1.52(0.78,3.23)	1.21(0.88,1.65)	0.10(-0.06,0.27)
SD CERTO SC + MTX/CER-TO+MTX		1.39(0.76,2.70)	1.16(0.88,1.59)	0.08(-0.07,0.24)
SD RITUX IV + MTX		0.61(0.31,1.21)	0.76(0.49,1.11)	-0.12(-0.27,0.05)
SD TOFA PO + MTX		1.57(0.77,3.31)	1.22(0.89,1.69)	0.11(-0.06,0.28)
SD GOLI SC + MTX		1.55(0.70,3.44)	1.21(0.83,1.73)	0.10(-0.09,0.28)
SD ABA SC + MTX		1.21(0.53,2.65)	1.10(0.70,1.54)	0.05(-0.15,0.23)
SD GOLI IV + MTX		0.57(0.26,1.31)	0.73(0.43,1.15)	-0.13(-0.30,0.07)
SD ANA SC + MTX		0.72(0.26,1.81)	0.84(0.44,1.33)	-0.08(-0.30,0.14)
SD TOCI IV + MTX		0.51(0.18,1.39)	0.68(0.32,1.19)	-0.16(-0.38,0.08)
SD CERTO SC + DMARD		0.35(0.11,1.14)	0.52(0.22,1.08)	-0.23(-0.47,0.03)
SD ADA SC + DMARD		0.21(0.06,0.76)	0.34(0.11,0.85)	-0.31(-0.51,-0.06)
SD ETN SC + DMARD		0.86(0.33,2.27)	0.93(0.50,1.47)	-0.04(-0.26,0.20)

(Continued)

SD TOCI SC + DMARD	0.33(0.10,1.24)	0.50(0.18,1.12)	-0.24(-0.45,0.05)
LD ADA SC	0.23(0.08,0.64)	0.37(0.18,0.74)	-0.31(-0.50,-0.10)
LD ETN SC	0.23(0.12,0.48)	0.38(0.23,0.63)	-0.30(-0.45,-0.15)
LD GOL I V	0.26(0.08,0.80)	0.41(0.16,0.88)	-0.28(-0.47,-0.05)
LD TOCI IV	0.04(0.01,0.17)	0.08(0.02,0.28)	-0.44(-0.60,-0.28)
LD ADA SC + MTX	1.10(0.50,2.53)	1.05(0.68,1.51)	0.02(-0.16,0.22)
LD RITUX IV + MTX	0.54(0.27,1.04)	0.70(0.44,1.02)	-0.14(-0.30,0.01)
LD ADA IV + MTX	0.98(0.16,5.36)	0.99(0.28,1.89)	0.00(-0.36,0.36)
LD ABA IV + MTX	0.52(0.24,1.15)	0.69(0.40,1.08)	-0.15(-0.32,0.04)
LD ANA SC + MTX	0.49(0.12,2.12)	0.66(0.21,1.38)	-0.16(-0.41,0.18)
LD CERTO SC + MTX	1.00(0.36,2.80)	1.00(0.53,1.57)	0.00(-0.23,0.24)
LD ETN SC + MTX	0.88(0.40,1.93)	0.93(0.57,1.33)	-0.03(-0.22,0.15)
LD GOL I V + MTX	0.52(0.18,1.45)	0.68(0.32,1.19)	-0.15(-0.36,0.09)
LD TOCI IV + MTX	0.41(0.14,1.14)	0.59(0.25,1.08)	-0.20(-0.42,0.03)
LD TOFA PO + MTX	0.85(0.24,2.97)	0.92(0.38,1.60)	-0.04(-0.30,0.25)
HD TOCI IV	0.65(0.36,1.23)	0.79(0.56,1.12)	-0.10(-0.25,0.05)
HD TOFA PO	0.70(0.26,1.68)	0.82(0.47,1.34)	-0.09(-0.32,0.13)
HD ADA SC	0.32(0.12,0.92)	0.48(0.25,0.95)	-0.25(-0.46,-0.02)
HD ETN SC	0.48(0.22,1.04)	0.65(0.38,1.02)	-0.17(-0.34,0.01)
HD GOL I SC	0.64(0.28,1.48)	0.78(0.47,1.24)	-0.11(-0.29,0.09)
HD ABA SC	0.96(0.21,5.15)	0.98(0.37,2.00)	-0.01(-0.35,0.37)
HD INF IV + MTX	1.23(0.63,2.38)	1.10(0.78,1.51)	0.05(-0.11,0.21)
HD TOCI IV + MTX	1.17(0.59,2.28)	1.08(0.76,1.49)	0.04(-0.13,0.20)
HD TOFA PO + MTX	1.26(0.62,2.64)	1.11(0.78,1.55)	0.06(-0.12,0.23)
HD GOL I SC + MTX	1.20(0.54,2.74)	1.09(0.71,1.57)	0.04(-0.15,0.23)
HD CERTO SC + MTX	1.69(0.83,3.46)	1.25(0.91,1.73)	0.12(-0.05,0.29)
HD ADA SC + MTX	1.39(0.51,3.97)	1.16(0.68,1.75)	0.08(-0.16,0.31)
HD TOCI IV + DMARD	0.24(0.09,0.77)	0.39(0.16,0.86)	-0.29(-0.48,-0.06)

(Continued)

SD ANA SC + SD ETN SC + MTX		0.63(0.24,1.71)	0.78(0.38,1.26)	-0.11(-0.31,0.13)
SD ANA SC + LD ETN SC + MTX		0.95(0.37,2.58)	0.97(0.52,1.47)	-0.01(-0.22,0.22)
SD ABA IV + MTX	SD INF IV + MTX	1.30(0.75,2.23)	1.15(0.85,1.58)	0.06(-0.07,0.19)
SD ADA SC + MTX		2.06(1.02,4.14)	1.41(1.01,2.07)	0.17(0.00,0.33)
SD CERTO SC + MTX/CER- TO+MTX		1.85(1.00,3.55)	1.35(1.00,1.92)	0.15(0.00,0.30)
SD RITUX IV + MTX		0.82(0.42,1.59)	0.89(0.58,1.31)	-0.04(-0.20,0.11)
SD TOFA PO + MTX		2.08(1.04,4.31)	1.42(1.02,2.10)	0.18(0.01,0.34)
SD GOLI SC + MTX		2.04(0.93,4.39)	1.42(0.96,2.10)	0.17(-0.02,0.35)
SD ABA SC + MTX		1.63(0.72,3.47)	1.28(0.83,1.89)	0.12(-0.08,0.29)
SD GOLI IV + MTX		0.77(0.34,1.71)	0.86(0.50,1.36)	-0.06(-0.24,0.13)
SD ANA SC + MTX		0.96(0.36,2.42)	0.97(0.52,1.62)	-0.01(-0.22,0.21)
SD TOCI IV + MTX		0.68(0.23,1.82)	0.79(0.37,1.41)	-0.09(-0.30,0.15)
SD CERTO SC + DMARD		0.46(0.14,1.58)	0.60(0.26,1.34)	-0.16(-0.40,0.10)
SD ADA SC + DMARD		0.28(0.08,1.04)	0.40(0.14,1.02)	-0.24(-0.44,0.01)
SD ETN SC + DMARD		1.14(0.39,3.45)	1.08(0.56,1.87)	0.03(-0.21,0.29)
SD TOCI SC + DMARD		0.44(0.12,1.72)	0.58(0.20,1.34)	-0.17(-0.40,0.13)
LD ADA SC		0.30(0.11,0.91)	0.43(0.21,0.94)	-0.24(-0.44,-0.02)
LD ETN SC		0.31(0.15,0.68)	0.44(0.25,0.76)	-0.23(-0.39,-0.08)
LD GOLI IV		0.35(0.11,1.01)	0.48(0.19,1.01)	-0.21(-0.41,0.00)
LD TOCI IV		0.06(0.01,0.23)	0.10(0.02,0.33)	-0.37(-0.56,-0.21)
LD ADA SC + MTX		1.46(0.70,3.34)	1.21(0.81,1.83)	0.09(-0.09,0.28)
LD RITUX IV + MTX		0.71(0.36,1.41)	0.82(0.51,1.23)	-0.08(-0.23,0.08)
LD ADA IV + MTX		1.30(0.21,7.03)	1.15(0.32,2.23)	0.06(-0.29,0.42)
LD ABA IV + MTX		0.70(0.33,1.51)	0.81(0.47,1.27)	-0.08(-0.25,0.10)
LD ANA SC + MTX		0.65(0.16,2.68)	0.77(0.25,1.63)	-0.09(-0.34,0.23)
LD CERTO SC + MTX		1.32(0.49,3.72)	1.16(0.64,1.91)	0.07(-0.16,0.31)
LD ETN SC + MTX		1.18(0.48,2.76)	1.09(0.64,1.72)	0.04(-0.17,0.24)

(Continued)

LD GOLI IV + MTX	0.68(0.24,1.89)	0.80(0.38,1.43)	-0.08(-0.29,0.15)	
LD TOCI IV + MTX	0.55(0.18,1.51)	0.68(0.30,1.28)	-0.13(-0.35,0.10)	
LD TOFA PO + MTX	1.14(0.33,3.94)	1.07(0.46,1.90)	0.03(-0.24,0.32)	
HD TOCI IV	0.87(0.46,1.66)	0.92(0.65,1.38)	-0.03(-0.19,0.12)	
HD TOFA PO	0.94(0.33,2.50)	0.96(0.52,1.73)	-0.02(-0.26,0.21)	
HD ADA SC	0.43(0.15,1.27)	0.56(0.28,1.17)	-0.18(-0.40,0.05)	
HD ETN SC	0.65(0.28,1.51)	0.76(0.43,1.27)	-0.10(-0.28,0.10)	
HD GOLI SC	0.85(0.38,2.01)	0.91(0.54,1.52)	-0.04(-0.23,0.17)	
HD ABA SC	1.28(0.27,7.19)	1.14(0.44,2.59)	0.06(-0.29,0.45)	
HD INF IV + MTX	1.63(0.96,2.74)	1.28(0.98,1.73)	0.12(-0.01,0.24)	
HD TOCI IV + MTX	1.56(0.79,3.03)	1.26(0.88,1.85)	0.11(-0.05,0.26)	
HD TOFA PO + MTX	1.67(0.82,3.47)	1.29(0.90,1.91)	0.12(-0.05,0.30)	
HD GOLI SC + MTX	1.60(0.73,3.62)	1.27(0.84,1.94)	0.11(-0.08,0.31)	
HD CERTO SC + MTX	2.24(1.11,4.53)	1.46(1.06,2.13)	0.19(0.03,0.35)	
HD ADA SC + MTX	1.85(0.66,5.21)	1.35(0.79,2.16)	0.15(-0.10,0.37)	
HD TOCI IV + DMARD	0.32(0.11,1.03)	0.45(0.19,1.02)	-0.22(-0.42,0.01)	
SD ANA SC + SD ETN SC + MTX	0.84(0.28,2.68)	0.91(0.41,1.67)	-0.04(-0.27,0.23)	
SD ANA SC + LD ETN SC + MTX	1.28(0.42,3.77)	1.14(0.56,1.93)	0.06(-0.19,0.31)	
SD ADA SC + MTX	SD ABA IV + MTX	1.57(0.80,3.04)	1.22(0.91,1.67)	0.11(-0.06,0.26)
SD CERTO SC + MTX/CER- TO+MTX	1.42(0.77,2.72)	1.17(0.88,1.65)	0.08(-0.06,0.24)	
SD RITUX IV + MTX	0.63(0.32,1.21)	0.77(0.50,1.11)	-0.11(-0.26,0.05)	
SD TOFA PO + MTX	1.62(0.79,3.31)	1.23(0.89,1.78)	0.12(-0.06,0.28)	
SD GOLI SC + MTX	1.58(0.71,3.44)	1.22(0.86,1.80)	0.11(-0.08,0.29)	
SD ABA SC + MTX	1.25(0.62,2.46)	1.11(0.77,1.49)	0.05(-0.11,0.21)	
SD GOLI IV + MTX	0.59(0.27,1.35)	0.74(0.43,1.17)	-0.12(-0.30,0.07)	
SD ANA SC + MTX	0.73(0.28,1.97)	0.85(0.45,1.40)	-0.08(-0.29,0.16)	
SD TOCI IV + MTX	0.52(0.18,1.42)	0.68(0.32,1.21)	-0.15(-0.37,0.08)	

(Continued)

SD CERTO SC + DMARD	0.36(0.11,1.20)	0.52(0.22,1.12)	-0.22(-0.47,0.04)
SD ADA SC + DMARD	0.21(0.06,0.81)	0.35(0.12,0.88)	-0.31(-0.52,-0.05)
SD ETN SC + DMARD	0.88(0.30,2.58)	0.93(0.49,1.59)	-0.03(-0.28,0.22)
SD TOCI SC + DMARD	0.34(0.09,1.33)	0.51(0.18,1.16)	-0.24(-0.46,0.07)
LD ADA SC	0.23(0.08,0.73)	0.38(0.18,0.81)	-0.30(-0.51,-0.07)
LD ETN SC	0.24(0.11,0.53)	0.39(0.22,0.65)	-0.30(-0.46,-0.13)
LD GOLIV	0.27(0.09,0.77)	0.42(0.16,0.86)	-0.27(-0.47,-0.06)
LD TOCI IV	0.05(0.01,0.17)	0.09(0.02,0.28)	-0.44(-0.62,-0.25)
LD ADA SC + MTX	1.13(0.52,2.45)	1.06(0.69,1.52)	0.03(-0.16,0.21)
LD RITUX IV + MTX	0.55(0.27,1.09)	0.71(0.45,1.05)	-0.14(-0.30,0.02)
LD ADA IV + MTX	1.02(0.16,5.57)	1.01(0.27,1.87)	0.01(-0.36,0.36)
LD ABA IV + MTX	0.54(0.28,1.03)	0.70(0.44,1.01)	-0.14(-0.28,0.01)
LD ANA SC + MTX	0.49(0.12,2.19)	0.66(0.21,1.45)	-0.16(-0.40,0.19)
LD CERTO SC + MTX	1.01(0.37,2.97)	1.01(0.55,1.63)	0.00(-0.23,0.25)
LD ETN SC + MTX	0.92(0.34,2.19)	0.95(0.54,1.46)	-0.02(-0.24,0.19)
LD GOLIV + MTX	0.53(0.19,1.50)	0.69(0.33,1.22)	-0.15(-0.36,0.09)
LD TOCI IV + MTX	0.41(0.14,1.18)	0.59(0.27,1.10)	-0.20(-0.41,0.04)
LD TOFA PO + MTX	0.86(0.25,3.13)	0.93(0.40,1.64)	-0.04(-0.29,0.26)
HD TOCI IV	0.67(0.34,1.33)	0.80(0.57,1.18)	-0.10(-0.26,0.07)
HD TOFA PO	0.72(0.25,1.95)	0.84(0.46,1.49)	-0.08(-0.32,0.16)
HD ADA SC	0.32(0.12,0.96)	0.49(0.25,0.97)	-0.25(-0.46,-0.01)
HD ETN SC	0.49(0.22,1.16)	0.66(0.38,1.08)	-0.16(-0.34,0.03)
HD GOLIV SC	0.65(0.29,1.57)	0.78(0.47,1.28)	-0.10(-0.30,0.11)
HD ABA SC	0.98(0.20,5.58)	0.99(0.37,2.16)	-0.01(-0.36,0.39)
HD INF IV + MTX	1.26(0.64,2.52)	1.11(0.80,1.58)	0.06(-0.11,0.22)
HD TOCI IV + MTX	1.20(0.60,2.35)	1.09(0.78,1.57)	0.04(-0.12,0.20)
HD TOFA PO + MTX	1.29(0.63,2.67)	1.13(0.79,1.61)	0.06(-0.11,0.23)
HD GOLIV SC + MTX	1.23(0.54,2.75)	1.10(0.72,1.65)	0.05(-0.15,0.24)

(Continued)

HD CERTO SC + MTX		1.73(0.85,3.54)	1.26(0.93,1.85)	0.13(-0.04,0.30)
HD ADA SC + MTX		1.43(0.51,3.93)	1.18(0.69,1.77)	0.09(-0.16,0.31)
HD TOCI IV + DMARD		0.25(0.08,0.80)	0.39(0.16,0.88)	-0.29(-0.49,-0.05)
SD ANA SC + SD ETN SC + MTX		0.65(0.20,2.08)	0.79(0.36,1.45)	-0.10(-0.34,0.18)
SD ANA SC + LD ETN SC + MTX		0.97(0.31,3.09)	0.99(0.49,1.63)	-0.01(-0.26,0.26)
SD CERTO SC + MTX/CER- TO+MTX	SD ADA SC + MTX	0.91(0.44,1.81)	0.96(0.72,1.32)	-0.02(-0.19,0.14)
SD RITUX IV + MTX		0.40(0.19,0.83)	0.63(0.41,0.91)	-0.22(-0.39,-0.05)
SD TOFA PO + MTX		1.03(0.46,2.14)	1.01(0.73,1.40)	0.01(-0.18,0.17)
SD GOLI SC + MTX		0.99(0.43,2.34)	1.00(0.71,1.43)	0.00(-0.19,0.20)
SD ABA SC + MTX		0.79(0.39,1.57)	0.91(0.63,1.20)	-0.06(-0.22,0.10)
SD GOLI IV + MTX		0.38(0.16,0.89)	0.61(0.36,0.94)	-0.23(-0.42,-0.03)
SD ANA SC + MTX		0.47(0.17,1.27)	0.70(0.36,1.10)	-0.18(-0.41,0.05)
SD TOCI IV + MTX		0.33(0.11,1.02)	0.56(0.26,1.01)	-0.26(-0.49,0.00)
SD CERTO SC + DMARD		0.23(0.06,0.84)	0.43(0.19,0.91)	-0.34(-0.59,-0.04)
SD ADA SC + DMARD		0.13(0.04,0.52)	0.29(0.09,0.70)	-0.42(-0.63,-0.15)
SD ETN SC + DMARD		0.56(0.19,1.62)	0.77(0.41,1.24)	-0.14(-0.38,0.11)
SD TOCI SC + DMARD		0.21(0.05,0.85)	0.41(0.15,0.92)	-0.34(-0.58,-0.04)
LD ADA SC		0.15(0.05,0.48)	0.31(0.15,0.62)	-0.41(-0.62,-0.16)
LD ETN SC		0.15(0.06,0.36)	0.32(0.18,0.54)	-0.40(-0.58,-0.22)
LD GOLI IV		0.17(0.05,0.51)	0.34(0.13,0.70)	-0.38(-0.58,-0.16)
LD TOCI IV		0.03(0.00,0.13)	0.07(0.01,0.24)	-0.55(-0.73,-0.34)
LD ADA SC + MTX		0.71(0.38,1.36)	0.87(0.62,1.14)	-0.08(-0.22,0.07)
LD RITUX IV + MTX		0.35(0.16,0.74)	0.58(0.36,0.85)	-0.25(-0.42,-0.07)
LD ADA IV + MTX		0.65(0.10,3.48)	0.82(0.23,1.52)	-0.10(-0.47,0.26)
LD ABA IV + MTX		0.34(0.15,0.77)	0.58(0.33,0.88)	-0.25(-0.43,-0.06)
LD ANA SC + MTX		0.32(0.07,1.39)	0.54(0.18,1.15)	-0.26(-0.53,0.08)
LD CERTO SC + MTX		0.65(0.22,1.91)	0.83(0.44,1.29)	-0.10(-0.35,0.14)
LD ETN SC + MTX		0.57(0.21,1.54)	0.78(0.44,1.20)	-0.13(-0.36,0.10)

(Continued)

LD GOLI IV + MTX		0.34(0.11,0.99)	0.56(0.27,1.00)	-0.26(-0.48,0.00)
LD TOCI IV + MTX		0.27(0.08,0.78)	0.48(0.22,0.88)	-0.30(-0.53,-0.06)
LD TOFA PO + MTX		0.56(0.14,1.95)	0.77(0.31,1.31)	-0.14(-0.42,0.16)
HD TOCI IV		0.42(0.20,0.90)	0.65(0.46,0.94)	-0.21(-0.37,-0.03)
HD TOFA PO		0.45(0.15,1.33)	0.68(0.39,1.16)	-0.19(-0.43,0.07)
HD ADA SC		0.21(0.07,0.65)	0.40(0.21,0.77)	-0.36(-0.57,-0.10)
HD ETN SC		0.32(0.12,0.80)	0.54(0.30,0.89)	-0.27(-0.47,-0.05)
HD GOLI SC		0.42(0.16,1.06)	0.65(0.38,1.04)	-0.21(-0.42,0.01)
HD ABA SC		0.62(0.12,3.54)	0.81(0.32,1.66)	-0.11(-0.47,0.28)
HD INF IV + MTX		0.80(0.36,1.74)	0.91(0.64,1.28)	-0.05(-0.24,0.13)
HD TOCI IV + MTX		0.76(0.36,1.61)	0.89(0.63,1.25)	-0.06(-0.24,0.11)
HD TOFA PO + MTX		0.83(0.38,1.77)	0.92(0.64,1.28)	-0.04(-0.23,0.13)
HD GOLI SC + MTX		0.78(0.33,1.82)	0.90(0.60,1.31)	-0.06(-0.25,0.14)
HD CERTO SC + MTX		1.11(0.49,2.40)	1.04(0.75,1.45)	0.02(-0.17,0.20)
HD ADA SC + MTX		0.92(0.37,2.26)	0.96(0.61,1.33)	-0.02(-0.23,0.17)
HD TOCI IV + DMARD		0.16(0.05,0.54)	0.32(0.13,0.71)	-0.39(-0.60,-0.15)
SD ANA SC + SD ETN SC + MTX		0.42(0.12,1.41)	0.65(0.30,1.16)	-0.21(-0.46,0.08)
SD ANA SC + LD ETN SC + MTX		0.62(0.19,2.04)	0.81(0.40,1.33)	-0.11(-0.38,0.16)
SD RITUX IV + MTX	SD CER- TO SC + MTX/CER- TO+MTX	0.44(0.21,0.90)	0.66(0.42,0.94)	-0.20(-0.36,-0.03)
SD TOFA PO + MTX		1.12(0.55,2.38)	1.05(0.76,1.42)	0.03(-0.14,0.19)
SD GOLI SC + MTX		1.10(0.50,2.45)	1.04(0.74,1.45)	0.02(-0.16,0.20)
SD ABA SC + MTX		0.87(0.37,1.95)	0.94(0.60,1.33)	-0.03(-0.24,0.15)
SD GOLI IV + MTX		0.42(0.18,0.93)	0.63(0.36,0.97)	-0.21(-0.39,-0.02)
SD ANA SC + MTX		0.51(0.20,1.29)	0.72(0.38,1.13)	-0.16(-0.37,0.06)
SD TOCI IV + MTX		0.36(0.12,1.04)	0.58(0.27,1.02)	-0.24(-0.46,0.01)
SD CERTO SC + DMARD		0.25(0.07,0.83)	0.44(0.19,0.90)	-0.31(-0.55,-0.05)
SD ADA SC + DMARD		0.15(0.04,0.54)	0.29(0.10,0.72)	-0.39(-0.59,-0.14)

(Continued)

SD ETN SC + DMARD	0.61(0.21,1.83)	0.79(0.42,1.29)	-0.12(-0.37,0.14)
SD TOCI SC + DMARD	0.23(0.07,0.87)	0.43(0.15,0.93)	-0.32(-0.55,-0.03)
LD ADA SC	0.16(0.06,0.51)	0.32(0.16,0.65)	-0.40(-0.59,-0.15)
LD ETN SC	0.17(0.08,0.37)	0.33(0.19,0.55)	-0.38(-0.54,-0.21)
LD GOLIV	0.19(0.06,0.55)	0.35(0.14,0.73)	-0.36(-0.56,-0.14)
LD TOCI IV	0.03(0.01,0.13)	0.07(0.01,0.24)	-0.53(-0.69,-0.33)
LD ADA SC + MTX	0.78(0.37,1.77)	0.90(0.59,1.28)	-0.06(-0.24,0.13)
LD RITUX IV + MTX	0.39(0.18,0.77)	0.60(0.37,0.88)	-0.23(-0.39,-0.06)
LD ADA IV + MTX	0.69(0.12,3.87)	0.85(0.23,1.58)	-0.09(-0.44,0.28)
LD ABA IV + MTX	0.37(0.17,0.81)	0.59(0.34,0.90)	-0.23(-0.41,-0.05)
LD ANA SC + MTX	0.35(0.09,1.48)	0.56(0.18,1.18)	-0.24(-0.49,0.09)
LD CERTO SC + MTX	0.70(0.29,1.84)	0.85(0.49,1.27)	-0.08(-0.28,0.14)
LD ETN SC + MTX	0.63(0.24,1.55)	0.81(0.46,1.21)	-0.11(-0.33,0.10)
LD GOLIV + MTX	0.37(0.13,1.04)	0.58(0.27,1.02)	-0.23(-0.45,0.01)
LD TOCI IV + MTX	0.29(0.10,0.83)	0.50(0.22,0.91)	-0.28(-0.50,-0.04)
LD TOFA PO + MTX	0.60(0.18,2.09)	0.79(0.34,1.34)	-0.12(-0.38,0.17)
HD TOCI IV	0.47(0.24,0.90)	0.68(0.48,0.94)	-0.18(-0.34,-0.03)
HD TOFA PO	0.50(0.17,1.37)	0.71(0.41,1.19)	-0.17(-0.40,0.08)
HD ADA SC	0.22(0.08,0.72)	0.41(0.22,0.82)	-0.34(-0.54,-0.07)
HD ETN SC	0.34(0.15,0.83)	0.56(0.32,0.91)	-0.25(-0.43,-0.05)
HD GOLIV SC	0.46(0.19,1.06)	0.67(0.41,1.03)	-0.19(-0.38,0.01)
HD ABA SC	0.69(0.14,4.04)	0.84(0.33,1.75)	-0.09(-0.45,0.31)
HD INF IV + MTX	0.88(0.43,1.77)	0.94(0.68,1.29)	-0.03(-0.20,0.13)
HD TOCI IV + MTX	0.84(0.41,1.64)	0.93(0.67,1.25)	-0.04(-0.21,0.12)
HD TOFA PO + MTX	0.89(0.43,1.90)	0.95(0.66,1.33)	-0.03(-0.20,0.15)
HD GOLIV SC + MTX	0.85(0.38,1.96)	0.93(0.62,1.32)	-0.04(-0.23,0.16)
HD CERTO SC + MTX	1.20(0.71,1.99)	1.07(0.86,1.35)	0.04(-0.08,0.16)
HD ADA SC + MTX	1.00(0.33,2.94)	1.00(0.58,1.50)	0.00(-0.26,0.23)

(Continued)

HD TOCI IV + DMARD		0.17(0.06,0.51)	0.34(0.13,0.70)	-0.37(-0.56,-0.16)
SD ANA SC + SD ETN SC + MTX		0.46(0.14,1.41)	0.67(0.31,1.16)	-0.19(-0.43,0.08)
SD ANA SC + LD ETN SC + MTX		0.68(0.21,2.11)	0.84(0.41,1.34)	-0.09(-0.36,0.17)
SD TOFA PO + MTX	SD RITUX IV + MTX	2.55(1.21,5.49)	1.60(1.10,2.49)	0.22(0.05,0.40)
SD GOL I SC + MTX		2.52(1.10,5.87)	1.59(1.05,2.58)	0.22(0.02,0.41)
SD ABA SC + MTX		1.99(0.85,4.70)	1.44(0.91,2.34)	0.16(-0.04,0.36)
SD GOL I IV + MTX		0.93(0.39,2.25)	0.96(0.54,1.63)	-0.01(-0.20,0.19)
SD ANA SC + MTX		1.18(0.43,3.10)	1.10(0.58,1.90)	0.04(-0.18,0.27)
SD TOCI IV + MTX		0.83(0.27,2.38)	0.89(0.41,1.67)	-0.04(-0.27,0.20)
SD CERTO SC + DMARD		0.58(0.17,1.88)	0.69(0.28,1.51)	-0.11(-0.36,0.14)
SD ADA SC + DMARD		0.34(0.09,1.22)	0.46(0.15,1.14)	-0.19(-0.40,0.04)
SD ETN SC + DMARD		1.41(0.45,4.13)	1.21(0.61,2.20)	0.08(-0.18,0.33)
SD TOCI SC + DMARD		0.54(0.14,2.01)	0.66(0.23,1.53)	-0.12(-0.36,0.16)
LD ADA SC		0.37(0.13,1.14)	0.49(0.23,1.10)	-0.19(-0.41,0.03)
LD ETN SC		0.39(0.17,0.86)	0.51(0.27,0.90)	-0.18(-0.36,-0.02)
LD GOL I IV		0.42(0.13,1.28)	0.55(0.21,1.17)	-0.16(-0.37,0.05)
LD TOCI IV		0.07(0.01,0.29)	0.11(0.02,0.39)	-0.32(-0.52,-0.16)
LD ADA SC + MTX		1.80(0.79,4.27)	1.37(0.86,2.21)	0.14(-0.06,0.34)
LD RITUX IV + MTX		0.88(0.51,1.51)	0.92(0.63,1.31)	-0.03(-0.15,0.09)
LD ADA IV + MTX		1.62(0.24,9.49)	1.30(0.35,2.76)	0.11(-0.27,0.49)
LD ABA IV + MTX		0.85(0.37,1.95)	0.90(0.52,1.50)	-0.04(-0.21,0.16)
LD ANA SC + MTX		0.80(0.18,3.55)	0.87(0.28,1.94)	-0.05(-0.30,0.30)
LD CERTO SC + MTX		1.61(0.57,4.78)	1.30(0.70,2.29)	0.11(-0.12,0.36)
LD ETN SC + MTX		1.44(0.56,3.77)	1.23(0.70,2.10)	0.08(-0.13,0.31)
LD GOL I IV + MTX		0.84(0.29,2.50)	0.89(0.41,1.69)	-0.04(-0.26,0.22)
LD TOCI IV + MTX		0.67(0.22,1.89)	0.77(0.33,1.52)	-0.08(-0.30,0.15)
LD TOFA PO + MTX		1.39(0.38,5.07)	1.20(0.51,2.24)	0.08(-0.20,0.37)
HD TOCI IV		1.05(0.53,2.18)	1.03(0.69,1.66)	0.01(-0.15,0.17)

(Continued)

HD TOFA PO		1.13(0.40,3.21)	1.07(0.57,2.12)	0.03(-0.21,0.26)
HD ADA SC		0.53(0.18,1.60)	0.64(0.31,1.40)	-0.13(-0.36,0.09)
HD ETN SC		0.79(0.34,1.90)	0.86(0.48,1.50)	-0.05(-0.24,0.15)
HD GOLI SC		1.05(0.42,2.59)	1.03(0.59,1.82)	0.01(-0.20,0.21)
HD ABA SC		1.58(0.32,8.91)	1.29(0.47,3.02)	0.11(-0.25,0.49)
HD INF IV + MTX		2.00(0.96,4.27)	1.45(0.98,2.27)	0.16(-0.01,0.33)
HD TOCI IV + MTX		1.91(0.92,3.98)	1.42(0.96,2.24)	0.15(-0.02,0.32)
HD TOFA PO + MTX		2.08(0.94,4.43)	1.47(0.97,2.29)	0.17(-0.01,0.35)
HD GOLI SC + MTX		1.95(0.83,4.69)	1.42(0.90,2.35)	0.16(-0.04,0.36)
HD CERTO SC + MTX		2.74(1.30,5.90)	1.64(1.13,2.61)	0.24(0.06,0.41)
HD ADA SC + MTX		2.29(0.79,6.68)	1.52(0.87,2.54)	0.20(-0.05,0.43)
HD TOCI IV + DMARD		0.39(0.13,1.27)	0.51(0.21,1.16)	-0.18(-0.37,0.05)
SD ANA SC + SD ETN SC + MTX		1.03(0.34,3.46)	1.02(0.46,1.94)	0.01(-0.23,0.30)
SD ANA SC + LD ETN SC + MTX		1.55(0.49,5.05)	1.27(0.62,2.33)	0.10(-0.16,0.37)
SD GOLI SC + MTX	SD TOFA PO + MTX	0.97(0.41,2.39)	0.99(0.69,1.43)	-0.01(-0.21,0.20)
SD ABA SC + MTX		0.78(0.31,1.85)	0.90(0.57,1.29)	-0.06(-0.27,0.14)
SD GOLI IV + MTX		0.37(0.14,0.93)	0.60(0.34,0.96)	-0.24(-0.44,-0.02)
SD ANA SC + MTX		0.46(0.16,1.29)	0.69(0.35,1.12)	-0.18(-0.42,0.06)
SD TOCI IV + MTX		0.32(0.10,0.97)	0.55(0.25,0.99)	-0.27(-0.49,-0.01)
SD CERTO SC + DMARD		0.22(0.06,0.78)	0.42(0.19,0.87)	-0.34(-0.59,-0.06)
SD ADA SC + DMARD		0.13(0.03,0.53)	0.28(0.09,0.70)	-0.42(-0.63,-0.15)
SD ETN SC + DMARD		0.55(0.17,1.73)	0.76(0.40,1.26)	-0.14(-0.41,0.13)
SD TOCI SC + DMARD		0.21(0.06,0.84)	0.41(0.14,0.92)	-0.35(-0.58,-0.04)
LD ADA SC		0.14(0.05,0.44)	0.30(0.15,0.60)	-0.42(-0.61,-0.18)
LD ETN SC		0.15(0.06,0.36)	0.31(0.18,0.54)	-0.41(-0.59,-0.22)
LD GOLI IV		0.17(0.05,0.53)	0.34(0.13,0.73)	-0.39(-0.60,-0.15)
LD TOCI IV		0.03(0.00,0.12)	0.07(0.01,0.24)	-0.55(-0.73,-0.35)
LD ADA SC + MTX		0.70(0.30,1.72)	0.86(0.56,1.26)	-0.08(-0.28,0.13)

(Continued)

LD RITUX IV + MTX		0.34(0.16,0.74)	0.57(0.35,0.86)	-0.25(-0.42,-0.07)
LD ADA IV + MTX		0.63(0.10,3.41)	0.81(0.22,1.47)	-0.11(-0.47,0.25)
LD ABA IV + MTX		0.33(0.14,0.79)	0.57(0.33,0.90)	-0.26(-0.44,-0.06)
LD ANA SC + MTX		0.31(0.07,1.42)	0.54(0.17,1.16)	-0.27(-0.53,0.08)
LD CERTO SC + MTX		0.63(0.22,1.81)	0.82(0.43,1.27)	-0.11(-0.35,0.13)
LD ETN SC + MTX		0.56(0.20,1.50)	0.77(0.44,1.19)	-0.14(-0.37,0.09)
LD GOLI IV + MTX		0.33(0.10,1.07)	0.55(0.26,1.03)	-0.26(-0.49,0.02)
LD TOCI IV + MTX		0.26(0.08,0.77)	0.48(0.21,0.88)	-0.31(-0.52,-0.06)
LD TOFA PO + MTX		0.55(0.17,1.67)	0.76(0.34,1.20)	-0.14(-0.39,0.11)
HD TOCI IV		0.41(0.20,0.91)	0.65(0.45,0.95)	-0.21(-0.37,-0.02)
HD TOFA PO		0.44(0.15,1.23)	0.67(0.39,1.12)	-0.20(-0.43,0.05)
HD ADA SC		0.20(0.07,0.63)	0.40(0.21,0.76)	-0.36(-0.57,-0.10)
HD ETN SC		0.31(0.12,0.76)	0.53(0.30,0.87)	-0.28(-0.47,-0.06)
HD GOLI SC		0.41(0.16,1.05)	0.64(0.39,1.02)	-0.21(-0.42,0.01)
HD ABA SC		0.61(0.12,3.64)	0.81(0.31,1.63)	-0.12(-0.48,0.29)
HD INF IV + MTX		0.79(0.36,1.73)	0.91(0.63,1.26)	-0.06(-0.24,0.13)
HD TOCI IV + MTX		0.74(0.34,1.59)	0.88(0.62,1.24)	-0.07(-0.25,0.11)
HD TOFA PO + MTX		0.80(0.48,1.30)	0.92(0.72,1.12)	-0.05(-0.17,0.06)
HD GOLI SC + MTX		0.76(0.32,1.91)	0.90(0.58,1.30)	-0.06(-0.27,0.15)
HD CERTO SC + MTX		1.07(0.50,2.42)	1.03(0.75,1.45)	0.02(-0.16,0.20)
HD ADA SC + MTX		0.88(0.32,2.70)	0.95(0.55,1.43)	-0.03(-0.27,0.22)
HD TOCI IV + DMARD		0.15(0.05,0.52)	0.32(0.13,0.71)	-0.40(-0.60,-0.15)
SD ANA SC + SD ETN SC + MTX		0.40(0.12,1.45)	0.64(0.28,1.17)	-0.21(-0.48,0.09)
SD ANA SC + LD ETN SC + MTX		0.60(0.18,2.12)	0.80(0.38,1.33)	-0.12(-0.39,0.17)
SD ABA SC + MTX	SD GOLI SC + MTX	0.79(0.30,1.98)	0.91(0.56,1.35)	-0.06(-0.28,0.16)
SD GOLI IV + MTX		0.37(0.14,0.96)	0.60(0.34,0.98)	-0.23(-0.44,-0.01)
SD ANA SC + MTX		0.47(0.16,1.31)	0.69(0.36,1.12)	-0.18(-0.42,0.06)
SD TOCI IV + MTX		0.33(0.10,1.03)	0.56(0.25,1.02)	-0.26(-0.51,0.01)

(Continued)

SD CERTO SC + DMARD	0.23(0.06,0.79)	0.43(0.19,0.89)	-0.33(-0.59,-0.05)
SD ADA SC + DMARD	0.14(0.03,0.53)	0.28(0.09,0.71)	-0.42(-0.64,-0.14)
SD ETN SC + DMARD	0.56(0.17,1.79)	0.77(0.38,1.28)	-0.14(-0.41,0.14)
SD TOCI SC + DMARD	0.21(0.06,0.83)	0.41(0.14,0.91)	-0.34(-0.58,-0.05)
LD ADA SC	0.15(0.05,0.49)	0.30(0.15,0.63)	-0.41(-0.63,-0.16)
LD ETN SC	0.15(0.06,0.37)	0.32(0.18,0.54)	-0.40(-0.59,-0.21)
LD GOLIV	0.17(0.05,0.55)	0.34(0.13,0.73)	-0.38(-0.59,-0.14)
LD TOCI IV	0.03(0.00,0.13)	0.07(0.01,0.25)	-0.55(-0.74,-0.33)
LD ADA SC + MTX	0.73(0.29,1.78)	0.87(0.54,1.27)	-0.08(-0.29,0.13)
LD RITUX IV + MTX	0.34(0.15,0.82)	0.58(0.35,0.91)	-0.25(-0.43,-0.05)
LD ADA IV + MTX	0.64(0.10,3.52)	0.82(0.22,1.51)	-0.10(-0.48,0.26)
LD ABA IV + MTX	0.34(0.14,0.86)	0.57(0.32,0.93)	-0.25(-0.44,-0.04)
LD ANA SC + MTX	0.32(0.07,1.48)	0.55(0.17,1.17)	-0.26(-0.55,0.09)
LD CERTO SC + MTX	0.65(0.21,2.08)	0.83(0.43,1.35)	-0.10(-0.36,0.17)
LD ETN SC + MTX	0.57(0.19,1.66)	0.78(0.42,1.24)	-0.13(-0.38,0.12)
LD GOLIV + MTX	0.33(0.11,1.06)	0.57(0.25,1.03)	-0.26(-0.49,0.01)
LD TOCI IV + MTX	0.27(0.08,0.84)	0.48(0.22,0.92)	-0.30(-0.53,-0.04)
LD TOFA PO + MTX	0.56(0.14,2.01)	0.76(0.31,1.35)	-0.14(-0.43,0.16)
HD TOCI IV	0.43(0.18,0.92)	0.66(0.44,0.96)	-0.20(-0.39,-0.02)
HD TOFA PO	0.45(0.15,1.37)	0.68(0.39,1.18)	-0.19(-0.43,0.08)
HD ADA SC	0.21(0.06,0.69)	0.40(0.21,0.80)	-0.36(-0.59,-0.08)
HD ETN SC	0.31(0.12,0.81)	0.53(0.30,0.90)	-0.27(-0.48,-0.05)
HD GOLIV	0.42(0.18,0.96)	0.65(0.41,0.98)	-0.21(-0.39,-0.01)
HD ABA SC	0.63(0.12,3.59)	0.81(0.32,1.67)	-0.11(-0.47,0.28)
HD INF IV + MTX	0.80(0.34,1.90)	0.91(0.62,1.34)	-0.05(-0.25,0.15)
HD TOCI IV + MTX	0.76(0.32,1.72)	0.89(0.62,1.30)	-0.07(-0.26,0.13)
HD TOFA PO + MTX	0.82(0.34,1.98)	0.92(0.62,1.35)	-0.05(-0.25,0.16)
HD GOLIV + MTX	0.78(0.42,1.45)	0.90(0.66,1.16)	-0.06(-0.20,0.09)

(Continued)

HD CERTO SC + MTX		1.11(0.45,2.57)	1.04(0.74,1.48)	0.02(-0.18,0.22)
HD ADA SC + MTX		0.91(0.28,2.80)	0.96(0.53,1.48)	-0.02(-0.30,0.23)
HD TOCI IV + DMARD		0.16(0.05,0.53)	0.32(0.13,0.70)	-0.39(-0.61,-0.15)
SD ANA SC + SD ETN SC + MTX		0.41(0.12,1.56)	0.65(0.28,1.23)	-0.21(-0.48,0.10)
SD ANA SC + LD ETN SC + MTX		0.62(0.17,2.19)	0.81(0.38,1.38)	-0.11(-0.41,0.18)
SD GOLI IV + MTX	SD ABA SC + MTX	0.47(0.18,1.28)	0.67(0.38,1.13)	-0.18(-0.39,0.06)
SD ANA SC + MTX		0.58(0.20,1.86)	0.76(0.39,1.39)	-0.13(-0.37,0.15)
SD TOCI IV + MTX		0.41(0.13,1.36)	0.61(0.28,1.18)	-0.21(-0.45,0.07)
SD CERTO SC + DMARD		0.29(0.08,1.13)	0.48(0.20,1.07)	-0.28(-0.55,0.03)
SD ADA SC + DMARD		0.17(0.04,0.76)	0.32(0.10,0.84)	-0.36(-0.59,-0.06)
SD ETN SC + DMARD		0.71(0.21,2.38)	0.84(0.43,1.51)	-0.08(-0.37,0.21)
SD TOCI SC + DMARD		0.28(0.07,1.15)	0.47(0.16,1.08)	-0.28(-0.54,0.03)
LD ADA SC		0.19(0.06,0.64)	0.34(0.17,0.75)	-0.35(-0.58,-0.09)
LD ETN SC		0.19(0.07,0.49)	0.35(0.19,0.63)	-0.35(-0.55,-0.14)
LD GOLI IV		0.21(0.06,0.70)	0.38(0.15,0.82)	-0.33(-0.56,-0.08)
LD TOCI IV		0.04(0.01,0.17)	0.08(0.01,0.27)	-0.49(-0.69,-0.26)
LD ADA SC + MTX		0.91(0.39,2.24)	0.96(0.63,1.44)	-0.02(-0.22,0.19)
LD RITUX IV + MTX		0.44(0.19,1.08)	0.64(0.38,1.04)	-0.19(-0.39,0.02)
LD ADA IV + MTX		0.82(0.13,4.51)	0.92(0.25,1.83)	-0.05(-0.42,0.33)
LD ABA IV + MTX		0.43(0.18,1.07)	0.63(0.36,1.04)	-0.20(-0.40,0.02)
LD ANA SC + MTX		0.40(0.09,1.99)	0.60(0.19,1.37)	-0.21(-0.49,0.16)
LD CERTO SC + MTX		0.81(0.27,2.63)	0.91(0.48,1.61)	-0.05(-0.30,0.23)
LD ETN SC + MTX		0.72(0.25,2.12)	0.86(0.47,1.45)	-0.08(-0.32,0.18)
LD GOLI IV + MTX		0.42(0.14,1.37)	0.62(0.29,1.18)	-0.20(-0.44,0.08)
LD TOCI IV + MTX		0.33(0.10,1.12)	0.53(0.24,1.06)	-0.25(-0.49,0.03)
LD TOFA PO + MTX		0.70(0.18,2.71)	0.84(0.34,1.58)	-0.09(-0.38,0.23)
HD TOCI IV		0.54(0.23,1.29)	0.72(0.48,1.16)	-0.15(-0.35,0.06)
HD TOFA PO		0.58(0.19,1.81)	0.75(0.42,1.40)	-0.13(-0.39,0.14)

(Continued)

HD ADA SC		0.26(0.08,0.88)	0.44(0.23,0.92)	-0.30(-0.53,-0.03)
HD ETN SC		0.39(0.15,1.05)	0.60(0.33,1.03)	-0.22(-0.43,0.01)
HD GOLI SC		0.54(0.19,1.44)	0.72(0.41,1.23)	-0.15(-0.39,0.08)
HD ABA SC		0.80(0.15,4.83)	0.90(0.34,2.00)	-0.05(-0.43,0.35)
HD INF IV + MTX		1.01(0.42,2.46)	1.01(0.68,1.58)	0.00(-0.20,0.21)
HD TOCI IV + MTX		0.96(0.41,2.31)	0.98(0.67,1.56)	-0.01(-0.21,0.20)
HD TOFA PO + MTX		1.02(0.42,2.59)	1.01(0.68,1.61)	0.01(-0.20,0.23)
HD GOLI SC + MTX		0.98(0.38,2.69)	0.99(0.64,1.61)	0.00(-0.23,0.23)
HD CERTO SC + MTX		1.37(0.59,3.51)	1.14(0.81,1.83)	0.07(-0.12,0.29)
HD ADA SC + MTX		1.15(0.40,3.40)	1.07(0.63,1.69)	0.03(-0.22,0.27)
HD TOCI IV + DMARD		0.20(0.06,0.73)	0.36(0.14,0.83)	-0.34(-0.57,-0.07)
SD ANA SC + SD ETN SC + MTX		0.52(0.15,1.89)	0.71(0.32,1.35)	-0.15(-0.42,0.15)
SD ANA SC + LD ETN SC + MTX		0.78(0.24,2.91)	0.89(0.44,1.60)	-0.06(-0.32,0.25)
SD ANA SC + MTX	SD GOLI IV + MTX	1.25(0.43,3.50)	1.14(0.58,2.11)	0.05(-0.19,0.29)
SD TOCI IV + MTX		0.88(0.28,2.81)	0.92(0.41,1.93)	-0.03(-0.28,0.24)
SD CERTO SC + DMARD		0.60(0.17,2.29)	0.71(0.29,1.72)	-0.10(-0.36,0.19)
SD ADA SC + DMARD		0.36(0.09,1.41)	0.48(0.15,1.26)	-0.18(-0.43,0.07)
SD ETN SC + DMARD		1.48(0.46,4.78)	1.26(0.63,2.44)	0.09(-0.17,0.36)
SD TOCI SC + DMARD		0.58(0.14,2.34)	0.68(0.23,1.72)	-0.11(-0.36,0.20)
LD ADA SC		0.39(0.12,1.34)	0.51(0.22,1.23)	-0.18(-0.42,0.06)
LD ETN SC		0.41(0.16,1.00)	0.52(0.27,1.00)	-0.17(-0.38,0.00)
LD GOLI IV		0.45(0.17,1.17)	0.57(0.24,1.11)	-0.15(-0.34,0.03)
LD TOCI IV		0.08(0.01,0.34)	0.12(0.02,0.42)	-0.31(-0.53,-0.13)
LD ADA SC + MTX		1.90(0.74,5.11)	1.43(0.85,2.58)	0.15(-0.07,0.37)
LD RITUX IV + MTX		0.94(0.39,2.24)	0.96(0.55,1.70)	-0.01(-0.22,0.17)
LD ADA IV + MTX		1.76(0.23,10.18)	1.36(0.35,3.06)	0.13(-0.27,0.50)
LD ABA IV + MTX		0.92(0.35,2.27)	0.95(0.52,1.66)	-0.02(-0.23,0.18)
LD ANA SC + MTX		0.84(0.19,4.05)	0.90(0.30,2.20)	-0.04(-0.31,0.32)

(Continued)

LD CERTO SC + MTX	1.73(0.55,5.37)	1.35(0.69,2.63)	0.13(-0.14,0.38)
LD ETN SC + MTX	1.52(0.52,4.45)	1.27(0.68,2.43)	0.10(-0.15,0.34)
LD GOLI IV + MTX	0.89(0.36,2.24)	0.93(0.49,1.66)	-0.02(-0.22,0.19)
LD TOCI IV + MTX	0.72(0.21,2.28)	0.80(0.34,1.75)	-0.07(-0.33,0.18)
LD TOFA PO + MTX	1.50(0.37,5.83)	1.26(0.51,2.57)	0.09(-0.21,0.40)
HD TOCI IV	1.13(0.47,2.63)	1.08(0.66,1.95)	0.03(-0.18,0.21)
HD TOFA PO	1.22(0.38,3.66)	1.13(0.56,2.37)	0.05(-0.23,0.28)
HD ADA SC	0.55(0.18,1.87)	0.66(0.31,1.57)	-0.12(-0.36,0.12)
HD ETN SC	0.84(0.31,2.23)	0.89(0.46,1.71)	-0.04(-0.26,0.18)
HD GOLI SC	1.12(0.42,2.87)	1.07(0.59,1.99)	0.02(-0.20,0.23)
HD ABA SC	1.69(0.31,10.13)	1.34(0.46,3.48)	0.12(-0.26,0.51)
HD INF IV + MTX	2.13(0.87,5.23)	1.51(0.92,2.69)	0.18(-0.03,0.37)
HD TOCI IV + MTX	2.05(0.82,4.82)	1.48(0.91,2.61)	0.17(-0.05,0.36)
HD TOFA PO + MTX	2.19(0.87,5.57)	1.53(0.93,2.69)	0.18(-0.03,0.39)
HD GOLI SC + MTX	2.07(0.80,5.42)	1.48(0.89,2.70)	0.17(-0.05,0.39)
HD CERTO SC + MTX	2.92(1.21,7.21)	1.70(1.08,3.06)	0.25(0.05,0.45)
HD ADA SC + MTX	2.44(0.73,7.73)	1.59(0.85,3.00)	0.21(-0.07,0.46)
HD TOCI IV + DMARD	0.41(0.12,1.43)	0.53(0.21,1.28)	-0.16(-0.41,0.07)
SD ANA SC + SD ETN SC + MTX	1.10(0.30,3.93)	1.06(0.45,2.20)	0.02(-0.25,0.31)
SD ANA SC + LD ETN SC + MTX	1.66(0.45,5.64)	1.33(0.61,2.64)	0.12(-0.17,0.40)
SD TOCI IV + MTX	SD ANA SC + MTX 0.70(0.20,2.50)	0.80(0.36,1.77)	-0.08(-0.35,0.20)
SD CERTO SC + DMARD	0.50(0.12,1.96)	0.63(0.24,1.59)	-0.15(-0.44,0.14)
SD ADA SC + DMARD	0.29(0.07,1.32)	0.42(0.13,1.20)	-0.23(-0.49,0.06)
SD ETN SC + DMARD	1.19(0.34,4.17)	1.10(0.54,2.30)	0.04(-0.25,0.33)
SD TOCI SC + DMARD	0.46(0.11,1.92)	0.60(0.20,1.48)	-0.16(-0.44,0.14)
LD ADA SC	0.31(0.09,1.15)	0.44(0.20,1.11)	-0.23(-0.49,0.02)
LD ETN SC	0.33(0.11,0.96)	0.46(0.23,0.96)	-0.22(-0.46,-0.01)
LD GOLI IV	0.36(0.10,1.24)	0.50(0.19,1.16)	-0.20(-0.45,0.04)

(Continued)

LD TOCI IV		0.06(0.01,0.30)	0.10(0.02,0.38)	-0.36(-0.60,-0.14)
LD ADA SC + MTX		1.53(0.54,4.58)	1.25(0.73,2.43)	0.10(-0.15,0.35)
LD RITUX IV + MTX		0.74(0.28,2.00)	0.83(0.47,1.62)	-0.07(-0.29,0.15)
LD ADA IV + MTX		1.40(0.18,9.16)	1.19(0.30,2.80)	0.08(-0.33,0.48)
LD ABA IV + MTX		0.73(0.24,2.19)	0.83(0.41,1.67)	-0.07(-0.32,0.17)
LD ANA SC + MTX		0.68(0.18,2.54)	0.80(0.29,1.65)	-0.08(-0.33,0.22)
LD CERTO SC + MTX		1.38(0.42,4.91)	1.19(0.60,2.37)	0.08(-0.21,0.36)
LD ETN SC + MTX		1.23(0.38,4.08)	1.12(0.59,2.30)	0.05(-0.22,0.32)
LD GOLI IV + MTX		0.71(0.22,2.47)	0.82(0.37,1.72)	-0.08(-0.34,0.21)
LD TOCI IV + MTX		0.57(0.16,2.01)	0.70(0.30,1.59)	-0.12(-0.39,0.16)
LD TOFA PO + MTX		1.18(0.26,4.90)	1.10(0.42,2.37)	0.04(-0.29,0.36)
HD TOCI IV		0.90(0.35,2.35)	0.94(0.57,1.81)	-0.02(-0.25,0.19)
HD TOFA PO		0.98(0.29,3.14)	0.99(0.50,2.13)	-0.01(-0.29,0.25)
HD ADA SC		0.44(0.13,1.65)	0.58(0.27,1.45)	-0.17(-0.44,0.10)
HD ETN SC		0.66(0.22,2.12)	0.77(0.40,1.62)	-0.09(-0.34,0.16)
HD GOLI SC		0.89(0.31,2.72)	0.94(0.51,1.90)	-0.03(-0.27,0.22)
HD ABA SC		1.34(0.24,8.97)	1.17(0.41,3.20)	0.07(-0.33,0.49)
HD INF IV + MTX		1.69(0.62,4.76)	1.31(0.80,2.53)	0.13(-0.11,0.36)
HD TOCI IV + MTX		1.61(0.61,4.65)	1.28(0.79,2.51)	0.11(-0.12,0.35)
HD TOFA PO + MTX		1.73(0.63,5.21)	1.32(0.79,2.67)	0.13(-0.11,0.38)
HD GOLI SC + MTX		1.65(0.58,5.18)	1.28(0.76,2.51)	0.12(-0.13,0.37)
HD CERTO SC + MTX		2.34(0.90,6.51)	1.49(0.96,2.81)	0.20(-0.02,0.42)
HD ADA SC + MTX		1.94(0.57,7.07)	1.37(0.74,2.82)	0.16(-0.13,0.44)
HD TOCI IV + DMARD		0.34(0.10,1.28)	0.47(0.18,1.18)	-0.21(-0.47,0.05)
SD ANA SC + SD ETN SC + MTX		0.89(0.25,3.60)	0.93(0.40,2.08)	-0.03(-0.32,0.30)
SD ANA SC + LD ETN SC + MTX		1.31(0.35,5.32)	1.16(0.53,2.44)	0.06(-0.24,0.38)
SD CERTO SC + DMARD	SD TOCI IV + MTX	0.69(0.17,2.87)	0.77(0.30,2.15)	-0.07(-0.36,0.20)
SD ADA SC + DMARD		0.40(0.09,1.87)	0.51(0.15,1.58)	-0.16(-0.42,0.12)

(Continued)

SD ETN SC + DMARD	1.72(0.44,6.77)	1.38(0.61,3.23)	0.12(-0.19,0.42)
SD TOCI SC + DMARD	0.65(0.15,2.82)	0.74(0.25,2.02)	-0.08(-0.36,0.22)
LD ADA SC	0.45(0.13,1.65)	0.56(0.24,1.49)	-0.14(-0.41,0.08)
LD ETN SC	0.46(0.16,1.50)	0.57(0.27,1.37)	-0.14(-0.38,0.07)
LD GOLIV	0.51(0.13,2.07)	0.62(0.21,1.70)	-0.12(-0.39,0.14)
LD TOCI IV	0.09(0.01,0.40)	0.13(0.02,0.46)	-0.28(-0.51,-0.10)
LD ADA SC + MTX	2.17(0.70,7.11)	1.55(0.83,3.37)	0.18(-0.08,0.43)
LD RITUX IV + MTX	1.06(0.37,3.23)	1.04(0.53,2.28)	0.01(-0.22,0.24)
LD ADA IV + MTX	1.98(0.23,13.19)	1.46(0.34,3.71)	0.16(-0.26,0.54)
LD ABA IV + MTX	1.03(0.33,3.27)	1.02(0.48,2.30)	0.01(-0.25,0.25)
LD ANA SC + MTX	0.95(0.19,5.03)	0.97(0.29,2.74)	-0.01(-0.31,0.36)
LD CERTO SC + MTX	1.96(0.52,7.60)	1.47(0.68,3.41)	0.15(-0.15,0.45)
LD ETN SC + MTX	1.74(0.48,6.39)	1.39(0.65,3.29)	0.13(-0.17,0.40)
LD GOLIV + MTX	1.02(0.25,3.92)	1.01(0.39,2.49)	0.00(-0.29,0.29)
LD TOCI IV + MTX	0.81(0.26,2.44)	0.86(0.39,1.85)	-0.04(-0.28,0.18)
LD TOFA PO + MTX	1.69(0.34,7.74)	1.36(0.50,3.23)	0.12(-0.23,0.45)
HD TOCI IV	1.29(0.51,3.31)	1.17(0.69,2.40)	0.06(-0.16,0.24)
HD TOFA PO	1.38(0.37,4.61)	1.22(0.56,2.95)	0.07(-0.23,0.32)
HD ADA SC	0.64(0.18,2.34)	0.73(0.33,1.88)	-0.09(-0.36,0.15)
HD ETN SC	0.94(0.29,3.21)	0.96(0.46,2.27)	-0.01(-0.27,0.24)
HD GOLIV SC	1.26(0.39,4.32)	1.16(0.57,2.76)	0.05(-0.22,0.31)
HD ABA SC	1.90(0.35,11.83)	1.45(0.51,4.05)	0.14(-0.23,0.54)
HD INF IV + MTX	2.42(0.81,7.42)	1.63(0.90,3.53)	0.21(-0.05,0.44)
HD TOCI IV + MTX	2.33(0.88,6.34)	1.61(0.94,3.39)	0.20(-0.03,0.40)
HD TOFA PO + MTX	2.51(0.77,8.00)	1.65(0.88,3.62)	0.21(-0.06,0.45)
HD GOLIV SC + MTX	2.34(0.71,8.13)	1.60(0.83,3.76)	0.20(-0.08,0.46)
HD CERTO SC + MTX	3.34(1.08,10.66)	1.87(1.03,4.06)	0.28(0.02,0.51)
HD ADA SC + MTX	2.76(0.73,10.83)	1.71(0.84,3.87)	0.24(-0.07,0.52)

(Continued)

HD TOCI IV + DMARD		0.48(0.13,1.88)	0.58(0.22,1.57)	-0.13(-0.39,0.12)
SD ANA SC + SD ETN SC + MTX		1.27(0.32,5.18)	1.16(0.47,2.80)	0.05(-0.25,0.36)
SD ANA SC + LD ETN SC + MTX		1.89(0.47,7.69)	1.44(0.63,3.35)	0.14(-0.17,0.45)
SD ADA SC + DMARD	SD CER- TO SC + DMARD	0.60(0.16,2.21)	0.67(0.22,1.78)	-0.08(-0.30,0.15)
SD ETN SC + DMARD		2.43(0.66,9.99)	1.75(0.76,4.25)	0.19(-0.09,0.50)
SD TOCI SC + DMARD		0.96(0.24,3.63)	0.97(0.33,2.46)	-0.01(-0.25,0.27)
LD ADA SC		0.65(0.18,2.32)	0.72(0.28,1.93)	-0.07(-0.32,0.13)
LD ETN SC		0.68(0.21,2.24)	0.74(0.32,1.86)	-0.06(-0.30,0.13)
LD GOLI IV		0.75(0.16,3.15)	0.80(0.24,2.39)	-0.05(-0.32,0.22)
LD TOCI IV		0.12(0.02,0.64)	0.16(0.03,0.68)	-0.20(-0.43,-0.05)
LD ADA SC + MTX		3.14(0.82,12.22)	2.02(0.89,4.88)	0.25(-0.05,0.52)
LD RITUX IV + MTX		1.52(0.46,5.28)	1.34(0.59,3.28)	0.08(-0.17,0.33)
LD ADA IV + MTX		2.77(0.33,19.55)	1.85(0.43,5.19)	0.22(-0.17,0.62)
LD ABA IV + MTX		1.50(0.41,5.47)	1.32(0.54,3.32)	0.08(-0.18,0.35)
LD ANA SC + MTX		1.39(0.25,7.96)	1.26(0.35,3.73)	0.06(-0.24,0.44)
LD CERTO SC + MTX		2.84(0.67,12.21)	1.90(0.77,4.65)	0.23(-0.08,0.54)
LD ETN SC + MTX		2.54(0.64,9.87)	1.80(0.76,4.44)	0.20(-0.09,0.49)
LD GOLI IV + MTX		1.50(0.35,6.23)	1.32(0.46,3.53)	0.08(-0.21,0.38)
LD TOCI IV + MTX		1.15(0.30,4.82)	1.10(0.41,3.01)	0.03(-0.23,0.31)
LD TOFA PO + MTX		2.41(0.44,12.35)	1.76(0.56,4.60)	0.19(-0.16,0.53)
HD TOCI IV		1.87(0.64,5.60)	1.53(0.75,3.52)	0.13(-0.10,0.33)
HD TOFA PO		1.98(0.59,6.42)	1.58(0.72,3.76)	0.15(-0.12,0.37)
HD ADA SC		0.92(0.26,3.13)	0.94(0.38,2.46)	-0.01(-0.26,0.20)
HD ETN SC		1.36(0.40,4.99)	1.25(0.53,3.13)	0.06(-0.19,0.32)
HD GOLI SC		1.83(0.50,6.69)	1.51(0.65,3.81)	0.13(-0.15,0.38)
HD ABA SC		2.77(0.51,16.05)	1.90(0.64,5.14)	0.22(-0.14,0.58)
HD INF IV + MTX		3.49(1.03,12.10)	2.11(1.02,4.80)	0.28(0.01,0.53)

(Continued)

HD TOCI IV + MTX		3.33(1.03,11.15)	2.08(1.02,4.74)	0.27(0.01,0.50)
HD TOFA PO + MTX		3.59(1.01,12.56)	2.14(1.01,4.94)	0.29(0.00,0.54)
HD GOLI SC + MTX		3.41(1.00,13.70)	2.08(1.00,5.04)	0.27(0.00,0.55)
HD CERTO SC + MTX		4.76(1.39,17.80)	2.42(1.20,5.58)	0.35(0.08,0.60)
HD ADA SC + MTX		3.98(0.87,18.35)	2.22(0.92,5.31)	0.31(-0.03,0.61)
HD TOCI IV + DMARD		0.69(0.22,2.34)	0.75(0.30,1.91)	-0.06(-0.27,0.16)
SD ANA SC + SD ETN SC + MTX		1.83(0.40,8.62)	1.50(0.52,4.00)	0.13(-0.19,0.45)
SD ANA SC + LD ETN SC + MTX		2.73(0.58,12.40)	1.86(0.70,4.57)	0.22(-0.11,0.54)
SD ETN SC + DMARD	SD ADA SC + DMARD	4.19(1.03,16.78)	2.67(1.02,7.96)	0.27(0.01,0.53)
SD TOCI SC + DMARD		1.61(0.45,5.68)	1.44(0.53,3.88)	0.07(-0.13,0.31)
LD ADA SC		1.10(0.25,5.16)	1.08(0.34,4.15)	0.01(-0.25,0.19)
LD ETN SC		1.12(0.30,4.34)	1.10(0.40,3.61)	0.02(-0.22,0.19)
LD GOLI IV		1.26(0.25,6.03)	1.21(0.34,4.43)	0.03(-0.23,0.28)
LD TOCI IV		0.21(0.03,1.31)	0.25(0.04,1.28)	-0.12(-0.36,0.02)
LD ADA SC + MTX		5.32(1.22,21.84)	3.02(1.15,9.46)	0.34(0.04,0.57)
LD RITUX IV + MTX		2.61(0.71,9.79)	2.03(0.79,6.26)	0.17(-0.07,0.37)
LD ADA IV + MTX		4.64(0.55,36.88)	2.76(0.64,9.90)	0.30(-0.09,0.69)
LD ABA IV + MTX		2.57(0.61,9.99)	2.01(0.71,6.28)	0.16(-0.10,0.39)
LD ANA SC + MTX		2.33(0.39,15.09)	1.86(0.49,6.95)	0.15(-0.15,0.52)
LD CERTO SC + MTX		4.80(1.03,20.93)	2.84(1.02,8.79)	0.31(0.00,0.58)
LD ETN SC + MTX		4.24(0.92,18.33)	2.70(0.95,8.61)	0.28(-0.02,0.54)
LD GOLI IV + MTX		2.50(0.53,11.38)	1.98(0.63,6.55)	0.15(-0.11,0.44)
LD TOCI IV + MTX		1.96(0.44,8.68)	1.69(0.55,5.53)	0.11(-0.15,0.37)
LD TOFA PO + MTX		4.02(0.75,22.03)	2.58(0.82,8.69)	0.27(-0.05,0.59)
HD TOCI IV		3.12(0.93,10.30)	2.29(0.95,6.72)	0.21(-0.02,0.37)
HD TOFA PO		3.34(0.77,14.33)	2.38(0.84,8.27)	0.23(-0.06,0.44)
HD ADA SC		1.53(0.37,7.20)	1.41(0.48,5.23)	0.07(-0.20,0.27)
HD ETN SC		2.29(0.55,9.79)	1.86(0.67,5.97)	0.14(-0.12,0.38)

(Continued)

HD GOLI SC		3.15(0.75,12.83)	2.30(0.82,7.36)	0.21(-0.06,0.44)
HD ABA SC		4.68(0.73,35.39)	2.80(0.79,11.14)	0.30(-0.07,0.66)
HD INF IV + MTX		5.90(1.53,22.18)	3.21(1.28,9.75)	0.36(0.10,0.58)
HD TOCI IV + MTX		5.62(1.49,20.38)	3.15(1.26,9.32)	0.35(0.09,0.55)
HD TOFA PO + MTX		6.10(1.44,22.51)	3.25(1.25,9.98)	0.37(0.09,0.59)
HD GOLI SC + MTX		5.85(1.36,23.34)	3.15(1.20,10.00)	0.36(0.07,0.59)
HD CERTO SC + MTX		8.25(2.16,30.92)	3.66(1.48,11.08)	0.44(0.17,0.65)
HD ADA SC + MTX		6.84(1.41,32.79)	3.36(1.23,10.84)	0.39(0.07,0.67)
HD TOCI IV + DMARD		1.17(0.38,3.50)	1.14(0.47,2.90)	0.02(-0.16,0.19)
SD ANA SC + SD ETN SC + MTX		3.13(0.63,15.56)	2.26(0.72,7.46)	0.20(-0.09,0.50)
SD ANA SC + LD ETN SC + MTX		4.64(0.94,21.72)	2.83(0.96,8.93)	0.30(-0.01,0.59)
SD TOCI SC + DMARD	SD ETN SC + DMARD	0.39(0.09,1.50)	0.55(0.19,1.27)	-0.20(-0.48,0.09)
LD ADA SC		0.26(0.07,1.01)	0.40(0.18,1.01)	-0.27(-0.54,0.00)
LD ETN SC		0.27(0.09,0.82)	0.42(0.21,0.87)	-0.26(-0.51,-0.04)
LD GOLI IV		0.30(0.07,1.17)	0.45(0.16,1.11)	-0.24(-0.51,0.04)
LD TOCI IV		0.05(0.01,0.26)	0.09(0.02,0.36)	-0.40(-0.66,-0.17)
LD ADA SC + MTX		1.29(0.41,4.09)	1.13(0.64,2.23)	0.06(-0.21,0.33)
LD RITUX IV + MTX		0.62(0.21,1.88)	0.76(0.40,1.50)	-0.11(-0.37,0.14)
LD ADA IV + MTX		1.16(0.15,7.23)	1.08(0.28,2.45)	0.03(-0.38,0.44)
LD ABA IV + MTX		0.61(0.18,1.97)	0.75(0.36,1.54)	-0.11(-0.39,0.16)
LD ANA SC + MTX		0.56(0.10,3.09)	0.71(0.21,1.89)	-0.13(-0.45,0.27)
LD CERTO SC + MTX		1.17(0.29,4.63)	1.08(0.51,2.27)	0.04(-0.29,0.35)
LD ETN SC + MTX		1.03(0.29,3.59)	1.02(0.51,2.04)	0.01(-0.29,0.30)
LD GOLI IV + MTX		0.61(0.16,2.30)	0.74(0.31,1.61)	-0.11(-0.41,0.18)
LD TOCI IV + MTX		0.48(0.12,1.70)	0.64(0.25,1.41)	-0.16(-0.45,0.12)
LD TOFA PO + MTX		1.00(0.19,4.51)	1.00(0.37,2.17)	0.00(-0.36,0.35)
HD TOCI IV		0.77(0.27,2.14)	0.86(0.51,1.63)	-0.06(-0.31,0.17)
HD TOFA PO		0.82(0.22,2.74)	0.89(0.46,1.91)	-0.05(-0.35,0.23)

(Continued)

HD ADA SC		0.37(0.10,1.42)	0.52(0.25,1.27)	-0.21(-0.49,0.07)
HD ETN SC		0.56(0.18,1.70)	0.71(0.36,1.41)	-0.13(-0.39,0.11)
HD GOL I SC		0.75(0.23,2.38)	0.85(0.45,1.72)	-0.07(-0.34,0.19)
HD ABA SC		1.14(0.20,7.19)	1.07(0.40,2.73)	0.03(-0.37,0.44)
HD INF IV + MTX		1.43(0.45,4.68)	1.19(0.70,2.32)	0.09(-0.19,0.36)
HD TOCI IV + MTX		1.35(0.48,4.16)	1.16(0.71,2.26)	0.07(-0.17,0.33)
HD TOFA PO + MTX		1.46(0.46,4.62)	1.21(0.70,2.29)	0.09(-0.19,0.35)
HD GOL I SC + MTX		1.38(0.43,4.58)	1.17(0.67,2.32)	0.08(-0.20,0.36)
HD CERTO SC + MTX		1.98(0.65,5.90)	1.36(0.84,2.66)	0.16(-0.10,0.41)
HD ADA SC + MTX		1.63(0.45,6.67)	1.25(0.65,2.55)	0.12(-0.19,0.43)
HD TOCI IV + DMARD		0.28(0.08,1.02)	0.43(0.17,1.02)	-0.25(-0.51,0.01)
SD ANA SC + SD ETN SC + MTX		0.73(0.18,3.07)	0.84(0.35,1.87)	-0.07(-0.38,0.26)
SD ANA SC + LD ETN SC + MTX		1.10(0.27,4.41)	1.05(0.47,2.23)	0.02(-0.30,0.34)
LD ADA SC	SD TOCI SC + DMARD	0.69(0.15,2.89)	0.75(0.26,2.49)	-0.06(-0.37,0.15)
LD ETN SC		0.72(0.18,2.77)	0.77(0.30,2.35)	-0.05(-0.34,0.14)
LD GOL I IV		0.77(0.15,3.70)	0.82(0.24,2.77)	-0.04(-0.35,0.22)
LD TOCI IV		0.13(0.02,0.74)	0.17(0.03,0.76)	-0.19(-0.49,-0.03)
LD ADA SC + MTX		3.34(0.82,13.39)	2.09(0.89,6.26)	0.26(-0.05,0.52)
LD RITUX IV + MTX		1.60(0.43,6.16)	1.39(0.59,4.04)	0.09(-0.19,0.32)
LD ADA IV + MTX		2.88(0.34,24.83)	1.91(0.45,6.86)	0.23(-0.19,0.65)
LD ABA IV + MTX		1.59(0.38,6.12)	1.39(0.54,3.95)	0.09(-0.22,0.34)
LD ANA SC + MTX		1.47(0.28,8.57)	1.30(0.38,4.59)	0.07(-0.25,0.44)
LD CERTO SC + MTX		3.02(0.67,13.54)	1.98(0.78,5.72)	0.23(-0.09,0.53)
LD ETN SC + MTX		2.65(0.56,11.24)	1.85(0.71,5.70)	0.21(-0.13,0.48)
LD GOL I IV + MTX		1.53(0.32,7.64)	1.35(0.46,4.40)	0.08(-0.24,0.40)
LD TOCI IV + MTX		1.23(0.28,5.39)	1.16(0.42,3.63)	0.04(-0.25,0.31)
LD TOFA PO + MTX		2.59(0.47,14.40)	1.82(0.61,5.73)	0.20(-0.16,0.54)

(Continued)

HD TOCI IV		1.97(0.59,6.57)	1.59(0.73,4.24)	0.14(-0.13,0.33)
HD TOFA PO		2.09(0.50,8.90)	1.64(0.67,5.08)	0.16(-0.16,0.39)
HD ADA SC		0.98(0.22,4.20)	0.98(0.36,3.28)	0.00(-0.32,0.22)
HD ETN SC		1.47(0.36,6.01)	1.31(0.52,3.96)	0.07(-0.22,0.32)
HD GOLI SC		1.94(0.48,7.88)	1.57(0.64,4.74)	0.13(-0.17,0.38)
HD ABA SC		2.90(0.46,23.04)	1.94(0.61,7.28)	0.23(-0.17,0.62)
HD INF IV + MTX		3.70(0.92,14.22)	2.19(0.95,6.30)	0.29(-0.02,0.52)
HD TOCI IV + MTX		3.55(0.95,12.45)	2.18(0.97,6.02)	0.28(-0.01,0.50)
HD TOFA PO + MTX		3.81(0.95,14.85)	2.24(0.97,6.42)	0.29(-0.01,0.54)
HD GOLI SC + MTX		3.63(0.90,14.77)	2.18(0.94,6.34)	0.28(-0.03,0.54)
HD CERTO SC + MTX		5.07(1.33,19.89)	2.51(1.15,7.28)	0.36(0.07,0.60)
HD ADA SC + MTX		4.25(0.84,20.80)	2.32(0.91,6.75)	0.31(-0.04,0.62)
HD TOCI IV + DMARD		0.72(0.24,2.22)	0.78(0.35,1.87)	-0.05(-0.26,0.13)
SD ANA SC + SD ETN SC + MTX		1.97(0.38,9.73)	1.57(0.52,4.79)	0.13(-0.20,0.45)
SD ANA SC + LD ETN SC + MTX		3.01(0.56,12.97)	1.96(0.69,5.90)	0.23(-0.13,0.52)
LD ETN SC	LD ADA SC	1.04(0.35,2.94)	1.03(0.42,2.40)	0.01(-0.16,0.16)
LD GOLI IV		1.15(0.29,4.45)	1.12(0.34,3.09)	0.02(-0.18,0.27)
LD TOCI IV		0.19(0.03,0.90)	0.23(0.04,0.91)	-0.13(-0.28,-0.01)
LD ADA SC + MTX		4.87(1.49,15.92)	2.83(1.31,5.92)	0.33(0.08,0.56)
LD RITUX IV + MTX		2.36(0.80,6.85)	1.89(0.85,4.11)	0.16(-0.04,0.37)
LD ADA IV + MTX		4.39(0.62,26.94)	2.69(0.67,6.30)	0.30(-0.07,0.66)
LD ABA IV + MTX		2.31(0.66,7.47)	1.86(0.74,4.26)	0.15(-0.07,0.39)
LD ANA SC + MTX		2.16(0.39,11.29)	1.77(0.46,4.90)	0.14(-0.13,0.51)
LD CERTO SC + MTX		4.38(1.11,17.68)	2.71(1.08,5.91)	0.30(0.02,0.59)
LD ETN SC + MTX		3.89(1.08,13.39)	2.52(1.06,5.44)	0.27(0.02,0.54)
LD GOLI IV + MTX		2.28(0.59,8.60)	1.83(0.66,4.47)	0.15(-0.09,0.44)
LD TOCI IV + MTX		1.81(0.49,5.91)	1.57(0.57,3.64)	0.10(-0.11,0.35)
LD TOFA PO + MTX		3.79(0.74,15.77)	2.50(0.79,5.64)	0.27(-0.05,0.57)

(Continued)

HD TOCI IV		2.90(1.06,7.27)	2.15(1.05,4.29)	0.21(0.01,0.38)
HD TOFA PO		3.08(1.11,8.05)	2.22(1.08,4.53)	0.22(0.02,0.40)
HD ADA SC		1.41(0.67,2.96)	1.31(0.73,2.36)	0.05(-0.07,0.19)
HD ETN SC		2.12(0.63,6.81)	1.76(0.69,4.07)	0.13(-0.08,0.37)
HD GOLI SC		2.88(0.90,8.57)	2.12(0.92,4.70)	0.20(-0.02,0.42)
HD ABA SC		4.27(0.90,22.60)	2.65(0.93,6.40)	0.30(-0.02,0.63)
HD INF IV + MTX		5.40(1.69,16.10)	2.99(1.40,6.04)	0.36(0.11,0.57)
HD TOCI IV + MTX		5.22(1.74,14.19)	2.94(1.43,5.80)	0.35(0.12,0.54)
HD TOFA PO + MTX		5.51(1.82,16.31)	2.99(1.48,6.04)	0.36(0.13,0.57)
HD GOLI SC + MTX		5.32(1.53,16.94)	2.96(1.34,6.13)	0.35(0.09,0.58)
HD CERTO SC + MTX		7.41(2.25,23.01)	3.40(1.66,6.78)	0.44(0.18,0.64)
HD ADA SC + MTX		6.10(1.57,24.34)	3.11(1.37,6.65)	0.39(0.09,0.65)
HD TOCI IV + DMARD		1.07(0.28,3.93)	1.05(0.34,2.76)	0.01(-0.16,0.24)
SD ANA SC + SD ETN SC + MTX		2.81(0.67,11.10)	2.09(0.73,4.98)	0.20(-0.07,0.50)
SD ANA SC + LD ETN SC + MTX		4.24(0.97,16.58)	2.64(0.98,5.85)	0.30(-0.01,0.58)
LD GOLI IV	LD ETN SC	1.11(0.33,3.54)	1.09(0.39,2.59)	0.02(-0.15,0.24)
LD TOCI IV		0.18(0.03,0.79)	0.22(0.04,0.81)	-0.14(-0.28,-0.02)
LD ADA SC + MTX		4.67(1.86,12.20)	2.73(1.50,5.07)	0.32(0.13,0.54)
LD RITUX IV + MTX		2.26(0.97,5.21)	1.82(0.98,3.37)	0.15(0.00,0.34)
LD ADA IV + MTX		4.10(0.66,25.89)	2.54(0.71,5.84)	0.30(-0.06,0.66)
LD ABA IV + MTX		2.21(0.89,5.52)	1.80(0.92,3.38)	0.14(-0.02,0.35)
LD ANA SC + MTX		2.08(0.48,9.29)	1.72(0.54,4.08)	0.13(-0.10,0.47)
LD CERTO SC + MTX		4.18(1.39,13.73)	2.59(1.27,5.14)	0.30(0.06,0.55)
LD ETN SC + MTX		3.74(1.36,10.23)	2.44(1.24,4.59)	0.27(0.06,0.49)
LD GOLI IV + MTX		2.14(0.71,6.86)	1.76(0.76,3.82)	0.14(-0.06,0.40)
LD TOCI IV + MTX		1.75(0.54,5.07)	1.53(0.61,3.27)	0.10(-0.10,0.33)
LD TOFA PO + MTX		3.63(0.92,13.79)	2.37(0.93,5.09)	0.26(-0.01,0.55)
HD TOCI IV		2.75(1.33,5.89)	2.06(1.22,3.69)	0.20(0.06,0.35)

(Continued)

HD TOFA PO		2.95(1.04,7.65)	2.15(1.03,4.40)	0.21(0.01,0.40)
HD ADA SC		1.35(0.49,4.07)	1.27(0.57,3.00)	0.05(-0.12,0.24)
HD ETN SC		2.03(0.82,4.99)	1.69(0.85,3.23)	0.13(-0.03,0.32)
HD GOLI SC		2.72(1.08,7.03)	2.06(1.06,3.99)	0.19(0.01,0.39)
HD ABA SC		4.14(0.85,22.78)	2.53(0.88,6.31)	0.30(-0.03,0.63)
HD INF IV + MTX		5.17(2.25,12.14)	2.87(1.68,5.13)	0.35(0.17,0.53)
HD TOCI IV + MTX		4.98(2.21,11.49)	2.83(1.64,5.15)	0.34(0.17,0.51)
HD TOFA PO + MTX		5.30(2.31,12.72)	2.91(1.67,5.28)	0.35(0.17,0.54)
HD GOLI SC + MTX		5.08(2.05,12.85)	2.85(1.59,5.23)	0.34(0.15,0.54)
HD CERTO SC + MTX		7.09(3.03,16.65)	3.29(1.95,5.89)	0.43(0.23,0.59)
HD ADA SC + MTX		5.98(1.81,19.47)	3.02(1.51,5.84)	0.38(0.11,0.62)
HD TOCI IV + DMARD		1.02(0.32,3.40)	1.02(0.39,2.53)	0.00(-0.16,0.23)
SD ANA SC + SD ETN SC + MTX		2.69(0.82,9.62)	2.02(0.86,4.34)	0.19(-0.03,0.48)
SD ANA SC + LD ETN SC + MTX		4.01(1.27,13.05)	2.54(1.19,5.03)	0.29(0.04,0.55)
LD TOCI IV	LD GOLI IV	0.17(0.03,0.91)	0.20(0.04,0.92)	-0.15(-0.39,-0.01)
LD ADA SC + MTX		4.25(1.31,14.65)	2.52(1.19,6.45)	0.30(0.06,0.53)
LD RITUX IV + MTX		2.07(0.67,6.74)	1.70(0.77,4.45)	0.13(-0.09,0.34)
LD ADA IV + MTX		3.84(0.48,26.26)	2.35(0.55,7.55)	0.27(-0.12,0.66)
LD ABA IV + MTX		2.02(0.62,7.01)	1.67(0.72,4.41)	0.13(-0.10,0.35)
LD ANA SC + MTX		1.89(0.36,10.40)	1.59(0.45,5.05)	0.11(-0.17,0.48)
LD CERTO SC + MTX		3.84(1.04,16.07)	2.38(1.03,6.81)	0.28(0.01,0.56)
LD ETN SC + MTX		3.42(0.94,12.61)	2.26(0.96,6.13)	0.25(-0.01,0.50)
LD GOLI IV + MTX		1.99(0.74,5.68)	1.63(0.81,3.78)	0.12(-0.06,0.35)
LD TOCI IV + MTX		1.61(0.39,6.55)	1.42(0.50,4.14)	0.08(-0.18,0.33)
LD TOFA PO + MTX		3.29(0.72,15.29)	2.19(0.80,6.39)	0.24(-0.06,0.55)
HD TOCI IV		2.51(0.84,7.85)	1.93(0.91,5.00)	0.18(-0.04,0.36)
HD TOFA PO		2.67(0.72,9.88)	1.99(0.81,5.75)	0.20(-0.08,0.41)
HD ADA SC		1.24(0.32,5.01)	1.17(0.44,3.65)	0.03(-0.22,0.25)

(Continued)

HD ETN SC		1.83(0.54,6.74)	1.57(0.65,4.33)	0.11(-0.13,0.34)
HD GOLI SC		2.47(0.75,8.14)	1.90(0.83,5.01)	0.17(-0.06,0.39)
HD ABA SC		3.74(0.60,27.98)	2.34(0.71,8.23)	0.27(-0.10,0.65)
HD INF IV + MTX		4.69(1.60,15.36)	2.65(1.30,6.97)	0.33(0.11,0.53)
HD TOCI IV + MTX		4.56(1.52,13.83)	2.62(1.27,6.60)	0.32(0.09,0.51)
HD TOFA PO + MTX		4.81(1.46,16.33)	2.67(1.23,7.00)	0.33(0.09,0.56)
HD GOLI SC + MTX		4.62(1.46,15.62)	2.64(1.23,6.90)	0.32(0.08,0.55)
HD CERTO SC + MTX		6.52(2.12,21.71)	3.02(1.47,8.12)	0.41(0.18,0.60)
HD ADA SC + MTX		5.35(1.40,22.28)	2.80(1.21,7.36)	0.36(0.07,0.62)
HD TOCI IV + DMARD		0.93(0.23,3.99)	0.94(0.32,3.16)	-0.01(-0.26,0.22)
SD ANA SC + SD ETN SC + MTX		2.41(0.61,11.84)	1.87(0.69,5.82)	0.17(-0.10,0.48)
SD ANA SC + LD ETN SC + MTX		3.65(0.85,16.59)	2.31(0.90,6.80)	0.26(-0.03,0.55)
LD ADA SC + MTX	LD TOCI IV	25.53(5.70,150.60)	12.46(3.50,66.43)	0.46(0.25,0.68)
LD RITUX IV + MTX		12.12(3.02,67.88)	8.24(2.38,43.65)	0.29(0.14,0.48)
LD ADA IV + MTX		23.04(2.12,238.20)	11.12(1.92,70.61)	0.44(0.07,0.80)
LD ABA IV + MTX		11.85(2.79,70.60)	8.06(2.28,45.31)	0.29(0.12,0.50)
LD ANA SC + MTX		11.47(1.62,90.12)	7.71(1.51,42.95)	0.27(0.04,0.62)
LD CERTO SC + MTX		22.25(4.67,152.50)	11.39(3.16,62.75)	0.44(0.19,0.70)
LD ETN SC + MTX		20.54(4.45,112.80)	10.99(3.07,57.41)	0.41(0.19,0.64)
LD GOLI IV + MTX		11.71(2.39,76.13)	8.05(2.04,42.32)	0.28(0.09,0.55)
LD TOCI IV + MTX		9.40(2.06,49.65)	6.78(1.84,32.50)	0.23(0.07,0.47)
LD TOFA PO + MTX		19.86(3.10,146.10)	10.62(2.49,64.70)	0.40(0.12,0.70)
HD TOCI IV		14.93(3.90,75.23)	9.42(2.87,47.66)	0.34(0.20,0.48)
HD TOFA PO		15.66(3.47,102.30)	9.71(2.62,55.93)	0.35(0.18,0.53)
HD ADA SC		7.35(1.51,48.47)	5.80(1.44,33.74)	0.19(0.05,0.36)
HD ETN SC		11.19(2.44,60.78)	7.80(2.04,39.32)	0.27(0.10,0.49)
HD GOLI SC		14.83(3.29,82.73)	9.44(2.55,47.97)	0.33(0.15,0.53)
HD ABA SC		22.78(3.05,200.40)	11.47(2.48,66.75)	0.43(0.14,0.75)

(Continued)

HD INF IV + MTX		28.18(6.73,162.10)	13.13(3.77,69.26)	0.49(0.30,0.68)
HD TOCI IV + MTX		26.62(6.91,137.90)	12.86(3.88,65.61)	0.48(0.30,0.65)
HD TOFA PO + MTX		28.74(6.44,171.10)	13.26(3.78,73.25)	0.50(0.29,0.69)
HD GOLI SC + MTX		27.56(5.96,166.40)	12.94(3.59,69.76)	0.49(0.27,0.69)
HD CERTO SC + MTX		38.93(9.22,211.20)	15.06(4.51,77.16)	0.57(0.37,0.74)
HD ADA SC + MTX		32.21(6.08,214.40)	13.87(3.73,74.13)	0.52(0.26,0.76)
HD TOCI IV + DMARD		5.61(1.03,35.62)	4.66(1.03,26.81)	0.14(0.00,0.37)
SD ANA SC + SD ETN SC + MTX		15.09(2.41,97.04)	9.22(2.04,48.43)	0.33(0.10,0.62)
SD ANA SC + LD ETN SC + MTX		22.49(3.81,146.20)	11.54(2.87,63.49)	0.44(0.16,0.70)
LD RITUX IV + MTX	LD ADA SC + MTX	0.49(0.20,1.16)	0.67(0.41,1.09)	-0.17(-0.37,0.04)
LD ADA IV + MTX		0.90(0.15,4.77)	0.95(0.27,1.84)	-0.02(-0.38,0.34)
LD ABA IV + MTX		0.47(0.19,1.20)	0.66(0.37,1.11)	-0.17(-0.37,0.04)
LD ANA SC + MTX		0.44(0.10,2.00)	0.63(0.21,1.39)	-0.18(-0.47,0.16)
LD CERTO SC + MTX		0.90(0.28,3.03)	0.95(0.50,1.70)	-0.02(-0.29,0.25)
LD ETN SC + MTX		0.80(0.26,2.32)	0.90(0.50,1.53)	-0.05(-0.31,0.20)
LD GOLI IV + MTX		0.46(0.15,1.53)	0.64(0.30,1.24)	-0.18(-0.43,0.10)
LD TOCI IV + MTX		0.37(0.11,1.16)	0.56(0.24,1.10)	-0.22(-0.47,0.04)
LD TOFA PO + MTX		0.76(0.19,2.96)	0.88(0.36,1.62)	-0.06(-0.36,0.25)
HD TOCI IV		0.59(0.26,1.36)	0.75(0.50,1.21)	-0.13(-0.32,0.07)
HD TOFA PO		0.64(0.20,1.86)	0.79(0.43,1.44)	-0.11(-0.37,0.15)
HD ADA SC		0.29(0.09,0.98)	0.46(0.23,0.98)	-0.27(-0.52,-0.01)
HD ETN SC		0.44(0.17,1.15)	0.62(0.34,1.09)	-0.19(-0.41,0.03)
HD GOLI SC		0.58(0.21,1.64)	0.75(0.44,1.31)	-0.13(-0.36,0.12)
HD ABA SC		0.89(0.16,4.91)	0.95(0.36,2.08)	-0.03(-0.41,0.37)
HD INF IV + MTX		1.11(0.47,2.56)	1.05(0.71,1.63)	0.03(-0.18,0.23)
HD TOCI IV + MTX		1.05(0.45,2.46)	1.02(0.70,1.62)	0.01(-0.18,0.22)
HD TOFA PO + MTX		1.15(0.48,2.67)	1.06(0.72,1.65)	0.03(-0.18,0.23)
HD GOLI SC + MTX		1.07(0.45,2.77)	1.03(0.68,1.67)	0.02(-0.19,0.24)

(Continued)

HD CERTO SC + MTX		1.55(0.62,3.71)	1.20(0.83,1.87)	0.10(-0.11,0.30)
HD ADA SC + MTX		1.26(0.50,3.32)	1.10(0.70,1.67)	0.05(-0.16,0.27)
HD TOCI IV + DMARD		0.22(0.06,0.79)	0.37(0.15,0.87)	-0.32(-0.55,-0.05)
SD ANA SC + SD ETN SC + MTX		0.57(0.17,2.15)	0.74(0.34,1.46)	-0.13(-0.40,0.18)
SD ANA SC + LD ETN SC + MTX		0.86(0.25,2.99)	0.93(0.46,1.64)	-0.04(-0.32,0.26)
LD ADA IV + MTX	LD RITUX IV + MTX	1.85(0.28,10.98)	1.41(0.40,3.03)	0.14(-0.22,0.52)
LD ABA IV + MTX		0.98(0.43,2.26)	0.99(0.56,1.67)	0.00(-0.18,0.18)
LD ANA SC + MTX		0.91(0.22,4.20)	0.94(0.30,2.19)	-0.02(-0.27,0.33)
LD CERTO SC + MTX		1.86(0.65,5.46)	1.42(0.75,2.53)	0.15(-0.10,0.39)
LD ETN SC + MTX		1.62(0.65,4.27)	1.33(0.76,2.35)	0.11(-0.10,0.33)
LD GOLI IV + MTX		0.96(0.32,2.91)	0.97(0.44,1.87)	-0.01(-0.23,0.25)
LD TOCI IV + MTX		0.77(0.26,2.21)	0.84(0.37,1.70)	-0.05(-0.27,0.17)
LD TOFA PO + MTX		1.58(0.46,5.37)	1.31(0.59,2.45)	0.11(-0.16,0.39)
HD TOCI IV		1.21(0.60,2.57)	1.12(0.74,1.88)	0.04(-0.12,0.21)
HD TOFA PO		1.30(0.45,3.67)	1.17(0.62,2.39)	0.06(-0.19,0.28)
HD ADA SC		0.60(0.21,1.86)	0.70(0.33,1.58)	-0.10(-0.32,0.12)
HD ETN SC		0.91(0.36,2.17)	0.94(0.51,1.66)	-0.02(-0.22,0.17)
HD GOLI SC		1.19(0.47,3.01)	1.12(0.63,2.04)	0.04(-0.17,0.25)
HD ABA SC		1.83(0.37,10.53)	1.41(0.52,3.31)	0.14(-0.21,0.52)
HD INF IV + MTX		2.29(1.04,5.06)	1.57(1.02,2.56)	0.19(0.01,0.37)
HD TOCI IV + MTX		2.19(1.06,4.52)	1.55(1.03,2.50)	0.18(0.01,0.35)
HD TOFA PO + MTX		2.36(1.10,5.07)	1.59(1.05,2.61)	0.20(0.02,0.37)
HD GOLI SC + MTX		2.24(0.93,5.53)	1.56(0.96,2.66)	0.19(-0.02,0.39)
HD CERTO SC + MTX		3.14(1.49,6.76)	1.77(1.23,2.94)	0.27(0.10,0.44)
HD ADA SC + MTX		2.59(0.92,8.01)	1.65(0.95,2.92)	0.22(-0.02,0.47)
HD TOCI IV + DMARD		0.45(0.15,1.41)	0.56(0.22,1.26)	-0.14(-0.34,0.07)
SD ANA SC + SD ETN SC + MTX		1.19(0.38,4.01)	1.11(0.50,2.21)	0.04(-0.20,0.33)
SD ANA SC + LD ETN SC + MTX		1.78(0.54,5.67)	1.40(0.66,2.56)	0.13(-0.13,0.40)

(Continued)

LD ABA IV + MTX	LD ADA IV + MTX	0.53(0.09,3.69)	0.70(0.32,2.65)	-0.15(-0.52,0.24)
LD ANA SC + MTX		0.50(0.06,4.61)	0.68(0.19,2.88)	-0.15(-0.59,0.29)
LD CERTO SC + MTX		1.01(0.15,7.25)	1.00(0.43,3.59)	0.00(-0.42,0.41)
LD ETN SC + MTX		0.91(0.13,6.17)	0.95(0.41,3.56)	-0.02(-0.43,0.37)
LD GOLI IV + MTX		0.53(0.08,4.13)	0.69(0.26,2.63)	-0.14(-0.55,0.27)
LD TOCI IV + MTX		0.42(0.07,3.01)	0.60(0.23,2.37)	-0.19(-0.57,0.20)
LD TOFA PO + MTX		0.86(0.12,7.05)	0.93(0.32,3.49)	-0.04(-0.46,0.40)
HD TOCI IV		0.67(0.12,4.36)	0.80(0.42,2.94)	-0.10(-0.46,0.26)
HD TOFA PO		0.70(0.11,5.26)	0.83(0.39,3.27)	-0.09(-0.47,0.32)
HD ADA SC		0.32(0.05,2.46)	0.49(0.22,2.01)	-0.25(-0.61,0.15)
HD ETN SC		0.50(0.08,3.29)	0.67(0.29,2.46)	-0.16(-0.53,0.21)
HD GOLI SC		0.66(0.11,4.61)	0.80(0.37,2.91)	-0.10(-0.48,0.28)
HD ABA SC		0.97(0.11,12.73)	0.98(0.34,4.67)	-0.01(-0.49,0.52)
HD INF IV + MTX		1.25(0.21,8.23)	1.11(0.59,4.10)	0.05(-0.33,0.42)
HD TOCI IV + MTX		1.18(0.22,7.94)	1.08(0.59,4.02)	0.04(-0.32,0.42)
HD TOFA PO + MTX		1.29(0.24,7.85)	1.12(0.61,3.92)	0.06(-0.30,0.42)
HD GOLI SC + MTX		1.21(0.22,8.24)	1.09(0.58,4.04)	0.05(-0.32,0.42)
HD CERTO SC + MTX		1.73(0.31,10.93)	1.27(0.68,4.58)	0.13(-0.24,0.49)
HD ADA SC + MTX		1.40(0.23,12.60)	1.16(0.55,4.66)	0.08(-0.33,0.50)
HD TOCI IV + DMARD		0.26(0.03,2.01)	0.41(0.13,1.71)	-0.28(-0.67,0.11)
SD ANA SC + SD ETN SC + MTX		0.67(0.09,5.59)	0.80(0.30,3.00)	-0.09(-0.52,0.34)
SD ANA SC + LD ETN SC + MTX		0.99(0.13,7.58)	1.00(0.39,3.57)	0.00(-0.44,0.42)
LD ANA SC + MTX	LD ABA IV + MTX	0.91(0.20,4.66)	0.94(0.29,2.52)	-0.02(-0.29,0.34)
LD CERTO SC + MTX		1.91(0.63,6.04)	1.45(0.74,2.79)	0.15(-0.10,0.41)
LD ETN SC + MTX		1.70(0.57,4.75)	1.36(0.71,2.52)	0.12(-0.13,0.36)
LD GOLI IV + MTX		0.97(0.32,2.95)	0.98(0.45,1.98)	-0.01(-0.24,0.24)
LD TOCI IV + MTX		0.78(0.24,2.42)	0.84(0.35,1.81)	-0.05(-0.29,0.19)

(Continued)

LD TOFA PO + MTX		1.61(0.43,6.11)	1.32(0.56,2.75)	0.11(-0.17,0.41)
HD TOCI IV		1.23(0.55,2.86)	1.14(0.71,2.11)	0.05(-0.14,0.22)
HD TOFA PO		1.32(0.42,3.99)	1.19(0.60,2.58)	0.06(-0.20,0.30)
HD ADA SC		0.61(0.20,2.00)	0.70(0.33,1.66)	-0.10(-0.34,0.14)
HD ETN SC		0.91(0.35,2.36)	0.94(0.49,1.82)	-0.02(-0.24,0.18)
HD GOLI SC		1.22(0.46,3.29)	1.14(0.62,2.17)	0.04(-0.18,0.26)
HD ABA SC		1.78(0.34,11.27)	1.40(0.49,3.73)	0.13(-0.24,0.53)
HD INF IV + MTX		2.33(0.99,5.52)	1.59(1.00,2.82)	0.20(0.00,0.39)
HD TOCI IV + MTX		2.21(0.98,5.30)	1.56(0.99,2.86)	0.19(0.00,0.37)
HD TOFA PO + MTX		2.39(1.03,5.58)	1.61(1.01,2.78)	0.20(0.01,0.39)
HD GOLI SC + MTX		2.27(0.91,5.99)	1.56(0.95,2.89)	0.19(-0.02,0.40)
HD CERTO SC + MTX		3.21(1.37,7.60)	1.81(1.17,3.32)	0.27(0.08,0.46)
HD ADA SC + MTX		2.67(0.86,8.46)	1.67(0.92,3.16)	0.23(-0.03,0.48)
HD TOCI IV + DMARD		0.45(0.14,1.69)	0.57(0.22,1.43)	-0.14(-0.36,0.11)
SD ANA SC + SD ETN SC + MTX		1.20(0.34,4.46)	1.12(0.47,2.44)	0.04(-0.23,0.34)
SD ANA SC + LD ETN SC + MTX		1.79(0.53,6.53)	1.40(0.67,2.80)	0.13(-0.14,0.42)
LD CERTO SC + MTX	LD ANA SC + MTX	2.06(0.40,9.99)	1.51(0.63,4.88)	0.16(-0.21,0.47)
LD ETN SC + MTX		1.78(0.36,8.78)	1.41(0.60,4.58)	0.13(-0.24,0.43)
LD GOLI IV + MTX		1.04(0.21,5.34)	1.03(0.39,3.31)	0.01(-0.35,0.33)
LD TOCI IV + MTX		0.84(0.16,4.23)	0.89(0.31,2.97)	-0.04(-0.40,0.26)
LD TOFA PO + MTX		1.72(0.27,11.39)	1.37(0.46,5.08)	0.12(-0.28,0.49)
HD TOCI IV		1.33(0.33,5.28)	1.20(0.57,3.73)	0.07(-0.26,0.30)
HD TOFA PO		1.41(0.29,6.98)	1.24(0.52,4.38)	0.08(-0.29,0.36)
HD ADA SC		0.65(0.13,3.66)	0.74(0.28,2.91)	-0.08(-0.45,0.20)
HD ETN SC		0.98(0.21,4.57)	0.99(0.40,3.28)	0.00(-0.35,0.28)
HD GOLI SC		1.30(0.28,6.49)	1.18(0.52,3.96)	0.06(-0.30,0.35)
HD ABA SC		2.01(0.23,17.30)	1.49(0.43,5.94)	0.15(-0.34,0.59)
HD INF IV + MTX		2.52(0.57,10.48)	1.68(0.78,5.22)	0.21(-0.14,0.48)

(Continued)

HD TOCI IV + MTX		2.39(0.53,10.14)	1.64(0.76,5.12)	0.20(-0.15,0.46)
HD TOFA PO + MTX		2.56(0.57,11.78)	1.68(0.78,5.35)	0.22(-0.13,0.50)
HD GOLI SC + MTX		2.46(0.52,11.41)	1.66(0.73,5.36)	0.21(-0.16,0.50)
HD CERTO SC + MTX		3.48(0.80,14.93)	1.93(0.93,5.96)	0.29(-0.05,0.55)
HD ADA SC + MTX		2.87(0.57,14.52)	1.73(0.77,5.56)	0.24(-0.14,0.55)
HD TOCI IV + DMARD		0.50(0.09,2.44)	0.60(0.19,2.03)	-0.12(-0.48,0.14)
SD ANA SC + SD ETN SC + MTX		1.34(0.24,7.63)	1.19(0.43,4.02)	0.06(-0.32,0.40)
SD ANA SC + LD ETN SC + MTX		1.96(0.34,11.07)	1.46(0.55,4.94)	0.15(-0.25,0.49)
LD ETN SC + MTX	LD CERTO SC + MTX	0.87(0.25,2.86)	0.93(0.50,1.83)	-0.03(-0.32,0.24)
LD GOLI IV + MTX		0.52(0.14,1.99)	0.69(0.30,1.49)	-0.15(-0.43,0.16)
LD TOCI IV + MTX		0.41(0.10,1.53)	0.59(0.24,1.31)	-0.20(-0.49,0.09)
LD TOFA PO + MTX		0.86(0.19,3.62)	0.92(0.37,1.95)	-0.04(-0.36,0.29)
HD TOCI IV		0.66(0.22,1.84)	0.80(0.48,1.51)	-0.10(-0.35,0.13)
HD TOFA PO		0.70(0.17,2.49)	0.83(0.42,1.81)	-0.09(-0.41,0.20)
HD ADA SC		0.32(0.08,1.30)	0.48(0.23,1.19)	-0.25(-0.54,0.05)
HD ETN SC		0.48(0.16,1.57)	0.66(0.34,1.35)	-0.16(-0.42,0.10)
HD GOLI SC		0.64(0.19,2.11)	0.79(0.43,1.60)	-0.11(-0.39,0.17)
HD ABA SC		0.98(0.16,6.38)	0.99(0.36,2.50)	0.00(-0.41,0.42)
HD INF IV + MTX		1.22(0.42,3.54)	1.10(0.69,2.09)	0.05(-0.20,0.29)
HD TOCI IV + MTX		1.18(0.41,3.38)	1.09(0.68,2.04)	0.04(-0.21,0.28)
HD TOFA PO + MTX		1.27(0.43,3.74)	1.12(0.70,2.08)	0.06(-0.20,0.30)
HD GOLI SC + MTX		1.20(0.39,3.86)	1.09(0.65,2.10)	0.04(-0.22,0.32)
HD CERTO SC + MTX		1.70(0.68,4.09)	1.26(0.86,2.19)	0.13(-0.09,0.33)
HD ADA SC + MTX		1.42(0.37,5.40)	1.16(0.62,2.27)	0.08(-0.23,0.38)
HD TOCI IV + DMARD		0.24(0.06,0.97)	0.40(0.15,0.97)	-0.29(-0.57,-0.01)
SD ANA SC + SD ETN SC + MTX		0.64(0.15,2.60)	0.79(0.33,1.71)	-0.10(-0.42,0.22)
SD ANA SC + LD ETN SC + MTX		0.97(0.22,3.75)	0.98(0.45,1.98)	-0.01(-0.34,0.31)

(Continued)

LD GOLI IV + MTX	LD ETN SC + MTX	0.58(0.17,2.03)	0.73(0.33,1.52)	-0.12(-0.38,0.17)
LD TOCI IV + MTX		0.46(0.13,1.54)	0.63(0.26,1.33)	-0.17(-0.43,0.10)
LD TOFA PO + MTX		0.98(0.24,4.00)	0.99(0.39,2.06)	0.00(-0.32,0.32)
HD TOCI IV		0.74(0.30,1.94)	0.84(0.53,1.54)	-0.07(-0.29,0.15)
HD TOFA PO		0.79(0.21,2.56)	0.88(0.45,1.77)	-0.06(-0.36,0.22)
HD ADA SC		0.36(0.10,1.25)	0.52(0.25,1.17)	-0.22(-0.49,0.05)
HD ETN SC		0.54(0.19,1.60)	0.69(0.38,1.35)	-0.14(-0.37,0.10)
HD GOLI SC		0.73(0.25,2.18)	0.84(0.47,1.61)	-0.07(-0.31,0.18)
HD ABA SC		1.11(0.20,6.49)	1.06(0.38,2.51)	0.03(-0.37,0.42)
HD INF IV + MTX		1.40(0.54,3.72)	1.18(0.75,2.06)	0.08(-0.15,0.31)
HD TOCI IV + MTX		1.33(0.50,3.47)	1.15(0.73,2.07)	0.07(-0.16,0.29)
HD TOFA PO + MTX		1.44(0.52,3.90)	1.19(0.73,2.14)	0.09(-0.16,0.32)
HD GOLI SC + MTX		1.37(0.48,4.04)	1.16(0.71,2.10)	0.08(-0.17,0.33)
HD CERTO SC + MTX		1.92(0.74,5.30)	1.34(0.88,2.42)	0.16(-0.07,0.38)
HD ADA SC + MTX		1.58(0.46,5.79)	1.23(0.68,2.37)	0.11(-0.18,0.39)
HD TOCI IV + DMARD		0.27(0.08,1.05)	0.42(0.16,1.04)	-0.26(-0.51,0.01)
SD ANA SC + SD ETN SC + MTX		0.73(0.21,2.58)	0.83(0.37,1.70)	-0.07(-0.34,0.23)
SD ANA SC + LD ETN SC + MTX		1.08(0.33,3.87)	1.04(0.52,2.01)	0.02(-0.26,0.31)
LD TOCI IV + MTX	LD GOLI IV + MTX	0.79(0.20,3.00)	0.85(0.33,2.15)	-0.05(-0.33,0.22)
LD TOFA PO + MTX		1.68(0.34,7.25)	1.36(0.50,3.21)	0.12(-0.23,0.44)
HD TOCI IV		1.27(0.42,3.58)	1.17(0.62,2.48)	0.05(-0.21,0.26)
HD TOFA PO		1.35(0.36,4.50)	1.20(0.57,2.84)	0.07(-0.24,0.31)
HD ADA SC		0.62(0.16,2.42)	0.72(0.30,1.92)	-0.09(-0.39,0.16)
HD ETN SC		0.93(0.28,3.25)	0.95(0.46,2.26)	-0.02(-0.29,0.23)
HD GOLI SC		1.24(0.41,3.80)	1.15(0.59,2.48)	0.05(-0.21,0.28)
HD ABA SC		1.89(0.32,12.68)	1.44(0.49,4.06)	0.15(-0.25,0.54)
HD INF IV + MTX		2.35(0.82,7.16)	1.62(0.90,3.50)	0.20(-0.05,0.43)

(Continued)

HD TOCI IV + MTX		2.28(0.77,6.69)	1.59(0.88,3.39)	0.19(-0.06,0.41)
HD TOFA PO + MTX		2.46(0.75,7.74)	1.63(0.87,3.64)	0.21(-0.07,0.44)
HD GOLI SC + MTX		2.32(0.75,7.19)	1.59(0.87,3.49)	0.20(-0.07,0.44)
HD CERTO SC + MTX		3.29(1.08,10.01)	1.84(1.03,4.04)	0.28(0.02,0.50)
HD ADA SC + MTX		2.72(0.72,9.55)	1.70(0.84,3.75)	0.23(-0.08,0.50)
HD TOCI IV + DMARD		0.46(0.12,1.91)	0.57(0.21,1.61)	-0.13(-0.41,0.12)
SD ANA SC + SD ETN SC + MTX		1.25(0.29,5.44)	1.15(0.45,2.89)	0.05(-0.26,0.38)
SD ANA SC + LD ETN SC + MTX		1.83(0.46,7.74)	1.41(0.62,3.45)	0.14(-0.18,0.44)
LD TOFA PO + MTX	LD TOCI IV + MTX	2.10(0.44,9.63)	1.57(0.56,3.92)	0.16(-0.16,0.49)
HD TOCI IV		1.60(0.63,4.23)	1.36(0.77,2.90)	0.10(-0.11,0.28)
HD TOFA PO		1.70(0.51,5.90)	1.41(0.66,3.53)	0.12(-0.16,0.35)
HD ADA SC		0.77(0.23,2.91)	0.83(0.35,2.29)	-0.05(-0.30,0.19)
HD ETN SC		1.17(0.38,4.05)	1.12(0.52,2.73)	0.03(-0.22,0.29)
HD GOLI SC		1.55(0.49,5.07)	1.33(0.63,3.18)	0.09(-0.16,0.34)
HD ABA SC		2.40(0.42,15.15)	1.68(0.56,5.08)	0.19(-0.19,0.57)
HD INF IV + MTX		2.99(1.08,9.45)	1.88(1.04,4.25)	0.25(0.02,0.49)
HD TOCI IV + MTX		2.87(1.08,7.82)	1.87(1.04,3.99)	0.24(0.02,0.43)
HD TOFA PO + MTX		3.07(1.00,9.38)	1.90(1.00,4.35)	0.26(0.00,0.48)
HD GOLI SC + MTX		2.87(0.89,10.00)	1.85(0.94,4.31)	0.24(-0.03,0.49)
HD CERTO SC + MTX		4.16(1.36,12.90)	2.16(1.15,4.86)	0.33(0.07,0.55)
HD ADA SC + MTX		3.39(0.89,13.77)	1.98(0.93,4.69)	0.28(-0.03,0.56)
HD TOCI IV + DMARD		0.60(0.16,2.30)	0.68(0.25,1.86)	-0.09(-0.34,0.16)
SD ANA SC + SD ETN SC + MTX		1.57(0.41,6.71)	1.33(0.55,3.50)	0.09(-0.19,0.42)
SD ANA SC + LD ETN SC + MTX		2.37(0.60,10.10)	1.67(0.71,4.07)	0.19(-0.11,0.50)
HD TOCI IV	LD TOFA PO + MTX	0.76(0.22,2.84)	0.85(0.49,2.18)	-0.07(-0.35,0.21)
HD TOFA PO		0.81(0.19,3.83)	0.89(0.44,2.52)	-0.05(-0.38,0.27)
HD ADA SC		0.37(0.09,1.85)	0.53(0.23,1.57)	-0.21(-0.52,0.11)

(Continued)

HD ETN SC		0.57(0.15,2.26)	0.71(0.35,1.77)	-0.13(-0.43,0.17)
HD GOLI SC		0.74(0.20,3.12)	0.85(0.44,2.15)	-0.07(-0.37,0.23)
HD ABA SC		1.16(0.16,8.45)	1.08(0.38,3.27)	0.03(-0.41,0.47)
HD INF IV + MTX		1.45(0.39,5.44)	1.20(0.68,2.88)	0.09(-0.21,0.37)
HD TOCI IV + MTX		1.35(0.40,5.29)	1.16(0.68,2.88)	0.07(-0.21,0.36)
HD TOFA PO + MTX		1.48(0.49,4.58)	1.20(0.75,2.60)	0.09(-0.16,0.33)
HD GOLI SC + MTX		1.40(0.39,5.69)	1.18(0.66,2.85)	0.08(-0.22,0.39)
HD CERTO SC + MTX		2.01(0.56,7.16)	1.37(0.81,3.39)	0.17(-0.13,0.43)
HD ADA SC + MTX		1.64(0.37,7.93)	1.25(0.64,3.23)	0.11(-0.23,0.45)
HD TOCI IV + DMARD		0.28(0.06,1.35)	0.43(0.15,1.24)	-0.25(-0.57,0.05)
SD ANA SC + SD ETN SC + MTX		0.75(0.15,3.85)	0.85(0.33,2.27)	-0.07(-0.41,0.30)
SD ANA SC + LD ETN SC + MTX		1.14(0.22,5.38)	1.07(0.45,2.75)	0.03(-0.34,0.37)
HD TOFA PO	HD TOCI IV	1.08(0.41,2.57)	1.05(0.57,1.78)	0.02(-0.21,0.22)
HD ADA SC		0.48(0.20,1.28)	0.61(0.32,1.18)	-0.15(-0.33,0.05)
HD ETN SC		0.74(0.31,1.78)	0.82(0.46,1.39)	-0.07(-0.24,0.13)
HD GOLI SC		0.98(0.42,2.30)	0.99(0.57,1.63)	-0.01(-0.19,0.20)
HD ABA SC		1.45(0.34,7.89)	1.22(0.48,2.68)	0.09(-0.24,0.46)
HD INF IV + MTX		1.88(0.93,3.87)	1.40(0.96,2.00)	0.15(-0.02,0.32)
HD TOCI IV + MTX		1.79(1.03,3.11)	1.37(1.02,1.82)	0.14(0.01,0.27)
HD TOFA PO + MTX		1.94(0.87,4.04)	1.41(0.92,2.06)	0.16(-0.03,0.33)
HD GOLI SC + MTX		1.84(0.81,4.44)	1.37(0.88,2.08)	0.15(-0.05,0.35)
HD CERTO SC + MTX		2.57(1.29,5.38)	1.59(1.14,2.27)	0.23(0.06,0.39)
HD ADA SC + MTX		2.17(0.71,6.31)	1.48(0.82,2.29)	0.19(-0.08,0.41)
HD TOCI IV + DMARD		0.37(0.14,1.05)	0.49(0.21,1.03)	-0.19(-0.35,0.01)
SD ANA SC + SD ETN SC + MTX		0.98(0.31,3.04)	0.99(0.44,1.80)	0.00(-0.24,0.27)
SD ANA SC + LD ETN SC + MTX		1.46(0.45,4.56)	1.24(0.60,2.09)	0.09(-0.17,0.35)
HD ADA SC	HD TOFA PO	0.46(0.17,1.32)	0.59(0.29,1.21)	-0.16(-0.36,0.06)

(Continued)

HD ETN SC		0.68(0.23,2.29)	0.78(0.37,1.64)	-0.09(-0.30,0.19)
HD GOLI SC		0.93(0.33,2.63)	0.96(0.50,1.81)	-0.02(-0.25,0.23)
HD ABA SC		1.42(0.31,7.05)	1.20(0.47,2.49)	0.09(-0.26,0.44)
HD INF IV + MTX		1.75(0.64,5.29)	1.34(0.78,2.41)	0.14(-0.11,0.39)
HD TOCI IV + MTX		1.69(0.62,4.72)	1.31(0.77,2.28)	0.13(-0.11,0.36)
HD TOFA PO + MTX		1.82(0.65,5.22)	1.36(0.79,2.36)	0.15(-0.10,0.38)
HD GOLI SC + MTX		1.73(0.57,5.23)	1.33(0.72,2.37)	0.13(-0.14,0.39)
HD CERTO SC + MTX		2.44(0.87,7.25)	1.53(0.93,2.65)	0.22(-0.03,0.45)
HD ADA SC + MTX		2.00(0.55,7.96)	1.42(0.70,2.61)	0.17(-0.14,0.46)
HD TOCI IV + DMARD		0.35(0.09,1.29)	0.48(0.17,1.17)	-0.21(-0.41,0.05)
SD ANA SC + SD ETN SC + MTX		0.91(0.24,3.71)	0.95(0.38,1.96)	-0.02(-0.30,0.31)
SD ANA SC + LD ETN SC + MTX		1.36(0.35,5.27)	1.18(0.51,2.29)	0.07(-0.23,0.39)
HD ETN SC	HD ADA SC	1.54(0.43,4.77)	1.36(0.54,2.89)	0.08(-0.16,0.32)
HD GOLI SC		2.03(0.61,6.02)	1.63(0.71,3.38)	0.15(-0.10,0.38)
HD ABA SC		3.03(0.62,15.42)	2.02(0.72,4.66)	0.24(-0.09,0.58)
HD INF IV + MTX		3.85(1.22,11.95)	2.29(1.13,4.47)	0.30(0.04,0.53)
HD TOCI IV + MTX		3.68(1.26,10.12)	2.24(1.15,4.29)	0.29(0.05,0.49)
HD TOFA PO + MTX		3.93(1.33,11.68)	2.30(1.19,4.49)	0.31(0.07,0.53)
HD GOLI SC + MTX		3.78(1.11,11.88)	2.26(1.07,4.47)	0.30(0.02,0.54)
HD CERTO SC + MTX		5.31(1.67,15.81)	2.61(1.36,4.92)	0.38(0.12,0.59)
HD ADA SC + MTX		4.34(1.09,16.97)	2.39(1.06,4.78)	0.33(0.02,0.60)
HD TOCI IV + DMARD		0.75(0.21,2.89)	0.80(0.28,2.17)	-0.05(-0.24,0.21)
SD ANA SC + SD ETN SC + MTX		2.00(0.46,7.90)	1.60(0.56,3.66)	0.14(-0.14,0.46)
SD ANA SC + LD ETN SC + MTX		3.04(0.69,11.57)	2.01(0.77,4.17)	0.24(-0.07,0.54)
HD GOLI SC	HD ETN SC	1.34(0.49,3.53)	1.21(0.63,2.32)	0.06(-0.16,0.29)
HD ABA SC		2.05(0.39,11.60)	1.52(0.54,3.72)	0.16(-0.21,0.53)
HD INF IV + MTX		2.55(1.06,6.32)	1.68(1.03,3.03)	0.22(0.01,0.41)

(Continued)

HD TOCI IV + MTX		2.44(0.96,5.82)	1.66(0.98,3.02)	0.21(-0.01,0.39)
HD TOFA PO + MTX		2.62(1.03,6.51)	1.72(1.01,3.00)	0.22(0.01,0.43)
HD GOLI SC + MTX		2.51(0.93,6.81)	1.68(0.96,3.12)	0.21(-0.02,0.43)
HD CERTO SC + MTX		3.52(1.39,8.85)	1.93(1.19,3.43)	0.29(0.08,0.49)
HD ADA SC + MTX		2.91(0.85,9.56)	1.78(0.91,3.37)	0.24(-0.04,0.50)
HD TOCI IV + DMARD		0.51(0.15,1.74)	0.61(0.23,1.48)	-0.12(-0.36,0.11)
SD ANA SC + SD ETN SC + MTX		1.31(0.37,4.89)	1.19(0.50,2.49)	0.06(-0.20,0.35)
SD ANA SC + LD ETN SC + MTX		1.98(0.56,6.95)	1.49(0.69,2.97)	0.15(-0.13,0.44)
HD ABA SC	HD GOLI SC	1.53(0.30,8.55)	1.26(0.47,2.95)	0.10(-0.27,0.48)
HD INF IV + MTX		1.93(0.76,4.66)	1.41(0.87,2.35)	0.16(-0.06,0.36)
HD TOCI IV + MTX		1.83(0.77,4.34)	1.38(0.86,2.35)	0.14(-0.06,0.34)
HD TOFA PO + MTX		1.97(0.74,4.83)	1.43(0.85,2.41)	0.16(-0.07,0.37)
HD GOLI SC + MTX		1.88(0.78,4.38)	1.39(0.88,2.23)	0.15(-0.06,0.35)
HD CERTO SC + MTX		2.63(1.05,6.51)	1.60(1.02,2.68)	0.23(0.01,0.43)
HD ADA SC + MTX		2.19(0.68,7.50)	1.48(0.80,2.66)	0.19(-0.09,0.45)
HD TOCI IV + DMARD		0.38(0.11,1.36)	0.50(0.20,1.23)	-0.19(-0.42,0.07)
SD ANA SC + SD ETN SC + MTX		0.98(0.28,3.66)	0.99(0.42,2.02)	0.00(-0.27,0.31)
SD ANA SC + LD ETN SC + MTX		1.50(0.41,5.27)	1.25(0.58,2.36)	0.10(-0.20,0.38)
HD INF IV + MTX	HD ABA SC	1.28(0.24,6.28)	1.12(0.54,2.82)	0.06(-0.33,0.41)
HD TOCI IV + MTX		1.22(0.21,5.94)	1.10(0.51,2.87)	0.05(-0.36,0.40)
HD TOFA PO + MTX		1.30(0.24,6.77)	1.13(0.55,2.99)	0.06(-0.33,0.43)
HD GOLI SC + MTX		1.26(0.22,6.45)	1.11(0.50,2.97)	0.06(-0.35,0.42)
HD CERTO SC + MTX		1.73(0.30,8.54)	1.27(0.65,3.26)	0.13(-0.26,0.48)
HD ADA SC + MTX		1.43(0.22,8.63)	1.17(0.52,3.08)	0.08(-0.34,0.48)
HD TOCI IV + DMARD		0.25(0.04,1.54)	0.40(0.12,1.32)	-0.28(-0.65,0.09)
SD ANA SC + SD ETN SC + MTX		0.66(0.09,3.85)	0.80(0.28,2.18)	-0.10(-0.52,0.31)
SD ANA SC + LD ETN SC + MTX		1.00(0.14,5.90)	1.00(0.38,2.72)	0.00(-0.44,0.40)

(Continued)

HD TOCI IV + MTX	HD INF IV + MTX	0.95(0.45,2.05)	0.98(0.69,1.41)	-0.01(-0.19,0.17)
HD TOFA PO + MTX		1.04(0.45,2.32)	1.02(0.69,1.49)	0.01(-0.19,0.20)
HD GOLI SC + MTX		0.97(0.40,2.34)	0.99(0.64,1.48)	-0.01(-0.22,0.20)
HD CERTO SC + MTX		1.38(0.63,2.98)	1.14(0.82,1.62)	0.08(-0.11,0.25)
HD ADA SC + MTX		1.14(0.38,3.46)	1.06(0.61,1.65)	0.03(-0.23,0.28)
HD TOCI IV + DMARD		0.19(0.06,0.65)	0.35(0.14,0.79)	-0.34(-0.55,-0.10)
SD ANA SC + SD ETN SC + MTX		0.51(0.16,1.69)	0.71(0.32,1.29)	-0.16(-0.40,0.12)
SD ANA SC + LD ETN SC + MTX		0.78(0.26,2.44)	0.89(0.44,1.47)	-0.06(-0.31,0.21)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.08(0.50,2.43)	1.04(0.70,1.49)	0.02(-0.17,0.21)
HD GOLI SC + MTX		1.03(0.44,2.50)	1.01(0.66,1.50)	0.01(-0.20,0.22)
HD CERTO SC + MTX		1.43(0.67,3.18)	1.16(0.84,1.65)	0.09(-0.10,0.27)
HD ADA SC + MTX		1.19(0.41,3.65)	1.08(0.62,1.65)	0.04(-0.21,0.28)
HD TOCI IV + DMARD		0.21(0.07,0.66)	0.36(0.15,0.79)	-0.33(-0.52,-0.10)
SD ANA SC + SD ETN SC + MTX		0.55(0.18,1.81)	0.73(0.33,1.31)	-0.14(-0.38,0.15)
SD ANA SC + LD ETN SC + MTX		0.81(0.25,2.63)	0.91(0.43,1.54)	-0.05(-0.32,0.23)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.95(0.37,2.42)	0.98(0.62,1.49)	-0.01(-0.23,0.21)
HD CERTO SC + MTX		1.34(0.62,2.99)	1.12(0.81,1.63)	0.07(-0.12,0.25)
HD ADA SC + MTX		1.09(0.39,3.55)	1.04(0.61,1.63)	0.02(-0.22,0.28)
HD TOCI IV + DMARD		0.19(0.06,0.68)	0.35(0.14,0.80)	-0.35(-0.56,-0.09)
SD ANA SC + SD ETN SC + MTX		0.51(0.15,1.83)	0.70(0.31,1.31)	-0.16(-0.43,0.14)
SD ANA SC + LD ETN SC + MTX		0.76(0.21,2.54)	0.88(0.42,1.51)	-0.07(-0.35,0.22)
HD CERTO SC + MTX	HD GOLI SC + MTX	1.42(0.58,3.45)	1.15(0.80,1.76)	0.08(-0.13,0.29)
HD ADA SC + MTX		1.17(0.37,3.71)	1.07(0.59,1.75)	0.04(-0.24,0.29)
HD TOCI IV + DMARD		0.20(0.06,0.71)	0.36(0.14,0.82)	-0.33(-0.57,-0.08)
SD ANA SC + SD ETN SC + MTX		0.53(0.15,1.94)	0.72(0.31,1.39)	-0.15(-0.42,0.15)
SD ANA SC + LD ETN SC + MTX		0.80(0.23,2.79)	0.90(0.42,1.57)	-0.05(-0.34,0.23)

(Continued)

HD ADA SC + MTX	HD CERTO SC + MTX	0.82(0.28,2.59)	0.93(0.54,1.40)	-0.05(-0.30,0.20)
HD TOCI IV + DMARD		0.14(0.05,0.46)	0.31(0.13,0.67)	-0.42(-0.61,-0.18)
SD ANA SC + SD ETN SC + MTX		0.38(0.11,1.26)	0.62(0.28,1.11)	-0.23(-0.49,0.05)
SD ANA SC + LD ETN SC + MTX		0.56(0.17,1.96)	0.78(0.38,1.28)	-0.14(-0.41,0.15)
HD TOCI IV + DMARD	HD ADA SC + MTX	0.17(0.04,0.77)	0.34(0.13,0.85)	-0.37(-0.63,-0.06)
SD ANA SC + SD ETN SC + MTX		0.46(0.11,1.88)	0.67(0.30,1.39)	-0.18(-0.48,0.15)
SD ANA SC + LD ETN SC + MTX		0.69(0.17,2.78)	0.84(0.40,1.62)	-0.08(-0.40,0.24)
SD ANA SC + SD ETN SC + MTX	HD TOCI IV + DMARD	2.66(0.61,11.12)	1.99(0.70,5.51)	0.18(-0.10,0.48)
SD ANA SC + LD ETN SC + MTX		3.96(0.90,15.38)	2.47(0.94,6.49)	0.28(-0.02,0.56)
SD ANA SC + LD ETN SC + MTX	SD ANA SC + SD ETN SC + MTX	1.49(0.55,4.14)	1.24(0.72,2.35)	0.09(-0.13,0.32)
Random-effects model	Residual deviance	212.5 vs 213 data points		
	Deviance informa- tion crite- ria	1368.54		
Fixed-effect model	Residual deviance	333.4 vs 213 data points		
	Deviance informa- tion crite- ria	1449.97		
Note				
Total participants	30,229			
Total studies	79			
2-arm	38			
3-arm	33			
4-arm	6			
5-arm	1			
7-arm	1			

Appendix 3. ACR50: subgroup - established RA (2-10 years)

ACR50 established: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	3.01(1.47,6.08)	2.68(1.43,4.76)	0.10(0.03,0.21)
DMARD		0.84(0.34,2.09)	0.85(0.36,1.97)	-0.01(-0.04,0.05)
MTX + DMARD		4.04(1.64,9.92)	3.40(1.57,6.61)	0.14(0.04,0.32)
SD ETN SC		5.37(2.65,11.01)	4.25(2.40,7.11)	0.20(0.09,0.34)
SD ADA SC		3.77(1.96,7.47)	3.23(1.84,5.56)	0.13(0.05,0.25)
SD TOFA PO		6.61(3.30,13.96)	4.94(2.87,8.12)	0.24(0.12,0.40)
SD TOCI IV		4.76(1.89,11.98)	3.88(1.78,7.41)	0.17(0.05,0.37)
SD GOLI SC		7.48(2.54,22.98)	5.37(2.31,10.43)	0.26(0.08,0.53)
SD GOLI IV		5.61(1.70,18.79)	4.37(1.63,9.29)	0.20(0.04,0.48)
SD ABA SC		10.25(2.56,47.10)	6.54(2.33,13.59)	0.34(0.08,0.68)
SD CERTO SC		9.70(3.03,32.66)	6.33(2.69,11.66)	0.32(0.10,0.61)
SD ETN SC + MTX		10.23(4.69,22.42)	6.55(3.78,10.40)	0.34(0.17,0.52)
SD INF IV + MTX		9.01(3.97,20.72)	6.07(3.35,10.05)	0.31(0.15,0.50)
SD ABA IV + MTX		11.51(4.85,26.93)	7.02(3.90,11.23)	0.36(0.18,0.56)
SD CERTO SC + MTX		17.37(7.32,41.58)	8.68(5.19,13.11)	0.47(0.26,0.66)
SD TOFA PO + MTX		18.69(7.47,51.23)	9.00(5.23,13.94)	0.48(0.26,0.70)
SD GOLI SC + MTX		20.69(8.35,53.21)	9.39(5.61,13.89)	0.51(0.29,0.70)
SD ADA SC + MTX		12.42(3.61,44.27)	7.34(3.09,13.11)	0.38(0.13,0.67)
SD RITUX IV + MTX		6.43(2.42,18.59)	4.85(2.22,9.41)	0.23(0.07,0.47)
SD GOLI IV + MTX		7.23(2.75,19.67)	5.24(2.47,9.63)	0.26(0.09,0.49)
SD ABA SC + MTX		12.38(3.67,41.58)	7.30(3.14,12.96)	0.38(0.13,0.66)
SD ANA SC + MTX		15.95(2.40,129.30)	8.35(2.22,16.03)	0.44(0.07,0.83)
SD TOCI IV + MTX		6.45(1.99,20.90)	4.85(1.87,9.96)	0.23(0.05,0.50)
SD CERTO SC + DMARD		4.83(1.75,13.91)	3.92(1.67,8.05)	0.18(0.04,0.40)

(Continued)

SD ADA SC + DMARD		2.67(0.74,10.00)	2.42(0.75,6.62)	0.09(-0.02,0.32)
SD ETN SC + DMARD		10.60(3.43,34.78)	6.67(2.98,12.03)	0.34(0.12,0.62)
LD ADA SC		3.47(1.47,8.34)	3.02(1.43,5.94)	0.12(0.03,0.28)
LD GOL I V		3.32(0.95,11.16)	2.90(0.96,7.10)	0.11(0.00,0.35)
LD TOCI IV		0.59(0.10,2.51)	0.61(0.11,2.31)	-0.02(-0.06,0.08)
LD RITUX IV + MTX		5.34(2.00,15.20)	4.23(1.89,8.52)	0.19(0.06,0.42)
LD ABA IV + MTX		6.29(2.28,17.23)	4.75(2.12,9.10)	0.23(0.07,0.45)
LD ANA SC + MTX		9.03(1.29,76.76)	6.06(1.27,14.67)	0.31(0.02,0.77)
LD CERTO SC + MTX		12.43(3.91,40.48)	7.33(3.29,12.79)	0.38(0.14,0.66)
LD ETN SC + MTX		9.76(3.29,29.06)	6.36(2.88,11.44)	0.32(0.12,0.59)
LD GOL I V + MTX		6.41(1.98,21.30)	4.83(1.87,10.01)	0.23(0.05,0.51)
LD TOCI IV + MTX		5.41(1.69,17.11)	4.26(1.62,9.01)	0.20(0.04,0.45)
LD TOFA PO + MTX		9.58(2.42,38.84)	6.30(2.24,12.60)	0.32(0.08,0.65)
HD TOCI IV		8.54(4.39,17.47)	5.86(3.58,9.35)	0.29(0.17,0.45)
HD TOFA PO		10.58(5.28,22.12)	6.69(4.12,10.32)	0.34(0.20,0.52)
HD ADA SC		4.95(2.16,11.79)	3.99(2.01,7.44)	0.18(0.06,0.36)
HD GOL I SC		8.87(3.71,21.75)	6.00(3.15,10.14)	0.30(0.13,0.51)
HD ETN SC		5.94(2.15,17.26)	4.57(2.00,9.00)	0.22(0.06,0.46)
HD ABA SC		14.79(3.72,67.13)	8.02(3.17,14.87)	0.43(0.14,0.74)
HD TOCI IV + MTX		14.79(6.72,33.84)	8.03(4.89,12.34)	0.43(0.25,0.61)
HD TOFA PO + MTX		15.00(5.88,40.02)	8.08(4.48,12.84)	0.43(0.22,0.65)
HD GOL I SC + MTX		15.89(6.41,40.49)	8.33(4.74,12.87)	0.44(0.24,0.65)
HD CERTO SC + MTX		20.66(8.33,52.67)	9.39(5.62,14.01)	0.51(0.29,0.70)
HD INF IV + MTX		12.70(4.73,34.29)	7.42(3.82,12.28)	0.39(0.18,0.62)
HD TOCI IV + DMARD		3.13(1.03,9.52)	2.78(1.03,6.40)	0.11(0.00,0.31)
DMARD	MTX	0.28(0.12,0.65)	0.32(0.14,0.68)	-0.11(-0.20,-0.04)
MTX + DMARD		1.35(0.70,2.54)	1.28(0.74,2.06)	0.04(-0.05,0.17)
SD ETN SC		1.80(1.09,2.94)	1.59(1.07,2.36)	0.09(0.01,0.19)

(Continued)

SD ADA SC	1.26(0.56,2.91)	1.21(0.62,2.42)	0.03(-0.09,0.16)
SD TOFA PO	2.21(0.85,5.98)	1.85(0.88,3.90)	0.14(-0.03,0.32)
SD TOCI IV	1.59(0.70,3.60)	1.45(0.74,2.67)	0.07(-0.05,0.24)
SD GOLI SC	2.54(0.79,8.01)	2.02(0.82,4.35)	0.16(-0.03,0.42)
SD GOLI IV	1.87(0.69,5.16)	1.63(0.72,3.14)	0.10(-0.04,0.34)
SD ABA SC	3.42(0.71,18.44)	2.43(0.76,6.30)	0.23(-0.05,0.59)
SD CERTO SC	3.22(0.82,13.12)	2.35(0.85,5.65)	0.22(-0.03,0.52)
SD ETN SC + MTX	3.43(2.12,5.48)	2.44(1.72,3.44)	0.23(0.12,0.36)
SD INF IV + MTX	3.02(1.88,4.88)	2.25(1.61,3.18)	0.20(0.09,0.33)
SD ABA IV + MTX	3.83(2.35,6.31)	2.60(1.86,3.66)	0.26(0.13,0.40)
SD CERTO SC + MTX	5.79(3.56,9.50)	3.22(2.33,4.53)	0.36(0.21,0.49)
SD TOFA PO + MTX	6.29(3.50,11.75)	3.33(2.32,4.86)	0.38(0.22,0.53)
SD GOLI SC + MTX	6.87(3.42,14.35)	3.47(2.27,5.52)	0.40(0.23,0.56)
SD ADA SC + MTX	4.16(1.46,11.69)	2.69(1.35,4.71)	0.28(0.05,0.53)
SD RITUX IV + MTX	2.16(1.06,4.48)	1.81(1.05,2.94)	0.13(0.01,0.31)
SD GOLI IV + MTX	2.42(1.19,5.00)	1.95(1.15,3.11)	0.15(0.02,0.33)
SD ABA SC + MTX	4.14(1.52,11.20)	2.69(1.40,4.63)	0.28(0.06,0.52)
SD ANA SC + MTX	5.32(0.89,36.66)	3.05(0.91,6.36)	0.34(-0.01,0.71)
SD TOCI IV + MTX	2.14(0.77,6.09)	1.79(0.81,3.51)	0.13(-0.03,0.37)
SD CERTO SC + DMARD	1.60(0.53,5.10)	1.46(0.59,3.42)	0.07(-0.09,0.30)
SD ADA SC + DMARD	0.90(0.24,3.18)	0.92(0.28,2.41)	-0.01(-0.15,0.21)
SD ETN SC + DMARD	3.56(1.26,10.16)	2.48(1.20,4.62)	0.24(0.03,0.49)
LD ADA SC	1.15(0.42,3.28)	1.13(0.48,2.61)	0.02(-0.12,0.19)
LD GOLI IV	1.10(0.39,3.08)	1.08(0.43,2.31)	0.01(-0.10,0.21)
LD TOCI IV	0.20(0.04,0.77)	0.23(0.04,0.79)	-0.12(-0.22,-0.03)
LD RITUX IV + MTX	1.79(0.88,3.78)	1.58(0.90,2.65)	0.09(-0.02,0.27)
LD ABA IV + MTX	2.10(1.02,4.29)	1.77(1.02,2.86)	0.12(0.00,0.30)
LD ANA SC + MTX	3.05(0.49,21.80)	2.25(0.54,5.41)	0.20(-0.08,0.64)

(Continued)

LD CERTO SC + MTX		4.17(1.63,10.69)	2.71(1.47,4.51)	0.28(0.07,0.51)
LD ETN SC + MTX		3.28(1.37,7.76)	2.37(1.29,3.99)	0.22(0.05,0.44)
LD GOLI IV + MTX		2.16(0.81,5.70)	1.81(0.83,3.36)	0.13(-0.03,0.36)
LD TOCI IV + MTX		1.80(0.65,5.01)	1.59(0.70,3.19)	0.09(-0.05,0.32)
LD TOFA PO + MTX		3.23(0.98,10.73)	2.34(0.99,4.42)	0.22(0.00,0.51)
HD TOCI IV		2.85(1.69,4.96)	2.18(1.47,3.40)	0.19(0.09,0.31)
HD TOFA PO		3.53(1.37,9.55)	2.49(1.26,5.07)	0.24(0.06,0.43)
HD ADA SC		1.66(0.60,4.70)	1.50(0.66,3.33)	0.08(-0.08,0.27)
HD GOLI SC		2.98(1.30,6.71)	2.23(1.22,3.97)	0.20(0.04,0.38)
HD ETN SC		1.99(0.85,4.71)	1.71(0.87,3.06)	0.11(-0.02,0.31)
HD ABA SC		4.88(1.08,25.35)	2.95(1.06,7.04)	0.32(0.01,0.65)
HD TOCI IV + MTX		4.95(2.86,8.78)	2.98(2.04,4.57)	0.32(0.19,0.46)
HD TOFA PO + MTX		5.01(2.74,9.20)	2.99(2.07,4.36)	0.33(0.17,0.48)
HD GOLI SC + MTX		5.27(2.59,10.98)	3.07(1.96,4.88)	0.34(0.17,0.51)
HD CERTO SC + MTX		6.93(3.84,12.54)	3.48(2.44,5.13)	0.40(0.24,0.55)
HD INF IV + MTX		4.22(2.12,8.71)	2.74(1.76,4.23)	0.28(0.12,0.46)
HD TOCI IV + DMARD		1.06(0.35,3.00)	1.05(0.41,2.33)	0.01(-0.12,0.19)
MTX + DMARD	DMARD	4.75(1.78,13.41)	3.95(1.66,9.80)	0.15(0.05,0.32)
SD ETN SC		6.38(2.80,14.83)	4.94(2.40,10.72)	0.20(0.10,0.34)
SD ADA SC		4.48(1.67,12.12)	3.78(1.56,9.27)	0.14(0.05,0.26)
SD TOFA PO		7.87(2.58,23.95)	5.77(2.21,14.80)	0.24(0.11,0.41)
SD TOCI IV		5.63(1.99,16.22)	4.50(1.81,11.05)	0.18(0.06,0.36)
SD GOLI SC		8.98(2.33,33.68)	6.24(2.07,17.07)	0.27(0.08,0.53)
SD GOLI IV		6.59(1.85,25.43)	5.06(1.74,14.10)	0.21(0.05,0.48)
SD ABA SC		12.25(2.29,68.23)	7.60(2.05,23.30)	0.34(0.08,0.69)
SD CERTO SC		11.38(2.59,51.27)	7.28(2.25,21.19)	0.33(0.10,0.62)
SD ETN SC + MTX		12.11(4.99,31.14)	7.57(3.60,17.11)	0.34(0.19,0.51)
SD INF IV + MTX		10.67(4.20,28.91)	7.00(3.23,16.24)	0.31(0.16,0.50)

(Continued)

SD ABA IV + MTX	13.55(5.12,36.64)	8.10(3.71,18.61)	0.37(0.19,0.56)
SD CERTO SC + MTX	20.42(7.69,56.02)	10.05(4.70,22.73)	0.47(0.28,0.66)
SD TOFA PO + MTX	22.07(8.24,65.85)	10.39(4.94,23.55)	0.49(0.28,0.69)
SD GOLI SC + MTX	24.47(8.47,73.59)	10.85(4.87,25.08)	0.51(0.30,0.70)
SD ADA SC + MTX	14.51(3.93,56.13)	8.29(3.16,21.02)	0.39(0.14,0.67)
SD RITUX IV + MTX	7.60(2.57,24.73)	5.60(2.25,14.24)	0.24(0.09,0.47)
SD GOLI IV + MTX	8.57(2.81,26.42)	6.07(2.41,14.87)	0.26(0.10,0.49)
SD ABA SC + MTX	14.58(4.01,54.98)	8.33(3.18,20.84)	0.39(0.14,0.66)
SD ANA SC + MTX	19.11(2.64,157.80)	9.44(2.33,25.66)	0.45(0.08,0.83)
SD TOCI IV + MTX	7.57(2.21,27.29)	5.55(2.01,14.63)	0.24(0.06,0.50)
SD CERTO SC + DMARD	5.76(2.02,16.38)	4.55(1.85,10.85)	0.18(0.06,0.39)
SD ADA SC + DMARD	3.16(1.20,8.26)	2.82(1.19,6.08)	0.09(0.01,0.30)
SD ETN SC + DMARD	12.48(4.39,38.15)	7.64(3.46,17.10)	0.35(0.14,0.61)
LD ADA SC	4.09(1.30,13.57)	3.51(1.27,10.05)	0.13(0.02,0.28)
LD GOLI IV	3.91(0.99,15.51)	3.36(1.00,10.37)	0.12(0.00,0.35)
LD TOCI IV	0.69(0.11,3.24)	0.70(0.12,2.99)	-0.01(-0.08,0.08)
LD RITUX IV + MTX	6.35(2.10,20.24)	4.91(1.92,12.60)	0.20(0.06,0.42)
LD ABA IV + MTX	7.37(2.47,22.77)	5.47(2.20,13.79)	0.23(0.08,0.45)
LD ANA SC + MTX	10.91(1.38,88.88)	7.03(1.34,21.59)	0.31(0.02,0.77)
LD CERTO SC + MTX	14.73(4.21,52.91)	8.40(3.32,20.38)	0.39(0.15,0.65)
LD ETN SC + MTX	11.52(3.62,38.11)	7.30(2.95,17.91)	0.33(0.13,0.58)
LD GOLI IV + MTX	7.63(2.08,28.74)	5.60(1.91,15.06)	0.24(0.06,0.51)
LD TOCI IV + MTX	6.40(1.89,22.37)	4.91(1.77,13.04)	0.20(0.05,0.45)
LD TOFA PO + MTX	11.42(2.71,50.51)	7.23(2.39,19.59)	0.32(0.09,0.64)
HD TOCI IV	10.13(4.65,22.67)	6.81(3.42,14.40)	0.30(0.18,0.44)
HD TOFA PO	12.63(4.20,38.26)	7.87(3.14,19.74)	0.35(0.19,0.53)
HD ADA SC	5.90(1.89,19.18)	4.66(1.74,12.78)	0.19(0.06,0.36)
HD GOLI SC	10.52(3.45,32.32)	6.98(2.79,17.25)	0.31(0.14,0.51)

(Continued)

HD ETN SC		7.02(2.25,22.38)	5.27(2.04,13.34)	0.22(0.07,0.45)
HD ABA SC		17.57(3.38,98.73)	9.21(2.78,26.24)	0.43(0.14,0.75)
HD TOCI IV + MTX		17.47(7.19,45.59)	9.31(4.54,20.47)	0.43(0.27,0.61)
HD TOFA PO + MTX		17.73(6.48,51.47)	9.30(4.28,21.36)	0.43(0.23,0.64)
HD GOLI SC + MTX		18.65(6.40,57.05)	9.60(4.21,22.52)	0.45(0.25,0.65)
HD CERTO SC + MTX		24.36(8.95,70.21)	10.84(5.07,24.65)	0.51(0.31,0.70)
HD INF IV + MTX		14.98(5.23,46.24)	8.53(3.75,20.19)	0.39(0.19,0.61)
HD TOCI IV + DMARD		3.72(1.91,7.08)	3.23(1.81,5.45)	0.11(0.03,0.27)
SD ETN SC	MTX + DMARD	1.34(0.67,2.67)	1.25(0.75,2.21)	0.05(-0.08,0.16)
SD ADA SC		0.94(0.35,2.57)	0.96(0.45,2.18)	-0.01(-0.19,0.14)
SD TOFA PO		1.66(0.54,5.08)	1.46(0.64,3.48)	0.09(-0.12,0.29)
SD TOCI IV		1.18(0.42,3.28)	1.14(0.51,2.52)	0.03(-0.15,0.21)
SD GOLI SC		1.89(0.50,6.85)	1.58(0.59,3.85)	0.12(-0.12,0.39)
SD GOLI IV		1.39(0.43,4.63)	1.28(0.51,2.98)	0.06(-0.13,0.31)
SD ABA SC		2.53(0.48,15.15)	1.90(0.58,5.57)	0.18(-0.13,0.56)
SD CERTO SC		2.42(0.52,11.13)	1.86(0.62,4.92)	0.17(-0.12,0.49)
SD ETN SC + MTX		2.55(1.52,4.28)	1.92(1.30,3.00)	0.18(0.08,0.29)
SD INF IV + MTX		2.24(1.16,4.47)	1.77(1.10,3.04)	0.16(0.03,0.30)
SD ABA IV + MTX		2.85(1.30,6.33)	2.05(1.19,3.73)	0.21(0.05,0.38)
SD CERTO SC + MTX		4.31(1.89,9.70)	2.53(1.47,4.66)	0.31(0.14,0.48)
SD TOFA PO + MTX		4.70(1.97,11.52)	2.62(1.50,4.93)	0.33(0.14,0.52)
SD GOLI SC + MTX		5.12(1.98,13.25)	2.74(1.51,5.40)	0.35(0.15,0.54)
SD ADA SC + MTX		3.08(0.90,10.40)	2.11(0.93,4.47)	0.23(-0.02,0.50)
SD RITUX IV + MTX		1.61(0.62,4.25)	1.43(0.70,2.91)	0.08(-0.08,0.29)
SD GOLI IV + MTX		1.80(0.67,4.70)	1.54(0.75,3.04)	0.11(-0.07,0.31)
SD ABA SC + MTX		3.07(0.94,9.88)	2.11(0.96,4.40)	0.23(-0.01,0.49)
SD ANA SC + MTX		3.97(0.61,31.66)	2.38(0.67,5.81)	0.29(-0.07,0.67)
SD TOCI IV + MTX		1.59(0.48,5.31)	1.41(0.56,3.27)	0.08(-0.11,0.34)

(Continued)

SD CERTO SC + DMARD		1.20(0.34,4.28)	1.15(0.43,3.01)	0.03(-0.18,0.27)
SD ADA SC + DMARD		0.67(0.16,2.64)	0.72(0.21,2.11)	-0.05(-0.24,0.17)
SD ETN SC + DMARD		2.66(0.82,8.47)	1.95(0.87,4.19)	0.19(-0.04,0.45)
LD ADA SC		0.86(0.27,2.82)	0.89(0.35,2.29)	-0.02(-0.22,0.16)
LD GOLIV		0.82(0.24,2.79)	0.86(0.30,2.17)	-0.03(-0.20,0.18)
LD TOCI IV		0.14(0.02,0.66)	0.18(0.03,0.69)	-0.16(-0.34,-0.04)
LD RITUX IV + MTX		1.34(0.52,3.60)	1.25(0.60,2.59)	0.05(-0.11,0.24)
LD ABA IV + MTX		1.56(0.62,4.03)	1.39(0.69,2.81)	0.08(-0.09,0.27)
LD ANA SC + MTX		2.28(0.32,17.50)	1.77(0.40,4.90)	0.16(-0.15,0.60)
LD CERTO SC + MTX		3.11(1.00,9.77)	2.13(1.00,4.41)	0.23(0.00,0.49)
LD ETN SC + MTX		2.44(0.92,6.48)	1.86(0.94,3.60)	0.17(-0.02,0.40)
LD GOLIV + MTX		1.61(0.50,5.06)	1.42(0.58,3.17)	0.08(-0.11,0.34)
LD TOCI IV + MTX		1.34(0.40,4.50)	1.25(0.49,2.99)	0.05(-0.14,0.29)
LD TOFA PO + MTX		2.42(0.62,9.38)	1.84(0.69,4.16)	0.17(-0.08,0.48)
HD TOCI IV		2.13(0.95,4.91)	1.72(0.97,3.35)	0.14(-0.01,0.29)
HD TOFA PO		2.64(0.85,8.04)	1.96(0.89,4.50)	0.20(-0.04,0.41)
HD ADA SC		1.25(0.38,3.93)	1.19(0.48,2.92)	0.04(-0.17,0.24)
HD GOLIV		2.22(0.78,6.08)	1.76(0.84,3.68)	0.15(-0.05,0.36)
HD ETN SC		1.49(0.54,4.17)	1.35(0.62,2.84)	0.07(-0.10,0.28)
HD ABA SC		3.63(0.73,21.55)	2.32(0.79,6.27)	0.27(-0.06,0.63)
HD TOCI IV + MTX		3.69(1.61,8.66)	2.35(1.35,4.50)	0.27(0.11,0.44)
HD TOFA PO + MTX		3.73(1.59,9.16)	2.35(1.34,4.45)	0.28(0.09,0.47)
HD GOLIV SC + MTX		3.92(1.53,10.33)	2.41(1.31,4.76)	0.29(0.09,0.49)
HD CERTO SC + MTX		5.14(2.18,12.37)	2.74(1.57,5.11)	0.36(0.17,0.53)
HD INF IV + MTX		3.15(1.31,7.82)	2.15(1.20,4.07)	0.23(0.05,0.44)
HD TOCI IV + DMARD		0.78(0.23,2.59)	0.82(0.30,2.09)	-0.04(-0.21,0.16)
SD ADA SC	SD ETN SC	0.71(0.30,1.64)	0.77(0.40,1.47)	-0.06(-0.22,0.08)
SD TOFA PO		1.23(0.46,3.30)	1.16(0.57,2.33)	0.04(-0.16,0.24)

(Continued)

SD TOCI IV	0.89(0.35,2.17)	0.91(0.44,1.75)	-0.02(-0.18,0.16)
SD GOLI SC	1.41(0.41,4.61)	1.27(0.51,2.69)	0.07(-0.16,0.34)
SD GOLI IV	1.04(0.35,3.24)	1.03(0.43,2.14)	0.01(-0.17,0.26)
SD ABA SC	1.90(0.39,10.18)	1.53(0.50,3.77)	0.14(-0.16,0.51)
SD CERTO SC	1.80(0.44,7.39)	1.48(0.54,3.40)	0.12(-0.15,0.44)
SD ETN SC + MTX	1.90(1.17,3.13)	1.53(1.11,2.15)	0.14(0.03,0.26)
SD INF IV + MTX	1.68(0.88,3.25)	1.42(0.91,2.20)	0.11(-0.03,0.26)
SD ABA IV + MTX	2.13(1.07,4.27)	1.64(1.04,2.55)	0.16(0.01,0.33)
SD CERTO SC + MTX	3.22(1.60,6.62)	2.03(1.33,3.13)	0.26(0.10,0.43)
SD TOFA PO + MTX	3.48(1.61,7.86)	2.10(1.36,3.31)	0.28(0.10,0.46)
SD GOLI SC + MTX	3.84(1.64,9.05)	2.19(1.35,3.59)	0.31(0.11,0.49)
SD ADA SC + MTX	2.29(0.73,7.27)	1.70(0.79,3.12)	0.18(-0.06,0.45)
SD RITUX IV + MTX	1.20(0.51,2.93)	1.14(0.60,2.05)	0.03(-0.12,0.24)
SD GOLI IV + MTX	1.35(0.57,3.21)	1.23(0.65,2.16)	0.06(-0.10,0.26)
SD ABA SC + MTX	2.29(0.76,7.00)	1.70(0.81,3.09)	0.18(-0.05,0.44)
SD ANA SC + MTX	2.94(0.47,22.26)	1.93(0.55,4.06)	0.24(-0.12,0.62)
SD TOCI IV + MTX	1.19(0.40,3.67)	1.13(0.48,2.31)	0.03(-0.16,0.29)
SD CERTO SC + DMARD	0.89(0.29,2.84)	0.92(0.38,2.08)	-0.02(-0.21,0.21)
SD ADA SC + DMARD	0.50(0.14,1.78)	0.57(0.19,1.50)	-0.10(-0.26,0.11)
SD ETN SC + DMARD	1.99(0.76,5.22)	1.57(0.82,2.68)	0.15(-0.05,0.38)
LD ADA SC	0.65(0.23,1.85)	0.71(0.31,1.59)	-0.07(-0.25,0.11)
LD GOLI IV	0.61(0.20,1.89)	0.68(0.25,1.57)	-0.08(-0.24,0.13)
LD TOCI IV	0.11(0.02,0.46)	0.14(0.03,0.52)	-0.21(-0.36,-0.09)
LD RITUX IV + MTX	1.00(0.42,2.44)	1.00(0.50,1.83)	0.00(-0.15,0.19)
LD ABA IV + MTX	1.16(0.49,2.80)	1.11(0.57,2.01)	0.03(-0.12,0.22)
LD ANA SC + MTX	1.69(0.26,12.73)	1.42(0.33,3.49)	0.11(-0.19,0.55)
LD CERTO SC + MTX	2.33(0.81,6.73)	1.72(0.85,3.04)	0.18(-0.04,0.43)
LD ETN SC + MTX	1.82(0.73,4.61)	1.49(0.79,2.58)	0.12(-0.06,0.35)

(Continued)

LD GOLI IV + MTX		1.19(0.40,3.71)	1.14(0.48,2.29)	0.03(-0.15,0.29)
LD TOCI IV + MTX		1.00(0.34,3.02)	1.00(0.42,2.10)	0.00(-0.18,0.24)
LD TOFA PO + MTX		1.80(0.50,6.60)	1.48(0.59,2.94)	0.12(-0.12,0.42)
HD TOCI IV		1.58(0.84,3.16)	1.37(0.88,2.22)	0.09(-0.04,0.24)
HD TOFA PO		1.97(0.73,5.20)	1.57(0.81,3.04)	0.15(-0.07,0.35)
HD ADA SC		0.92(0.33,2.65)	0.94(0.42,2.05)	-0.01(-0.20,0.19)
HD GOLI SC		1.66(0.65,4.05)	1.41(0.73,2.55)	0.10(-0.09,0.31)
HD ETN SC		1.11(0.48,2.65)	1.08(0.56,1.89)	0.02(-0.12,0.21)
HD ABA SC		2.74(0.60,14.42)	1.87(0.69,4.21)	0.23(-0.10,0.57)
HD TOCI IV + MTX		2.75(1.37,5.68)	1.88(1.22,3.00)	0.23(0.07,0.39)
HD TOFA PO + MTX		2.78(1.31,6.13)	1.89(1.20,3.01)	0.23(0.06,0.41)
HD GOLI SC + MTX		2.95(1.25,7.06)	1.94(1.16,3.24)	0.24(0.05,0.44)
HD CERTO SC + MTX		3.81(1.78,8.36)	2.19(1.42,3.46)	0.31(0.13,0.48)
HD INF IV + MTX		2.34(1.03,5.59)	1.72(1.02,2.86)	0.19(0.01,0.39)
HD TOCI IV + DMARD		0.59(0.20,1.66)	0.66(0.26,1.44)	-0.09(-0.24,0.10)
SD TOFA PO	SD ADA SC	1.74(0.76,4.14)	1.52(0.82,2.83)	0.10(-0.05,0.27)
SD TOCI IV		1.26(0.45,3.46)	1.20(0.53,2.52)	0.04(-0.12,0.23)
SD GOLI SC		2.00(0.55,6.90)	1.66(0.63,3.70)	0.13(-0.09,0.40)
SD GOLI IV		1.48(0.41,5.41)	1.34(0.48,3.20)	0.07(-0.12,0.35)
SD ABA SC		2.70(0.59,14.14)	2.02(0.66,4.83)	0.20(-0.08,0.56)
SD CERTO SC		2.55(0.64,10.19)	1.95(0.71,4.42)	0.18(-0.07,0.49)
SD ETN SC + MTX		2.70(1.11,6.73)	2.02(1.08,3.72)	0.20(0.02,0.39)
SD INF IV + MTX		2.38(0.94,6.12)	1.86(0.95,3.52)	0.17(-0.01,0.37)
SD ABA IV + MTX		3.04(1.15,7.85)	2.15(1.11,4.00)	0.22(0.02,0.43)
SD CERTO SC + MTX		4.60(1.74,11.84)	2.67(1.45,4.75)	0.33(0.11,0.53)
SD TOFA PO + MTX		4.95(1.80,13.82)	2.76(1.48,4.99)	0.35(0.12,0.56)
SD GOLI SC + MTX		5.47(1.97,15.38)	2.88(1.57,5.19)	0.37(0.14,0.58)
SD ADA SC + MTX		3.27(0.87,12.49)	2.23(0.90,4.61)	0.24(-0.02,0.54)

(Continued)

SD RITUX IV + MTX	1.71(0.58,5.26)	1.50(0.65,3.18)	0.10(-0.09,0.34)
SD GOL I IV + MTX	1.92(0.64,5.65)	1.62(0.70,3.34)	0.12(-0.07,0.36)
SD ABA SC + MTX	3.27(0.87,11.74)	2.24(0.90,4.53)	0.24(-0.02,0.53)
SD ANA SC + MTX	4.23(0.60,35.03)	2.55(0.66,5.57)	0.30(-0.07,0.70)
SD TOCI IV + MTX	1.71(0.49,5.80)	1.50(0.56,3.31)	0.10(-0.11,0.36)
SD CERTO SC + DMARD	1.27(0.40,4.21)	1.20(0.47,2.86)	0.04(-0.14,0.28)
SD ADA SC + DMARD	0.71(0.18,2.78)	0.75(0.22,2.15)	-0.05(-0.20,0.19)
SD ETN SC + DMARD	2.82(0.84,9.66)	2.06(0.87,4.20)	0.21(-0.03,0.49)
LD ADA SC	0.92(0.42,1.98)	0.93(0.49,1.70)	-0.01(-0.12,0.12)
LD GOL I IV	0.87(0.23,3.20)	0.89(0.28,2.36)	-0.02(-0.18,0.22)
LD TOCI IV	0.15(0.03,0.70)	0.19(0.04,0.74)	-0.15(-0.27,-0.04)
LD RITUX IV + MTX	1.42(0.48,4.34)	1.31(0.55,2.87)	0.06(-0.11,0.29)
LD ABA IV + MTX	1.65(0.55,4.88)	1.46(0.62,3.08)	0.09(-0.09,0.32)
LD ANA SC + MTX	2.39(0.32,20.29)	1.86(0.39,4.88)	0.17(-0.14,0.63)
LD CERTO SC + MTX	3.31(0.95,11.76)	2.26(0.96,4.52)	0.25(-0.01,0.53)
LD ETN SC + MTX	2.58(0.81,8.33)	1.96(0.84,3.93)	0.19(-0.04,0.45)
LD GOL I IV + MTX	1.71(0.48,6.04)	1.49(0.55,3.40)	0.10(-0.11,0.37)
LD TOCI IV + MTX	1.43(0.43,4.62)	1.32(0.50,2.95)	0.06(-0.12,0.31)
LD TOFA PO + MTX	2.54(0.60,10.95)	1.94(0.67,4.29)	0.18(-0.08,0.51)
HD TOCI IV	2.26(1.07,4.69)	1.81(1.05,3.07)	0.16(0.01,0.31)
HD TOFA PO	2.80(1.21,6.50)	2.06(1.14,3.67)	0.21(0.04,0.39)
HD ADA SC	1.32(0.62,2.79)	1.24(0.68,2.15)	0.05(-0.07,0.19)
HD GOL I SC	2.34(0.84,6.67)	1.84(0.87,3.71)	0.17(-0.03,0.39)
HD ETN SC	1.58(0.50,4.94)	1.41(0.57,3.07)	0.08(-0.11,0.32)
HD ABA SC	3.89(0.85,20.41)	2.46(0.89,5.43)	0.29(-0.03,0.63)
HD TOCI IV + MTX	3.92(1.62,9.54)	2.47(1.38,4.38)	0.29(0.10,0.48)
HD TOFA PO + MTX	3.95(1.45,11.00)	2.48(1.30,4.54)	0.29(0.07,0.51)
HD GOL I SC + MTX	4.17(1.48,12.15)	2.55(1.32,4.76)	0.31(0.08,0.53)

(Continued)

HD CERTO SC + MTX		5.46(1.94,15.08)	2.87(1.55,5.11)	0.37(0.14,0.58)
HD INF IV + MTX		3.36(1.12,9.87)	2.28(1.09,4.36)	0.25(0.02,0.49)
HD TOCI IV + DMARD		0.83(0.25,2.67)	0.86(0.30,2.11)	-0.03(-0.18,0.18)
SD TOCI IV	SD TOFA PO	0.72(0.23,2.22)	0.78(0.33,1.76)	-0.06(-0.27,0.16)
SD GOLI SC		1.13(0.30,4.41)	1.09(0.42,2.50)	0.03(-0.23,0.33)
SD GOLI IV		0.86(0.21,3.25)	0.90(0.30,2.11)	-0.03(-0.27,0.26)
SD ABA SC		1.53(0.32,8.07)	1.32(0.43,3.11)	0.09(-0.21,0.47)
SD CERTO SC		1.45(0.36,5.84)	1.28(0.48,2.83)	0.08(-0.20,0.40)
SD ETN SC + MTX		1.54(0.55,4.24)	1.32(0.67,2.58)	0.10(-0.13,0.32)
SD INF IV + MTX		1.36(0.46,3.95)	1.22(0.59,2.42)	0.07(-0.16,0.30)
SD ABA IV + MTX		1.74(0.58,5.05)	1.42(0.69,2.74)	0.12(-0.12,0.36)
SD CERTO SC + MTX		2.63(0.85,7.68)	1.76(0.91,3.24)	0.23(-0.04,0.46)
SD TOFA PO + MTX		2.83(0.89,9.18)	1.81(0.93,3.40)	0.24(-0.03,0.50)
SD GOLI SC + MTX		3.13(0.99,9.62)	1.90(0.99,3.49)	0.27(0.00,0.50)
SD ADA SC + MTX		1.87(0.44,7.68)	1.47(0.56,3.11)	0.14(-0.17,0.46)
SD RITUX IV + MTX		0.98(0.29,3.30)	0.98(0.40,2.19)	0.00(-0.24,0.26)
SD GOLI IV + MTX		1.10(0.33,3.54)	1.06(0.45,2.25)	0.02(-0.22,0.28)
SD ABA SC + MTX		1.88(0.45,7.52)	1.48(0.57,3.09)	0.14(-0.16,0.46)
SD ANA SC + MTX		2.42(0.31,21.34)	1.68(0.41,3.78)	0.21(-0.21,0.62)
SD TOCI IV + MTX		0.97(0.25,3.75)	0.98(0.35,2.31)	-0.01(-0.25,0.30)
SD CERTO SC + DMARD		0.72(0.21,2.59)	0.79(0.31,1.91)	-0.06(-0.28,0.20)
SD ADA SC + DMARD		0.40(0.09,1.78)	0.49(0.14,1.50)	-0.15(-0.35,0.12)
SD ETN SC + DMARD		1.61(0.44,6.20)	1.35(0.56,2.86)	0.10(-0.17,0.41)
LD ADA SC		0.53(0.18,1.51)	0.61(0.27,1.36)	-0.11(-0.30,0.08)
LD GOLI IV		0.50(0.12,1.92)	0.59(0.18,1.58)	-0.12(-0.33,0.14)
LD TOCI IV		0.09(0.01,0.42)	0.12(0.02,0.49)	-0.25(-0.43,-0.11)
LD RITUX IV + MTX		0.82(0.24,2.76)	0.87(0.34,1.97)	-0.04(-0.26,0.22)
LD ABA IV + MTX		0.95(0.28,3.09)	0.96(0.39,2.12)	-0.01(-0.24,0.25)

(Continued)

LD ANA SC + MTX	1.37(0.17,12.35)	1.23(0.25,3.38)	0.07(-0.28,0.55)
LD CERTO SC + MTX	1.90(0.48,7.42)	1.49(0.60,3.09)	0.14(-0.15,0.45)
LD ETN SC + MTX	1.47(0.41,5.25)	1.29(0.53,2.71)	0.08(-0.18,0.37)
LD GOLI IV + MTX	0.98(0.25,3.70)	0.99(0.35,2.27)	0.00(-0.25,0.29)
LD TOCI IV + MTX	0.82(0.21,3.06)	0.87(0.31,2.07)	-0.04(-0.27,0.25)
LD TOFA PO + MTX	1.44(0.31,6.91)	1.27(0.41,2.98)	0.08(-0.22,0.44)
HD TOCI IV	1.30(0.50,3.33)	1.19(0.64,2.27)	0.06(-0.15,0.26)
HD TOFA PO	1.60(0.88,2.96)	1.35(0.92,2.05)	0.10(-0.03,0.24)
HD ADA SC	0.75(0.27,2.15)	0.81(0.38,1.71)	-0.05(-0.25,0.16)
HD GOLI SC	1.34(0.42,4.06)	1.22(0.55,2.47)	0.06(-0.18,0.31)
HD ETN SC	0.90(0.26,3.17)	0.93(0.37,2.13)	-0.02(-0.25,0.25)
HD ABA SC	2.21(0.46,11.37)	1.61(0.58,3.50)	0.18(-0.16,0.53)
HD TOCI IV + MTX	2.24(0.79,6.42)	1.63(0.87,3.05)	0.19(-0.05,0.42)
HD TOFA PO + MTX	2.24(0.70,7.22)	1.63(0.79,3.12)	0.19(-0.08,0.45)
HD GOLI SC + MTX	2.38(0.74,7.39)	1.67(0.83,3.19)	0.20(-0.07,0.45)
HD CERTO SC + MTX	3.15(0.98,9.47)	1.91(0.99,3.46)	0.27(-0.01,0.50)
HD INF IV + MTX	1.92(0.56,6.18)	1.50(0.68,2.93)	0.15(-0.12,0.41)
HD TOCI IV + DMARD	0.47(0.13,1.67)	0.56(0.19,1.45)	-0.13(-0.33,0.10)
SD GOLI SC	SD TOCI IV 1.58(0.41,6.09)	1.38(0.51,3.54)	0.09(-0.17,0.37)
SD GOLI IV	1.18(0.32,4.30)	1.13(0.41,2.74)	0.03(-0.19,0.30)
SD ABA SC	2.18(0.40,12.62)	1.68(0.50,4.73)	0.16(-0.17,0.54)
SD CERTO SC	2.05(0.43,9.44)	1.63(0.55,4.26)	0.15(-0.16,0.47)
SD ETN SC + MTX	2.13(0.85,5.52)	1.67(0.90,3.42)	0.16(-0.03,0.34)
SD INF IV + MTX	1.90(0.75,4.83)	1.56(0.82,3.13)	0.13(-0.06,0.32)
SD ABA IV + MTX	2.42(0.93,6.29)	1.79(0.95,3.60)	0.19(-0.02,0.38)
SD CERTO SC + MTX	3.63(1.44,9.57)	2.22(1.24,4.41)	0.28(0.08,0.48)
SD TOFA PO + MTX	3.95(1.45,11.20)	2.29(1.25,4.69)	0.30(0.08,0.51)
SD GOLI SC + MTX	4.34(1.52,12.39)	2.40(1.28,4.92)	0.33(0.10,0.53)

(Continued)

SD ADA SC + MTX	2.62(0.68,9.67)	1.87(0.76,4.13)	0.20(-0.07,0.49)
SD RITUX IV + MTX	1.36(0.46,4.08)	1.25(0.56,2.77)	0.06(-0.15,0.29)
SD GOL I IV + MTX	1.53(0.51,4.48)	1.35(0.61,2.92)	0.08(-0.13,0.30)
SD ABA SC + MTX	2.60(0.71,9.32)	1.86(0.78,4.17)	0.20(-0.07,0.48)
SD ANA SC + MTX	3.39(0.46,28.16)	2.10(0.56,5.23)	0.26(-0.12,0.66)
SD TOCI IV + MTX	1.35(0.46,4.03)	1.24(0.54,2.65)	0.06(-0.14,0.29)
SD CERTO SC + DMARD	1.01(0.27,3.77)	1.01(0.37,2.68)	0.00(-0.22,0.25)
SD ADA SC + DMARD	0.56(0.14,2.28)	0.63(0.19,1.89)	-0.08(-0.29,0.15)
SD ETN SC + DMARD	2.22(0.64,8.05)	1.71(0.72,3.94)	0.16(-0.09,0.44)
LD ADA SC	0.73(0.22,2.48)	0.78(0.31,2.06)	-0.05(-0.26,0.15)
LD GOL I IV	0.69(0.18,2.61)	0.75(0.25,2.04)	-0.06(-0.26,0.18)
LD TOCI IV	0.12(0.02,0.52)	0.16(0.03,0.57)	-0.19(-0.37,-0.07)
LD RITUX IV + MTX	1.13(0.37,3.40)	1.10(0.47,2.45)	0.02(-0.17,0.24)
LD ABA IV + MTX	1.32(0.44,3.93)	1.22(0.54,2.70)	0.05(-0.16,0.27)
LD ANA SC + MTX	1.90(0.25,16.32)	1.55(0.33,4.45)	0.13(-0.20,0.58)
LD CERTO SC + MTX	2.63(0.76,9.00)	1.87(0.83,4.07)	0.20(-0.05,0.48)
LD ETN SC + MTX	2.03(0.63,6.68)	1.62(0.72,3.59)	0.14(-0.09,0.40)
LD GOL I IV + MTX	1.36(0.38,4.95)	1.25(0.47,3.02)	0.06(-0.17,0.33)
LD TOCI IV + MTX	1.13(0.38,3.33)	1.10(0.46,2.37)	0.02(-0.17,0.24)
LD TOFA PO + MTX	2.01(0.49,8.77)	1.61(0.58,3.97)	0.14(-0.13,0.47)
HD TOCI IV	1.80(0.84,3.86)	1.51(0.90,2.80)	0.12(-0.04,0.26)
HD TOFA PO	2.23(0.72,6.85)	1.72(0.81,3.95)	0.17(-0.07,0.38)
HD ADA SC	1.05(0.31,3.42)	1.04(0.41,2.58)	0.01(-0.22,0.22)
HD GOL I SC	1.87(0.61,5.68)	1.54(0.71,3.46)	0.12(-0.10,0.35)
HD ETN SC	1.25(0.39,4.10)	1.18(0.49,2.75)	0.04(-0.17,0.28)
HD ABA SC	3.14(0.60,18.06)	2.05(0.69,5.37)	0.25(-0.10,0.61)
HD TOCI IV + MTX	3.11(1.37,7.40)	2.06(1.21,3.96)	0.25(0.07,0.42)
HD TOFA PO + MTX	3.14(1.15,8.96)	2.06(1.10,4.26)	0.25(0.03,0.47)

(Continued)

HD GOLI SC + MTX		3.30(1.14,9.73)	2.11(1.08,4.46)	0.26(0.03,0.48)
HD CERTO SC + MTX		4.34(1.62,12.05)	2.39(1.32,4.83)	0.33(0.11,0.53)
HD INF IV + MTX		2.66(0.94,7.79)	1.88(0.96,3.94)	0.21(-0.01,0.43)
HD TOCI IV + DMARD		0.66(0.19,2.27)	0.72(0.26,1.88)	-0.06(-0.26,0.14)
SD GOLI IV	SD GOLI SC	0.74(0.16,3.46)	0.81(0.27,2.34)	-0.06(-0.36,0.26)
SD ABA SC		1.35(0.22,9.27)	1.21(0.36,3.71)	0.07(-0.31,0.48)
SD CERTO SC		1.30(0.24,6.31)	1.18(0.39,3.22)	0.06(-0.31,0.40)
SD ETN SC + MTX		1.36(0.40,4.70)	1.21(0.59,2.91)	0.07(-0.21,0.32)
SD INF IV + MTX		1.20(0.34,4.27)	1.12(0.53,2.72)	0.04(-0.24,0.30)
SD ABA IV + MTX		1.52(0.44,5.38)	1.29(0.62,3.11)	0.10(-0.19,0.36)
SD CERTO SC + MTX		2.27(0.66,8.08)	1.59(0.81,3.75)	0.19(-0.10,0.45)
SD TOFA PO + MTX		2.48(0.67,9.64)	1.65(0.81,3.93)	0.21(-0.10,0.49)
SD GOLI SC + MTX		2.73(0.81,9.24)	1.73(0.90,3.88)	0.23(-0.05,0.48)
SD ADA SC + MTX		1.63(0.36,7.86)	1.34(0.51,3.51)	0.11(-0.22,0.45)
SD RITUX IV + MTX		0.86(0.22,3.33)	0.90(0.36,2.32)	-0.03(-0.32,0.25)
SD GOLI IV + MTX		0.95(0.25,3.77)	0.97(0.39,2.50)	-0.01(-0.30,0.28)
SD ABA SC + MTX		1.63(0.35,7.65)	1.34(0.52,3.42)	0.11(-0.23,0.44)
SD ANA SC + MTX		2.10(0.26,20.11)	1.51(0.38,4.26)	0.17(-0.27,0.61)
SD TOCI IV + MTX		0.86(0.19,3.78)	0.90(0.32,2.46)	-0.03(-0.34,0.28)
SD CERTO SC + DMARD		0.64(0.14,2.84)	0.73(0.26,2.10)	-0.09(-0.39,0.20)
SD ADA SC + DMARD		0.35(0.07,1.89)	0.45(0.12,1.61)	-0.17(-0.45,0.12)
SD ETN SC + DMARD		1.41(0.32,6.53)	1.24(0.49,3.31)	0.08(-0.25,0.41)
LD ADA SC		0.46(0.12,1.84)	0.56(0.22,1.60)	-0.14(-0.43,0.10)
LD GOLI IV		0.44(0.09,2.02)	0.54(0.16,1.68)	-0.14(-0.43,0.13)
LD TOCI IV		0.08(0.01,0.44)	0.11(0.02,0.51)	-0.28(-0.55,-0.09)
LD RITUX IV + MTX		0.71(0.18,2.83)	0.79(0.31,2.08)	-0.07(-0.35,0.21)
LD ABA IV + MTX		0.82(0.21,3.22)	0.88(0.35,2.29)	-0.04(-0.32,0.24)
LD ANA SC + MTX		1.20(0.14,11.81)	1.12(0.23,3.63)	0.04(-0.35,0.53)

(Continued)

LD CERTO SC + MTX		1.65(0.38,7.43)	1.35(0.54,3.42)	0.11(-0.21,0.44)
LD ETN SC + MTX		1.29(0.31,5.46)	1.17(0.48,2.98)	0.06(-0.26,0.36)
LD GOLI IV + MTX		0.85(0.19,3.97)	0.89(0.31,2.52)	-0.03(-0.33,0.29)
LD TOCI IV + MTX		0.72(0.16,3.22)	0.79(0.27,2.23)	-0.07(-0.36,0.24)
LD TOFA PO + MTX		1.28(0.25,6.87)	1.16(0.39,3.21)	0.05(-0.29,0.42)
HD TOCI IV		1.13(0.35,3.78)	1.09(0.54,2.60)	0.03(-0.25,0.26)
HD TOFA PO		1.40(0.38,5.44)	1.24(0.58,3.18)	0.08(-0.23,0.35)
HD ADA SC		0.66(0.17,2.65)	0.75(0.30,2.07)	-0.08(-0.37,0.18)
HD GOLI SC		1.17(0.44,3.25)	1.10(0.60,2.31)	0.03(-0.19,0.25)
HD ETN SC		0.79(0.19,3.21)	0.85(0.32,2.30)	-0.05(-0.34,0.24)
HD ABA SC		1.92(0.33,13.06)	1.46(0.50,4.21)	0.15(-0.24,0.55)
HD TOCI IV + MTX		1.97(0.58,7.18)	1.48(0.75,3.55)	0.16(-0.13,0.42)
HD TOFA PO + MTX		1.96(0.53,7.70)	1.48(0.70,3.59)	0.16(-0.15,0.44)
HD GOLI SC + MTX		2.07(0.63,7.23)	1.52(0.78,3.53)	0.17(-0.11,0.43)
HD CERTO SC + MTX		2.74(0.77,9.95)	1.73(0.88,4.05)	0.24(-0.06,0.50)
HD INF IV + MTX		1.69(0.45,6.56)	1.36(0.62,3.34)	0.12(-0.19,0.41)
HD TOCI IV + DMARD		0.42(0.10,1.83)	0.52(0.17,1.57)	-0.15(-0.44,0.11)
SD ABA SC	SD GOLI IV	1.83(0.28,12.96)	1.48(0.42,5.16)	0.13(-0.26,0.53)
SD CERTO SC		1.72(0.32,9.36)	1.43(0.47,4.59)	0.11(-0.24,0.46)
SD ETN SC + MTX		1.83(0.59,5.58)	1.49(0.74,3.61)	0.13(-0.12,0.33)
SD INF IV + MTX		1.61(0.53,4.83)	1.38(0.68,3.31)	0.10(-0.15,0.30)
SD ABA IV + MTX		2.05(0.68,6.20)	1.59(0.80,3.84)	0.15(-0.09,0.36)
SD CERTO SC + MTX		3.09(1.01,9.42)	1.97(1.00,4.70)	0.25(0.00,0.46)
SD TOFA PO + MTX		3.36(1.09,10.84)	2.04(1.05,4.86)	0.27(0.02,0.50)
SD GOLI SC + MTX		3.67(1.06,12.65)	2.12(1.03,5.34)	0.29(0.01,0.52)
SD ADA SC + MTX		2.23(0.53,8.94)	1.65(0.66,4.26)	0.17(-0.14,0.47)
SD RITUX IV + MTX		1.16(0.35,4.00)	1.11(0.49,2.81)	0.03(-0.22,0.26)
SD GOLI IV + MTX		1.29(0.49,3.47)	1.19(0.63,2.56)	0.05(-0.15,0.24)

(Continued)

SD ABA SC + MTX	2.20(0.55,9.17)	1.64(0.68,4.41)	0.17(-0.13,0.46)
SD ANA SC + MTX	2.86(0.37,25.79)	1.85(0.49,5.45)	0.23(-0.19,0.65)
SD TOCI IV + MTX	1.15(0.27,4.96)	1.11(0.40,3.17)	0.03(-0.27,0.31)
SD CERTO SC + DMARD	0.87(0.19,3.86)	0.90(0.31,2.80)	-0.03(-0.33,0.24)
SD ADA SC + DMARD	0.48(0.10,2.36)	0.56(0.15,1.90)	-0.11(-0.40,0.15)
SD ETN SC + DMARD	1.91(0.44,8.10)	1.52(0.58,4.19)	0.13(-0.18,0.43)
LD ADA SC	0.62(0.15,2.60)	0.70(0.25,2.16)	-0.08(-0.37,0.15)
LD GOL I IV	0.59(0.20,1.75)	0.67(0.28,1.54)	-0.08(-0.29,0.10)
LD TOCI IV	0.11(0.01,0.56)	0.14(0.02,0.61)	-0.22(-0.49,-0.05)
LD RITUX IV + MTX	0.96(0.28,3.30)	0.97(0.41,2.47)	-0.01(-0.26,0.22)
LD ABA IV + MTX	1.12(0.32,3.89)	1.08(0.46,2.80)	0.02(-0.24,0.25)
LD ANA SC + MTX	1.63(0.20,14.91)	1.38(0.29,4.58)	0.10(-0.27,0.57)
LD CERTO SC + MTX	2.23(0.55,8.94)	1.66(0.69,4.28)	0.17(-0.13,0.46)
LD ETN SC + MTX	1.74(0.46,6.35)	1.44(0.62,3.66)	0.11(-0.17,0.38)
LD GOL I IV + MTX	1.15(0.41,3.30)	1.10(0.53,2.41)	0.03(-0.18,0.24)
LD TOCI IV + MTX	0.97(0.23,3.94)	0.97(0.35,2.76)	-0.01(-0.28,0.26)
LD TOFA PO + MTX	1.74(0.38,8.13)	1.43(0.51,3.92)	0.11(-0.20,0.44)
HD TOCI IV	1.53(0.49,4.82)	1.34(0.66,3.34)	0.09(-0.17,0.28)
HD TOFA PO	1.88(0.49,7.57)	1.51(0.67,4.29)	0.14(-0.17,0.39)
HD ADA SC	0.90(0.21,3.79)	0.93(0.34,2.80)	-0.02(-0.33,0.22)
HD GOL I SC	1.59(0.44,5.81)	1.36(0.60,3.66)	0.09(-0.19,0.34)
HD ETN SC	1.06(0.29,3.92)	1.04(0.43,2.77)	0.01(-0.26,0.26)
HD ABA SC	2.64(0.42,18.45)	1.81(0.57,5.79)	0.21(-0.19,0.60)
HD TOCI IV + MTX	2.65(0.83,8.23)	1.83(0.91,4.49)	0.21(-0.04,0.43)
HD TOFA PO + MTX	2.68(0.86,8.46)	1.83(0.92,4.35)	0.21(-0.04,0.44)
HD GOL I SC + MTX	2.81(0.81,9.90)	1.88(0.90,4.77)	0.23(-0.05,0.47)
HD CERTO SC + MTX	3.70(1.18,11.73)	2.13(1.08,5.12)	0.29(0.04,0.51)
HD INF IV + MTX	2.26(0.65,7.75)	1.67(0.78,4.19)	0.17(-0.10,0.42)

(Continued)

HD TOCI IV + DMARD		0.56(0.13,2.32)	0.64(0.21,1.96)	-0.09(-0.38,0.13)
SD CERTO SC	SD ABA SC	0.94(0.13,5.99)	0.96(0.32,3.09)	-0.02(-0.44,0.39)
SD ETN SC + MTX		1.01(0.18,4.82)	1.01(0.42,2.96)	0.00(-0.39,0.33)
SD INF IV + MTX		0.88(0.16,4.45)	0.93(0.37,2.84)	-0.03(-0.42,0.30)
SD ABA IV + MTX		1.13(0.19,5.78)	1.07(0.44,3.23)	0.03(-0.38,0.37)
SD CERTO SC + MTX		1.70(0.29,8.79)	1.33(0.57,3.95)	0.13(-0.29,0.46)
SD TOFA PO + MTX		1.84(0.29,10.11)	1.37(0.57,4.11)	0.15(-0.29,0.50)
SD GOLI SC + MTX		2.00(0.34,11.30)	1.42(0.63,4.22)	0.17(-0.25,0.52)
SD ADA SC + MTX		1.20(0.17,7.97)	1.11(0.37,3.53)	0.04(-0.40,0.45)
SD RITUX IV + MTX		0.63(0.10,3.75)	0.74(0.26,2.54)	-0.10(-0.49,0.26)
SD GOLI IV + MTX		0.71(0.12,3.96)	0.80(0.28,2.60)	-0.08(-0.48,0.28)
SD ABA SC + MTX		1.21(0.16,7.70)	1.11(0.37,3.47)	0.04(-0.41,0.44)
SD ANA SC + MTX		1.55(0.13,19.67)	1.25(0.29,4.21)	0.10(-0.43,0.60)
SD TOCI IV + MTX		0.63(0.09,3.71)	0.75(0.23,2.50)	-0.10(-0.51,0.28)
SD CERTO SC + DMARD		0.47(0.08,2.70)	0.60(0.21,2.06)	-0.15(-0.54,0.19)
SD ADA SC + DMARD		0.26(0.04,1.81)	0.38(0.09,1.55)	-0.24(-0.62,0.11)
SD ETN SC + DMARD		1.02(0.16,6.39)	1.01(0.36,3.22)	0.00(-0.41,0.41)
LD ADA SC		0.34(0.06,1.80)	0.46(0.17,1.57)	-0.21(-0.59,0.10)
LD GOLI IV		0.32(0.04,2.08)	0.45(0.12,1.71)	-0.21(-0.60,0.14)
LD TOCI IV		0.06(0.01,0.45)	0.09(0.01,0.51)	-0.35(-0.70,-0.08)
LD RITUX IV + MTX		0.52(0.09,3.10)	0.65(0.22,2.26)	-0.14(-0.52,0.22)
LD ABA IV + MTX		0.61(0.10,3.44)	0.73(0.25,2.41)	-0.10(-0.50,0.24)
LD ANA SC + MTX		0.88(0.07,11.24)	0.93(0.16,3.56)	-0.03(-0.51,0.52)
LD CERTO SC + MTX		1.23(0.18,7.57)	1.12(0.40,3.51)	0.05(-0.39,0.44)
LD ETN SC + MTX		0.95(0.15,5.58)	0.97(0.34,3.10)	-0.01(-0.43,0.37)
LD GOLI IV + MTX		0.63(0.09,3.98)	0.75(0.23,2.54)	-0.10(-0.51,0.29)
LD TOCI IV + MTX		0.52(0.08,3.21)	0.65(0.20,2.27)	-0.13(-0.53,0.24)
LD TOFA PO + MTX		0.95(0.12,6.83)	0.97(0.27,3.23)	-0.01(-0.45,0.42)

(Continued)

HD TOCI IV		0.83(0.16,4.00)	0.89(0.39,2.68)	-0.04(-0.42,0.27)
HD TOFA PO		1.04(0.20,4.89)	1.03(0.46,3.00)	0.01(-0.37,0.33)
HD ADA SC		0.48(0.09,2.52)	0.61(0.23,2.00)	-0.15(-0.53,0.17)
HD GOLI SC		0.87(0.15,4.66)	0.92(0.36,2.90)	-0.03(-0.44,0.31)
HD ETN SC		0.58(0.09,3.39)	0.70(0.24,2.36)	-0.12(-0.51,0.24)
HD ABA SC		1.44(0.48,4.29)	1.20(0.65,2.44)	0.08(-0.17,0.33)
HD TOCI IV + MTX		1.45(0.26,7.48)	1.22(0.54,3.66)	0.09(-0.31,0.42)
HD TOFA PO + MTX		1.47(0.24,8.02)	1.23(0.50,3.68)	0.09(-0.33,0.45)
HD GOLI SC + MTX		1.55(0.25,8.58)	1.26(0.52,3.83)	0.10(-0.32,0.46)
HD CERTO SC + MTX		2.03(0.34,10.70)	1.43(0.64,4.20)	0.17(-0.25,0.51)
HD INF IV + MTX		1.24(0.20,6.94)	1.13(0.44,3.45)	0.05(-0.37,0.42)
HD TOCI IV + DMARD		0.30(0.05,1.86)	0.43(0.13,1.60)	-0.22(-0.60,0.11)
SD ETN SC + MTX	SD CERTO SC	1.06(0.25,4.54)	1.03(0.47,2.76)	0.01(-0.32,0.32)
SD INF IV + MTX		0.93(0.21,4.09)	0.96(0.42,2.58)	-0.02(-0.36,0.29)
SD ABA IV + MTX		1.19(0.27,5.16)	1.11(0.49,2.90)	0.04(-0.31,0.35)
SD CERTO SC + MTX		1.80(0.40,7.80)	1.37(0.63,3.49)	0.14(-0.22,0.45)
SD TOFA PO + MTX		1.95(0.42,9.15)	1.42(0.65,3.65)	0.16(-0.21,0.48)
SD GOLI SC + MTX		2.12(0.48,9.77)	1.47(0.71,3.77)	0.18(-0.17,0.49)
SD ADA SC + MTX		1.27(0.23,7.50)	1.15(0.41,3.19)	0.06(-0.33,0.45)
SD RITUX IV + MTX		0.67(0.14,3.26)	0.77(0.29,2.24)	-0.09(-0.43,0.25)
SD GOLI IV + MTX		0.75(0.16,3.52)	0.83(0.32,2.32)	-0.06(-0.40,0.26)
SD ABA SC + MTX		1.27(0.23,7.04)	1.15(0.41,3.12)	0.06(-0.33,0.43)
SD ANA SC + MTX		1.64(0.18,18.45)	1.29(0.32,3.87)	0.11(-0.36,0.59)
SD TOCI IV + MTX		0.66(0.12,3.66)	0.77(0.26,2.35)	-0.09(-0.44,0.28)
SD CERTO SC + DMARD		0.50(0.10,2.51)	0.62(0.22,1.90)	-0.14(-0.47,0.18)
SD ADA SC + DMARD		0.28(0.05,1.65)	0.39(0.10,1.42)	-0.22(-0.55,0.10)
SD ETN SC + DMARD		1.10(0.21,5.81)	1.06(0.39,3.00)	0.02(-0.36,0.39)
LD ADA SC		0.36(0.08,1.59)	0.48(0.18,1.42)	-0.20(-0.51,0.08)

(Continued)

LD GOLI IV		0.34(0.06,1.86)	0.46(0.13,1.57)	-0.20(-0.52,0.12)
LD TOCI IV		0.06(0.01,0.42)	0.10(0.02,0.49)	-0.34(-0.64,-0.09)
LD RITUX IV + MTX		0.56(0.11,2.76)	0.68(0.24,2.04)	-0.12(-0.46,0.20)
LD ABA IV + MTX		0.64(0.13,3.13)	0.75(0.28,2.21)	-0.09(-0.44,0.24)
LD ANA SC + MTX		0.93(0.10,10.84)	0.96(0.19,3.34)	-0.01(-0.44,0.51)
LD CERTO SC + MTX		1.30(0.24,6.79)	1.16(0.43,3.15)	0.06(-0.32,0.43)
LD ETN SC + MTX		1.01(0.20,5.38)	1.00(0.38,2.87)	0.00(-0.36,0.37)
LD GOLI IV + MTX		0.67(0.13,3.52)	0.77(0.26,2.31)	-0.09(-0.43,0.27)
LD TOCI IV + MTX		0.56(0.11,2.98)	0.68(0.22,2.08)	-0.12(-0.46,0.23)
LD TOFA PO + MTX		1.00(0.16,6.21)	1.00(0.30,3.00)	0.00(-0.39,0.41)
HD TOCI IV		0.89(0.22,3.58)	0.93(0.43,2.46)	-0.03(-0.35,0.26)
HD TOFA PO		1.09(0.27,4.37)	1.06(0.50,2.71)	0.02(-0.31,0.31)
HD ADA SC		0.52(0.12,2.29)	0.64(0.26,1.83)	-0.14(-0.46,0.16)
HD GOLI SC		0.92(0.21,4.03)	0.95(0.41,2.57)	-0.02(-0.36,0.30)
HD ETN SC		0.62(0.13,3.05)	0.73(0.26,2.17)	-0.10(-0.44,0.23)
HD ABA SC		1.53(0.24,10.61)	1.26(0.43,3.62)	0.10(-0.32,0.51)
HD TOCI IV + MTX		1.55(0.36,6.66)	1.27(0.60,3.26)	0.10(-0.25,0.41)
HD TOFA PO + MTX		1.55(0.33,7.27)	1.28(0.56,3.34)	0.10(-0.26,0.43)
HD GOLI SC + MTX		1.63(0.37,7.55)	1.31(0.59,3.41)	0.11(-0.24,0.44)
HD CERTO SC + MTX		2.15(0.47,9.77)	1.48(0.69,3.75)	0.18(-0.18,0.50)
HD INF IV + MTX		1.31(0.28,6.39)	1.17(0.49,3.18)	0.06(-0.30,0.40)
HD TOCI IV + DMARD		0.32(0.06,1.61)	0.44(0.14,1.43)	-0.21(-0.53,0.09)
SD INF IV + MTX	SD ETN SC + MTX	0.88(0.49,1.63)	0.93(0.63,1.35)	-0.03(-0.16,0.11)
SD ABA IV + MTX		1.12(0.57,2.21)	1.07(0.71,1.58)	0.03(-0.13,0.19)
SD CERTO SC + MTX		1.69(0.85,3.36)	1.32(0.92,1.92)	0.13(-0.04,0.29)
SD TOFA PO + MTX		1.82(0.87,4.08)	1.36(0.92,2.06)	0.14(-0.03,0.33)
SD GOLI SC + MTX		2.01(0.87,4.73)	1.42(0.93,2.23)	0.17(-0.04,0.36)
SD ADA SC + MTX		1.21(0.39,3.85)	1.11(0.52,1.95)	0.04(-0.20,0.32)

(Continued)

SD RITUX IV + MTX	0.63(0.27,1.51)	0.74(0.40,1.28)	-0.10(-0.27,0.10)
SD GOLI IV + MTX	0.71(0.30,1.68)	0.80(0.43,1.36)	-0.08(-0.26,0.12)
SD ABA SC + MTX	1.20(0.40,3.63)	1.11(0.54,1.92)	0.04(-0.19,0.30)
SD ANA SC + MTX	1.55(0.25,11.52)	1.26(0.37,2.55)	0.10(-0.26,0.49)
SD TOCI IV + MTX	0.63(0.21,1.91)	0.74(0.31,1.47)	-0.10(-0.31,0.15)
SD CERTO SC + DMARD	0.47(0.15,1.57)	0.60(0.25,1.34)	-0.16(-0.38,0.10)
SD ADA SC + DMARD	0.26(0.07,0.98)	0.38(0.12,0.98)	-0.24(-0.43,-0.01)
SD ETN SC + DMARD	1.04(0.36,3.03)	1.02(0.51,1.78)	0.01(-0.22,0.26)
LD ADA SC	0.34(0.11,1.02)	0.46(0.21,1.01)	-0.21(-0.42,0.00)
LD GOLI IV	0.32(0.10,0.99)	0.45(0.16,1.00)	-0.21(-0.40,0.00)
LD TOCI IV	0.06(0.01,0.24)	0.09(0.02,0.34)	-0.35(-0.53,-0.19)
LD RITUX IV + MTX	0.52(0.22,1.26)	0.65(0.34,1.15)	-0.13(-0.30,0.05)
LD ABA IV + MTX	0.61(0.26,1.46)	0.73(0.38,1.25)	-0.10(-0.28,0.09)
LD ANA SC + MTX	0.88(0.14,6.69)	0.93(0.22,2.20)	-0.03(-0.34,0.42)
LD CERTO SC + MTX	1.22(0.42,3.50)	1.12(0.56,1.90)	0.05(-0.19,0.29)
LD ETN SC + MTX	0.96(0.41,2.27)	0.97(0.54,1.55)	-0.01(-0.19,0.20)
LD GOLI IV + MTX	0.63(0.21,1.86)	0.74(0.32,1.41)	-0.10(-0.31,0.14)
LD TOCI IV + MTX	0.53(0.18,1.61)	0.65(0.28,1.34)	-0.13(-0.34,0.11)
LD TOFA PO + MTX	0.94(0.26,3.45)	0.96(0.38,1.84)	-0.01(-0.27,0.29)
HD TOCI IV	0.83(0.43,1.70)	0.89(0.60,1.41)	-0.04(-0.20,0.12)
HD TOFA PO	1.04(0.37,2.90)	1.02(0.56,1.91)	0.01(-0.23,0.25)
HD ADA SC	0.49(0.16,1.46)	0.62(0.29,1.29)	-0.15(-0.37,0.08)
HD GOLI SC	0.87(0.34,2.20)	0.92(0.50,1.60)	-0.03(-0.24,0.18)
HD ETN SC	0.58(0.24,1.46)	0.70(0.35,1.25)	-0.12(-0.29,0.09)
HD ABA SC	1.42(0.30,7.84)	1.21(0.46,2.66)	0.08(-0.26,0.46)
HD TOCI IV + MTX	1.45(0.72,3.01)	1.22(0.83,1.87)	0.09(-0.08,0.26)
HD TOFA PO + MTX	1.46(0.69,3.19)	1.23(0.80,1.86)	0.09(-0.09,0.27)
HD GOLI SC + MTX	1.53(0.66,3.67)	1.26(0.79,2.01)	0.10(-0.10,0.31)

(Continued)

HD CERTO SC + MTX		2.02(0.96,4.29)	1.43(0.98,2.12)	0.17(-0.01,0.34)
HD INF IV + MTX		1.23(0.54,2.85)	1.13(0.68,1.77)	0.05(-0.14,0.25)
HD TOCI IV + DMARD		0.31(0.10,0.91)	0.43(0.17,0.94)	-0.22(-0.41,-0.02)
SD ABA IV + MTX	SD INF IV + MTX	1.27(0.68,2.35)	1.15(0.79,1.68)	0.05(-0.09,0.20)
SD CERTO SC + MTX		1.92(0.97,3.79)	1.42(0.99,2.14)	0.15(-0.01,0.31)
SD TOFA PO + MTX		2.08(0.98,4.52)	1.47(0.99,2.28)	0.17(0.00,0.35)
SD GOLI SC + MTX		2.28(0.98,5.44)	1.54(0.99,2.51)	0.20(0.00,0.39)
SD ADA SC + MTX		1.37(0.44,4.24)	1.20(0.57,2.14)	0.07(-0.18,0.34)
SD RITUX IV + MTX		0.72(0.30,1.70)	0.80(0.43,1.39)	-0.07(-0.25,0.12)
SD GOLI IV + MTX		0.80(0.33,1.94)	0.87(0.47,1.51)	-0.05(-0.23,0.15)
SD ABA SC + MTX		1.37(0.47,3.92)	1.20(0.60,2.08)	0.07(-0.16,0.32)
SD ANA SC + MTX		1.78(0.28,12.80)	1.37(0.39,2.84)	0.14(-0.24,0.52)
SD TOCI IV + MTX		0.71(0.23,2.23)	0.80(0.34,1.63)	-0.07(-0.29,0.19)
SD CERTO SC + DMARD		0.54(0.16,1.80)	0.65(0.26,1.47)	-0.13(-0.36,0.13)
SD ADA SC + DMARD		0.30(0.07,1.13)	0.41(0.12,1.08)	-0.21(-0.42,0.03)
SD ETN SC + DMARD		1.18(0.38,3.66)	1.10(0.53,2.07)	0.04(-0.20,0.30)
LD ADA SC		0.38(0.12,1.19)	0.50(0.22,1.13)	-0.18(-0.40,0.03)
LD GOLI IV		0.36(0.12,1.15)	0.48(0.18,1.09)	-0.18(-0.37,0.03)
LD TOCI IV		0.07(0.01,0.28)	0.10(0.02,0.37)	-0.32(-0.51,-0.16)
LD RITUX IV + MTX		0.60(0.25,1.43)	0.71(0.37,1.25)	-0.10(-0.28,0.08)
LD ABA IV + MTX		0.69(0.30,1.60)	0.79(0.42,1.34)	-0.08(-0.25,0.10)
LD ANA SC + MTX		1.00(0.15,7.64)	1.00(0.23,2.46)	0.00(-0.32,0.44)
LD CERTO SC + MTX		1.38(0.48,3.98)	1.21(0.61,2.10)	0.07(-0.16,0.32)
LD ETN SC + MTX		1.08(0.42,2.77)	1.05(0.55,1.81)	0.02(-0.18,0.24)
LD GOLI IV + MTX		0.71(0.24,2.12)	0.80(0.35,1.56)	-0.07(-0.28,0.18)
LD TOCI IV + MTX		0.60(0.20,1.81)	0.71(0.29,1.47)	-0.10(-0.31,0.13)
LD TOFA PO + MTX		1.07(0.31,3.79)	1.04(0.42,2.04)	0.02(-0.24,0.31)
HD TOCI IV		0.95(0.47,1.93)	0.97(0.63,1.56)	-0.01(-0.18,0.14)

(Continued)

HD TOFA PO		1.18(0.41,3.43)	1.10(0.59,2.17)	0.04(-0.21,0.28)
HD ADA SC		0.55(0.18,1.69)	0.66(0.30,1.44)	-0.12(-0.35,0.11)
HD GOLI SC		0.99(0.39,2.52)	0.99(0.54,1.78)	0.00(-0.21,0.21)
HD ETN SC		0.66(0.25,1.70)	0.76(0.37,1.40)	-0.09(-0.28,0.12)
HD ABA SC		1.61(0.34,8.89)	1.31(0.49,2.99)	0.11(-0.23,0.49)
HD TOCI IV + MTX		1.64(0.81,3.46)	1.32(0.89,2.11)	0.12(-0.05,0.29)
HD TOFA PO + MTX		1.66(0.77,3.60)	1.33(0.86,2.07)	0.12(-0.06,0.30)
HD GOLI SC + MTX		1.74(0.75,4.15)	1.36(0.85,2.25)	0.13(-0.07,0.33)
HD CERTO SC + MTX		2.29(1.09,4.91)	1.54(1.04,2.37)	0.20(0.02,0.37)
HD INF IV + MTX		1.40(0.72,2.77)	1.22(0.81,1.78)	0.08(-0.07,0.24)
HD TOCI IV + DMARD		0.35(0.11,1.07)	0.46(0.18,1.05)	-0.19(-0.40,0.01)
SD CERTO SC + MTX	SD ABA IV + MTX	1.51(0.75,3.04)	1.24(0.86,1.84)	0.10(-0.07,0.26)
SD TOFA PO + MTX		1.63(0.77,3.60)	1.28(0.87,1.95)	0.12(-0.06,0.30)
SD GOLI SC + MTX		1.80(0.77,4.27)	1.33(0.88,2.12)	0.14(-0.06,0.34)
SD ADA SC + MTX		1.08(0.34,3.37)	1.04(0.49,1.85)	0.02(-0.23,0.29)
SD RITUX IV + MTX		0.56(0.24,1.37)	0.70(0.37,1.21)	-0.13(-0.31,0.07)
SD GOLI IV + MTX		0.63(0.26,1.49)	0.76(0.41,1.27)	-0.10(-0.29,0.09)
SD ABA SC + MTX		1.07(0.45,2.58)	1.04(0.58,1.59)	0.02(-0.17,0.22)
SD ANA SC + MTX		1.40(0.22,10.19)	1.19(0.34,2.43)	0.08(-0.31,0.47)
SD TOCI IV + MTX		0.56(0.18,1.75)	0.69(0.30,1.39)	-0.13(-0.35,0.13)
SD CERTO SC + DMARD		0.42(0.12,1.47)	0.56(0.23,1.28)	-0.18(-0.42,0.09)
SD ADA SC + DMARD		0.24(0.06,0.91)	0.35(0.11,0.94)	-0.26(-0.48,-0.02)
SD ETN SC + DMARD		0.92(0.30,3.02)	0.95(0.46,1.78)	-0.02(-0.26,0.26)
LD ADA SC		0.30(0.10,0.95)	0.43(0.19,0.96)	-0.24(-0.46,-0.01)
LD GOLI IV		0.29(0.09,0.89)	0.42(0.15,0.93)	-0.24(-0.43,-0.03)
LD TOCI IV		0.05(0.01,0.23)	0.09(0.02,0.32)	-0.38(-0.58,-0.19)
LD RITUX IV + MTX		0.47(0.19,1.13)	0.61(0.31,1.08)	-0.16(-0.34,0.03)
LD ABA IV + MTX		0.55(0.27,1.07)	0.68(0.40,1.04)	-0.13(-0.28,0.02)

(Continued)

LD ANA SC + MTX		0.79(0.12,5.87)	0.87(0.20,2.05)	-0.05(-0.38,0.38)
LD CERTO SC + MTX		1.09(0.38,3.14)	1.05(0.53,1.78)	0.02(-0.22,0.27)
LD ETN SC + MTX		0.85(0.32,2.23)	0.91(0.48,1.54)	-0.04(-0.25,0.19)
LD GOLI IV + MTX		0.56(0.19,1.68)	0.69(0.31,1.35)	-0.12(-0.34,0.12)
LD TOCI IV + MTX		0.47(0.15,1.47)	0.61(0.25,1.26)	-0.16(-0.37,0.09)
LD TOFA PO + MTX		0.85(0.24,3.02)	0.91(0.37,1.74)	-0.04(-0.30,0.26)
HD TOCI IV		0.75(0.36,1.56)	0.84(0.56,1.34)	-0.07(-0.24,0.10)
HD TOFA PO		0.92(0.32,2.80)	0.95(0.53,1.87)	-0.02(-0.27,0.24)
HD ADA SC		0.43(0.14,1.33)	0.58(0.27,1.21)	-0.18(-0.42,0.06)
HD GOLI SC		0.77(0.30,2.00)	0.86(0.47,1.51)	-0.06(-0.28,0.16)
HD ETN SC		0.52(0.19,1.38)	0.66(0.32,1.21)	-0.14(-0.34,0.07)
HD ABA SC		1.28(0.26,7.22)	1.14(0.43,2.53)	0.06(-0.30,0.44)
HD TOCI IV + MTX		1.29(0.62,2.77)	1.14(0.78,1.81)	0.06(-0.11,0.24)
HD TOFA PO + MTX		1.30(0.61,2.88)	1.15(0.75,1.75)	0.06(-0.12,0.25)
HD GOLI SC + MTX		1.37(0.59,3.31)	1.18(0.75,1.89)	0.08(-0.13,0.28)
HD CERTO SC + MTX		1.80(0.86,3.88)	1.33(0.92,2.04)	0.14(-0.04,0.32)
HD INF IV + MTX		1.10(0.49,2.51)	1.05(0.65,1.65)	0.02(-0.16,0.22)
HD TOCI IV + DMARD		0.27(0.08,0.87)	0.40(0.15,0.92)	-0.25(-0.46,-0.03)
SD TOFA PO + MTX	SD CERTO SC + MTX	1.09(0.51,2.36)	1.04(0.72,1.49)	0.02(-0.16,0.20)
SD GOLI SC + MTX		1.19(0.51,2.86)	1.08(0.72,1.61)	0.04(-0.16,0.24)
SD ADA SC + MTX		0.71(0.23,2.24)	0.84(0.40,1.42)	-0.08(-0.33,0.19)
SD RITUX IV + MTX		0.37(0.16,0.90)	0.56(0.30,0.95)	-0.22(-0.41,-0.02)
SD GOLI IV + MTX		0.42(0.17,0.99)	0.61(0.33,0.99)	-0.20(-0.38,0.00)
SD ABA SC + MTX		0.72(0.24,2.13)	0.85(0.41,1.40)	-0.08(-0.33,0.18)
SD ANA SC + MTX		0.92(0.15,6.65)	0.96(0.27,1.86)	-0.02(-0.39,0.37)
SD TOCI IV + MTX		0.37(0.12,1.18)	0.56(0.24,1.09)	-0.23(-0.45,0.04)
SD CERTO SC + DMARD		0.28(0.08,0.98)	0.45(0.19,0.99)	-0.28(-0.52,0.00)
SD ADA SC + DMARD		0.15(0.04,0.62)	0.28(0.09,0.75)	-0.37(-0.58,-0.11)

(Continued)

SD ETN SC + DMARD		0.61(0.19,1.95)	0.78(0.37,1.37)	-0.12(-0.37,0.16)
LD ADA SC		0.20(0.07,0.63)	0.35(0.16,0.74)	-0.34(-0.55,-0.10)
LD GOL I V		0.19(0.06,0.59)	0.34(0.13,0.74)	-0.34(-0.53,-0.12)
LD TOCI IV		0.03(0.01,0.15)	0.07(0.01,0.25)	-0.48(-0.67,-0.28)
LD RITUX IV + MTX		0.31(0.13,0.76)	0.49(0.26,0.86)	-0.26(-0.44,-0.06)
LD ABA IV + MTX		0.36(0.15,0.86)	0.55(0.28,0.92)	-0.23(-0.42,-0.04)
LD ANA SC + MTX		0.52(0.08,4.01)	0.70(0.16,1.64)	-0.15(-0.48,0.29)
LD CERTO SC + MTX		0.72(0.29,1.80)	0.85(0.47,1.29)	-0.08(-0.28,0.14)
LD ETN SC + MTX		0.57(0.21,1.52)	0.74(0.39,1.22)	-0.13(-0.36,0.10)
LD GOL I V + MTX		0.38(0.13,1.13)	0.56(0.25,1.06)	-0.22(-0.44,0.03)
LD TOCI IV + MTX		0.31(0.10,0.96)	0.49(0.21,0.98)	-0.26(-0.47,-0.01)
LD TOFA PO + MTX		0.56(0.16,2.02)	0.73(0.30,1.35)	-0.14(-0.40,0.16)
HD TOCI IV		0.49(0.24,1.02)	0.68(0.46,1.01)	-0.17(-0.34,0.00)
HD TOFA PO		0.61(0.21,1.86)	0.77(0.45,1.41)	-0.12(-0.37,0.15)
HD ADA SC		0.29(0.09,0.93)	0.46(0.22,0.96)	-0.28(-0.51,-0.02)
HD GOL I SC		0.51(0.20,1.30)	0.70(0.39,1.16)	-0.16(-0.37,0.06)
HD ETN SC		0.34(0.13,0.93)	0.53(0.26,0.96)	-0.24(-0.44,-0.02)
HD ABA SC		0.85(0.17,4.69)	0.92(0.35,1.92)	-0.04(-0.40,0.35)
HD TOCI IV + MTX		0.86(0.40,1.79)	0.93(0.64,1.35)	-0.04(-0.22,0.14)
HD TOFA PO + MTX		0.87(0.40,1.85)	0.93(0.62,1.34)	-0.03(-0.22,0.14)
HD GOL I SC + MTX		0.91(0.39,2.20)	0.96(0.61,1.46)	-0.02(-0.23,0.19)
HD CERTO SC + MTX		1.20(0.70,2.03)	1.08(0.85,1.38)	0.04(-0.08,0.16)
HD INF IV + MTX		0.73(0.31,1.70)	0.85(0.52,1.29)	-0.08(-0.27,0.13)
HD TOCI IV + DMARD		0.18(0.05,0.58)	0.32(0.13,0.72)	-0.35(-0.56,-0.12)
SD GOL I SC + MTX	SD TOFA PO + MTX	1.10(0.43,2.84)	1.04(0.69,1.61)	0.02(-0.20,0.24)
SD ADA SC + MTX		0.66(0.19,2.18)	0.82(0.38,1.42)	-0.10(-0.37,0.18)
SD RITUX IV + MTX		0.34(0.14,0.89)	0.55(0.29,0.94)	-0.24(-0.44,-0.03)
SD GOL I V + MTX		0.39(0.15,0.97)	0.59(0.31,0.98)	-0.22(-0.42,-0.01)

(Continued)

SD ABA SC + MTX	0.66(0.21,2.09)	0.82(0.39,1.39)	-0.10(-0.36,0.17)
SD ANA SC + MTX	0.85(0.13,6.50)	0.93(0.27,1.83)	-0.04(-0.43,0.36)
SD TOCI IV + MTX	0.34(0.10,1.14)	0.54(0.23,1.07)	-0.24(-0.48,0.03)
SD CERTO SC + DMARD	0.26(0.07,0.94)	0.44(0.18,0.97)	-0.30(-0.56,-0.01)
SD ADA SC + DMARD	0.14(0.03,0.57)	0.28(0.09,0.72)	-0.38(-0.62,-0.13)
SD ETN SC + DMARD	0.57(0.17,1.86)	0.75(0.35,1.35)	-0.13(-0.41,0.15)
LD ADA SC	0.19(0.05,0.61)	0.34(0.15,0.72)	-0.36(-0.59,-0.10)
LD GOL I IV	0.18(0.05,0.58)	0.33(0.12,0.73)	-0.36(-0.57,-0.12)
LD TOCI IV	0.03(0.01,0.14)	0.07(0.01,0.24)	-0.50(-0.71,-0.29)
LD RITUX IV + MTX	0.29(0.11,0.75)	0.48(0.24,0.85)	-0.28(-0.48,-0.07)
LD ABA IV + MTX	0.33(0.13,0.84)	0.53(0.28,0.91)	-0.25(-0.45,-0.04)
LD ANA SC + MTX	0.48(0.07,3.81)	0.68(0.16,1.59)	-0.17(-0.51,0.28)
LD CERTO SC + MTX	0.67(0.22,2.03)	0.82(0.41,1.38)	-0.10(-0.35,0.17)
LD ETN SC + MTX	0.52(0.18,1.47)	0.71(0.37,1.21)	-0.15(-0.39,0.09)
LD GOL I IV + MTX	0.35(0.11,1.07)	0.55(0.24,1.03)	-0.24(-0.47,0.01)
LD TOCI IV + MTX	0.29(0.09,0.94)	0.48(0.20,0.96)	-0.28(-0.51,-0.02)
LD TOFA PO + MTX	0.52(0.16,1.63)	0.71(0.30,1.23)	-0.15(-0.40,0.11)
HD TOCI IV	0.46(0.20,1.01)	0.65(0.44,1.01)	-0.19(-0.37,0.00)
HD TOFA PO	0.57(0.17,1.77)	0.75(0.42,1.37)	-0.14(-0.41,0.13)
HD ADA SC	0.26(0.08,0.89)	0.45(0.21,0.93)	-0.30(-0.55,-0.03)
HD GOL I SC	0.47(0.16,1.31)	0.67(0.36,1.16)	-0.18(-0.41,0.06)
HD ETN SC	0.32(0.11,0.89)	0.51(0.25,0.94)	-0.26(-0.48,-0.03)
HD ABA SC	0.78(0.15,4.72)	0.89(0.34,1.94)	-0.06(-0.43,0.35)
HD TOCI IV + MTX	0.79(0.34,1.79)	0.90(0.61,1.36)	-0.06(-0.25,0.14)
HD TOFA PO + MTX	0.80(0.47,1.33)	0.90(0.68,1.15)	-0.05(-0.18,0.07)
HD GOL I SC + MTX	0.84(0.33,2.18)	0.93(0.58,1.45)	-0.04(-0.26,0.18)
HD CERTO SC + MTX	1.10(0.47,2.52)	1.04(0.72,1.54)	0.02(-0.17,0.22)
HD INF IV + MTX	0.67(0.26,1.70)	0.83(0.48,1.30)	-0.09(-0.31,0.13)

(Continued)

HD TOCI IV + DMARD		0.17(0.05,0.55)	0.31(0.12,0.69)	-0.37(-0.59,-0.13)
SD ADA SC + MTX	SD GOL SC + MTX	0.60(0.17,2.09)	0.78(0.36,1.36)	-0.12(-0.40,0.17)
SD RITUX IV + MTX		0.31(0.11,0.87)	0.52(0.26,0.93)	-0.27(-0.48,-0.03)
SD GOL IV + MTX		0.35(0.13,0.95)	0.57(0.29,0.97)	-0.24(-0.46,-0.01)
SD ABA SC + MTX		0.60(0.17,2.00)	0.78(0.36,1.35)	-0.12(-0.39,0.16)
SD ANA SC + MTX		0.77(0.12,6.30)	0.89(0.25,1.77)	-0.06(-0.46,0.35)
SD TOCI IV + MTX		0.31(0.09,1.07)	0.52(0.21,1.03)	-0.27(-0.51,0.02)
SD CERTO SC + DMARD		0.23(0.06,0.87)	0.42(0.17,0.93)	-0.32(-0.57,-0.03)
SD ADA SC + DMARD		0.13(0.03,0.53)	0.26(0.08,0.70)	-0.41(-0.63,-0.14)
SD ETN SC + DMARD		0.51(0.15,1.84)	0.72(0.33,1.33)	-0.16(-0.43,0.14)
LD ADA SC		0.17(0.05,0.57)	0.33(0.15,0.70)	-0.38(-0.60,-0.12)
LD GOL IV		0.16(0.05,0.55)	0.31(0.11,0.72)	-0.38(-0.59,-0.14)
LD TOCI IV		0.03(0.00,0.13)	0.07(0.01,0.24)	-0.52(-0.72,-0.31)
LD RITUX IV + MTX		0.26(0.10,0.71)	0.46(0.22,0.84)	-0.30(-0.51,-0.08)
LD ABA IV + MTX		0.30(0.11,0.83)	0.51(0.25,0.91)	-0.27(-0.49,-0.04)
LD ANA SC + MTX		0.44(0.06,3.62)	0.65(0.15,1.55)	-0.19(-0.54,0.26)
LD CERTO SC + MTX		0.60(0.19,1.96)	0.79(0.39,1.35)	-0.12(-0.38,0.16)
LD ETN SC + MTX		0.48(0.15,1.41)	0.69(0.34,1.18)	-0.18(-0.42,0.08)
LD GOL IV + MTX		0.31(0.09,1.04)	0.52(0.22,1.02)	-0.27(-0.50,0.01)
LD TOCI IV + MTX		0.26(0.08,0.91)	0.46(0.19,0.95)	-0.30(-0.53,-0.02)
LD TOFA PO + MTX		0.47(0.12,1.86)	0.68(0.26,1.30)	-0.18(-0.46,0.14)
HD TOCI IV		0.42(0.18,0.97)	0.63(0.41,0.98)	-0.21(-0.40,-0.01)
HD TOFA PO		0.51(0.17,1.62)	0.71(0.41,1.30)	-0.16(-0.41,0.12)
HD ADA SC		0.24(0.07,0.80)	0.43(0.20,0.87)	-0.32(-0.56,-0.05)
HD GOL SC		0.43(0.18,1.00)	0.64(0.38,1.00)	-0.20(-0.39,0.00)
HD ETN SC		0.29(0.10,0.89)	0.49(0.23,0.94)	-0.28(-0.50,-0.03)
HD ABA SC		0.71(0.13,3.99)	0.86(0.32,1.77)	-0.08(-0.45,0.31)
HD TOCI IV + MTX		0.73(0.30,1.75)	0.86(0.57,1.32)	-0.08(-0.28,0.13)

(Continued)

HD TOFA PO + MTX		0.72(0.29,1.85)	0.86(0.54,1.33)	-0.08(-0.29,0.14)
HD GOLI SC + MTX		0.77(0.40,1.45)	0.89(0.63,1.19)	-0.06(-0.22,0.09)
HD CERTO SC + MTX		1.00(0.41,2.52)	1.00(0.67,1.50)	0.00(-0.21,0.21)
HD INF IV + MTX		0.61(0.22,1.67)	0.79(0.45,1.26)	-0.12(-0.35,0.12)
HD TOCI IV + DMARD		0.15(0.04,0.52)	0.30(0.12,0.68)	-0.39(-0.61,-0.14)
SD RITUX IV + MTX	SD ADA SC + MTX	0.52(0.15,1.93)	0.67(0.32,1.56)	-0.14(-0.42,0.14)
SD GOLI IV + MTX		0.59(0.16,2.07)	0.73(0.34,1.63)	-0.12(-0.41,0.15)
SD ABA SC + MTX		1.00(0.24,4.20)	1.00(0.44,2.30)	0.00(-0.33,0.32)
SD ANA SC + MTX		1.29(0.17,12.03)	1.13(0.31,3.02)	0.06(-0.38,0.51)
SD TOCI IV + MTX		0.52(0.12,2.23)	0.67(0.27,1.68)	-0.14(-0.45,0.17)
SD CERTO SC + DMARD		0.39(0.08,1.77)	0.54(0.21,1.49)	-0.20(-0.52,0.11)
SD ADA SC + DMARD		0.22(0.04,1.13)	0.34(0.10,1.09)	-0.28(-0.59,0.02)
SD ETN SC + DMARD		0.86(0.19,3.76)	0.92(0.40,2.20)	-0.03(-0.38,0.30)
LD ADA SC		0.28(0.06,1.19)	0.42(0.17,1.14)	-0.25(-0.56,0.03)
LD GOLI IV		0.27(0.06,1.20)	0.41(0.14,1.14)	-0.25(-0.55,0.03)
LD TOCI IV		0.05(0.01,0.27)	0.09(0.02,0.35)	-0.40(-0.69,-0.14)
LD RITUX IV + MTX		0.44(0.12,1.53)	0.59(0.27,1.34)	-0.18(-0.46,0.09)
LD ABA IV + MTX		0.51(0.14,1.82)	0.66(0.30,1.50)	-0.15(-0.43,0.12)
LD ANA SC + MTX		0.74(0.09,6.89)	0.84(0.18,2.55)	-0.07(-0.47,0.42)
LD CERTO SC + MTX		1.01(0.26,4.08)	1.01(0.47,2.30)	0.00(-0.32,0.32)
LD ETN SC + MTX		0.79(0.20,3.05)	0.88(0.41,1.99)	-0.05(-0.36,0.25)
LD GOLI IV + MTX		0.52(0.12,2.20)	0.67(0.27,1.66)	-0.14(-0.45,0.17)
LD TOCI IV + MTX		0.44(0.10,1.90)	0.59(0.23,1.52)	-0.18(-0.48,0.14)
LD TOFA PO + MTX		0.78(0.16,3.86)	0.87(0.32,2.17)	-0.06(-0.40,0.31)
HD TOCI IV		0.69(0.21,2.27)	0.80(0.46,1.79)	-0.09(-0.36,0.17)
HD TOFA PO		0.85(0.21,3.69)	0.91(0.46,2.34)	-0.04(-0.36,0.28)
HD ADA SC		0.41(0.09,1.76)	0.56(0.23,1.51)	-0.19(-0.51,0.11)
HD GOLI SC		0.72(0.19,2.75)	0.83(0.40,1.97)	-0.08(-0.39,0.22)

(Continued)

HD ETN SC		0.48(0.12,1.85)	0.64(0.28,1.50)	-0.16(-0.46,0.13)
HD ABA SC		1.20(0.18,8.04)	1.10(0.39,3.07)	0.04(-0.39,0.46)
HD TOCI IV + MTX		1.19(0.38,3.99)	1.09(0.65,2.39)	0.04(-0.23,0.31)
HD TOFA PO + MTX		1.20(0.36,3.99)	1.10(0.62,2.36)	0.04(-0.24,0.31)
HD GOLI SC + MTX		1.28(0.36,4.50)	1.13(0.62,2.52)	0.06(-0.24,0.34)
HD CERTO SC + MTX		1.67(0.51,5.47)	1.28(0.76,2.72)	0.12(-0.15,0.39)
HD INF IV + MTX		1.02(0.29,3.62)	1.01(0.53,2.23)	0.00(-0.29,0.29)
HD TOCI IV + DMARD		0.25(0.06,1.09)	0.39(0.14,1.07)	-0.26(-0.56,0.02)
SD GOLI IV + MTX	SD RITUX IV + MTX	1.12(0.40,3.04)	1.08(0.54,2.17)	0.02(-0.19,0.23)
SD ABA SC + MTX		1.92(0.55,6.31)	1.49(0.67,3.11)	0.14(-0.13,0.41)
SD ANA SC + MTX		2.42(0.37,19.71)	1.67(0.47,4.05)	0.20(-0.17,0.60)
SD TOCI IV + MTX		0.99(0.28,3.48)	1.00(0.39,2.34)	0.00(-0.25,0.27)
SD CERTO SC + DMARD		0.74(0.20,2.86)	0.81(0.30,2.12)	-0.06(-0.32,0.21)
SD ADA SC + DMARD		0.42(0.09,1.81)	0.51(0.14,1.55)	-0.14(-0.39,0.11)
SD ETN SC + DMARD		1.64(0.45,5.84)	1.37(0.59,3.04)	0.11(-0.17,0.39)
LD ADA SC		0.54(0.15,1.88)	0.62(0.25,1.63)	-0.11(-0.36,0.11)
LD GOLI IV		0.51(0.14,1.74)	0.60(0.21,1.50)	-0.11(-0.34,0.11)
LD TOCI IV		0.09(0.01,0.41)	0.13(0.02,0.48)	-0.25(-0.48,-0.09)
LD RITUX IV + MTX		0.83(0.41,1.69)	0.88(0.52,1.45)	-0.03(-0.18,0.10)
LD ABA IV + MTX		0.97(0.35,2.67)	0.98(0.47,2.00)	-0.01(-0.22,0.20)
LD ANA SC + MTX		1.38(0.20,11.43)	1.23(0.28,3.45)	0.07(-0.26,0.52)
LD CERTO SC + MTX		1.93(0.59,6.27)	1.50(0.71,3.09)	0.14(-0.11,0.41)
LD ETN SC + MTX		1.52(0.48,4.60)	1.31(0.61,2.72)	0.09(-0.15,0.33)
LD GOLI IV + MTX		1.00(0.29,3.25)	1.00(0.41,2.20)	0.00(-0.24,0.25)
LD TOCI IV + MTX		0.83(0.24,2.91)	0.88(0.35,2.11)	-0.03(-0.28,0.22)
LD TOFA PO + MTX		1.49(0.37,5.95)	1.30(0.49,2.95)	0.08(-0.20,0.39)
HD TOCI IV		1.33(0.53,3.25)	1.21(0.69,2.38)	0.06(-0.15,0.23)
HD TOFA PO		1.65(0.48,5.44)	1.38(0.65,3.21)	0.11(-0.17,0.35)

(Continued)

HD ADA SC		0.77(0.22,2.73)	0.83(0.35,2.12)	-0.05(-0.31,0.19)
HD GOLI SC		1.38(0.46,4.05)	1.24(0.60,2.63)	0.07(-0.18,0.29)
HD ETN SC		0.92(0.30,2.83)	0.94(0.42,2.05)	-0.02(-0.25,0.22)
HD ABA SC		2.28(0.40,13.35)	1.63(0.55,4.36)	0.19(-0.19,0.56)
HD TOCI IV + MTX		2.30(0.89,5.73)	1.65(0.94,3.19)	0.19(-0.03,0.38)
HD TOFA PO + MTX		2.32(0.89,5.86)	1.65(0.93,3.13)	0.19(-0.03,0.39)
HD GOLI SC + MTX		2.44(0.88,6.86)	1.70(0.93,3.36)	0.20(-0.03,0.42)
HD CERTO SC + MTX		3.21(1.26,8.19)	1.91(1.12,3.64)	0.27(0.05,0.46)
HD INF IV + MTX		1.95(0.71,5.37)	1.51(0.82,2.92)	0.15(-0.08,0.37)
HD TOCI IV + DMARD		0.49(0.13,1.74)	0.58(0.20,1.51)	-0.12(-0.36,0.10)
SD ABA SC + MTX	SD GOLI IV + MTX	1.70(0.50,5.91)	1.37(0.63,2.89)	0.12(-0.15,0.40)
SD ANA SC + MTX		2.19(0.32,18.87)	1.57(0.44,3.79)	0.18(-0.22,0.59)
SD TOCI IV + MTX		0.89(0.26,3.23)	0.92(0.37,2.18)	-0.02(-0.27,0.25)
SD CERTO SC + DMARD		0.66(0.18,2.55)	0.74(0.29,1.95)	-0.08(-0.34,0.19)
SD ADA SC + DMARD		0.37(0.09,1.65)	0.47(0.14,1.43)	-0.16(-0.41,0.09)
SD ETN SC + DMARD		1.47(0.41,5.27)	1.27(0.56,2.80)	0.08(-0.19,0.37)
LD ADA SC		0.48(0.14,1.71)	0.58(0.24,1.51)	-0.13(-0.38,0.09)
LD GOLI IV		0.46(0.16,1.26)	0.56(0.24,1.17)	-0.13(-0.32,0.04)
LD TOCI IV		0.08(0.01,0.38)	0.12(0.02,0.45)	-0.27(-0.50,-0.10)
LD RITUX IV + MTX		0.74(0.27,2.10)	0.81(0.40,1.68)	-0.06(-0.27,0.15)
LD ABA IV + MTX		0.87(0.31,2.39)	0.91(0.44,1.82)	-0.03(-0.24,0.18)
LD ANA SC + MTX		1.25(0.18,10.77)	1.15(0.26,3.19)	0.05(-0.30,0.50)
LD CERTO SC + MTX		1.73(0.53,5.55)	1.39(0.66,2.81)	0.12(-0.14,0.39)
LD ETN SC + MTX		1.35(0.45,4.08)	1.21(0.59,2.47)	0.07(-0.17,0.31)
LD GOLI IV + MTX		0.89(0.34,2.35)	0.92(0.46,1.77)	-0.02(-0.21,0.19)
LD TOCI IV + MTX		0.75(0.22,2.65)	0.82(0.32,1.94)	-0.06(-0.30,0.20)
LD TOFA PO + MTX		1.34(0.34,5.31)	1.20(0.46,2.62)	0.06(-0.21,0.37)
HD TOCI IV		1.18(0.48,2.91)	1.12(0.65,2.18)	0.04(-0.17,0.21)

(Continued)

HD TOFA PO		1.45(0.45,4.82)	1.27(0.62,2.94)	0.08(-0.19,0.33)
HD ADA SC		0.69(0.19,2.43)	0.77(0.32,1.91)	-0.07(-0.34,0.17)
HD GOLI SC		1.24(0.41,3.64)	1.15(0.57,2.41)	0.05(-0.20,0.27)
HD ETN SC		0.82(0.28,2.54)	0.87(0.40,1.89)	-0.04(-0.26,0.20)
HD ABA SC		2.03(0.38,12.21)	1.51(0.53,3.94)	0.16(-0.21,0.54)
HD TOCI IV + MTX		2.05(0.82,5.14)	1.53(0.90,2.94)	0.16(-0.05,0.36)
HD TOFA PO + MTX		2.07(0.81,5.27)	1.53(0.89,2.84)	0.17(-0.05,0.37)
HD GOLI SC + MTX		2.19(0.81,6.05)	1.57(0.89,3.11)	0.18(-0.05,0.40)
HD CERTO SC + MTX		2.85(1.15,7.15)	1.77(1.08,3.32)	0.24(0.03,0.44)
HD INF IV + MTX		1.74(0.63,4.86)	1.40(0.76,2.74)	0.12(-0.11,0.35)
HD TOCI IV + DMARD		0.43(0.12,1.55)	0.53(0.19,1.38)	-0.14(-0.38,0.08)
SD ANA SC + MTX	SD ABA SC + MTX	1.30(0.17,11.09)	1.14(0.31,2.89)	0.06(-0.37,0.49)
SD TOCI IV + MTX		0.52(0.12,2.16)	0.68(0.26,1.63)	-0.14(-0.44,0.17)
SD CERTO SC + DMARD		0.39(0.09,1.75)	0.54(0.20,1.47)	-0.20(-0.52,0.11)
SD ADA SC + DMARD		0.22(0.04,1.10)	0.34(0.10,1.07)	-0.28(-0.58,0.02)
SD ETN SC + DMARD		0.86(0.21,3.58)	0.92(0.40,2.13)	-0.04(-0.35,0.29)
LD ADA SC		0.28(0.07,1.19)	0.42(0.17,1.14)	-0.25(-0.55,0.03)
LD GOLI IV		0.27(0.06,1.10)	0.41(0.14,1.07)	-0.25(-0.54,0.02)
LD TOCI IV		0.05(0.01,0.26)	0.09(0.02,0.34)	-0.40(-0.67,-0.15)
LD RITUX IV + MTX		0.43(0.13,1.54)	0.59(0.27,1.34)	-0.18(-0.45,0.09)
LD ABA IV + MTX		0.51(0.17,1.57)	0.66(0.33,1.34)	-0.15(-0.40,0.09)
LD ANA SC + MTX		0.73(0.10,6.66)	0.84(0.19,2.41)	-0.07(-0.46,0.41)
LD CERTO SC + MTX		1.02(0.26,4.03)	1.01(0.46,2.22)	0.00(-0.31,0.32)
LD ETN SC + MTX		0.79(0.21,2.91)	0.88(0.41,1.94)	-0.05(-0.35,0.24)
LD GOLI IV + MTX		0.52(0.13,2.09)	0.67(0.27,1.59)	-0.14(-0.44,0.16)
LD TOCI IV + MTX		0.44(0.11,1.82)	0.60(0.23,1.47)	-0.18(-0.47,0.13)
LD TOFA PO + MTX		0.78(0.16,3.79)	0.87(0.32,2.09)	-0.06(-0.39,0.30)
HD TOCI IV		0.69(0.23,2.20)	0.80(0.47,1.75)	-0.09(-0.35,0.16)

(Continued)

HD TOFA PO		0.86(0.22,3.47)	0.91(0.47,2.27)	-0.04(-0.36,0.27)
HD ADA SC		0.40(0.10,1.69)	0.55(0.24,1.46)	-0.20(-0.50,0.10)
HD GOL I SC		0.72(0.20,2.62)	0.83(0.41,1.90)	-0.08(-0.37,0.21)
HD ETN SC		0.48(0.13,1.80)	0.64(0.28,1.48)	-0.16(-0.44,0.12)
HD ABA SC		1.18(0.20,8.27)	1.09(0.40,3.03)	0.04(-0.37,0.47)
HD TOCI IV + MTX		1.21(0.39,3.85)	1.10(0.65,2.32)	0.05(-0.22,0.30)
HD TOFA PO + MTX		1.21(0.38,3.92)	1.10(0.63,2.31)	0.05(-0.23,0.31)
HD GOL I SC + MTX		1.27(0.38,4.38)	1.13(0.63,2.42)	0.06(-0.23,0.34)
HD CERTO SC + MTX		1.68(0.54,5.38)	1.28(0.76,2.69)	0.12(-0.15,0.38)
HD INF IV + MTX		1.02(0.32,3.46)	1.01(0.55,2.13)	0.01(-0.27,0.28)
HD TOCI IV + DMARD		0.26(0.06,1.10)	0.39(0.14,1.07)	-0.26(-0.56,0.02)
SD TOCI IV + MTX	SD ANA SC + MTX	0.40(0.04,3.21)	0.60(0.21,2.32)	-0.20(-0.63,0.22)
SD CERTO SC + DMARD		0.30(0.03,2.48)	0.48(0.16,1.99)	-0.26(-0.69,0.16)
SD ADA SC + DMARD		0.17(0.02,1.51)	0.31(0.08,1.37)	-0.34(-0.75,0.06)
SD ETN SC + DMARD		0.66(0.07,5.14)	0.81(0.32,2.99)	-0.10(-0.53,0.33)
LD ADA SC		0.22(0.02,1.72)	0.37(0.14,1.54)	-0.32(-0.71,0.08)
LD GOL I IV		0.21(0.02,1.64)	0.36(0.11,1.44)	-0.31(-0.72,0.08)
LD TOCI IV		0.04(0.00,0.37)	0.08(0.01,0.43)	-0.46(-0.85,-0.09)
LD RITUX IV + MTX		0.34(0.04,2.28)	0.53(0.21,1.86)	-0.24(-0.63,0.14)
LD ABA IV + MTX		0.39(0.05,2.76)	0.58(0.23,2.13)	-0.21(-0.61,0.18)
LD ANA SC + MTX		0.56(0.13,2.39)	0.76(0.26,1.64)	-0.11(-0.42,0.18)
LD CERTO SC + MTX		0.78(0.09,5.84)	0.89(0.35,3.12)	-0.06(-0.49,0.37)
LD ETN SC + MTX		0.61(0.07,4.38)	0.77(0.31,2.75)	-0.11(-0.53,0.30)
LD GOL I IV + MTX		0.41(0.04,3.03)	0.60(0.21,2.20)	-0.20(-0.63,0.21)
LD TOCI IV + MTX		0.34(0.04,2.62)	0.53(0.18,2.04)	-0.24(-0.65,0.17)
LD TOFA PO + MTX		0.61(0.06,5.07)	0.78(0.25,2.87)	-0.11(-0.56,0.34)
HD TOCI IV		0.54(0.07,3.36)	0.71(0.36,2.51)	-0.15(-0.53,0.22)
HD TOFA PO		0.66(0.08,5.13)	0.80(0.38,3.16)	-0.10(-0.52,0.32)

(Continued)

HD ADA SC		0.31(0.03,2.47)	0.49(0.20,2.01)	-0.26(-0.66,0.15)
HD GOLI SC		0.56(0.07,3.89)	0.73(0.32,2.67)	-0.14(-0.55,0.25)
HD ETN SC		0.37(0.04,2.62)	0.56(0.22,2.04)	-0.22(-0.63,0.18)
HD ABA SC		0.94(0.08,10.52)	0.97(0.32,3.99)	-0.01(-0.53,0.50)
HD TOCI IV + MTX		0.92(0.12,5.90)	0.96(0.50,3.40)	-0.02(-0.41,0.36)
HD TOFA PO + MTX		0.94(0.12,5.88)	0.97(0.47,3.32)	-0.01(-0.42,0.37)
HD GOLI SC + MTX		0.98(0.13,6.73)	0.99(0.48,3.61)	0.00(-0.41,0.39)
HD CERTO SC + MTX		1.30(0.17,8.36)	1.12(0.58,4.03)	0.06(-0.33,0.45)
HD INF IV + MTX		0.80(0.10,5.40)	0.89(0.41,3.15)	-0.05(-0.46,0.35)
HD TOCI IV + DMARD		0.20(0.02,1.55)	0.35(0.11,1.42)	-0.33(-0.73,0.07)
SD CERTO SC + DMARD	SD TOCI IV + MTX	0.75(0.17,3.29)	0.82(0.29,2.45)	-0.05(-0.35,0.22)
SD ADA SC + DMARD		0.42(0.09,2.00)	0.51(0.14,1.70)	-0.13(-0.42,0.12)
SD ETN SC + DMARD		1.65(0.39,7.10)	1.38(0.55,3.61)	0.11(-0.21,0.41)
LD ADA SC		0.54(0.13,2.21)	0.63(0.24,1.88)	-0.11(-0.39,0.12)
LD GOLI IV		0.51(0.12,2.20)	0.61(0.19,1.81)	-0.11(-0.39,0.14)
LD TOCI IV		0.09(0.02,0.41)	0.13(0.03,0.48)	-0.25(-0.50,-0.08)
LD RITUX IV + MTX		0.84(0.23,3.02)	0.88(0.36,2.27)	-0.03(-0.30,0.21)
LD ABA IV + MTX		0.97(0.28,3.42)	0.98(0.42,2.44)	-0.01(-0.27,0.24)
LD ANA SC + MTX		1.41(0.17,13.53)	1.25(0.26,4.02)	0.07(-0.31,0.55)
LD CERTO SC + MTX		1.95(0.48,7.98)	1.51(0.63,3.78)	0.15(-0.16,0.45)
LD ETN SC + MTX		1.53(0.40,5.83)	1.31(0.56,3.28)	0.09(-0.20,0.37)
LD GOLI IV + MTX		0.99(0.24,4.22)	1.00(0.36,2.72)	0.00(-0.29,0.29)
LD TOCI IV + MTX		0.85(0.25,2.73)	0.89(0.37,2.06)	-0.03(-0.28,0.20)
LD TOFA PO + MTX		1.49(0.31,7.21)	1.29(0.45,3.49)	0.08(-0.23,0.43)
HD TOCI IV		1.33(0.49,3.66)	1.21(0.66,2.67)	0.06(-0.17,0.24)
HD TOFA PO		1.65(0.44,6.31)	1.38(0.62,3.73)	0.11(-0.20,0.36)
HD ADA SC		0.77(0.19,3.23)	0.83(0.33,2.46)	-0.05(-0.34,0.21)
HD GOLI SC		1.37(0.39,4.94)	1.23(0.55,3.15)	0.07(-0.22,0.32)

(Continued)

HD ETN SC		0.93(0.24,3.53)	0.95(0.38,2.54)	-0.01(-0.29,0.24)
HD ABA SC		2.27(0.39,15.04)	1.63(0.55,4.95)	0.18(-0.21,0.57)
HD TOCI IV + MTX		2.29(0.83,6.50)	1.65(0.91,3.72)	0.19(-0.05,0.39)
HD TOFA PO + MTX		2.33(0.70,7.71)	1.65(0.82,3.92)	0.19(-0.08,0.43)
HD GOLI SC + MTX		2.45(0.70,8.76)	1.70(0.82,4.17)	0.20(-0.08,0.46)
HD CERTO SC + MTX		3.22(0.99,10.62)	1.92(1.00,4.50)	0.27(0.00,0.50)
HD INF IV + MTX		1.98(0.57,6.85)	1.52(0.71,3.69)	0.15(-0.13,0.40)
HD TOCI IV + DMARD		0.49(0.12,1.95)	0.58(0.20,1.70)	-0.12(-0.40,0.11)
SD ADA SC + DMARD	SD CER- TO SC + DMARD	0.55(0.13,2.34)	0.62(0.19,1.90)	-0.08(-0.31,0.15)
SD ETN SC + DMARD		2.20(0.56,8.91)	1.69(0.67,4.39)	0.16(-0.12,0.46)
LD ADA SC		0.73(0.19,2.64)	0.78(0.28,2.19)	-0.05(-0.30,0.15)
LD GOLI IV		0.69(0.14,3.18)	0.74(0.21,2.43)	-0.06(-0.31,0.20)
LD TOCI IV		0.12(0.02,0.67)	0.15(0.03,0.71)	-0.19(-0.42,-0.04)
LD RITUX IV + MTX		1.12(0.28,4.31)	1.09(0.39,2.95)	0.02(-0.24,0.28)
LD ABA IV + MTX		1.30(0.34,5.01)	1.21(0.45,3.27)	0.05(-0.21,0.31)
LD ANA SC + MTX		1.85(0.22,19.38)	1.52(0.29,5.21)	0.12(-0.23,0.61)
LD CERTO SC + MTX		2.59(0.58,11.10)	1.86(0.69,4.83)	0.20(-0.11,0.50)
LD ETN SC + MTX		2.03(0.50,8.17)	1.62(0.61,4.22)	0.14(-0.14,0.43)
LD GOLI IV + MTX		1.34(0.30,6.07)	1.24(0.41,3.55)	0.05(-0.22,0.36)
LD TOCI IV + MTX		1.12(0.26,4.84)	1.09(0.36,3.17)	0.02(-0.24,0.30)
LD TOFA PO + MTX		2.01(0.38,10.64)	1.60(0.50,4.60)	0.14(-0.18,0.49)
HD TOCI IV		1.78(0.58,5.38)	1.50(0.70,3.58)	0.12(-0.12,0.31)
HD TOFA PO		2.21(0.63,7.63)	1.71(0.74,4.28)	0.17(-0.10,0.39)
HD ADA SC		1.04(0.27,3.82)	1.03(0.39,2.84)	0.01(-0.26,0.23)
HD GOLI SC		1.85(0.50,6.84)	1.53(0.63,3.97)	0.12(-0.15,0.38)
HD ETN SC		1.24(0.31,4.88)	1.17(0.42,3.22)	0.04(-0.23,0.30)
HD ABA SC		3.07(0.54,18.58)	2.03(0.66,5.61)	0.24(-0.13,0.61)

(Continued)

HD TOCI IV + MTX		3.08(0.93,10.53)	2.05(0.96,4.92)	0.24(-0.02,0.47)
HD TOFA PO + MTX		3.11(0.82,11.54)	2.05(0.89,5.04)	0.25(-0.04,0.51)
HD GOLI SC + MTX		3.28(0.87,12.37)	2.11(0.92,5.18)	0.26(-0.03,0.52)
HD CERTO SC + MTX		4.31(1.19,15.33)	2.39(1.10,5.66)	0.33(0.04,0.56)
HD INF IV + MTX		2.63(0.70,10.14)	1.88(0.79,4.71)	0.21(-0.08,0.48)
HD TOCI IV + DMARD		0.65(0.19,2.23)	0.71(0.26,1.86)	-0.07(-0.28,0.14)
SD ETN SC + DMARD	SD ADA SC + DMARD	3.96(0.96,16.87)	2.69(0.97,8.53)	0.24(-0.01,0.51)
LD ADA SC		1.29(0.28,6.03)	1.23(0.38,4.70)	0.03(-0.22,0.22)
LD GOLI IV		1.23(0.23,6.37)	1.18(0.30,4.70)	0.02(-0.22,0.27)
LD TOCI IV		0.22(0.03,1.35)	0.25(0.04,1.30)	-0.10(-0.34,0.02)
LD RITUX IV + MTX		2.00(0.45,9.24)	1.72(0.55,6.23)	0.10(-0.14,0.34)
LD ABA IV + MTX		2.31(0.55,10.35)	1.92(0.64,6.71)	0.13(-0.11,0.37)
LD ANA SC + MTX		3.43(0.37,35.91)	2.44(0.44,10.08)	0.21(-0.14,0.68)
LD CERTO SC + MTX		4.66(0.94,23.07)	2.95(0.96,9.82)	0.28(-0.01,0.57)
LD ETN SC + MTX		3.61(0.83,17.21)	2.57(0.88,8.68)	0.23(-0.04,0.50)
LD GOLI IV + MTX		2.40(0.49,12.55)	1.96(0.58,7.12)	0.14(-0.12,0.42)
LD TOCI IV + MTX		2.01(0.42,9.41)	1.74(0.51,6.04)	0.10(-0.15,0.37)
LD TOFA PO + MTX		3.59(0.66,21.36)	2.52(0.73,9.55)	0.22(-0.07,0.56)
HD TOCI IV		3.20(0.91,11.22)	2.40(0.94,7.30)	0.20(-0.02,0.37)
HD TOFA PO		3.97(0.88,17.13)	2.75(0.92,9.37)	0.25(-0.03,0.46)
HD ADA SC		1.86(0.42,8.53)	1.64(0.52,5.97)	0.09(-0.16,0.30)
HD GOLI SC		3.32(0.76,14.84)	2.44(0.83,8.40)	0.21(-0.06,0.44)
HD ETN SC		2.24(0.51,9.86)	1.87(0.61,6.43)	0.12(-0.12,0.37)
HD ABA SC		5.51(0.79,39.89)	3.24(0.85,12.27)	0.32(-0.05,0.68)
HD TOCI IV + MTX		5.51(1.52,21.29)	3.29(1.27,10.27)	0.33(0.09,0.53)
HD TOFA PO + MTX		5.58(1.39,23.39)	3.26(1.23,10.64)	0.33(0.07,0.57)
HD GOLI SC + MTX		5.90(1.41,25.44)	3.38(1.24,10.98)	0.34(0.07,0.58)
HD CERTO SC + MTX		7.71(1.89,32.25)	3.80(1.43,12.17)	0.41(0.15,0.63)

(Continued)

HD INF IV + MTX		4.74(1.13,21.25)	3.00(1.08,9.94)	0.29(0.02,0.54)
HD TOCI IV + DMARD		1.17(0.36,3.79)	1.13(0.45,3.11)	0.02(-0.17,0.18)
LD ADA SC	SD ETN SC + DMARD	0.33(0.08,1.31)	0.46(0.19,1.23)	-0.22(-0.51,0.05)
LD GOL I IV		0.31(0.07,1.40)	0.44(0.14,1.27)	-0.22(-0.51,0.06)
LD TOCI IV		0.05(0.01,0.30)	0.09(0.02,0.38)	-0.36(-0.64,-0.14)
LD RITUX IV + MTX		0.51(0.14,1.86)	0.64(0.28,1.52)	-0.14(-0.42,0.12)
LD ABA IV + MTX		0.59(0.16,2.07)	0.71(0.32,1.63)	-0.11(-0.40,0.15)
LD ANA SC + MTX		0.85(0.11,8.09)	0.91(0.20,2.70)	-0.04(-0.42,0.45)
LD CERTO SC + MTX		1.18(0.28,4.75)	1.10(0.47,2.45)	0.04(-0.29,0.36)
LD ETN SC + MTX		0.92(0.24,3.46)	0.95(0.42,2.15)	-0.02(-0.33,0.28)
LD GOL I IV + MTX		0.61(0.14,2.65)	0.73(0.27,1.86)	-0.11(-0.42,0.22)
LD TOCI IV + MTX		0.51(0.12,2.09)	0.64(0.24,1.64)	-0.14(-0.43,0.16)
LD TOFA PO + MTX		0.91(0.19,4.62)	0.95(0.34,2.38)	-0.02(-0.36,0.34)
HD TOCI IV		0.81(0.27,2.37)	0.88(0.50,1.82)	-0.05(-0.31,0.18)
HD TOFA PO		1.01(0.27,3.63)	1.00(0.50,2.36)	0.00(-0.31,0.28)
HD ADA SC		0.47(0.12,1.82)	0.60(0.26,1.55)	-0.16(-0.46,0.12)
HD GOL I SC		0.84(0.22,2.98)	0.90(0.42,2.05)	-0.04(-0.35,0.24)
HD ETN SC		0.56(0.16,1.95)	0.69(0.30,1.57)	-0.12(-0.40,0.14)
HD ABA SC		1.40(0.23,8.73)	1.20(0.41,3.14)	0.08(-0.34,0.48)
HD TOCI IV + MTX		1.39(0.45,4.42)	1.19(0.68,2.54)	0.08(-0.19,0.33)
HD TOFA PO + MTX		1.41(0.42,4.83)	1.20(0.65,2.56)	0.08(-0.20,0.36)
HD GOL I SC + MTX		1.49(0.41,5.36)	1.23(0.64,2.73)	0.09(-0.21,0.38)
HD CERTO SC + MTX		1.94(0.58,6.49)	1.39(0.78,2.92)	0.16(-0.13,0.42)
HD INF IV + MTX		1.19(0.34,4.18)	1.10(0.56,2.40)	0.04(-0.25,0.32)
HD TOCI IV + DMARD		0.30(0.08,1.01)	0.42(0.16,1.01)	-0.23(-0.49,0.00)
LD GOL I IV	LD ADA SC	0.95(0.22,4.00)	0.96(0.27,2.93)	-0.01(-0.20,0.24)
LD TOCI IV		0.17(0.03,0.88)	0.20(0.03,0.89)	-0.14(-0.30,-0.01)
LD RITUX IV + MTX		1.55(0.45,5.33)	1.40(0.52,3.56)	0.07(-0.13,0.31)

(Continued)

LD ABA IV + MTX		1.80(0.52,6.25)	1.56(0.59,3.88)	0.10(-0.11,0.34)
LD ANA SC + MTX		2.64(0.32,23.26)	2.01(0.38,6.04)	0.18(-0.15,0.64)
LD CERTO SC + MTX		3.61(0.88,14.55)	2.40(0.91,5.72)	0.26(-0.02,0.55)
LD ETN SC + MTX		2.80(0.75,10.53)	2.09(0.80,5.03)	0.20(-0.05,0.47)
LD GOL I IV + MTX		1.85(0.46,7.54)	1.59(0.53,4.25)	0.11(-0.12,0.40)
LD TOCI IV + MTX		1.57(0.39,6.08)	1.42(0.47,3.80)	0.07(-0.14,0.34)
LD TOFA PO + MTX		2.77(0.57,13.40)	2.06(0.65,5.41)	0.19(-0.09,0.54)
HD TOCI IV		2.46(0.93,6.55)	1.93(0.95,4.17)	0.17(-0.02,0.34)
HD TOFA PO		3.07(1.07,8.74)	2.21(1.05,4.83)	0.22(0.01,0.42)
HD ADA SC		1.44(0.65,3.13)	1.33(0.72,2.46)	0.06(-0.07,0.20)
HD GOL I SC		2.56(0.77,8.42)	1.97(0.82,4.71)	0.18(-0.05,0.41)
HD ETN SC		1.72(0.47,6.28)	1.51(0.56,3.89)	0.09(-0.12,0.34)
HD ABA SC		4.23(0.79,23.84)	2.62(0.84,6.72)	0.30(-0.04,0.64)
HD TOCI IV + MTX		4.25(1.43,12.74)	2.64(1.27,5.75)	0.30(0.08,0.51)
HD TOFA PO + MTX		4.32(1.32,14.45)	2.65(1.20,5.93)	0.30(0.06,0.54)
HD GOL I SC + MTX		4.57(1.34,15.22)	2.74(1.23,6.09)	0.32(0.06,0.55)
HD CERTO SC + MTX		5.97(1.79,19.51)	3.08(1.46,6.70)	0.38(0.12,0.60)
HD INF IV + MTX		3.69(1.04,12.57)	2.44(1.02,5.61)	0.26(0.01,0.51)
HD TOCI IV + DMARD		0.91(0.23,3.37)	0.92(0.28,2.63)	-0.01(-0.20,0.20)
LD TOCI IV	LD GOL I IV	0.18(0.03,0.97)	0.21(0.03,0.97)	-0.13(-0.36,0.00)
LD RITUX IV + MTX		1.61(0.48,5.91)	1.45(0.58,4.17)	0.08(-0.14,0.29)
LD ABA IV + MTX		1.91(0.54,6.97)	1.63(0.64,4.72)	0.11(-0.11,0.32)
LD ANA SC + MTX		2.71(0.34,26.19)	2.04(0.42,7.72)	0.18(-0.16,0.64)
LD CERTO SC + MTX		3.83(0.97,14.94)	2.49(0.97,7.05)	0.26(-0.01,0.53)
LD ETN SC + MTX		2.95(0.79,11.52)	2.15(0.85,6.29)	0.20(-0.05,0.46)
LD GOL I IV + MTX		1.96(0.66,5.88)	1.65(0.73,4.02)	0.11(-0.07,0.32)
LD TOCI IV + MTX		1.63(0.39,7.02)	1.46(0.49,4.61)	0.08(-0.16,0.33)
LD TOFA PO + MTX		2.93(0.62,13.99)	2.13(0.70,6.55)	0.20(-0.08,0.52)

(Continued)

HD TOCI IV		2.61(0.81,8.59)	2.01(0.88,5.73)	0.17(-0.05,0.34)
HD TOFA PO		3.19(0.82,13.52)	2.28(0.88,7.41)	0.22(-0.04,0.45)
HD ADA SC		1.51(0.35,6.45)	1.38(0.46,4.69)	0.06(-0.20,0.28)
HD GOLI SC		2.70(0.72,10.22)	2.06(0.80,6.15)	0.18(-0.07,0.40)
HD ETN SC		1.81(0.50,6.93)	1.58(0.59,4.66)	0.09(-0.13,0.33)
HD ABA SC		4.45(0.70,31.35)	2.69(0.78,9.79)	0.30(-0.07,0.66)
HD TOCI IV + MTX		4.50(1.38,15.12)	2.74(1.20,7.77)	0.30(0.07,0.50)
HD TOFA PO + MTX		4.55(1.41,14.70)	2.75(1.22,7.36)	0.30(0.07,0.51)
HD GOLI SC + MTX		4.78(1.38,17.07)	2.83(1.22,7.96)	0.31(0.07,0.54)
HD CERTO SC + MTX		6.28(1.96,20.63)	3.22(1.45,8.65)	0.38(0.15,0.58)
HD INF IV + MTX		3.86(1.13,13.52)	2.52(1.08,6.99)	0.26(0.03,0.49)
HD TOCI IV + DMARD		0.96(0.21,4.24)	0.96(0.29,3.35)	-0.01(-0.25,0.20)
LD RITUX IV + MTX	LD TOCI IV	9.16(1.99,56.51)	6.92(1.78,37.78)	0.21(0.07,0.43)
LD ABA IV + MTX		10.70(2.29,67.10)	7.72(2.00,42.78)	0.24(0.08,0.46)
LD ANA SC + MTX		16.16(1.40,200.30)	9.73(1.35,63.50)	0.32(0.02,0.78)
LD CERTO SC + MTX		21.02(4.03,140.00)	11.70(2.99,63.85)	0.40(0.16,0.67)
LD ETN SC + MTX		16.69(3.41,106.30)	10.26(2.67,55.69)	0.34(0.13,0.59)
LD GOLI IV + MTX		10.97(2.10,75.57)	7.77(1.86,44.20)	0.25(0.07,0.52)
LD TOCI IV + MTX		9.20(2.07,51.29)	6.87(1.86,34.95)	0.21(0.06,0.45)
LD TOFA PO + MTX		16.80(2.68,125.80)	10.19(2.27,58.61)	0.34(0.09,0.66)
HD TOCI IV		14.50(3.83,77.33)	9.64(2.83,48.60)	0.31(0.19,0.46)
HD TOFA PO		18.08(3.77,117.20)	11.04(2.79,61.95)	0.36(0.20,0.54)
HD ADA SC		8.56(1.64,53.20)	6.66(1.53,37.47)	0.20(0.05,0.38)
HD GOLI SC		15.01(3.19,95.36)	9.76(2.49,54.89)	0.32(0.14,0.53)
HD ETN SC		10.17(2.02,66.08)	7.45(1.81,42.46)	0.23(0.07,0.47)
HD ABA SC		25.35(3.24,254.00)	12.86(2.59,78.02)	0.44(0.14,0.77)
HD TOCI IV + MTX		25.26(6.42,138.30)	13.18(3.84,67.50)	0.44(0.27,0.62)
HD TOFA PO + MTX		25.35(5.76,155.60)	13.11(3.65,69.81)	0.44(0.23,0.66)

(Continued)

HD GOLI SC + MTX		26.90(5.82,164.10)	13.57(3.64,74.17)	0.46(0.25,0.67)
HD CERTO SC + MTX		35.15(7.94,203.30)	15.25(4.27,79.07)	0.52(0.31,0.72)
HD INF IV + MTX		21.32(4.76,131.90)	11.92(3.27,63.50)	0.40(0.19,0.63)
HD TOCI IV + DMARD		5.33(1.01,36.04)	4.55(1.01,27.50)	0.12(0.00,0.33)
LD ABA IV + MTX	LD RITUX IV + MTX	1.16(0.41,3.22)	1.11(0.53,2.34)	0.03(-0.17,0.23)
LD ANA SC + MTX		1.67(0.25,13.36)	1.41(0.33,3.97)	0.10(-0.22,0.55)
LD CERTO SC + MTX		2.31(0.71,7.65)	1.70(0.79,3.69)	0.18(-0.07,0.44)
LD ETN SC + MTX		1.82(0.58,5.63)	1.49(0.69,3.17)	0.12(-0.11,0.37)
LD GOLI IV + MTX		1.21(0.36,3.94)	1.14(0.47,2.60)	0.04(-0.19,0.29)
LD TOCI IV + MTX		1.00(0.28,3.51)	1.00(0.38,2.47)	0.00(-0.23,0.25)
LD TOFA PO + MTX		1.80(0.44,7.19)	1.48(0.55,3.42)	0.12(-0.16,0.43)
HD TOCI IV		1.60(0.64,3.99)	1.38(0.76,2.81)	0.09(-0.10,0.26)
HD TOFA PO		1.97(0.59,6.65)	1.57(0.72,3.82)	0.14(-0.12,0.38)
HD ADA SC		0.92(0.27,3.29)	0.94(0.38,2.48)	-0.02(-0.26,0.21)
HD GOLI SC		1.65(0.55,5.02)	1.40(0.67,3.10)	0.10(-0.13,0.33)
HD ETN SC		1.11(0.37,3.39)	1.08(0.48,2.41)	0.02(-0.20,0.25)
HD ABA SC		2.76(0.49,16.52)	1.88(0.62,5.18)	0.22(-0.15,0.59)
HD TOCI IV + MTX		2.76(1.08,6.96)	1.88(1.04,3.82)	0.22(0.02,0.41)
HD TOFA PO + MTX		2.77(1.07,7.21)	1.88(1.04,3.72)	0.22(0.01,0.42)
HD GOLI SC + MTX		2.92(1.07,8.13)	1.94(1.04,3.96)	0.24(0.01,0.45)
HD CERTO SC + MTX		3.87(1.50,9.95)	2.19(1.24,4.33)	0.30(0.09,0.49)
HD INF IV + MTX		2.35(0.86,6.55)	1.73(0.91,3.53)	0.18(-0.03,0.40)
HD TOCI IV + DMARD		0.59(0.15,2.10)	0.66(0.22,1.76)	-0.08(-0.32,0.13)
LD ANA SC + MTX	LD ABA IV + MTX	1.46(0.20,11.51)	1.27(0.28,3.57)	0.08(-0.26,0.52)
LD CERTO SC + MTX		1.98(0.60,6.52)	1.53(0.72,3.21)	0.15(-0.10,0.41)
LD ETN SC + MTX		1.56(0.51,4.80)	1.33(0.64,2.77)	0.09(-0.14,0.34)
LD GOLI IV + MTX		1.03(0.31,3.49)	1.02(0.42,2.33)	0.01(-0.23,0.27)

(Continued)

LD TOCI IV + MTX		0.87(0.25,3.01)	0.90(0.36,2.16)	-0.03(-0.26,0.22)
LD TOFA PO + MTX		1.55(0.38,6.29)	1.33(0.50,3.09)	0.09(-0.19,0.40)
HD TOCI IV		1.37(0.56,3.39)	1.23(0.71,2.48)	0.07(-0.13,0.24)
HD TOFA PO		1.68(0.50,5.83)	1.40(0.66,3.41)	0.11(-0.16,0.36)
HD ADA SC		0.80(0.23,2.82)	0.85(0.35,2.19)	-0.04(-0.30,0.19)
HD GOLI SC		1.41(0.47,4.22)	1.26(0.62,2.72)	0.07(-0.16,0.30)
HD ETN SC		0.95(0.31,2.89)	0.97(0.43,2.08)	-0.01(-0.23,0.22)
HD ABA SC		2.33(0.45,14.25)	1.65(0.58,4.56)	0.19(-0.17,0.57)
HD TOCI IV + MTX		2.37(0.97,5.94)	1.68(0.98,3.34)	0.19(-0.01,0.38)
HD TOFA PO + MTX		2.38(0.94,6.08)	1.68(0.97,3.26)	0.19(-0.01,0.40)
HD GOLI SC + MTX		2.49(0.93,7.08)	1.73(0.96,3.53)	0.21(-0.02,0.43)
HD CERTO SC + MTX		3.30(1.31,8.53)	1.96(1.16,3.85)	0.27(0.06,0.47)
HD INF IV + MTX		2.01(0.75,5.50)	1.54(0.84,3.05)	0.15(-0.06,0.37)
HD TOCI IV + DMARD		0.50(0.14,1.77)	0.59(0.21,1.54)	-0.11(-0.34,0.10)
LD CERTO SC + MTX	LD ANA SC + MTX	1.40(0.15,10.56)	1.20(0.42,5.41)	0.07(-0.40,0.45)
LD ETN SC + MTX		1.08(0.12,8.16)	1.05(0.37,4.81)	0.02(-0.46,0.39)
LD GOLI IV + MTX		0.72(0.08,5.62)	0.81(0.25,3.72)	-0.07(-0.55,0.30)
LD TOCI IV + MTX		0.60(0.06,4.73)	0.71(0.21,3.39)	-0.10(-0.58,0.26)
LD TOFA PO + MTX		1.06(0.12,9.47)	1.04(0.32,4.93)	0.01(-0.46,0.43)
HD TOCI IV		0.95(0.13,6.37)	0.97(0.41,4.32)	-0.01(-0.45,0.30)
HD TOFA PO		1.17(0.13,9.01)	1.10(0.42,5.38)	0.04(-0.44,0.39)
HD ADA SC		0.55(0.06,4.26)	0.66(0.23,3.31)	-0.12(-0.59,0.22)
HD GOLI SC		0.97(0.12,7.08)	0.98(0.37,4.51)	-0.01(-0.47,0.34)
HD ETN SC		0.66(0.08,4.83)	0.77(0.25,3.45)	-0.08(-0.55,0.26)
HD ABA SC		1.65(0.13,20.12)	1.31(0.38,7.09)	0.11(-0.44,0.58)
HD TOCI IV + MTX		1.63(0.22,11.26)	1.31(0.57,5.77)	0.11(-0.33,0.44)
HD TOFA PO + MTX		1.67(0.21,11.09)	1.33(0.56,5.73)	0.12(-0.33,0.45)
HD GOLI SC + MTX		1.76(0.21,12.43)	1.37(0.56,6.10)	0.13(-0.33,0.48)

(Continued)

HD CERTO SC + MTX		2.28(0.29,15.46)	1.53(0.65,6.73)	0.19(-0.26,0.53)
HD INF IV + MTX		1.40(0.17,9.75)	1.21(0.48,5.32)	0.08(-0.38,0.43)
HD TOCI IV + DMARD		0.34(0.04,2.90)	0.47(0.14,2.42)	-0.19(-0.66,0.15)
LD ETN SC + MTX	LD CERTO SC + MTX	0.78(0.22,2.80)	0.87(0.41,1.85)	-0.06(-0.35,0.23)
LD GOLI IV + MTX		0.52(0.13,1.98)	0.67(0.27,1.54)	-0.14(-0.43,0.15)
LD TOCI IV + MTX		0.43(0.11,1.68)	0.59(0.24,1.40)	-0.18(-0.47,0.11)
LD TOFA PO + MTX		0.77(0.17,3.40)	0.87(0.33,2.00)	-0.06(-0.38,0.28)
HD TOCI IV		0.68(0.23,2.04)	0.80(0.47,1.64)	-0.09(-0.34,0.15)
HD TOFA PO		0.85(0.22,3.34)	0.91(0.47,2.17)	-0.04(-0.35,0.27)
HD ADA SC		0.40(0.10,1.61)	0.55(0.24,1.40)	-0.20(-0.50,0.10)
HD GOLI SC		0.71(0.20,2.44)	0.82(0.41,1.79)	-0.08(-0.37,0.20)
HD ETN SC		0.48(0.13,1.73)	0.63(0.28,1.42)	-0.16(-0.44,0.12)
HD ABA SC		1.17(0.20,7.79)	1.08(0.39,2.89)	0.04(-0.37,0.46)
HD TOCI IV + MTX		1.19(0.40,3.58)	1.09(0.65,2.21)	0.04(-0.22,0.29)
HD TOFA PO + MTX		1.20(0.40,3.68)	1.10(0.64,2.20)	0.04(-0.22,0.30)
HD GOLI SC + MTX		1.26(0.39,4.12)	1.13(0.64,2.31)	0.06(-0.22,0.33)
HD CERTO SC + MTX		1.65(0.64,4.28)	1.27(0.83,2.38)	0.12(-0.10,0.33)
HD INF IV + MTX		1.02(0.31,3.28)	1.01(0.54,2.05)	0.00(-0.27,0.27)
HD TOCI IV + DMARD		0.25(0.06,1.02)	0.38(0.14,1.01)	-0.27(-0.55,0.00)
LD GOLI IV + MTX	LD ETN SC + MTX	0.66(0.18,2.42)	0.77(0.31,1.74)	-0.09(-0.36,0.19)
LD TOCI IV + MTX		0.55(0.15,2.10)	0.67(0.26,1.66)	-0.12(-0.39,0.16)
LD TOFA PO + MTX		0.99(0.22,4.31)	0.99(0.37,2.32)	0.00(-0.32,0.33)
HD TOCI IV		0.88(0.32,2.37)	0.92(0.54,1.85)	-0.03(-0.27,0.18)
HD TOFA PO		1.08(0.31,3.96)	1.05(0.53,2.49)	0.02(-0.28,0.29)
HD ADA SC		0.51(0.14,1.90)	0.63(0.27,1.59)	-0.14(-0.42,0.13)
HD GOLI SC		0.91(0.28,2.99)	0.94(0.47,2.05)	-0.02(-0.29,0.24)
HD ETN SC		0.61(0.19,2.02)	0.72(0.32,1.60)	-0.10(-0.36,0.15)

(Continued)

HD ABA SC		1.50(0.27,9.56)	1.24(0.45,3.31)	0.09(-0.30,0.49)
HD TOCI IV + MTX		1.52(0.56,4.18)	1.26(0.74,2.50)	0.10(-0.14,0.31)
HD TOFA PO + MTX		1.53(0.54,4.46)	1.27(0.73,2.49)	0.10(-0.14,0.33)
HD GOL I SC + MTX		1.61(0.53,5.02)	1.30(0.72,2.64)	0.11(-0.15,0.36)
HD CERTO SC + MTX		2.11(0.76,6.02)	1.46(0.88,2.88)	0.18(-0.07,0.41)
HD INF IV + MTX		1.30(0.44,3.92)	1.16(0.63,2.31)	0.06(-0.19,0.31)
HD TOCI IV + DMARD		0.32(0.08,1.21)	0.44(0.16,1.15)	-0.21(-0.47,0.04)
LD TOCI IV + MTX	LD GOL I IV + MTX	0.84(0.20,3.41)	0.88(0.32,2.42)	-0.03(-0.31,0.24)
LD TOFA PO + MTX		1.49(0.33,6.96)	1.29(0.47,3.45)	0.08(-0.23,0.42)
HD TOCI IV		1.33(0.43,4.09)	1.21(0.62,2.88)	0.06(-0.20,0.26)
HD TOFA PO		1.63(0.44,6.47)	1.38(0.63,3.84)	0.11(-0.19,0.37)
HD ADA SC		0.78(0.19,3.21)	0.84(0.32,2.43)	-0.05(-0.35,0.20)
HD GOL I SC		1.37(0.39,4.95)	1.23(0.55,3.20)	0.07(-0.22,0.32)
HD ETN SC		0.92(0.26,3.33)	0.95(0.40,2.44)	-0.01(-0.29,0.23)
HD ABA SC		2.28(0.36,15.71)	1.63(0.53,5.06)	0.18(-0.23,0.58)
HD TOCI IV + MTX		2.29(0.74,7.20)	1.65(0.86,3.92)	0.19(-0.07,0.41)
HD TOFA PO + MTX		2.31(0.75,7.41)	1.64(0.85,3.78)	0.19(-0.07,0.43)
HD GOL I SC + MTX		2.44(0.73,8.26)	1.69(0.85,4.07)	0.20(-0.08,0.44)
HD CERTO SC + MTX		3.19(1.02,10.06)	1.92(1.01,4.44)	0.27(0.01,0.49)
HD INF IV + MTX		1.97(0.58,6.61)	1.52(0.72,3.61)	0.15(-0.13,0.40)
HD TOCI IV + DMARD		0.49(0.11,2.04)	0.58(0.19,1.74)	-0.12(-0.41,0.12)
LD TOFA PO + MTX	LD TOCI IV + MTX	1.78(0.37,8.74)	1.46(0.50,4.09)	0.12(-0.19,0.46)
HD TOCI IV		1.58(0.60,4.37)	1.37(0.73,3.10)	0.09(-0.12,0.26)
HD TOFA PO		1.98(0.53,7.29)	1.57(0.68,4.29)	0.15(-0.15,0.38)
HD ADA SC		0.92(0.24,3.59)	0.94(0.36,2.71)	-0.02(-0.29,0.22)
HD GOL I SC		1.64(0.46,6.05)	1.40(0.61,3.68)	0.10(-0.17,0.35)
HD ETN SC		1.10(0.30,4.06)	1.07(0.43,2.87)	0.02(-0.24,0.27)

(Continued)

HD ABA SC		2.73(0.45,17.79)	1.85(0.60,5.61)	0.22(-0.17,0.59)
HD TOCI IV + MTX		2.76(1.01,7.82)	1.87(1.01,4.30)	0.22(0.00,0.42)
HD TOFA PO + MTX		2.78(0.85,9.12)	1.88(0.91,4.54)	0.22(-0.04,0.46)
HD GOLI SC + MTX		2.92(0.88,10.05)	1.93(0.93,4.81)	0.24(-0.03,0.48)
HD CERTO SC + MTX		3.83(1.20,12.17)	2.19(1.10,5.23)	0.30(0.04,0.52)
HD INF IV + MTX		2.36(0.68,7.90)	1.72(0.79,4.23)	0.18(-0.09,0.43)
HD TOCI IV + DMARD		0.58(0.14,2.26)	0.66(0.22,1.93)	-0.08(-0.34,0.14)
HD TOCI IV	LD TOFA PO + MTX	0.89(0.24,3.27)	0.93(0.48,2.43)	-0.03(-0.34,0.22)
HD TOFA PO		1.12(0.23,5.17)	1.07(0.48,3.16)	0.03(-0.34,0.33)
HD ADA SC		0.52(0.11,2.57)	0.64(0.25,2.04)	-0.14(-0.49,0.17)
HD GOLI SC		0.92(0.21,3.85)	0.95(0.43,2.59)	-0.02(-0.36,0.27)
HD ETN SC		0.61(0.14,2.71)	0.73(0.30,2.05)	-0.10(-0.43,0.19)
HD ABA SC		1.52(0.22,11.95)	1.26(0.42,4.11)	0.10(-0.35,0.53)
HD TOCI IV + MTX		1.54(0.41,5.65)	1.27(0.67,3.22)	0.10(-0.20,0.36)
HD TOFA PO + MTX		1.55(0.49,4.96)	1.27(0.72,2.95)	0.10(-0.17,0.34)
HD GOLI SC + MTX		1.64(0.41,6.37)	1.31(0.66,3.36)	0.12(-0.21,0.40)
HD CERTO SC + MTX		2.15(0.57,8.03)	1.48(0.79,3.70)	0.18(-0.13,0.45)
HD INF IV + MTX		1.32(0.33,5.21)	1.17(0.57,3.00)	0.06(-0.26,0.35)
HD TOCI IV + DMARD		0.33(0.07,1.59)	0.45(0.15,1.42)	-0.21(-0.53,0.08)
HD TOFA PO	HD TOCI IV	1.24(0.49,3.16)	1.14(0.64,2.02)	0.05(-0.17,0.27)
HD ADA SC		0.59(0.22,1.55)	0.69(0.33,1.34)	-0.11(-0.30,0.09)
HD GOLI SC		1.03(0.41,2.58)	1.02(0.55,1.77)	0.01(-0.19,0.22)
HD ETN SC		0.70(0.26,1.86)	0.78(0.37,1.45)	-0.08(-0.26,0.15)
HD ABA SC		1.71(0.38,8.82)	1.37(0.51,2.83)	0.13(-0.21,0.49)
HD TOCI IV + MTX		1.73(0.98,3.14)	1.37(0.99,1.90)	0.13(-0.01,0.27)
HD TOFA PO + MTX		1.75(0.77,3.95)	1.37(0.85,2.08)	0.13(-0.06,0.32)
HD GOLI SC + MTX		1.85(0.78,4.44)	1.41(0.86,2.22)	0.15(-0.06,0.35)

(Continued)

HD CERTO SC + MTX		2.41(1.09,5.50)	1.59(1.05,2.36)	0.21(0.02,0.39)
HD INF IV + MTX		1.48(0.61,3.53)	1.26(0.72,1.97)	0.09(-0.11,0.30)
HD TOCI IV + DMARD		0.37(0.13,1.02)	0.48(0.19,1.01)	-0.18(-0.34,0.00)
HD ADA SC	HD TOFA PO	0.47(0.17,1.31)	0.60(0.29,1.20)	-0.16(-0.36,0.06)
HD GOLI SC		0.84(0.27,2.54)	0.90(0.43,1.73)	-0.04(-0.29,0.22)
HD ETN SC		0.57(0.16,1.98)	0.69(0.28,1.51)	-0.12(-0.37,0.16)
HD ABA SC		1.39(0.30,7.02)	1.20(0.45,2.42)	0.08(-0.27,0.44)
HD TOCI IV + MTX		1.40(0.50,4.03)	1.20(0.67,2.13)	0.08(-0.17,0.33)
HD TOFA PO + MTX		1.40(0.44,4.57)	1.20(0.62,2.20)	0.08(-0.19,0.36)
HD GOLI SC + MTX		1.49(0.47,4.61)	1.24(0.65,2.22)	0.10(-0.18,0.36)
HD CERTO SC + MTX		1.96(0.61,5.87)	1.41(0.77,2.41)	0.16(-0.12,0.41)
HD INF IV + MTX		1.20(0.36,3.87)	1.11(0.53,2.05)	0.04(-0.23,0.32)
HD TOCI IV + DMARD		0.29(0.08,1.06)	0.41(0.15,1.04)	-0.23(-0.44,0.01)
HD GOLI SC	HD ADA SC	1.77(0.55,5.82)	1.49(0.66,3.38)	0.12(-0.12,0.36)
HD ETN SC		1.20(0.33,4.34)	1.14(0.43,2.81)	0.03(-0.20,0.30)
HD ABA SC		2.95(0.58,16.90)	1.97(0.69,4.88)	0.24(-0.11,0.60)
HD TOCI IV + MTX		3.00(1.00,9.18)	2.00(1.00,4.20)	0.24(0.00,0.47)
HD TOFA PO + MTX		3.04(0.89,9.90)	2.01(0.93,4.27)	0.24(-0.02,0.49)
HD GOLI SC + MTX		3.17(0.96,10.70)	2.06(0.97,4.46)	0.26(-0.01,0.51)
HD CERTO SC + MTX		4.17(1.23,13.41)	2.33(1.13,4.81)	0.32(0.05,0.55)
HD INF IV + MTX		2.55(0.74,8.89)	1.84(0.81,4.06)	0.20(-0.07,0.47)
HD TOCI IV + DMARD		0.63(0.16,2.29)	0.70(0.23,1.88)	-0.07(-0.28,0.15)
HD ETN SC	HD GOLI SC	0.67(0.21,2.21)	0.77(0.33,1.67)	-0.08(-0.32,0.17)
HD ABA SC		1.66(0.32,9.56)	1.33(0.48,3.10)	0.12(-0.25,0.50)
HD TOCI IV + MTX		1.68(0.65,4.45)	1.34(0.79,2.46)	0.12(-0.10,0.34)
HD TOFA PO + MTX		1.68(0.61,4.95)	1.34(0.75,2.48)	0.12(-0.12,0.36)
HD GOLI SC + MTX		1.77(0.76,4.30)	1.37(0.86,2.34)	0.13(-0.06,0.33)

(Continued)

HD CERTO SC + MTX		2.34(0.87,6.39)	1.55(0.93,2.81)	0.20(-0.03,0.42)
HD INF IV + MTX		1.43(0.50,4.21)	1.23(0.65,2.32)	0.08(-0.16,0.33)
HD TOCI IV + DMARD		0.35(0.10,1.27)	0.47(0.17,1.18)	-0.19(-0.42,0.05)
HD ABA SC	HD ETN SC	2.47(0.45,15.55)	1.72(0.59,4.88)	0.20(-0.17,0.58)
HD TOCI IV + MTX		2.50(0.91,6.90)	1.75(0.95,3.70)	0.20(-0.02,0.41)
HD TOFA PO + MTX		2.52(0.89,7.07)	1.75(0.93,3.64)	0.21(-0.03,0.42)
HD GOLI SC + MTX		2.64(0.87,8.00)	1.79(0.93,3.91)	0.22(-0.03,0.45)
HD CERTO SC + MTX		3.47(1.23,9.81)	2.03(1.11,4.22)	0.28(0.05,0.49)
HD INF IV + MTX		2.11(0.72,6.50)	1.60(0.82,3.44)	0.16(-0.08,0.40)
HD TOCI IV + DMARD		0.52(0.14,1.92)	0.61(0.22,1.66)	-0.10(-0.34,0.11)
HD TOCI IV + MTX	HD ABA SC	1.01(0.18,4.85)	1.01(0.49,2.61)	0.00(-0.38,0.35)
HD TOFA PO + MTX		1.03(0.17,5.35)	1.02(0.45,2.69)	0.01(-0.40,0.38)
HD GOLI SC + MTX		1.07(0.18,5.66)	1.03(0.47,2.79)	0.02(-0.38,0.39)
HD CERTO SC + MTX		1.41(0.24,7.32)	1.17(0.57,3.04)	0.08(-0.31,0.44)
HD INF IV + MTX		0.86(0.14,4.62)	0.92(0.40,2.50)	-0.04(-0.43,0.35)
HD TOCI IV + DMARD		0.21(0.03,1.24)	0.35(0.11,1.17)	-0.31(-0.66,0.04)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.01(0.44,2.30)	1.00(0.64,1.50)	0.00(-0.19,0.20)
HD GOLI SC + MTX		1.06(0.44,2.61)	1.03(0.64,1.61)	0.01(-0.20,0.23)
HD CERTO SC + MTX		1.39(0.62,3.13)	1.16(0.79,1.71)	0.08(-0.11,0.27)
HD INF IV + MTX		0.85(0.35,2.08)	0.92(0.54,1.44)	-0.04(-0.25,0.17)
HD TOCI IV + DMARD		0.21(0.07,0.64)	0.35(0.14,0.75)	-0.31(-0.51,-0.10)
HD GOLI SC + MTX	HD TOFA PO + MTX	1.05(0.41,2.66)	1.03(0.64,1.67)	0.01(-0.21,0.23)
HD CERTO SC + MTX		1.38(0.60,3.13)	1.16(0.79,1.78)	0.08(-0.12,0.27)
HD INF IV + MTX		0.84(0.33,2.16)	0.92(0.54,1.50)	-0.04(-0.26,0.18)
HD TOCI IV + DMARD		0.21(0.06,0.70)	0.35(0.13,0.80)	-0.31(-0.54,-0.07)
HD CERTO SC + MTX	HD GOLI SC + MTX	1.31(0.53,3.32)	1.13(0.74,1.79)	0.06(-0.15,0.28)

(Continued)

HD INF IV + MTX		0.80(0.30,2.17)	0.89(0.51,1.50)	-0.05(-0.29,0.19)
HD TOCI IV + DMARD		0.20(0.06,0.69)	0.34(0.13,0.79)	-0.33(-0.56,-0.08)
HD INF IV + MTX	HD CERTO SC + MTX	0.61(0.25,1.53)	0.79(0.47,1.22)	-0.12(-0.33,0.10)
HD TOCI IV + DMARD		0.15(0.04,0.51)	0.30(0.12,0.67)	-0.39(-0.61,-0.15)
HD TOCI IV + DMARD	HD INF IV + MTX	0.25(0.07,0.84)	0.38(0.14,0.89)	-0.27(-0.52,-0.03)
Random-effects model	Residual deviance	165.2 vs 163 data points		
	Deviance information criteria	1084.66		
Fixed-effect model	Residual deviance	vs data points		
	Deviance information criteria			

Note

Total participants	24,984
Total studies	60
2-arm	28
3-arm	25
4-arm	5
5-arm	1
7-arm	1

Appendix 4. ACR50: subgroup - late RA (> 10 years)

ACR50 late RA: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
PL + MTX	PL	9.03(2.77,32.14)	5.98(2.40,14.46)	0.31(0.11,0.55)

(Continued)

SD ETN SC		12.36(4.09,40.45)	7.19(3.20,16.25)	0.38(0.18,0.60)
SD ADA SC		3.25(1.25,9.09)	2.84(1.22,6.57)	0.11(0.02,0.28)
SD RITUX IV		7.61(1.05,48.91)	5.31(1.05,15.48)	0.27(0.00,0.67)
SD ADA SC + MTX		78.18(21.30,316.50)	13.37(7.38,25.96)	0.77(0.56,0.89)
SD RITUX IV + MTX		29.22(7.62,123.90)	10.42(4.86,21.99)	0.59(0.30,0.81)
SD INF IV + MTX		28.50(5.64,150.40)	10.32(4.06,21.95)	0.59(0.24,0.84)
SD ANA SC + MTX		21.62(5.29,100.60)	9.34(3.88,20.73)	0.52(0.22,0.78)
LD ETN SC		6.53(2.15,21.87)	4.84(1.95,12.08)	0.24(0.08,0.45)
LD ADA SC + MTX		52.44(14.07,203.40)	12.33(6.47,24.47)	0.71(0.45,0.86)
LD ADA IV + MTX		37.02(4.69,310.40)	11.04(3.64,24.02)	0.64(0.19,0.89)
LD RITUX IV + MTX		29.07(7.11,128.80)	10.41(4.65,22.13)	0.59(0.29,0.81)
HD ETN SC		11.74(2.36,61.75)	6.95(2.11,17.43)	0.37(0.08,0.71)
HD INF IV + MTX		70.87(14.10,366.00)	13.00(6.55,25.50)	0.76(0.46,0.90)
HD ADA SC + MTX		64.44(15.62,288.90)	12.83(6.77,25.34)	0.74(0.47,0.88)
SD ETN SC	PL + MTX	1.38(0.76,2.56)	1.20(0.86,1.84)	0.07(-0.06,0.21)
SD ADA SC		0.36(0.07,1.79)	0.48(0.15,1.54)	-0.19(-0.49,0.11)
SD RITUX IV		0.85(0.16,3.46)	0.91(0.23,1.91)	-0.03(-0.30,0.29)
SD ADA SC + MTX		8.66(4.91,16.96)	2.24(1.53,3.76)	0.45(0.31,0.57)
SD RITUX IV + MTX		3.25(1.67,6.41)	1.74(1.27,2.63)	0.27(0.11,0.41)
SD INF IV + MTX		3.14(1.10,10.16)	1.70(1.05,2.87)	0.26(0.02,0.48)
SD ANA SC + MTX		2.43(1.15,5.27)	1.55(1.08,2.37)	0.21(0.03,0.37)
LD ETN SC		0.73(0.40,1.35)	0.82(0.55,1.23)	-0.07(-0.21,0.06)
LD ADA SC + MTX		5.81(3.23,10.66)	2.06(1.46,3.26)	0.39(0.25,0.50)
LD ADA IV + MTX		4.10(0.76,22.94)	1.81(0.83,3.35)	0.32(-0.06,0.58)
LD RITUX IV + MTX		3.25(1.52,6.96)	1.73(1.23,2.67)	0.27(0.09,0.42)
HD ETN SC		1.30(0.38,4.74)	1.16(0.51,2.26)	0.06(-0.20,0.35)
HD INF IV + MTX		7.73(2.84,23.51)	2.15(1.46,3.72)	0.43(0.23,0.60)
HD ADA SC + MTX		7.10(3.18,16.90)	2.14(1.47,3.57)	0.42(0.25,0.56)

(Continued)

SD ADA SC	SD ETN SC	0.26(0.05,1.24)	0.40(0.13,1.16)	-0.27(-0.55,0.04)
SD RITUX IV		0.62(0.10,2.82)	0.75(0.18,1.61)	-0.11(-0.40,0.24)
SD ADA SC + MTX		6.29(2.78,15.30)	1.84(1.36,2.85)	0.37(0.22,0.53)
SD RITUX IV + MTX		2.38(0.95,5.71)	1.44(0.97,2.17)	0.20(-0.01,0.38)
SD INF IV + MTX		2.30(0.68,8.47)	1.42(0.81,2.29)	0.19(-0.09,0.43)
SD ANA SC + MTX		1.77(0.66,4.65)	1.30(0.79,1.97)	0.14(-0.09,0.34)
LD ETN SC		0.53(0.32,0.88)	0.68(0.46,0.93)	-0.14(-0.26,-0.03)
LD ADA SC + MTX		4.22(1.81,9.69)	1.70(1.25,2.56)	0.31(0.14,0.47)
LD ADA IV + MTX		2.98(0.48,17.74)	1.53(0.64,2.60)	0.24(-0.16,0.52)
LD RITUX IV + MTX		2.37(0.88,6.08)	1.44(0.93,2.18)	0.20(-0.03,0.39)
HD ETN SC		0.95(0.32,2.95)	0.97(0.45,1.61)	-0.01(-0.24,0.24)
HD INF IV + MTX		5.61(1.73,19.73)	1.79(1.24,2.83)	0.35(0.13,0.54)
HD ADA SC + MTX		5.18(1.90,14.64)	1.77(1.27,2.74)	0.34(0.15,0.51)
SD RITUX IV	SD ADA SC	2.31(0.26,19.14)	1.86(0.32,6.88)	0.15(-0.19,0.59)
SD ADA SC + MTX		24.02(4.41,138.70)	4.70(2.08,11.58)	0.65(0.35,0.84)
SD RITUX IV + MTX		8.97(1.62,51.78)	3.68(1.35,9.85)	0.47(0.11,0.74)
SD INF IV + MTX		8.70(1.25,61.66)	3.61(1.16,9.86)	0.47(0.05,0.76)
SD ANA SC + MTX		6.65(1.16,40.42)	3.29(1.11,9.28)	0.40(0.03,0.71)
LD ETN SC		2.02(0.43,9.84)	1.71(0.53,5.65)	0.12(-0.15,0.40)
LD ADA SC + MTX		15.95(2.91,90.03)	4.33(1.79,10.94)	0.59(0.25,0.80)
LD ADA IV + MTX		11.47(1.14,117.00)	3.86(1.09,10.54)	0.52(0.03,0.82)
LD RITUX IV + MTX		8.91(1.55,53.22)	3.67(1.32,9.84)	0.47(0.09,0.75)
HD ETN SC		3.59(0.53,25.06)	2.43(0.62,7.85)	0.25(-0.11,0.63)
HD INF IV + MTX		21.42(3.13,149.10)	4.57(1.86,11.37)	0.63(0.26,0.84)
HD ADA SC + MTX		19.49(3.30,119.80)	4.51(1.91,11.25)	0.62(0.28,0.83)
SD ADA SC + MTX	SD RITUX IV	10.16(2.23,60.86)	2.46(1.20,10.85)	0.48(0.14,0.75)
SD RITUX IV + MTX	IV	3.78(0.98,19.16)	1.91(1.00,7.58)	0.30(0.00,0.57)
SD INF IV + MTX		3.74(0.63,27.40)	1.88(0.81,8.12)	0.29(-0.11,0.64)

(Continued)

SD ANA SC + MTX		2.86(0.57,17.81)	1.71(0.78,7.20)	0.23(-0.13,0.56)
LD ETN SC		0.86(0.19,5.08)	0.90(0.40,3.77)	-0.03(-0.38,0.24)
LD ADA SC + MTX		6.77(1.49,39.92)	2.26(1.11,9.79)	0.42(0.08,0.70)
LD ADA IV + MTX		4.91(0.54,48.35)	1.98(0.72,9.04)	0.33(-0.14,0.72)
LD RITUX IV + MTX		3.77(0.86,21.06)	1.90(0.95,7.79)	0.30(-0.03,0.59)
HD ETN SC		1.54(0.23,13.15)	1.28(0.43,6.03)	0.09(-0.32,0.49)
HD INF IV + MTX		9.21(1.56,66.83)	2.38(1.13,10.47)	0.46(0.09,0.76)
HD ADA SC + MTX		8.35(1.68,54.98)	2.35(1.15,10.26)	0.45(0.10,0.74)
SD RITUX IV + MTX	SD ADA SC + MTX	0.37(0.15,0.90)	0.79(0.51,0.98)	-0.17(-0.38,-0.02)
SD INF IV + MTX		0.36(0.10,1.31)	0.79(0.41,1.05)	-0.18(-0.46,0.04)
SD ANA SC + MTX		0.28(0.10,0.73)	0.71(0.41,0.94)	-0.24(-0.46,-0.05)
LD ETN SC		0.08(0.03,0.19)	0.36(0.21,0.56)	-0.52(-0.65,-0.36)
LD ADA SC + MTX		0.67(0.38,1.07)	0.93(0.77,1.01)	-0.06(-0.17,0.01)
LD ADA IV + MTX		0.47(0.08,2.60)	0.85(0.35,1.15)	-0.12(-0.52,0.11)
LD RITUX IV + MTX		0.38(0.13,0.94)	0.79(0.49,0.99)	-0.17(-0.40,-0.01)
HD ETN SC		0.15(0.04,0.60)	0.53(0.21,0.89)	-0.39(-0.65,-0.09)
HD INF IV + MTX		0.89(0.26,3.07)	0.98(0.70,1.21)	-0.02(-0.24,0.14)
HD ADA SC + MTX		0.82(0.38,1.70)	0.97(0.77,1.10)	-0.03(-0.17,0.07)
SD INF IV + MTX	SD RITUX IV + MTX	0.96(0.28,3.76)	0.99(0.56,1.53)	-0.01(-0.28,0.26)
SD ANA SC + MTX		0.74(0.27,2.13)	0.90(0.56,1.33)	-0.06(-0.29,0.16)
LD ETN SC		0.22(0.09,0.55)	0.47(0.28,0.73)	-0.34(-0.52,-0.13)
LD ADA SC + MTX		1.79(0.74,4.31)	1.17(0.92,1.72)	0.11(-0.06,0.30)
LD ADA IV + MTX		1.26(0.21,7.77)	1.07(0.45,1.76)	0.05(-0.35,0.35)
LD RITUX IV + MTX		0.99(0.51,1.98)	1.00(0.75,1.29)	0.00(-0.15,0.14)
HD ETN SC		0.40(0.10,1.73)	0.67(0.28,1.24)	-0.21(-0.50,0.12)
HD INF IV + MTX		2.36(0.72,8.88)	1.23(0.91,1.91)	0.15(-0.06,0.38)
HD ADA SC + MTX		2.19(0.76,6.44)	1.21(0.93,1.86)	0.14(-0.05,0.36)

(Continued)

SD ANA SC + MTX	SD INF IV + MTX	0.77(0.19,2.90)	0.92(0.53,1.63)	-0.05(-0.34,0.24)
LD ETN SC		0.23(0.06,0.77)	0.48(0.27,0.86)	-0.34(-0.57,-0.05)
LD ADA SC + MTX		1.85(0.50,6.31)	1.18(0.86,2.17)	0.12(-0.11,0.39)
LD ADA IV + MTX		1.30(0.17,9.16)	1.07(0.44,2.07)	0.05(-0.39,0.41)
LD RITUX IV + MTX		1.03(0.25,3.75)	1.01(0.63,1.79)	0.01(-0.27,0.29)
HD ETN SC		0.41(0.07,2.16)	0.69(0.27,1.42)	-0.20(-0.54,0.17)
HD INF IV + MTX		2.46(1.05,5.75)	1.24(1.01,2.01)	0.16(0.01,0.36)
HD ADA SC + MTX		2.25(0.55,8.92)	1.22(0.87,2.31)	0.15(-0.10,0.44)
LD ETN SC	SD ANA SC + MTX	0.30(0.11,0.78)	0.53(0.31,0.86)	-0.28(-0.48,-0.05)
LD ADA SC + MTX		2.38(0.91,6.30)	1.30(0.98,2.18)	0.17(-0.02,0.39)
LD ADA IV + MTX		1.67(0.27,10.90)	1.17(0.50,2.16)	0.10(-0.30,0.43)
LD RITUX IV + MTX		1.34(0.44,3.87)	1.11(0.72,1.80)	0.06(-0.18,0.29)
HD ETN SC		0.54(0.13,2.43)	0.75(0.31,1.49)	-0.14(-0.45,0.20)
HD INF IV + MTX		3.16(0.88,12.20)	1.36(0.96,2.41)	0.21(-0.02,0.47)
HD ADA SC + MTX		2.92(0.96,9.18)	1.35(0.99,2.34)	0.21(-0.01,0.44)
LD ADA SC + MTX	LD ETN SC	7.94(3.42,18.41)	2.52(1.67,4.23)	0.46(0.28,0.60)
LD ADA IV + MTX		5.61(0.90,33.83)	2.23(0.93,4.23)	0.39(-0.02,0.65)
LD RITUX IV + MTX		4.46(1.67,11.67)	2.12(1.33,3.56)	0.34(0.11,0.53)
HD ETN SC		1.79(0.53,6.27)	1.42(0.63,2.73)	0.13(-0.12,0.41)
HD INF IV + MTX		10.54(3.32,37.56)	2.65(1.67,4.71)	0.50(0.27,0.67)
HD ADA SC + MTX		9.76(3.59,27.53)	2.62(1.70,4.54)	0.49(0.29,0.64)
LD ADA IV + MTX	LD ADA SC + MTX	0.70(0.13,3.73)	0.92(0.38,1.27)	-0.06(-0.44,0.18)
LD RITUX IV + MTX		0.56(0.21,1.44)	0.86(0.55,1.10)	-0.11(-0.32,0.07)
HD ETN SC		0.22(0.06,0.93)	0.57(0.23,0.98)	-0.32(-0.59,-0.01)
HD INF IV + MTX		1.32(0.40,4.66)	1.05(0.77,1.40)	0.04(-0.17,0.24)
HD ADA SC + MTX		1.22(0.58,2.64)	1.04(0.86,1.27)	0.03(-0.10,0.16)

(Continued)

LD RITUX IV + MTX	LD ADA IV + MTX	0.79(0.12,5.12)	0.94(0.55,2.21)	-0.05(-0.36,0.36)
HD ETN SC		0.32(0.04,2.57)	0.65(0.25,1.65)	-0.24(-0.61,0.21)
HD INF IV + MTX		1.92(0.27,14.27)	1.14(0.77,2.87)	0.10(-0.19,0.52)
HD ADA SC + MTX		1.75(0.28,10.64)	1.13(0.79,2.77)	0.09(-0.18,0.49)
HD ETN SC	LD RITUX IV + MTX	0.40(0.10,1.79)	0.68(0.28,1.27)	-0.21(-0.50,0.13)
HD INF IV + MTX		2.36(0.69,9.30)	1.23(0.90,2.00)	0.15(-0.07,0.40)
HD ADA SC + MTX		2.19(0.72,6.90)	1.21(0.92,1.95)	0.14(-0.06,0.37)
HD INF IV + MTX	HD ETN SC	5.95(1.14,31.00)	1.83(1.04,4.69)	0.36(0.03,0.66)
HD ADA SC + MTX		5.45(1.21,24.49)	1.82(1.05,4.56)	0.35(0.04,0.63)
HD ADA SC + MTX	HD INF IV + MTX	0.92(0.23,3.55)	0.99(0.73,1.38)	-0.01(-0.22,0.22)
Random-effects model	Residual deviance	31.33 vs 33 data points		
	Deviance information criteria	198.481		
Fixed-effect model	Residual deviance	32.58 vs 33 data points		
	Deviance information criteria	198.437		
Note				
Total participants	3481			
Total Studies	12			
2-arm	4			
3-arm	7			
4-arm	1			

Appendix 5. ACR50: subgroup - trial duration (<= 6 months)

ACR50 short: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	2.55(1.22,5.33)	2.33(1.21,4.30)	0.08(0.01,0.19)
DMARD + PL		2.23(0.35,15.88)	2.07(0.37,8.76)	0.07(-0.04,0.43)
MTX + DMARD		4.87(1.89,13.63)	3.93(1.80,7.95)	0.18(0.05,0.40)
SD ETN SC		7.47(3.69,15.72)	5.33(3.13,8.70)	0.27(0.13,0.43)
SD ADA SC		3.51(2.03,6.27)	3.04(1.90,4.88)	0.13(0.06,0.22)
SD TOFA PO		6.49(3.24,13.34)	4.84(2.82,7.90)	0.24(0.12,0.40)
SD GOLI SC		6.87(2.62,18.68)	5.04(2.37,9.33)	0.25(0.09,0.48)
SD GOLI IV		4.85(1.73,13.91)	3.92(1.65,7.98)	0.18(0.04,0.41)
SD TOCI IV		4.06(1.65,10.59)	3.42(1.58,6.88)	0.15(0.04,0.33)
SD ABA SC		9.70(2.55,42.23)	6.30(2.33,12.94)	0.33(0.08,0.66)
SD CERTO SC		9.56(3.10,31.95)	6.25(2.73,11.67)	0.32(0.11,0.61)
SD ETN SC + MTX		13.71(6.17,32.64)	7.65(4.60,12.03)	0.41(0.23,0.61)
SD ABA IV + MTX		9.91(4.17,23.64)	6.38(3.46,10.53)	0.33(0.16,0.54)
SD CERTO SC + MTX		14.70(6.35,35.45)	7.94(4.70,12.27)	0.43(0.24,0.63)
SD INF IV + MTX		8.50(3.54,20.49)	5.80(3.03,9.91)	0.30(0.13,0.50)
SD ADA SC + MTX		18.53(6.63,55.31)	8.89(4.84,13.93)	0.48(0.25,0.71)
SD TOFA PO + MTX		17.33(6.20,45.92)	8.60(4.64,13.30)	0.47(0.23,0.68)
SD GOLI SC + MTX		17.44(6.73,46.14)	8.63(4.89,13.52)	0.47(0.25,0.68)
SD RITUX IV + MTX		9.11(3.28,25.67)	6.05(2.84,10.82)	0.31(0.12,0.55)
SD GOLI IV + MTX		6.25(2.39,16.37)	4.72(2.18,8.78)	0.23(0.07,0.44)
SD ANA SC + MTX		7.55(2.54,21.72)	5.37(2.32,10.03)	0.27(0.08,0.51)
SD ABA SC + MTX		10.68(3.19,35.56)	6.67(2.80,12.04)	0.35(0.11,0.63)
SD TOCI IV + MTX		5.36(1.74,17.50)	4.23(1.66,9.07)	0.20(0.04,0.46)
SD CERTO SC + DMARD		8.22(2.18,37.10)	5.67(2.02,12.39)	0.29(0.07,0.63)
SD ADA SC + DMARD		7.12(0.90,64.70)	5.16(0.91,14.25)	0.26(-0.01,0.74)
SD TOCI SC + DMARD		11.64(1.44,99.75)	6.98(1.40,15.58)	0.37(0.03,0.80)

(Continued)

LD ADA SC	3.30(1.50,7.54)	2.89(1.45,5.55)	0.12(0.03,0.26)
LD ETN SC	4.15(1.36,12.15)	3.49(1.33,7.44)	0.15(0.02,0.38)
LD GOL I V	2.89(0.87,9.18)	2.59(0.87,6.21)	0.10(-0.01,0.31)
LD TOCI IV	0.51(0.08,2.31)	0.52(0.09,2.15)	-0.03(-0.06,0.07)
LD ADA SC + MTX	10.23(3.07,34.66)	6.52(2.71,12.01)	0.34(0.11,0.62)
LD RITUX IV + MTX	8.96(3.27,25.59)	6.00(2.83,10.74)	0.31(0.12,0.55)
LD ADA IV + MTX	9.05(1.24,57.71)	6.05(1.23,13.65)	0.31(0.01,0.72)
LD ABA IV + MTX	5.37(2.01,14.58)	4.21(1.89,8.23)	0.20(0.06,0.41)
LD ANA SC + MTX	5.03(0.99,23.55)	4.03(0.99,10.23)	0.19(0.00,0.54)
LD CERTO SC + MTX	10.48(3.40,34.48)	6.62(2.93,12.00)	0.35(0.12,0.63)
LD GOL I V + MTX	5.57(1.76,17.07)	4.33(1.67,8.93)	0.20(0.04,0.46)
LD TOCI IV + MTX	4.58(1.48,14.58)	3.74(1.44,8.24)	0.17(0.03,0.41)
LD TOFA PO + MTX	7.70(1.88,30.51)	5.44(1.78,11.31)	0.27(0.05,0.60)
HD TOCI IV	7.18(3.51,15.04)	5.19(3.00,8.55)	0.26(0.13,0.42)
HD TOFA PO	10.26(5.29,21.10)	6.53(4.10,9.99)	0.34(0.20,0.51)
HD ADA SC	4.74(2.21,10.66)	3.85(2.05,6.91)	0.17(0.07,0.34)
HD GOL I SC	7.91(3.29,18.94)	5.53(2.85,9.48)	0.28(0.12,0.48)
HD ETN SC	7.29(1.60,31.99)	5.25(1.54,11.43)	0.26(0.03,0.61)
HD ABA SC	13.97(3.81,59.84)	7.75(3.21,14.13)	0.42(0.14,0.73)
HD TOCI IV + MTX	12.46(5.56,29.67)	7.28(4.26,11.67)	0.39(0.21,0.58)
HD INF IV + MTX	11.45(4.40,31.21)	6.95(3.60,11.69)	0.37(0.17,0.60)
HD TOFA PO + MTX	9.77(3.55,25.79)	6.33(3.05,10.91)	0.33(0.13,0.56)
HD GOL I SC + MTX	13.39(5.17,35.25)	7.57(4.09,12.40)	0.40(0.19,0.63)
HD CERTO SC + MTX	17.57(7.13,44.53)	8.69(5.06,13.19)	0.47(0.26,0.68)
HD ADA SC + MTX	14.67(4.28,54.00)	7.94(3.51,13.68)	0.43(0.16,0.71)
HD TOCI IV + DMARD	8.38(1.22,68.40)	5.74(1.20,14.29)	0.29(0.01,0.75)
SD ANA SC + SD ETN SC + MTX	8.79(2.43,33.12)	5.93(2.23,11.66)	0.30(0.08,0.62)
SD ANA SC + LD ETN SC + MTX	12.92(3.62,49.50)	7.40(3.12,13.21)	0.39(0.13,0.70)

(Continued)

DMARD + PL	MTX	0.89(0.13,6.94)	0.91(0.15,4.20)	-0.01(-0.17,0.36)
MTX + DMARD		1.90(0.80,4.89)	1.67(0.82,3.39)	0.10(-0.03,0.29)
SD ETN SC		2.90(1.34,6.71)	2.26(1.25,4.32)	0.18(0.05,0.34)
SD ADA SC		1.36(0.65,3.06)	1.30(0.70,2.60)	0.04(-0.07,0.15)
SD TOFA PO		2.51(0.96,6.87)	2.05(0.97,4.54)	0.15(-0.01,0.32)
SD GOL I SC		2.67(1.03,6.99)	2.14(1.03,4.20)	0.16(0.00,0.37)
SD GOL I IV		1.90(0.80,4.49)	1.68(0.83,3.13)	0.09(-0.03,0.29)
SD TOCI IV		1.59(0.71,3.59)	1.47(0.75,2.75)	0.06(-0.04,0.22)
SD ABA SC		3.84(0.84,19.22)	2.70(0.86,6.84)	0.24(-0.03,0.59)
SD CERTO SC		3.76(0.93,15.37)	2.67(0.95,6.49)	0.24(-0.01,0.54)
SD ETN SC + MTX		5.35(2.71,11.94)	3.24(2.05,5.68)	0.32(0.17,0.50)
SD ABA IV + MTX		3.88(2.45,6.23)	2.71(1.97,3.80)	0.25(0.13,0.38)
SD CERTO SC + MTX		5.77(3.65,9.24)	3.37(2.45,4.79)	0.34(0.21,0.48)
SD INF IV + MTX		3.32(2.03,5.43)	2.46(1.73,3.49)	0.21(0.10,0.35)
SD ADA SC + MTX		7.23(3.37,16.26)	3.72(2.39,6.02)	0.40(0.20,0.58)
SD TOFA PO + MTX		6.75(3.33,13.51)	3.62(2.36,5.62)	0.38(0.19,0.55)
SD GOL I SC + MTX		6.80(3.52,13.59)	3.65(2.41,5.68)	0.39(0.21,0.55)
SD RITUX IV + MTX		3.55(1.76,7.28)	2.56(1.57,4.06)	0.23(0.07,0.42)
SD GOL I IV + MTX		2.43(1.24,4.79)	2.00(1.20,3.22)	0.14(0.03,0.31)
SD ANA SC + MTX		2.90(1.32,6.64)	2.25(1.26,3.85)	0.18(0.03,0.39)
SD ABA SC + MTX		4.14(1.60,10.51)	2.81(1.46,4.80)	0.26(0.06,0.50)
SD TOCI IV + MTX		2.12(0.79,5.62)	1.81(0.82,3.51)	0.11(-0.03,0.34)
SD CERTO SC + DMARD		3.26(0.72,17.46)	2.43(0.76,6.58)	0.20(-0.04,0.56)
SD ADA SC + DMARD		2.78(0.33,28.96)	2.19(0.37,7.38)	0.17(-0.11,0.67)
SD TOCI SC + DMARD		4.59(0.50,43.80)	2.96(0.56,8.33)	0.29(-0.07,0.73)
LD ADA SC		1.29(0.47,3.56)	1.24(0.53,2.86)	0.03(-0.10,0.19)
LD ETN SC		1.62(0.48,5.30)	1.49(0.53,3.67)	0.07(-0.09,0.29)
LD GOL I IV		1.13(0.42,2.93)	1.11(0.46,2.31)	0.01(-0.09,0.18)

(Continued)

LD TOCI IV		0.20(0.04,0.78)	0.23(0.04,0.80)	-0.11(-0.20,-0.03)
LD ADA SC + MTX		3.94(1.54,11.17)	2.72(1.42,4.93)	0.25(0.06,0.50)
LD RITUX IV + MTX		3.50(1.73,7.27)	2.53(1.55,3.99)	0.22(0.07,0.42)
LD ADA IV + MTX		3.51(0.58,20.32)	2.53(0.62,6.00)	0.22(-0.05,0.62)
LD ABA IV + MTX		2.09(1.08,4.13)	1.79(1.06,2.91)	0.11(0.01,0.28)
LD ANA SC + MTX		1.95(0.46,7.82)	1.70(0.50,4.07)	0.10(-0.07,0.42)
LD CERTO SC + MTX		4.09(1.68,10.25)	2.79(1.52,4.80)	0.26(0.07,0.49)
LD GOLI IV + MTX		2.17(0.85,5.42)	1.84(0.88,3.45)	0.12(-0.02,0.33)
LD TOCI IV + MTX		1.79(0.69,4.69)	1.60(0.73,3.17)	0.09(-0.04,0.29)
LD TOFA PO + MTX		2.99(0.90,9.84)	2.30(0.91,4.62)	0.19(-0.01,0.48)
HD TOCI IV		2.79(1.68,4.85)	2.21(1.48,3.48)	0.17(0.08,0.29)
HD TOFA PO		4.00(1.56,10.84)	2.77(1.39,5.90)	0.26(0.08,0.44)
HD ADA SC		1.85(0.69,5.13)	1.65(0.73,3.71)	0.09(-0.06,0.27)
HD GOLI SC		3.07(1.46,6.49)	2.34(1.35,4.05)	0.19(0.06,0.36)
HD ETN SC		2.86(0.63,12.73)	2.22(0.68,5.46)	0.18(-0.05,0.52)
HD ABA SC		5.45(1.22,27.20)	3.29(1.16,7.69)	0.33(0.03,0.66)
HD TOCI IV + MTX		4.87(2.87,8.65)	3.08(2.13,4.75)	0.30(0.17,0.45)
HD INF IV + MTX		4.46(2.35,8.54)	2.92(1.93,4.47)	0.28(0.13,0.45)
HD TOFA PO + MTX		3.81(1.87,7.74)	2.67(1.64,4.23)	0.24(0.09,0.43)
HD GOLI SC + MTX		5.23(2.66,10.42)	3.19(2.07,5.05)	0.32(0.15,0.50)
HD CERTO SC + MTX		6.85(3.97,12.00)	3.66(2.58,5.37)	0.39(0.23,0.53)
HD ADA SC + MTX		5.71(2.09,16.60)	3.32(1.79,5.83)	0.34(0.11,0.59)
HD TOCI IV + DMARD		3.33(0.43,29.84)	2.47(0.49,7.72)	0.21(-0.09,0.67)
SD ANA SC + SD ETN SC + MTX		3.39(1.00,12.78)	2.49(1.00,5.38)	0.22(0.00,0.52)
SD ANA SC + LD ETN SC + MTX		5.03(1.51,18.48)	3.12(1.38,6.26)	0.31(0.06,0.60)
MTX + DMARD	DMARD + PL	2.13(0.26,17.12)	1.84(0.39,11.46)	0.10(-0.27,0.36)
SD ETN SC		3.28(0.42,22.89)	2.51(0.57,14.53)	0.19(-0.20,0.40)
SD ADA SC		1.54(0.21,10.73)	1.44(0.34,8.66)	0.05(-0.31,0.21)

(Continued)

SD TOFA PO	2.84(0.38,20.69)	2.29(0.53,13.86)	0.16(-0.21,0.38)
SD GOLI SC	3.00(0.36,23.68)	2.35(0.50,14.38)	0.17(-0.22,0.44)
SD GOLI IV	2.13(0.24,17.08)	1.84(0.36,11.35)	0.10(-0.28,0.36)
SD TOCI IV	1.78(0.21,13.15)	1.61(0.33,9.66)	0.07(-0.30,0.30)
SD ABA SC	4.23(0.45,41.99)	2.89(0.58,18.44)	0.24(-0.16,0.61)
SD CERTO SC	4.23(0.46,37.08)	2.93(0.61,18.40)	0.24(-0.16,0.57)
SD ETN SC + MTX	6.03(0.81,44.15)	3.61(0.88,20.24)	0.33(-0.05,0.58)
SD ABA IV + MTX	4.31(0.52,33.57)	2.98(0.67,17.79)	0.25(-0.14,0.51)
SD CERTO SC + MTX	6.38(0.78,49.00)	3.72(0.87,21.82)	0.35(-0.06,0.60)
SD INF IV + MTX	3.73(0.47,27.63)	2.72(0.62,15.81)	0.22(-0.17,0.47)
SD ADA SC + MTX	8.00(0.89,72.65)	4.14(0.94,25.18)	0.39(-0.03,0.69)
SD TOFA PO + MTX	7.62(0.84,60.65)	4.01(0.90,23.12)	0.38(-0.04,0.65)
SD GOLI SC + MTX	7.62(0.87,62.09)	4.02(0.93,23.87)	0.39(-0.03,0.65)
SD RITUX IV + MTX	4.04(0.43,31.73)	2.86(0.58,16.82)	0.23(-0.18,0.51)
SD GOLI IV + MTX	2.72(0.32,21.26)	2.21(0.47,13.52)	0.15(-0.23,0.41)
SD ANA SC + MTX	3.24(0.36,26.83)	2.47(0.50,15.15)	0.18(-0.21,0.48)
SD ABA SC + MTX	4.59(0.48,41.94)	3.06(0.63,19.18)	0.26(-0.15,0.59)
SD TOCI IV + MTX	2.37(0.25,20.03)	2.00(0.37,12.81)	0.12(-0.27,0.41)
SD CERTO SC + DMARD	3.61(1.08,13.20)	2.60(1.04,8.93)	0.20(0.01,0.42)
SD ADA SC + DMARD	3.16(1.27,8.05)	2.30(1.21,4.97)	0.18(0.02,0.43)
SD TOCI SC + DMARD	5.09(2.01,12.61)	3.06(1.52,6.63)	0.28(0.05,0.52)
LD ADA SC	1.43(0.19,11.26)	1.36(0.30,8.78)	0.04(-0.32,0.24)
LD ETN SC	1.79(0.20,15.67)	1.61(0.31,10.96)	0.07(-0.30,0.34)
LD GOLI IV	1.26(0.13,10.61)	1.22(0.21,8.05)	0.03(-0.34,0.27)
LD TOCI IV	0.22(0.02,2.29)	0.25(0.03,2.19)	-0.09(-0.46,0.05)
LD ADA SC + MTX	4.42(0.47,43.81)	2.98(0.62,19.68)	0.25(-0.16,0.58)
LD RITUX IV + MTX	3.96(0.44,31.31)	2.81(0.59,16.79)	0.23(-0.18,0.51)
LD ADA IV + MTX	3.88(0.28,53.46)	2.70(0.38,19.90)	0.21(-0.22,0.68)

(Continued)

LD ABA IV + MTX		2.30(0.27,18.75)	1.95(0.40,12.17)	0.12(-0.27,0.38)
LD ANA SC + MTX		2.17(0.18,24.21)	1.85(0.27,13.25)	0.10(-0.29,0.49)
LD CERTO SC + MTX		4.55(0.52,41.05)	3.04(0.66,19.40)	0.26(-0.14,0.58)
LD GOLI IV + MTX		2.45(0.27,20.29)	2.03(0.39,12.75)	0.13(-0.26,0.42)
LD TOCI IV + MTX		2.00(0.22,16.94)	1.76(0.33,11.51)	0.09(-0.29,0.37)
LD TOFA PO + MTX		3.32(0.29,32.80)	2.49(0.42,16.29)	0.19(-0.24,0.55)
HD TOCI IV		3.16(0.40,23.05)	2.45(0.56,14.82)	0.18(-0.20,0.39)
HD TOFA PO		4.62(0.60,33.78)	3.11(0.73,18.54)	0.26(-0.12,0.48)
HD ADA SC		2.07(0.27,15.63)	1.80(0.41,11.40)	0.10(-0.27,0.32)
HD GOLI SC		3.49(0.40,25.46)	2.62(0.56,15.44)	0.20(-0.20,0.45)
HD ETN SC		3.18(0.27,31.90)	2.43(0.39,15.19)	0.17(-0.24,0.56)
HD ABA SC		6.06(0.64,63.98)	3.54(0.76,22.23)	0.32(-0.10,0.68)
HD TOCI IV + MTX		5.44(0.69,41.42)	3.41(0.80,19.88)	0.31(-0.09,0.56)
HD INF IV + MTX		5.01(0.60,39.15)	3.23(0.73,18.73)	0.28(-0.12,0.56)
HD TOFA PO + MTX		4.32(0.49,35.01)	2.97(0.63,17.59)	0.25(-0.16,0.52)
HD GOLI SC + MTX		5.91(0.68,48.66)	3.54(0.80,21.87)	0.32(-0.09,0.60)
HD CERTO SC + MTX		7.64(0.93,59.67)	4.05(0.96,23.39)	0.39(-0.02,0.65)
HD ADA SC + MTX		6.24(0.67,64.15)	3.63(0.77,23.11)	0.33(-0.09,0.68)
HD TOCI IV + DMARD		3.73(1.99,7.03)	2.60(1.49,4.71)	0.22(0.05,0.41)
SD ANA SC + SD ETN SC + MTX		3.76(0.41,35.98)	2.69(0.54,16.75)	0.21(-0.18,0.58)
SD ANA SC + LD ETN SC + MTX		5.60(0.62,54.38)	3.38(0.75,20.57)	0.31(-0.10,0.65)
SD ETN SC	MTX + DMARD	1.54(0.64,3.39)	1.36(0.75,2.52)	0.08(-0.10,0.23)
SD ADA SC		0.72(0.24,2.02)	0.77(0.36,1.79)	-0.05(-0.28,0.10)
SD TOFA PO		1.33(0.40,4.19)	1.23(0.53,2.97)	0.05(-0.19,0.26)
SD GOLI SC		1.40(0.40,4.68)	1.27(0.52,3.04)	0.07(-0.18,0.31)
SD GOLI IV		1.00(0.28,3.27)	1.00(0.37,2.43)	0.00(-0.23,0.23)
SD TOCI IV		0.83(0.25,2.62)	0.87(0.35,2.11)	-0.03(-0.25,0.17)
SD ABA SC		1.99(0.38,11.67)	1.59(0.49,4.61)	0.14(-0.19,0.52)

(Continued)

SD CERTO SC	1.96(0.42,9.09)	1.57(0.53,4.20)	0.14(-0.18,0.46)
SD ETN SC + MTX	2.82(1.66,4.83)	1.94(1.31,3.11)	0.22(0.11,0.34)
SD ABA IV + MTX	2.04(0.72,5.40)	1.62(0.81,3.34)	0.15(-0.07,0.35)
SD CERTO SC + MTX	3.04(1.08,8.19)	2.01(1.05,4.16)	0.24(0.02,0.44)
SD INF IV + MTX	1.75(0.62,4.68)	1.47(0.72,3.08)	0.11(-0.11,0.31)
SD ADA SC + MTX	3.82(1.14,12.55)	2.23(1.08,4.82)	0.30(0.03,0.54)
SD TOFA PO + MTX	3.55(1.10,10.34)	2.15(1.06,4.52)	0.28(0.02,0.50)
SD GOLI SC + MTX	3.59(1.14,10.56)	2.17(1.08,4.56)	0.28(0.03,0.51)
SD RITUX IV + MTX	1.87(0.58,5.74)	1.53(0.68,3.32)	0.13(-0.11,0.37)
SD GOLI IV + MTX	1.29(0.39,3.85)	1.20(0.51,2.69)	0.05(-0.19,0.26)
SD ANA SC + MTX	1.53(0.43,5.13)	1.35(0.54,3.16)	0.08(-0.16,0.33)
SD ABA SC + MTX	2.18(0.58,7.72)	1.67(0.68,3.80)	0.16(-0.11,0.44)
SD TOCI IV + MTX	1.11(0.29,4.07)	1.08(0.39,2.74)	0.02(-0.22,0.28)
SD CERTO SC + DMARD	1.68(0.32,9.50)	1.44(0.43,4.18)	0.10(-0.21,0.48)
SD ADA SC + DMARD	1.46(0.15,14.94)	1.31(0.22,4.59)	0.07(-0.28,0.57)
SD TOCI SC + DMARD	2.40(0.23,23.89)	1.76(0.32,5.23)	0.18(-0.23,0.65)
LD ADA SC	0.67(0.20,2.36)	0.73(0.29,2.01)	-0.06(-0.30,0.14)
LD ETN SC	0.85(0.23,2.95)	0.88(0.31,2.26)	-0.03(-0.26,0.20)
LD GOLI IV	0.59(0.15,2.15)	0.66(0.21,1.80)	-0.08(-0.30,0.13)
LD TOCI IV	0.10(0.02,0.51)	0.13(0.02,0.57)	-0.20(-0.42,-0.06)
LD ADA SC + MTX	2.08(0.56,7.92)	1.63(0.67,3.84)	0.15(-0.11,0.44)
LD RITUX IV + MTX	1.83(0.57,5.64)	1.51(0.68,3.33)	0.12(-0.11,0.36)
LD ADA IV + MTX	1.83(0.24,12.73)	1.50(0.31,4.34)	0.12(-0.22,0.54)
LD ABA IV + MTX	1.10(0.35,3.33)	1.07(0.46,2.42)	0.02(-0.20,0.23)
LD ANA SC + MTX	1.02(0.17,5.31)	1.02(0.24,3.09)	0.00(-0.27,0.36)
LD CERTO SC + MTX	2.14(0.60,7.60)	1.66(0.70,3.79)	0.16(-0.10,0.43)
LD GOLI IV + MTX	1.15(0.29,3.90)	1.11(0.39,2.69)	0.02(-0.22,0.27)
LD TOCI IV + MTX	0.93(0.24,3.37)	0.95(0.33,2.44)	-0.01(-0.25,0.23)

(Continued)

LD TOFA PO + MTX		1.57(0.33,6.88)	1.36(0.43,3.49)	0.09(-0.19,0.42)
HD TOCI IV		1.48(0.54,3.99)	1.32(0.66,2.87)	0.08(-0.13,0.25)
HD TOFA PO		2.12(0.64,6.62)	1.66(0.75,3.86)	0.16(-0.10,0.38)
HD ADA SC		0.96(0.28,3.27)	0.97(0.40,2.51)	-0.01(-0.25,0.21)
HD GOLI SC		1.62(0.51,4.77)	1.40(0.63,3.11)	0.10(-0.14,0.31)
HD ETN SC		1.49(0.31,6.49)	1.32(0.39,3.28)	0.08(-0.19,0.41)
HD ABA SC		2.87(0.53,16.08)	1.94(0.65,5.25)	0.23(-0.13,0.58)
HD TOCI IV + MTX		2.56(0.88,7.15)	1.84(0.93,3.90)	0.20(-0.03,0.41)
HD INF IV + MTX		2.35(0.76,7.02)	1.75(0.84,3.79)	0.18(-0.06,0.41)
HD TOFA PO + MTX		2.00(0.62,6.01)	1.60(0.72,3.48)	0.14(-0.10,0.37)
HD GOLI SC + MTX		2.76(0.86,8.32)	1.92(0.91,4.03)	0.22(-0.03,0.45)
HD CERTO SC + MTX		3.60(1.23,10.18)	2.17(1.13,4.55)	0.28(0.05,0.49)
HD ADA SC + MTX		3.03(0.76,11.72)	2.00(0.82,4.54)	0.24(-0.06,0.53)
HD TOCI IV + DMARD		1.76(0.20,15.95)	1.47(0.28,4.71)	0.11(-0.25,0.58)
SD ANA SC + SD ETN SC + MTX		1.79(0.56,5.67)	1.48(0.64,3.06)	0.11(-0.10,0.39)
SD ANA SC + LD ETN SC + MTX		2.65(0.86,8.33)	1.85(0.90,3.65)	0.21(-0.03,0.46)
SD ADA SC	SD ETN SC	0.47(0.19,1.12)	0.57(0.31,1.09)	-0.14(-0.32,0.02)
SD TOFA PO		0.87(0.31,2.38)	0.91(0.45,1.82)	-0.03(-0.25,0.18)
SD GOLI SC		0.92(0.30,2.85)	0.95(0.42,1.95)	-0.02(-0.25,0.23)
SD GOLI IV		0.65(0.21,2.02)	0.74(0.30,1.59)	-0.08(-0.29,0.15)
SD TOCI IV		0.55(0.19,1.60)	0.64(0.29,1.39)	-0.12(-0.31,0.09)
SD ABA SC		1.31(0.29,6.76)	1.18(0.41,2.80)	0.06(-0.25,0.44)
SD CERTO SC		1.29(0.33,5.22)	1.17(0.46,2.57)	0.06(-0.22,0.38)
SD ETN SC + MTX		1.85(1.00,3.56)	1.43(1.00,2.12)	0.14(0.00,0.30)
SD ABA IV + MTX		1.33(0.52,3.31)	1.20(0.65,2.11)	0.06(-0.14,0.27)
SD CERTO SC + MTX		1.99(0.77,4.98)	1.49(0.85,2.55)	0.16(-0.06,0.37)
SD INF IV + MTX		1.15(0.43,2.84)	1.09(0.57,1.93)	0.03(-0.18,0.24)
SD ADA SC + MTX		2.50(0.82,7.64)	1.65(0.89,2.96)	0.22(-0.05,0.46)

(Continued)

SD TOFA PO + MTX	2.34(0.78,6.42)	1.61(0.86,2.83)	0.20(-0.06,0.43)
SD GOLI SC + MTX	2.34(0.85,6.53)	1.61(0.91,2.83)	0.20(-0.04,0.43)
SD RITUX IV + MTX	1.21(0.42,3.54)	1.13(0.54,2.15)	0.04(-0.18,0.29)
SD GOLI IV + MTX	0.84(0.29,2.25)	0.89(0.40,1.70)	-0.04(-0.25,0.18)
SD ANA SC + MTX	1.00(0.31,3.17)	1.00(0.43,2.06)	0.00(-0.23,0.26)
SD ABA SC + MTX	1.42(0.41,4.78)	1.25(0.53,2.42)	0.08(-0.18,0.36)
SD TOCI IV + MTX	0.72(0.21,2.46)	0.80(0.31,1.77)	-0.07(-0.29,0.20)
SD CERTO SC + DMARD	1.09(0.25,5.83)	1.06(0.36,2.67)	0.02(-0.26,0.40)
SD ADA SC + DMARD	0.95(0.11,9.39)	0.97(0.17,2.97)	-0.01(-0.33,0.49)
SD TOCI SC + DMARD	1.58(0.17,14.63)	1.32(0.25,3.31)	0.10(-0.29,0.56)
LD ADA SC	0.44(0.15,1.29)	0.54(0.24,1.21)	-0.15(-0.34,0.05)
LD ETN SC	0.55(0.20,1.50)	0.65(0.28,1.31)	-0.11(-0.28,0.09)
LD GOLI IV	0.38(0.11,1.32)	0.49(0.16,1.21)	-0.16(-0.35,0.06)
LD TOCI IV	0.07(0.01,0.31)	0.10(0.02,0.39)	-0.29(-0.46,-0.14)
LD ADA SC + MTX	1.35(0.39,4.98)	1.20(0.52,2.49)	0.07(-0.19,0.37)
LD RITUX IV + MTX	1.20(0.40,3.48)	1.12(0.53,2.12)	0.04(-0.19,0.29)
LD ADA IV + MTX	1.19(0.16,8.17)	1.12(0.24,2.83)	0.04(-0.29,0.47)
LD ABA IV + MTX	0.72(0.25,2.02)	0.80(0.36,1.59)	-0.06(-0.27,0.15)
LD ANA SC + MTX	0.67(0.12,3.35)	0.75(0.18,2.06)	-0.08(-0.33,0.28)
LD CERTO SC + MTX	1.41(0.42,4.72)	1.24(0.55,2.41)	0.08(-0.18,0.36)
LD GOLI IV + MTX	0.75(0.21,2.45)	0.82(0.31,1.77)	-0.06(-0.28,0.20)
LD TOCI IV + MTX	0.61(0.18,2.03)	0.70(0.27,1.61)	-0.09(-0.31,0.15)
LD TOFA PO + MTX	1.02(0.24,4.31)	1.01(0.34,2.29)	0.00(-0.25,0.34)
HD TOCI IV	0.97(0.39,2.30)	0.98(0.54,1.75)	-0.01(-0.20,0.18)
HD TOFA PO	1.38(0.50,3.78)	1.22(0.65,2.34)	0.07(-0.16,0.30)
HD ADA SC	0.63(0.23,1.84)	0.72(0.34,1.55)	-0.09(-0.30,0.13)
HD GOLI SC	1.06(0.39,2.86)	1.04(0.52,1.97)	0.01(-0.20,0.24)
HD ETN SC	0.97(0.27,3.52)	0.98(0.35,1.97)	-0.01(-0.22,0.29)

(Continued)

HD ABA SC		1.86(0.41,9.56)	1.44(0.54,3.12)	0.15(-0.19,0.50)
HD TOCI IV + MTX		1.69(0.64,4.20)	1.37(0.76,2.40)	0.12(-0.10,0.33)
HD INF IV + MTX		1.54(0.53,4.27)	1.30(0.67,2.34)	0.10(-0.14,0.33)
HD TOFA PO + MTX		1.31(0.44,3.69)	1.18(0.57,2.20)	0.06(-0.17,0.30)
HD GOLI SC + MTX		1.80(0.65,5.05)	1.42(0.75,2.55)	0.14(-0.10,0.37)
HD CERTO SC + MTX		2.36(0.89,6.34)	1.62(0.93,2.81)	0.20(-0.03,0.42)
HD ADA SC + MTX		1.96(0.53,7.54)	1.48(0.65,2.85)	0.16(-0.13,0.46)
HD TOCI IV + DMARD		1.15(0.15,9.90)	1.09(0.22,3.02)	0.03(-0.31,0.51)
SD ANA SC + SD ETN SC + MTX		1.17(0.37,3.97)	1.10(0.47,2.14)	0.03(-0.19,0.32)
SD ANA SC + LD ETN SC + MTX		1.71(0.54,5.87)	1.37(0.65,2.47)	0.12(-0.12,0.41)
SD TOFA PO	SD ADA SC	1.83(0.84,4.08)	1.58(0.87,2.81)	0.11(-0.03,0.27)
SD GOLI SC		1.95(0.68,5.74)	1.66(0.73,3.35)	0.12(-0.06,0.36)
SD GOLI IV		1.38(0.45,4.18)	1.29(0.51,2.78)	0.05(-0.11,0.28)
SD TOCI IV		1.16(0.44,3.05)	1.13(0.51,2.32)	0.02(-0.11,0.21)
SD ABA SC		2.76(0.64,13.71)	2.07(0.70,4.84)	0.20(-0.07,0.55)
SD CERTO SC		2.75(0.76,10.23)	2.07(0.80,4.32)	0.20(-0.05,0.50)
SD ETN SC + MTX		3.92(1.59,10.02)	2.51(1.40,4.41)	0.28(0.09,0.49)
SD ABA IV + MTX		2.86(1.13,6.78)	2.11(1.10,3.65)	0.21(0.02,0.41)
SD CERTO SC + MTX		4.23(1.71,10.34)	2.61(1.46,4.38)	0.30(0.10,0.50)
SD INF IV + MTX		2.43(0.95,6.12)	1.91(0.96,3.45)	0.17(-0.01,0.38)
SD ADA SC + MTX		5.24(1.82,15.68)	2.90(1.53,4.96)	0.36(0.12,0.59)
SD TOFA PO + MTX		4.92(1.66,13.45)	2.81(1.44,4.83)	0.34(0.10,0.56)
SD GOLI SC + MTX		4.98(1.79,13.53)	2.82(1.51,4.81)	0.34(0.11,0.56)
SD RITUX IV + MTX		2.61(0.87,7.53)	1.99(0.89,3.76)	0.19(-0.02,0.43)
SD GOLI IV + MTX		1.79(0.63,4.89)	1.55(0.69,3.06)	0.10(-0.07,0.32)
SD ANA SC + MTX		2.14(0.70,6.29)	1.76(0.75,3.46)	0.14(-0.05,0.39)
SD ABA SC + MTX		3.04(0.88,9.99)	2.18(0.90,4.19)	0.22(-0.02,0.50)
SD TOCI IV + MTX		1.53(0.48,4.91)	1.39(0.54,3.00)	0.07(-0.10,0.33)

(Continued)

SD CERTO SC + DMARD	2.35(0.54,11.30)	1.87(0.61,4.51)	0.16(-0.09,0.52)
SD ADA SC + DMARD	2.04(0.23,19.03)	1.71(0.28,5.02)	0.13(-0.16,0.62)
SD TOCI SC + DMARD	3.33(0.37,30.29)	2.30(0.43,5.62)	0.24(-0.12,0.68)
LD ADA SC	0.94(0.45,1.99)	0.95(0.51,1.71)	-0.01(-0.11,0.12)
LD ETN SC	1.18(0.35,3.85)	1.14(0.41,2.67)	0.03(-0.14,0.26)
LD GOLIV	0.82(0.23,2.66)	0.85(0.28,2.10)	-0.03(-0.16,0.18)
LD TOCI IV	0.14(0.02,0.64)	0.17(0.03,0.69)	-0.15(-0.24,-0.05)
LD ADA SC + MTX	2.92(0.86,9.85)	2.12(0.88,4.13)	0.21(-0.02,0.49)
LD RITUX IV + MTX	2.56(0.88,7.45)	1.97(0.90,3.74)	0.18(-0.02,0.42)
LD ADA IV + MTX	2.56(0.36,16.19)	1.97(0.41,4.74)	0.18(-0.12,0.59)
LD ABA IV + MTX	1.55(0.54,4.17)	1.40(0.60,2.78)	0.07(-0.09,0.29)
LD ANA SC + MTX	1.43(0.27,6.74)	1.32(0.32,3.43)	0.06(-0.14,0.41)
LD CERTO SC + MTX	2.98(0.93,9.80)	2.16(0.94,4.12)	0.22(-0.01,0.49)
LD GOLIV + MTX	1.58(0.48,5.13)	1.42(0.55,3.14)	0.08(-0.10,0.33)
LD TOCI IV + MTX	1.31(0.41,4.03)	1.24(0.47,2.68)	0.04(-0.12,0.28)
LD TOFA PO + MTX	2.18(0.50,8.90)	1.78(0.56,3.90)	0.14(-0.09,0.47)
HD TOCI IV	2.05(1.00,4.19)	1.71(1.00,2.83)	0.13(0.00,0.28)
HD TOFA PO	2.92(1.38,6.40)	2.14(1.26,3.61)	0.21(0.06,0.39)
HD ADA SC	1.35(0.65,2.83)	1.26(0.70,2.18)	0.05(-0.06,0.20)
HD GOLIV SC	2.25(0.87,5.69)	1.81(0.90,3.39)	0.15(-0.02,0.36)
HD ETN SC	2.09(0.41,9.89)	1.73(0.47,4.11)	0.14(-0.11,0.49)
HD ABA SC	3.97(0.94,19.17)	2.52(0.95,5.29)	0.29(-0.01,0.62)
HD TOCI IV + MTX	3.55(1.54,8.35)	2.39(1.37,4.02)	0.26(0.08,0.45)
HD INF IV + MTX	3.27(1.17,8.74)	2.28(1.13,4.07)	0.24(0.03,0.47)
HD TOFA PO + MTX	2.80(0.96,7.65)	2.08(0.97,3.80)	0.20(-0.01,0.43)
HD GOLIV SC + MTX	3.86(1.36,10.41)	2.50(1.26,4.36)	0.28(0.06,0.50)
HD CERTO SC + MTX	5.04(1.93,13.17)	2.83(1.59,4.73)	0.34(0.13,0.55)
HD ADA SC + MTX	4.17(1.17,15.23)	2.59(1.12,4.81)	0.30(0.03,0.58)

(Continued)

HD TOCI IV + DMARD		2.44(0.31,20.12)	1.92(0.37,5.12)	0.17(-0.14,0.63)
SD ANA SC + SD ETN SC + MTX		2.50(0.65,10.02)	1.94(0.70,4.17)	0.18(-0.06,0.49)
SD ANA SC + LD ETN SC + MTX		3.70(0.95,14.48)	2.43(0.96,4.71)	0.27(-0.01,0.57)
SD GOLI SC	SD TOFA PO	1.07(0.33,3.41)	1.05(0.44,2.23)	0.01(-0.22,0.27)
SD GOLI IV		0.76(0.21,2.49)	0.82(0.31,1.88)	-0.05(-0.27,0.19)
SD TOCI IV		0.63(0.21,1.98)	0.71(0.30,1.64)	-0.09(-0.28,0.14)
SD ABA SC		1.50(0.33,7.50)	1.30(0.44,3.08)	0.09(-0.21,0.45)
SD CERTO SC		1.47(0.40,6.07)	1.29(0.52,2.88)	0.08(-0.18,0.41)
SD ETN SC + MTX		2.13(0.75,6.41)	1.59(0.83,3.04)	0.17(-0.06,0.42)
SD ABA IV + MTX		1.56(0.50,4.36)	1.33(0.62,2.54)	0.10(-0.15,0.33)
SD CERTO SC + MTX		2.29(0.77,6.57)	1.65(0.85,3.06)	0.19(-0.06,0.42)
SD INF IV + MTX		1.34(0.43,3.79)	1.21(0.55,2.39)	0.06(-0.17,0.30)
SD ADA SC + MTX		2.88(0.84,9.69)	1.84(0.90,3.43)	0.25(-0.04,0.51)
SD TOFA PO + MTX		2.68(0.78,8.94)	1.78(0.85,3.37)	0.23(-0.05,0.49)
SD GOLI SC + MTX		2.72(0.83,8.49)	1.78(0.90,3.34)	0.23(-0.04,0.48)
SD RITUX IV + MTX		1.41(0.41,4.66)	1.25(0.53,2.59)	0.08(-0.18,0.35)
SD GOLI IV + MTX		0.97(0.29,3.00)	0.98(0.40,2.10)	-0.01(-0.23,0.24)
SD ANA SC + MTX		1.17(0.33,3.85)	1.11(0.44,2.36)	0.03(-0.21,0.30)
SD ABA SC + MTX		1.66(0.41,6.23)	1.38(0.53,2.88)	0.11(-0.18,0.42)
SD TOCI IV + MTX		0.83(0.23,3.18)	0.88(0.32,2.12)	-0.04(-0.26,0.25)
SD CERTO SC + DMARD		1.28(0.28,6.58)	1.18(0.38,2.94)	0.05(-0.24,0.43)
SD ADA SC + DMARD		1.12(0.12,10.72)	1.08(0.17,3.24)	0.02(-0.31,0.52)
SD TOCI SC + DMARD		1.81(0.19,16.82)	1.45(0.27,3.63)	0.13(-0.26,0.59)
LD ADA SC		0.51(0.18,1.45)	0.60(0.27,1.32)	-0.12(-0.30,0.07)
LD ETN SC		0.64(0.17,2.38)	0.72(0.25,1.81)	-0.08(-0.30,0.18)
LD GOLI IV		0.45(0.11,1.63)	0.54(0.16,1.42)	-0.13(-0.33,0.10)
LD TOCI IV		0.08(0.01,0.41)	0.11(0.02,0.48)	-0.26(-0.42,-0.11)
LD ADA SC + MTX		1.58(0.41,5.85)	1.34(0.52,2.78)	0.10(-0.18,0.40)

(Continued)

LD RITUX IV + MTX		1.38(0.42,4.49)	1.24(0.54,2.57)	0.07(-0.18,0.34)
LD ADA IV + MTX		1.39(0.19,9.58)	1.24(0.27,3.23)	0.07(-0.26,0.50)
LD ABA IV + MTX		0.83(0.25,2.63)	0.88(0.35,1.92)	-0.04(-0.26,0.21)
LD ANA SC + MTX		0.78(0.13,3.89)	0.84(0.19,2.28)	-0.05(-0.30,0.31)
LD CERTO SC + MTX		1.62(0.44,6.17)	1.36(0.55,2.88)	0.11(-0.17,0.41)
LD GOL I IV + MTX		0.86(0.22,3.03)	0.90(0.32,2.10)	-0.03(-0.26,0.24)
LD TOCI IV + MTX		0.70(0.19,2.61)	0.77(0.28,1.90)	-0.07(-0.28,0.21)
LD TOFA PO + MTX		1.20(0.25,5.45)	1.13(0.34,2.69)	0.04(-0.24,0.39)
HD TOCI IV		1.11(0.43,2.87)	1.08(0.56,2.10)	0.02(-0.18,0.22)
HD TOFA PO		1.60(0.90,2.88)	1.35(0.93,2.00)	0.10(-0.02,0.23)
HD ADA SC		0.73(0.27,1.99)	0.80(0.39,1.63)	-0.06(-0.25,0.14)
HD GOL I SC		1.23(0.40,3.50)	1.15(0.53,2.29)	0.04(-0.19,0.27)
HD ETN SC		1.13(0.20,5.55)	1.09(0.29,2.72)	0.03(-0.27,0.39)
HD ABA SC		2.16(0.48,10.85)	1.59(0.61,3.46)	0.18(-0.15,0.53)
HD TOCI IV + MTX		1.93(0.68,5.49)	1.50(0.77,2.88)	0.15(-0.09,0.38)
HD INF IV + MTX		1.78(0.55,5.55)	1.44(0.66,2.83)	0.13(-0.13,0.38)
HD TOFA PO + MTX		1.52(0.45,4.85)	1.31(0.58,2.68)	0.09(-0.16,0.35)
HD GOL I SC + MTX		2.08(0.64,6.48)	1.56(0.75,3.02)	0.17(-0.10,0.42)
HD CERTO SC + MTX		2.74(0.88,8.31)	1.79(0.92,3.32)	0.23(-0.03,0.48)
HD ADA SC + MTX		2.28(0.55,9.15)	1.64(0.66,3.26)	0.19(-0.12,0.50)
HD TOCI IV + DMARD		1.32(0.16,11.50)	1.20(0.23,3.30)	0.06(-0.28,0.53)
SD ANA SC + SD ETN SC + MTX		1.37(0.31,5.84)	1.23(0.42,2.78)	0.07(-0.21,0.40)
SD ANA SC + LD ETN SC + MTX		2.02(0.47,8.79)	1.53(0.59,3.25)	0.16(-0.15,0.49)
SD GOL I IV	SD GOL I SC	0.71(0.25,2.07)	0.78(0.35,1.67)	-0.07(-0.27,0.15)
SD TOCI IV		0.59(0.18,1.91)	0.68(0.29,1.62)	-0.10(-0.33,0.12)
SD ABA SC		1.43(0.28,7.98)	1.25(0.41,3.36)	0.08(-0.26,0.46)
SD CERTO SC		1.40(0.31,6.48)	1.24(0.45,3.20)	0.07(-0.24,0.41)
SD ETN SC + MTX		2.01(0.66,6.45)	1.52(0.79,3.27)	0.16(-0.10,0.41)

(Continued)

SD ABA IV + MTX	1.44(0.51,4.14)	1.26(0.66,2.63)	0.08(-0.15,0.30)
SD CERTO SC + MTX	2.15(0.75,6.13)	1.57(0.85,3.21)	0.18(-0.07,0.40)
SD INF IV + MTX	1.24(0.42,3.63)	1.15(0.58,2.41)	0.05(-0.19,0.27)
SD ADA SC + MTX	2.73(0.80,9.04)	1.75(0.87,3.59)	0.23(-0.05,0.49)
SD TOFA PO + MTX	2.52(0.77,8.08)	1.69(0.86,3.57)	0.21(-0.06,0.46)
SD GOLLI SC + MTX	2.54(0.87,7.55)	1.70(0.92,3.41)	0.22(-0.03,0.45)
SD RITUX IV + MTX	1.33(0.40,4.33)	1.20(0.54,2.60)	0.06(-0.20,0.32)
SD GOLLI IV + MTX	0.91(0.30,2.76)	0.93(0.43,2.03)	-0.02(-0.25,0.21)
SD ANA SC + MTX	1.09(0.31,3.82)	1.05(0.45,2.47)	0.02(-0.24,0.29)
SD ABA SC + MTX	1.54(0.40,5.88)	1.31(0.54,2.99)	0.10(-0.19,0.39)
SD TOCI IV + MTX	0.79(0.21,3.01)	0.85(0.32,2.10)	-0.05(-0.30,0.23)
SD CERTO SC + DMARD	1.21(0.23,6.88)	1.14(0.35,3.20)	0.04(-0.28,0.42)
SD ADA SC + DMARD	1.05(0.11,11.51)	1.03(0.18,3.58)	0.01(-0.35,0.53)
SD TOCI SC + DMARD	1.72(0.17,17.02)	1.39(0.26,4.00)	0.12(-0.30,0.59)
LD ADA SC	0.48(0.14,1.64)	0.58(0.24,1.46)	-0.13(-0.38,0.08)
LD ETN SC	0.60(0.15,2.48)	0.69(0.24,1.93)	-0.09(-0.36,0.18)
LD GOLLI IV	0.42(0.12,1.50)	0.51(0.18,1.35)	-0.14(-0.37,0.07)
LD TOCI IV	0.07(0.01,0.39)	0.10(0.02,0.45)	-0.27(-0.50,-0.10)
LD ADA SC + MTX	1.47(0.39,5.82)	1.28(0.53,2.93)	0.08(-0.20,0.39)
LD RITUX IV + MTX	1.31(0.40,4.29)	1.19(0.55,2.59)	0.06(-0.20,0.32)
LD ADA IV + MTX	1.32(0.17,9.67)	1.19(0.25,3.34)	0.06(-0.30,0.50)
LD ABA IV + MTX	0.78(0.25,2.51)	0.84(0.37,1.93)	-0.05(-0.28,0.18)
LD ANA SC + MTX	0.73(0.13,3.79)	0.80(0.20,2.33)	-0.06(-0.34,0.30)
LD CERTO SC + MTX	1.53(0.42,5.72)	1.30(0.56,2.95)	0.09(-0.19,0.39)
LD GOLLI IV + MTX	0.81(0.24,2.74)	0.86(0.34,2.01)	-0.04(-0.28,0.21)
LD TOCI IV + MTX	0.66(0.18,2.47)	0.74(0.28,1.88)	-0.08(-0.32,0.19)
LD TOFA PO + MTX	1.10(0.25,5.05)	1.07(0.36,2.69)	0.02(-0.26,0.36)
HD TOCI IV	1.04(0.38,2.96)	1.03(0.54,2.19)	0.01(-0.22,0.21)

(Continued)

HD TOFA PO		1.50(0.48,4.82)	1.29(0.65,2.92)	0.09(-0.18,0.33)
HD ADA SC		0.69(0.20,2.33)	0.76(0.33,1.86)	-0.07(-0.33,0.16)
HD GOLI SC		1.15(0.48,2.78)	1.10(0.61,2.05)	0.03(-0.16,0.21)
HD ETN SC		1.06(0.19,5.99)	1.04(0.29,2.93)	0.01(-0.30,0.40)
HD ABA SC		2.04(0.39,11.51)	1.52(0.54,3.83)	0.16(-0.20,0.53)
HD TOCI IV + MTX		1.82(0.61,5.33)	1.44(0.75,3.01)	0.13(-0.12,0.37)
HD INF IV + MTX		1.67(0.54,5.22)	1.37(0.67,2.88)	0.11(-0.14,0.36)
HD TOFA PO + MTX		1.42(0.44,4.60)	1.25(0.59,2.72)	0.08(-0.18,0.33)
HD GOLI SC + MTX		1.96(0.68,5.76)	1.50(0.79,3.02)	0.15(-0.09,0.39)
HD CERTO SC + MTX		2.55(0.85,7.57)	1.70(0.92,3.50)	0.22(-0.04,0.45)
HD ADA SC + MTX		2.14(0.53,8.76)	1.56(0.67,3.49)	0.17(-0.14,0.48)
HD TOCI IV + DMARD		1.25(0.15,11.99)	1.16(0.22,3.70)	0.05(-0.32,0.53)
SD ANA SC + SD ETN SC + MTX		1.28(0.28,6.10)	1.17(0.41,3.04)	0.05(-0.25,0.40)
SD ANA SC + LD ETN SC + MTX		1.89(0.42,8.64)	1.46(0.56,3.47)	0.14(-0.18,0.48)
SD TOCI IV	SD GOLI IV	0.84(0.27,2.73)	0.88(0.37,2.20)	-0.03(-0.25,0.17)
SD ABA SC		2.03(0.37,12.03)	1.60(0.49,4.81)	0.14(-0.20,0.52)
SD CERTO SC		1.97(0.40,9.85)	1.59(0.53,4.59)	0.14(-0.19,0.47)
SD ETN SC + MTX		2.83(0.95,9.18)	1.94(0.97,4.54)	0.22(-0.01,0.45)
SD ABA IV + MTX		2.04(0.77,5.57)	1.62(0.85,3.49)	0.15(-0.06,0.34)
SD CERTO SC + MTX		3.04(1.14,8.11)	2.01(1.08,4.30)	0.24(0.03,0.44)
SD INF IV + MTX		1.74(0.65,4.76)	1.47(0.75,3.13)	0.11(-0.09,0.31)
SD ADA SC + MTX		3.83(1.20,12.87)	2.23(1.11,5.08)	0.29(0.04,0.53)
SD TOFA PO + MTX		3.54(1.17,10.64)	2.16(1.09,4.73)	0.28(0.03,0.50)
SD GOLI SC + MTX		3.61(1.25,10.53)	2.17(1.13,4.72)	0.28(0.05,0.50)
SD RITUX IV + MTX		1.87(0.61,5.77)	1.53(0.71,3.45)	0.13(-0.10,0.36)
SD GOLI IV + MTX		1.29(0.53,3.09)	1.20(0.63,2.34)	0.05(-0.13,0.22)
SD ANA SC + MTX		1.53(0.48,5.04)	1.35(0.60,3.13)	0.08(-0.14,0.33)
SD ABA SC + MTX		2.19(0.62,7.85)	1.68(0.72,3.95)	0.16(-0.10,0.44)

(Continued)

SD TOCI IV + MTX	1.11(0.31,4.10)	1.08(0.41,2.78)	0.02(-0.22,0.27)
SD CERTO SC + DMARD	1.70(0.32,10.48)	1.44(0.42,4.61)	0.11(-0.22,0.49)
SD ADA SC + DMARD	1.48(0.15,17.24)	1.32(0.22,5.01)	0.07(-0.28,0.59)
SD TOCI SC + DMARD	2.42(0.24,26.07)	1.76(0.32,5.68)	0.19(-0.23,0.66)
LD ADA SC	0.68(0.19,2.42)	0.74(0.29,2.04)	-0.06(-0.30,0.13)
LD ETN SC	0.86(0.20,3.51)	0.89(0.29,2.61)	-0.03(-0.29,0.23)
LD GOLIV	0.59(0.21,1.63)	0.66(0.28,1.45)	-0.08(-0.26,0.08)
LD TOCI IV	0.10(0.02,0.54)	0.14(0.02,0.58)	-0.20(-0.42,-0.05)
LD ADA SC + MTX	2.07(0.58,8.04)	1.62(0.68,4.06)	0.15(-0.11,0.44)
LD RITUX IV + MTX	1.85(0.60,5.61)	1.51(0.71,3.42)	0.12(-0.10,0.35)
LD ADA IV + MTX	1.85(0.25,12.96)	1.51(0.32,4.48)	0.12(-0.21,0.55)
LD ABA IV + MTX	1.10(0.37,3.37)	1.07(0.48,2.50)	0.02(-0.19,0.23)
LD ANA SC + MTX	1.03(0.20,5.24)	1.02(0.26,3.06)	0.00(-0.26,0.35)
LD CERTO SC + MTX	2.18(0.63,7.71)	1.66(0.73,3.93)	0.16(-0.10,0.43)
LD GOLIV + MTX	1.15(0.42,2.99)	1.11(0.53,2.24)	0.02(-0.16,0.22)
LD TOCI IV + MTX	0.94(0.26,3.46)	0.96(0.36,2.54)	-0.01(-0.25,0.24)
LD TOFA PO + MTX	1.57(0.36,6.71)	1.37(0.46,3.51)	0.09(-0.18,0.41)
HD TOCI IV	1.48(0.55,4.06)	1.32(0.67,2.96)	0.07(-0.13,0.25)
HD TOFA PO	2.12(0.65,7.37)	1.66(0.76,4.24)	0.16(-0.10,0.39)
HD ADA SC	0.97(0.28,3.50)	0.98(0.39,2.69)	-0.01(-0.25,0.21)
HD GOLIV SC	1.63(0.57,4.63)	1.41(0.69,3.14)	0.09(-0.12,0.30)
HD ETN SC	1.49(0.28,8.50)	1.32(0.36,4.08)	0.08(-0.22,0.45)
HD ABA SC	2.92(0.52,16.92)	1.96(0.64,5.56)	0.23(-0.14,0.58)
HD TOCI IV + MTX	2.56(0.94,7.24)	1.84(0.96,4.08)	0.20(-0.01,0.41)
HD INF IV + MTX	2.34(0.81,6.94)	1.75(0.87,3.85)	0.18(-0.05,0.40)
HD TOFA PO + MTX	2.01(0.67,6.03)	1.60(0.76,3.56)	0.14(-0.09,0.37)
HD GOLIV SC + MTX	2.76(0.95,8.09)	1.91(0.97,4.20)	0.22(-0.01,0.44)
HD CERTO SC + MTX	3.63(1.30,10.32)	2.18(1.15,4.70)	0.28(0.06,0.49)

(Continued)

HD ADA SC + MTX		3.02(0.81,12.32)	1.99(0.87,4.80)	0.24(-0.04,0.53)
HD TOCI IV + DMARD		1.77(0.20,17.84)	1.47(0.28,5.19)	0.11(-0.25,0.60)
SD ANA SC + SD ETN SC + MTX		1.79(0.41,8.73)	1.48(0.52,4.18)	0.11(-0.17,0.45)
SD ANA SC + LD ETN SC + MTX		2.65(0.61,12.84)	1.86(0.71,4.88)	0.21(-0.10,0.53)
SD ABA SC	SD TOCI IV	2.40(0.47,13.22)	1.82(0.56,5.15)	0.17(-0.14,0.54)
SD CERTO SC		2.36(0.52,10.79)	1.81(0.62,4.78)	0.17(-0.12,0.49)
SD ETN SC + MTX		3.37(1.19,9.90)	2.22(1.12,4.82)	0.26(0.04,0.47)
SD ABA IV + MTX		2.44(0.96,6.12)	1.85(0.97,3.66)	0.18(-0.01,0.37)
SD CERTO SC + MTX		3.62(1.42,9.19)	2.31(1.25,4.58)	0.27(0.08,0.46)
SD INF IV + MTX		2.08(0.81,5.33)	1.68(0.86,3.40)	0.14(-0.04,0.34)
SD ADA SC + MTX		4.53(1.51,13.99)	2.55(1.30,5.20)	0.33(0.09,0.56)
SD TOFA PO + MTX		4.24(1.43,12.16)	2.47(1.25,4.99)	0.31(0.08,0.53)
SD GOLI SC + MTX		4.29(1.51,11.84)	2.50(1.29,5.09)	0.31(0.09,0.52)
SD RITUX IV + MTX		2.24(0.76,6.40)	1.76(0.82,3.72)	0.16(-0.05,0.38)
SD GOLI IV + MTX		1.52(0.53,4.29)	1.36(0.62,2.96)	0.08(-0.12,0.28)
SD ANA SC + MTX		1.83(0.58,5.72)	1.55(0.67,3.41)	0.11(-0.10,0.35)
SD ABA SC + MTX		2.61(0.73,8.75)	1.93(0.80,4.20)	0.19(-0.06,0.46)
SD TOCI IV + MTX		1.32(0.45,3.81)	1.23(0.53,2.64)	0.05(-0.13,0.27)
SD CERTO SC + DMARD		2.01(0.41,11.52)	1.64(0.50,4.75)	0.13(-0.15,0.51)
SD ADA SC + DMARD		1.76(0.19,18.97)	1.50(0.25,5.34)	0.10(-0.22,0.61)
SD TOCI SC + DMARD		2.91(0.31,29.40)	2.02(0.38,6.03)	0.22(-0.17,0.68)
LD ADA SC		0.81(0.25,2.57)	0.84(0.34,2.17)	-0.03(-0.23,0.15)
LD ETN SC		1.02(0.25,3.87)	1.02(0.32,2.81)	0.00(-0.22,0.24)
LD GOLI IV		0.70(0.20,2.49)	0.75(0.26,2.01)	-0.05(-0.23,0.15)
LD TOCI IV		0.12(0.02,0.51)	0.15(0.03,0.57)	-0.17(-0.34,-0.06)
LD ADA SC + MTX		2.48(0.73,8.79)	1.86(0.79,4.18)	0.18(-0.06,0.46)
LD RITUX IV + MTX		2.19(0.74,6.47)	1.73(0.81,3.71)	0.15(-0.06,0.38)
LD ADA IV + MTX		2.21(0.31,14.42)	1.73(0.38,4.79)	0.15(-0.16,0.57)

(Continued)

LD ABA IV + MTX		1.32(0.46,3.75)	1.23(0.56,2.70)	0.05(-0.14,0.25)
LD ANA SC + MTX		1.23(0.23,6.10)	1.17(0.29,3.36)	0.03(-0.20,0.38)
LD CERTO SC + MTX		2.57(0.76,8.78)	1.91(0.82,4.19)	0.19(-0.05,0.46)
LD GOL I IV + MTX		1.36(0.40,4.50)	1.26(0.49,3.02)	0.05(-0.15,0.30)
LD TOCI IV + MTX		1.12(0.39,3.15)	1.09(0.46,2.36)	0.02(-0.15,0.22)
LD TOFA PO + MTX		1.87(0.43,7.90)	1.57(0.51,3.91)	0.12(-0.13,0.43)
HD TOCI IV		1.75(0.85,3.68)	1.51(0.90,2.75)	0.10(-0.03,0.24)
HD TOFA PO		2.52(0.81,7.62)	1.91(0.87,4.35)	0.19(-0.05,0.40)
HD ADA SC		1.16(0.37,3.74)	1.12(0.48,2.76)	0.03(-0.18,0.22)
HD GOL I SC		1.93(0.68,5.43)	1.60(0.76,3.48)	0.13(-0.08,0.33)
HD ETN SC		1.77(0.33,9.17)	1.51(0.41,4.25)	0.11(-0.17,0.46)
HD ABA SC		3.44(0.68,19.23)	2.23(0.75,5.82)	0.26(-0.07,0.61)
HD TOCI IV + MTX		3.05(1.36,6.97)	2.10(1.22,3.98)	0.23(0.07,0.40)
HD INF IV + MTX		2.79(1.00,7.89)	2.01(1.00,4.14)	0.21(0.00,0.43)
HD TOFA PO + MTX		2.38(0.80,7.01)	1.83(0.85,3.90)	0.17(-0.04,0.40)
HD GOL I SC + MTX		3.29(1.17,9.41)	2.19(1.11,4.52)	0.25(0.03,0.47)
HD CERTO SC + MTX		4.31(1.60,11.61)	2.50(1.34,5.06)	0.32(0.10,0.51)
HD ADA SC + MTX		3.59(1.00,13.30)	2.27(1.00,4.96)	0.27(0.00,0.55)
HD TOCI IV + DMARD		2.11(0.26,19.54)	1.69(0.33,5.43)	0.14(-0.20,0.62)
SD ANA SC + SD ETN SC + MTX		2.14(0.52,9.37)	1.70(0.60,4.34)	0.15(-0.12,0.47)
SD ANA SC + LD ETN SC + MTX		3.18(0.72,13.73)	2.13(0.79,5.13)	0.24(-0.06,0.55)
SD CERTO SC	SD ABA SC	0.98(0.16,5.86)	0.99(0.35,3.01)	0.00(-0.41,0.38)
SD ETN SC + MTX		1.42(0.27,7.03)	1.21(0.53,3.52)	0.08(-0.31,0.42)
SD ABA IV + MTX		1.01(0.19,5.06)	1.01(0.42,3.03)	0.00(-0.38,0.34)
SD CERTO SC + MTX		1.52(0.27,7.46)	1.25(0.55,3.56)	0.10(-0.30,0.43)
SD INF IV + MTX		0.86(0.16,4.39)	0.91(0.37,2.72)	-0.03(-0.42,0.31)
SD ADA SC + MTX		1.91(0.32,10.24)	1.39(0.59,3.94)	0.15(-0.26,0.51)
SD TOFA PO + MTX		1.76(0.31,9.04)	1.34(0.57,3.86)	0.13(-0.27,0.48)

(Continued)

SD GOLII SC + MTX	1.80(0.31,9.37)	1.36(0.59,3.88)	0.14(-0.27,0.48)
SD RITUX IV + MTX	0.93(0.16,5.22)	0.96(0.36,2.96)	-0.02(-0.41,0.35)
SD GOLII IV + MTX	0.64(0.11,3.26)	0.75(0.27,2.32)	-0.10(-0.48,0.24)
SD ANA SC + MTX	0.76(0.12,4.18)	0.85(0.29,2.61)	-0.06(-0.46,0.30)
SD ABA SC + MTX	1.09(0.17,6.86)	1.05(0.36,3.28)	0.02(-0.40,0.41)
SD TOCI IV + MTX	0.55(0.09,3.27)	0.67(0.21,2.32)	-0.12(-0.51,0.24)
SD CERTO SC + DMARD	0.86(0.12,5.57)	0.91(0.27,2.92)	-0.03(-0.45,0.38)
SD ADA SC + DMARD	0.74(0.06,8.62)	0.83(0.14,3.14)	-0.06(-0.51,0.47)
SD TOCI SC + DMARD	1.19(0.10,13.54)	1.10(0.20,3.70)	0.04(-0.45,0.54)
LD ADA SC	0.34(0.06,1.60)	0.47(0.17,1.45)	-0.21(-0.56,0.08)
LD ETN SC	0.42(0.07,2.39)	0.55(0.18,1.87)	-0.17(-0.55,0.16)
LD GOLII IV	0.29(0.05,1.74)	0.41(0.12,1.51)	-0.22(-0.58,0.10)
LD TOCI IV	0.05(0.01,0.39)	0.08(0.01,0.45)	-0.35(-0.69,-0.09)
LD ADA SC + MTX	1.04(0.17,6.22)	1.02(0.35,3.17)	0.01(-0.40,0.39)
LD RITUX IV + MTX	0.91(0.16,5.00)	0.95(0.36,2.91)	-0.02(-0.41,0.34)
LD ADA IV + MTX	0.91(0.09,9.57)	0.95(0.18,3.49)	-0.02(-0.47,0.49)
LD ABA IV + MTX	0.55(0.10,2.93)	0.67(0.24,2.19)	-0.13(-0.50,0.22)
LD ANA SC + MTX	0.51(0.06,3.92)	0.64(0.14,2.39)	-0.13(-0.54,0.29)
LD CERTO SC + MTX	1.07(0.18,6.44)	1.04(0.38,3.25)	0.01(-0.39,0.41)
LD GOLII IV + MTX	0.57(0.09,3.17)	0.69(0.22,2.22)	-0.12(-0.50,0.24)
LD TOCI IV + MTX	0.47(0.07,2.80)	0.60(0.18,2.10)	-0.15(-0.53,0.20)
LD TOFA PO + MTX	0.78(0.11,5.52)	0.86(0.24,2.90)	-0.05(-0.47,0.37)
HD TOCI IV	0.74(0.14,3.42)	0.82(0.35,2.46)	-0.07(-0.44,0.24)
HD TOFA PO	1.06(0.21,4.79)	1.04(0.47,2.96)	0.01(-0.36,0.32)
HD ADA SC	0.49(0.09,2.32)	0.61(0.24,1.88)	-0.15(-0.51,0.15)
HD GOLII SC	0.80(0.15,3.94)	0.87(0.35,2.62)	-0.05(-0.43,0.28)
HD ETN SC	0.75(0.09,5.41)	0.84(0.21,2.92)	-0.06(-0.49,0.36)
HD ABA SC	1.43(0.49,4.28)	1.20(0.66,2.42)	0.08(-0.16,0.32)

(Continued)

HD TOCI IV + MTX		1.28(0.24,6.31)	1.15(0.51,3.38)	0.06(-0.33,0.39)
HD INF IV + MTX		1.16(0.20,6.26)	1.09(0.44,3.30)	0.03(-0.37,0.40)
HD TOFA PO + MTX		0.99(0.18,5.18)	0.99(0.38,3.01)	0.00(-0.39,0.35)
HD GOLI SC + MTX		1.39(0.23,7.24)	1.20(0.48,3.49)	0.08(-0.34,0.43)
HD CERTO SC + MTX		1.79(0.32,9.60)	1.36(0.59,3.90)	0.14(-0.27,0.49)
HD ADA SC + MTX		1.51(0.24,9.19)	1.25(0.45,3.67)	0.10(-0.33,0.48)
HD TOCI IV + DMARD		0.88(0.08,9.11)	0.93(0.17,3.28)	-0.03(-0.48,0.48)
SD ANA SC + SD ETN SC + MTX		0.89(0.12,6.25)	0.94(0.28,3.11)	-0.02(-0.45,0.40)
SD ANA SC + LD ETN SC + MTX		1.34(0.19,9.17)	1.18(0.39,3.69)	0.07(-0.38,0.48)
SD ETN SC + MTX	SD CERTO SC	1.44(0.35,6.09)	1.23(0.58,3.08)	0.09(-0.25,0.39)
SD ABA IV + MTX		1.03(0.24,4.46)	1.02(0.44,2.67)	0.01(-0.33,0.33)
SD CERTO SC + MTX		1.53(0.35,6.74)	1.27(0.59,3.20)	0.10(-0.25,0.42)
SD INF IV + MTX		0.89(0.20,3.86)	0.93(0.39,2.47)	-0.03(-0.37,0.29)
SD ADA SC + MTX		1.93(0.39,9.53)	1.41(0.62,3.56)	0.16(-0.22,0.50)
SD TOFA PO + MTX		1.79(0.36,8.51)	1.36(0.60,3.41)	0.14(-0.24,0.47)
SD GOLI SC + MTX		1.83(0.40,8.16)	1.38(0.62,3.47)	0.14(-0.22,0.46)
SD RITUX IV + MTX		0.94(0.20,4.53)	0.97(0.37,2.62)	-0.01(-0.37,0.33)
SD GOLI IV + MTX		0.64(0.14,3.00)	0.75(0.29,2.11)	-0.09(-0.43,0.23)
SD ANA SC + MTX		0.77(0.16,3.87)	0.85(0.31,2.42)	-0.06(-0.40,0.29)
SD ABA SC + MTX		1.10(0.20,6.15)	1.06(0.37,2.97)	0.02(-0.35,0.41)
SD TOCI IV + MTX		0.56(0.11,2.83)	0.68(0.23,2.06)	-0.12(-0.45,0.22)
SD CERTO SC + DMARD		0.86(0.14,5.67)	0.91(0.27,2.78)	-0.03(-0.41,0.39)
SD ADA SC + DMARD		0.76(0.07,8.49)	0.84(0.14,2.99)	-0.06(-0.48,0.47)
SD TOCI SC + DMARD		1.22(0.11,13.82)	1.12(0.21,3.48)	0.05(-0.41,0.55)
LD ADA SC		0.34(0.08,1.43)	0.46(0.19,1.31)	-0.20(-0.51,0.06)
LD ETN SC		0.44(0.08,2.08)	0.56(0.18,1.68)	-0.16(-0.50,0.14)
LD GOLI IV		0.30(0.05,1.55)	0.42(0.12,1.38)	-0.22(-0.54,0.08)
LD TOCI IV		0.05(0.01,0.35)	0.09(0.01,0.42)	-0.35(-0.64,-0.11)

(Continued)

LD ADA SC + MTX		1.05(0.20,5.69)	1.03(0.37,2.84)	0.01(-0.37,0.39)
LD RITUX IV + MTX		0.93(0.19,4.42)	0.95(0.37,2.61)	-0.02(-0.37,0.32)
LD ADA IV + MTX		0.94(0.10,8.31)	0.97(0.19,3.04)	-0.01(-0.44,0.47)
LD ABA IV + MTX		0.56(0.12,2.65)	0.68(0.25,1.99)	-0.12(-0.45,0.20)
LD ANA SC + MTX		0.52(0.07,3.42)	0.64(0.14,2.16)	-0.13(-0.49,0.27)
LD CERTO SC + MTX		1.09(0.21,5.81)	1.05(0.40,2.90)	0.02(-0.35,0.39)
LD GOLI IV + MTX		0.58(0.11,3.15)	0.70(0.23,2.15)	-0.12(-0.46,0.24)
LD TOCI IV + MTX		0.48(0.09,2.36)	0.61(0.20,1.82)	-0.15(-0.49,0.18)
LD TOFA PO + MTX		0.80(0.13,4.89)	0.87(0.25,2.65)	-0.05(-0.43,0.35)
HD TOCI IV		0.74(0.19,3.03)	0.83(0.38,2.18)	-0.07(-0.39,0.22)
HD TOFA PO		1.07(0.28,4.04)	1.04(0.50,2.55)	0.02(-0.31,0.30)
HD ADA SC		0.49(0.12,2.01)	0.61(0.26,1.69)	-0.15(-0.46,0.13)
HD GOLI SC		0.82(0.19,3.48)	0.88(0.37,2.37)	-0.05(-0.38,0.26)
HD ETN SC		0.76(0.11,5.00)	0.85(0.21,2.60)	-0.06(-0.44,0.36)
HD ABA SC		1.44(0.25,9.00)	1.22(0.44,3.30)	0.09(-0.32,0.48)
HD TOCI IV + MTX		1.30(0.30,5.51)	1.16(0.54,2.94)	0.06(-0.28,0.37)
HD INF IV + MTX		1.18(0.26,5.48)	1.10(0.47,2.90)	0.04(-0.31,0.38)
HD TOFA PO + MTX		1.02(0.20,4.79)	1.01(0.39,2.71)	0.00(-0.36,0.34)
HD GOLI SC + MTX		1.40(0.30,6.39)	1.21(0.53,3.13)	0.08(-0.28,0.41)
HD CERTO SC + MTX		1.82(0.40,8.22)	1.37(0.64,3.42)	0.14(-0.21,0.47)
HD ADA SC + MTX		1.55(0.27,8.61)	1.27(0.47,3.34)	0.10(-0.30,0.48)
HD TOCI IV + DMARD		0.89(0.09,9.32)	0.93(0.17,3.13)	-0.03(-0.45,0.49)
SD ANA SC + SD ETN SC + MTX		0.91(0.15,5.45)	0.95(0.30,2.76)	-0.02(-0.40,0.38)
SD ANA SC + LD ETN SC + MTX		1.35(0.23,8.14)	1.19(0.42,3.20)	0.07(-0.33,0.46)
SD ABA IV + MTX	SD ETN SC + MTX	0.72(0.29,1.63)	0.84(0.48,1.32)	-0.08(-0.29,0.12)
SD CERTO SC + MTX		1.08(0.44,2.50)	1.04(0.64,1.62)	0.02(-0.20,0.22)
SD INF IV + MTX		0.62(0.24,1.44)	0.76(0.43,1.23)	-0.11(-0.32,0.09)
SD ADA SC + MTX		1.35(0.45,3.90)	1.15(0.65,1.89)	0.07(-0.19,0.31)

(Continued)

SD TOFA PO + MTX	1.26(0.44,3.27)	1.12(0.64,1.79)	0.05(-0.20,0.28)
SD GOLI SC + MTX	1.27(0.46,3.32)	1.12(0.67,1.79)	0.06(-0.19,0.29)
SD RITUX IV + MTX	0.66(0.23,1.80)	0.79(0.40,1.38)	-0.10(-0.33,0.14)
SD GOLI IV + MTX	0.46(0.15,1.19)	0.62(0.29,1.11)	-0.18(-0.40,0.04)
SD ANA SC + MTX	0.54(0.17,1.61)	0.70(0.32,1.30)	-0.14(-0.38,0.11)
SD ABA SC + MTX	0.78(0.22,2.46)	0.87(0.39,1.55)	-0.06(-0.33,0.21)
SD TOCI IV + MTX	0.39(0.11,1.31)	0.56(0.23,1.17)	-0.21(-0.44,0.06)
SD CERTO SC + DMARD	0.60(0.12,3.11)	0.74(0.25,1.75)	-0.12(-0.43,0.27)
SD ADA SC + DMARD	0.52(0.06,4.99)	0.67(0.12,1.95)	-0.15(-0.50,0.36)
SD TOCI SC + DMARD	0.86(0.09,7.91)	0.92(0.18,2.18)	-0.04(-0.45,0.43)
LD ADA SC	0.24(0.08,0.74)	0.38(0.18,0.82)	-0.29(-0.52,-0.06)
LD ETN SC	0.30(0.09,0.95)	0.45(0.18,0.97)	-0.25(-0.47,-0.01)
LD GOLI IV	0.21(0.06,0.67)	0.34(0.12,0.78)	-0.30(-0.52,-0.09)
LD TOCI IV	0.04(0.01,0.17)	0.07(0.01,0.27)	-0.43(-0.63,-0.25)
LD ADA SC + MTX	0.74(0.21,2.46)	0.84(0.38,1.57)	-0.07(-0.34,0.21)
LD RITUX IV + MTX	0.65(0.23,1.80)	0.78(0.39,1.37)	-0.10(-0.34,0.14)
LD ADA IV + MTX	0.65(0.09,4.15)	0.78(0.17,1.82)	-0.10(-0.44,0.32)
LD ABA IV + MTX	0.39(0.14,1.05)	0.55(0.26,1.03)	-0.21(-0.41,0.01)
LD ANA SC + MTX	0.36(0.07,1.78)	0.52(0.13,1.34)	-0.22(-0.49,0.14)
LD CERTO SC + MTX	0.76(0.23,2.42)	0.86(0.40,1.55)	-0.07(-0.32,0.21)
LD GOLI IV + MTX	0.41(0.12,1.24)	0.57(0.23,1.13)	-0.20(-0.43,0.05)
LD TOCI IV + MTX	0.33(0.09,1.08)	0.49(0.19,1.05)	-0.24(-0.47,0.02)
LD TOFA PO + MTX	0.55(0.13,2.27)	0.71(0.24,1.50)	-0.14(-0.41,0.20)
HD TOCI IV	0.52(0.22,1.20)	0.68(0.40,1.12)	-0.15(-0.35,0.04)
HD TOFA PO	0.75(0.26,2.11)	0.85(0.48,1.55)	-0.07(-0.32,0.18)
HD ADA SC	0.34(0.11,1.07)	0.50(0.24,1.04)	-0.24(-0.47,0.01)
HD GOLI SC	0.57(0.20,1.49)	0.72(0.38,1.27)	-0.13(-0.36,0.10)
HD ETN SC	0.52(0.12,2.08)	0.68(0.22,1.43)	-0.15(-0.41,0.18)

(Continued)

HD ABA SC		1.01(0.21,5.24)	1.01(0.39,2.09)	0.00(-0.35,0.37)
HD TOCI IV + MTX		0.91(0.36,2.18)	0.95(0.57,1.53)	-0.02(-0.24,0.19)
HD INF IV + MTX		0.83(0.30,2.14)	0.91(0.50,1.50)	-0.04(-0.28,0.18)
HD TOFA PO + MTX		0.71(0.25,1.87)	0.83(0.42,1.41)	-0.08(-0.31,0.15)
HD GOLI SC + MTX		0.97(0.35,2.58)	0.99(0.55,1.63)	-0.01(-0.25,0.23)
HD CERTO SC + MTX		1.28(0.49,3.17)	1.13(0.69,1.77)	0.06(-0.17,0.27)
HD ADA SC + MTX		1.07(0.30,3.72)	1.03(0.48,1.81)	0.02(-0.28,0.30)
HD TOCI IV + DMARD		0.62(0.08,5.30)	0.76(0.16,1.99)	-0.11(-0.47,0.37)
SD ANA SC + SD ETN SC + MTX		0.63(0.23,1.77)	0.77(0.35,1.30)	-0.11(-0.31,0.14)
SD ANA SC + LD ETN SC + MTX		0.93(0.35,2.55)	0.96(0.49,1.49)	-0.02(-0.24,0.21)
SD CERTO SC + MTX	SD ABA IV + MTX	1.48(0.77,2.87)	1.24(0.87,1.84)	0.09(-0.06,0.25)
SD INF IV + MTX		0.85(0.46,1.58)	0.91(0.61,1.33)	-0.04(-0.18,0.10)
SD ADA SC + MTX		1.87(0.76,4.62)	1.37(0.85,2.22)	0.15(-0.07,0.36)
SD TOFA PO + MTX		1.73(0.74,3.98)	1.33(0.84,2.08)	0.13(-0.07,0.32)
SD GOLI SC + MTX		1.75(0.77,4.07)	1.34(0.87,2.17)	0.13(-0.06,0.33)
SD RITUX IV + MTX		0.91(0.39,2.12)	0.95(0.54,1.55)	-0.02(-0.20,0.18)
SD GOLI IV + MTX		0.62(0.28,1.41)	0.74(0.41,1.24)	-0.10(-0.27,0.08)
SD ANA SC + MTX		0.75(0.29,1.92)	0.83(0.42,1.47)	-0.06(-0.26,0.15)
SD ABA SC + MTX		1.07(0.47,2.38)	1.04(0.60,1.58)	0.02(-0.16,0.20)
SD TOCI IV + MTX		0.54(0.19,1.59)	0.67(0.29,1.33)	-0.13(-0.34,0.11)
SD CERTO SC + DMARD		0.84(0.17,4.57)	0.90(0.29,2.25)	-0.04(-0.36,0.36)
SD ADA SC + DMARD		0.72(0.08,7.90)	0.81(0.14,2.56)	-0.07(-0.43,0.46)
SD TOCI SC + DMARD		1.18(0.12,11.75)	1.10(0.21,2.85)	0.04(-0.38,0.52)
LD ADA SC		0.33(0.11,1.00)	0.45(0.21,1.00)	-0.21(-0.43,0.00)
LD ETN SC		0.42(0.11,1.47)	0.55(0.20,1.30)	-0.17(-0.41,0.08)
LD GOLI IV		0.29(0.09,0.82)	0.41(0.16,0.88)	-0.23(-0.41,-0.04)
LD TOCI IV		0.05(0.01,0.22)	0.08(0.02,0.31)	-0.35(-0.55,-0.18)
LD ADA SC + MTX		1.02(0.35,3.10)	1.01(0.49,1.84)	0.00(-0.22,0.26)

(Continued)

LD RITUX IV + MTX		0.90(0.39,2.11)	0.94(0.54,1.54)	-0.02(-0.21,0.18)
LD ADA IV + MTX		0.90(0.14,5.40)	0.94(0.22,2.18)	-0.02(-0.34,0.38)
LD ABA IV + MTX		0.54(0.28,1.04)	0.67(0.40,1.02)	-0.13(-0.26,0.01)
LD ANA SC + MTX		0.50(0.11,2.13)	0.63(0.18,1.53)	-0.14(-0.37,0.18)
LD CERTO SC + MTX		1.06(0.40,2.92)	1.03(0.54,1.80)	0.01(-0.20,0.25)
LD GOLI IV + MTX		0.56(0.19,1.54)	0.68(0.30,1.30)	-0.12(-0.32,0.10)
LD TOCI IV + MTX		0.46(0.16,1.33)	0.59(0.26,1.20)	-0.16(-0.36,0.06)
LD TOFA PO + MTX		0.77(0.21,2.79)	0.85(0.32,1.73)	-0.06(-0.30,0.24)
HD TOCI IV		0.72(0.36,1.49)	0.81(0.53,1.31)	-0.07(-0.24,0.08)
HD TOFA PO		1.03(0.37,3.13)	1.02(0.56,2.06)	0.01(-0.24,0.26)
HD ADA SC		0.47(0.16,1.49)	0.60(0.29,1.32)	-0.16(-0.38,0.08)
HD GOLI SC		0.79(0.33,1.92)	0.86(0.49,1.51)	-0.05(-0.25,0.14)
HD ETN SC		0.73(0.15,3.56)	0.82(0.25,1.99)	-0.07(-0.35,0.30)
HD ABA SC		1.41(0.28,7.27)	1.21(0.45,2.68)	0.08(-0.28,0.45)
HD TOCI IV + MTX		1.26(0.62,2.64)	1.14(0.76,1.78)	0.05(-0.12,0.23)
HD INF IV + MTX		1.15(0.53,2.49)	1.08(0.67,1.68)	0.03(-0.14,0.21)
HD TOFA PO + MTX		0.98(0.42,2.28)	0.99(0.57,1.61)	0.00(-0.20,0.20)
HD GOLI SC + MTX		1.35(0.59,3.12)	1.18(0.73,1.92)	0.07(-0.12,0.27)
HD CERTO SC + MTX		1.77(0.87,3.66)	1.34(0.92,2.05)	0.14(-0.03,0.30)
HD ADA SC + MTX		1.48(0.47,4.65)	1.24(0.62,2.18)	0.09(-0.16,0.35)
HD TOCI IV + DMARD		0.86(0.10,8.16)	0.91(0.18,2.62)	-0.04(-0.40,0.46)
SD ANA SC + SD ETN SC + MTX		0.88(0.24,3.53)	0.92(0.37,1.97)	-0.03(-0.29,0.29)
SD ANA SC + LD ETN SC + MTX		1.30(0.36,4.98)	1.15(0.50,2.24)	0.06(-0.22,0.37)
SD INF IV + MTX	SD CERTO SC + MTX	0.58(0.29,1.14)	0.73(0.47,1.07)	-0.13(-0.29,0.03)
SD ADA SC + MTX		1.26(0.51,3.23)	1.11(0.70,1.71)	0.05(-0.16,0.27)
SD TOFA PO + MTX		1.17(0.49,2.73)	1.08(0.69,1.62)	0.04(-0.17,0.24)
SD GOLI SC + MTX		1.19(0.52,2.71)	1.08(0.71,1.62)	0.04(-0.15,0.24)
SD RITUX IV + MTX		0.62(0.26,1.44)	0.76(0.43,1.21)	-0.11(-0.30,0.09)

(Continued)

SD GOL I IV + MTX	0.42(0.19,0.95)	0.60(0.33,0.97)	-0.19(-0.37,-0.01)
SD ANA SC + MTX	0.50(0.20,1.32)	0.67(0.35,1.15)	-0.16(-0.35,0.07)
SD ABA SC + MTX	0.72(0.25,2.00)	0.84(0.41,1.39)	-0.08(-0.31,0.17)
SD TOCI IV + MTX	0.37(0.12,1.09)	0.54(0.23,1.05)	-0.22(-0.43,0.02)
SD CERTO SC + DMARD	0.56(0.11,3.11)	0.72(0.24,1.74)	-0.14(-0.46,0.27)
SD ADA SC + DMARD	0.49(0.05,5.17)	0.66(0.12,1.93)	-0.16(-0.52,0.36)
SD TOCI SC + DMARD	0.80(0.08,7.86)	0.89(0.17,2.15)	-0.05(-0.48,0.43)
LD ADA SC	0.22(0.07,0.68)	0.37(0.17,0.77)	-0.31(-0.53,-0.08)
LD ETN SC	0.28(0.08,1.00)	0.44(0.17,1.00)	-0.27(-0.51,0.00)
LD GOL I IV	0.20(0.06,0.56)	0.33(0.13,0.70)	-0.32(-0.51,-0.13)
LD TOCI IV	0.03(0.01,0.14)	0.07(0.01,0.24)	-0.45(-0.64,-0.27)
LD ADA SC + MTX	0.68(0.24,2.10)	0.82(0.40,1.42)	-0.09(-0.32,0.18)
LD RITUX IV + MTX	0.60(0.26,1.43)	0.76(0.43,1.21)	-0.12(-0.30,0.09)
LD ADA IV + MTX	0.60(0.09,3.69)	0.76(0.17,1.69)	-0.12(-0.44,0.29)
LD ABA IV + MTX	0.36(0.16,0.83)	0.53(0.29,0.90)	-0.22(-0.39,-0.04)
LD ANA SC + MTX	0.34(0.07,1.47)	0.51(0.14,1.21)	-0.23(-0.48,0.09)
LD CERTO SC + MTX	0.71(0.30,1.75)	0.83(0.46,1.30)	-0.08(-0.27,0.13)
LD GOL I IV + MTX	0.38(0.13,1.04)	0.55(0.24,1.02)	-0.22(-0.42,0.01)
LD TOCI IV + MTX	0.31(0.10,0.89)	0.47(0.20,0.94)	-0.25(-0.46,-0.03)
LD TOFA PO + MTX	0.52(0.14,1.87)	0.68(0.26,1.34)	-0.15(-0.40,0.15)
HD TOCI IV	0.49(0.25,0.99)	0.66(0.43,0.99)	-0.17(-0.33,0.00)
HD TOFA PO	0.70(0.24,2.03)	0.82(0.47,1.52)	-0.09(-0.33,0.17)
HD ADA SC	0.32(0.11,0.98)	0.48(0.24,0.99)	-0.25(-0.48,0.00)
HD GOL I SC	0.53(0.22,1.29)	0.70(0.40,1.15)	-0.15(-0.34,0.06)
HD ETN SC	0.50(0.10,2.34)	0.67(0.20,1.52)	-0.16(-0.46,0.20)
HD ABA SC	0.94(0.20,5.03)	0.97(0.38,2.04)	-0.01(-0.37,0.36)
HD TOCI IV + MTX	0.85(0.42,1.78)	0.92(0.62,1.37)	-0.04(-0.21,0.14)
HD INF IV + MTX	0.78(0.35,1.72)	0.88(0.54,1.32)	-0.06(-0.24,0.13)

(Continued)

HD TOFA PO + MTX		0.66(0.28,1.53)	0.80(0.46,1.25)	-0.10(-0.29,0.10)
HD GOLI SC + MTX		0.91(0.40,2.14)	0.95(0.60,1.46)	-0.02(-0.22,0.18)
HD CERTO SC + MTX		1.19(0.73,1.95)	1.09(0.85,1.39)	0.04(-0.08,0.16)
HD ADA SC + MTX		0.99(0.33,3.20)	1.00(0.51,1.66)	0.00(-0.25,0.27)
HD TOCI IV + DMARD		0.58(0.07,5.40)	0.74(0.15,2.00)	-0.13(-0.50,0.38)
SD ANA SC + SD ETN SC + MTX		0.59(0.16,2.30)	0.75(0.30,1.49)	-0.12(-0.39,0.20)
SD ANA SC + LD ETN SC + MTX		0.88(0.24,3.37)	0.93(0.41,1.72)	-0.03(-0.32,0.28)
SD ADA SC + MTX	SD INF IV + MTX	2.18(0.86,5.75)	1.51(0.92,2.57)	0.18(-0.04,0.40)
SD TOFA PO + MTX		2.03(0.85,4.87)	1.46(0.91,2.42)	0.17(-0.04,0.37)
SD GOLI SC + MTX		2.06(0.89,4.80)	1.48(0.94,2.44)	0.17(-0.03,0.36)
SD RITUX IV + MTX		1.06(0.45,2.52)	1.04(0.59,1.76)	0.01(-0.17,0.21)
SD GOLI IV + MTX		0.73(0.31,1.69)	0.81(0.44,1.41)	-0.07(-0.24,0.11)
SD ANA SC + MTX		0.87(0.34,2.30)	0.91(0.47,1.67)	-0.03(-0.22,0.19)
SD ABA SC + MTX		1.25(0.44,3.44)	1.14(0.57,2.02)	0.05(-0.17,0.29)
SD TOCI IV + MTX		0.63(0.22,1.93)	0.73(0.32,1.52)	-0.09(-0.30,0.15)
SD CERTO SC + DMARD		0.97(0.20,5.33)	0.98(0.32,2.58)	-0.01(-0.32,0.39)
SD ADA SC + DMARD		0.84(0.10,8.93)	0.90(0.16,2.89)	-0.04(-0.39,0.48)
SD TOCI SC + DMARD		1.37(0.15,14.07)	1.20(0.23,3.21)	0.07(-0.34,0.55)
LD ADA SC		0.39(0.13,1.20)	0.50(0.22,1.15)	-0.17(-0.40,0.03)
LD ETN SC		0.48(0.13,1.78)	0.60(0.22,1.48)	-0.14(-0.38,0.12)
LD GOLI IV		0.34(0.11,0.99)	0.45(0.17,0.99)	-0.19(-0.38,0.00)
LD TOCI IV		0.06(0.01,0.25)	0.09(0.02,0.34)	-0.32(-0.51,-0.16)
LD ADA SC + MTX		1.18(0.40,3.77)	1.10(0.53,2.12)	0.04(-0.19,0.31)
LD RITUX IV + MTX		1.05(0.45,2.50)	1.03(0.58,1.74)	0.01(-0.17,0.21)
LD ADA IV + MTX		1.04(0.17,6.64)	1.03(0.24,2.47)	0.01(-0.30,0.43)
LD ABA IV + MTX		0.63(0.28,1.45)	0.73(0.40,1.27)	-0.09(-0.26,0.08)
LD ANA SC + MTX		0.59(0.13,2.58)	0.70(0.19,1.72)	-0.10(-0.34,0.22)
LD CERTO SC + MTX		1.24(0.45,3.54)	1.13(0.58,2.06)	0.05(-0.17,0.29)

(Continued)

LD GOLI IV + MTX		0.66(0.23,1.87)	0.75(0.34,1.49)	-0.09(-0.29,0.14)
LD TOCI IV + MTX		0.54(0.18,1.62)	0.65(0.28,1.36)	-0.12(-0.32,0.10)
LD TOFA PO + MTX		0.90(0.24,3.31)	0.94(0.35,1.96)	-0.02(-0.27,0.28)
HD TOCI IV		0.85(0.41,1.80)	0.90(0.57,1.51)	-0.04(-0.21,0.12)
HD TOFA PO		1.20(0.41,3.71)	1.12(0.60,2.35)	0.04(-0.21,0.29)
HD ADA SC		0.55(0.18,1.77)	0.66(0.31,1.51)	-0.12(-0.36,0.12)
HD GOLI SC		0.93(0.38,2.26)	0.96(0.53,1.70)	-0.02(-0.22,0.18)
HD ETN SC		0.86(0.18,4.11)	0.90(0.27,2.21)	-0.03(-0.32,0.33)
HD ABA SC		1.66(0.34,8.63)	1.33(0.50,3.05)	0.12(-0.24,0.48)
HD TOCI IV + MTX		1.47(0.70,3.18)	1.25(0.81,2.06)	0.09(-0.08,0.27)
HD INF IV + MTX		1.34(0.72,2.58)	1.19(0.81,1.76)	0.07(-0.07,0.22)
HD TOFA PO + MTX		1.14(0.49,2.74)	1.09(0.63,1.85)	0.03(-0.16,0.23)
HD GOLI SC + MTX		1.58(0.68,3.68)	1.30(0.79,2.17)	0.11(-0.09,0.30)
HD CERTO SC + MTX		2.07(0.98,4.36)	1.48(0.99,2.34)	0.17(0.00,0.34)
HD ADA SC + MTX		1.72(0.56,5.49)	1.36(0.68,2.48)	0.13(-0.13,0.39)
HD TOCI IV + DMARD		1.00(0.12,9.28)	1.00(0.20,2.94)	0.00(-0.37,0.49)
SD ANA SC + SD ETN SC + MTX		1.03(0.28,4.10)	1.02(0.40,2.22)	0.01(-0.26,0.33)
SD ANA SC + LD ETN SC + MTX		1.51(0.41,5.90)	1.27(0.55,2.56)	0.10(-0.19,0.41)
SD TOFA PO + MTX	SD ADA SC + MTX	0.93(0.32,2.60)	0.97(0.58,1.61)	-0.02(-0.26,0.23)
SD GOLI SC + MTX		0.94(0.33,2.66)	0.97(0.60,1.63)	-0.01(-0.26,0.23)
SD RITUX IV + MTX		0.49(0.16,1.39)	0.69(0.36,1.20)	-0.17(-0.41,0.08)
SD GOLI IV + MTX		0.33(0.11,0.94)	0.54(0.28,0.96)	-0.25(-0.48,-0.02)
SD ANA SC + MTX		0.40(0.13,1.26)	0.61(0.29,1.13)	-0.21(-0.45,0.05)
SD ABA SC + MTX		0.57(0.17,1.94)	0.76(0.35,1.38)	-0.13(-0.40,0.16)
SD TOCI IV + MTX		0.29(0.08,1.00)	0.49(0.20,1.00)	-0.27(-0.53,0.00)
SD CERTO SC + DMARD		0.45(0.08,2.71)	0.65(0.22,1.63)	-0.19(-0.54,0.23)
SD ADA SC + DMARD		0.39(0.04,4.54)	0.59(0.10,1.81)	-0.22(-0.61,0.33)
SD TOCI SC + DMARD		0.63(0.06,6.86)	0.80(0.15,2.04)	-0.11(-0.57,0.40)

(Continued)

LD ADA SC	0.18(0.05,0.62)	0.33(0.15,0.72)	-0.36(-0.61,-0.10)
LD ETN SC	0.22(0.05,0.91)	0.40(0.15,0.94)	-0.32(-0.60,-0.02)
LD GOL I V	0.15(0.04,0.52)	0.30(0.11,0.67)	-0.38(-0.61,-0.13)
LD TOCI IV	0.03(0.00,0.13)	0.06(0.01,0.23)	-0.51(-0.73,-0.27)
LD ADA SC + MTX	0.54(0.21,1.44)	0.74(0.39,1.19)	-0.14(-0.35,0.09)
LD RITUX IV + MTX	0.48(0.16,1.38)	0.68(0.35,1.19)	-0.17(-0.42,0.08)
LD ADA IV + MTX	0.48(0.07,3.13)	0.69(0.16,1.58)	-0.17(-0.51,0.26)
LD ABA IV + MTX	0.29(0.10,0.81)	0.48(0.24,0.89)	-0.28(-0.50,-0.05)
LD ANA SC + MTX	0.27(0.05,1.29)	0.46(0.12,1.14)	-0.28(-0.57,0.06)
LD CERTO SC + MTX	0.57(0.17,1.85)	0.75(0.37,1.36)	-0.13(-0.40,0.14)
LD GOL I V + MTX	0.30(0.09,0.98)	0.50(0.21,0.99)	-0.27(-0.51,-0.01)
LD TOCI IV + MTX	0.25(0.07,0.83)	0.43(0.18,0.90)	-0.30(-0.55,-0.04)
LD TOFA PO + MTX	0.41(0.09,1.73)	0.62(0.22,1.30)	-0.20(-0.50,0.13)
HD TOCI IV	0.39(0.15,0.98)	0.59(0.37,0.99)	-0.22(-0.44,-0.01)
HD TOFA PO	0.55(0.16,1.84)	0.74(0.42,1.44)	-0.14(-0.42,0.14)
HD ADA SC	0.26(0.07,0.90)	0.44(0.21,0.94)	-0.30(-0.56,-0.02)
HD GOL I SC	0.42(0.14,1.25)	0.63(0.34,1.14)	-0.20(-0.44,0.05)
HD ETN SC	0.39(0.07,2.09)	0.60(0.18,1.44)	-0.21(-0.54,0.18)
HD ABA SC	0.75(0.14,4.22)	0.87(0.34,1.90)	-0.07(-0.44,0.33)
HD TOCI IV + MTX	0.67(0.25,1.75)	0.83(0.52,1.36)	-0.10(-0.32,0.13)
HD INF IV + MTX	0.62(0.22,1.72)	0.79(0.45,1.33)	-0.12(-0.35,0.13)
HD TOFA PO + MTX	0.53(0.18,1.46)	0.72(0.39,1.24)	-0.15(-0.39,0.09)
HD GOL I SC + MTX	0.72(0.25,2.04)	0.86(0.50,1.44)	-0.08(-0.32,0.17)
HD CERTO SC + MTX	0.94(0.36,2.41)	0.97(0.63,1.58)	-0.01(-0.24,0.21)
HD ADA SC + MTX	0.79(0.30,2.09)	0.90(0.50,1.38)	-0.05(-0.28,0.17)
HD TOCI IV + DMARD	0.47(0.05,4.71)	0.67(0.13,1.86)	-0.18(-0.58,0.34)
SD ANA SC + SD ETN SC + MTX	0.47(0.11,2.11)	0.67(0.26,1.44)	-0.18(-0.48,0.18)
SD ANA SC + LD ETN SC + MTX	0.69(0.16,3.13)	0.84(0.36,1.67)	-0.09(-0.41,0.26)

(Continued)

SD GOLI SC + MTX	SD TOFA PO + MTX	1.02(0.39,2.62)	1.01(0.64,1.63)	0.00(-0.22,0.23)
SD RITUX IV + MTX		0.53(0.19,1.44)	0.71(0.38,1.21)	-0.15(-0.38,0.09)
SD GOLI IV + MTX		0.36(0.14,0.97)	0.56(0.29,0.98)	-0.23(-0.44,-0.01)
SD ANA SC + MTX		0.43(0.15,1.31)	0.62(0.31,1.16)	-0.20(-0.42,0.06)
SD ABA SC + MTX		0.62(0.19,2.01)	0.78(0.37,1.41)	-0.11(-0.37,0.17)
SD TOCI IV + MTX		0.31(0.09,1.05)	0.50(0.21,1.03)	-0.26(-0.49,0.01)
SD CERTO SC + DMARD		0.48(0.09,2.99)	0.67(0.22,1.70)	-0.17(-0.51,0.26)
SD ADA SC + DMARD		0.41(0.04,4.67)	0.60(0.10,1.92)	-0.21(-0.58,0.34)
SD TOCI SC + DMARD		0.68(0.07,7.40)	0.82(0.16,2.18)	-0.09(-0.53,0.42)
LD ADA SC		0.19(0.06,0.67)	0.34(0.16,0.76)	-0.35(-0.58,-0.08)
LD ETN SC		0.24(0.06,0.99)	0.41(0.15,1.00)	-0.31(-0.56,0.00)
LD GOLI IV		0.17(0.05,0.54)	0.31(0.11,0.69)	-0.36(-0.58,-0.12)
LD TOCI IV		0.03(0.00,0.14)	0.06(0.01,0.24)	-0.49(-0.70,-0.26)
LD ADA SC + MTX		0.59(0.18,2.01)	0.76(0.36,1.39)	-0.13(-0.38,0.16)
LD RITUX IV + MTX		0.52(0.19,1.41)	0.71(0.38,1.20)	-0.15(-0.38,0.08)
LD ADA IV + MTX		0.53(0.08,3.36)	0.71(0.16,1.66)	-0.15(-0.49,0.27)
LD ABA IV + MTX		0.31(0.12,0.83)	0.50(0.26,0.90)	-0.26(-0.47,-0.04)
LD ANA SC + MTX		0.29(0.06,1.38)	0.47(0.13,1.18)	-0.27(-0.54,0.08)
LD CERTO SC + MTX		0.61(0.20,1.91)	0.78(0.38,1.39)	-0.12(-0.37,0.15)
LD GOLI IV + MTX		0.32(0.10,1.01)	0.51(0.22,1.00)	-0.25(-0.48,0.00)
LD TOCI IV + MTX		0.26(0.08,0.90)	0.44(0.18,0.94)	-0.29(-0.52,-0.02)
LD TOFA PO + MTX		0.45(0.14,1.41)	0.64(0.26,1.17)	-0.18(-0.42,0.08)
HD TOCI IV		0.42(0.18,1.04)	0.61(0.38,1.02)	-0.21(-0.40,0.01)
HD TOFA PO		0.60(0.18,1.99)	0.76(0.42,1.50)	-0.13(-0.40,0.16)
HD ADA SC		0.27(0.08,0.97)	0.45(0.22,0.98)	-0.29(-0.54,-0.01)
HD GOLI SC		0.46(0.17,1.26)	0.65(0.36,1.14)	-0.18(-0.41,0.05)
HD ETN SC		0.42(0.08,2.30)	0.62(0.18,1.51)	-0.20(-0.50,0.20)
HD ABA SC		0.82(0.16,4.55)	0.91(0.35,1.97)	-0.05(-0.42,0.34)

(Continued)

HD TOCI IV + MTX		0.73(0.30,1.84)	0.85(0.55,1.41)	-0.08(-0.28,0.14)
HD INF IV + MTX		0.66(0.26,1.74)	0.81(0.48,1.34)	-0.10(-0.31,0.13)
HD TOFA PO + MTX		0.57(0.31,1.05)	0.74(0.50,1.03)	-0.13(-0.28,0.01)
HD GOLI SC + MTX		0.78(0.30,2.06)	0.89(0.53,1.46)	-0.06(-0.28,0.17)
HD CERTO SC + MTX		1.02(0.42,2.56)	1.01(0.67,1.61)	0.01(-0.20,0.22)
HD ADA SC + MTX		0.86(0.24,3.07)	0.93(0.45,1.67)	-0.04(-0.32,0.26)
HD TOCI IV + DMARD		0.50(0.06,4.95)	0.68(0.14,1.96)	-0.16(-0.55,0.35)
SD ANA SC + SD ETN SC + MTX		0.51(0.12,2.21)	0.70(0.27,1.46)	-0.16(-0.45,0.19)
SD ANA SC + LD ETN SC + MTX		0.75(0.19,3.18)	0.87(0.37,1.70)	-0.07(-0.38,0.27)
SD RITUX IV + MTX	SD GOLI SC + MTX	0.52(0.19,1.41)	0.71(0.38,1.19)	-0.15(-0.38,0.08)
SD GOLI IV + MTX		0.36(0.14,0.92)	0.55(0.29,0.95)	-0.23(-0.44,-0.02)
SD ANA SC + MTX		0.43(0.15,1.22)	0.62(0.30,1.11)	-0.20(-0.42,0.05)
SD ABA SC + MTX		0.61(0.19,1.90)	0.78(0.37,1.36)	-0.12(-0.37,0.15)
SD TOCI IV + MTX		0.31(0.09,1.02)	0.49(0.21,1.01)	-0.26(-0.50,0.00)
SD CERTO SC + DMARD		0.47(0.09,2.81)	0.66(0.22,1.66)	-0.18(-0.50,0.25)
SD ADA SC + DMARD		0.41(0.04,4.63)	0.60(0.10,1.87)	-0.21(-0.57,0.34)
SD TOCI SC + DMARD		0.67(0.07,6.90)	0.82(0.16,2.04)	-0.10(-0.52,0.40)
LD ADA SC		0.19(0.06,0.64)	0.34(0.16,0.74)	-0.35(-0.58,-0.09)
LD ETN SC		0.24(0.06,0.89)	0.41(0.15,0.93)	-0.31(-0.57,-0.03)
LD GOLI IV		0.16(0.05,0.52)	0.30(0.11,0.67)	-0.36(-0.57,-0.14)
LD TOCI IV		0.03(0.00,0.14)	0.06(0.01,0.24)	-0.49(-0.70,-0.27)
LD ADA SC + MTX		0.58(0.18,1.98)	0.75(0.35,1.40)	-0.13(-0.39,0.16)
LD RITUX IV + MTX		0.51(0.19,1.37)	0.70(0.37,1.19)	-0.16(-0.38,0.08)
LD ADA IV + MTX		0.51(0.07,3.30)	0.70(0.16,1.65)	-0.15(-0.50,0.27)
LD ABA IV + MTX		0.31(0.12,0.80)	0.49(0.25,0.88)	-0.26(-0.46,-0.05)
LD ANA SC + MTX		0.28(0.06,1.32)	0.47(0.13,1.15)	-0.27(-0.53,0.07)
LD CERTO SC + MTX		0.61(0.20,1.83)	0.77(0.38,1.34)	-0.12(-0.37,0.14)
LD GOLI IV + MTX		0.32(0.10,0.97)	0.51(0.22,0.99)	-0.26(-0.49,-0.01)

(Continued)

LD TOCI IV + MTX		0.26(0.08,0.86)	0.44(0.19,0.92)	-0.29(-0.52,-0.03)
LD TOFA PO + MTX		0.44(0.11,1.66)	0.64(0.23,1.27)	-0.19(-0.45,0.12)
HD TOCI IV		0.41(0.18,0.97)	0.61(0.38,0.98)	-0.21(-0.40,-0.01)
HD TOFA PO		0.58(0.19,1.91)	0.75(0.43,1.46)	-0.13(-0.39,0.15)
HD ADA SC		0.27(0.08,0.90)	0.45(0.22,0.94)	-0.29(-0.53,-0.02)
HD GOLI SC		0.45(0.20,1.02)	0.65(0.39,1.02)	-0.19(-0.37,0.01)
HD ETN SC		0.41(0.08,2.13)	0.61(0.18,1.44)	-0.20(-0.51,0.18)
HD ABA SC		0.80(0.16,4.44)	0.90(0.35,1.94)	-0.05(-0.42,0.34)
HD TOCI IV + MTX		0.71(0.30,1.73)	0.85(0.54,1.35)	-0.08(-0.28,0.13)
HD INF IV + MTX		0.66(0.26,1.65)	0.81(0.47,1.29)	-0.10(-0.32,0.12)
HD TOFA PO + MTX		0.56(0.21,1.46)	0.74(0.41,1.21)	-0.14(-0.36,0.09)
HD GOLI SC + MTX		0.77(0.41,1.44)	0.88(0.62,1.20)	-0.06(-0.21,0.09)
HD CERTO SC + MTX		1.01(0.42,2.41)	1.00(0.66,1.54)	0.00(-0.21,0.21)
HD ADA SC + MTX		0.84(0.24,2.97)	0.92(0.44,1.62)	-0.04(-0.33,0.25)
HD TOCI IV + DMARD		0.49(0.05,4.87)	0.68(0.14,1.91)	-0.17(-0.55,0.35)
SD ANA SC + SD ETN SC + MTX		0.50(0.12,2.19)	0.69(0.26,1.45)	-0.16(-0.45,0.18)
SD ANA SC + LD ETN SC + MTX		0.74(0.18,3.07)	0.86(0.37,1.65)	-0.07(-0.38,0.26)
SD GOLI IV + MTX	SD RITUX IV + MTX	0.69(0.25,1.77)	0.79(0.40,1.48)	-0.08(-0.30,0.12)
SD ANA SC + MTX		0.82(0.28,2.52)	0.88(0.42,1.80)	-0.04(-0.28,0.20)
SD ABA SC + MTX		1.17(0.36,3.75)	1.10(0.51,2.18)	0.04(-0.22,0.30)
SD TOCI IV + MTX		0.59(0.18,1.97)	0.71(0.29,1.56)	-0.11(-0.35,0.15)
SD CERTO SC + DMARD		0.90(0.17,5.65)	0.94(0.30,2.70)	-0.02(-0.36,0.39)
SD ADA SC + DMARD		0.78(0.08,9.40)	0.86(0.15,3.09)	-0.05(-0.43,0.49)
SD TOCI SC + DMARD		1.27(0.13,14.09)	1.15(0.22,3.44)	0.06(-0.37,0.56)
LD ADA SC		0.36(0.11,1.28)	0.48(0.21,1.21)	-0.19(-0.45,0.04)
LD ETN SC		0.46(0.11,1.83)	0.58(0.21,1.50)	-0.15(-0.43,0.12)
LD GOLI IV		0.32(0.09,1.04)	0.43(0.16,1.03)	-0.20(-0.43,0.01)
LD TOCI IV		0.06(0.01,0.26)	0.09(0.02,0.34)	-0.33(-0.57,-0.14)

(Continued)

LD ADA SC + MTX	1.11(0.34,3.88)	1.06(0.49,2.22)	0.02(-0.24,0.31)
LD RITUX IV + MTX	0.99(0.51,1.88)	0.99(0.65,1.51)	0.00(-0.15,0.14)
LD ADA IV + MTX	1.00(0.14,6.65)	1.00(0.23,2.57)	0.00(-0.35,0.43)
LD ABA IV + MTX	0.59(0.22,1.57)	0.70(0.36,1.36)	-0.11(-0.32,0.10)
LD ANA SC + MTX	0.54(0.11,2.68)	0.66(0.18,1.80)	-0.12(-0.39,0.23)
LD CERTO SC + MTX	1.15(0.37,3.69)	1.09(0.53,2.17)	0.03(-0.22,0.30)
LD GOLI IV + MTX	0.61(0.19,1.96)	0.72(0.31,1.55)	-0.10(-0.34,0.14)
LD TOCI IV + MTX	0.50(0.15,1.65)	0.62(0.26,1.41)	-0.14(-0.37,0.11)
LD TOFA PO + MTX	0.84(0.21,3.37)	0.90(0.33,2.03)	-0.04(-0.31,0.28)
HD TOCI IV	0.79(0.33,1.93)	0.86(0.51,1.59)	-0.05(-0.26,0.13)
HD TOFA PO	1.12(0.34,3.93)	1.07(0.54,2.48)	0.03(-0.25,0.30)
HD ADA SC	0.52(0.15,1.84)	0.64(0.29,1.58)	-0.13(-0.40,0.12)
HD GOLI SC	0.87(0.31,2.43)	0.91(0.48,1.82)	-0.03(-0.26,0.19)
HD ETN SC	0.80(0.15,4.28)	0.87(0.26,2.31)	-0.05(-0.37,0.33)
HD ABA SC	1.53(0.28,9.04)	1.27(0.46,3.25)	0.10(-0.28,0.49)
HD TOCI IV + MTX	1.38(0.56,3.47)	1.20(0.73,2.24)	0.07(-0.14,0.28)
HD INF IV + MTX	1.27(0.48,3.24)	1.14(0.64,2.10)	0.05(-0.17,0.27)
HD TOFA PO + MTX	1.07(0.39,2.89)	1.04(0.55,1.96)	0.01(-0.21,0.24)
HD GOLI SC + MTX	1.48(0.54,3.96)	1.25(0.71,2.34)	0.09(-0.14,0.32)
HD CERTO SC + MTX	1.94(0.79,4.73)	1.42(0.89,2.54)	0.16(-0.06,0.36)
HD ADA SC + MTX	1.62(0.47,5.96)	1.30(0.62,2.63)	0.11(-0.17,0.40)
HD TOCI IV + DMARD	0.92(0.11,9.66)	0.95(0.19,3.11)	-0.02(-0.40,0.49)
SD ANA SC + SD ETN SC + MTX	0.96(0.23,4.34)	0.97(0.37,2.35)	-0.01(-0.31,0.34)
SD ANA SC + LD ETN SC + MTX	1.41(0.34,6.29)	1.21(0.51,2.72)	0.08(-0.23,0.41)
SD ANA SC + MTX	SD GOLI IV + MTX 1.19(0.42,3.49)	1.13(0.54,2.32)	0.04(-0.17,0.27)
SD ABA SC + MTX	1.71(0.53,5.26)	1.41(0.65,2.84)	0.12(-0.13,0.37)
SD TOCI IV + MTX	0.86(0.27,2.91)	0.90(0.37,2.08)	-0.03(-0.25,0.22)
SD CERTO SC + DMARD	1.33(0.25,7.66)	1.21(0.36,3.53)	0.06(-0.26,0.44)

(Continued)

SD ADA SC + DMARD	1.16(0.12,13.18)	1.11(0.18,3.92)	0.03(-0.33,0.56)
SD TOCI SC + DMARD	1.89(0.19,19.88)	1.48(0.28,4.42)	0.14(-0.27,0.62)
LD ADA SC	0.53(0.16,1.75)	0.62(0.26,1.55)	-0.11(-0.34,0.09)
LD ETN SC	0.66(0.17,2.67)	0.74(0.26,2.06)	-0.07(-0.32,0.19)
LD GOLIV	0.46(0.17,1.20)	0.55(0.24,1.14)	-0.12(-0.30,0.03)
LD TOCI IV	0.08(0.01,0.38)	0.11(0.02,0.44)	-0.25(-0.46,-0.10)
LD ADA SC + MTX	1.62(0.51,5.62)	1.36(0.62,2.92)	0.10(-0.14,0.38)
LD RITUX IV + MTX	1.43(0.55,3.95)	1.26(0.66,2.51)	0.07(-0.13,0.30)
LD ADA IV + MTX	1.44(0.21,9.33)	1.27(0.28,3.37)	0.08(-0.25,0.49)
LD ABA IV + MTX	0.87(0.33,2.24)	0.90(0.45,1.79)	-0.03(-0.22,0.16)
LD ANA SC + MTX	0.80(0.16,3.82)	0.86(0.22,2.32)	-0.04(-0.30,0.30)
LD CERTO SC + MTX	1.68(0.56,5.33)	1.39(0.67,2.85)	0.11(-0.12,0.37)
LD GOLIV + MTX	0.89(0.35,2.22)	0.92(0.45,1.73)	-0.02(-0.20,0.17)
LD TOCI IV + MTX	0.74(0.23,2.42)	0.80(0.32,1.86)	-0.06(-0.27,0.18)
LD TOFA PO + MTX	1.22(0.31,4.94)	1.15(0.41,2.68)	0.04(-0.21,0.36)
HD TOCI IV	1.15(0.49,2.78)	1.10(0.64,2.14)	0.03(-0.16,0.20)
HD TOFA PO	1.64(0.53,5.48)	1.38(0.68,3.27)	0.11(-0.15,0.35)
HD ADA SC	0.76(0.23,2.52)	0.82(0.35,2.04)	-0.05(-0.30,0.17)
HD GOLIV SC	1.26(0.48,3.39)	1.17(0.61,2.36)	0.05(-0.16,0.25)
HD ETN SC	1.17(0.22,6.09)	1.11(0.31,3.07)	0.03(-0.26,0.40)
HD ABA SC	2.26(0.44,12.43)	1.63(0.58,4.10)	0.18(-0.18,0.55)
HD TOCI IV + MTX	1.99(0.85,4.98)	1.54(0.91,2.96)	0.15(-0.04,0.35)
HD INF IV + MTX	1.83(0.73,4.68)	1.46(0.82,2.74)	0.13(-0.07,0.34)
HD TOFA PO + MTX	1.57(0.57,4.17)	1.34(0.70,2.57)	0.10(-0.12,0.31)
HD GOLIV SC + MTX	2.16(0.84,5.68)	1.59(0.89,3.06)	0.17(-0.04,0.38)
HD CERTO SC + MTX	2.82(1.16,6.73)	1.82(1.09,3.42)	0.24(0.03,0.42)
HD ADA SC + MTX	2.36(0.70,8.41)	1.66(0.79,3.45)	0.19(-0.08,0.47)
HD TOCI IV + DMARD	1.38(0.16,13.49)	1.23(0.23,3.99)	0.07(-0.30,0.56)

(Continued)

SD ANA SC + SD ETN SC + MTX		1.39(0.33,6.30)	1.24(0.45,3.12)	0.07(-0.21,0.41)
SD ANA SC + LD ETN SC + MTX		2.05(0.51,8.91)	1.55(0.63,3.58)	0.16(-0.14,0.48)
SD ABA SC + MTX	SD ANA SC + MTX	1.43(0.41,4.94)	1.24(0.56,2.72)	0.08(-0.19,0.35)
SD TOCI IV + MTX		0.72(0.20,2.57)	0.80(0.31,1.92)	-0.06(-0.32,0.19)
SD CERTO SC + DMARD		1.11(0.20,7.12)	1.07(0.33,3.31)	0.02(-0.32,0.43)
SD ADA SC + DMARD		0.97(0.10,10.92)	0.98(0.16,3.54)	-0.01(-0.39,0.52)
SD TOCI SC + DMARD		1.57(0.15,16.87)	1.31(0.25,4.05)	0.10(-0.34,0.59)
LD ADA SC		0.45(0.12,1.63)	0.55(0.23,1.47)	-0.15(-0.41,0.08)
LD ETN SC		0.55(0.13,2.41)	0.66(0.22,1.90)	-0.11(-0.39,0.17)
LD GOLI IV		0.39(0.11,1.34)	0.49(0.18,1.25)	-0.16(-0.40,0.05)
LD TOCI IV		0.07(0.01,0.34)	0.10(0.02,0.41)	-0.29(-0.53,-0.11)
LD ADA SC + MTX		1.36(0.39,4.97)	1.20(0.54,2.71)	0.07(-0.20,0.36)
LD RITUX IV + MTX		1.20(0.40,3.62)	1.12(0.56,2.37)	0.04(-0.20,0.27)
LD ADA IV + MTX		1.21(0.17,8.02)	1.12(0.26,3.10)	0.04(-0.30,0.46)
LD ABA IV + MTX		0.72(0.25,2.06)	0.80(0.38,1.66)	-0.06(-0.29,0.14)
LD ANA SC + MTX		0.67(0.17,2.39)	0.76(0.24,1.71)	-0.07(-0.30,0.20)
LD CERTO SC + MTX		1.42(0.41,4.80)	1.24(0.57,2.68)	0.08(-0.19,0.34)
LD GOLI IV + MTX		0.75(0.21,2.52)	0.82(0.33,1.87)	-0.06(-0.32,0.19)
LD TOCI IV + MTX		0.61(0.18,2.13)	0.71(0.28,1.70)	-0.09(-0.34,0.15)
LD TOFA PO + MTX		1.03(0.24,4.37)	1.02(0.35,2.48)	0.01(-0.29,0.33)
HD TOCI IV		0.97(0.37,2.52)	0.98(0.54,1.98)	-0.01(-0.23,0.18)
HD TOFA PO		1.39(0.41,4.89)	1.23(0.59,2.98)	0.07(-0.21,0.32)
HD ADA SC		0.63(0.18,2.29)	0.72(0.32,1.88)	-0.09(-0.36,0.15)
HD GOLI SC		1.05(0.35,3.16)	1.03(0.52,2.28)	0.01(-0.23,0.24)
HD ETN SC		0.98(0.17,5.43)	0.99(0.27,2.84)	0.00(-0.34,0.37)
HD ABA SC		1.86(0.35,11.26)	1.43(0.50,3.92)	0.14(-0.23,0.52)
HD TOCI IV + MTX		1.66(0.64,4.52)	1.36(0.78,2.77)	0.12(-0.11,0.32)
HD INF IV + MTX		1.55(0.54,4.27)	1.30(0.70,2.60)	0.10(-0.14,0.32)

(Continued)

HD TOFA PO + MTX		1.32(0.43,3.77)	1.19(0.59,2.41)	0.06(-0.18,0.29)
HD GOLI SC + MTX		1.80(0.62,5.18)	1.41(0.76,2.92)	0.13(-0.11,0.36)
HD CERTO SC + MTX		2.38(0.87,6.21)	1.62(0.93,3.17)	0.20(-0.03,0.41)
HD ADA SC + MTX		1.98(0.52,7.37)	1.48(0.66,3.27)	0.16(-0.15,0.45)
HD TOCI IV + DMARD		1.15(0.13,11.61)	1.09(0.21,3.69)	0.03(-0.36,0.53)
SD ANA SC + SD ETN SC + MTX		1.17(0.26,5.61)	1.11(0.40,2.91)	0.03(-0.27,0.38)
SD ANA SC + LD ETN SC + MTX		1.74(0.39,7.94)	1.39(0.55,3.36)	0.13(-0.21,0.46)
SD TOCI IV + MTX	SD ABA SC + MTX	0.50(0.14,1.98)	0.64(0.27,1.59)	-0.14(-0.42,0.14)
SD CERTO SC + DMARD		0.79(0.13,5.14)	0.86(0.27,2.58)	-0.05(-0.43,0.37)
SD ADA SC + DMARD		0.68(0.06,8.08)	0.79(0.13,2.79)	-0.08(-0.50,0.46)
SD TOCI SC + DMARD		1.11(0.10,12.55)	1.06(0.19,3.28)	0.02(-0.45,0.53)
LD ADA SC		0.31(0.08,1.27)	0.44(0.19,1.20)	-0.23(-0.52,0.04)
LD ETN SC		0.39(0.08,1.79)	0.53(0.18,1.53)	-0.19(-0.50,0.11)
LD GOLI IV		0.27(0.07,1.04)	0.40(0.14,1.03)	-0.24(-0.51,0.01)
LD TOCI IV		0.05(0.01,0.25)	0.08(0.01,0.33)	-0.37(-0.64,-0.14)
LD ADA SC + MTX		0.95(0.25,3.82)	0.97(0.43,2.22)	-0.01(-0.31,0.30)
LD RITUX IV + MTX		0.83(0.26,2.73)	0.90(0.46,1.93)	-0.04(-0.30,0.22)
LD ADA IV + MTX		0.85(0.11,6.07)	0.91(0.21,2.60)	-0.04(-0.41,0.41)
LD ABA IV + MTX		0.50(0.18,1.48)	0.64(0.33,1.31)	-0.14(-0.38,0.08)
LD ANA SC + MTX		0.47(0.09,2.56)	0.61(0.16,1.79)	-0.15(-0.47,0.21)
LD CERTO SC + MTX		0.98(0.28,3.71)	0.99(0.47,2.22)	0.00(-0.29,0.29)
LD GOLI IV + MTX		0.52(0.14,1.92)	0.66(0.28,1.53)	-0.14(-0.41,0.14)
LD TOCI IV + MTX		0.42(0.11,1.69)	0.57(0.23,1.42)	-0.17(-0.45,0.11)
LD TOFA PO + MTX		0.72(0.16,3.37)	0.82(0.28,2.06)	-0.07(-0.39,0.27)
HD TOCI IV		0.67(0.23,2.06)	0.78(0.45,1.68)	-0.09(-0.34,0.14)
HD TOFA PO		0.97(0.26,3.87)	0.98(0.50,2.46)	-0.01(-0.32,0.29)
HD ADA SC		0.44(0.12,1.81)	0.58(0.26,1.55)	-0.17(-0.47,0.11)
HD GOLI SC		0.74(0.22,2.50)	0.83(0.42,1.89)	-0.07(-0.34,0.19)

(Continued)

HD ETN SC		0.69(0.12,4.05)	0.80(0.23,2.30)	-0.08(-0.43,0.32)
HD ABA SC		1.33(0.22,8.53)	1.16(0.41,3.13)	0.07(-0.34,0.47)
HD TOCI IV + MTX		1.16(0.41,3.64)	1.09(0.64,2.33)	0.04(-0.21,0.28)
HD INF IV + MTX		1.08(0.36,3.38)	1.04(0.57,2.21)	0.02(-0.24,0.27)
HD TOFA PO + MTX		0.93(0.28,2.97)	0.96(0.48,2.02)	-0.02(-0.30,0.24)
HD GOLI SC + MTX		1.26(0.41,4.13)	1.13(0.62,2.42)	0.05(-0.21,0.32)
HD CERTO SC + MTX		1.66(0.56,5.01)	1.30(0.76,2.69)	0.12(-0.14,0.36)
HD ADA SC + MTX		1.39(0.35,5.75)	1.19(0.55,2.67)	0.08(-0.24,0.39)
HD TOCI IV + DMARD		0.81(0.08,8.56)	0.88(0.17,2.85)	-0.05(-0.47,0.47)
SD ANA SC + SD ETN SC + MTX		0.82(0.18,4.16)	0.89(0.32,2.30)	-0.04(-0.38,0.32)
SD ANA SC + LD ETN SC + MTX		1.21(0.26,5.77)	1.11(0.45,2.70)	0.04(-0.30,0.40)
SD CERTO SC + DMARD	SD TOCI IV + MTX	1.53(0.27,10.01)	1.33(0.39,4.46)	0.08(-0.26,0.48)
SD ADA SC + DMARD		1.32(0.13,16.60)	1.21(0.19,4.93)	0.05(-0.32,0.58)
SD TOCI SC + DMARD		2.13(0.20,24.44)	1.61(0.30,5.56)	0.16(-0.27,0.65)
LD ADA SC		0.61(0.17,2.33)	0.68(0.27,1.99)	-0.08(-0.35,0.13)
LD ETN SC		0.77(0.16,3.43)	0.82(0.25,2.57)	-0.05(-0.33,0.22)
LD GOLI IV		0.53(0.13,2.12)	0.61(0.20,1.79)	-0.10(-0.35,0.12)
LD TOCI IV		0.09(0.02,0.42)	0.13(0.02,0.48)	-0.22(-0.47,-0.07)
LD ADA SC + MTX		1.90(0.47,7.47)	1.51(0.60,3.92)	0.13(-0.16,0.42)
LD RITUX IV + MTX		1.67(0.50,5.51)	1.41(0.63,3.34)	0.10(-0.15,0.35)
LD ADA IV + MTX		1.67(0.21,12.25)	1.40(0.29,4.38)	0.10(-0.27,0.54)
LD ABA IV + MTX		0.99(0.30,3.28)	0.99(0.43,2.44)	0.00(-0.24,0.22)
LD ANA SC + MTX		0.93(0.16,4.97)	0.95(0.23,2.98)	-0.01(-0.30,0.34)
LD CERTO SC + MTX		1.93(0.53,7.53)	1.53(0.65,3.92)	0.14(-0.14,0.42)
LD GOLI IV + MTX		1.03(0.27,4.02)	1.02(0.38,2.79)	0.00(-0.25,0.27)
LD TOCI IV + MTX		0.85(0.27,2.64)	0.89(0.37,2.07)	-0.03(-0.25,0.18)
LD TOFA PO + MTX		1.41(0.30,6.84)	1.26(0.40,3.66)	0.07(-0.22,0.40)
HD TOCI IV		1.33(0.52,3.52)	1.22(0.67,2.70)	0.06(-0.15,0.22)

(Continued)

HD TOFA PO		1.92(0.50,7.06)	1.54(0.66,4.14)	0.14(-0.16,0.38)
HD ADA SC		0.88(0.24,3.41)	0.91(0.37,2.61)	-0.02(-0.30,0.20)
HD GOLI SC		1.46(0.44,4.96)	1.30(0.58,3.30)	0.08(-0.18,0.30)
HD ETN SC		1.36(0.23,7.82)	1.23(0.34,3.79)	0.06(-0.27,0.43)
HD ABA SC		2.60(0.44,16.75)	1.81(0.58,5.41)	0.21(-0.17,0.59)
HD TOCI IV + MTX		2.30(0.87,6.38)	1.70(0.93,3.76)	0.18(-0.03,0.37)
HD INF IV + MTX		2.13(0.64,6.85)	1.62(0.76,3.81)	0.16(-0.10,0.40)
HD TOFA PO + MTX		1.81(0.55,6.06)	1.48(0.69,3.56)	0.12(-0.13,0.37)
HD GOLI SC + MTX		2.50(0.77,8.24)	1.77(0.85,4.23)	0.20(-0.06,0.44)
HD CERTO SC + MTX		3.24(1.07,10.27)	2.02(1.04,4.72)	0.26(0.02,0.48)
HD ADA SC + MTX		2.73(0.65,11.85)	1.85(0.76,4.70)	0.22(-0.09,0.52)
HD TOCI IV + DMARD		1.57(0.17,17.11)	1.35(0.25,5.05)	0.09(-0.30,0.59)
SD ANA SC + SD ETN SC + MTX		1.62(0.35,8.40)	1.38(0.47,4.07)	0.10(-0.21,0.45)
SD ANA SC + LD ETN SC + MTX		2.41(0.52,11.85)	1.73(0.64,4.70)	0.19(-0.14,0.52)
SD ADA SC + DMARD	SD CER- TO SC + DMARD	0.88(0.19,4.18)	0.92(0.26,2.10)	-0.03(-0.29,0.31)
SD TOCI SC + DMARD		1.42(0.28,6.67)	1.20(0.39,2.61)	0.07(-0.22,0.41)
LD ADA SC		0.40(0.08,1.98)	0.51(0.19,1.72)	-0.17(-0.52,0.11)
LD ETN SC		0.50(0.08,2.87)	0.61(0.18,2.17)	-0.13(-0.51,0.19)
LD GOLI IV		0.35(0.05,2.01)	0.46(0.12,1.71)	-0.19(-0.56,0.12)
LD TOCI IV		0.06(0.01,0.46)	0.09(0.01,0.52)	-0.31(-0.66,-0.07)
LD ADA SC + MTX		1.22(0.19,7.88)	1.13(0.38,3.77)	0.04(-0.37,0.43)
LD RITUX IV + MTX		1.09(0.18,5.74)	1.05(0.37,3.35)	0.02(-0.39,0.36)
LD ADA IV + MTX		1.08(0.10,11.13)	1.05(0.20,3.96)	0.02(-0.44,0.51)
LD ABA IV + MTX		0.64(0.11,3.53)	0.74(0.25,2.54)	-0.09(-0.48,0.24)
LD ANA SC + MTX		0.60(0.06,4.51)	0.71(0.14,2.76)	-0.10(-0.51,0.32)
LD CERTO SC + MTX		1.26(0.20,7.79)	1.15(0.40,3.74)	0.05(-0.36,0.43)
LD GOLI IV + MTX		0.67(0.10,3.90)	0.76(0.23,2.61)	-0.08(-0.47,0.27)

(Continued)

LD TOCI IV + MTX	0.56(0.08,3.18)	0.67(0.19,2.32)	-0.11(-0.50,0.21)
LD TOFA PO + MTX	0.93(0.11,6.43)	0.96(0.24,3.33)	-0.01(-0.45,0.40)
HD TOCI IV	0.87(0.17,4.07)	0.91(0.37,2.81)	-0.03(-0.41,0.26)
HD TOFA PO	1.25(0.24,5.67)	1.15(0.48,3.41)	0.05(-0.34,0.35)
HD ADA SC	0.57(0.11,2.97)	0.67(0.26,2.30)	-0.11(-0.47,0.18)
HD GOLI SC	0.96(0.16,4.71)	0.98(0.35,3.07)	-0.01(-0.41,0.30)
HD ETN SC	0.88(0.11,6.45)	0.92(0.22,3.38)	-0.03(-0.46,0.40)
HD ABA SC	1.67(0.25,11.35)	1.33(0.45,4.24)	0.12(-0.31,0.52)
HD TOCI IV + MTX	1.52(0.28,7.23)	1.28(0.53,3.83)	0.10(-0.30,0.41)
HD INF IV + MTX	1.39(0.23,7.23)	1.22(0.45,3.76)	0.07(-0.34,0.41)
HD TOFA PO + MTX	1.19(0.19,6.29)	1.11(0.39,3.47)	0.04(-0.37,0.38)
HD GOLI SC + MTX	1.64(0.27,8.62)	1.33(0.51,4.00)	0.11(-0.31,0.45)
HD CERTO SC + MTX	2.11(0.38,10.95)	1.50(0.63,4.48)	0.18(-0.23,0.51)
HD ADA SC + MTX	1.76(0.26,12.19)	1.37(0.48,4.45)	0.13(-0.30,0.53)
HD TOCI IV + DMARD	1.04(0.25,4.07)	1.02(0.34,2.14)	0.01(-0.25,0.31)
SD ANA SC + SD ETN SC + MTX	1.05(0.15,6.85)	1.03(0.31,3.45)	0.01(-0.41,0.41)
SD ANA SC + LD ETN SC + MTX	1.55(0.23,9.96)	1.29(0.43,4.04)	0.10(-0.33,0.49)
SD TOCI SC + DMARD	SD ADA SC + DMARD 1.61(0.43,5.86)	1.29(0.59,3.28)	0.09(-0.17,0.38)
LD ADA SC	0.46(0.05,4.29)	0.56(0.17,3.50)	-0.14(-0.63,0.17)
LD ETN SC	0.58(0.05,5.95)	0.68(0.17,4.35)	-0.10(-0.60,0.25)
LD GOLI IV	0.40(0.03,3.89)	0.51(0.11,3.14)	-0.15(-0.66,0.18)
LD TOCI IV	0.07(0.00,0.86)	0.10(0.01,0.88)	-0.28(-0.77,-0.01)
LD ADA SC + MTX	1.41(0.11,16.29)	1.24(0.34,7.81)	0.07(-0.47,0.50)
LD RITUX IV + MTX	1.25(0.11,12.11)	1.15(0.33,6.71)	0.05(-0.49,0.43)
LD ADA IV + MTX	1.22(0.07,19.91)	1.13(0.18,7.95)	0.04(-0.53,0.57)
LD ABA IV + MTX	0.75(0.07,7.20)	0.82(0.22,4.96)	-0.06(-0.58,0.30)
LD ANA SC + MTX	0.69(0.04,9.40)	0.77(0.14,5.34)	-0.07(-0.60,0.39)
LD CERTO SC + MTX	1.46(0.13,15.84)	1.27(0.36,7.79)	0.08(-0.45,0.49)

(Continued)

LD GOLI IV + MTX		0.79(0.06,7.74)	0.85(0.21,5.10)	-0.05(-0.58,0.33)
LD TOCI IV + MTX		0.63(0.05,6.70)	0.72(0.18,4.74)	-0.09(-0.60,0.28)
LD TOFA PO + MTX		1.07(0.07,12.79)	1.04(0.22,6.72)	0.01(-0.54,0.46)
HD TOCI IV		1.00(0.10,8.74)	1.00(0.33,5.87)	0.00(-0.51,0.32)
HD TOFA PO		1.44(0.14,12.73)	1.26(0.43,7.38)	0.08(-0.43,0.41)
HD ADA SC		0.66(0.07,6.25)	0.74(0.23,4.65)	-0.08(-0.58,0.24)
HD GOLI SC		1.12(0.10,9.87)	1.08(0.32,6.18)	0.02(-0.51,0.36)
HD ETN SC		1.03(0.07,11.56)	1.02(0.21,6.08)	0.01(-0.54,0.45)
HD ABA SC		1.94(0.17,22.89)	1.47(0.42,8.94)	0.14(-0.39,0.58)
HD TOCI IV + MTX		1.73(0.17,15.76)	1.40(0.47,8.02)	0.12(-0.39,0.48)
HD INF IV + MTX		1.59(0.14,14.67)	1.33(0.41,7.52)	0.10(-0.43,0.47)
HD TOFA PO + MTX		1.39(0.12,13.06)	1.23(0.35,7.17)	0.07(-0.47,0.44)
HD GOLI SC + MTX		1.87(0.16,18.51)	1.45(0.46,8.73)	0.14(-0.40,0.51)
HD CERTO SC + MTX		2.45(0.23,22.88)	1.66(0.56,9.49)	0.21(-0.32,0.57)
HD ADA SC + MTX		2.00(0.16,24.85)	1.49(0.43,9.38)	0.15(-0.41,0.59)
HD TOCI IV + DMARD		1.19(0.39,3.59)	1.10(0.54,2.53)	0.03(-0.20,0.26)
SD ANA SC + SD ETN SC + MTX		1.22(0.10,13.91)	1.13(0.29,7.02)	0.04(-0.49,0.47)
SD ANA SC + LD ETN SC + MTX		1.79(0.16,20.19)	1.40(0.40,8.29)	0.13(-0.41,0.56)
LD ADA SC	SD TOCI SC + DMARD	0.28(0.03,2.70)	0.42(0.15,2.32)	-0.25(-0.70,0.13)
LD ETN SC		0.35(0.03,3.77)	0.51(0.14,2.86)	-0.21(-0.67,0.21)
LD GOLI IV		0.25(0.02,2.59)	0.38(0.09,2.18)	-0.27(-0.72,0.14)
LD TOCI IV		0.04(0.00,0.55)	0.08(0.01,0.60)	-0.39(-0.83,-0.04)
LD ADA SC + MTX		0.87(0.08,10.35)	0.93(0.30,5.27)	-0.03(-0.53,0.44)
LD RITUX IV + MTX		0.77(0.07,7.57)	0.86(0.29,4.52)	-0.06(-0.56,0.37)
LD ADA IV + MTX		0.76(0.05,13.19)	0.87(0.16,5.25)	-0.06(-0.60,0.51)
LD ABA IV + MTX		0.46(0.04,4.68)	0.61(0.20,3.34)	-0.17(-0.64,0.25)
LD ANA SC + MTX		0.42(0.03,5.99)	0.59(0.11,3.69)	-0.17(-0.67,0.32)

(Continued)

LD CERTO SC + MTX		0.89(0.08,10.27)	0.94(0.31,5.11)	-0.03(-0.53,0.44)
LD GOLI IV + MTX		0.47(0.04,5.09)	0.63(0.18,3.50)	-0.16(-0.64,0.27)
LD TOCI IV + MTX		0.38(0.03,4.05)	0.54(0.16,2.98)	-0.20(-0.67,0.23)
LD TOFA PO + MTX		0.65(0.05,7.86)	0.78(0.19,4.34)	-0.09(-0.62,0.39)
HD TOCI IV		0.61(0.07,5.69)	0.74(0.30,3.93)	-0.11(-0.57,0.28)
HD TOFA PO		0.89(0.10,8.27)	0.94(0.39,4.87)	-0.03(-0.49,0.37)
HD ADA SC		0.40(0.04,3.86)	0.55(0.21,3.03)	-0.19(-0.64,0.20)
HD GOLI SC		0.68(0.07,6.33)	0.79(0.29,4.15)	-0.09(-0.57,0.31)
HD ETN SC		0.62(0.05,7.80)	0.76(0.18,4.17)	-0.10(-0.62,0.40)
HD ABA SC		1.19(0.10,14.94)	1.09(0.35,5.83)	0.04(-0.48,0.53)
HD TOCI IV + MTX		1.07(0.11,10.15)	1.03(0.42,5.29)	0.01(-0.46,0.43)
HD INF IV + MTX		0.98(0.09,9.35)	0.99(0.37,5.08)	0.00(-0.50,0.42)
HD TOFA PO + MTX		0.85(0.08,8.39)	0.91(0.31,4.83)	-0.04(-0.54,0.39)
HD GOLI SC + MTX		1.15(0.11,11.85)	1.07(0.41,5.66)	0.03(-0.47,0.47)
HD CERTO SC + MTX		1.48(0.15,15.21)	1.22(0.51,6.46)	0.09(-0.39,0.52)
HD ADA SC + MTX		1.22(0.11,15.19)	1.11(0.38,6.22)	0.05(-0.47,0.53)
HD TOCI IV + DMARD		0.74(0.24,2.21)	0.86(0.41,1.71)	-0.06(-0.31,0.16)
SD ANA SC + SD ETN SC + MTX		0.73(0.07,8.86)	0.84(0.25,4.60)	-0.07(-0.56,0.42)
SD ANA SC + LD ETN SC + MTX		1.08(0.10,13.00)	1.04(0.35,5.48)	0.02(-0.48,0.51)
LD ETN SC	LD ADA SC	1.27(0.31,4.68)	1.20(0.38,3.26)	0.04(-0.16,0.27)
LD GOLI IV		0.87(0.21,3.40)	0.89(0.26,2.61)	-0.02(-0.19,0.20)
LD TOCI IV		0.15(0.02,0.78)	0.18(0.03,0.81)	-0.14(-0.29,-0.02)
LD ADA SC + MTX		3.08(0.77,12.14)	2.22(0.82,5.23)	0.22(-0.04,0.52)
LD RITUX IV + MTX		2.71(0.76,9.32)	2.06(0.81,4.76)	0.19(-0.05,0.45)
LD ADA IV + MTX		2.73(0.34,19.06)	2.06(0.40,5.83)	0.19(-0.13,0.61)
LD ABA IV + MTX		1.63(0.47,5.45)	1.46(0.55,3.58)	0.08(-0.12,0.31)
LD ANA SC + MTX		1.51(0.26,8.30)	1.38(0.31,4.20)	0.07(-0.17,0.43)
LD CERTO SC + MTX		3.18(0.83,12.39)	2.27(0.86,5.26)	0.22(-0.03,0.52)

(Continued)

LD GOLIV + MTX	1.68(0.44,6.31)	1.49(0.51,3.85)	0.09(-0.13,0.35)
LD TOCIV + MTX	1.39(0.38,4.91)	1.29(0.45,3.30)	0.05(-0.14,0.30)
LD TOFA PO + MTX	2.33(0.47,10.82)	1.86(0.54,4.86)	0.15(-0.11,0.49)
HD TOCIV	2.17(0.81,5.72)	1.79(0.86,3.80)	0.14(-0.04,0.31)
HD TOFA PO	3.11(1.16,8.68)	2.25(1.11,4.86)	0.22(0.03,0.41)
HD ADA SC	1.43(0.67,3.15)	1.32(0.72,2.50)	0.06(-0.07,0.19)
HD GOLIV SC	2.37(0.77,7.38)	1.90(0.82,4.35)	0.16(-0.05,0.38)
HD ETN SC	2.21(0.39,11.68)	1.80(0.46,5.05)	0.14(-0.13,0.50)
HD ABA SC	4.24(0.90,21.81)	2.63(0.92,6.43)	0.29(-0.02,0.63)
HD TOCIV + MTX	3.79(1.30,10.94)	2.51(1.20,5.31)	0.27(0.05,0.48)
HD INF IV + MTX	3.45(1.06,11.42)	2.37(1.04,5.27)	0.24(0.01,0.50)
HD TOFA PO + MTX	2.97(0.84,9.82)	2.19(0.88,4.93)	0.21(-0.03,0.46)
HD GOLIV SC + MTX	4.08(1.21,13.31)	2.61(1.14,5.69)	0.28(0.04,0.52)
HD CERTO SC + MTX	5.32(1.70,17.15)	2.98(1.42,6.31)	0.35(0.11,0.58)
HD ADA SC + MTX	4.45(1.08,19.08)	2.70(1.06,6.24)	0.31(0.01,0.61)
HD TOCIV + DMARD	2.62(0.31,22.55)	2.01(0.38,5.95)	0.18(-0.15,0.64)
SD ANA SC + SD ETN SC + MTX	2.64(0.59,12.25)	2.02(0.66,5.25)	0.18(-0.08,0.51)
SD ANA SC + LD ETN SC + MTX	3.89(0.88,17.58)	2.53(0.91,5.94)	0.27(-0.02,0.59)
LD GOLIV	LD ETN SC 0.70(0.15,3.24)	0.75(0.21,2.56)	-0.05(-0.29,0.18)
LD TOCIV	0.12(0.02,0.76)	0.15(0.02,0.78)	-0.17(-0.40,-0.03)
LD ADA SC + MTX	2.45(0.54,12.34)	1.84(0.64,5.60)	0.18(-0.12,0.50)
LD RITUX IV + MTX	2.15(0.54,8.88)	1.71(0.65,4.89)	0.15(-0.12,0.42)
LD ADA IV + MTX	2.16(0.25,18.72)	1.70(0.33,5.98)	0.15(-0.21,0.60)
LD ABA IV + MTX	1.29(0.32,5.11)	1.21(0.43,3.54)	0.04(-0.21,0.29)
LD ANA SC + MTX	1.21(0.18,7.76)	1.15(0.25,4.17)	0.03(-0.26,0.41)
LD CERTO SC + MTX	2.55(0.57,11.64)	1.89(0.67,5.41)	0.19(-0.11,0.50)
LD GOLIV + MTX	1.35(0.30,6.06)	1.25(0.40,3.89)	0.05(-0.22,0.33)
LD TOCIV + MTX	1.10(0.25,5.00)	1.08(0.34,3.40)	0.02(-0.24,0.28)

(Continued)

LD TOFA PO + MTX		1.86(0.34,10.20)	1.55(0.44,4.90)	0.11(-0.19,0.47)
HD TOCI IV		1.73(0.52,6.13)	1.49(0.65,4.15)	0.10(-0.14,0.31)
HD TOFA PO		2.49(0.68,9.22)	1.88(0.78,5.19)	0.19(-0.09,0.41)
HD ADA SC		1.14(0.31,4.44)	1.11(0.43,3.31)	0.02(-0.22,0.24)
HD GOLI SC		1.89(0.51,7.31)	1.58(0.63,4.45)	0.12(-0.14,0.37)
HD ETN SC		1.77(0.32,8.88)	1.50(0.42,4.43)	0.11(-0.18,0.45)
HD ABA SC		3.37(0.59,21.05)	2.20(0.69,6.73)	0.25(-0.11,0.62)
HD TOCI IV + MTX		3.00(0.85,11.33)	2.09(0.90,5.62)	0.23(-0.04,0.47)
HD INF IV + MTX		2.76(0.71,10.86)	1.98(0.79,5.37)	0.21(-0.07,0.47)
HD TOFA PO + MTX		2.37(0.58,9.39)	1.81(0.69,5.02)	0.17(-0.11,0.43)
HD GOLI SC + MTX		3.23(0.86,12.76)	2.16(0.91,5.85)	0.24(-0.03,0.51)
HD CERTO SC + MTX		4.24(1.15,16.26)	2.47(1.09,6.51)	0.31(0.03,0.56)
HD ADA SC + MTX		3.54(0.75,18.25)	2.24(0.82,6.48)	0.27(-0.06,0.59)
HD TOCI IV + DMARD		2.08(0.22,20.49)	1.67(0.29,6.32)	0.14(-0.23,0.61)
SD ANA SC + SD ETN SC + MTX		2.10(0.45,10.90)	1.67(0.55,5.09)	0.14(-0.15,0.48)
SD ANA SC + LD ETN SC + MTX		3.12(0.68,15.79)	2.10(0.76,5.94)	0.23(-0.08,0.56)
LD TOCI IV	LD GOLI IV	0.17(0.03,0.96)	0.20(0.03,0.96)	-0.12(-0.32,0.00)
LD ADA SC + MTX		3.49(0.94,15.36)	2.44(0.96,7.07)	0.23(-0.01,0.51)
LD RITUX IV + MTX		3.11(0.95,10.65)	2.29(0.97,6.20)	0.20(-0.01,0.43)
LD ADA IV + MTX		3.15(0.43,23.07)	2.26(0.49,8.01)	0.20(-0.12,0.62)
LD ABA IV + MTX		1.86(0.59,6.26)	1.63(0.67,4.52)	0.09(-0.09,0.30)
LD ANA SC + MTX		1.75(0.31,9.20)	1.54(0.37,5.29)	0.08(-0.16,0.42)
LD CERTO SC + MTX		3.64(0.99,14.23)	2.51(1.00,7.11)	0.24(0.00,0.51)
LD GOLI IV + MTX		1.93(0.69,5.50)	1.66(0.75,3.95)	0.10(-0.06,0.30)
LD TOCI IV + MTX		1.60(0.41,6.53)	1.45(0.49,4.54)	0.07(-0.14,0.31)
LD TOFA PO + MTX		2.65(0.56,12.60)	2.06(0.63,6.39)	0.16(-0.09,0.49)
HD TOCI IV		2.49(0.85,7.87)	2.00(0.89,5.42)	0.16(-0.03,0.32)
HD TOFA PO		3.52(0.97,14.43)	2.49(0.98,8.02)	0.24(-0.01,0.45)

(Continued)

HD ADA SC		1.66(0.43,6.78)	1.49(0.53,4.98)	0.08(-0.16,0.27)
HD GOLI SC		2.74(0.85,9.01)	2.12(0.89,5.90)	0.17(-0.03,0.37)
HD ETN SC		2.53(0.42,15.64)	1.98(0.50,7.37)	0.16(-0.13,0.52)
HD ABA SC		4.84(0.84,30.92)	2.94(0.88,9.98)	0.31(-0.03,0.65)
HD TOCI IV + MTX		4.33(1.46,14.12)	2.79(1.26,7.54)	0.28(0.08,0.48)
HD INF IV + MTX		3.98(1.27,12.76)	2.65(1.17,6.91)	0.26(0.05,0.47)
HD TOFA PO + MTX		3.36(1.05,11.84)	2.40(1.03,6.55)	0.22(0.01,0.45)
HD GOLI SC + MTX		4.66(1.46,15.43)	2.89(1.28,7.75)	0.30(0.08,0.51)
HD CERTO SC + MTX		6.13(2.02,18.97)	3.31(1.52,8.79)	0.36(0.15,0.56)
HD ADA SC + MTX		5.09(1.28,22.23)	2.99(1.18,8.64)	0.32(0.04,0.60)
HD TOCI IV + DMARD		2.96(0.32,33.53)	2.21(0.39,9.52)	0.19(-0.16,0.67)
SD ANA SC + SD ETN SC + MTX		3.02(0.64,15.66)	2.25(0.71,7.45)	0.19(-0.07,0.52)
SD ANA SC + LD ETN SC + MTX		4.48(0.95,23.21)	2.81(0.96,8.96)	0.29(-0.01,0.61)
LD ADA SC + MTX	LD TOCI IV	20.08(3.82,137.60)	11.95(2.95,69.30)	0.36(0.14,0.64)
LD RITUX IV + MTX		17.68(3.85,106.00)	11.21(2.94,60.92)	0.33(0.14,0.57)
LD ADA IV + MTX		17.82(2.04,187.20)	10.83(1.87,68.75)	0.33(0.04,0.74)
LD ABA IV + MTX		10.78(2.31,63.96)	8.05(2.01,44.35)	0.22(0.08,0.43)
LD ANA SC + MTX		9.99(1.34,82.22)	7.51(1.30,46.80)	0.21(0.02,0.55)
LD CERTO SC + MTX		20.67(4.15,138.30)	12.32(3.09,70.88)	0.37(0.15,0.64)
LD GOLI IV + MTX		11.13(2.03,73.87)	8.17(1.83,48.35)	0.23(0.06,0.47)
LD TOCI IV + MTX		9.08(2.05,51.80)	7.03(1.86,37.56)	0.19(0.06,0.41)
LD TOFA PO + MTX		15.36(2.43,118.40)	9.98(2.11,61.52)	0.29(0.07,0.62)
HD TOCI IV		14.03(3.83,77.39)	9.78(2.87,53.02)	0.28(0.16,0.42)
HD TOFA PO		20.22(3.95,139.10)	12.31(2.91,74.78)	0.36(0.20,0.54)
HD ADA SC		9.39(1.85,62.71)	7.31(1.68,45.24)	0.20(0.07,0.36)
HD GOLI SC		15.76(3.27,98.50)	10.45(2.61,59.14)	0.30(0.14,0.49)
HD ETN SC		14.52(1.92,131.90)	9.72(1.76,65.53)	0.28(0.05,0.63)
HD ABA SC		28.65(3.64,268.10)	14.57(2.89,92.29)	0.44(0.15,0.76)

(Continued)

HD TOCI IV + MTX		24.32(6.37,137.50)	13.61(3.92,74.19)	0.41(0.24,0.59)
HD INF IV + MTX		22.63(5.08,140.80)	13.02(3.43,74.04)	0.39(0.19,0.61)
HD TOFA PO + MTX		19.19(4.16,119.50)	11.85(3.09,65.92)	0.35(0.15,0.57)
HD GOLI SC + MTX		26.64(5.66,168.80)	14.22(3.68,81.14)	0.43(0.22,0.64)
HD CERTO SC + MTX		34.59(7.89,207.90)	16.15(4.32,89.67)	0.49(0.29,0.69)
HD ADA SC + MTX		29.29(5.38,202.30)	14.69(3.71,86.02)	0.45(0.18,0.72)
HD TOCI IV + DMARD		17.18(1.46,248.40)	10.89(1.41,81.13)	0.32(0.03,0.77)
SD ANA SC + SD ETN SC + MTX		17.47(2.81,138.90)	11.06(2.35,67.58)	0.33(0.09,0.64)
SD ANA SC + LD ETN SC + MTX		25.95(4.22,209.40)	13.76(3.14,85.61)	0.42(0.15,0.72)
LD RITUX IV + MTX	LD ADA SC + MTX	0.89(0.25,2.93)	0.93(0.44,2.01)	-0.03(-0.32,0.23)
LD ADA IV + MTX		0.89(0.14,5.17)	0.94(0.23,2.28)	-0.03(-0.37,0.37)
LD ABA IV + MTX		0.53(0.16,1.77)	0.66(0.30,1.49)	-0.13(-0.41,0.11)
LD ANA SC + MTX		0.49(0.08,2.68)	0.63(0.16,1.83)	-0.14(-0.47,0.21)
LD CERTO SC + MTX		1.04(0.28,3.88)	1.02(0.47,2.33)	0.01(-0.29,0.31)
LD GOLI IV + MTX		0.55(0.14,2.09)	0.68(0.27,1.63)	-0.12(-0.42,0.15)
LD TOCI IV + MTX		0.45(0.11,1.74)	0.59(0.23,1.45)	-0.16(-0.45,0.11)
LD TOFA PO + MTX		0.76(0.15,3.48)	0.85(0.28,2.11)	-0.06(-0.39,0.28)
HD TOCI IV		0.71(0.23,2.08)	0.81(0.45,1.70)	-0.08(-0.34,0.15)
HD TOFA PO		1.01(0.27,3.89)	1.00(0.50,2.52)	0.00(-0.31,0.29)
HD ADA SC		0.46(0.12,1.87)	0.60(0.27,1.59)	-0.16(-0.47,0.12)
HD GOLI SC		0.78(0.23,2.58)	0.86(0.42,1.95)	-0.06(-0.34,0.19)
HD ETN SC		0.72(0.11,4.33)	0.82(0.22,2.34)	-0.07(-0.44,0.33)
HD ABA SC		1.39(0.24,8.22)	1.19(0.43,3.25)	0.08(-0.33,0.47)
HD TOCI IV + MTX		1.23(0.40,3.65)	1.13(0.63,2.34)	0.05(-0.22,0.29)
HD INF IV + MTX		1.13(0.34,3.64)	1.07(0.55,2.28)	0.03(-0.25,0.29)
HD TOFA PO + MTX		0.96(0.28,3.11)	0.98(0.48,2.11)	-0.01(-0.29,0.25)
HD GOLI SC + MTX		1.33(0.38,4.31)	1.17(0.60,2.52)	0.07(-0.23,0.32)
HD CERTO SC + MTX		1.74(0.55,5.24)	1.33(0.76,2.75)	0.13(-0.14,0.37)

(Continued)

HD ADA SC + MTX		1.44(0.53,4.02)	1.21(0.69,2.28)	0.08(-0.15,0.32)
HD TOCI IV + DMARD		0.85(0.08,8.81)	0.90(0.16,3.01)	-0.04(-0.47,0.48)
SD ANA SC + SD ETN SC + MTX		0.86(0.18,4.25)	0.91(0.33,2.40)	-0.03(-0.37,0.32)
SD ANA SC + LD ETN SC + MTX		1.28(0.27,6.13)	1.14(0.46,2.84)	0.06(-0.30,0.41)
LD ADA IV + MTX	LD RITUX IV + MTX	1.01(0.14,6.86)	1.01(0.23,2.59)	0.00(-0.35,0.43)
LD ABA IV + MTX		0.60(0.22,1.60)	0.71(0.36,1.36)	-0.10(-0.32,0.10)
LD ANA SC + MTX		0.56(0.11,2.75)	0.67(0.18,1.81)	-0.12(-0.39,0.23)
LD CERTO SC + MTX		1.17(0.37,3.73)	1.10(0.53,2.17)	0.04(-0.22,0.30)
LD GOLI IV + MTX		0.62(0.19,2.01)	0.73(0.31,1.58)	-0.10(-0.34,0.15)
LD TOCI IV + MTX		0.51(0.16,1.69)	0.63(0.26,1.43)	-0.13(-0.37,0.11)
LD TOFA PO + MTX		0.86(0.21,3.45)	0.91(0.33,2.05)	-0.03(-0.31,0.28)
HD TOCI IV		0.80(0.33,1.98)	0.87(0.52,1.63)	-0.05(-0.26,0.14)
HD TOFA PO		1.15(0.35,3.87)	1.09(0.55,2.45)	0.03(-0.25,0.29)
HD ADA SC		0.53(0.16,1.87)	0.64(0.29,1.57)	-0.13(-0.40,0.12)
HD GOLI SC		0.88(0.31,2.45)	0.92(0.49,1.84)	-0.03(-0.26,0.19)
HD ETN SC		0.82(0.16,4.34)	0.88(0.26,2.35)	-0.04(-0.36,0.33)
HD ABA SC		1.57(0.30,9.12)	1.29(0.46,3.23)	0.11(-0.27,0.49)
HD TOCI IV + MTX		1.39(0.57,3.48)	1.21(0.74,2.23)	0.08(-0.13,0.28)
HD INF IV + MTX		1.28(0.49,3.35)	1.15(0.65,2.14)	0.06(-0.17,0.27)
HD TOFA PO + MTX		1.09(0.39,2.93)	1.05(0.56,1.98)	0.02(-0.21,0.24)
HD GOLI SC + MTX		1.51(0.56,4.04)	1.26(0.71,2.35)	0.09(-0.14,0.32)
HD CERTO SC + MTX		1.97(0.79,4.81)	1.44(0.89,2.57)	0.16(-0.06,0.36)
HD ADA SC + MTX		1.64(0.49,6.07)	1.31(0.64,2.73)	0.11(-0.16,0.41)
HD TOCI IV + DMARD		0.95(0.11,9.48)	0.97(0.19,3.12)	-0.01(-0.40,0.49)
SD ANA SC + SD ETN SC + MTX		0.98(0.23,4.32)	0.99(0.37,2.35)	0.00(-0.30,0.34)
SD ANA SC + LD ETN SC + MTX		1.45(0.35,6.17)	1.23(0.51,2.71)	0.08(-0.23,0.41)
LD ABA IV + MTX	LD ADA IV + MTX	0.59(0.09,4.02)	0.71(0.26,3.09)	-0.11(-0.52,0.21)

(Continued)

LD ANA SC + MTX		0.55(0.06,5.19)	0.68(0.15,3.39)	-0.11(-0.56,0.30)
LD CERTO SC + MTX		1.19(0.16,8.73)	1.11(0.40,4.77)	0.04(-0.41,0.40)
LD GOLI IV + MTX		0.61(0.08,4.62)	0.73(0.24,3.36)	-0.10(-0.53,0.24)
LD TOCI IV + MTX		0.51(0.07,3.85)	0.63(0.20,2.98)	-0.13(-0.56,0.21)
LD TOFA PO + MTX		0.85(0.10,7.52)	0.91(0.26,4.28)	-0.03(-0.49,0.38)
HD TOCI IV		0.80(0.14,5.08)	0.86(0.38,3.73)	-0.05(-0.45,0.25)
HD TOFA PO		1.14(0.17,8.32)	1.08(0.45,5.10)	0.03(-0.40,0.37)
HD ADA SC		0.52(0.08,4.11)	0.64(0.24,3.18)	-0.13(-0.56,0.20)
HD GOLI SC		0.88(0.13,6.38)	0.92(0.36,4.23)	-0.03(-0.45,0.31)
HD ETN SC		0.81(0.08,8.04)	0.88(0.21,4.52)	-0.04(-0.53,0.40)
HD ABA SC		1.55(0.16,16.31)	1.27(0.39,6.59)	0.10(-0.41,0.54)
HD TOCI IV + MTX		1.39(0.23,9.45)	1.21(0.53,5.39)	0.08(-0.33,0.40)
HD INF IV + MTX		1.28(0.20,8.57)	1.15(0.48,5.05)	0.06(-0.37,0.39)
HD TOFA PO + MTX		1.08(0.17,7.33)	1.05(0.41,4.55)	0.02(-0.41,0.36)
HD GOLI SC + MTX		1.49(0.22,10.58)	1.25(0.52,5.58)	0.09(-0.34,0.43)
HD CERTO SC + MTX		1.96(0.32,13.10)	1.44(0.63,6.28)	0.16(-0.26,0.49)
HD ADA SC + MTX		1.63(0.23,11.76)	1.29(0.51,5.67)	0.11(-0.33,0.48)
HD TOCI IV + DMARD		0.98(0.06,14.45)	0.99(0.17,5.63)	0.00(-0.55,0.54)
SD ANA SC + SD ETN SC + MTX		0.98(0.12,8.38)	0.99(0.30,4.75)	-0.01(-0.46,0.41)
SD ANA SC + LD ETN SC + MTX		1.44(0.19,12.99)	1.22(0.41,5.84)	0.08(-0.38,0.50)
LD ANA SC + MTX	LD ABA IV + MTX	0.92(0.19,4.30)	0.94(0.26,2.59)	-0.01(-0.25,0.32)
LD CERTO SC + MTX		1.95(0.64,6.17)	1.54(0.74,3.25)	0.14(-0.09,0.40)
LD GOLI IV + MTX		1.04(0.32,3.17)	1.03(0.42,2.29)	0.01(-0.21,0.23)
LD TOCI IV + MTX		0.85(0.27,2.78)	0.89(0.36,2.11)	-0.03(-0.24,0.20)
LD TOFA PO + MTX		1.43(0.36,5.59)	1.28(0.46,3.01)	0.07(-0.18,0.38)
HD TOCI IV		1.34(0.58,3.23)	1.23(0.70,2.45)	0.06(-0.12,0.22)
HD TOFA PO		1.92(0.61,6.50)	1.54(0.74,3.75)	0.14(-0.11,0.37)
HD ADA SC		0.88(0.27,3.11)	0.91(0.38,2.39)	-0.02(-0.26,0.20)

(Continued)

HD GOLI SC		1.46(0.54,3.92)	1.30(0.66,2.69)	0.08(-0.13,0.27)
HD ETN SC		1.35(0.25,7.07)	1.23(0.35,3.50)	0.06(-0.24,0.42)
HD ABA SC		2.62(0.50,14.41)	1.82(0.61,4.86)	0.21(-0.15,0.57)
HD TOCI IV + MTX		2.33(0.98,5.70)	1.71(0.99,3.36)	0.18(0.00,0.37)
HD INF IV + MTX		2.13(0.85,5.36)	1.62(0.90,3.11)	0.16(-0.04,0.36)
HD TOFA PO + MTX		1.81(0.67,4.71)	1.48(0.77,2.89)	0.12(-0.08,0.33)
HD GOLI SC + MTX		2.50(0.96,6.54)	1.78(0.98,3.51)	0.20(-0.01,0.40)
HD CERTO SC + MTX		3.27(1.36,7.90)	2.03(1.19,3.83)	0.26(0.07,0.45)
HD ADA SC + MTX		2.75(0.78,9.46)	1.85(0.85,3.88)	0.22(-0.05,0.49)
HD TOCI IV + DMARD		1.60(0.18,16.02)	1.37(0.27,4.57)	0.10(-0.27,0.59)
SD ANA SC + SD ETN SC + MTX		1.61(0.39,7.05)	1.38(0.50,3.44)	0.10(-0.18,0.42)
SD ANA SC + LD ETN SC + MTX		2.39(0.60,10.16)	1.73(0.70,4.03)	0.19(-0.10,0.50)
LD CERTO SC + MTX	LD ANA SC + MTX	2.12(0.39,11.79)	1.63(0.57,6.33)	0.15(-0.21,0.46)
LD GOLI IV + MTX		1.12(0.20,6.14)	1.08(0.34,4.18)	0.02(-0.33,0.30)
LD TOCI IV + MTX		0.92(0.17,5.10)	0.94(0.29,3.72)	-0.01(-0.36,0.26)
LD TOFA PO + MTX		1.52(0.24,9.73)	1.34(0.38,5.44)	0.08(-0.29,0.44)
HD TOCI IV		1.44(0.33,6.72)	1.29(0.53,4.77)	0.07(-0.26,0.29)
HD TOFA PO		2.04(0.40,11.78)	1.61(0.61,6.93)	0.15(-0.22,0.41)
HD ADA SC		0.95(0.18,5.59)	0.96(0.32,4.19)	-0.01(-0.37,0.24)
HD GOLI SC		1.57(0.33,7.96)	1.36(0.52,5.22)	0.09(-0.25,0.34)
HD ETN SC		1.48(0.18,11.79)	1.30(0.29,6.00)	0.07(-0.34,0.47)
HD ABA SC		2.79(0.38,24.14)	1.89(0.55,8.66)	0.22(-0.22,0.61)
HD TOCI IV + MTX		2.50(0.56,11.77)	1.80(0.74,6.80)	0.20(-0.14,0.44)
HD INF IV + MTX		2.28(0.51,11.10)	1.71(0.68,6.33)	0.17(-0.16,0.44)
HD TOFA PO + MTX		1.95(0.42,9.75)	1.56(0.59,5.83)	0.13(-0.21,0.40)
HD GOLI SC + MTX		2.69(0.58,13.19)	1.87(0.76,6.95)	0.21(-0.13,0.47)
HD CERTO SC + MTX		3.52(0.80,16.77)	2.14(0.90,7.86)	0.27(-0.05,0.53)
HD ADA SC + MTX		2.97(0.52,17.42)	1.94(0.68,7.53)	0.23(-0.15,0.55)

(Continued)

HD TOCI IV + DMARD		1.72(0.14,23.13)	1.44(0.24,7.80)	0.11(-0.35,0.61)
SD ANA SC + SD ETN SC + MTX		1.74(0.28,12.85)	1.45(0.43,6.32)	0.11(-0.28,0.48)
SD ANA SC + LD ETN SC + MTX		2.59(0.40,18.65)	1.82(0.57,7.71)	0.20(-0.20,0.56)
LD GOLI IV + MTX	LD CERTO SC + MTX	0.53(0.14,1.88)	0.66(0.28,1.51)	-0.13(-0.41,0.13)
LD TOCI IV + MTX		0.43(0.12,1.63)	0.57(0.22,1.39)	-0.17(-0.45,0.10)
LD TOFA PO + MTX		0.73(0.16,3.21)	0.83(0.29,1.96)	-0.07(-0.38,0.26)
HD TOCI IV		0.68(0.24,1.95)	0.79(0.45,1.62)	-0.08(-0.33,0.13)
HD TOFA PO		0.99(0.26,3.66)	0.99(0.50,2.37)	0.00(-0.32,0.28)
HD ADA SC		0.45(0.12,1.75)	0.58(0.26,1.49)	-0.17(-0.46,0.10)
HD GOLI SC		0.74(0.23,2.43)	0.83(0.43,1.82)	-0.07(-0.33,0.19)
HD ETN SC		0.70(0.12,3.91)	0.80(0.22,2.18)	-0.08(-0.43,0.31)
HD ABA SC		1.34(0.23,8.00)	1.17(0.42,2.99)	0.07(-0.34,0.46)
HD TOCI IV + MTX		1.19(0.42,3.47)	1.10(0.64,2.21)	0.04(-0.21,0.27)
HD INF IV + MTX		1.09(0.36,3.29)	1.05(0.57,2.10)	0.02(-0.24,0.26)
HD TOFA PO + MTX		0.93(0.30,2.82)	0.96(0.50,1.95)	-0.02(-0.28,0.23)
HD GOLI SC + MTX		1.28(0.42,3.90)	1.14(0.63,2.33)	0.06(-0.21,0.31)
HD CERTO SC + MTX		1.66(0.68,4.11)	1.30(0.84,2.39)	0.12(-0.09,0.32)
HD ADA SC + MTX		1.40(0.36,5.68)	1.19(0.55,2.57)	0.08(-0.24,0.39)
HD TOCI IV + DMARD		0.82(0.08,8.19)	0.89(0.17,2.87)	-0.04(-0.47,0.46)
SD ANA SC + SD ETN SC + MTX		0.83(0.18,4.14)	0.90(0.33,2.29)	-0.04(-0.37,0.32)
SD ANA SC + LD ETN SC + MTX		1.23(0.26,5.77)	1.12(0.45,2.65)	0.05(-0.30,0.40)
LD TOCI IV + MTX	LD GOLI IV + MTX	0.83(0.22,3.17)	0.87(0.32,2.38)	-0.03(-0.29,0.21)
LD TOFA PO + MTX		1.37(0.31,6.19)	1.24(0.42,3.38)	0.06(-0.22,0.39)
HD TOCI IV		1.30(0.45,3.78)	1.20(0.61,2.82)	0.05(-0.18,0.24)
HD TOFA PO		1.85(0.52,7.01)	1.50(0.68,4.10)	0.13(-0.15,0.37)
HD ADA SC		0.86(0.23,3.36)	0.89(0.36,2.56)	-0.03(-0.30,0.20)
HD GOLI SC		1.41(0.46,4.48)	1.26(0.60,3.05)	0.07(-0.17,0.29)

(Continued)

HD ETN SC		1.31(0.23,7.51)	1.20(0.33,3.81)	0.05(-0.27,0.42)
HD ABA SC		2.52(0.44,15.71)	1.76(0.59,5.29)	0.20(-0.18,0.57)
HD TOCI IV + MTX		2.25(0.76,6.73)	1.67(0.85,3.87)	0.18(-0.06,0.39)
HD INF IV + MTX		2.04(0.67,6.49)	1.58(0.78,3.68)	0.15(-0.09,0.38)
HD TOFA PO + MTX		1.75(0.56,5.82)	1.44(0.69,3.51)	0.12(-0.13,0.36)
HD GOLI SC + MTX		2.42(0.80,7.62)	1.73(0.88,4.09)	0.19(-0.05,0.42)
HD CERTO SC + MTX		3.17(1.10,9.53)	1.98(1.05,4.53)	0.26(0.02,0.47)
HD ADA SC + MTX		2.63(0.67,10.67)	1.80(0.78,4.36)	0.21(-0.09,0.51)
HD TOCI IV + DMARD		1.52(0.17,15.87)	1.33(0.25,4.95)	0.08(-0.30,0.58)
SD ANA SC + SD ETN SC + MTX		1.56(0.34,7.82)	1.34(0.47,3.96)	0.09(-0.21,0.43)
SD ANA SC + LD ETN SC + MTX		2.33(0.51,11.57)	1.68(0.64,4.61)	0.18(-0.14,0.52)
LD TOFA PO + MTX	LD TOCI IV + MTX	1.67(0.35,7.78)	1.43(0.44,4.13)	0.10(-0.19,0.42)
HD TOCI IV		1.57(0.62,4.10)	1.38(0.74,3.08)	0.09(-0.11,0.24)
HD TOFA PO		2.27(0.62,8.42)	1.75(0.74,4.80)	0.17(-0.11,0.40)
HD ADA SC		1.02(0.29,3.86)	1.02(0.42,2.94)	0.00(-0.24,0.22)
HD GOLI SC		1.71(0.53,5.66)	1.46(0.65,3.65)	0.10(-0.14,0.32)
HD ETN SC		1.58(0.27,9.48)	1.38(0.36,4.47)	0.09(-0.23,0.46)
HD ABA SC		3.03(0.53,19.91)	2.03(0.66,6.26)	0.24(-0.13,0.61)
HD TOCI IV + MTX		2.71(1.04,7.39)	1.93(1.03,4.31)	0.21(0.01,0.40)
HD INF IV + MTX		2.49(0.79,8.16)	1.83(0.87,4.40)	0.19(-0.05,0.42)
HD TOFA PO + MTX		2.14(0.63,7.21)	1.67(0.74,4.12)	0.15(-0.10,0.39)
HD GOLI SC + MTX		2.95(0.90,9.54)	2.01(0.94,4.76)	0.23(-0.02,0.46)
HD CERTO SC + MTX		3.84(1.30,11.94)	2.29(1.16,5.34)	0.29(0.06,0.51)
HD ADA SC + MTX		3.24(0.79,13.56)	2.08(0.86,5.38)	0.25(-0.05,0.54)
HD TOCI IV + DMARD		1.87(0.20,19.42)	1.54(0.28,5.80)	0.12(-0.25,0.60)
SD ANA SC + SD ETN SC + MTX		1.90(0.40,9.49)	1.56(0.51,4.50)	0.12(-0.18,0.46)
SD ANA SC + LD ETN SC + MTX		2.82(0.60,13.84)	1.95(0.71,5.41)	0.22(-0.10,0.55)

(Continued)

HD TOCI IV	LD TOFA PO + MTX	0.94(0.26,3.62)	0.96(0.47,2.72)	-0.01(-0.32,0.22)
HD TOFA PO		1.34(0.29,6.55)	1.20(0.53,3.89)	0.07(-0.29,0.36)
HD ADA SC		0.62(0.13,3.05)	0.71(0.28,2.41)	-0.10(-0.44,0.18)
HD GOLI SC		1.03(0.25,4.19)	1.02(0.46,2.93)	0.01(-0.32,0.27)
HD ETN SC		0.95(0.14,6.80)	0.97(0.25,3.62)	-0.01(-0.41,0.39)
HD ABA SC		1.84(0.27,13.28)	1.42(0.46,4.82)	0.14(-0.30,0.54)
HD TOCI IV + MTX		1.63(0.44,6.31)	1.34(0.67,3.81)	0.11(-0.19,0.37)
HD INF IV + MTX		1.51(0.38,5.94)	1.28(0.60,3.53)	0.09(-0.23,0.36)
HD TOFA PO + MTX		1.27(0.40,4.13)	1.16(0.61,2.80)	0.05(-0.21,0.28)
HD GOLI SC + MTX		1.75(0.46,7.03)	1.39(0.67,3.87)	0.13(-0.18,0.40)
HD CERTO SC + MTX		2.30(0.62,8.73)	1.59(0.81,4.38)	0.19(-0.11,0.45)
HD ADA SC + MTX		1.93(0.39,10.08)	1.45(0.58,4.30)	0.15(-0.22,0.49)
HD TOCI IV + DMARD		1.14(0.11,14.27)	1.09(0.20,4.67)	0.03(-0.42,0.55)
SD ANA SC + SD ETN SC + MTX		1.16(0.20,6.79)	1.09(0.36,3.57)	0.03(-0.35,0.39)
SD ANA SC + LD ETN SC + MTX		1.71(0.30,9.81)	1.36(0.49,4.22)	0.12(-0.27,0.48)
HD TOFA PO	HD TOCI IV	1.43(0.56,3.74)	1.25(0.69,2.33)	0.08(-0.13,0.29)
HD ADA SC		0.66(0.26,1.74)	0.74(0.37,1.48)	-0.08(-0.26,0.12)
HD GOLI SC		1.10(0.46,2.61)	1.06(0.58,1.85)	0.02(-0.16,0.22)
HD ETN SC		1.01(0.21,4.71)	1.01(0.29,2.40)	0.00(-0.26,0.36)
HD ABA SC		1.96(0.43,9.65)	1.49(0.56,3.17)	0.16(-0.17,0.50)
HD TOCI IV + MTX		1.75(0.99,3.08)	1.40(0.99,1.98)	0.13(0.00,0.26)
HD INF IV + MTX		1.59(0.69,3.67)	1.33(0.78,2.15)	0.10(-0.08,0.30)
HD TOFA PO + MTX		1.36(0.55,3.21)	1.21(0.66,2.01)	0.07(-0.12,0.27)
HD GOLI SC + MTX		1.88(0.79,4.42)	1.45(0.86,2.33)	0.15(-0.05,0.35)
HD CERTO SC + MTX		2.45(1.15,5.21)	1.66(1.09,2.53)	0.21(0.03,0.38)
HD ADA SC + MTX		2.04(0.66,6.69)	1.51(0.75,2.66)	0.17(-0.09,0.43)
HD TOCI IV + DMARD		1.20(0.15,10.25)	1.12(0.22,3.10)	0.04(-0.30,0.52)

(Continued)

SD ANA SC + SD ETN SC + MTX		1.21(0.33,4.84)	1.13(0.43,2.40)	0.04(-0.21,0.36)
SD ANA SC + LD ETN SC + MTX		1.79(0.48,6.85)	1.42(0.59,2.73)	0.13(-0.15,0.44)
HD ADA SC	HD TOFA PO	0.46(0.17,1.22)	0.59(0.29,1.14)	-0.16(-0.36,0.04)
HD GOLI SC		0.77(0.25,2.21)	0.85(0.40,1.61)	-0.06(-0.30,0.19)
HD ETN SC		0.70(0.13,3.58)	0.80(0.22,1.95)	-0.08(-0.38,0.30)
HD ABA SC		1.35(0.30,6.83)	1.18(0.46,2.40)	0.07(-0.26,0.43)
HD TOCI IV + MTX		1.21(0.43,3.48)	1.12(0.60,1.99)	0.05(-0.20,0.29)
HD INF IV + MTX		1.12(0.34,3.46)	1.07(0.51,1.99)	0.03(-0.25,0.29)
HD TOFA PO + MTX		0.95(0.28,3.08)	0.97(0.44,1.87)	-0.01(-0.28,0.27)
HD GOLI SC + MTX		1.30(0.40,4.07)	1.16(0.57,2.11)	0.06(-0.21,0.33)
HD CERTO SC + MTX		1.71(0.55,5.12)	1.33(0.71,2.31)	0.13(-0.14,0.38)
HD ADA SC + MTX		1.44(0.35,5.74)	1.22(0.51,2.30)	0.09(-0.23,0.40)
HD TOCI IV + DMARD		0.82(0.10,7.14)	0.88(0.17,2.34)	-0.05(-0.40,0.43)
SD ANA SC + SD ETN SC + MTX		0.85(0.20,3.81)	0.91(0.33,1.97)	-0.04(-0.33,0.31)
SD ANA SC + LD ETN SC + MTX		1.26(0.30,5.48)	1.14(0.45,2.26)	0.06(-0.26,0.39)
HD GOLI SC	HD ADA SC	1.66(0.53,5.13)	1.43(0.63,3.11)	0.10(-0.12,0.33)
HD ETN SC		1.54(0.27,7.84)	1.36(0.35,3.57)	0.08(-0.20,0.45)
HD ABA SC		2.95(0.62,15.08)	1.99(0.71,4.63)	0.23(-0.09,0.58)
HD TOCI IV + MTX		2.63(0.90,7.64)	1.88(0.93,3.82)	0.21(-0.02,0.43)
HD INF IV + MTX		2.43(0.72,7.91)	1.81(0.80,3.81)	0.19(-0.07,0.44)
HD TOFA PO + MTX		2.06(0.60,6.84)	1.63(0.69,3.58)	0.15(-0.10,0.41)
HD GOLI SC + MTX		2.86(0.85,9.26)	1.96(0.89,4.07)	0.23(-0.03,0.48)
HD CERTO SC + MTX		3.72(1.17,11.58)	2.24(1.11,4.50)	0.29(0.04,0.53)
HD ADA SC + MTX		3.11(0.74,13.00)	2.05(0.81,4.44)	0.25(-0.06,0.55)
HD TOCI IV + DMARD		1.81(0.21,15.25)	1.51(0.28,4.33)	0.12(-0.22,0.58)
SD ANA SC + SD ETN SC + MTX		1.85(0.42,8.59)	1.53(0.52,3.79)	0.12(-0.15,0.47)
SD ANA SC + LD ETN SC + MTX		2.74(0.60,12.43)	1.93(0.70,4.38)	0.22(-0.10,0.54)

(Continued)

HD ETN SC	HD GOLI SC	0.92(0.18,4.68)	0.95(0.28,2.45)	-0.02(-0.31,0.35)
HD ABA SC		1.78(0.36,9.35)	1.39(0.51,3.24)	0.13(-0.22,0.50)
HD TOCI IV + MTX		1.59(0.64,3.95)	1.31(0.77,2.36)	0.11(-0.10,0.31)
HD INF IV + MTX		1.45(0.55,3.90)	1.25(0.69,2.30)	0.09(-0.13,0.31)
HD TOFA PO + MTX		1.24(0.45,3.40)	1.14(0.59,2.14)	0.05(-0.17,0.28)
HD GOLI SC + MTX		1.70(0.74,3.87)	1.36(0.84,2.25)	0.12(-0.07,0.31)
HD CERTO SC + MTX		2.25(0.87,5.71)	1.56(0.93,2.76)	0.19(-0.03,0.40)
HD ADA SC + MTX		1.87(0.53,6.68)	1.42(0.66,2.80)	0.14(-0.14,0.43)
HD TOCI IV + DMARD		1.08(0.13,10.71)	1.05(0.21,3.23)	0.02(-0.34,0.52)
SD ANA SC + SD ETN SC + MTX		1.11(0.27,4.84)	1.07(0.39,2.47)	0.02(-0.26,0.36)
SD ANA SC + LD ETN SC + MTX		1.65(0.40,6.88)	1.34(0.54,2.83)	0.11(-0.19,0.44)
HD ABA SC	HD ETN SC	1.92(0.27,15.51)	1.46(0.46,5.62)	0.15(-0.30,0.56)
HD TOCI IV + MTX		1.73(0.36,8.34)	1.39(0.59,4.64)	0.12(-0.24,0.41)
HD INF IV + MTX		1.57(0.31,8.12)	1.31(0.53,4.47)	0.10(-0.28,0.41)
HD TOFA PO + MTX		1.36(0.24,6.81)	1.21(0.45,4.06)	0.07(-0.32,0.38)
HD GOLI SC + MTX		1.85(0.36,9.57)	1.43(0.60,4.86)	0.14(-0.24,0.45)
HD CERTO SC + MTX		2.42(0.49,12.49)	1.63(0.72,5.55)	0.20(-0.17,0.51)
HD ADA SC + MTX		2.05(0.33,12.63)	1.50(0.54,5.25)	0.16(-0.25,0.52)
HD TOCI IV + DMARD		1.16(0.11,14.39)	1.10(0.20,5.07)	0.03(-0.43,0.55)
SD ANA SC + SD ETN SC + MTX		1.21(0.21,7.35)	1.13(0.37,3.89)	0.04(-0.35,0.41)
SD ANA SC + LD ETN SC + MTX		1.79(0.32,10.19)	1.40(0.52,4.57)	0.13(-0.26,0.48)
HD TOCI IV + MTX	HD ABA SC	0.89(0.17,4.27)	0.94(0.45,2.44)	-0.03(-0.40,0.32)
HD INF IV + MTX		0.81(0.15,4.30)	0.89(0.39,2.42)	-0.05(-0.43,0.33)
HD TOFA PO + MTX		0.69(0.13,3.64)	0.82(0.34,2.24)	-0.09(-0.46,0.29)
HD GOLI SC + MTX		0.96(0.17,4.95)	0.98(0.43,2.59)	-0.01(-0.40,0.36)
HD CERTO SC + MTX		1.26(0.23,6.53)	1.12(0.53,2.89)	0.06(-0.33,0.42)
HD ADA SC + MTX		1.04(0.17,6.26)	1.02(0.40,2.76)	0.01(-0.40,0.42)

(Continued)

HD TOCI IV + DMARD		0.62(0.05,6.51)	0.77(0.14,2.50)	-0.11(-0.56,0.42)
SD ANA SC + SD ETN SC + MTX		0.63(0.09,4.31)	0.77(0.25,2.32)	-0.11(-0.52,0.33)
SD ANA SC + LD ETN SC + MTX		0.91(0.14,6.39)	0.96(0.34,2.73)	-0.02(-0.44,0.42)
HD INF IV + MTX	HD TOCI IV + MTX	0.92(0.38,2.17)	0.96(0.56,1.51)	-0.02(-0.22,0.19)
HD TOFA PO + MTX		0.78(0.31,1.89)	0.87(0.48,1.42)	-0.06(-0.26,0.15)
HD GOLI SC + MTX		1.08(0.44,2.58)	1.04(0.62,1.64)	0.02(-0.19,0.22)
HD CERTO SC + MTX		1.41(0.64,3.07)	1.18(0.79,1.78)	0.08(-0.11,0.27)
HD ADA SC + MTX		1.17(0.38,3.85)	1.08(0.54,1.85)	0.04(-0.22,0.31)
HD TOCI IV + DMARD		0.69(0.09,6.07)	0.80(0.17,2.20)	-0.09(-0.45,0.40)
SD ANA SC + SD ETN SC + MTX		0.70(0.19,2.89)	0.81(0.32,1.69)	-0.08(-0.35,0.25)
SD ANA SC + LD ETN SC + MTX		1.03(0.28,4.07)	1.02(0.44,1.95)	0.01(-0.28,0.32)
HD TOFA PO + MTX	HD INF IV + MTX	0.86(0.32,2.19)	0.92(0.50,1.58)	-0.04(-0.26,0.18)
HD GOLI SC + MTX		1.18(0.46,2.98)	1.09(0.65,1.86)	0.04(-0.18,0.25)
HD CERTO SC + MTX		1.53(0.66,3.63)	1.24(0.81,2.05)	0.10(-0.10,0.30)
HD ADA SC + MTX		1.29(0.38,4.39)	1.14(0.56,2.10)	0.06(-0.22,0.34)
HD TOCI IV + DMARD		0.75(0.09,6.98)	0.84(0.17,2.50)	-0.06(-0.45,0.44)
SD ANA SC + SD ETN SC + MTX		0.77(0.19,3.21)	0.85(0.33,1.85)	-0.06(-0.35,0.27)
SD ANA SC + LD ETN SC + MTX		1.13(0.29,4.59)	1.07(0.45,2.18)	0.03(-0.28,0.35)
HD GOLI SC + MTX	HD TOFA PO + MTX	1.38(0.52,3.67)	1.19(0.69,2.19)	0.07(-0.15,0.30)
HD CERTO SC + MTX		1.80(0.75,4.53)	1.36(0.86,2.41)	0.14(-0.07,0.35)
HD ADA SC + MTX		1.51(0.43,5.51)	1.25(0.60,2.48)	0.10(-0.19,0.39)
HD TOCI IV + DMARD		0.87(0.10,8.84)	0.92(0.18,2.89)	-0.03(-0.41,0.48)
SD ANA SC + SD ETN SC + MTX		0.90(0.22,3.87)	0.94(0.36,2.18)	-0.02(-0.32,0.31)
SD ANA SC + LD ETN SC + MTX		1.33(0.33,5.74)	1.17(0.49,2.54)	0.07(-0.24,0.39)
HD CERTO SC + MTX	HD GOLI SC + MTX	1.32(0.53,3.14)	1.14(0.74,1.85)	0.07(-0.15,0.27)
HD ADA SC + MTX		1.09(0.32,3.87)	1.04(0.51,1.94)	0.02(-0.26,0.31)

(Continued)

HD TOCI IV + DMARD		0.63(0.07,6.39)	0.77(0.15,2.23)	-0.11(-0.50,0.41)
SD ANA SC + SD ETN SC + MTX		0.65(0.16,2.81)	0.79(0.30,1.70)	-0.10(-0.39,0.24)
SD ANA SC + LD ETN SC + MTX		0.96(0.24,4.08)	0.98(0.42,1.97)	-0.01(-0.32,0.32)
HD ADA SC + MTX	HD CERTO SC + MTX	0.84(0.26,2.74)	0.92(0.46,1.54)	-0.04(-0.31,0.23)
HD TOCI IV + DMARD		0.49(0.06,4.58)	0.68(0.14,1.83)	-0.17(-0.55,0.34)
SD ANA SC + SD ETN SC + MTX		0.49(0.13,2.04)	0.69(0.27,1.39)	-0.17(-0.44,0.17)
SD ANA SC + LD ETN SC + MTX		0.74(0.19,2.97)	0.86(0.37,1.59)	-0.07(-0.37,0.25)
HD TOCI IV + DMARD	HD ADA SC + MTX	0.61(0.05,6.65)	0.76(0.14,2.40)	-0.11(-0.56,0.41)
SD ANA SC + SD ETN SC + MTX		0.59(0.12,3.12)	0.75(0.28,1.88)	-0.12(-0.46,0.26)
SD ANA SC + LD ETN SC + MTX		0.87(0.18,4.53)	0.93(0.38,2.19)	-0.03(-0.39,0.34)
SD ANA SC + SD ETN SC + MTX	HD TOCI IV + DMARD	1.01(0.10,10.84)	1.00(0.28,5.37)	0.00(-0.50,0.45)
SD ANA SC + LD ETN SC + MTX		1.49(0.15,15.67)	1.25(0.38,6.50)	0.09(-0.42,0.53)
SD ANA SC + LD ETN SC + MTX	SD ANA SC + SD ETN SC + MTX	1.47(0.54,4.10)	1.24(0.69,2.45)	0.08(-0.14,0.31)
Random-effects model	Residual deviance	180 vs 175 data points		
	Deviance informa- tion crite- ria	1121.54		
Fixed-effect model	Residual deviance	251.8 vs 175 data points		
	Deviance informa- tion crite- ria	1166.12		
Note				
Total participants	24,122			
Total studies	66			
2-arm	35			
3-arm	23			

(Continued)

4-arm	6
5-arm	1
7-arm	1

Appendix 6. ACR50: subgroup - trial duration (> 6-12 months)
ACR50 intermediate: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	PL + MTX	2.81(1.01,7.87)	2.13(1.01,3.59)	0.20(0.00,0.45)
SD ETN SC + MTX		4.74(1.71,13.91)	2.85(1.52,4.32)	0.33(0.09,0.57)
SD INF IV + MTX		3.14(0.90,13.36)	2.28(0.92,4.49)	0.23(-0.01,0.56)
SD ADA SC + MTX		6.83(2.41,20.66)	3.35(1.92,4.83)	0.42(0.17,0.64)
SD RITUX IV + MTX		1.42(0.50,4.08)	1.32(0.55,2.65)	0.06(-0.08,0.29)
SD TOFA PO + MTX		5.57(1.78,16.57)	3.08(1.56,4.66)	0.37(0.10,0.60)
LD ADA SC + MTX		5.79(2.05,17.54)	3.13(1.72,4.65)	0.38(0.13,0.61)
LD RITUX IV + MTX		0.98(0.35,2.82)	0.99(0.39,2.13)	0.00(-0.11,0.20)
LD ETN SC + MTX		3.84(1.43,11.41)	2.56(1.33,4.10)	0.27(0.06,0.53)
HD ETN SC		2.51(0.91,6.89)	1.98(0.92,3.39)	0.17(-0.01,0.42)
HD INF IV + MTX		7.84(2.21,31.05)	3.54(1.80,5.41)	0.45(0.15,0.69)
HD TOFA PO + MTX		8.98(2.97,27.44)	3.72(2.17,5.17)	0.48(0.22,0.68)
SD ETN SC + MTX	SD ETN SC	1.68(0.41,7.67)	1.33(0.62,3.05)	0.12(-0.20,0.44)
SD INF IV + MTX		1.12(0.22,6.35)	1.07(0.39,2.80)	0.03(-0.32,0.41)
SD ADA SC + MTX		2.43(0.58,10.48)	1.57(0.77,3.45)	0.21(-0.12,0.50)
SD RITUX IV + MTX		0.50(0.12,2.21)	0.62(0.23,1.70)	-0.14(-0.42,0.16)
SD TOFA PO + MTX		1.99(0.41,8.74)	1.44(0.62,3.22)	0.17(-0.20,0.47)
LD ADA SC + MTX		2.06(0.49,9.44)	1.47(0.69,3.30)	0.17(-0.16,0.47)
LD RITUX IV + MTX		0.35(0.08,1.47)	0.47(0.16,1.31)	-0.20(-0.46,0.07)
LD ETN SC + MTX		1.36(0.33,6.05)	1.20(0.54,2.82)	0.07(-0.24,0.38)

(Continued)

HD ETN SC		0.89(0.32,2.50)	0.93(0.49,1.75)	-0.03(-0.23,0.19)
HD INF IV + MTX		2.80(0.54,15.37)	1.66(0.73,3.72)	0.25(-0.14,0.57)
HD TOFA PO + MTX		3.22(0.69,14.41)	1.74(0.85,3.75)	0.28(-0.08,0.56)
SD INF IV + MTX	SD ETN SC + MTX	0.66(0.13,3.80)	0.80(0.30,1.88)	-0.10(-0.44,0.30)
SD ADA SC + MTX		1.45(0.32,6.48)	1.18(0.60,2.34)	0.09(-0.25,0.40)
SD RITUX IV + MTX		0.30(0.07,1.29)	0.47(0.18,1.17)	-0.26(-0.54,0.05)
SD TOFA PO + MTX		1.18(0.23,5.09)	1.08(0.50,2.19)	0.04(-0.32,0.36)
LD ADA SC + MTX		1.23(0.27,5.46)	1.10(0.55,2.22)	0.05(-0.28,0.37)
LD RITUX IV + MTX		0.21(0.05,0.88)	0.35(0.13,0.93)	-0.32(-0.58,-0.02)
LD ETN SC + MTX		0.81(0.29,2.29)	0.90(0.53,1.52)	-0.05(-0.27,0.18)
HD ETN SC		0.53(0.12,2.17)	0.70(0.30,1.53)	-0.15(-0.45,0.17)
HD INF IV + MTX		1.66(0.31,8.96)	1.24(0.60,2.49)	0.12(-0.26,0.46)
HD TOFA PO + MTX		1.90(0.39,8.32)	1.30(0.69,2.50)	0.15(-0.20,0.45)
SD ADA SC + MTX	SD INF IV + MTX	2.17(0.37,11.79)	1.46(0.65,3.74)	0.19(-0.22,0.53)
SD RITUX IV + MTX		0.45(0.08,2.40)	0.58(0.20,1.82)	-0.17(-0.51,0.17)
SD TOFA PO + MTX		1.78(0.28,9.05)	1.35(0.55,3.48)	0.14(-0.29,0.48)
LD ADA SC + MTX		1.82(0.31,10.15)	1.36(0.58,3.53)	0.14(-0.27,0.50)
LD RITUX IV + MTX		0.31(0.05,1.62)	0.44(0.14,1.42)	-0.22(-0.57,0.08)
LD ETN SC + MTX		1.23(0.22,6.52)	1.12(0.46,3.05)	0.05(-0.34,0.40)
HD ETN SC		0.80(0.14,3.96)	0.87(0.33,2.41)	-0.05(-0.42,0.29)
HD INF IV + MTX		2.47(0.77,7.67)	1.52(0.90,3.03)	0.21(-0.05,0.44)
HD TOFA PO + MTX		2.85(0.46,14.83)	1.62(0.73,4.00)	0.25(-0.17,0.56)
SD RITUX IV + MTX	SD ADA SC + MTX	0.21(0.05,0.92)	0.40(0.16,0.95)	-0.35(-0.61,-0.02)
SD TOFA PO + MTX		0.82(0.16,3.58)	0.92(0.44,1.72)	-0.05(-0.39,0.28)
LD ADA SC + MTX		0.85(0.31,2.31)	0.94(0.60,1.41)	-0.04(-0.25,0.18)
LD RITUX IV + MTX		0.14(0.03,0.64)	0.30(0.11,0.77)	-0.41(-0.66,-0.09)
LD ETN SC + MTX		0.56(0.13,2.51)	0.76(0.38,1.53)	-0.14(-0.44,0.21)

(Continued)

HD ETN SC		0.37(0.08,1.57)	0.59(0.26,1.25)	-0.24(-0.53,0.10)
HD INF IV + MTX		1.15(0.20,6.47)	1.05(0.51,2.00)	0.03(-0.35,0.39)
HD TOFA PO + MTX		1.33(0.27,5.83)	1.11(0.61,1.99)	0.07(-0.28,0.37)
SD TOFA PO + MTX	SD RITUX IV + MTX	3.95(0.82,17.29)	2.32(0.89,5.80)	0.31(-0.04,0.57)
LD ADA SC + MTX		4.06(0.91,18.89)	2.34(0.95,5.90)	0.31(-0.02,0.58)
LD RITUX IV + MTX		0.69(0.24,1.98)	0.75(0.33,1.68)	-0.06(-0.24,0.11)
LD ETN SC + MTX		2.70(0.63,11.96)	1.92(0.76,4.98)	0.21(-0.09,0.49)
HD ETN SC		1.77(0.41,7.58)	1.49(0.55,4.07)	0.11(-0.17,0.39)
HD INF IV + MTX		5.54(1.05,30.12)	2.65(1.03,6.75)	0.39(0.01,0.67)
HD TOFA PO + MTX		6.36(1.35,28.09)	2.80(1.17,6.76)	0.42(0.06,0.66)
LD ADA SC + MTX	SD TOFA PO + MTX	1.03(0.24,5.17)	1.01(0.52,2.14)	0.01(-0.32,0.36)
LD RITUX IV + MTX		0.17(0.04,0.81)	0.32(0.12,0.88)	-0.36(-0.61,-0.04)
LD ETN SC + MTX		0.69(0.16,3.41)	0.83(0.40,1.84)	-0.09(-0.40,0.27)
HD ETN SC		0.45(0.10,2.11)	0.64(0.28,1.50)	-0.19(-0.49,0.17)
HD INF IV + MTX		1.40(0.26,8.53)	1.15(0.56,2.40)	0.08(-0.30,0.45)
HD TOFA PO + MTX		1.61(0.61,4.39)	1.20(0.83,1.93)	0.11(-0.10,0.31)
LD RITUX IV + MTX	LD ADA SC + MTX	0.17(0.04,0.75)	0.32(0.12,0.84)	-0.37(-0.63,-0.05)
LD ETN SC + MTX		0.66(0.15,2.95)	0.82(0.39,1.68)	-0.10(-0.41,0.24)
HD ETN SC		0.43(0.10,1.87)	0.63(0.28,1.38)	-0.20(-0.49,0.14)
HD INF IV + MTX		1.36(0.24,7.78)	1.13(0.53,2.23)	0.07(-0.32,0.43)
HD TOFA PO + MTX		1.56(0.31,6.82)	1.19(0.64,2.23)	0.10(-0.25,0.41)
LD ETN SC + MTX	LD RITUX IV + MTX	3.91(0.95,17.62)	2.58(0.97,7.05)	0.27(-0.01,0.54)
HD ETN SC		2.55(0.60,11.03)	2.00(0.69,5.81)	0.17(-0.09,0.43)
HD INF IV + MTX		7.97(1.55,44.08)	3.54(1.29,9.51)	0.45(0.09,0.71)
HD TOFA PO + MTX		9.20(2.02,39.56)	3.75(1.48,9.45)	0.48(0.14,0.70)
HD ETN SC	LD ETN SC + MTX	0.65(0.15,2.65)	0.78(0.33,1.75)	-0.10(-0.41,0.21)

(Continued)

HD INF IV + MTX		2.04(0.40,10.79)	1.38(0.64,2.88)	0.17(-0.21,0.50)
HD TOFA PO + MTX		2.33(0.49,10.00)	1.45(0.74,2.89)	0.20(-0.16,0.49)
HD INF IV + MTX	HD ETN SC	3.13(0.60,16.97)	1.77(0.77,4.04)	0.27(-0.11,0.58)
HD TOFA PO + MTX		3.60(0.77,15.84)	1.88(0.89,4.11)	0.30(-0.06,0.57)
HD TOFA PO + MTX	HD INF IV + MTX	1.15(0.20,6.02)	1.05(0.57,2.07)	0.03(-0.33,0.38)
Random-effects model	Residual deviance	18.31 vs 18 data points		
	Deviance information criteria	132.003		
Fixed-effect model	Residual deviance	18.03 vs data points		
	Deviance information criteria	131.437		
Note				
Total participants	3209			
Total studies	6			
3-arm	6			

Appendix 7. HAQ: main analysis

HAQ: mean difference for all treatments

Treatment	Reference	MD (95% CrI)
MTX	PL	0.04(-0.39,0.50)
DMARD		0.04(-0.37,0.45)
MTX + DMARD		-0.30(-0.83,0.23)
SD ETN SC		-0.34(-0.70,0.03)
SD ADA SC		-0.29(-0.51,-0.06)
SD TOFA PO		-0.40(-0.68,-0.13)

(Continued)

SD CERTO	-0.33(-0.66,0.01)
SD ANA	-0.20(-0.63,0.23)
SD RITUX IV	-0.33(-0.93,0.29)
SD ETN SC + MTX	-0.58(-0.99,-0.16)
SD CERTO SC + MTX	-0.24(-0.72,0.24)
SD RITUX IV + MTX	-0.14(-0.64,0.39)
SD ADA SC + MTX	-0.27(-0.77,0.25)
SD GOLI SC + MTX	0.04(-0.49,0.59)
SD TOFA PO + MTX	-0.39(-0.99,0.22)
SD TOCI IV + MTX	-0.16(-0.67,0.37)
SD ABA SC + MTX	-0.18(-0.83,0.49)
SD GOLI IV + MTX	0.35(-0.25,0.97)
SD ETN SC + DMARD	-0.28(-0.81,0.27)
SD CERTO + DMARD	-0.33(-0.71,0.04)
LD ADA SC	-0.32(-0.61,-0.03)
LD ANA	-0.20(-0.62,0.22)
LD ADA SC + MTX	-0.23(-0.74,0.30)
LD RITUX IV + MTX	-0.08(-0.58,0.45)
LD ADA IV + MTX	-0.25(-0.88,0.38)
LD CERTO SC + MTX	-0.16(-0.75,0.44)
LD ETN SC + MTX	-0.32(-0.87,0.23)
LD TOFA PO + MTX	-0.31(-0.92,0.30)
HD TOCI IV	-0.28(-0.74,0.20)
HD TOFA PO	-0.52(-0.79,-0.25)
HD ADA SC	-0.43(-0.72,-0.14)
HD ANA	-0.30(-0.73,0.13)
HD GOLI SC	0.09(-0.49,0.69)
HD TOCI IV + MTX	-0.26(-0.73,0.23)

(Continued)

HD CERTO SC + MTX		-0.29(-0.78,0.22)
HD TOFA PO + MTX		-0.47(-1.07,0.14)
HD GOLI SC + MTX		0.08(-0.46,0.62)
HD ADA SC + MTX		-0.27(-0.85,0.33)
DMARD	MTX	-0.01(-0.36,0.34)
MTX + DMARD		-0.35(-0.75,0.05)
SD ETN SC		-0.38(-0.65,-0.11)
SD ADA SC		-0.33(-0.83,0.16)
SD TOFA PO		-0.45(-0.97,0.07)
SD CERTO		-0.37(-0.93,0.19)
SD ANA		-0.25(-0.87,0.36)
SD RITUX IV		-0.37(-0.79,0.05)
SD ETN SC + MTX		-0.62(-0.86,-0.39)
SD CERTO SC + MTX		-0.29(-0.48,-0.10)
SD RITUX IV + MTX		-0.18(-0.44,0.07)
SD ADA SC + MTX		-0.32(-0.56,-0.07)
SD GOLI SC + MTX		0.00(-0.31,0.31)
SD TOFA PO + MTX		-0.44(-0.85,-0.03)
SD TOCI IV + MTX		-0.20(-0.48,0.08)
SD ABA SC + MTX		-0.22(-0.70,0.27)
SD GOLI IV + MTX		0.31(-0.11,0.73)
SD ETN SC + DMARD		-0.32(-0.81,0.17)
SD CERTO + DMARD		-0.37(-0.83,0.08)
LD ADA SC		-0.36(-0.90,0.16)
LD ANA		-0.25(-0.87,0.36)
LD ADA SC + MTX		-0.27(-0.53,-0.01)
LD RITUX IV + MTX		-0.12(-0.38,0.14)
LD ADA IV + MTX		-0.29(-0.74,0.15)

(Continued)

LD CERTO SC + MTX		-0.20(-0.60,0.20)
LD ETN SC + MTX		-0.36(-0.75,0.02)
LD TOFA PO + MTX		-0.36(-0.77,0.05)
HD TOCI IV		-0.32(-0.60,-0.04)
HD TOFA PO		-0.56(-1.09,-0.05)
HD ADA SC		-0.47(-1.02,0.05)
HD ANA		-0.35(-0.97,0.27)
HD GOLI SC		0.05(-0.34,0.44)
HD TOCI IV + MTX		-0.30(-0.53,-0.08)
HD CERTO SC + MTX		-0.33(-0.56,-0.09)
HD TOFA PO + MTX		-0.51(-0.93,-0.11)
HD GOLI SC + MTX		0.03(-0.27,0.34)
HD ADA SC + MTX		-0.31(-0.70,0.08)
MTX + DMARD	DMARD	-0.34(-0.81,0.14)
SD ETN SC		-0.38(-0.68,-0.06)
SD ADA SC		-0.33(-0.80,0.14)
SD TOFA PO		-0.44(-0.94,0.05)
SD CERTO		-0.37(-0.89,0.17)
SD ANA		-0.24(-0.83,0.35)
SD RITUX IV		-0.36(-0.91,0.18)
SD ETN SC + MTX		-0.62(-0.97,-0.27)
SD CERTO SC + MTX		-0.28(-0.68,0.12)
SD RITUX IV + MTX		-0.17(-0.61,0.27)
SD ADA SC + MTX		-0.31(-0.74,0.13)
SD GOLI SC + MTX		0.01(-0.46,0.48)
SD TOFA PO + MTX		-0.43(-0.97,0.11)
SD TOCI IV + MTX		-0.20(-0.63,0.24)
SD ABA SC + MTX		-0.21(-0.81,0.39)

(Continued)

SD GOLI IV + MTX		0.32(-0.23,0.86)
SD ETN SC + DMARD		-0.32(-0.66,0.04)
SD CERTO + DMARD		-0.37(-0.74,0.00)
LD ADA SC		-0.36(-0.86,0.15)
LD ANA		-0.24(-0.83,0.35)
LD ADA SC + MTX		-0.27(-0.71,0.18)
LD RITUX IV + MTX		-0.11(-0.55,0.33)
LD ADA IV + MTX		-0.29(-0.85,0.28)
LD CERTO SC + MTX		-0.20(-0.73,0.34)
LD ETN SC + MTX		-0.36(-0.85,0.13)
LD TOFA PO + MTX		-0.35(-0.89,0.19)
HD TOCI IV		-0.31(-0.65,0.03)
HD TOFA PO		-0.56(-1.05,-0.07)
HD ADA SC		-0.47(-0.98,0.04)
HD ANA		-0.34(-0.93,0.25)
HD GOLI SC		0.05(-0.47,0.58)
HD TOCI IV + MTX		-0.30(-0.68,0.09)
HD CERTO SC + MTX		-0.32(-0.74,0.10)
HD TOFA PO + MTX		-0.51(-1.05,0.03)
HD GOLI SC + MTX		0.04(-0.42,0.51)
HD ADA SC + MTX		-0.31(-0.82,0.22)
SD ETN SC	MTX + DMARD	-0.03(-0.42,0.36)
SD ADA SC		0.02(-0.56,0.59)
SD TOFA PO		-0.10(-0.70,0.49)
SD CERTO		-0.03(-0.65,0.61)
SD ANA		0.10(-0.58,0.78)
SD RITUX IV		-0.02(-0.61,0.56)
SD ETN SC + MTX		-0.28(-0.60,0.05)

(Continued)

SD CERTO SC + MTX	0.06(-0.38,0.50)
SD RITUX IV + MTX	0.17(-0.30,0.64)
SD ADA SC + MTX	0.03(-0.44,0.50)
SD GOLI SC + MTX	0.35(-0.16,0.85)
SD TOFA PO + MTX	-0.09(-0.66,0.48)
SD TOCI IV + MTX	0.15(-0.34,0.63)
SD ABA SC + MTX	0.13(-0.50,0.76)
SD GOLI IV + MTX	0.66(0.08,1.24)
SD ETN SC + DMARD	0.02(-0.56,0.61)
SD CERTO + DMARD	-0.03(-0.58,0.52)
LD ADA SC	-0.01(-0.62,0.59)
LD ANA	0.10(-0.58,0.77)
LD ADA SC + MTX	0.07(-0.40,0.55)
LD RITUX IV + MTX	0.23(-0.25,0.71)
LD ADA IV + MTX	0.05(-0.54,0.65)
LD CERTO SC + MTX	0.14(-0.42,0.71)
LD ETN SC + MTX	-0.02(-0.52,0.48)
LD TOFA PO + MTX	-0.01(-0.58,0.57)
HD TOCI IV	0.03(-0.44,0.49)
HD TOFA PO	-0.21(-0.82,0.38)
HD ADA SC	-0.13(-0.74,0.48)
HD ANA	0.00(-0.68,0.68)
HD GOLI SC	0.40(-0.17,0.95)
HD TOCI IV + MTX	0.04(-0.40,0.50)
HD CERTO SC + MTX	0.02(-0.45,0.48)
HD TOFA PO + MTX	-0.17(-0.74,0.40)
HD GOLI SC + MTX	0.38(-0.12,0.88)
HD ADA SC + MTX	0.04(-0.52,0.60)

(Continued)

SD ADA SC	SD ETN SC	0.05(-0.39,0.48)
SD TOFA PO		-0.07(-0.53,0.39)
SD CERTO		0.01(-0.49,0.51)
SD ANA		0.14(-0.43,0.70)
SD RITUX IV		0.01(-0.49,0.52)
SD ETN SC + MTX		-0.24(-0.45,-0.03)
SD CERTO SC + MTX		0.09(-0.23,0.43)
SD RITUX IV + MTX		0.20(-0.17,0.58)
SD ADA SC + MTX		0.06(-0.30,0.44)
SD GOLI SC + MTX		0.38(-0.03,0.79)
SD TOFA PO + MTX		-0.06(-0.54,0.43)
SD TOCI IV + MTX		0.18(-0.20,0.56)
SD ABA SC + MTX		0.16(-0.39,0.72)
SD GOLI IV + MTX		0.69(0.20,1.19)
SD ETN SC + DMARD		0.06(-0.41,0.53)
SD CERTO + DMARD		0.01(-0.40,0.42)
LD ADA SC		0.02(-0.45,0.49)
LD ANA		0.13(-0.43,0.69)
LD ADA SC + MTX		0.11(-0.26,0.49)
LD RITUX IV + MTX		0.26(-0.11,0.64)
LD ADA IV + MTX		0.09(-0.43,0.61)
LD CERTO SC + MTX		0.18(-0.30,0.66)
LD ETN SC + MTX		0.02(-0.40,0.44)
LD TOFA PO + MTX		0.02(-0.47,0.52)
HD TOCI IV		0.06(-0.28,0.41)
HD TOFA PO		-0.18(-0.64,0.27)
HD ADA SC		-0.10(-0.57,0.38)
HD ANA		0.03(-0.53,0.60)

(Continued)

HD GOLI SC		0.43(-0.04,0.91)
HD TOCI IV + MTX		0.08(-0.26,0.42)
HD CERTO SC + MTX		0.05(-0.30,0.41)
HD TOFA PO + MTX		-0.13(-0.62,0.36)
HD GOLI SC + MTX		0.41(0.01,0.82)
HD ADA SC + MTX		0.07(-0.40,0.55)
SD TOFA PO	SD ADA SC	-0.12(-0.43,0.19)
SD CERTO		-0.04(-0.45,0.37)
SD ANA		0.09(-0.40,0.57)
SD RITUX IV		-0.04(-0.69,0.62)
SD ETN SC + MTX		-0.29(-0.77,0.18)
SD CERTO SC + MTX		0.04(-0.49,0.58)
SD RITUX IV + MTX		0.15(-0.41,0.72)
SD ADA SC + MTX		0.01(-0.54,0.57)
SD GOLI SC + MTX		0.33(-0.25,0.92)
SD TOFA PO + MTX		-0.11(-0.75,0.54)
SD TOCI IV + MTX		0.13(-0.43,0.70)
SD ABA SC + MTX		0.11(-0.58,0.82)
SD GOLI IV + MTX		0.64(-0.01,1.30)
SD ETN SC + DMARD		0.01(-0.57,0.60)
SD CERTO + DMARD		-0.04(-0.48,0.39)
LD ADA SC		-0.03(-0.32,0.26)
LD ANA		0.08(-0.40,0.56)
LD ADA SC + MTX		0.06(-0.50,0.62)
LD RITUX IV + MTX		0.21(-0.35,0.78)
LD ADA IV + MTX		0.04(-0.63,0.70)
LD CERTO SC + MTX		0.13(-0.51,0.77)
LD ETN SC + MTX		-0.03(-0.63,0.56)

(Continued)

LD TOFA PO + MTX		-0.03(-0.67,0.63)
HD TOCI IV		0.01(-0.51,0.54)
HD TOFA PO		-0.23(-0.54,0.08)
HD ADA SC		-0.15(-0.44,0.15)
HD ANA		-0.02(-0.51,0.47)
HD GOLI SC		0.38(-0.25,1.02)
HD TOCI IV + MTX		0.03(-0.50,0.56)
HD CERTO SC + MTX		0.00(-0.55,0.56)
HD TOFA PO + MTX		-0.18(-0.83,0.47)
HD GOLI SC + MTX		0.36(-0.22,0.95)
HD ADA SC + MTX		0.02(-0.61,0.65)
SD CERTO	SD TOFA PO	0.07(-0.36,0.52)
SD ANA		0.20(-0.31,0.72)
SD RITUX IV		0.08(-0.59,0.75)
SD ETN SC + MTX		-0.18(-0.67,0.32)
SD CERTO SC + MTX		0.16(-0.39,0.72)
SD RITUX IV + MTX		0.27(-0.31,0.86)
SD ADA SC + MTX		0.13(-0.44,0.71)
SD GOLI SC + MTX		0.44(-0.16,1.06)
SD TOFA PO + MTX		0.01(-0.65,0.68)
SD TOCI IV + MTX		0.25(-0.33,0.84)
SD ABA SC + MTX		0.23(-0.48,0.95)
SD GOLI IV + MTX		0.76(0.09,1.44)
SD ETN SC + DMARD		0.12(-0.47,0.74)
SD CERTO + DMARD		0.07(-0.39,0.53)
LD ADA SC		0.09(-0.29,0.47)
LD ANA		0.20(-0.30,0.71)
LD ADA SC + MTX		0.17(-0.40,0.76)

(Continued)

LD RITUX IV + MTX		0.33(-0.25,0.92)
LD ADA IV + MTX		0.15(-0.53,0.84)
LD CERTO SC + MTX		0.24(-0.41,0.90)
LD ETN SC + MTX		0.08(-0.53,0.70)
LD TOFA PO + MTX		0.09(-0.57,0.77)
HD TOCI IV		0.13(-0.42,0.68)
HD TOFA PO		-0.11(-0.37,0.15)
HD ADA SC		-0.03(-0.41,0.36)
HD ANA		0.10(-0.41,0.61)
HD GOLI SC		0.50(-0.15,1.15)
HD TOCI IV + MTX		0.15(-0.40,0.70)
HD CERTO SC + MTX		0.12(-0.45,0.69)
HD TOFA PO + MTX		-0.07(-0.73,0.61)
HD GOLI SC + MTX		0.48(-0.12,1.09)
HD ADA SC + MTX		0.14(-0.50,0.79)
SD ANA	SD CERTO	0.13(-0.43,0.67)
SD RITUX IV		0.00(-0.70,0.70)
SD ETN SC + MTX		-0.25(-0.80,0.28)
SD CERTO SC + MTX		0.09(-0.51,0.67)
SD RITUX IV + MTX		0.19(-0.42,0.81)
SD ADA SC + MTX		0.06(-0.55,0.67)
SD GOLI SC + MTX		0.37(-0.27,1.01)
SD TOFA PO + MTX		-0.06(-0.75,0.63)
SD TOCI IV + MTX		0.17(-0.45,0.79)
SD ABA SC + MTX		0.15(-0.58,0.90)
SD GOLI IV + MTX		0.68(-0.02,1.38)
SD ETN SC + DMARD		0.05(-0.59,0.68)
SD CERTO + DMARD		0.00(-0.51,0.50)

(Continued)

LD ADA SC	0.01(-0.44,0.45)
LD ANA	0.13(-0.42,0.66)
LD ADA SC + MTX	0.10(-0.51,0.72)
LD RITUX IV + MTX	0.25(-0.36,0.87)
LD ADA IV + MTX	0.08(-0.63,0.79)
LD CERTO SC + MTX	0.17(-0.51,0.86)
LD ETN SC + MTX	0.01(-0.64,0.65)
LD TOFA PO + MTX	0.02(-0.68,0.72)
HD TOCI IV	0.06(-0.53,0.64)
HD TOFA PO	-0.19(-0.63,0.24)
HD ADA SC	-0.10(-0.56,0.35)
HD ANA	0.03(-0.53,0.57)
HD GOLI SC	0.42(-0.26,1.11)
HD TOCI IV + MTX	0.07(-0.52,0.66)
HD CERTO SC + MTX	0.04(-0.57,0.65)
HD TOFA PO + MTX	-0.14(-0.84,0.56)
HD GOLI SC + MTX	0.41(-0.23,1.04)
HD ADA SC + MTX	0.07(-0.62,0.74)
SD RITUX IV	SD ANA -0.12(-0.86,0.63)
SD ETN SC + MTX	-0.38(-0.97,0.22)
SD CERTO SC + MTX	-0.04(-0.68,0.60)
SD RITUX IV + MTX	0.07(-0.59,0.74)
SD ADA SC + MTX	-0.07(-0.73,0.60)
SD GOLI SC + MTX	0.25(-0.43,0.94)
SD TOFA PO + MTX	-0.19(-0.92,0.55)
SD TOCI IV + MTX	0.05(-0.62,0.72)
SD ABA SC + MTX	0.03(-0.76,0.82)
SD GOLI IV + MTX	0.56(-0.19,1.31)

(Continued)

SD ETN SC + DMARD		-0.07(-0.75,0.61)
SD CERTO + DMARD		-0.13(-0.70,0.43)
LD ADA SC		-0.12(-0.63,0.40)
LD ANA		0.00(-0.43,0.43)
LD ADA SC + MTX		-0.03(-0.69,0.65)
LD RITUX IV + MTX		0.13(-0.53,0.81)
LD ADA IV + MTX		-0.05(-0.80,0.71)
LD CERTO SC + MTX		0.04(-0.68,0.78)
LD ETN SC + MTX		-0.12(-0.81,0.58)
LD TOFA PO + MTX		-0.11(-0.85,0.64)
HD TOCI IV		-0.07(-0.70,0.56)
HD TOFA PO		-0.31(-0.83,0.19)
HD ADA SC		-0.23(-0.75,0.29)
HD ANA		-0.10(-0.54,0.33)
HD GOLI SC		0.29(-0.43,1.02)
HD TOCI IV + MTX		-0.06(-0.69,0.59)
HD CERTO SC + MTX		-0.08(-0.74,0.58)
HD TOFA PO + MTX		-0.27(-0.99,0.48)
HD GOLI SC + MTX		0.28(-0.40,0.97)
HD ADA SC + MTX		-0.07(-0.78,0.66)
SD ETN SC + MTX	SD RITUX IV	-0.25(-0.74,0.23)
SD CERTO SC + MTX		0.08(-0.38,0.54)
SD RITUX IV + MTX		0.19(-0.23,0.61)
SD ADA SC + MTX		0.06(-0.43,0.55)
SD GOLI SC + MTX		0.37(-0.15,0.89)
SD TOFA PO + MTX		-0.07(-0.65,0.52)
SD TOCI IV + MTX		0.17(-0.33,0.67)
SD ABA SC + MTX		0.15(-0.49,0.80)

(Continued)

SD GOLI IV + MTX		0.68(0.08,1.27)
SD ETN SC + DMARD		0.05(-0.60,0.71)
SD CERTO + DMARD		-0.01(-0.63,0.61)
LD ADA SC		0.01(-0.68,0.68)
LD ANA		0.13(-0.64,0.86)
LD ADA SC + MTX		0.10(-0.39,0.60)
LD RITUX IV + MTX		0.25(-0.17,0.68)
LD ADA IV + MTX		0.08(-0.53,0.69)
LD CERTO SC + MTX		0.17(-0.41,0.74)
LD ETN SC + MTX		0.01(-0.57,0.57)
LD TOFA PO + MTX		0.01(-0.57,0.60)
HD TOCI IV		0.05(-0.45,0.56)
HD TOFA PO		-0.19(-0.86,0.47)
HD ADA SC		-0.10(-0.80,0.57)
HD ANA		0.02(-0.73,0.77)
HD GOLI SC		0.42(-0.15,0.99)
HD TOCI IV + MTX		0.07(-0.41,0.54)
HD CERTO SC + MTX		0.04(-0.43,0.52)
HD TOFA PO + MTX		-0.14(-0.73,0.44)
HD GOLI SC + MTX		0.40(-0.11,0.92)
HD ADA SC + MTX		0.06(-0.51,0.63)
SD CERTO SC + MTX	SD ETN SC + MTX	0.34(0.03,0.64)
SD RITUX IV + MTX		0.44(0.10,0.80)
SD ADA SC + MTX		0.31(-0.03,0.65)
SD GOLI SC + MTX		0.62(0.24,1.01)
SD TOFA PO + MTX		0.19(-0.28,0.66)
SD TOCI IV + MTX		0.42(0.06,0.79)
SD ABA SC + MTX		0.41(-0.14,0.95)

(Continued)

SD GOLI IV + MTX		0.93(0.45,1.42)
SD ETN SC + DMARD		0.30(-0.19,0.80)
SD CERTO + DMARD		0.25(-0.20,0.70)
LD ADA SC		0.26(-0.25,0.77)
LD ANA		0.38(-0.22,0.97)
LD ADA SC + MTX		0.35(0.00,0.71)
LD RITUX IV + MTX		0.50(0.16,0.86)
LD ADA IV + MTX		0.33(-0.17,0.83)
LD CERTO SC + MTX		0.42(-0.03,0.89)
LD ETN SC + MTX		0.26(-0.12,0.64)
LD TOFA PO + MTX		0.27(-0.21,0.74)
HD TOCI IV		0.30(-0.03,0.64)
HD TOFA PO		0.06(-0.43,0.55)
HD ADA SC		0.15(-0.37,0.66)
HD ANA		0.28(-0.32,0.88)
HD GOLI SC		0.67(0.22,1.13)
HD TOCI IV + MTX		0.32(0.01,0.64)
HD CERTO SC + MTX		0.30(-0.03,0.63)
HD TOFA PO + MTX		0.11(-0.36,0.59)
HD GOLI SC + MTX		0.66(0.28,1.04)
HD ADA SC + MTX		0.31(-0.13,0.77)
SD RITUX IV + MTX	SD CERTO SC + MTX	0.11(-0.21,0.43)
SD ADA SC + MTX		-0.03(-0.34,0.29)
SD GOLI SC + MTX		0.29(-0.07,0.65)
SD TOFA PO + MTX		-0.15(-0.60,0.30)
SD TOCI IV + MTX		0.09(-0.26,0.43)
SD ABA SC + MTX		0.07(-0.45,0.59)
SD GOLI IV + MTX		0.60(0.14,1.06)

(Continued)

SD ETN SC + DMARD	-0.03(-0.56,0.50)	
SD CERTO + DMARD	-0.09(-0.59,0.41)	
LD ADA SC	-0.07(-0.64,0.48)	
LD ANA	0.04(-0.61,0.68)	
LD ADA SC + MTX	0.02(-0.31,0.35)	
LD RITUX IV + MTX	0.17(-0.15,0.49)	
LD ADA IV + MTX	-0.01(-0.49,0.48)	
LD CERTO SC + MTX	0.09(-0.31,0.48)	
LD ETN SC + MTX	-0.08(-0.51,0.36)	
LD TOFA PO + MTX	-0.07(-0.52,0.38)	
HD TOCI IV	-0.03(-0.37,0.31)	
HD TOFA PO	-0.27(-0.83,0.27)	
HD ADA SC	-0.19(-0.76,0.38)	
HD ANA	-0.06(-0.71,0.59)	
HD GOLI SC	0.34(-0.10,0.77)	
HD TOCI IV + MTX	-0.01(-0.31,0.28)	
HD CERTO SC + MTX	-0.04(-0.27,0.19)	
HD TOFA PO + MTX	-0.23(-0.68,0.23)	
HD GOLI SC + MTX	0.32(-0.04,0.68)	
HD ADA SC + MTX	-0.02(-0.45,0.42)	
SD ADA SC + MTX	SD RITUX IV + MTX	-0.14(-0.49,0.22)
SD GOLI SC + MTX	0.18(-0.22,0.58)	
SD TOFA PO + MTX	-0.26(-0.74,0.22)	
SD TOCI IV + MTX	-0.02(-0.40,0.36)	
SD ABA SC + MTX	-0.04(-0.59,0.52)	
SD GOLI IV + MTX	0.49(-0.01,0.98)	
SD ETN SC + DMARD	-0.14(-0.70,0.42)	
SD CERTO + DMARD	-0.20(-0.72,0.33)	

(Continued)

LD ADA SC	-0.18(-0.78,0.40)
LD ANA	-0.07(-0.74,0.59)
LD ADA SC + MTX	-0.09(-0.46,0.28)
LD RITUX IV + MTX	0.06(-0.20,0.32)
LD ADA IV + MTX	-0.12(-0.62,0.40)
LD CERTO SC + MTX	-0.02(-0.50,0.45)
LD ETN SC + MTX	-0.19(-0.65,0.28)
LD TOFA PO + MTX	-0.18(-0.67,0.31)
HD TOCI IV	-0.14(-0.52,0.24)
HD TOFA PO	-0.38(-0.97,0.19)
HD ADA SC	-0.30(-0.89,0.29)
HD ANA	-0.17(-0.85,0.49)
HD GOLI SC	0.23(-0.24,0.70)
HD TOCI IV + MTX	-0.12(-0.46,0.22)
HD CERTO SC + MTX	-0.15(-0.49,0.20)
HD TOFA PO + MTX	-0.34(-0.82,0.15)
HD GOLI SC + MTX	0.21(-0.19,0.61)
HD ADA SC + MTX	-0.13(-0.59,0.34)
SD GOLI SC + MTX	SD ADA SC + MTX 0.32(-0.09,0.71)
SD TOFA PO + MTX	-0.12(-0.60,0.36)
SD TOCI IV + MTX	0.11(-0.26,0.49)
SD ABA SC + MTX	0.10(-0.45,0.65)
SD GOLI IV + MTX	0.62(0.13,1.11)
SD ETN SC + DMARD	-0.01(-0.56,0.55)
SD CERTO + DMARD	-0.06(-0.58,0.45)
LD ADA SC	-0.05(-0.64,0.54)
LD ANA	0.07(-0.60,0.72)
LD ADA SC + MTX	0.04(-0.24,0.33)

(Continued)

LD RITUX IV + MTX		0.20(-0.17,0.55)
LD ADA IV + MTX		0.02(-0.46,0.51)
LD CERTO SC + MTX		0.11(-0.36,0.58)
LD ETN SC + MTX		-0.05(-0.51,0.41)
LD TOFA PO + MTX		-0.04(-0.53,0.44)
HD TOCI IV		0.00(-0.39,0.37)
HD TOFA PO		-0.25(-0.82,0.33)
HD ADA SC		-0.16(-0.75,0.42)
HD ANA		-0.03(-0.70,0.63)
HD GOLI SC		0.37(-0.10,0.83)
HD TOCI IV + MTX		0.01(-0.33,0.35)
HD CERTO SC + MTX		-0.01(-0.36,0.33)
HD TOFA PO + MTX		-0.20(-0.68,0.28)
HD GOLI SC + MTX		0.35(-0.05,0.74)
HD ADA SC + MTX		0.00(-0.39,0.40)
SD TOFA PO + MTX	SD GOLI SC + MTX	-0.44(-0.95,0.07)
SD TOCI IV + MTX		-0.20(-0.61,0.22)
SD ABA SC + MTX		-0.22(-0.79,0.36)
SD GOLI IV + MTX		0.31(-0.21,0.83)
SD ETN SC + DMARD		-0.32(-0.90,0.27)
SD CERTO + DMARD		-0.38(-0.93,0.18)
LD ADA SC		-0.36(-0.98,0.25)
LD ANA		-0.25(-0.93,0.44)
LD ADA SC + MTX		-0.27(-0.67,0.14)
LD RITUX IV + MTX		-0.12(-0.52,0.28)
LD ADA IV + MTX		-0.29(-0.83,0.25)
LD CERTO SC + MTX		-0.20(-0.70,0.30)
LD ETN SC + MTX		-0.36(-0.86,0.13)

(Continued)

LD TOFA PO + MTX	-0.36(-0.87,0.16)
HD TOCI IV	-0.32(-0.74,0.09)
HD TOFA PO	-0.56(-1.17,0.04)
HD ADA SC	-0.48(-1.10,0.13)
HD ANA	-0.35(-1.04,0.34)
HD GOLI SC	0.05(-0.35,0.45)
HD TOCI IV + MTX	-0.30(-0.68,0.08)
HD CERTO SC + MTX	-0.33(-0.71,0.05)
HD TOFA PO + MTX	-0.51(-1.03,-0.01)
HD GOLI SC + MTX	0.03(-0.28,0.34)
HD ADA SC + MTX	-0.31(-0.80,0.19)
SD TOCI IV + MTX	SD TOFA PO + MTX 0.24(-0.26,0.73)
SD ABA SC + MTX	0.22(-0.42,0.85)
SD GOLI IV + MTX	0.75(0.16,1.34)
SD ETN SC + DMARD	0.11(-0.52,0.76)
SD CERTO + DMARD	0.06(-0.55,0.67)
LD ADA SC	0.08(-0.60,0.74)
LD ANA	0.19(-0.55,0.92)
LD ADA SC + MTX	0.17(-0.32,0.66)
LD RITUX IV + MTX	0.32(-0.16,0.80)
LD ADA IV + MTX	0.14(-0.46,0.75)
LD CERTO SC + MTX	0.23(-0.33,0.80)
LD ETN SC + MTX	0.07(-0.49,0.63)
LD TOFA PO + MTX	0.08(-0.33,0.49)
HD TOCI IV	0.12(-0.38,0.61)
HD TOFA PO	-0.12(-0.79,0.53)
HD ADA SC	-0.04(-0.72,0.63)
HD ANA	0.09(-0.65,0.82)

(Continued)

HD GOLI SC		0.49(-0.08,1.05)
HD TOCI IV + MTX		0.13(-0.33,0.60)
HD CERTO SC + MTX		0.11(-0.36,0.58)
HD TOFA PO + MTX		-0.08(-0.48,0.33)
HD GOLI SC + MTX		0.47(-0.04,0.98)
HD ADA SC + MTX		0.12(-0.43,0.69)
SD ABA SC + MTX	SD TOCI IV + MTX	-0.02(-0.58,0.55)
SD GOLI IV + MTX		0.51(0.00,1.02)
SD ETN SC + DMARD		-0.12(-0.67,0.44)
SD CERTO + DMARD		-0.17(-0.71,0.35)
LD ADA SC		-0.16(-0.75,0.43)
LD ANA		-0.05(-0.72,0.62)
LD ADA SC + MTX		-0.07(-0.45,0.32)
LD RITUX IV + MTX		0.08(-0.30,0.46)
LD ADA IV + MTX		-0.09(-0.62,0.44)
LD CERTO SC + MTX		0.00(-0.49,0.49)
LD ETN SC + MTX		-0.16(-0.64,0.31)
LD TOFA PO + MTX		-0.16(-0.66,0.34)
HD TOCI IV		-0.12(-0.49,0.26)
HD TOFA PO		-0.36(-0.94,0.21)
HD ADA SC		-0.28(-0.87,0.31)
HD ANA		-0.15(-0.82,0.52)
HD GOLI SC		0.25(-0.23,0.73)
HD TOCI IV + MTX		-0.10(-0.38,0.18)
HD CERTO SC + MTX		-0.13(-0.49,0.24)
HD TOFA PO + MTX		-0.31(-0.81,0.18)
HD GOLI SC + MTX		0.23(-0.18,0.64)
HD ADA SC + MTX		-0.11(-0.59,0.37)

(Continued)

SD GOLI IV + MTX	SD ABA SC + MTX	0.53(-0.12,1.18)
SD ETN SC + DMARD		-0.10(-0.79,0.59)
SD CERTO + DMARD		-0.16(-0.83,0.51)
LD ADA SC		-0.14(-0.87,0.57)
LD ANA		-0.03(-0.82,0.75)
LD ADA SC + MTX		-0.05(-0.61,0.51)
LD RITUX IV + MTX		0.10(-0.45,0.65)
LD ADA IV + MTX		-0.08(-0.73,0.59)
LD CERTO SC + MTX		0.02(-0.61,0.65)
LD ETN SC + MTX		-0.14(-0.76,0.48)
LD TOFA PO + MTX		-0.14(-0.78,0.50)
HD TOCI IV		-0.10(-0.67,0.46)
HD TOFA PO		-0.34(-1.06,0.37)
HD ADA SC		-0.25(-0.99,0.46)
HD ANA		-0.13(-0.92,0.65)
HD GOLI SC		0.27(-0.35,0.89)
HD TOCI IV + MTX		-0.08(-0.62,0.45)
HD CERTO SC + MTX		-0.11(-0.65,0.43)
HD TOFA PO + MTX		-0.30(-0.93,0.34)
HD GOLI SC + MTX		0.25(-0.32,0.82)
HD ADA SC + MTX		-0.09(-0.72,0.54)
SD ETN SC + DMARD	SD GOLI IV + MTX	-0.63(-1.28,0.02)
SD CERTO + DMARD		-0.69(-1.31,-0.07)
LD ADA SC		-0.67(-1.35,0.00)
LD ANA		-0.56(-1.30,0.19)
LD ADA SC + MTX		-0.58(-1.07,-0.08)
LD RITUX IV + MTX		-0.43(-0.92,0.06)
LD ADA IV + MTX		-0.61(-1.21,0.01)

(Continued)

LD CERTO SC + MTX		-0.51(-1.09,0.06)
LD ETN SC + MTX		-0.68(-1.24,-0.11)
LD TOFA PO + MTX		-0.67(-1.26,-0.07)
HD TOCI IV		-0.63(-1.14,-0.12)
HD TOFA PO		-0.87(-1.55,-0.20)
HD ADA SC		-0.78(-1.47,-0.11)
HD ANA		-0.66(-1.41,0.09)
HD GOLI SC		-0.26(-0.83,0.32)
HD TOCI IV + MTX		-0.61(-1.09,-0.13)
HD CERTO SC + MTX		-0.64(-1.12,-0.16)
HD TOFA PO + MTX		-0.82(-1.42,-0.24)
HD GOLI SC + MTX		-0.28(-0.79,0.25)
HD ADA SC + MTX		-0.62(-1.19,-0.04)
SD CERTO + DMARD	SD ETN SC + DMARD	-0.05(-0.56,0.45)
LD ADA SC		-0.04(-0.66,0.57)
LD ANA		0.08(-0.61,0.75)
LD ADA SC + MTX		0.05(-0.52,0.61)
LD RITUX IV + MTX		0.20(-0.36,0.76)
LD ADA IV + MTX		0.03(-0.64,0.69)
LD CERTO SC + MTX		0.12(-0.52,0.75)
LD ETN SC + MTX		-0.04(-0.64,0.55)
LD TOFA PO + MTX		-0.04(-0.69,0.60)
HD TOCI IV		0.00(-0.49,0.48)
HD TOFA PO		-0.24(-0.85,0.35)
HD ADA SC		-0.16(-0.78,0.46)
HD ANA		-0.03(-0.72,0.65)
HD GOLI SC		0.37(-0.26,1.00)
HD TOCI IV + MTX		0.02(-0.50,0.54)

(Continued)

HD CERTO SC + MTX		-0.01(-0.56,0.54)
HD TOFA PO + MTX		-0.19(-0.84,0.44)
HD GOLI SC + MTX		0.35(-0.23,0.93)
HD ADA SC + MTX		0.01(-0.62,0.64)
LD ADA SC	SD CERTO + DMARD	0.01(-0.46,0.49)
LD ANA		0.13(-0.43,0.69)
LD ADA SC + MTX		0.10(-0.42,0.63)
LD RITUX IV + MTX		0.25(-0.26,0.78)
LD ADA IV + MTX		0.08(-0.56,0.72)
LD CERTO SC + MTX		0.17(-0.43,0.78)
LD ETN SC + MTX		0.01(-0.56,0.58)
LD TOFA PO + MTX		0.02(-0.60,0.64)
HD TOCI IV		0.06(-0.41,0.52)
HD TOFA PO		-0.19(-0.64,0.27)
HD ADA SC		-0.10(-0.57,0.37)
HD ANA		0.03(-0.54,0.60)
HD GOLI SC		0.42(-0.17,1.03)
HD TOCI IV + MTX		0.07(-0.41,0.57)
HD CERTO SC + MTX		0.05(-0.46,0.57)
HD TOFA PO + MTX		-0.14(-0.75,0.48)
HD GOLI SC + MTX		0.41(-0.14,0.96)
HD ADA SC + MTX		0.07(-0.53,0.67)
LD ANA	LD ADA SC	0.11(-0.40,0.63)
LD ADA SC + MTX		0.09(-0.50,0.69)
LD RITUX IV + MTX		0.24(-0.35,0.84)
LD ADA IV + MTX		0.07(-0.62,0.76)
LD CERTO SC + MTX		0.16(-0.50,0.82)
LD ETN SC + MTX		0.00(-0.62,0.62)

(Continued)

LD TOFA PO + MTX		0.00(-0.67,0.69)
HD TOCI IV		0.04(-0.51,0.60)
HD TOFA PO		-0.20(-0.58,0.18)
HD ADA SC		-0.12(-0.43,0.20)
HD ANA		0.01(-0.51,0.53)
HD GOLI SC		0.41(-0.25,1.08)
HD TOCI IV + MTX		0.06(-0.50,0.62)
HD CERTO SC + MTX		0.03(-0.54,0.62)
HD TOFA PO + MTX		-0.15(-0.82,0.53)
HD GOLI SC + MTX		0.39(-0.21,1.01)
HD ADA SC + MTX		0.05(-0.60,0.71)
LD ADA SC + MTX	LD ANA	-0.02(-0.68,0.65)
LD RITUX IV + MTX		0.12(-0.53,0.80)
LD ADA IV + MTX		-0.05(-0.80,0.72)
LD CERTO SC + MTX		0.04(-0.68,0.78)
LD ETN SC + MTX		-0.12(-0.81,0.57)
LD TOFA PO + MTX		-0.11(-0.85,0.64)
HD TOCI IV		-0.07(-0.70,0.56)
HD TOFA PO		-0.31(-0.82,0.19)
HD ADA SC		-0.23(-0.74,0.29)
HD ANA		-0.10(-0.53,0.33)
HD GOLI SC		0.30(-0.42,1.02)
HD TOCI IV + MTX		-0.05(-0.69,0.59)
HD CERTO SC + MTX		-0.08(-0.73,0.58)
HD TOFA PO + MTX		-0.27(-1.00,0.48)
HD GOLI SC + MTX		0.28(-0.40,0.97)
HD ADA SC + MTX		-0.06(-0.78,0.67)
LD RITUX IV + MTX	LD ADA SC + MTX	0.15(-0.22,0.52)

(Continued)

LD ADA IV + MTX	-0.02(-0.49,0.44)	
LD CERTO SC + MTX	0.07(-0.41,0.54)	
LD ETN SC + MTX	-0.09(-0.56,0.37)	
LD TOFA PO + MTX	-0.09(-0.58,0.40)	
HD TOCI IV	-0.05(-0.44,0.34)	
HD TOFA PO	-0.29(-0.88,0.28)	
HD ADA SC	-0.20(-0.81,0.38)	
HD ANA	-0.08(-0.75,0.59)	
HD GOLI SC	0.32(-0.16,0.79)	
HD TOCI IV + MTX	-0.03(-0.38,0.32)	
HD CERTO SC + MTX	-0.06(-0.42,0.30)	
HD TOFA PO + MTX	-0.24(-0.73,0.24)	
HD GOLI SC + MTX	0.30(-0.10,0.71)	
HD ADA SC + MTX	-0.04(-0.44,0.36)	
LD ADA IV + MTX	LD RITUX IV + MTX	-0.17(-0.68,0.34)
LD CERTO SC + MTX	-0.08(-0.55,0.39)	
LD ETN SC + MTX	-0.25(-0.71,0.22)	
LD TOFA PO + MTX	-0.24(-0.72,0.25)	
HD TOCI IV	-0.20(-0.59,0.18)	
HD TOFA PO	-0.44(-1.03,0.14)	
HD ADA SC	-0.36(-0.96,0.23)	
HD ANA	-0.23(-0.91,0.44)	
HD GOLI SC	0.17(-0.30,0.64)	
HD TOCI IV + MTX	-0.18(-0.52,0.16)	
HD CERTO SC + MTX	-0.21(-0.56,0.14)	
HD TOFA PO + MTX	-0.39(-0.88,0.09)	
HD GOLI SC + MTX	0.15(-0.24,0.55)	
HD ADA SC + MTX	-0.19(-0.66,0.28)	

(Continued)

LD CERTO SC + MTX	LD ADA IV + MTX	0.09(-0.51,0.69)
LD ETN SC + MTX		-0.07(-0.66,0.51)
LD TOFA PO + MTX		-0.06(-0.68,0.54)
HD TOCI IV		-0.03(-0.55,0.50)
HD TOFA PO		-0.27(-0.95,0.41)
HD ADA SC		-0.18(-0.88,0.51)
HD ANA		-0.06(-0.82,0.70)
HD GOLI SC		0.34(-0.25,0.93)
HD TOCI IV + MTX		-0.01(-0.51,0.49)
HD CERTO SC + MTX		-0.04(-0.54,0.47)
HD TOFA PO + MTX		-0.22(-0.83,0.38)
HD GOLI SC + MTX		0.33(-0.21,0.86)
HD ADA SC + MTX		-0.02(-0.59,0.55)
LD ETN SC + MTX	LD CERTO SC + MTX	-0.16(-0.71,0.39)
LD TOFA PO + MTX		-0.16(-0.73,0.42)
HD TOCI IV		-0.11(-0.61,0.37)
HD TOFA PO		-0.36(-1.01,0.29)
HD ADA SC		-0.27(-0.94,0.39)
HD ANA		-0.14(-0.88,0.59)
HD GOLI SC		0.25(-0.30,0.81)
HD TOCI IV + MTX		-0.10(-0.56,0.36)
HD CERTO SC + MTX		-0.13(-0.53,0.28)
HD TOFA PO + MTX		-0.31(-0.88,0.26)
HD GOLI SC + MTX		0.23(-0.26,0.74)
HD ADA SC + MTX		-0.11(-0.66,0.45)
LD TOFA PO + MTX	LD ETN SC + MTX	0.00(-0.55,0.57)
HD TOCI IV		0.05(-0.42,0.51)
HD TOFA PO		-0.20(-0.81,0.42)

(Continued)

HD ADA SC		-0.11(-0.73,0.51)
HD ANA		0.02(-0.69,0.71)
HD GOLI SC		0.41(-0.13,0.96)
HD TOCI IV + MTX		0.06(-0.38,0.50)
HD CERTO SC + MTX		0.04(-0.42,0.49)
HD TOFA PO + MTX		-0.15(-0.71,0.41)
HD GOLI SC + MTX		0.40(-0.09,0.89)
HD ADA SC + MTX		0.05(-0.49,0.60)
HD TOCI IV	LD TOFA PO + MTX	0.04(-0.46,0.53)
HD TOFA PO		-0.20(-0.88,0.46)
HD ADA SC		-0.12(-0.80,0.55)
HD ANA		0.01(-0.74,0.75)
HD GOLI SC		0.41(-0.16,0.98)
HD TOCI IV + MTX		0.06(-0.41,0.53)
HD CERTO SC + MTX		0.03(-0.45,0.50)
HD TOFA PO + MTX		-0.16(-0.57,0.26)
HD GOLI SC + MTX		0.39(-0.12,0.91)
HD ADA SC + MTX		0.05(-0.52,0.61)
HD TOFA PO	HD TOCI IV	-0.24(-0.79,0.30)
HD ADA SC		-0.16(-0.72,0.40)
HD ANA		-0.03(-0.67,0.61)
HD GOLI SC		0.37(-0.12,0.86)
HD TOCI IV + MTX		0.02(-0.28,0.32)
HD CERTO SC + MTX		-0.01(-0.38,0.36)
HD TOFA PO + MTX		-0.20(-0.69,0.30)
HD GOLI SC + MTX		0.35(-0.06,0.77)
HD ADA SC + MTX		0.01(-0.47,0.49)
HD ADA SC	HD TOFA PO	0.09(-0.30,0.47)

(Continued)

HD ANA		0.21(-0.30,0.73)
HD GOLI SC		0.61(-0.03,1.26)
HD TOCI IV + MTX		0.26(-0.28,0.81)
HD CERTO SC + MTX		0.23(-0.33,0.81)
HD TOFA PO + MTX		0.05(-0.62,0.72)
HD GOLI SC + MTX		0.59(0.00,1.20)
HD ADA SC + MTX		0.25(-0.39,0.90)
HD ANA	HD ADA SC	0.13(-0.39,0.65)
HD GOLI SC		0.53(-0.13,1.19)
HD TOCI IV + MTX		0.17(-0.38,0.74)
HD CERTO SC + MTX		0.15(-0.43,0.73)
HD TOFA PO + MTX		-0.04(-0.71,0.64)
HD GOLI SC + MTX		0.51(-0.10,1.13)
HD ADA SC + MTX		0.17(-0.48,0.82)
HD GOLI SC	HD ANA	0.40(-0.32,1.13)
HD TOCI IV + MTX		0.05(-0.59,0.69)
HD CERTO SC + MTX		0.02(-0.64,0.68)
HD TOFA PO + MTX		-0.17(-0.91,0.58)
HD GOLI SC + MTX		0.38(-0.31,1.08)
HD ADA SC + MTX		0.04(-0.68,0.78)
HD TOCI IV + MTX	HD GOLI SC	-0.35(-0.80,0.10)
HD CERTO SC + MTX		-0.38(-0.83,0.08)
HD TOFA PO + MTX		-0.56(-1.13,0.00)
HD GOLI SC + MTX		-0.02(-0.41,0.38)
HD ADA SC + MTX		-0.36(-0.91,0.19)
HD CERTO SC + MTX	HD TOCI IV + MTX	-0.03(-0.35,0.30)
HD TOFA PO + MTX		-0.21(-0.68,0.26)
HD GOLI SC + MTX		0.33(-0.04,0.71)

(Continued)

HD ADA SC + MTX		-0.01(-0.46,0.45)
HD TOFA PO + MTX	HD CERTO SC + MTX	-0.18(-0.66,0.29)
HD GOLI SC + MTX		0.36(-0.02,0.74)
HD ADA SC + MTX		0.02(-0.43,0.48)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.55(0.04,1.06)
HD ADA SC + MTX		0.21(-0.36,0.77)
HD ADA SC + MTX	HD GOLI SC + MTX	-0.34(-0.84,0.15)
Random-effects model	Total residual de- viance	125.3 vs 127 data points
	Deviance informa- tion criteria	-289.413
Note		
Total participants	16,355	
Total studies	48	
2-arm	25	
3-arm	15	
4-arm	8	

Appendix 8. HAQ: subgroup - established RA (2-10 years)

HAQ established: mean difference (MD) for all treatment comparisons - random-effects model

Treatment	Reference	MD (95% CrI)
MTX	PL	0.04(-0.46,0.56)
DMARD		0.04(-0.44,0.52)
MTX + DMARD		-0.31(-0.92,0.31)
SD ETN SC		-0.34(-0.76,0.09)
SD ADA SC		-0.27(-0.58,0.04)
SD TOFA PO		-0.40(-0.72,-0.09)
SD CERTO SC		-0.32(-0.70,0.07)

(Continued)

SD ANA		-0.20(-0.70,0.31)
SD ETN SC + MTX		-0.59(-1.07,-0.09)
SD CERTO SC + MTX		-0.25(-0.80,0.32)
SD GOLI SC + MTX		0.04(-0.58,0.66)
SD TOFA PO + MTX		-0.39(-1.09,0.31)
SD RITUX IV + MTX		0.04(-0.66,0.77)
SD ADA SC + MTX		-0.26(-0.97,0.48)
SD TOCI IV + MTX		-0.12(-0.78,0.56)
SD ABA SC + MTX		-0.18(-0.92,0.57)
SD GOLI IV + MTX		0.35(-0.35,1.07)
SD CERTO SC + DMARD		-0.33(-0.77,0.11)
SD ETN SC + DMARD		-0.46(-1.17,0.24)
LD ADA SC		-0.31(-0.66,0.04)
LD ANA		-0.20(-0.69,0.30)
LD RITUX IV + MTX		0.14(-0.56,0.87)
LD CERTO SC + MTX		-0.16(-0.84,0.53)
LD ETN SC + MTX		-0.32(-0.96,0.33)
LD TOFA PO + MTX		-0.31(-1.01,0.39)
HD TOCI IV		-0.27(-0.82,0.28)
HD TOFA PO		-0.52(-0.84,-0.20)
HD ADA SC		-0.42(-0.77,-0.07)
HD ANA		-0.30(-0.81,0.21)
HD GOLI SC		0.09(-0.58,0.78)
HD TOCI IV + MTX		-0.24(-0.81,0.34)
HD CERTO SC + MTX		-0.29(-0.86,0.30)
HD TOFA PO + MTX		-0.47(-1.16,0.23)
HD GOLI SC + MTX		0.07(-0.54,0.70)
DMARD	MTX	-0.01(-0.41,0.40)

(Continued)

MTX + DMARD	-0.35(-0.81,0.12)
SD ETN SC	-0.38(-0.69,-0.07)
SD ADA SC	-0.31(-0.91,0.27)
SD TOFA PO	-0.45(-1.06,0.14)
SD CERTO SC	-0.36(-1.00,0.28)
SD ANA	-0.24(-0.96,0.46)
SD ETN SC + MTX	-0.63(-0.90,-0.36)
SD CERTO SC + MTX	-0.29(-0.51,-0.07)
SD GOLI SC + MTX	0.00(-0.36,0.35)
SD TOFA PO + MTX	-0.43(-0.91,0.05)
SD RITUX IV + MTX	0.00(-0.50,0.51)
SD ADA SC + MTX	-0.30(-0.82,0.22)
SD TOCI IV + MTX	-0.16(-0.61,0.29)
SD ABA SC + MTX	-0.22(-0.78,0.33)
SD GOLI IV + MTX	0.31(-0.18,0.81)
SD CERTO SC + DMARD	-0.37(-0.91,0.15)
SD ETN SC + DMARD	-0.51(-1.17,0.16)
LD ADA SC	-0.35(-0.98,0.26)
LD ANA	-0.24(-0.96,0.47)
LD RITUX IV + MTX	0.10(-0.41,0.61)
LD CERTO SC + MTX	-0.20(-0.66,0.26)
LD ETN SC + MTX	-0.36(-0.82,0.09)
LD TOFA PO + MTX	-0.35(-0.84,0.13)
HD TOCI IV	-0.31(-0.66,0.03)
HD TOFA PO	-0.56(-1.17,0.03)
HD ADA SC	-0.47(-1.09,0.14)
HD ANA	-0.34(-1.06,0.36)
HD GOLI SC	0.05(-0.40,0.51)

(Continued)

HD TOCI IV + MTX		-0.29(-0.59,0.02)
HD CERTO SC + MTX		-0.33(-0.60,-0.06)
HD TOFA PO + MTX		-0.51(-0.98,-0.03)
HD GOL I SC + MTX		0.03(-0.32,0.39)
MTX + DMARD	DMARD	-0.34(-0.90,0.22)
SD ETN SC		-0.38(-0.74,-0.01)
SD ADA SC		-0.31(-0.89,0.26)
SD TOFA PO		-0.44(-1.02,0.13)
SD CERTO SC		-0.35(-0.97,0.27)
SD ANA		-0.23(-0.93,0.46)
SD ETN SC + MTX		-0.62(-1.03,-0.21)
SD CERTO SC + MTX		-0.28(-0.75,0.19)
SD GOL I SC + MTX		0.00(-0.54,0.55)
SD TOFA PO + MTX		-0.43(-1.06,0.20)
SD RITUX IV + MTX		0.00(-0.64,0.66)
SD ADA SC + MTX		-0.29(-0.95,0.36)
SD TOCI IV + MTX		-0.15(-0.74,0.44)
SD ABA SC + MTX		-0.22(-0.90,0.47)
SD GOL I IV + MTX		0.32(-0.32,0.95)
SD CERTO SC + DMARD		-0.37(-0.80,0.06)
SD ETN SC + DMARD		-0.50(-1.01,0.02)
LD ADA SC		-0.35(-0.94,0.24)
LD ANA		-0.23(-0.93,0.46)
LD RITUX IV + MTX		0.10(-0.55,0.76)
LD CERTO SC + MTX		-0.20(-0.81,0.42)
LD ETN SC + MTX		-0.36(-0.93,0.22)
LD TOFA PO + MTX		-0.35(-0.98,0.28)
HD TOCI IV		-0.31(-0.70,0.09)

(Continued)

HD TOFA PO		-0.55(-1.13,0.02)
HD ADA SC		-0.46(-1.06,0.13)
HD ANA		-0.34(-1.03,0.36)
HD GOLI SC		0.06(-0.55,0.67)
HD TOCI IV + MTX		-0.28(-0.75,0.19)
HD CERTO SC + MTX		-0.33(-0.81,0.16)
HD TOFA PO + MTX		-0.51(-1.13,0.12)
HD GOLI SC + MTX		0.04(-0.50,0.57)
SD ETN SC	MTX + DMARD	-0.04(-0.48,0.41)
SD ADA SC		0.03(-0.66,0.72)
SD TOFA PO		-0.10(-0.80,0.59)
SD CERTO SC		-0.01(-0.74,0.71)
SD ANA		0.11(-0.69,0.90)
SD ETN SC + MTX		-0.28(-0.66,0.10)
SD CERTO SC + MTX		0.06(-0.46,0.57)
SD GOLI SC + MTX		0.34(-0.24,0.93)
SD TOFA PO + MTX		-0.09(-0.75,0.58)
SD RITUX IV + MTX		0.35(-0.33,1.03)
SD ADA SC + MTX		0.05(-0.65,0.74)
SD TOCI IV + MTX		0.19(-0.44,0.83)
SD ABA SC + MTX		0.13(-0.60,0.84)
SD GOLI IV + MTX		0.66(-0.01,1.34)
SD CERTO SC + DMARD		-0.03(-0.67,0.61)
SD ETN SC + DMARD		-0.16(-0.92,0.60)
LD ADA SC		0.00(-0.72,0.70)
LD ANA		0.11(-0.68,0.90)
LD RITUX IV + MTX		0.45(-0.24,1.13)
LD CERTO SC + MTX		0.14(-0.51,0.80)

(Continued)

LD ETN SC + MTX		-0.02(-0.61,0.57)
LD TOFA PO + MTX		-0.01(-0.68,0.67)
HD TOCI IV		0.03(-0.51,0.59)
HD TOFA PO		-0.21(-0.91,0.47)
HD ADA SC		-0.12(-0.83,0.59)
HD ANA		0.01(-0.79,0.80)
HD GOLI SC		0.40(-0.25,1.05)
HD TOCI IV + MTX		0.06(-0.48,0.61)
HD CERTO SC + MTX		0.01(-0.52,0.55)
HD TOFA PO + MTX		-0.16(-0.83,0.50)
HD GOLI SC + MTX		0.38(-0.20,0.96)
SD ADA SC	SD ETN SC	0.07(-0.46,0.59)
SD TOFA PO		-0.06(-0.60,0.46)
SD CERTO SC		0.02(-0.55,0.61)
SD ANA		0.14(-0.52,0.80)
SD ETN SC + MTX		-0.25(-0.49,0.00)
SD CERTO SC + MTX		0.09(-0.29,0.48)
SD GOLI SC + MTX		0.38(-0.09,0.85)
SD TOFA PO + MTX		-0.05(-0.62,0.52)
SD RITUX IV + MTX		0.38(-0.21,0.98)
SD ADA SC + MTX		0.08(-0.52,0.69)
SD TOCI IV + MTX		0.22(-0.31,0.77)
SD ABA SC + MTX		0.16(-0.48,0.80)
SD GOLI IV + MTX		0.69(0.11,1.28)
SD CERTO SC + DMARD		0.01(-0.47,0.48)
SD ETN SC + DMARD		-0.12(-0.76,0.51)
LD ADA SC		0.03(-0.53,0.58)
LD ANA		0.14(-0.52,0.80)

(Continued)

LD RITUX IV + MTX		0.48(-0.11,1.08)
LD CERTO SC + MTX		0.18(-0.37,0.74)
LD ETN SC + MTX		0.02(-0.47,0.51)
LD TOFA PO + MTX		0.03(-0.55,0.60)
HD TOCI IV		0.07(-0.33,0.47)
HD TOFA PO		-0.18(-0.71,0.35)
HD ADA SC		-0.08(-0.64,0.47)
HD ANA		0.04(-0.62,0.70)
HD GOLI SC		0.43(-0.11,0.98)
HD TOCI IV + MTX		0.10(-0.32,0.52)
HD CERTO SC + MTX		0.05(-0.36,0.46)
HD TOFA PO + MTX		-0.13(-0.69,0.44)
HD GOLI SC + MTX		0.41(-0.06,0.89)
SD TOFA PO	SD ADA SC	-0.13(-0.51,0.24)
SD CERTO SC		-0.04(-0.54,0.45)
SD ANA		0.07(-0.51,0.66)
SD ETN SC + MTX		-0.31(-0.88,0.26)
SD CERTO SC + MTX		0.02(-0.61,0.66)
SD GOLI SC + MTX		0.31(-0.37,1.01)
SD TOFA PO + MTX		-0.12(-0.88,0.65)
SD RITUX IV + MTX		0.31(-0.45,1.10)
SD ADA SC + MTX		0.01(-0.77,0.81)
SD TOCI IV + MTX		0.16(-0.57,0.90)
SD ABA SC + MTX		0.09(-0.72,0.90)
SD GOLI IV + MTX		0.62(-0.13,1.40)
SD CERTO SC + DMARD		-0.06(-0.59,0.47)
SD ETN SC + DMARD		-0.19(-0.96,0.58)
LD ADA SC		-0.04(-0.39,0.31)

(Continued)

LD ANA		0.07(-0.51,0.66)
LD RITUX IV + MTX		0.41(-0.36,1.20)
LD CERTO SC + MTX		0.11(-0.64,0.87)
LD ETN SC + MTX		-0.05(-0.75,0.66)
LD TOFA PO + MTX		-0.04(-0.81,0.73)
HD TOCI IV		0.00(-0.62,0.63)
HD TOFA PO		-0.24(-0.62,0.12)
HD ADA SC		-0.15(-0.50,0.20)
HD ANA		-0.03(-0.62,0.56)
HD GOLI SC		0.36(-0.37,1.12)
HD TOCI IV + MTX		0.03(-0.61,0.69)
HD CERTO SC + MTX		-0.02(-0.67,0.64)
HD TOFA PO + MTX		-0.20(-0.95,0.57)
HD GOLI SC + MTX		0.35(-0.34,1.04)
SD CERTO SC	SD TOFA PO	0.09(-0.41,0.59)
SD ANA		0.21(-0.38,0.81)
SD ETN SC + MTX		-0.18(-0.75,0.41)
SD CERTO SC + MTX		0.16(-0.48,0.81)
SD GOLI SC + MTX		0.44(-0.25,1.15)
SD TOFA PO + MTX		0.01(-0.75,0.78)
SD RITUX IV + MTX		0.44(-0.32,1.24)
SD ADA SC + MTX		0.15(-0.64,0.95)
SD TOCI IV + MTX		0.29(-0.44,1.04)
SD ABA SC + MTX		0.22(-0.59,1.04)
SD GOLI IV + MTX		0.76(-0.01,1.54)
SD CERTO SC + DMARD		0.07(-0.47,0.61)
SD ETN SC + DMARD		-0.06(-0.83,0.72)
LD ADA SC		0.09(-0.35,0.54)

(Continued)

LD ANA		0.21(-0.39,0.80)
LD RITUX IV + MTX		0.54(-0.23,1.33)
LD CERTO SC + MTX		0.24(-0.51,1.01)
LD ETN SC + MTX		0.08(-0.62,0.80)
LD TOFA PO + MTX		0.09(-0.67,0.87)
HD TOCI IV		0.13(-0.50,0.77)
HD TOFA PO		-0.11(-0.42,0.19)
HD ADA SC		-0.02(-0.46,0.43)
HD ANA		0.11(-0.49,0.70)
HD GOLI SC		0.50(-0.24,1.26)
HD TOCI IV + MTX		0.16(-0.49,0.82)
HD CERTO SC + MTX		0.11(-0.54,0.78)
HD TOFA PO + MTX		-0.06(-0.82,0.70)
HD GOLI SC + MTX		0.48(-0.21,1.18)
SD ANA	SD CERTO SC	0.12(-0.52,0.75)
SD ETN SC + MTX		-0.27(-0.89,0.35)
SD CERTO SC + MTX		0.07(-0.61,0.75)
SD GOLI SC + MTX		0.36(-0.38,1.08)
SD TOFA PO + MTX		-0.07(-0.87,0.73)
SD RITUX IV + MTX		0.36(-0.45,1.17)
SD ADA SC + MTX		0.06(-0.76,0.88)
SD TOCI IV + MTX		0.20(-0.57,0.98)
SD ABA SC + MTX		0.14(-0.71,0.98)
SD GOLI IV + MTX		0.67(-0.14,1.48)
SD CERTO SC + DMARD		-0.02(-0.60,0.56)
SD ETN SC + DMARD		-0.15(-0.97,0.66)
LD ADA SC		0.01(-0.51,0.53)
LD ANA		0.12(-0.52,0.75)

(Continued)

LD RITUX IV + MTX		0.46(-0.35,1.27)
LD CERTO SC + MTX		0.16(-0.63,0.94)
LD ETN SC + MTX		-0.01(-0.76,0.75)
LD TOFA PO + MTX		0.00(-0.80,0.81)
HD TOCI IV		0.05(-0.63,0.72)
HD TOFA PO		-0.20(-0.71,0.30)
HD ADA SC		-0.11(-0.63,0.41)
HD ANA		0.02(-0.62,0.65)
HD GOLI SC		0.41(-0.37,1.20)
HD TOCI IV + MTX		0.07(-0.62,0.77)
HD CERTO SC + MTX		0.03(-0.67,0.72)
HD TOFA PO + MTX		-0.15(-0.94,0.64)
HD GOLI SC + MTX		0.39(-0.34,1.12)
SD ETN SC + MTX	SD ANA	-0.39(-1.09,0.31)
SD CERTO SC + MTX		-0.05(-0.79,0.70)
SD GOLI SC + MTX		0.24(-0.56,1.04)
SD TOFA PO + MTX		-0.19(-1.05,0.66)
SD RITUX IV + MTX		0.24(-0.62,1.12)
SD ADA SC + MTX		-0.06(-0.93,0.83)
SD TOCI IV + MTX		0.08(-0.75,0.93)
SD ABA SC + MTX		0.02(-0.89,0.93)
SD GOLI IV + MTX		0.55(-0.31,1.43)
SD CERTO SC + DMARD		-0.13(-0.81,0.53)
SD ETN SC + DMARD		-0.27(-1.13,0.60)
LD ADA SC		-0.11(-0.72,0.50)
LD ANA		0.00(-0.50,0.50)
LD RITUX IV + MTX		0.34(-0.53,1.22)
LD CERTO SC + MTX		0.04(-0.80,0.89)

(Continued)

LD ETN SC + MTX		-0.13(-0.94,0.70)
LD TOFA PO + MTX		-0.11(-0.98,0.75)
HD TOCI IV		-0.07(-0.81,0.67)
HD TOFA PO		-0.32(-0.91,0.27)
HD ADA SC		-0.23(-0.84,0.39)
HD ANA		-0.10(-0.61,0.41)
HD GOLI SC		0.29(-0.55,1.15)
HD TOCI IV + MTX		-0.05(-0.81,0.72)
HD CERTO SC + MTX		-0.09(-0.86,0.68)
HD TOFA PO + MTX		-0.27(-1.13,0.60)
HD GOLI SC + MTX		0.27(-0.52,1.08)
SD CERTO SC + MTX	SD ETN SC + MTX	0.34(-0.01,0.69)
SD GOLI SC + MTX		0.62(0.18,1.07)
SD TOFA PO + MTX		0.20(-0.35,0.75)
SD RITUX IV + MTX		0.63(0.06,1.20)
SD ADA SC + MTX		0.33(-0.26,0.91)
SD TOCI IV + MTX		0.47(-0.05,0.99)
SD ABA SC + MTX		0.41(-0.21,1.02)
SD GOLI IV + MTX		0.94(0.38,1.50)
SD CERTO SC + DMARD		0.25(-0.27,0.77)
SD ETN SC + DMARD		0.12(-0.54,0.78)
LD ADA SC		0.28(-0.33,0.87)
LD ANA		0.39(-0.31,1.08)
LD RITUX IV + MTX		0.73(0.15,1.30)
LD CERTO SC + MTX		0.43(-0.10,0.96)
LD ETN SC + MTX		0.26(-0.19,0.72)
LD TOFA PO + MTX		0.27(-0.28,0.83)
HD TOCI IV		0.31(-0.08,0.72)

(Continued)

HD TOFA PO		0.07(-0.52,0.64)
HD ADA SC		0.16(-0.43,0.75)
HD ANA		0.29(-0.42,0.98)
HD GOLI SC		0.68(0.16,1.21)
HD TOCI IV + MTX		0.34(-0.06,0.74)
HD CERTO SC + MTX		0.30(-0.09,0.68)
HD TOFA PO + MTX		0.12(-0.43,0.67)
HD GOLI SC + MTX		0.66(0.22,1.11)
SD GOLI SC + MTX	SD CERTO SC + MTX	0.29(-0.13,0.70)
SD TOFA PO + MTX		-0.14(-0.67,0.39)
SD RITUX IV + MTX		0.29(-0.26,0.84)
SD ADA SC + MTX		-0.01(-0.57,0.56)
SD TOCI IV + MTX		0.13(-0.37,0.64)
SD ABA SC + MTX		0.07(-0.53,0.66)
SD GOLI IV + MTX		0.60(0.06,1.15)
SD CERTO SC + DMARD		-0.08(-0.67,0.49)
SD ETN SC + DMARD		-0.22(-0.91,0.48)
LD ADA SC		-0.06(-0.73,0.59)
LD ANA		0.05(-0.70,0.79)
LD RITUX IV + MTX		0.39(-0.17,0.94)
LD CERTO SC + MTX		0.09(-0.37,0.55)
LD ETN SC + MTX		-0.07(-0.59,0.43)
LD TOFA PO + MTX		-0.06(-0.60,0.47)
HD TOCI IV		-0.02(-0.43,0.39)
HD TOFA PO		-0.27(-0.92,0.36)
HD ADA SC		-0.18(-0.84,0.47)
HD ANA		-0.05(-0.80,0.69)
HD GOLI SC		0.34(-0.16,0.85)

(Continued)

HD TOCI IV + MTX		0.00(-0.38,0.39)
HD CERTO SC + MTX		-0.04(-0.32,0.23)
HD TOFA PO + MTX		-0.22(-0.75,0.30)
HD GOLI SC + MTX		0.32(-0.10,0.74)
SD TOFA PO + MTX	SD GOLI SC + MTX	-0.43(-1.03,0.17)
SD RITUX IV + MTX		0.00(-0.62,0.63)
SD ADA SC + MTX		-0.30(-0.92,0.33)
SD TOCI IV + MTX		-0.15(-0.73,0.42)
SD ABA SC + MTX		-0.22(-0.88,0.44)
SD GOLI IV + MTX		0.31(-0.30,0.92)
SD CERTO SC + DMARD		-0.37(-1.01,0.26)
SD ETN SC + DMARD		-0.50(-1.26,0.25)
LD ADA SC		-0.35(-1.06,0.36)
LD ANA		-0.24(-1.04,0.55)
LD RITUX IV + MTX		0.10(-0.52,0.73)
LD CERTO SC + MTX		-0.20(-0.78,0.38)
LD ETN SC + MTX		-0.36(-0.93,0.21)
LD TOFA PO + MTX		-0.35(-0.95,0.25)
HD TOCI IV		-0.31(-0.80,0.18)
HD TOFA PO		-0.56(-1.26,0.13)
HD ADA SC		-0.46(-1.18,0.24)
HD ANA		-0.34(-1.14,0.45)
HD GOLI SC		0.05(-0.40,0.52)
HD TOCI IV + MTX		-0.28(-0.75,0.19)
HD CERTO SC + MTX		-0.33(-0.78,0.12)
HD TOFA PO + MTX		-0.51(-1.10,0.09)
HD GOLI SC + MTX		0.03(-0.32,0.40)
SD RITUX IV + MTX	SD TOFA PO + MTX	0.43(-0.27,1.12)

(Continued)

SD ADA SC + MTX	0.13(-0.57,0.84)
SD TOCI IV + MTX	0.27(-0.38,0.93)
SD ABA SC + MTX	0.21(-0.52,0.94)
SD GOLI IV + MTX	0.74(0.05,1.43)
SD CERTO SC + DMARD	0.06(-0.66,0.77)
SD ETN SC + DMARD	-0.07(-0.89,0.74)
LD ADA SC	0.08(-0.71,0.86)
LD ANA	0.19(-0.67,1.05)
LD RITUX IV + MTX	0.53(-0.17,1.24)
LD CERTO SC + MTX	0.23(-0.44,0.89)
LD ETN SC + MTX	0.07(-0.59,0.73)
LD TOFA PO + MTX	0.08(-0.41,0.56)
HD TOCI IV	0.12(-0.47,0.71)
HD TOFA PO	-0.13(-0.90,0.64)
HD ADA SC	-0.03(-0.82,0.75)
HD ANA	0.09(-0.77,0.95)
HD GOLI SC	0.48(-0.17,1.15)
HD TOCI IV + MTX	0.15(-0.43,0.72)
HD CERTO SC + MTX	0.10(-0.44,0.65)
HD TOFA PO + MTX	-0.08(-0.55,0.41)
HD GOLI SC + MTX	0.46(-0.13,1.06)
SD ADA SC + MTX	SD RITUX IV + MTX -0.30(-1.02,0.42)
SD TOCI IV + MTX	-0.16(-0.83,0.52)
SD ABA SC + MTX	-0.22(-0.97,0.53)
SD GOLI IV + MTX	0.31(-0.39,1.02)
SD CERTO SC + DMARD	-0.37(-1.11,0.36)
SD ETN SC + DMARD	-0.51(-1.34,0.33)
LD ADA SC	-0.35(-1.16,0.44)

(Continued)

LD ANA		-0.24(-1.12,0.61)
LD RITUX IV + MTX		0.10(-0.41,0.61)
LD CERTO SC + MTX		-0.20(-0.89,0.49)
LD ETN SC + MTX		-0.36(-1.04,0.32)
LD TOFA PO + MTX		-0.35(-1.05,0.35)
HD TOCI IV		-0.31(-0.92,0.29)
HD TOFA PO		-0.56(-1.35,0.21)
HD ADA SC		-0.46(-1.26,0.32)
HD ANA		-0.34(-1.23,0.52)
HD GOLI SC		0.05(-0.64,0.73)
HD TOCI IV + MTX		-0.29(-0.88,0.30)
HD CERTO SC + MTX		-0.33(-0.91,0.25)
HD TOFA PO + MTX		-0.51(-1.20,0.19)
HD GOLI SC + MTX		0.03(-0.59,0.65)
SD TOCI IV + MTX	SD ADA SC + MTX	0.14(-0.54,0.82)
SD ABA SC + MTX		0.08(-0.68,0.83)
SD GOLI IV + MTX		0.61(-0.10,1.33)
SD CERTO SC + DMARD		-0.07(-0.82,0.66)
SD ETN SC + DMARD		-0.21(-1.05,0.63)
LD ADA SC		-0.05(-0.87,0.75)
LD ANA		0.06(-0.83,0.93)
LD RITUX IV + MTX		0.40(-0.32,1.13)
LD CERTO SC + MTX		0.10(-0.59,0.79)
LD ETN SC + MTX		-0.06(-0.75,0.62)
LD TOFA PO + MTX		-0.05(-0.76,0.65)
HD TOCI IV		-0.01(-0.64,0.60)
HD TOFA PO		-0.26(-1.06,0.53)
HD ADA SC		-0.17(-0.99,0.64)

(Continued)

HD ANA		-0.04(-0.93,0.83)
HD GOLI SC		0.35(-0.34,1.04)
HD TOCI IV + MTX		0.01(-0.59,0.62)
HD CERTO SC + MTX		-0.03(-0.62,0.55)
HD TOFA PO + MTX		-0.21(-0.91,0.49)
HD GOLI SC + MTX		0.33(-0.30,0.96)
SD ABA SC + MTX	SD TOCI IV + MTX	-0.06(-0.78,0.65)
SD GOLI IV + MTX		0.47(-0.20,1.14)
SD CERTO SC + DMARD		-0.22(-0.90,0.47)
SD ETN SC + DMARD		-0.35(-1.13,0.43)
LD ADA SC		-0.19(-0.96,0.55)
LD ANA		-0.08(-0.92,0.75)
LD RITUX IV + MTX		0.26(-0.42,0.94)
LD CERTO SC + MTX		-0.04(-0.68,0.60)
LD ETN SC + MTX		-0.21(-0.85,0.43)
LD TOFA PO + MTX		-0.20(-0.86,0.46)
HD TOCI IV		-0.16(-0.68,0.38)
HD TOFA PO		-0.40(-1.15,0.33)
HD ADA SC		-0.31(-1.07,0.44)
HD ANA		-0.18(-1.03,0.65)
HD GOLI SC		0.21(-0.43,0.85)
HD TOCI IV + MTX		-0.13(-0.58,0.32)
HD CERTO SC + MTX		-0.17(-0.70,0.35)
HD TOFA PO + MTX		-0.35(-1.00,0.30)
HD GOLI SC + MTX		0.19(-0.38,0.76)
SD GOLI IV + MTX	SD ABA SC + MTX	0.53(-0.21,1.28)
SD CERTO SC + DMARD		-0.15(-0.92,0.61)
SD ETN SC + DMARD		-0.29(-1.15,0.58)

(Continued)

LD ADA SC		-0.13(-0.95,0.70)
LD ANA		-0.02(-0.92,0.88)
LD RITUX IV + MTX		0.32(-0.43,1.07)
LD CERTO SC + MTX		0.02(-0.70,0.75)
LD ETN SC + MTX		-0.14(-0.86,0.58)
LD TOFA PO + MTX		-0.13(-0.87,0.60)
HD TOCI IV		-0.09(-0.74,0.56)
HD TOFA PO		-0.34(-1.16,0.47)
HD ADA SC		-0.24(-1.07,0.58)
HD ANA		-0.12(-1.03,0.78)
HD GOLI SC		0.27(-0.45,1.00)
HD TOCI IV + MTX		-0.07(-0.69,0.58)
HD CERTO SC + MTX		-0.11(-0.73,0.52)
HD TOFA PO + MTX		-0.29(-1.02,0.45)
HD GOLI SC + MTX		0.25(-0.40,0.91)
SD CERTO SC + DMARD	SD GOLI IV + MTX	-0.68(-1.41,0.03)
SD ETN SC + DMARD		-0.82(-1.63,0.01)
LD ADA SC		-0.66(-1.46,0.12)
LD ANA		-0.55(-1.43,0.30)
LD RITUX IV + MTX		-0.21(-0.92,0.50)
LD CERTO SC + MTX		-0.51(-1.19,0.17)
LD ETN SC + MTX		-0.68(-1.34,0.00)
LD TOFA PO + MTX		-0.66(-1.36,0.03)
HD TOCI IV		-0.62(-1.22,-0.03)
HD TOFA PO		-0.87(-1.65,-0.11)
HD ADA SC		-0.78(-1.57,0.01)
HD ANA		-0.65(-1.52,0.21)
HD GOLI SC		-0.26(-0.93,0.41)

(Continued)

HD TOCI IV + MTX		-0.60(-1.18,-0.02)
HD CERTO SC + MTX		-0.64(-1.21,-0.08)
HD TOFA PO + MTX		-0.82(-1.50,-0.13)
HD GOLI SC + MTX		-0.28(-0.89,0.33)
SD ETN SC + DMARD	SD CERTO SC + DMARD	-0.13(-0.81,0.55)
LD ADA SC		0.02(-0.53,0.58)
LD ANA		0.13(-0.53,0.80)
LD RITUX IV + MTX		0.47(-0.26,1.21)
LD CERTO SC + MTX		0.17(-0.52,0.88)
LD ETN SC + MTX		0.01(-0.66,0.67)
LD TOFA PO + MTX		0.02(-0.69,0.74)
HD TOCI IV		0.06(-0.49,0.61)
HD TOFA PO		-0.18(-0.72,0.35)
HD ADA SC		-0.09(-0.65,0.47)
HD ANA		0.03(-0.64,0.70)
HD GOLI SC		0.42(-0.27,1.13)
HD TOCI IV + MTX		0.09(-0.50,0.68)
HD CERTO SC + MTX		0.04(-0.55,0.65)
HD TOFA PO + MTX		-0.14(-0.85,0.57)
HD GOLI SC + MTX		0.41(-0.23,1.05)
LD ADA SC	SD ETN SC + DMARD	0.16(-0.64,0.94)
LD ANA		0.27(-0.61,1.14)
LD RITUX IV + MTX		0.61(-0.23,1.45)
LD CERTO SC + MTX		0.30(-0.50,1.11)
LD ETN SC + MTX		0.14(-0.64,0.92)
LD TOFA PO + MTX		0.15(-0.66,0.97)
HD TOCI IV		0.19(-0.46,0.85)

(Continued)

HD TOFA PO		-0.05(-0.83,0.72)
HD ADA SC		0.04(-0.75,0.83)
HD ANA		0.17(-0.71,1.03)
HD GOLI SC		0.56(-0.24,1.36)
HD TOCI IV + MTX		0.22(-0.48,0.92)
HD CERTO SC + MTX		0.17(-0.54,0.90)
HD TOFA PO + MTX		0.00(-0.81,0.81)
HD GOLI SC + MTX		0.54(-0.21,1.29)
LD ANA	LD ADA SC	0.11(-0.50,0.72)
LD RITUX IV + MTX		0.45(-0.34,1.25)
LD CERTO SC + MTX		0.15(-0.62,0.92)
LD ETN SC + MTX		-0.01(-0.74,0.73)
LD TOFA PO + MTX		0.00(-0.79,0.79)
HD TOCI IV		0.04(-0.61,0.69)
HD TOFA PO		-0.21(-0.65,0.23)
HD ADA SC		-0.11(-0.48,0.24)
HD ANA		0.01(-0.61,0.62)
HD GOLI SC		0.40(-0.36,1.18)
HD TOCI IV + MTX		0.06(-0.60,0.75)
HD CERTO SC + MTX		0.02(-0.65,0.71)
HD TOFA PO + MTX		-0.16(-0.93,0.62)
HD GOLI SC + MTX		0.38(-0.32,1.10)
LD RITUX IV + MTX	LD ANA	0.34(-0.52,1.22)
LD CERTO SC + MTX		0.04(-0.81,0.89)
LD ETN SC + MTX		-0.12(-0.92,0.69)
LD TOFA PO + MTX		-0.11(-0.97,0.75)
HD TOCI IV		-0.07(-0.81,0.67)
HD TOFA PO		-0.32(-0.91,0.27)

(Continued)

HD ADA SC		-0.23(-0.83,0.39)
HD ANA		-0.10(-0.60,0.40)
HD GOLI SC		0.29(-0.55,1.14)
HD TOCI IV + MTX		-0.05(-0.80,0.72)
HD CERTO SC + MTX		-0.09(-0.85,0.68)
HD TOFA PO + MTX		-0.27(-1.12,0.59)
HD GOLI SC + MTX		0.27(-0.52,1.07)
LD CERTO SC + MTX	LD RITUX IV + MTX	-0.30(-0.99,0.38)
LD ETN SC + MTX		-0.46(-1.14,0.21)
LD TOFA PO + MTX		-0.45(-1.15,0.25)
HD TOCI IV		-0.41(-1.03,0.19)
HD TOFA PO		-0.66(-1.45,0.12)
HD ADA SC		-0.56(-1.37,0.23)
HD ANA		-0.44(-1.32,0.43)
HD GOLI SC		-0.05(-0.73,0.63)
HD TOCI IV + MTX		-0.39(-0.98,0.21)
HD CERTO SC + MTX		-0.43(-1.01,0.15)
HD TOFA PO + MTX		-0.61(-1.30,0.09)
HD GOLI SC + MTX		-0.07(-0.69,0.56)
LD ETN SC + MTX	LD CERTO SC + MTX	-0.16(-0.81,0.48)
LD TOFA PO + MTX		-0.15(-0.82,0.52)
HD TOCI IV		-0.11(-0.68,0.46)
HD TOFA PO		-0.36(-1.11,0.39)
HD ADA SC		-0.26(-1.03,0.50)
HD ANA		-0.14(-1.00,0.71)
HD GOLI SC		0.25(-0.39,0.90)
HD TOCI IV + MTX		-0.08(-0.64,0.47)
HD CERTO SC + MTX		-0.13(-0.60,0.33)

(Continued)

HD TOFA PO + MTX		-0.31(-0.97,0.36)
HD GOLI SC + MTX		0.23(-0.35,0.82)
LD TOFA PO + MTX	LD ETN SC + MTX	0.01(-0.65,0.67)
HD TOCI IV		0.05(-0.50,0.61)
HD TOFA PO		-0.19(-0.92,0.51)
HD ADA SC		-0.10(-0.83,0.62)
HD ANA		0.02(-0.80,0.83)
HD GOLI SC		0.41(-0.23,1.06)
HD TOCI IV + MTX		0.08(-0.46,0.63)
HD CERTO SC + MTX		0.03(-0.49,0.56)
HD TOFA PO + MTX		-0.15(-0.80,0.51)
HD GOLI SC + MTX		0.40(-0.18,0.97)
HD TOCI IV	LD TOFA PO + MTX	0.04(-0.55,0.64)
HD TOFA PO		-0.20(-0.98,0.56)
HD ADA SC		-0.11(-0.90,0.68)
HD ANA		0.01(-0.86,0.88)
HD GOLI SC		0.40(-0.26,1.07)
HD TOCI IV + MTX		0.07(-0.50,0.65)
HD CERTO SC + MTX		0.02(-0.54,0.58)
HD TOFA PO + MTX		-0.16(-0.64,0.33)
HD GOLI SC + MTX		0.39(-0.22,0.98)
HD TOFA PO	HD TOCI IV	-0.25(-0.88,0.38)
HD ADA SC		-0.15(-0.81,0.50)
HD ANA		-0.03(-0.78,0.71)
HD GOLI SC		0.36(-0.20,0.94)
HD TOCI IV + MTX		0.03(-0.34,0.40)
HD CERTO SC + MTX		-0.02(-0.46,0.42)
HD TOFA PO + MTX		-0.20(-0.78,0.39)

(Continued)

HD GOLI SC + MTX		0.35(-0.15,0.83)
HD ADA SC	HD TOFA PO	0.09(-0.35,0.54)
HD ANA		0.22(-0.37,0.82)
HD GOLI SC		0.61(-0.13,1.37)
HD TOCI IV + MTX		0.27(-0.38,0.94)
HD CERTO SC + MTX		0.23(-0.42,0.89)
HD TOFA PO + MTX		0.05(-0.71,0.82)
HD GOLI SC + MTX		0.59(-0.09,1.29)
HD ANA	HD ADA SC	0.12(-0.49,0.74)
HD GOLI SC		0.52(-0.24,1.28)
HD TOCI IV + MTX		0.18(-0.48,0.85)
HD CERTO SC + MTX		0.13(-0.54,0.81)
HD TOFA PO + MTX		-0.05(-0.82,0.74)
HD GOLI SC + MTX		0.50(-0.20,1.21)
HD GOLI SC	HD ANA	0.39(-0.45,1.24)
HD TOCI IV + MTX		0.05(-0.71,0.83)
HD CERTO SC + MTX		0.01(-0.75,0.78)
HD TOFA PO + MTX		-0.17(-1.03,0.69)
HD GOLI SC + MTX		0.37(-0.42,1.17)
HD TOCI IV + MTX	HD GOLI SC	-0.34(-0.89,0.21)
HD CERTO SC + MTX		-0.38(-0.91,0.15)
HD TOFA PO + MTX		-0.56(-1.22,0.10)
HD GOLI SC + MTX		-0.02(-0.49,0.44)
HD CERTO SC + MTX	HD TOCI IV + MTX	-0.05(-0.46,0.36)
HD TOFA PO + MTX		-0.22(-0.79,0.34)
HD GOLI SC + MTX		0.32(-0.16,0.79)
HD TOFA PO + MTX	HD CERTO SC + MTX	-0.18(-0.72,0.37)
HD GOLI SC + MTX		0.36(-0.08,0.81)

(Continued)

HD GOLI SC + MTX	HD TOFA PO + MTX	0.54(-0.05,1.14)
Random-effects model	Total residual de- viance	99.73
	Deviance informa- tion criteria	-252.066
Fixed-effect model	Total residual de- viance	322.3
	Deviance informa- tion criteria	-52.613
Note		
Total participants	14,018	
Total studies	39	
2-arm	22	
3-arm	11	
4-arm	6	

Appendix 9. HAQ: subgroup - late RA (> 10 years)

HAQ late: mean difference (MD) for all treatment comparisons - random-effects model

Treatment	Reference	MD (95% CrI)
SD RITUX IV	MTX + PL	-0.44(-0.70,-0.18)
SD RITUX IV + MTX		-0.30(-0.45,-0.11)
SD ADA SC + MTX		-0.33(-0.49,-0.17)
SD TOCI IV + MTX		-0.26(-0.48,-0.04)
LD ADA SC + MTX		-0.31(-0.46,-0.15)
LD RITUX IV + MTX		-0.25(-0.42,-0.07)
LD ADA IV + MTX		-0.32(-0.67,0.03)
HD TOCI IV + MTX		-0.34(-0.56,-0.12)
HD ADA SC + MTX		-0.33(-0.55,-0.11)
SD RITUX IV + MTX	SD RITUX IV	0.14(-0.12,0.42)
SD ADA SC + MTX		0.11(-0.20,0.42)

(Continued)

SD TOCI IV + MTX		0.18(-0.17,0.52)
LD ADA SC + MTX		0.13(-0.17,0.44)
LD RITUX IV + MTX		0.19(-0.08,0.47)
LD ADA IV + MTX		0.12(-0.32,0.55)
HD TOCI IV + MTX		0.10(-0.24,0.45)
HD ADA SC + MTX		0.11(-0.24,0.47)
SD ADA SC + MTX	SD RITUX IV + MTX	-0.04(-0.28,0.19)
SD TOCI IV + MTX		0.04(-0.25,0.30)
LD ADA SC + MTX		-0.02(-0.24,0.21)
LD RITUX IV + MTX		0.05(-0.14,0.22)
LD ADA IV + MTX		-0.03(-0.42,0.36)
HD TOCI IV + MTX		-0.04(-0.34,0.22)
HD ADA SC + MTX		-0.04(-0.33,0.24)
SD TOCI IV + MTX	SD ADA SC + MTX	0.07(-0.20,0.35)
LD ADA SC + MTX		0.02(-0.13,0.19)
LD RITUX IV + MTX		0.08(-0.15,0.33)
LD ADA IV + MTX		0.01(-0.36,0.38)
HD TOCI IV + MTX		-0.01(-0.28,0.27)
HD ADA SC + MTX		0.00(-0.23,0.23)
LD ADA SC + MTX	SD TOCI IV + MTX	-0.05(-0.31,0.23)
LD RITUX IV + MTX		0.01(-0.27,0.30)
LD ADA IV + MTX		-0.06(-0.48,0.35)
HD TOCI IV + MTX		-0.08(-0.30,0.14)
HD ADA SC + MTX		-0.07(-0.38,0.24)
LD RITUX IV + MTX	LD ADA SC + MTX	0.06(-0.17,0.29)
LD ADA IV + MTX		-0.01(-0.38,0.35)
HD TOCI IV + MTX		-0.03(-0.30,0.23)
HD ADA SC + MTX		-0.02(-0.25,0.20)

(Continued)

LD ADA IV + MTX	LD RITUX IV + MTX	-0.07(-0.47,0.31)
HD TOCI IV + MTX		-0.09(-0.38,0.18)
HD ADA SC + MTX		-0.08(-0.37,0.20)
HD TOCI IV + MTX	LD ADA IV + MTX	-0.02(-0.42,0.40)
HD ADA SC + MTX		-0.01(-0.41,0.40)
HD ADA SC + MTX	HD TOCI IV + MTX	0.01(-0.31,0.32)
Random-effects model	Total residual de- viance	19.24 vs 22 data point
	Deviance informa- tion criteria	-35.801
Fixed-effect model	Total residual de- viance	19.04 vs 22 data point
	Deviance informa- tion criteria	-37.435
Note		
Total participants	2084	
Total studies	7	
2-arm	1	
3-arm	4	
4-arm	2	

Appendix 10. HAQ: subgroup - trial duration (<= 6 months)

HAQ short duration: mean difference (MD) for all treatment comparisons - random-effects model		
Treatment	Reference	MD (95% CrI)
MTX + PL	PL	1.08(0.60,1.58)
DMARD + PL		-0.01(-0.30,0.29)
MTX + DMARD		-0.15(-0.56,0.25)
SD ETN SC		-0.31(-0.57,-0.05)
SD ADA SC + PL		-0.30(-0.45,-0.14)
SD TOFA PO		-0.39(-0.59,-0.20)

(Continued)

SD CERTO SC	-0.36(-0.60,-0.11)
SD ANA	-0.20(-0.49,0.09)
SD RITUX IV	0.65(0.08,1.23)
SD ETN SC + MTX	-0.42(-0.74,-0.09)
SD CERTO SC + MTX	0.80(0.30,1.31)
SD RITUX IV + MTX	0.80(0.28,1.34)
SD ADA SC + MTX	0.77(0.24,1.31)
SD GOLI SC + MTX	1.08(0.56,1.62)
SD TOFA PO + MTX	0.65(0.10,1.22)
SD TOCI IV + MTX	0.88(0.37,1.41)
SD ABA SC + MTX	0.86(0.25,1.47)
SD GOLI IV + MTX	1.40(0.84,1.96)
SD ETN SC + DMARD	-0.36(-0.75,0.04)
SD CERTO SC + DMARD	-0.35(-0.61,-0.09)
LD ADA SC	-0.32(-0.52,-0.12)
LD ANA	-0.20(-0.48,0.08)
LD ADA SC + MTX	0.86(0.33,1.42)
LD RITUX IV + MTX	0.84(0.31,1.38)
LD ADA IV + MTX	0.80(0.19,1.42)
LD CERTO SC + MTX	0.89(0.33,1.46)
LD TOFA PO + MTX	0.73(0.18,1.29)
HD TOFA PO	-0.51(-0.70,-0.32)
HD ADA SC	-0.44(-0.64,-0.23)
HD TOCI IV	0.88(0.33,1.45)
HD ANA	-0.30(-0.59,0.00)
HD GOLI SC	1.12(0.58,1.68)
HD TOCI IV + MTX	0.77(0.27,1.29)
HD CERTO SC + MTX	0.76(0.26,1.28)

(Continued)

HD TOFA PO + MTX		0.57(0.02,1.14)
HD GOLI SC + MTX		1.11(0.59,1.65)
HD ADA SC + MTX		0.79(0.23,1.37)
DMARD + PL	MTX + PL	-1.09(-1.56,-0.63)
MTX + DMARD		-1.24(-1.66,-0.82)
SD ETN SC		-1.39(-1.79,-1.01)
SD ADA SC + PL		-1.38(-1.89,-0.88)
SD TOFA PO		-1.48(-2.01,-0.96)
SD CERTO SC		-1.45(-1.99,-0.91)
SD ANA		-1.28(-1.85,-0.73)
SD RITUX IV		-0.44(-0.76,-0.11)
SD ETN SC + MTX		-1.50(-1.84,-1.17)
SD CERTO SC + MTX		-0.28(-0.41,-0.16)
SD RITUX IV + MTX		-0.28(-0.50,-0.06)
SD ADA SC + MTX		-0.31(-0.54,-0.09)
SD GOLI SC + MTX		0.00(-0.21,0.20)
SD TOFA PO + MTX		-0.44(-0.70,-0.17)
SD TOCI IV + MTX		-0.20(-0.39,-0.01)
SD ABA SC + MTX		-0.22(-0.59,0.15)
SD GOLI IV + MTX		0.31(0.03,0.59)
SD ETN SC + DMARD		-1.44(-1.97,-0.91)
SD CERTO SC + DMARD		-1.43(-1.94,-0.94)
LD ADA SC		-1.41(-1.93,-0.89)
LD ANA		-1.28(-1.84,-0.73)
LD ADA SC + MTX		-0.22(-0.49,0.04)
LD RITUX IV + MTX		-0.24(-0.47,-0.01)
LD ADA IV + MTX		-0.29(-0.69,0.11)
LD CERTO SC + MTX		-0.20(-0.49,0.09)

(Continued)

LD TOFA PO + MTX		-0.36(-0.62,-0.09)
HD TOFA PO		-1.59(-2.12,-1.08)
HD ADA SC		-1.52(-2.05,-1.00)
HD TOCI IV		-0.20(-0.48,0.09)
HD ANA		-1.38(-1.95,-0.82)
HD GOLI SC		0.04(-0.23,0.30)
HD TOCI IV + MTX		-0.31(-0.47,-0.14)
HD CERTO SC + MTX		-0.32(-0.48,-0.17)
HD TOFA PO + MTX		-0.52(-0.78,-0.25)
HD GOLI SC + MTX		0.03(-0.18,0.23)
HD ADA SC + MTX		-0.29(-0.59,0.00)
MTX + DMARD	DMARD + PL	-0.15(-0.53,0.24)
SD ETN SC		-0.30(-0.54,-0.06)
SD ADA SC + PL		-0.29(-0.62,0.05)
SD TOFA PO		-0.39(-0.74,-0.04)
SD CERTO SC		-0.36(-0.73,0.03)
SD ANA		-0.19(-0.60,0.23)
SD RITUX IV		0.65(0.09,1.23)
SD ETN SC + MTX		-0.41(-0.71,-0.11)
SD CERTO SC + MTX		0.81(0.34,1.30)
SD RITUX IV + MTX		0.81(0.30,1.34)
SD ADA SC + MTX		0.78(0.26,1.30)
SD GOLI SC + MTX		1.09(0.59,1.60)
SD TOFA PO + MTX		0.65(0.13,1.21)
SD TOCI IV + MTX		0.89(0.40,1.40)
SD ABA SC + MTX		0.87(0.28,1.46)
SD GOLI IV + MTX		1.40(0.87,1.95)
SD ETN SC + DMARD		-0.35(-0.61,-0.08)

(Continued)

SD CERTO SC + DMARD		-0.34(-0.60,-0.09)
LD ADA SC		-0.32(-0.67,0.04)
LD ANA		-0.19(-0.60,0.22)
LD ADA SC + MTX		0.87(0.34,1.41)
LD RITUX IV + MTX		0.85(0.34,1.38)
LD ADA IV + MTX		0.80(0.21,1.42)
LD CERTO SC + MTX		0.89(0.35,1.45)
LD TOFA PO + MTX		0.73(0.20,1.28)
HD TOFA PO		-0.50(-0.85,-0.15)
HD ADA SC		-0.43(-0.78,-0.07)
HD TOCI IV		0.89(0.36,1.44)
HD ANA		-0.29(-0.71,0.13)
HD GOLI SC		1.13(0.60,1.67)
HD TOCI IV + MTX		0.78(0.29,1.28)
HD CERTO SC + MTX		0.77(0.28,1.27)
HD TOFA PO + MTX		0.57(0.05,1.12)
HD GOLI SC + MTX		1.12(0.62,1.63)
HD ADA SC + MTX		0.80(0.25,1.36)
SD ETN SC	MTX + DMARD	-0.16(-0.46,0.14)
SD ADA SC + PL		-0.14(-0.58,0.29)
SD TOFA PO		-0.24(-0.69,0.20)
SD CERTO SC		-0.21(-0.68,0.26)
SD ANA		-0.04(-0.55,0.45)
SD RITUX IV		0.80(0.27,1.33)
SD ETN SC + MTX		-0.27(-0.51,-0.03)
SD CERTO SC + MTX		0.95(0.52,1.39)
SD RITUX IV + MTX		0.96(0.49,1.43)
SD ADA SC + MTX		0.92(0.44,1.40)

(Continued)

SD GOLI SC + MTX		1.23(0.77,1.70)
SD TOFA PO + MTX		0.80(0.31,1.30)
SD TOCI IV + MTX		1.04(0.58,1.50)
SD ABA SC + MTX		1.02(0.46,1.57)
SD GOLI IV + MTX		1.55(1.05,2.05)
SD ETN SC + DMARD		-0.20(-0.67,0.26)
SD CERTO SC + DMARD		-0.20(-0.62,0.22)
LD ADA SC		-0.17(-0.62,0.28)
LD ANA		-0.04(-0.54,0.44)
LD ADA SC + MTX		1.02(0.52,1.51)
LD RITUX IV + MTX		1.00(0.52,1.47)
LD ADA IV + MTX		0.95(0.38,1.52)
LD CERTO SC + MTX		1.04(0.53,1.55)
LD TOFA PO + MTX		0.88(0.38,1.38)
HD TOFA PO		-0.35(-0.80,0.09)
HD ADA SC		-0.28(-0.73,0.17)
HD TOCI IV		1.04(0.54,1.54)
HD ANA		-0.14(-0.65,0.35)
HD GOLI SC		1.27(0.78,1.77)
HD TOCI IV + MTX		0.93(0.48,1.38)
HD CERTO SC + MTX		0.91(0.47,1.36)
HD TOFA PO + MTX		0.72(0.23,1.22)
HD GOLI SC + MTX		1.27(0.81,1.74)
HD ADA SC + MTX		0.95(0.43,1.46)
SD ADA SC + PL	SD ETN SC	0.01(-0.29,0.31)
SD TOFA PO		-0.08(-0.41,0.23)
SD CERTO SC		-0.05(-0.40,0.31)
SD ANA		0.11(-0.28,0.50)

(Continued)

SD RITUX IV	0.96(0.45,1.47)
SD ETN SC + MTX	-0.11(-0.30,0.08)
SD CERTO SC + MTX	1.11(0.70,1.53)
SD RITUX IV + MTX	1.11(0.67,1.57)
SD ADA SC + MTX	1.08(0.62,1.53)
SD GOLI SC + MTX	1.39(0.95,1.84)
SD TOFA PO + MTX	0.96(0.49,1.44)
SD TOCI IV + MTX	1.19(0.76,1.63)
SD ABA SC + MTX	1.17(0.63,1.71)
SD GOLI IV + MTX	1.70(1.22,2.19)
SD ETN SC + DMARD	-0.05(-0.40,0.31)
SD CERTO SC + DMARD	-0.04(-0.33,0.25)
LD ADA SC	-0.01(-0.34,0.31)
LD ANA	0.11(-0.27,0.49)
LD ADA SC + MTX	1.17(0.70,1.65)
LD RITUX IV + MTX	1.15(0.70,1.61)
LD ADA IV + MTX	1.11(0.56,1.66)
LD CERTO SC + MTX	1.20(0.71,1.69)
LD TOFA PO + MTX	1.04(0.56,1.52)
HD TOFA PO	-0.20(-0.52,0.12)
HD ADA SC	-0.13(-0.46,0.20)
HD TOCI IV	1.19(0.71,1.68)
HD ANA	0.01(-0.38,0.40)
HD GOLI SC	1.43(0.96,1.91)
HD TOCI IV + MTX	1.08(0.66,1.51)
HD CERTO SC + MTX	1.07(0.65,1.50)
HD TOFA PO + MTX	0.88(0.41,1.36)
HD GOLI SC + MTX	1.42(0.98,1.87)

(Continued)

HD ADA SC + MTX		1.10(0.61,1.60)
SD TOFA PO	SD ADA SC + PL	-0.10(-0.33,0.13)
SD CERTO SC		-0.07(-0.36,0.23)
SD ANA		0.10(-0.24,0.43)
SD RITUX IV		0.94(0.35,1.55)
SD ETN SC + MTX		-0.12(-0.48,0.24)
SD CERTO SC + MTX		1.10(0.58,1.62)
SD RITUX IV + MTX		1.10(0.55,1.66)
SD ADA SC + MTX		1.07(0.51,1.63)
SD GOLI SC + MTX		1.38(0.83,1.93)
SD TOFA PO + MTX		0.94(0.37,1.54)
SD TOCI IV + MTX		1.18(0.65,1.73)
SD ABA SC + MTX		1.16(0.53,1.79)
SD GOLI IV + MTX		1.69(1.11,2.28)
SD ETN SC + DMARD		-0.06(-0.48,0.37)
SD CERTO SC + DMARD		-0.05(-0.36,0.25)
LD ADA SC		-0.03(-0.23,0.17)
LD ANA		0.10(-0.22,0.42)
LD ADA SC + MTX		1.16(0.60,1.74)
LD RITUX IV + MTX		1.14(0.59,1.70)
LD ADA IV + MTX		1.09(0.47,1.74)
LD CERTO SC + MTX		1.18(0.60,1.78)
LD TOFA PO + MTX		1.02(0.45,1.61)
HD TOFA PO		-0.21(-0.44,0.01)
HD ADA SC		-0.14(-0.34,0.06)
HD TOCI IV		1.18(0.61,1.77)
HD ANA		0.00(-0.34,0.34)
HD GOLI SC		1.42(0.86,2.00)

(Continued)

HD TOCI IV + MTX		1.07(0.54,1.61)
HD CERTO SC + MTX		1.06(0.53,1.60)
HD TOFA PO + MTX		0.86(0.30,1.46)
HD GOLI SC + MTX		1.41(0.87,1.96)
HD ADA SC + MTX		1.09(0.51,1.68)
SD CERTO SC	SD TOFA PO	0.03(-0.28,0.35)
SD ANA		0.19(-0.16,0.55)
SD RITUX IV		1.04(0.43,1.66)
SD ETN SC + MTX		-0.03(-0.40,0.36)
SD CERTO SC + MTX		1.19(0.66,1.74)
SD RITUX IV + MTX		1.20(0.64,1.77)
SD ADA SC + MTX		1.16(0.60,1.74)
SD GOLI SC + MTX		1.47(0.92,2.05)
SD TOFA PO + MTX		1.04(0.47,1.65)
SD TOCI IV + MTX		1.27(0.73,1.84)
SD ABA SC + MTX		1.26(0.62,1.90)
SD GOLI IV + MTX		1.79(1.20,2.39)
SD ETN SC + DMARD		0.04(-0.39,0.48)
SD CERTO SC + DMARD		0.04(-0.28,0.37)
LD ADA SC		0.07(-0.19,0.34)
LD ANA		0.19(-0.14,0.54)
LD ADA SC + MTX		1.26(0.69,1.85)
LD RITUX IV + MTX		1.24(0.68,1.81)
LD ADA IV + MTX		1.19(0.55,1.85)
LD CERTO SC + MTX		1.28(0.69,1.89)
LD TOFA PO + MTX		1.12(0.54,1.72)
HD TOFA PO		-0.11(-0.30,0.07)
HD ADA SC		-0.04(-0.31,0.23)

(Continued)

HD TOCI IV		1.28(0.69,1.88)
HD ANA		0.10(-0.26,0.46)
HD GOLI SC		1.51(0.95,2.11)
HD TOCI IV + MTX		1.17(0.63,1.73)
HD CERTO SC + MTX		1.15(0.62,1.71)
HD TOFA PO + MTX		0.96(0.39,1.57)
HD GOLI SC + MTX		1.50(0.96,2.08)
HD ADA SC + MTX		1.18(0.60,1.79)
SD ANA	SD CERTO SC	0.16(-0.23,0.54)
SD RITUX IV		1.01(0.38,1.64)
SD ETN SC + MTX		-0.06(-0.47,0.35)
SD CERTO SC + MTX		1.16(0.61,1.72)
SD RITUX IV + MTX		1.17(0.58,1.75)
SD ADA SC + MTX		1.13(0.55,1.71)
SD GOLI SC + MTX		1.44(0.86,2.02)
SD TOFA PO + MTX		1.01(0.41,1.62)
SD TOCI IV + MTX		1.25(0.68,1.82)
SD ABA SC + MTX		1.23(0.57,1.88)
SD GOLI IV + MTX		1.76(1.15,2.37)
SD ETN SC + DMARD		0.01(-0.46,0.47)
SD CERTO SC + DMARD		0.01(-0.35,0.37)
LD ADA SC		0.04(-0.28,0.35)
LD ANA		0.16(-0.22,0.53)
LD ADA SC + MTX		1.23(0.63,1.83)
LD RITUX IV + MTX		1.21(0.62,1.79)
LD ADA IV + MTX		1.16(0.49,1.83)
LD CERTO SC + MTX		1.25(0.63,1.87)
LD TOFA PO + MTX		1.09(0.49,1.70)

(Continued)

HD TOFA PO		-0.14(-0.46,0.17)
HD ADA SC		-0.07(-0.39,0.24)
HD TOCI IV		1.25(0.64,1.86)
HD ANA		0.07(-0.32,0.44)
HD GOLI SC		1.48(0.89,2.08)
HD TOCI IV + MTX		1.14(0.57,1.70)
HD CERTO SC + MTX		1.12(0.56,1.69)
HD TOFA PO + MTX		0.93(0.33,1.54)
HD GOLI SC + MTX		1.48(0.90,2.06)
HD ADA SC + MTX		1.16(0.54,1.77)
SD RITUX IV	SD ANA	0.85(0.20,1.50)
SD ETN SC + MTX		-0.22(-0.66,0.22)
SD CERTO SC + MTX		1.00(0.43,1.58)
SD RITUX IV + MTX		1.00(0.40,1.61)
SD ADA SC + MTX		0.97(0.37,1.59)
SD GOLI SC + MTX		1.28(0.68,1.89)
SD TOFA PO + MTX		0.85(0.23,1.48)
SD TOCI IV + MTX		1.08(0.50,1.68)
SD ABA SC + MTX		1.06(0.39,1.74)
SD GOLI IV + MTX		1.59(0.97,2.23)
SD ETN SC + DMARD		-0.16(-0.65,0.34)
SD CERTO SC + DMARD		-0.15(-0.55,0.24)
LD ADA SC		-0.12(-0.48,0.23)
LD ANA		0.00(-0.29,0.29)
LD ADA SC + MTX		1.06(0.45,1.69)
LD RITUX IV + MTX		1.04(0.44,1.65)
LD ADA IV + MTX		1.00(0.32,1.69)
LD CERTO SC + MTX		1.09(0.45,1.72)

(Continued)

LD TOFA PO + MTX		0.93(0.31,1.56)
HD TOFA PO		-0.31(-0.66,0.04)
HD ADA SC		-0.24(-0.59,0.12)
HD TOCI IV		1.08(0.46,1.72)
HD ANA		-0.10(-0.40,0.20)
HD GOLI SC		1.32(0.71,1.95)
HD TOCI IV + MTX		0.97(0.40,1.57)
HD CERTO SC + MTX		0.96(0.38,1.55)
HD TOFA PO + MTX		0.77(0.15,1.41)
HD GOLI SC + MTX		1.31(0.71,1.92)
HD ADA SC + MTX		0.99(0.36,1.63)
SD ETN SC + MTX	SD RITUX IV	-1.07(-1.54,-0.60)
SD CERTO SC + MTX		0.15(-0.20,0.51)
SD RITUX IV + MTX		0.16(-0.17,0.49)
SD ADA SC + MTX		0.12(-0.27,0.52)
SD GOLI SC + MTX		0.43(0.05,0.82)
SD TOFA PO + MTX		0.00(-0.42,0.42)
SD TOCI IV + MTX		0.23(-0.14,0.61)
SD ABA SC + MTX		0.22(-0.27,0.71)
SD GOLI IV + MTX		0.75(0.32,1.18)
SD ETN SC + DMARD		-1.00(-1.63,-0.37)
SD CERTO SC + DMARD		-1.00(-1.60,-0.40)
LD ADA SC		-0.97(-1.59,-0.36)
LD ANA		-0.85(-1.49,-0.21)
LD ADA SC + MTX		0.22(-0.20,0.63)
LD RITUX IV + MTX		0.20(-0.14,0.53)
LD ADA IV + MTX		0.15(-0.37,0.67)
LD CERTO SC + MTX		0.24(-0.20,0.68)

(Continued)

LD TOFA PO + MTX		0.08(-0.34,0.50)
HD TOFA PO		-1.15(-1.77,-0.55)
HD ADA SC		-1.08(-1.70,-0.48)
HD TOCI IV		0.24(-0.19,0.67)
HD ANA		-0.94(-1.60,-0.30)
HD GOLI SC		0.47(0.06,0.90)
HD TOCI IV + MTX		0.13(-0.24,0.49)
HD CERTO SC + MTX		0.11(-0.25,0.47)
HD TOFA PO + MTX		-0.08(-0.50,0.34)
HD GOLI SC + MTX		0.46(0.08,0.85)
HD ADA SC + MTX		0.14(-0.30,0.58)
SD CERTO SC + MTX	SD ETN SC + MTX	1.22(0.86,1.58)
SD RITUX IV + MTX		1.22(0.82,1.63)
SD ADA SC + MTX		1.19(0.78,1.60)
SD GOLI SC + MTX		1.50(1.11,1.90)
SD TOFA PO + MTX		1.07(0.64,1.51)
SD TOCI IV + MTX		1.30(0.92,1.69)
SD ABA SC + MTX		1.28(0.78,1.78)
SD GOLI IV + MTX		1.81(1.38,2.25)
SD ETN SC + DMARD		0.06(-0.34,0.47)
SD CERTO SC + DMARD		0.07(-0.28,0.42)
LD ADA SC		0.10(-0.28,0.48)
LD ANA		0.22(-0.21,0.65)
LD ADA SC + MTX		1.28(0.85,1.71)
LD RITUX IV + MTX		1.26(0.86,1.67)
LD ADA IV + MTX		1.22(0.70,1.74)
LD CERTO SC + MTX		1.31(0.86,1.76)
LD TOFA PO + MTX		1.15(0.72,1.58)

(Continued)

HD TOFA PO		-0.09(-0.47,0.29)
HD ADA SC		-0.02(-0.40,0.37)
HD TOCI IV		1.31(0.87,1.75)
HD ANA		0.12(-0.32,0.56)
HD GOLI SC		1.54(1.12,1.98)
HD TOCI IV + MTX		1.19(0.82,1.57)
HD CERTO SC + MTX		1.18(0.81,1.55)
HD TOFA PO + MTX		0.99(0.56,1.42)
HD GOLI SC + MTX		1.53(1.14,1.93)
HD ADA SC + MTX		1.21(0.76,1.66)
SD RITUX IV + MTX	SD CERTO SC + MTX	0.00(-0.25,0.26)
SD ADA SC + MTX		-0.03(-0.29,0.23)
SD GOLI SC + MTX		0.28(0.03,0.52)
SD TOFA PO + MTX		-0.15(-0.45,0.15)
SD TOCI IV + MTX		0.08(-0.15,0.31)
SD ABA SC + MTX		0.06(-0.33,0.45)
SD GOLI IV + MTX		0.59(0.29,0.90)
SD ETN SC + DMARD		-1.16(-1.71,-0.61)
SD CERTO SC + DMARD		-1.15(-1.67,-0.64)
LD ADA SC		-1.12(-1.66,-0.59)
LD ANA		-1.00(-1.58,-0.43)
LD ADA SC + MTX		0.06(-0.24,0.36)
LD RITUX IV + MTX		0.04(-0.22,0.31)
LD ADA IV + MTX		0.00(-0.42,0.42)
LD CERTO SC + MTX		0.09(-0.21,0.38)
LD TOFA PO + MTX		-0.07(-0.37,0.22)
HD TOFA PO		-1.31(-1.85,-0.77)
HD ADA SC		-1.24(-1.78,-0.70)

(Continued)

HD TOCI IV		0.08(-0.23,0.40)
HD ANA		-1.10(-1.68,-0.52)
HD GOLI SC		0.32(0.03,0.62)
HD TOCI IV + MTX		-0.03(-0.23,0.19)
HD CERTO SC + MTX		-0.04(-0.19,0.11)
HD TOFA PO + MTX		-0.23(-0.53,0.07)
HD GOLI SC + MTX		0.31(0.07,0.56)
HD ADA SC + MTX		-0.01(-0.33,0.31)
SD ADA SC + MTX	SD RITUX IV + MTX	-0.03(-0.35,0.28)
SD GOLI SC + MTX		0.28(-0.03,0.58)
SD TOFA PO + MTX		-0.16(-0.50,0.19)
SD TOCI IV + MTX		0.08(-0.21,0.37)
SD ABA SC + MTX		0.06(-0.37,0.49)
SD GOLI IV + MTX		0.59(0.23,0.95)
SD ETN SC + DMARD		-1.16(-1.74,-0.58)
SD CERTO SC + DMARD		-1.15(-1.71,-0.61)
LD ADA SC		-1.13(-1.70,-0.56)
LD ANA		-1.00(-1.60,-0.41)
LD ADA SC + MTX		0.06(-0.29,0.40)
LD RITUX IV + MTX		0.04(-0.20,0.27)
LD ADA IV + MTX		-0.01(-0.46,0.45)
LD CERTO SC + MTX		0.08(-0.29,0.45)
LD TOFA PO + MTX		-0.08(-0.42,0.27)
HD TOFA PO		-1.31(-1.89,-0.75)
HD ADA SC		-1.24(-1.82,-0.68)
HD TOCI IV		0.08(-0.28,0.44)
HD ANA		-1.10(-1.71,-0.50)
HD GOLI SC		0.32(-0.03,0.66)

(Continued)

HD TOCI IV + MTX		-0.03(-0.31,0.25)
HD CERTO SC + MTX		-0.04(-0.32,0.23)
HD TOFA PO + MTX		-0.24(-0.58,0.11)
HD GOLI SC + MTX		0.31(0.00,0.61)
HD ADA SC + MTX		-0.01(-0.38,0.35)
SD GOLI SC + MTX	SD ADA SC + MTX	0.31(0.00,0.62)
SD TOFA PO + MTX		-0.12(-0.47,0.23)
SD TOCI IV + MTX		0.11(-0.18,0.41)
SD ABA SC + MTX		0.09(-0.34,0.53)
SD GOLI IV + MTX		0.62(0.26,0.98)
SD ETN SC + DMARD		-1.13(-1.71,-0.55)
SD CERTO SC + DMARD		-1.12(-1.67,-0.57)
LD ADA SC		-1.09(-1.67,-0.53)
LD ANA		-0.97(-1.58,-0.37)
LD ADA SC + MTX		0.09(-0.20,0.38)
LD RITUX IV + MTX		0.07(-0.25,0.39)
LD ADA IV + MTX		0.03(-0.42,0.47)
LD CERTO SC + MTX		0.12(-0.25,0.48)
LD TOFA PO + MTX		-0.04(-0.40,0.31)
HD TOFA PO		-1.28(-1.86,-0.72)
HD ADA SC		-1.21(-1.78,-0.64)
HD TOCI IV		0.11(-0.25,0.48)
HD ANA		-1.07(-1.68,-0.46)
HD GOLI SC		0.35(0.00,0.70)
HD TOCI IV + MTX		0.00(-0.28,0.29)
HD CERTO SC + MTX		-0.01(-0.29,0.26)
HD TOFA PO + MTX		-0.20(-0.55,0.15)
HD GOLI SC + MTX		0.34(0.03,0.65)

(Continued)

HD ADA SC + MTX		0.02(-0.28,0.32)
SD TOFA PO + MTX	SD GOLI SC + MTX	-0.43(-0.77,-0.09)
SD TOCI IV + MTX		-0.20(-0.48,0.08)
SD ABA SC + MTX		-0.22(-0.64,0.21)
SD GOLI IV + MTX		0.32(-0.03,0.66)
SD ETN SC + DMARD		-1.43(-2.01,-0.87)
SD CERTO SC + DMARD		-1.43(-1.98,-0.89)
LD ADA SC		-1.40(-1.97,-0.85)
LD ANA		-1.28(-1.88,-0.69)
LD ADA SC + MTX		-0.22(-0.56,0.12)
LD RITUX IV + MTX		-0.24(-0.55,0.07)
LD ADA IV + MTX		-0.28(-0.73,0.17)
LD CERTO SC + MTX		-0.19(-0.55,0.16)
LD TOFA PO + MTX		-0.35(-0.69,-0.01)
HD TOFA PO		-1.58(-2.16,-1.03)
HD ADA SC		-1.52(-2.09,-0.96)
HD TOCI IV		-0.19(-0.55,0.16)
HD ANA		-1.38(-1.99,-0.78)
HD GOLI SC		0.04(-0.23,0.32)
HD TOCI IV + MTX		-0.31(-0.57,-0.04)
HD CERTO SC + MTX		-0.32(-0.58,-0.06)
HD TOFA PO + MTX		-0.51(-0.85,-0.17)
HD GOLI SC + MTX		0.03(-0.18,0.25)
HD ADA SC + MTX		-0.29(-0.65,0.07)
SD TOCI IV + MTX	SD TOFA PO + MTX	0.23(-0.09,0.56)
SD ABA SC + MTX		0.22(-0.24,0.67)
SD GOLI IV + MTX		0.75(0.36,1.13)
SD ETN SC + DMARD		-1.00(-1.61,-0.41)

(Continued)

SD CERTO SC + DMARD	-1.00(-1.58,-0.44)	
LD ADA SC	-0.97(-1.57,-0.39)	
LD ANA	-0.85(-1.48,-0.24)	
LD ADA SC + MTX	0.22(-0.16,0.58)	
LD RITUX IV + MTX	0.20(-0.16,0.55)	
LD ADA IV + MTX	0.15(-0.33,0.63)	
LD CERTO SC + MTX	0.24(-0.15,0.63)	
LD TOFA PO + MTX	0.08(-0.19,0.34)	
HD TOFA PO	-1.15(-1.76,-0.58)	
HD ADA SC	-1.08(-1.69,-0.50)	
HD TOCI IV	0.24(-0.15,0.62)	
HD ANA	-0.94(-1.59,-0.33)	
HD GOLI SC	0.47(0.10,0.85)	
HD TOCI IV + MTX	0.13(-0.19,0.44)	
HD CERTO SC + MTX	0.11(-0.20,0.42)	
HD TOFA PO + MTX	-0.08(-0.34,0.19)	
HD GOLI SC + MTX	0.46(0.12,0.80)	
HD ADA SC + MTX	0.14(-0.25,0.54)	
SD ABA SC + MTX	SD TOCI IV + MTX	-0.02(-0.44,0.39)
SD GOLI IV + MTX	0.51(0.17,0.85)	
SD ETN SC + DMARD	-1.24(-1.81,-0.68)	
SD CERTO SC + DMARD	-1.23(-1.78,-0.71)	
LD ADA SC	-1.20(-1.76,-0.66)	
LD ANA	-1.08(-1.67,-0.50)	
LD ADA SC + MTX	-0.02(-0.35,0.30)	
LD RITUX IV + MTX	-0.04(-0.34,0.26)	
LD ADA IV + MTX	-0.09(-0.53,0.36)	
LD CERTO SC + MTX	0.00(-0.34,0.35)	

(Continued)

LD TOFA PO + MTX		-0.16(-0.48,0.17)
HD TOFA PO		-1.39(-1.95,-0.84)
HD ADA SC		-1.32(-1.88,-0.77)
HD TOCI IV		0.00(-0.34,0.34)
HD ANA		-1.18(-1.78,-0.59)
HD GOLI SC		0.24(-0.09,0.57)
HD TOCI IV + MTX		-0.11(-0.30,0.08)
HD CERTO SC + MTX		-0.12(-0.37,0.12)
HD TOFA PO + MTX		-0.31(-0.64,0.01)
HD GOLI SC + MTX		0.23(-0.05,0.51)
HD ADA SC + MTX		-0.09(-0.44,0.25)
SD GOLI IV + MTX	SD ABA SC + MTX	0.53(0.07,0.99)
SD ETN SC + DMARD		-1.22(-1.86,-0.57)
SD CERTO SC + DMARD		-1.21(-1.84,-0.59)
LD ADA SC		-1.18(-1.82,-0.54)
LD ANA		-1.06(-1.73,-0.39)
LD ADA SC + MTX		0.00(-0.46,0.46)
LD RITUX IV + MTX		-0.02(-0.45,0.42)
LD ADA IV + MTX		-0.07(-0.61,0.48)
LD CERTO SC + MTX		0.02(-0.45,0.50)
LD TOFA PO + MTX		-0.14(-0.59,0.32)
HD TOFA PO		-1.37(-2.01,-0.73)
HD ADA SC		-1.30(-1.94,-0.66)
HD TOCI IV		0.02(-0.44,0.49)
HD ANA		-1.16(-1.84,-0.48)
HD GOLI SC		0.26(-0.19,0.72)
HD TOCI IV + MTX		-0.09(-0.49,0.32)
HD CERTO SC + MTX		-0.10(-0.51,0.30)

(Continued)

HD TOFA PO + MTX		-0.29(-0.75,0.16)
HD GOLI SC + MTX		0.25(-0.18,0.68)
HD ADA SC + MTX		-0.07(-0.54,0.40)
SD ETN SC + DMARD	SD GOLI IV + MTX	-1.75(-2.35,-1.15)
SD CERTO SC + DMARD		-1.74(-2.32,-1.18)
LD ADA SC		-1.72(-2.31,-1.13)
LD ANA		-1.59(-2.22,-0.98)
LD ADA SC + MTX		-0.53(-0.92,-0.14)
LD RITUX IV + MTX		-0.55(-0.91,-0.19)
LD ADA IV + MTX		-0.60(-1.09,-0.11)
LD CERTO SC + MTX		-0.51(-0.91,-0.11)
LD TOFA PO + MTX		-0.67(-1.05,-0.28)
HD TOFA PO		-1.90(-2.50,-1.31)
HD ADA SC		-1.83(-2.43,-1.24)
HD TOCI IV		-0.51(-0.91,-0.11)
HD ANA		-1.69(-2.32,-1.07)
HD GOLI SC		-0.27(-0.65,0.12)
HD TOCI IV + MTX		-0.62(-0.95,-0.29)
HD CERTO SC + MTX		-0.63(-0.95,-0.31)
HD TOFA PO + MTX		-0.83(-1.21,-0.44)
HD GOLI SC + MTX		-0.28(-0.63,0.06)
HD ADA SC + MTX		-0.60(-1.01,-0.20)
SD CERTO SC + DMARD	SD ETN SC + DMARD	0.01(-0.36,0.37)
LD ADA SC		0.03(-0.41,0.47)
LD ANA		0.16(-0.33,0.64)
LD ADA SC + MTX		1.22(0.63,1.82)
LD RITUX IV + MTX		1.20(0.62,1.78)
LD ADA IV + MTX		1.15(0.50,1.82)

(Continued)

LD CERTO SC + MTX		1.24(0.63,1.86)
LD TOFA PO + MTX		1.08(0.49,1.69)
HD TOFA PO		-0.15(-0.60,0.28)
HD ADA SC		-0.08(-0.53,0.36)
HD TOCI IV		1.24(0.64,1.84)
HD ANA		0.06(-0.44,0.55)
HD GOLI SC		1.48(0.89,2.07)
HD TOCI IV + MTX		1.13(0.58,1.69)
HD CERTO SC + MTX		1.12(0.56,1.67)
HD TOFA PO + MTX		0.92(0.33,1.52)
HD GOLI SC + MTX		1.47(0.90,2.04)
HD ADA SC + MTX		1.15(0.54,1.76)
LD ADA SC	SD CERTO SC + DMARD	0.03(-0.30,0.36)
LD ANA		0.15(-0.24,0.54)
LD ADA SC + MTX		1.21(0.65,1.79)
LD RITUX IV + MTX		1.19(0.65,1.75)
LD ADA IV + MTX		1.15(0.52,1.79)
LD CERTO SC + MTX		1.24(0.66,1.83)
LD TOFA PO + MTX		1.08(0.51,1.66)
HD TOFA PO		-0.16(-0.48,0.17)
HD ADA SC		-0.09(-0.42,0.25)
HD TOCI IV		1.23(0.67,1.82)
HD ANA		0.05(-0.34,0.45)
HD GOLI SC		1.47(0.91,2.05)
HD TOCI IV + MTX		1.12(0.60,1.66)
HD CERTO SC + MTX		1.11(0.59,1.65)
HD TOFA PO + MTX		0.92(0.35,1.50)
HD GOLI SC + MTX		1.46(0.92,2.01)

(Continued)

HD ADA SC + MTX		1.14(0.57,1.73)
LD ANA	LD ADA SC	0.12(-0.22,0.47)
LD ADA SC + MTX		1.18(0.61,1.78)
LD RITUX IV + MTX		1.16(0.60,1.74)
LD ADA IV + MTX		1.12(0.48,1.78)
LD CERTO SC + MTX		1.21(0.61,1.82)
LD TOFA PO + MTX		1.05(0.47,1.65)
HD TOFA PO		-0.18(-0.45,0.08)
HD ADA SC		-0.11(-0.33,0.10)
HD TOCI IV		1.21(0.62,1.81)
HD ANA		0.02(-0.33,0.38)
HD GOLI SC		1.44(0.87,2.04)
HD TOCI IV + MTX		1.10(0.56,1.65)
HD CERTO SC + MTX		1.08(0.55,1.63)
HD TOFA PO + MTX		0.89(0.31,1.49)
HD GOLI SC + MTX		1.43(0.88,2.00)
HD ADA SC + MTX		1.11(0.52,1.71)
LD ADA SC + MTX	LD ANA	1.06(0.46,1.68)
LD RITUX IV + MTX		1.04(0.45,1.65)
LD ADA IV + MTX		1.00(0.32,1.69)
LD CERTO SC + MTX		1.09(0.45,1.72)
LD TOFA PO + MTX		0.93(0.31,1.56)
HD TOFA PO		-0.31(-0.65,0.03)
HD ADA SC		-0.24(-0.59,0.11)
HD TOCI IV		1.08(0.47,1.72)
HD ANA		-0.10(-0.40,0.20)
HD GOLI SC		1.32(0.71,1.94)
HD TOCI IV + MTX		0.97(0.40,1.56)

(Continued)

HD CERTO SC + MTX		0.96(0.39,1.54)
HD TOFA PO + MTX		0.77(0.15,1.40)
HD GOLI SC + MTX		1.31(0.72,1.92)
HD ADA SC + MTX		0.99(0.36,1.63)
LD RITUX IV + MTX	LD ADA SC + MTX	-0.02(-0.37,0.33)
LD ADA IV + MTX		-0.07(-0.49,0.36)
LD CERTO SC + MTX		0.02(-0.37,0.42)
LD TOFA PO + MTX		-0.14(-0.51,0.24)
HD TOFA PO		-1.37(-1.97,-0.80)
HD ADA SC		-1.30(-1.90,-0.73)
HD TOCI IV		0.02(-0.36,0.41)
HD ANA		-1.16(-1.79,-0.54)
HD GOLI SC		0.26(-0.12,0.64)
HD TOCI IV + MTX		-0.09(-0.40,0.23)
HD CERTO SC + MTX		-0.10(-0.41,0.21)
HD TOFA PO + MTX		-0.29(-0.67,0.08)
HD GOLI SC + MTX		0.25(-0.09,0.59)
HD ADA SC + MTX		-0.07(-0.38,0.24)
LD ADA IV + MTX	LD RITUX IV + MTX	-0.05(-0.50,0.42)
LD CERTO SC + MTX		0.04(-0.33,0.42)
LD TOFA PO + MTX		-0.12(-0.47,0.24)
HD TOFA PO		-1.35(-1.92,-0.79)
HD ADA SC		-1.28(-1.86,-0.72)
HD TOCI IV		0.04(-0.32,0.41)
HD ANA		-1.14(-1.76,-0.53)
HD GOLI SC		0.28(-0.07,0.63)
HD TOCI IV + MTX		-0.07(-0.35,0.22)
HD CERTO SC + MTX		-0.08(-0.36,0.19)

(Continued)

HD TOFA PO + MTX		-0.27(-0.63,0.08)
HD GOLI SC + MTX		0.27(-0.04,0.58)
HD ADA SC + MTX		-0.05(-0.42,0.32)
LD CERTO SC + MTX	LD ADA IV + MTX	0.09(-0.41,0.58)
LD TOFA PO + MTX		-0.07(-0.55,0.41)
HD TOFA PO		-1.30(-1.96,-0.66)
HD ADA SC		-1.23(-1.90,-0.59)
HD TOCI IV		0.09(-0.40,0.57)
HD ANA		-1.09(-1.79,-0.41)
HD GOLI SC		0.32(-0.15,0.81)
HD TOCI IV + MTX		-0.02(-0.46,0.41)
HD CERTO SC + MTX		-0.04(-0.46,0.39)
HD TOFA PO + MTX		-0.23(-0.71,0.25)
HD GOLI SC + MTX		0.31(-0.13,0.76)
HD ADA SC + MTX		-0.01(-0.47,0.47)
LD TOFA PO + MTX	LD CERTO SC + MTX	-0.16(-0.55,0.24)
HD TOFA PO		-1.39(-2.00,-0.80)
HD ADA SC		-1.32(-1.93,-0.73)
HD TOCI IV		0.00(-0.41,0.41)
HD ANA		-1.18(-1.83,-0.54)
HD GOLI SC		0.23(-0.16,0.63)
HD TOCI IV + MTX		-0.11(-0.44,0.23)
HD CERTO SC + MTX		-0.13(-0.42,0.17)
HD TOFA PO + MTX		-0.32(-0.71,0.08)
HD GOLI SC + MTX		0.23(-0.13,0.58)
HD ADA SC + MTX		-0.09(-0.50,0.32)
HD TOFA PO	LD TOFA PO + MTX	-1.23(-1.83,-0.65)
HD ADA SC		-1.16(-1.76,-0.58)

(Continued)

HD TOCI IV		0.16(-0.23,0.54)
HD ANA		-1.02(-1.66,-0.40)
HD GOLI SC		0.39(0.02,0.77)
HD TOCI IV + MTX		0.05(-0.27,0.37)
HD CERTO SC + MTX		0.03(-0.28,0.34)
HD TOFA PO + MTX		-0.16(-0.42,0.11)
HD GOLI SC + MTX		0.39(0.05,0.72)
HD ADA SC + MTX		0.07(-0.33,0.46)
HD ADA SC	HD TOFA PO	0.07(-0.20,0.34)
HD TOCI IV		1.39(0.81,1.99)
HD ANA		0.21(-0.14,0.57)
HD GOLI SC		1.63(1.06,2.22)
HD TOCI IV + MTX		1.28(0.74,1.84)
HD CERTO SC + MTX		1.27(0.73,1.82)
HD TOFA PO + MTX		1.07(0.50,1.68)
HD GOLI SC + MTX		1.62(1.07,2.19)
HD ADA SC + MTX		1.30(0.71,1.91)
HD TOCI IV	HD ADA SC	1.32(0.73,1.93)
HD ANA		0.14(-0.22,0.50)
HD GOLI SC		1.56(0.98,2.15)
HD TOCI IV + MTX		1.21(0.67,1.77)
HD CERTO SC + MTX		1.20(0.65,1.75)
HD TOFA PO + MTX		1.01(0.43,1.61)
HD GOLI SC + MTX		1.55(0.99,2.12)
HD ADA SC + MTX		1.23(0.64,1.83)
HD ANA	HD TOCI IV	-1.18(-1.82,-0.56)
HD GOLI SC		0.24(-0.15,0.63)
HD TOCI IV + MTX		-0.11(-0.44,0.22)

(Continued)

HD CERTO SC + MTX		-0.12(-0.45,0.20)
HD TOFA PO + MTX		-0.32(-0.71,0.07)
HD GOLI SC + MTX		0.23(-0.12,0.58)
HD ADA SC + MTX		-0.09(-0.50,0.31)
HD GOLI SC	HD ANA	1.42(0.81,2.05)
HD TOCI IV + MTX		1.07(0.49,1.67)
HD CERTO SC + MTX		1.06(0.48,1.65)
HD TOFA PO + MTX		0.87(0.24,1.50)
HD GOLI SC + MTX		1.41(0.81,2.02)
HD ADA SC + MTX		1.09(0.46,1.73)
HD TOCI IV + MTX	HD GOLI SC	-0.35(-0.66,-0.03)
HD CERTO SC + MTX		-0.36(-0.67,-0.05)
HD TOFA PO + MTX		-0.55(-0.93,-0.18)
HD GOLI SC + MTX		-0.01(-0.28,0.26)
HD ADA SC + MTX		-0.33(-0.72,0.07)
HD CERTO SC + MTX	HD TOCI IV + MTX	-0.01(-0.24,0.21)
HD TOFA PO + MTX		-0.21(-0.52,0.11)
HD GOLI SC + MTX		0.34(0.07,0.60)
HD ADA SC + MTX		0.02(-0.32,0.35)
HD TOFA PO + MTX	HD CERTO SC + MTX	-0.19(-0.50,0.12)
HD GOLI SC + MTX		0.35(0.09,0.61)
HD ADA SC + MTX		0.03(-0.30,0.37)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.54(0.21,0.88)
HD ADA SC + MTX		0.22(-0.17,0.62)
HD ADA SC + MTX	HD GOLI SC + MTX	-0.32(-0.68,0.04)
Random-effects model	Total residual deviance	108.9
	Deviance information criteria	-253.47

(Continued)

Fixed-Effect Model	Total residual deviance	443.8
	Deviance information criteria	188.147
Note		
Total participants	13,213	
Total studies	42	
2-arm	23	
3-arm	11	
4-arm	8	

Appendix 11. Remission: main analysis

Remission combined: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX + DMARD	MTX + PL	0.70(0.21,2.15)	0.71(0.22,2.05)	-0.01(-0.04,0.05)
PL		0.98(0.11,8.09)	0.98(0.11,6.26)	0.00(-0.04,0.22)
SD ETN SC		1.80(0.77,4.19)	1.74(0.77,3.68)	0.03(-0.01,0.12)
SD ADA SC		1.19(0.19,7.38)	1.18(0.20,5.85)	0.01(-0.04,0.20)
SD GOL I IV		1.45(0.42,4.98)	1.42(0.44,4.26)	0.02(-0.03,0.14)
SD GOL I SC		3.40(0.34,33.10)	3.07(0.35,14.16)	0.09(-0.03,0.55)
SD ETN SC + MTX		3.19(1.51,6.77)	2.91(1.48,5.42)	0.08(0.02,0.19)
SD ABA IV + MTX		4.86(2.53,9.91)	4.15(2.36,7.26)	0.14(0.06,0.26)
SD ABA SC + MTX		3.81(1.63,9.06)	3.39(1.59,6.76)	0.11(0.03,0.24)
SD GOL I SC + MTX		10.48(3.72,31.95)	7.37(3.29,14.41)	0.28(0.11,0.53)
SD ADA SC + MTX		4.68(1.54,16.01)	4.02(1.50,9.94)	0.13(0.02,0.37)
SD INF IV + MTX		3.97(1.79,9.33)	3.51(1.73,6.90)	0.11(0.03,0.25)
SD RITUX IV + MTX		2.26(0.90,5.87)	2.14(0.90,4.87)	0.05(0.00,0.17)
SD GOL I IV + MTX		3.75(1.42,10.74)	3.34(1.39,7.59)	0.10(0.02,0.28)

(Continued)

SD CERTO + MTX		3.18(1.25,8.54)	2.90(1.24,6.48)	0.08(0.01,0.23)
SD TOFA PO + MTX		4.43(0.95,27.56)	3.84(0.96,13.18)	0.13(0.00,0.50)
LD GOLIV		2.24(0.69,7.63)	2.13(0.70,5.97)	0.05(-0.01,0.21)
LD RITUX IV + MTX		1.50(0.58,3.98)	1.47(0.59,3.53)	0.02(-0.02,0.11)
LD ETN SC + MTX		2.99(1.04,8.23)	2.74(1.04,6.27)	0.08(0.00,0.23)
LD GOLIV + MTX		1.35(0.38,4.84)	1.33(0.39,4.15)	0.01(-0.03,0.14)
HD TOCI IV		6.93(1.80,28.87)	5.48(1.73,13.53)	0.20(0.03,0.51)
HD GOLIV SC		4.59(1.15,19.15)	3.96(1.14,11.02)	0.13(0.01,0.41)
HD TOCI IV + MTX		12.77(3.97,47.17)	8.35(3.48,16.66)	0.33(0.11,0.63)
HD GOLIV SC + MTX		9.28(3.29,27.72)	6.78(2.97,13.56)	0.26(0.09,0.50)
HD INF IV + MTX		3.52(1.27,9.89)	3.16(1.26,7.17)	0.10(0.01,0.27)
HD TOFA PO + MTX		11.09(2.48,65.57)	7.66(2.32,18.02)	0.29(0.06,0.70)
PL	MTX + DMARD	1.39(0.12,16.02)	1.37(0.13,12.69)	0.01(-0.06,0.23)
SD ETN SC		2.59(0.92,7.87)	2.46(0.93,7.20)	0.04(0.00,0.12)
SD ADA SC		1.72(0.21,15.45)	1.68(0.22,12.35)	0.02(-0.05,0.21)
SD GOLIV		2.08(0.40,11.51)	2.01(0.42,9.93)	0.03(-0.04,0.15)
SD GOLIV SC		4.89(0.38,66.45)	4.29(0.39,31.89)	0.10(-0.03,0.56)
SD ETN SC + MTX		4.59(1.94,11.53)	4.10(1.82,10.14)	0.09(0.04,0.18)
SD ABA IV + MTX		6.98(1.93,28.27)	5.85(1.79,21.70)	0.15(0.06,0.27)
SD ABA SC + MTX		5.43(1.36,24.12)	4.74(1.33,18.88)	0.12(0.02,0.26)
SD GOLIV SC + MTX		15.18(3.36,75.90)	10.34(2.82,39.73)	0.29(0.11,0.54)
SD ADA SC + MTX		6.74(1.41,37.63)	5.66(1.37,25.28)	0.14(0.02,0.38)
SD INF IV + MTX		5.68(1.47,25.34)	4.92(1.42,19.65)	0.12(0.03,0.27)
SD RITUX IV + MTX		3.26(0.77,14.95)	3.03(0.78,12.66)	0.06(-0.02,0.18)
SD GOLIV + MTX		5.39(1.22,26.74)	4.71(1.20,20.16)	0.11(0.01,0.29)
SD CERTO + MTX		4.58(1.05,22.26)	4.09(1.05,17.58)	0.09(0.00,0.25)
SD TOFA PO + MTX		6.41(0.92,54.71)	5.41(0.93,29.41)	0.13(0.00,0.51)
LD GOLIV		3.21(0.63,18.15)	2.99(0.65,14.50)	0.06(-0.02,0.22)

(Continued)

LD RITUX IV + MTX		2.16(0.49,10.31)	2.08(0.51,9.23)	0.03(-0.04,0.12)
LD ETN SC + MTX		4.26(1.13,17.46)	3.83(1.12,14.05)	0.09(0.01,0.23)
LD GOLI IV + MTX		1.94(0.36,11.09)	1.88(0.38,9.70)	0.03(-0.04,0.15)
HD TOCI IV		9.98(1.77,63.04)	7.64(1.67,33.66)	0.21(0.04,0.52)
HD GOLI SC		6.58(1.13,43.05)	5.55(1.12,27.21)	0.14(0.01,0.42)
HD TOCI IV + MTX		18.27(3.69,107.80)	11.57(3.07,46.42)	0.34(0.12,0.64)
HD GOLI SC + MTX		13.37(2.93,69.16)	9.54(2.54,37.77)	0.27(0.10,0.51)
HD INF IV + MTX		5.02(1.13,25.11)	4.43(1.12,18.99)	0.11(0.01,0.28)
HD TOFA PO + MTX		16.14(2.38,133.20)	10.64(2.17,46.84)	0.30(0.06,0.71)
SD ETN SC	PL	1.86(0.19,18.82)	1.79(0.23,16.93)	0.03(-0.19,0.13)
SD ADA SC		1.22(0.07,22.02)	1.21(0.09,18.28)	0.01(-0.21,0.20)
SD GOLI IV		1.48(0.13,18.96)	1.45(0.16,16.73)	0.02(-0.20,0.15)
SD GOLI SC		3.51(0.84,16.83)	3.00(0.85,11.73)	0.08(-0.01,0.43)
SD ETN SC + MTX		3.30(0.36,33.04)	2.99(0.43,27.70)	0.08(-0.14,0.20)
SD ABA IV + MTX		5.01(0.56,49.45)	4.24(0.64,39.07)	0.13(-0.09,0.27)
SD ABA SC + MTX		3.97(0.40,40.40)	3.48(0.48,32.69)	0.10(-0.12,0.25)
SD GOLI SC + MTX		10.92(1.52,87.02)	7.47(1.35,56.90)	0.27(0.06,0.50)
SD ADA SC + MTX		4.95(0.45,57.22)	4.16(0.52,41.03)	0.13(-0.11,0.37)
SD INF IV + MTX		4.14(0.44,42.18)	3.62(0.51,33.82)	0.10(-0.11,0.26)
SD RITUX IV + MTX		2.34(0.23,25.19)	2.20(0.28,21.68)	0.05(-0.17,0.17)
SD GOLI IV + MTX		3.84(0.39,43.24)	3.39(0.45,34.05)	0.10(-0.12,0.28)
SD CERTO + MTX		3.27(0.32,37.80)	2.95(0.38,30.52)	0.08(-0.14,0.24)
SD TOFA PO + MTX		4.66(0.34,72.48)	3.94(0.40,43.94)	0.12(-0.12,0.49)
LD GOLI IV		2.30(0.21,29.17)	2.16(0.25,24.49)	0.04(-0.17,0.21)
LD RITUX IV + MTX		1.56(0.15,16.84)	1.52(0.19,15.35)	0.02(-0.20,0.12)
LD ETN SC + MTX		3.07(0.29,33.96)	2.79(0.35,27.74)	0.07(-0.15,0.24)
LD GOLI IV + MTX		1.36(0.12,17.67)	1.33(0.15,15.69)	0.01(-0.20,0.14)
HD TOCI IV		7.14(0.55,98.72)	5.54(0.61,59.26)	0.19(-0.08,0.51)

(Continued)

HD GOLI SC		4.68(1.02,25.32)	3.94(1.01,20.87)	0.12(0.00,0.32)
HD TOCI IV + MTX		13.18(1.15,172.20)	8.41(1.11,84.04)	0.31(0.02,0.63)
HD GOLI SC + MTX		9.64(1.37,75.71)	6.86(1.26,51.02)	0.24(0.05,0.47)
HD INF IV + MTX		3.64(0.36,40.20)	3.23(0.42,31.55)	0.09(-0.13,0.27)
HD TOFA PO + MTX		11.77(0.84,177.10)	7.66(0.88,76.14)	0.28(-0.02,0.69)
SD ADA SC	SD ETN SC	0.66(0.09,4.94)	0.68(0.10,4.05)	-0.02(-0.12,0.17)
SD GOLI IV		0.80(0.18,3.60)	0.81(0.20,3.20)	-0.01(-0.11,0.11)
SD GOLI SC		1.90(0.16,21.31)	1.77(0.18,10.21)	0.06(-0.09,0.52)
SD ETN SC + MTX		1.78(0.99,3.19)	1.67(0.99,2.87)	0.05(0.00,0.12)
SD ABA IV + MTX		2.71(0.95,8.10)	2.39(0.96,6.32)	0.10(-0.01,0.23)
SD ABA SC + MTX		2.11(0.66,7.05)	1.94(0.69,5.63)	0.07(-0.04,0.22)
SD GOLI SC + MTX		5.87(1.55,23.32)	4.22(1.44,11.94)	0.25(0.05,0.50)
SD ADA SC + MTX		2.61(0.67,11.36)	2.31(0.70,7.67)	0.10(-0.04,0.34)
SD INF IV + MTX		2.21(0.71,7.37)	2.02(0.74,5.77)	0.08(-0.03,0.22)
SD RITUX IV + MTX		1.26(0.35,4.51)	1.23(0.39,3.90)	0.02(-0.08,0.14)
SD GOLI IV + MTX		2.08(0.57,8.23)	1.91(0.61,6.20)	0.07(-0.05,0.25)
SD CERTO + MTX		1.77(0.51,6.51)	1.67(0.55,5.26)	0.05(-0.06,0.21)
SD TOFA PO + MTX		2.45(0.43,18.19)	2.19(0.46,9.57)	0.09(-0.06,0.47)
LD GOLI IV		1.25(0.29,5.60)	1.23(0.32,4.59)	0.02(-0.09,0.18)
LD RITUX IV + MTX		0.84(0.23,3.05)	0.85(0.26,2.80)	-0.01(-0.11,0.09)
LD ETN SC + MTX		1.66(0.52,5.22)	1.57(0.55,4.27)	0.04(-0.05,0.19)
LD GOLI IV + MTX		0.75(0.16,3.46)	0.76(0.18,3.07)	-0.02(-0.11,0.11)
HD TOCI IV		3.87(0.80,19.79)	3.14(0.82,10.47)	0.16(-0.02,0.48)
HD GOLI SC		2.55(0.51,13.26)	2.26(0.55,8.27)	0.10(-0.06,0.38)
HD TOCI IV + MTX		7.08(1.71,33.40)	4.75(1.56,13.93)	0.29(0.06,0.60)
HD GOLI SC + MTX		5.19(1.38,20.64)	3.89(1.32,11.33)	0.22(0.04,0.47)
HD INF IV + MTX		1.95(0.53,7.41)	1.81(0.56,5.71)	0.06(-0.05,0.24)
HD TOFA PO + MTX		6.18(1.09,43.57)	4.34(1.08,14.33)	0.26(0.01,0.66)

(Continued)

SD GOLI IV	SD ADA SC	1.21(0.13,10.80)	1.20(0.16,9.59)	0.01(-0.19,0.14)
SD GOLI SC		2.89(0.15,53.58)	2.56(0.17,28.63)	0.08(-0.15,0.53)
SD ETN SC + MTX		2.67(0.37,19.12)	2.45(0.43,15.83)	0.07(-0.13,0.20)
SD ABA IV + MTX		4.09(0.60,29.39)	3.50(0.66,22.83)	0.13(-0.08,0.26)
SD ABA SC + MTX		3.18(0.43,24.47)	2.84(0.49,19.34)	0.09(-0.11,0.24)
SD GOLI SC + MTX		8.85(1.06,76.90)	6.18(1.04,42.23)	0.26(0.01,0.53)
SD ADA SC + MTX		3.94(0.47,35.70)	3.37(0.53,24.92)	0.12(-0.10,0.36)
SD INF IV + MTX		3.35(0.47,25.34)	2.96(0.53,19.92)	0.10(-0.10,0.25)
SD RITUX IV + MTX		1.89(0.24,14.91)	1.81(0.29,12.88)	0.04(-0.16,0.17)
SD GOLI IV + MTX		3.20(0.38,25.90)	2.85(0.44,19.93)	0.09(-0.12,0.27)
SD CERTO + MTX		2.67(0.35,21.18)	2.45(0.41,17.27)	0.07(-0.13,0.23)
SD TOFA PO + MTX		3.73(0.35,48.40)	3.19(0.40,28.58)	0.11(-0.11,0.49)
LD GOLI IV		1.90(0.21,16.63)	1.80(0.25,13.84)	0.04(-0.16,0.21)
LD RITUX IV + MTX		1.26(0.16,10.02)	1.24(0.20,9.04)	0.01(-0.18,0.11)
LD ETN SC + MTX		2.50(0.30,20.34)	2.30(0.36,16.43)	0.06(-0.14,0.23)
LD GOLI IV + MTX		1.13(0.12,10.41)	1.12(0.15,9.19)	0.01(-0.19,0.14)
HD TOCI IV		5.81(1.78,19.48)	4.50(1.54,15.03)	0.18(0.05,0.40)
HD GOLI SC		3.86(0.38,38.51)	3.30(0.44,25.76)	0.11(-0.11,0.40)
HD TOCI IV + MTX		10.69(2.61,48.07)	6.85(1.93,30.17)	0.30(0.12,0.54)
HD GOLI SC + MTX		7.83(0.97,65.92)	5.66(0.98,38.74)	0.24(-0.01,0.49)
HD INF IV + MTX		2.95(0.37,24.65)	2.66(0.43,19.04)	0.08(-0.12,0.27)
HD TOFA PO + MTX		9.32(0.87,117.10)	6.23(0.90,46.60)	0.27(-0.02,0.69)
SD GOLI SC	SD GOLI IV	2.40(0.17,30.12)	2.18(0.19,15.31)	0.07(-0.11,0.53)
SD ETN SC + MTX		2.22(0.52,9.29)	2.06(0.56,7.76)	0.06(-0.07,0.18)
SD ABA IV + MTX		3.39(0.84,14.08)	2.93(0.86,10.93)	0.12(-0.02,0.25)
SD ABA SC + MTX		2.64(0.60,11.90)	2.38(0.64,9.48)	0.08(-0.06,0.23)
SD GOLI SC + MTX		7.34(1.40,36.77)	5.19(1.31,19.86)	0.26(0.04,0.52)
SD ADA SC + MTX		3.25(0.63,18.48)	2.83(0.67,12.57)	0.11(-0.05,0.35)

(Continued)

SD INF IV + MTX		2.76(0.64,12.20)	2.47(0.68,9.65)	0.09(-0.05,0.24)
SD RITUX IV + MTX		1.57(0.34,7.38)	1.51(0.37,6.31)	0.03(-0.10,0.15)
SD GOL I IV + MTX		2.60(0.82,8.89)	2.35(0.84,7.13)	0.08(-0.02,0.23)
SD CERTO + MTX		2.21(0.47,10.55)	2.05(0.51,8.45)	0.06(-0.08,0.22)
SD TOFA PO + MTX		3.09(0.43,26.32)	2.70(0.47,14.75)	0.10(-0.07,0.48)
LD GOL I IV		1.55(0.46,5.56)	1.49(0.49,4.77)	0.03(-0.06,0.16)
LD RITUX IV + MTX		1.05(0.22,4.98)	1.04(0.25,4.51)	0.00(-0.12,0.10)
LD ETN SC + MTX		2.06(0.41,10.12)	1.93(0.45,8.15)	0.06(-0.08,0.22)
LD GOL I IV + MTX		0.93(0.26,3.38)	0.93(0.28,3.10)	0.00(-0.10,0.09)
HD TOCI IV		4.85(0.77,30.70)	3.85(0.80,16.78)	0.17(-0.03,0.49)
HD GOL I SC		3.23(0.49,20.08)	2.81(0.53,13.04)	0.11(-0.07,0.39)
HD TOCI IV + MTX		8.85(1.63,52.81)	5.80(1.47,22.87)	0.30(0.06,0.61)
HD GOL I SC + MTX		6.52(1.24,33.35)	4.79(1.20,18.81)	0.23(0.03,0.48)
HD INF IV + MTX		2.44(0.49,11.97)	2.23(0.53,9.24)	0.07(-0.07,0.25)
HD TOFA PO + MTX		7.74(1.11,64.66)	5.28(1.09,23.09)	0.27(0.01,0.68)
SD ETN SC + MTX	SD GOL I SC	0.93(0.09,10.54)	0.94(0.18,8.90)	-0.01(-0.47,0.16)
SD ABA IV + MTX		1.44(0.14,15.64)	1.35(0.27,12.31)	0.05(-0.41,0.23)
SD ABA SC + MTX		1.12(0.10,12.39)	1.11(0.20,10.17)	0.01(-0.45,0.20)
SD GOL I SC + MTX		3.11(0.37,27.05)	2.37(0.55,17.83)	0.17(-0.23,0.42)
SD ADA SC + MTX		1.39(0.11,17.51)	1.31(0.21,13.03)	0.04(-0.43,0.31)
SD INF IV + MTX		1.18(0.11,13.44)	1.15(0.21,10.99)	0.02(-0.44,0.21)
SD RITUX IV + MTX		0.67(0.06,8.08)	0.70(0.12,7.10)	-0.04(-0.50,0.13)
SD GOL I IV + MTX		1.09(0.10,14.45)	1.08(0.19,11.23)	0.01(-0.45,0.24)
SD CERTO + MTX		0.93(0.08,11.91)	0.94(0.16,9.80)	-0.01(-0.47,0.20)
SD TOFA PO + MTX		1.33(0.08,22.74)	1.26(0.16,14.42)	0.03(-0.44,0.42)
LD GOL I IV		0.64(0.05,9.43)	0.68(0.10,7.97)	-0.04(-0.50,0.17)
LD RITUX IV + MTX		0.44(0.04,5.28)	0.48(0.08,4.85)	-0.07(-0.53,0.08)
LD ETN SC + MTX		0.87(0.07,10.81)	0.89(0.15,8.85)	-0.01(-0.48,0.19)

(Continued)

LD GOLIV + MTX		0.39(0.03,5.66)	0.43(0.06,5.13)	-0.07(-0.53,0.10)
HD TOCI IV		2.03(0.14,30.73)	1.75(0.26,18.67)	0.09(-0.38,0.45)
HD GOLIV SC		1.33(0.23,8.13)	1.26(0.37,6.82)	0.03(-0.29,0.22)
HD TOCI IV + MTX		3.74(0.29,53.12)	2.66(0.47,26.15)	0.22(-0.27,0.57)
HD GOLIV SC + MTX		2.75(0.32,23.94)	2.18(0.51,16.38)	0.15(-0.25,0.39)
HD INF IV + MTX		1.04(0.09,12.54)	1.03(0.17,10.17)	0.00(-0.46,0.22)
HD TOFA PO + MTX		3.32(0.21,55.39)	2.43(0.36,24.14)	0.18(-0.32,0.63)
SD ABA IV + MTX	SD ETN SC + MTX	1.52(0.58,4.26)	1.42(0.63,3.42)	0.05(-0.08,0.19)
SD ABA SC + MTX		1.19(0.39,3.74)	1.16(0.45,3.07)	0.02(-0.11,0.17)
SD GOLIV SC + MTX		3.31(0.92,12.29)	2.53(0.93,6.45)	0.19(-0.01,0.46)
SD ADA SC + MTX		1.46(0.40,6.15)	1.37(0.45,4.25)	0.05(-0.11,0.29)
SD INF IV + MTX		1.24(0.42,3.88)	1.20(0.48,3.16)	0.03(-0.11,0.18)
SD RITUX IV + MTX		0.71(0.21,2.35)	0.74(0.25,2.11)	-0.03(-0.16,0.10)
SD GOLIV IV + MTX		1.18(0.34,4.34)	1.15(0.39,3.38)	0.02(-0.12,0.21)
SD CERTO + MTX		1.00(0.30,3.51)	1.00(0.35,2.90)	0.00(-0.13,0.16)
SD TOFA PO + MTX		1.39(0.24,9.76)	1.32(0.28,5.30)	0.04(-0.13,0.42)
LD GOLIV IV		0.70(0.17,3.03)	0.73(0.20,2.55)	-0.03(-0.16,0.14)
LD RITUX IV + MTX		0.47(0.14,1.62)	0.51(0.17,1.54)	-0.06(-0.18,0.04)
LD ETN SC + MTX		0.93(0.33,2.61)	0.94(0.37,2.22)	-0.01(-0.11,0.13)
LD GOLIV IV + MTX		0.42(0.10,1.85)	0.45(0.12,1.71)	-0.07(-0.19,0.06)
HD TOCI IV		2.18(0.47,10.79)	1.88(0.53,5.79)	0.11(-0.09,0.43)
HD GOLIV SC		1.43(0.30,7.10)	1.35(0.35,4.57)	0.04(-0.12,0.33)
HD TOCI IV + MTX		3.98(1.00,18.03)	2.85(1.00,7.54)	0.24(0.00,0.55)
HD GOLIV SC + MTX		2.93(0.83,10.84)	2.33(0.86,6.07)	0.17(-0.03,0.43)
HD INF IV + MTX		1.10(0.31,3.96)	1.09(0.36,3.14)	0.01(-0.13,0.19)
HD TOFA PO + MTX		3.46(0.64,23.59)	2.59(0.69,7.83)	0.21(-0.05,0.62)
SD ABA SC + MTX	SD ABA IV + MTX	0.79(0.33,1.78)	0.82(0.39,1.59)	-0.03(-0.15,0.09)

(Continued)

SD GOLI SC + MTX		2.15(0.60,7.78)	1.77(0.67,4.16)	0.14(-0.08,0.41)
SD ADA SC + MTX		0.97(0.29,3.26)	0.97(0.35,2.42)	0.00(-0.16,0.22)
SD INF IV + MTX		0.82(0.33,2.05)	0.85(0.39,1.78)	-0.03(-0.15,0.11)
SD RITUX IV + MTX		0.46(0.14,1.45)	0.52(0.18,1.37)	-0.09(-0.22,0.05)
SD GOLI IV + MTX		0.77(0.23,2.64)	0.81(0.29,2.13)	-0.03(-0.19,0.16)
SD CERTO + MTX		0.66(0.20,2.12)	0.70(0.25,1.84)	-0.05(-0.20,0.12)
SD TOFA PO + MTX		0.92(0.17,6.21)	0.93(0.21,3.47)	-0.01(-0.20,0.37)
LD GOLI IV		0.46(0.12,1.82)	0.51(0.15,1.62)	-0.09(-0.23,0.09)
LD RITUX IV + MTX		0.31(0.09,0.99)	0.35(0.12,0.99)	-0.12(-0.25,0.00)
LD ETN SC + MTX		0.61(0.17,2.00)	0.66(0.22,1.75)	-0.06(-0.21,0.11)
LD GOLI IV + MTX		0.28(0.07,1.15)	0.32(0.08,1.12)	-0.12(-0.25,0.02)
HD TOCI IV		1.43(0.31,6.62)	1.32(0.37,3.72)	0.06(-0.15,0.38)
HD GOLI SC		0.94(0.20,4.47)	0.95(0.25,2.98)	-0.01(-0.19,0.28)
HD TOCI IV + MTX		2.63(0.66,11.24)	2.00(0.72,4.81)	0.18(-0.07,0.50)
HD GOLI SC + MTX		1.92(0.54,6.83)	1.64(0.61,3.91)	0.12(-0.10,0.38)
HD INF IV + MTX		0.73(0.22,2.27)	0.77(0.28,1.91)	-0.04(-0.19,0.13)
HD TOFA PO + MTX		2.28(0.43,14.91)	1.83(0.50,5.03)	0.15(-0.12,0.57)
SD GOLI SC + MTX	SD ABA SC + MTX	2.75(0.71,11.09)	2.17(0.76,5.88)	0.17(-0.06,0.45)
SD ADA SC + MTX		1.23(0.48,3.41)	1.19(0.53,2.58)	0.03(-0.09,0.22)
SD INF IV + MTX		1.04(0.35,3.29)	1.03(0.42,2.72)	0.00(-0.15,0.16)
SD RITUX IV + MTX		0.59(0.17,2.13)	0.63(0.21,1.93)	-0.05(-0.20,0.09)
SD GOLI IV + MTX		0.99(0.27,3.78)	0.99(0.32,2.98)	0.00(-0.17,0.19)
SD CERTO + MTX		0.84(0.23,3.09)	0.86(0.28,2.57)	-0.02(-0.18,0.15)
SD TOFA PO + MTX		1.17(0.20,8.65)	1.14(0.24,4.72)	0.02(-0.17,0.41)
LD GOLI IV		0.59(0.14,2.59)	0.63(0.17,2.23)	-0.05(-0.21,0.12)
LD RITUX IV + MTX		0.39(0.11,1.42)	0.44(0.14,1.36)	-0.08(-0.23,0.03)
LD ETN SC + MTX		0.78(0.20,2.92)	0.81(0.25,2.47)	-0.03(-0.18,0.14)
LD GOLI IV + MTX		0.35(0.08,1.63)	0.39(0.10,1.53)	-0.09(-0.24,0.05)

(Continued)

HD TOCI IV		1.83(0.37,9.29)	1.61(0.43,5.14)	0.09(-0.13,0.42)
HD GOLI SC		1.20(0.24,6.15)	1.16(0.29,4.09)	0.02(-0.17,0.31)
HD TOCI IV + MTX		3.35(0.77,15.81)	2.45(0.82,6.72)	0.22(-0.04,0.54)
HD GOLI SC + MTX		2.45(0.63,9.73)	1.99(0.70,5.52)	0.15(-0.07,0.41)
HD INF IV + MTX		0.92(0.25,3.42)	0.93(0.31,2.78)	-0.01(-0.17,0.18)
HD TOFA PO + MTX		2.91(0.51,21.10)	2.23(0.58,7.09)	0.18(-0.09,0.60)
SD ADA SC + MTX	SD GOLI SC + MTX	0.45(0.09,2.18)	0.55(0.17,1.76)	-0.14(-0.43,0.15)
SD INF IV + MTX		0.38(0.10,1.46)	0.48(0.18,1.34)	-0.17(-0.44,0.06)
SD RITUX IV + MTX		0.21(0.05,0.91)	0.29(0.10,0.92)	-0.23(-0.49,-0.01)
SD GOLI IV + MTX		0.36(0.08,1.58)	0.46(0.15,1.42)	-0.17(-0.45,0.08)
SD CERTO + MTX		0.30(0.07,1.30)	0.40(0.13,1.23)	-0.19(-0.47,0.04)
SD TOFA PO + MTX		0.42(0.06,3.35)	0.53(0.11,2.17)	-0.15(-0.45,0.26)
LD GOLI IV		0.21(0.04,1.08)	0.29(0.08,1.06)	-0.23(-0.49,0.01)
LD RITUX IV + MTX		0.14(0.03,0.60)	0.20(0.06,0.65)	-0.26(-0.51,-0.06)
LD ETN SC + MTX		0.28(0.06,1.23)	0.37(0.12,1.18)	-0.20(-0.47,0.03)
LD GOLI IV + MTX		0.13(0.02,0.67)	0.18(0.04,0.72)	-0.26(-0.52,-0.05)
HD TOCI IV		0.66(0.12,3.78)	0.75(0.20,2.41)	-0.08(-0.40,0.28)
HD GOLI SC		0.43(0.13,1.45)	0.54(0.19,1.29)	-0.14(-0.35,0.07)
HD TOCI IV + MTX		1.22(0.24,6.35)	1.13(0.39,3.15)	0.04(-0.30,0.41)
HD GOLI SC + MTX		0.89(0.41,1.95)	0.92(0.54,1.58)	-0.02(-0.19,0.14)
HD INF IV + MTX		0.33(0.07,1.45)	0.43(0.14,1.33)	-0.18(-0.45,0.06)
HD TOFA PO + MTX		1.06(0.16,8.20)	1.04(0.27,3.31)	0.01(-0.35,0.47)
SD INF IV + MTX	SD ADA SC + MTX	0.85(0.20,3.33)	0.87(0.29,2.78)	-0.02(-0.27,0.16)
SD RITUX IV + MTX		0.48(0.10,2.03)	0.53(0.15,1.85)	-0.08(-0.32,0.08)
SD GOLI IV + MTX		0.80(0.17,3.67)	0.83(0.24,2.95)	-0.03(-0.28,0.18)
SD CERTO + MTX		0.68(0.14,2.98)	0.73(0.21,2.54)	-0.05(-0.30,0.14)
SD TOFA PO + MTX		0.95(0.13,7.48)	0.96(0.18,4.42)	-0.01(-0.28,0.38)

(Continued)

LD GOLI IV		0.48(0.09,2.45)	0.53(0.12,2.14)	-0.08(-0.33,0.11)
LD RITUX IV + MTX		0.32(0.07,1.35)	0.37(0.10,1.31)	-0.11(-0.35,0.03)
LD ETN SC + MTX		0.63(0.13,2.83)	0.68(0.18,2.42)	-0.05(-0.30,0.13)
LD GOLI IV + MTX		0.29(0.05,1.56)	0.33(0.07,1.48)	-0.11(-0.35,0.04)
HD TOCI IV		1.47(0.24,8.64)	1.35(0.32,4.96)	0.06(-0.23,0.40)
HD GOLI SC		0.97(0.16,5.74)	0.97(0.22,3.94)	0.00(-0.27,0.30)
HD TOCI IV + MTX		2.71(0.49,14.90)	2.05(0.60,6.77)	0.19(-0.13,0.52)
HD GOLI SC + MTX		1.98(0.41,9.38)	1.68(0.52,5.54)	0.12(-0.17,0.40)
HD INF IV + MTX		0.75(0.16,3.37)	0.79(0.22,2.74)	-0.04(-0.29,0.17)
HD TOFA PO + MTX		2.38(0.34,18.69)	1.88(0.43,6.82)	0.15(-0.18,0.58)
SD RITUX IV + MTX	SD INF IV + MTX	0.57(0.16,1.95)	0.61(0.21,1.78)	-0.06(-0.21,0.08)
SD GOLI IV + MTX		0.94(0.26,3.51)	0.95(0.31,2.80)	-0.01(-0.18,0.19)
SD CERTO + MTX		0.80(0.22,2.85)	0.83(0.28,2.40)	-0.03(-0.19,0.14)
SD TOFA PO + MTX		1.11(0.19,8.08)	1.09(0.23,4.48)	0.01(-0.18,0.40)
LD GOLI IV		0.56(0.13,2.42)	0.60(0.16,2.10)	-0.06(-0.22,0.11)
LD RITUX IV + MTX		0.38(0.11,1.33)	0.42(0.13,1.28)	-0.09(-0.24,0.03)
LD ETN SC + MTX		0.75(0.19,2.67)	0.78(0.24,2.27)	-0.03(-0.19,0.14)
LD GOLI IV + MTX		0.34(0.07,1.51)	0.38(0.09,1.43)	-0.09(-0.24,0.04)
HD TOCI IV		1.74(0.35,8.80)	1.55(0.41,4.85)	0.08(-0.14,0.41)
HD GOLI SC		1.16(0.23,5.75)	1.13(0.27,3.86)	0.02(-0.18,0.30)
HD TOCI IV + MTX		3.19(0.76,14.64)	2.36(0.81,6.31)	0.21(-0.04,0.53)
HD GOLI SC + MTX		2.36(0.61,8.95)	1.93(0.68,5.10)	0.14(-0.08,0.40)
HD INF IV + MTX		0.89(0.31,2.44)	0.90(0.36,2.08)	-0.01(-0.15,0.13)
HD TOFA PO + MTX		2.78(0.50,19.03)	2.15(0.56,6.62)	0.18(-0.10,0.59)
SD GOLI IV + MTX	SD RITUX IV + MTX	1.66(0.42,6.80)	1.56(0.47,5.23)	0.05(-0.09,0.24)
SD CERTO + MTX		1.41(0.37,5.49)	1.36(0.42,4.41)	0.03(-0.10,0.19)
SD TOFA PO + MTX		1.95(0.31,14.95)	1.78(0.35,8.03)	0.07(-0.10,0.45)

(Continued)

LD GOLIV		0.99(0.22,4.71)	0.99(0.25,3.87)	0.00(-0.13,0.17)
LD RITUX IV + MTX		0.67(0.27,1.65)	0.69(0.31,1.57)	-0.03(-0.12,0.04)
LD ETN SC + MTX		1.31(0.32,5.33)	1.27(0.36,4.26)	0.02(-0.11,0.19)
LD GOLIV + MTX		0.59(0.12,2.88)	0.62(0.14,2.59)	-0.03(-0.16,0.10)
HD TOCI IV		3.08(0.58,17.34)	2.55(0.62,9.19)	0.14(-0.06,0.47)
HD GOLIV SC		2.01(0.37,11.18)	1.82(0.42,7.17)	0.08(-0.09,0.37)
HD TOCI IV + MTX		5.62(1.26,29.31)	3.84(1.21,12.06)	0.27(0.03,0.59)
HD GOLIV SC + MTX		4.11(1.00,17.68)	3.14(1.00,9.76)	0.20(0.00,0.46)
HD INF IV + MTX		1.56(0.39,6.21)	1.48(0.43,4.88)	0.04(-0.10,0.22)
HD TOFA PO + MTX		4.96(0.82,35.53)	3.52(0.85,12.24)	0.24(-0.02,0.65)
SD CERTO + MTX	SD GOLIV + MTX	0.85(0.21,3.44)	0.87(0.26,2.87)	-0.02(-0.21,0.16)
SD TOFA PO + MTX		1.18(0.19,9.19)	1.15(0.23,5.14)	0.02(-0.20,0.40)
LD GOLIV		0.60(0.19,1.85)	0.64(0.23,1.68)	-0.05(-0.20,0.08)
LD RITUX IV + MTX		0.40(0.10,1.58)	0.44(0.13,1.50)	-0.08(-0.26,0.04)
LD ETN SC + MTX		0.79(0.18,3.32)	0.82(0.23,2.80)	-0.03(-0.22,0.15)
LD GOLIV + MTX		0.36(0.10,1.17)	0.40(0.13,1.15)	-0.08(-0.24,0.02)
HD TOCI IV		1.84(0.33,10.57)	1.63(0.40,5.76)	0.09(-0.15,0.42)
HD GOLIV SC		1.22(0.21,6.51)	1.18(0.26,4.42)	0.03(-0.20,0.31)
HD TOCI IV + MTX		3.37(0.71,17.26)	2.46(0.77,7.61)	0.22(-0.06,0.54)
HD GOLIV SC + MTX		2.47(0.57,10.76)	2.01(0.65,6.17)	0.15(-0.10,0.42)
HD INF IV + MTX		0.93(0.22,3.86)	0.94(0.28,3.12)	-0.01(-0.20,0.18)
HD TOFA PO + MTX		2.95(0.47,22.24)	2.25(0.54,7.71)	0.18(-0.11,0.60)
SD TOFA PO + MTX	SD CERTO + MTX	1.39(0.22,10.48)	1.32(0.26,5.76)	0.04(-0.16,0.42)
LD GOLIV		0.70(0.15,3.29)	0.73(0.19,2.78)	-0.03(-0.20,0.14)
LD RITUX IV + MTX		0.47(0.12,1.82)	0.51(0.15,1.71)	-0.06(-0.22,0.05)
LD ETN SC + MTX		0.93(0.22,3.77)	0.94(0.27,3.11)	-0.01(-0.18,0.17)
LD GOLIV + MTX		0.42(0.08,2.06)	0.45(0.11,1.88)	-0.07(-0.22,0.07)

(Continued)

HD TOCI IV		2.19(0.42,11.58)	1.89(0.48,6.34)	0.11(-0.12,0.44)
HD GOLI SC		1.44(0.25,7.80)	1.36(0.30,5.12)	0.04(-0.16,0.33)
HD TOCI IV + MTX		4.02(0.87,19.52)	2.85(0.90,8.47)	0.24(-0.02,0.55)
HD GOLI SC + MTX		2.93(0.69,12.45)	2.33(0.75,7.03)	0.17(-0.06,0.43)
HD INF IV + MTX		1.11(0.27,4.48)	1.09(0.32,3.56)	0.01(-0.16,0.20)
HD TOFA PO + MTX		3.50(0.57,25.92)	2.61(0.63,8.77)	0.20(-0.08,0.62)
LD GOLI IV	SD TOFA PO + MTX	0.51(0.06,3.59)	0.56(0.11,3.10)	-0.07(-0.45,0.13)
LD RITUX IV + MTX		0.34(0.04,2.14)	0.38(0.08,2.01)	-0.10(-0.48,0.06)
LD ETN SC + MTX		0.67(0.08,4.23)	0.71(0.15,3.54)	-0.05(-0.43,0.16)
LD GOLI IV + MTX		0.30(0.04,2.17)	0.35(0.06,2.01)	-0.11(-0.48,0.06)
HD TOCI IV		1.57(0.17,12.59)	1.42(0.27,7.37)	0.07(-0.34,0.41)
HD GOLI SC		1.01(0.11,8.36)	1.01(0.19,5.78)	0.00(-0.39,0.31)
HD TOCI IV + MTX		2.87(0.34,21.54)	2.14(0.50,10.18)	0.19(-0.23,0.54)
HD GOLI SC + MTX		2.13(0.27,14.17)	1.77(0.42,8.28)	0.12(-0.28,0.42)
HD INF IV + MTX		0.80(0.10,5.01)	0.83(0.18,4.09)	-0.03(-0.41,0.19)
HD TOFA PO + MTX		2.51(0.78,7.97)	1.91(0.84,5.02)	0.15(-0.04,0.40)
LD RITUX IV + MTX	LD GOLI IV	0.67(0.14,3.16)	0.69(0.17,2.91)	-0.03(-0.19,0.08)
LD ETN SC + MTX		1.33(0.27,6.27)	1.29(0.31,5.14)	0.03(-0.15,0.19)
LD GOLI IV + MTX		0.60(0.17,2.13)	0.62(0.19,1.99)	-0.03(-0.17,0.06)
HD TOCI IV		3.09(0.51,19.56)	2.56(0.56,10.74)	0.14(-0.08,0.47)
HD GOLI SC		2.08(0.31,12.45)	1.87(0.37,8.26)	0.08(-0.13,0.36)
HD TOCI IV + MTX		5.69(1.07,33.26)	3.88(1.05,14.48)	0.27(0.01,0.58)
HD GOLI SC + MTX		4.19(0.83,20.60)	3.20(0.86,11.72)	0.20(-0.03,0.46)
HD INF IV + MTX		1.57(0.32,7.49)	1.49(0.37,5.88)	0.04(-0.13,0.23)
HD TOFA PO + MTX		4.98(0.72,41.12)	3.54(0.76,14.75)	0.24(-0.04,0.65)
LD ETN SC + MTX	LD RITUX IV + MTX	1.99(0.47,8.10)	1.86(0.50,6.51)	0.05(-0.06,0.21)
LD GOLI IV + MTX		0.89(0.18,4.47)	0.90(0.20,3.94)	-0.01(-0.10,0.12)

(Continued)

HD TOCI IV		4.64(0.88,26.29)	3.70(0.89,13.62)	0.17(-0.01,0.49)
HD GOLI SC		3.04(0.55,17.31)	2.66(0.58,10.88)	0.11(-0.05,0.39)
HD TOCI IV + MTX		8.48(1.87,44.14)	5.60(1.69,18.05)	0.30(0.07,0.61)
HD GOLI SC + MTX		6.21(1.48,27.00)	4.58(1.39,14.77)	0.23(0.04,0.48)
HD INF IV + MTX		2.34(0.57,9.51)	2.14(0.60,7.37)	0.07(-0.05,0.25)
HD TOFA PO + MTX		7.45(1.20,54.85)	5.13(1.18,18.55)	0.27(0.02,0.68)
LD GOLI IV + MTX	LD ETN SC + MTX	0.45(0.09,2.36)	0.48(0.11,2.15)	-0.06(-0.22,0.08)
HD TOCI IV		2.34(0.43,13.32)	1.99(0.49,7.41)	0.12(-0.11,0.44)
HD GOLI SC		1.54(0.28,8.83)	1.44(0.33,5.85)	0.05(-0.15,0.34)
HD TOCI IV + MTX		4.26(0.92,23.05)	3.01(0.93,9.99)	0.24(-0.01,0.56)
HD GOLI SC + MTX		3.14(0.72,13.83)	2.47(0.78,7.96)	0.17(-0.05,0.43)
HD INF IV + MTX		1.18(0.28,5.15)	1.16(0.34,4.06)	0.02(-0.16,0.20)
HD TOFA PO + MTX		3.72(0.61,28.41)	2.75(0.67,10.26)	0.21(-0.07,0.62)
HD TOCI IV	LD GOLI IV + MTX	5.18(0.80,34.35)	4.10(0.83,18.72)	0.18(-0.02,0.50)
HD GOLI SC		3.45(0.51,22.27)	2.98(0.55,14.47)	0.11(-0.06,0.39)
HD TOCI IV + MTX		9.49(1.71,57.08)	6.21(1.55,25.67)	0.30(0.07,0.61)
HD GOLI SC + MTX		6.98(1.34,36.74)	5.09(1.27,20.68)	0.24(0.04,0.48)
HD INF IV + MTX		2.63(0.51,13.20)	2.39(0.56,10.09)	0.08(-0.06,0.26)
HD TOFA PO + MTX		8.33(1.18,70.80)	5.66(1.15,26.06)	0.27(0.02,0.68)
HD GOLI SC	HD TOCI IV	0.66(0.09,4.65)	0.73(0.16,3.30)	-0.06(-0.41,0.26)
HD TOCI IV + MTX		1.83(0.81,4.49)	1.49(0.88,3.09)	0.12(-0.04,0.30)
HD GOLI SC + MTX		1.34(0.24,7.54)	1.23(0.38,4.56)	0.05(-0.30,0.36)
HD INF IV + MTX		0.51(0.09,2.83)	0.58(0.16,2.36)	-0.10(-0.43,0.14)
HD TOFA PO + MTX		1.61(0.20,14.77)	1.39(0.32,5.74)	0.09(-0.31,0.54)
HD TOCI IV + MTX	HD GOLI SC	2.79(0.45,18.52)	2.09(0.57,8.62)	0.19(-0.16,0.53)
HD GOLI SC + MTX		2.04(0.62,6.84)	1.70(0.72,4.85)	0.12(-0.10,0.32)

(Continued)

HD INF IV + MTX		0.76(0.14,4.27)	0.80(0.20,3.48)	-0.03(-0.32,0.18)
HD TOFA PO + MTX		2.47(0.31,22.14)	1.92(0.41,8.54)	0.16(-0.21,0.59)
HD GOLI SC + MTX	HD TOCI IV + MTX	0.73(0.14,3.66)	0.81(0.29,2.43)	-0.07(-0.43,0.27)
HD INF IV + MTX		0.28(0.05,1.32)	0.38(0.12,1.24)	-0.22(-0.55,0.05)
HD TOFA PO + MTX		0.88(0.12,7.15)	0.93(0.24,3.06)	-0.03(-0.43,0.44)
HD INF IV + MTX	HD GOLI SC + MTX	0.38(0.08,1.63)	0.47(0.15,1.45)	-0.16(-0.42,0.08)
HD TOFA PO + MTX		1.19(0.19,9.27)	1.13(0.29,3.57)	0.04(-0.32,0.49)
HD TOFA PO + MTX	HD INF IV + MTX	3.15(0.51,24.06)	2.38(0.58,8.44)	0.19(-0.10,0.61)
Random-effects model	Residual deviance	77.83 vs 76 data points		
	Deviance information criteria	494.211		
Fixed-effect model	Residual deviance	114.7 vs 76 data points		
	Deviance information criteria	519.067		
Note				
Total participants	14,125			
Total studies	30			
2-arm	17			
3-arm	11			
4-arm	1			
5-arm	1			

Appendix 12. Remission: subgroup - established RA (2-10 years)

Remission established: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

(Continued)

Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX + DMARD	MTX + PL	0.70(0.22,2.23)	0.71(0.22,2.11)	-0.01(-0.04,0.05)
PL		1.02(0.12,8.51)	1.02(0.13,6.35)	0.00(-0.05,0.25)
SD ETN SC		1.79(0.76,4.33)	1.73(0.77,3.73)	0.04(-0.01,0.13)
SD ADA SC		1.22(0.20,8.20)	1.21(0.21,6.15)	0.01(-0.04,0.24)
SD GOL I IV		1.42(0.41,5.02)	1.39(0.42,4.22)	0.02(-0.03,0.15)
SD GOL I SC		3.62(0.36,35.55)	3.21(0.38,13.57)	0.11(-0.03,0.59)
SD ETN SC + MTX		3.21(1.48,7.01)	2.89(1.44,5.42)	0.09(0.02,0.22)
SD ABA IV + MTX		4.73(2.39,9.83)	3.99(2.23,6.95)	0.15(0.06,0.28)
SD ABA SC + MTX		3.50(1.34,8.74)	3.12(1.32,6.43)	0.10(0.02,0.26)
SD GOL I SC + MTX		10.54(3.79,32.51)	7.16(3.30,13.55)	0.30(0.12,0.56)
SD ADA SC + MTX		3.94(1.73,9.61)	3.44(1.67,6.81)	0.12(0.03,0.28)
SD INF IV + MTX		2.26(0.88,6.08)	2.13(0.88,4.89)	0.06(-0.01,0.19)
SD RITUX IV + MTX		3.63(1.35,10.50)	3.21(1.33,7.25)	0.11(0.02,0.30)
SD GOL I IV + MTX		3.27(1.24,8.88)	2.94(1.22,6.48)	0.09(0.01,0.26)
SD CERTO + MTX		10.74(1.18,283.80)	7.24(1.17,21.74)	0.31(0.01,0.88)
SD TOFA PO + MTX		4.30(0.91,25.42)	3.69(0.92,11.98)	0.13(0.00,0.51)
LD GOL I IV		2.21(0.65,7.72)	2.09(0.66,5.86)	0.05(-0.02,0.23)
LD RITUX IV + MTX		1.51(0.58,4.16)	1.48(0.59,3.61)	0.02(-0.02,0.13)
LD ETN SC + MTX		2.96(1.03,8.69)	2.70(1.03,6.35)	0.08(0.00,0.26)
LD GOL I IV + MTX		1.31(0.37,4.63)	1.29(0.38,3.96)	0.01(-0.03,0.14)
HD TOCI IV		7.03(1.84,31.06)	5.42(1.76,13.25)	0.22(0.04,0.55)
HD GOL I SC		4.69(1.16,20.27)	3.97(1.15,10.81)	0.15(0.01,0.45)
HD TOCI IV + MTX		12.92(4.14,49.77)	8.11(3.56,15.88)	0.35(0.13,0.66)
HD GOL I SC + MTX		9.48(3.37,28.37)	6.67(2.99,12.84)	0.28(0.10,0.53)
HD INF IV + MTX		3.49(1.22,10.51)	3.11(1.21,7.20)	0.10(0.01,0.30)
HD TOFA PO + MTX		10.91(2.39,64.71)	7.33(2.23,16.48)	0.31(0.06,0.71)

(Continued)

PL	MTX + DMARD	1.45(0.13,16.52)	1.42(0.14,12.42)	0.01(-0.07,0.26)
SD ETN SC		2.56(0.89,7.68)	2.42(0.89,6.93)	0.05(-0.01,0.13)
SD ADA SC		1.76(0.21,16.15)	1.71(0.22,12.41)	0.02(-0.06,0.25)
SD GOLI IV		2.04(0.37,11.34)	1.96(0.40,9.70)	0.03(-0.05,0.17)
SD GOLI SC		5.22(0.39,68.59)	4.45(0.40,30.13)	0.12(-0.04,0.61)
SD ETN SC + MTX		4.56(1.89,11.45)	4.02(1.76,9.98)	0.10(0.04,0.20)
SD ABA IV + MTX		6.74(1.80,27.16)	5.57(1.67,20.56)	0.16(0.05,0.30)
SD ABA SC + MTX		4.96(1.09,22.38)	4.33(1.08,17.14)	0.11(0.01,0.28)
SD GOLI SC + MTX		15.31(3.22,75.02)	10.02(2.67,37.41)	0.31(0.12,0.57)
SD ADA SC + MTX		5.62(1.39,25.28)	4.81(1.35,18.90)	0.13(0.03,0.29)
SD INF IV + MTX		3.25(0.73,15.40)	2.99(0.75,12.72)	0.07(-0.02,0.20)
SD RITUX IV + MTX		5.18(1.15,25.60)	4.48(1.13,19.01)	0.12(0.01,0.31)
SD GOLI IV + MTX		4.67(1.04,22.15)	4.11(1.04,16.92)	0.11(0.00,0.28)
SD CERTO + MTX		15.62(1.25,484.40)	9.93(1.23,54.76)	0.32(0.01,0.89)
SD TOFA PO + MTX		6.20(0.89,51.49)	5.14(0.90,27.65)	0.14(-0.01,0.52)
LD GOLI IV		3.16(0.59,17.69)	2.92(0.61,13.92)	0.06(-0.03,0.25)
LD RITUX IV + MTX		2.15(0.48,10.46)	2.06(0.50,9.20)	0.04(-0.04,0.14)
LD ETN SC + MTX		4.24(1.07,17.46)	3.78(1.07,13.63)	0.09(0.00,0.26)
LD GOLI IV + MTX		1.87(0.34,10.69)	1.81(0.36,9.21)	0.03(-0.05,0.15)
HD TOCI IV		10.18(1.72,66.28)	7.53(1.62,32.99)	0.23(0.04,0.56)
HD GOLI SC		6.78(1.08,43.15)	5.55(1.07,25.91)	0.16(0.01,0.46)
HD TOCI IV + MTX		18.61(3.66,112.50)	11.21(2.96,44.17)	0.36(0.13,0.67)
HD GOLI SC + MTX		13.61(2.86,68.76)	9.29(2.45,35.46)	0.29(0.10,0.54)
HD INF IV + MTX		4.98(1.07,25.53)	4.33(1.06,18.66)	0.11(0.00,0.31)
HD TOFA PO + MTX		15.72(2.31,130.70)	10.00(2.09,43.78)	0.32(0.06,0.72)
SD ETN SC	PL	1.76(0.18,17.32)	1.69(0.24,15.33)	0.03(-0.21,0.14)
SD ADA SC		1.21(0.07,20.18)	1.20(0.09,16.14)	0.01(-0.23,0.23)
SD GOLI IV		1.41(0.12,16.35)	1.38(0.15,14.33)	0.02(-0.23,0.16)

(Continued)

SD GOLI SC		3.52(0.81,16.88)	2.95(0.83,11.43)	0.09(-0.01,0.45)
SD ETN SC + MTX		3.14(0.34,30.37)	2.82(0.41,24.64)	0.08(-0.16,0.23)
SD ABA IV + MTX		4.66(0.50,44.57)	3.92(0.58,34.30)	0.14(-0.12,0.29)
SD ABA SC + MTX		3.40(0.34,34.84)	3.01(0.42,27.46)	0.09(-0.15,0.27)
SD GOLI SC + MTX		10.48(1.43,79.41)	6.91(1.28,49.53)	0.29(0.06,0.52)
SD ADA SC + MTX		3.92(0.40,39.59)	3.40(0.47,30.44)	0.11(-0.14,0.29)
SD INF IV + MTX		2.25(0.22,23.79)	2.11(0.28,19.89)	0.05(-0.20,0.19)
SD RITUX IV + MTX		3.60(0.34,38.36)	3.15(0.42,29.24)	0.10(-0.15,0.30)
SD GOLI IV + MTX		3.21(0.31,33.38)	2.87(0.39,26.31)	0.09(-0.16,0.27)
SD CERTO + MTX		11.15(0.48,564.20)	6.80(0.54,81.10)	0.29(-0.09,0.88)
SD TOFA PO + MTX		4.29(0.30,70.57)	3.60(0.36,41.14)	0.12(-0.15,0.50)
LD GOLI IV		2.17(0.18,25.75)	2.04(0.23,20.97)	0.05(-0.20,0.23)
LD RITUX IV + MTX		1.49(0.15,16.00)	1.45(0.19,14.02)	0.02(-0.22,0.14)
LD ETN SC + MTX		2.92(0.27,31.42)	2.64(0.33,24.82)	0.08(-0.17,0.26)
LD GOLI IV + MTX		1.29(0.11,15.14)	1.27(0.14,13.32)	0.01(-0.23,0.15)
HD TOCI IV		7.04(0.55,89.56)	5.25(0.62,50.27)	0.20(-0.09,0.54)
HD GOLI SC		4.55(1.02,24.12)	3.76(1.01,19.15)	0.13(0.00,0.35)
HD TOCI IV + MTX		12.86(1.15,155.00)	7.82(1.11,70.11)	0.33(0.03,0.66)
HD GOLI SC + MTX		9.38(1.32,73.10)	6.43(1.21,45.84)	0.26(0.05,0.50)
HD INF IV + MTX		3.46(0.32,37.71)	3.04(0.39,28.79)	0.09(-0.16,0.30)
HD TOFA PO + MTX		10.89(0.78,168.40)	6.93(0.82,67.45)	0.29(-0.04,0.70)
SD ADA SC	SD ETN SC	0.69(0.09,5.40)	0.71(0.10,4.25)	-0.02(-0.14,0.20)
SD GOLI IV		0.80(0.17,3.58)	0.81(0.19,3.12)	-0.01(-0.12,0.12)
SD GOLI SC		2.02(0.17,22.98)	1.85(0.19,9.98)	0.07(-0.10,0.55)
SD ETN SC + MTX		1.78(0.98,3.28)	1.66(0.98,2.89)	0.05(0.00,0.13)
SD ABA IV + MTX		2.64(0.86,8.24)	2.31(0.88,6.23)	0.11(-0.02,0.25)
SD ABA SC + MTX		1.95(0.52,6.80)	1.80(0.56,5.28)	0.07(-0.06,0.23)
SD GOLI SC + MTX		5.93(1.54,23.52)	4.14(1.42,11.54)	0.26(0.06,0.53)

(Continued)

SD ADA SC + MTX		2.19(0.66,7.51)	1.98(0.70,5.75)	0.08(-0.04,0.25)
SD INF IV + MTX		1.26(0.35,4.76)	1.23(0.39,4.03)	0.02(-0.09,0.16)
SD RITUX IV + MTX		2.03(0.55,7.94)	1.86(0.59,5.85)	0.07(-0.06,0.26)
SD GOLI IV + MTX		1.83(0.49,6.84)	1.70(0.53,5.28)	0.06(-0.07,0.23)
SD CERTO + MTX		6.05(0.54,173.40)	4.14(0.58,17.25)	0.27(-0.05,0.85)
SD TOFA PO + MTX		2.40(0.41,17.30)	2.13(0.45,8.97)	0.09(-0.07,0.47)
LD GOLI IV		1.24(0.27,5.59)	1.21(0.30,4.48)	0.02(-0.10,0.20)
LD RITUX IV + MTX		0.84(0.23,3.24)	0.85(0.26,2.91)	-0.01(-0.12,0.10)
LD ETN SC + MTX		1.65(0.51,5.30)	1.56(0.55,4.24)	0.05(-0.06,0.21)
LD GOLI IV + MTX		0.73(0.15,3.38)	0.75(0.18,2.98)	-0.02(-0.13,0.11)
HD TOCI IV		3.97(0.79,21.11)	3.13(0.81,10.30)	0.18(-0.02,0.52)
HD GOLI SC		2.63(0.51,13.94)	2.30(0.55,8.37)	0.11(-0.06,0.41)
HD TOCI IV + MTX		7.26(1.70,35.12)	4.66(1.54,13.53)	0.31(0.07,0.62)
HD GOLI SC + MTX		5.29(1.38,21.36)	3.84(1.31,10.96)	0.24(0.04,0.50)
HD INF IV + MTX		1.95(0.50,7.90)	1.80(0.54,5.80)	0.07(-0.06,0.27)
HD TOFA PO + MTX		6.14(1.05,42.98)	4.19(1.05,13.49)	0.27(0.01,0.68)
SD GOLI IV	SD ADA SC	1.16(0.12,10.30)	1.15(0.15,8.96)	0.01(-0.22,0.15)
SD GOLI SC		2.93(0.15,54.59)	2.56(0.19,26.46)	0.09(-0.17,0.57)
SD ETN SC + MTX		2.61(0.34,18.74)	2.38(0.42,15.27)	0.08(-0.16,0.22)
SD ABA IV + MTX		3.86(0.53,27.42)	3.29(0.61,20.65)	0.13(-0.10,0.29)
SD ABA SC + MTX		2.85(0.34,21.22)	2.55(0.41,16.70)	0.09(-0.15,0.26)
SD GOLI SC + MTX		8.70(1.00,72.73)	5.85(1.00,37.81)	0.28(0.00,0.56)
SD ADA SC + MTX		3.21(0.42,24.69)	2.81(0.50,19.01)	0.10(-0.13,0.28)
SD INF IV + MTX		1.85(0.23,14.89)	1.75(0.28,12.48)	0.04(-0.19,0.19)
SD RITUX IV + MTX		2.95(0.36,24.01)	2.63(0.43,18.22)	0.09(-0.14,0.29)
SD GOLI IV + MTX		2.65(0.31,21.24)	2.41(0.38,16.56)	0.08(-0.16,0.26)
SD CERTO + MTX		9.30(0.48,342.30)	5.75(0.54,50.05)	0.28(-0.08,0.87)
SD TOFA PO + MTX		3.54(0.30,45.36)	3.02(0.36,26.00)	0.11(-0.14,0.50)

(Continued)

LD GOLIV		1.78(0.20,16.52)	1.69(0.25,13.47)	0.04(-0.19,0.23)
LD RITUX IV + MTX		1.22(0.15,9.80)	1.21(0.19,8.76)	0.01(-0.21,0.13)
LD ETN SC + MTX		2.42(0.28,19.81)	2.22(0.34,15.66)	0.07(-0.17,0.26)
LD GOLIV + MTX		1.07(0.11,9.71)	1.06(0.14,8.49)	0.00(-0.22,0.14)
HD TOCI IV		5.76(1.72,19.49)	4.34(1.48,14.65)	0.19(0.05,0.42)
HD GOLIV SC		3.83(0.39,38.62)	3.22(0.45,25.05)	0.12(-0.12,0.43)
HD TOCI IV + MTX		10.55(2.48,49.64)	6.46(1.81,28.75)	0.32(0.13,0.57)
HD GOLIV SC + MTX		7.76(0.92,64.05)	5.42(0.94,35.92)	0.26(-0.01,0.53)
HD INF IV + MTX		2.84(0.34,23.63)	2.53(0.41,17.70)	0.09(-0.15,0.29)
HD TOFA PO + MTX		9.03(0.76,112.30)	5.86(0.81,42.45)	0.29(-0.04,0.70)
SD GOLIV SC	SD GOLIV	2.54(0.19,35.63)	2.26(0.21,15.81)	0.08(-0.11,0.57)
SD ETN SC + MTX		2.25(0.52,9.72)	2.06(0.57,7.98)	0.07(-0.08,0.20)
SD ABA IV + MTX		3.33(0.79,14.04)	2.86(0.82,10.67)	0.12(-0.03,0.27)
SD ABA SC + MTX		2.45(0.50,11.43)	2.22(0.55,8.97)	0.08(-0.08,0.25)
SD GOLIV SC + MTX		7.47(1.48,40.23)	5.10(1.36,19.75)	0.28(0.06,0.55)
SD ADA SC + MTX		2.77(0.62,12.74)	2.45(0.67,9.74)	0.10(-0.06,0.27)
SD INF IV + MTX		1.59(0.33,7.86)	1.53(0.38,6.60)	0.03(-0.11,0.18)
SD RITUX IV + MTX		2.55(0.78,8.64)	2.29(0.80,6.92)	0.08(-0.03,0.24)
SD GOLIV + MTX		2.31(0.47,11.30)	2.10(0.52,8.80)	0.07(-0.08,0.25)
SD CERTO + MTX		7.77(0.58,252.40)	5.09(0.62,27.52)	0.28(-0.05,0.86)
SD TOFA PO + MTX		3.07(0.41,26.15)	2.64(0.45,14.11)	0.11(-0.08,0.49)
LD GOLIV		1.55(0.43,5.55)	1.49(0.46,4.72)	0.03(-0.07,0.18)
LD RITUX IV + MTX		1.06(0.22,5.21)	1.06(0.25,4.64)	0.00(-0.13,0.12)
LD ETN SC + MTX		2.09(0.40,10.76)	1.93(0.44,8.34)	0.06(-0.09,0.24)
LD GOLIV + MTX		0.92(0.25,3.40)	0.92(0.27,3.10)	0.00(-0.11,0.10)
HD TOCI IV		5.02(0.80,33.52)	3.86(0.83,17.14)	0.19(-0.02,0.53)
HD GOLIV SC		3.28(0.50,22.95)	2.80(0.55,13.84)	0.12(-0.07,0.43)
HD TOCI IV + MTX		9.19(1.68,56.26)	5.76(1.51,22.84)	0.32(0.07,0.64)

(Continued)

HD GOLIS SC + MTX		6.66(1.27,35.02)	4.72(1.22,18.47)	0.25(0.03,0.51)
HD INF IV + MTX		2.44(0.48,13.07)	2.21(0.53,9.75)	0.08(-0.08,0.29)
HD TOFA PO + MTX		7.78(1.07,64.92)	5.12(1.06,22.12)	0.28(0.01,0.69)
SD ETN SC + MTX	SD GOLIS SC	0.89(0.08,10.10)	0.90(0.18,8.44)	-0.01(-0.50,0.18)
SD ABA IV + MTX		1.31(0.12,14.37)	1.24(0.26,11.15)	0.04(-0.45,0.25)
SD ABA SC + MTX		0.96(0.08,11.17)	0.96(0.18,9.10)	-0.01(-0.50,0.22)
SD GOLIS SC + MTX		2.96(0.34,25.94)	2.21(0.56,16.14)	0.18(-0.24,0.44)
SD ADA SC + MTX		1.10(0.10,12.89)	1.08(0.21,10.13)	0.01(-0.48,0.24)
SD INF IV + MTX		0.63(0.05,7.62)	0.67(0.12,6.55)	-0.05(-0.53,0.15)
SD RITUX IV + MTX		1.01(0.08,12.47)	1.01(0.18,9.79)	0.00(-0.49,0.24)
SD GOLIS IV + MTX		0.91(0.08,11.45)	0.93(0.17,9.11)	-0.01(-0.49,0.22)
SD CERTO + MTX		3.11(0.13,171.40)	2.18(0.22,26.61)	0.18(-0.38,0.82)
SD TOFA PO + MTX		1.21(0.08,21.40)	1.16(0.15,13.28)	0.02(-0.47,0.42)
LD GOLIS IV		0.61(0.05,8.20)	0.66(0.10,6.84)	-0.05(-0.54,0.18)
LD RITUX IV + MTX		0.42(0.03,5.11)	0.46(0.08,4.64)	-0.08(-0.57,0.10)
LD ETN SC + MTX		0.83(0.07,10.66)	0.85(0.15,8.61)	-0.02(-0.51,0.21)
LD GOLIS IV + MTX		0.37(0.03,4.99)	0.41(0.06,4.46)	-0.09(-0.57,0.10)
HD TOCI IV		1.99(0.14,28.76)	1.69(0.26,16.67)	0.10(-0.41,0.48)
HD GOLIS SC		1.30(0.22,8.06)	1.23(0.37,6.71)	0.03(-0.32,0.24)
HD TOCI IV + MTX		3.67(0.27,50.42)	2.51(0.48,23.04)	0.23(-0.29,0.59)
HD GOLIS SC + MTX		2.62(0.31,23.79)	2.05(0.52,15.43)	0.15(-0.27,0.42)
HD INF IV + MTX		0.98(0.08,12.35)	0.98(0.17,9.59)	0.00(-0.49,0.25)
HD TOFA PO + MTX		3.07(0.20,54.35)	2.23(0.36,21.96)	0.18(-0.34,0.63)
SD ABA IV + MTX	SD ETN SC + MTX	1.48(0.53,4.24)	1.38(0.59,3.35)	0.05(-0.09,0.21)
SD ABA SC + MTX		1.09(0.31,3.61)	1.08(0.37,2.92)	0.01(-0.14,0.18)
SD GOLIS SC + MTX		3.32(0.91,12.57)	2.48(0.93,6.26)	0.21(-0.01,0.48)
SD ADA SC + MTX		1.23(0.40,3.93)	1.19(0.46,3.09)	0.03(-0.12,0.20)

(Continued)

SD INF IV + MTX		0.71(0.21,2.48)	0.74(0.25,2.17)	-0.04(-0.17,0.11)
SD RITUX IV + MTX		1.13(0.32,4.15)	1.11(0.38,3.22)	0.02(-0.14,0.21)
SD GOLI IV + MTX		1.02(0.29,3.55)	1.02(0.35,2.89)	0.00(-0.15,0.18)
SD CERTO + MTX		3.40(0.32,96.36)	2.50(0.37,9.56)	0.21(-0.12,0.80)
SD TOFA PO + MTX		1.35(0.24,9.23)	1.28(0.28,4.96)	0.04(-0.15,0.42)
LD GOLI IV		0.69(0.16,2.98)	0.73(0.19,2.49)	-0.04(-0.18,0.15)
LD RITUX IV + MTX		0.47(0.14,1.68)	0.51(0.17,1.58)	-0.07(-0.20,0.05)
LD ETN SC + MTX		0.92(0.32,2.70)	0.94(0.37,2.26)	-0.01(-0.13,0.15)
LD GOLI IV + MTX		0.41(0.09,1.76)	0.45(0.11,1.64)	-0.07(-0.21,0.06)
HD TOCI IV		2.21(0.46,11.41)	1.88(0.52,5.73)	0.12(-0.10,0.47)
HD GOLI SC		1.47(0.30,7.52)	1.38(0.35,4.55)	0.05(-0.14,0.36)
HD TOCI IV + MTX		4.06(1.01,18.90)	2.80(1.01,7.22)	0.25(0.00,0.57)
HD GOLI SC + MTX		2.97(0.82,11.42)	2.30(0.85,6.00)	0.18(-0.03,0.45)
HD INF IV + MTX		1.09(0.30,4.14)	1.08(0.35,3.17)	0.01(-0.14,0.22)
HD TOFA PO + MTX		3.44(0.61,23.13)	2.52(0.66,7.40)	0.22(-0.06,0.62)
SD ABA SC + MTX	SD ABA IV + MTX	0.74(0.29,1.75)	0.78(0.35,1.55)	-0.04(-0.17,0.09)
SD GOLI SC + MTX		2.25(0.64,8.15)	1.80(0.71,4.15)	0.15(-0.08,0.44)
SD ADA SC + MTX		0.83(0.33,2.17)	0.86(0.40,1.83)	-0.03(-0.16,0.13)
SD INF IV + MTX		0.48(0.15,1.60)	0.53(0.19,1.48)	-0.09(-0.24,0.07)
SD RITUX IV + MTX		0.77(0.22,2.72)	0.81(0.29,2.19)	-0.04(-0.20,0.17)
SD GOLI IV + MTX		0.69(0.21,2.32)	0.74(0.26,1.95)	-0.05(-0.21,0.14)
SD CERTO + MTX		2.30(0.22,64.08)	1.81(0.27,6.40)	0.16(-0.19,0.75)
SD TOFA PO + MTX		0.91(0.17,6.04)	0.92(0.21,3.36)	-0.01(-0.21,0.37)
LD GOLI IV		0.46(0.11,1.93)	0.52(0.15,1.70)	-0.09(-0.25,0.10)
LD RITUX IV + MTX		0.32(0.10,1.08)	0.37(0.13,1.07)	-0.12(-0.27,0.01)
LD ETN SC + MTX		0.63(0.17,2.23)	0.68(0.22,1.89)	-0.06(-0.22,0.13)
LD GOLI IV + MTX		0.27(0.06,1.16)	0.32(0.09,1.14)	-0.13(-0.27,0.02)
HD TOCI IV		1.49(0.32,7.39)	1.36(0.39,3.84)	0.07(-0.16,0.42)

(Continued)

HD GOL I SC		0.99(0.21,4.87)	0.99(0.26,3.09)	0.00(-0.20,0.31)
HD TOCI IV + MTX		2.75(0.71,11.99)	2.03(0.77,4.78)	0.20(-0.06,0.53)
HD GOL I SC + MTX		2.02(0.55,7.41)	1.67(0.63,4.00)	0.13(-0.10,0.41)
HD INF IV + MTX		0.74(0.22,2.50)	0.78(0.28,2.02)	-0.04(-0.20,0.16)
HD TOFA PO + MTX		2.31(0.43,15.08)	1.82(0.50,4.87)	0.16(-0.12,0.57)
SD GOL I SC + MTX	SD ABA SC + MTX	3.08(0.76,13.00)	2.32(0.81,6.60)	0.20(-0.05,0.48)
SD ADA SC + MTX		1.13(0.36,3.92)	1.10(0.43,3.12)	0.02(-0.15,0.19)
SD INF IV + MTX		0.65(0.18,2.58)	0.69(0.22,2.27)	-0.05(-0.22,0.11)
SD RITUX IV + MTX		1.04(0.27,4.32)	1.03(0.33,3.37)	0.01(-0.18,0.21)
SD GOL I IV + MTX		0.93(0.25,3.73)	0.94(0.31,3.04)	-0.01(-0.19,0.18)
SD CERTO + MTX		3.14(0.27,91.33)	2.32(0.33,9.80)	0.20(-0.15,0.79)
SD TOFA PO + MTX		1.24(0.21,9.08)	1.19(0.26,5.02)	0.03(-0.18,0.41)
LD GOL I IV		0.63(0.14,3.03)	0.67(0.18,2.55)	-0.05(-0.22,0.15)
LD RITUX IV + MTX		0.43(0.12,1.76)	0.47(0.15,1.65)	-0.08(-0.24,0.06)
LD ETN SC + MTX		0.85(0.21,3.58)	0.87(0.26,2.88)	-0.02(-0.20,0.18)
LD GOL I IV + MTX		0.37(0.08,1.84)	0.42(0.10,1.70)	-0.09(-0.25,0.06)
HD TOCI IV		2.03(0.39,11.76)	1.74(0.46,5.96)	0.11(-0.13,0.46)
HD GOL I SC		1.35(0.26,7.64)	1.28(0.31,4.78)	0.04(-0.17,0.36)
HD TOCI IV + MTX		3.75(0.85,19.24)	2.60(0.89,7.76)	0.24(-0.03,0.57)
HD GOL I SC + MTX		2.75(0.68,11.78)	2.15(0.74,6.29)	0.17(-0.07,0.45)
HD INF IV + MTX		1.00(0.26,4.19)	1.00(0.32,3.25)	0.00(-0.18,0.21)
HD TOFA PO + MTX		3.16(0.54,22.86)	2.33(0.61,7.65)	0.20(-0.09,0.62)
SD ADA SC + MTX	SD GOL I SC + MTX	0.37(0.09,1.49)	0.48(0.19,1.35)	-0.18(-0.46,0.07)
SD INF IV + MTX		0.21(0.05,0.90)	0.30(0.10,0.92)	-0.24(-0.52,-0.02)
SD RITUX IV + MTX		0.34(0.08,1.49)	0.45(0.15,1.34)	-0.19(-0.47,0.07)
SD GOL I IV + MTX		0.31(0.07,1.31)	0.41(0.14,1.22)	-0.20(-0.48,0.05)
SD CERTO + MTX		1.03(0.08,31.79)	1.02(0.15,3.86)	0.01(-0.43,0.64)

(Continued)

SD TOFA PO + MTX		0.41(0.06,3.16)	0.52(0.11,2.04)	-0.16(-0.48,0.26)
LD GOLI IV		0.21(0.04,1.04)	0.29(0.08,1.03)	-0.24(-0.52,0.01)
LD RITUX IV + MTX		0.14(0.03,0.61)	0.21(0.07,0.67)	-0.27(-0.54,-0.07)
LD ETN SC + MTX		0.28(0.06,1.23)	0.38(0.12,1.17)	-0.21(-0.49,0.04)
LD GOLI IV + MTX		0.12(0.02,0.63)	0.18(0.05,0.70)	-0.28(-0.55,-0.06)
HD TOCI IV		0.66(0.11,3.95)	0.76(0.21,2.34)	-0.08(-0.42,0.31)
HD GOLI SC		0.44(0.13,1.52)	0.56(0.20,1.31)	-0.15(-0.37,0.09)
HD TOCI IV + MTX		1.23(0.24,6.60)	1.13(0.41,2.97)	0.05(-0.31,0.42)
HD GOLI SC + MTX		0.89(0.41,1.99)	0.93(0.55,1.57)	-0.02(-0.20,0.15)
HD INF IV + MTX		0.33(0.07,1.53)	0.43(0.14,1.36)	-0.19(-0.47,0.08)
HD TOFA PO + MTX		1.04(0.16,7.84)	1.03(0.27,3.02)	0.01(-0.37,0.46)
SD INF IV + MTX	SD ADA SC + MTX	0.58(0.16,2.08)	0.62(0.20,1.86)	-0.06(-0.24,0.09)
SD RITUX IV + MTX		0.92(0.24,3.53)	0.94(0.31,2.77)	-0.01(-0.20,0.19)
SD GOLI IV + MTX		0.83(0.22,3.06)	0.85(0.28,2.51)	-0.02(-0.21,0.16)
SD CERTO + MTX		2.75(0.25,80.90)	2.09(0.30,8.25)	0.18(-0.17,0.78)
SD TOFA PO + MTX		1.09(0.18,7.62)	1.08(0.23,4.23)	0.01(-0.21,0.40)
LD GOLI IV		0.56(0.12,2.44)	0.61(0.16,2.09)	-0.06(-0.24,0.13)
LD RITUX IV + MTX		0.38(0.10,1.41)	0.43(0.14,1.35)	-0.09(-0.26,0.04)
LD ETN SC + MTX		0.76(0.19,2.89)	0.79(0.24,2.38)	-0.03(-0.22,0.15)
LD GOLI IV + MTX		0.33(0.07,1.50)	0.38(0.09,1.42)	-0.10(-0.27,0.05)
HD TOCI IV		1.80(0.35,9.44)	1.58(0.42,4.83)	0.09(-0.15,0.44)
HD GOLI SC		1.19(0.23,6.33)	1.15(0.29,3.95)	0.02(-0.19,0.34)
HD TOCI IV + MTX		3.30(0.75,15.65)	2.35(0.81,6.23)	0.23(-0.05,0.55)
HD GOLI SC + MTX		2.40(0.61,9.56)	1.93(0.69,5.15)	0.15(-0.09,0.43)
HD INF IV + MTX		0.89(0.30,2.55)	0.91(0.36,2.11)	-0.02(-0.15,0.15)
HD TOFA PO + MTX		2.79(0.48,18.97)	2.11(0.55,6.33)	0.19(-0.11,0.60)
SD RITUX IV + MTX	SD INF IV + MTX	1.61(0.39,6.53)	1.51(0.44,4.92)	0.05(-0.11,0.25)

(Continued)

SD GOLIV + MTX		1.45(0.36,5.50)	1.38(0.41,4.35)	0.04(-0.12,0.22)
SD CERTO + MTX		4.83(0.41,139.90)	3.36(0.46,14.62)	0.25(-0.09,0.83)
SD TOFA PO + MTX		1.90(0.30,14.52)	1.73(0.34,7.58)	0.07(-0.12,0.46)
LD GOLIV		0.98(0.19,4.59)	0.98(0.23,3.74)	0.00(-0.15,0.18)
LD RITUX IV + MTX		0.67(0.26,1.69)	0.69(0.30,1.60)	-0.03(-0.13,0.05)
LD ETN SC + MTX		1.31(0.30,5.36)	1.27(0.35,4.26)	0.03(-0.13,0.21)
LD GOLIV + MTX		0.58(0.11,2.82)	0.60(0.13,2.53)	-0.04(-0.18,0.10)
HD TOCI IV		3.11(0.58,17.79)	2.52(0.63,8.80)	0.16(-0.07,0.50)
HD GOLIV SC		2.07(0.38,11.71)	1.84(0.43,7.08)	0.09(-0.10,0.40)
HD TOCI IV + MTX		5.76(1.23,29.64)	3.78(1.18,11.45)	0.29(0.03,0.61)
HD GOLIV SC + MTX		4.20(0.99,17.74)	3.10(0.99,9.28)	0.22(0.00,0.48)
HD INF IV + MTX		1.55(0.37,6.58)	1.46(0.42,4.93)	0.05(-0.11,0.25)
HD TOFA PO + MTX		4.86(0.78,36.18)	3.38(0.81,11.54)	0.25(-0.03,0.66)
SD GOLIV + MTX	SD RITUX IV + MTX	0.90(0.21,3.64)	0.91(0.28,2.98)	-0.01(-0.22,0.18)
SD CERTO + MTX		3.00(0.26,85.82)	2.23(0.32,9.56)	0.19(-0.17,0.79)
SD TOFA PO + MTX		1.19(0.17,9.07)	1.15(0.22,5.06)	0.02(-0.21,0.41)
LD GOLIV		0.61(0.19,1.95)	0.65(0.23,1.76)	-0.05(-0.21,0.09)
LD RITUX IV + MTX		0.42(0.10,1.77)	0.46(0.13,1.66)	-0.08(-0.28,0.06)
LD ETN SC + MTX		0.82(0.19,3.57)	0.84(0.24,2.91)	-0.02(-0.23,0.17)
LD GOLIV + MTX		0.36(0.10,1.22)	0.40(0.13,1.18)	-0.09(-0.25,0.02)
HD TOCI IV		1.96(0.35,10.94)	1.68(0.43,5.67)	0.10(-0.16,0.45)
HD GOLIV SC		1.28(0.22,7.76)	1.23(0.29,4.76)	0.03(-0.20,0.36)
HD TOCI IV + MTX		3.60(0.76,18.40)	2.51(0.81,7.46)	0.24(-0.05,0.56)
HD GOLIV SC + MTX		2.61(0.59,11.59)	2.06(0.67,6.26)	0.17(-0.09,0.44)
HD INF IV + MTX		0.96(0.22,4.22)	0.97(0.28,3.26)	0.00(-0.21,0.21)
HD TOFA PO + MTX		3.03(0.46,22.18)	2.25(0.54,7.62)	0.20(-0.12,0.61)
SD CERTO + MTX	SD GOLIV + MTX	3.38(0.30,95.03)	2.47(0.35,10.37)	0.21(-0.15,0.80)

(Continued)

SD TOFA PO + MTX		1.33(0.21,10.15)	1.26(0.26,5.55)	0.04(-0.19,0.42)
LD GOL I IV		0.68(0.14,3.34)	0.71(0.17,2.77)	-0.04(-0.22,0.15)
LD RITUX IV + MTX		0.46(0.12,1.94)	0.50(0.15,1.80)	-0.07(-0.24,0.06)
LD ETN SC + MTX		0.91(0.21,3.88)	0.92(0.26,3.14)	-0.01(-0.20,0.18)
LD GOL I IV + MTX		0.40(0.08,2.00)	0.44(0.10,1.85)	-0.08(-0.25,0.07)
HD TOCI IV		2.18(0.40,12.48)	1.84(0.48,6.34)	0.12(-0.13,0.47)
HD GOL I SC		1.43(0.25,8.39)	1.34(0.32,5.14)	0.05(-0.17,0.36)
HD TOCI IV + MTX		3.99(0.88,20.79)	2.74(0.91,8.32)	0.25(-0.02,0.58)
HD GOL I SC + MTX		2.92(0.68,12.70)	2.27(0.74,6.77)	0.18(-0.06,0.45)
HD INF IV + MTX		1.07(0.25,4.68)	1.06(0.31,3.59)	0.01(-0.18,0.22)
HD TOFA PO + MTX		3.37(0.53,25.33)	2.47(0.60,8.31)	0.21(-0.09,0.63)
SD TOFA PO + MTX	SD CERTO + MTX	0.39(0.01,6.54)	0.53(0.08,4.31)	-0.16(-0.78,0.32)
LD GOL I IV		0.20(0.01,2.58)	0.29(0.06,2.25)	-0.25(-0.83,0.10)
LD RITUX IV + MTX		0.14(0.00,1.63)	0.21(0.04,1.55)	-0.28(-0.86,0.04)
LD ETN SC + MTX		0.27(0.01,3.26)	0.38(0.08,2.75)	-0.22(-0.81,0.14)
LD GOL I IV + MTX		0.12(0.00,1.60)	0.18(0.03,1.53)	-0.29(-0.87,0.04)
HD TOCI IV		0.63(0.02,9.38)	0.74(0.15,5.59)	-0.09(-0.72,0.39)
HD GOL I SC		0.43(0.01,6.41)	0.56(0.10,4.40)	-0.15(-0.78,0.29)
HD TOCI IV + MTX		1.18(0.04,15.85)	1.10(0.28,7.55)	0.04(-0.60,0.51)
HD GOL I SC + MTX		0.86(0.03,10.85)	0.91(0.23,6.33)	-0.03(-0.66,0.40)
HD INF IV + MTX		0.32(0.01,3.83)	0.44(0.09,3.13)	-0.20(-0.80,0.17)
HD TOFA PO + MTX		1.00(0.03,16.78)	1.00(0.20,7.22)	0.00(-0.66,0.53)
LD GOL I IV	SD TOFA PO + MTX	0.51(0.06,3.84)	0.57(0.11,3.26)	-0.07(-0.46,0.15)
LD RITUX IV + MTX		0.35(0.05,2.23)	0.40(0.09,2.08)	-0.11(-0.49,0.06)
LD ETN SC + MTX		0.69(0.09,4.57)	0.73(0.16,3.73)	-0.05(-0.43,0.18)
LD GOL I IV + MTX		0.30(0.03,2.31)	0.35(0.06,2.12)	-0.11(-0.49,0.07)
HD TOCI IV		1.63(0.17,14.23)	1.45(0.29,7.68)	0.08(-0.34,0.46)

(Continued)

HD GOLI SC		1.08(0.12,9.33)	1.06(0.20,6.10)	0.01(-0.38,0.35)
HD TOCI IV + MTX		3.03(0.35,24.24)	2.17(0.52,10.32)	0.21(-0.23,0.57)
HD GOLI SC + MTX		2.18(0.29,14.76)	1.78(0.45,8.32)	0.14(-0.27,0.45)
HD INF IV + MTX		0.81(0.10,5.60)	0.84(0.19,4.34)	-0.03(-0.41,0.22)
HD TOFA PO + MTX		2.54(0.77,8.35)	1.90(0.84,4.96)	0.16(-0.05,0.42)
LD RITUX IV + MTX	LD GOLI IV	0.68(0.14,3.49)	0.70(0.18,3.15)	-0.03(-0.21,0.10)
LD ETN SC + MTX		1.34(0.26,6.97)	1.29(0.32,5.50)	0.03(-0.16,0.22)
LD GOLI IV + MTX		0.59(0.16,2.13)	0.62(0.19,1.99)	-0.04(-0.18,0.06)
HD TOCI IV		3.21(0.52,21.14)	2.57(0.58,10.98)	0.16(-0.09,0.50)
HD GOLI SC		2.11(0.33,14.71)	1.88(0.39,8.95)	0.09(-0.13,0.40)
HD TOCI IV + MTX		5.89(1.07,35.70)	3.84(1.05,14.58)	0.29(0.01,0.61)
HD GOLI SC + MTX		4.28(0.85,22.51)	3.16(0.88,12.10)	0.22(-0.03,0.49)
HD INF IV + MTX		1.57(0.32,8.29)	1.48(0.38,6.27)	0.05(-0.15,0.26)
HD TOFA PO + MTX		5.02(0.68,41.56)	3.45(0.73,14.51)	0.25(-0.05,0.66)
LD ETN SC + MTX	LD RITUX IV + MTX	1.97(0.45,8.35)	1.83(0.49,6.47)	0.06(-0.07,0.24)
LD GOLI IV + MTX		0.87(0.17,4.33)	0.87(0.19,3.78)	-0.01(-0.12,0.12)
HD TOCI IV		4.73(0.84,27.17)	3.68(0.86,13.18)	0.19(-0.02,0.53)
HD GOLI SC		3.09(0.56,17.99)	2.66(0.59,10.63)	0.12(-0.05,0.42)
HD TOCI IV + MTX		8.66(1.83,45.28)	5.47(1.63,17.09)	0.32(0.08,0.64)
HD GOLI SC + MTX		6.35(1.46,27.01)	4.52(1.36,13.87)	0.25(0.05,0.51)
HD INF IV + MTX		2.32(0.54,9.92)	2.11(0.57,7.28)	0.08(-0.06,0.28)
HD TOFA PO + MTX		7.28(1.16,54.51)	4.88(1.13,17.36)	0.28(0.02,0.69)
LD GOLI IV + MTX	LD ETN SC + MTX	0.44(0.08,2.25)	0.48(0.11,2.06)	-0.07(-0.25,0.08)
HD TOCI IV		2.39(0.42,14.52)	2.00(0.49,7.43)	0.13(-0.12,0.48)
HD GOLI SC		1.58(0.27,9.48)	1.46(0.33,5.95)	0.06(-0.17,0.37)
HD TOCI IV + MTX		4.41(0.89,24.33)	2.98(0.92,9.81)	0.26(-0.02,0.59)
HD GOLI SC + MTX		3.20(0.73,14.55)	2.45(0.79,7.88)	0.19(-0.05,0.46)

(Continued)

HD INF IV + MTX		1.17(0.26,5.51)	1.15(0.32,4.19)	0.02(-0.18,0.23)
HD TOFA PO + MTX		3.68(0.58,28.24)	2.65(0.64,9.74)	0.22(-0.08,0.63)
HD TOCI IV	LD GOLI IV + MTX	5.42(0.85,36.93)	4.15(0.87,18.80)	0.20(-0.02,0.54)
HD GOLI SC		3.57(0.54,25.19)	3.03(0.59,15.30)	0.13(-0.06,0.43)
HD TOCI IV + MTX		9.93(1.80,60.87)	6.18(1.59,25.14)	0.33(0.08,0.64)
HD GOLI SC + MTX		7.23(1.42,39.03)	5.08(1.33,20.87)	0.26(0.05,0.52)
HD INF IV + MTX		2.67(0.52,14.26)	2.40(0.56,10.66)	0.09(-0.07,0.29)
HD TOFA PO + MTX		8.50(1.13,72.78)	5.57(1.11,24.42)	0.29(0.01,0.70)
HD GOLI SC	HD TOCI IV	0.66(0.09,4.91)	0.73(0.17,3.28)	-0.07(-0.44,0.29)
HD TOCI IV + MTX		1.83(0.81,4.61)	1.46(0.88,3.04)	0.12(-0.05,0.31)
HD GOLI SC + MTX		1.35(0.23,7.71)	1.23(0.39,4.44)	0.06(-0.33,0.39)
HD INF IV + MTX		0.49(0.08,2.84)	0.58(0.16,2.31)	-0.11(-0.46,0.16)
HD TOFA PO + MTX		1.55(0.18,14.57)	1.33(0.31,5.42)	0.09(-0.35,0.55)
HD TOCI IV + MTX	HD GOLI SC	2.78(0.43,18.85)	2.03(0.57,8.00)	0.20(-0.18,0.55)
HD GOLI SC + MTX		2.00(0.60,7.01)	1.65(0.71,4.74)	0.12(-0.11,0.34)
HD INF IV + MTX		0.74(0.12,4.36)	0.79(0.20,3.43)	-0.04(-0.36,0.20)
HD TOFA PO + MTX		2.37(0.29,21.00)	1.83(0.41,7.89)	0.16(-0.23,0.59)
HD GOLI SC + MTX	HD TOCI IV + MTX	0.73(0.13,3.62)	0.82(0.30,2.30)	-0.07(-0.44,0.28)
HD INF IV + MTX		0.27(0.05,1.32)	0.39(0.12,1.22)	-0.24(-0.57,0.05)
HD TOFA PO + MTX		0.84(0.10,7.14)	0.90(0.23,2.86)	-0.04(-0.47,0.44)
HD INF IV + MTX	HD GOLI SC + MTX	0.37(0.08,1.66)	0.47(0.15,1.46)	-0.17(-0.45,0.09)
HD TOFA PO + MTX		1.16(0.18,8.74)	1.10(0.29,3.31)	0.03(-0.34,0.48)
HD TOFA PO + MTX	HD INF IV + MTX	3.12(0.48,24.05)	2.31(0.56,8.31)	0.20(-0.11,0.62)
Random-effects model	Residual deviance	75.74 vs 74 data points		
	Deviance informa-	478.266		

(Continued)

	tion criteria	
Fixed-effect model	Residual deviance	113.5 vs 74 data points
	Deviance information criteria	504.534
Note		
Total participants	13,479	
Total studies	29	
2-arm	16	
3-arm	11	
4-arm	1	
5-arm	1	

Appendix 13. Remission: subgroup - trial duration (<= 6 months) network 1

Remission short, network 1: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
PL	MTX + PL	1.02(0.13,7.23)	1.02(0.14,5.92)	0.00(-0.04,0.17)
SD ADA SC		1.30(0.23,7.29)	1.29(0.24,5.96)	0.01(-0.03,0.17)
SD GOLI IV		1.43(0.46,4.54)	1.40(0.47,4.03)	0.02(-0.02,0.11)
SD GOLI SC		3.56(0.42,30.78)	3.25(0.43,15.03)	0.09(-0.02,0.50)
SD ABA IV + MTX		4.64(2.54,9.03)	4.07(2.39,7.01)	0.12(0.05,0.22)
SD GOLI SC + MTX		10.73(4.13,31.34)	7.80(3.64,15.92)	0.26(0.11,0.49)
SD ABA SC + MTX		3.62(1.47,8.24)	3.29(1.44,6.52)	0.09(0.02,0.21)
SD INF IV + MTX		3.76(1.87,8.65)	3.40(1.81,6.79)	0.09(0.03,0.22)
SD GOLI IV + MTX		3.64(1.48,9.89)	3.31(1.45,7.52)	0.09(0.02,0.24)
SD CERTO + MTX		3.21(1.36,7.93)	2.96(1.34,6.33)	0.07(0.01,0.20)
SD ADA SC + MTX		10.55(1.27,278.50)	7.69(1.25,28.95)	0.26(0.01,0.87)

(Continued)

SD RITUX IV + MTX		4.64(1.13,21.72)	4.07(1.13,12.45)	0.12(0.00,0.41)
LD GOLI IV		2.23(0.73,6.90)	2.13(0.74,5.67)	0.04(-0.01,0.17)
LD RITUX IV + MTX		4.78(1.18,22.42)	4.18(1.17,12.68)	0.12(0.01,0.42)
LD GOLI IV + MTX		1.32(0.41,4.19)	1.30(0.42,3.75)	0.01(-0.02,0.10)
HD TOCI IV		7.52(2.12,29.66)	6.01(2.03,15.14)	0.19(0.04,0.48)
HD GOLI SC		4.61(1.28,18.39)	4.05(1.27,11.58)	0.12(0.01,0.36)
HD TOCI IV + MTX		13.01(4.27,48.87)	8.89(3.78,18.95)	0.30(0.11,0.60)
HD GOLI SC + MTX		9.34(3.56,27.52)	7.07(3.21,14.86)	0.23(0.09,0.46)
HD INF IV + MTX		3.42(1.37,9.17)	3.13(1.35,7.04)	0.08(0.01,0.23)
SD ADA SC	PL	1.32(0.09,17.85)	1.30(0.10,15.38)	0.01(-0.17,0.17)
SD GOLI IV		1.41(0.14,14.45)	1.39(0.17,13.08)	0.01(-0.16,0.11)
SD GOLI SC		3.53(0.89,15.52)	3.10(0.90,11.21)	0.08(-0.01,0.40)
SD ABA IV + MTX		4.61(0.60,39.26)	4.02(0.65,31.84)	0.11(-0.07,0.23)
SD GOLI SC + MTX		10.77(1.72,70.14)	7.69(1.51,47.78)	0.25(0.08,0.45)
SD ABA SC + MTX		3.55(0.40,31.45)	3.22(0.45,26.18)	0.08(-0.10,0.21)
SD INF IV + MTX		3.74(0.48,33.61)	3.37(0.53,27.59)	0.09(-0.09,0.22)
SD GOLI IV + MTX		3.65(0.43,33.50)	3.29(0.48,27.39)	0.08(-0.10,0.24)
SD CERTO + MTX		3.19(0.37,28.06)	2.92(0.43,23.81)	0.07(-0.11,0.20)
SD ADA SC + MTX		11.28(0.57,490.80)	7.61(0.61,90.41)	0.25(-0.05,0.86)
SD RITUX IV + MTX		4.66(0.41,58.97)	4.01(0.46,38.62)	0.11(-0.09,0.41)
LD GOLI IV		2.23(0.24,21.68)	2.12(0.28,18.65)	0.04(-0.13,0.17)
LD RITUX IV + MTX		4.78(0.43,62.35)	4.10(0.49,41.53)	0.11(-0.08,0.42)
LD GOLI IV + MTX		1.31(0.13,13.37)	1.30(0.16,12.13)	0.01(-0.16,0.11)
HD TOCI IV		7.60(0.68,86.19)	5.93(0.72,52.77)	0.18(-0.05,0.48)
HD GOLI SC		4.58(1.12,21.84)	3.94(1.10,18.47)	0.11(0.01,0.29)
HD TOCI IV + MTX		13.21(1.31,144.40)	8.78(1.23,74.37)	0.29(0.04,0.60)
HD GOLI SC + MTX		9.44(1.55,63.26)	6.98(1.40,44.69)	0.22(0.06,0.42)
HD INF IV + MTX		3.40(0.40,31.17)	3.09(0.44,25.68)	0.07(-0.10,0.23)

(Continued)

SD GOLI IV	SD ADA SC	1.11(0.14,8.73)	1.10(0.16,7.93)	0.00(-0.16,0.11)
SD GOLI SC		2.71(0.19,47.64)	2.47(0.21,25.90)	0.07(-0.12,0.49)
SD ABA IV + MTX		3.55(0.59,23.21)	3.14(0.65,18.80)	0.10(-0.07,0.22)
SD GOLI SC + MTX		8.30(1.14,63.29)	6.02(1.11,37.52)	0.24(0.02,0.48)
SD ABA SC + MTX		2.75(0.41,19.04)	2.52(0.46,15.52)	0.07(-0.10,0.20)
SD INF IV + MTX		2.90(0.47,20.44)	2.64(0.53,16.67)	0.08(-0.09,0.21)
SD GOLI IV + MTX		2.82(0.40,20.17)	2.58(0.45,16.28)	0.07(-0.10,0.23)
SD CERTO + MTX		2.48(0.36,17.55)	2.31(0.42,14.61)	0.06(-0.11,0.20)
SD ADA SC + MTX		8.67(0.54,322.10)	6.02(0.58,50.30)	0.24(-0.05,0.86)
SD RITUX IV + MTX		3.58(0.40,37.56)	3.13(0.45,24.46)	0.10(-0.09,0.40)
LD GOLI IV		1.73(0.22,13.67)	1.66(0.26,11.58)	0.03(-0.14,0.17)
LD RITUX IV + MTX		3.67(0.42,38.80)	3.20(0.47,25.07)	0.10(-0.09,0.41)
LD GOLI IV + MTX		1.02(0.13,7.94)	1.02(0.15,7.23)	0.00(-0.16,0.10)
HD TOCI IV		5.86(1.95,17.74)	4.61(1.68,14.05)	0.17(0.05,0.37)
HD GOLI SC		3.52(0.41,33.97)	3.10(0.46,23.66)	0.10(-0.09,0.36)
HD TOCI IV + MTX		10.08(2.86,42.71)	6.75(2.14,27.63)	0.28(0.11,0.51)
HD GOLI SC + MTX		7.19(1.00,57.28)	5.45(1.00,35.01)	0.21(0.00,0.45)
HD INF IV + MTX		2.63(0.38,19.53)	2.42(0.44,15.73)	0.07(-0.10,0.22)
SD GOLI SC	SD GOLI IV	2.50(0.22,29.37)	2.30(0.24,15.68)	0.07(-0.08,0.48)
SD ABA IV + MTX		3.25(0.91,12.19)	2.89(0.92,9.88)	0.10(-0.01,0.21)
SD GOLI SC + MTX		7.64(1.73,36.50)	5.56(1.58,20.65)	0.24(0.07,0.47)
SD ABA SC + MTX		2.51(0.59,10.11)	2.31(0.63,8.40)	0.07(-0.04,0.19)
SD INF IV + MTX		2.66(0.70,10.96)	2.44(0.73,8.99)	0.07(-0.03,0.20)
SD GOLI IV + MTX		2.55(0.88,7.86)	2.34(0.90,6.62)	0.07(-0.01,0.19)
SD CERTO + MTX		2.26(0.54,9.70)	2.12(0.57,8.02)	0.06(-0.05,0.19)
SD ADA SC + MTX		7.71(0.64,222.50)	5.48(0.67,31.74)	0.24(-0.03,0.85)
SD RITUX IV + MTX		3.29(0.53,22.27)	2.91(0.56,14.12)	0.10(-0.05,0.40)
LD GOLI IV		1.56(0.50,4.98)	1.51(0.53,4.43)	0.03(-0.05,0.13)

(Continued)

LD RITUX IV + MTX		3.40(0.55,23.16)	2.99(0.58,14.60)	0.10(-0.04,0.41)
LD GOLI IV + MTX		0.92(0.28,3.05)	0.93(0.30,2.87)	0.00(-0.08,0.07)
HD TOCI IV		5.29(0.90,31.93)	4.24(0.92,18.03)	0.17(-0.01,0.47)
HD GOLI SC		3.25(0.58,19.52)	2.88(0.61,13.26)	0.10(-0.04,0.35)
HD TOCI IV + MTX		9.18(1.86,52.28)	6.28(1.67,24.03)	0.28(0.07,0.59)
HD GOLI SC + MTX		6.61(1.47,31.64)	5.04(1.39,19.09)	0.21(0.04,0.44)
HD INF IV + MTX		2.41(0.56,10.60)	2.23(0.59,8.62)	0.06(-0.05,0.21)
SD ABA IV + MTX	SD GOLI SC	1.31(0.14,12.45)	1.26(0.25,10.16)	0.03(-0.39,0.19)
SD GOLI SC + MTX		3.06(0.42,22.38)	2.40(0.58,15.49)	0.16(-0.19,0.38)
SD ABA SC + MTX		1.01(0.10,10.03)	1.01(0.18,8.47)	0.00(-0.42,0.17)
SD INF IV + MTX		1.07(0.11,10.50)	1.06(0.20,8.78)	0.01(-0.41,0.18)
SD GOLI IV + MTX		1.03(0.10,10.66)	1.02(0.18,8.85)	0.00(-0.41,0.19)
SD CERTO + MTX		0.90(0.09,9.21)	0.92(0.16,7.91)	-0.01(-0.42,0.16)
SD ADA SC + MTX		3.17(0.15,138.40)	2.36(0.22,27.91)	0.16(-0.32,0.79)
SD RITUX IV + MTX		1.30(0.11,18.12)	1.25(0.17,12.61)	0.03(-0.39,0.35)
LD GOLI IV		0.63(0.06,6.88)	0.66(0.10,6.07)	-0.04(-0.45,0.13)
LD RITUX IV + MTX		1.36(0.11,18.80)	1.29(0.18,12.79)	0.03(-0.38,0.36)
LD GOLI IV + MTX		0.37(0.03,4.33)	0.40(0.06,4.03)	-0.07(-0.48,0.07)
HD TOCI IV		2.13(0.16,25.65)	1.85(0.27,16.56)	0.10(-0.35,0.42)
HD GOLI SC		1.30(0.24,6.99)	1.25(0.37,5.92)	0.03(-0.28,0.19)
HD TOCI IV + MTX		3.73(0.31,45.30)	2.73(0.46,23.56)	0.20(-0.25,0.54)
HD GOLI SC + MTX		2.66(0.36,20.08)	2.17(0.53,14.30)	0.13(-0.22,0.35)
HD INF IV + MTX		0.97(0.09,9.98)	0.97(0.17,8.40)	0.00(-0.42,0.18)
SD GOLI SC + MTX	SD ABA IV + MTX	2.31(0.73,7.75)	1.91(0.77,4.51)	0.14(-0.05,0.39)
SD ABA SC + MTX		0.78(0.33,1.62)	0.81(0.37,1.49)	-0.03(-0.13,0.07)
SD INF IV + MTX		0.82(0.36,1.96)	0.84(0.41,1.75)	-0.02(-0.13,0.09)
SD GOLI IV + MTX		0.79(0.25,2.49)	0.81(0.30,2.11)	-0.03(-0.16,0.13)

(Continued)

SD CERTO + MTX		0.69(0.23,2.03)	0.73(0.28,1.81)	-0.04(-0.17,0.09)
SD ADA SC + MTX		2.28(0.24,61.63)	1.89(0.29,7.79)	0.14(-0.15,0.77)
SD RITUX IV + MTX		1.00(0.21,4.99)	1.00(0.25,3.30)	0.00(-0.16,0.30)
LD GOL I V		0.48(0.13,1.70)	0.52(0.16,1.57)	-0.07(-0.19,0.07)
LD RITUX IV + MTX		1.04(0.22,5.26)	1.03(0.26,3.41)	0.00(-0.16,0.31)
LD GOL I V + MTX		0.28(0.07,1.05)	0.32(0.09,1.04)	-0.10(-0.22,0.00)
HD TOCI IV		1.63(0.38,7.24)	1.48(0.44,4.18)	0.07(-0.12,0.38)
HD GOL I SC		0.99(0.24,4.38)	0.99(0.28,3.13)	0.00(-0.16,0.26)
HD TOCI IV + MTX		2.80(0.77,11.87)	2.18(0.81,5.35)	0.18(-0.04,0.50)
HD GOL I SC + MTX		2.01(0.63,6.82)	1.74(0.69,4.15)	0.11(-0.07,0.35)
HD INF IV + MTX		0.74(0.25,2.18)	0.77(0.30,1.90)	-0.03(-0.15,0.11)
SD ABA SC + MTX	SD GOL I SC + MTX	0.33(0.08,1.20)	0.42(0.14,1.16)	-0.17(-0.41,0.03)
SD INF IV + MTX		0.35(0.10,1.25)	0.44(0.17,1.19)	-0.17(-0.41,0.03)
SD GOL I V + MTX		0.33(0.09,1.35)	0.42(0.15,1.27)	-0.17(-0.41,0.05)
SD CERTO + MTX		0.30(0.08,1.10)	0.38(0.13,1.08)	-0.18(-0.43,0.01)
SD ADA SC + MTX		1.02(0.09,26.57)	1.01(0.14,4.24)	0.00(-0.38,0.64)
SD RITUX IV + MTX		0.43(0.08,2.62)	0.52(0.13,1.96)	-0.14(-0.40,0.19)
LD GOL I V		0.20(0.05,0.91)	0.27(0.08,0.92)	-0.21(-0.45,-0.01)
LD RITUX IV + MTX		0.44(0.08,2.70)	0.54(0.13,1.99)	-0.13(-0.40,0.20)
LD GOL I V + MTX		0.12(0.03,0.56)	0.17(0.04,0.61)	-0.25(-0.48,-0.07)
HD TOCI IV		0.69(0.13,3.71)	0.77(0.21,2.43)	-0.07(-0.36,0.27)
HD GOL I SC		0.42(0.14,1.33)	0.52(0.20,1.22)	-0.14(-0.32,0.06)
HD TOCI IV + MTX		1.21(0.26,6.11)	1.14(0.39,3.14)	0.04(-0.28,0.39)
HD GOL I SC + MTX		0.87(0.43,1.82)	0.91(0.55,1.53)	-0.03(-0.17,0.12)
HD INF IV + MTX		0.32(0.08,1.22)	0.40(0.14,1.17)	-0.18(-0.42,0.03)
SD INF IV + MTX	SD ABA SC + MTX	1.04(0.40,3.38)	1.04(0.45,2.89)	0.00(-0.11,0.14)
SD GOL I V + MTX		1.01(0.30,3.90)	1.01(0.35,3.22)	0.00(-0.14,0.16)

(Continued)

SD CERTO + MTX		0.89(0.27,3.19)	0.90(0.32,2.76)	-0.01(-0.15,0.13)
SD ADA SC + MTX		3.03(0.29,84.52)	2.40(0.34,11.34)	0.17(-0.12,0.79)
SD RITUX IV + MTX		1.30(0.26,7.55)	1.25(0.30,4.94)	0.03(-0.13,0.33)
LD GOL I IV		0.62(0.16,2.62)	0.65(0.19,2.31)	-0.04(-0.17,0.10)
LD RITUX IV + MTX		1.34(0.27,7.82)	1.28(0.31,5.03)	0.03(-0.13,0.34)
LD GOL I IV + MTX		0.37(0.09,1.59)	0.40(0.11,1.52)	-0.07(-0.20,0.04)
HD TOCI IV		2.10(0.46,10.73)	1.84(0.51,6.23)	0.10(-0.09,0.41)
HD GOL I SC		1.29(0.29,6.69)	1.24(0.33,4.64)	0.03(-0.13,0.29)
HD TOCI IV + MTX		3.64(0.92,17.80)	2.72(0.94,8.17)	0.21(-0.01,0.53)
HD GOL I SC + MTX		2.63(0.74,10.50)	2.18(0.78,6.45)	0.14(-0.04,0.39)
HD INF IV + MTX		0.95(0.29,3.51)	0.95(0.34,2.97)	-0.01(-0.13,0.15)
SD GOL I IV + MTX	SD INF IV + MTX	0.96(0.28,3.24)	0.97(0.33,2.69)	0.00(-0.15,0.15)
SD CERTO + MTX		0.85(0.25,2.66)	0.87(0.30,2.31)	-0.02(-0.15,0.12)
SD ADA SC + MTX		2.79(0.27,77.24)	2.24(0.32,9.97)	0.16(-0.13,0.78)
SD RITUX IV + MTX		1.23(0.23,6.51)	1.19(0.27,4.22)	0.02(-0.15,0.32)
LD GOL I IV		0.59(0.14,2.20)	0.62(0.17,1.97)	-0.05(-0.18,0.09)
LD RITUX IV + MTX		1.26(0.24,6.78)	1.22(0.29,4.30)	0.03(-0.15,0.33)
LD GOL I IV + MTX		0.35(0.08,1.32)	0.38(0.10,1.28)	-0.08(-0.21,0.03)
HD TOCI IV		2.00(0.42,9.02)	1.76(0.48,5.20)	0.10(-0.11,0.40)
HD GOL I SC		1.22(0.26,5.62)	1.18(0.31,3.95)	0.02(-0.15,0.28)
HD TOCI IV + MTX		3.44(0.86,15.09)	2.59(0.89,6.83)	0.21(-0.02,0.52)
HD GOL I SC + MTX		2.47(0.70,8.84)	2.06(0.74,5.39)	0.14(-0.05,0.38)
HD INF IV + MTX		0.91(0.35,2.26)	0.92(0.40,1.98)	-0.01(-0.12,0.11)
SD CERTO + MTX	SD GOL I IV + MTX	0.88(0.23,3.24)	0.89(0.29,2.80)	-0.01(-0.18,0.13)
SD ADA SC + MTX		2.98(0.27,81.52)	2.34(0.32,11.07)	0.17(-0.14,0.79)
SD RITUX IV + MTX		1.27(0.23,7.74)	1.23(0.27,4.98)	0.03(-0.16,0.33)
LD GOL I IV		0.61(0.21,1.74)	0.64(0.24,1.62)	-0.04(-0.16,0.06)

(Continued)

LD RITUX IV + MTX		1.31(0.23,7.91)	1.26(0.28,5.06)	0.03(-0.16,0.34)
LD GOL I IV + MTX		0.36(0.12,1.06)	0.40(0.14,1.05)	-0.07(-0.20,0.00)
HD TOCI IV		2.07(0.41,10.99)	1.80(0.47,6.31)	0.10(-0.11,0.41)
HD GOL I SC		1.27(0.25,6.53)	1.23(0.30,4.60)	0.03(-0.16,0.29)
HD TOCI IV + MTX		3.57(0.82,18.21)	2.66(0.86,8.18)	0.21(-0.03,0.53)
HD GOL I SC + MTX		2.61(0.65,10.30)	2.15(0.71,6.30)	0.14(-0.07,0.38)
HD INF IV + MTX		0.94(0.24,3.52)	0.95(0.30,2.97)	-0.01(-0.17,0.15)
SD ADA SC + MTX	SD CERTO + MTX	3.34(0.33,97.49)	2.61(0.37,12.59)	0.18(-0.11,0.80)
SD RITUX IV + MTX		1.45(0.28,8.31)	1.38(0.32,5.29)	0.04(-0.12,0.34)
LD GOL I IV		0.70(0.16,2.87)	0.72(0.19,2.53)	-0.03(-0.17,0.11)
LD RITUX IV + MTX		1.49(0.29,8.70)	1.41(0.33,5.49)	0.04(-0.12,0.35)
LD GOL I IV + MTX		0.41(0.10,1.71)	0.44(0.11,1.62)	-0.06(-0.19,0.05)
HD TOCI IV		2.34(0.49,11.91)	2.02(0.54,6.76)	0.11(-0.09,0.42)
HD GOL I SC		1.42(0.30,7.41)	1.36(0.35,5.11)	0.04(-0.13,0.30)
HD TOCI IV + MTX		4.05(0.97,19.75)	2.98(0.98,9.09)	0.22(0.00,0.54)
HD GOL I SC + MTX		2.93(0.79,11.69)	2.39(0.83,6.97)	0.15(-0.03,0.39)
HD INF IV + MTX		1.07(0.29,3.90)	1.06(0.34,3.26)	0.01(-0.13,0.16)
SD RITUX IV + MTX	SD ADA SC + MTX	0.43(0.01,5.91)	0.53(0.08,4.32)	-0.13(-0.77,0.26)
LD GOL I IV		0.20(0.01,2.39)	0.27(0.05,2.18)	-0.21(-0.83,0.08)
LD RITUX IV + MTX		0.44(0.01,6.24)	0.54(0.09,4.41)	-0.13(-0.77,0.26)
LD GOL I IV + MTX		0.12(0.00,1.42)	0.17(0.03,1.38)	-0.24(-0.85,0.02)
HD TOCI IV		0.69(0.02,8.56)	0.77(0.14,5.61)	-0.07(-0.72,0.33)
HD GOL I SC		0.42(0.01,5.69)	0.52(0.09,4.24)	-0.14(-0.77,0.24)
HD TOCI IV + MTX		1.23(0.04,14.53)	1.14(0.24,7.79)	0.04(-0.64,0.46)
HD GOL I SC + MTX		0.87(0.03,9.72)	0.90(0.21,6.37)	-0.03(-0.67,0.35)
HD INF IV + MTX		0.32(0.01,3.55)	0.40(0.08,3.05)	-0.17(-0.80,0.13)
LD GOL I IV	SD RITUX IV + MTX	0.48(0.07,2.91)	0.53(0.11,2.59)	-0.07(-0.37,0.10)

(Continued)

LD RITUX IV + MTX		1.03(0.32,3.38)	1.03(0.39,2.72)	0.00(-0.18,0.19)
LD GOLI IV + MTX		0.28(0.04,1.72)	0.32(0.07,1.64)	-0.10(-0.40,0.04)
HD TOCI IV		1.64(0.21,10.95)	1.48(0.30,6.69)	0.07(-0.28,0.39)
HD GOLI SC		1.00(0.13,6.82)	1.00(0.20,4.94)	0.00(-0.32,0.27)
HD TOCI IV + MTX		2.84(0.41,18.48)	2.18(0.54,9.28)	0.18(-0.17,0.51)
HD GOLI SC + MTX		2.04(0.33,11.71)	1.74(0.46,7.51)	0.11(-0.22,0.37)
HD INF IV + MTX		0.74(0.12,4.15)	0.77(0.19,3.51)	-0.03(-0.34,0.15)
LD RITUX IV + MTX	LD GOLI IV	2.17(0.36,14.89)	1.97(0.40,9.39)	0.08(-0.10,0.38)
LD GOLI IV + MTX		0.59(0.19,1.89)	0.62(0.21,1.80)	-0.03(-0.14,0.04)
HD TOCI IV		3.40(0.59,19.68)	2.83(0.64,11.27)	0.14(-0.06,0.44)
HD GOLI SC		2.10(0.38,11.85)	1.91(0.42,8.22)	0.07(-0.10,0.32)
HD TOCI IV + MTX		5.89(1.23,32.83)	4.17(1.18,15.06)	0.25(0.03,0.56)
HD GOLI SC + MTX		4.29(0.96,19.28)	3.36(0.97,11.80)	0.19(-0.01,0.42)
HD INF IV + MTX		1.54(0.36,6.75)	1.47(0.41,5.54)	0.04(-0.11,0.19)
LD GOLI IV + MTX	LD RITUX IV + MTX	0.27(0.04,1.68)	0.31(0.06,1.61)	-0.11(-0.41,0.04)
HD TOCI IV		1.58(0.20,10.50)	1.44(0.29,6.43)	0.07(-0.28,0.38)
HD GOLI SC		0.96(0.13,6.78)	0.97(0.20,4.90)	0.00(-0.32,0.27)
HD TOCI IV + MTX		2.76(0.39,17.69)	2.13(0.53,8.73)	0.17(-0.19,0.51)
HD GOLI SC + MTX		1.97(0.33,11.42)	1.70(0.45,7.20)	0.11(-0.22,0.37)
HD INF IV + MTX		0.72(0.12,4.00)	0.75(0.18,3.37)	-0.04(-0.35,0.15)
HD TOCI IV	LD GOLI IV + MTX	5.79(0.98,34.99)	4.60(0.99,19.95)	0.18(0.00,0.47)
HD GOLI SC		3.51(0.62,21.01)	3.10(0.65,14.48)	0.10(-0.04,0.35)
HD TOCI IV + MTX		9.97(2.01,58.65)	6.76(1.79,26.50)	0.28(0.08,0.59)
HD GOLI SC + MTX		7.14(1.56,34.84)	5.40(1.46,20.76)	0.22(0.05,0.45)
HD INF IV + MTX		2.60(0.60,11.86)	2.39(0.63,9.67)	0.07(-0.04,0.22)
HD GOLI SC	HD TOCI IV	0.60(0.09,4.24)	0.67(0.16,3.11)	-0.07(-0.39,0.23)
HD TOCI IV + MTX		1.71(0.85,4.09)	1.45(0.90,2.96)	0.10(-0.03,0.27)

(Continued)

HD GOLI SC + MTX		1.24(0.24,6.87)	1.17(0.37,4.39)	0.04(-0.29,0.33)
HD INF IV + MTX		0.45(0.09,2.37)	0.52(0.15,2.08)	-0.11(-0.41,0.11)
HD TOCI IV + MTX	HD GOLI SC	2.91(0.47,17.65)	2.22(0.58,8.48)	0.18(-0.14,0.51)
HD GOLI SC + MTX		2.05(0.67,6.28)	1.74(0.75,4.57)	0.11(-0.07,0.29)
HD INF IV + MTX		0.74(0.14,3.71)	0.77(0.20,3.14)	-0.03(-0.29,0.14)
HD GOLI SC + MTX	HD TOCI IV + MTX	0.71(0.14,3.45)	0.80(0.29,2.39)	-0.07(-0.41,0.25)
HD INF IV + MTX		0.26(0.05,1.15)	0.35(0.12,1.12)	-0.22(-0.52,0.02)
HD INF IV + MTX	HD GOLI SC + MTX	0.36(0.09,1.39)	0.44(0.15,1.31)	-0.15(-0.39,0.05)
Random-effects model	Residual deviance	54.1 vs 52 data points		
	Deviance information criteria	326.692		
Fixed-effect model	Residual deviance	67.08 vs 52 data points		
	Deviance information criteria	333.907		
Note				
Total participants	9626			
Total studies	20			
2-arm	11			
3-arm	7			
4-arm	1			
5-arm	1			

Appendix 14. Remission: subgroup - trial duration (<= 6 months) network 2

Remission short, network 2: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

(Continued)

SD ETN SC	MTX + DMARD	3.16(1.02,10.45)	2.59(1.02,5.96)	0.16(0.00,0.40)
SD ETN SC + MTX		4.41(1.96,11.94)	3.29(1.76,6.51)	0.23(0.08,0.43)
SD ETN SC + MTX	SD ETN SC	1.39(0.71,3.08)	1.26(0.81,2.38)	0.07(-0.08,0.20)
Random-effects model	Residual deviance	12.14 vs 10 data points		
	Deviance information criteria	69.459		
Fixed-effect model	Residual deviance	18.44 vs 10 data points		
	Deviance information criteria	73.457		
Note				
Total participants	1392			
Total studies	5			
2-arm	5			

Appendix 15. Withdrawals due to adverse events: main analysis

Withdrawals: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Refer-ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	3.10(1.12,5.73)	2.98(1.12,5.25)	0.04(0.00,0.09)
DMARD		1.22(0.47,2.89)	1.22(0.48,2.79)	0.00(-0.01,0.04)
MTX + DMARD		6.88(2.16,18.40)	6.11(2.09,13.62)	0.11(0.03,0.27)
SD ETN SC		2.60(0.98,4.77)	2.51(0.98,4.46)	0.03(0.00,0.07)
SD ADA SC		1.96(0.95,3.70)	1.92(0.96,3.52)	0.02(0.00,0.05)
SD TOCI IV		1.59(0.61,3.68)	1.57(0.61,3.50)	0.01(-0.01,0.05)
SD CERTO SC		2.94(0.87,16.78)	2.82(0.87,13.25)	0.04(0.00,0.22)
SD TOFA		0.27(0.01,2.00)	0.28(0.01,1.96)	-0.01(-0.03,0.02)
SD TOC SC + PL IV		1.15(0.35,3.23)	1.15(0.36,3.10)	0.00(-0.02,0.04)
SD RITUX IV		17.34(1.88,260.80)	12.73(1.84,42.45)	0.25(0.02,0.83)
SD ANA		1.31(0.38,5.06)	1.30(0.39,4.69)	0.01(-0.01,0.08)

(Continued)

SD ETN SC + MTX	2.58(0.89,5.37)	2.50(0.89,4.97)	0.03(0.00,0.08)
SD ADA SC + MTX	4.52(1.45,9.52)	4.21(1.43,8.17)	0.07(0.01,0.16)
SD INF IV + MTX	5.75(1.89,13.05)	5.22(1.84,10.50)	0.09(0.02,0.21)
SD ABA IV + MTX	2.95(0.96,6.66)	2.83(0.96,6.01)	0.04(0.00,0.10)
SD RITUX IV + MTX	3.88(1.07,17.77)	3.66(1.07,12.91)	0.06(0.00,0.27)
SD CERTO SC + MTX	4.31(1.33,10.05)	4.02(1.32,8.45)	0.06(0.01,0.15)
SD GOLI SC + MTX	3.75(0.88,13.26)	3.55(0.89,10.46)	0.05(0.00,0.21)
SD TOFA PO + MTX	5.76(1.76,13.89)	5.24(1.73,11.07)	0.09(0.02,0.21)
SD ABA SC + MTX	1.56(0.47,4.05)	1.54(0.48,3.83)	0.01(-0.01,0.06)
SD TOCI IV + MTX	3.04(0.88,9.39)	2.92(0.88,8.03)	0.04(0.00,0.15)
SD ETN SC + DMARD	1.28(0.51,2.82)	1.27(0.52,2.72)	0.01(-0.01,0.03)
SD CERTO + DMARD	1.73(0.50,5.05)	1.70(0.51,4.70)	0.01(-0.01,0.07)
SD ABA IV + DMARD	1.66(0.47,4.64)	1.64(0.47,4.33)	0.01(-0.01,0.07)
SD ADA SC + DMARD	1.41(0.30,6.24)	1.40(0.30,5.66)	0.01(-0.02,0.10)
SD TOCI SC + DMARD	2.99(0.53,32.55)	2.87(0.54,19.83)	0.04(-0.01,0.39)
LD ETN SC	2.30(0.84,4.86)	2.24(0.84,4.54)	0.03(0.00,0.08)
LD ADA SC	0.68(0.23,1.93)	0.69(0.23,1.89)	-0.01(-0.02,0.02)
LD ANA	0.98(0.29,3.69)	0.98(0.30,3.49)	0.00(-0.02,0.05)
LD TOCI IV	1.85(0.40,6.07)	1.82(0.40,5.51)	0.02(-0.02,0.09)
LD RITUX IV + MTX	5.85(1.49,28.36)	5.29(1.47,17.52)	0.09(0.01,0.37)
LD ABA IV + MTX	3.83(0.87,12.23)	3.61(0.88,10.03)	0.05(0.00,0.19)
LD CERTO SC + MTX	3.49(0.40,13.84)	3.31(0.41,11.15)	0.05(-0.01,0.21)
LD ETN SC + MTX	1.48(0.32,6.59)	1.47(0.33,5.93)	0.01(-0.02,0.10)
LD TOCI IV + MTX	1.27(0.24,5.29)	1.27(0.24,4.88)	0.01(-0.02,0.08)
HD TOCI IV	2.47(0.88,5.24)	2.39(0.88,4.86)	0.03(0.00,0.08)
HD GOLI SC	1.62(0.18,9.11)	1.59(0.18,7.88)	0.01(-0.02,0.14)
HD ADA SC	0.71(0.23,1.91)	0.72(0.23,1.87)	-0.01(-0.02,0.02)
HD TOFA	2.08(0.51,9.04)	2.03(0.52,7.87)	0.02(-0.01,0.13)

(Continued)

HD ANA		2.33(0.82,7.82)	2.26(0.82,6.89)	0.03(0.00,0.12)
HD TOCI IV + MTX		3.17(1.01,8.67)	3.02(1.01,7.50)	0.04(0.00,0.14)
HD GOLI SC + MTX		4.97(1.35,18.57)	4.58(1.34,13.50)	0.07(0.01,0.27)
HD INF IV + MTX		5.25(1.46,12.43)	4.81(1.44,10.24)	0.08(0.01,0.19)
HD TOFA PO + MTX		4.42(1.38,11.69)	4.13(1.36,9.66)	0.06(0.01,0.18)
HD CERTO SC + MTX		4.83(1.23,13.41)	4.46(1.22,10.78)	0.07(0.01,0.20)
HD TOCI IV + DMARD		2.40(0.75,6.94)	2.33(0.76,6.20)	0.03(-0.01,0.11)
DMARD	MTX	0.41(0.21,0.87)	0.43(0.22,0.88)	-0.03(-0.08,0.00)
MTX + DMARD		2.33(1.13,5.01)	2.14(1.12,4.13)	0.07(0.01,0.20)
SD ETN SC		0.85(0.59,1.28)	0.86(0.61,1.26)	-0.01(-0.03,0.01)
SD ADA SC		0.66(0.31,1.63)	0.67(0.33,1.59)	-0.02(-0.07,0.02)
SD TOCI IV		0.55(0.20,1.45)	0.56(0.21,1.42)	-0.03(-0.08,0.02)
SD CERTO SC		1.03(0.24,6.88)	1.02(0.26,5.58)	0.00(-0.08,0.18)
SD TOFA		0.09(0.00,0.86)	0.09(0.00,0.86)	-0.05(-0.11,0.00)
SD TOC SC + PL IV		0.38(0.13,1.21)	0.40(0.14,1.21)	-0.03(-0.09,0.01)
SD RITUX IV		6.00(0.81,64.99)	4.49(0.82,15.08)	0.21(-0.01,0.76)
SD ANA		0.46(0.10,2.27)	0.48(0.11,2.15)	-0.03(-0.09,0.05)
SD ETN SC + MTX		0.84(0.55,1.33)	0.85(0.57,1.31)	-0.01(-0.03,0.02)
SD ADA SC + MTX		1.47(0.91,2.40)	1.43(0.91,2.22)	0.02(0.00,0.08)
SD INF IV + MTX		1.90(1.14,3.12)	1.80(1.13,2.78)	0.05(0.01,0.13)
SD ABA IV + MTX		0.96(0.52,1.64)	0.97(0.53,1.59)	0.00(-0.04,0.03)
SD RITUX IV + MTX		1.35(0.51,4.96)	1.32(0.52,3.70)	0.02(-0.03,0.21)
SD CERTO SC + MTX		1.39(0.74,2.52)	1.36(0.76,2.34)	0.02(-0.02,0.08)
SD GOLI SC + MTX		1.23(0.46,3.62)	1.21(0.48,3.11)	0.01(-0.04,0.14)
SD TOFA PO + MTX		1.91(1.02,3.27)	1.81(1.02,2.90)	0.05(0.00,0.14)
SD ABA SC + MTX		0.52(0.26,1.05)	0.54(0.27,1.05)	-0.03(-0.07,0.00)
SD TOCI IV + MTX		1.04(0.35,3.03)	1.04(0.37,2.77)	0.00(-0.05,0.09)
SD ETN SC + DMARD		0.44(0.20,0.94)	0.45(0.21,0.94)	-0.03(-0.08,0.00)

(Continued)

SD CERTO + DMARD		0.59(0.19,1.84)	0.60(0.20,1.76)	-0.02(-0.07,0.03)
SD ABA IV + DMARD		0.56(0.21,1.51)	0.57(0.22,1.47)	-0.02(-0.07,0.02)
SD ADA SC + DMARD		0.50(0.12,2.02)	0.51(0.13,1.91)	-0.03(-0.08,0.05)
SD TOCI SC + DMARD		1.03(0.19,9.50)	1.03(0.21,6.14)	0.00(-0.07,0.33)
LD ETN SC		0.76(0.46,1.31)	0.77(0.47,1.29)	-0.01(-0.04,0.01)
LD ADA SC		0.23(0.07,0.89)	0.24(0.07,0.89)	-0.04(-0.10,0.00)
LD ANA		0.33(0.08,1.68)	0.35(0.09,1.62)	-0.04(-0.09,0.02)
LD TOCI IV		0.64(0.17,1.99)	0.65(0.18,1.89)	-0.02(-0.08,0.05)
LD RITUX IV + MTX		2.03(0.76,7.40)	1.90(0.77,5.06)	0.05(-0.01,0.31)
LD ABA IV + MTX		1.28(0.44,3.32)	1.26(0.45,2.92)	0.01(-0.04,0.12)
LD CERTO SC + MTX		1.13(0.20,4.27)	1.12(0.21,3.55)	0.01(-0.05,0.15)
LD ETN SC + MTX		0.52(0.13,1.80)	0.54(0.14,1.70)	-0.02(-0.08,0.05)
LD TOCI IV + MTX		0.45(0.08,1.69)	0.47(0.09,1.62)	-0.03(-0.09,0.03)
HD TOCI IV		0.82(0.44,1.51)	0.82(0.45,1.48)	-0.01(-0.05,0.02)
HD GOLI SC		0.54(0.07,2.76)	0.56(0.08,2.50)	-0.02(-0.08,0.09)
HD ADA SC		0.25(0.06,0.83)	0.26(0.07,0.84)	-0.04(-0.10,-0.01)
HD TOFA		0.72(0.12,3.83)	0.73(0.13,3.47)	-0.01(-0.09,0.10)
HD ANA		0.83(0.21,3.42)	0.84(0.23,3.12)	-0.01(-0.08,0.09)
HD TOCI IV + MTX		1.04(0.46,2.56)	1.04(0.48,2.36)	0.00(-0.04,0.08)
HD GOLI SC + MTX		1.70(0.65,4.99)	1.63(0.66,3.95)	0.04(-0.02,0.20)
HD INF IV + MTX		1.69(0.87,3.17)	1.62(0.87,2.82)	0.04(-0.01,0.12)
HD TOFA PO + MTX		1.47(0.80,2.70)	1.42(0.81,2.44)	0.02(-0.01,0.10)
HD CERTO SC + MTX		1.58(0.63,3.62)	1.52(0.64,3.14)	0.03(-0.02,0.14)
HD TOCI IV + DMARD		0.81(0.33,2.21)	0.82(0.34,2.09)	-0.01(-0.06,0.06)
MTX + DMARD	DMARD	5.53(1.99,14.90)	4.92(1.92,11.77)	0.10(0.03,0.26)
SD ETN SC		2.08(0.99,4.11)	2.02(0.99,3.91)	0.02(0.00,0.06)
SD ADA SC		1.60(0.69,4.02)	1.58(0.70,3.85)	0.01(-0.01,0.05)
SD TOCI IV		1.31(0.48,3.47)	1.30(0.49,3.33)	0.01(-0.02,0.04)

(Continued)

SD CERTO SC	2.52(0.49,16.43)	2.43(0.50,13.02)	0.03(-0.03,0.21)
SD TOFA	0.21(0.00,2.23)	0.21(0.00,2.19)	-0.02(-0.06,0.02)
SD TOC SC + PL IV	0.93(0.29,2.88)	0.93(0.30,2.79)	0.00(-0.03,0.04)
SD RITUX IV	14.16(1.88,174.10)	10.24(1.84,40.02)	0.25(0.02,0.82)
SD ANA	1.09(0.24,5.35)	1.09(0.25,5.00)	0.00(-0.04,0.07)
SD ETN SC + MTX	2.05(0.89,4.39)	2.00(0.90,4.13)	0.02(0.00,0.07)
SD ADA SC + MTX	3.55(1.47,7.89)	3.33(1.44,7.02)	0.06(0.01,0.14)
SD INF IV + MTX	4.60(1.83,10.64)	4.18(1.77,9.10)	0.08(0.02,0.19)
SD ABA IV + MTX	2.30(0.87,5.54)	2.22(0.88,5.14)	0.03(0.00,0.09)
SD RITUX IV + MTX	3.21(0.97,14.89)	3.03(0.97,10.94)	0.05(0.00,0.26)
SD CERTO SC + MTX	3.30(1.40,8.27)	3.10(1.38,7.41)	0.05(0.01,0.14)
SD GOLI SC + MTX	2.96(0.88,10.47)	2.81(0.88,8.73)	0.05(0.00,0.20)
SD TOFA PO + MTX	4.57(1.69,10.85)	4.16(1.65,9.21)	0.08(0.02,0.20)
SD ABA SC + MTX	1.26(0.47,3.42)	1.25(0.48,3.29)	0.01(-0.02,0.05)
SD TOCI IV + MTX	2.45(0.71,7.82)	2.35(0.72,6.95)	0.03(-0.01,0.13)
SD ETN SC + DMARD	1.04(0.56,1.99)	1.04(0.57,1.96)	0.00(-0.02,0.02)
SD CERTO + DMARD	1.42(0.49,3.66)	1.41(0.50,3.49)	0.01(-0.02,0.06)
SD ABA IV + DMARD	1.34(0.69,2.64)	1.33(0.69,2.54)	0.01(-0.01,0.05)
SD ADA SC + DMARD	1.18(0.32,3.95)	1.17(0.33,3.66)	0.00(-0.02,0.08)
SD TOCI SC + DMARD	2.45(0.60,18.52)	2.36(0.60,11.56)	0.03(-0.01,0.36)
LD ETN SC	1.83(0.80,4.24)	1.79(0.80,4.01)	0.02(-0.01,0.06)
LD ADA SC	0.56(0.14,2.27)	0.57(0.14,2.22)	-0.01(-0.05,0.02)
LD ANA	0.82(0.20,3.74)	0.82(0.20,3.57)	0.00(-0.04,0.05)
LD TOCI IV	1.50(0.36,5.38)	1.48(0.37,4.95)	0.01(-0.03,0.08)
LD RITUX IV + MTX	4.94(1.42,22.86)	4.43(1.40,15.30)	0.09(0.01,0.36)
LD ABA IV + MTX	3.08(0.78,10.12)	2.91(0.78,8.63)	0.05(-0.01,0.17)
LD CERTO SC + MTX	2.78(0.44,11.03)	2.63(0.45,9.07)	0.04(-0.02,0.20)
LD ETN SC + MTX	1.26(0.28,4.65)	1.25(0.28,4.29)	0.01(-0.03,0.09)

(Continued)

LD TOCI IV + MTX		1.09(0.19,4.45)	1.09(0.19,4.11)	0.00(-0.03,0.07)
HD TOCI IV		1.99(0.93,3.88)	1.93(0.93,3.70)	0.02(0.00,0.06)
HD GOLI SC		1.35(0.15,8.10)	1.34(0.15,7.20)	0.01(-0.04,0.14)
HD ADA SC		0.59(0.14,2.08)	0.60(0.15,2.04)	-0.01(-0.04,0.02)
HD TOFA		1.73(0.26,9.88)	1.70(0.27,8.54)	0.02(-0.04,0.13)
HD ANA		1.97(0.49,8.48)	1.92(0.50,7.59)	0.02(-0.02,0.12)
HD TOCI IV + MTX		2.58(0.94,6.70)	2.47(0.95,6.01)	0.04(0.00,0.12)
HD GOLI SC + MTX		4.10(1.18,15.88)	3.78(1.17,12.18)	0.07(0.01,0.25)
HD INF IV + MTX		4.14(1.45,9.85)	3.80(1.43,8.51)	0.07(0.01,0.18)
HD TOFA PO + MTX		3.54(1.33,8.88)	3.30(1.31,7.67)	0.06(0.01,0.16)
HD CERTO SC + MTX		3.85(1.19,10.54)	3.55(1.18,8.78)	0.06(0.00,0.19)
HD TOCI IV + DMARD		1.95(1.05,3.79)	1.90(1.05,3.55)	0.02(0.00,0.08)
SD ETN SC	MTX + DMARD	0.37(0.17,0.79)	0.40(0.21,0.81)	-0.08(-0.21,-0.01)
SD ADA SC		0.28(0.10,0.88)	0.31(0.13,0.89)	-0.09(-0.24,-0.01)
SD TOCI IV		0.24(0.07,0.80)	0.26(0.09,0.81)	-0.09(-0.26,-0.01)
SD CERTO SC		0.45(0.09,3.17)	0.49(0.11,2.70)	-0.06(-0.25,0.13)
SD TOFA		0.04(0.00,0.38)	0.05(0.00,0.40)	-0.12(-0.29,-0.03)
SD TOC SC + PL IV		0.17(0.04,0.68)	0.19(0.05,0.69)	-0.10(-0.27,-0.02)
SD RITUX IV		2.57(0.28,29.12)	2.11(0.31,7.78)	0.14(-0.12,0.67)
SD ANA		0.20(0.03,1.19)	0.22(0.04,1.18)	-0.10(-0.27,0.01)
SD ETN SC + MTX		0.36(0.17,0.74)	0.40(0.21,0.76)	-0.08(-0.21,-0.01)
SD ADA SC + MTX		0.63(0.26,1.50)	0.66(0.31,1.44)	-0.04(-0.17,0.03)
SD INF IV + MTX		0.83(0.41,1.53)	0.85(0.46,1.46)	-0.02(-0.12,0.04)
SD ABA IV + MTX		0.41(0.15,1.01)	0.45(0.18,1.01)	-0.07(-0.22,0.00)
SD RITUX IV + MTX		0.58(0.16,2.42)	0.62(0.19,2.05)	-0.04(-0.19,0.13)
SD CERTO SC + MTX		0.59(0.24,1.51)	0.63(0.28,1.46)	-0.05(-0.18,0.04)
SD GOLI SC + MTX		0.54(0.16,2.03)	0.57(0.19,1.86)	-0.05(-0.19,0.08)
SD TOFA PO + MTX		0.83(0.30,2.06)	0.85(0.36,1.90)	-0.02(-0.16,0.07)

(Continued)

SD ABA SC + MTX	0.22(0.08,0.61)	0.25(0.09,0.63)	-0.09(-0.25,-0.02)	
SD TOCI IV + MTX	0.44(0.12,1.66)	0.48(0.15,1.58)	-0.06(-0.22,0.05)	
SD ETN SC + DMARD	0.19(0.06,0.52)	0.21(0.08,0.54)	-0.10(-0.26,-0.02)	
SD CERTO + DMARD	0.26(0.07,0.96)	0.29(0.08,0.96)	-0.09(-0.25,0.00)	
SD ABA IV + DMARD	0.24(0.07,0.81)	0.27(0.09,0.82)	-0.09(-0.25,-0.01)	
SD ADA SC + DMARD	0.21(0.04,1.02)	0.24(0.05,1.01)	-0.09(-0.25,0.00)	
SD TOCI SC + DMARD	0.44(0.08,5.05)	0.47(0.09,3.48)	-0.06(-0.23,0.26)	
LD ETN SC	0.33(0.14,0.78)	0.36(0.17,0.80)	-0.08(-0.22,-0.01)	
LD ADA SC	0.10(0.02,0.43)	0.12(0.03,0.45)	-0.11(-0.27,-0.03)	
LD ANA	0.14(0.03,0.87)	0.16(0.04,0.88)	-0.10(-0.27,-0.01)	
LD TOCI IV	0.27(0.05,1.08)	0.30(0.07,1.08)	-0.09(-0.26,0.01)	
LD RITUX IV + MTX	0.88(0.25,3.66)	0.90(0.29,2.76)	-0.01(-0.16,0.22)	
LD ABA IV + MTX	0.54(0.16,1.87)	0.58(0.18,1.73)	-0.05(-0.19,0.06)	
LD CERTO SC + MTX	0.48(0.07,2.19)	0.52(0.08,1.97)	-0.06(-0.21,0.09)	
LD ETN SC + MTX	0.22(0.05,0.97)	0.25(0.06,0.98)	-0.09(-0.25,0.00)	
LD TOCI IV + MTX	0.19(0.03,0.80)	0.22(0.04,0.82)	-0.09(-0.26,-0.01)	
HD TOCI IV	0.35(0.13,0.94)	0.39(0.17,0.95)	-0.08(-0.23,0.00)	
HD GOLI SC	0.24(0.02,1.37)	0.27(0.03,1.32)	-0.09(-0.25,0.03)	
HD ADA SC	0.10(0.02,0.44)	0.12(0.03,0.46)	-0.11(-0.28,-0.03)	
HD TOFA	0.31(0.05,2.02)	0.34(0.06,1.89)	-0.08(-0.26,0.06)	
HD ANA	0.35(0.08,1.77)	0.38(0.10,1.67)	-0.08(-0.25,0.05)	
HD TOCI IV + MTX	0.45(0.15,1.46)	0.49(0.18,1.40)	-0.06(-0.21,0.03)	
HD GOLI SC + MTX	0.73(0.20,2.55)	0.76(0.24,2.22)	-0.03(-0.17,0.12)	
HD INF IV + MTX	0.73(0.30,1.70)	0.76(0.34,1.60)	-0.03(-0.15,0.05)	
HD TOFA PO + MTX	0.63(0.24,1.67)	0.66(0.29,1.59)	-0.04(-0.18,0.05)	
HD CERTO SC + MTX	0.66(0.20,2.10)	0.70(0.24,1.91)	-0.04(-0.17,0.08)	
HD TOCI IV + DMARD	0.35(0.11,1.20)	0.39(0.13,1.18)	-0.07(-0.24,0.01)	
SD ADA SC	SD ETN SC	0.76(0.37,1.84)	0.77(0.39,1.79)	-0.01(-0.05,0.03)

(Continued)

SD TOCI IV	0.64(0.24,1.60)	0.66(0.26,1.57)	-0.02(-0.06,0.02)
SD CERTO SC	1.20(0.29,7.82)	1.18(0.31,6.28)	0.01(-0.06,0.19)
SD TOFA	0.10(0.00,0.98)	0.11(0.00,0.98)	-0.04(-0.09,0.00)
SD TOC SC + PL IV	0.45(0.15,1.39)	0.47(0.16,1.37)	-0.03(-0.07,0.01)
SD RITUX IV	7.02(0.94,80.12)	5.23(0.94,17.44)	0.22(0.00,0.78)
SD ANA	0.54(0.12,2.57)	0.55(0.13,2.45)	-0.02(-0.08,0.05)
SD ETN SC + MTX	0.99(0.63,1.51)	0.99(0.64,1.48)	0.00(-0.02,0.03)
SD ADA SC + MTX	1.72(0.92,3.17)	1.66(0.93,2.87)	0.03(0.00,0.10)
SD INF IV + MTX	2.25(1.21,4.07)	2.10(1.20,3.56)	0.06(0.01,0.15)
SD ABA IV + MTX	1.14(0.55,2.13)	1.13(0.56,2.02)	0.01(-0.03,0.05)
SD RITUX IV + MTX	1.56(0.57,6.29)	1.51(0.58,4.73)	0.03(-0.02,0.22)
SD CERTO SC + MTX	1.62(0.80,3.28)	1.57(0.81,2.98)	0.03(-0.01,0.10)
SD GOLI SC + MTX	1.45(0.47,4.57)	1.42(0.49,3.88)	0.02(-0.03,0.16)
SD TOFA PO + MTX	2.22(1.08,4.41)	2.08(1.07,3.77)	0.05(0.00,0.16)
SD ABA SC + MTX	0.61(0.27,1.36)	0.62(0.28,1.34)	-0.02(-0.06,0.02)
SD TOCI IV + MTX	1.20(0.38,3.68)	1.19(0.40,3.30)	0.01(-0.04,0.11)
SD ETN SC + DMARD	0.51(0.24,1.04)	0.52(0.26,1.04)	-0.02(-0.06,0.00)
SD CERTO + DMARD	0.69(0.21,2.15)	0.70(0.23,2.06)	-0.01(-0.06,0.04)
SD ABA IV + DMARD	0.65(0.25,1.78)	0.67(0.26,1.72)	-0.02(-0.06,0.03)
SD ADA SC + DMARD	0.57(0.13,2.40)	0.59(0.14,2.25)	-0.02(-0.06,0.06)
SD TOCI SC + DMARD	1.19(0.24,11.56)	1.18(0.25,7.13)	0.01(-0.05,0.34)
LD ETN SC	0.90(0.54,1.49)	0.90(0.55,1.46)	0.00(-0.03,0.02)
LD ADA SC	0.28(0.07,1.01)	0.29(0.08,1.01)	-0.04(-0.08,0.00)
LD ANA	0.39(0.10,1.84)	0.41(0.11,1.78)	-0.03(-0.08,0.03)
LD TOCI IV	0.74(0.19,2.39)	0.75(0.20,2.25)	-0.01(-0.06,0.06)
LD RITUX IV + MTX	2.37(0.84,9.50)	2.20(0.85,6.26)	0.06(-0.01,0.32)
LD ABA IV + MTX	1.49(0.45,4.26)	1.45(0.46,3.67)	0.02(-0.03,0.14)
LD CERTO SC + MTX	1.32(0.23,5.22)	1.30(0.24,4.36)	0.02(-0.04,0.17)

(Continued)

LD ETN SC + MTX		0.62(0.15,2.09)	0.63(0.16,1.97)	-0.02(-0.06,0.05)
LD TOCI IV + MTX		0.53(0.10,2.17)	0.54(0.10,2.05)	-0.02(-0.07,0.05)
HD TOCI IV		0.96(0.48,1.84)	0.96(0.50,1.78)	0.00(-0.04,0.03)
HD GOLI SC		0.64(0.08,3.42)	0.65(0.08,3.06)	-0.02(-0.07,0.10)
HD ADA SC		0.29(0.08,0.98)	0.30(0.08,0.98)	-0.04(-0.08,0.00)
HD TOFA		0.84(0.14,4.49)	0.85(0.15,4.02)	-0.01(-0.08,0.11)
HD ANA		0.98(0.26,3.87)	0.98(0.27,3.51)	0.00(-0.06,0.09)
HD TOCI IV + MTX		1.24(0.52,3.08)	1.23(0.54,2.82)	0.01(-0.03,0.09)
HD GOLI SC + MTX		2.01(0.69,6.29)	1.91(0.70,4.95)	0.04(-0.02,0.22)
HD INF IV + MTX		1.99(0.92,3.94)	1.88(0.92,3.46)	0.05(0.00,0.14)
HD TOFA PO + MTX		1.71(0.83,3.55)	1.65(0.84,3.14)	0.03(-0.01,0.13)
HD CERTO SC + MTX		1.86(0.68,4.63)	1.77(0.69,3.98)	0.04(-0.02,0.15)
HD TOCI IV + DMARD		0.96(0.37,2.54)	0.96(0.39,2.38)	0.00(-0.04,0.07)
SD TOCI IV	SD ADA SC	0.81(0.37,1.75)	0.82(0.38,1.70)	-0.01(-0.04,0.03)
SD CERTO SC		1.52(0.37,9.81)	1.49(0.38,7.90)	0.02(-0.04,0.20)
SD TOFA		0.14(0.00,1.12)	0.14(0.00,1.11)	-0.03(-0.07,0.00)
SD TOC SC + PL IV		0.58(0.21,1.56)	0.59(0.21,1.54)	-0.02(-0.05,0.02)
SD RITUX IV		9.13(1.02,124.00)	6.71(1.01,23.65)	0.23(0.00,0.80)
SD ANA		0.67(0.18,3.07)	0.68(0.19,2.90)	-0.01(-0.05,0.06)
SD ETN SC + MTX		1.28(0.48,3.00)	1.26(0.49,2.82)	0.01(-0.03,0.06)
SD ADA SC + MTX		2.19(0.80,5.46)	2.09(0.81,4.80)	0.04(-0.01,0.13)
SD INF IV + MTX		2.89(1.04,7.38)	2.68(1.04,6.12)	0.07(0.00,0.18)
SD ABA IV + MTX		1.46(0.49,3.64)	1.43(0.51,3.38)	0.02(-0.03,0.08)
SD RITUX IV + MTX		2.04(0.54,10.36)	1.95(0.55,7.84)	0.04(-0.02,0.25)
SD CERTO SC + MTX		2.14(0.71,5.54)	2.04(0.72,4.87)	0.04(-0.01,0.13)
SD GOLI SC + MTX		1.90(0.47,6.64)	1.83(0.48,5.52)	0.03(-0.03,0.18)
SD TOFA PO + MTX		2.87(0.97,7.71)	2.65(0.98,6.36)	0.07(0.00,0.19)
SD ABA SC + MTX		0.78(0.25,2.25)	0.79(0.26,2.17)	-0.01(-0.05,0.04)

(Continued)

SD TOCI IV + MTX		1.54(0.44,4.96)	1.51(0.45,4.36)	0.02(-0.03,0.12)
SD ETN SC + DMARD		0.65(0.30,1.40)	0.66(0.31,1.39)	-0.01(-0.04,0.01)
SD CERTO + DMARD		0.89(0.24,2.86)	0.89(0.25,2.70)	0.00(-0.05,0.05)
SD ABA IV + DMARD		0.86(0.27,2.42)	0.86(0.28,2.30)	-0.01(-0.04,0.05)
SD ADA SC + DMARD		0.74(0.16,3.18)	0.75(0.17,2.94)	-0.01(-0.05,0.07)
SD TOCI SC + DMARD		1.54(0.29,15.81)	1.50(0.29,9.51)	0.02(-0.04,0.36)
LD ETN SC		1.16(0.44,2.74)	1.16(0.46,2.59)	0.01(-0.03,0.05)
LD ADA SC		0.35(0.11,1.01)	0.36(0.12,1.01)	-0.02(-0.06,0.00)
LD ANA		0.49(0.14,2.28)	0.50(0.15,2.19)	-0.02(-0.05,0.04)
LD TOCI IV		0.96(0.21,3.13)	0.96(0.22,2.90)	0.00(-0.05,0.07)
LD RITUX IV + MTX		3.08(0.78,16.12)	2.84(0.79,10.43)	0.07(-0.01,0.35)
LD ABA IV + MTX		1.92(0.46,6.61)	1.85(0.48,5.54)	0.03(-0.03,0.16)
LD CERTO SC + MTX		1.71(0.25,8.18)	1.66(0.26,6.54)	0.03(-0.04,0.19)
LD ETN SC + MTX		0.78(0.16,3.34)	0.79(0.17,3.07)	-0.01(-0.05,0.08)
LD TOCI IV + MTX		0.68(0.13,2.88)	0.69(0.14,2.69)	-0.01(-0.05,0.06)
HD TOCI IV		1.26(0.47,2.57)	1.24(0.48,2.44)	0.01(-0.03,0.05)
HD GOLI SC		0.80(0.09,5.09)	0.80(0.10,4.48)	-0.01(-0.05,0.12)
HD ADA SC		0.37(0.12,0.98)	0.38(0.12,0.99)	-0.02(-0.05,0.00)
HD TOFA		1.07(0.19,5.71)	1.06(0.20,5.05)	0.00(-0.05,0.12)
HD ANA		1.20(0.37,4.77)	1.19(0.38,4.27)	0.01(-0.04,0.10)
HD TOCI IV + MTX		1.63(0.56,4.30)	1.59(0.58,3.85)	0.02(-0.02,0.11)
HD GOLI SC + MTX		2.60(0.71,9.46)	2.43(0.72,7.29)	0.06(-0.01,0.24)
HD INF IV + MTX		2.64(0.81,6.77)	2.47(0.81,5.71)	0.06(-0.01,0.17)
HD TOFA PO + MTX		2.21(0.76,6.31)	2.10(0.77,5.40)	0.04(-0.01,0.15)
HD CERTO SC + MTX		2.45(0.65,7.02)	2.31(0.66,5.90)	0.05(-0.02,0.17)
HD TOCI IV + DMARD		1.24(0.40,3.52)	1.23(0.41,3.24)	0.01(-0.03,0.08)
SD CERTO SC	SD TOCI IV	1.94(0.39,12.65)	1.88(0.41,10.21)	0.03(-0.04,0.21)
SD TOFA		0.16(0.00,1.65)	0.17(0.00,1.62)	-0.03(-0.07,0.01)

(Continued)

SD TOC SC + PL IV	0.72(0.37,1.37)	0.73(0.37,1.35)	-0.01(-0.03,0.01)
SD RITUX IV	11.08(1.26,174.80)	8.04(1.25,33.84)	0.24(0.01,0.82)
SD ANA	0.83(0.21,4.13)	0.84(0.22,3.87)	-0.01(-0.05,0.07)
SD ETN SC + MTX	1.52(0.56,4.60)	1.49(0.57,4.29)	0.02(-0.02,0.07)
SD ADA SC + MTX	2.68(0.92,7.69)	2.53(0.93,6.71)	0.05(0.00,0.14)
SD INF IV + MTX	3.45(1.19,10.63)	3.17(1.18,9.08)	0.07(0.01,0.19)
SD ABA IV + MTX	1.78(0.56,5.40)	1.73(0.57,4.95)	0.02(-0.02,0.09)
SD RITUX IV + MTX	2.47(0.65,14.93)	2.34(0.66,10.94)	0.04(-0.02,0.26)
SD CERTO SC + MTX	2.58(0.81,7.94)	2.44(0.81,6.99)	0.05(-0.01,0.14)
SD GOLI SC + MTX	2.31(0.57,9.13)	2.21(0.58,7.72)	0.04(-0.02,0.20)
SD TOFA PO + MTX	3.45(1.12,11.10)	3.17(1.11,9.16)	0.07(0.01,0.20)
SD ABA SC + MTX	0.95(0.29,3.09)	0.95(0.30,2.96)	0.00(-0.04,0.05)
SD TOCI IV + MTX	1.92(0.60,5.94)	1.86(0.61,5.30)	0.03(-0.02,0.12)
SD ETN SC + DMARD	0.79(0.32,2.13)	0.80(0.34,2.08)	-0.01(-0.04,0.02)
SD CERTO + DMARD	1.10(0.30,3.98)	1.10(0.31,3.74)	0.00(-0.04,0.06)
SD ABA IV + DMARD	1.06(0.32,3.38)	1.06(0.33,3.24)	0.00(-0.04,0.05)
SD ADA SC + DMARD	0.91(0.19,4.20)	0.91(0.20,3.87)	0.00(-0.04,0.08)
SD TOCI SC + DMARD	1.91(0.34,21.36)	1.85(0.36,12.70)	0.03(-0.03,0.37)
LD ETN SC	1.41(0.51,4.14)	1.39(0.52,3.90)	0.01(-0.03,0.06)
LD ADA SC	0.44(0.10,1.65)	0.44(0.11,1.63)	-0.02(-0.06,0.01)
LD ANA	0.61(0.15,3.07)	0.62(0.16,2.95)	-0.01(-0.05,0.04)
LD TOCI IV	1.14(0.28,3.90)	1.13(0.29,3.63)	0.00(-0.04,0.07)
LD RITUX IV + MTX	3.74(0.87,23.98)	3.40(0.87,15.48)	0.08(-0.01,0.36)
LD ABA IV + MTX	2.32(0.60,9.07)	2.21(0.61,7.69)	0.04(-0.02,0.17)
LD CERTO SC + MTX	2.11(0.32,10.24)	2.02(0.33,8.47)	0.03(-0.03,0.19)
LD ETN SC + MTX	0.97(0.18,4.42)	0.97(0.19,4.00)	0.00(-0.05,0.09)
LD TOCI IV + MTX	0.82(0.17,3.29)	0.82(0.17,3.09)	-0.01(-0.04,0.06)
HD TOCI IV	1.51(0.62,3.61)	1.48(0.63,3.42)	0.02(-0.02,0.06)

(Continued)

HD GOLI SC		1.01(0.10,6.70)	1.01(0.11,5.94)	0.00(-0.05,0.13)
HD ADA SC		0.46(0.11,1.57)	0.47(0.12,1.55)	-0.02(-0.06,0.01)
HD TOFA		1.34(0.23,7.74)	1.32(0.25,6.81)	0.01(-0.05,0.12)
HD ANA		1.46(0.40,6.43)	1.44(0.41,5.82)	0.01(-0.03,0.11)
HD TOCI IV + MTX		1.98(0.69,5.77)	1.92(0.70,5.14)	0.03(-0.01,0.12)
HD GOLI SC + MTX		3.26(0.80,11.93)	3.02(0.81,9.60)	0.06(-0.01,0.25)
HD INF IV + MTX		3.15(0.93,9.83)	2.93(0.93,8.35)	0.06(0.00,0.18)
HD TOFA PO + MTX		2.65(0.89,9.57)	2.50(0.90,8.07)	0.05(-0.01,0.16)
HD CERTO SC + MTX		2.87(0.77,9.83)	2.68(0.78,8.26)	0.06(-0.01,0.19)
HD TOCI IV + DMARD		1.52(0.48,4.67)	1.49(0.49,4.29)	0.02(-0.03,0.09)
SD TOFA	SD CERTO SC	0.08(0.00,0.98)	0.08(0.00,0.98)	-0.05(-0.22,0.00)
SD TOC SC + PL IV		0.36(0.05,2.04)	0.38(0.06,1.98)	-0.04(-0.21,0.03)
SD RITUX IV		5.72(0.33,138.30)	4.19(0.38,26.23)	0.20(-0.10,0.81)
SD ANA		0.43(0.06,2.58)	0.45(0.08,2.47)	-0.03(-0.20,0.04)
SD ETN SC + MTX		0.83(0.12,3.49)	0.84(0.14,3.31)	-0.01(-0.19,0.06)
SD ADA SC + MTX		1.41(0.19,6.58)	1.38(0.22,5.73)	0.02(-0.17,0.14)
SD INF IV + MTX		1.81(0.27,8.78)	1.72(0.32,7.27)	0.04(-0.14,0.19)
SD ABA IV + MTX		0.92(0.13,3.90)	0.92(0.16,3.62)	0.00(-0.18,0.08)
SD RITUX IV + MTX		1.23(0.15,9.69)	1.21(0.19,7.46)	0.01(-0.17,0.25)
SD CERTO SC + MTX		1.33(0.20,5.69)	1.30(0.23,5.05)	0.02(-0.16,0.12)
SD GOLI SC + MTX		1.16(0.15,8.47)	1.15(0.18,6.94)	0.01(-0.17,0.19)
SD TOFA PO + MTX		1.85(0.25,8.74)	1.75(0.30,7.31)	0.04(-0.15,0.18)
SD ABA SC + MTX		0.50(0.07,2.26)	0.51(0.08,2.18)	-0.03(-0.20,0.03)
SD TOCI IV + MTX		0.99(0.14,5.92)	0.99(0.16,5.27)	0.00(-0.17,0.12)
SD ETN SC + DMARD		0.42(0.06,1.98)	0.43(0.08,1.94)	-0.03(-0.21,0.02)
SD CERTO + DMARD		0.58(0.08,2.97)	0.59(0.09,2.81)	-0.02(-0.20,0.05)
SD ABA IV + DMARD		0.53(0.07,3.06)	0.55(0.09,2.90)	-0.03(-0.20,0.05)
SD ADA SC + DMARD		0.46(0.05,3.98)	0.48(0.06,3.65)	-0.03(-0.20,0.08)

(Continued)

SD TOCI SC + DMARD		0.98(0.10,15.14)	0.98(0.11,10.46)	0.00(-0.18,0.33)
LD ETN SC		0.74(0.11,3.25)	0.75(0.14,3.08)	-0.01(-0.20,0.06)
LD ADA SC		0.22(0.03,1.25)	0.23(0.04,1.25)	-0.05(-0.22,0.01)
LD ANA		0.32(0.04,1.89)	0.34(0.05,1.85)	-0.04(-0.21,0.03)
LD TOCI IV		0.57(0.07,3.46)	0.59(0.09,3.23)	-0.02(-0.20,0.07)
LD RITUX IV + MTX		1.89(0.26,15.75)	1.78(0.30,10.34)	0.05(-0.14,0.35)
LD ABA IV + MTX		1.20(0.15,6.68)	1.18(0.17,5.77)	0.01(-0.17,0.15)
LD CERTO SC + MTX		1.06(0.09,6.73)	1.06(0.10,5.65)	0.00(-0.18,0.17)
LD ETN SC + MTX		0.48(0.06,3.74)	0.50(0.07,3.45)	-0.03(-0.20,0.08)
LD TOCI IV + MTX		0.45(0.04,3.12)	0.47(0.04,2.93)	-0.03(-0.21,0.06)
HD TOCI IV		0.79(0.12,3.45)	0.80(0.14,3.26)	-0.01(-0.19,0.06)
HD GOLI SC		0.52(0.04,4.22)	0.54(0.05,3.81)	-0.02(-0.20,0.10)
HD ADA SC		0.23(0.03,1.19)	0.24(0.03,1.18)	-0.04(-0.22,0.00)
HD TOFA		0.67(0.09,5.10)	0.68(0.11,4.58)	-0.02(-0.19,0.11)
HD ANA		0.76(0.11,4.16)	0.77(0.14,3.80)	-0.01(-0.19,0.09)
HD TOCI IV + MTX		1.02(0.14,6.37)	1.02(0.17,5.62)	0.00(-0.19,0.12)
HD GOLI SC + MTX		1.58(0.21,10.64)	1.52(0.25,8.37)	0.03(-0.15,0.24)
HD INF IV + MTX		1.65(0.21,8.03)	1.58(0.26,6.70)	0.03(-0.16,0.17)
HD TOFA PO + MTX		1.41(0.20,7.04)	1.38(0.24,6.02)	0.02(-0.16,0.15)
HD CERTO SC + MTX		1.51(0.19,7.72)	1.46(0.22,6.53)	0.03(-0.16,0.17)
HD TOCI IV + DMARD		0.80(0.10,4.54)	0.81(0.13,4.14)	-0.01(-0.19,0.09)
SD TOC SC + PL IV	SD TOFA	4.37(0.39,237.10)	4.27(0.40,230.40)	0.02(-0.02,0.06)
SD RITUX IV		90.29(2.36,2738.00)	51.22(2.27,1449.00)	0.27(0.02,0.84)
SD ANA		5.12(0.51,202.90)	4.96(0.52,188.50)	0.02(-0.01,0.09)
SD ETN SC + MTX		9.32(0.97,538.50)	8.84(0.97,503.00)	0.04(0.00,0.10)
SD ADA SC + MTX		17.06(1.57,1008.00)	15.37(1.54,889.20)	0.08(0.02,0.17)
SD INF IV + MTX		21.14(2.16,1164.00)	18.66(2.07,1032.00)	0.10(0.03,0.22)
SD ABA IV + MTX		11.22(1.08,671.50)	10.51(1.07,616.10)	0.05(0.00,0.12)

(Continued)

SD RITUX IV + MTX	16.10(1.40,919.80)	14.67(1.38,803.50)	0.07(0.01,0.28)
SD CERTO SC + MTX	15.61(1.50,871.80)	14.25(1.46,783.10)	0.07(0.01,0.17)
SD GOLI SC + MTX	12.69(1.27,961.90)	11.72(1.26,881.00)	0.06(0.01,0.23)
SD TOFA PO + MTX	21.37(2.07,1357.00)	18.89(1.99,1173.00)	0.10(0.02,0.23)
SD ABA SC + MTX	6.23(0.56,355.00)	6.02(0.57,341.50)	0.02(-0.01,0.07)
SD TOCI IV + MTX	12.02(0.91,425.90)	11.14(0.91,397.10)	0.05(0.00,0.16)
SD ETN SC + DMARD	5.06(0.48,222.60)	4.94(0.49,214.90)	0.02(-0.02,0.05)
SD CERTO + DMARD	6.71(0.63,291.80)	6.47(0.64,278.50)	0.03(-0.01,0.09)
SD ABA IV + DMARD	6.65(0.56,390.70)	6.40(0.57,369.70)	0.03(-0.01,0.09)
SD ADA SC + DMARD	5.92(0.39,309.10)	5.74(0.39,294.20)	0.02(-0.02,0.11)
SD TOCI SC + DMARD	13.23(0.72,691.70)	12.18(0.73,511.00)	0.05(-0.01,0.40)
LD ETN SC	8.60(0.88,483.30)	8.20(0.89,457.00)	0.04(0.00,0.09)
LD ADA SC	2.70(0.23,151.70)	2.67(0.24,148.30)	0.01(-0.03,0.04)
LD ANA	3.58(0.38,160.00)	3.52(0.39,156.70)	0.01(-0.02,0.06)
LD TOCI IV	6.87(0.54,406.80)	6.62(0.55,385.60)	0.03(-0.01,0.11)
LD RITUX IV + MTX	25.15(1.89,1318.00)	21.63(1.84,1104.00)	0.11(0.02,0.38)
LD ABA IV + MTX	15.16(1.01,766.30)	13.85(1.01,685.00)	0.07(0.00,0.20)
LD CERTO SC + MTX	13.36(0.59,1200.00)	12.17(0.60,1027.00)	0.06(-0.01,0.22)
LD ETN SC + MTX	6.03(0.42,326.80)	5.84(0.43,313.40)	0.02(-0.02,0.12)
LD TOCI IV + MTX	4.95(0.31,384.40)	4.82(0.32,362.00)	0.02(-0.02,0.10)
HD TOCI IV	9.13(0.93,494.60)	8.68(0.93,464.70)	0.04(0.00,0.10)
HD GOLI SC	5.91(0.32,670.90)	5.69(0.32,609.00)	0.02(-0.02,0.16)
HD ADA SC	2.64(0.25,181.10)	2.61(0.26,175.70)	0.01(-0.03,0.04)
HD TOFA	7.51(1.09,383.70)	7.10(1.08,364.20)	0.03(0.00,0.14)
HD ANA	8.79(0.87,362.20)	8.31(0.87,334.70)	0.04(0.00,0.13)
HD TOCI IV + MTX	12.29(1.07,538.20)	11.41(1.07,498.40)	0.05(0.00,0.16)
HD GOLI SC + MTX	18.81(1.79,1361.00)	16.75(1.74,1194.00)	0.09(0.02,0.29)
HD INF IV + MTX	19.27(1.70,1144.00)	17.26(1.66,1022.00)	0.09(0.02,0.21)

(Continued)

HD TOFA PO + MTX		16.49(1.52,1010.00)	15.01(1.49,906.60)	0.08(0.01,0.19)
HD CERTO SC + MTX		17.97(1.58,959.70)	16.16(1.55,853.10)	0.08(0.01,0.22)
HD TOCI IV + DMARD		9.42(0.82,558.60)	8.94(0.83,522.00)	0.04(-0.01,0.13)
SD RITUX IV	SD TOC SC + PL IV	15.60(1.57,249.50)	10.99(1.55,51.72)	0.25(0.01,0.83)
SD ANA		1.15(0.26,6.72)	1.15(0.27,6.31)	0.00(-0.04,0.07)
SD ETN SC + MTX		2.15(0.66,7.39)	2.09(0.67,6.93)	0.02(-0.02,0.08)
SD ADA SC + MTX		3.81(1.07,12.64)	3.56(1.06,11.19)	0.06(0.00,0.15)
SD INF IV + MTX		4.91(1.34,17.81)	4.46(1.31,14.86)	0.08(0.01,0.20)
SD ABA IV + MTX		2.48(0.66,8.85)	2.39(0.68,8.11)	0.03(-0.02,0.10)
SD RITUX IV + MTX		3.47(0.78,21.79)	3.27(0.79,16.32)	0.05(-0.01,0.27)
SD CERTO SC + MTX		3.62(0.97,13.08)	3.39(0.97,11.55)	0.06(0.00,0.15)
SD GOLI SC + MTX		3.24(0.68,14.40)	3.07(0.69,12.21)	0.05(-0.01,0.20)
SD TOFA PO + MTX		4.81(1.33,18.40)	4.38(1.31,15.04)	0.08(0.01,0.21)
SD ABA SC + MTX		1.35(0.35,5.15)	1.34(0.36,4.91)	0.01(-0.03,0.06)
SD TOCI IV + MTX		2.65(0.70,9.57)	2.54(0.71,8.60)	0.04(-0.01,0.13)
SD ETN SC + DMARD		1.10(0.38,3.56)	1.10(0.40,3.48)	0.00(-0.03,0.03)
SD CERTO + DMARD		1.51(0.35,6.42)	1.49(0.36,5.99)	0.01(-0.03,0.07)
SD ABA IV + DMARD		1.45(0.39,5.58)	1.43(0.40,5.26)	0.01(-0.03,0.06)
SD ADA SC + DMARD		1.28(0.25,6.49)	1.27(0.26,5.95)	0.01(-0.03,0.09)
SD TOCI SC + DMARD		2.70(0.44,31.01)	2.58(0.45,19.46)	0.04(-0.02,0.38)
LD ETN SC		1.98(0.59,6.66)	1.93(0.60,6.27)	0.02(-0.02,0.07)
LD ADA SC		0.61(0.13,2.73)	0.62(0.14,2.68)	-0.01(-0.05,0.02)
LD ANA		0.86(0.19,4.86)	0.86(0.20,4.64)	0.00(-0.04,0.05)
LD TOCI IV		1.60(0.34,6.66)	1.58(0.36,6.18)	0.01(-0.03,0.09)
LD RITUX IV + MTX		5.29(1.06,35.09)	4.75(1.06,22.36)	0.09(0.00,0.37)
LD ABA IV + MTX		3.26(0.74,14.34)	3.07(0.75,12.22)	0.05(-0.01,0.18)
LD CERTO SC + MTX		2.94(0.40,16.23)	2.80(0.41,13.62)	0.04(-0.02,0.20)
LD ETN SC + MTX		1.37(0.24,6.62)	1.36(0.25,6.06)	0.01(-0.04,0.10)

(Continued)

LD TOCI IV + MTX		1.15(0.21,5.27)	1.14(0.22,4.93)	0.00(-0.04,0.08)
HD TOCI IV		2.13(0.72,6.03)	2.06(0.73,5.69)	0.02(-0.01,0.07)
HD GOLI SC		1.42(0.14,10.92)	1.41(0.14,9.53)	0.01(-0.04,0.14)
HD ADA SC		0.63(0.15,2.52)	0.64(0.15,2.47)	-0.01(-0.05,0.02)
HD TOFA		1.87(0.29,12.04)	1.83(0.31,10.73)	0.02(-0.04,0.13)
HD ANA		2.04(0.49,10.56)	1.98(0.50,9.53)	0.02(-0.02,0.12)
HD TOCI IV + MTX		2.79(0.80,8.98)	2.66(0.81,8.07)	0.04(-0.01,0.13)
HD GOLI SC + MTX		4.52(0.97,18.85)	4.12(0.97,15.15)	0.07(0.00,0.26)
HD INF IV + MTX		4.45(1.14,15.67)	4.08(1.13,13.41)	0.07(0.01,0.19)
HD TOFA PO + MTX		3.74(1.05,15.53)	3.49(1.05,13.29)	0.06(0.00,0.17)
HD CERTO SC + MTX		4.05(0.93,16.67)	3.75(0.94,14.04)	0.07(0.00,0.20)
HD TOCI IV + DMARD		2.12(0.59,7.72)	2.06(0.60,7.09)	0.02(-0.02,0.10)
SD ANA	SD RITUX IV	0.07(0.00,1.16)	0.10(0.01,1.15)	-0.24(-0.83,0.01)
SD ETN SC + MTX		0.14(0.01,1.09)	0.19(0.05,1.09)	-0.22(-0.77,0.00)
SD ADA SC + MTX		0.24(0.02,1.91)	0.31(0.09,1.82)	-0.19(-0.72,0.04)
SD INF IV + MTX		0.32(0.03,2.44)	0.40(0.11,2.26)	-0.16(-0.68,0.07)
SD ABA IV + MTX		0.15(0.01,1.37)	0.21(0.06,1.35)	-0.22(-0.76,0.02)
SD RITUX IV + MTX		0.22(0.03,1.73)	0.31(0.07,1.64)	-0.19(-0.67,0.04)
SD CERTO SC + MTX		0.23(0.02,1.99)	0.30(0.07,1.89)	-0.19(-0.74,0.05)
SD GOLI SC + MTX		0.21(0.02,2.17)	0.28(0.06,2.03)	-0.19(-0.76,0.06)
SD TOFA PO + MTX		0.31(0.03,2.49)	0.39(0.10,2.30)	-0.16(-0.68,0.08)
SD ABA SC + MTX		0.09(0.01,0.78)	0.12(0.03,0.79)	-0.24(-0.80,-0.01)
SD TOCI IV + MTX		0.18(0.01,1.59)	0.24(0.05,1.54)	-0.20(-0.78,0.03)
SD ETN SC + DMARD		0.07(0.01,0.58)	0.10(0.03,0.60)	-0.25(-0.82,-0.02)
SD CERTO + DMARD		0.09(0.01,1.03)	0.13(0.03,1.03)	-0.24(-0.80,0.00)
SD ABA IV + DMARD		0.09(0.01,0.83)	0.13(0.03,0.83)	-0.24(-0.81,-0.01)
SD ADA SC + DMARD		0.09(0.00,0.88)	0.12(0.02,0.88)	-0.24(-0.81,-0.01)
SD TOCI SC + DMARD		0.19(0.01,2.74)	0.26(0.03,2.32)	-0.19(-0.77,0.10)

(Continued)

LD ETN SC		0.13(0.01,1.02)	0.17(0.05,1.01)	-0.23(-0.78,0.00)
LD ADA SC		0.04(0.00,0.39)	0.06(0.01,0.41)	-0.26(-0.84,-0.03)
LD ANA		0.05(0.00,0.84)	0.08(0.01,0.85)	-0.25(-0.83,-0.01)
LD TOCI IV		0.10(0.01,1.01)	0.14(0.03,1.01)	-0.23(-0.80,0.00)
LD RITUX IV + MTX		0.33(0.04,2.64)	0.44(0.09,2.38)	-0.15(-0.61,0.09)
LD ABA IV + MTX		0.21(0.02,2.01)	0.27(0.06,1.89)	-0.19(-0.73,0.06)
LD CERTO SC + MTX		0.17(0.01,2.03)	0.24(0.03,1.89)	-0.20(-0.76,0.06)
LD ETN SC + MTX		0.08(0.01,0.87)	0.12(0.02,0.88)	-0.24(-0.78,-0.01)
LD TOCI IV + MTX		0.07(0.00,0.86)	0.10(0.01,0.87)	-0.24(-0.79,-0.01)
HD TOCI IV		0.13(0.01,1.05)	0.18(0.05,1.05)	-0.22(-0.78,0.00)
HD GOLI SC		0.08(0.00,1.36)	0.13(0.01,1.31)	-0.23(-0.80,0.02)
HD ADA SC		0.04(0.00,0.40)	0.06(0.01,0.42)	-0.26(-0.84,-0.02)
HD TOFA		0.12(0.01,2.02)	0.17(0.02,1.90)	-0.22(-0.81,0.05)
HD ANA		0.14(0.01,1.78)	0.18(0.03,1.69)	-0.22(-0.81,0.03)
HD TOCI IV + MTX		0.18(0.02,1.42)	0.25(0.06,1.39)	-0.20(-0.75,0.02)
HD GOLI SC + MTX		0.28(0.02,2.84)	0.37(0.08,2.48)	-0.17(-0.73,0.11)
HD INF IV + MTX		0.28(0.02,2.45)	0.36(0.09,2.27)	-0.17(-0.71,0.06)
HD TOFA PO + MTX		0.24(0.02,2.16)	0.31(0.08,2.04)	-0.19(-0.72,0.05)
HD CERTO SC + MTX		0.28(0.02,2.38)	0.35(0.07,2.23)	-0.17(-0.73,0.06)
HD TOCI IV + DMARD		0.13(0.01,1.21)	0.18(0.04,1.19)	-0.22(-0.79,0.01)
SD ETN SC + MTX	SD ANA	1.84(0.37,8.78)	1.79(0.40,8.13)	0.02(-0.05,0.08)
SD ADA SC + MTX		3.21(0.57,17.02)	3.01(0.60,14.73)	0.05(-0.03,0.16)
SD INF IV + MTX		4.21(0.75,22.03)	3.84(0.76,18.07)	0.08(-0.02,0.20)
SD ABA IV + MTX		2.06(0.39,10.94)	1.99(0.41,9.90)	0.03(-0.05,0.10)
SD RITUX IV + MTX		2.88(0.43,27.56)	2.72(0.45,21.34)	0.05(-0.04,0.27)
SD CERTO SC + MTX		3.16(0.54,14.38)	2.97(0.56,12.58)	0.05(-0.04,0.15)
SD GOLI SC + MTX		2.79(0.43,16.71)	2.65(0.45,14.36)	0.04(-0.04,0.21)
SD TOFA PO + MTX		4.13(0.73,23.47)	3.78(0.74,19.15)	0.08(-0.02,0.21)

(Continued)

SD ABA SC + MTX	1.13(0.20,6.18)	1.12(0.21,5.91)	0.00(-0.07,0.06)	
SD TOCI IV + MTX	2.35(0.34,11.77)	2.26(0.36,10.37)	0.03(-0.05,0.14)	
SD ETN SC + DMARD	0.95(0.21,4.25)	0.95(0.23,4.11)	0.00(-0.07,0.04)	
SD CERTO + DMARD	1.31(0.22,7.06)	1.30(0.23,6.66)	0.01(-0.07,0.07)	
SD ABA IV + DMARD	1.24(0.21,6.35)	1.23(0.23,6.03)	0.01(-0.07,0.07)	
SD ADA SC + DMARD	1.11(0.15,6.45)	1.11(0.16,6.00)	0.00(-0.07,0.09)	
SD TOCI SC + DMARD	2.28(0.29,39.40)	2.19(0.31,24.14)	0.03(-0.05,0.38)	
LD ETN SC	1.68(0.34,7.96)	1.65(0.36,7.44)	0.02(-0.06,0.08)	
LD ADA SC	0.51(0.09,2.71)	0.52(0.10,2.66)	-0.01(-0.08,0.02)	
LD ANA	0.76(0.23,2.51)	0.77(0.24,2.44)	-0.01(-0.06,0.03)	
LD TOCI IV	1.36(0.20,7.81)	1.34(0.21,7.22)	0.01(-0.07,0.09)	
LD RITUX IV + MTX	4.38(0.68,43.49)	3.97(0.70,29.32)	0.08(-0.02,0.37)	
LD ABA IV + MTX	2.85(0.37,17.37)	2.69(0.39,14.91)	0.05(-0.04,0.18)	
LD CERTO SC + MTX	2.50(0.23,18.65)	2.39(0.24,15.57)	0.04(-0.05,0.20)	
LD ETN SC + MTX	1.15(0.14,7.59)	1.15(0.15,6.96)	0.00(-0.07,0.10)	
LD TOCI IV + MTX	0.95(0.11,7.17)	0.95(0.12,6.63)	0.00(-0.08,0.08)	
HD TOCI IV	1.81(0.34,8.14)	1.76(0.36,7.62)	0.02(-0.06,0.08)	
HD GOLI SC	1.21(0.09,11.22)	1.21(0.09,10.00)	0.00(-0.07,0.14)	
HD ADA SC	0.55(0.08,2.59)	0.56(0.09,2.55)	-0.01(-0.08,0.02)	
HD TOFA	1.57(0.25,11.87)	1.55(0.26,10.42)	0.01(-0.06,0.13)	
HD ANA	1.76(0.63,5.69)	1.71(0.65,5.33)	0.02(-0.02,0.08)	
HD TOCI IV + MTX	2.44(0.41,11.47)	2.34(0.43,10.27)	0.03(-0.05,0.13)	
HD GOLI SC + MTX	3.95(0.58,24.60)	3.63(0.60,19.54)	0.07(-0.03,0.27)	
HD INF IV + MTX	3.65(0.64,20.36)	3.39(0.66,17.05)	0.07(-0.03,0.19)	
HD TOFA PO + MTX	3.23(0.59,19.19)	3.03(0.61,16.12)	0.05(-0.03,0.18)	
HD CERTO SC + MTX	3.40(0.54,18.21)	3.16(0.56,15.23)	0.06(-0.03,0.19)	
HD TOCI IV + DMARD	1.78(0.33,8.84)	1.74(0.35,8.12)	0.02(-0.05,0.10)	
SD ADA SC + MTX	SD ETN SC + MTX	1.75(0.91,3.37)	1.68(0.92,3.09)	0.03(0.00,0.10)

(Continued)

SD INF IV + MTX	2.28(1.20,4.20)	2.12(1.19,3.71)	0.06(0.01,0.14)
SD ABA IV + MTX	1.15(0.53,2.20)	1.14(0.54,2.10)	0.01(-0.03,0.05)
SD RITUX IV + MTX	1.60(0.56,6.34)	1.55(0.57,4.96)	0.03(-0.03,0.22)
SD CERTO SC + MTX	1.65(0.77,3.49)	1.59(0.78,3.20)	0.03(-0.01,0.10)
SD GOL I SC + MTX	1.47(0.50,4.84)	1.43(0.52,4.13)	0.02(-0.03,0.16)
SD TOFA PO + MTX	2.28(1.05,4.54)	2.13(1.04,3.99)	0.05(0.00,0.15)
SD ABA SC + MTX	0.63(0.26,1.39)	0.64(0.27,1.37)	-0.02(-0.06,0.02)
SD TOCI IV + MTX	1.23(0.38,3.83)	1.21(0.40,3.46)	0.01(-0.04,0.11)
SD ETN SC + DMARD	0.51(0.23,1.20)	0.53(0.25,1.19)	-0.02(-0.07,0.01)
SD CERTO + DMARD	0.70(0.20,2.33)	0.71(0.21,2.23)	-0.01(-0.07,0.04)
SD ABA IV + DMARD	0.67(0.24,1.93)	0.68(0.25,1.86)	-0.02(-0.06,0.03)
SD ADA SC + DMARD	0.58(0.14,2.59)	0.59(0.15,2.43)	-0.02(-0.07,0.06)
SD TOCI SC + DMARD	1.21(0.23,11.79)	1.19(0.25,7.39)	0.01(-0.06,0.34)
LD ETN SC	0.91(0.49,1.73)	0.91(0.51,1.68)	0.00(-0.04,0.03)
LD ADA SC	0.28(0.07,1.09)	0.29(0.08,1.08)	-0.04(-0.09,0.00)
LD ANA	0.40(0.09,1.94)	0.41(0.10,1.87)	-0.03(-0.09,0.03)
LD TOCI IV	0.76(0.18,2.56)	0.77(0.20,2.40)	-0.01(-0.07,0.06)
LD RITUX IV + MTX	2.43(0.78,9.60)	2.25(0.79,6.75)	0.06(-0.01,0.32)
LD ABA IV + MTX	1.51(0.48,4.44)	1.47(0.49,3.86)	0.02(-0.03,0.14)
LD CERTO SC + MTX	1.34(0.22,5.44)	1.31(0.23,4.55)	0.02(-0.05,0.17)
LD ETN SC + MTX	0.62(0.16,2.15)	0.64(0.17,2.02)	-0.02(-0.07,0.05)
LD TOCI IV + MTX	0.54(0.09,2.11)	0.55(0.10,2.02)	-0.02(-0.08,0.05)
HD TOCI IV	0.98(0.46,2.03)	0.98(0.48,1.96)	0.00(-0.04,0.04)
HD GOL I SC	0.64(0.08,3.35)	0.66(0.09,3.02)	-0.02(-0.07,0.10)
HD ADA SC	0.29(0.07,1.05)	0.30(0.08,1.05)	-0.03(-0.09,0.00)
HD TOFA	0.84(0.14,5.02)	0.85(0.15,4.46)	-0.01(-0.08,0.11)
HD ANA	0.99(0.23,4.25)	0.99(0.25,3.85)	0.00(-0.07,0.10)
HD TOCI IV + MTX	1.25(0.49,3.39)	1.24(0.51,3.09)	0.01(-0.04,0.09)

(Continued)

HD GOLI SC + MTX		2.01(0.73,6.45)	1.90(0.74,5.11)	0.04(-0.02,0.22)
HD INF IV + MTX		2.04(0.93,4.21)	1.92(0.94,3.71)	0.05(0.00,0.14)
HD TOFA PO + MTX		1.75(0.80,3.67)	1.68(0.81,3.27)	0.03(-0.01,0.12)
HD CERTO SC + MTX		1.92(0.63,4.93)	1.83(0.64,4.24)	0.04(-0.02,0.15)
HD TOCI IV + DMARD		0.97(0.36,2.71)	0.97(0.38,2.55)	0.00(-0.05,0.07)
SD INF IV + MTX	SD ADA SC + MTX	1.31(0.67,2.57)	1.28(0.70,2.34)	0.02(-0.04,0.10)
SD ABA IV + MTX		0.66(0.32,1.28)	0.68(0.34,1.26)	-0.03(-0.09,0.02)
SD RITUX IV + MTX		0.90(0.31,3.63)	0.91(0.34,2.93)	-0.01(-0.08,0.18)
SD CERTO SC + MTX		0.94(0.44,2.05)	0.95(0.47,1.92)	0.00(-0.07,0.06)
SD GOLI SC + MTX		0.84(0.28,2.69)	0.86(0.31,2.39)	-0.01(-0.09,0.11)
SD TOFA PO + MTX		1.28(0.67,2.52)	1.25(0.69,2.28)	0.02(-0.03,0.10)
SD ABA SC + MTX		0.36(0.18,0.70)	0.38(0.19,0.72)	-0.05(-0.12,-0.01)
SD TOCI IV + MTX		0.71(0.21,2.35)	0.73(0.23,2.17)	-0.02(-0.11,0.07)
SD ETN SC + DMARD		0.30(0.13,0.74)	0.32(0.14,0.75)	-0.06(-0.14,-0.01)
SD CERTO + DMARD		0.40(0.12,1.44)	0.42(0.13,1.41)	-0.05(-0.14,0.02)
SD ABA IV + DMARD		0.38(0.14,1.15)	0.41(0.15,1.14)	-0.05(-0.13,0.01)
SD ADA SC + DMARD		0.34(0.08,1.47)	0.36(0.09,1.42)	-0.05(-0.14,0.03)
SD TOCI SC + DMARD		0.70(0.13,6.98)	0.72(0.14,4.72)	-0.02(-0.12,0.31)
LD ETN SC		0.52(0.26,1.09)	0.54(0.29,1.09)	-0.04(-0.11,0.00)
LD ADA SC		0.16(0.04,0.70)	0.17(0.05,0.72)	-0.07(-0.17,-0.01)
LD ANA		0.23(0.05,1.21)	0.25(0.06,1.19)	-0.06(-0.16,0.01)
LD TOCI IV		0.43(0.11,1.52)	0.45(0.12,1.47)	-0.04(-0.14,0.03)
LD RITUX IV + MTX		1.36(0.46,5.70)	1.32(0.49,4.11)	0.03(-0.06,0.28)
LD ABA IV + MTX		0.87(0.26,2.47)	0.88(0.28,2.23)	-0.01(-0.09,0.10)
LD CERTO SC + MTX		0.77(0.13,3.02)	0.79(0.14,2.65)	-0.02(-0.11,0.12)
LD ETN SC + MTX		0.35(0.09,1.35)	0.38(0.10,1.31)	-0.05(-0.13,0.02)
LD TOCI IV + MTX		0.31(0.05,1.23)	0.33(0.06,1.21)	-0.05(-0.14,0.01)
HD TOCI IV		0.56(0.26,1.20)	0.58(0.28,1.18)	-0.03(-0.11,0.01)

(Continued)

HD GOLI SC		0.37(0.04,2.09)	0.40(0.05,1.95)	-0.05(-0.14,0.07)
HD ADA SC		0.16(0.04,0.67)	0.18(0.05,0.68)	-0.07(-0.16,-0.01)
HD TOFA		0.49(0.09,2.90)	0.51(0.10,2.66)	-0.04(-0.15,0.08)
HD ANA		0.57(0.13,2.57)	0.59(0.15,2.40)	-0.03(-0.14,0.07)
HD TOCI IV + MTX		0.72(0.28,1.92)	0.74(0.31,1.81)	-0.02(-0.10,0.06)
HD GOLI SC + MTX		1.15(0.43,3.51)	1.14(0.46,2.97)	0.01(-0.07,0.17)
HD INF IV + MTX		1.17(0.51,2.47)	1.16(0.54,2.25)	0.01(-0.06,0.09)
HD TOFA PO + MTX		0.99(0.51,2.02)	0.99(0.54,1.88)	0.00(-0.06,0.07)
HD CERTO SC + MTX		1.09(0.38,2.75)	1.08(0.40,2.45)	0.01(-0.08,0.11)
HD TOCI IV + DMARD		0.55(0.20,1.69)	0.58(0.22,1.62)	-0.03(-0.12,0.04)
SD ABA IV + MTX	SD INF IV + MTX	0.50(0.23,1.06)	0.54(0.26,1.05)	-0.05(-0.14,0.00)
SD RITUX IV + MTX		0.70(0.24,2.60)	0.73(0.27,2.22)	-0.03(-0.12,0.15)
SD CERTO SC + MTX		0.73(0.32,1.63)	0.75(0.35,1.56)	-0.02(-0.12,0.05)
SD GOLI SC + MTX		0.65(0.21,2.18)	0.68(0.23,1.95)	-0.03(-0.14,0.09)
SD TOFA PO + MTX		1.00(0.45,2.09)	1.00(0.49,1.93)	0.00(-0.09,0.08)
SD ABA SC + MTX		0.27(0.12,0.66)	0.30(0.13,0.68)	-0.07(-0.18,-0.02)
SD TOCI IV + MTX		0.55(0.15,1.85)	0.58(0.18,1.74)	-0.04(-0.16,0.05)
SD ETN SC + DMARD		0.23(0.09,0.56)	0.25(0.11,0.58)	-0.08(-0.19,-0.02)
SD CERTO + DMARD		0.31(0.09,1.08)	0.34(0.10,1.07)	-0.07(-0.19,0.00)
SD ABA IV + DMARD		0.30(0.10,0.92)	0.32(0.11,0.93)	-0.07(-0.18,0.00)
SD ADA SC + DMARD		0.26(0.06,1.19)	0.29(0.07,1.17)	-0.07(-0.18,0.01)
SD TOCI SC + DMARD		0.53(0.09,5.68)	0.56(0.11,3.78)	-0.04(-0.17,0.28)
LD ETN SC		0.40(0.20,0.82)	0.43(0.23,0.83)	-0.06(-0.15,-0.01)
LD ADA SC		0.12(0.03,0.51)	0.14(0.04,0.53)	-0.09(-0.21,-0.02)
LD ANA		0.17(0.04,1.01)	0.19(0.05,1.01)	-0.09(-0.21,0.00)
LD TOCI IV		0.33(0.07,1.19)	0.36(0.09,1.18)	-0.07(-0.19,0.01)
LD RITUX IV + MTX		1.07(0.35,4.08)	1.07(0.38,3.02)	0.01(-0.09,0.23)
LD ABA IV + MTX		0.67(0.21,1.93)	0.70(0.23,1.79)	-0.03(-0.12,0.07)

(Continued)

LD CERTO SC + MTX		0.59(0.09,2.46)	0.62(0.10,2.16)	-0.04(-0.15,0.11)
LD ETN SC + MTX		0.28(0.07,1.03)	0.30(0.08,1.02)	-0.07(-0.18,0.00)
LD TOCI IV + MTX		0.23(0.04,0.93)	0.26(0.05,0.94)	-0.08(-0.19,0.00)
HD TOCI IV		0.43(0.20,0.96)	0.46(0.23,0.97)	-0.06(-0.16,0.00)
HD GOLI SC		0.28(0.03,1.63)	0.31(0.04,1.55)	-0.07(-0.19,0.05)
HD ADA SC		0.13(0.03,0.49)	0.14(0.04,0.50)	-0.09(-0.21,-0.02)
HD TOFA		0.38(0.06,2.16)	0.41(0.07,2.01)	-0.06(-0.20,0.07)
HD ANA		0.42(0.10,2.01)	0.45(0.12,1.89)	-0.06(-0.18,0.06)
HD TOCI IV + MTX		0.56(0.21,1.51)	0.59(0.24,1.45)	-0.04(-0.14,0.04)
HD GOLI SC + MTX		0.90(0.30,2.87)	0.91(0.34,2.46)	-0.01(-0.11,0.14)
HD INF IV + MTX		0.89(0.44,1.71)	0.90(0.48,1.60)	-0.01(-0.08,0.06)
HD TOFA PO + MTX		0.77(0.36,1.66)	0.79(0.39,1.57)	-0.02(-0.10,0.05)
HD CERTO SC + MTX		0.85(0.30,2.16)	0.86(0.32,1.96)	-0.01(-0.11,0.09)
HD TOCI IV + DMARD		0.43(0.15,1.34)	0.46(0.17,1.31)	-0.05(-0.17,0.02)
SD RITUX IV + MTX	SD ABA IV + MTX	1.41(0.46,5.59)	1.37(0.48,4.44)	0.02(-0.04,0.21)
SD CERTO SC + MTX		1.44(0.65,3.43)	1.40(0.67,3.16)	0.02(-0.03,0.10)
SD GOLI SC + MTX		1.30(0.42,4.51)	1.28(0.44,3.89)	0.01(-0.05,0.16)
SD TOFA PO + MTX		1.98(0.92,4.34)	1.86(0.92,3.84)	0.05(0.00,0.15)
SD ABA SC + MTX		0.54(0.29,1.06)	0.56(0.31,1.05)	-0.02(-0.07,0.00)
SD TOCI IV + MTX		1.08(0.33,3.72)	1.08(0.35,3.35)	0.00(-0.06,0.10)
SD ETN SC + DMARD		0.45(0.18,1.23)	0.47(0.19,1.22)	-0.03(-0.09,0.01)
SD CERTO + DMARD		0.61(0.18,2.27)	0.62(0.20,2.19)	-0.02(-0.08,0.04)
SD ABA IV + DMARD		0.59(0.20,1.92)	0.61(0.21,1.84)	-0.02(-0.08,0.03)
SD ADA SC + DMARD		0.51(0.11,2.48)	0.53(0.12,2.35)	-0.02(-0.09,0.06)
SD TOCI SC + DMARD		1.07(0.18,11.24)	1.07(0.20,6.98)	0.00(-0.07,0.34)
LD ETN SC		0.79(0.37,1.81)	0.80(0.39,1.75)	-0.01(-0.06,0.03)
LD ADA SC		0.24(0.06,1.08)	0.26(0.07,1.08)	-0.04(-0.11,0.00)
LD ANA		0.36(0.08,1.86)	0.37(0.09,1.81)	-0.03(-0.11,0.03)

(Continued)

LD TOCI IV		0.65(0.16,2.50)	0.67(0.17,2.33)	-0.02(-0.08,0.06)
LD RITUX IV + MTX		2.12(0.70,8.53)	1.98(0.71,6.20)	0.06(-0.02,0.31)
LD ABA IV + MTX		1.34(0.47,3.63)	1.31(0.48,3.21)	0.02(-0.04,0.13)
LD CERTO SC + MTX		1.19(0.20,5.06)	1.18(0.21,4.32)	0.01(-0.06,0.16)
LD ETN SC + MTX		0.55(0.12,2.24)	0.57(0.13,2.10)	-0.02(-0.09,0.05)
LD TOCI IV + MTX		0.47(0.08,1.98)	0.49(0.08,1.88)	-0.03(-0.09,0.04)
HD TOCI IV		0.85(0.36,2.06)	0.86(0.39,1.99)	-0.01(-0.06,0.04)
HD GOLI SC		0.58(0.07,3.08)	0.59(0.08,2.82)	-0.02(-0.09,0.09)
HD ADA SC		0.26(0.06,1.02)	0.27(0.07,1.02)	-0.04(-0.11,0.00)
HD TOFA		0.75(0.15,4.54)	0.76(0.16,4.05)	-0.01(-0.09,0.10)
HD ANA		0.85(0.21,4.02)	0.86(0.22,3.64)	-0.01(-0.08,0.09)
HD TOCI IV + MTX		1.10(0.41,3.36)	1.10(0.43,3.08)	0.01(-0.05,0.09)
HD GOLI SC + MTX		1.80(0.58,5.90)	1.71(0.60,4.89)	0.04(-0.03,0.21)
HD INF IV + MTX		1.77(0.76,4.22)	1.69(0.78,3.71)	0.04(-0.01,0.14)
HD TOFA PO + MTX		1.53(0.70,3.53)	1.48(0.72,3.16)	0.03(-0.02,0.11)
HD CERTO SC + MTX		1.60(0.60,4.81)	1.54(0.62,4.14)	0.03(-0.03,0.15)
HD TOCI IV + DMARD		0.85(0.30,2.69)	0.86(0.32,2.53)	-0.01(-0.07,0.06)
SD CERTO SC + MTX	SD RITUX IV + MTX	1.02(0.21,3.21)	1.02(0.28,2.94)	0.00(-0.20,0.08)
SD GOLI SC + MTX		0.95(0.16,4.08)	0.95(0.21,3.61)	0.00(-0.20,0.12)
SD TOFA PO + MTX		1.40(0.37,4.09)	1.36(0.42,3.69)	0.02(-0.14,0.12)
SD ABA SC + MTX		0.39(0.09,1.26)	0.41(0.12,1.24)	-0.04(-0.24,0.01)
SD TOCI IV + MTX		0.79(0.12,3.06)	0.80(0.16,2.82)	-0.01(-0.23,0.08)
SD ETN SC + DMARD		0.33(0.06,1.14)	0.35(0.08,1.13)	-0.05(-0.26,0.00)
SD CERTO + DMARD		0.44(0.08,2.02)	0.46(0.11,1.95)	-0.04(-0.25,0.03)
SD ABA IV + DMARD		0.42(0.09,1.66)	0.44(0.11,1.63)	-0.04(-0.25,0.02)
SD ADA SC + DMARD		0.37(0.05,2.23)	0.39(0.06,2.11)	-0.04(-0.26,0.04)
SD TOCI SC + DMARD		0.79(0.07,8.30)	0.80(0.09,5.59)	-0.01(-0.21,0.29)
LD ETN SC		0.57(0.14,1.71)	0.59(0.18,1.67)	-0.03(-0.23,0.02)

(Continued)

LD ADA SC		0.18(0.03,0.97)	0.19(0.03,0.97)	-0.06(-0.28,0.00)
LD ANA		0.25(0.04,1.64)	0.27(0.05,1.59)	-0.05(-0.26,0.02)
LD TOCI IV		0.46(0.07,2.17)	0.48(0.09,2.08)	-0.04(-0.24,0.04)
LD RITUX IV + MTX		1.49(0.65,3.70)	1.41(0.67,3.26)	0.03(-0.04,0.15)
LD ABA IV + MTX		0.92(0.19,3.72)	0.93(0.22,3.37)	0.00(-0.18,0.11)
LD CERTO SC + MTX		0.82(0.09,4.54)	0.83(0.11,3.86)	-0.01(-0.22,0.15)
LD ETN SC + MTX		0.39(0.05,1.91)	0.42(0.07,1.84)	-0.04(-0.24,0.04)
LD TOCI IV + MTX		0.33(0.04,1.68)	0.35(0.05,1.63)	-0.04(-0.25,0.03)
HD TOCI IV		0.61(0.15,1.88)	0.63(0.20,1.83)	-0.03(-0.22,0.03)
HD GOLI SC		0.39(0.04,2.46)	0.41(0.05,2.29)	-0.04(-0.25,0.07)
HD ADA SC		0.18(0.02,0.93)	0.19(0.03,0.93)	-0.06(-0.28,0.00)
HD TOFA		0.52(0.07,3.62)	0.54(0.08,3.29)	-0.03(-0.24,0.09)
HD ANA		0.61(0.09,3.43)	0.63(0.12,3.14)	-0.03(-0.24,0.08)
HD TOCI IV + MTX		0.80(0.16,2.84)	0.81(0.20,2.65)	-0.01(-0.22,0.07)
HD GOLI SC + MTX		1.28(0.23,5.07)	1.25(0.29,4.26)	0.02(-0.19,0.19)
HD INF IV + MTX		1.29(0.30,4.10)	1.25(0.37,3.69)	0.02(-0.17,0.12)
HD TOFA PO + MTX		1.09(0.28,3.25)	1.09(0.33,3.00)	0.01(-0.16,0.09)
HD CERTO SC + MTX		1.16(0.24,4.11)	1.15(0.30,3.68)	0.01(-0.18,0.12)
HD TOCI IV + DMARD		0.61(0.12,2.47)	0.63(0.15,2.35)	-0.03(-0.23,0.05)
SD GOLI SC + MTX	SD CERTO SC + MTX	0.89(0.28,3.10)	0.90(0.31,2.73)	-0.01(-0.09,0.13)
SD TOFA PO + MTX		1.37(0.61,3.04)	1.32(0.64,2.73)	0.02(-0.04,0.12)
SD ABA SC + MTX		0.37(0.15,0.95)	0.40(0.16,0.95)	-0.05(-0.13,0.00)
SD TOCI IV + MTX		0.74(0.22,2.59)	0.76(0.24,2.39)	-0.02(-0.11,0.08)
SD ETN SC + DMARD		0.31(0.12,0.79)	0.33(0.14,0.80)	-0.05(-0.14,-0.01)
SD CERTO + DMARD		0.43(0.12,1.44)	0.45(0.14,1.42)	-0.04(-0.13,0.02)
SD ABA IV + DMARD		0.41(0.13,1.22)	0.43(0.15,1.20)	-0.04(-0.13,0.01)
SD ADA SC + DMARD		0.35(0.08,1.61)	0.37(0.09,1.57)	-0.05(-0.14,0.03)
SD TOCI SC + DMARD		0.76(0.13,6.94)	0.77(0.14,4.68)	-0.02(-0.12,0.31)

(Continued)

LD ETN SC		0.55(0.26,1.25)	0.57(0.28,1.23)	-0.03(-0.11,0.01)
LD ADA SC		0.17(0.04,0.71)	0.18(0.05,0.72)	-0.07(-0.16,-0.01)
LD ANA		0.25(0.06,1.37)	0.26(0.06,1.35)	-0.06(-0.16,0.01)
LD TOCI IV		0.45(0.10,1.61)	0.48(0.12,1.56)	-0.04(-0.13,0.03)
LD RITUX IV + MTX		1.42(0.49,6.62)	1.37(0.52,4.65)	0.03(-0.05,0.28)
LD ABA IV + MTX		0.94(0.25,2.71)	0.95(0.28,2.47)	0.00(-0.09,0.10)
LD CERTO SC + MTX		0.84(0.14,2.91)	0.86(0.15,2.55)	-0.01(-0.10,0.12)
LD ETN SC + MTX		0.37(0.10,1.57)	0.39(0.10,1.51)	-0.05(-0.13,0.03)
LD TOCI IV + MTX		0.32(0.05,1.45)	0.34(0.06,1.42)	-0.05(-0.14,0.02)
HD TOCI IV		0.57(0.25,1.37)	0.60(0.28,1.35)	-0.03(-0.11,0.02)
HD GOLI SC		0.40(0.04,2.11)	0.43(0.05,1.96)	-0.04(-0.14,0.07)
HD ADA SC		0.17(0.04,0.68)	0.19(0.05,0.69)	-0.07(-0.16,-0.01)
HD TOFA		0.52(0.10,3.16)	0.54(0.11,2.89)	-0.04(-0.14,0.09)
HD ANA		0.57(0.14,2.93)	0.60(0.15,2.70)	-0.03(-0.13,0.08)
HD TOCI IV + MTX		0.77(0.27,2.33)	0.78(0.30,2.17)	-0.02(-0.10,0.07)
HD GOLI SC + MTX		1.24(0.38,3.90)	1.21(0.41,3.25)	0.01(-0.08,0.18)
HD INF IV + MTX		1.24(0.50,2.74)	1.21(0.53,2.50)	0.02(-0.06,0.11)
HD TOFA PO + MTX		1.06(0.47,2.47)	1.06(0.50,2.29)	0.00(-0.06,0.09)
HD CERTO SC + MTX		1.13(0.48,2.54)	1.12(0.51,2.29)	0.01(-0.05,0.11)
HD TOCI IV + DMARD		0.59(0.20,1.82)	0.61(0.23,1.73)	-0.03(-0.11,0.04)
SD TOFA PO + MTX	SD GOLI SC + MTX	1.50(0.43,4.80)	1.45(0.47,4.22)	0.03(-0.10,0.14)
SD ABA SC + MTX		0.43(0.12,1.39)	0.45(0.14,1.37)	-0.04(-0.19,0.01)
SD TOCI IV + MTX		0.83(0.17,3.80)	0.84(0.20,3.48)	-0.01(-0.16,0.09)
SD ETN SC + DMARD		0.34(0.09,1.35)	0.36(0.11,1.34)	-0.04(-0.20,0.01)
SD CERTO + DMARD		0.48(0.10,2.21)	0.50(0.12,2.13)	-0.03(-0.19,0.03)
SD ABA IV + DMARD		0.45(0.11,1.84)	0.47(0.13,1.79)	-0.04(-0.19,0.03)
SD ADA SC + DMARD		0.38(0.07,2.34)	0.40(0.08,2.21)	-0.04(-0.18,0.05)
SD TOCI SC + DMARD		0.85(0.12,9.05)	0.86(0.14,6.20)	-0.01(-0.16,0.31)

(Continued)

LD ETN SC		0.61(0.20,1.97)	0.63(0.23,1.92)	-0.02(-0.16,0.03)
LD ADA SC		0.18(0.04,1.15)	0.19(0.04,1.14)	-0.06(-0.21,0.00)
LD ANA		0.26(0.05,1.85)	0.27(0.06,1.79)	-0.05(-0.21,0.02)
LD TOCI IV		0.49(0.09,2.41)	0.51(0.11,2.29)	-0.03(-0.19,0.05)
LD RITUX IV + MTX		1.59(0.39,8.09)	1.52(0.43,6.02)	0.03(-0.10,0.29)
LD ABA IV + MTX		1.05(0.22,4.07)	1.04(0.25,3.57)	0.00(-0.14,0.13)
LD CERTO SC + MTX		0.94(0.10,4.65)	0.94(0.11,3.97)	0.00(-0.14,0.14)
LD ETN SC + MTX		0.42(0.07,2.04)	0.44(0.09,1.94)	-0.04(-0.19,0.05)
LD TOCI IV + MTX		0.34(0.05,2.00)	0.36(0.07,1.92)	-0.04(-0.20,0.03)
HD TOCI IV		0.66(0.19,2.12)	0.67(0.22,2.05)	-0.02(-0.17,0.03)
HD GOLI SC		0.44(0.06,2.47)	0.46(0.06,2.28)	-0.03(-0.18,0.07)
HD ADA SC		0.19(0.04,0.98)	0.21(0.05,0.98)	-0.06(-0.21,0.00)
HD TOFA		0.58(0.06,4.14)	0.60(0.07,3.76)	-0.03(-0.20,0.09)
HD ANA		0.64(0.13,3.81)	0.66(0.16,3.49)	-0.02(-0.19,0.08)
HD TOCI IV + MTX		0.86(0.21,3.26)	0.87(0.25,3.04)	-0.01(-0.15,0.08)
HD GOLI SC + MTX		1.36(0.52,3.68)	1.32(0.56,3.27)	0.02(-0.06,0.14)
HD INF IV + MTX		1.36(0.39,4.39)	1.32(0.43,3.98)	0.02(-0.10,0.12)
HD TOFA PO + MTX		1.15(0.35,3.84)	1.14(0.39,3.43)	0.01(-0.12,0.11)
HD CERTO SC + MTX		1.24(0.32,4.81)	1.22(0.36,4.24)	0.01(-0.11,0.14)
HD TOCI IV + DMARD		0.65(0.17,2.85)	0.66(0.20,2.68)	-0.02(-0.17,0.06)
SD ABA SC + MTX	SD TOFA PO + MTX	0.28(0.12,0.65)	0.30(0.14,0.66)	-0.07(-0.18,-0.02)
SD TOCI IV + MTX		0.55(0.15,1.91)	0.58(0.18,1.79)	-0.04(-0.17,0.05)
SD ETN SC + DMARD		0.23(0.09,0.63)	0.25(0.11,0.65)	-0.08(-0.20,-0.02)
SD CERTO + DMARD		0.31(0.09,1.17)	0.34(0.10,1.16)	-0.07(-0.19,0.01)
SD ABA IV + DMARD		0.29(0.10,0.96)	0.32(0.12,0.97)	-0.07(-0.18,0.00)
SD ADA SC + DMARD		0.26(0.06,1.28)	0.28(0.07,1.25)	-0.07(-0.20,0.02)
SD TOCI SC + DMARD		0.55(0.10,5.34)	0.58(0.11,3.62)	-0.04(-0.17,0.28)
LD ETN SC		0.40(0.20,0.90)	0.43(0.23,0.90)	-0.06(-0.16,-0.01)

(Continued)

LD ADA SC		0.12(0.03,0.52)	0.14(0.04,0.54)	-0.09(-0.22,-0.02)
LD ANA		0.18(0.04,0.99)	0.19(0.05,0.99)	-0.08(-0.21,0.00)
LD TOCI IV		0.33(0.08,1.19)	0.36(0.09,1.18)	-0.06(-0.19,0.01)
LD RITUX IV + MTX		1.06(0.36,4.40)	1.05(0.39,3.26)	0.01(-0.09,0.23)
LD ABA IV + MTX		0.67(0.20,2.18)	0.70(0.23,1.99)	-0.03(-0.13,0.08)
LD CERTO SC + MTX		0.61(0.09,2.40)	0.64(0.11,2.13)	-0.03(-0.15,0.10)
LD ETN SC + MTX		0.28(0.06,1.10)	0.30(0.07,1.09)	-0.07(-0.19,0.01)
LD TOCI IV + MTX		0.24(0.04,1.01)	0.26(0.04,1.01)	-0.08(-0.20,0.00)
HD TOCI IV		0.43(0.19,1.04)	0.46(0.22,1.04)	-0.06(-0.16,0.00)
HD GOLI SC		0.29(0.03,1.68)	0.31(0.04,1.59)	-0.07(-0.19,0.05)
HD ADA SC		0.13(0.03,0.53)	0.14(0.04,0.54)	-0.09(-0.22,-0.02)
HD TOFA		0.37(0.07,2.34)	0.40(0.09,2.17)	-0.06(-0.19,0.07)
HD ANA		0.43(0.10,2.09)	0.46(0.11,1.94)	-0.06(-0.19,0.06)
HD TOCI IV + MTX		0.57(0.20,1.56)	0.60(0.23,1.50)	-0.04(-0.15,0.04)
HD GOLI SC + MTX		0.91(0.30,2.95)	0.92(0.33,2.57)	-0.01(-0.12,0.14)
HD INF IV + MTX		0.89(0.39,2.13)	0.90(0.42,1.96)	-0.01(-0.10,0.08)
HD TOFA PO + MTX		0.78(0.47,1.32)	0.80(0.50,1.28)	-0.02(-0.08,0.02)
HD CERTO SC + MTX		0.83(0.28,2.37)	0.85(0.31,2.13)	-0.01(-0.12,0.10)
HD TOCI IV + DMARD		0.43(0.15,1.42)	0.46(0.17,1.38)	-0.06(-0.17,0.02)
SD TOCI IV + MTX	SD ABA SC + MTX	1.98(0.54,7.25)	1.92(0.55,6.45)	0.03(-0.02,0.13)
SD ETN SC + DMARD		0.83(0.31,2.44)	0.83(0.32,2.38)	-0.01(-0.05,0.02)
SD CERTO + DMARD		1.10(0.30,4.32)	1.09(0.31,4.09)	0.00(-0.04,0.06)
SD ABA IV + DMARD		1.07(0.33,3.53)	1.07(0.34,3.37)	0.00(-0.04,0.05)
SD ADA SC + DMARD		0.94(0.18,4.61)	0.94(0.19,4.27)	0.00(-0.05,0.08)
SD TOCI SC + DMARD		1.94(0.33,21.80)	1.88(0.34,13.97)	0.03(-0.03,0.37)
LD ETN SC		1.45(0.62,3.58)	1.43(0.63,3.42)	0.01(-0.02,0.06)
LD ADA SC		0.44(0.10,2.10)	0.45(0.11,2.07)	-0.02(-0.07,0.02)
LD ANA		0.66(0.14,3.58)	0.67(0.15,3.45)	-0.01(-0.06,0.04)

(Continued)

LD TOCI IV		1.19(0.28,4.91)	1.18(0.29,4.51)	0.01(-0.04,0.08)
LD RITUX IV + MTX		3.86(1.18,17.07)	3.50(1.17,11.65)	0.08(0.01,0.35)
LD ABA IV + MTX		2.45(0.72,7.32)	2.33(0.73,6.35)	0.04(-0.01,0.16)
LD CERTO SC + MTX		2.19(0.34,9.45)	2.10(0.34,8.02)	0.03(-0.03,0.19)
LD ETN SC + MTX		1.00(0.23,4.25)	1.00(0.24,3.96)	0.00(-0.04,0.08)
LD TOCI IV + MTX		0.87(0.13,3.80)	0.87(0.13,3.54)	0.00(-0.05,0.07)
HD TOCI IV		1.55(0.59,4.07)	1.52(0.60,3.87)	0.02(-0.02,0.06)
HD GOLI SC		1.07(0.12,5.91)	1.07(0.13,5.34)	0.00(-0.05,0.12)
HD ADA SC		0.47(0.10,2.01)	0.48(0.11,1.97)	-0.02(-0.06,0.02)
HD TOFA		1.38(0.26,8.10)	1.36(0.28,7.27)	0.01(-0.05,0.12)
HD ANA		1.60(0.35,7.74)	1.57(0.37,6.99)	0.02(-0.04,0.11)
HD TOCI IV + MTX		2.03(0.67,6.58)	1.96(0.68,5.95)	0.03(-0.02,0.12)
HD GOLI SC + MTX		3.20(1.01,11.32)	2.97(1.01,9.37)	0.06(0.00,0.24)
HD INF IV + MTX		3.26(1.23,8.35)	3.02(1.21,7.28)	0.06(0.01,0.17)
HD TOFA PO + MTX		2.82(1.18,7.00)	2.65(1.17,6.19)	0.05(0.01,0.14)
HD CERTO SC + MTX		2.99(0.95,9.37)	2.80(0.95,7.92)	0.06(0.00,0.18)
HD TOCI IV + DMARD		1.56(0.49,5.11)	1.53(0.50,4.73)	0.02(-0.03,0.09)
SD ETN SC + DMARD	SD TOCI IV + MTX	0.42(0.13,1.48)	0.44(0.15,1.46)	-0.03(-0.14,0.01)
SD CERTO + DMARD		0.57(0.13,2.75)	0.58(0.15,2.63)	-0.02(-0.12,0.04)
SD ABA IV + DMARD		0.55(0.14,2.19)	0.56(0.16,2.10)	-0.02(-0.12,0.03)
SD ADA SC + DMARD		0.47(0.09,2.47)	0.49(0.10,2.36)	-0.03(-0.12,0.05)
SD TOCI SC + DMARD		1.02(0.15,11.97)	1.01(0.17,7.82)	0.00(-0.11,0.33)
LD ETN SC		0.75(0.23,2.33)	0.76(0.26,2.25)	-0.01(-0.11,0.04)
LD ADA SC		0.23(0.05,1.05)	0.24(0.05,1.05)	-0.04(-0.15,0.00)
LD ANA		0.32(0.07,2.09)	0.33(0.08,2.03)	-0.04(-0.14,0.03)
LD TOCI IV		0.61(0.13,2.31)	0.63(0.15,2.19)	-0.02(-0.12,0.04)
LD RITUX IV + MTX		1.93(0.47,13.68)	1.82(0.50,8.72)	0.05(-0.06,0.33)
LD ABA IV + MTX		1.20(0.30,5.18)	1.18(0.33,4.51)	0.01(-0.09,0.14)

(Continued)

LD CERTO SC + MTX		1.12(0.14,6.32)	1.11(0.15,5.28)	0.01(-0.11,0.16)
LD ETN SC + MTX		0.48(0.10,2.96)	0.50(0.11,2.76)	-0.03(-0.13,0.07)
LD TOCI IV + MTX		0.44(0.07,1.86)	0.46(0.08,1.81)	-0.03(-0.12,0.03)
HD TOCI IV		0.78(0.28,2.44)	0.79(0.31,2.34)	-0.01(-0.10,0.04)
HD GOLI SC		0.51(0.06,3.80)	0.53(0.06,3.42)	-0.02(-0.13,0.10)
HD ADA SC		0.23(0.05,1.08)	0.24(0.05,1.08)	-0.04(-0.15,0.00)
HD TOFA		0.71(0.11,4.57)	0.72(0.13,4.14)	-0.02(-0.13,0.10)
HD ANA		0.79(0.16,4.42)	0.80(0.18,4.00)	-0.01(-0.12,0.09)
HD TOCI IV + MTX		1.06(0.34,3.10)	1.05(0.36,2.90)	0.00(-0.08,0.08)
HD GOLI SC + MTX		1.68(0.38,8.14)	1.61(0.41,6.45)	0.03(-0.07,0.22)
HD INF IV + MTX		1.64(0.46,6.02)	1.57(0.49,5.25)	0.03(-0.06,0.15)
HD TOFA PO + MTX		1.39(0.41,5.38)	1.36(0.44,4.71)	0.02(-0.07,0.14)
HD CERTO SC + MTX		1.57(0.34,6.02)	1.52(0.37,5.28)	0.03(-0.08,0.15)
HD TOCI IV + DMARD		0.79(0.22,3.36)	0.80(0.24,3.14)	-0.01(-0.11,0.07)
SD CERTO + DMARD	SD ETN SC + DMARD	1.39(0.40,3.86)	1.38(0.40,3.65)	0.01(-0.02,0.06)
SD ABA IV + DMARD		1.30(0.50,3.23)	1.29(0.51,3.07)	0.01(-0.02,0.05)
SD ADA SC + DMARD		1.13(0.26,4.48)	1.13(0.27,4.12)	0.00(-0.03,0.08)
SD TOCI SC + DMARD		2.33(0.50,21.45)	2.24(0.51,13.22)	0.03(-0.02,0.37)
LD ETN SC		1.75(0.78,4.17)	1.71(0.79,3.93)	0.02(-0.01,0.06)
LD ADA SC		0.55(0.14,1.84)	0.55(0.14,1.81)	-0.01(-0.04,0.02)
LD ANA		0.79(0.19,3.58)	0.80(0.20,3.43)	-0.01(-0.04,0.05)
LD TOCI IV		1.43(0.34,5.30)	1.42(0.35,4.89)	0.01(-0.03,0.08)
LD RITUX IV + MTX		4.68(1.26,23.89)	4.24(1.25,16.44)	0.09(0.01,0.36)
LD ABA IV + MTX		2.96(0.72,10.28)	2.80(0.72,8.76)	0.05(-0.01,0.17)
LD CERTO SC + MTX		2.66(0.40,10.81)	2.53(0.41,8.85)	0.04(-0.02,0.20)
LD ETN SC + MTX		1.21(0.25,4.70)	1.20(0.26,4.32)	0.00(-0.03,0.09)
LD TOCI IV + MTX		1.05(0.18,4.30)	1.05(0.18,4.00)	0.00(-0.04,0.08)
HD TOCI IV		1.89(0.81,4.21)	1.85(0.81,3.98)	0.02(-0.01,0.06)

(Continued)

HD GOLI SC		1.24(0.14,7.96)	1.23(0.14,6.96)	0.01(-0.04,0.13)
HD ADA SC		0.57(0.15,1.87)	0.57(0.16,1.84)	-0.01(-0.04,0.01)
HD TOFA		1.67(0.28,9.51)	1.64(0.29,8.34)	0.02(-0.03,0.13)
HD ANA		1.87(0.46,7.61)	1.83(0.48,6.80)	0.02(-0.02,0.12)
HD TOCI IV + MTX		2.46(0.87,6.60)	2.36(0.88,5.87)	0.04(0.00,0.12)
HD GOLI SC + MTX		3.92(1.14,14.50)	3.62(1.13,11.20)	0.07(0.00,0.26)
HD INF IV + MTX		3.92(1.37,10.22)	3.61(1.35,8.57)	0.07(0.01,0.18)
HD TOFA PO + MTX		3.39(1.22,8.78)	3.19(1.21,7.60)	0.06(0.01,0.16)
HD CERTO SC + MTX		3.67(1.10,11.01)	3.40(1.09,9.12)	0.06(0.00,0.19)
HD TOCI IV + DMARD		1.91(0.75,4.42)	1.86(0.76,4.08)	0.02(-0.01,0.09)
SD ABA IV + DMARD	SD CERTO + DMARD	0.94(0.30,3.33)	0.94(0.31,3.18)	0.00(-0.05,0.05)
SD ADA SC + DMARD		0.83(0.15,4.32)	0.83(0.16,4.04)	-0.01(-0.07,0.08)
SD TOCI SC + DMARD		1.85(0.33,16.46)	1.79(0.34,10.19)	0.02(-0.04,0.35)
LD ETN SC		1.31(0.40,4.34)	1.29(0.42,4.12)	0.01(-0.05,0.06)
LD ADA SC		0.39(0.07,1.94)	0.40(0.08,1.91)	-0.02(-0.08,0.02)
LD ANA		0.58(0.11,3.43)	0.59(0.12,3.29)	-0.01(-0.08,0.04)
LD TOCI IV		1.04(0.21,4.88)	1.03(0.22,4.56)	0.00(-0.06,0.08)
LD RITUX IV + MTX		3.60(0.71,18.43)	3.26(0.73,13.17)	0.08(-0.02,0.35)
LD ABA IV + MTX		2.27(0.40,8.91)	2.16(0.42,7.70)	0.04(-0.04,0.16)
LD CERTO SC + MTX		1.98(0.24,9.17)	1.89(0.25,7.80)	0.03(-0.05,0.18)
LD ETN SC + MTX		0.86(0.17,4.71)	0.87(0.17,4.31)	0.00(-0.07,0.09)
LD TOCI IV + MTX		0.74(0.12,4.29)	0.75(0.13,4.01)	-0.01(-0.07,0.07)
HD TOCI IV		1.39(0.42,4.44)	1.37(0.43,4.20)	0.01(-0.04,0.06)
HD GOLI SC		0.91(0.09,7.34)	0.92(0.09,6.43)	0.00(-0.07,0.13)
HD ADA SC		0.41(0.09,1.89)	0.42(0.09,1.86)	-0.02(-0.08,0.01)
HD TOFA		1.25(0.17,8.18)	1.24(0.19,7.38)	0.01(-0.07,0.12)
HD ANA		1.39(0.30,7.33)	1.37(0.31,6.54)	0.01(-0.06,0.11)
HD TOCI IV + MTX		1.85(0.48,6.83)	1.78(0.50,6.20)	0.03(-0.04,0.11)

(Continued)

HD GOLI SC + MTX		2.94(0.60,15.08)	2.73(0.62,11.65)	0.06(-0.03,0.25)
HD INF IV + MTX		2.88(0.75,10.33)	2.69(0.76,8.90)	0.06(-0.01,0.18)
HD TOFA PO + MTX		2.52(0.67,9.17)	2.38(0.69,7.95)	0.05(-0.02,0.16)
HD CERTO SC + MTX		2.69(0.67,9.81)	2.53(0.69,8.44)	0.05(-0.02,0.18)
HD TOCI IV + DMARD		1.35(0.45,4.64)	1.33(0.47,4.33)	0.01(-0.04,0.09)
SD ADA SC + DMARD	SD ABA IV + DMARD	0.88(0.21,3.50)	0.89(0.22,3.29)	0.00(-0.05,0.06)
SD TOCI SC + DMARD		1.84(0.40,15.36)	1.78(0.41,10.07)	0.02(-0.03,0.35)
LD ETN SC		1.35(0.49,4.05)	1.33(0.51,3.86)	0.01(-0.04,0.06)
LD ADA SC		0.41(0.09,1.97)	0.42(0.10,1.93)	-0.02(-0.08,0.02)
LD ANA		0.61(0.12,3.20)	0.62(0.13,3.08)	-0.01(-0.07,0.04)
LD TOCI IV		1.09(0.25,4.69)	1.08(0.25,4.37)	0.00(-0.05,0.07)
LD RITUX IV + MTX		3.63(0.89,17.74)	3.30(0.90,12.40)	0.08(-0.01,0.35)
LD ABA IV + MTX		2.29(0.50,9.18)	2.18(0.52,7.94)	0.04(-0.03,0.17)
LD CERTO SC + MTX		2.03(0.28,9.64)	1.95(0.29,8.03)	0.03(-0.04,0.19)
LD ETN SC + MTX		0.92(0.18,4.09)	0.92(0.19,3.80)	0.00(-0.05,0.08)
LD TOCI IV + MTX		0.80(0.12,4.04)	0.80(0.13,3.78)	-0.01(-0.06,0.07)
HD TOCI IV		1.46(0.53,3.79)	1.44(0.55,3.62)	0.01(-0.03,0.06)
HD GOLI SC		1.00(0.10,6.64)	1.00(0.10,6.02)	0.00(-0.06,0.12)
HD ADA SC		0.43(0.09,1.89)	0.44(0.10,1.86)	-0.02(-0.07,0.01)
HD TOFA		1.27(0.19,8.28)	1.25(0.20,7.30)	0.01(-0.06,0.12)
HD ANA		1.46(0.33,7.39)	1.44(0.35,6.66)	0.01(-0.05,0.11)
HD TOCI IV + MTX		1.91(0.57,6.17)	1.85(0.59,5.62)	0.03(-0.03,0.11)
HD GOLI SC + MTX		3.02(0.75,12.91)	2.80(0.76,10.46)	0.06(-0.01,0.24)
HD INF IV + MTX		3.07(0.87,9.09)	2.85(0.88,8.04)	0.06(-0.01,0.17)
HD TOFA PO + MTX		2.62(0.82,8.06)	2.47(0.83,7.11)	0.05(-0.01,0.15)
HD CERTO SC + MTX		2.82(0.74,9.54)	2.63(0.75,8.18)	0.06(-0.01,0.18)
HD TOCI IV + DMARD		1.45(0.60,3.77)	1.43(0.62,3.55)	0.01(-0.02,0.07)

(Continued)

SD TOCI SC + DMARD	SD ADA SC + DMARD	2.07(0.34,27.25)	1.98(0.35,17.22)	0.03(-0.05,0.37)
LD ETN SC		1.53(0.35,6.97)	1.51(0.37,6.62)	0.01(-0.07,0.07)
LD ADA SC		0.48(0.07,2.65)	0.49(0.08,2.60)	-0.01(-0.10,0.02)
LD ANA		0.68(0.12,4.95)	0.69(0.13,4.72)	-0.01(-0.09,0.05)
LD TOCI IV		1.24(0.19,7.93)	1.23(0.21,7.38)	0.01(-0.07,0.08)
LD RITUX IV + MTX		4.13(0.69,31.08)	3.74(0.71,21.92)	0.08(-0.02,0.35)
LD ABA IV + MTX		2.55(0.44,14.21)	2.42(0.46,12.33)	0.04(-0.05,0.18)
LD CERTO SC + MTX		2.28(0.25,14.73)	2.17(0.27,12.41)	0.03(-0.06,0.19)
LD ETN SC + MTX		1.08(0.17,6.01)	1.07(0.18,5.62)	0.00(-0.08,0.09)
LD TOCI IV + MTX		0.90(0.11,5.76)	0.90(0.12,5.41)	0.00(-0.09,0.07)
HD TOCI IV		1.62(0.41,7.14)	1.59(0.43,6.69)	0.02(-0.06,0.07)
HD GOLI SC		1.11(0.08,9.24)	1.11(0.08,8.34)	0.00(-0.09,0.12)
HD ADA SC		0.49(0.08,2.76)	0.50(0.09,2.71)	-0.01(-0.10,0.02)
HD TOFA		1.42(0.17,12.52)	1.40(0.18,11.15)	0.01(-0.08,0.13)
HD ANA		1.69(0.28,10.54)	1.65(0.31,9.64)	0.02(-0.07,0.11)
HD TOCI IV + MTX		2.17(0.47,10.43)	2.09(0.49,9.60)	0.03(-0.04,0.12)
HD GOLI SC + MTX		3.52(0.61,20.06)	3.21(0.64,16.36)	0.06(-0.03,0.24)
HD INF IV + MTX		3.47(0.71,15.60)	3.20(0.73,13.54)	0.06(-0.02,0.17)
HD TOFA PO + MTX		2.93(0.64,15.08)	2.75(0.66,12.86)	0.05(-0.03,0.16)
HD CERTO SC + MTX		3.26(0.58,15.34)	3.02(0.60,13.30)	0.06(-0.03,0.18)
HD TOCI IV + DMARD		1.66(0.42,6.93)	1.62(0.44,6.49)	0.02(-0.05,0.09)
LD ETN SC	SD TOCI SC + DMARD	0.74(0.07,3.88)	0.75(0.12,3.70)	-0.01(-0.35,0.05)
LD ADA SC		0.24(0.01,1.58)	0.25(0.02,1.56)	-0.04(-0.39,0.01)
LD ANA		0.34(0.02,2.39)	0.35(0.03,2.33)	-0.04(-0.39,0.03)
LD TOCI IV		0.57(0.04,4.60)	0.59(0.07,4.32)	-0.02(-0.35,0.06)
LD RITUX IV + MTX		1.96(0.19,18.88)	1.83(0.27,14.50)	0.04(-0.25,0.30)
LD ABA IV + MTX		1.18(0.10,9.75)	1.16(0.15,8.54)	0.01(-0.33,0.15)

(Continued)

LD CERTO SC + MTX		0.99(0.09,9.20)	0.99(0.11,7.69)	0.00(-0.32,0.17)
LD ETN SC + MTX		0.51(0.04,3.40)	0.53(0.06,3.22)	-0.03(-0.36,0.05)
LD TOCI IV + MTX		0.41(0.03,3.45)	0.43(0.04,3.27)	-0.03(-0.38,0.05)
HD TOCI IV		0.78(0.09,4.24)	0.79(0.13,4.04)	-0.01(-0.34,0.05)
HD GOLI SC		0.49(0.02,6.37)	0.51(0.04,5.81)	-0.03(-0.37,0.11)
HD ADA SC		0.24(0.02,1.69)	0.25(0.03,1.67)	-0.04(-0.39,0.01)
HD TOFA		0.69(0.03,7.36)	0.70(0.04,6.68)	-0.02(-0.38,0.11)
HD ANA		0.76(0.05,5.66)	0.77(0.08,5.22)	-0.01(-0.37,0.09)
HD TOCI IV + MTX		1.02(0.10,5.63)	1.02(0.15,5.17)	0.00(-0.31,0.09)
HD GOLI SC + MTX		1.57(0.16,11.86)	1.51(0.22,9.86)	0.03(-0.28,0.21)
HD INF IV + MTX		1.63(0.16,8.70)	1.57(0.24,7.68)	0.03(-0.29,0.15)
HD TOFA PO + MTX		1.40(0.15,8.64)	1.36(0.21,7.45)	0.02(-0.30,0.14)
HD CERTO SC + MTX		1.43(0.16,10.29)	1.39(0.22,8.74)	0.02(-0.28,0.17)
HD TOCI IV + DMARD		0.79(0.10,3.53)	0.81(0.15,3.36)	-0.01(-0.32,0.06)
LD ADA SC	LD ETN SC	0.30(0.08,1.22)	0.31(0.09,1.21)	-0.03(-0.08,0.01)
LD ANA		0.43(0.11,2.16)	0.44(0.12,2.07)	-0.02(-0.08,0.03)
LD TOCI IV		0.82(0.20,2.75)	0.83(0.21,2.57)	-0.01(-0.06,0.06)
LD RITUX IV + MTX		2.65(0.85,10.20)	2.45(0.85,7.18)	0.06(-0.01,0.33)
LD ABA IV + MTX		1.66(0.50,5.08)	1.61(0.51,4.41)	0.03(-0.03,0.15)
LD CERTO SC + MTX		1.47(0.24,6.01)	1.44(0.25,5.04)	0.02(-0.04,0.17)
LD ETN SC + MTX		0.69(0.16,2.48)	0.70(0.17,2.34)	-0.01(-0.07,0.06)
LD TOCI IV + MTX		0.59(0.10,2.49)	0.60(0.10,2.35)	-0.02(-0.07,0.05)
HD TOCI IV		1.07(0.49,2.36)	1.07(0.51,2.27)	0.00(-0.04,0.04)
HD GOLI SC		0.70(0.08,4.00)	0.71(0.09,3.59)	-0.01(-0.07,0.11)
HD ADA SC		0.32(0.09,1.19)	0.33(0.09,1.18)	-0.03(-0.08,0.00)
HD TOFA		0.96(0.17,5.29)	0.97(0.18,4.74)	0.00(-0.07,0.11)
HD ANA		1.06(0.26,4.60)	1.06(0.27,4.15)	0.00(-0.06,0.10)
HD TOCI IV + MTX		1.38(0.53,3.94)	1.35(0.54,3.55)	0.02(-0.03,0.10)

(Continued)

HD GOLI SC + MTX		2.25(0.72,7.04)	2.12(0.74,5.65)	0.05(-0.01,0.22)
HD INF IV + MTX		2.24(0.91,5.05)	2.10(0.92,4.43)	0.05(0.00,0.15)
HD TOFA PO + MTX		1.94(0.84,4.19)	1.86(0.85,3.71)	0.04(-0.01,0.13)
HD CERTO SC + MTX		2.07(0.71,5.33)	1.96(0.73,4.60)	0.04(-0.01,0.16)
HD TOCI IV + DMARD		1.07(0.37,3.06)	1.07(0.39,2.86)	0.00(-0.05,0.07)
LD ANA	LD ADA SC	1.44(0.31,8.09)	1.43(0.31,7.57)	0.01(-0.02,0.06)
LD TOCI IV		2.66(0.40,14.95)	2.59(0.41,13.66)	0.02(-0.02,0.10)
LD RITUX IV + MTX		8.62(1.37,57.32)	7.68(1.35,40.36)	0.10(0.01,0.38)
LD ABA IV + MTX		5.56(0.94,24.86)	5.16(0.94,21.40)	0.06(0.00,0.19)
LD CERTO SC + MTX		4.88(0.47,30.85)	4.58(0.48,25.09)	0.05(-0.01,0.21)
LD ETN SC + MTX		2.20(0.37,13.74)	2.15(0.38,12.44)	0.02(-0.02,0.11)
LD TOCI IV + MTX		1.92(0.29,12.66)	1.90(0.29,11.49)	0.01(-0.02,0.09)
HD TOCI IV		3.45(0.85,14.87)	3.32(0.85,13.75)	0.03(0.00,0.09)
HD GOLI SC		2.36(0.20,18.20)	2.30(0.20,16.26)	0.02(-0.03,0.14)
HD ADA SC		1.02(0.28,3.57)	1.02(0.29,3.50)	0.00(-0.02,0.02)
HD TOFA		2.99(0.46,23.86)	2.90(0.47,21.13)	0.03(-0.02,0.14)
HD ANA		3.54(0.81,18.38)	3.41(0.81,16.47)	0.03(-0.01,0.13)
HD TOCI IV + MTX		4.59(1.12,25.04)	4.33(1.11,21.54)	0.05(0.00,0.15)
HD GOLI SC + MTX		7.41(1.26,35.91)	6.72(1.25,28.23)	0.08(0.01,0.27)
HD INF IV + MTX		7.39(1.53,30.49)	6.71(1.50,25.84)	0.08(0.01,0.20)
HD TOFA PO + MTX		6.24(1.50,26.17)	5.79(1.48,22.53)	0.07(0.01,0.18)
HD CERTO SC + MTX		6.85(1.31,32.18)	6.25(1.29,26.32)	0.08(0.01,0.21)
HD TOCI IV + DMARD		3.49(0.83,16.32)	3.37(0.84,14.62)	0.03(0.00,0.12)
LD TOCI IV	LD ANA	1.82(0.25,9.92)	1.79(0.26,9.13)	0.02(-0.04,0.10)
LD RITUX IV + MTX		6.14(0.88,38.40)	5.47(0.89,27.35)	0.09(-0.01,0.37)
LD ABA IV + MTX		3.75(0.56,22.34)	3.53(0.57,18.83)	0.05(-0.02,0.19)
LD CERTO SC + MTX		3.29(0.29,22.13)	3.12(0.30,18.27)	0.05(-0.03,0.21)
LD ETN SC + MTX		1.57(0.19,9.74)	1.55(0.20,8.84)	0.01(-0.05,0.10)

(Continued)

LD TOCI IV + MTX		1.28(0.15,9.16)	1.27(0.16,8.47)	0.01(-0.05,0.09)
HD TOCI IV		2.43(0.48,9.80)	2.36(0.50,9.15)	0.03(-0.03,0.08)
HD GOLI SC		1.62(0.11,13.13)	1.60(0.12,11.58)	0.01(-0.05,0.14)
HD ADA SC		0.72(0.09,3.37)	0.73(0.10,3.29)	-0.01(-0.06,0.02)
HD TOFA		2.10(0.32,16.47)	2.05(0.34,14.50)	0.02(-0.04,0.13)
HD ANA		2.32(0.81,7.38)	2.25(0.82,6.87)	0.03(-0.01,0.10)
HD TOCI IV + MTX		3.20(0.54,15.11)	3.04(0.56,13.35)	0.04(-0.03,0.14)
HD GOLI SC + MTX		5.38(0.80,27.56)	4.89(0.81,21.65)	0.07(-0.01,0.27)
HD INF IV + MTX		5.09(0.89,23.21)	4.66(0.90,19.49)	0.07(0.00,0.19)
HD TOFA PO + MTX		4.37(0.81,22.35)	4.06(0.82,18.77)	0.06(-0.01,0.18)
HD CERTO SC + MTX		4.57(0.79,22.13)	4.21(0.80,18.75)	0.07(-0.01,0.20)
HD TOCI IV + DMARD		2.40(0.47,11.30)	2.32(0.48,10.27)	0.03(-0.03,0.11)
LD RITUX IV + MTX	LD TOCI IV	3.28(0.72,21.10)	2.98(0.73,15.12)	0.07(-0.02,0.35)
LD ABA IV + MTX		2.10(0.37,10.21)	2.01(0.40,8.71)	0.03(-0.05,0.16)
LD CERTO SC + MTX		1.78(0.23,11.92)	1.72(0.24,9.97)	0.03(-0.05,0.19)
LD ETN SC + MTX		0.87(0.15,4.94)	0.87(0.16,4.57)	0.00(-0.08,0.08)
LD TOCI IV + MTX		0.73(0.12,3.60)	0.74(0.13,3.42)	-0.01(-0.08,0.06)
HD TOCI IV		1.29(0.45,4.64)	1.27(0.47,4.44)	0.01(-0.05,0.06)
HD GOLI SC		0.89(0.08,6.92)	0.90(0.09,6.19)	0.00(-0.09,0.12)
HD ADA SC		0.39(0.08,2.25)	0.40(0.08,2.22)	-0.02(-0.10,0.02)
HD TOFA		1.16(0.15,9.94)	1.15(0.16,8.89)	0.01(-0.09,0.12)
HD ANA		1.31(0.26,8.56)	1.29(0.28,7.68)	0.01(-0.07,0.11)
HD TOCI IV + MTX		1.70(0.54,6.34)	1.65(0.57,5.89)	0.02(-0.04,0.10)
HD GOLI SC + MTX		2.79(0.59,13.55)	2.58(0.62,11.16)	0.06(-0.03,0.24)
HD INF IV + MTX		2.72(0.68,11.98)	2.54(0.70,10.42)	0.06(-0.03,0.18)
HD TOFA PO + MTX		2.33(0.65,10.94)	2.21(0.67,9.58)	0.04(-0.03,0.15)
HD CERTO SC + MTX		2.50(0.57,11.84)	2.34(0.60,10.12)	0.05(-0.03,0.18)
HD TOCI IV + DMARD		1.30(0.33,6.43)	1.29(0.35,5.99)	0.01(-0.06,0.09)

(Continued)

LD ABA IV + MTX	LD RITUX IV + MTX	0.62(0.13,2.39)	0.66(0.16,2.22)	-0.04(-0.27,0.08)
LD CERTO SC + MTX		0.56(0.06,3.24)	0.60(0.07,2.83)	-0.04(-0.31,0.12)
LD ETN SC + MTX		0.26(0.04,1.20)	0.29(0.05,1.19)	-0.08(-0.35,0.01)
LD TOCI IV + MTX		0.22(0.03,1.15)	0.24(0.04,1.14)	-0.08(-0.35,0.01)
HD TOCI IV		0.40(0.10,1.34)	0.43(0.15,1.32)	-0.06(-0.33,0.01)
HD GOLI SC		0.27(0.03,1.63)	0.30(0.03,1.56)	-0.07(-0.35,0.04)
HD ADA SC		0.12(0.01,0.64)	0.13(0.02,0.66)	-0.10(-0.38,-0.01)
HD TOFA		0.36(0.05,2.62)	0.39(0.07,2.41)	-0.06(-0.35,0.07)
HD ANA		0.40(0.06,2.30)	0.43(0.09,2.15)	-0.06(-0.34,0.06)
HD TOCI IV + MTX		0.54(0.11,1.99)	0.57(0.15,1.89)	-0.05(-0.32,0.05)
HD GOLI SC + MTX		0.83(0.14,3.38)	0.85(0.21,2.93)	-0.01(-0.29,0.15)
HD INF IV + MTX		0.82(0.20,2.59)	0.84(0.27,2.38)	-0.02(-0.26,0.09)
HD TOFA PO + MTX		0.75(0.18,2.27)	0.77(0.24,2.13)	-0.02(-0.25,0.06)
HD CERTO SC + MTX		0.77(0.17,2.79)	0.79(0.23,2.51)	-0.02(-0.28,0.10)
HD TOCI IV + DMARD		0.40(0.08,1.65)	0.43(0.12,1.59)	-0.06(-0.33,0.03)
LD CERTO SC + MTX	LD ABA IV + MTX	0.87(0.12,5.00)	0.88(0.14,4.36)	-0.01(-0.13,0.14)
LD ETN SC + MTX		0.41(0.08,2.14)	0.43(0.09,2.03)	-0.04(-0.17,0.05)
LD TOCI IV + MTX		0.36(0.05,1.88)	0.38(0.06,1.81)	-0.04(-0.18,0.03)
HD TOCI IV		0.63(0.20,2.35)	0.65(0.23,2.26)	-0.03(-0.15,0.04)
HD GOLI SC		0.43(0.04,3.00)	0.45(0.04,2.76)	-0.04(-0.17,0.08)
HD ADA SC		0.19(0.04,1.04)	0.21(0.04,1.04)	-0.06(-0.19,0.00)
HD TOFA		0.58(0.09,3.96)	0.60(0.11,3.63)	-0.03(-0.17,0.09)
HD ANA		0.63(0.12,3.99)	0.65(0.15,3.68)	-0.02(-0.16,0.08)
HD TOCI IV + MTX		0.83(0.24,3.43)	0.84(0.27,3.17)	-0.01(-0.13,0.09)
HD GOLI SC + MTX		1.36(0.34,5.61)	1.32(0.38,4.67)	0.02(-0.10,0.19)
HD INF IV + MTX		1.31(0.42,4.73)	1.28(0.45,4.21)	0.02(-0.08,0.12)
HD TOFA PO + MTX		1.17(0.35,3.83)	1.15(0.39,3.53)	0.01(-0.10,0.10)

(Continued)

HD CERTO SC + MTX		1.18(0.35,5.34)	1.17(0.39,4.66)	0.01(-0.09,0.14)
HD TOCI IV + DMARD		0.64(0.16,2.81)	0.66(0.19,2.67)	-0.02(-0.15,0.06)
LD ETN SC + MTX	LD CERTO SC + MTX	0.46(0.07,3.96)	0.48(0.08,3.68)	-0.03(-0.19,0.06)
LD TOCI IV + MTX		0.40(0.05,3.88)	0.42(0.05,3.67)	-0.04(-0.20,0.05)
HD TOCI IV		0.71(0.16,4.53)	0.73(0.19,4.33)	-0.02(-0.17,0.05)
HD GOLI SC		0.48(0.03,6.26)	0.51(0.04,5.75)	-0.03(-0.19,0.09)
HD ADA SC		0.21(0.04,2.13)	0.22(0.05,2.10)	-0.05(-0.21,0.01)
HD TOFA		0.67(0.08,8.97)	0.68(0.09,8.20)	-0.02(-0.19,0.11)
HD ANA		0.72(0.12,7.23)	0.73(0.14,6.73)	-0.02(-0.18,0.09)
HD TOCI IV + MTX		0.95(0.18,6.83)	0.95(0.22,6.35)	0.00(-0.16,0.10)
HD GOLI SC + MTX		1.54(0.27,12.02)	1.48(0.31,10.30)	0.03(-0.13,0.19)
HD INF IV + MTX		1.54(0.34,9.25)	1.48(0.38,8.37)	0.03(-0.12,0.13)
HD TOFA PO + MTX		1.27(0.32,8.90)	1.24(0.37,7.99)	0.02(-0.12,0.12)
HD CERTO SC + MTX		1.36(0.38,8.62)	1.32(0.42,7.83)	0.02(-0.10,0.13)
HD TOCI IV + DMARD		0.71(0.17,4.89)	0.73(0.19,4.59)	-0.02(-0.17,0.07)
LD TOCI IV + MTX	LD ETN SC + MTX	0.87(0.12,5.40)	0.88(0.13,5.11)	0.00(-0.09,0.06)
HD TOCI IV		1.55(0.41,6.44)	1.53(0.44,6.08)	0.02(-0.06,0.07)
HD GOLI SC		1.09(0.09,8.28)	1.08(0.09,7.38)	0.00(-0.09,0.13)
HD ADA SC		0.47(0.08,2.82)	0.48(0.09,2.77)	-0.02(-0.11,0.02)
HD TOFA		1.30(0.19,11.98)	1.29(0.20,10.81)	0.01(-0.09,0.13)
HD ANA		1.59(0.24,10.01)	1.56(0.26,9.11)	0.02(-0.09,0.11)
HD TOCI IV + MTX		2.11(0.46,9.23)	2.03(0.48,8.44)	0.03(-0.05,0.12)
HD GOLI SC + MTX		3.37(0.69,15.82)	3.09(0.71,13.13)	0.06(-0.02,0.24)
HD INF IV + MTX		3.24(0.80,12.75)	3.01(0.82,11.40)	0.06(-0.01,0.17)
HD TOFA PO + MTX		2.77(0.72,14.24)	2.61(0.74,12.29)	0.05(-0.02,0.16)
HD CERTO SC + MTX		2.99(0.57,14.18)	2.79(0.60,12.47)	0.05(-0.04,0.18)
HD TOCI IV + DMARD		1.57(0.37,8.18)	1.54(0.39,7.65)	0.02(-0.06,0.09)

(Continued)

HD TOCI IV	LD TOCI IV + MTX	1.79(0.48,9.72)	1.75(0.50,9.20)	0.02(-0.05,0.07)
HD GOLI SC		1.15(0.14,13.22)	1.15(0.14,11.88)	0.00(-0.06,0.13)
HD ADA SC		0.52(0.11,3.57)	0.53(0.12,3.49)	-0.01(-0.09,0.02)
HD TOFA		1.65(0.24,15.03)	1.62(0.26,13.35)	0.01(-0.06,0.13)
HD ANA		1.91(0.27,14.13)	1.86(0.29,12.88)	0.02(-0.07,0.12)
HD TOCI IV + MTX		2.34(0.61,13.07)	2.24(0.63,11.72)	0.03(-0.03,0.12)
HD GOLI SC + MTX		3.87(0.70,28.06)	3.56(0.72,23.65)	0.06(-0.02,0.25)
HD INF IV + MTX		3.82(0.87,22.47)	3.52(0.88,19.76)	0.07(-0.01,0.19)
HD TOFA PO + MTX		3.29(0.75,19.51)	3.08(0.77,17.42)	0.05(-0.02,0.16)
HD CERTO SC + MTX		3.57(0.68,22.55)	3.30(0.70,19.56)	0.06(-0.02,0.19)
HD TOCI IV + DMARD		1.81(0.38,12.15)	1.77(0.40,11.15)	0.02(-0.05,0.10)
HD GOLI SC	HD TOCI IV	0.67(0.08,3.76)	0.68(0.08,3.37)	-0.01(-0.07,0.11)
HD ADA SC		0.30(0.08,1.10)	0.31(0.08,1.10)	-0.03(-0.09,0.00)
HD TOFA		0.90(0.14,5.15)	0.90(0.15,4.61)	0.00(-0.08,0.11)
HD ANA		1.02(0.25,4.24)	1.02(0.27,3.87)	0.00(-0.07,0.10)
HD TOCI IV + MTX		1.31(0.62,2.97)	1.29(0.64,2.74)	0.01(-0.02,0.08)
HD GOLI SC + MTX		2.09(0.65,6.95)	1.97(0.67,5.57)	0.05(-0.02,0.22)
HD INF IV + MTX		2.08(0.82,4.98)	1.97(0.83,4.36)	0.05(-0.01,0.15)
HD TOFA PO + MTX		1.77(0.76,4.46)	1.70(0.77,3.95)	0.03(-0.02,0.13)
HD CERTO SC + MTX		1.94(0.62,5.34)	1.84(0.63,4.59)	0.04(-0.02,0.16)
HD TOCI IV + DMARD		0.98(0.41,2.63)	0.98(0.42,2.47)	0.00(-0.04,0.06)
HD ADA SC	HD GOLI SC	0.43(0.06,4.25)	0.43(0.07,4.15)	-0.02(-0.15,0.02)
HD TOFA		1.33(0.16,16.40)	1.31(0.18,14.89)	0.01(-0.12,0.12)
HD ANA		1.48(0.19,18.42)	1.45(0.21,16.51)	0.01(-0.12,0.12)
HD TOCI IV + MTX		1.93(0.28,17.16)	1.86(0.31,15.78)	0.03(-0.10,0.13)
HD GOLI SC + MTX		3.12(0.64,21.46)	2.88(0.68,18.85)	0.06(-0.03,0.22)
HD INF IV + MTX		3.12(0.53,27.43)	2.88(0.56,23.72)	0.06(-0.05,0.17)

(Continued)

HD TOFA PO + MTX		2.69(0.45,23.24)	2.53(0.49,20.88)	0.05(-0.07,0.15)
HD CERTO SC + MTX		2.81(0.43,27.49)	2.62(0.46,24.09)	0.05(-0.07,0.18)
HD TOCI IV + DMARD		1.43(0.23,14.99)	1.41(0.25,13.84)	0.01(-0.11,0.10)
HD TOFA	HD ADA SC	3.13(0.49,18.47)	3.02(0.50,16.34)	0.03(-0.01,0.14)
HD ANA		3.24(0.79,19.98)	3.12(0.79,17.83)	0.03(-0.01,0.13)
HD TOCI IV + MTX		4.33(1.13,18.72)	4.10(1.12,16.72)	0.05(0.00,0.15)
HD GOLI SC + MTX		7.26(1.58,35.84)	6.56(1.55,28.74)	0.08(0.01,0.27)
HD INF IV + MTX		7.15(1.65,30.74)	6.49(1.62,26.12)	0.08(0.01,0.20)
HD TOFA PO + MTX		6.05(1.50,26.47)	5.57(1.47,22.99)	0.07(0.01,0.18)
HD CERTO SC + MTX		6.70(1.34,28.73)	6.11(1.33,24.30)	0.08(0.01,0.21)
HD TOCI IV + DMARD		3.33(0.83,15.41)	3.21(0.83,14.08)	0.03(0.00,0.11)
HD ANA	HD TOFA	1.11(0.17,6.20)	1.10(0.19,5.65)	0.00(-0.11,0.10)
HD TOCI IV + MTX		1.46(0.22,10.93)	1.43(0.25,9.74)	0.02(-0.10,0.13)
HD GOLI SC + MTX		2.32(0.32,19.22)	2.18(0.35,14.99)	0.05(-0.08,0.25)
HD INF IV + MTX		2.32(0.37,16.42)	2.19(0.40,13.67)	0.05(-0.08,0.19)
HD TOFA PO + MTX		2.09(0.33,10.76)	1.99(0.36,9.37)	0.04(-0.08,0.16)
HD CERTO SC + MTX		2.17(0.31,18.28)	2.06(0.34,14.85)	0.05(-0.08,0.20)
HD TOCI IV + DMARD		1.18(0.17,8.33)	1.17(0.19,7.64)	0.01(-0.11,0.10)
HD TOCI IV + MTX	HD ANA	1.32(0.27,6.07)	1.30(0.29,5.38)	0.01(-0.09,0.12)
HD GOLI SC + MTX		2.12(0.40,11.43)	2.00(0.43,8.78)	0.04(-0.07,0.24)
HD INF IV + MTX		2.04(0.41,9.42)	1.93(0.44,7.93)	0.04(-0.07,0.17)
HD TOFA PO + MTX		1.82(0.39,8.12)	1.74(0.42,7.03)	0.03(-0.07,0.15)
HD CERTO SC + MTX		1.97(0.34,8.66)	1.87(0.37,7.38)	0.04(-0.07,0.18)
HD TOCI IV + DMARD		1.02(0.21,4.29)	1.02(0.23,3.97)	0.00(-0.10,0.08)
HD GOLI SC + MTX	HD TOCI IV + MTX	1.54(0.43,7.13)	1.49(0.45,5.59)	0.03(-0.06,0.22)
HD INF IV + MTX		1.59(0.53,4.84)	1.53(0.56,4.20)	0.03(-0.05,0.14)
HD TOFA PO + MTX		1.36(0.48,4.33)	1.33(0.51,3.81)	0.02(-0.06,0.12)

(Continued)

HD CERTO SC + MTX		1.52(0.39,4.84)	1.47(0.42,4.24)	0.03(-0.07,0.14)
HD TOCI IV + DMARD		0.75(0.25,2.48)	0.76(0.27,2.33)	-0.01(-0.10,0.06)
HD INF IV + MTX	HD GOLI SC + MTX	0.99(0.29,3.09)	0.99(0.34,2.81)	0.00(-0.15,0.10)
HD TOFA PO + MTX		0.84(0.27,2.75)	0.85(0.32,2.52)	-0.01(-0.16,0.09)
HD CERTO SC + MTX		0.91(0.23,3.61)	0.92(0.27,3.18)	-0.01(-0.17,0.11)
HD TOCI IV + DMARD		0.47(0.12,2.10)	0.49(0.14,2.00)	-0.05(-0.22,0.04)
HD TOFA PO + MTX	HD INF IV + MTX	0.86(0.37,2.15)	0.87(0.41,2.00)	-0.01(-0.10,0.07)
HD CERTO SC + MTX		0.94(0.30,2.74)	0.95(0.33,2.49)	0.00(-0.11,0.10)
HD TOCI IV + DMARD		0.48(0.16,1.67)	0.51(0.19,1.61)	-0.05(-0.16,0.03)
HD CERTO SC + MTX	HD TOFA PO + MTX	1.08(0.36,3.03)	1.07(0.39,2.68)	0.00(-0.09,0.12)
HD TOCI IV + DMARD		0.55(0.18,1.81)	0.57(0.20,1.73)	-0.03(-0.14,0.04)
HD TOCI IV + DMARD	HD CERTO SC + MTX	0.52(0.16,2.00)	0.54(0.18,1.92)	-0.04(-0.16,0.04)
Random-effects model	Residual deviance	181.1 vs 179 data points		
	Deviance information criteria	904.308		
Fixed-effect model	Residual deviance	vs data points		
	Deviance information criteria			
Note				
Total participants				
Total studies				
2-arm				

Appendix 16. Withdrawals due to adverse events: subgroup - established RA (2 to 10 years)

Withdrawals established: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	4.16(1.40,14.34)	3.82(1.39,11.43)	0.07(0.01,0.21)
DMARD		1.15(0.35,3.27)	1.15(0.35,3.11)	0.00(-0.02,0.05)
MTX + DMARD		12.33(3.59,52.86)	9.51(3.35,26.49)	0.22(0.05,0.52)
SD ETN SC		4.38(1.53,13.94)	4.02(1.51,11.03)	0.07(0.01,0.23)
SD ADA SC		1.88(0.74,4.66)	1.83(0.74,4.34)	0.02(-0.01,0.07)
SD TOCI IV		1.10(0.28,4.22)	1.09(0.28,3.94)	0.00(-0.02,0.06)
SD CERTO SC		2.79(0.85,13.90)	2.67(0.86,11.36)	0.04(0.00,0.19)
SD TOC SC + PL IV		0.74(0.16,3.46)	0.74(0.16,3.29)	-0.01(-0.03,0.05)
SD ANA		1.33(0.43,5.50)	1.31(0.44,4.98)	0.01(-0.02,0.10)
SD ETN SC + MTX		3.99(1.26,13.55)	3.71(1.26,10.84)	0.07(0.01,0.22)
SD INF IV + MTX		10.77(3.24,41.96)	8.52(3.04,23.16)	0.19(0.05,0.47)
SD ABA IV + MTX		4.10(1.10,17.02)	3.79(1.10,12.95)	0.07(0.00,0.25)
SD CERTO SC + MTX		5.89(1.67,21.44)	5.22(1.64,14.98)	0.10(0.02,0.31)
SD ADA SC + MTX		5.65(1.51,22.53)	5.05(1.48,15.90)	0.10(0.01,0.32)
SD GOLI SC + MTX		6.12(1.21,34.77)	5.38(1.20,20.95)	0.11(0.00,0.42)
SD TOFA PO + MTX		7.66(2.03,28.75)	6.48(1.98,18.76)	0.14(0.02,0.37)
SD ABA SC + MTX		2.35(0.48,10.73)	2.28(0.49,8.91)	0.03(-0.01,0.18)
SD ETN SC + DMARD		2.14(0.72,6.14)	2.08(0.73,5.55)	0.03(-0.01,0.11)
SD CERTO SC + DMARD		1.56(0.44,5.61)	1.54(0.45,5.07)	0.01(-0.02,0.10)
SD ADA SC + DMARD		1.38(0.24,7.00)	1.37(0.25,6.12)	0.01(-0.02,0.12)
LD ETN SC		4.75(1.40,18.66)	4.33(1.38,13.86)	0.08(0.01,0.29)
LD ADA SC		0.67(0.18,2.27)	0.67(0.19,2.20)	-0.01(-0.03,0.03)
LD ANA		1.01(0.30,3.95)	1.01(0.30,3.68)	0.00(-0.02,0.07)
LD ABA IV + MTX		4.98(1.18,25.38)	4.52(1.18,17.01)	0.09(0.00,0.35)
LD CERTO SC + MTX		4.16(0.64,22.14)	3.85(0.65,14.79)	0.07(-0.01,0.34)
LD ETN SC + MTX		2.59(0.50,12.69)	2.50(0.51,10.09)	0.04(-0.01,0.21)

(Continued)

HD TOCI IV		2.73(0.85,8.26)	2.61(0.86,7.25)	0.04(0.00,0.13)
HD ADA SC		0.68(0.18,2.20)	0.68(0.19,2.14)	-0.01(-0.03,0.02)
HD ANA		2.47(0.84,8.49)	2.39(0.84,7.29)	0.03(0.00,0.15)
HD TOCI IV + MTX		3.65(0.83,15.79)	3.42(0.83,12.09)	0.06(0.00,0.25)
HD GOLI SC + MTX		8.63(1.73,51.09)	7.22(1.69,25.93)	0.15(0.02,0.50)
HD TOFA PO + MTX		5.91(1.60,21.68)	5.21(1.57,15.42)	0.11(0.01,0.31)
HD CERTO SC + MTX		6.36(1.50,25.92)	5.57(1.48,17.21)	0.11(0.01,0.36)
HD INF IV + MTX		11.49(2.97,47.79)	9.00(2.82,24.75)	0.20(0.04,0.51)
HD TOCI IV + DMARD		2.26(0.57,8.05)	2.19(0.58,6.96)	0.03(-0.01,0.14)
DMARD	MTX	0.27(0.10,0.74)	0.30(0.12,0.75)	-0.06(-0.19,-0.01)
MTX + DMARD		3.04(1.41,6.63)	2.48(1.34,4.54)	0.14(0.03,0.35)
SD ETN SC		1.06(0.67,1.79)	1.05(0.70,1.68)	0.00(-0.04,0.06)
SD ADA SC		0.44(0.14,1.36)	0.47(0.17,1.33)	-0.05(-0.18,0.02)
SD TOCI IV		0.27(0.05,1.13)	0.29(0.06,1.13)	-0.07(-0.20,0.01)
SD CERTO SC		0.69(0.13,4.72)	0.71(0.16,4.09)	-0.03(-0.18,0.13)
SD TOC SC + PL IV		0.18(0.03,0.90)	0.20(0.04,0.91)	-0.07(-0.21,0.00)
SD ANA		0.32(0.06,1.80)	0.35(0.07,1.71)	-0.06(-0.21,0.04)
SD ETN SC + MTX		0.97(0.59,1.57)	0.97(0.62,1.50)	0.00(-0.05,0.05)
SD INF IV + MTX		2.64(1.44,4.87)	2.24(1.37,3.66)	0.12(0.03,0.29)
SD ABA IV + MTX		0.98(0.49,1.91)	0.98(0.51,1.75)	0.00(-0.05,0.09)
SD CERTO SC + MTX		1.38(0.78,2.67)	1.32(0.80,2.34)	0.03(-0.02,0.14)
SD ADA SC + MTX		1.36(0.65,3.10)	1.31(0.67,2.57)	0.03(-0.04,0.17)
SD GOLI SC + MTX		1.52(0.39,5.54)	1.43(0.42,3.94)	0.04(-0.07,0.29)
SD TOFA PO + MTX		1.82(0.96,3.36)	1.67(0.97,2.74)	0.06(0.00,0.20)
SD ABA SC + MTX		0.55(0.19,1.57)	0.58(0.21,1.47)	-0.03(-0.12,0.05)
SD ETN SC + DMARD		0.52(0.19,1.31)	0.54(0.22,1.29)	-0.04(-0.15,0.02)
SD CERTO SC + DMARD		0.37(0.09,1.52)	0.39(0.11,1.48)	-0.05(-0.19,0.03)
SD ADA SC + DMARD		0.32(0.07,1.58)	0.35(0.08,1.51)	-0.06(-0.19,0.04)

(Continued)

LD ETN SC		1.18(0.55,2.68)	1.15(0.58,2.33)	0.01(-0.05,0.14)
LD ADA SC		0.16(0.04,0.70)	0.17(0.04,0.72)	-0.08(-0.22,-0.01)
LD ANA		0.24(0.04,1.36)	0.26(0.05,1.33)	-0.07(-0.21,0.02)
LD ABA IV + MTX		1.24(0.45,3.45)	1.20(0.47,2.83)	0.02(-0.06,0.19)
LD CERTO SC + MTX		0.97(0.21,4.35)	0.97(0.23,3.42)	0.00(-0.11,0.22)
LD ETN SC + MTX		0.61(0.17,2.10)	0.64(0.18,1.92)	-0.03(-0.13,0.09)
HD TOCI IV		0.66(0.29,1.33)	0.68(0.32,1.30)	-0.03(-0.12,0.02)
HD ADA SC		0.17(0.03,0.74)	0.18(0.03,0.75)	-0.08(-0.22,-0.01)
HD ANA		0.59(0.11,2.75)	0.62(0.14,2.51)	-0.03(-0.19,0.09)
HD TOCI IV + MTX		0.87(0.26,2.62)	0.89(0.28,2.30)	-0.01(-0.11,0.12)
HD GOLI SC + MTX		2.06(0.61,7.76)	1.84(0.63,4.84)	0.08(-0.04,0.37)
HD TOFA PO + MTX		1.40(0.76,2.63)	1.34(0.77,2.28)	0.03(-0.02,0.14)
HD CERTO SC + MTX		1.49(0.61,3.96)	1.41(0.64,3.12)	0.04(-0.04,0.22)
HD INF IV + MTX		2.84(1.22,6.43)	2.35(1.19,4.46)	0.13(0.01,0.34)
HD TOCI IV + DMARD		0.53(0.17,1.74)	0.56(0.20,1.66)	-0.04(-0.15,0.05)
MTX + DMARD	DMARD	11.40(3.26,38.36)	8.53(2.95,22.99)	0.21(0.06,0.50)
SD ETN SC		3.98(1.50,10.12)	3.64(1.45,8.55)	0.07(0.02,0.21)
SD ADA SC		1.66(0.50,5.14)	1.63(0.51,4.88)	0.02(-0.03,0.06)
SD TOCI IV		0.95(0.21,3.89)	0.95(0.22,3.69)	0.00(-0.04,0.06)
SD CERTO SC		2.53(0.46,16.45)	2.41(0.47,13.75)	0.04(-0.03,0.19)
SD TOC SC + PL IV		0.65(0.12,3.28)	0.65(0.13,3.12)	-0.01(-0.05,0.04)
SD ANA		1.20(0.24,7.26)	1.19(0.25,6.54)	0.00(-0.05,0.10)
SD ETN SC + MTX		3.57(1.22,9.72)	3.31(1.20,8.18)	0.06(0.01,0.20)
SD INF IV + MTX		9.77(3.01,30.69)	7.62(2.76,20.19)	0.19(0.05,0.45)
SD ABA IV + MTX		3.60(1.05,12.86)	3.33(1.05,10.27)	0.06(0.00,0.24)
SD CERTO SC + MTX		5.09(1.64,16.53)	4.53(1.60,12.70)	0.10(0.02,0.29)
SD ADA SC + MTX		5.10(1.47,17.33)	4.53(1.43,12.98)	0.09(0.01,0.30)
SD GOLI SC + MTX		5.49(1.09,29.09)	4.79(1.09,18.35)	0.10(0.00,0.42)

(Continued)

SD TOFA PO + MTX		6.59(1.93,21.27)	5.60(1.84,15.33)	0.13(0.03,0.35)
SD ABA SC + MTX		1.98(0.46,8.73)	1.92(0.47,7.49)	0.02(-0.02,0.17)
SD ETN SC + DMARD		1.88(0.59,5.45)	1.83(0.60,5.06)	0.02(-0.02,0.09)
SD CERTO SC + DMARD		1.38(0.47,4.20)	1.36(0.48,3.94)	0.01(-0.03,0.07)
SD ADA SC + DMARD		1.20(0.35,4.15)	1.19(0.36,3.76)	0.00(-0.03,0.10)
LD ETN SC		4.42(1.34,14.67)	3.99(1.33,11.28)	0.08(0.01,0.26)
LD ADA SC		0.59(0.11,2.75)	0.60(0.12,2.68)	-0.01(-0.06,0.02)
LD ANA		0.85(0.16,5.46)	0.86(0.17,5.11)	0.00(-0.05,0.07)
LD ABA IV + MTX		4.52(1.07,20.02)	4.06(1.06,14.38)	0.08(0.00,0.33)
LD CERTO SC + MTX		3.68(0.56,19.15)	3.39(0.57,13.89)	0.06(-0.02,0.32)
LD ETN SC + MTX		2.34(0.46,10.32)	2.25(0.47,8.67)	0.03(-0.02,0.19)
HD TOCI IV		2.36(0.98,5.77)	2.27(0.98,5.24)	0.03(0.00,0.11)
HD ADA SC		0.59(0.12,2.80)	0.60(0.12,2.74)	-0.01(-0.05,0.03)
HD ANA		2.16(0.46,11.61)	2.09(0.47,9.96)	0.03(-0.03,0.15)
HD TOCI IV + MTX		3.16(0.85,10.58)	2.95(0.86,8.87)	0.05(0.00,0.22)
HD GOLI SC + MTX		7.85(1.73,35.07)	6.42(1.68,20.82)	0.15(0.02,0.49)
HD TOFA PO + MTX		5.16(1.56,15.90)	4.55(1.52,12.28)	0.10(0.02,0.29)
HD CERTO SC + MTX		5.60(1.40,19.90)	4.86(1.38,14.30)	0.11(0.01,0.34)
HD INF IV + MTX		10.45(2.75,36.46)	8.01(2.55,22.09)	0.20(0.05,0.49)
HD TOCI IV + DMARD		1.96(1.04,3.88)	1.90(1.04,3.58)	0.02(0.00,0.10)
SD ETN SC	MTX + DMARD	0.35(0.15,0.82)	0.43(0.22,0.84)	-0.14(-0.35,-0.02)
SD ADA SC		0.15(0.04,0.56)	0.19(0.07,0.59)	-0.20(-0.48,-0.04)
SD TOCI IV		0.09(0.01,0.47)	0.11(0.02,0.51)	-0.21(-0.51,-0.05)
SD CERTO SC		0.23(0.04,1.66)	0.29(0.07,1.56)	-0.17(-0.47,0.05)
SD TOC SC + PL IV		0.06(0.01,0.37)	0.08(0.01,0.41)	-0.22(-0.52,-0.05)
SD ANA		0.11(0.02,0.68)	0.14(0.03,0.71)	-0.20(-0.51,-0.03)
SD ETN SC + MTX		0.32(0.15,0.67)	0.39(0.21,0.71)	-0.14(-0.35,-0.03)
SD INF IV + MTX		0.86(0.43,1.81)	0.90(0.52,1.59)	-0.02(-0.17,0.10)

(Continued)

SD ABA IV + MTX	0.32(0.12,0.92)	0.40(0.17,0.93)	-0.14(-0.36,-0.01)
SD CERTO SC + MTX	0.45(0.18,1.31)	0.53(0.25,1.25)	-0.11(-0.31,0.03)
SD ADA SC + MTX	0.45(0.15,1.34)	0.53(0.21,1.27)	-0.11(-0.33,0.04)
SD GOLI SC + MTX	0.50(0.11,2.13)	0.58(0.15,1.75)	-0.09(-0.34,0.13)
SD TOFA PO + MTX	0.60(0.21,1.60)	0.67(0.30,1.46)	-0.08(-0.28,0.07)
SD ABA SC + MTX	0.18(0.05,0.73)	0.23(0.07,0.77)	-0.18(-0.43,-0.03)
SD ETN SC + DMARD	0.17(0.05,0.54)	0.22(0.08,0.58)	-0.19(-0.46,-0.04)
SD CERTO SC + DMARD	0.12(0.03,0.60)	0.16(0.05,0.63)	-0.20(-0.49,-0.03)
SD ADA SC + DMARD	0.10(0.02,0.65)	0.14(0.03,0.69)	-0.20(-0.48,-0.03)
LD ETN SC	0.38(0.14,1.16)	0.47(0.19,1.13)	-0.13(-0.34,0.02)
LD ADA SC	0.05(0.01,0.27)	0.07(0.02,0.30)	-0.22(-0.52,-0.06)
LD ANA	0.08(0.01,0.49)	0.10(0.02,0.53)	-0.21(-0.52,-0.04)
LD ABA IV + MTX	0.41(0.11,1.50)	0.48(0.15,1.36)	-0.12(-0.35,0.06)
LD CERTO SC + MTX	0.32(0.06,1.72)	0.39(0.09,1.52)	-0.14(-0.39,0.09)
LD ETN SC + MTX	0.20(0.05,0.81)	0.26(0.07,0.85)	-0.17(-0.43,-0.02)
HD TOCI IV	0.21(0.07,0.60)	0.27(0.11,0.64)	-0.17(-0.44,-0.03)
HD ADA SC	0.05(0.01,0.28)	0.07(0.01,0.31)	-0.22(-0.52,-0.06)
HD ANA	0.20(0.03,1.08)	0.25(0.06,1.07)	-0.17(-0.49,0.01)
HD TOCI IV + MTX	0.28(0.07,1.02)	0.35(0.11,1.02)	-0.15(-0.42,0.00)
HD GOLI SC + MTX	0.69(0.16,3.23)	0.75(0.22,2.35)	-0.05(-0.29,0.23)
HD TOFA PO + MTX	0.47(0.17,1.21)	0.55(0.24,1.17)	-0.10(-0.31,0.03)
HD CERTO SC + MTX	0.49(0.15,1.77)	0.57(0.22,1.56)	-0.10(-0.32,0.09)
HD INF IV + MTX	0.92(0.34,2.53)	0.94(0.43,2.00)	-0.01(-0.20,0.18)
HD TOCI IV + DMARD	0.17(0.05,0.69)	0.22(0.07,0.72)	-0.18(-0.46,-0.03)
SD ADA SC	SD ETN SC 0.42(0.14,1.21)	0.45(0.17,1.19)	-0.05(-0.19,0.01)
SD TOCI IV	0.25(0.05,0.97)	0.27(0.06,0.97)	-0.07(-0.22,0.00)
SD CERTO SC	0.64(0.13,4.25)	0.67(0.15,3.71)	-0.03(-0.19,0.13)
SD TOC SC + PL IV	0.17(0.03,0.80)	0.19(0.04,0.81)	-0.08(-0.23,-0.01)

(Continued)

SD ANA	0.30(0.06,1.67)	0.33(0.07,1.59)	-0.06(-0.22,0.04)
SD ETN SC + MTX	0.91(0.54,1.45)	0.92(0.57,1.39)	-0.01(-0.06,0.04)
SD INF IV + MTX	2.48(1.15,5.38)	2.12(1.12,3.88)	0.11(0.01,0.30)
SD ABA IV + MTX	0.92(0.38,2.10)	0.93(0.41,1.89)	-0.01(-0.09,0.10)
SD CERTO SC + MTX	1.32(0.59,2.84)	1.27(0.62,2.47)	0.03(-0.05,0.15)
SD ADA SC + MTX	1.29(0.52,3.11)	1.25(0.56,2.61)	0.02(-0.06,0.17)
SD GOLI SC + MTX	1.39(0.33,5.60)	1.33(0.36,4.02)	0.03(-0.08,0.29)
SD TOFA PO + MTX	1.70(0.76,3.63)	1.58(0.79,2.93)	0.06(-0.03,0.20)
SD ABA SC + MTX	0.52(0.15,1.66)	0.55(0.17,1.55)	-0.04(-0.14,0.06)
SD ETN SC + DMARD	0.49(0.20,1.09)	0.52(0.23,1.08)	-0.05(-0.16,0.01)
SD CERTO SC + DMARD	0.34(0.09,1.40)	0.37(0.11,1.36)	-0.06(-0.20,0.02)
SD ADA SC + DMARD	0.30(0.07,1.42)	0.32(0.08,1.38)	-0.06(-0.20,0.03)
LD ETN SC	1.11(0.54,2.35)	1.10(0.56,2.08)	0.01(-0.06,0.12)
LD ADA SC	0.15(0.03,0.64)	0.17(0.04,0.66)	-0.08(-0.23,-0.02)
LD ANA	0.23(0.04,1.22)	0.25(0.05,1.20)	-0.07(-0.23,0.01)
LD ABA IV + MTX	1.17(0.37,3.52)	1.15(0.40,2.86)	0.01(-0.08,0.19)
LD CERTO SC + MTX	0.92(0.18,4.15)	0.93(0.20,3.21)	-0.01(-0.13,0.21)
LD ETN SC + MTX	0.58(0.15,2.02)	0.61(0.17,1.83)	-0.03(-0.15,0.08)
HD TOCI IV	0.61(0.26,1.33)	0.64(0.30,1.30)	-0.03(-0.14,0.02)
HD ADA SC	0.16(0.03,0.64)	0.17(0.03,0.65)	-0.08(-0.23,-0.01)
HD ANA	0.56(0.11,2.56)	0.59(0.13,2.34)	-0.04(-0.20,0.09)
HD TOCI IV + MTX	0.82(0.23,2.51)	0.84(0.26,2.20)	-0.01(-0.13,0.12)
HD GOLI SC + MTX	1.94(0.52,7.83)	1.74(0.55,4.94)	0.07(-0.05,0.37)
HD TOFA PO + MTX	1.33(0.60,2.88)	1.28(0.63,2.46)	0.03(-0.05,0.15)
HD CERTO SC + MTX	1.42(0.51,3.99)	1.35(0.55,3.15)	0.03(-0.06,0.22)
HD INF IV + MTX	2.69(1.00,6.71)	2.23(1.00,4.53)	0.12(0.00,0.35)
HD TOCI IV + DMARD	0.49(0.17,1.59)	0.52(0.19,1.52)	-0.04(-0.17,0.04)
SD TOCI IV	SD ADA SC 0.59(0.18,1.65)	0.60(0.19,1.60)	-0.02(-0.06,0.03)

(Continued)

SD CERTO SC	1.52(0.35,8.50)	1.49(0.37,7.21)	0.02(-0.05,0.17)
SD TOC SC + PL IV	0.40(0.11,1.39)	0.41(0.11,1.37)	-0.02(-0.07,0.02)
SD ANA	0.71(0.16,4.21)	0.72(0.18,3.82)	-0.01(-0.07,0.09)
SD ETN SC + MTX	2.20(0.67,6.68)	2.08(0.69,5.74)	0.05(-0.02,0.18)
SD INF IV + MTX	6.02(1.69,21.72)	4.84(1.61,13.66)	0.17(0.03,0.44)
SD ABA IV + MTX	2.22(0.60,8.65)	2.09(0.61,7.04)	0.05(-0.02,0.22)
SD CERTO SC + MTX	3.17(0.87,11.36)	2.86(0.87,8.58)	0.08(-0.01,0.28)
SD ADA SC + MTX	3.09(0.85,11.78)	2.80(0.86,8.86)	0.08(-0.01,0.29)
SD GOLI SC + MTX	3.34(0.63,19.92)	3.01(0.65,12.39)	0.09(-0.02,0.40)
SD TOFA PO + MTX	4.10(1.07,14.42)	3.56(1.07,10.15)	0.12(0.00,0.34)
SD ABA SC + MTX	1.25(0.24,6.01)	1.24(0.25,5.06)	0.01(-0.05,0.16)
SD ETN SC + DMARD	1.16(0.47,2.78)	1.15(0.49,2.60)	0.01(-0.03,0.07)
SD CERTO SC + DMARD	0.83(0.22,3.65)	0.83(0.23,3.37)	-0.01(-0.06,0.08)
SD ADA SC + DMARD	0.72(0.14,4.11)	0.73(0.14,3.72)	-0.01(-0.06,0.10)
LD ETN SC	2.67(0.77,9.32)	2.48(0.78,7.28)	0.06(-0.01,0.25)
LD ADA SC	0.36(0.11,1.10)	0.37(0.11,1.09)	-0.03(-0.07,0.00)
LD ANA	0.53(0.11,2.91)	0.54(0.12,2.75)	-0.02(-0.08,0.05)
LD ABA IV + MTX	2.76(0.59,13.23)	2.54(0.60,9.67)	0.07(-0.02,0.32)
LD CERTO SC + MTX	2.21(0.30,12.79)	2.09(0.32,8.93)	0.05(-0.04,0.31)
LD ETN SC + MTX	1.42(0.24,6.86)	1.40(0.25,5.62)	0.02(-0.05,0.18)
HD TOCI IV	1.43(0.49,4.51)	1.40(0.50,4.08)	0.02(-0.03,0.11)
HD ADA SC	0.36(0.10,1.12)	0.37(0.11,1.11)	-0.03(-0.07,0.00)
HD ANA	1.32(0.32,5.93)	1.30(0.34,5.23)	0.01(-0.05,0.13)
HD TOCI IV + MTX	1.91(0.47,8.16)	1.82(0.49,6.50)	0.04(-0.03,0.21)
HD GOLI SC + MTX	4.72(0.87,25.90)	3.98(0.88,14.16)	0.13(-0.01,0.48)
HD TOFA PO + MTX	3.18(0.88,11.05)	2.87(0.88,8.41)	0.08(-0.01,0.27)
HD CERTO SC + MTX	3.37(0.79,13.32)	3.01(0.80,9.47)	0.09(-0.01,0.33)
HD INF IV + MTX	6.51(1.52,25.77)	5.11(1.47,14.75)	0.18(0.03,0.47)

(Continued)

HD TOCI IV + DMARD		1.20(0.33,4.67)	1.19(0.34,4.23)	0.01(-0.04,0.11)
SD CERTO SC	SD TOCI IV	2.68(0.41,19.00)	2.55(0.43,16.33)	0.04(-0.04,0.19)
SD TOC SC + PL IV		0.68(0.34,1.37)	0.69(0.35,1.35)	-0.01(-0.03,0.01)
SD ANA		1.23(0.20,9.09)	1.22(0.21,8.32)	0.01(-0.06,0.10)
SD ETN SC + MTX		3.66(0.80,19.86)	3.40(0.81,16.57)	0.06(-0.01,0.20)
SD INF IV + MTX		10.03(1.96,59.04)	7.87(1.86,38.07)	0.19(0.04,0.46)
SD ABA IV + MTX		3.73(0.70,22.24)	3.44(0.72,17.77)	0.06(-0.02,0.24)
SD CERTO SC + MTX		5.29(0.99,31.10)	4.68(0.99,23.45)	0.10(0.00,0.30)
SD ADA SC + MTX		5.06(1.19,30.49)	4.50(1.18,22.84)	0.09(0.01,0.31)
SD GOLI SC + MTX		5.65(0.91,43.68)	4.95(0.92,28.00)	0.10(0.00,0.42)
SD TOFA PO + MTX		6.78(1.52,38.03)	5.78(1.46,27.53)	0.13(0.02,0.36)
SD ABA SC + MTX		2.18(0.29,14.06)	2.10(0.31,11.88)	0.03(-0.04,0.18)
SD ETN SC + DMARD		1.98(0.52,8.46)	1.92(0.54,7.84)	0.02(-0.03,0.10)
SD CERTO SC + DMARD		1.47(0.25,7.41)	1.45(0.26,6.83)	0.01(-0.05,0.09)
SD ADA SC + DMARD		1.23(0.17,9.90)	1.22(0.19,8.87)	0.01(-0.05,0.11)
LD ETN SC		4.44(1.09,25.96)	4.03(1.08,19.92)	0.08(0.00,0.27)
LD ADA SC		0.61(0.13,3.05)	0.62(0.14,2.98)	-0.01(-0.07,0.02)
LD ANA		0.90(0.16,5.80)	0.91(0.17,5.45)	0.00(-0.07,0.07)
LD ABA IV + MTX		4.67(0.74,33.52)	4.18(0.75,24.35)	0.08(-0.01,0.34)
LD CERTO SC + MTX		3.87(0.38,28.37)	3.55(0.39,20.57)	0.06(-0.03,0.33)
LD ETN SC + MTX		2.36(0.35,17.59)	2.26(0.36,14.29)	0.03(-0.03,0.20)
HD TOCI IV		2.50(0.63,10.96)	2.39(0.65,10.03)	0.04(-0.02,0.12)
HD ADA SC		0.63(0.13,2.99)	0.64(0.14,2.92)	-0.01(-0.07,0.02)
HD ANA		2.28(0.38,14.45)	2.20(0.40,12.67)	0.03(-0.05,0.15)
HD TOCI IV + MTX		3.28(0.68,20.69)	3.06(0.70,17.13)	0.05(-0.02,0.23)
HD GOLI SC + MTX		8.12(1.32,66.92)	6.67(1.30,36.81)	0.15(0.01,0.49)
HD TOFA PO + MTX		5.31(1.17,30.10)	4.69(1.15,23.16)	0.10(0.01,0.30)
HD CERTO SC + MTX		5.80(1.02,35.17)	5.03(1.02,24.92)	0.11(0.00,0.35)

(Continued)

HD INF IV + MTX		10.98(1.76,71.90)	8.40(1.68,41.28)	0.20(0.03,0.50)
HD TOCI IV + DMARD		2.09(0.46,10.33)	2.02(0.48,9.30)	0.03(-0.03,0.13)
SD TOC SC + PL IV	SD CERTO SC	0.25(0.03,1.97)	0.27(0.04,1.92)	-0.05(-0.19,0.03)
SD ANA		0.46(0.07,2.99)	0.48(0.09,2.79)	-0.03(-0.18,0.07)
SD ETN SC + MTX		1.40(0.20,7.14)	1.36(0.23,5.99)	0.02(-0.13,0.18)
SD INF IV + MTX		3.85(0.51,21.76)	3.18(0.56,13.11)	0.15(-0.07,0.43)
SD ABA IV + MTX		1.41(0.17,8.32)	1.37(0.20,6.72)	0.02(-0.13,0.21)
SD CERTO SC + MTX		2.04(0.28,11.93)	1.89(0.32,8.85)	0.06(-0.11,0.28)
SD ADA SC + MTX		2.03(0.26,11.15)	1.88(0.29,8.30)	0.06(-0.11,0.28)
SD GOLI SC + MTX		2.17(0.23,16.64)	1.98(0.26,10.56)	0.06(-0.11,0.38)
SD TOFA PO + MTX		2.72(0.34,13.73)	2.42(0.38,9.93)	0.09(-0.10,0.32)
SD ABA SC + MTX		0.79(0.09,5.50)	0.80(0.10,4.78)	-0.01(-0.16,0.15)
SD ETN SC + DMARD		0.74(0.12,3.87)	0.75(0.14,3.57)	-0.02(-0.17,0.08)
SD CERTO SC + DMARD		0.51(0.08,3.54)	0.53(0.09,3.29)	-0.03(-0.17,0.08)
SD ADA SC + DMARD		0.48(0.04,3.96)	0.50(0.05,3.58)	-0.03(-0.18,0.09)
LD ETN SC		1.72(0.23,10.93)	1.63(0.27,8.27)	0.04(-0.13,0.25)
LD ADA SC		0.23(0.03,1.32)	0.25(0.04,1.31)	-0.05(-0.19,0.01)
LD ANA		0.35(0.05,2.17)	0.37(0.06,2.09)	-0.04(-0.19,0.04)
LD ABA IV + MTX		1.78(0.21,12.49)	1.68(0.24,8.89)	0.04(-0.13,0.30)
LD CERTO SC + MTX		1.43(0.14,11.25)	1.39(0.17,7.97)	0.02(-0.14,0.30)
LD ETN SC + MTX		0.91(0.09,6.45)	0.92(0.11,5.41)	0.00(-0.15,0.17)
HD TOCI IV		0.95(0.13,4.84)	0.96(0.16,4.35)	0.00(-0.16,0.11)
HD ADA SC		0.24(0.03,1.25)	0.26(0.03,1.24)	-0.05(-0.19,0.01)
HD ANA		0.86(0.13,4.89)	0.87(0.15,4.35)	-0.01(-0.16,0.12)
HD TOCI IV + MTX		1.24(0.15,8.44)	1.21(0.17,6.67)	0.01(-0.14,0.21)
HD GOLI SC + MTX		3.00(0.33,23.62)	2.60(0.37,13.39)	0.10(-0.09,0.46)
HD TOFA PO + MTX		2.12(0.27,10.88)	1.95(0.30,8.36)	0.06(-0.11,0.26)
HD CERTO SC + MTX		2.14(0.27,14.72)	1.98(0.31,10.09)	0.06(-0.11,0.33)

(Continued)

HD INF IV + MTX		4.07(0.51,24.65)	3.31(0.55,14.20)	0.16(-0.07,0.47)
HD TOCI IV + DMARD		0.76(0.10,4.67)	0.78(0.11,4.20)	-0.01(-0.16,0.11)
SD ANA	SD TOC SC + PL IV	1.80(0.27,14.61)	1.77(0.28,13.22)	0.01(-0.05,0.11)
SD ETN SC + MTX		5.49(1.00,31.67)	5.00(1.00,26.65)	0.07(0.00,0.22)
SD INF IV + MTX		14.95(2.51,95.09)	11.53(2.31,61.42)	0.20(0.05,0.47)
SD ABA IV + MTX		5.54(0.91,35.38)	5.04(0.92,28.47)	0.07(0.00,0.25)
SD CERTO SC + MTX		7.83(1.28,49.12)	6.86(1.25,37.88)	0.11(0.01,0.31)
SD ADA SC + MTX		7.49(1.44,50.57)	6.60(1.40,37.92)	0.10(0.01,0.32)
SD GOLI SC + MTX		8.23(1.19,69.88)	7.17(1.17,46.33)	0.11(0.01,0.43)
SD TOFA PO + MTX		9.99(1.84,62.80)	8.42(1.75,45.86)	0.14(0.03,0.37)
SD ABA SC + MTX		3.21(0.38,22.77)	3.07(0.40,19.26)	0.04(-0.03,0.19)
SD ETN SC + DMARD		2.94(0.63,14.61)	2.83(0.64,13.47)	0.03(-0.02,0.11)
SD CERTO SC + DMARD		2.17(0.31,12.32)	2.11(0.32,11.32)	0.02(-0.04,0.10)
SD ADA SC + DMARD		1.82(0.23,15.61)	1.78(0.24,13.89)	0.01(-0.04,0.12)
LD ETN SC		6.63(1.32,42.11)	5.95(1.30,32.66)	0.09(0.01,0.28)
LD ADA SC		0.90(0.17,5.28)	0.90(0.18,5.14)	0.00(-0.05,0.03)
LD ANA		1.34(0.19,9.24)	1.33(0.20,8.68)	0.01(-0.05,0.07)
LD ABA IV + MTX		6.84(0.99,52.99)	6.10(0.99,38.94)	0.09(0.00,0.35)
LD CERTO SC + MTX		5.60(0.50,46.64)	5.08(0.52,34.66)	0.07(-0.02,0.33)
LD ETN SC + MTX		3.44(0.46,28.88)	3.27(0.47,24.09)	0.04(-0.02,0.21)
HD TOCI IV		3.67(0.78,19.07)	3.48(0.79,17.25)	0.04(-0.01,0.13)
HD ADA SC		0.91(0.16,4.99)	0.91(0.17,4.81)	0.00(-0.06,0.03)
HD ANA		3.37(0.50,23.43)	3.23(0.51,20.50)	0.04(-0.03,0.16)
HD TOCI IV + MTX		4.87(0.80,34.83)	4.49(0.81,27.96)	0.06(-0.01,0.24)
HD GOLI SC + MTX		11.77(1.71,109.60)	9.59(1.64,62.61)	0.16(0.02,0.50)
HD TOFA PO + MTX		7.86(1.40,49.76)	6.88(1.37,38.21)	0.11(0.01,0.31)
HD CERTO SC + MTX		8.37(1.33,55.91)	7.24(1.30,40.16)	0.12(0.01,0.36)
HD INF IV + MTX		16.24(2.30,110.50)	12.33(2.14,66.29)	0.21(0.04,0.50)

(Continued)

HD TOCI IV + DMARD		3.05(0.56,16.80)	2.92(0.57,15.06)	0.03(-0.02,0.14)
SD ETN SC + MTX	SD ANA	2.94(0.51,16.94)	2.75(0.54,13.83)	0.05(-0.04,0.21)
SD INF IV + MTX		7.78(1.37,51.01)	6.27(1.31,30.15)	0.18(0.02,0.46)
SD ABA IV + MTX		3.03(0.47,19.87)	2.83(0.50,15.70)	0.06(-0.04,0.25)
SD CERTO SC + MTX		4.42(0.67,25.87)	3.94(0.70,19.35)	0.09(-0.03,0.31)
SD ADA SC + MTX		4.28(0.61,25.46)	3.82(0.63,18.80)	0.09(-0.03,0.31)
SD GOLI SC + MTX		4.72(0.42,39.83)	4.18(0.45,24.37)	0.10(-0.05,0.42)
SD TOFA PO + MTX		5.57(0.87,33.21)	4.79(0.88,22.98)	0.12(-0.01,0.36)
SD ABA SC + MTX		1.71(0.23,12.07)	1.67(0.24,10.10)	0.02(-0.07,0.18)
SD ETN SC + DMARD		1.59(0.26,7.75)	1.55(0.29,7.09)	0.02(-0.08,0.10)
SD CERTO SC + DMARD		1.19(0.17,7.10)	1.18(0.18,6.46)	0.01(-0.09,0.09)
SD ADA SC + DMARD		1.05(0.11,7.48)	1.05(0.12,6.66)	0.00(-0.10,0.11)
LD ETN SC		3.64(0.56,21.91)	3.34(0.59,16.88)	0.07(-0.04,0.28)
LD ADA SC		0.48(0.08,2.79)	0.49(0.09,2.72)	-0.02(-0.11,0.03)
LD ANA		0.75(0.21,2.44)	0.75(0.22,2.36)	-0.01(-0.07,0.03)
LD ABA IV + MTX		3.63(0.53,31.01)	3.32(0.56,21.28)	0.07(-0.04,0.34)
LD CERTO SC + MTX		3.10(0.29,23.29)	2.88(0.31,16.91)	0.06(-0.06,0.32)
LD ETN SC + MTX		1.90(0.22,14.40)	1.84(0.23,11.78)	0.03(-0.07,0.20)
HD TOCI IV		2.01(0.35,10.73)	1.94(0.37,9.47)	0.03(-0.07,0.13)
HD ADA SC		0.50(0.07,2.65)	0.51(0.07,2.59)	-0.01(-0.11,0.03)
HD ANA		1.80(0.62,5.47)	1.74(0.63,5.05)	0.02(-0.03,0.10)
HD TOCI IV + MTX		2.65(0.31,18.29)	2.51(0.33,14.37)	0.05(-0.07,0.24)
HD GOLI SC + MTX		6.47(0.74,53.84)	5.39(0.75,30.22)	0.14(-0.02,0.50)
HD TOFA PO + MTX		4.32(0.65,25.79)	3.86(0.68,19.21)	0.09(-0.03,0.30)
HD CERTO SC + MTX		4.72(0.62,30.94)	4.17(0.65,21.43)	0.10(-0.03,0.36)
HD INF IV + MTX		8.30(1.37,56.91)	6.57(1.32,32.12)	0.19(0.02,0.50)
HD TOCI IV + DMARD		1.62(0.25,9.74)	1.58(0.27,8.41)	0.02(-0.08,0.13)
SD INF IV + MTX	SD ETN SC + MTX	2.73(1.34,5.75)	2.30(1.29,4.24)	0.12(0.02,0.31)

(Continued)

SD ABA IV + MTX	1.01(0.43,2.41)	1.01(0.46,2.15)	0.00(-0.07,0.11)	
SD CERTO SC + MTX	1.43(0.68,3.28)	1.37(0.71,2.82)	0.03(-0.04,0.16)	
SD ADA SC + MTX	1.43(0.57,3.65)	1.37(0.61,3.00)	0.03(-0.05,0.18)	
SD GOLI SC + MTX	1.55(0.36,6.33)	1.47(0.38,4.54)	0.04(-0.07,0.30)	
SD TOFA PO + MTX	1.89(0.83,4.04)	1.73(0.85,3.31)	0.06(-0.02,0.21)	
SD ABA SC + MTX	0.57(0.17,1.90)	0.60(0.19,1.76)	-0.03(-0.13,0.07)	
SD ETN SC + DMARD	0.53(0.20,1.41)	0.56(0.23,1.37)	-0.04(-0.16,0.02)	
SD CERTO SC + DMARD	0.38(0.10,1.69)	0.41(0.11,1.62)	-0.05(-0.19,0.04)	
SD ADA SC + DMARD	0.33(0.07,1.71)	0.35(0.08,1.62)	-0.05(-0.19,0.04)	
LD ETN SC	1.22(0.53,2.87)	1.20(0.56,2.53)	0.02(-0.06,0.14)	
LD ADA SC	0.16(0.04,0.75)	0.18(0.04,0.76)	-0.07(-0.22,-0.01)	
LD ANA	0.25(0.04,1.41)	0.27(0.05,1.38)	-0.06(-0.22,0.02)	
LD ABA IV + MTX	1.28(0.42,4.02)	1.24(0.44,3.22)	0.02(-0.07,0.20)	
LD CERTO SC + MTX	1.00(0.20,4.70)	1.00(0.22,3.67)	0.00(-0.12,0.22)	
LD ETN SC + MTX	0.63(0.18,2.13)	0.66(0.19,1.93)	-0.03(-0.13,0.09)	
HD TOCI IV	0.67(0.28,1.60)	0.69(0.31,1.53)	-0.03(-0.13,0.03)	
HD ADA SC	0.17(0.03,0.80)	0.19(0.03,0.81)	-0.07(-0.22,-0.01)	
HD ANA	0.62(0.11,2.93)	0.64(0.14,2.69)	-0.03(-0.19,0.09)	
HD TOCI IV + MTX	0.90(0.25,2.94)	0.91(0.28,2.56)	-0.01(-0.12,0.13)	
HD GOLI SC + MTX	2.12(0.58,8.85)	1.89(0.61,5.57)	0.08(-0.04,0.38)	
HD TOFA PO + MTX	1.47(0.64,3.21)	1.40(0.67,2.74)	0.03(-0.04,0.15)	
HD CERTO SC + MTX	1.54(0.55,4.66)	1.46(0.58,3.63)	0.04(-0.05,0.23)	
HD INF IV + MTX	2.93(1.15,7.44)	2.43(1.13,5.14)	0.13(0.01,0.36)	
HD TOCI IV + DMARD	0.54(0.18,1.92)	0.57(0.20,1.81)	-0.04(-0.16,0.05)	
SD ABA IV + MTX	SD INF IV + MTX	0.37(0.16,0.85)	0.44(0.20,0.88)	-0.12(-0.30,-0.02)
SD CERTO SC + MTX		0.52(0.23,1.35)	0.59(0.30,1.28)	-0.08(-0.25,0.04)
SD ADA SC + MTX		0.51(0.19,1.47)	0.58(0.25,1.37)	-0.08(-0.28,0.05)
SD GOLI SC + MTX		0.57(0.13,2.29)	0.64(0.17,1.87)	-0.07(-0.29,0.15)

(Continued)

SD TOFA PO + MTX		0.68(0.28,1.61)	0.74(0.36,1.47)	-0.05(-0.23,0.07)
SD ABA SC + MTX		0.21(0.07,0.67)	0.26(0.09,0.72)	-0.15(-0.37,-0.03)
SD ETN SC + DMARD		0.20(0.06,0.59)	0.24(0.09,0.62)	-0.16(-0.41,-0.03)
SD CERTO SC + DMARD		0.14(0.03,0.65)	0.18(0.05,0.68)	-0.17(-0.44,-0.03)
SD ADA SC + DMARD		0.12(0.02,0.67)	0.15(0.03,0.71)	-0.18(-0.43,-0.03)
LD ETN SC		0.44(0.17,1.29)	0.51(0.22,1.24)	-0.10(-0.29,0.03)
LD ADA SC		0.06(0.01,0.30)	0.08(0.02,0.32)	-0.20(-0.47,-0.05)
LD ANA		0.09(0.01,0.57)	0.12(0.02,0.60)	-0.19(-0.47,-0.03)
LD ABA IV + MTX		0.46(0.14,1.52)	0.53(0.18,1.39)	-0.09(-0.29,0.07)
LD CERTO SC + MTX		0.36(0.07,1.88)	0.43(0.10,1.62)	-0.11(-0.34,0.10)
LD ETN SC + MTX		0.23(0.06,0.94)	0.29(0.08,0.95)	-0.15(-0.38,-0.01)
HD TOCI IV		0.25(0.09,0.62)	0.30(0.13,0.66)	-0.15(-0.38,-0.03)
HD ADA SC		0.06(0.01,0.30)	0.08(0.02,0.33)	-0.20(-0.48,-0.05)
HD ANA		0.23(0.04,1.16)	0.28(0.06,1.14)	-0.15(-0.44,0.01)
HD TOCI IV + MTX		0.33(0.09,1.15)	0.39(0.12,1.12)	-0.12(-0.35,0.02)
HD GOLI SC + MTX		0.77(0.19,3.72)	0.82(0.25,2.53)	-0.04(-0.25,0.26)
HD TOFA PO + MTX		0.53(0.23,1.24)	0.60(0.29,1.19)	-0.08(-0.26,0.03)
HD CERTO SC + MTX		0.57(0.19,1.91)	0.64(0.24,1.63)	-0.07(-0.28,0.11)
HD INF IV + MTX		1.07(0.49,2.28)	1.06(0.56,1.85)	0.01(-0.12,0.16)
HD TOCI IV + DMARD		0.20(0.06,0.79)	0.25(0.08,0.81)	-0.16(-0.40,-0.02)
SD CERTO SC + MTX	SD ABA IV + MTX	1.41(0.56,3.91)	1.35(0.60,3.37)	0.03(-0.07,0.16)
SD ADA SC + MTX		1.38(0.50,4.02)	1.33(0.55,3.37)	0.03(-0.08,0.18)
SD GOLI SC + MTX		1.53(0.30,7.38)	1.44(0.33,5.22)	0.04(-0.11,0.30)
SD TOFA PO + MTX		1.83(0.73,4.69)	1.67(0.76,3.88)	0.06(-0.04,0.22)
SD ABA SC + MTX		0.56(0.25,1.25)	0.59(0.27,1.21)	-0.03(-0.13,0.02)
SD ETN SC + DMARD		0.53(0.14,1.61)	0.56(0.18,1.56)	-0.04(-0.20,0.02)
SD CERTO SC + DMARD		0.39(0.08,1.90)	0.42(0.09,1.82)	-0.05(-0.23,0.04)
SD ADA SC + DMARD		0.33(0.06,1.92)	0.36(0.07,1.80)	-0.05(-0.22,0.05)

(Continued)

LD ETN SC		1.19(0.44,3.64)	1.17(0.49,3.18)	0.01(-0.09,0.15)
LD ADA SC		0.17(0.03,0.82)	0.18(0.04,0.83)	-0.08(-0.25,-0.01)
LD ANA		0.25(0.04,1.69)	0.27(0.05,1.64)	-0.07(-0.25,0.03)
LD ABA IV + MTX		1.25(0.43,3.75)	1.22(0.46,3.10)	0.02(-0.07,0.19)
LD CERTO SC + MTX		0.96(0.19,5.92)	0.96(0.21,4.52)	0.00(-0.14,0.23)
LD ETN SC + MTX		0.62(0.15,2.72)	0.64(0.17,2.44)	-0.03(-0.17,0.10)
HD TOCI IV		0.67(0.21,1.82)	0.69(0.25,1.74)	-0.03(-0.17,0.04)
HD ADA SC		0.17(0.02,0.86)	0.18(0.03,0.86)	-0.08(-0.26,0.00)
HD ANA		0.62(0.10,3.49)	0.64(0.12,3.15)	-0.03(-0.22,0.09)
HD TOCI IV + MTX		0.90(0.20,3.21)	0.91(0.23,2.82)	-0.01(-0.15,0.13)
HD GOLI SC + MTX		2.13(0.48,10.08)	1.89(0.52,6.28)	0.08(-0.07,0.38)
HD TOFA PO + MTX		1.43(0.57,3.62)	1.37(0.61,3.11)	0.03(-0.06,0.16)
HD CERTO SC + MTX		1.53(0.50,5.03)	1.45(0.54,4.12)	0.04(-0.07,0.22)
HD INF IV + MTX		2.87(1.05,8.09)	2.39(1.04,5.83)	0.13(0.01,0.35)
HD TOCI IV + DMARD		0.54(0.14,2.26)	0.57(0.17,2.12)	-0.04(-0.20,0.06)
SD ADA SC + MTX	SD CERTO SC + MTX	0.98(0.37,2.66)	0.98(0.42,2.30)	0.00(-0.13,0.14)
SD GOLI SC + MTX		1.07(0.28,4.14)	1.06(0.32,3.12)	0.01(-0.14,0.24)
SD TOFA PO + MTX		1.30(0.52,3.03)	1.24(0.58,2.53)	0.03(-0.09,0.16)
SD ABA SC + MTX		0.40(0.11,1.27)	0.44(0.13,1.23)	-0.07(-0.22,0.02)
SD ETN SC + DMARD		0.37(0.11,1.09)	0.41(0.15,1.08)	-0.07(-0.25,0.01)
SD CERTO SC + DMARD		0.26(0.06,1.16)	0.30(0.08,1.15)	-0.08(-0.29,0.01)
SD ADA SC + DMARD		0.23(0.04,1.19)	0.26(0.05,1.18)	-0.09(-0.28,0.01)
LD ETN SC		0.85(0.32,2.34)	0.87(0.37,2.07)	-0.02(-0.14,0.11)
LD ADA SC		0.11(0.02,0.54)	0.13(0.03,0.56)	-0.11(-0.32,-0.02)
LD ANA		0.17(0.03,1.09)	0.20(0.04,1.09)	-0.10(-0.31,0.00)
LD ABA IV + MTX		0.88(0.26,2.89)	0.90(0.30,2.46)	-0.01(-0.15,0.16)
LD CERTO SC + MTX		0.72(0.15,2.75)	0.75(0.18,2.28)	-0.03(-0.17,0.15)
LD ETN SC + MTX		0.44(0.11,1.73)	0.48(0.12,1.61)	-0.06(-0.23,0.06)

(Continued)

HD TOCI IV		0.47(0.16,1.14)	0.51(0.20,1.13)	-0.06(-0.23,0.01)
HD ADA SC		0.12(0.02,0.60)	0.14(0.03,0.62)	-0.11(-0.32,-0.02)
HD ANA		0.42(0.07,2.30)	0.46(0.10,2.12)	-0.07(-0.29,0.07)
HD TOCI IV + MTX		0.62(0.16,2.16)	0.66(0.19,1.94)	-0.04(-0.21,0.09)
HD GOLI SC + MTX		1.47(0.42,6.21)	1.37(0.46,4.06)	0.04(-0.10,0.33)
HD TOFA PO + MTX		1.01(0.41,2.38)	1.01(0.46,2.10)	0.00(-0.12,0.11)
HD CERTO SC + MTX		1.09(0.45,2.50)	1.08(0.50,2.12)	0.01(-0.10,0.15)
HD INF IV + MTX		2.06(0.68,5.54)	1.77(0.72,3.94)	0.10(-0.05,0.30)
HD TOCI IV + DMARD		0.38(0.11,1.41)	0.42(0.13,1.36)	-0.07(-0.26,0.03)
SD GOLI SC + MTX	SD ADA SC + MTX	1.11(0.21,5.08)	1.09(0.25,3.71)	0.01(-0.17,0.27)
SD TOFA PO + MTX		1.30(0.61,3.02)	1.24(0.66,2.57)	0.03(-0.07,0.16)
SD ABA SC + MTX		0.40(0.11,1.44)	0.44(0.13,1.38)	-0.06(-0.23,0.04)
SD ETN SC + DMARD		0.37(0.11,1.22)	0.41(0.14,1.20)	-0.07(-0.27,0.01)
SD CERTO SC + DMARD		0.27(0.06,1.35)	0.30(0.08,1.32)	-0.08(-0.29,0.02)
SD ADA SC + DMARD		0.24(0.04,1.32)	0.27(0.05,1.29)	-0.08(-0.29,0.02)
LD ETN SC		0.87(0.30,2.59)	0.89(0.35,2.27)	-0.01(-0.16,0.12)
LD ADA SC		0.11(0.02,0.62)	0.13(0.03,0.64)	-0.11(-0.32,-0.02)
LD ANA		0.18(0.03,1.17)	0.20(0.04,1.16)	-0.10(-0.32,0.01)
LD ABA IV + MTX		0.92(0.24,2.98)	0.93(0.28,2.52)	-0.01(-0.17,0.16)
LD CERTO SC + MTX		0.72(0.13,3.46)	0.75(0.16,2.86)	-0.03(-0.21,0.18)
LD ETN SC + MTX		0.45(0.09,1.92)	0.49(0.12,1.76)	-0.06(-0.24,0.07)
HD TOCI IV		0.48(0.15,1.33)	0.51(0.19,1.31)	-0.06(-0.24,0.02)
HD ADA SC		0.12(0.02,0.67)	0.13(0.03,0.68)	-0.11(-0.32,-0.01)
HD ANA		0.44(0.07,2.46)	0.47(0.10,2.29)	-0.06(-0.29,0.08)
HD TOCI IV + MTX		0.63(0.15,2.43)	0.66(0.18,2.15)	-0.04(-0.22,0.10)
HD GOLI SC + MTX		1.53(0.34,6.42)	1.41(0.40,4.41)	0.05(-0.13,0.32)
HD TOFA PO + MTX		1.01(0.46,2.37)	1.01(0.52,2.12)	0.00(-0.11,0.11)
HD CERTO SC + MTX		1.07(0.34,3.87)	1.06(0.38,3.09)	0.01(-0.14,0.20)

(Continued)

HD INF IV + MTX		2.10(0.61,6.08)	1.80(0.67,4.32)	0.10(-0.06,0.31)
HD TOCI IV + DMARD		0.39(0.10,1.58)	0.43(0.12,1.51)	-0.07(-0.26,0.03)
SD TOFA PO + MTX	SD GOLI SC + MTX	1.18(0.26,5.22)	1.15(0.35,4.32)	0.02(-0.24,0.19)
SD ABA SC + MTX		0.37(0.06,2.32)	0.41(0.08,2.17)	-0.07(-0.35,0.06)
SD ETN SC + DMARD		0.35(0.06,1.73)	0.39(0.10,1.68)	-0.08(-0.38,0.03)
SD CERTO SC + DMARD		0.26(0.04,1.50)	0.29(0.05,1.46)	-0.09(-0.41,0.02)
SD ADA SC + DMARD		0.23(0.02,1.66)	0.26(0.03,1.59)	-0.09(-0.41,0.03)
LD ETN SC		0.80(0.17,3.36)	0.82(0.24,3.02)	-0.02(-0.28,0.12)
LD ADA SC		0.10(0.02,0.69)	0.12(0.02,0.70)	-0.12(-0.43,-0.01)
LD ANA		0.16(0.02,1.65)	0.18(0.03,1.61)	-0.11(-0.43,0.02)
LD ABA IV + MTX		0.83(0.15,4.66)	0.85(0.20,3.97)	-0.02(-0.27,0.18)
LD CERTO SC + MTX		0.64(0.10,4.03)	0.68(0.13,3.34)	-0.04(-0.30,0.18)
LD ETN SC + MTX		0.41(0.07,2.34)	0.45(0.09,2.16)	-0.07(-0.34,0.07)
HD TOCI IV		0.43(0.09,1.94)	0.48(0.13,1.86)	-0.07(-0.37,0.04)
HD ADA SC		0.11(0.01,0.79)	0.13(0.02,0.79)	-0.12(-0.43,-0.01)
HD ANA		0.40(0.05,3.78)	0.43(0.07,3.42)	-0.07(-0.39,0.10)
HD TOCI IV + MTX		0.57(0.10,2.97)	0.61(0.15,2.64)	-0.05(-0.33,0.11)
HD GOLI SC + MTX		1.40(0.43,4.95)	1.31(0.50,3.80)	0.04(-0.13,0.25)
HD TOFA PO + MTX		0.93(0.20,4.03)	0.94(0.27,3.49)	-0.01(-0.27,0.15)
HD CERTO SC + MTX		1.02(0.23,4.37)	1.02(0.29,3.72)	0.00(-0.24,0.19)
HD INF IV + MTX		1.87(0.39,9.22)	1.64(0.48,6.66)	0.08(-0.16,0.33)
HD TOCI IV + DMARD		0.36(0.06,2.02)	0.40(0.09,1.92)	-0.08(-0.38,0.04)
SD ABA SC + MTX	SD TOFA PO + MTX	0.31(0.09,1.05)	0.35(0.11,1.04)	-0.10(-0.28,0.01)
SD ETN SC + DMARD		0.28(0.09,0.92)	0.32(0.12,0.93)	-0.11(-0.31,0.00)
SD CERTO SC + DMARD		0.20(0.05,1.00)	0.24(0.07,1.00)	-0.12(-0.34,0.00)
SD ADA SC + DMARD		0.18(0.03,1.04)	0.21(0.04,1.04)	-0.12(-0.34,0.00)
LD ETN SC		0.66(0.24,1.88)	0.70(0.29,1.72)	-0.04(-0.20,0.08)

(Continued)

LD ADA SC		0.09(0.02,0.45)	0.10(0.03,0.47)	-0.14(-0.37,-0.03)
LD ANA		0.13(0.02,0.88)	0.16(0.03,0.89)	-0.13(-0.37,-0.01)
LD ABA IV + MTX		0.68(0.21,2.22)	0.73(0.25,1.91)	-0.04(-0.19,0.13)
LD CERTO SC + MTX		0.54(0.10,2.69)	0.59(0.13,2.24)	-0.06(-0.24,0.15)
LD ETN SC + MTX		0.34(0.08,1.40)	0.39(0.10,1.34)	-0.09(-0.28,0.04)
HD TOCI IV		0.36(0.13,0.93)	0.41(0.17,0.94)	-0.09(-0.28,0.00)
HD ADA SC		0.09(0.01,0.47)	0.11(0.02,0.49)	-0.14(-0.37,-0.03)
HD ANA		0.32(0.06,1.76)	0.37(0.08,1.66)	-0.10(-0.34,0.05)
HD TOCI IV + MTX		0.48(0.12,1.68)	0.53(0.15,1.56)	-0.07(-0.26,0.06)
HD GOLI SC + MTX		1.17(0.30,4.64)	1.13(0.35,3.13)	0.02(-0.15,0.28)
HD TOFA PO + MTX		0.78(0.46,1.36)	0.81(0.51,1.29)	-0.03(-0.12,0.04)
HD CERTO SC + MTX		0.82(0.28,2.66)	0.85(0.34,2.19)	-0.02(-0.18,0.15)
HD INF IV + MTX		1.57(0.56,4.36)	1.42(0.62,3.24)	0.06(-0.08,0.27)
HD TOCI IV + DMARD		0.30(0.08,1.17)	0.34(0.11,1.15)	-0.10(-0.31,0.01)
SD ETN SC + DMARD	SD ABA SC + MTX	0.93(0.22,3.79)	0.94(0.25,3.63)	0.00(-0.14,0.06)
SD CERTO SC + DMARD		0.69(0.12,4.29)	0.71(0.14,4.01)	-0.01(-0.16,0.07)
SD ADA SC + DMARD		0.59(0.09,4.03)	0.60(0.10,3.73)	-0.02(-0.16,0.08)
LD ETN SC		2.13(0.60,8.40)	1.99(0.64,7.20)	0.05(-0.05,0.21)
LD ADA SC		0.30(0.05,1.87)	0.31(0.06,1.85)	-0.04(-0.19,0.01)
LD ANA		0.46(0.05,3.64)	0.47(0.06,3.46)	-0.03(-0.19,0.05)
LD ABA IV + MTX		2.26(0.59,8.74)	2.08(0.62,7.19)	0.05(-0.04,0.25)
LD CERTO SC + MTX		1.71(0.28,12.60)	1.63(0.30,9.56)	0.03(-0.09,0.27)
LD ETN SC + MTX		1.09(0.22,6.05)	1.08(0.24,5.23)	0.00(-0.12,0.15)
HD TOCI IV		1.20(0.30,4.59)	1.18(0.33,4.31)	0.01(-0.12,0.08)
HD ADA SC		0.30(0.04,2.03)	0.31(0.05,2.00)	-0.04(-0.19,0.02)
HD ANA		1.09(0.16,8.11)	1.09(0.18,7.29)	0.00(-0.16,0.12)
HD TOCI IV + MTX		1.62(0.31,7.06)	1.55(0.34,6.04)	0.02(-0.10,0.18)
HD GOLI SC + MTX		3.78(0.73,21.88)	3.19(0.76,14.15)	0.11(-0.02,0.44)

(Continued)

HD TOFA PO + MTX		2.54(0.77,8.87)	2.30(0.80,7.40)	0.07(-0.03,0.22)
HD CERTO SC + MTX		2.71(0.71,11.35)	2.43(0.74,9.16)	0.07(-0.03,0.27)
HD INF IV + MTX		5.13(1.43,18.96)	4.03(1.33,13.25)	0.17(0.03,0.42)
HD TOCI IV + DMARD		0.98(0.20,4.88)	0.98(0.23,4.49)	0.00(-0.13,0.10)
SD CERTO SC + DMARD	SD ETN SC + DMARD	0.73(0.19,3.11)	0.74(0.21,2.90)	-0.01(-0.09,0.07)
SD ADA SC + DMARD		0.63(0.13,3.47)	0.64(0.14,3.15)	-0.02(-0.09,0.08)
LD ETN SC		2.32(0.79,7.27)	2.16(0.80,5.78)	0.06(-0.01,0.23)
LD ADA SC		0.32(0.07,1.21)	0.33(0.08,1.20)	-0.03(-0.11,0.01)
LD ANA		0.47(0.09,2.82)	0.48(0.10,2.69)	-0.02(-0.11,0.05)
LD ABA IV + MTX		2.43(0.59,10.18)	2.24(0.60,7.61)	0.06(-0.03,0.29)
LD CERTO SC + MTX		1.95(0.32,10.32)	1.85(0.34,7.67)	0.04(-0.05,0.29)
LD ETN SC + MTX		1.21(0.25,5.31)	1.20(0.26,4.49)	0.01(-0.06,0.16)
HD TOCI IV		1.26(0.47,3.72)	1.24(0.49,3.40)	0.01(-0.05,0.09)
HD ADA SC		0.32(0.06,1.26)	0.33(0.07,1.25)	-0.03(-0.11,0.01)
HD ANA		1.15(0.24,5.74)	1.14(0.26,5.06)	0.01(-0.08,0.13)
HD TOCI IV + MTX		1.70(0.43,6.49)	1.64(0.45,5.33)	0.03(-0.05,0.19)
HD GOLI SC + MTX		4.11(0.85,22.42)	3.48(0.86,12.51)	0.12(-0.01,0.46)
HD TOFA PO + MTX		2.75(0.88,8.37)	2.50(0.88,6.62)	0.07(-0.01,0.25)
HD CERTO SC + MTX		2.90(0.80,11.04)	2.62(0.81,8.10)	0.08(-0.01,0.31)
HD INF IV + MTX		5.53(1.54,19.06)	4.37(1.47,11.80)	0.18(0.03,0.45)
HD TOCI IV + DMARD		1.06(0.31,3.76)	1.05(0.33,3.46)	0.00(-0.06,0.09)
SD ADA SC + DMARD	SD CER-TO SC + DMARD	0.87(0.17,4.47)	0.87(0.18,4.08)	0.00(-0.08,0.10)
LD ETN SC		3.26(0.68,14.59)	2.98(0.70,11.42)	0.07(-0.02,0.26)
LD ADA SC		0.43(0.06,2.38)	0.44(0.06,2.34)	-0.02(-0.11,0.02)
LD ANA		0.64(0.11,4.35)	0.64(0.12,4.07)	-0.01(-0.10,0.06)
LD ABA IV + MTX		3.24(0.58,19.34)	2.95(0.60,13.98)	0.07(-0.03,0.33)
LD CERTO SC + MTX		2.61(0.34,17.40)	2.43(0.35,12.75)	0.05(-0.05,0.32)

(Continued)

LD ETN SC + MTX		1.66(0.24,9.45)	1.61(0.25,7.83)	0.02(-0.07,0.19)
HD TOCI IV		1.75(0.47,5.92)	1.70(0.50,5.38)	0.02(-0.05,0.11)
HD ADA SC		0.42(0.08,2.44)	0.43(0.08,2.38)	-0.02(-0.10,0.02)
HD ANA		1.54(0.29,10.14)	1.51(0.32,8.63)	0.02(-0.07,0.15)
HD TOCI IV + MTX		2.30(0.47,11.24)	2.18(0.50,9.15)	0.04(-0.04,0.22)
HD GOLI SC + MTX		5.61(0.92,35.60)	4.71(0.93,21.37)	0.13(-0.01,0.48)
HD TOFA PO + MTX		3.85(0.77,16.28)	3.44(0.79,12.54)	0.09(-0.02,0.28)
HD CERTO SC + MTX		4.01(0.77,19.98)	3.55(0.78,14.41)	0.09(-0.01,0.34)
HD INF IV + MTX		7.55(1.54,36.27)	5.86(1.48,21.72)	0.19(0.03,0.48)
HD TOCI IV + DMARD		1.42(0.40,5.17)	1.39(0.42,4.71)	0.01(-0.05,0.11)
LD ETN SC	SD ADA SC + DMARD	3.71(0.67,19.35)	3.36(0.70,16.02)	0.07(-0.03,0.26)
LD ADA SC		0.50(0.07,3.64)	0.51(0.08,3.57)	-0.02(-0.13,0.02)
LD ANA		0.71(0.09,6.60)	0.71(0.10,6.20)	-0.01(-0.12,0.07)
LD ABA IV + MTX		3.82(0.62,22.35)	3.44(0.65,17.55)	0.07(-0.03,0.32)
LD CERTO SC + MTX		2.97(0.33,24.44)	2.75(0.36,18.94)	0.06(-0.06,0.30)
LD ETN SC + MTX		1.92(0.24,13.82)	1.85(0.27,11.72)	0.02(-0.08,0.18)
HD TOCI IV		2.00(0.44,8.92)	1.92(0.47,8.26)	0.03(-0.06,0.11)
HD ADA SC		0.50(0.07,3.63)	0.51(0.08,3.53)	-0.02(-0.13,0.02)
HD ANA		1.77(0.25,14.77)	1.72(0.28,13.03)	0.02(-0.09,0.15)
HD TOCI IV + MTX		2.69(0.44,14.78)	2.52(0.47,12.76)	0.04(-0.05,0.21)
HD GOLI SC + MTX		6.44(0.90,47.97)	5.29(0.91,31.43)	0.14(-0.01,0.48)
HD TOFA PO + MTX		4.45(0.76,22.61)	3.92(0.77,18.48)	0.09(-0.02,0.28)
HD CERTO SC + MTX		4.70(0.78,26.70)	4.09(0.80,20.69)	0.10(-0.02,0.33)
HD INF IV + MTX		8.93(1.42,51.00)	6.82(1.36,33.32)	0.19(0.03,0.47)
HD TOCI IV + DMARD		1.64(0.42,6.67)	1.60(0.45,6.23)	0.02(-0.06,0.11)
LD ADA SC	LD ETN SC	0.13(0.03,0.64)	0.15(0.04,0.66)	-0.09(-0.29,-0.01)
LD ANA		0.20(0.03,1.31)	0.23(0.04,1.29)	-0.08(-0.29,0.02)
LD ABA IV + MTX		1.06(0.28,3.66)	1.05(0.32,3.03)	0.00(-0.14,0.18)

(Continued)

LD CERTO SC + MTX		0.82(0.15,4.12)	0.84(0.17,3.30)	-0.02(-0.19,0.20)
LD ETN SC + MTX		0.52(0.11,2.06)	0.55(0.13,1.88)	-0.04(-0.21,0.08)
HD TOCI IV		0.55(0.19,1.45)	0.58(0.23,1.40)	-0.04(-0.21,0.02)
HD ADA SC		0.14(0.02,0.68)	0.15(0.03,0.68)	-0.09(-0.29,-0.01)
HD ANA		0.51(0.08,2.69)	0.54(0.11,2.47)	-0.05(-0.26,0.09)
HD TOCI IV + MTX		0.72(0.18,2.65)	0.75(0.21,2.34)	-0.02(-0.19,0.11)
HD GOLI SC + MTX		1.75(0.40,8.10)	1.60(0.45,5.29)	0.06(-0.10,0.35)
HD TOFA PO + MTX		1.18(0.42,3.21)	1.15(0.47,2.76)	0.02(-0.11,0.15)
HD CERTO SC + MTX		1.27(0.39,4.03)	1.23(0.44,3.36)	0.02(-0.12,0.20)
HD INF IV + MTX		2.41(0.70,7.54)	2.05(0.75,5.18)	0.11(-0.04,0.34)
HD TOCI IV + DMARD		0.45(0.13,1.70)	0.48(0.15,1.63)	-0.05(-0.22,0.04)
LD ANA	LD ADA SC	1.54(0.27,9.03)	1.53(0.28,8.47)	0.01(-0.03,0.08)
LD ABA IV + MTX		7.75(1.31,43.87)	6.86(1.30,32.11)	0.10(0.01,0.35)
LD CERTO SC + MTX		6.18(0.79,46.45)	5.60(0.79,33.25)	0.08(-0.01,0.34)
LD ETN SC + MTX		3.94(0.57,25.49)	3.73(0.58,20.90)	0.04(-0.01,0.21)
HD TOCI IV		4.00(0.90,19.67)	3.78(0.91,17.85)	0.05(0.00,0.14)
HD ADA SC		1.01(0.24,4.75)	1.01(0.24,4.65)	0.00(-0.03,0.03)
HD ANA		3.84(0.71,17.97)	3.65(0.72,15.84)	0.04(-0.01,0.16)
HD TOCI IV + MTX		5.36(0.87,36.14)	4.96(0.88,29.48)	0.07(0.00,0.25)
HD GOLI SC + MTX		13.44(1.89,96.52)	10.86(1.83,53.58)	0.16(0.02,0.51)
HD TOFA PO + MTX		8.95(1.82,41.65)	7.76(1.76,31.67)	0.11(0.02,0.31)
HD CERTO SC + MTX		9.49(1.74,51.76)	8.16(1.69,38.07)	0.12(0.02,0.36)
HD INF IV + MTX		18.00(3.26,96.45)	13.61(3.01,58.71)	0.21(0.05,0.51)
HD TOCI IV + DMARD		3.38(0.62,18.86)	3.24(0.63,16.78)	0.03(-0.01,0.14)
LD ABA IV + MTX	LD ANA	4.88(0.72,43.50)	4.41(0.73,30.76)	0.08(-0.02,0.35)
LD CERTO SC + MTX		4.08(0.43,36.38)	3.74(0.45,25.78)	0.07(-0.03,0.34)
LD ETN SC + MTX		2.55(0.29,21.37)	2.44(0.30,17.43)	0.03(-0.04,0.21)
HD TOCI IV		2.70(0.45,15.69)	2.59(0.47,13.98)	0.04(-0.04,0.14)

(Continued)

HD ADA SC		0.67(0.10,3.83)	0.68(0.10,3.69)	-0.01(-0.08,0.03)
HD ANA		2.43(0.83,7.61)	2.33(0.84,6.98)	0.03(-0.01,0.12)
HD TOCI IV + MTX		3.64(0.39,24.25)	3.40(0.41,19.48)	0.06(-0.04,0.24)
HD GOLI SC + MTX		8.39(0.98,80.29)	6.96(0.98,44.53)	0.15(0.00,0.51)
HD TOFA PO + MTX		5.99(0.89,36.38)	5.26(0.90,27.40)	0.10(-0.01,0.31)
HD CERTO SC + MTX		6.21(0.90,42.89)	5.44(0.91,30.30)	0.11(0.00,0.36)
HD INF IV + MTX		11.36(1.66,82.92)	8.85(1.59,46.36)	0.20(0.03,0.51)
HD TOCI IV + DMARD		2.28(0.31,13.22)	2.20(0.33,11.80)	0.03(-0.05,0.14)
LD CERTO SC + MTX	LD ABA IV + MTX	0.77(0.12,4.94)	0.80(0.15,3.92)	-0.02(-0.24,0.20)
LD ETN SC + MTX		0.49(0.10,2.67)	0.53(0.12,2.41)	-0.05(-0.26,0.09)
HD TOCI IV		0.52(0.14,1.86)	0.56(0.19,1.79)	-0.05(-0.27,0.04)
HD ADA SC		0.13(0.02,0.82)	0.15(0.02,0.82)	-0.09(-0.35,-0.01)
HD ANA		0.51(0.06,3.18)	0.54(0.09,2.92)	-0.05(-0.32,0.08)
HD TOCI IV + MTX		0.71(0.14,3.06)	0.74(0.18,2.72)	-0.03(-0.24,0.11)
HD GOLI SC + MTX		1.68(0.33,9.35)	1.53(0.38,6.24)	0.06(-0.14,0.36)
HD TOFA PO + MTX		1.12(0.37,3.82)	1.10(0.43,3.33)	0.01(-0.16,0.14)
HD CERTO SC + MTX		1.22(0.30,4.91)	1.19(0.36,4.04)	0.02(-0.16,0.20)
HD INF IV + MTX		2.30(0.60,8.38)	1.95(0.66,6.14)	0.10(-0.07,0.33)
HD TOCI IV + DMARD		0.44(0.09,2.16)	0.47(0.12,2.05)	-0.05(-0.29,0.05)
LD ETN SC + MTX	LD CERTO SC + MTX	0.63(0.09,4.48)	0.66(0.11,3.95)	-0.03(-0.25,0.12)
HD TOCI IV		0.64(0.13,3.64)	0.67(0.17,3.40)	-0.03(-0.27,0.07)
HD ADA SC		0.17(0.02,1.36)	0.18(0.03,1.35)	-0.08(-0.34,0.01)
HD ANA		0.60(0.07,6.05)	0.63(0.11,5.35)	-0.03(-0.31,0.12)
HD TOCI IV + MTX		0.87(0.14,5.80)	0.88(0.18,5.02)	-0.01(-0.25,0.15)
HD GOLI SC + MTX		2.13(0.36,16.41)	1.86(0.42,10.89)	0.08(-0.13,0.39)
HD TOFA PO + MTX		1.46(0.29,7.82)	1.39(0.35,6.63)	0.03(-0.18,0.19)
HD CERTO SC + MTX		1.53(0.38,7.09)	1.44(0.45,5.81)	0.04(-0.14,0.21)

(Continued)

HD INF IV + MTX		2.99(0.50,16.18)	2.45(0.58,11.51)	0.13(-0.10,0.38)
HD TOCI IV + DMARD		0.53(0.10,3.94)	0.56(0.13,3.66)	-0.04(-0.28,0.08)
HD TOCI IV	LD ETN SC + MTX	1.04(0.27,4.60)	1.04(0.31,4.33)	0.00(-0.14,0.08)
HD ADA SC		0.25(0.04,1.96)	0.27(0.04,1.93)	-0.04(-0.21,0.01)
HD ANA		0.96(0.13,7.30)	0.97(0.16,6.58)	0.00(-0.18,0.12)
HD TOCI IV + MTX		1.41(0.26,7.53)	1.36(0.30,6.43)	0.02(-0.12,0.17)
HD GOLI SC + MTX		3.42(0.63,19.26)	2.89(0.67,13.47)	0.11(-0.04,0.41)
HD TOFA PO + MTX		2.30(0.57,9.28)	2.11(0.61,7.87)	0.06(-0.06,0.22)
HD CERTO SC + MTX		2.41(0.55,12.18)	2.18(0.60,9.63)	0.07(-0.06,0.28)
HD INF IV + MTX		4.68(1.01,21.09)	3.70(1.01,14.81)	0.16(0.00,0.42)
HD TOCI IV + DMARD		0.87(0.17,4.86)	0.88(0.20,4.50)	-0.01(-0.16,0.09)
HD ADA SC	HD TOCI IV	0.26(0.05,1.10)	0.27(0.05,1.10)	-0.05(-0.14,0.00)
HD ANA		0.94(0.19,4.46)	0.94(0.22,3.96)	0.00(-0.11,0.12)
HD TOCI IV + MTX		1.34(0.48,3.67)	1.31(0.50,3.12)	0.02(-0.04,0.16)
HD GOLI SC + MTX		3.26(0.80,14.57)	2.80(0.81,8.80)	0.11(-0.01,0.43)
HD TOFA PO + MTX		2.14(0.84,5.92)	1.97(0.86,4.84)	0.06(-0.01,0.22)
HD CERTO SC + MTX		2.33(0.74,7.94)	2.12(0.76,5.94)	0.07(-0.02,0.29)
HD INF IV + MTX		4.35(1.45,14.16)	3.47(1.39,9.01)	0.16(0.02,0.42)
HD TOCI IV + DMARD		0.84(0.29,2.43)	0.85(0.31,2.28)	-0.01(-0.08,0.07)
HD ANA	HD ADA SC	3.67(0.72,21.32)	3.51(0.73,18.39)	0.04(-0.01,0.16)
HD TOCI IV + MTX		5.15(0.96,35.80)	4.76(0.96,28.99)	0.07(0.00,0.25)
HD GOLI SC + MTX		12.95(1.77,115.10)	10.61(1.72,64.66)	0.16(0.02,0.51)
HD TOFA PO + MTX		8.79(1.73,50.82)	7.66(1.68,39.38)	0.11(0.02,0.31)
HD CERTO SC + MTX		9.24(1.63,61.35)	7.95(1.59,42.40)	0.12(0.02,0.37)
HD INF IV + MTX		17.57(3.18,112.80)	13.18(2.95,66.15)	0.21(0.05,0.51)
HD TOCI IV + DMARD		3.31(0.61,19.74)	3.16(0.62,17.49)	0.04(-0.01,0.14)
HD TOCI IV + MTX	HD ANA	1.47(0.20,9.19)	1.42(0.22,7.27)	0.02(-0.12,0.22)

(Continued)

HD GOLI SC + MTX		3.36(0.42,29.91)	2.91(0.46,16.31)	0.11(-0.06,0.48)
HD TOFA PO + MTX		2.39(0.42,13.63)	2.20(0.46,10.07)	0.07(-0.07,0.28)
HD CERTO SC + MTX		2.53(0.41,16.39)	2.30(0.44,11.42)	0.07(-0.07,0.33)
HD INF IV + MTX		4.64(0.83,29.95)	3.77(0.85,16.58)	0.16(-0.02,0.48)
HD TOCI IV + DMARD		0.90(0.15,5.07)	0.91(0.16,4.53)	0.00(-0.13,0.11)
HD GOLI SC + MTX	HD TOCI IV + MTX	2.48(0.44,12.93)	2.17(0.49,8.68)	0.09(-0.08,0.40)
HD TOFA PO + MTX		1.63(0.46,6.29)	1.53(0.51,5.27)	0.04(-0.09,0.21)
HD CERTO SC + MTX		1.72(0.43,7.79)	1.60(0.48,6.01)	0.05(-0.09,0.27)
HD INF IV + MTX		3.25(0.77,13.96)	2.66(0.81,9.43)	0.14(-0.03,0.40)
HD TOCI IV + DMARD		0.62(0.16,2.73)	0.64(0.19,2.54)	-0.03(-0.19,0.07)
HD TOFA PO + MTX	HD GOLI SC + MTX	0.68(0.16,2.60)	0.73(0.24,2.32)	-0.04(-0.32,0.11)
HD CERTO SC + MTX		0.71(0.15,3.14)	0.76(0.22,2.66)	-0.04(-0.33,0.15)
HD INF IV + MTX		1.38(0.25,6.03)	1.28(0.36,4.39)	0.04(-0.26,0.30)
HD TOCI IV + DMARD		0.25(0.05,1.36)	0.30(0.08,1.32)	-0.12(-0.44,0.02)
HD CERTO SC + MTX	HD TOFA PO + MTX	1.05(0.36,3.44)	1.05(0.41,2.82)	0.01(-0.12,0.18)
HD INF IV + MTX		2.03(0.72,5.44)	1.75(0.76,3.98)	0.10(-0.04,0.30)
HD TOCI IV + DMARD		0.38(0.11,1.44)	0.42(0.13,1.40)	-0.07(-0.25,0.03)
HD INF IV + MTX	HD CERTO SC + MTX	1.88(0.50,6.44)	1.65(0.58,4.56)	0.08(-0.10,0.31)
HD TOCI IV + DMARD		0.35(0.09,1.60)	0.39(0.12,1.54)	-0.08(-0.30,0.04)
HD TOCI IV + DMARD	HD INF IV + MTX	0.19(0.04,0.85)	0.24(0.07,0.86)	-0.17(-0.45,-0.01)
Random-effects model	Residual deviance	119.1 vs 119 data points		
	Deviance information criteria	622.675		
Fixed-effect model	Residual deviance	123.8 vs 119 data points		

(Continued)

Deviance information criteria 622.968

Note

Total participants 20,301

Total studies 48

2-arm 30

3-arm 13

4-arm 5

Appendix 17. Withdrawals due to adverse events: subgroup - late RA (> 10 years)
Withdrawals late: odds ratios, risk ratios and risk difference for all treatment comparisons - random effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX + PL	PL	2.70(0.42,18.18)	2.63(0.43,15.53)	0.02(-0.01,0.16)
SD ETN SC		1.24(0.22,7.53)	1.24(0.23,7.13)	0.00(-0.02,0.06)
SD ADA SC		5.91(0.86,132.50)	5.50(0.86,89.14)	0.06(0.00,0.35)
SD RITUX IV		36.20(1.14,1221.00)	22.61(1.14,115.20)	0.31(0.00,0.93)
SD ADA SC + MTX		3.94(0.51,30.99)	3.75(0.52,24.30)	0.04(-0.01,0.26)
SD RITUX IV + MTX		9.81(0.76,167.10)	8.62(0.77,64.71)	0.10(0.00,0.69)
SD ETN SC + MTX		3.63(0.09,276.70)	3.50(0.10,61.27)	0.03(-0.02,0.80)
SD INF IV + MTX		1.84(0.16,18.50)	1.82(0.16,15.68)	0.01(-0.02,0.17)
LD ETN SC		1.27(0.24,7.42)	1.27(0.24,6.95)	0.00(-0.02,0.06)
LD RITUX IV + MTX		6.93(0.45,113.20)	6.30(0.46,52.49)	0.07(-0.01,0.60)
HD INF IV + MTX		1.37(0.12,15.94)	1.36(0.12,13.75)	0.00(-0.02,0.14)
SD ETN SC	MTX + PL	0.47(0.16,1.27)	0.48(0.18,1.26)	-0.02(-0.12,0.00)
SD ADA SC		2.26(0.15,83.91)	2.15(0.17,57.17)	0.04(-0.14,0.35)
SD RITUX IV		12.49(0.87,298.80)	7.50(0.88,46.18)	0.27(0.00,0.87)
SD ADA SC + MTX		1.47(0.56,3.45)	1.43(0.58,3.11)	0.01(-0.02,0.13)

(Continued)

SD RITUX IV + MTX		3.42(0.63,35.37)	3.02(0.64,16.33)	0.07(-0.01,0.61)
SD ETN SC + MTX		1.23(0.07,71.41)	1.21(0.07,19.33)	0.01(-0.07,0.73)
SD INF IV + MTX		0.64(0.14,2.92)	0.65(0.15,2.64)	-0.01(-0.08,0.08)
LD ETN SC		0.47(0.17,1.37)	0.48(0.19,1.36)	-0.02(-0.12,0.01)
LD RITUX IV + MTX		2.53(0.35,25.06)	2.34(0.36,13.34)	0.04(-0.04,0.52)
HD INF IV + MTX		0.51(0.10,2.39)	0.52(0.10,2.22)	-0.01(-0.10,0.06)
SD ADA SC	SD ETN SC	4.96(0.35,179.90)	4.62(0.37,117.30)	0.06(-0.04,0.35)
SD RITUX IV		26.58(1.53,769.90)	15.92(1.50,105.40)	0.30(0.01,0.91)
SD ADA SC + MTX		3.15(0.81,12.13)	2.99(0.81,10.21)	0.03(0.00,0.22)
SD RITUX IV + MTX		7.41(1.02,95.24)	6.48(1.01,42.96)	0.09(0.00,0.67)
SD ETN SC + MTX		2.70(0.11,176.40)	2.58(0.11,45.07)	0.02(-0.03,0.78)
SD INF IV + MTX		1.39(0.24,9.02)	1.38(0.24,7.91)	0.01(-0.03,0.14)
LD ETN SC		0.99(0.40,2.86)	0.99(0.41,2.79)	0.00(-0.03,0.03)
LD RITUX IV + MTX		5.47(0.56,68.87)	4.93(0.57,34.34)	0.07(-0.01,0.58)
HD INF IV + MTX		1.09(0.16,6.93)	1.08(0.16,6.27)	0.00(-0.04,0.12)
SD RITUX IV	SD ADA SC	5.66(0.06,320.10)	3.86(0.08,31.65)	0.23(-0.27,0.88)
SD ADA SC + MTX		0.63(0.01,11.32)	0.65(0.02,8.64)	-0.03(-0.34,0.23)
SD RITUX IV + MTX		1.51(0.03,55.04)	1.45(0.04,19.78)	0.03(-0.32,0.65)
SD ETN SC + MTX		0.51(0.01,87.27)	0.54(0.01,19.52)	-0.03(-0.33,0.75)
SD INF IV + MTX		0.27(0.01,5.93)	0.29(0.01,5.05)	-0.05(-0.35,0.13)
LD ETN SC		0.20(0.01,3.10)	0.22(0.01,2.93)	-0.06(-0.35,0.05)
LD RITUX IV + MTX		1.11(0.02,39.98)	1.10(0.03,17.39)	0.01(-0.32,0.57)
HD INF IV + MTX		0.21(0.00,5.18)	0.23(0.01,4.48)	-0.06(-0.35,0.11)
SD ADA SC + MTX	SD RITUX IV	0.12(0.00,2.00)	0.19(0.03,1.88)	-0.25(-0.85,0.03)
SD RITUX IV + MTX		0.31(0.01,3.19)	0.48(0.05,2.70)	-0.15(-0.71,0.12)
SD ETN SC + MTX		0.11(0.00,13.37)	0.17(0.01,5.47)	-0.20(-0.88,0.42)
SD INF IV + MTX		0.05(0.00,1.16)	0.09(0.01,1.14)	-0.28(-0.90,0.00)
LD ETN SC		0.04(0.00,0.70)	0.06(0.01,0.71)	-0.30(-0.91,-0.01)

(Continued)

LD RITUX IV + MTX		0.21(0.01,2.60)	0.35(0.03,2.22)	-0.18(-0.74,0.09)
HD INF IV + MTX		0.04(0.00,0.87)	0.07(0.01,0.88)	-0.29(-0.90,0.00)
SD RITUX IV + MTX	SD ADA SC + MTX	2.41(0.35,26.99)	2.17(0.38,13.90)	0.05(-0.07,0.58)
SD ETN SC + MTX		0.84(0.04,57.07)	0.85(0.04,15.50)	0.00(-0.15,0.70)
SD INF IV + MTX		0.45(0.08,2.68)	0.47(0.09,2.48)	-0.02(-0.18,0.06)
LD ETN SC		0.31(0.09,1.38)	0.33(0.10,1.36)	-0.03(-0.22,0.01)
LD RITUX IV + MTX		1.75(0.20,20.27)	1.65(0.22,11.34)	0.03(-0.11,0.49)
HD INF IV + MTX		0.34(0.05,2.21)	0.36(0.06,2.08)	-0.03(-0.19,0.04)
SD ETN SC + MTX	SD RITUX IV + MTX	0.38(0.01,27.97)	0.42(0.01,8.97)	-0.04(-0.61,0.58)
SD INF IV + MTX		0.18(0.01,1.71)	0.21(0.02,1.63)	-0.08(-0.63,0.02)
LD ETN SC		0.13(0.01,1.12)	0.15(0.02,1.12)	-0.09(-0.67,0.00)
LD RITUX IV + MTX		0.71(0.14,3.24)	0.77(0.17,2.70)	-0.02(-0.28,0.16)
HD INF IV + MTX		0.14(0.01,1.39)	0.17(0.02,1.35)	-0.09(-0.65,0.01)
SD INF IV + MTX	SD ETN SC + MTX	0.50(0.01,12.90)	0.52(0.02,12.19)	-0.02(-0.75,0.10)
LD ETN SC		0.38(0.01,8.85)	0.40(0.02,8.64)	-0.02(-0.78,0.03)
LD RITUX IV + MTX		1.85(0.03,106.20)	1.73(0.08,65.42)	0.02(-0.63,0.52)
HD INF IV + MTX		0.40(0.01,11.23)	0.42(0.02,10.54)	-0.02(-0.76,0.07)
LD ETN SC	SD INF IV + MTX	0.73(0.11,4.60)	0.74(0.13,4.48)	0.00(-0.14,0.03)
LD RITUX IV + MTX		4.05(0.35,59.56)	3.61(0.38,35.42)	0.05(-0.05,0.55)
HD INF IV + MTX		0.77(0.14,3.87)	0.78(0.15,3.66)	0.00(-0.10,0.06)
LD RITUX IV + MTX	LD ETN SC	5.43(0.55,68.53)	4.90(0.55,34.17)	0.07(-0.01,0.58)
HD INF IV + MTX		1.10(0.15,6.61)	1.10(0.15,5.80)	0.00(-0.04,0.12)
HD INF IV + MTX	LD RITUX IV + MTX	0.19(0.01,2.60)	0.22(0.02,2.46)	-0.06(-0.56,0.04)
Random-effects model	Residual deviance	26.96 vs 24 data points		
	Deviance informa-	122.322		

(Continued)

	tion criteria	
Fixed-effect model	Residual deviance	27.51 vs 24 data points
	Deviance information criteria	122.485
Note		
Total participants	3276	
Total studies	9	
2-arm	4	
3-arm	4	
4-arm	1	

Appendix 18. Withdrawals due to adverse events: subgroup - trial duration (<= 6 months)

Withdrawals short: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	1.11(0.30,3.75)	1.11(0.31,3.58)	0.00(-0.02,0.05)
DMARD + PL		3.39(0.98,11.24)	3.23(0.98,9.44)	0.05(0.00,0.17)
MTX + DMARD		3.08(0.54,14.28)	2.95(0.55,11.47)	0.04(-0.01,0.20)
SD ETN SC		1.27(0.34,4.27)	1.26(0.35,4.03)	0.01(-0.02,0.06)
SD ADA SC		2.00(1.00,4.48)	1.95(1.00,4.24)	0.02(0.00,0.06)
SD TOCI IV		0.98(0.37,2.60)	0.98(0.38,2.53)	0.00(-0.02,0.03)
SD CERTO SC		2.92(0.85,12.52)	2.81(0.85,10.59)	0.04(0.00,0.16)
SD TOC SC + PL IV		0.70(0.20,2.23)	0.70(0.20,2.18)	-0.01(-0.02,0.02)
SD RITUX IV		7.58(0.55,151.10)	6.69(0.56,38.26)	0.11(-0.01,0.74)
SD ETN SC + MTX		1.01(0.22,3.98)	1.01(0.23,3.81)	0.00(-0.02,0.05)
SD ADA SC + MTX		1.44(0.31,6.62)	1.43(0.32,5.97)	0.01(-0.02,0.09)
SD INF IV + MTX		2.98(0.68,11.68)	2.86(0.68,9.66)	0.04(-0.01,0.18)

(Continued)

SD ABA IV + MTX		1.09(0.22,3.96)	1.09(0.22,3.76)	0.00(-0.02,0.05)
SD CERTO SC + MTX		1.50(0.35,6.04)	1.49(0.36,5.52)	0.01(-0.02,0.09)
SD RITUX IV + MTX		2.15(0.38,14.47)	2.10(0.38,11.41)	0.02(-0.01,0.20)
SD GOLI SC + MTX		1.16(0.22,6.22)	1.16(0.23,5.69)	0.00(-0.02,0.09)
SD TOFA PO + MTX		1.97(0.39,10.08)	1.93(0.39,8.63)	0.02(-0.01,0.14)
SD ABA SC + MTX		0.61(0.10,2.67)	0.61(0.10,2.59)	-0.01(-0.02,0.03)
SD TOCI IV + MTX		1.24(0.27,5.65)	1.24(0.28,5.18)	0.00(-0.02,0.08)
SD ETN SC + DMARD		2.41(0.83,7.47)	2.34(0.83,6.75)	0.03(0.00,0.11)
SD CERTO SC + DMARD		3.17(0.85,12.73)	3.03(0.85,10.52)	0.04(0.00,0.18)
SD ADA SC + DMARD		4.17(0.70,22.23)	3.90(0.70,15.74)	0.06(-0.01,0.29)
SD TOCI SC + DMARD		9.78(1.20,77.69)	8.22(1.20,33.00)	0.15(0.00,0.59)
LD ADA SC		0.71(0.17,2.12)	0.72(0.17,2.08)	-0.01(-0.02,0.02)
LD ETN SC		2.45(0.54,11.59)	2.38(0.55,9.66)	0.03(-0.01,0.16)
LD TOCI IV		0.75(0.14,3.61)	0.76(0.14,3.44)	0.00(-0.02,0.04)
LD RITUX IV + MTX		1.98(0.34,14.46)	1.94(0.35,11.35)	0.02(-0.02,0.21)
LD ABA IV + MTX		1.36(0.21,6.99)	1.35(0.21,6.27)	0.01(-0.02,0.10)
LD CERTO SC + MTX		0.98(0.12,6.19)	0.98(0.12,5.64)	0.00(-0.02,0.09)
LD TOCI IV + MTX		0.53(0.09,2.70)	0.54(0.09,2.63)	-0.01(-0.02,0.03)
HD TOCI IV		0.89(0.26,3.16)	0.90(0.27,3.03)	0.00(-0.02,0.04)
HD ADA SC		0.74(0.20,2.32)	0.74(0.20,2.26)	-0.01(-0.02,0.02)
HD GOLI SC		0.59(0.05,4.89)	0.59(0.05,4.53)	-0.01(-0.03,0.07)
HD TOCI IV + MTX		1.24(0.34,4.88)	1.24(0.35,4.57)	0.00(-0.02,0.06)
HD GOLI SC + MTX		1.72(0.31,8.68)	1.69(0.32,7.58)	0.01(-0.02,0.12)
HD TOFA PO + MTX		1.68(0.35,9.23)	1.66(0.35,8.00)	0.01(-0.02,0.13)
HD CERTO SC + MTX		1.56(0.33,7.71)	1.54(0.34,6.83)	0.01(-0.02,0.11)
HD INF IV + MTX		3.17(0.64,13.94)	3.03(0.64,11.19)	0.04(-0.01,0.20)
HD TOCI IV + DMARD		6.54(1.64,26.27)	5.85(1.62,17.84)	0.10(0.01,0.34)
DMARD + PL	MTX	3.06(0.54,23.08)	2.91(0.55,19.70)	0.04(-0.02,0.17)

(Continued)

MTX + DMARD	2.92(0.45,13.15)	2.78(0.46,11.30)	0.04(-0.03,0.19)
SD ETN SC	1.20(0.25,4.31)	1.19(0.27,4.13)	0.00(-0.04,0.05)
SD ADA SC	1.81(0.50,8.47)	1.77(0.52,8.10)	0.02(-0.03,0.06)
SD TOCI IV	0.89(0.32,2.89)	0.89(0.33,2.85)	0.00(-0.04,0.02)
SD CERTO SC	2.69(0.45,21.20)	2.58(0.46,18.20)	0.03(-0.03,0.16)
SD TOC SC + PL IV	0.62(0.18,2.43)	0.63(0.19,2.40)	-0.01(-0.05,0.01)
SD RITUX IV	6.81(0.71,93.71)	5.84(0.72,33.71)	0.11(-0.01,0.72)
SD ETN SC + MTX	0.92(0.20,3.52)	0.92(0.21,3.39)	0.00(-0.05,0.04)
SD ADA SC + MTX	1.28(0.64,2.91)	1.27(0.64,2.80)	0.01(-0.01,0.06)
SD INF IV + MTX	2.69(1.30,5.51)	2.58(1.29,4.92)	0.03(0.00,0.14)
SD ABA IV + MTX	0.95(0.49,1.87)	0.96(0.50,1.83)	0.00(-0.02,0.02)
SD CERTO SC + MTX	1.35(0.72,2.59)	1.33(0.72,2.47)	0.01(-0.01,0.05)
SD RITUX IV + MTX	1.96(0.65,7.23)	1.91(0.66,6.14)	0.02(-0.01,0.17)
SD GOLI SC + MTX	1.07(0.39,3.04)	1.07(0.40,2.87)	0.00(-0.02,0.06)
SD TOFA PO + MTX	1.75(0.75,4.46)	1.71(0.75,4.11)	0.02(-0.01,0.10)
SD ABA SC + MTX	0.52(0.19,1.56)	0.53(0.19,1.54)	-0.01(-0.04,0.01)
SD TOCI IV + MTX	1.18(0.34,3.72)	1.17(0.34,3.55)	0.00(-0.02,0.06)
SD ETN SC + DMARD	2.20(0.44,13.50)	2.14(0.45,12.30)	0.02(-0.03,0.11)
SD CERTO SC + DMARD	2.71(0.52,26.30)	2.60(0.54,21.79)	0.04(-0.02,0.19)
SD ADA SC + DMARD	3.89(0.39,40.36)	3.64(0.41,28.92)	0.06(-0.03,0.29)
SD TOCI SC + DMARD	9.51(0.77,96.91)	7.80(0.78,47.08)	0.15(-0.01,0.58)
LD ADA SC	0.63(0.10,3.03)	0.64(0.10,2.96)	-0.01(-0.06,0.02)
LD ETN SC	2.24(0.34,13.33)	2.17(0.35,11.70)	0.02(-0.03,0.16)
LD TOCI IV	0.70(0.16,2.25)	0.70(0.17,2.21)	-0.01(-0.04,0.02)
LD RITUX IV + MTX	1.83(0.55,7.25)	1.79(0.56,6.33)	0.02(-0.01,0.16)
LD ABA IV + MTX	1.19(0.40,3.43)	1.19(0.41,3.25)	0.00(-0.02,0.07)
LD CERTO SC + MTX	0.93(0.17,3.71)	0.93(0.17,3.51)	0.00(-0.03,0.07)
LD TOCI IV + MTX	0.49(0.08,2.06)	0.50(0.09,2.03)	-0.01(-0.05,0.02)

(Continued)

HD TOCI IV		0.81(0.40,1.70)	0.82(0.41,1.67)	0.00(-0.03,0.01)
HD ADA SC		0.66(0.12,3.48)	0.67(0.13,3.42)	-0.01(-0.06,0.02)
HD GOLI SC		0.56(0.05,2.97)	0.57(0.06,2.83)	-0.01(-0.04,0.05)
HD TOCI IV + MTX		1.12(0.48,2.77)	1.12(0.49,2.70)	0.00(-0.02,0.04)
HD GOLI SC + MTX		1.50(0.62,4.60)	1.48(0.63,4.19)	0.01(-0.01,0.10)
HD TOFA PO + MTX		1.57(0.67,4.11)	1.54(0.68,3.83)	0.01(-0.01,0.09)
HD CERTO SC + MTX		1.46(0.62,3.50)	1.44(0.62,3.29)	0.01(-0.01,0.08)
HD INF IV + MTX		2.87(1.22,7.01)	2.73(1.21,6.14)	0.04(0.00,0.16)
HD TOCI IV + DMARD		5.90(0.99,49.48)	5.26(0.99,34.87)	0.09(0.00,0.34)
MTX + DMARD	DMARD + PL	0.90(0.10,6.94)	0.91(0.12,5.89)	-0.01(-0.15,0.17)
SD ETN SC		0.38(0.05,2.53)	0.40(0.07,2.43)	-0.04(-0.17,0.04)
SD ADA SC		0.60(0.19,1.93)	0.62(0.21,1.89)	-0.02(-0.14,0.02)
SD TOCI IV		0.29(0.06,1.44)	0.30(0.07,1.42)	-0.05(-0.17,0.01)
SD CERTO SC		0.88(0.14,5.75)	0.88(0.17,5.10)	-0.01(-0.14,0.12)
SD TOC SC + PL IV		0.20(0.04,1.13)	0.21(0.04,1.12)	-0.05(-0.18,0.00)
SD RITUX IV		2.22(0.10,67.50)	2.03(0.12,19.44)	0.06(-0.13,0.70)
SD ETN SC + MTX		0.30(0.03,1.88)	0.31(0.04,1.83)	-0.04(-0.17,0.02)
SD ADA SC + MTX		0.42(0.05,3.03)	0.44(0.06,2.81)	-0.03(-0.17,0.07)
SD INF IV + MTX		0.89(0.10,6.25)	0.90(0.12,5.16)	-0.01(-0.15,0.14)
SD ABA IV + MTX		0.31(0.03,2.03)	0.33(0.04,1.96)	-0.04(-0.17,0.03)
SD CERTO SC + MTX		0.44(0.06,3.07)	0.46(0.06,2.87)	-0.03(-0.17,0.06)
SD RITUX IV + MTX		0.61(0.07,6.67)	0.63(0.08,5.53)	-0.02(-0.16,0.18)
SD GOLI SC + MTX		0.34(0.04,2.89)	0.36(0.04,2.69)	-0.04(-0.17,0.05)
SD TOFA PO + MTX		0.57(0.06,4.36)	0.59(0.07,3.86)	-0.02(-0.16,0.11)
SD ABA SC + MTX		0.18(0.02,1.27)	0.19(0.02,1.26)	-0.05(-0.18,0.01)
SD TOCI IV + MTX		0.36(0.05,2.45)	0.38(0.06,2.34)	-0.04(-0.17,0.05)
SD ETN SC + DMARD		0.71(0.32,1.70)	0.73(0.34,1.65)	-0.02(-0.10,0.03)
SD CERTO SC + DMARD		0.93(0.30,3.16)	0.93(0.32,2.90)	0.00(-0.09,0.10)

(Continued)

SD ADA SC + DMARD		1.27(0.35,4.05)	1.24(0.37,3.33)	0.01(-0.06,0.19)
SD TOCI SC + DMARD		2.74(0.57,17.79)	2.39(0.59,9.33)	0.09(-0.03,0.50)
LD ADA SC		0.20(0.04,1.08)	0.21(0.04,1.07)	-0.05(-0.17,0.00)
LD ETN SC		0.71(0.10,6.19)	0.73(0.11,5.42)	-0.02(-0.15,0.12)
LD TOCI IV		0.22(0.03,1.87)	0.23(0.03,1.82)	-0.05(-0.18,0.02)
LD RITUX IV + MTX		0.55(0.06,5.59)	0.57(0.07,4.57)	-0.02(-0.16,0.17)
LD ABA IV + MTX		0.39(0.04,3.22)	0.41(0.04,2.99)	-0.04(-0.17,0.06)
LD CERTO SC + MTX		0.29(0.02,2.74)	0.31(0.03,2.56)	-0.04(-0.17,0.06)
LD TOCI IV + MTX		0.15(0.02,1.12)	0.16(0.02,1.12)	-0.05(-0.18,0.00)
HD TOCI IV		0.26(0.04,1.77)	0.27(0.05,1.73)	-0.05(-0.17,0.02)
HD ADA SC		0.21(0.05,1.08)	0.22(0.05,1.08)	-0.05(-0.17,0.00)
HD GOLI SC		0.18(0.01,1.90)	0.19(0.01,1.83)	-0.05(-0.18,0.03)
HD TOCI IV + MTX		0.36(0.06,2.49)	0.38(0.07,2.39)	-0.04(-0.17,0.04)
HD GOLI SC + MTX		0.48(0.06,4.25)	0.50(0.06,3.81)	-0.03(-0.16,0.09)
HD TOFA PO + MTX		0.50(0.06,3.97)	0.52(0.07,3.54)	-0.03(-0.16,0.09)
HD CERTO SC + MTX		0.46(0.05,3.44)	0.47(0.06,3.17)	-0.03(-0.16,0.08)
HD INF IV + MTX		0.94(0.09,6.85)	0.95(0.11,5.77)	0.00(-0.15,0.16)
HD TOCI IV + DMARD		1.91(1.01,3.79)	1.78(1.01,3.21)	0.05(0.00,0.20)
SD ETN SC	MTX + DMARD	0.43(0.12,1.35)	0.45(0.14,1.34)	-0.03(-0.18,0.01)
SD ADA SC		0.66(0.13,4.13)	0.67(0.15,3.95)	-0.02(-0.18,0.04)
SD TOCI IV		0.33(0.06,2.20)	0.35(0.07,2.16)	-0.04(-0.21,0.02)
SD CERTO SC		0.99(0.13,9.94)	0.99(0.15,8.63)	0.00(-0.18,0.14)
SD TOC SC + PL IV		0.24(0.03,1.70)	0.25(0.04,1.67)	-0.04(-0.21,0.01)
SD RITUX IV		2.52(0.15,60.44)	2.26(0.17,22.31)	0.07(-0.11,0.69)
SD ETN SC + MTX		0.34(0.12,0.84)	0.36(0.14,0.84)	-0.04(-0.17,0.00)
SD ADA SC + MTX		0.45(0.09,3.49)	0.47(0.10,3.22)	-0.03(-0.18,0.06)
SD INF IV + MTX		0.93(0.18,6.70)	0.93(0.21,5.86)	0.00(-0.15,0.13)
SD ABA IV + MTX		0.33(0.06,2.27)	0.34(0.07,2.21)	-0.04(-0.19,0.03)

(Continued)

SD CERTO SC + MTX	0.47(0.09,3.17)	0.48(0.11,3.03)	-0.03(-0.18,0.05)	
SD RITUX IV + MTX	0.66(0.11,8.71)	0.68(0.12,7.23)	-0.02(-0.16,0.17)	
SD GOLI SC + MTX	0.37(0.06,3.20)	0.39(0.07,3.04)	-0.03(-0.19,0.05)	
SD TOFA PO + MTX	0.62(0.11,4.75)	0.64(0.13,4.21)	-0.02(-0.17,0.09)	
SD ABA SC + MTX	0.18(0.03,1.49)	0.19(0.03,1.47)	-0.05(-0.20,0.01)	
SD TOCI IV + MTX	0.39(0.06,3.43)	0.41(0.08,3.25)	-0.03(-0.19,0.06)	
SD ETN SC + DMARD	0.79(0.12,5.95)	0.80(0.14,5.53)	-0.01(-0.18,0.09)	
SD CERTO SC + DMARD	1.03(0.14,10.75)	1.03(0.17,9.18)	0.00(-0.17,0.16)	
SD ADA SC + DMARD	1.40(0.12,16.85)	1.36(0.14,12.84)	0.02(-0.16,0.26)	
SD TOCI SC + DMARD	3.35(0.27,42.87)	2.86(0.30,23.36)	0.10(-0.10,0.55)	
LD ADA SC	0.23(0.03,1.63)	0.24(0.04,1.61)	-0.04(-0.21,0.01)	
LD ETN SC	0.82(0.12,5.84)	0.83(0.14,5.26)	-0.01(-0.16,0.11)	
LD TOCI IV	0.24(0.03,2.22)	0.26(0.04,2.15)	-0.04(-0.20,0.03)	
LD RITUX IV + MTX	0.61(0.10,7.69)	0.63(0.11,6.64)	-0.02(-0.17,0.16)	
LD ABA IV + MTX	0.42(0.06,3.37)	0.44(0.07,3.17)	-0.03(-0.18,0.06)	
LD CERTO SC + MTX	0.32(0.03,3.06)	0.34(0.04,2.85)	-0.03(-0.19,0.05)	
LD TOCI IV + MTX	0.18(0.02,1.40)	0.19(0.02,1.39)	-0.05(-0.21,0.01)	
HD TOCI IV	0.29(0.06,2.22)	0.30(0.07,2.16)	-0.04(-0.20,0.02)	
HD ADA SC	0.24(0.03,1.87)	0.25(0.04,1.84)	-0.04(-0.21,0.01)	
HD GOLI SC	0.20(0.01,2.18)	0.21(0.01,2.12)	-0.04(-0.21,0.03)	
HD TOCI IV + MTX	0.40(0.08,3.22)	0.41(0.09,3.10)	-0.03(-0.19,0.04)	
HD GOLI SC + MTX	0.55(0.08,4.15)	0.57(0.10,3.79)	-0.02(-0.18,0.08)	
HD TOFA PO + MTX	0.56(0.09,4.34)	0.58(0.11,3.95)	-0.02(-0.18,0.08)	
HD CERTO SC + MTX	0.51(0.09,3.71)	0.53(0.10,3.48)	-0.02(-0.18,0.07)	
HD INF IV + MTX	0.99(0.17,7.26)	0.99(0.20,6.40)	0.00(-0.15,0.16)	
HD TOCI IV + DMARD	2.16(0.24,21.17)	2.00(0.28,15.79)	0.05(-0.13,0.30)	
SD ADA SC	SD ETN SC	1.62(0.37,7.02)	1.60(0.38,6.65)	0.01(-0.05,0.06)
SD TOCI IV		0.79(0.19,3.40)	0.79(0.20,3.30)	-0.01(-0.06,0.03)

(Continued)

SD CERTO SC	2.32(0.38,17.04)	2.24(0.40,14.61)	0.03(-0.04,0.15)
SD TOC SC + PL IV	0.55(0.11,2.67)	0.56(0.11,2.61)	-0.01(-0.06,0.02)
SD RITUX IV	6.17(0.39,134.40)	5.35(0.40,39.89)	0.11(-0.02,0.74)
SD ETN SC + MTX	0.78(0.37,1.73)	0.79(0.38,1.70)	0.00(-0.03,0.02)
SD ADA SC + MTX	1.10(0.26,6.30)	1.09(0.28,5.77)	0.00(-0.05,0.09)
SD INF IV + MTX	2.30(0.52,10.85)	2.22(0.53,9.35)	0.03(-0.02,0.17)
SD ABA IV + MTX	0.81(0.19,3.95)	0.81(0.20,3.78)	0.00(-0.05,0.05)
SD CERTO SC + MTX	1.11(0.28,6.13)	1.11(0.29,5.61)	0.00(-0.04,0.08)
SD RITUX IV + MTX	1.64(0.32,16.45)	1.61(0.33,13.21)	0.01(-0.03,0.20)
SD GOLI SC + MTX	0.90(0.18,5.88)	0.90(0.19,5.40)	0.00(-0.06,0.08)
SD TOFA PO + MTX	1.49(0.32,9.16)	1.47(0.33,8.08)	0.01(-0.04,0.13)
SD ABA SC + MTX	0.44(0.09,2.63)	0.45(0.09,2.56)	-0.01(-0.06,0.03)
SD TOCI IV + MTX	0.96(0.20,6.07)	0.96(0.21,5.69)	0.00(-0.05,0.08)
SD ETN SC + DMARD	1.90(0.34,11.43)	1.86(0.36,10.27)	0.02(-0.04,0.11)
SD CERTO SC + DMARD	2.44(0.41,19.48)	2.33(0.43,16.34)	0.03(-0.04,0.19)
SD ADA SC + DMARD	3.25(0.31,31.78)	3.07(0.32,23.73)	0.05(-0.04,0.29)
SD TOCI SC + DMARD	7.75(0.69,93.28)	6.45(0.70,45.67)	0.14(-0.01,0.58)
LD ADA SC	0.56(0.08,2.79)	0.57(0.09,2.73)	-0.01(-0.07,0.02)
LD ETN SC	1.93(0.41,9.68)	1.88(0.43,8.58)	0.02(-0.03,0.14)
LD TOCI IV	0.58(0.09,3.58)	0.59(0.09,3.44)	-0.01(-0.06,0.04)
LD RITUX IV + MTX	1.48(0.29,15.74)	1.46(0.30,12.57)	0.01(-0.04,0.20)
LD ABA IV + MTX	0.99(0.19,6.57)	0.99(0.19,6.03)	0.00(-0.05,0.09)
LD CERTO SC + MTX	0.79(0.09,5.77)	0.79(0.10,5.33)	0.00(-0.05,0.08)
LD TOCI IV + MTX	0.43(0.05,2.85)	0.44(0.06,2.77)	-0.01(-0.07,0.03)
HD TOCI IV	0.69(0.18,3.35)	0.69(0.19,3.23)	-0.01(-0.06,0.03)
HD ADA SC	0.58(0.09,3.10)	0.59(0.10,3.02)	-0.01(-0.07,0.02)
HD GOLI SC	0.48(0.03,4.58)	0.49(0.03,4.33)	-0.01(-0.06,0.06)
HD TOCI IV + MTX	0.94(0.24,4.81)	0.95(0.25,4.59)	0.00(-0.05,0.06)

(Continued)

HD GOLI SC + MTX		1.30(0.26,8.54)	1.29(0.27,7.57)	0.01(-0.04,0.12)
HD TOFA PO + MTX		1.34(0.27,8.65)	1.33(0.28,7.71)	0.01(-0.04,0.11)
HD CERTO SC + MTX		1.21(0.26,7.19)	1.20(0.27,6.53)	0.00(-0.04,0.10)
HD INF IV + MTX		2.43(0.52,12.82)	2.33(0.54,10.65)	0.03(-0.02,0.19)
HD TOCI IV + DMARD		4.96(0.65,42.82)	4.46(0.67,29.86)	0.09(-0.02,0.34)
SD TOCI IV	SD ADA SC	0.48(0.19,1.31)	0.49(0.20,1.30)	-0.02(-0.05,0.01)
SD CERTO SC		1.43(0.32,7.10)	1.41(0.33,6.07)	0.02(-0.04,0.14)
SD TOC SC + PL IV		0.34(0.10,1.17)	0.35(0.11,1.16)	-0.03(-0.06,0.00)
SD RITUX IV		3.65(0.28,85.75)	3.29(0.30,22.52)	0.09(-0.04,0.72)
SD ETN SC + MTX		0.48(0.10,2.30)	0.49(0.10,2.22)	-0.02(-0.06,0.03)
SD ADA SC + MTX		0.70(0.14,3.36)	0.71(0.15,3.11)	-0.01(-0.05,0.07)
SD INF IV + MTX		1.47(0.30,6.43)	1.44(0.31,5.46)	0.02(-0.04,0.15)
SD ABA IV + MTX		0.54(0.10,2.13)	0.55(0.10,2.05)	-0.02(-0.06,0.03)
SD CERTO SC + MTX		0.74(0.15,3.28)	0.75(0.16,3.05)	-0.01(-0.05,0.07)
SD RITUX IV + MTX		1.06(0.17,7.31)	1.05(0.18,5.98)	0.00(-0.05,0.18)
SD GOLI SC + MTX		0.59(0.11,3.24)	0.60(0.11,3.03)	-0.02(-0.05,0.07)
SD TOFA PO + MTX		0.96(0.16,4.85)	0.96(0.17,4.25)	0.00(-0.05,0.12)
SD ABA SC + MTX		0.30(0.04,1.36)	0.31(0.05,1.35)	-0.03(-0.07,0.01)
SD TOCI IV + MTX		0.62(0.13,3.12)	0.63(0.13,2.91)	-0.01(-0.05,0.06)
SD ETN SC + DMARD		1.20(0.46,3.11)	1.19(0.47,2.88)	0.01(-0.03,0.08)
SD CERTO SC + DMARD		1.55(0.43,6.48)	1.51(0.44,5.53)	0.02(-0.03,0.16)
SD ADA SC + DMARD		2.06(0.35,11.30)	1.97(0.37,8.29)	0.04(-0.03,0.27)
SD TOCI SC + DMARD		4.83(0.61,35.37)	4.13(0.62,15.62)	0.13(-0.02,0.56)
LD ADA SC		0.34(0.09,0.97)	0.35(0.10,0.97)	-0.03(-0.06,0.00)
LD ETN SC		1.21(0.22,7.27)	1.20(0.23,6.17)	0.01(-0.05,0.15)
LD TOCI IV		0.36(0.07,1.79)	0.37(0.07,1.74)	-0.02(-0.06,0.03)
LD RITUX IV + MTX		0.97(0.16,7.03)	0.97(0.17,5.65)	0.00(-0.05,0.19)
LD ABA IV + MTX		0.66(0.10,3.49)	0.67(0.10,3.21)	-0.01(-0.05,0.08)

(Continued)

LD CERTO SC + MTX		0.50(0.05,3.20)	0.51(0.06,2.95)	-0.02(-0.06,0.07)
LD TOCI IV + MTX		0.26(0.04,1.33)	0.27(0.04,1.31)	-0.03(-0.07,0.01)
HD TOCI IV		0.44(0.12,1.79)	0.45(0.12,1.75)	-0.02(-0.06,0.02)
HD ADA SC		0.36(0.11,1.05)	0.37(0.12,1.05)	-0.02(-0.06,0.00)
HD GOLI SC		0.29(0.02,2.64)	0.30(0.02,2.49)	-0.03(-0.06,0.05)
HD TOCI IV + MTX		0.60(0.16,2.47)	0.61(0.16,2.37)	-0.01(-0.05,0.04)
HD GOLI SC + MTX		0.83(0.14,4.49)	0.84(0.15,4.05)	-0.01(-0.05,0.10)
HD TOFA PO + MTX		0.87(0.15,4.22)	0.87(0.16,3.79)	0.00(-0.05,0.10)
HD CERTO SC + MTX		0.79(0.15,4.15)	0.79(0.16,3.78)	-0.01(-0.05,0.09)
HD INF IV + MTX		1.59(0.28,7.28)	1.55(0.29,5.97)	0.02(-0.04,0.17)
HD TOCI IV + DMARD		3.24(0.86,12.32)	2.96(0.87,8.70)	0.08(-0.01,0.31)
SD CERTO SC	SD TOCI IV	3.02(0.55,15.80)	2.89(0.56,13.66)	0.04(-0.02,0.16)
SD TOC SC + PL IV		0.69(0.34,1.40)	0.70(0.34,1.39)	-0.01(-0.02,0.01)
SD RITUX IV		7.31(0.68,131.90)	6.42(0.69,38.38)	0.11(-0.01,0.74)
SD ETN SC + MTX		0.96(0.21,5.03)	0.96(0.22,4.78)	0.00(-0.03,0.05)
SD ADA SC + MTX		1.46(0.37,5.37)	1.44(0.37,4.94)	0.01(-0.02,0.09)
SD INF IV + MTX		2.99(0.80,10.91)	2.86(0.81,9.27)	0.04(0.00,0.17)
SD ABA IV + MTX		1.09(0.26,3.56)	1.09(0.26,3.43)	0.00(-0.02,0.04)
SD CERTO SC + MTX		1.50(0.41,5.06)	1.48(0.41,4.72)	0.01(-0.02,0.08)
SD RITUX IV + MTX		2.24(0.45,11.73)	2.18(0.46,9.67)	0.02(-0.01,0.19)
SD GOLI SC + MTX		1.17(0.28,5.58)	1.16(0.29,5.11)	0.00(-0.02,0.08)
SD TOFA PO + MTX		1.99(0.44,8.07)	1.95(0.44,7.06)	0.02(-0.02,0.13)
SD ABA SC + MTX		0.60(0.11,2.59)	0.61(0.11,2.52)	-0.01(-0.03,0.03)
SD TOCI IV + MTX		1.28(0.33,4.58)	1.27(0.33,4.30)	0.01(-0.02,0.07)
SD ETN SC + DMARD		2.45(0.65,9.83)	2.38(0.66,8.88)	0.03(-0.01,0.11)
SD CERTO SC + DMARD		3.15(0.70,17.46)	3.02(0.71,14.55)	0.04(-0.01,0.18)
SD ADA SC + DMARD		4.44(0.56,28.99)	4.15(0.57,21.07)	0.06(-0.01,0.29)
SD TOCI SC + DMARD		10.45(0.99,89.45)	8.62(0.99,41.13)	0.15(0.00,0.59)

(Continued)

LD ADA SC		0.71(0.13,2.55)	0.71(0.13,2.51)	-0.01(-0.03,0.02)
LD ETN SC		2.47(0.45,13.58)	2.39(0.46,11.51)	0.03(-0.02,0.16)
LD TOCI IV		0.75(0.17,2.99)	0.75(0.17,2.90)	0.00(-0.03,0.04)
LD RITUX IV + MTX		1.97(0.40,11.32)	1.93(0.41,9.46)	0.02(-0.02,0.20)
LD ABA IV + MTX		1.35(0.25,5.66)	1.34(0.26,5.20)	0.01(-0.02,0.09)
LD CERTO SC + MTX		1.01(0.13,5.92)	1.01(0.14,5.40)	0.00(-0.03,0.09)
LD TOCI IV + MTX		0.53(0.10,2.50)	0.53(0.10,2.44)	-0.01(-0.03,0.03)
HD TOCI IV		0.89(0.34,2.41)	0.89(0.34,2.35)	0.00(-0.02,0.02)
HD ADA SC		0.72(0.18,2.83)	0.73(0.18,2.75)	-0.01(-0.03,0.02)
HD GOLI SC		0.61(0.05,4.55)	0.62(0.05,4.23)	-0.01(-0.03,0.07)
HD TOCI IV + MTX		1.24(0.42,3.68)	1.23(0.43,3.51)	0.00(-0.02,0.05)
HD GOLI SC + MTX		1.66(0.37,7.62)	1.64(0.38,6.67)	0.01(-0.02,0.12)
HD TOFA PO + MTX		1.74(0.42,7.29)	1.71(0.42,6.43)	0.01(-0.02,0.12)
HD CERTO SC + MTX		1.60(0.39,6.87)	1.58(0.40,6.15)	0.01(-0.02,0.10)
HD INF IV + MTX		3.18(0.76,12.25)	3.03(0.76,10.30)	0.04(0.00,0.18)
HD TOCI IV + DMARD		6.64(1.26,36.78)	5.89(1.25,25.18)	0.10(0.01,0.34)
SD TOC SC + PL IV	SD CERTO SC	0.23(0.04,1.44)	0.24(0.04,1.43)	-0.04(-0.16,0.01)
SD RITUX IV		2.44(0.14,76.28)	2.22(0.16,21.26)	0.07(-0.10,0.71)
SD ETN SC + MTX		0.34(0.04,2.10)	0.35(0.05,2.04)	-0.04(-0.16,0.03)
SD ADA SC + MTX		0.48(0.06,3.27)	0.49(0.07,3.07)	-0.03(-0.15,0.06)
SD INF IV + MTX		0.98(0.11,7.46)	0.98(0.12,6.43)	0.00(-0.13,0.15)
SD ABA IV + MTX		0.36(0.04,2.42)	0.38(0.04,2.34)	-0.03(-0.16,0.03)
SD CERTO SC + MTX		0.50(0.06,3.74)	0.52(0.07,3.48)	-0.03(-0.15,0.07)
SD RITUX IV + MTX		0.72(0.09,6.72)	0.73(0.10,5.65)	-0.01(-0.14,0.16)
SD GOLI SC + MTX		0.39(0.04,3.32)	0.41(0.05,3.05)	-0.03(-0.16,0.06)
SD TOFA PO + MTX		0.65(0.08,5.01)	0.66(0.09,4.45)	-0.02(-0.15,0.11)
SD ABA SC + MTX		0.21(0.02,1.54)	0.22(0.02,1.51)	-0.04(-0.17,0.01)
SD TOCI IV + MTX		0.45(0.05,2.95)	0.46(0.06,2.76)	-0.03(-0.16,0.05)

(Continued)

SD ETN SC + DMARD		0.83(0.15,4.44)	0.84(0.17,4.10)	-0.01(-0.13,0.09)
SD CERTO SC + DMARD		1.09(0.16,7.46)	1.09(0.18,6.30)	0.00(-0.13,0.15)
SD ADA SC + DMARD		1.40(0.16,12.37)	1.36(0.18,9.47)	0.02(-0.11,0.26)
SD TOCI SC + DMARD		3.30(0.29,36.82)	2.86(0.32,17.86)	0.11(-0.08,0.55)
LD ADA SC		0.23(0.03,1.33)	0.24(0.04,1.32)	-0.04(-0.17,0.01)
LD ETN SC		0.83(0.10,6.50)	0.84(0.11,5.51)	-0.01(-0.14,0.14)
LD TOCI IV		0.24(0.03,1.92)	0.25(0.04,1.86)	-0.04(-0.16,0.02)
LD RITUX IV + MTX		0.70(0.08,5.92)	0.71(0.09,5.04)	-0.01(-0.14,0.16)
LD ABA IV + MTX		0.45(0.04,3.83)	0.46(0.05,3.55)	-0.03(-0.15,0.07)
LD CERTO SC + MTX		0.33(0.02,3.24)	0.35(0.03,3.02)	-0.03(-0.16,0.06)
LD TOCI IV + MTX		0.18(0.02,1.28)	0.19(0.02,1.27)	-0.04(-0.17,0.01)
HD TOCI IV		0.31(0.05,1.88)	0.32(0.05,1.84)	-0.04(-0.16,0.02)
HD ADA SC		0.25(0.03,1.38)	0.26(0.04,1.37)	-0.04(-0.16,0.01)
HD GOLI SC		0.19(0.01,2.56)	0.21(0.01,2.46)	-0.04(-0.17,0.04)
HD TOCI IV + MTX		0.41(0.06,2.64)	0.43(0.07,2.53)	-0.03(-0.15,0.04)
HD GOLI SC + MTX		0.57(0.06,4.86)	0.59(0.07,4.36)	-0.02(-0.15,0.10)
HD TOFA PO + MTX		0.59(0.07,4.29)	0.60(0.08,3.94)	-0.02(-0.15,0.10)
HD CERTO SC + MTX		0.55(0.06,4.54)	0.57(0.07,4.12)	-0.02(-0.15,0.09)
HD INF IV + MTX		1.05(0.11,8.22)	1.04(0.13,6.95)	0.00(-0.13,0.17)
HD TOCI IV + DMARD		2.17(0.30,15.51)	2.02(0.33,11.21)	0.06(-0.09,0.30)
SD RITUX IV	SD TOC SC + PL IV	10.51(0.89,207.80)	9.09(0.89,65.09)	0.12(0.00,0.74)
SD ETN SC + MTX		1.39(0.27,8.22)	1.38(0.28,7.82)	0.00(-0.03,0.06)
SD ADA SC + MTX		2.09(0.45,9.00)	2.05(0.45,8.36)	0.01(-0.01,0.09)
SD INF IV + MTX		4.26(0.98,18.60)	4.05(0.98,16.17)	0.04(0.00,0.18)
SD ABA IV + MTX		1.56(0.31,6.10)	1.55(0.32,5.83)	0.01(-0.02,0.05)
SD CERTO SC + MTX		2.15(0.51,8.92)	2.11(0.52,8.35)	0.01(-0.01,0.09)
SD RITUX IV + MTX		3.24(0.57,18.99)	3.12(0.57,15.36)	0.03(-0.01,0.20)
SD GOLI SC + MTX		1.69(0.35,9.56)	1.67(0.36,8.67)	0.01(-0.02,0.09)

(Continued)

SD TOFA PO + MTX		2.90(0.57,13.65)	2.81(0.58,12.22)	0.02(-0.01,0.14)
SD ABA SC + MTX		0.86(0.14,4.47)	0.86(0.15,4.31)	0.00(-0.03,0.03)
SD TOCI IV + MTX		1.88(0.39,7.68)	1.85(0.40,7.21)	0.01(-0.01,0.08)
SD ETN SC + DMARD		3.50(0.79,16.67)	3.37(0.80,15.21)	0.03(-0.01,0.12)
SD CERTO SC + DMARD		4.58(0.91,28.39)	4.34(0.91,23.91)	0.05(0.00,0.19)
SD ADA SC + DMARD		6.27(0.70,48.05)	5.77(0.70,35.39)	0.06(-0.01,0.30)
SD TOCI SC + DMARD		14.73(1.30,149.20)	12.08(1.29,70.17)	0.15(0.01,0.59)
LD ADA SC		1.00(0.16,4.56)	1.00(0.17,4.44)	0.00(-0.03,0.03)
LD ETN SC		3.54(0.57,22.62)	3.39(0.58,19.49)	0.03(-0.01,0.17)
LD TOCI IV		1.07(0.21,5.14)	1.07(0.22,4.96)	0.00(-0.02,0.05)
LD RITUX IV + MTX		2.86(0.49,18.72)	2.77(0.49,15.58)	0.02(-0.01,0.21)
LD ABA IV + MTX		1.91(0.31,10.00)	1.88(0.32,9.23)	0.01(-0.02,0.09)
LD CERTO SC + MTX		1.45(0.17,9.86)	1.44(0.17,8.96)	0.01(-0.02,0.09)
LD TOCI IV + MTX		0.76(0.13,4.19)	0.76(0.13,4.05)	0.00(-0.03,0.03)
HD TOCI IV		1.29(0.39,4.35)	1.28(0.40,4.25)	0.00(-0.02,0.03)
HD ADA SC		1.03(0.23,4.93)	1.03(0.23,4.79)	0.00(-0.03,0.03)
HD GOLI SC		0.87(0.07,7.33)	0.87(0.07,6.80)	0.00(-0.03,0.07)
HD TOCI IV + MTX		1.79(0.50,6.47)	1.77(0.50,6.14)	0.01(-0.01,0.06)
HD GOLI SC + MTX		2.42(0.48,13.41)	2.36(0.48,11.96)	0.02(-0.01,0.12)
HD TOFA PO + MTX		2.50(0.51,12.15)	2.44(0.52,11.00)	0.02(-0.01,0.13)
HD CERTO SC + MTX		2.34(0.49,11.62)	2.29(0.49,10.60)	0.02(-0.01,0.11)
HD INF IV + MTX		4.61(0.93,20.76)	4.35(0.93,17.43)	0.05(0.00,0.19)
HD TOCI IV + DMARD		9.62(1.52,58.01)	8.47(1.50,42.43)	0.10(0.01,0.34)
SD ETN SC + MTX	SD RITUX IV	0.13(0.01,2.02)	0.15(0.02,1.98)	-0.11(-0.74,0.01)
SD ADA SC + MTX		0.18(0.01,2.01)	0.22(0.04,1.97)	-0.10(-0.70,0.02)
SD INF IV + MTX		0.39(0.03,4.05)	0.44(0.07,3.82)	-0.07(-0.66,0.06)
SD ABA IV + MTX		0.14(0.01,1.59)	0.16(0.02,1.57)	-0.11(-0.72,0.01)
SD CERTO SC + MTX		0.19(0.01,2.30)	0.22(0.04,2.26)	-0.10(-0.70,0.02)

(Continued)

SD RITUX IV + MTX		0.29(0.02,2.48)	0.33(0.06,2.36)	-0.08(-0.66,0.04)
SD GOLI SC + MTX		0.16(0.01,1.84)	0.19(0.02,1.81)	-0.10(-0.72,0.01)
SD TOFA PO + MTX		0.25(0.02,3.22)	0.29(0.04,3.10)	-0.09(-0.68,0.04)
SD ABA SC + MTX		0.08(0.00,1.02)	0.09(0.01,1.02)	-0.12(-0.74,0.00)
SD TOCI IV + MTX		0.17(0.01,1.79)	0.19(0.03,1.75)	-0.10(-0.72,0.01)
SD ETN SC + DMARD		0.33(0.01,6.01)	0.36(0.04,5.45)	-0.08(-0.72,0.07)
SD CERTO SC + DMARD		0.46(0.01,8.38)	0.50(0.05,7.37)	-0.06(-0.71,0.13)
SD ADA SC + DMARD		0.58(0.01,13.09)	0.63(0.04,10.38)	-0.04(-0.70,0.22)
SD TOCI SC + DMARD		1.28(0.03,35.73)	1.22(0.09,20.39)	0.02(-0.64,0.48)
LD ADA SC		0.10(0.00,1.35)	0.11(0.01,1.34)	-0.12(-0.75,0.00)
LD ETN SC		0.34(0.01,6.22)	0.38(0.03,5.53)	-0.08(-0.72,0.10)
LD TOCI IV		0.10(0.00,1.21)	0.12(0.01,1.20)	-0.11(-0.74,0.00)
LD RITUX IV + MTX		0.26(0.02,2.38)	0.30(0.06,2.28)	-0.09(-0.65,0.03)
LD ABA IV + MTX		0.18(0.01,2.30)	0.21(0.02,2.23)	-0.10(-0.72,0.02)
LD CERTO SC + MTX		0.13(0.01,1.81)	0.16(0.02,1.75)	-0.10(-0.72,0.01)
LD TOCI IV + MTX		0.07(0.00,0.93)	0.09(0.01,0.93)	-0.12(-0.74,0.00)
HD TOCI IV		0.12(0.01,1.27)	0.14(0.02,1.26)	-0.11(-0.73,0.00)
HD ADA SC		0.10(0.00,1.35)	0.11(0.01,1.34)	-0.11(-0.75,0.00)
HD GOLI SC		0.08(0.00,1.34)	0.09(0.01,1.33)	-0.11(-0.74,0.01)
HD TOCI IV + MTX		0.16(0.01,1.74)	0.19(0.03,1.72)	-0.10(-0.72,0.01)
HD GOLI SC + MTX		0.23(0.01,2.71)	0.26(0.03,2.60)	-0.09(-0.70,0.03)
HD TOFA PO + MTX		0.22(0.01,2.86)	0.26(0.04,2.80)	-0.09(-0.69,0.03)
HD CERTO SC + MTX		0.21(0.01,2.41)	0.24(0.04,2.34)	-0.10(-0.70,0.03)
HD INF IV + MTX		0.41(0.03,4.56)	0.45(0.07,4.27)	-0.06(-0.65,0.07)
HD TOCI IV + DMARD		0.87(0.03,19.65)	0.89(0.09,14.68)	-0.01(-0.65,0.27)
SD ADA SC + MTX	SD ETN SC + MTX	1.45(0.32,8.40)	1.44(0.33,7.73)	0.01(-0.04,0.09)
SD INF IV + MTX		2.91(0.65,14.89)	2.80(0.66,12.53)	0.03(-0.02,0.17)
SD ABA IV + MTX		1.03(0.25,5.18)	1.03(0.25,4.95)	0.00(-0.04,0.05)

(Continued)

SD CERTO SC + MTX		1.48(0.36,7.67)	1.46(0.37,7.09)	0.01(-0.04,0.08)
SD RITUX IV + MTX		2.12(0.39,19.71)	2.06(0.40,16.29)	0.02(-0.03,0.20)
SD GOLI SC + MTX		1.16(0.24,7.64)	1.16(0.25,7.09)	0.00(-0.04,0.08)
SD TOFA PO + MTX		1.96(0.39,10.92)	1.92(0.40,9.63)	0.02(-0.03,0.14)
SD ABA SC + MTX		0.57(0.12,3.64)	0.57(0.12,3.53)	-0.01(-0.05,0.03)
SD TOCI IV + MTX		1.25(0.23,7.97)	1.24(0.24,7.49)	0.00(-0.04,0.08)
SD ETN SC + DMARD		2.41(0.41,17.16)	2.35(0.42,15.45)	0.03(-0.03,0.11)
SD CERTO SC + DMARD		3.14(0.50,28.53)	2.99(0.52,23.65)	0.04(-0.02,0.19)
SD ADA SC + DMARD		4.12(0.40,44.83)	3.85(0.41,33.49)	0.06(-0.03,0.29)
SD TOCI SC + DMARD		9.94(0.85,118.40)	8.15(0.85,60.89)	0.15(-0.01,0.59)
LD ADA SC		0.73(0.11,3.98)	0.73(0.11,3.89)	-0.01(-0.05,0.02)
LD ETN SC		2.48(0.45,14.38)	2.40(0.46,12.84)	0.03(-0.02,0.15)
LD TOCI IV		0.75(0.10,5.00)	0.75(0.11,4.75)	0.00(-0.05,0.04)
LD RITUX IV + MTX		1.89(0.34,18.95)	1.85(0.35,15.39)	0.02(-0.03,0.20)
LD ABA IV + MTX		1.29(0.23,8.26)	1.28(0.24,7.52)	0.01(-0.04,0.09)
LD CERTO SC + MTX		1.02(0.11,7.45)	1.02(0.11,6.81)	0.00(-0.05,0.08)
LD TOCI IV + MTX		0.55(0.06,3.54)	0.56(0.06,3.43)	-0.01(-0.06,0.03)
HD TOCI IV		0.89(0.22,4.38)	0.89(0.23,4.24)	0.00(-0.05,0.04)
HD ADA SC		0.74(0.11,4.66)	0.75(0.11,4.55)	0.00(-0.06,0.03)
HD GOLI SC		0.62(0.04,5.74)	0.62(0.04,5.46)	-0.01(-0.06,0.07)
HD TOCI IV + MTX		1.21(0.28,6.42)	1.21(0.29,6.10)	0.00(-0.04,0.06)
HD GOLI SC + MTX		1.68(0.29,10.64)	1.65(0.30,9.52)	0.01(-0.04,0.12)
HD TOFA PO + MTX		1.75(0.31,10.93)	1.72(0.32,9.88)	0.01(-0.04,0.12)
HD CERTO SC + MTX		1.59(0.32,8.88)	1.57(0.33,8.04)	0.01(-0.04,0.10)
HD INF IV + MTX		3.15(0.58,16.51)	3.01(0.59,13.91)	0.04(-0.02,0.19)
HD TOCI IV + DMARD		6.42(0.89,65.47)	5.72(0.89,44.98)	0.10(0.00,0.34)
SD INF IV + MTX	SD ADA SC + MTX	2.10(0.70,5.68)	2.02(0.71,5.25)	0.03(-0.02,0.13)
SD ABA IV + MTX		0.74(0.25,1.97)	0.75(0.26,1.94)	-0.01(-0.06,0.02)

(Continued)

SD CERTO SC + MTX		1.03(0.38,2.80)	1.03(0.40,2.71)	0.00(-0.04,0.04)
SD RITUX IV + MTX		1.51(0.42,6.65)	1.48(0.44,5.93)	0.01(-0.03,0.14)
SD GOLJ SC + MTX		0.81(0.22,3.21)	0.82(0.23,3.03)	0.00(-0.06,0.06)
SD TOFA PO + MTX		1.35(0.58,3.33)	1.33(0.59,3.16)	0.01(-0.02,0.08)
SD ABA SC + MTX		0.41(0.11,1.49)	0.42(0.11,1.48)	-0.01(-0.08,0.01)
SD TOCI IV + MTX		0.88(0.21,3.51)	0.89(0.22,3.38)	0.00(-0.06,0.05)
SD ETN SC + DMARD		1.70(0.27,12.24)	1.67(0.29,11.07)	0.02(-0.07,0.11)
SD CERTO SC + DMARD		2.20(0.32,20.20)	2.12(0.34,16.83)	0.03(-0.07,0.18)
SD ADA SC + DMARD		2.99(0.26,30.76)	2.82(0.28,22.84)	0.05(-0.06,0.29)
SD TOCI SC + DMARD		7.15(0.47,76.37)	5.94(0.50,39.68)	0.14(-0.04,0.58)
LD ADA SC		0.50(0.07,2.67)	0.51(0.07,2.62)	-0.01(-0.10,0.02)
LD ETN SC		1.73(0.22,12.01)	1.69(0.23,10.59)	0.02(-0.07,0.15)
LD TOCI IV		0.53(0.10,2.15)	0.54(0.11,2.11)	-0.01(-0.09,0.02)
LD RITUX IV + MTX		1.40(0.34,6.80)	1.37(0.35,6.07)	0.01(-0.03,0.13)
LD ABA IV + MTX		0.92(0.25,3.29)	0.92(0.26,3.12)	0.00(-0.05,0.06)
LD CERTO SC + MTX		0.71(0.11,3.53)	0.71(0.11,3.34)	-0.01(-0.07,0.06)
LD TOCI IV + MTX		0.37(0.06,1.87)	0.38(0.06,1.85)	-0.02(-0.09,0.01)
HD TOCI IV		0.63(0.22,1.77)	0.64(0.24,1.75)	-0.01(-0.08,0.01)
HD ADA SC		0.51(0.07,2.96)	0.52(0.08,2.90)	-0.01(-0.10,0.02)
HD GOLJ SC		0.42(0.04,2.90)	0.43(0.04,2.74)	-0.01(-0.08,0.05)
HD TOCI IV + MTX		0.86(0.27,2.83)	0.86(0.29,2.75)	0.00(-0.07,0.03)
HD GOLJ SC + MTX		1.16(0.36,4.50)	1.16(0.37,4.11)	0.00(-0.04,0.09)
HD TOFA PO + MTX		1.20(0.52,3.16)	1.19(0.53,3.01)	0.00(-0.02,0.07)
HD CERTO SC + MTX		1.12(0.36,3.67)	1.11(0.37,3.43)	0.00(-0.04,0.07)
HD INF IV + MTX		2.20(0.66,7.04)	2.11(0.67,6.33)	0.03(-0.02,0.15)
HD TOCI IV + DMARD		4.49(0.61,41.34)	4.04(0.63,29.17)	0.09(-0.03,0.33)
SD ABA IV + MTX	SD INF IV + MTX	0.35(0.14,0.85)	0.37(0.16,0.86)	-0.03(-0.14,0.00)
SD CERTO SC + MTX		0.50(0.18,1.36)	0.52(0.20,1.34)	-0.03(-0.13,0.01)

(Continued)

SD RITUX IV + MTX		0.71(0.19,3.30)	0.73(0.21,2.91)	-0.01(-0.11,0.12)
SD GOLI SC + MTX		0.39(0.12,1.47)	0.41(0.13,1.43)	-0.03(-0.14,0.02)
SD TOFA PO + MTX		0.65(0.21,2.03)	0.66(0.23,1.93)	-0.02(-0.11,0.05)
SD ABA SC + MTX		0.20(0.06,0.64)	0.21(0.07,0.65)	-0.04(-0.16,-0.01)
SD TOCI IV + MTX		0.43(0.10,1.71)	0.45(0.11,1.66)	-0.03(-0.15,0.02)
SD ETN SC + DMARD		0.80(0.14,5.44)	0.81(0.16,4.95)	-0.01(-0.15,0.09)
SD CERTO SC + DMARD		1.01(0.16,11.39)	1.01(0.19,9.71)	0.00(-0.14,0.16)
SD ADA SC + DMARD		1.43(0.13,16.55)	1.39(0.15,12.63)	0.02(-0.14,0.26)
SD TOCI SC + DMARD		3.44(0.27,40.63)	2.93(0.30,19.51)	0.11(-0.10,0.54)
LD ADA SC		0.24(0.03,1.37)	0.25(0.04,1.36)	-0.04(-0.18,0.01)
LD ETN SC		0.81(0.13,5.80)	0.82(0.15,4.92)	-0.01(-0.14,0.13)
LD TOCI IV		0.26(0.05,1.03)	0.27(0.06,1.03)	-0.04(-0.16,0.00)
LD RITUX IV + MTX		0.68(0.15,3.26)	0.69(0.17,2.87)	-0.02(-0.11,0.12)
LD ABA IV + MTX		0.44(0.13,1.51)	0.46(0.14,1.48)	-0.03(-0.13,0.02)
LD CERTO SC + MTX		0.33(0.06,1.63)	0.35(0.06,1.57)	-0.03(-0.14,0.03)
LD TOCI IV + MTX		0.18(0.03,0.95)	0.19(0.03,0.95)	-0.05(-0.17,0.00)
HD TOCI IV		0.30(0.11,0.84)	0.32(0.12,0.84)	-0.04(-0.16,0.00)
HD ADA SC		0.24(0.04,1.50)	0.26(0.05,1.48)	-0.04(-0.18,0.01)
HD GOLI SC		0.20(0.02,1.34)	0.22(0.02,1.30)	-0.04(-0.16,0.02)
HD TOCI IV + MTX		0.41(0.13,1.38)	0.43(0.14,1.36)	-0.03(-0.15,0.01)
HD GOLI SC + MTX		0.56(0.17,2.17)	0.58(0.19,2.02)	-0.02(-0.12,0.05)
HD TOFA PO + MTX		0.58(0.19,1.92)	0.60(0.21,1.83)	-0.02(-0.11,0.04)
HD CERTO SC + MTX		0.54(0.17,1.71)	0.55(0.19,1.65)	-0.02(-0.12,0.03)
HD INF IV + MTX		1.08(0.49,2.25)	1.07(0.51,2.11)	0.00(-0.05,0.07)
HD TOCI IV + DMARD		2.19(0.29,22.07)	2.04(0.32,15.50)	0.06(-0.11,0.31)
SD CERTO SC + MTX	SD ABA IV + MTX	1.40(0.57,3.57)	1.39(0.57,3.42)	0.01(-0.02,0.06)
SD RITUX IV + MTX		1.99(0.55,9.38)	1.94(0.56,8.14)	0.02(-0.02,0.18)
SD GOLI SC + MTX		1.14(0.32,4.03)	1.13(0.33,3.79)	0.00(-0.03,0.07)

(Continued)

SD TOFA PO + MTX		1.84(0.64,5.70)	1.80(0.65,5.35)	0.02(-0.01,0.10)
SD ABA SC + MTX		0.55(0.24,1.27)	0.56(0.25,1.26)	-0.01(-0.04,0.01)
SD TOCI IV + MTX		1.22(0.31,4.69)	1.21(0.32,4.49)	0.00(-0.03,0.06)
SD ETN SC + DMARD		2.25(0.43,16.91)	2.18(0.45,15.36)	0.02(-0.03,0.11)
SD CERTO SC + DMARD		2.90(0.51,33.96)	2.77(0.53,28.74)	0.04(-0.02,0.19)
SD ADA SC + DMARD		4.01(0.36,50.25)	3.74(0.38,37.99)	0.06(-0.03,0.29)
SD TOCI SC + DMARD		9.66(0.78,109.60)	7.90(0.79,58.74)	0.15(-0.01,0.58)
LD ADA SC		0.67(0.09,4.03)	0.67(0.09,3.94)	-0.01(-0.06,0.02)
LD ETN SC		2.30(0.36,17.41)	2.23(0.38,14.95)	0.02(-0.03,0.16)
LD TOCI IV		0.73(0.14,2.85)	0.73(0.14,2.78)	-0.01(-0.05,0.03)
LD RITUX IV + MTX		1.90(0.46,9.12)	1.85(0.47,8.10)	0.02(-0.02,0.17)
LD ABA IV + MTX		1.23(0.45,3.65)	1.23(0.45,3.49)	0.00(-0.02,0.07)
LD CERTO SC + MTX		0.95(0.15,4.55)	0.95(0.16,4.29)	0.00(-0.04,0.07)
LD TOCI IV + MTX		0.51(0.08,2.66)	0.52(0.08,2.62)	-0.01(-0.05,0.02)
HD TOCI IV		0.84(0.32,2.34)	0.84(0.34,2.31)	0.00(-0.04,0.02)
HD ADA SC		0.68(0.12,4.34)	0.69(0.13,4.24)	-0.01(-0.06,0.02)
HD GOLI SC		0.57(0.05,3.42)	0.58(0.05,3.20)	-0.01(-0.05,0.06)
HD TOCI IV + MTX		1.16(0.41,3.87)	1.15(0.42,3.77)	0.00(-0.03,0.04)
HD GOLI SC + MTX		1.56(0.52,5.99)	1.54(0.53,5.36)	0.01(-0.02,0.10)
HD TOFA PO + MTX		1.62(0.57,5.30)	1.59(0.58,4.92)	0.01(-0.01,0.09)
HD CERTO SC + MTX		1.53(0.50,4.70)	1.51(0.51,4.38)	0.01(-0.02,0.08)
HD INF IV + MTX		3.03(1.06,8.79)	2.87(1.06,7.86)	0.04(0.00,0.16)
HD TOCI IV + DMARD		6.08(0.88,65.01)	5.42(0.88,47.28)	0.09(0.00,0.34)
SD RITUX IV + MTX	SD CERTO SC + MTX	1.44(0.39,6.06)	1.42(0.40,5.29)	0.01(-0.03,0.15)
SD GOLI SC + MTX		0.81(0.24,2.77)	0.82(0.25,2.60)	0.00(-0.05,0.05)
SD TOFA PO + MTX		1.30(0.45,3.97)	1.28(0.46,3.72)	0.01(-0.03,0.09)
SD ABA SC + MTX		0.39(0.11,1.39)	0.40(0.12,1.37)	-0.02(-0.08,0.01)
SD TOCI IV + MTX		0.86(0.20,3.23)	0.87(0.21,3.11)	0.00(-0.06,0.05)

(Continued)

SD ETN SC + DMARD		1.63(0.27,10.75)	1.60(0.30,9.88)	0.02(-0.07,0.10)
SD CERTO SC + DMARD		2.00(0.34,20.65)	1.93(0.36,17.12)	0.03(-0.06,0.18)
SD ADA SC + DMARD		2.91(0.24,31.58)	2.73(0.26,23.67)	0.05(-0.06,0.28)
SD TOCI SC + DMARD		6.97(0.49,74.76)	5.73(0.52,39.56)	0.14(-0.04,0.57)
LD ADA SC		0.48(0.06,2.60)	0.48(0.07,2.56)	-0.01(-0.09,0.02)
LD ETN SC		1.66(0.22,10.92)	1.63(0.23,9.61)	0.02(-0.07,0.15)
LD TOCI IV		0.51(0.10,1.96)	0.52(0.11,1.92)	-0.01(-0.08,0.02)
LD RITUX IV + MTX		1.33(0.35,5.87)	1.31(0.36,5.31)	0.01(-0.03,0.15)
LD ABA IV + MTX		0.88(0.25,2.99)	0.89(0.26,2.87)	0.00(-0.05,0.05)
LD CERTO SC + MTX		0.68(0.13,2.60)	0.69(0.13,2.46)	-0.01(-0.06,0.05)
LD TOCI IV + MTX		0.36(0.05,1.75)	0.37(0.06,1.73)	-0.02(-0.09,0.01)
HD TOCI IV		0.60(0.23,1.57)	0.61(0.24,1.55)	-0.01(-0.07,0.01)
HD ADA SC		0.49(0.08,2.82)	0.50(0.09,2.77)	-0.01(-0.09,0.02)
HD GOLI SC		0.40(0.04,2.39)	0.41(0.04,2.27)	-0.01(-0.08,0.04)
HD TOCI IV + MTX		0.84(0.29,2.45)	0.84(0.30,2.40)	0.00(-0.06,0.03)
HD GOLI SC + MTX		1.13(0.36,3.85)	1.12(0.38,3.52)	0.00(-0.04,0.08)
HD TOFA PO + MTX		1.17(0.39,3.71)	1.16(0.40,3.46)	0.00(-0.03,0.07)
HD CERTO SC + MTX		1.08(0.48,2.41)	1.07(0.49,2.30)	0.00(-0.03,0.05)
HD INF IV + MTX		2.13(0.70,6.78)	2.05(0.71,6.14)	0.03(-0.01,0.15)
HD TOCI IV + DMARD		4.33(0.60,39.11)	3.90(0.62,28.12)	0.08(-0.03,0.33)
SD GOLI SC + MTX	SD RITUX IV + MTX	0.54(0.10,2.49)	0.55(0.12,2.40)	-0.02(-0.16,0.04)
SD TOFA PO + MTX		0.89(0.21,3.52)	0.90(0.23,3.36)	0.00(-0.13,0.06)
SD ABA SC + MTX		0.27(0.05,1.32)	0.28(0.06,1.31)	-0.03(-0.20,0.00)
SD TOCI IV + MTX		0.60(0.10,2.89)	0.62(0.11,2.78)	-0.01(-0.16,0.03)
SD ETN SC + DMARD		1.15(0.13,9.29)	1.14(0.15,8.49)	0.01(-0.18,0.10)
SD CERTO SC + DMARD		1.42(0.14,15.13)	1.39(0.17,12.81)	0.02(-0.17,0.17)
SD ADA SC + DMARD		2.07(0.11,22.08)	1.97(0.14,17.07)	0.04(-0.17,0.27)
SD TOCI SC + DMARD		4.77(0.27,60.57)	3.99(0.30,30.37)	0.12(-0.13,0.56)

(Continued)

LD ADA SC		0.33(0.03,2.14)	0.35(0.04,2.10)	-0.03(-0.21,0.01)
LD ETN SC		1.11(0.11,9.72)	1.10(0.13,8.32)	0.00(-0.17,0.14)
LD TOCI IV		0.35(0.05,1.74)	0.36(0.05,1.72)	-0.03(-0.19,0.01)
LD RITUX IV + MTX		0.91(0.28,2.83)	0.91(0.29,2.67)	0.00(-0.08,0.07)
LD ABA IV + MTX		0.61(0.11,2.71)	0.62(0.12,2.60)	-0.01(-0.17,0.04)
LD CERTO SC + MTX		0.46(0.05,2.78)	0.48(0.05,2.65)	-0.02(-0.18,0.04)
LD TOCI IV + MTX		0.25(0.03,1.44)	0.26(0.03,1.43)	-0.03(-0.20,0.01)
HD TOCI IV		0.42(0.09,1.47)	0.43(0.11,1.46)	-0.02(-0.19,0.01)
HD ADA SC		0.35(0.03,2.26)	0.36(0.04,2.22)	-0.03(-0.21,0.01)
HD GOLI SC		0.27(0.02,2.29)	0.28(0.02,2.20)	-0.03(-0.19,0.03)
HD TOCI IV + MTX		0.57(0.12,2.26)	0.58(0.14,2.22)	-0.02(-0.17,0.02)
HD GOLI SC + MTX		0.77(0.15,3.75)	0.78(0.17,3.46)	-0.01(-0.15,0.07)
HD TOFA PO + MTX		0.80(0.18,3.17)	0.81(0.20,3.01)	-0.01(-0.13,0.05)
HD CERTO SC + MTX		0.74(0.16,3.09)	0.75(0.18,2.96)	-0.01(-0.14,0.05)
HD INF IV + MTX		1.48(0.30,5.91)	1.44(0.34,5.38)	0.01(-0.11,0.13)
HD TOCI IV + DMARD		3.10(0.27,32.15)	2.83(0.32,23.28)	0.07(-0.14,0.32)
SD TOFA PO + MTX	SD GOLI SC + MTX	1.68(0.36,6.34)	1.65(0.37,5.96)	0.01(-0.05,0.10)
SD ABA SC + MTX		0.49(0.11,2.38)	0.50(0.12,2.33)	-0.01(-0.08,0.02)
SD TOCI IV + MTX		1.11(0.22,4.32)	1.10(0.24,4.17)	0.00(-0.07,0.05)
SD ETN SC + DMARD		2.09(0.29,14.85)	2.03(0.31,13.63)	0.02(-0.06,0.11)
SD CERTO SC + DMARD		2.64(0.34,25.59)	2.54(0.36,21.85)	0.03(-0.06,0.18)
SD ADA SC + DMARD		3.57(0.28,41.74)	3.31(0.30,31.20)	0.05(-0.05,0.29)
SD TOCI SC + DMARD		8.39(0.61,111.10)	6.85(0.62,56.25)	0.14(-0.02,0.58)
LD ADA SC		0.59(0.07,3.79)	0.59(0.08,3.73)	-0.01(-0.09,0.02)
LD ETN SC		2.15(0.24,16.00)	2.08(0.26,13.92)	0.02(-0.07,0.15)
LD TOCI IV		0.64(0.10,2.90)	0.65(0.11,2.82)	-0.01(-0.08,0.03)
LD RITUX IV + MTX		1.71(0.34,8.96)	1.68(0.36,8.05)	0.01(-0.04,0.15)
LD ABA IV + MTX		1.11(0.24,4.67)	1.11(0.25,4.45)	0.00(-0.06,0.07)

(Continued)

LD CERTO SC + MTX		0.85(0.11,4.67)	0.85(0.11,4.44)	0.00(-0.07,0.06)
LD TOCI IV + MTX		0.47(0.05,2.56)	0.48(0.05,2.51)	-0.01(-0.09,0.02)
HD TOCI IV		0.77(0.21,2.59)	0.78(0.23,2.54)	0.00(-0.08,0.02)
HD ADA SC		0.62(0.09,3.84)	0.63(0.10,3.75)	-0.01(-0.09,0.02)
HD GOLI SC		0.50(0.06,2.96)	0.51(0.06,2.84)	-0.01(-0.07,0.04)
HD TOCI IV + MTX		1.07(0.26,3.67)	1.07(0.28,3.56)	0.00(-0.07,0.04)
HD GOLI SC + MTX		1.40(0.52,4.07)	1.38(0.54,3.84)	0.01(-0.02,0.07)
HD TOFA PO + MTX		1.45(0.34,6.13)	1.42(0.36,5.71)	0.01(-0.05,0.09)
HD CERTO SC + MTX		1.33(0.35,5.21)	1.32(0.36,4.90)	0.01(-0.04,0.08)
HD INF IV + MTX		2.71(0.65,10.12)	2.58(0.66,8.95)	0.03(-0.02,0.16)
HD TOCI IV + DMARD		5.45(0.62,54.43)	4.88(0.65,39.70)	0.09(-0.03,0.33)
SD ABA SC + MTX	SD TOFA PO + MTX	0.30(0.08,1.17)	0.31(0.08,1.16)	-0.02(-0.13,0.00)
SD TOCI IV + MTX		0.65(0.15,2.73)	0.66(0.16,2.64)	-0.01(-0.11,0.04)
SD ETN SC + DMARD		1.28(0.19,9.68)	1.26(0.21,8.84)	0.01(-0.12,0.10)
SD CERTO SC + DMARD		1.57(0.24,16.86)	1.54(0.27,14.15)	0.02(-0.10,0.17)
SD ADA SC + DMARD		2.23(0.15,22.92)	2.12(0.17,17.33)	0.04(-0.11,0.28)
SD TOCI SC + DMARD		5.24(0.35,61.42)	4.38(0.38,31.90)	0.13(-0.07,0.57)
LD ADA SC		0.37(0.04,2.20)	0.38(0.05,2.16)	-0.02(-0.15,0.01)
LD ETN SC		1.28(0.15,10.16)	1.26(0.16,8.97)	0.01(-0.11,0.14)
LD TOCI IV		0.39(0.07,1.74)	0.40(0.08,1.72)	-0.02(-0.13,0.01)
LD RITUX IV + MTX		1.05(0.23,5.10)	1.04(0.24,4.65)	0.00(-0.06,0.11)
LD ABA IV + MTX		0.68(0.18,2.52)	0.69(0.19,2.44)	-0.01(-0.09,0.04)
LD CERTO SC + MTX		0.51(0.07,2.95)	0.52(0.08,2.77)	-0.02(-0.11,0.05)
LD TOCI IV + MTX		0.29(0.04,1.42)	0.29(0.04,1.40)	-0.02(-0.14,0.01)
HD TOCI IV		0.46(0.15,1.44)	0.47(0.16,1.43)	-0.02(-0.12,0.01)
HD ADA SC		0.38(0.05,2.35)	0.39(0.06,2.31)	-0.02(-0.14,0.02)
HD GOLI SC		0.31(0.03,2.23)	0.32(0.03,2.12)	-0.02(-0.12,0.04)
HD TOCI IV + MTX		0.64(0.18,2.24)	0.65(0.20,2.19)	-0.01(-0.11,0.02)

(Continued)

HD GOLI SC + MTX		0.86(0.25,3.53)	0.86(0.27,3.30)	0.00(-0.08,0.07)
HD TOFA PO + MTX		0.90(0.40,2.02)	0.90(0.42,1.97)	0.00(-0.05,0.04)
HD CERTO SC + MTX		0.82(0.24,2.95)	0.83(0.26,2.81)	-0.01(-0.08,0.05)
HD INF IV + MTX		1.62(0.48,5.69)	1.57(0.50,5.11)	0.02(-0.04,0.13)
HD TOCI IV + DMARD		3.31(0.40,34.04)	3.01(0.44,25.25)	0.08(-0.08,0.32)
SD TOCI IV + MTX	SD ABA SC + MTX	2.19(0.39,10.76)	2.16(0.40,10.28)	0.01(-0.02,0.08)
SD ETN SC + DMARD		3.97(0.68,37.58)	3.82(0.70,34.13)	0.03(-0.01,0.12)
SD CERTO SC + DMARD		5.08(0.76,70.23)	4.79(0.77,59.89)	0.05(-0.01,0.19)
SD ADA SC + DMARD		7.25(0.61,104.80)	6.67(0.62,80.67)	0.06(-0.01,0.30)
SD TOCI SC + DMARD		16.82(1.33,239.10)	13.58(1.32,133.60)	0.15(0.01,0.59)
LD ADA SC		1.19(0.15,8.61)	1.18(0.16,8.39)	0.00(-0.04,0.03)
LD ETN SC		4.03(0.55,35.89)	3.87(0.57,31.34)	0.03(-0.01,0.17)
LD TOCI IV		1.32(0.20,6.33)	1.31(0.21,6.16)	0.00(-0.03,0.04)
LD RITUX IV + MTX		3.43(0.62,20.07)	3.30(0.63,18.11)	0.03(-0.01,0.19)
LD ABA IV + MTX		2.23(0.62,9.10)	2.18(0.62,8.61)	0.01(-0.01,0.09)
LD CERTO SC + MTX		1.75(0.21,10.16)	1.74(0.21,9.45)	0.01(-0.02,0.09)
LD TOCI IV + MTX		0.91(0.12,5.85)	0.91(0.12,5.72)	0.00(-0.03,0.03)
HD TOCI IV		1.54(0.41,5.70)	1.52(0.42,5.59)	0.01(-0.02,0.03)
HD ADA SC		1.23(0.20,9.65)	1.23(0.21,9.42)	0.00(-0.03,0.03)
HD GOLI SC		1.02(0.08,6.93)	1.02(0.08,6.54)	0.00(-0.03,0.07)
HD TOCI IV + MTX		2.09(0.52,8.73)	2.06(0.53,8.45)	0.01(-0.02,0.06)
HD GOLI SC + MTX		2.86(0.71,13.35)	2.78(0.72,12.02)	0.02(-0.01,0.12)
HD TOFA PO + MTX		2.91(0.78,11.82)	2.83(0.78,11.04)	0.02(0.00,0.12)
HD CERTO SC + MTX		2.76(0.70,10.72)	2.68(0.71,9.99)	0.02(-0.01,0.10)
HD INF IV + MTX		5.40(1.47,20.63)	5.05(1.44,18.46)	0.05(0.01,0.19)
HD TOCI IV + DMARD		10.91(1.42,138.90)	9.56(1.40,101.60)	0.10(0.01,0.35)
SD ETN SC + DMARD	SD TOCI IV + MTX	1.97(0.32,12.41)	1.92(0.34,11.26)	0.02(-0.06,0.10)

(Continued)

SD CERTO SC + DMARD		2.53(0.36,21.24)	2.43(0.39,17.95)	0.03(-0.05,0.18)
SD ADA SC + DMARD		3.49(0.31,33.03)	3.24(0.33,24.56)	0.05(-0.05,0.29)
SD TOCI SC + DMARD		8.22(0.61,101.50)	6.77(0.62,49.38)	0.14(-0.02,0.58)
LD ADA SC		0.56(0.07,2.99)	0.57(0.08,2.94)	-0.01(-0.09,0.02)
LD ETN SC		1.99(0.24,13.21)	1.94(0.26,11.45)	0.02(-0.06,0.16)
LD TOCI IV		0.58(0.12,2.56)	0.59(0.12,2.51)	-0.01(-0.07,0.02)
LD RITUX IV + MTX		1.57(0.30,9.88)	1.54(0.31,8.59)	0.01(-0.04,0.16)
LD ABA IV + MTX		1.03(0.21,5.12)	1.03(0.21,4.81)	0.00(-0.06,0.07)
LD CERTO SC + MTX		0.78(0.10,5.14)	0.79(0.11,4.82)	0.00(-0.06,0.07)
LD TOCI IV + MTX		0.43(0.07,1.94)	0.43(0.07,1.91)	-0.01(-0.08,0.01)
HD TOCI IV		0.71(0.23,2.39)	0.71(0.24,2.36)	-0.01(-0.06,0.02)
HD ADA SC		0.59(0.08,3.31)	0.60(0.09,3.27)	-0.01(-0.09,0.02)
HD GOLI SC		0.46(0.04,3.78)	0.47(0.04,3.58)	-0.01(-0.07,0.05)
HD TOCI IV + MTX		0.97(0.31,3.59)	0.97(0.32,3.47)	0.00(-0.05,0.03)
HD GOLI SC + MTX		1.31(0.31,6.31)	1.30(0.32,5.73)	0.01(-0.04,0.10)
HD TOFA PO + MTX		1.36(0.32,6.42)	1.35(0.33,6.00)	0.01(-0.04,0.10)
HD CERTO SC + MTX		1.25(0.29,5.96)	1.24(0.30,5.59)	0.01(-0.04,0.09)
HD INF IV + MTX		2.46(0.57,11.59)	2.35(0.59,10.26)	0.03(-0.02,0.17)
HD TOCI IV + DMARD		5.23(0.72,42.60)	4.67(0.74,31.27)	0.09(-0.02,0.33)
SD CERTO SC + DMARD	SD ETN SC + DMARD	1.29(0.37,5.39)	1.27(0.39,4.66)	0.01(-0.05,0.13)
SD ADA SC + DMARD		1.74(0.37,7.43)	1.67(0.38,5.74)	0.03(-0.04,0.24)
SD TOCI SC + DMARD		3.92(0.61,26.92)	3.35(0.62,13.27)	0.12(-0.02,0.54)
LD ADA SC		0.28(0.06,1.21)	0.29(0.06,1.20)	-0.03(-0.11,0.00)
LD ETN SC		1.00(0.14,7.23)	1.00(0.15,6.28)	0.00(-0.09,0.14)
LD TOCI IV		0.30(0.04,2.21)	0.31(0.05,2.15)	-0.03(-0.12,0.03)
LD RITUX IV + MTX		0.80(0.09,7.31)	0.81(0.10,6.03)	-0.01(-0.10,0.18)
LD ABA IV + MTX		0.54(0.06,3.59)	0.55(0.07,3.34)	-0.02(-0.11,0.07)
LD CERTO SC + MTX		0.40(0.04,3.56)	0.42(0.05,3.26)	-0.03(-0.11,0.07)

(Continued)

LD TOCI IV + MTX		0.21(0.03,1.44)	0.22(0.03,1.42)	-0.03(-0.12,0.01)
HD TOCI IV		0.36(0.07,1.92)	0.37(0.08,1.87)	-0.03(-0.11,0.02)
HD ADA SC		0.30(0.07,1.24)	0.31(0.08,1.23)	-0.03(-0.11,0.01)
HD GOLI SC		0.25(0.01,2.71)	0.26(0.02,2.56)	-0.03(-0.12,0.05)
HD TOCI IV + MTX		0.50(0.10,2.74)	0.52(0.11,2.62)	-0.02(-0.11,0.04)
HD GOLI SC + MTX		0.68(0.09,4.95)	0.69(0.10,4.48)	-0.01(-0.10,0.10)
HD TOFA PO + MTX		0.70(0.10,4.95)	0.71(0.11,4.42)	-0.01(-0.10,0.10)
HD CERTO SC + MTX		0.65(0.09,4.34)	0.66(0.10,3.96)	-0.01(-0.10,0.09)
HD INF IV + MTX		1.33(0.17,7.96)	1.31(0.19,6.75)	0.01(-0.08,0.17)
HD TOCI IV + DMARD		2.66(0.92,7.61)	2.44(0.92,5.92)	0.07(0.00,0.27)
SD ADA SC + DMARD	SD CER- TO SC + DMARD	1.37(0.21,6.53)	1.34(0.23,5.15)	0.02(-0.10,0.22)
SD TOCI SC + DMARD		3.06(0.38,24.04)	2.65(0.41,12.27)	0.10(-0.06,0.52)
LD ADA SC		0.22(0.03,1.17)	0.24(0.04,1.16)	-0.05(-0.19,0.00)
LD ETN SC		0.79(0.09,6.25)	0.80(0.10,5.42)	-0.01(-0.16,0.13)
LD TOCI IV		0.24(0.03,1.83)	0.25(0.03,1.79)	-0.04(-0.19,0.02)
LD RITUX IV + MTX		0.65(0.06,6.01)	0.67(0.07,5.07)	-0.02(-0.17,0.17)
LD ABA IV + MTX		0.44(0.03,2.82)	0.45(0.04,2.66)	-0.03(-0.18,0.05)
LD CERTO SC + MTX		0.32(0.02,2.84)	0.34(0.02,2.66)	-0.04(-0.18,0.06)
LD TOCI IV + MTX		0.16(0.02,1.27)	0.17(0.02,1.26)	-0.05(-0.19,0.01)
HD TOCI IV		0.29(0.04,1.48)	0.30(0.05,1.46)	-0.04(-0.19,0.01)
HD ADA SC		0.23(0.04,1.26)	0.24(0.05,1.25)	-0.05(-0.19,0.01)
HD GOLI SC		0.19(0.01,2.45)	0.20(0.01,2.34)	-0.04(-0.19,0.04)
HD TOCI IV + MTX		0.40(0.05,2.30)	0.42(0.06,2.21)	-0.03(-0.18,0.03)
HD GOLI SC + MTX		0.54(0.05,4.20)	0.56(0.06,3.80)	-0.02(-0.17,0.09)
HD TOFA PO + MTX		0.55(0.05,3.76)	0.57(0.07,3.37)	-0.02(-0.17,0.09)
HD CERTO SC + MTX		0.53(0.05,3.72)	0.55(0.06,3.39)	-0.02(-0.18,0.08)
HD INF IV + MTX		1.04(0.09,6.44)	1.04(0.10,5.55)	0.00(-0.16,0.15)

(Continued)

HD TOCI IV + DMARD		2.08(0.52,7.65)	1.93(0.55,6.07)	0.05(-0.06,0.25)
SD TOCI SC + DMARD	SD ADA SC + DMARD	2.19(0.34,21.65)	1.94(0.38,13.85)	0.07(-0.12,0.48)
LD ADA SC		0.16(0.02,1.32)	0.17(0.03,1.30)	-0.06(-0.30,0.01)
LD ETN SC		0.58(0.06,7.71)	0.61(0.08,6.71)	-0.03(-0.26,0.12)
LD TOCI IV		0.17(0.02,2.21)	0.18(0.02,2.15)	-0.06(-0.30,0.03)
LD RITUX IV + MTX		0.44(0.04,8.02)	0.47(0.05,6.54)	-0.04(-0.27,0.16)
LD ABA IV + MTX		0.30(0.02,4.07)	0.32(0.03,3.76)	-0.05(-0.29,0.07)
LD CERTO SC + MTX		0.22(0.01,3.43)	0.24(0.02,3.20)	-0.06(-0.29,0.05)
LD TOCI IV + MTX		0.12(0.01,1.49)	0.13(0.01,1.48)	-0.07(-0.30,0.01)
HD TOCI IV		0.20(0.03,2.11)	0.22(0.03,2.07)	-0.06(-0.29,0.02)
HD ADA SC		0.17(0.03,1.29)	0.18(0.03,1.28)	-0.06(-0.30,0.01)
HD GOLI SC		0.13(0.01,2.51)	0.15(0.01,2.36)	-0.06(-0.30,0.03)
HD TOCI IV + MTX		0.30(0.03,2.85)	0.32(0.05,2.73)	-0.05(-0.29,0.04)
HD GOLI SC + MTX		0.38(0.03,5.33)	0.40(0.04,4.69)	-0.04(-0.28,0.09)
HD TOFA PO + MTX		0.40(0.04,5.84)	0.42(0.05,5.16)	-0.04(-0.28,0.09)
HD CERTO SC + MTX		0.36(0.03,4.47)	0.38(0.04,4.15)	-0.05(-0.28,0.07)
HD INF IV + MTX		0.74(0.06,8.95)	0.76(0.08,7.46)	-0.02(-0.26,0.16)
HD TOCI IV + DMARD		1.54(0.40,6.56)	1.46(0.47,5.47)	0.03(-0.13,0.20)
LD ADA SC	SD TOCI SC + DMARD	0.07(0.01,0.80)	0.08(0.01,0.81)	-0.15(-0.59,-0.01)
LD ETN SC		0.25(0.02,3.29)	0.29(0.04,2.99)	-0.11(-0.57,0.09)
LD TOCI IV		0.07(0.01,1.06)	0.09(0.01,1.06)	-0.15(-0.59,0.00)
LD RITUX IV + MTX		0.20(0.01,3.64)	0.24(0.03,3.22)	-0.12(-0.57,0.11)
LD ABA IV + MTX		0.13(0.01,2.02)	0.16(0.02,1.92)	-0.14(-0.58,0.04)
LD CERTO SC + MTX		0.09(0.01,1.81)	0.12(0.01,1.73)	-0.14(-0.58,0.03)
LD TOCI IV + MTX		0.05(0.00,0.82)	0.06(0.01,0.83)	-0.16(-0.60,-0.01)
HD TOCI IV		0.08(0.01,1.05)	0.10(0.02,1.04)	-0.15(-0.59,0.00)
HD ADA SC		0.07(0.01,0.74)	0.09(0.02,0.75)	-0.15(-0.59,-0.01)

(Continued)

HD GOLI SC		0.06(0.00,1.19)	0.08(0.00,1.18)	-0.15(-0.59,0.01)
HD TOCI IV + MTX		0.12(0.01,1.52)	0.15(0.02,1.48)	-0.14(-0.58,0.02)
HD GOLI SC + MTX		0.17(0.01,2.41)	0.20(0.03,2.28)	-0.13(-0.57,0.05)
HD TOFA PO + MTX		0.17(0.02,2.64)	0.20(0.03,2.42)	-0.13(-0.56,0.06)
HD CERTO SC + MTX		0.16(0.01,2.27)	0.19(0.03,2.13)	-0.13(-0.57,0.05)
HD INF IV + MTX		0.31(0.03,4.12)	0.36(0.05,3.63)	-0.10(-0.54,0.12)
HD TOCI IV + DMARD		0.69(0.10,3.93)	0.73(0.17,3.47)	-0.04(-0.43,0.14)
LD ETN SC	LD ADA SC	3.55(0.54,22.64)	3.41(0.55,19.87)	0.03(-0.01,0.17)
LD TOCI IV		1.09(0.15,7.77)	1.09(0.16,7.44)	0.00(-0.03,0.05)
LD RITUX IV + MTX		2.66(0.43,29.58)	2.59(0.44,24.04)	0.02(-0.02,0.22)
LD ABA IV + MTX		1.90(0.25,16.00)	1.87(0.25,14.73)	0.01(-0.02,0.10)
LD CERTO SC + MTX		1.41(0.15,13.12)	1.40(0.15,12.07)	0.01(-0.02,0.10)
LD TOCI IV + MTX		0.73(0.10,6.56)	0.73(0.10,6.29)	0.00(-0.03,0.04)
HD TOCI IV		1.23(0.29,8.12)	1.22(0.29,7.76)	0.00(-0.02,0.04)
HD ADA SC		1.04(0.28,4.33)	1.04(0.28,4.24)	0.00(-0.02,0.03)
HD GOLI SC		0.83(0.06,12.86)	0.83(0.06,12.01)	0.00(-0.03,0.08)
HD TOCI IV + MTX		1.69(0.38,11.29)	1.67(0.39,10.64)	0.01(-0.02,0.07)
HD GOLI SC + MTX		2.41(0.35,20.58)	2.36(0.35,18.19)	0.02(-0.02,0.13)
HD TOFA PO + MTX		2.37(0.42,25.52)	2.33(0.43,22.58)	0.02(-0.01,0.14)
HD CERTO SC + MTX		2.19(0.38,19.66)	2.15(0.39,17.88)	0.02(-0.02,0.12)
HD INF IV + MTX		4.40(0.73,36.52)	4.16(0.74,30.80)	0.05(-0.01,0.20)
HD TOCI IV + DMARD		9.65(1.66,55.55)	8.50(1.63,41.19)	0.10(0.01,0.34)
LD TOCI IV	LD ETN SC	0.31(0.03,2.07)	0.32(0.04,2.02)	-0.03(-0.17,0.02)
LD RITUX IV + MTX		0.79(0.10,8.70)	0.80(0.11,7.21)	-0.01(-0.14,0.18)
LD ABA IV + MTX		0.54(0.06,4.59)	0.55(0.07,4.33)	-0.02(-0.15,0.07)
LD CERTO SC + MTX		0.41(0.04,3.60)	0.43(0.04,3.32)	-0.02(-0.15,0.06)
LD TOCI IV + MTX		0.21(0.02,2.05)	0.22(0.03,2.01)	-0.04(-0.17,0.02)
HD TOCI IV		0.36(0.06,2.20)	0.38(0.07,2.17)	-0.03(-0.16,0.02)

(Continued)

HD ADA SC		0.30(0.04,2.09)	0.31(0.05,2.05)	-0.03(-0.17,0.01)
HD GOLI SC		0.24(0.01,2.81)	0.26(0.02,2.68)	-0.03(-0.16,0.04)
HD TOCI IV + MTX		0.52(0.08,3.07)	0.53(0.09,2.95)	-0.02(-0.16,0.04)
HD GOLI SC + MTX		0.67(0.09,6.12)	0.68(0.10,5.53)	-0.01(-0.14,0.10)
HD TOFA PO + MTX		0.71(0.09,6.08)	0.72(0.11,5.57)	-0.01(-0.14,0.10)
HD CERTO SC + MTX		0.64(0.10,5.01)	0.65(0.11,4.62)	-0.01(-0.14,0.09)
HD INF IV + MTX		1.28(0.18,8.98)	1.26(0.21,7.63)	0.01(-0.12,0.16)
HD TOCI IV + DMARD		2.58(0.27,22.63)	2.38(0.30,16.75)	0.06(-0.10,0.31)
LD RITUX IV + MTX	LD TOCI IV	2.54(0.49,21.10)	2.46(0.50,18.63)	0.02(-0.02,0.19)
LD ABA IV + MTX		1.75(0.34,10.05)	1.72(0.35,9.37)	0.01(-0.02,0.08)
LD CERTO SC + MTX		1.30(0.18,9.93)	1.30(0.19,9.41)	0.00(-0.03,0.08)
LD TOCI IV + MTX		0.71(0.11,3.93)	0.72(0.11,3.86)	0.00(-0.04,0.03)
HD TOCI IV		1.18(0.38,4.93)	1.18(0.39,4.86)	0.00(-0.03,0.03)
HD ADA SC		0.99(0.15,6.59)	0.99(0.15,6.46)	0.00(-0.05,0.03)
HD GOLI SC		0.80(0.07,6.92)	0.80(0.07,6.65)	0.00(-0.04,0.06)
HD TOCI IV + MTX		1.66(0.50,6.99)	1.64(0.51,6.77)	0.01(-0.02,0.05)
HD GOLI SC + MTX		2.23(0.51,12.84)	2.17(0.52,11.56)	0.02(-0.01,0.11)
HD TOFA PO + MTX		2.26(0.52,13.28)	2.21(0.53,11.95)	0.02(-0.02,0.12)
HD CERTO SC + MTX		2.13(0.48,11.19)	2.08(0.49,10.39)	0.01(-0.02,0.10)
HD INF IV + MTX		4.12(0.94,22.44)	3.90(0.94,20.02)	0.04(0.00,0.18)
HD TOCI IV + DMARD		9.02(0.98,83.30)	7.89(0.98,60.86)	0.10(0.00,0.34)
LD ABA IV + MTX	LD RITUX IV + MTX	0.67(0.11,3.36)	0.68(0.12,3.21)	-0.01(-0.15,0.05)
LD CERTO SC + MTX		0.50(0.05,3.42)	0.52(0.06,3.28)	-0.02(-0.17,0.05)
LD TOCI IV + MTX		0.27(0.03,1.61)	0.28(0.04,1.60)	-0.03(-0.19,0.01)
HD TOCI IV		0.45(0.09,1.82)	0.46(0.11,1.80)	-0.02(-0.18,0.01)
HD ADA SC		0.38(0.04,2.46)	0.39(0.05,2.42)	-0.02(-0.21,0.02)
HD GOLI SC		0.31(0.02,2.34)	0.32(0.03,2.23)	-0.02(-0.19,0.03)
HD TOCI IV + MTX		0.61(0.13,2.72)	0.63(0.14,2.66)	-0.01(-0.17,0.03)

(Continued)

HD GOLI SC + MTX		0.85(0.15,4.06)	0.86(0.17,3.81)	0.00(-0.14,0.07)
HD TOFA PO + MTX		0.85(0.17,4.17)	0.86(0.19,3.94)	0.00(-0.12,0.06)
HD CERTO SC + MTX		0.81(0.16,3.57)	0.82(0.18,3.39)	-0.01(-0.14,0.06)
HD INF IV + MTX		1.58(0.31,7.33)	1.54(0.35,6.63)	0.02(-0.10,0.13)
HD TOCI IV + DMARD		3.45(0.31,36.59)	3.11(0.36,26.63)	0.07(-0.12,0.32)
LD CERTO SC + MTX	LD ABA IV + MTX	0.77(0.09,4.51)	0.78(0.10,4.25)	0.00(-0.08,0.06)
LD TOCI IV + MTX		0.41(0.05,2.61)	0.42(0.06,2.56)	-0.01(-0.09,0.02)
HD TOCI IV		0.68(0.20,2.62)	0.69(0.21,2.60)	-0.01(-0.08,0.02)
HD ADA SC		0.54(0.08,4.28)	0.55(0.09,4.16)	-0.01(-0.10,0.02)
HD GOLI SC		0.46(0.04,3.35)	0.47(0.04,3.17)	-0.01(-0.09,0.05)
HD TOCI IV + MTX		0.93(0.25,3.85)	0.93(0.27,3.73)	0.00(-0.07,0.04)
HD GOLI SC + MTX		1.27(0.32,5.68)	1.26(0.34,5.22)	0.01(-0.05,0.09)
HD TOFA PO + MTX		1.33(0.35,5.24)	1.31(0.36,4.90)	0.01(-0.05,0.09)
HD CERTO SC + MTX		1.22(0.31,4.90)	1.21(0.33,4.62)	0.00(-0.05,0.08)
HD INF IV + MTX		2.40(0.63,8.96)	2.29(0.65,8.15)	0.03(-0.02,0.15)
HD TOCI IV + DMARD		4.92(0.56,58.39)	4.40(0.58,42.34)	0.09(-0.03,0.33)
LD TOCI IV + MTX	LD CERTO SC + MTX	0.54(0.06,4.77)	0.55(0.07,4.66)	-0.01(-0.09,0.03)
HD TOCI IV		0.91(0.18,5.50)	0.91(0.19,5.39)	0.00(-0.08,0.02)
HD ADA SC		0.74(0.08,6.79)	0.75(0.09,6.66)	0.00(-0.10,0.03)
HD GOLI SC		0.62(0.04,5.52)	0.63(0.04,5.25)	-0.01(-0.08,0.05)
HD TOCI IV + MTX		1.24(0.23,8.46)	1.23(0.25,8.19)	0.00(-0.07,0.04)
HD GOLI SC + MTX		1.66(0.31,13.02)	1.63(0.33,12.31)	0.01(-0.05,0.10)
HD TOFA PO + MTX		1.71(0.32,13.32)	1.68(0.34,11.98)	0.01(-0.05,0.10)
HD CERTO SC + MTX		1.57(0.38,8.66)	1.55(0.39,8.27)	0.01(-0.04,0.08)
HD INF IV + MTX		3.24(0.61,21.17)	3.06(0.63,19.24)	0.04(-0.02,0.17)
HD TOCI IV + DMARD		6.84(0.65,88.72)	6.04(0.67,65.43)	0.09(-0.03,0.34)
HD TOCI IV	LD TOCI IV + MTX	1.64(0.43,8.55)	1.62(0.44,8.34)	0.01(-0.02,0.03)

(Continued)

HD ADA SC		1.35(0.21,10.50)	1.34(0.22,10.18)	0.00(-0.04,0.03)
HD GOLI SC		1.11(0.09,12.12)	1.11(0.09,11.47)	0.00(-0.03,0.07)
HD TOCI IV + MTX		2.29(0.57,13.30)	2.26(0.58,12.88)	0.01(-0.01,0.06)
HD GOLI SC + MTX		3.20(0.52,25.25)	3.10(0.53,22.96)	0.02(-0.01,0.12)
HD TOFA PO + MTX		3.19(0.55,22.26)	3.09(0.56,20.61)	0.02(-0.01,0.13)
HD CERTO SC + MTX		2.98(0.54,23.00)	2.91(0.55,21.48)	0.02(-0.01,0.11)
HD INF IV + MTX		5.91(1.03,40.58)	5.53(1.03,35.84)	0.05(0.00,0.19)
HD TOCI IV + DMARD		12.37(1.61,104.90)	10.84(1.58,78.96)	0.10(0.01,0.35)
HD ADA SC	HD TOCI IV	0.83(0.17,3.61)	0.83(0.17,3.53)	0.00(-0.04,0.03)
HD GOLI SC		0.66(0.07,4.19)	0.66(0.07,3.90)	-0.01(-0.03,0.06)
HD TOCI IV + MTX		1.39(0.64,2.92)	1.37(0.65,2.86)	0.01(-0.01,0.04)
HD GOLI SC + MTX		1.86(0.60,6.64)	1.83(0.61,5.79)	0.01(-0.01,0.11)
HD TOFA PO + MTX		1.96(0.62,6.46)	1.92(0.63,5.86)	0.02(-0.01,0.11)
HD CERTO SC + MTX		1.77(0.58,5.60)	1.74(0.59,5.16)	0.01(-0.01,0.09)
HD INF IV + MTX		3.51(1.17,10.94)	3.33(1.17,9.37)	0.04(0.00,0.18)
HD TOCI IV + DMARD		7.28(1.06,52.01)	6.47(1.06,36.95)	0.10(0.00,0.34)
HD GOLI SC	HD ADA SC	0.79(0.05,8.97)	0.79(0.06,8.35)	0.00(-0.03,0.08)
HD TOCI IV + MTX		1.66(0.34,8.86)	1.64(0.35,8.37)	0.01(-0.02,0.06)
HD GOLI SC + MTX		2.37(0.35,15.50)	2.31(0.35,13.80)	0.02(-0.02,0.13)
HD TOFA PO + MTX		2.33(0.38,17.76)	2.28(0.39,15.68)	0.02(-0.02,0.13)
HD CERTO SC + MTX		2.14(0.35,14.86)	2.10(0.35,13.44)	0.01(-0.02,0.11)
HD INF IV + MTX		4.42(0.67,26.42)	4.17(0.68,22.23)	0.05(-0.01,0.20)
HD TOCI IV + DMARD		9.33(1.63,49.48)	8.25(1.60,35.54)	0.10(0.01,0.34)
HD TOCI IV + MTX	HD GOLI SC	2.12(0.32,21.15)	2.09(0.34,20.51)	0.01(-0.05,0.05)
HD GOLI SC + MTX		2.69(0.59,24.71)	2.60(0.60,23.79)	0.02(-0.02,0.10)
HD TOFA PO + MTX		2.94(0.38,37.19)	2.85(0.41,34.95)	0.02(-0.04,0.11)
HD CERTO SC + MTX		2.63(0.43,27.76)	2.57(0.45,26.47)	0.02(-0.03,0.09)

(Continued)

HD INF IV + MTX		5.22(0.76,61.62)	4.89(0.77,56.54)	0.04(-0.01,0.18)
HD TOCI IV + DMARD		10.78(0.86,228.60)	9.41(0.87,171.10)	0.10(-0.01,0.34)
HD GOLI SC + MTX	HD TOCI IV + MTX	1.38(0.39,5.21)	1.37(0.40,4.67)	0.01(-0.03,0.10)
HD TOFA PO + MTX		1.39(0.40,5.14)	1.38(0.41,4.60)	0.01(-0.03,0.10)
HD CERTO SC + MTX		1.30(0.35,4.44)	1.29(0.36,4.08)	0.01(-0.03,0.08)
HD INF IV + MTX		2.60(0.72,8.87)	2.49(0.73,7.77)	0.04(-0.01,0.17)
HD TOCI IV + DMARD		5.27(0.75,37.47)	4.71(0.76,26.81)	0.09(-0.02,0.33)
HD TOFA PO + MTX	HD GOLI SC + MTX	1.04(0.26,3.64)	1.04(0.28,3.43)	0.00(-0.08,0.07)
HD CERTO SC + MTX		0.97(0.24,3.38)	0.97(0.26,3.22)	0.00(-0.08,0.06)
HD INF IV + MTX		1.90(0.44,6.86)	1.84(0.47,6.16)	0.02(-0.05,0.14)
HD TOCI IV + DMARD		3.96(0.40,39.07)	3.58(0.44,28.51)	0.08(-0.06,0.32)
HD CERTO SC + MTX	HD TOFA PO + MTX	0.91(0.26,3.43)	0.92(0.27,3.24)	0.00(-0.07,0.06)
HD INF IV + MTX		1.82(0.52,6.26)	1.76(0.54,5.62)	0.02(-0.04,0.14)
HD TOCI IV + DMARD		3.85(0.42,36.87)	3.47(0.46,26.58)	0.08(-0.07,0.32)
HD INF IV + MTX	HD CERTO SC + MTX	2.00(0.55,6.87)	1.92(0.56,6.22)	0.03(-0.03,0.14)
HD TOCI IV + DMARD		4.22(0.52,38.97)	3.79(0.54,28.18)	0.08(-0.05,0.33)
HD TOCI IV + DMARD	HD INF IV + MTX	2.01(0.26,22.03)	1.88(0.30,16.07)	0.05(-0.13,0.30)
Random-effects model	Residual deviance	128 vs 132 data points		
	Deviance information criteria	641.601		
Fixed-effect model	Residual deviance	131 vs 132 data points		
	Deviance information criteria	641.171		

Note

(Continued)

Total participants	20,850
Total studies	52
2-arm	34
3-arm	11
4-arm	6
7-arm	1

Appendix 19. Withdrawals due to adverse events: subgroup - trial duration (6 to 12 months)
Withdrawals intermediate: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	MTX + PL	1.99(0.58,6.33)	1.91(0.59,5.20)	0.04(-0.02,0.18)
SD ETN SC + MTX		1.43(0.34,6.31)	1.41(0.35,5.26)	0.02(-0.03,0.17)
SD ADA SC + MTX		1.63(0.54,5.06)	1.59(0.55,4.32)	0.03(-0.02,0.14)
SD INF IV + MTX		0.64(0.14,2.88)	0.65(0.15,2.68)	-0.02(-0.04,0.07)
SD RITUX IV + MTX		0.25(0.01,2.63)	0.26(0.01,2.49)	-0.03(-0.05,0.06)
SD TOFA PO + MTX		1.74(0.56,5.52)	1.69(0.57,4.65)	0.03(-0.02,0.16)
LD ETN SC		1.78(0.58,6.22)	1.72(0.59,5.12)	0.03(-0.02,0.17)
LD RITUX IV + MTX		1.89(0.36,12.55)	1.82(0.37,8.63)	0.04(-0.03,0.29)
LD ETN SC + MTX		0.76(0.13,3.84)	0.77(0.14,3.46)	-0.01(-0.04,0.10)
HD INF IV + MTX		0.51(0.10,2.39)	0.52(0.10,2.26)	-0.02(-0.05,0.05)
HD TOFA PO + MTX		1.23(0.38,3.95)	1.22(0.39,3.52)	0.01(-0.03,0.11)
SD ETN SC + MTX	SD ETN SC	0.73(0.12,4.66)	0.75(0.14,4.02)	-0.02(-0.17,0.13)
SD ADA SC + MTX		0.81(0.18,4.57)	0.82(0.21,3.97)	-0.01(-0.15,0.12)
SD INF IV + MTX		0.32(0.05,2.28)	0.34(0.06,2.14)	-0.05(-0.19,0.05)
SD RITUX IV + MTX		0.13(0.00,1.87)	0.14(0.00,1.79)	-0.07(-0.21,0.03)
SD TOFA PO + MTX		0.87(0.18,4.77)	0.88(0.21,4.08)	-0.01(-0.15,0.13)
LD ETN SC		0.90(0.37,2.59)	0.91(0.41,2.36)	-0.01(-0.09,0.08)

(Continued)

LD RITUX IV + MTX		0.95(0.12,8.78)	0.96(0.15,6.44)	0.00(-0.16,0.25)
LD ETN SC + MTX		0.38(0.05,2.81)	0.40(0.06,2.58)	-0.05(-0.19,0.07)
HD INF IV + MTX		0.25(0.04,1.89)	0.27(0.04,1.81)	-0.06(-0.20,0.03)
HD TOFA PO + MTX		0.61(0.12,3.45)	0.63(0.15,3.12)	-0.03(-0.17,0.08)
SD ADA SC + MTX	SD ETN SC + MTX	1.14(0.18,7.31)	1.13(0.21,6.24)	0.01(-0.15,0.13)
SD INF IV + MTX		0.45(0.06,3.66)	0.47(0.07,3.37)	-0.03(-0.18,0.06)
SD RITUX IV + MTX		0.17(0.00,2.77)	0.18(0.00,2.60)	-0.05(-0.19,0.05)
SD TOFA PO + MTX		1.23(0.19,7.83)	1.22(0.22,6.65)	0.01(-0.14,0.14)
LD ETN SC		1.25(0.21,8.21)	1.23(0.24,6.99)	0.01(-0.14,0.16)
LD RITUX IV + MTX		1.33(0.14,14.20)	1.30(0.16,10.48)	0.02(-0.14,0.27)
LD ETN SC + MTX		0.53(0.10,2.49)	0.55(0.12,2.37)	-0.03(-0.14,0.05)
HD INF IV + MTX		0.36(0.04,2.95)	0.37(0.05,2.81)	-0.04(-0.18,0.04)
HD TOFA PO + MTX		0.88(0.13,5.64)	0.88(0.15,5.03)	-0.01(-0.16,0.10)
SD INF IV + MTX	SD ADA SC + MTX	0.39(0.06,2.49)	0.41(0.07,2.33)	-0.04(-0.16,0.05)
SD RITUX IV + MTX		0.15(0.00,2.02)	0.16(0.00,1.92)	-0.06(-0.17,0.04)
SD TOFA PO + MTX		1.08(0.21,5.10)	1.07(0.24,4.39)	0.00(-0.12,0.13)
LD ETN SC		1.10(0.22,5.67)	1.09(0.26,4.78)	0.01(-0.12,0.15)
LD RITUX IV + MTX		1.17(0.16,10.34)	1.15(0.18,7.56)	0.01(-0.12,0.27)
LD ETN SC + MTX		0.46(0.06,3.13)	0.48(0.07,2.86)	-0.03(-0.15,0.08)
HD INF IV + MTX		0.31(0.04,1.93)	0.33(0.05,1.85)	-0.04(-0.16,0.03)
HD TOFA PO + MTX		0.76(0.15,3.56)	0.77(0.17,3.22)	-0.02(-0.14,0.09)
SD RITUX IV + MTX	SD INF IV + MTX	0.38(0.01,6.14)	0.39(0.01,5.73)	-0.02(-0.10,0.07)
SD TOFA PO + MTX		2.74(0.41,17.55)	2.59(0.43,15.01)	0.04(-0.05,0.17)
LD ETN SC		2.78(0.45,19.95)	2.64(0.47,16.66)	0.04(-0.05,0.19)
LD RITUX IV + MTX		2.92(0.32,32.83)	2.74(0.34,24.34)	0.05(-0.05,0.30)
LD ETN SC + MTX		1.20(0.12,10.87)	1.19(0.13,9.61)	0.00(-0.08,0.11)
HD INF IV + MTX		0.79(0.14,3.96)	0.80(0.15,3.80)	-0.01(-0.07,0.05)

(Continued)

HD TOFA PO + MTX		1.94(0.28,12.38)	1.88(0.30,11.03)	0.02(-0.07,0.12)
SD TOFA PO + MTX	SD RITUX IV + MTX	7.15(0.48,331.20)	6.62(0.51,287.70)	0.06(-0.04,0.19)
LD ETN SC		7.24(0.50,284.80)	6.67(0.53,240.60)	0.06(-0.04,0.20)
LD RITUX IV + MTX		7.53(0.85,282.10)	6.80(0.86,238.80)	0.06(-0.01,0.28)
LD ETN SC + MTX		3.23(0.15,137.40)	3.13(0.16,122.50)	0.02(-0.07,0.13)
HD INF IV + MTX		2.10(0.12,91.78)	2.07(0.13,86.53)	0.01(-0.08,0.08)
HD TOFA PO + MTX		4.97(0.34,226.00)	4.73(0.36,203.00)	0.04(-0.05,0.14)
LD ETN SC	SD TOFA PO + MTX	1.03(0.21,5.39)	1.03(0.24,4.59)	0.00(-0.13,0.15)
LD RITUX IV + MTX		1.08(0.14,10.04)	1.08(0.16,7.20)	0.01(-0.14,0.27)
LD ETN SC + MTX		0.43(0.06,3.17)	0.45(0.07,2.90)	-0.04(-0.17,0.08)
HD INF IV + MTX		0.29(0.04,1.99)	0.30(0.04,1.91)	-0.05(-0.18,0.04)
HD TOFA PO + MTX		0.71(0.24,1.98)	0.72(0.27,1.87)	-0.02(-0.11,0.04)
LD RITUX IV + MTX	LD ETN SC	1.04(0.13,9.29)	1.03(0.15,6.80)	0.00(-0.15,0.26)
LD ETN SC + MTX		0.42(0.05,3.01)	0.44(0.06,2.74)	-0.04(-0.18,0.07)
HD INF IV + MTX		0.28(0.04,1.94)	0.30(0.04,1.86)	-0.05(-0.19,0.03)
HD TOFA PO + MTX		0.69(0.12,3.47)	0.71(0.15,3.16)	-0.02(-0.17,0.08)
LD ETN SC + MTX	LD RITUX IV + MTX	0.40(0.03,4.13)	0.43(0.04,3.79)	-0.04(-0.30,0.08)
HD INF IV + MTX		0.27(0.02,2.52)	0.29(0.03,2.40)	-0.05(-0.31,0.04)
HD TOFA PO + MTX		0.65(0.07,5.02)	0.67(0.09,4.56)	-0.03(-0.28,0.09)
HD INF IV + MTX	LD ETN SC + MTX	0.68(0.07,6.41)	0.69(0.08,5.95)	-0.01(-0.12,0.06)
HD TOFA PO + MTX		1.63(0.22,12.55)	1.59(0.24,11.11)	0.02(-0.09,0.12)
HD TOFA PO + MTX	HD INF IV + MTX	2.48(0.35,17.87)	2.39(0.37,15.96)	0.03(-0.05,0.13)
Random-effects model	Residual deviance	19.23 vs 19 data points		
	Deviance information criteria	109.73		

(Continued)

Fixed-effect model	Residual deviance	19.57 vs 19 data points
	Deviance information criteria	109.933
Note		
Total participants	3279	
Total studies	7	
2-arm	2	
3-arm	5	

Appendix 20. Serious adverse events: main analysis

SAE: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	1.32(0.38,6.19)	1.30(0.39,5.23)	0.01(-0.03,0.15)
DMARD		0.63(0.20,2.49)	0.63(0.21,2.37)	-0.01(-0.04,0.05)
MTX + DMARD		0.74(0.14,4.06)	0.75(0.14,3.67)	-0.01(-0.04,0.09)
SD ETN SC		1.55(0.50,6.08)	1.52(0.51,5.18)	0.02(-0.02,0.14)
SD ADA SC		1.08(0.66,1.94)	1.08(0.67,1.88)	0.00(-0.01,0.03)
SD TOCI IV		1.22(0.47,3.38)	1.21(0.48,3.10)	0.01(-0.02,0.08)
SD TOFA PO		0.38(0.15,0.93)	0.39(0.15,0.94)	-0.02(-0.04,0.00)
SD TOCI SC		1.07(0.33,3.70)	1.07(0.34,3.39)	0.00(-0.03,0.09)
SD CERTO SC		4.67(1.33,19.91)	4.11(1.31,12.87)	0.11(0.01,0.35)
SD GOLII IV		1.46(0.17,14.63)	1.43(0.18,9.91)	0.01(-0.03,0.32)
SD RITUX IV		0.55(0.07,5.11)	0.56(0.07,4.50)	-0.01(-0.04,0.13)
SD INF IV + MTX		1.16(0.31,5.32)	1.15(0.32,4.67)	0.01(-0.03,0.13)
SD ETN SC + MTX		1.28(0.34,5.50)	1.27(0.35,4.80)	0.01(-0.03,0.14)
SD ADA SC + MTX		1.20(0.34,5.99)	1.19(0.35,5.12)	0.01(-0.03,0.14)

(Continued)

SD ABA IV + MTX	1.07(0.30,4.66)	1.06(0.30,4.17)	0.00(-0.03,0.11)
SD RITUX IV + MTX	1.43(0.37,7.39)	1.40(0.38,6.09)	0.01(-0.03,0.17)
SD ABA SC + MTX	0.89(0.24,4.28)	0.89(0.25,3.87)	0.00(-0.03,0.10)
SD GOL I SC + MTX	2.75(0.52,20.39)	2.58(0.53,12.10)	0.06(-0.02,0.39)
SD CERTO SC + MTX	2.02(0.54,11.76)	1.94(0.55,8.55)	0.03(-0.02,0.26)
SD TOFA PO + MTX	2.59(0.63,14.30)	2.44(0.64,9.80)	0.05(-0.01,0.31)
SD GOL I IV + MTX	4.39(0.59,34.27)	3.89(0.60,16.03)	0.10(-0.01,0.53)
SD ANA SC + MTX	1.80(0.35,12.98)	1.75(0.36,9.03)	0.03(-0.02,0.28)
SD ETN SC + DMARD	1.28(0.44,4.62)	1.26(0.45,4.11)	0.01(-0.02,0.10)
SD ABA IV + DMARD	0.67(0.18,2.94)	0.68(0.19,2.77)	-0.01(-0.04,0.06)
SD ADA SC + DMARD	0.45(0.10,2.35)	0.46(0.11,2.25)	-0.02(-0.04,0.04)
SD ANA + DMARD	0.64(0.17,2.85)	0.65(0.17,2.67)	-0.01(-0.04,0.06)
SD CERTO SC + DMARD	0.44(0.08,2.73)	0.45(0.08,2.57)	-0.02(-0.04,0.06)
SD TOCI SC + DMARD	0.81(0.18,4.36)	0.81(0.19,3.89)	-0.01(-0.04,0.10)
LD ADA SC	0.64(0.30,1.38)	0.65(0.30,1.36)	-0.01(-0.03,0.01)
LD ETN SC	0.99(0.21,5.85)	0.99(0.22,5.04)	0.00(-0.04,0.14)
LD GOL I IV	6.90(1.23,55.27)	5.64(1.22,19.92)	0.17(0.01,0.64)
LD RITUX IV + MTX	1.23(0.31,6.12)	1.22(0.31,5.22)	0.01(-0.03,0.15)
LD ABA IV + MTX	1.67(0.38,8.47)	1.63(0.39,6.78)	0.02(-0.02,0.20)
LD CERTO SC + MTX	2.27(0.26,18.03)	2.16(0.26,11.59)	0.04(-0.03,0.36)
LD ETN SC + MTX	0.64(0.13,3.60)	0.65(0.13,3.31)	-0.01(-0.04,0.08)
LD GOL I IV + MTX	3.95(0.66,32.35)	3.55(0.67,15.74)	0.09(-0.01,0.51)
HD TOCI IV	1.24(0.34,5.83)	1.23(0.35,5.01)	0.01(-0.03,0.14)
HD TOFA PO	0.52(0.23,1.24)	0.53(0.24,1.23)	-0.02(-0.04,0.01)
HD GOL I SC	1.78(0.34,12.98)	1.73(0.35,9.30)	0.03(-0.03,0.28)
HD ADA SC	0.96(0.48,2.09)	0.96(0.49,2.02)	0.00(-0.02,0.03)
HD GOL I SC + MTX	3.85(0.63,25.39)	3.49(0.64,14.17)	0.09(-0.01,0.44)
HD TOCI IV + MTX	1.44(0.34,7.89)	1.42(0.35,6.47)	0.01(-0.03,0.19)

(Continued)

HD TOFA PO + MTX		2.11(0.52,12.09)	2.02(0.53,8.78)	0.04(-0.02,0.27)
HD INF IV + MTX		1.37(0.35,6.87)	1.36(0.35,5.76)	0.01(-0.03,0.17)
HD CERTO SC + MTX		2.54(0.59,16.81)	2.40(0.60,10.92)	0.05(-0.02,0.34)
HD TOCI IV + DMARD		0.95(0.27,3.95)	0.96(0.28,3.57)	0.00(-0.03,0.09)
DMARD	MTX	0.46(0.20,1.02)	0.47(0.22,1.02)	-0.02(-0.12,0.00)
MTX + DMARD		0.55(0.14,1.81)	0.57(0.15,1.76)	-0.02(-0.12,0.03)
SD ETN SC		1.14(0.58,2.31)	1.13(0.60,2.23)	0.01(-0.05,0.05)
SD ADA SC		0.82(0.19,2.78)	0.82(0.22,2.69)	-0.01(-0.14,0.03)
SD TOCI IV		0.88(0.19,4.16)	0.88(0.21,3.92)	-0.01(-0.13,0.06)
SD TOFA PO		0.29(0.05,1.22)	0.30(0.06,1.22)	-0.03(-0.17,0.00)
SD TOCI SC		0.77(0.14,4.64)	0.78(0.16,4.27)	-0.01(-0.13,0.08)
SD CERTO SC		3.34(0.45,28.48)	2.98(0.49,19.53)	0.09(-0.07,0.34)
SD GOLI IV		1.04(0.13,7.94)	1.04(0.14,6.09)	0.00(-0.09,0.25)
SD RITUX IV		0.42(0.07,1.90)	0.44(0.08,1.80)	-0.02(-0.11,0.05)
SD INF IV + MTX		0.89(0.55,1.34)	0.89(0.57,1.31)	0.00(-0.04,0.02)
SD ETN SC + MTX		0.97(0.43,1.95)	0.97(0.46,1.86)	0.00(-0.06,0.05)
SD ADA SC + MTX		0.92(0.48,1.67)	0.92(0.50,1.61)	0.00(-0.05,0.04)
SD ABA IV + MTX		0.80(0.51,1.20)	0.81(0.53,1.19)	-0.01(-0.05,0.01)
SD RITUX IV + MTX		1.05(0.65,1.79)	1.05(0.66,1.70)	0.00(-0.03,0.05)
SD ABA SC + MTX		0.68(0.36,1.20)	0.69(0.37,1.18)	-0.01(-0.07,0.01)
SD GOLI SC + MTX		1.99(0.68,6.54)	1.87(0.69,5.14)	0.04(-0.02,0.28)
SD CERTO SC + MTX		1.55(0.91,2.73)	1.50(0.91,2.47)	0.02(0.00,0.13)
SD TOFA PO + MTX		1.93(0.88,4.43)	1.83(0.89,3.79)	0.04(-0.01,0.20)
SD GOLI IV + MTX		3.06(0.54,19.59)	2.68(0.55,12.28)	0.08(-0.03,0.45)
SD ANA SC + MTX		1.32(0.45,4.19)	1.30(0.46,3.53)	0.01(-0.04,0.18)
SD ETN SC + DMARD		0.93(0.39,2.13)	0.94(0.42,2.07)	0.00(-0.08,0.04)
SD ABA IV + DMARD		0.49(0.18,1.33)	0.51(0.19,1.31)	-0.02(-0.12,0.01)
SD ADA SC + DMARD		0.33(0.09,1.06)	0.34(0.10,1.06)	-0.03(-0.13,0.00)

(Continued)

SD ANA + DMARD		0.47(0.15,1.31)	0.48(0.16,1.29)	-0.02(-0.12,0.01)
SD CERTO SC + DMARD		0.32(0.06,1.43)	0.33(0.07,1.40)	-0.03(-0.14,0.02)
SD TOCI SC + DMARD		0.61(0.16,2.08)	0.62(0.17,1.99)	-0.02(-0.11,0.05)
LD ADA SC		0.46(0.09,2.07)	0.48(0.11,2.04)	-0.02(-0.16,0.02)
LD ETN SC		0.75(0.28,2.04)	0.76(0.30,1.93)	-0.01(-0.08,0.05)
LD GOLIV IV		5.07(0.99,30.48)	3.97(0.99,15.67)	0.15(0.00,0.57)
LD RITUX IV + MTX		0.90(0.55,1.57)	0.91(0.56,1.52)	0.00(-0.04,0.04)
LD ABA IV + MTX		1.23(0.56,2.58)	1.21(0.58,2.38)	0.01(-0.03,0.10)
LD CERTO SC + MTX		1.57(0.36,6.28)	1.51(0.37,4.91)	0.02(-0.05,0.27)
LD ETN SC + MTX		0.48(0.16,1.34)	0.49(0.17,1.31)	-0.02(-0.10,0.01)
LD GOLIV IV + MTX		2.88(0.52,16.55)	2.56(0.54,11.00)	0.07(-0.03,0.43)
HD TOCI IV		0.91(0.44,1.90)	0.91(0.46,1.82)	0.00(-0.06,0.05)
HD TOFA PO		0.39(0.07,1.82)	0.41(0.08,1.80)	-0.03(-0.17,0.01)
HD GOLIV SC		1.30(0.36,4.60)	1.28(0.37,3.89)	0.01(-0.05,0.19)
HD ADA SC		0.73(0.16,2.78)	0.74(0.18,2.69)	-0.01(-0.14,0.03)
HD GOLIV SC + MTX		2.77(0.98,8.62)	2.48(0.99,6.04)	0.07(0.00,0.34)
HD TOCI IV + MTX		1.04(0.41,2.80)	1.04(0.43,2.56)	0.00(-0.05,0.10)
HD TOFA PO + MTX		1.62(0.71,3.71)	1.56(0.73,3.23)	0.02(-0.02,0.16)
HD INF IV + MTX		1.03(0.59,1.77)	1.03(0.60,1.68)	0.00(-0.03,0.05)
HD CERTO SC + MTX		1.90(0.89,4.37)	1.80(0.90,3.55)	0.04(0.00,0.22)
HD TOCI IV + DMARD		0.69(0.26,1.84)	0.71(0.28,1.79)	-0.01(-0.10,0.03)
MTX + DMARD	DMARD	1.23(0.26,4.52)	1.23(0.27,4.20)	0.00(-0.03,0.08)
SD ETN SC		2.47(1.21,5.34)	2.38(1.20,4.94)	0.03(0.01,0.11)
SD ADA SC		1.75(0.48,5.24)	1.72(0.50,5.03)	0.02(-0.04,0.05)
SD TOCI IV		1.88(0.43,7.81)	1.83(0.45,7.34)	0.02(-0.04,0.09)
SD TOFA PO		0.61(0.11,2.37)	0.62(0.12,2.34)	-0.01(-0.07,0.01)
SD TOCI SC		1.67(0.34,8.83)	1.64(0.35,8.08)	0.01(-0.04,0.10)
SD CERTO SC		7.36(1.10,47.68)	6.36(1.09,33.14)	0.12(0.00,0.36)

(Continued)

SD GOLII IV	2.34(0.26,17.59)	2.25(0.27,13.34)	0.03(-0.03,0.31)
SD RITUX IV	0.93(0.13,5.38)	0.93(0.13,4.80)	0.00(-0.04,0.12)
SD INF IV + MTX	1.91(0.78,4.86)	1.87(0.79,4.43)	0.02(-0.01,0.11)
SD ETN SC + MTX	2.10(0.75,5.64)	2.04(0.76,5.14)	0.02(-0.01,0.12)
SD ADA SC + MTX	1.97(0.74,5.38)	1.92(0.75,4.85)	0.02(-0.01,0.12)
SD ABA IV + MTX	1.73(0.72,4.31)	1.69(0.73,4.00)	0.01(-0.01,0.09)
SD RITUX IV + MTX	2.27(0.89,6.25)	2.19(0.90,5.56)	0.03(0.00,0.15)
SD ABA SC + MTX	1.47(0.55,3.88)	1.45(0.56,3.61)	0.01(-0.02,0.08)
SD GOLII SC + MTX	4.31(1.18,18.62)	3.93(1.17,13.56)	0.07(0.00,0.37)
SD CERTO SC + MTX	3.40(1.24,9.31)	3.18(1.23,7.77)	0.05(0.00,0.23)
SD TOFA PO + MTX	4.19(1.43,12.67)	3.83(1.41,10.16)	0.06(0.01,0.29)
SD GOLII IV + MTX	6.65(1.04,48.72)	5.71(1.04,29.61)	0.11(0.00,0.52)
SD ANA SC + MTX	2.83(0.75,12.17)	2.70(0.76,9.57)	0.04(-0.01,0.27)
SD ETN SC + DMARD	2.01(1.07,3.92)	1.95(1.07,3.73)	0.02(0.00,0.08)
SD ABA IV + DMARD	1.06(0.58,1.94)	1.06(0.59,1.88)	0.00(-0.02,0.03)
SD ADA SC + DMARD	0.70(0.30,1.67)	0.70(0.31,1.64)	-0.01(-0.03,0.02)
SD ANA + DMARD	1.00(0.50,2.08)	1.00(0.50,2.00)	0.00(-0.02,0.03)
SD CERTO SC + DMARD	0.69(0.18,2.56)	0.69(0.18,2.44)	-0.01(-0.04,0.04)
SD TOCI SC + DMARD	1.28(0.48,3.49)	1.27(0.49,3.26)	0.01(-0.02,0.08)
LD ADA SC	1.00(0.22,3.79)	1.00(0.24,3.68)	0.00(-0.06,0.03)
LD ETN SC	1.61(0.52,5.00)	1.58(0.53,4.49)	0.01(-0.02,0.12)
LD GOLII IV	10.93(1.79,72.89)	8.52(1.74,36.66)	0.18(0.02,0.63)
LD RITUX IV + MTX	1.93(0.77,5.40)	1.88(0.77,4.86)	0.02(-0.01,0.12)
LD ABA IV + MTX	2.66(0.90,8.38)	2.54(0.90,7.24)	0.03(0.00,0.18)
LD CERTO SC + MTX	3.33(0.61,18.14)	3.11(0.61,12.90)	0.05(-0.01,0.34)
LD ETN SC + MTX	1.05(0.27,3.72)	1.05(0.28,3.53)	0.00(-0.03,0.07)
LD GOLII IV + MTX	6.26(0.97,42.72)	5.46(0.97,25.22)	0.10(0.00,0.50)
HD TOCI IV	1.95(1.00,4.21)	1.90(1.00,3.89)	0.02(0.00,0.11)

(Continued)

HD TOFA PO		0.83(0.18,3.68)	0.83(0.19,3.60)	0.00(-0.06,0.02)
HD GOLI SC		2.76(0.71,12.48)	2.62(0.72,9.84)	0.04(-0.01,0.26)
HD ADA SC		1.56(0.38,5.47)	1.54(0.40,5.21)	0.01(-0.04,0.05)
HD GOLI SC + MTX		6.03(1.61,24.27)	5.27(1.58,16.49)	0.10(0.01,0.42)
HD TOCI IV + MTX		2.25(0.85,6.67)	2.18(0.85,5.70)	0.03(0.00,0.16)
HD TOFA PO + MTX		3.49(1.15,10.74)	3.26(1.14,8.78)	0.05(0.00,0.25)
HD INF IV + MTX		2.21(0.84,6.17)	2.14(0.84,5.57)	0.02(0.00,0.14)
HD CERTO SC + MTX		4.14(1.31,13.83)	3.79(1.30,10.42)	0.06(0.01,0.32)
HD TOCI IV + DMARD		1.51(0.87,2.64)	1.49(0.88,2.52)	0.01(0.00,0.06)
SD ETN SC	MTX + DMARD	2.07(0.61,8.51)	1.99(0.63,7.91)	0.02(-0.03,0.11)
SD ADA SC		1.45(0.29,7.77)	1.44(0.32,7.46)	0.01(-0.09,0.05)
SD TOCI IV		1.62(0.28,9.88)	1.59(0.30,9.28)	0.01(-0.08,0.08)
SD TOFA PO		0.51(0.07,3.22)	0.52(0.08,3.17)	-0.01(-0.12,0.02)
SD TOCI SC		1.41(0.22,10.26)	1.39(0.23,9.55)	0.01(-0.09,0.09)
SD CERTO SC		6.03(0.71,62.12)	5.22(0.74,44.98)	0.11(-0.03,0.35)
SD GOLI IV		1.88(0.17,22.71)	1.82(0.18,17.86)	0.02(-0.06,0.30)
SD RITUX IV		0.77(0.09,5.73)	0.78(0.10,5.25)	0.00(-0.08,0.11)
SD INF IV + MTX		1.59(0.48,6.58)	1.56(0.50,6.12)	0.01(-0.04,0.10)
SD ETN SC + MTX		1.72(0.66,5.48)	1.68(0.67,5.18)	0.02(-0.02,0.09)
SD ADA SC + MTX		1.64(0.46,7.91)	1.61(0.48,7.20)	0.01(-0.04,0.12)
SD ABA IV + MTX		1.44(0.41,6.00)	1.41(0.42,5.69)	0.01(-0.05,0.09)
SD RITUX IV + MTX		1.89(0.55,8.74)	1.83(0.57,8.00)	0.02(-0.03,0.14)
SD ABA SC + MTX		1.21(0.32,5.57)	1.20(0.34,5.24)	0.00(-0.06,0.08)
SD GOLI SC + MTX		3.67(0.71,22.21)	3.33(0.73,17.24)	0.06(-0.01,0.35)
SD CERTO SC + MTX		2.81(0.73,13.04)	2.64(0.76,11.29)	0.04(-0.01,0.23)
SD TOFA PO + MTX		3.53(0.79,17.73)	3.23(0.80,14.86)	0.06(-0.01,0.28)
SD GOLI IV + MTX		5.66(0.71,56.08)	4.81(0.73,34.07)	0.10(-0.02,0.51)
SD ANA SC + MTX		2.41(0.48,13.72)	2.29(0.50,11.11)	0.03(-0.03,0.24)

(Continued)

SD ETN SC + DMARD	1.65(0.44,7.67)	1.62(0.46,7.31)	0.01(-0.05,0.08)
SD ABA IV + DMARD	0.87(0.20,4.57)	0.87(0.21,4.41)	0.00(-0.08,0.05)
SD ADA SC + DMARD	0.59(0.11,3.41)	0.60(0.12,3.35)	-0.01(-0.10,0.03)
SD ANA + DMARD	0.82(0.19,4.49)	0.83(0.20,4.36)	0.00(-0.08,0.05)
SD CERTO SC + DMARD	0.59(0.08,4.47)	0.60(0.09,4.23)	-0.01(-0.10,0.05)
SD TOCI SC + DMARD	1.08(0.20,6.42)	1.08(0.21,5.99)	0.00(-0.08,0.08)
LD ADA SC	0.85(0.14,5.65)	0.85(0.16,5.47)	0.00(-0.10,0.03)
LD ETN SC	1.39(0.28,6.71)	1.36(0.30,6.18)	0.01(-0.06,0.11)
LD GOL I IV	8.93(1.27,83.42)	6.96(1.25,44.05)	0.17(0.01,0.62)
LD RITUX IV + MTX	1.63(0.44,7.33)	1.59(0.46,6.82)	0.01(-0.04,0.12)
LD ABA IV + MTX	2.25(0.55,10.90)	2.16(0.57,9.69)	0.03(-0.03,0.17)
LD CERTO SC + MTX	2.90(0.38,20.52)	2.72(0.39,15.39)	0.04(-0.03,0.34)
LD ETN SC + MTX	0.86(0.20,4.02)	0.87(0.21,3.83)	0.00(-0.07,0.06)
LD GOL I IV + MTX	5.16(0.64,51.52)	4.50(0.66,31.65)	0.09(-0.02,0.49)
HD TOCI IV	1.62(0.43,7.95)	1.59(0.45,7.35)	0.01(-0.05,0.11)
HD TOFA PO	0.71(0.11,4.62)	0.72(0.12,4.56)	-0.01(-0.11,0.03)
HD GOL I SC	2.32(0.42,14.31)	2.22(0.44,11.65)	0.03(-0.04,0.25)
HD ADA SC	1.27(0.23,7.35)	1.26(0.25,7.04)	0.01(-0.09,0.05)
HD GOL I SC + MTX	5.02(1.02,28.62)	4.36(1.02,20.17)	0.09(0.00,0.40)
HD TOCI IV + MTX	1.89(0.46,10.81)	1.83(0.48,9.52)	0.02(-0.04,0.16)
HD TOFA PO + MTX	2.94(0.63,15.21)	2.76(0.65,12.87)	0.04(-0.02,0.24)
HD INF IV + MTX	1.84(0.52,8.32)	1.79(0.54,7.66)	0.02(-0.03,0.13)
HD CERTO SC + MTX	3.39(0.85,17.96)	3.11(0.86,14.44)	0.05(-0.01,0.31)
HD TOCI IV + DMARD	1.26(0.29,6.68)	1.25(0.31,6.34)	0.01(-0.07,0.07)
SD ADA SC	SD ETN SC 0.70(0.20,2.02)	0.71(0.24,1.98)	-0.02(-0.13,0.02)
SD TOCI IV	0.77(0.19,2.97)	0.78(0.21,2.82)	-0.01(-0.12,0.06)
SD TOFA PO	0.25(0.05,0.90)	0.26(0.06,0.90)	-0.04(-0.16,0.00)
SD TOCI SC	0.68(0.14,3.30)	0.69(0.16,3.04)	-0.02(-0.13,0.07)

(Continued)

SD CERTO SC	3.00(0.44,17.80)	2.69(0.49,12.42)	0.09(-0.07,0.33)
SD GOLI IV	0.95(0.11,6.84)	0.96(0.12,5.27)	0.00(-0.09,0.25)
SD RITUX IV	0.37(0.05,2.05)	0.39(0.06,1.91)	-0.03(-0.11,0.06)
SD INF IV + MTX	0.77(0.34,1.74)	0.78(0.35,1.66)	-0.01(-0.07,0.04)
SD ETN SC + MTX	0.84(0.35,1.88)	0.85(0.37,1.77)	-0.01(-0.06,0.05)
SD ADA SC + MTX	0.79(0.33,1.98)	0.80(0.35,1.86)	-0.01(-0.06,0.06)
SD ABA IV + MTX	0.69(0.32,1.55)	0.70(0.33,1.50)	-0.01(-0.07,0.03)
SD RITUX IV + MTX	0.92(0.39,2.26)	0.93(0.40,2.09)	0.00(-0.05,0.08)
SD ABA SC + MTX	0.58(0.25,1.43)	0.60(0.26,1.40)	-0.02(-0.08,0.02)
SD GOLI SC + MTX	1.73(0.50,6.33)	1.64(0.51,4.73)	0.03(-0.03,0.29)
SD CERTO SC + MTX	1.36(0.57,3.20)	1.33(0.58,2.78)	0.02(-0.03,0.15)
SD TOFA PO + MTX	1.66(0.63,4.87)	1.59(0.64,4.06)	0.03(-0.03,0.22)
SD GOLI IV + MTX	2.73(0.45,18.38)	2.42(0.46,10.85)	0.08(-0.04,0.46)
SD ANA SC + MTX	1.15(0.32,4.39)	1.14(0.34,3.61)	0.01(-0.06,0.20)
SD ETN SC + DMARD	0.80(0.41,1.58)	0.81(0.43,1.54)	-0.01(-0.07,0.03)
SD ABA IV + DMARD	0.43(0.16,1.06)	0.44(0.18,1.06)	-0.03(-0.11,0.00)
SD ADA SC + DMARD	0.28(0.09,0.87)	0.30(0.09,0.88)	-0.04(-0.13,0.00)
SD ANA + DMARD	0.41(0.14,1.06)	0.42(0.15,1.06)	-0.03(-0.12,0.00)
SD CERTO SC + DMARD	0.28(0.06,1.17)	0.30(0.06,1.15)	-0.03(-0.13,0.01)
SD TOCI SC + DMARD	0.51(0.15,1.80)	0.53(0.16,1.71)	-0.02(-0.11,0.04)
LD ADA SC	0.41(0.10,1.42)	0.42(0.11,1.41)	-0.03(-0.15,0.01)
LD ETN SC	0.65(0.24,1.75)	0.67(0.25,1.66)	-0.02(-0.07,0.05)
LD GOLI IV	4.37(0.83,26.03)	3.51(0.84,13.41)	0.14(-0.01,0.56)
LD RITUX IV + MTX	0.79(0.32,1.93)	0.80(0.34,1.82)	-0.01(-0.06,0.06)
LD ABA IV + MTX	1.07(0.38,2.98)	1.06(0.40,2.63)	0.00(-0.05,0.12)
LD CERTO SC + MTX	1.36(0.26,6.57)	1.33(0.27,4.86)	0.02(-0.06,0.27)
LD ETN SC + MTX	0.42(0.12,1.33)	0.44(0.13,1.30)	-0.03(-0.10,0.02)
LD GOLI IV + MTX	2.56(0.41,15.02)	2.32(0.43,9.33)	0.07(-0.04,0.44)

(Continued)

HD TOCI IV		0.79(0.34,1.92)	0.80(0.35,1.82)	-0.01(-0.07,0.05)
HD TOFA PO		0.33(0.07,1.28)	0.35(0.09,1.27)	-0.03(-0.16,0.01)
HD GOLI SC		1.13(0.28,4.72)	1.12(0.30,3.82)	0.01(-0.06,0.19)
HD ADA SC		0.61(0.16,2.11)	0.63(0.18,2.06)	-0.02(-0.14,0.03)
HD GOLI SC + MTX		2.49(0.69,8.84)	2.26(0.70,6.11)	0.06(-0.02,0.35)
HD TOCI IV + MTX		0.91(0.31,2.82)	0.92(0.33,2.53)	0.00(-0.06,0.11)
HD TOFA PO + MTX		1.36(0.50,4.12)	1.33(0.52,3.53)	0.02(-0.04,0.18)
HD INF IV + MTX		0.89(0.36,2.23)	0.89(0.37,2.07)	-0.01(-0.06,0.08)
HD CERTO SC + MTX		1.65(0.59,4.87)	1.58(0.60,3.85)	0.03(-0.02,0.24)
HD TOCI IV + DMARD		0.62(0.24,1.47)	0.63(0.25,1.43)	-0.02(-0.09,0.02)
SD TOCI IV	SD ADA SC	1.11(0.50,2.57)	1.11(0.51,2.40)	0.00(-0.02,0.06)
SD TOFA PO		0.35(0.12,0.97)	0.36(0.12,0.97)	-0.02(-0.06,0.00)
SD TOCI SC		0.98(0.34,2.96)	0.98(0.35,2.75)	0.00(-0.03,0.07)
SD CERTO SC		4.27(1.05,18.66)	3.78(1.05,12.53)	0.11(0.00,0.34)
SD GOLI IV		1.32(0.15,13.23)	1.30(0.16,9.17)	0.01(-0.04,0.31)
SD RITUX IV		0.51(0.06,4.56)	0.52(0.07,4.00)	-0.02(-0.05,0.12)
SD INF IV + MTX		1.09(0.29,4.61)	1.08(0.30,4.07)	0.00(-0.03,0.12)
SD ETN SC + MTX		1.18(0.32,4.97)	1.17(0.33,4.34)	0.01(-0.03,0.13)
SD ADA SC + MTX		1.12(0.31,5.13)	1.12(0.32,4.44)	0.00(-0.04,0.14)
SD ABA IV + MTX		0.98(0.27,3.98)	0.98(0.28,3.60)	0.00(-0.04,0.10)
SD RITUX IV + MTX		1.33(0.34,6.06)	1.31(0.35,5.04)	0.01(-0.03,0.16)
SD ABA SC + MTX		0.83(0.22,3.65)	0.84(0.23,3.33)	-0.01(-0.04,0.09)
SD GOLI SC + MTX		2.57(0.47,17.20)	2.42(0.48,10.44)	0.05(-0.02,0.38)
SD CERTO SC + MTX		1.89(0.50,9.64)	1.82(0.51,7.22)	0.03(-0.02,0.25)
SD TOFA PO + MTX		2.38(0.62,11.91)	2.25(0.64,8.45)	0.05(-0.02,0.30)
SD GOLI IV + MTX		4.04(0.52,33.18)	3.59(0.54,15.66)	0.10(-0.02,0.53)
SD ANA SC + MTX		1.65(0.33,10.63)	1.61(0.34,7.73)	0.02(-0.03,0.27)
SD ETN SC + DMARD		1.17(0.41,3.76)	1.16(0.42,3.42)	0.01(-0.03,0.10)

(Continued)

SD ABA IV + DMARD	0.61(0.17,2.53)	0.62(0.18,2.40)	-0.01(-0.05,0.05)
SD ADA SC + DMARD	0.41(0.10,2.04)	0.42(0.10,1.96)	-0.02(-0.05,0.04)
SD ANA + DMARD	0.59(0.15,2.47)	0.60(0.16,2.33)	-0.01(-0.05,0.05)
SD CERTO SC + DMARD	0.40(0.07,2.51)	0.41(0.07,2.36)	-0.02(-0.05,0.05)
SD TOCI SC + DMARD	0.73(0.17,3.86)	0.74(0.18,3.45)	-0.01(-0.04,0.10)
LD ADA SC	0.59(0.26,1.29)	0.60(0.27,1.28)	-0.01(-0.04,0.01)
LD ETN SC	0.93(0.20,4.96)	0.93(0.20,4.30)	0.00(-0.04,0.13)
LD GOL I IV	6.29(1.07,49.60)	5.15(1.07,18.65)	0.16(0.00,0.64)
LD RITUX IV + MTX	1.14(0.28,5.13)	1.14(0.29,4.36)	0.01(-0.03,0.14)
LD ABA IV + MTX	1.54(0.36,7.36)	1.51(0.37,6.00)	0.02(-0.03,0.19)
LD CERTO SC + MTX	2.06(0.25,15.74)	1.97(0.25,10.23)	0.04(-0.04,0.35)
LD ETN SC + MTX	0.59(0.12,3.21)	0.60(0.12,2.95)	-0.01(-0.05,0.08)
LD GOL I IV + MTX	3.65(0.56,29.09)	3.29(0.57,14.53)	0.09(-0.02,0.50)
HD TOCI IV	1.13(0.31,4.81)	1.13(0.32,4.20)	0.00(-0.03,0.13)
HD TOFA PO	0.48(0.18,1.33)	0.49(0.18,1.32)	-0.02(-0.05,0.01)
HD GOL I SC	1.68(0.32,10.68)	1.63(0.33,7.71)	0.02(-0.03,0.27)
HD ADA SC	0.89(0.45,1.82)	0.90(0.46,1.77)	0.00(-0.03,0.03)
HD GOL I SC + MTX	3.54(0.62,20.74)	3.20(0.64,11.83)	0.08(-0.01,0.43)
HD TOCI IV + MTX	1.30(0.31,6.77)	1.28(0.32,5.57)	0.01(-0.03,0.18)
HD TOFA PO + MTX	1.98(0.50,10.20)	1.90(0.51,7.58)	0.03(-0.02,0.26)
HD INF IV + MTX	1.27(0.33,5.82)	1.26(0.34,4.91)	0.01(-0.03,0.16)
HD CERTO SC + MTX	2.34(0.56,13.33)	2.22(0.57,9.02)	0.05(-0.02,0.33)
HD TOCI IV + DMARD	0.87(0.25,3.30)	0.88(0.26,3.04)	0.00(-0.04,0.08)
SD TOFA PO	SD TOCI IV 0.31(0.08,1.15)	0.32(0.08,1.15)	-0.03(-0.10,0.00)
SD TOCI SC	0.88(0.44,1.81)	0.89(0.45,1.73)	0.00(-0.04,0.04)
SD CERTO SC	3.92(0.73,21.61)	3.45(0.75,15.00)	0.10(-0.02,0.34)
SD GOL I IV	1.16(0.11,13.04)	1.15(0.12,9.53)	0.01(-0.08,0.30)
SD RITUX IV	0.45(0.05,4.54)	0.46(0.06,4.04)	-0.02(-0.09,0.11)

(Continued)

SD INF IV + MTX	1.01(0.21,4.72)	1.01(0.22,4.24)	0.00(-0.07,0.11)
SD ETN SC + MTX	1.07(0.24,5.27)	1.06(0.25,4.66)	0.00(-0.07,0.12)
SD ADA SC + MTX	1.05(0.22,5.40)	1.05(0.23,4.74)	0.00(-0.07,0.13)
SD ABA IV + MTX	0.92(0.19,4.16)	0.93(0.20,3.80)	0.00(-0.07,0.09)
SD RITUX IV + MTX	1.21(0.24,6.23)	1.19(0.26,5.32)	0.01(-0.06,0.15)
SD ABA SC + MTX	0.78(0.15,3.75)	0.79(0.16,3.46)	-0.01(-0.08,0.08)
SD GOLI SC + MTX	2.31(0.36,17.01)	2.18(0.38,11.04)	0.05(-0.05,0.37)
SD CERTO SC + MTX	1.72(0.34,9.55)	1.67(0.36,7.47)	0.03(-0.05,0.24)
SD TOFA PO + MTX	2.21(0.45,11.93)	2.09(0.47,8.99)	0.04(-0.04,0.29)
SD GOLI IV + MTX	3.63(0.36,32.71)	3.20(0.38,17.27)	0.09(-0.05,0.52)
SD ANA SC + MTX	1.50(0.25,10.21)	1.46(0.26,7.55)	0.02(-0.06,0.27)
SD ETN SC + DMARD	1.05(0.28,4.15)	1.05(0.30,3.82)	0.00(-0.06,0.09)
SD ABA IV + DMARD	0.56(0.12,2.74)	0.57(0.13,2.62)	-0.02(-0.09,0.05)
SD ADA SC + DMARD	0.38(0.07,2.10)	0.39(0.08,2.01)	-0.02(-0.09,0.03)
SD ANA + DMARD	0.53(0.11,2.65)	0.54(0.12,2.53)	-0.02(-0.09,0.05)
SD CERTO SC + DMARD	0.36(0.05,2.78)	0.37(0.06,2.65)	-0.02(-0.09,0.05)
SD TOCI SC + DMARD	0.66(0.12,4.24)	0.67(0.13,3.84)	-0.01(-0.08,0.09)
LD ADA SC	0.53(0.16,1.61)	0.55(0.18,1.59)	-0.02(-0.09,0.01)
LD ETN SC	0.84(0.15,5.15)	0.84(0.16,4.48)	-0.01(-0.08,0.12)
LD GOLI IV	5.66(0.78,51.04)	4.61(0.79,21.30)	0.16(-0.01,0.63)
LD RITUX IV + MTX	1.04(0.20,5.24)	1.04(0.21,4.63)	0.00(-0.07,0.13)
LD ABA IV + MTX	1.42(0.25,7.65)	1.39(0.27,6.38)	0.02(-0.06,0.18)
LD CERTO SC + MTX	1.84(0.19,15.72)	1.76(0.20,10.42)	0.03(-0.06,0.34)
LD ETN SC + MTX	0.55(0.08,3.39)	0.56(0.09,3.15)	-0.02(-0.09,0.07)
LD GOLI IV + MTX	3.26(0.40,30.45)	2.92(0.42,16.40)	0.08(-0.04,0.50)
HD TOCI IV	1.04(0.22,5.24)	1.03(0.24,4.64)	0.00(-0.07,0.12)
HD TOFA PO	0.43(0.12,1.55)	0.44(0.13,1.53)	-0.02(-0.10,0.01)
HD GOLI SC	1.49(0.21,10.95)	1.46(0.22,8.15)	0.02(-0.06,0.26)

(Continued)

HD ADA SC		0.80(0.27,2.38)	0.81(0.29,2.31)	-0.01(-0.07,0.03)
HD GOLI SC + MTX		3.20(0.46,21.06)	2.89(0.48,13.02)	0.08(-0.03,0.42)
HD TOCI IV + MTX		1.18(0.22,7.12)	1.17(0.24,5.82)	0.01(-0.07,0.17)
HD TOFA PO + MTX		1.84(0.37,10.27)	1.77(0.39,7.89)	0.03(-0.05,0.26)
HD INF IV + MTX		1.19(0.23,5.88)	1.18(0.24,5.10)	0.01(-0.06,0.15)
HD CERTO SC + MTX		2.09(0.37,13.28)	1.99(0.39,9.35)	0.04(-0.05,0.32)
HD TOCI IV + DMARD		0.80(0.17,3.74)	0.81(0.18,3.44)	-0.01(-0.08,0.08)
SD TOCI SC	SD TOFA PO	2.84(0.63,13.82)	2.76(0.64,12.44)	0.02(-0.01,0.11)
SD CERTO SC		12.27(2.90,70.20)	10.49(2.78,46.77)	0.13(0.03,0.37)
SD GOLI IV		3.97(0.39,46.38)	3.80(0.40,31.97)	0.04(-0.01,0.34)
SD RITUX IV		1.45(0.16,15.81)	1.44(0.16,13.70)	0.01(-0.02,0.15)
SD INF IV + MTX		3.08(0.68,19.11)	2.98(0.68,16.68)	0.03(-0.01,0.15)
SD ETN SC + MTX		3.40(0.73,20.80)	3.29(0.73,18.03)	0.03(-0.01,0.16)
SD ADA SC + MTX		3.16(0.73,20.78)	3.06(0.74,17.66)	0.03(-0.01,0.17)
SD ABA IV + MTX		2.77(0.64,16.88)	2.69(0.65,14.98)	0.02(-0.01,0.13)
SD RITUX IV + MTX		3.78(0.83,24.29)	3.63(0.83,20.20)	0.04(0.00,0.20)
SD ABA SC + MTX		2.36(0.54,14.79)	2.31(0.55,13.28)	0.02(-0.01,0.12)
SD GOLI SC + MTX		7.05(1.17,68.25)	6.49(1.16,41.07)	0.08(0.00,0.41)
SD CERTO SC + MTX		5.42(1.18,37.02)	5.09(1.17,27.85)	0.06(0.00,0.28)
SD TOFA PO + MTX		6.80(1.55,46.08)	6.25(1.53,32.52)	0.07(0.01,0.33)
SD GOLI IV + MTX		11.17(1.38,111.20)	9.61(1.37,56.64)	0.13(0.01,0.55)
SD ANA SC + MTX		4.71(0.79,41.17)	4.45(0.79,29.17)	0.05(0.00,0.31)
SD ETN SC + DMARD		3.33(0.93,16.14)	3.21(0.94,14.62)	0.03(0.00,0.13)
SD ABA IV + DMARD		1.70(0.40,10.47)	1.68(0.40,9.72)	0.01(-0.01,0.08)
SD ADA SC + DMARD		1.18(0.24,7.51)	1.17(0.24,7.06)	0.00(-0.02,0.06)
SD ANA + DMARD		1.64(0.35,9.45)	1.62(0.36,8.73)	0.01(-0.02,0.08)
SD CERTO SC + DMARD		1.11(0.18,9.34)	1.11(0.19,8.48)	0.00(-0.02,0.08)
SD TOCI SC + DMARD		2.10(0.39,13.79)	2.06(0.40,12.27)	0.01(-0.01,0.13)

(Continued)

LD ADA SC		1.69(0.51,6.16)	1.67(0.52,5.95)	0.01(-0.01,0.04)
LD ETN SC		2.60(0.51,19.38)	2.53(0.52,16.63)	0.02(-0.01,0.16)
LD GOLI IV		18.17(2.62,186.60)	14.36(2.54,74.34)	0.19(0.02,0.66)
LD RITUX IV + MTX		3.20(0.70,21.37)	3.10(0.71,18.13)	0.03(-0.01,0.17)
LD ABA IV + MTX		4.31(0.87,29.92)	4.11(0.88,24.05)	0.04(0.00,0.22)
LD CERTO SC + MTX		5.77(0.69,54.24)	5.35(0.70,35.20)	0.06(-0.01,0.38)
LD ETN SC + MTX		1.71(0.28,12.36)	1.69(0.28,11.15)	0.01(-0.02,0.11)
LD GOLI IV + MTX		10.45(1.43,104.60)	9.13(1.42,55.26)	0.11(0.01,0.53)
HD TOCI IV		3.24(0.76,20.29)	3.12(0.76,17.30)	0.03(0.00,0.16)
HD TOFA PO		1.38(0.54,3.62)	1.37(0.54,3.55)	0.00(-0.01,0.03)
HD GOLI SC		4.68(0.74,38.28)	4.40(0.75,28.30)	0.05(0.00,0.30)
HD ADA SC		2.56(0.81,8.50)	2.51(0.81,8.09)	0.02(-0.01,0.06)
HD GOLI SC + MTX		9.72(1.53,81.82)	8.60(1.52,47.54)	0.11(0.01,0.46)
HD TOCI IV + MTX		3.74(0.74,27.08)	3.59(0.74,22.00)	0.04(-0.01,0.21)
HD TOFA PO + MTX		5.59(1.34,40.53)	5.22(1.33,29.59)	0.06(0.01,0.30)
HD INF IV + MTX		3.67(0.80,23.77)	3.53(0.80,19.77)	0.03(0.00,0.19)
HD CERTO SC + MTX		6.58(1.28,50.90)	6.04(1.27,34.89)	0.07(0.01,0.36)
HD TOCI IV + DMARD		2.51(0.55,13.87)	2.45(0.55,12.66)	0.02(-0.01,0.11)
SD CERTO SC	SD TOCI SC	4.45(0.71,28.16)	3.90(0.73,19.68)	0.11(-0.03,0.35)
SD GOLI IV		1.30(0.11,16.36)	1.28(0.12,11.99)	0.01(-0.08,0.31)
SD RITUX IV		0.51(0.05,5.93)	0.53(0.05,5.21)	-0.01(-0.10,0.12)
SD INF IV + MTX		1.15(0.19,6.36)	1.14(0.20,5.67)	0.00(-0.08,0.12)
SD ETN SC + MTX		1.23(0.21,7.03)	1.22(0.23,6.16)	0.01(-0.08,0.13)
SD ADA SC + MTX		1.20(0.20,6.90)	1.19(0.22,6.10)	0.01(-0.08,0.14)
SD ABA IV + MTX		1.04(0.17,5.48)	1.04(0.18,5.01)	0.00(-0.08,0.10)
SD RITUX IV + MTX		1.38(0.21,8.05)	1.35(0.23,6.98)	0.01(-0.08,0.16)
SD ABA SC + MTX		0.89(0.14,4.93)	0.89(0.15,4.54)	0.00(-0.09,0.09)
SD GOLI SC + MTX		2.63(0.34,21.44)	2.46(0.36,14.39)	0.05(-0.06,0.38)

(Continued)

SD CERTO SC + MTX	1.96(0.33,12.48)	1.88(0.35,9.94)	0.03(-0.06,0.24)
SD TOFA PO + MTX	2.54(0.41,15.93)	2.39(0.43,11.97)	0.05(-0.05,0.30)
SD GOLIV + MTX	4.02(0.36,43.09)	3.52(0.38,23.51)	0.10(-0.05,0.52)
SD ANA SC + MTX	1.72(0.22,13.22)	1.67(0.24,9.98)	0.02(-0.07,0.27)
SD ETN SC + DMARD	1.19(0.25,5.55)	1.18(0.27,5.08)	0.01(-0.07,0.10)
SD ABA IV + DMARD	0.64(0.11,3.62)	0.65(0.12,3.43)	-0.01(-0.10,0.06)
SD ADA SC + DMARD	0.43(0.07,2.68)	0.44(0.07,2.56)	-0.02(-0.10,0.04)
SD ANA + DMARD	0.60(0.10,3.41)	0.61(0.11,3.21)	-0.01(-0.10,0.05)
SD CERTO SC + DMARD	0.41(0.05,3.40)	0.42(0.06,3.22)	-0.02(-0.10,0.06)
SD TOCI SC + DMARD	0.76(0.12,5.40)	0.76(0.13,4.91)	-0.01(-0.09,0.10)
LD ADA SC	0.60(0.15,2.23)	0.61(0.17,2.19)	-0.01(-0.10,0.02)
LD ETN SC	0.96(0.13,6.45)	0.96(0.15,5.69)	0.00(-0.09,0.13)
LD GOLIV	6.55(0.75,67.05)	5.21(0.77,28.89)	0.16(-0.02,0.63)
LD RITUX IV + MTX	1.17(0.18,6.85)	1.16(0.20,6.08)	0.01(-0.08,0.13)
LD ABA IV + MTX	1.63(0.23,10.03)	1.59(0.25,8.48)	0.02(-0.07,0.19)
LD CERTO SC + MTX	2.08(0.18,19.56)	1.97(0.20,13.31)	0.04(-0.07,0.35)
LD ETN SC + MTX	0.61(0.08,4.40)	0.62(0.09,4.02)	-0.01(-0.10,0.08)
LD GOLIV + MTX	3.63(0.39,39.12)	3.24(0.41,21.84)	0.08(-0.05,0.50)
HD TOCI IV	1.17(0.21,6.70)	1.17(0.22,5.87)	0.01(-0.08,0.13)
HD TOFA PO	0.49(0.11,2.09)	0.50(0.12,2.05)	-0.02(-0.10,0.02)
HD GOLIV SC	1.65(0.20,14.59)	1.60(0.21,10.90)	0.02(-0.07,0.27)
HD ADA SC	0.92(0.25,3.19)	0.92(0.28,3.07)	0.00(-0.08,0.04)
HD GOLIV SC + MTX	3.62(0.45,27.61)	3.23(0.48,17.42)	0.08(-0.04,0.42)
HD TOCI IV + MTX	1.34(0.21,9.16)	1.33(0.23,7.69)	0.01(-0.08,0.17)
HD TOFA PO + MTX	2.06(0.34,13.42)	1.98(0.37,10.48)	0.03(-0.06,0.26)
HD INF IV + MTX	1.35(0.21,7.75)	1.33(0.23,6.77)	0.01(-0.08,0.16)
HD CERTO SC + MTX	2.41(0.34,16.62)	2.27(0.37,12.03)	0.04(-0.06,0.33)
HD TOCI IV + DMARD	0.91(0.16,4.82)	0.92(0.17,4.42)	0.00(-0.09,0.09)

(Continued)

SD GOLI IV	SD CERTO SC	0.32(0.02,4.48)	0.36(0.03,3.45)	-0.08(-0.34,0.22)
SD RITUX IV		0.12(0.01,1.83)	0.14(0.01,1.72)	-0.12(-0.36,0.06)
SD INF IV + MTX		0.27(0.03,2.00)	0.31(0.04,1.84)	-0.10(-0.34,0.06)
SD ETN SC + MTX		0.28(0.03,2.10)	0.31(0.05,1.92)	-0.10(-0.34,0.07)
SD ADA SC + MTX		0.27(0.04,2.22)	0.30(0.05,2.00)	-0.10(-0.34,0.08)
SD ABA IV + MTX		0.24(0.03,1.75)	0.28(0.04,1.66)	-0.10(-0.35,0.05)
SD RITUX IV + MTX		0.32(0.03,2.58)	0.36(0.05,2.28)	-0.09(-0.34,0.10)
SD ABA SC + MTX		0.20(0.03,1.53)	0.23(0.04,1.48)	-0.11(-0.35,0.03)
SD GOLI SC + MTX		0.59(0.05,7.42)	0.63(0.08,4.77)	-0.05(-0.32,0.33)
SD CERTO SC + MTX		0.45(0.05,4.23)	0.49(0.07,3.38)	-0.07(-0.33,0.19)
SD TOFA PO + MTX		0.57(0.07,5.23)	0.61(0.10,3.92)	-0.05(-0.32,0.24)
SD GOLI IV + MTX		0.91(0.07,10.37)	0.92(0.09,5.76)	-0.01(-0.29,0.43)
SD ANA SC + MTX		0.38(0.04,4.46)	0.42(0.06,3.50)	-0.08(-0.33,0.20)
SD ETN SC + DMARD		0.27(0.05,1.73)	0.30(0.07,1.62)	-0.10(-0.34,0.04)
SD ABA IV + DMARD		0.14(0.02,1.07)	0.17(0.03,1.06)	-0.12(-0.36,0.00)
SD ADA SC + DMARD		0.09(0.01,0.83)	0.11(0.02,0.84)	-0.13(-0.36,-0.01)
SD ANA + DMARD		0.14(0.02,1.04)	0.16(0.03,1.03)	-0.12(-0.36,0.00)
SD CERTO SC + DMARD		0.09(0.01,0.93)	0.10(0.01,0.94)	-0.13(-0.36,0.00)
SD TOCI SC + DMARD		0.17(0.02,1.47)	0.20(0.03,1.42)	-0.11(-0.35,0.03)
LD ADA SC		0.14(0.03,0.65)	0.16(0.04,0.67)	-0.12(-0.36,-0.02)
LD ETN SC		0.21(0.03,2.01)	0.24(0.04,1.85)	-0.11(-0.35,0.07)
LD GOLI IV		1.51(0.12,17.57)	1.38(0.17,7.40)	0.05(-0.26,0.55)
LD RITUX IV + MTX		0.27(0.03,2.17)	0.30(0.04,1.99)	-0.10(-0.34,0.08)
LD ABA IV + MTX		0.36(0.04,3.05)	0.40(0.06,2.63)	-0.08(-0.33,0.13)
LD CERTO SC + MTX		0.46(0.04,6.19)	0.51(0.05,4.20)	-0.07(-0.32,0.28)
LD ETN SC + MTX		0.14(0.01,1.31)	0.16(0.02,1.28)	-0.12(-0.36,0.02)
LD GOLI IV + MTX		0.84(0.08,9.26)	0.86(0.10,5.38)	-0.02(-0.29,0.40)
HD TOCI IV		0.27(0.03,2.08)	0.30(0.05,1.92)	-0.10(-0.34,0.07)

(Continued)

HD TOFA PO		0.11(0.02,0.51)	0.13(0.03,0.53)	-0.13(-0.36,-0.03)
HD GOLI SC		0.38(0.03,4.22)	0.42(0.05,3.28)	-0.08(-0.34,0.20)
HD ADA SC		0.21(0.05,0.93)	0.24(0.07,0.94)	-0.11(-0.35,0.00)
HD GOLI SC + MTX		0.81(0.06,9.63)	0.83(0.09,5.72)	-0.02(-0.31,0.37)
HD TOCI IV + MTX		0.30(0.04,2.71)	0.34(0.06,2.39)	-0.09(-0.34,0.11)
HD TOFA PO + MTX		0.44(0.06,4.61)	0.49(0.09,3.62)	-0.07(-0.32,0.20)
HD INF IV + MTX		0.31(0.03,2.44)	0.35(0.04,2.17)	-0.09(-0.34,0.09)
HD CERTO SC + MTX		0.56(0.05,5.92)	0.60(0.08,4.22)	-0.06(-0.32,0.27)
HD TOCI IV + DMARD		0.20(0.03,1.43)	0.23(0.04,1.38)	-0.11(-0.35,0.03)
SD RITUX IV	SD GOLI IV	0.38(0.03,5.73)	0.40(0.03,5.39)	-0.03(-0.29,0.08)
SD INF IV + MTX		0.84(0.10,6.86)	0.85(0.13,6.52)	-0.01(-0.26,0.08)
SD ETN SC + MTX		0.91(0.12,8.29)	0.92(0.15,7.71)	0.00(-0.26,0.09)
SD ADA SC + MTX		0.82(0.11,7.87)	0.83(0.14,7.37)	-0.01(-0.25,0.09)
SD ABA IV + MTX		0.76(0.09,6.22)	0.77(0.12,5.85)	-0.01(-0.27,0.07)
SD RITUX IV + MTX		1.00(0.13,8.42)	1.00(0.17,7.81)	0.00(-0.24,0.11)
SD ABA SC + MTX		0.63(0.08,5.56)	0.64(0.10,5.34)	-0.02(-0.28,0.06)
SD GOLI SC + MTX		1.98(0.19,22.32)	1.85(0.23,17.70)	0.03(-0.20,0.29)
SD CERTO SC + MTX		1.51(0.18,13.58)	1.46(0.23,11.67)	0.02(-0.21,0.18)
SD TOFA PO + MTX		1.81(0.23,17.33)	1.71(0.29,14.57)	0.03(-0.20,0.24)
SD GOLI IV + MTX		2.83(0.50,21.68)	2.45(0.54,16.80)	0.07(-0.08,0.37)
SD ANA SC + MTX		1.25(0.12,11.97)	1.23(0.16,10.38)	0.01(-0.23,0.21)
SD ETN SC + DMARD		0.85(0.12,7.56)	0.86(0.16,7.17)	-0.01(-0.27,0.07)
SD ABA IV + DMARD		0.46(0.06,4.38)	0.47(0.07,4.25)	-0.02(-0.30,0.04)
SD ADA SC + DMARD		0.30(0.03,3.25)	0.32(0.04,3.17)	-0.03(-0.32,0.02)
SD ANA + DMARD		0.43(0.05,4.27)	0.44(0.07,4.18)	-0.03(-0.30,0.04)
SD CERTO SC + DMARD		0.30(0.03,3.86)	0.32(0.03,3.67)	-0.03(-0.32,0.04)
SD TOCI SC + DMARD		0.57(0.06,5.87)	0.58(0.08,5.48)	-0.02(-0.29,0.07)
LD ADA SC		0.48(0.04,4.31)	0.49(0.05,4.21)	-0.03(-0.33,0.03)

(Continued)

LD ETN SC		0.70(0.08,7.60)	0.71(0.10,7.20)	-0.01(-0.27,0.10)
LD GOLI IV		4.58(1.04,30.01)	3.62(1.03,21.69)	0.13(0.00,0.48)
LD RITUX IV + MTX		0.83(0.11,7.49)	0.84(0.14,7.01)	-0.01(-0.25,0.09)
LD ABA IV + MTX		1.14(0.13,10.94)	1.13(0.17,9.94)	0.01(-0.24,0.14)
LD CERTO SC + MTX		1.46(0.11,22.72)	1.41(0.13,17.78)	0.02(-0.24,0.30)
LD ETN SC + MTX		0.46(0.05,4.79)	0.48(0.06,4.49)	-0.02(-0.30,0.05)
LD GOLI IV + MTX		2.69(0.51,18.96)	2.35(0.56,14.97)	0.06(-0.07,0.36)
HD TOCI IV		0.83(0.11,7.70)	0.84(0.15,7.24)	-0.01(-0.26,0.09)
HD TOFA PO		0.36(0.03,3.75)	0.38(0.04,3.67)	-0.03(-0.34,0.02)
HD GOLI SC		1.20(0.12,15.08)	1.19(0.15,12.76)	0.01(-0.23,0.21)
HD ADA SC		0.68(0.06,6.47)	0.70(0.09,6.25)	-0.02(-0.32,0.04)
HD GOLI SC + MTX		2.78(0.28,30.13)	2.49(0.34,22.16)	0.06(-0.16,0.37)
HD TOCI IV + MTX		0.92(0.12,10.84)	0.93(0.15,9.73)	0.00(-0.24,0.14)
HD TOFA PO + MTX		1.46(0.19,14.57)	1.41(0.24,12.41)	0.02(-0.21,0.20)
HD INF IV + MTX		0.97(0.12,8.78)	0.98(0.15,8.09)	0.00(-0.25,0.11)
HD CERTO SC + MTX		1.83(0.19,18.85)	1.73(0.24,15.58)	0.03(-0.20,0.27)
HD TOCI IV + DMARD		0.63(0.08,6.18)	0.65(0.11,5.85)	-0.02(-0.28,0.06)
SD INF IV + MTX	SD RITUX IV	2.12(0.42,12.74)	2.05(0.45,11.91)	0.02(-0.06,0.10)
SD ETN SC + MTX		2.27(0.41,15.08)	2.20(0.44,14.09)	0.02(-0.07,0.12)
SD ADA SC + MTX		2.16(0.41,13.79)	2.09(0.43,13.07)	0.02(-0.07,0.12)
SD ABA IV + MTX		1.88(0.39,11.60)	1.84(0.42,11.02)	0.01(-0.07,0.09)
SD RITUX IV + MTX		2.49(0.57,15.78)	2.39(0.60,14.65)	0.02(-0.04,0.13)
SD ABA SC + MTX		1.59(0.30,9.80)	1.56(0.33,9.43)	0.01(-0.09,0.07)
SD GOLI SC + MTX		4.90(0.68,36.64)	4.39(0.70,30.32)	0.06(-0.02,0.35)
SD CERTO SC + MTX		3.82(0.70,22.45)	3.53(0.73,19.95)	0.04(-0.03,0.22)
SD TOFA PO + MTX		4.55(0.79,32.27)	4.15(0.81,27.50)	0.06(-0.02,0.28)
SD GOLI IV + MTX		7.54(0.65,97.23)	6.30(0.67,65.26)	0.11(-0.02,0.51)
SD ANA SC + MTX		3.15(0.43,22.82)	2.95(0.46,20.15)	0.03(-0.05,0.24)

(Continued)

SD ETN SC + DMARD		2.24(0.38,16.18)	2.16(0.42,15.52)	0.02(-0.08,0.09)
SD ABA IV + DMARD		1.16(0.18,8.50)	1.15(0.20,8.21)	0.00(-0.12,0.05)
SD ADA SC + DMARD		0.76(0.11,6.61)	0.77(0.12,6.44)	0.00(-0.13,0.04)
SD ANA + DMARD		1.10(0.16,8.53)	1.10(0.18,8.27)	0.00(-0.12,0.05)
SD CERTO SC + DMARD		0.75(0.08,8.38)	0.76(0.09,8.13)	0.00(-0.13,0.05)
SD TOCI SC + DMARD		1.44(0.18,12.21)	1.42(0.20,11.52)	0.01(-0.11,0.09)
LD ADA SC		1.13(0.11,10.42)	1.13(0.12,10.16)	0.00(-0.14,0.04)
LD ETN SC		1.80(0.29,12.98)	1.76(0.32,12.29)	0.01(-0.08,0.11)
LD GOLIV		12.36(1.19,152.20)	9.52(1.18,85.34)	0.17(0.01,0.61)
LD RITUX IV + MTX		2.10(0.49,12.69)	2.04(0.52,11.93)	0.02(-0.05,0.11)
LD ABA IV + MTX		2.90(0.50,19.26)	2.75(0.53,17.83)	0.03(-0.05,0.17)
LD CERTO SC + MTX		3.72(0.44,32.20)	3.43(0.46,25.64)	0.04(-0.05,0.34)
LD ETN SC + MTX		1.14(0.18,8.36)	1.14(0.20,8.08)	0.00(-0.11,0.07)
LD GOLIV + MTX		7.10(0.57,85.63)	6.03(0.60,61.31)	0.10(-0.03,0.48)
HD TOCI IV		2.13(0.39,15.30)	2.07(0.42,14.36)	0.02(-0.07,0.11)
HD TOFA PO		0.96(0.09,8.01)	0.96(0.10,7.79)	0.00(-0.15,0.03)
HD GOLIV SC		3.17(0.41,27.83)	2.97(0.43,23.50)	0.03(-0.06,0.25)
HD ADA SC		1.73(0.19,16.10)	1.71(0.22,15.40)	0.01(-0.12,0.06)
HD GOLIV SC + MTX		6.60(0.99,50.10)	5.68(0.99,37.38)	0.09(0.00,0.40)
HD TOCI IV + MTX		2.41(0.43,20.11)	2.32(0.46,18.37)	0.02(-0.06,0.16)
HD TOFA PO + MTX		3.77(0.62,26.53)	3.52(0.65,23.64)	0.05(-0.03,0.24)
HD INF IV + MTX		2.48(0.48,15.41)	2.39(0.50,14.33)	0.02(-0.06,0.13)
HD CERTO SC + MTX		4.61(0.78,29.98)	4.19(0.80,25.76)	0.06(-0.02,0.29)
HD TOCI IV + DMARD		1.63(0.27,13.23)	1.60(0.30,12.58)	0.01(-0.10,0.08)
SD ETN SC + MTX	SD INF IV + MTX	1.09(0.46,2.51)	1.09(0.48,2.39)	0.00(-0.05,0.07)
SD ADA SC + MTX		1.05(0.49,2.21)	1.04(0.50,2.10)	0.00(-0.04,0.06)
SD ABA IV + MTX		0.90(0.52,1.58)	0.91(0.54,1.54)	0.00(-0.05,0.02)
SD RITUX IV + MTX		1.19(0.64,2.42)	1.18(0.65,2.27)	0.01(-0.03,0.07)

(Continued)

SD ABA SC + MTX	0.76(0.36,1.54)	0.77(0.38,1.51)	-0.01(-0.06,0.02)
SD GOLI SC + MTX	2.26(0.69,7.83)	2.11(0.70,6.17)	0.05(-0.01,0.30)
SD CERTO SC + MTX	1.76(0.88,3.73)	1.69(0.88,3.31)	0.03(-0.01,0.15)
SD TOFA PO + MTX	2.18(0.91,5.69)	2.04(0.91,4.73)	0.04(0.00,0.22)
SD GOLI IV + MTX	3.52(0.58,24.65)	3.04(0.60,15.51)	0.09(-0.02,0.47)
SD ANA SC + MTX	1.51(0.47,4.87)	1.47(0.49,4.08)	0.02(-0.04,0.19)
SD ETN SC + DMARD	1.05(0.41,2.72)	1.05(0.43,2.62)	0.00(-0.07,0.05)
SD ABA IV + DMARD	0.56(0.19,1.65)	0.57(0.20,1.62)	-0.02(-0.10,0.02)
SD ADA SC + DMARD	0.37(0.10,1.33)	0.38(0.11,1.31)	-0.02(-0.12,0.01)
SD ANA + DMARD	0.53(0.16,1.61)	0.54(0.17,1.58)	-0.02(-0.11,0.02)
SD CERTO SC + DMARD	0.37(0.07,1.78)	0.38(0.07,1.72)	-0.02(-0.13,0.02)
SD TOCI SC + DMARD	0.69(0.18,2.53)	0.70(0.19,2.39)	-0.01(-0.10,0.05)
LD ADA SC	0.52(0.10,2.43)	0.54(0.12,2.38)	-0.02(-0.14,0.02)
LD ETN SC	0.85(0.28,2.61)	0.86(0.30,2.47)	0.00(-0.07,0.07)
LD GOLI IV	5.64(1.13,36.21)	4.42(1.11,18.80)	0.15(0.01,0.58)
LD RITUX IV + MTX	1.02(0.54,2.09)	1.02(0.56,1.98)	0.00(-0.04,0.05)
LD ABA IV + MTX	1.39(0.60,3.29)	1.36(0.62,2.99)	0.01(-0.03,0.12)
LD CERTO SC + MTX	1.75(0.40,7.77)	1.68(0.41,5.96)	0.03(-0.04,0.29)
LD ETN SC + MTX	0.54(0.17,1.69)	0.56(0.18,1.66)	-0.02(-0.09,0.03)
LD GOLI IV + MTX	3.27(0.57,20.03)	2.88(0.59,12.96)	0.08(-0.02,0.45)
HD TOCI IV	1.02(0.44,2.46)	1.02(0.46,2.33)	0.00(-0.05,0.06)
HD TOFA PO	0.45(0.08,2.13)	0.46(0.09,2.10)	-0.02(-0.15,0.02)
HD GOLI SC	1.46(0.37,5.86)	1.43(0.39,4.80)	0.02(-0.05,0.21)
HD ADA SC	0.83(0.18,3.35)	0.84(0.21,3.24)	-0.01(-0.12,0.04)
HD GOLI SC + MTX	3.15(1.02,10.20)	2.80(1.02,7.42)	0.08(0.00,0.36)
HD TOCI IV + MTX	1.17(0.43,3.54)	1.16(0.45,3.20)	0.01(-0.05,0.11)
HD TOFA PO + MTX	1.84(0.77,4.74)	1.76(0.78,4.14)	0.03(-0.01,0.18)
HD INF IV + MTX	1.16(0.67,2.08)	1.15(0.68,1.96)	0.01(-0.02,0.06)

(Continued)

HD CERTO SC + MTX		2.16(0.89,5.72)	2.02(0.89,4.69)	0.04(0.00,0.25)
HD TOCI IV + DMARD		0.79(0.27,2.28)	0.80(0.29,2.19)	-0.01(-0.09,0.04)
SD ADA SC + MTX	SD ETN SC + MTX	0.94(0.37,2.65)	0.94(0.39,2.48)	0.00(-0.07,0.07)
SD ABA IV + MTX		0.82(0.35,2.07)	0.83(0.38,1.98)	-0.01(-0.08,0.04)
SD RITUX IV + MTX		1.09(0.46,3.00)	1.09(0.48,2.73)	0.00(-0.05,0.09)
SD ABA SC + MTX		0.70(0.27,1.95)	0.71(0.29,1.87)	-0.01(-0.09,0.04)
SD GOLI SC + MTX		2.06(0.57,8.59)	1.94(0.59,6.64)	0.04(-0.03,0.30)
SD CERTO SC + MTX		1.63(0.66,4.15)	1.57(0.68,3.61)	0.02(-0.02,0.16)
SD TOFA PO + MTX		2.01(0.73,6.26)	1.90(0.74,5.24)	0.04(-0.02,0.22)
SD GOLI IV + MTX		3.25(0.48,21.79)	2.85(0.50,13.68)	0.08(-0.04,0.47)
SD ANA SC + MTX		1.39(0.36,5.36)	1.36(0.38,4.47)	0.01(-0.05,0.20)
SD ETN SC + DMARD		0.95(0.37,2.65)	0.96(0.40,2.55)	0.00(-0.08,0.05)
SD ABA IV + DMARD		0.50(0.16,1.65)	0.52(0.18,1.61)	-0.02(-0.12,0.02)
SD ADA SC + DMARD		0.34(0.09,1.28)	0.35(0.10,1.27)	-0.03(-0.13,0.01)
SD ANA + DMARD		0.49(0.14,1.67)	0.50(0.16,1.64)	-0.02(-0.12,0.02)
SD CERTO SC + DMARD		0.34(0.06,1.67)	0.35(0.06,1.63)	-0.03(-0.13,0.02)
SD TOCI SC + DMARD		0.62(0.15,2.46)	0.64(0.17,2.31)	-0.01(-0.11,0.05)
LD ADA SC		0.49(0.09,2.25)	0.50(0.11,2.21)	-0.02(-0.15,0.02)
LD ETN SC		0.79(0.24,2.43)	0.80(0.25,2.28)	-0.01(-0.09,0.06)
LD GOLI IV		5.29(0.89,34.38)	4.18(0.90,17.42)	0.15(-0.01,0.58)
LD RITUX IV + MTX		0.93(0.40,2.53)	0.93(0.42,2.34)	0.00(-0.06,0.07)
LD ABA IV + MTX		1.27(0.43,3.97)	1.25(0.46,3.53)	0.01(-0.06,0.13)
LD CERTO SC + MTX		1.66(0.31,7.96)	1.59(0.33,5.90)	0.02(-0.05,0.28)
LD ETN SC + MTX		0.51(0.16,1.39)	0.52(0.16,1.35)	-0.02(-0.10,0.02)
LD GOLI IV + MTX		3.13(0.45,19.11)	2.75(0.47,12.09)	0.08(-0.04,0.44)
HD TOCI IV		0.94(0.36,2.72)	0.95(0.38,2.56)	0.00(-0.07,0.07)
HD TOFA PO		0.41(0.08,1.95)	0.42(0.09,1.91)	-0.03(-0.15,0.02)
HD GOLI SC		1.39(0.31,5.82)	1.36(0.33,4.69)	0.01(-0.07,0.20)

(Continued)

HD ADA SC		0.75(0.16,2.90)	0.76(0.18,2.80)	-0.01(-0.14,0.03)
HD GOLI SC + MTX		2.89(0.80,11.15)	2.59(0.82,7.80)	0.07(-0.01,0.36)
HD TOCI IV + MTX		1.08(0.34,3.80)	1.08(0.36,3.37)	0.00(-0.06,0.12)
HD TOFA PO + MTX		1.68(0.57,5.29)	1.61(0.59,4.55)	0.02(-0.03,0.19)
HD INF IV + MTX		1.07(0.45,2.78)	1.06(0.47,2.57)	0.00(-0.06,0.08)
HD CERTO SC + MTX		1.95(0.73,6.04)	1.85(0.75,4.92)	0.04(-0.02,0.25)
HD TOCI IV + DMARD		0.73(0.23,2.33)	0.74(0.25,2.24)	-0.01(-0.10,0.04)
SD ABA IV + MTX	SD ADA SC + MTX	0.87(0.45,1.69)	0.88(0.47,1.65)	0.00(-0.06,0.03)
SD RITUX IV + MTX		1.16(0.53,2.65)	1.15(0.55,2.51)	0.01(-0.04,0.07)
SD ABA SC + MTX		0.74(0.41,1.29)	0.75(0.43,1.27)	-0.01(-0.07,0.01)
SD GOLI SC + MTX		2.20(0.65,8.78)	2.05(0.66,6.93)	0.04(-0.02,0.30)
SD CERTO SC + MTX		1.69(0.78,4.13)	1.62(0.79,3.72)	0.03(-0.01,0.15)
SD TOFA PO + MTX		2.12(0.93,5.06)	1.98(0.93,4.34)	0.04(0.00,0.21)
SD GOLI IV + MTX		3.45(0.53,22.58)	3.03(0.55,14.59)	0.09(-0.03,0.47)
SD ANA SC + MTX		1.45(0.39,5.40)	1.41(0.41,4.60)	0.02(-0.05,0.19)
SD ETN SC + DMARD		1.02(0.37,2.72)	1.02(0.40,2.62)	0.00(-0.09,0.05)
SD ABA IV + DMARD		0.54(0.17,1.69)	0.55(0.19,1.66)	-0.02(-0.12,0.02)
SD ADA SC + DMARD		0.36(0.09,1.30)	0.37(0.10,1.30)	-0.02(-0.14,0.01)
SD ANA + DMARD		0.51(0.14,1.68)	0.52(0.16,1.65)	-0.02(-0.13,0.02)
SD CERTO SC + DMARD		0.35(0.06,1.74)	0.36(0.07,1.69)	-0.02(-0.14,0.02)
SD TOCI SC + DMARD		0.66(0.16,2.68)	0.67(0.18,2.50)	-0.01(-0.11,0.05)
LD ADA SC		0.52(0.09,2.35)	0.53(0.11,2.30)	-0.02(-0.16,0.02)
LD ETN SC		0.82(0.26,2.61)	0.83(0.29,2.47)	-0.01(-0.09,0.07)
LD GOLI IV		5.68(1.01,36.39)	4.44(1.01,18.67)	0.15(0.00,0.57)
LD RITUX IV + MTX		0.99(0.44,2.29)	0.99(0.46,2.18)	0.00(-0.06,0.06)
LD ABA IV + MTX		1.35(0.51,3.37)	1.33(0.53,3.08)	0.01(-0.04,0.11)
LD CERTO SC + MTX		1.69(0.34,8.53)	1.62(0.36,6.60)	0.03(-0.05,0.28)
LD ETN SC + MTX		0.52(0.15,1.74)	0.54(0.17,1.69)	-0.02(-0.11,0.03)

(Continued)

LD GOLI IV + MTX		3.22(0.51,20.51)	2.86(0.54,13.14)	0.08(-0.04,0.45)
HD TOCI IV		0.98(0.40,2.65)	0.98(0.43,2.51)	0.00(-0.07,0.06)
HD TOFA PO		0.42(0.07,1.97)	0.43(0.08,1.94)	-0.02(-0.16,0.01)
HD GOLI SC		1.42(0.34,5.82)	1.39(0.36,4.85)	0.02(-0.06,0.20)
HD ADA SC		0.80(0.15,3.29)	0.80(0.18,3.17)	-0.01(-0.14,0.04)
HD GOLI SC + MTX		3.01(0.90,11.42)	2.69(0.91,8.50)	0.07(0.00,0.35)
HD TOCI IV + MTX		1.13(0.39,3.69)	1.12(0.41,3.32)	0.00(-0.06,0.11)
HD TOFA PO + MTX		1.76(0.77,4.21)	1.69(0.78,3.70)	0.03(-0.01,0.16)
HD INF IV + MTX		1.12(0.49,2.57)	1.11(0.51,2.41)	0.00(-0.05,0.07)
HD CERTO SC + MTX		2.06(0.79,6.21)	1.93(0.81,5.24)	0.04(-0.01,0.24)
HD TOCI IV + DMARD		0.76(0.25,2.35)	0.77(0.27,2.26)	-0.01(-0.10,0.04)
SD RITUX IV + MTX	SD ABA IV + MTX	1.33(0.69,2.68)	1.31(0.71,2.50)	0.01(-0.02,0.09)
SD ABA SC + MTX		0.84(0.47,1.48)	0.85(0.49,1.45)	0.00(-0.04,0.02)
SD GOLI SC + MTX		2.48(0.78,9.26)	2.31(0.79,6.89)	0.05(-0.01,0.31)
SD CERTO SC + MTX		1.94(1.00,4.06)	1.85(1.00,3.58)	0.03(0.00,0.16)
SD TOFA PO + MTX		2.43(1.05,5.95)	2.26(1.05,5.08)	0.05(0.00,0.23)
SD GOLI IV + MTX		3.89(0.67,26.04)	3.35(0.68,16.14)	0.09(-0.02,0.48)
SD ANA SC + MTX		1.66(0.51,5.57)	1.60(0.53,4.63)	0.02(-0.03,0.21)
SD ETN SC + DMARD		1.18(0.47,2.92)	1.17(0.49,2.81)	0.01(-0.05,0.05)
SD ABA IV + DMARD		0.61(0.21,1.79)	0.62(0.22,1.74)	-0.01(-0.09,0.02)
SD ADA SC + DMARD		0.40(0.12,1.43)	0.42(0.13,1.41)	-0.02(-0.11,0.01)
SD ANA + DMARD		0.59(0.18,1.80)	0.60(0.19,1.75)	-0.01(-0.09,0.02)
SD CERTO SC + DMARD		0.40(0.07,1.92)	0.41(0.08,1.84)	-0.02(-0.11,0.03)
SD TOCI SC + DMARD		0.76(0.20,2.90)	0.77(0.21,2.70)	-0.01(-0.08,0.06)
LD ADA SC		0.58(0.12,2.61)	0.59(0.13,2.55)	-0.01(-0.12,0.02)
LD ETN SC		0.93(0.32,2.84)	0.94(0.34,2.66)	0.00(-0.06,0.08)
LD GOLI IV		6.30(1.24,40.25)	4.95(1.22,19.94)	0.16(0.01,0.58)
LD RITUX IV + MTX		1.13(0.60,2.34)	1.12(0.62,2.20)	0.00(-0.03,0.07)

(Continued)

LD ABA IV + MTX		1.53(0.72,3.35)	1.49(0.73,3.06)	0.02(-0.01,0.12)
LD CERTO SC + MTX		1.94(0.43,8.74)	1.86(0.45,6.53)	0.03(-0.03,0.30)
LD ETN SC + MTX		0.60(0.18,1.86)	0.61(0.19,1.81)	-0.01(-0.08,0.03)
LD GOLI IV + MTX		3.58(0.63,22.53)	3.16(0.65,14.45)	0.08(-0.02,0.46)
HD TOCI IV		1.13(0.50,2.76)	1.12(0.53,2.58)	0.00(-0.04,0.07)
HD TOFA PO		0.49(0.09,2.31)	0.50(0.10,2.27)	-0.02(-0.13,0.02)
HD GOLI SC		1.63(0.41,6.48)	1.58(0.42,5.26)	0.02(-0.04,0.22)
HD ADA SC		0.90(0.20,3.69)	0.91(0.22,3.52)	0.00(-0.11,0.04)
HD GOLI SC + MTX		3.46(1.09,12.03)	3.05(1.09,8.52)	0.08(0.00,0.36)
HD TOCI IV + MTX		1.30(0.49,3.82)	1.28(0.50,3.47)	0.01(-0.03,0.12)
HD TOFA PO + MTX		2.03(0.85,5.12)	1.94(0.86,4.38)	0.03(-0.01,0.19)
HD INF IV + MTX		1.29(0.67,2.56)	1.27(0.68,2.38)	0.01(-0.02,0.08)
HD CERTO SC + MTX		2.36(0.99,6.39)	2.20(0.99,5.15)	0.05(0.00,0.26)
HD TOCI IV + DMARD		0.87(0.31,2.49)	0.88(0.33,2.39)	0.00(-0.07,0.05)
SD ABA SC + MTX	SD RITUX IV + MTX	0.64(0.28,1.37)	0.65(0.30,1.35)	-0.02(-0.10,0.01)
SD GOLI SC + MTX		1.86(0.56,6.73)	1.76(0.58,5.32)	0.04(-0.03,0.27)
SD CERTO SC + MTX		1.48(0.70,3.10)	1.43(0.72,2.81)	0.02(-0.02,0.13)
SD TOFA PO + MTX		1.84(0.70,4.82)	1.75(0.73,4.19)	0.03(-0.02,0.20)
SD GOLI IV + MTX		2.92(0.46,20.20)	2.57(0.48,12.96)	0.08(-0.04,0.45)
SD ANA SC + MTX		1.25(0.37,4.20)	1.24(0.39,3.58)	0.01(-0.06,0.17)
SD ETN SC + DMARD		0.88(0.31,2.27)	0.88(0.34,2.20)	-0.01(-0.11,0.04)
SD ABA IV + DMARD		0.47(0.14,1.36)	0.48(0.16,1.34)	-0.02(-0.15,0.01)
SD ADA SC + DMARD		0.31(0.08,1.09)	0.33(0.09,1.08)	-0.03(-0.16,0.00)
SD ANA + DMARD		0.45(0.13,1.39)	0.47(0.14,1.37)	-0.03(-0.15,0.01)
SD CERTO SC + DMARD		0.30(0.05,1.46)	0.32(0.06,1.44)	-0.03(-0.16,0.02)
SD TOCI SC + DMARD		0.58(0.13,2.10)	0.59(0.15,2.00)	-0.02(-0.14,0.04)
LD ADA SC		0.43(0.08,2.19)	0.45(0.09,2.16)	-0.03(-0.18,0.02)
LD ETN SC		0.71(0.24,2.06)	0.72(0.26,1.97)	-0.01(-0.10,0.05)

(Continued)

LD GOLI IV		4.74(0.90,29.07)	3.81(0.91,16.09)	0.14(-0.01,0.56)
LD RITUX IV + MTX		0.85(0.51,1.45)	0.86(0.54,1.41)	-0.01(-0.05,0.02)
LD ABA IV + MTX		1.16(0.45,2.80)	1.15(0.48,2.59)	0.01(-0.06,0.10)
LD CERTO SC + MTX		1.48(0.31,6.46)	1.44(0.33,4.91)	0.02(-0.07,0.26)
LD ETN SC + MTX		0.45(0.13,1.40)	0.47(0.14,1.37)	-0.02(-0.13,0.02)
LD GOLI IV + MTX		2.73(0.43,16.96)	2.44(0.46,11.26)	0.07(-0.04,0.43)
HD TOCI IV		0.86(0.34,2.04)	0.87(0.37,1.95)	-0.01(-0.09,0.05)
HD TOFA PO		0.37(0.06,1.82)	0.38(0.07,1.80)	-0.03(-0.19,0.01)
HD GOLI SC		1.22(0.31,4.73)	1.21(0.33,3.88)	0.01(-0.07,0.19)
HD ADA SC		0.68(0.14,2.96)	0.69(0.16,2.85)	-0.01(-0.17,0.03)
HD GOLI SC + MTX		2.59(0.83,9.14)	2.33(0.84,6.53)	0.07(-0.01,0.33)
HD TOCI IV + MTX		0.98(0.35,2.96)	0.98(0.37,2.72)	0.00(-0.08,0.09)
HD TOFA PO + MTX		1.53(0.60,3.96)	1.47(0.62,3.50)	0.02(-0.04,0.16)
HD INF IV + MTX		0.98(0.45,2.01)	0.98(0.47,1.92)	0.00(-0.06,0.05)
HD CERTO SC + MTX		1.81(0.73,4.73)	1.72(0.74,3.87)	0.03(-0.02,0.21)
HD TOCI IV + DMARD		0.67(0.22,1.93)	0.68(0.24,1.86)	-0.01(-0.12,0.03)
SD GOLI SC + MTX	SD ABA SC + MTX	2.95(0.88,11.72)	2.71(0.89,8.91)	0.06(0.00,0.33)
SD CERTO SC + MTX		2.28(1.07,5.45)	2.15(1.07,4.78)	0.04(0.00,0.18)
SD TOFA PO + MTX		2.86(1.22,7.48)	2.65(1.21,6.30)	0.05(0.01,0.24)
SD GOLI IV + MTX		4.71(0.76,32.59)	4.00(0.77,19.95)	0.10(-0.01,0.49)
SD ANA SC + MTX		1.95(0.57,7.11)	1.88(0.58,5.89)	0.03(-0.02,0.22)
SD ETN SC + DMARD		1.39(0.50,3.77)	1.36(0.53,3.59)	0.01(-0.04,0.06)
SD ABA IV + DMARD		0.72(0.23,2.28)	0.73(0.25,2.20)	-0.01(-0.08,0.03)
SD ADA SC + DMARD		0.49(0.13,1.81)	0.50(0.14,1.78)	-0.01(-0.09,0.02)
SD ANA + DMARD		0.70(0.20,2.30)	0.71(0.21,2.22)	-0.01(-0.08,0.03)
SD CERTO SC + DMARD		0.48(0.09,2.32)	0.49(0.09,2.25)	-0.01(-0.09,0.03)
SD TOCI SC + DMARD		0.88(0.22,3.64)	0.89(0.24,3.41)	0.00(-0.07,0.07)
LD ADA SC		0.69(0.13,3.15)	0.70(0.14,3.08)	-0.01(-0.11,0.03)

(Continued)

LD ETN SC		1.11(0.36,3.59)	1.10(0.37,3.35)	0.00(-0.05,0.09)
LD GOLI IV		7.54(1.41,50.69)	5.85(1.37,26.19)	0.16(0.01,0.60)
LD RITUX IV + MTX		1.33(0.61,3.19)	1.31(0.63,3.02)	0.01(-0.02,0.08)
LD ABA IV + MTX		1.82(0.73,4.57)	1.76(0.75,4.10)	0.02(-0.01,0.14)
LD CERTO SC + MTX		2.28(0.49,10.87)	2.16(0.50,8.46)	0.04(-0.02,0.31)
LD ETN SC + MTX		0.71(0.21,2.36)	0.72(0.22,2.28)	-0.01(-0.07,0.04)
LD GOLI IV + MTX		4.26(0.70,28.12)	3.73(0.71,18.64)	0.09(-0.01,0.47)
HD TOCI IV		1.33(0.55,3.61)	1.31(0.57,3.37)	0.01(-0.03,0.08)
HD TOFA PO		0.58(0.10,2.72)	0.59(0.12,2.66)	-0.01(-0.12,0.02)
HD GOLI SC		1.97(0.46,7.91)	1.89(0.47,6.46)	0.03(-0.03,0.23)
HD ADA SC		1.07(0.22,4.64)	1.07(0.24,4.44)	0.00(-0.09,0.05)
HD GOLI SC + MTX		4.09(1.26,15.06)	3.59(1.24,10.89)	0.09(0.01,0.38)
HD TOCI IV + MTX		1.54(0.53,5.07)	1.51(0.54,4.49)	0.01(-0.03,0.14)
HD TOFA PO + MTX		2.39(0.98,6.30)	2.26(0.98,5.41)	0.04(0.00,0.20)
HD INF IV + MTX		1.52(0.70,3.53)	1.48(0.71,3.26)	0.01(-0.02,0.10)
HD CERTO SC + MTX		2.81(1.07,8.50)	2.59(1.07,6.85)	0.05(0.00,0.27)
HD TOCI IV + DMARD		1.03(0.34,3.18)	1.03(0.35,3.03)	0.00(-0.06,0.06)
SD CERTO SC + MTX	SD GOLI SC + MTX	0.78(0.22,2.53)	0.80(0.27,2.31)	-0.02(-0.23,0.09)
SD TOFA PO + MTX		0.97(0.22,3.91)	0.97(0.28,3.46)	0.00(-0.22,0.15)
SD GOLI IV + MTX		1.55(0.18,12.61)	1.44(0.21,8.27)	0.04(-0.19,0.39)
SD ANA SC + MTX		0.66(0.14,3.21)	0.69(0.17,2.82)	-0.02(-0.25,0.11)
SD ETN SC + DMARD		0.47(0.11,1.80)	0.50(0.15,1.74)	-0.04(-0.33,0.02)
SD ABA IV + DMARD		0.24(0.05,1.02)	0.27(0.07,1.02)	-0.06(-0.37,0.00)
SD ADA SC + DMARD		0.16(0.03,0.78)	0.18(0.04,0.79)	-0.07(-0.39,0.00)
SD ANA + DMARD		0.23(0.05,1.04)	0.25(0.06,1.04)	-0.07(-0.37,0.00)
SD CERTO SC + DMARD		0.16(0.02,1.09)	0.18(0.02,1.09)	-0.07(-0.39,0.00)
SD TOCI SC + DMARD		0.30(0.05,1.50)	0.33(0.07,1.46)	-0.06(-0.35,0.02)
LD ADA SC		0.22(0.03,1.44)	0.24(0.05,1.43)	-0.07(-0.40,0.01)

(Continued)

LD ETN SC		0.36(0.09,1.68)	0.39(0.11,1.62)	-0.05(-0.31,0.03)
LD GOLI IV		2.62(0.35,18.37)	2.17(0.41,10.49)	0.09(-0.13,0.50)
LD RITUX IV + MTX		0.46(0.12,1.54)	0.49(0.15,1.51)	-0.04(-0.30,0.02)
LD ABA IV + MTX		0.62(0.14,2.30)	0.65(0.17,2.15)	-0.03(-0.27,0.06)
LD CERTO SC + MTX		0.75(0.12,4.20)	0.78(0.15,3.47)	-0.02(-0.23,0.20)
LD ETN SC + MTX		0.24(0.05,1.02)	0.26(0.06,1.02)	-0.06(-0.35,0.00)
LD GOLI IV + MTX		1.51(0.17,11.67)	1.42(0.20,7.80)	0.03(-0.19,0.37)
HD TOCI IV		0.46(0.11,1.63)	0.49(0.15,1.59)	-0.04(-0.31,0.02)
HD TOFA PO		0.19(0.02,1.22)	0.20(0.04,1.21)	-0.07(-0.41,0.01)
HD GOLI SC		0.62(0.18,2.32)	0.66(0.21,2.14)	-0.03(-0.22,0.08)
HD ADA SC		0.35(0.05,2.18)	0.37(0.08,2.11)	-0.06(-0.39,0.02)
HD GOLI SC + MTX		1.36(0.53,3.57)	1.30(0.58,2.98)	0.02(-0.09,0.20)
HD TOCI IV + MTX		0.53(0.11,2.19)	0.56(0.14,2.08)	-0.04(-0.29,0.05)
HD TOFA PO + MTX		0.82(0.18,3.20)	0.84(0.22,2.90)	-0.01(-0.23,0.11)
HD INF IV + MTX		0.52(0.14,1.76)	0.55(0.18,1.70)	-0.04(-0.29,0.03)
HD CERTO SC + MTX		0.93(0.23,3.46)	0.94(0.29,3.02)	0.00(-0.20,0.15)
HD TOCI IV + DMARD		0.35(0.07,1.39)	0.38(0.09,1.37)	-0.05(-0.34,0.01)
SD TOFA PO + MTX	SD CERTO SC + MTX	1.24(0.47,3.28)	1.21(0.51,2.93)	0.01(-0.07,0.14)
SD GOLI IV + MTX		1.97(0.32,14.28)	1.79(0.36,8.69)	0.06(-0.10,0.42)
SD ANA SC + MTX		0.85(0.25,3.00)	0.86(0.28,2.58)	-0.01(-0.12,0.12)
SD ETN SC + DMARD		0.59(0.21,1.59)	0.61(0.25,1.55)	-0.03(-0.18,0.02)
SD ABA IV + DMARD		0.31(0.10,0.99)	0.33(0.12,0.99)	-0.05(-0.23,0.00)
SD ADA SC + DMARD		0.21(0.05,0.78)	0.23(0.07,0.79)	-0.05(-0.24,-0.01)
SD ANA + DMARD		0.30(0.08,0.99)	0.32(0.10,0.99)	-0.05(-0.23,0.00)
SD CERTO SC + DMARD		0.20(0.04,1.03)	0.22(0.04,1.02)	-0.05(-0.25,0.00)
SD TOCI SC + DMARD		0.39(0.09,1.49)	0.41(0.11,1.46)	-0.04(-0.22,0.02)
LD ADA SC		0.31(0.05,1.46)	0.32(0.07,1.45)	-0.05(-0.27,0.01)
LD ETN SC		0.48(0.15,1.51)	0.51(0.17,1.47)	-0.03(-0.18,0.03)

(Continued)

LD GOLIV		3.16(0.59,22.08)	2.63(0.63,11.15)	0.11(-0.04,0.53)
LD RITUX IV + MTX		0.58(0.27,1.25)	0.60(0.30,1.23)	-0.03(-0.15,0.01)
LD ABA IV + MTX		0.78(0.30,1.96)	0.80(0.33,1.85)	-0.01(-0.13,0.06)
LD CERTO SC + MTX		1.02(0.22,3.73)	1.02(0.24,3.07)	0.00(-0.11,0.20)
LD ETN SC + MTX		0.31(0.09,0.96)	0.33(0.10,0.96)	-0.04(-0.21,0.00)
LD GOLIV + MTX		1.80(0.30,12.15)	1.67(0.34,7.95)	0.05(-0.10,0.40)
HD TOCI IV		0.58(0.23,1.47)	0.60(0.26,1.43)	-0.03(-0.16,0.02)
HD TOFA PO		0.26(0.04,1.29)	0.27(0.05,1.28)	-0.05(-0.28,0.01)
HD GOLIV SC		0.84(0.20,3.36)	0.86(0.22,2.83)	-0.01(-0.14,0.15)
HD ADA SC		0.46(0.09,1.99)	0.48(0.12,1.94)	-0.04(-0.26,0.02)
HD GOLIV SC + MTX		1.76(0.53,6.62)	1.63(0.57,4.72)	0.04(-0.05,0.29)
HD TOCI IV + MTX		0.65(0.23,2.10)	0.68(0.26,1.97)	-0.02(-0.15,0.06)
HD TOFA PO + MTX		1.04(0.38,2.78)	1.03(0.41,2.53)	0.00(-0.09,0.11)
HD INF IV + MTX		0.66(0.30,1.40)	0.68(0.34,1.35)	-0.02(-0.13,0.02)
HD CERTO SC + MTX		1.22(0.61,2.45)	1.19(0.63,2.19)	0.01(-0.04,0.13)
HD TOCI IV + DMARD		0.44(0.14,1.42)	0.47(0.17,1.40)	-0.04(-0.21,0.02)
SD GOLIV + MTX	SD TOFA PO + MTX	1.63(0.26,10.42)	1.50(0.29,6.85)	0.04(-0.14,0.38)
SD ANA SC + MTX		0.68(0.17,2.72)	0.71(0.20,2.41)	-0.02(-0.18,0.11)
SD ETN SC + DMARD		0.49(0.15,1.37)	0.51(0.19,1.35)	-0.04(-0.24,0.02)
SD ABA IV + DMARD		0.26(0.07,0.85)	0.28(0.09,0.86)	-0.06(-0.28,-0.01)
SD ADA SC + DMARD		0.17(0.04,0.64)	0.19(0.05,0.65)	-0.07(-0.30,-0.01)
SD ANA + DMARD		0.24(0.06,0.85)	0.27(0.08,0.86)	-0.06(-0.29,-0.01)
SD CERTO SC + DMARD		0.17(0.03,0.85)	0.18(0.03,0.86)	-0.07(-0.30,-0.01)
SD TOCI SC + DMARD		0.31(0.07,1.34)	0.33(0.08,1.31)	-0.06(-0.27,0.02)
LD ADA SC		0.25(0.04,1.17)	0.26(0.06,1.16)	-0.06(-0.32,0.00)
LD ETN SC		0.39(0.10,1.26)	0.42(0.12,1.24)	-0.05(-0.24,0.01)
LD GOLIV		2.70(0.43,16.94)	2.26(0.49,9.26)	0.10(-0.09,0.50)
LD RITUX IV + MTX		0.47(0.18,1.21)	0.50(0.21,1.19)	-0.04(-0.21,0.01)

(Continued)

LD ABA IV + MTX		0.63(0.20,1.86)	0.66(0.23,1.77)	-0.03(-0.19,0.05)
LD CERTO SC + MTX		0.80(0.14,4.11)	0.82(0.16,3.27)	-0.01(-0.19,0.20)
LD ETN SC + MTX		0.24(0.06,0.93)	0.27(0.07,0.93)	-0.06(-0.27,0.00)
LD GOL I IV + MTX		1.53(0.23,9.91)	1.43(0.26,6.41)	0.03(-0.15,0.36)
HD TOCI IV		0.46(0.17,1.36)	0.49(0.20,1.33)	-0.04(-0.22,0.02)
HD TOFA PO		0.20(0.03,0.97)	0.22(0.04,0.97)	-0.07(-0.33,0.00)
HD GOL I SC		0.66(0.15,3.17)	0.69(0.18,2.72)	-0.02(-0.21,0.13)
HD ADA SC		0.38(0.07,1.52)	0.40(0.09,1.49)	-0.05(-0.31,0.02)
HD GOL I SC + MTX		1.44(0.37,5.51)	1.36(0.41,4.24)	0.03(-0.11,0.26)
HD TOCI IV + MTX		0.54(0.17,1.89)	0.57(0.19,1.77)	-0.03(-0.20,0.05)
HD TOFA PO + MTX		0.83(0.41,1.71)	0.85(0.45,1.60)	-0.01(-0.11,0.05)
HD INF IV + MTX		0.53(0.20,1.36)	0.56(0.23,1.33)	-0.03(-0.20,0.02)
HD CERTO SC + MTX		0.97(0.32,3.10)	0.98(0.35,2.68)	0.00(-0.13,0.14)
HD TOCI IV + DMARD		0.36(0.10,1.20)	0.39(0.13,1.18)	-0.05(-0.26,0.01)
SD ANA SC + MTX	SD GOL I IV + MTX	0.43(0.05,3.71)	0.48(0.08,3.16)	-0.06(-0.43,0.13)
SD ETN SC + DMARD		0.30(0.04,1.95)	0.33(0.07,1.88)	-0.09(-0.48,0.03)
SD ABA IV + DMARD		0.16(0.02,1.13)	0.19(0.03,1.13)	-0.11(-0.52,0.00)
SD ADA SC + DMARD		0.10(0.01,0.80)	0.12(0.02,0.81)	-0.12(-0.53,0.00)
SD ANA + DMARD		0.15(0.02,1.06)	0.18(0.03,1.06)	-0.11(-0.51,0.00)
SD CERTO SC + DMARD		0.10(0.01,1.04)	0.12(0.02,1.04)	-0.12(-0.52,0.00)
SD TOCI SC + DMARD		0.20(0.02,1.52)	0.23(0.03,1.46)	-0.10(-0.51,0.02)
LD ADA SC		0.15(0.02,1.22)	0.17(0.03,1.21)	-0.12(-0.54,0.00)
LD ETN SC		0.24(0.03,1.76)	0.28(0.05,1.70)	-0.09(-0.48,0.03)
LD GOL I IV		1.66(0.47,6.30)	1.46(0.55,4.85)	0.06(-0.12,0.31)
LD RITUX IV + MTX		0.29(0.04,1.86)	0.34(0.07,1.80)	-0.09(-0.46,0.03)
LD ABA IV + MTX		0.40(0.05,2.91)	0.45(0.09,2.66)	-0.07(-0.45,0.07)
LD CERTO SC + MTX		0.51(0.05,5.40)	0.56(0.07,4.23)	-0.05(-0.42,0.19)
LD ETN SC + MTX		0.16(0.02,1.06)	0.19(0.03,1.05)	-0.11(-0.51,0.00)

(Continued)

LD GOLI IV + MTX		0.93(0.25,3.96)	0.94(0.31,3.35)	-0.01(-0.22,0.20)
HD TOCI IV		0.29(0.04,1.99)	0.34(0.07,1.92)	-0.09(-0.47,0.03)
HD TOFA PO		0.12(0.01,1.05)	0.14(0.03,1.05)	-0.12(-0.55,0.00)
HD GOLI SC		0.41(0.05,3.42)	0.46(0.07,3.01)	-0.07(-0.43,0.13)
HD ADA SC		0.23(0.02,1.84)	0.25(0.05,1.80)	-0.10(-0.53,0.02)
HD GOLI SC + MTX		0.91(0.12,7.69)	0.92(0.17,5.80)	-0.01(-0.35,0.26)
HD TOCI IV + MTX		0.34(0.04,2.45)	0.38(0.07,2.26)	-0.08(-0.45,0.06)
HD TOFA PO + MTX		0.51(0.08,3.53)	0.56(0.13,3.18)	-0.05(-0.40,0.12)
HD INF IV + MTX		0.34(0.05,2.09)	0.38(0.07,2.00)	-0.08(-0.45,0.04)
HD CERTO SC + MTX		0.62(0.08,4.49)	0.66(0.12,3.83)	-0.04(-0.39,0.16)
HD TOCI IV + DMARD		0.23(0.03,1.53)	0.26(0.05,1.50)	-0.10(-0.49,0.02)
SD ETN SC + DMARD	SD ANA SC + MTX	0.70(0.17,2.81)	0.72(0.22,2.69)	-0.02(-0.22,0.04)
SD ABA IV + DMARD		0.37(0.08,1.65)	0.39(0.10,1.61)	-0.04(-0.26,0.01)
SD ADA SC + DMARD		0.25(0.05,1.26)	0.26(0.06,1.25)	-0.04(-0.27,0.01)
SD ANA + DMARD		0.35(0.07,1.57)	0.37(0.09,1.53)	-0.04(-0.26,0.01)
SD CERTO SC + DMARD		0.25(0.03,1.62)	0.26(0.04,1.57)	-0.04(-0.27,0.02)
SD TOCI SC + DMARD		0.46(0.08,2.37)	0.48(0.10,2.25)	-0.03(-0.25,0.04)
LD ADA SC		0.36(0.04,2.25)	0.37(0.06,2.21)	-0.04(-0.30,0.02)
LD ETN SC		0.56(0.12,2.51)	0.58(0.14,2.35)	-0.02(-0.22,0.05)
LD GOLI IV		3.83(0.55,31.58)	3.09(0.61,17.01)	0.12(-0.06,0.55)
LD RITUX IV + MTX		0.68(0.18,2.40)	0.70(0.22,2.30)	-0.02(-0.19,0.05)
LD ABA IV + MTX		0.93(0.23,3.40)	0.93(0.26,3.15)	0.00(-0.16,0.09)
LD CERTO SC + MTX		1.19(0.19,6.81)	1.17(0.22,5.50)	0.01(-0.14,0.24)
LD ETN SC + MTX		0.36(0.08,1.61)	0.38(0.09,1.58)	-0.04(-0.24,0.02)
LD GOLI IV + MTX		2.20(0.28,17.70)	1.99(0.33,11.53)	0.06(-0.13,0.42)
HD TOCI IV		0.68(0.18,2.73)	0.70(0.21,2.61)	-0.02(-0.20,0.05)
HD TOFA PO		0.28(0.04,1.92)	0.30(0.05,1.89)	-0.04(-0.30,0.01)
HD GOLI SC		0.99(0.18,5.06)	1.00(0.20,4.43)	0.00(-0.16,0.16)

(Continued)

HD ADA SC		0.55(0.08,2.91)	0.56(0.11,2.82)	-0.03(-0.28,0.03)
HD GOL I SC + MTX		2.07(0.47,9.26)	1.88(0.52,7.19)	0.05(-0.07,0.31)
HD TOCI IV + MTX		0.80(0.18,3.42)	0.81(0.21,3.13)	-0.01(-0.18,0.09)
HD TOFA PO + MTX		1.22(0.30,4.91)	1.20(0.34,4.34)	0.01(-0.13,0.15)
HD INF IV + MTX		0.78(0.22,2.66)	0.79(0.26,2.52)	-0.01(-0.18,0.06)
HD CERTO SC + MTX		1.42(0.35,5.88)	1.37(0.41,5.02)	0.02(-0.11,0.20)
HD TOCI IV + DMARD		0.53(0.11,2.29)	0.55(0.14,2.22)	-0.03(-0.24,0.03)
SD ABA IV + DMARD	SD ETN SC + DMARD	0.53(0.22,1.24)	0.54(0.23,1.22)	-0.02(-0.08,0.01)
SD ADA SC + DMARD		0.35(0.12,0.99)	0.36(0.13,0.99)	-0.03(-0.10,0.00)
SD ANA + DMARD		0.50(0.19,1.28)	0.51(0.20,1.26)	-0.02(-0.08,0.01)
SD CERTO SC + DMARD		0.35(0.08,1.42)	0.36(0.08,1.37)	-0.03(-0.10,0.02)
SD TOCI SC + DMARD		0.63(0.20,2.22)	0.64(0.21,2.11)	-0.01(-0.07,0.05)
LD ADA SC		0.50(0.12,1.77)	0.51(0.14,1.74)	-0.02(-0.12,0.02)
LD ETN SC		0.81(0.26,2.48)	0.82(0.27,2.31)	-0.01(-0.06,0.08)
LD GOL I IV		5.45(0.94,33.63)	4.39(0.95,16.67)	0.15(0.00,0.59)
LD RITUX IV + MTX		0.97(0.36,2.72)	0.97(0.37,2.49)	0.00(-0.05,0.08)
LD ABA IV + MTX		1.30(0.43,4.19)	1.28(0.45,3.57)	0.01(-0.04,0.14)
LD CERTO SC + MTX		1.68(0.29,9.16)	1.62(0.31,6.62)	0.03(-0.05,0.30)
LD ETN SC + MTX		0.53(0.13,1.80)	0.54(0.14,1.73)	-0.02(-0.08,0.04)
LD GOL I IV + MTX		3.12(0.47,20.12)	2.80(0.49,12.01)	0.08(-0.03,0.47)
HD TOCI IV		0.97(0.41,2.40)	0.97(0.43,2.24)	0.00(-0.04,0.07)
HD TOFA PO		0.42(0.09,1.53)	0.43(0.11,1.52)	-0.02(-0.12,0.01)
HD GOL I SC		1.40(0.32,6.48)	1.37(0.34,5.09)	0.02(-0.05,0.22)
HD ADA SC		0.77(0.21,2.41)	0.78(0.23,2.33)	-0.01(-0.10,0.03)
HD GOL I SC + MTX		3.00(0.79,11.92)	2.70(0.80,8.13)	0.07(-0.01,0.38)
HD TOCI IV + MTX		1.13(0.37,3.53)	1.12(0.38,3.09)	0.00(-0.05,0.13)
HD TOFA PO + MTX		1.72(0.59,5.47)	1.66(0.60,4.62)	0.03(-0.03,0.20)
HD INF IV + MTX		1.11(0.40,3.12)	1.10(0.41,2.83)	0.00(-0.04,0.10)

(Continued)

HD CERTO SC + MTX		2.05(0.66,6.90)	1.94(0.68,5.29)	0.04(-0.02,0.27)
HD TOCI IV + DMARD		0.76(0.32,1.69)	0.77(0.33,1.65)	-0.01(-0.06,0.03)
SD ADA SC + DMARD	SD ABA IV + DMARD	0.66(0.23,1.89)	0.67(0.24,1.85)	-0.01(-0.05,0.02)
SD ANA + DMARD		0.95(0.37,2.40)	0.95(0.39,2.31)	0.00(-0.04,0.03)
SD CERTO SC + DMARD		0.66(0.15,2.70)	0.66(0.16,2.59)	-0.01(-0.05,0.04)
SD TOCI SC + DMARD		1.21(0.39,3.91)	1.20(0.40,3.66)	0.00(-0.03,0.08)
LD ADA SC		0.94(0.19,4.08)	0.94(0.20,3.95)	0.00(-0.07,0.03)
LD ETN SC		1.51(0.43,5.52)	1.49(0.45,5.09)	0.01(-0.03,0.12)
LD GOL I IV		10.09(1.53,75.14)	7.91(1.50,38.29)	0.17(0.02,0.62)
LD RITUX IV + MTX		1.82(0.61,6.07)	1.78(0.63,5.55)	0.02(-0.02,0.12)
LD ABA IV + MTX		2.51(0.70,9.02)	2.40(0.72,7.73)	0.03(-0.01,0.18)
LD CERTO SC + MTX		3.14(0.52,18.76)	2.93(0.53,13.87)	0.05(-0.02,0.34)
LD ETN SC + MTX		0.98(0.22,4.02)	0.98(0.23,3.80)	0.00(-0.05,0.07)
LD GOL I IV + MTX		5.91(0.83,45.07)	5.13(0.84,27.29)	0.10(-0.01,0.49)
HD TOCI IV		1.82(0.77,5.12)	1.78(0.78,4.68)	0.02(-0.01,0.10)
HD TOFA PO		0.78(0.15,3.82)	0.79(0.16,3.74)	0.00(-0.08,0.03)
HD GOL I SC		2.62(0.58,12.98)	2.49(0.59,10.41)	0.03(-0.02,0.26)
HD ADA SC		1.47(0.32,5.79)	1.45(0.34,5.55)	0.01(-0.06,0.05)
HD GOL I SC + MTX		5.69(1.34,26.59)	4.95(1.32,17.60)	0.10(0.01,0.42)
HD TOCI IV + MTX		2.13(0.68,7.44)	2.05(0.69,6.54)	0.02(-0.01,0.16)
HD TOFA PO + MTX		3.29(0.97,11.66)	3.07(0.97,9.70)	0.05(0.00,0.24)
HD INF IV + MTX		2.09(0.69,6.86)	2.02(0.70,6.22)	0.02(-0.01,0.14)
HD CERTO SC + MTX		3.91(1.09,15.15)	3.58(1.08,11.68)	0.06(0.00,0.31)
HD TOCI IV + DMARD		1.44(0.63,3.23)	1.42(0.65,3.10)	0.01(-0.02,0.06)
SD ANA + DMARD	SD ADA SC + DMARD	1.43(0.46,4.34)	1.42(0.48,4.20)	0.01(-0.02,0.05)
SD CERTO SC + DMARD		0.98(0.20,4.76)	0.98(0.20,4.51)	0.00(-0.04,0.05)
SD TOCI SC + DMARD		1.81(0.48,6.66)	1.78(0.49,6.24)	0.01(-0.02,0.09)

(Continued)

LD ADA SC		1.44(0.24,7.20)	1.43(0.25,6.94)	0.01(-0.06,0.04)
LD ETN SC		2.25(0.55,9.63)	2.20(0.56,8.79)	0.02(-0.02,0.13)
LD GOL I IV		16.15(1.98,122.00)	12.22(1.91,62.43)	0.18(0.02,0.64)
LD RITUX IV + MTX		2.75(0.78,10.76)	2.65(0.79,9.78)	0.03(-0.01,0.14)
LD ABA IV + MTX		3.77(0.94,15.63)	3.58(0.94,13.76)	0.04(0.00,0.19)
LD CERTO SC + MTX		4.77(0.70,32.76)	4.40(0.71,23.85)	0.06(-0.01,0.36)
LD ETN SC + MTX		1.47(0.29,6.93)	1.46(0.30,6.51)	0.01(-0.03,0.08)
LD GOL I IV + MTX		9.17(1.06,72.09)	7.80(1.06,45.57)	0.11(0.00,0.51)
HD TOCI IV		2.75(0.97,9.19)	2.66(0.97,8.40)	0.03(0.00,0.12)
HD TOFA PO		1.18(0.19,6.10)	1.17(0.20,5.97)	0.00(-0.06,0.03)
HD GOL I SC		3.93(0.76,23.07)	3.67(0.77,18.71)	0.04(-0.01,0.27)
HD ADA SC		2.20(0.41,9.67)	2.16(0.43,9.22)	0.02(-0.04,0.06)
HD GOL I SC + MTX		8.53(1.73,46.07)	7.31(1.68,31.81)	0.10(0.01,0.43)
HD TOCI IV + MTX		3.19(0.88,12.82)	3.05(0.89,11.09)	0.03(0.00,0.18)
HD TOFA PO + MTX		4.88(1.33,21.39)	4.52(1.31,17.87)	0.05(0.01,0.26)
HD INF IV + MTX		3.18(0.84,12.23)	3.03(0.85,11.01)	0.03(0.00,0.16)
HD CERTO SC + MTX		5.81(1.42,26.15)	5.28(1.39,20.12)	0.07(0.01,0.33)
HD TOCI IV + DMARD		2.16(0.76,5.90)	2.11(0.76,5.65)	0.02(-0.01,0.08)
SD CERTO SC + DMARD	SD ANA + DMARD	0.70(0.15,3.00)	0.71(0.15,2.89)	-0.01(-0.05,0.04)
SD TOCI SC + DMARD		1.25(0.39,4.40)	1.25(0.40,4.08)	0.00(-0.03,0.08)
LD ADA SC		1.01(0.20,4.45)	1.01(0.21,4.33)	0.00(-0.07,0.03)
LD ETN SC		1.57(0.45,6.44)	1.55(0.46,5.94)	0.01(-0.03,0.12)
LD GOL I IV		11.02(1.58,82.43)	8.43(1.54,41.91)	0.18(0.02,0.62)
LD RITUX IV + MTX		1.92(0.61,6.90)	1.86(0.62,6.33)	0.02(-0.02,0.13)
LD ABA IV + MTX		2.64(0.73,10.38)	2.52(0.74,8.95)	0.03(-0.01,0.18)
LD CERTO SC + MTX		3.37(0.52,21.60)	3.14(0.53,15.79)	0.05(-0.02,0.34)
LD ETN SC + MTX		1.04(0.22,4.60)	1.04(0.23,4.33)	0.00(-0.04,0.07)
LD GOL I IV + MTX		6.34(0.82,49.57)	5.47(0.84,29.87)	0.10(-0.01,0.50)

(Continued)

HD TOCI IV		1.95(0.72,5.47)	1.90(0.73,5.06)	0.02(-0.01,0.11)
HD TOFA PO		0.82(0.15,4.15)	0.83(0.17,4.04)	0.00(-0.08,0.03)
HD GOLI SC		2.80(0.59,14.12)	2.66(0.61,11.41)	0.04(-0.02,0.26)
HD ADA SC		1.54(0.32,6.46)	1.52(0.34,6.24)	0.01(-0.06,0.05)
HD GOLI SC + MTX		6.05(1.41,29.32)	5.25(1.38,19.59)	0.10(0.01,0.42)
HD TOCI IV + MTX		2.23(0.66,8.36)	2.16(0.67,7.30)	0.02(-0.01,0.16)
HD TOFA PO + MTX		3.46(0.97,13.39)	3.21(0.97,11.04)	0.05(0.00,0.25)
HD INF IV + MTX		2.19(0.66,7.82)	2.12(0.68,7.05)	0.02(-0.01,0.15)
HD CERTO SC + MTX		4.07(1.07,16.84)	3.73(1.06,13.00)	0.06(0.00,0.32)
HD TOCI IV + DMARD		1.51(0.60,3.67)	1.49(0.61,3.51)	0.01(-0.02,0.06)
SD TOCI SC + DMARD	SD CER- TO SC + DMARD	1.84(0.36,10.22)	1.81(0.37,9.67)	0.01(-0.04,0.10)
LD ADA SC		1.45(0.21,10.21)	1.44(0.22,9.85)	0.01(-0.07,0.04)
LD ETN SC		2.35(0.40,13.39)	2.29(0.42,12.27)	0.02(-0.03,0.13)
LD GOLI IV		16.49(1.62,145.80)	12.41(1.56,80.73)	0.18(0.02,0.64)
LD RITUX IV + MTX		2.81(0.58,15.17)	2.71(0.60,13.86)	0.02(-0.02,0.14)
LD ABA IV + MTX		3.91(0.69,22.50)	3.69(0.71,19.30)	0.04(-0.01,0.19)
LD CERTO SC + MTX		4.84(0.51,48.28)	4.41(0.53,35.63)	0.05(-0.02,0.36)
LD ETN SC + MTX		1.46(0.23,9.21)	1.45(0.25,8.69)	0.01(-0.05,0.09)
LD GOLI IV + MTX		9.44(0.88,90.20)	7.94(0.88,56.94)	0.11(0.00,0.50)
HD TOCI IV		2.88(0.64,13.40)	2.77(0.66,12.30)	0.02(-0.02,0.13)
HD TOFA PO		1.21(0.16,8.49)	1.21(0.17,8.27)	0.00(-0.08,0.03)
HD GOLI SC		3.93(0.55,34.46)	3.71(0.57,27.35)	0.04(-0.02,0.28)
HD ADA SC		2.22(0.34,14.61)	2.17(0.36,13.97)	0.02(-0.06,0.06)
HD GOLI SC + MTX		8.51(1.28,71.10)	7.35(1.25,48.69)	0.10(0.01,0.44)
HD TOCI IV + MTX		3.25(0.63,19.14)	3.10(0.65,16.82)	0.03(-0.02,0.18)
HD TOFA PO + MTX		5.08(0.98,28.44)	4.67(0.98,24.43)	0.05(0.00,0.26)
HD INF IV + MTX		3.24(0.65,18.74)	3.09(0.67,16.57)	0.03(-0.02,0.16)

(Continued)

HD CERTO SC + MTX		5.91(1.05,37.13)	5.38(1.04,28.90)	0.07(0.00,0.33)
HD TOCI IV + DMARD		2.18(0.52,9.76)	2.13(0.54,9.11)	0.02(-0.03,0.08)
LD ADA SC	SD TOCI SC + DMARD	0.80(0.13,4.09)	0.80(0.14,3.96)	-0.01(-0.12,0.03)
LD ETN SC		1.25(0.27,5.83)	1.24(0.30,5.30)	0.01(-0.07,0.11)
LD GOLIV		8.47(1.16,73.25)	6.58(1.15,38.20)	0.17(0.01,0.61)
LD RITUX IV + MTX		1.50(0.41,6.39)	1.48(0.43,5.83)	0.01(-0.05,0.11)
LD ABA IV + MTX		2.02(0.49,9.52)	1.95(0.51,8.30)	0.02(-0.04,0.17)
LD CERTO SC + MTX		2.62(0.37,19.05)	2.46(0.39,13.89)	0.04(-0.04,0.33)
LD ETN SC + MTX		0.81(0.16,4.16)	0.82(0.17,3.96)	0.00(-0.08,0.06)
LD GOLIV + MTX		4.74(0.59,42.79)	4.18(0.61,26.98)	0.09(-0.02,0.48)
HD TOCI IV		1.51(0.47,5.54)	1.48(0.49,5.16)	0.01(-0.05,0.10)
HD TOFA PO		0.65(0.10,3.67)	0.66(0.11,3.62)	-0.01(-0.12,0.02)
HD GOLIV SC		2.17(0.39,12.49)	2.08(0.41,10.37)	0.03(-0.05,0.25)
HD ADA SC		1.22(0.22,5.82)	1.21(0.24,5.60)	0.01(-0.10,0.05)
HD GOLIV SC + MTX		4.65(0.93,26.84)	4.06(0.94,18.35)	0.09(0.00,0.41)
HD TOCI IV + MTX		1.76(0.44,7.85)	1.71(0.45,7.03)	0.02(-0.04,0.15)
HD TOFA PO + MTX		2.76(0.60,12.01)	2.58(0.62,10.29)	0.04(-0.03,0.23)
HD INF IV + MTX		1.70(0.46,7.43)	1.66(0.48,6.67)	0.02(-0.05,0.13)
HD CERTO SC + MTX		3.15(0.73,15.95)	2.90(0.75,12.41)	0.05(-0.02,0.30)
HD TOCI IV + DMARD		1.19(0.39,3.55)	1.18(0.41,3.42)	0.00(-0.06,0.05)
LD ETN SC	LD ADA SC	1.59(0.28,9.81)	1.57(0.29,8.54)	0.01(-0.03,0.15)
LD GOLIV		10.84(1.75,102.40)	8.64(1.71,38.74)	0.18(0.02,0.65)
LD RITUX IV + MTX		1.96(0.39,10.77)	1.92(0.41,9.33)	0.02(-0.02,0.16)
LD ABA IV + MTX		2.71(0.51,16.21)	2.61(0.52,13.13)	0.03(-0.02,0.21)
LD CERTO SC + MTX		3.47(0.36,31.74)	3.24(0.37,20.74)	0.05(-0.02,0.37)
LD ETN SC + MTX		1.00(0.17,6.54)	1.00(0.18,5.97)	0.00(-0.03,0.10)
LD GOLIV + MTX		6.27(0.89,56.60)	5.54(0.90,29.64)	0.10(0.00,0.52)

(Continued)

HD TOCI IV		1.94(0.44,10.37)	1.89(0.45,9.01)	0.02(-0.02,0.15)
HD TOFA PO		0.81(0.25,2.64)	0.81(0.26,2.59)	0.00(-0.04,0.02)
HD GOLI SC		2.75(0.43,22.86)	2.63(0.44,16.38)	0.04(-0.02,0.29)
HD ADA SC		1.53(0.64,3.69)	1.51(0.64,3.55)	0.01(-0.02,0.04)
HD GOLI SC + MTX		5.87(0.92,45.19)	5.19(0.92,26.11)	0.10(0.00,0.46)
HD TOCI IV + MTX		2.28(0.40,14.43)	2.21(0.41,11.61)	0.03(-0.03,0.20)
HD TOFA PO + MTX		3.38(0.66,22.14)	3.20(0.67,16.02)	0.05(-0.01,0.29)
HD INF IV + MTX		2.24(0.46,12.53)	2.18(0.47,10.32)	0.03(-0.02,0.18)
HD CERTO SC + MTX		3.96(0.72,27.13)	3.69(0.73,18.22)	0.06(-0.01,0.35)
HD TOCI IV + DMARD		1.51(0.32,7.27)	1.49(0.33,6.63)	0.01(-0.03,0.10)
LD GOLI IV	LD ETN SC	6.83(1.04,49.43)	5.29(1.03,27.62)	0.16(0.00,0.59)
LD RITUX IV + MTX		1.21(0.41,3.66)	1.20(0.44,3.44)	0.01(-0.06,0.08)
LD ABA IV + MTX		1.63(0.46,5.83)	1.59(0.49,5.26)	0.02(-0.05,0.14)
LD CERTO SC + MTX		2.07(0.34,11.64)	1.97(0.36,8.95)	0.03(-0.05,0.30)
LD ETN SC + MTX		0.63(0.14,2.73)	0.65(0.15,2.64)	-0.01(-0.11,0.05)
LD GOLI IV + MTX		3.93(0.50,27.79)	3.41(0.52,19.30)	0.08(-0.03,0.46)
HD TOCI IV		1.22(0.38,4.00)	1.21(0.41,3.73)	0.01(-0.07,0.08)
HD TOFA PO		0.51(0.08,2.75)	0.52(0.09,2.69)	-0.02(-0.15,0.02)
HD GOLI SC		1.76(0.37,7.99)	1.68(0.38,6.77)	0.02(-0.06,0.21)
HD ADA SC		0.96(0.17,4.65)	0.96(0.19,4.47)	0.00(-0.14,0.04)
HD GOLI SC + MTX		3.83(0.85,15.86)	3.35(0.86,11.52)	0.08(-0.01,0.37)
HD TOCI IV + MTX		1.41(0.37,5.43)	1.39(0.39,4.85)	0.01(-0.06,0.14)
HD TOFA PO + MTX		2.14(0.66,7.89)	2.03(0.68,6.92)	0.03(-0.03,0.20)
HD INF IV + MTX		1.38(0.42,4.39)	1.36(0.45,4.10)	0.01(-0.06,0.10)
HD CERTO SC + MTX		2.55(0.72,9.23)	2.35(0.74,7.73)	0.05(-0.02,0.26)
HD TOCI IV + DMARD		0.95(0.26,3.27)	0.95(0.29,3.11)	0.00(-0.10,0.05)
LD RITUX IV + MTX	LD GOLI IV	0.17(0.03,1.00)	0.22(0.06,1.00)	-0.15(-0.57,0.00)
LD ABA IV + MTX		0.24(0.03,1.45)	0.30(0.07,1.39)	-0.13(-0.56,0.03)

(Continued)

LD CERTO SC + MTX		0.30(0.03,2.89)	0.37(0.05,2.40)	-0.11(-0.54,0.13)
LD ETN SC + MTX		0.09(0.01,0.61)	0.12(0.02,0.64)	-0.17(-0.62,-0.02)
LD GOL I IV + MTX		0.56(0.17,2.02)	0.64(0.22,1.76)	-0.06(-0.32,0.11)
HD TOCI IV		0.17(0.03,1.09)	0.22(0.05,1.08)	-0.15(-0.58,0.00)
HD TOFA PO		0.08(0.01,0.54)	0.10(0.02,0.55)	-0.18(-0.66,-0.02)
HD GOL I SC		0.25(0.03,2.00)	0.31(0.06,1.80)	-0.13(-0.55,0.07)
HD ADA SC		0.14(0.02,0.86)	0.18(0.04,0.86)	-0.17(-0.64,-0.01)
HD GOL I SC + MTX		0.54(0.08,4.00)	0.61(0.13,3.18)	-0.06(-0.46,0.21)
HD TOCI IV + MTX		0.20(0.03,1.35)	0.26(0.05,1.31)	-0.14(-0.56,0.02)
HD TOFA PO + MTX		0.31(0.05,1.96)	0.38(0.09,1.79)	-0.12(-0.52,0.06)
HD INF IV + MTX		0.20(0.03,1.12)	0.26(0.06,1.11)	-0.14(-0.56,0.01)
HD CERTO SC + MTX		0.38(0.05,2.33)	0.45(0.10,2.05)	-0.10(-0.51,0.10)
HD TOCI IV + DMARD		0.14(0.02,0.88)	0.17(0.04,0.89)	-0.16(-0.60,-0.01)
LD ABA IV + MTX	LD RITUX IV + MTX	1.36(0.52,3.30)	1.33(0.54,3.04)	0.01(-0.04,0.11)
LD CERTO SC + MTX		1.71(0.36,7.85)	1.64(0.38,6.18)	0.03(-0.05,0.28)
LD ETN SC + MTX		0.52(0.16,1.67)	0.53(0.17,1.62)	-0.02(-0.11,0.02)
LD GOL I IV + MTX		3.25(0.50,19.21)	2.87(0.51,12.56)	0.08(-0.03,0.44)
HD TOCI IV		1.03(0.39,2.39)	1.02(0.42,2.28)	0.00(-0.07,0.06)
HD TOFA PO		0.43(0.07,2.03)	0.45(0.09,2.00)	-0.02(-0.16,0.02)
HD GOL I SC		1.42(0.35,5.66)	1.38(0.37,4.70)	0.01(-0.06,0.21)
HD ADA SC		0.79(0.16,3.43)	0.80(0.19,3.31)	-0.01(-0.14,0.04)
HD GOL I SC + MTX		3.03(0.94,11.06)	2.71(0.94,8.04)	0.07(0.00,0.35)
HD TOCI IV + MTX		1.15(0.39,3.49)	1.15(0.41,3.18)	0.01(-0.06,0.11)
HD TOFA PO + MTX		1.78(0.69,4.56)	1.70(0.71,4.01)	0.03(-0.02,0.18)
HD INF IV + MTX		1.15(0.53,2.34)	1.14(0.55,2.20)	0.00(-0.04,0.07)
HD CERTO SC + MTX		2.10(0.84,5.76)	1.97(0.85,4.67)	0.04(-0.01,0.24)
HD TOCI IV + DMARD		0.77(0.26,2.20)	0.78(0.28,2.12)	-0.01(-0.10,0.04)

(Continued)

LD CERTO SC + MTX	LD ABA IV + MTX	1.26(0.24,6.61)	1.23(0.26,5.30)	0.01(-0.10,0.25)
LD ETN SC + MTX		0.39(0.10,1.49)	0.41(0.11,1.46)	-0.03(-0.17,0.02)
LD GOLI IV + MTX		2.37(0.35,16.71)	2.14(0.39,10.92)	0.06(-0.07,0.42)
HD TOCI IV		0.74(0.26,2.18)	0.75(0.30,2.09)	-0.01(-0.12,0.05)
HD TOFA PO		0.31(0.05,1.76)	0.32(0.07,1.73)	-0.04(-0.22,0.01)
HD GOLI SC		1.05(0.23,4.85)	1.05(0.25,3.97)	0.00(-0.11,0.18)
HD ADA SC		0.58(0.11,2.69)	0.60(0.13,2.61)	-0.02(-0.20,0.03)
HD GOLI SC + MTX		2.22(0.61,9.17)	2.02(0.64,6.89)	0.06(-0.04,0.33)
HD TOCI IV + MTX		0.83(0.27,2.90)	0.85(0.29,2.68)	-0.01(-0.11,0.09)
HD TOFA PO + MTX		1.32(0.46,4.03)	1.28(0.49,3.58)	0.01(-0.07,0.16)
HD INF IV + MTX		0.84(0.33,2.15)	0.85(0.36,2.03)	-0.01(-0.10,0.05)
HD CERTO SC + MTX		1.55(0.52,4.90)	1.49(0.54,4.11)	0.03(-0.05,0.20)
HD TOCI IV + DMARD		0.56(0.16,1.93)	0.58(0.19,1.89)	-0.02(-0.16,0.03)
LD ETN SC + MTX	LD CERTO SC + MTX	0.30(0.05,1.92)	0.32(0.07,1.86)	-0.05(-0.33,0.02)
LD GOLI IV + MTX		1.88(0.19,18.68)	1.71(0.24,12.62)	0.05(-0.20,0.41)
HD TOCI IV		0.59(0.11,3.13)	0.61(0.15,2.96)	-0.03(-0.28,0.05)
HD TOFA PO		0.23(0.03,1.92)	0.25(0.04,1.90)	-0.06(-0.37,0.01)
HD GOLI SC		0.83(0.11,5.66)	0.84(0.14,4.82)	-0.01(-0.26,0.16)
HD ADA SC		0.44(0.06,3.66)	0.46(0.09,3.55)	-0.04(-0.35,0.03)
HD GOLI SC + MTX		1.78(0.32,10.84)	1.64(0.39,8.10)	0.04(-0.15,0.31)
HD TOCI IV + MTX		0.68(0.11,4.01)	0.70(0.15,3.74)	-0.02(-0.27,0.09)
HD TOFA PO + MTX		1.04(0.19,6.11)	1.03(0.24,5.45)	0.00(-0.22,0.15)
HD INF IV + MTX		0.66(0.15,3.06)	0.69(0.19,2.93)	-0.02(-0.26,0.06)
HD CERTO SC + MTX		1.20(0.31,5.73)	1.17(0.37,5.12)	0.01(-0.16,0.17)
HD TOCI IV + DMARD		0.46(0.07,2.65)	0.48(0.10,2.57)	-0.04(-0.32,0.03)
LD GOLI IV + MTX	LD ETN SC + MTX	6.13(0.83,43.62)	5.25(0.84,29.87)	0.10(-0.01,0.48)
HD TOCI IV		1.88(0.56,7.62)	1.83(0.58,7.10)	0.02(-0.03,0.11)

(Continued)

HD TOFA PO		0.82(0.12,5.16)	0.83(0.13,5.03)	0.00(-0.10,0.03)
HD GOLI SC		2.74(0.49,14.78)	2.60(0.51,12.17)	0.03(-0.03,0.25)
HD ADA SC		1.46(0.26,8.32)	1.44(0.28,7.97)	0.01(-0.08,0.05)
HD GOLI SC + MTX		5.83(1.36,27.75)	5.02(1.32,20.70)	0.09(0.01,0.41)
HD TOCI IV + MTX		2.19(0.52,10.32)	2.11(0.54,9.41)	0.02(-0.03,0.16)
HD TOFA PO + MTX		3.42(0.87,13.28)	3.18(0.88,11.55)	0.05(-0.01,0.23)
HD INF IV + MTX		2.17(0.65,7.50)	2.09(0.67,6.91)	0.02(-0.02,0.13)
HD CERTO SC + MTX		3.95(1.14,15.46)	3.60(1.13,12.95)	0.06(0.00,0.29)
HD TOCI IV + DMARD		1.46(0.35,6.28)	1.44(0.37,5.99)	0.01(-0.05,0.07)
HD TOCI IV	LD GOLI IV + MTX	0.30(0.05,2.05)	0.34(0.08,1.97)	-0.08(-0.45,0.03)
HD TOFA PO		0.14(0.01,1.02)	0.15(0.03,1.02)	-0.11(-0.53,0.00)
HD GOLI SC		0.44(0.05,3.88)	0.48(0.08,3.35)	-0.06(-0.42,0.14)
HD ADA SC		0.24(0.03,1.75)	0.27(0.06,1.71)	-0.09(-0.50,0.02)
HD GOLI SC + MTX		0.94(0.12,8.65)	0.94(0.17,6.55)	-0.01(-0.33,0.27)
HD TOCI IV + MTX		0.34(0.05,2.58)	0.39(0.08,2.40)	-0.07(-0.43,0.06)
HD TOFA PO + MTX		0.54(0.09,3.74)	0.59(0.13,3.25)	-0.05(-0.38,0.13)
HD INF IV + MTX		0.36(0.06,2.22)	0.40(0.09,2.10)	-0.07(-0.43,0.04)
HD CERTO SC + MTX		0.67(0.09,4.60)	0.71(0.14,3.79)	-0.03(-0.37,0.16)
HD TOCI IV + DMARD		0.24(0.03,1.69)	0.27(0.06,1.63)	-0.09(-0.47,0.02)
HD TOFA PO	HD TOCI IV	0.43(0.08,1.99)	0.44(0.09,1.96)	-0.02(-0.16,0.01)
HD GOLI SC		1.39(0.35,6.05)	1.36(0.37,4.99)	0.01(-0.06,0.21)
HD ADA SC		0.80(0.17,3.09)	0.81(0.19,2.99)	-0.01(-0.13,0.04)
HD GOLI SC + MTX		3.05(0.89,11.48)	2.72(0.89,8.07)	0.07(-0.01,0.36)
HD TOCI IV + MTX		1.15(0.53,2.56)	1.14(0.55,2.36)	0.01(-0.04,0.09)
HD TOFA PO + MTX		1.80(0.61,4.93)	1.72(0.63,4.32)	0.03(-0.03,0.18)
HD INF IV + MTX		1.14(0.45,2.80)	1.13(0.47,2.64)	0.00(-0.05,0.08)
HD CERTO SC + MTX		2.11(0.73,6.38)	1.98(0.75,5.17)	0.04(-0.02,0.25)

(Continued)

HD TOCI IV + DMARD		0.77(0.31,1.88)	0.78(0.33,1.81)	-0.01(-0.08,0.03)
HD GOLI SC	HD TOFA PO	3.40(0.52,26.74)	3.23(0.53,18.87)	0.04(-0.01,0.30)
HD ADA SC		1.83(0.61,5.97)	1.80(0.62,5.68)	0.01(-0.01,0.06)
HD GOLI SC + MTX		7.54(1.02,53.03)	6.65(1.02,30.60)	0.10(0.00,0.46)
HD TOCI IV + MTX		2.71(0.52,18.48)	2.62(0.53,14.87)	0.03(-0.01,0.21)
HD TOFA PO + MTX		4.18(0.88,27.29)	3.94(0.88,20.32)	0.05(0.00,0.29)
HD INF IV + MTX		2.59(0.53,15.27)	2.51(0.54,12.69)	0.03(-0.01,0.18)
HD CERTO SC + MTX		4.75(0.85,34.40)	4.42(0.85,23.12)	0.06(0.00,0.36)
HD TOCI IV + DMARD		1.83(0.38,9.43)	1.80(0.39,8.52)	0.01(-0.02,0.11)
HD ADA SC	HD GOLI SC	0.53(0.08,3.39)	0.54(0.11,3.27)	-0.03(-0.28,0.04)
HD GOLI SC + MTX		2.14(0.65,7.60)	1.95(0.69,6.20)	0.06(-0.04,0.28)
HD TOCI IV + MTX		0.81(0.16,4.00)	0.82(0.19,3.64)	-0.01(-0.20,0.11)
HD TOFA PO + MTX		1.26(0.27,5.74)	1.24(0.32,4.99)	0.01(-0.15,0.17)
HD INF IV + MTX		0.79(0.20,3.25)	0.80(0.24,3.05)	-0.01(-0.19,0.07)
HD CERTO SC + MTX		1.44(0.34,7.29)	1.39(0.39,6.22)	0.02(-0.13,0.22)
HD TOCI IV + DMARD		0.55(0.11,2.33)	0.57(0.14,2.26)	-0.02(-0.24,0.04)
HD GOLI SC + MTX	HD ADA SC	3.96(0.66,25.40)	3.58(0.67,14.63)	0.09(-0.01,0.43)
HD TOCI IV + MTX		1.43(0.31,8.45)	1.41(0.32,6.87)	0.01(-0.04,0.19)
HD TOFA PO + MTX		2.20(0.53,12.89)	2.11(0.55,9.58)	0.04(-0.02,0.27)
HD INF IV + MTX		1.42(0.32,7.34)	1.40(0.34,6.12)	0.01(-0.04,0.16)
HD CERTO SC + MTX		2.62(0.57,15.86)	2.47(0.58,10.84)	0.05(-0.02,0.34)
HD TOCI IV + DMARD		0.97(0.25,4.31)	0.97(0.26,3.94)	0.00(-0.04,0.09)
HD TOCI IV + MTX	HD GOLI SC + MTX	0.37(0.09,1.50)	0.42(0.12,1.45)	-0.06(-0.35,0.03)
HD TOFA PO + MTX		0.59(0.14,2.27)	0.64(0.18,2.10)	-0.04(-0.28,0.08)
HD INF IV + MTX		0.38(0.11,1.22)	0.42(0.15,1.20)	-0.07(-0.33,0.01)
HD CERTO SC + MTX		0.69(0.17,2.72)	0.73(0.23,2.42)	-0.03(-0.27,0.10)

(Continued)

HD TOCI IV + DMARD		0.25(0.06,1.03)	0.28(0.08,1.03)	-0.08(-0.40,0.00)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.54(0.46,5.11)	1.48(0.49,4.51)	0.02(-0.06,0.17)
HD INF IV + MTX		1.00(0.31,2.85)	1.00(0.34,2.69)	0.00(-0.10,0.07)
HD CERTO SC + MTX		1.83(0.51,6.30)	1.74(0.54,5.27)	0.03(-0.05,0.23)
HD TOCI IV + DMARD		0.67(0.21,2.15)	0.68(0.23,2.06)	-0.01(-0.14,0.03)
HD INF IV + MTX	HD TOFA PO + MTX	0.63(0.24,1.64)	0.66(0.27,1.60)	-0.02(-0.17,0.03)
HD CERTO SC + MTX		1.15(0.37,3.77)	1.13(0.41,3.25)	0.01(-0.10,0.17)
HD TOCI IV + DMARD		0.43(0.12,1.46)	0.46(0.15,1.44)	-0.04(-0.22,0.02)
HD CERTO SC + MTX	HD INF IV + MTX	1.85(0.72,5.14)	1.75(0.74,4.24)	0.03(-0.02,0.22)
HD TOCI IV + DMARD		0.67(0.21,2.04)	0.69(0.24,1.98)	-0.01(-0.12,0.03)
HD TOCI IV + DMARD	HD CERTO SC + MTX	0.37(0.10,1.33)	0.40(0.13,1.31)	-0.05(-0.29,0.01)
Random-effects model	Residual deviance	152 vs 153 data points		
	Deviance information criteria	843.894		
Fixed-effect model	Residual deviance	161.1 vs 153 data points		
	Deviance information criteria	845.774		
Note				
Total participants	28,661			
Total studies	61			
2-arm	38			
3-arm	16			
4-arm	6			
5-arm	1			

Appendix 21. Serious adverse events: subgroup - established RA (2 to 10 years)

SAE established: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	1.96(0.39,5.90)	1.90(0.39,5.24)	0.02(-0.02,0.12)
DMARD		0.76(0.20,2.86)	0.76(0.20,2.73)	-0.01(-0.03,0.05)
MTX + DMARD		1.08(0.19,4.61)	1.08(0.20,4.15)	0.00(-0.03,0.09)
SD ETN SC		2.30(0.66,6.73)	2.22(0.67,5.90)	0.04(-0.01,0.14)
SD ADA SC		1.52(0.73,3.04)	1.49(0.73,2.90)	0.01(-0.01,0.05)
SD TOCI IV		1.69(0.57,4.79)	1.65(0.58,4.33)	0.02(-0.01,0.10)
SD TOFA PO		0.37(0.15,0.95)	0.38(0.16,0.95)	-0.02(-0.04,0.00)
SD CERTO SC		4.55(1.35,24.41)	4.09(1.34,16.75)	0.09(0.01,0.31)
SD TOC SC + PL IV		1.46(0.40,5.21)	1.44(0.41,4.65)	0.01(-0.02,0.11)
SD GOLI IV		1.88(0.12,52.25)	1.83(0.12,24.92)	0.02(-0.03,0.51)
SD INF IV + MTX		1.89(0.45,6.27)	1.84(0.46,5.47)	0.02(-0.02,0.13)
SD ETN SC + MTX		1.85(0.37,6.22)	1.81(0.38,5.44)	0.02(-0.02,0.13)
SD ABA IV + MTX		1.52(0.30,5.17)	1.50(0.31,4.64)	0.01(-0.02,0.11)
SD CERTO SC + MTX		2.78(0.59,10.08)	2.64(0.60,8.00)	0.05(-0.01,0.21)
SD ADA SC + MTX		2.30(0.36,7.68)	2.22(0.37,6.52)	0.03(-0.02,0.16)
SD ABA SC + MTX		1.10(0.21,4.40)	1.09(0.22,4.02)	0.00(-0.03,0.09)
SD GOLI SC + MTX		4.26(0.71,17.63)	3.89(0.71,12.29)	0.08(-0.01,0.33)
SD RITUX IV + MTX		1.59(0.31,5.87)	1.56(0.31,5.16)	0.02(-0.02,0.12)
SD TOFA PO + MTX		4.59(0.80,17.14)	4.14(0.81,11.97)	0.09(-0.01,0.31)
SD GOLI IV + MTX		5.40(0.45,107.10)	4.77(0.46,32.58)	0.11(-0.02,0.71)
SD ETN SC + DMARD		2.12(0.67,6.42)	2.05(0.68,5.62)	0.03(-0.01,0.13)
SD ADA SC + DMARD		0.54(0.11,2.58)	0.55(0.12,2.47)	-0.01(-0.04,0.04)
SD CERTO SC + DMARD		0.52(0.09,3.17)	0.53(0.09,2.99)	-0.01(-0.04,0.05)
LD ADA SC		0.77(0.30,1.68)	0.78(0.31,1.65)	-0.01(-0.03,0.02)
LD ETN SC		1.51(0.33,6.09)	1.48(0.34,5.28)	0.01(-0.02,0.13)

(Continued)

LD GOL I IV		9.67(0.64,176.00)	7.62(0.65,38.84)	0.20(-0.01,0.77)
LD RITUX IV + MTX		1.03(0.19,3.98)	1.03(0.20,3.67)	0.00(-0.03,0.08)
LD ABA IV + MTX		2.31(0.39,9.43)	2.23(0.40,7.69)	0.03(-0.02,0.20)
LD CERTO SC + MTX		2.65(0.32,13.80)	2.52(0.33,9.96)	0.04(-0.02,0.28)
LD ETN SC + MTX		0.94(0.18,4.22)	0.94(0.19,3.86)	0.00(-0.03,0.09)
LD GOL I IV + MTX		5.28(0.35,98.46)	4.68(0.36,33.02)	0.11(-0.02,0.67)
HD TOCI IV		1.62(0.39,6.09)	1.59(0.40,5.38)	0.02(-0.02,0.13)
HD TOFA PO		0.49(0.20,1.18)	0.50(0.21,1.17)	-0.01(-0.03,0.00)
HD ADA SC		1.17(0.51,2.71)	1.16(0.52,2.61)	0.00(-0.02,0.04)
HD GOL I SC		2.50(0.38,12.40)	2.39(0.39,9.42)	0.04(-0.02,0.25)
HD GOL I SC + MTX		5.84(0.85,23.62)	5.10(0.86,14.31)	0.12(0.00,0.40)
HD TOCI IV + MTX		1.98(0.41,8.14)	1.92(0.42,6.85)	0.03(-0.02,0.17)
HD TOFA PO + MTX		3.77(0.70,14.44)	3.47(0.71,10.70)	0.07(-0.01,0.28)
HD CERTO SC + MTX		3.56(0.84,13.69)	3.31(0.85,9.97)	0.07(-0.01,0.27)
HD INF IV + MTX		1.84(0.36,6.84)	1.79(0.37,5.88)	0.02(-0.02,0.14)
HD TOCI IV + DMARD		1.16(0.27,5.05)	1.15(0.27,4.52)	0.00(-0.03,0.10)
DMARD	MTX	0.41(0.16,0.98)	0.42(0.17,0.98)	-0.03(-0.10,0.00)
MTX + DMARD		0.57(0.18,1.64)	0.58(0.19,1.59)	-0.02(-0.09,0.03)
SD ETN SC		1.23(0.58,2.42)	1.21(0.60,2.32)	0.01(-0.04,0.06)
SD ADA SC		0.82(0.22,3.48)	0.83(0.25,3.36)	-0.01(-0.11,0.04)
SD TOCI IV		0.89(0.21,4.69)	0.90(0.23,4.41)	-0.01(-0.11,0.08)
SD TOFA PO		0.19(0.05,1.01)	0.20(0.06,1.01)	-0.04(-0.15,0.00)
SD CERTO SC		2.31(0.42,19.65)	2.15(0.46,14.43)	0.06(-0.07,0.30)
SD TOC SC + PL IV		0.78(0.15,4.75)	0.79(0.17,4.40)	-0.01(-0.11,0.08)
SD GOL I IV		0.93(0.07,23.30)	0.94(0.07,11.95)	0.00(-0.10,0.49)
SD INF IV + MTX		1.00(0.62,1.57)	1.00(0.64,1.54)	0.00(-0.03,0.04)
SD ETN SC + MTX		0.95(0.47,1.96)	0.95(0.49,1.87)	0.00(-0.05,0.05)
SD ABA IV + MTX		0.80(0.49,1.19)	0.81(0.51,1.18)	-0.01(-0.05,0.01)

(Continued)

SD CERTO SC + MTX	1.51(0.92,2.49)	1.46(0.92,2.29)	0.02(0.00,0.11)
SD ADA SC + MTX	1.11(0.49,2.42)	1.11(0.51,2.25)	0.00(-0.04,0.08)
SD ABA SC + MTX	0.59(0.27,1.18)	0.60(0.28,1.17)	-0.02(-0.07,0.01)
SD GOLI SC + MTX	2.22(0.64,6.56)	2.06(0.66,5.32)	0.05(-0.02,0.26)
SD RITUX IV + MTX	0.85(0.46,1.57)	0.86(0.48,1.52)	-0.01(-0.05,0.04)
SD TOFA PO + MTX	2.23(0.97,5.52)	2.06(0.98,4.48)	0.06(0.00,0.22)
SD GOLI IV + MTX	2.67(0.43,47.82)	2.40(0.45,16.29)	0.08(-0.03,0.67)
SD ETN SC + DMARD	1.14(0.43,2.79)	1.13(0.45,2.67)	0.01(-0.06,0.07)
SD ADA SC + DMARD	0.29(0.09,0.96)	0.31(0.09,0.96)	-0.03(-0.12,0.00)
SD CERTO SC + DMARD	0.28(0.06,1.45)	0.29(0.06,1.43)	-0.03(-0.12,0.01)
LD ADA SC	0.42(0.09,1.60)	0.43(0.11,1.59)	-0.03(-0.14,0.01)
LD ETN SC	0.80(0.30,1.90)	0.81(0.31,1.81)	-0.01(-0.07,0.05)
LD GOLI IV	4.77(0.85,81.13)	3.72(0.86,19.33)	0.17(-0.01,0.73)
LD RITUX IV + MTX	0.56(0.29,1.06)	0.57(0.30,1.06)	-0.02(-0.07,0.00)
LD ABA IV + MTX	1.19(0.56,2.57)	1.18(0.57,2.33)	0.01(-0.03,0.10)
LD CERTO SC + MTX	1.45(0.24,5.28)	1.41(0.25,4.30)	0.02(-0.05,0.21)
LD ETN SC + MTX	0.50(0.17,1.32)	0.52(0.18,1.29)	-0.02(-0.09,0.02)
LD GOLI IV + MTX	2.68(0.49,45.71)	2.42(0.51,16.27)	0.08(-0.03,0.62)
HD TOCI IV	0.87(0.41,1.83)	0.88(0.43,1.75)	-0.01(-0.06,0.05)
HD TOFA PO	0.26(0.07,1.26)	0.27(0.07,1.25)	-0.04(-0.14,0.00)
HD ADA SC	0.61(0.16,2.93)	0.63(0.18,2.83)	-0.02(-0.12,0.03)
HD GOLI SC	1.32(0.35,4.40)	1.29(0.36,3.74)	0.01(-0.05,0.17)
HD GOLI SC + MTX	3.00(1.10,8.04)	2.64(1.09,5.79)	0.09(0.00,0.33)
HD TOCI IV + MTX	1.05(0.42,2.61)	1.04(0.44,2.41)	0.00(-0.05,0.09)
HD TOFA PO + MTX	1.88(0.73,4.58)	1.77(0.74,3.90)	0.04(-0.01,0.19)
HD CERTO SC + MTX	1.88(0.89,3.98)	1.78(0.90,3.50)	0.04(-0.01,0.18)
HD INF IV + MTX	0.97(0.49,1.89)	0.97(0.51,1.79)	0.00(-0.04,0.05)
HD TOCI IV + DMARD	0.62(0.21,1.71)	0.64(0.23,1.64)	-0.02(-0.09,0.03)

(Continued)

MTX + DMARD	DMARD	1.36(0.35,4.84)	1.35(0.36,4.47)	0.01(-0.03,0.08)
SD ETN SC		2.95(1.26,7.79)	2.80(1.24,7.26)	0.04(0.01,0.12)
SD ADA SC		1.98(0.52,7.97)	1.93(0.54,7.59)	0.02(-0.03,0.06)
SD TOCI IV		2.15(0.48,10.49)	2.09(0.50,9.63)	0.02(-0.03,0.10)
SD TOFA PO		0.47(0.11,2.81)	0.48(0.12,2.76)	-0.01(-0.07,0.01)
SD CERTO SC		6.23(0.92,44.44)	5.53(0.92,32.46)	0.10(0.00,0.31)
SD TOC SC + PL IV		1.94(0.36,10.55)	1.89(0.37,9.48)	0.02(-0.04,0.11)
SD GOLI IV		2.27(0.18,57.03)	2.17(0.18,27.77)	0.03(-0.04,0.51)
SD INF IV + MTX		2.45(0.90,6.95)	2.35(0.91,6.35)	0.03(0.00,0.12)
SD ETN SC + MTX		2.34(0.86,6.83)	2.25(0.86,6.27)	0.03(-0.01,0.11)
SD ABA IV + MTX		1.90(0.71,5.44)	1.86(0.72,5.06)	0.02(-0.01,0.09)
SD CERTO SC + MTX		3.70(1.33,10.74)	3.46(1.31,9.24)	0.05(0.01,0.19)
SD ADA SC + MTX		2.77(0.81,8.47)	2.64(0.82,7.66)	0.04(-0.01,0.15)
SD ABA SC + MTX		1.41(0.44,4.63)	1.40(0.45,4.36)	0.01(-0.03,0.08)
SD GOLI SC + MTX		5.36(1.32,21.74)	4.75(1.31,16.88)	0.09(0.01,0.32)
SD RITUX IV + MTX		2.07(0.65,6.43)	2.01(0.66,5.91)	0.02(-0.01,0.11)
SD TOFA PO + MTX		5.58(1.73,18.92)	4.94(1.67,14.94)	0.09(0.01,0.29)
SD GOLI IV + MTX		6.73(0.82,121.50)	5.74(0.82,37.64)	0.11(0.00,0.71)
SD ETN SC + DMARD		2.72(1.02,7.85)	2.61(1.02,7.26)	0.03(0.00,0.11)
SD ADA SC + DMARD		0.74(0.31,1.65)	0.74(0.31,1.62)	0.00(-0.03,0.02)
SD CERTO SC + DMARD		0.70(0.18,2.38)	0.71(0.18,2.29)	-0.01(-0.04,0.04)
LD ADA SC		1.03(0.21,4.28)	1.03(0.22,4.17)	0.00(-0.06,0.03)
LD ETN SC		1.88(0.61,6.75)	1.84(0.62,6.19)	0.02(-0.02,0.11)
LD GOLI IV		11.82(1.38,182.20)	8.82(1.37,46.95)	0.20(0.01,0.77)
LD RITUX IV + MTX		1.38(0.43,4.39)	1.37(0.44,4.15)	0.01(-0.03,0.07)
LD ABA IV + MTX		2.92(0.88,10.07)	2.78(0.88,8.61)	0.04(0.00,0.18)
LD CERTO SC + MTX		3.43(0.45,16.59)	3.22(0.46,13.21)	0.05(-0.02,0.27)
LD ETN SC + MTX		1.20(0.33,4.69)	1.19(0.34,4.41)	0.00(-0.04,0.08)

(Continued)

LD GOLI IV + MTX		6.52(0.76,107.20)	5.63(0.77,38.47)	0.11(0.00,0.67)
HD TOCI IV		2.12(1.07,4.54)	2.06(1.06,4.29)	0.02(0.00,0.10)
HD TOFA PO		0.63(0.14,3.48)	0.64(0.16,3.42)	-0.01(-0.06,0.02)
HD ADA SC		1.56(0.34,6.43)	1.54(0.35,6.19)	0.01(-0.05,0.05)
HD GOLI SC		3.21(0.60,16.83)	3.02(0.61,13.75)	0.04(-0.01,0.24)
HD GOLI SC + MTX		7.20(1.84,31.16)	6.09(1.78,22.25)	0.12(0.01,0.39)
HD TOCI IV + MTX		2.52(0.93,7.29)	2.43(0.93,6.54)	0.03(0.00,0.15)
HD TOFA PO + MTX		4.63(1.38,16.09)	4.20(1.36,12.91)	0.07(0.01,0.26)
HD CERTO SC + MTX		4.71(1.42,14.36)	4.29(1.39,11.75)	0.07(0.01,0.26)
HD INF IV + MTX		2.36(0.75,7.70)	2.27(0.76,7.03)	0.03(-0.01,0.13)
HD TOCI IV + DMARD		1.51(0.90,2.62)	1.49(0.90,2.52)	0.01(0.00,0.06)
SD ETN SC	MTX + DMARD	2.14(0.69,7.09)	2.05(0.71,6.66)	0.03(-0.02,0.10)
SD ADA SC		1.45(0.30,7.18)	1.43(0.32,6.81)	0.01(-0.08,0.06)
SD TOCI IV		1.60(0.28,9.19)	1.57(0.30,8.53)	0.02(-0.07,0.10)
SD TOFA PO		0.35(0.07,2.21)	0.36(0.07,2.18)	-0.02(-0.11,0.01)
SD CERTO SC		4.18(0.54,46.06)	3.77(0.57,33.19)	0.09(-0.05,0.31)
SD TOC SC + PL IV		1.42(0.22,9.70)	1.40(0.24,8.97)	0.01(-0.08,0.10)
SD GOLI IV		1.69(0.10,61.18)	1.65(0.11,31.36)	0.02(-0.08,0.51)
SD INF IV + MTX		1.78(0.57,5.86)	1.72(0.59,5.43)	0.02(-0.03,0.10)
SD ETN SC + MTX		1.71(0.64,4.59)	1.66(0.67,4.35)	0.02(-0.03,0.08)
SD ABA IV + MTX		1.41(0.43,4.65)	1.39(0.45,4.41)	0.01(-0.05,0.07)
SD CERTO SC + MTX		2.69(0.83,9.40)	2.52(0.84,8.55)	0.04(-0.01,0.17)
SD ADA SC + MTX		2.00(0.52,8.04)	1.92(0.54,7.30)	0.03(-0.03,0.13)
SD ABA SC + MTX		1.07(0.28,3.91)	1.07(0.30,3.72)	0.00(-0.07,0.06)
SD GOLI SC + MTX		3.87(0.80,22.09)	3.46(0.81,17.69)	0.07(-0.01,0.31)
SD RITUX IV + MTX		1.50(0.44,5.59)	1.47(0.46,5.23)	0.01(-0.05,0.10)
SD TOFA PO + MTX		4.05(1.05,17.25)	3.66(1.04,14.00)	0.08(0.00,0.28)
SD GOLI IV + MTX		4.85(0.64,118.10)	4.14(0.66,42.92)	0.10(-0.01,0.71)

(Continued)

SD ETN SC + DMARD		2.00(0.54,7.48)	1.93(0.57,7.01)	0.02(-0.04,0.10)
SD ADA SC + DMARD		0.52(0.12,2.69)	0.53(0.12,2.63)	-0.01(-0.09,0.03)
SD CERTO SC + DMARD		0.50(0.09,3.53)	0.51(0.09,3.37)	-0.01(-0.10,0.04)
LD ADA SC		0.75(0.13,3.80)	0.75(0.14,3.72)	-0.01(-0.10,0.03)
LD ETN SC		1.42(0.36,5.64)	1.39(0.38,5.33)	0.01(-0.05,0.09)
LD GOLIV		8.77(1.13,208.10)	6.47(1.13,53.45)	0.19(0.00,0.76)
LD RITUX IV + MTX		0.99(0.29,3.92)	0.99(0.31,3.74)	0.00(-0.07,0.06)
LD ABA IV + MTX		2.12(0.56,8.51)	2.02(0.58,7.49)	0.03(-0.03,0.16)
LD CERTO SC + MTX		2.65(0.32,14.88)	2.49(0.33,12.20)	0.04(-0.04,0.25)
LD ETN SC + MTX		0.89(0.22,3.61)	0.89(0.23,3.47)	0.00(-0.08,0.06)
LD GOLIV + MTX		4.84(0.71,118.60)	4.13(0.72,42.49)	0.10(-0.01,0.65)
HD TOCI IV		1.58(0.46,5.65)	1.55(0.48,5.24)	0.01(-0.04,0.10)
HD TOFA PO		0.48(0.09,2.82)	0.49(0.09,2.77)	-0.02(-0.11,0.02)
HD ADA SC		1.11(0.22,6.26)	1.11(0.24,6.00)	0.00(-0.09,0.05)
HD GOLIV SC		2.28(0.40,14.03)	2.17(0.42,11.53)	0.03(-0.04,0.22)
HD GOLIV SC + MTX		5.21(1.22,28.19)	4.44(1.20,20.46)	0.11(0.01,0.38)
HD TOCI IV + MTX		1.84(0.45,7.48)	1.78(0.47,6.76)	0.02(-0.05,0.14)
HD TOFA PO + MTX		3.36(0.85,14.74)	3.08(0.86,12.33)	0.06(-0.01,0.25)
HD CERTO SC + MTX		3.33(0.94,13.50)	3.05(0.95,11.55)	0.06(0.00,0.23)
HD INF IV + MTX		1.72(0.50,6.42)	1.67(0.53,5.91)	0.02(-0.04,0.11)
HD TOCI IV + DMARD		1.11(0.29,4.52)	1.10(0.31,4.32)	0.00(-0.07,0.07)
SD ADA SC	SD ETN SC	0.68(0.21,2.00)	0.69(0.24,1.94)	-0.02(-0.12,0.03)
SD TOCI IV		0.72(0.19,2.97)	0.73(0.21,2.78)	-0.02(-0.12,0.07)
SD TOFA PO		0.16(0.04,0.74)	0.17(0.05,0.75)	-0.05(-0.16,-0.01)
SD CERTO SC		2.02(0.37,13.99)	1.88(0.40,10.33)	0.06(-0.09,0.29)
SD TOC SC + PL IV		0.64(0.14,3.14)	0.66(0.15,2.91)	-0.02(-0.13,0.08)
SD GOLIV		0.79(0.05,19.56)	0.81(0.06,9.33)	-0.01(-0.12,0.48)
SD INF IV + MTX		0.82(0.36,1.94)	0.83(0.37,1.84)	-0.01(-0.07,0.06)

(Continued)

SD ETN SC + MTX	0.78(0.38,1.69)	0.79(0.40,1.61)	-0.01(-0.06,0.04)
SD ABA IV + MTX	0.65(0.28,1.59)	0.67(0.30,1.52)	-0.02(-0.08,0.03)
SD CERTO SC + MTX	1.24(0.53,3.02)	1.22(0.55,2.69)	0.01(-0.04,0.12)
SD ADA SC + MTX	0.92(0.32,2.57)	0.93(0.33,2.38)	0.00(-0.06,0.08)
SD ABA SC + MTX	0.48(0.17,1.37)	0.50(0.19,1.34)	-0.03(-0.10,0.02)
SD GOLI SC + MTX	1.80(0.45,6.53)	1.70(0.47,4.91)	0.04(-0.04,0.26)
SD RITUX IV + MTX	0.69(0.28,1.85)	0.71(0.29,1.76)	-0.02(-0.08,0.05)
SD TOFA PO + MTX	1.88(0.64,5.53)	1.75(0.66,4.39)	0.05(-0.02,0.23)
SD GOLI IV + MTX	2.24(0.31,43.59)	2.03(0.33,13.85)	0.07(-0.05,0.66)
SD ETN SC + DMARD	0.92(0.45,1.90)	0.93(0.47,1.82)	0.00(-0.06,0.05)
SD ADA SC + DMARD	0.24(0.07,0.79)	0.26(0.08,0.81)	-0.05(-0.13,-0.01)
SD CERTO SC + DMARD	0.23(0.05,1.09)	0.25(0.05,1.09)	-0.04(-0.14,0.00)
LD ADA SC	0.35(0.09,1.16)	0.36(0.10,1.15)	-0.04(-0.15,0.00)
LD ETN SC	0.65(0.25,1.65)	0.67(0.27,1.58)	-0.02(-0.08,0.04)
LD GOLI IV	3.94(0.51,64.81)	3.19(0.52,15.77)	0.15(-0.03,0.73)
LD RITUX IV + MTX	0.46(0.18,1.25)	0.48(0.19,1.22)	-0.03(-0.10,0.01)
LD ABA IV + MTX	1.00(0.34,2.96)	1.00(0.36,2.64)	0.00(-0.06,0.11)
LD CERTO SC + MTX	1.22(0.17,4.95)	1.20(0.18,3.97)	0.01(-0.08,0.21)
LD ETN SC + MTX	0.41(0.13,1.36)	0.43(0.14,1.33)	-0.03(-0.11,0.02)
LD GOLI IV + MTX	2.20(0.28,34.53)	2.02(0.29,13.51)	0.06(-0.05,0.62)
HD TOCI IV	0.72(0.29,1.74)	0.73(0.31,1.66)	-0.01(-0.07,0.04)
HD TOFA PO	0.21(0.06,0.92)	0.22(0.07,0.93)	-0.05(-0.15,0.00)
HD ADA SC	0.51(0.14,1.82)	0.53(0.16,1.78)	-0.03(-0.14,0.02)
HD GOLI SC	1.09(0.23,4.28)	1.08(0.25,3.57)	0.00(-0.08,0.17)
HD GOLI SC + MTX	2.40(0.73,8.31)	2.17(0.75,5.84)	0.07(-0.02,0.33)
HD TOCI IV + MTX	0.86(0.28,2.55)	0.87(0.30,2.34)	-0.01(-0.08,0.08)
HD TOFA PO + MTX	1.56(0.47,4.79)	1.50(0.49,3.89)	0.03(-0.04,0.20)
HD CERTO SC + MTX	1.53(0.59,4.30)	1.47(0.61,3.63)	0.03(-0.03,0.19)

(Continued)

HD INF IV + MTX		0.79(0.30,2.16)	0.81(0.32,2.02)	-0.01(-0.07,0.07)
HD TOCI IV + DMARD		0.52(0.18,1.43)	0.53(0.19,1.39)	-0.03(-0.10,0.02)
SD TOCI IV	SD ADA SC	1.09(0.50,2.49)	1.08(0.52,2.33)	0.00(-0.02,0.07)
SD TOFA PO		0.24(0.08,0.76)	0.25(0.09,0.77)	-0.03(-0.08,-0.01)
SD CERTO SC		3.06(0.75,17.88)	2.79(0.76,12.62)	0.08(-0.02,0.30)
SD TOC SC + PL IV		0.97(0.34,2.76)	0.97(0.35,2.54)	0.00(-0.04,0.08)
SD GOL I IV		1.27(0.07,27.30)	1.25(0.08,12.99)	0.01(-0.06,0.50)
SD INF IV + MTX		1.20(0.33,4.77)	1.19(0.34,4.25)	0.01(-0.04,0.12)
SD ETN SC + MTX		1.14(0.29,4.42)	1.14(0.30,3.95)	0.01(-0.04,0.11)
SD ABA IV + MTX		0.96(0.23,3.86)	0.96(0.24,3.51)	0.00(-0.05,0.09)
SD CERTO SC + MTX		1.80(0.45,7.39)	1.74(0.46,6.04)	0.03(-0.03,0.19)
SD ADA SC + MTX		1.42(0.26,5.81)	1.39(0.27,4.99)	0.02(-0.04,0.14)
SD ABA SC + MTX		0.70(0.16,3.29)	0.71(0.17,3.03)	-0.01(-0.06,0.07)
SD GOL I SC + MTX		2.82(0.51,12.81)	2.59(0.52,8.93)	0.07(-0.03,0.32)
SD RITUX IV + MTX		1.04(0.23,4.37)	1.04(0.24,3.93)	0.00(-0.05,0.11)
SD TOFA PO + MTX		2.96(0.57,11.61)	2.71(0.59,8.51)	0.07(-0.02,0.29)
SD GOL I IV + MTX		3.68(0.31,60.18)	3.28(0.32,18.17)	0.10(-0.04,0.69)
SD ETN SC + DMARD		1.37(0.52,3.89)	1.35(0.54,3.51)	0.01(-0.03,0.10)
SD ADA SC + DMARD		0.37(0.08,1.81)	0.38(0.08,1.76)	-0.03(-0.07,0.03)
SD CERTO SC + DMARD		0.36(0.06,2.04)	0.37(0.06,1.95)	-0.03(-0.07,0.04)
LD ADA SC		0.50(0.22,1.07)	0.51(0.23,1.06)	-0.02(-0.06,0.00)
LD ETN SC		0.97(0.22,4.50)	0.97(0.23,4.00)	0.00(-0.05,0.11)
LD GOL I IV		6.59(0.46,83.79)	5.19(0.47,21.73)	0.18(-0.02,0.75)
LD RITUX IV + MTX		0.68(0.15,3.18)	0.69(0.15,2.96)	-0.01(-0.06,0.07)
LD ABA IV + MTX		1.47(0.27,6.54)	1.44(0.28,5.50)	0.02(-0.04,0.18)
LD CERTO SC + MTX		1.74(0.20,10.56)	1.68(0.21,7.95)	0.03(-0.05,0.26)
LD ETN SC + MTX		0.60(0.12,2.94)	0.61(0.13,2.72)	-0.02(-0.06,0.07)
LD GOL I IV + MTX		3.63(0.24,51.00)	3.22(0.25,18.00)	0.09(-0.04,0.65)

(Continued)

HD TOCI IV		1.07(0.28,4.37)	1.07(0.29,3.89)	0.00(-0.04,0.11)
HD TOFA PO		0.32(0.11,0.99)	0.33(0.12,0.99)	-0.03(-0.07,0.00)
HD ADA SC		0.78(0.37,1.59)	0.79(0.38,1.57)	-0.01(-0.04,0.02)
HD GOLI SC		1.64(0.26,8.47)	1.59(0.27,6.60)	0.02(-0.04,0.23)
HD GOLI SC + MTX		3.70(0.65,16.83)	3.30(0.66,10.82)	0.10(-0.02,0.38)
HD TOCI IV + MTX		1.28(0.27,6.06)	1.26(0.28,5.17)	0.01(-0.04,0.15)
HD TOFA PO + MTX		2.42(0.47,10.13)	2.26(0.48,7.76)	0.06(-0.03,0.26)
HD CERTO SC + MTX		2.28(0.57,10.24)	2.14(0.58,7.74)	0.05(-0.02,0.26)
HD INF IV + MTX		1.20(0.25,5.10)	1.18(0.26,4.46)	0.01(-0.04,0.13)
HD TOCI IV + DMARD		0.78(0.17,3.23)	0.79(0.18,2.99)	-0.01(-0.05,0.08)
SD TOFA PO	SD TOCI IV	0.22(0.05,0.91)	0.23(0.06,0.91)	-0.04(-0.12,0.00)
SD CERTO SC		2.75(0.54,20.04)	2.52(0.57,14.46)	0.07(-0.05,0.30)
SD TOC SC + PL IV		0.88(0.43,1.74)	0.88(0.45,1.67)	0.00(-0.04,0.04)
SD GOLI IV		1.16(0.06,27.62)	1.15(0.07,13.48)	0.01(-0.09,0.49)
SD INF IV + MTX		1.12(0.24,5.05)	1.11(0.25,4.53)	0.00(-0.08,0.12)
SD ETN SC + MTX		1.06(0.22,4.62)	1.06(0.23,4.14)	0.00(-0.08,0.11)
SD ABA IV + MTX		0.89(0.17,4.18)	0.90(0.18,3.81)	0.00(-0.09,0.09)
SD CERTO SC + MTX		1.67(0.34,7.87)	1.61(0.36,6.57)	0.03(-0.06,0.19)
SD ADA SC + MTX		1.28(0.20,6.39)	1.26(0.21,5.59)	0.01(-0.07,0.14)
SD ABA SC + MTX		0.65(0.12,3.39)	0.66(0.13,3.14)	-0.01(-0.10,0.08)
SD GOLI SC + MTX		2.56(0.40,13.46)	2.35(0.42,9.78)	0.06(-0.05,0.31)
SD RITUX IV + MTX		0.97(0.18,4.75)	0.97(0.19,4.30)	0.00(-0.08,0.11)
SD TOFA PO + MTX		2.64(0.42,12.84)	2.41(0.44,9.51)	0.07(-0.05,0.28)
SD GOLI IV + MTX		3.41(0.22,61.85)	3.02(0.24,19.34)	0.09(-0.06,0.69)
SD ETN SC + DMARD		1.27(0.34,4.44)	1.26(0.36,4.01)	0.01(-0.06,0.10)
SD ADA SC + DMARD		0.34(0.06,1.91)	0.35(0.06,1.86)	-0.03(-0.11,0.03)
SD CERTO SC + DMARD		0.32(0.04,2.17)	0.33(0.05,2.07)	-0.03(-0.11,0.03)
LD ADA SC		0.46(0.15,1.35)	0.48(0.16,1.34)	-0.02(-0.10,0.01)

(Continued)

LD ETN SC		0.89(0.16,4.48)	0.90(0.18,4.08)	0.00(-0.09,0.10)
LD GOLI IV		5.99(0.36,88.57)	4.66(0.38,23.50)	0.18(-0.04,0.74)
LD RITUX IV + MTX		0.63(0.11,3.31)	0.65(0.12,3.11)	-0.01(-0.10,0.07)
LD ABA IV + MTX		1.35(0.20,7.19)	1.33(0.21,6.07)	0.01(-0.07,0.18)
LD CERTO SC + MTX		1.61(0.15,10.72)	1.55(0.16,8.10)	0.03(-0.07,0.25)
LD ETN SC + MTX		0.55(0.09,3.13)	0.57(0.10,2.94)	-0.02(-0.10,0.07)
LD GOLI IV + MTX		3.24(0.19,51.29)	2.87(0.20,18.93)	0.09(-0.06,0.64)
HD TOCI IV		1.00(0.21,4.73)	1.00(0.22,4.29)	0.00(-0.08,0.11)
HD TOFA PO		0.29(0.08,1.15)	0.30(0.08,1.15)	-0.03(-0.12,0.00)
HD ADA SC		0.71(0.24,2.05)	0.72(0.26,2.00)	-0.01(-0.09,0.03)
HD GOLI SC		1.49(0.20,8.95)	1.46(0.21,7.38)	0.02(-0.08,0.22)
HD GOLI SC + MTX		3.39(0.47,18.48)	3.00(0.50,12.23)	0.09(-0.04,0.37)
HD TOCI IV + MTX		1.18(0.22,6.35)	1.17(0.23,5.49)	0.01(-0.08,0.15)
HD TOFA PO + MTX		2.17(0.35,10.99)	2.03(0.37,8.57)	0.05(-0.06,0.25)
HD CERTO SC + MTX		2.09(0.45,10.78)	1.97(0.47,8.32)	0.05(-0.05,0.25)
HD INF IV + MTX		1.10(0.18,5.34)	1.09(0.20,4.74)	0.00(-0.08,0.13)
HD TOCI IV + DMARD		0.72(0.13,3.49)	0.73(0.14,3.22)	-0.01(-0.09,0.07)
SD CERTO SC	SD TOFA PO	12.44(2.55,73.20)	10.94(2.45,52.33)	0.11(0.03,0.32)
SD TOC SC + PL IV		3.99(0.81,18.05)	3.85(0.81,16.08)	0.03(0.00,0.13)
SD GOLI IV		5.00(0.25,137.40)	4.75(0.25,67.34)	0.04(-0.01,0.53)
SD INF IV + MTX		5.05(0.92,20.77)	4.83(0.92,18.27)	0.04(0.00,0.15)
SD ETN SC + MTX		4.93(0.93,20.71)	4.71(0.94,18.23)	0.04(0.00,0.15)
SD ABA IV + MTX		4.04(0.73,16.71)	3.90(0.74,15.08)	0.03(0.00,0.13)
SD CERTO SC + MTX		7.49(1.44,33.76)	6.94(1.43,27.00)	0.07(0.01,0.23)
SD ADA SC + MTX		5.98(0.93,25.95)	5.63(0.93,21.85)	0.05(0.00,0.18)
SD ABA SC + MTX		2.96(0.49,15.03)	2.89(0.50,13.55)	0.02(-0.01,0.11)
SD GOLI SC + MTX		11.33(1.54,60.51)	10.03(1.53,42.27)	0.10(0.01,0.35)
SD RITUX IV + MTX		4.23(0.77,19.73)	4.07(0.77,17.37)	0.03(0.00,0.14)

(Continued)

SD TOFA PO + MTX		12.35(1.88,52.11)	10.85(1.85,37.92)	0.11(0.01,0.33)
SD GOL I IV + MTX		14.11(1.10,325.50)	12.12(1.09,104.00)	0.13(0.00,0.73)
SD ETN SC + DMARD		5.66(1.30,21.61)	5.35(1.30,18.91)	0.05(0.01,0.15)
SD ADA SC + DMARD		1.51(0.24,7.91)	1.50(0.24,7.46)	0.01(-0.02,0.06)
SD CERTO SC + DMARD		1.44(0.18,9.45)	1.44(0.19,8.88)	0.00(-0.02,0.07)
LD ADA SC		2.05(0.59,6.36)	2.03(0.60,6.19)	0.01(-0.01,0.04)
LD ETN SC		4.04(0.69,18.56)	3.90(0.70,16.21)	0.03(-0.01,0.14)
LD GOL I IV		24.13(1.44,460.60)	18.77(1.43,115.20)	0.21(0.01,0.78)
LD RITUX IV + MTX		2.78(0.50,13.35)	2.73(0.50,12.22)	0.02(-0.01,0.10)
LD ABA IV + MTX		6.20(0.89,30.14)	5.85(0.89,24.31)	0.05(0.00,0.22)
LD CERTO SC + MTX		7.22(0.69,46.10)	6.70(0.69,33.71)	0.06(0.00,0.30)
LD ETN SC + MTX		2.49(0.39,14.93)	2.45(0.40,13.39)	0.02(-0.01,0.11)
LD GOL I IV + MTX		13.82(0.71,270.00)	11.89(0.72,95.32)	0.13(0.00,0.69)
HD TOCI IV		4.39(0.80,20.33)	4.22(0.81,17.98)	0.04(0.00,0.15)
HD TOFA PO		1.31(0.54,3.37)	1.31(0.54,3.31)	0.00(-0.01,0.02)
HD ADA SC		3.22(0.94,9.73)	3.14(0.94,9.28)	0.02(0.00,0.06)
HD GOL I SC		6.55(0.89,38.98)	6.14(0.89,30.39)	0.06(0.00,0.27)
HD GOL I SC + MTX		15.78(2.00,79.86)	13.36(1.96,50.15)	0.13(0.01,0.42)
HD TOCI IV + MTX		5.32(0.84,26.88)	5.05(0.84,22.38)	0.04(0.00,0.19)
HD TOFA PO + MTX		10.06(1.46,44.56)	9.05(1.45,33.23)	0.09(0.01,0.30)
HD CERTO SC + MTX		9.49(1.66,44.50)	8.60(1.64,33.59)	0.09(0.01,0.30)
HD INF IV + MTX		4.87(0.82,21.86)	4.66(0.82,18.99)	0.04(0.00,0.17)
HD TOCI IV + DMARD		3.25(0.54,16.14)	3.16(0.54,14.37)	0.02(-0.01,0.12)
SD TOC SC + PL IV	SD CERTO SC	0.32(0.04,1.88)	0.35(0.05,1.77)	-0.08(-0.30,0.05)
SD GOL I IV		0.39(0.02,7.16)	0.43(0.02,4.77)	-0.06(-0.28,0.34)
SD INF IV + MTX		0.43(0.05,2.44)	0.46(0.07,2.23)	-0.06(-0.30,0.08)
SD ETN SC + MTX		0.41(0.05,2.40)	0.44(0.06,2.19)	-0.07(-0.30,0.08)
SD ABA IV + MTX		0.34(0.04,1.98)	0.37(0.05,1.87)	-0.07(-0.30,0.05)

(Continued)

SD CERTO SC + MTX	0.65(0.07,4.07)	0.68(0.10,3.40)	-0.04(-0.28,0.16)
SD ADA SC + MTX	0.45(0.05,3.02)	0.49(0.07,2.67)	-0.06(-0.29,0.11)
SD ABA SC + MTX	0.25(0.03,1.71)	0.27(0.04,1.64)	-0.08(-0.31,0.04)
SD GOLI SC + MTX	0.88(0.08,6.96)	0.89(0.11,5.01)	-0.01(-0.25,0.27)
SD RITUX IV + MTX	0.36(0.04,2.25)	0.40(0.05,2.09)	-0.07(-0.30,0.07)
SD TOFA PO + MTX	0.97(0.10,6.22)	0.97(0.13,4.70)	0.00(-0.26,0.24)
SD GOLI IV + MTX	1.22(0.07,21.66)	1.19(0.08,8.54)	0.02(-0.24,0.58)
SD ETN SC + DMARD	0.46(0.07,2.53)	0.49(0.09,2.30)	-0.06(-0.29,0.08)
SD ADA SC + DMARD	0.11(0.01,0.92)	0.13(0.02,0.93)	-0.10(-0.32,-0.01)
SD CERTO SC + DMARD	0.11(0.01,0.96)	0.13(0.01,0.96)	-0.10(-0.31,0.00)
LD ADA SC	0.16(0.03,0.75)	0.18(0.04,0.76)	-0.10(-0.32,-0.01)
LD ETN SC	0.33(0.04,2.29)	0.36(0.05,2.10)	-0.07(-0.30,0.07)
LD GOLI IV	2.16(0.09,35.08)	1.87(0.11,10.26)	0.10(-0.22,0.66)
LD RITUX IV + MTX	0.24(0.03,1.49)	0.27(0.03,1.44)	-0.09(-0.31,0.03)
LD ABA IV + MTX	0.51(0.05,3.43)	0.54(0.07,2.96)	-0.05(-0.29,0.13)
LD CERTO SC + MTX	0.58(0.04,5.23)	0.61(0.05,4.03)	-0.04(-0.29,0.21)
LD ETN SC + MTX	0.21(0.02,1.44)	0.24(0.03,1.39)	-0.09(-0.31,0.03)
LD GOLI IV + MTX	1.20(0.05,21.01)	1.17(0.06,8.42)	0.02(-0.25,0.57)
HD TOCI IV	0.36(0.05,2.32)	0.39(0.06,2.13)	-0.07(-0.30,0.07)
HD TOFA PO	0.11(0.02,0.50)	0.12(0.03,0.51)	-0.11(-0.32,-0.02)
HD ADA SC	0.25(0.04,1.10)	0.28(0.06,1.09)	-0.09(-0.30,0.00)
HD GOLI SC	0.51(0.05,4.48)	0.55(0.06,3.58)	-0.05(-0.29,0.18)
HD GOLI SC + MTX	1.26(0.12,9.71)	1.22(0.16,6.04)	0.02(-0.24,0.35)
HD TOCI IV + MTX	0.42(0.05,3.00)	0.46(0.07,2.63)	-0.06(-0.29,0.11)
HD TOFA PO + MTX	0.79(0.08,5.26)	0.81(0.10,4.15)	-0.02(-0.27,0.21)
HD CERTO SC + MTX	0.78(0.09,5.39)	0.81(0.12,4.17)	-0.02(-0.28,0.22)
HD INF IV + MTX	0.41(0.05,2.60)	0.45(0.06,2.36)	-0.06(-0.30,0.09)
HD TOCI IV + DMARD	0.25(0.03,1.71)	0.27(0.04,1.63)	-0.08(-0.31,0.04)

(Continued)

SD GOLI IV	SD TOC SC + PL IV	1.31(0.06,35.13)	1.29(0.07,17.60)	0.01(-0.09,0.50)
SD INF IV + MTX		1.28(0.23,6.92)	1.26(0.25,6.17)	0.01(-0.09,0.12)
SD ETN SC + MTX		1.20(0.20,6.39)	1.19(0.22,5.75)	0.01(-0.08,0.11)
SD ABA IV + MTX		1.02(0.16,5.64)	1.02(0.17,5.09)	0.00(-0.09,0.10)
SD CERTO SC + MTX		1.93(0.33,10.52)	1.85(0.35,8.85)	0.03(-0.07,0.20)
SD ADA SC + MTX		1.45(0.20,8.80)	1.42(0.21,7.63)	0.02(-0.08,0.15)
SD ABA SC + MTX		0.75(0.11,4.55)	0.76(0.12,4.20)	-0.01(-0.11,0.08)
SD GOLI SC + MTX		2.87(0.40,18.47)	2.63(0.42,13.74)	0.07(-0.05,0.32)
SD RITUX IV + MTX		1.10(0.16,6.25)	1.10(0.18,5.60)	0.00(-0.09,0.11)
SD TOFA PO + MTX		3.00(0.41,17.48)	2.73(0.43,13.40)	0.07(-0.05,0.29)
SD GOLI IV + MTX		3.87(0.23,79.95)	3.35(0.25,25.62)	0.09(-0.06,0.70)
SD ETN SC + DMARD		1.43(0.33,6.22)	1.40(0.36,5.65)	0.02(-0.07,0.11)
SD ADA SC + DMARD		0.37(0.06,2.54)	0.38(0.06,2.46)	-0.02(-0.12,0.03)
SD CERTO SC + DMARD		0.36(0.05,2.86)	0.37(0.05,2.73)	-0.02(-0.12,0.04)
LD ADA SC		0.52(0.14,1.88)	0.53(0.15,1.86)	-0.02(-0.11,0.01)
LD ETN SC		1.02(0.16,6.15)	1.02(0.17,5.56)	0.00(-0.09,0.11)
LD GOLI IV		6.71(0.39,114.40)	5.16(0.41,31.45)	0.18(-0.04,0.75)
LD RITUX IV + MTX		0.73(0.11,4.41)	0.74(0.11,4.07)	-0.01(-0.11,0.07)
LD ABA IV + MTX		1.56(0.20,9.63)	1.52(0.21,8.15)	0.02(-0.08,0.18)
LD CERTO SC + MTX		1.80(0.16,13.73)	1.73(0.17,10.47)	0.03(-0.08,0.26)
LD ETN SC + MTX		0.63(0.09,4.02)	0.64(0.10,3.74)	-0.01(-0.11,0.07)
LD GOLI IV + MTX		3.69(0.22,64.74)	3.23(0.23,25.19)	0.09(-0.06,0.65)
HD TOCI IV		1.11(0.19,6.52)	1.10(0.21,5.79)	0.00(-0.09,0.12)
HD TOFA PO		0.33(0.08,1.57)	0.34(0.08,1.55)	-0.03(-0.12,0.01)
HD ADA SC		0.79(0.22,2.79)	0.80(0.24,2.71)	-0.01(-0.10,0.03)
HD GOLI SC		1.71(0.20,12.11)	1.65(0.22,9.83)	0.02(-0.08,0.22)
HD GOLI SC + MTX		3.84(0.46,24.30)	3.38(0.48,16.34)	0.10(-0.04,0.38)
HD TOCI IV + MTX		1.31(0.20,8.60)	1.29(0.22,7.37)	0.01(-0.08,0.15)

(Continued)

HD TOFA PO + MTX		2.48(0.34,14.84)	2.29(0.36,11.67)	0.05(-0.06,0.26)
HD CERTO SC + MTX		2.37(0.42,14.34)	2.21(0.45,11.46)	0.05(-0.05,0.26)
HD INF IV + MTX		1.24(0.18,7.29)	1.23(0.20,6.48)	0.01(-0.09,0.13)
HD TOCI IV + DMARD		0.79(0.14,4.68)	0.80(0.15,4.35)	-0.01(-0.10,0.08)
SD INF IV + MTX	SD GOL I IV	1.06(0.04,14.72)	1.06(0.08,13.26)	0.00(-0.49,0.11)
SD ETN SC + MTX		1.00(0.04,15.05)	1.00(0.07,13.60)	0.00(-0.49,0.10)
SD ABA IV + MTX		0.84(0.03,13.09)	0.85(0.07,11.96)	-0.01(-0.49,0.09)
SD CERTO SC + MTX		1.61(0.05,25.92)	1.55(0.10,22.04)	0.02(-0.47,0.18)
SD ADA SC + MTX		1.14(0.05,16.99)	1.13(0.10,15.00)	0.00(-0.47,0.14)
SD ABA SC + MTX		0.64(0.02,9.88)	0.65(0.04,9.23)	-0.02(-0.50,0.07)
SD GOL I SC + MTX		2.20(0.14,25.21)	2.03(0.24,21.07)	0.04(-0.39,0.28)
SD RITUX IV + MTX		0.92(0.03,12.15)	0.93(0.05,11.13)	0.00(-0.49,0.09)
SD TOFA PO + MTX		2.29(0.08,34.30)	2.11(0.16,27.82)	0.04(-0.43,0.27)
SD GOL I IV + MTX		2.89(0.49,28.72)	2.37(0.53,22.84)	0.07(-0.07,0.44)
SD ETN SC + DMARD		1.16(0.05,16.68)	1.15(0.10,15.28)	0.01(-0.48,0.11)
SD ADA SC + DMARD		0.32(0.01,5.03)	0.33(0.02,4.87)	-0.03(-0.52,0.03)
SD CERTO SC + DMARD		0.29(0.01,4.92)	0.30(0.02,4.77)	-0.03(-0.51,0.03)
LD ADA SC		0.39(0.02,6.60)	0.41(0.04,6.44)	-0.03(-0.51,0.03)
LD ETN SC		0.85(0.03,14.28)	0.86(0.06,13.00)	-0.01(-0.49,0.10)
LD GOL I IV		4.52(1.07,55.75)	3.34(1.05,37.84)	0.14(0.00,0.53)
LD RITUX IV + MTX		0.62(0.02,8.93)	0.63(0.04,8.43)	-0.02(-0.50,0.06)
LD ABA IV + MTX		1.29(0.06,18.60)	1.27(0.11,16.42)	0.01(-0.47,0.16)
LD CERTO SC + MTX		1.51(0.03,30.51)	1.46(0.05,25.29)	0.02(-0.48,0.24)
LD ETN SC + MTX		0.53(0.02,7.96)	0.55(0.03,7.55)	-0.02(-0.51,0.06)
LD GOL I IV + MTX		2.67(0.51,27.32)	2.29(0.56,21.59)	0.06(-0.08,0.45)
HD TOCI IV		0.93(0.04,12.50)	0.94(0.07,11.45)	0.00(-0.49,0.10)
HD TOFA PO		0.26(0.01,5.24)	0.27(0.02,5.12)	-0.04(-0.52,0.02)
HD ADA SC		0.61(0.03,10.74)	0.62(0.06,10.32)	-0.02(-0.50,0.05)

(Continued)

HD GOLI SC		1.40(0.05,17.22)	1.36(0.10,15.33)	0.01(-0.45,0.19)
HD GOLI SC + MTX		3.15(0.16,34.11)	2.76(0.27,27.90)	0.07(-0.37,0.34)
HD TOCI IV + MTX		1.11(0.04,16.32)	1.10(0.08,14.56)	0.00(-0.48,0.14)
HD TOFA PO + MTX		1.91(0.07,28.08)	1.80(0.13,23.61)	0.03(-0.44,0.24)
HD CERTO SC + MTX		2.04(0.05,31.07)	1.91(0.11,25.09)	0.03(-0.46,0.22)
HD INF IV + MTX		1.05(0.04,13.99)	1.04(0.07,12.82)	0.00(-0.49,0.11)
HD TOCI IV + DMARD		0.68(0.03,8.51)	0.70(0.05,7.99)	-0.01(-0.50,0.07)
SD ETN SC + MTX	SD INF IV + MTX	0.95(0.42,2.16)	0.95(0.44,2.06)	0.00(-0.06,0.05)
SD ABA IV + MTX		0.80(0.45,1.39)	0.81(0.47,1.36)	-0.01(-0.06,0.02)
SD CERTO SC + MTX		1.50(0.75,3.07)	1.46(0.77,2.81)	0.02(-0.02,0.11)
SD ADA SC + MTX		1.10(0.45,2.72)	1.09(0.47,2.52)	0.00(-0.05,0.09)
SD ABA SC + MTX		0.59(0.25,1.32)	0.61(0.26,1.29)	-0.02(-0.08,0.01)
SD GOLI SC + MTX		2.16(0.66,7.28)	2.00(0.68,5.93)	0.05(-0.02,0.26)
SD RITUX IV + MTX		0.84(0.40,1.87)	0.85(0.42,1.79)	-0.01(-0.07,0.04)
SD TOFA PO + MTX		2.21(0.87,6.63)	2.04(0.87,5.27)	0.06(-0.01,0.23)
SD GOLI IV + MTX		2.74(0.41,48.63)	2.44(0.42,17.20)	0.08(-0.04,0.67)
SD ETN SC + DMARD		1.14(0.40,3.16)	1.13(0.43,2.96)	0.01(-0.07,0.07)
SD ADA SC + DMARD		0.30(0.08,1.09)	0.31(0.09,1.09)	-0.03(-0.13,0.00)
SD CERTO SC + DMARD		0.28(0.06,1.46)	0.29(0.06,1.44)	-0.03(-0.13,0.02)
LD ADA SC		0.42(0.09,1.74)	0.43(0.10,1.71)	-0.03(-0.15,0.01)
LD ETN SC		0.79(0.28,2.14)	0.80(0.30,2.04)	-0.01(-0.08,0.05)
LD GOLI IV		4.85(0.72,82.94)	3.81(0.73,20.70)	0.16(-0.01,0.73)
LD RITUX IV + MTX		0.55(0.26,1.27)	0.57(0.27,1.25)	-0.02(-0.09,0.01)
LD ABA IV + MTX		1.21(0.50,2.89)	1.19(0.52,2.62)	0.01(-0.04,0.11)
LD CERTO SC + MTX		1.45(0.24,5.89)	1.41(0.25,4.84)	0.02(-0.06,0.21)
LD ETN SC + MTX		0.50(0.16,1.42)	0.51(0.17,1.39)	-0.02(-0.10,0.02)
LD GOLI IV + MTX		2.69(0.43,50.10)	2.43(0.45,17.39)	0.08(-0.04,0.62)
HD TOCI IV		0.88(0.36,2.18)	0.89(0.38,2.08)	0.00(-0.07,0.05)

(Continued)

HD TOFA PO		0.26(0.06,1.33)	0.27(0.07,1.33)	-0.04(-0.15,0.01)
HD ADA SC		0.62(0.15,2.63)	0.63(0.17,2.56)	-0.02(-0.13,0.03)
HD GOLI SC		1.29(0.33,4.74)	1.27(0.35,4.04)	0.01(-0.06,0.18)
HD GOLI SC + MTX		2.93(1.03,8.58)	2.59(1.03,6.38)	0.09(0.00,0.33)
HD TOCI IV + MTX		1.03(0.37,3.07)	1.03(0.39,2.81)	0.00(-0.07,0.09)
HD TOFA PO + MTX		1.86(0.68,5.16)	1.76(0.68,4.36)	0.04(-0.02,0.20)
HD CERTO SC + MTX		1.87(0.80,4.58)	1.77(0.81,3.97)	0.04(-0.01,0.18)
HD INF IV + MTX		0.97(0.50,1.92)	0.97(0.51,1.83)	0.00(-0.04,0.05)
HD TOCI IV + DMARD		0.62(0.20,1.93)	0.64(0.22,1.86)	-0.02(-0.10,0.04)
SD ABA IV + MTX	SD ETN SC + MTX	0.84(0.35,1.84)	0.85(0.37,1.78)	-0.01(-0.07,0.04)
SD CERTO SC + MTX		1.57(0.68,3.73)	1.52(0.70,3.40)	0.02(-0.03,0.13)
SD ADA SC + MTX		1.17(0.41,3.58)	1.16(0.42,3.22)	0.01(-0.06,0.10)
SD ABA SC + MTX		0.63(0.21,1.64)	0.65(0.23,1.60)	-0.02(-0.09,0.03)
SD GOLI SC + MTX		2.28(0.56,8.90)	2.12(0.59,6.95)	0.05(-0.03,0.28)
SD RITUX IV + MTX		0.87(0.36,2.32)	0.88(0.38,2.18)	0.00(-0.07,0.06)
SD TOFA PO + MTX		2.37(0.78,7.41)	2.20(0.80,6.04)	0.06(-0.01,0.24)
SD GOLI IV + MTX		2.72(0.45,58.61)	2.45(0.46,20.08)	0.08(-0.04,0.68)
SD ETN SC + DMARD		1.18(0.45,3.04)	1.17(0.47,2.86)	0.01(-0.06,0.07)
SD ADA SC + DMARD		0.31(0.08,1.11)	0.32(0.09,1.10)	-0.03(-0.12,0.00)
SD CERTO SC + DMARD		0.30(0.06,1.55)	0.31(0.06,1.53)	-0.03(-0.13,0.02)
LD ADA SC		0.44(0.09,1.71)	0.45(0.11,1.68)	-0.03(-0.14,0.01)
LD ETN SC		0.84(0.28,2.41)	0.85(0.30,2.29)	-0.01(-0.08,0.06)
LD GOLI IV		5.01(0.75,96.66)	3.88(0.76,22.99)	0.17(-0.01,0.74)
LD RITUX IV + MTX		0.58(0.23,1.56)	0.60(0.25,1.53)	-0.02(-0.09,0.02)
LD ABA IV + MTX		1.27(0.43,3.63)	1.24(0.45,3.25)	0.01(-0.05,0.12)
LD CERTO SC + MTX		1.51(0.21,6.24)	1.46(0.23,5.18)	0.02(-0.06,0.21)
LD ETN SC + MTX		0.52(0.18,1.40)	0.54(0.19,1.37)	-0.02(-0.09,0.02)
LD GOLI IV + MTX		2.83(0.44,53.74)	2.53(0.45,20.04)	0.08(-0.04,0.63)

(Continued)

HD TOCI IV		0.92(0.36,2.38)	0.93(0.38,2.26)	0.00(-0.07,0.06)
HD TOFA PO		0.28(0.06,1.33)	0.29(0.07,1.32)	-0.04(-0.15,0.01)
HD ADA SC		0.65(0.16,3.13)	0.66(0.18,3.03)	-0.02(-0.13,0.03)
HD GOLI SC		1.37(0.29,5.77)	1.35(0.30,4.81)	0.01(-0.07,0.19)
HD GOLI SC + MTX		3.07(0.90,11.35)	2.71(0.91,8.03)	0.09(-0.01,0.34)
HD TOCI IV + MTX		1.08(0.36,3.51)	1.07(0.38,3.18)	0.00(-0.06,0.10)
HD TOFA PO + MTX		2.01(0.60,6.31)	1.88(0.62,5.17)	0.04(-0.03,0.21)
HD CERTO SC + MTX		1.98(0.74,5.48)	1.85(0.76,4.67)	0.04(-0.02,0.19)
HD INF IV + MTX		1.01(0.40,2.69)	1.01(0.42,2.52)	0.00(-0.06,0.07)
HD TOCI IV + DMARD		0.65(0.21,2.04)	0.67(0.22,1.95)	-0.01(-0.10,0.04)
SD CERTO SC + MTX	SD ABA IV + MTX	1.90(1.00,3.75)	1.81(1.00,3.43)	0.03(0.00,0.13)
SD ADA SC + MTX		1.38(0.57,3.64)	1.36(0.59,3.28)	0.01(-0.03,0.10)
SD ABA SC + MTX		0.74(0.39,1.36)	0.75(0.41,1.34)	-0.01(-0.05,0.02)
SD GOLI SC + MTX		2.74(0.82,9.31)	2.52(0.83,7.34)	0.06(-0.01,0.28)
SD RITUX IV + MTX		1.08(0.50,2.33)	1.07(0.52,2.22)	0.00(-0.04,0.06)
SD TOFA PO + MTX		2.83(1.12,7.91)	2.58(1.12,6.37)	0.07(0.00,0.25)
SD GOLI IV + MTX		3.47(0.51,60.68)	3.05(0.52,20.36)	0.09(-0.02,0.69)
SD ETN SC + DMARD		1.44(0.49,3.89)	1.41(0.52,3.64)	0.02(-0.05,0.09)
SD ADA SC + DMARD		0.38(0.10,1.31)	0.39(0.11,1.30)	-0.02(-0.10,0.01)
SD CERTO SC + DMARD		0.35(0.07,1.90)	0.36(0.08,1.85)	-0.02(-0.11,0.02)
LD ADA SC		0.53(0.11,2.17)	0.54(0.12,2.15)	-0.02(-0.12,0.02)
LD ETN SC		1.01(0.35,2.66)	1.00(0.37,2.52)	0.00(-0.05,0.07)
LD GOLI IV		6.15(1.03,98.16)	4.73(1.02,24.52)	0.18(0.00,0.74)
LD RITUX IV + MTX		0.70(0.33,1.60)	0.71(0.35,1.55)	-0.01(-0.06,0.02)
LD ABA IV + MTX		1.51(0.72,3.34)	1.47(0.73,3.01)	0.02(-0.01,0.12)
LD CERTO SC + MTX		1.86(0.30,7.15)	1.78(0.31,5.90)	0.03(-0.04,0.22)
LD ETN SC + MTX		0.63(0.21,1.82)	0.65(0.22,1.76)	-0.01(-0.08,0.03)
LD GOLI IV + MTX		3.47(0.60,57.15)	3.08(0.61,20.44)	0.09(-0.02,0.64)

(Continued)

HD TOCI IV		1.12(0.44,2.77)	1.11(0.46,2.62)	0.00(-0.05,0.07)
HD TOFA PO		0.33(0.07,1.69)	0.34(0.08,1.67)	-0.03(-0.12,0.01)
HD ADA SC		0.78(0.18,3.81)	0.79(0.20,3.66)	-0.01(-0.10,0.04)
HD GOLI SC		1.62(0.42,6.28)	1.57(0.43,5.32)	0.02(-0.04,0.19)
HD GOLI SC + MTX		3.65(1.36,11.85)	3.20(1.32,8.55)	0.09(0.01,0.35)
HD TOCI IV + MTX		1.31(0.49,3.78)	1.29(0.50,3.44)	0.01(-0.04,0.11)
HD TOFA PO + MTX		2.34(0.85,6.64)	2.19(0.86,5.59)	0.05(-0.01,0.21)
HD CERTO SC + MTX		2.37(1.05,5.68)	2.20(1.05,4.92)	0.05(0.00,0.20)
HD INF IV + MTX		1.22(0.57,2.71)	1.21(0.59,2.54)	0.01(-0.03,0.08)
HD TOCI IV + DMARD		0.80(0.26,2.46)	0.81(0.28,2.32)	-0.01(-0.08,0.05)
SD ADA SC + MTX	SD CERTO SC + MTX	0.73(0.28,1.92)	0.75(0.31,1.82)	-0.02(-0.11,0.05)
SD ABA SC + MTX		0.39(0.15,0.93)	0.42(0.17,0.94)	-0.04(-0.15,0.00)
SD GOLI SC + MTX		1.45(0.41,4.99)	1.39(0.44,3.99)	0.03(-0.08,0.23)
SD RITUX IV + MTX		0.56(0.26,1.24)	0.58(0.29,1.22)	-0.03(-0.14,0.02)
SD TOFA PO + MTX		1.48(0.54,4.28)	1.42(0.57,3.55)	0.03(-0.05,0.19)
SD GOLI IV + MTX		1.78(0.27,40.10)	1.66(0.29,13.19)	0.05(-0.09,0.65)
SD ETN SC + DMARD		0.76(0.26,1.99)	0.78(0.29,1.90)	-0.02(-0.14,0.05)
SD ADA SC + DMARD		0.20(0.05,0.71)	0.21(0.06,0.73)	-0.06(-0.21,-0.01)
SD CERTO SC + DMARD		0.19(0.04,0.96)	0.20(0.04,0.96)	-0.06(-0.21,0.00)
LD ADA SC		0.28(0.05,1.11)	0.30(0.07,1.11)	-0.05(-0.22,0.00)
LD ETN SC		0.53(0.18,1.50)	0.56(0.20,1.45)	-0.03(-0.15,0.03)
LD GOLI IV		3.11(0.53,62.39)	2.57(0.54,15.29)	0.13(-0.04,0.72)
LD RITUX IV + MTX		0.36(0.16,0.85)	0.39(0.18,0.86)	-0.04(-0.16,-0.01)
LD ABA IV + MTX		0.80(0.32,1.99)	0.82(0.34,1.86)	-0.01(-0.10,0.07)
LD CERTO SC + MTX		0.97(0.17,3.36)	0.97(0.19,2.87)	0.00(-0.10,0.15)
LD ETN SC + MTX		0.33(0.10,1.03)	0.35(0.11,1.03)	-0.05(-0.18,0.00)
LD GOLI IV + MTX		1.78(0.30,34.81)	1.67(0.31,12.62)	0.05(-0.08,0.60)
HD TOCI IV		0.59(0.23,1.40)	0.62(0.26,1.36)	-0.03(-0.14,0.02)

(Continued)

HD TOFA PO		0.17(0.04,0.88)	0.18(0.05,0.88)	-0.06(-0.23,0.00)
HD ADA SC		0.41(0.09,1.95)	0.43(0.12,1.90)	-0.04(-0.21,0.02)
HD GOLI SC		0.88(0.20,3.24)	0.89(0.23,2.78)	-0.01(-0.13,0.14)
HD GOLI SC + MTX		1.99(0.63,6.11)	1.81(0.66,4.57)	0.06(-0.04,0.29)
HD TOCI IV + MTX		0.69(0.24,1.93)	0.71(0.27,1.80)	-0.02(-0.13,0.06)
HD TOFA PO + MTX		1.25(0.43,3.53)	1.22(0.46,3.02)	0.02(-0.06,0.16)
HD CERTO SC + MTX		1.26(0.62,2.45)	1.23(0.65,2.20)	0.02(-0.04,0.12)
HD INF IV + MTX		0.65(0.27,1.47)	0.67(0.30,1.42)	-0.02(-0.12,0.03)
HD TOCI IV + DMARD		0.42(0.13,1.31)	0.44(0.15,1.28)	-0.04(-0.17,0.01)
SD ABA SC + MTX	SD ADA SC + MTX	0.53(0.17,1.57)	0.55(0.19,1.54)	-0.02(-0.12,0.02)
SD GOLI SC + MTX		2.01(0.43,7.61)	1.86(0.45,6.26)	0.05(-0.05,0.25)
SD RITUX IV + MTX		0.76(0.28,2.16)	0.77(0.31,2.07)	-0.01(-0.10,0.05)
SD TOFA PO + MTX		2.03(0.84,5.26)	1.89(0.86,4.45)	0.05(-0.01,0.21)
SD GOLI IV + MTX		2.55(0.29,45.08)	2.29(0.31,15.26)	0.07(-0.07,0.66)
SD ETN SC + DMARD		1.00(0.30,3.39)	1.00(0.33,3.24)	0.00(-0.10,0.07)
SD ADA SC + DMARD		0.26(0.07,1.10)	0.28(0.07,1.10)	-0.04(-0.16,0.00)
SD CERTO SC + DMARD		0.25(0.05,1.58)	0.27(0.05,1.55)	-0.04(-0.16,0.01)
LD ADA SC		0.36(0.07,1.97)	0.38(0.09,1.94)	-0.04(-0.17,0.02)
LD ETN SC		0.72(0.20,2.36)	0.73(0.22,2.26)	-0.01(-0.11,0.05)
LD GOLI IV		4.47(0.59,68.73)	3.51(0.61,18.38)	0.16(-0.04,0.72)
LD RITUX IV + MTX		0.51(0.18,1.44)	0.53(0.20,1.42)	-0.03(-0.12,0.01)
LD ABA IV + MTX		1.08(0.35,3.32)	1.08(0.38,3.03)	0.00(-0.08,0.11)
LD CERTO SC + MTX		1.31(0.21,5.45)	1.28(0.23,4.55)	0.01(-0.09,0.20)
LD ETN SC + MTX		0.44(0.11,1.54)	0.46(0.13,1.50)	-0.03(-0.14,0.02)
LD GOLI IV + MTX		2.49(0.38,38.28)	2.23(0.40,15.17)	0.07(-0.06,0.61)
HD TOCI IV		0.79(0.28,2.40)	0.80(0.30,2.27)	-0.01(-0.10,0.05)
HD TOFA PO		0.22(0.05,1.42)	0.24(0.06,1.41)	-0.05(-0.18,0.01)
HD ADA SC		0.54(0.12,3.30)	0.55(0.14,3.17)	-0.03(-0.16,0.04)

(Continued)

HD GOLI SC		1.19(0.24,5.36)	1.17(0.26,4.56)	0.01(-0.09,0.17)
HD GOLI SC + MTX		2.65(0.74,10.32)	2.34(0.76,7.75)	0.08(-0.02,0.33)
HD TOCI IV + MTX		0.93(0.28,3.19)	0.93(0.30,2.92)	0.00(-0.09,0.09)
HD TOFA PO + MTX		1.68(0.67,4.64)	1.60(0.68,3.99)	0.03(-0.03,0.18)
HD CERTO SC + MTX		1.70(0.57,5.21)	1.61(0.59,4.53)	0.03(-0.04,0.17)
HD INF IV + MTX		0.87(0.31,2.44)	0.88(0.34,2.33)	-0.01(-0.09,0.06)
HD TOCI IV + DMARD		0.55(0.16,2.05)	0.57(0.17,1.96)	-0.02(-0.13,0.04)
SD GOLI SC + MTX	SD ABA SC + MTX	3.69(0.99,15.15)	3.31(0.99,12.09)	0.07(0.00,0.30)
SD RITUX IV + MTX		1.42(0.57,4.03)	1.40(0.59,3.76)	0.01(-0.03,0.08)
SD TOFA PO + MTX		3.83(1.26,12.32)	3.44(1.24,10.14)	0.08(0.01,0.26)
SD GOLI IV + MTX		4.73(0.63,90.95)	4.07(0.64,32.54)	0.10(-0.01,0.70)
SD ETN SC + DMARD		1.92(0.57,6.26)	1.86(0.60,5.76)	0.02(-0.04,0.10)
SD ADA SC + DMARD		0.51(0.13,2.07)	0.52(0.14,2.03)	-0.01(-0.09,0.02)
SD CERTO SC + DMARD		0.47(0.09,2.76)	0.48(0.10,2.68)	-0.01(-0.09,0.04)
LD ADA SC		0.72(0.13,3.27)	0.73(0.14,3.20)	-0.01(-0.10,0.02)
LD ETN SC		1.36(0.44,4.27)	1.34(0.46,4.00)	0.01(-0.04,0.09)
LD GOLI IV		8.24(1.28,164.20)	6.26(1.26,40.30)	0.19(0.00,0.76)
LD RITUX IV + MTX		0.92(0.37,2.60)	0.93(0.39,2.51)	0.00(-0.05,0.04)
LD ABA IV + MTX		2.05(0.78,5.69)	1.97(0.79,5.18)	0.03(-0.01,0.15)
LD CERTO SC + MTX		2.49(0.38,10.82)	2.32(0.39,9.07)	0.04(-0.03,0.24)
LD ETN SC + MTX		0.85(0.25,2.92)	0.85(0.26,2.79)	0.00(-0.06,0.05)
LD GOLI IV + MTX		4.69(0.74,95.89)	4.05(0.74,33.23)	0.10(-0.01,0.65)
HD TOCI IV		1.49(0.50,4.41)	1.47(0.53,4.14)	0.01(-0.04,0.09)
HD TOFA PO		0.45(0.08,2.61)	0.45(0.09,2.58)	-0.02(-0.11,0.01)
HD ADA SC		1.06(0.21,5.46)	1.06(0.23,5.26)	0.00(-0.09,0.05)
HD GOLI SC		2.18(0.50,9.75)	2.08(0.51,8.02)	0.03(-0.03,0.21)
HD GOLI SC + MTX		4.91(1.55,18.50)	4.24(1.48,13.49)	0.11(0.01,0.37)
HD TOCI IV + MTX		1.76(0.57,5.91)	1.71(0.58,5.43)	0.02(-0.03,0.13)

(Continued)

HD TOFA PO + MTX		3.23(0.98,10.47)	2.97(0.98,8.68)	0.06(0.00,0.23)
HD CERTO SC + MTX		3.19(1.18,9.28)	2.92(1.17,7.96)	0.06(0.01,0.22)
HD INF IV + MTX		1.61(0.65,4.64)	1.57(0.67,4.33)	0.02(-0.02,0.10)
HD TOCI IV + DMARD		1.07(0.30,3.84)	1.07(0.32,3.58)	0.00(-0.06,0.07)
SD RITUX IV + MTX	SD GOLI SC + MTX	0.38(0.10,1.47)	0.42(0.12,1.44)	-0.06(-0.27,0.02)
SD TOFA PO + MTX		1.00(0.27,6.16)	1.00(0.32,4.94)	0.00(-0.17,0.19)
SD GOLI IV + MTX		1.36(0.16,17.59)	1.30(0.19,6.69)	0.03(-0.20,0.58)
SD ETN SC + DMARD		0.51(0.13,2.10)	0.54(0.17,2.02)	-0.05(-0.28,0.04)
SD ADA SC + DMARD		0.14(0.03,0.64)	0.16(0.03,0.65)	-0.09(-0.34,-0.01)
SD CERTO SC + DMARD		0.13(0.02,0.86)	0.14(0.02,0.88)	-0.09(-0.33,0.00)
LD ADA SC		0.18(0.03,1.02)	0.20(0.05,1.02)	-0.09(-0.34,0.00)
LD ETN SC		0.37(0.08,1.52)	0.40(0.11,1.48)	-0.06(-0.28,0.02)
LD GOLI IV		2.28(0.32,25.66)	1.93(0.34,8.10)	0.10(-0.14,0.65)
LD RITUX IV + MTX		0.26(0.06,0.91)	0.29(0.08,0.92)	-0.08(-0.30,0.00)
LD ABA IV + MTX		0.55(0.15,2.13)	0.59(0.18,2.00)	-0.04(-0.25,0.06)
LD CERTO SC + MTX		0.67(0.08,3.57)	0.70(0.09,3.12)	-0.03(-0.24,0.15)
LD ETN SC + MTX		0.23(0.05,1.05)	0.25(0.06,1.04)	-0.08(-0.32,0.00)
LD GOLI IV + MTX		1.33(0.16,15.12)	1.28(0.18,6.26)	0.02(-0.20,0.54)
HD TOCI IV		0.40(0.11,1.47)	0.44(0.14,1.44)	-0.06(-0.27,0.02)
HD TOFA PO		0.12(0.02,0.79)	0.13(0.03,0.79)	-0.10(-0.35,0.00)
HD ADA SC		0.27(0.06,1.64)	0.30(0.08,1.62)	-0.08(-0.33,0.02)
HD GOLI SC		0.60(0.14,2.04)	0.64(0.17,1.88)	-0.03(-0.21,0.08)
HD GOLI SC + MTX		1.36(0.55,3.67)	1.29(0.60,3.09)	0.03(-0.08,0.19)
HD TOCI IV + MTX		0.48(0.12,2.02)	0.51(0.14,1.93)	-0.05(-0.27,0.05)
HD TOFA PO + MTX		0.83(0.21,4.16)	0.85(0.25,3.65)	-0.01(-0.19,0.14)
HD CERTO SC + MTX		0.87(0.21,3.58)	0.89(0.26,3.19)	-0.01(-0.21,0.13)
HD INF IV + MTX		0.44(0.12,1.70)	0.48(0.14,1.64)	-0.05(-0.26,0.03)
HD TOCI IV + DMARD		0.29(0.06,1.27)	0.32(0.08,1.25)	-0.07(-0.30,0.01)

(Continued)

SD TOFA PO + MTX	SD RITUX IV + MTX	2.72(0.89,7.80)	2.47(0.90,6.36)	0.07(-0.01,0.24)
SD GOL I IV + MTX		3.12(0.48,76.53)	2.79(0.49,25.89)	0.08(-0.03,0.68)
SD ETN SC + DMARD		1.33(0.42,3.98)	1.31(0.45,3.75)	0.01(-0.07,0.08)
SD ADA SC + DMARD		0.35(0.09,1.52)	0.36(0.10,1.49)	-0.03(-0.12,0.01)
SD CERTO SC + DMARD		0.32(0.06,2.05)	0.34(0.07,2.00)	-0.03(-0.12,0.03)
LD ADA SC		0.49(0.10,2.03)	0.50(0.11,2.00)	-0.02(-0.13,0.02)
LD ETN SC		0.96(0.29,2.70)	0.96(0.31,2.55)	0.00(-0.08,0.06)
LD GOL I IV		5.72(0.93,126.70)	4.39(0.94,32.30)	0.17(0.00,0.75)
LD RITUX IV + MTX		0.66(0.33,1.27)	0.67(0.35,1.25)	-0.01(-0.07,0.01)
LD ABA IV + MTX		1.42(0.51,3.91)	1.39(0.54,3.60)	0.02(-0.04,0.13)
LD CERTO SC + MTX		1.70(0.25,6.95)	1.64(0.27,5.60)	0.02(-0.06,0.23)
LD ETN SC + MTX		0.61(0.17,1.78)	0.62(0.18,1.73)	-0.02(-0.10,0.03)
LD GOL I IV + MTX		3.15(0.53,72.16)	2.81(0.54,27.02)	0.08(-0.02,0.64)
HD TOCI IV		1.03(0.39,2.94)	1.02(0.42,2.78)	0.00(-0.06,0.06)
HD TOFA PO		0.31(0.07,1.63)	0.32(0.08,1.61)	-0.03(-0.14,0.01)
HD ADA SC		0.71(0.17,3.74)	0.72(0.19,3.62)	-0.01(-0.12,0.04)
HD GOL I SC		1.54(0.36,6.06)	1.50(0.38,5.04)	0.02(-0.05,0.19)
HD GOL I SC + MTX		3.45(1.07,11.28)	3.02(1.06,8.47)	0.09(0.00,0.34)
HD TOCI IV + MTX		1.23(0.41,3.76)	1.21(0.43,3.45)	0.01(-0.05,0.10)
HD TOFA PO + MTX		2.32(0.68,6.53)	2.15(0.69,5.46)	0.05(-0.02,0.21)
HD CERTO SC + MTX		2.25(0.83,5.74)	2.11(0.84,4.92)	0.05(-0.01,0.20)
HD INF IV + MTX		1.14(0.46,2.79)	1.13(0.48,2.61)	0.00(-0.05,0.08)
HD TOCI IV + DMARD		0.73(0.21,2.45)	0.74(0.23,2.36)	-0.01(-0.09,0.05)
SD GOL I IV + MTX	SD TOFA PO + MTX	1.24(0.14,25.44)	1.19(0.17,9.33)	0.02(-0.18,0.60)
SD ETN SC + DMARD		0.50(0.14,1.67)	0.54(0.17,1.62)	-0.05(-0.25,0.03)
SD ADA SC + DMARD		0.13(0.03,0.53)	0.15(0.04,0.56)	-0.10(-0.30,-0.01)
SD CERTO SC + DMARD		0.12(0.02,0.73)	0.14(0.02,0.75)	-0.10(-0.30,-0.01)

(Continued)

LD ADA SC		0.17(0.04,0.97)	0.19(0.05,0.97)	-0.09(-0.32,0.00)
LD ETN SC		0.36(0.09,1.23)	0.39(0.11,1.22)	-0.07(-0.26,0.01)
LD GOL I IV		2.22(0.23,37.58)	1.88(0.27,10.55)	0.10(-0.16,0.68)
LD RITUX IV + MTX		0.25(0.08,0.73)	0.28(0.10,0.75)	-0.08(-0.27,-0.01)
LD ABA IV + MTX		0.54(0.17,1.69)	0.58(0.20,1.62)	-0.04(-0.22,0.04)
LD CERTO SC + MTX		0.62(0.09,3.08)	0.66(0.11,2.64)	-0.03(-0.23,0.14)
LD ETN SC + MTX		0.22(0.05,0.77)	0.25(0.06,0.79)	-0.08(-0.28,-0.01)
LD GOL I IV + MTX		1.20(0.17,22.16)	1.17(0.19,8.91)	0.02(-0.19,0.57)
HD TOCI IV		0.39(0.13,1.19)	0.42(0.16,1.17)	-0.06(-0.24,0.01)
HD TOFA PO		0.11(0.02,0.71)	0.12(0.03,0.71)	-0.10(-0.33,-0.01)
HD ADA SC		0.26(0.06,1.51)	0.28(0.08,1.49)	-0.08(-0.30,0.01)
HD GOL I SC		0.58(0.09,2.55)	0.62(0.12,2.31)	-0.04(-0.23,0.10)
HD GOL I SC + MTX		1.32(0.31,4.99)	1.27(0.36,3.95)	0.03(-0.15,0.25)
HD TOCI IV + MTX		0.45(0.13,1.68)	0.49(0.16,1.59)	-0.05(-0.23,0.04)
HD TOFA PO + MTX		0.83(0.42,1.64)	0.85(0.46,1.53)	-0.01(-0.11,0.06)
HD CERTO SC + MTX		0.84(0.27,2.51)	0.86(0.32,2.28)	-0.01(-0.17,0.10)
HD INF IV + MTX		0.42(0.14,1.25)	0.46(0.17,1.23)	-0.06(-0.23,0.01)
HD TOCI IV + DMARD		0.27(0.07,0.98)	0.31(0.09,0.98)	-0.08(-0.27,0.00)
SD ETN SC + DMARD	SD GOL I IV + MTX	0.41(0.02,3.36)	0.45(0.07,3.18)	-0.07(-0.67,0.06)
SD ADA SC + DMARD		0.11(0.01,1.01)	0.13(0.02,1.01)	-0.12(-0.72,0.00)
SD CERTO SC + DMARD		0.09(0.01,1.10)	0.11(0.01,1.09)	-0.12(-0.72,0.00)
LD ADA SC		0.13(0.01,1.67)	0.16(0.03,1.65)	-0.12(-0.71,0.01)
LD ETN SC		0.30(0.01,2.23)	0.34(0.04,2.16)	-0.08(-0.69,0.04)
LD GOL I IV		1.62(0.50,6.95)	1.39(0.57,5.18)	0.05(-0.12,0.33)
LD RITUX IV + MTX		0.21(0.01,1.46)	0.24(0.03,1.44)	-0.10(-0.69,0.01)
LD ABA IV + MTX		0.44(0.02,3.24)	0.48(0.07,3.03)	-0.06(-0.66,0.08)
LD CERTO SC + MTX		0.50(0.01,5.23)	0.55(0.03,4.67)	-0.05(-0.67,0.15)
LD ETN SC + MTX		0.18(0.01,1.35)	0.21(0.02,1.33)	-0.11(-0.70,0.01)

(Continued)

LD GOL I IV + MTX		0.93(0.23,4.35)	0.95(0.28,3.54)	-0.01(-0.26,0.22)
HD TOCI IV		0.33(0.02,2.36)	0.37(0.05,2.28)	-0.08(-0.68,0.03)
HD TOFA PO		0.09(0.00,1.15)	0.10(0.01,1.14)	-0.12(-0.73,0.00)
HD ADA SC		0.20(0.01,2.59)	0.23(0.04,2.52)	-0.11(-0.70,0.03)
HD GOL I SC		0.46(0.02,4.11)	0.51(0.06,3.64)	-0.06(-0.65,0.12)
HD GOL I SC + MTX		1.07(0.06,8.37)	1.06(0.17,6.75)	0.00(-0.56,0.26)
HD TOCI IV + MTX		0.38(0.02,3.04)	0.43(0.05,2.86)	-0.07(-0.68,0.06)
HD TOFA PO + MTX		0.66(0.04,6.57)	0.71(0.09,5.59)	-0.04(-0.61,0.16)
HD CERTO SC + MTX		0.72(0.03,4.74)	0.76(0.08,4.30)	-0.03(-0.64,0.13)
HD INF IV + MTX		0.36(0.02,2.66)	0.40(0.05,2.55)	-0.08(-0.67,0.04)
HD TOCI IV + DMARD		0.23(0.01,2.02)	0.26(0.04,1.96)	-0.10(-0.70,0.03)
SD ADA SC + DMARD	SD ETN SC + DMARD	0.27(0.07,0.92)	0.28(0.08,0.92)	-0.04(-0.12,0.00)
SD CERTO SC + DMARD		0.26(0.05,1.22)	0.27(0.05,1.20)	-0.04(-0.13,0.01)
LD ADA SC		0.37(0.10,1.16)	0.39(0.11,1.15)	-0.04(-0.14,0.00)
LD ETN SC		0.69(0.22,2.35)	0.71(0.24,2.20)	-0.01(-0.09,0.06)
LD GOL I IV		4.34(0.47,70.46)	3.48(0.49,17.47)	0.16(-0.02,0.73)
LD RITUX IV + MTX		0.49(0.16,1.62)	0.51(0.17,1.57)	-0.03(-0.10,0.03)
LD ABA IV + MTX		1.06(0.31,3.65)	1.06(0.32,3.22)	0.00(-0.07,0.13)
LD CERTO SC + MTX		1.27(0.16,6.01)	1.25(0.17,4.79)	0.01(-0.08,0.22)
LD ETN SC + MTX		0.44(0.12,1.66)	0.46(0.13,1.60)	-0.03(-0.11,0.03)
LD GOL I IV + MTX		2.40(0.27,37.95)	2.18(0.29,14.36)	0.07(-0.04,0.62)
HD TOCI IV		0.78(0.28,2.22)	0.79(0.30,2.09)	-0.01(-0.08,0.06)
HD TOFA PO		0.23(0.06,0.95)	0.24(0.07,0.95)	-0.04(-0.15,0.00)
HD ADA SC		0.56(0.16,1.80)	0.58(0.18,1.76)	-0.02(-0.12,0.02)
HD GOL I SC		1.20(0.23,5.00)	1.18(0.24,4.19)	0.01(-0.08,0.18)
HD GOL I SC + MTX		2.59(0.65,10.42)	2.33(0.66,7.23)	0.08(-0.02,0.34)
HD TOCI IV + MTX		0.90(0.28,3.12)	0.91(0.29,2.81)	0.00(-0.07,0.10)
HD TOFA PO + MTX		1.68(0.46,6.35)	1.60(0.47,5.13)	0.03(-0.04,0.21)

(Continued)

HD CERTO SC + MTX		1.67(0.56,5.34)	1.59(0.58,4.41)	0.03(-0.04,0.20)
HD INF IV + MTX		0.86(0.27,2.78)	0.86(0.29,2.57)	-0.01(-0.08,0.09)
HD TOCI IV + DMARD		0.56(0.17,1.71)	0.58(0.18,1.64)	-0.02(-0.09,0.04)
SD CERTO SC + DMARD	SD ADA SC + DMARD	0.96(0.21,4.43)	0.96(0.22,4.25)	0.00(-0.04,0.05)
LD ADA SC		1.42(0.23,7.43)	1.41(0.24,7.19)	0.01(-0.05,0.04)
LD ETN SC		2.62(0.66,11.84)	2.53(0.67,10.82)	0.02(-0.01,0.12)
LD GOL I IV		16.18(1.71,259.20)	12.00(1.68,79.82)	0.21(0.01,0.77)
LD RITUX IV + MTX		1.90(0.46,7.60)	1.86(0.47,7.17)	0.01(-0.02,0.08)
LD ABA IV + MTX		4.02(1.00,17.26)	3.79(1.00,15.13)	0.04(0.00,0.19)
LD CERTO SC + MTX		4.78(0.53,27.51)	4.41(0.54,22.26)	0.05(-0.01,0.28)
LD ETN SC + MTX		1.66(0.37,8.11)	1.64(0.37,7.66)	0.01(-0.03,0.09)
LD GOL I IV + MTX		9.11(0.93,166.80)	7.76(0.94,66.04)	0.12(0.00,0.68)
HD TOCI IV		2.93(1.03,9.02)	2.82(1.03,8.43)	0.03(0.00,0.11)
HD TOFA PO		0.90(0.16,5.31)	0.91(0.17,5.21)	0.00(-0.06,0.02)
HD ADA SC		2.14(0.38,10.97)	2.09(0.40,10.50)	0.02(-0.04,0.06)
HD GOL I SC		4.36(0.71,27.18)	4.07(0.72,21.91)	0.05(-0.01,0.25)
HD GOL I SC + MTX		9.74(2.04,52.03)	8.24(1.95,37.68)	0.12(0.02,0.40)
HD TOCI IV + MTX		3.47(0.97,13.17)	3.28(0.97,11.99)	0.04(0.00,0.16)
HD TOFA PO + MTX		6.38(1.50,28.50)	5.71(1.47,22.87)	0.08(0.01,0.27)
HD CERTO SC + MTX		6.48(1.48,26.19)	5.82(1.45,21.42)	0.08(0.01,0.27)
HD INF IV + MTX		3.28(0.81,13.81)	3.14(0.81,12.75)	0.03(-0.01,0.14)
HD TOCI IV + DMARD		2.08(0.79,5.83)	2.04(0.80,5.57)	0.02(-0.01,0.08)
LD ADA SC	SD CER-TO SC + DMARD	1.43(0.20,9.17)	1.42(0.21,8.89)	0.01(-0.06,0.04)
LD ETN SC		2.83(0.50,17.09)	2.73(0.51,15.83)	0.02(-0.03,0.13)
LD GOL I IV		17.55(1.27,287.30)	12.83(1.26,94.88)	0.20(0.00,0.77)
LD RITUX IV + MTX		2.03(0.33,10.35)	1.99(0.34,9.84)	0.01(-0.04,0.08)
LD ABA IV + MTX		4.36(0.63,25.11)	4.09(0.64,21.71)	0.04(-0.01,0.20)

(Continued)

LD CERTO SC + MTX		4.87(0.42,40.97)	4.50(0.43,32.29)	0.05(-0.02,0.29)
LD ETN SC + MTX		1.74(0.28,11.44)	1.72(0.29,10.66)	0.01(-0.04,0.09)
LD GOLI IV + MTX		10.24(0.72,172.80)	8.78(0.73,73.72)	0.12(-0.01,0.67)
HD TOCI IV		3.11(0.74,13.65)	2.98(0.75,12.82)	0.03(-0.01,0.12)
HD TOFA PO		0.89(0.14,6.81)	0.90(0.15,6.69)	0.00(-0.07,0.02)
HD ADA SC		2.20(0.35,13.64)	2.16(0.36,13.11)	0.02(-0.05,0.06)
HD GOLI SC		4.77(0.54,33.58)	4.46(0.55,28.50)	0.05(-0.02,0.25)
HD GOLI SC + MTX		10.91(1.43,69.85)	9.17(1.39,51.80)	0.12(0.01,0.40)
HD TOCI IV + MTX		3.60(0.73,19.77)	3.42(0.74,17.76)	0.04(-0.01,0.16)
HD TOFA PO + MTX		6.65(1.16,39.61)	5.97(1.15,33.50)	0.08(0.00,0.27)
HD CERTO SC + MTX		6.65(1.12,35.45)	6.00(1.11,29.35)	0.08(0.00,0.27)
HD INF IV + MTX		3.54(0.55,18.29)	3.37(0.56,16.76)	0.03(-0.02,0.14)
HD TOCI IV + DMARD		2.20(0.57,9.58)	2.14(0.58,9.14)	0.02(-0.02,0.08)
LD ETN SC	LD ADA SC	1.89(0.42,10.33)	1.85(0.43,9.07)	0.02(-0.02,0.13)
LD GOLI IV		13.34(0.97,180.00)	10.13(0.97,49.19)	0.20(0.00,0.77)
LD RITUX IV + MTX		1.35(0.30,7.16)	1.34(0.31,6.55)	0.01(-0.03,0.09)
LD ABA IV + MTX		2.89(0.58,15.87)	2.76(0.59,13.02)	0.04(-0.01,0.20)
LD CERTO SC + MTX		3.42(0.37,24.54)	3.21(0.38,17.98)	0.05(-0.02,0.29)
LD ETN SC + MTX		1.16(0.23,6.78)	1.16(0.23,6.22)	0.00(-0.03,0.09)
LD GOLI IV + MTX		7.43(0.45,113.80)	6.40(0.46,40.22)	0.12(-0.01,0.67)
HD TOCI IV		2.10(0.51,10.85)	2.05(0.52,9.53)	0.02(-0.02,0.14)
HD TOFA PO		0.64(0.21,2.12)	0.64(0.21,2.08)	-0.01(-0.04,0.01)
HD ADA SC		1.53(0.68,3.54)	1.51(0.69,3.40)	0.01(-0.01,0.04)
HD GOLI SC		3.25(0.50,19.74)	3.07(0.51,15.16)	0.05(-0.02,0.25)
HD GOLI SC + MTX		7.31(1.33,41.87)	6.35(1.32,26.06)	0.12(0.01,0.41)
HD TOCI IV + MTX		2.46(0.52,14.10)	2.38(0.53,11.88)	0.03(-0.01,0.18)
HD TOFA PO + MTX		4.64(0.90,24.96)	4.24(0.90,18.78)	0.08(0.00,0.28)
HD CERTO SC + MTX		4.57(1.08,25.10)	4.20(1.08,18.91)	0.07(0.00,0.28)

(Continued)

HD INF IV + MTX		2.34(0.52,12.01)	2.27(0.53,10.29)	0.03(-0.01,0.16)
HD TOCI IV + DMARD		1.49(0.32,8.08)	1.48(0.33,7.24)	0.01(-0.02,0.11)
LD GOLI IV	LD ETN SC	5.85(0.87,122.00)	4.57(0.87,31.29)	0.17(0.00,0.75)
LD RITUX IV + MTX		0.68(0.24,2.34)	0.69(0.26,2.23)	-0.01(-0.09,0.04)
LD ABA IV + MTX		1.49(0.47,5.17)	1.45(0.49,4.57)	0.02(-0.05,0.14)
LD CERTO SC + MTX		1.85(0.25,8.58)	1.77(0.26,7.16)	0.03(-0.06,0.23)
LD ETN SC + MTX		0.62(0.16,2.50)	0.63(0.18,2.40)	-0.01(-0.10,0.05)
LD GOLI IV + MTX		3.32(0.45,69.20)	2.95(0.47,25.84)	0.08(-0.03,0.64)
HD TOCI IV		1.11(0.36,3.54)	1.10(0.38,3.31)	0.00(-0.07,0.08)
HD TOFA PO		0.33(0.07,1.76)	0.34(0.08,1.73)	-0.03(-0.14,0.01)
HD ADA SC		0.80(0.15,3.82)	0.80(0.17,3.69)	-0.01(-0.12,0.04)
HD GOLI SC		1.59(0.33,7.69)	1.54(0.35,6.42)	0.02(-0.06,0.20)
HD GOLI SC + MTX		3.67(0.94,15.33)	3.20(0.95,11.05)	0.09(0.00,0.35)
HD TOCI IV + MTX		1.29(0.37,4.83)	1.27(0.39,4.39)	0.01(-0.06,0.12)
HD TOFA PO + MTX		2.34(0.64,8.99)	2.19(0.66,7.42)	0.05(-0.02,0.23)
HD CERTO SC + MTX		2.38(0.72,7.52)	2.22(0.75,6.48)	0.05(-0.02,0.21)
HD INF IV + MTX		1.20(0.41,3.91)	1.19(0.44,3.64)	0.01(-0.06,0.09)
HD TOCI IV + DMARD		0.81(0.21,2.75)	0.82(0.23,2.61)	-0.01(-0.09,0.05)
LD RITUX IV + MTX	LD GOLI IV	0.12(0.01,0.67)	0.16(0.02,0.68)	-0.19(-0.76,-0.01)
LD ABA IV + MTX		0.25(0.02,1.57)	0.31(0.06,1.51)	-0.15(-0.72,0.03)
LD CERTO SC + MTX		0.29(0.01,2.81)	0.37(0.03,2.66)	-0.13(-0.74,0.10)
LD ETN SC + MTX		0.10(0.00,0.76)	0.14(0.02,0.77)	-0.19(-0.77,0.00)
LD GOLI IV + MTX		0.59(0.15,1.96)	0.69(0.22,1.66)	-0.06(-0.34,0.11)
HD TOCI IV		0.19(0.01,1.30)	0.24(0.04,1.29)	-0.17(-0.74,0.01)
HD TOFA PO		0.05(0.00,0.85)	0.07(0.01,0.85)	-0.21(-0.78,0.00)
HD ADA SC		0.11(0.01,1.72)	0.15(0.04,1.69)	-0.19(-0.75,0.02)
HD GOLI SC		0.27(0.02,1.97)	0.34(0.04,1.83)	-0.14(-0.71,0.06)
HD GOLI SC + MTX		0.61(0.04,3.92)	0.69(0.15,3.19)	-0.06(-0.63,0.19)

(Continued)

HD TOCI IV + MTX		0.22(0.01,1.51)	0.28(0.04,1.48)	-0.16(-0.74,0.02)
HD TOFA PO + MTX		0.38(0.02,3.10)	0.47(0.08,2.83)	-0.12(-0.70,0.10)
HD CERTO SC + MTX		0.40(0.02,2.81)	0.48(0.07,2.58)	-0.11(-0.71,0.08)
HD INF IV + MTX		0.20(0.01,1.24)	0.26(0.04,1.22)	-0.17(-0.74,0.01)
HD TOCI IV + DMARD		0.13(0.01,1.13)	0.17(0.03,1.13)	-0.18(-0.75,0.00)
LD ABA IV + MTX	LD RITUX IV + MTX	2.17(0.77,6.04)	2.08(0.78,5.48)	0.03(-0.01,0.15)
LD CERTO SC + MTX		2.60(0.36,10.41)	2.45(0.37,8.54)	0.04(-0.03,0.24)
LD ETN SC + MTX		0.91(0.25,2.83)	0.92(0.26,2.71)	0.00(-0.06,0.05)
LD GOL I IV + MTX		4.82(0.79,95.19)	4.16(0.80,34.24)	0.10(0.00,0.66)
HD TOCI IV		1.58(0.58,4.42)	1.54(0.60,4.17)	0.01(-0.03,0.09)
HD TOFA PO		0.47(0.10,2.50)	0.47(0.11,2.47)	-0.01(-0.10,0.01)
HD ADA SC		1.12(0.23,5.97)	1.11(0.25,5.74)	0.00(-0.08,0.05)
HD GOL I SC		2.36(0.53,9.25)	2.24(0.54,7.73)	0.03(-0.02,0.21)
HD GOL I SC + MTX		5.23(1.59,18.35)	4.50(1.54,13.09)	0.11(0.01,0.37)
HD TOCI IV + MTX		1.86(0.62,5.73)	1.80(0.63,5.25)	0.02(-0.02,0.13)
HD TOFA PO + MTX		3.43(1.05,10.42)	3.14(1.04,8.72)	0.07(0.00,0.24)
HD CERTO SC + MTX		3.44(1.27,9.01)	3.15(1.25,7.74)	0.06(0.01,0.23)
HD INF IV + MTX		1.75(0.67,4.42)	1.70(0.68,4.11)	0.02(-0.02,0.10)
HD TOCI IV + DMARD		1.12(0.31,3.79)	1.11(0.32,3.58)	0.00(-0.05,0.07)
LD CERTO SC + MTX	LD ABA IV + MTX	1.20(0.17,5.21)	1.18(0.18,4.38)	0.01(-0.11,0.19)
LD ETN SC + MTX		0.41(0.11,1.43)	0.43(0.13,1.40)	-0.03(-0.16,0.02)
LD GOL I IV + MTX		2.28(0.37,32.76)	2.08(0.40,12.94)	0.06(-0.08,0.61)
HD TOCI IV		0.73(0.24,2.17)	0.75(0.27,2.08)	-0.01(-0.13,0.05)
HD TOFA PO		0.21(0.04,1.39)	0.22(0.05,1.39)	-0.05(-0.21,0.01)
HD ADA SC		0.52(0.10,3.23)	0.54(0.12,3.11)	-0.03(-0.19,0.03)
HD GOL I SC		1.08(0.24,4.61)	1.08(0.27,3.93)	0.00(-0.11,0.16)
HD GOL I SC + MTX		2.42(0.71,8.77)	2.17(0.74,6.58)	0.07(-0.03,0.32)

(Continued)

HD TOCI IV + MTX		0.86(0.26,2.93)	0.87(0.28,2.71)	-0.01(-0.12,0.08)
HD TOFA PO + MTX		1.58(0.46,5.21)	1.50(0.49,4.41)	0.03(-0.06,0.18)
HD CERTO SC + MTX		1.56(0.55,4.52)	1.49(0.58,3.98)	0.03(-0.06,0.17)
HD INF IV + MTX		0.81(0.29,2.28)	0.82(0.32,2.16)	-0.01(-0.11,0.05)
HD TOCI IV + DMARD		0.52(0.13,1.90)	0.54(0.15,1.84)	-0.03(-0.16,0.03)
LD ETN SC + MTX	LD CERTO SC + MTX	0.34(0.07,2.73)	0.36(0.09,2.64)	-0.04(-0.25,0.03)
LD GOLI IV + MTX		1.95(0.20,68.80)	1.79(0.23,28.25)	0.05(-0.16,0.63)
HD TOCI IV		0.61(0.14,4.32)	0.63(0.17,4.11)	-0.02(-0.23,0.07)
HD TOFA PO		0.19(0.03,1.86)	0.20(0.03,1.84)	-0.06(-0.30,0.01)
HD ADA SC		0.44(0.07,4.81)	0.46(0.09,4.54)	-0.04(-0.28,0.04)
HD GOLI SC		0.94(0.14,8.93)	0.94(0.16,7.66)	0.00(-0.20,0.16)
HD GOLI SC + MTX		2.09(0.37,17.72)	1.88(0.42,13.69)	0.06(-0.12,0.31)
HD TOCI IV + MTX		0.72(0.15,4.92)	0.74(0.18,4.57)	-0.02(-0.22,0.09)
HD TOFA PO + MTX		1.33(0.26,9.72)	1.29(0.30,8.11)	0.02(-0.16,0.20)
HD CERTO SC + MTX		1.29(0.38,6.96)	1.26(0.43,6.26)	0.02(-0.12,0.15)
HD INF IV + MTX		0.67(0.16,4.26)	0.70(0.19,3.98)	-0.02(-0.21,0.07)
HD TOCI IV + DMARD		0.44(0.09,3.58)	0.46(0.11,3.45)	-0.04(-0.25,0.04)
LD GOLI IV + MTX	LD ETN SC + MTX	5.52(0.74,109.30)	4.70(0.74,40.75)	0.10(-0.01,0.66)
HD TOCI IV		1.79(0.49,6.20)	1.74(0.51,5.76)	0.02(-0.04,0.10)
HD TOFA PO		0.55(0.08,3.44)	0.55(0.09,3.39)	-0.01(-0.10,0.02)
HD ADA SC		1.28(0.24,6.59)	1.27(0.26,6.37)	0.01(-0.08,0.05)
HD GOLI SC		2.57(0.48,14.56)	2.44(0.50,12.02)	0.04(-0.03,0.23)
HD GOLI SC + MTX		5.95(1.41,26.39)	5.10(1.38,19.11)	0.11(0.01,0.38)
HD TOCI IV + MTX		2.11(0.52,8.39)	2.03(0.54,7.44)	0.02(-0.03,0.14)
HD TOFA PO + MTX		3.80(1.00,16.97)	3.45(1.00,13.75)	0.07(0.00,0.25)
HD CERTO SC + MTX		3.74(1.16,14.09)	3.42(1.15,12.04)	0.06(0.01,0.24)
HD INF IV + MTX		1.90(0.62,6.79)	1.85(0.63,6.26)	0.02(-0.02,0.11)

(Continued)

HD TOCI IV + DMARD		1.27(0.30,5.18)	1.26(0.32,4.84)	0.01(-0.06,0.08)
HD TOCI IV	LD GOLI IV + MTX	0.33(0.02,2.33)	0.37(0.05,2.28)	-0.08(-0.64,0.03)
HD TOFA PO		0.09(0.01,1.73)	0.10(0.01,1.72)	-0.12(-0.69,0.01)
HD ADA SC		0.21(0.02,3.37)	0.24(0.04,3.27)	-0.10(-0.66,0.03)
HD GOLI SC		0.48(0.03,3.51)	0.52(0.06,3.22)	-0.05(-0.61,0.11)
HD GOLI SC + MTX		1.11(0.08,7.30)	1.09(0.18,5.87)	0.01(-0.52,0.26)
HD TOCI IV + MTX		0.39(0.02,2.70)	0.43(0.05,2.60)	-0.07(-0.64,0.05)
HD TOFA PO + MTX		0.67(0.03,5.31)	0.71(0.09,4.94)	-0.03(-0.59,0.15)
HD CERTO SC + MTX		0.69(0.03,5.01)	0.73(0.08,4.55)	-0.03(-0.60,0.13)
HD INF IV + MTX		0.36(0.02,2.11)	0.40(0.05,2.03)	-0.08(-0.62,0.04)
HD TOCI IV + DMARD		0.23(0.01,2.04)	0.27(0.04,2.00)	-0.10(-0.66,0.02)
HD TOFA PO	HD TOCI IV	0.29(0.07,1.56)	0.30(0.08,1.55)	-0.03(-0.14,0.01)
HD ADA SC		0.72(0.16,3.15)	0.73(0.18,3.03)	-0.01(-0.12,0.04)
HD GOLI SC		1.49(0.31,6.74)	1.45(0.32,5.68)	0.02(-0.06,0.19)
HD GOLI SC + MTX		3.31(0.97,12.50)	2.91(0.98,8.99)	0.09(0.00,0.35)
HD TOCI IV + MTX		1.16(0.55,2.52)	1.15(0.57,2.34)	0.01(-0.04,0.08)
HD TOFA PO + MTX		2.16(0.68,6.69)	2.02(0.70,5.58)	0.05(-0.02,0.22)
HD CERTO SC + MTX		2.19(0.73,6.02)	2.06(0.74,5.12)	0.04(-0.02,0.21)
HD INF IV + MTX		1.10(0.39,3.12)	1.10(0.41,2.85)	0.00(-0.06,0.09)
HD TOCI IV + DMARD		0.72(0.28,1.73)	0.73(0.30,1.67)	-0.01(-0.08,0.03)
HD ADA SC	HD TOFA PO	2.36(0.77,7.53)	2.32(0.77,7.13)	0.02(-0.01,0.06)
HD GOLI SC		5.11(0.67,28.98)	4.80(0.68,22.31)	0.05(-0.01,0.26)
HD GOLI SC + MTX		11.88(1.52,62.49)	10.12(1.50,40.49)	0.13(0.01,0.42)
HD TOCI IV + MTX		4.05(0.67,19.24)	3.85(0.68,16.06)	0.04(-0.01,0.18)
HD TOFA PO + MTX		7.48(1.14,35.73)	6.75(1.14,27.02)	0.09(0.00,0.29)
HD CERTO SC + MTX		7.27(1.36,33.78)	6.61(1.35,25.82)	0.08(0.01,0.29)
HD INF IV + MTX		3.73(0.64,18.72)	3.58(0.65,16.11)	0.04(-0.01,0.16)

(Continued)

HD TOCI IV + DMARD		2.47(0.42,11.88)	2.41(0.43,10.69)	0.02(-0.01,0.11)
HD GOLI SC	HD ADA SC	2.15(0.30,12.14)	2.07(0.31,9.45)	0.03(-0.03,0.24)
HD GOLI SC + MTX		4.89(0.75,23.04)	4.28(0.75,15.01)	0.11(-0.01,0.40)
HD TOCI IV + MTX		1.66(0.32,8.66)	1.63(0.33,7.37)	0.02(-0.03,0.17)
HD TOFA PO + MTX		3.17(0.57,14.30)	2.92(0.58,10.85)	0.07(-0.02,0.27)
HD CERTO SC + MTX		3.05(0.68,14.59)	2.82(0.69,10.97)	0.06(-0.01,0.27)
HD INF IV + MTX		1.57(0.30,7.33)	1.54(0.31,6.34)	0.02(-0.04,0.14)
HD TOCI IV + DMARD		0.99(0.22,4.96)	0.99(0.23,4.47)	0.00(-0.04,0.09)
HD GOLI SC + MTX	HD GOLI SC	2.28(0.71,8.29)	2.04(0.75,6.87)	0.07(-0.03,0.28)
HD TOCI IV + MTX		0.80(0.16,4.19)	0.81(0.19,3.84)	-0.01(-0.18,0.10)
HD TOFA PO + MTX		1.47(0.31,7.45)	1.40(0.35,6.40)	0.02(-0.12,0.19)
HD CERTO SC + MTX		1.44(0.34,6.72)	1.38(0.38,5.78)	0.02(-0.12,0.18)
HD INF IV + MTX		0.74(0.19,3.34)	0.76(0.22,3.13)	-0.01(-0.18,0.07)
HD TOCI IV + DMARD		0.47(0.09,2.69)	0.49(0.10,2.57)	-0.03(-0.22,0.04)
HD TOCI IV + MTX	HD GOLI SC + MTX	0.36(0.08,1.32)	0.40(0.12,1.28)	-0.08(-0.34,0.02)
HD TOFA PO + MTX		0.62(0.16,2.68)	0.67(0.20,2.37)	-0.04(-0.26,0.12)
HD CERTO SC + MTX		0.63(0.18,2.17)	0.67(0.23,1.99)	-0.04(-0.27,0.09)
HD INF IV + MTX		0.33(0.10,1.06)	0.38(0.13,1.06)	-0.09(-0.33,0.00)
HD TOCI IV + DMARD		0.21(0.05,0.91)	0.25(0.06,0.91)	-0.10(-0.37,0.00)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.88(0.49,6.42)	1.77(0.51,5.44)	0.04(-0.05,0.21)
HD CERTO SC + MTX		1.84(0.57,5.76)	1.74(0.60,4.89)	0.04(-0.04,0.19)
HD INF IV + MTX		0.93(0.30,2.85)	0.93(0.32,2.68)	0.00(-0.10,0.08)
HD TOCI IV + DMARD		0.61(0.19,1.90)	0.62(0.21,1.83)	-0.02(-0.12,0.03)
HD CERTO SC + MTX	HD TOFA PO + MTX	1.00(0.31,3.23)	1.00(0.37,2.90)	0.00(-0.14,0.12)
HD INF IV + MTX		0.51(0.17,1.59)	0.54(0.21,1.54)	-0.04(-0.20,0.02)
HD TOCI IV + DMARD		0.33(0.09,1.24)	0.36(0.11,1.23)	-0.06(-0.24,0.01)

(Continued)

HD INF IV + MTX	HD CERTO SC + MTX	0.51(0.19,1.40)	0.55(0.22,1.36)	-0.04(-0.19,0.02)
HD TOCI IV + DMARD		0.33(0.09,1.13)	0.35(0.11,1.12)	-0.06(-0.24,0.01)
HD TOCI IV + DMARD	HD INF IV + MTX	0.65(0.18,2.20)	0.67(0.20,2.11)	-0.01(-0.11,0.04)
Random-effect model	Residual deviance	125.1 vs 127 data points		
	Deviance informa- tion crite- ria	688.58		
Fixed-effect model	Residual deviance	130.2 vs 127 data points		
	Deviance informa- tion crite- ria	689.019		
Note				
Total participants	22,022			
Total studies	50			
2-arm	30			
3-arm	14			
4-arm	5			
5-arm	1			

Appendix 22. Serious adverse events: subgroup - late RA (> 10 years)

SAE late: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD RITUX IV	MTX + PL	0.79(0.09,4.27)	0.80(0.09,3.70)	-0.01(-0.06,0.13)
SD RITUX IV + MTX		2.02(0.71,5.91)	1.90(0.72,4.90)	0.05(-0.02,0.17)
SD INF IV + MTX		0.48(0.16,1.42)	0.50(0.17,1.39)	-0.03(-0.06,0.02)
SD ANA SC + MTX		1.26(0.39,4.26)	1.24(0.41,3.65)	0.01(-0.04,0.14)
LD RITUX IV + MTX		2.67(0.96,7.84)	2.43(0.96,6.09)	0.08(0.00,0.22)

(Continued)

HD INF IV + MTX		0.94(0.35,2.57)	0.94(0.36,2.37)	0.00(-0.04,0.07)
SD RITUX IV + MTX	SD RITUX IV	2.56(0.50,21.54)	2.38(0.55,18.75)	0.06(-0.07,0.17)
SD INF IV + MTX		0.61(0.08,6.91)	0.62(0.10,6.58)	-0.02(-0.15,0.05)
SD ANA SC + MTX		1.61(0.20,19.67)	1.56(0.23,17.05)	0.02(-0.12,0.16)
LD RITUX IV + MTX		3.39(0.68,28.39)	3.03(0.72,23.75)	0.09(-0.04,0.22)
HD INF IV + MTX		1.20(0.17,12.80)	1.19(0.19,11.66)	0.01(-0.13,0.10)
SD INF IV + MTX	SD RITUX IV + MTX	0.24(0.05,1.10)	0.26(0.06,1.09)	-0.08(-0.19,0.01)
SD ANA SC + MTX		0.63(0.13,3.18)	0.65(0.15,2.79)	-0.04(-0.17,0.11)
LD RITUX IV + MTX		1.32(0.54,3.31)	1.27(0.58,2.84)	0.03(-0.07,0.14)
HD INF IV + MTX		0.47(0.11,1.98)	0.50(0.13,1.87)	-0.05(-0.18,0.05)
SD ANA SC + MTX	SD INF IV + MTX	2.61(0.54,13.70)	2.49(0.56,11.58)	0.04(-0.03,0.17)
LD RITUX IV + MTX		5.58(1.23,25.49)	4.91(1.21,19.87)	0.11(0.01,0.25)
HD INF IV + MTX		1.95(0.65,5.91)	1.89(0.67,5.46)	0.02(-0.02,0.09)
LD RITUX IV + MTX	SD ANA SC + MTX	2.13(0.43,10.31)	1.97(0.48,8.18)	0.07(-0.09,0.22)
HD INF IV + MTX		0.74(0.15,3.47)	0.76(0.18,3.20)	-0.02(-0.15,0.08)
HD INF IV + MTX	LD RITUX IV + MTX	0.35(0.08,1.48)	0.39(0.10,1.42)	-0.08(-0.23,0.03)
Random-effects model	Residual deviance	11.23 vs 12 data points		
	Deviance information criteria	65.874		
Fixed-effect model	Residual deviance	11.24 vs 12 data points		
	Deviance information criteria	65.611		
Note				
Total participants	1390			
Total studies	4			
2-arm	1			

(Continued)

3-arm 2

4-arm 1

Appendix 23. Serious adverse events: subgroup - trial duration (<= 6 months) network 1

SAE short, network 1: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
DMARD + PL	PL	0.96(0.14,6.18)	0.96(0.15,5.17)	0.00(-0.04,0.15)
MTX + DMARD		0.93(0.06,13.23)	0.93(0.06,9.40)	0.00(-0.04,0.28)
SD ADA SC		1.11(0.59,2.11)	1.11(0.60,2.04)	0.00(-0.02,0.04)
SD ETN SC		1.62(0.21,13.99)	1.58(0.22,9.90)	0.02(-0.03,0.29)
SD TOC IV + PL SC		1.27(0.41,3.80)	1.26(0.42,3.48)	0.01(-0.02,0.09)
SD TOFA PO		0.39(0.14,1.05)	0.40(0.14,1.05)	-0.02(-0.04,0.00)
SD CERTO SC		4.43(1.10,21.91)	3.94(1.10,13.92)	0.10(0.00,0.37)
SD TOC SC + PL IV		1.10(0.26,4.60)	1.09(0.27,4.06)	0.00(-0.03,0.11)
SD ETN SC + MTX		1.66(0.15,21.12)	1.62(0.16,13.16)	0.02(-0.04,0.38)
SD ETN SC + DMARD		1.45(0.29,6.57)	1.42(0.30,5.47)	0.01(-0.03,0.16)
SD ADA SC + DMARD		0.67(0.08,5.30)	0.68(0.08,4.61)	-0.01(-0.04,0.13)
SD ANA + DMARD		0.95(0.12,7.22)	0.95(0.12,5.96)	0.00(-0.04,0.18)
SD CERTO SC + DMARD		0.66(0.06,6.85)	0.67(0.06,5.67)	-0.01(-0.04,0.17)
SD TOCI SC + DMARD		1.25(0.14,10.79)	1.23(0.14,8.01)	0.01(-0.04,0.25)
LD ADA SC		0.65(0.25,1.49)	0.66(0.26,1.47)	-0.01(-0.03,0.02)
HD TOFA PO		0.53(0.22,1.37)	0.54(0.22,1.35)	-0.02(-0.04,0.01)
HD ADA SC		1.00(0.45,2.30)	1.00(0.46,2.21)	0.00(-0.02,0.04)
HD TOCI IV + DMARD		1.47(0.20,10.44)	1.45(0.21,7.81)	0.02(-0.03,0.25)
MTX + DMARD	DMARD + PL	0.91(0.04,25.54)	0.91(0.04,19.57)	0.00(-0.15,0.27)
SD ADA SC		1.18(0.20,7.16)	1.18(0.24,6.85)	0.01(-0.14,0.05)

(Continued)

SD ETN SC		1.63(0.11,29.72)	1.59(0.13,22.57)	0.02(-0.13,0.28)
SD TOC IV + PL SC		1.34(0.18,10.39)	1.33(0.21,9.65)	0.01(-0.13,0.09)
SD TOFA PO		0.40(0.04,3.31)	0.41(0.05,3.25)	-0.02(-0.18,0.02)
SD CERTO SC		4.76(0.43,57.12)	4.15(0.49,40.20)	0.10(-0.08,0.37)
SD TOC SC + PL IV		1.18(0.14,10.56)	1.17(0.16,9.81)	0.00(-0.14,0.10)
SD ETN SC + MTX		1.71(0.09,40.13)	1.65(0.10,28.01)	0.02(-0.12,0.37)
SD ETN SC + DMARD		1.52(0.57,4.02)	1.48(0.60,3.82)	0.01(-0.04,0.08)
SD ADA SC + DMARD		0.70(0.25,1.88)	0.71(0.26,1.80)	-0.01(-0.07,0.04)
SD ANA + DMARD		1.00(0.42,2.36)	1.00(0.44,2.21)	0.00(-0.04,0.07)
SD CERTO SC + DMARD		0.69(0.15,2.76)	0.71(0.16,2.55)	-0.01(-0.08,0.08)
SD TOCI SC + DMARD		1.29(0.46,4.02)	1.28(0.47,3.50)	0.01(-0.03,0.15)
LD ADA SC		0.68(0.09,5.06)	0.69(0.11,4.90)	-0.01(-0.16,0.03)
HD TOFA PO		0.56(0.06,4.78)	0.57(0.08,4.64)	-0.01(-0.17,0.03)
HD ADA SC		1.04(0.16,7.57)	1.04(0.19,7.26)	0.00(-0.15,0.05)
HD TOCI IV + DMARD		1.52(0.81,2.99)	1.48(0.82,2.76)	0.01(-0.01,0.12)
SD ADA SC	MTX + DMARD	1.22(0.08,20.81)	1.21(0.11,19.91)	0.01(-0.27,0.06)
SD ETN SC		1.76(0.38,9.71)	1.68(0.44,9.08)	0.02(-0.11,0.15)
SD TOC IV + PL SC		1.39(0.08,26.66)	1.37(0.11,24.75)	0.01(-0.26,0.10)
SD TOFA PO		0.42(0.02,8.11)	0.43(0.03,7.96)	-0.02(-0.30,0.02)
SD CERTO SC		4.76(0.23,123.50)	4.17(0.30,86.98)	0.10(-0.19,0.37)
SD TOC SC + PL IV		1.22(0.06,26.45)	1.21(0.08,24.20)	0.01(-0.26,0.11)
SD ETN SC + MTX		1.81(0.63,6.63)	1.73(0.66,6.05)	0.02(-0.04,0.18)
SD ETN SC + DMARD		1.64(0.07,34.32)	1.60(0.10,30.75)	0.02(-0.25,0.16)
SD ADA SC + DMARD		0.74(0.02,20.69)	0.75(0.03,18.63)	-0.01(-0.28,0.13)
SD ANA + DMARD		1.12(0.04,27.80)	1.12(0.05,24.55)	0.00(-0.27,0.17)
SD CERTO SC + DMARD		0.74(0.02,25.08)	0.75(0.02,21.69)	-0.01(-0.28,0.17)
SD TOCI SC + DMARD		1.44(0.04,39.90)	1.41(0.05,33.84)	0.01(-0.26,0.24)
LD ADA SC		0.69(0.04,12.56)	0.70(0.06,12.17)	-0.01(-0.29,0.04)

(Continued)

HD TOFA PO		0.58(0.03,10.77)	0.59(0.05,10.42)	-0.01(-0.29,0.03)
HD ADA SC		1.09(0.07,21.03)	1.08(0.09,19.95)	0.00(-0.28,0.06)
HD TOCI IV + DMARD		1.68(0.06,42.31)	1.64(0.08,35.79)	0.02(-0.25,0.24)
SD ETN SC	SD ADA SC	1.47(0.17,13.61)	1.44(0.17,9.75)	0.02(-0.05,0.28)
SD TOC IV + PL SC		1.14(0.45,2.86)	1.13(0.46,2.66)	0.00(-0.02,0.07)
SD TOFA PO		0.35(0.10,1.12)	0.36(0.11,1.12)	-0.02(-0.06,0.00)
SD CERTO SC		3.98(0.83,23.16)	3.55(0.84,14.95)	0.10(-0.01,0.37)
SD TOC SC + PL IV		0.99(0.28,3.51)	1.00(0.28,3.18)	0.00(-0.04,0.09)
SD ETN SC + MTX		1.50(0.12,19.86)	1.47(0.13,12.19)	0.02(-0.05,0.38)
SD ETN SC + DMARD		1.31(0.30,5.28)	1.29(0.31,4.51)	0.01(-0.03,0.15)
SD ADA SC + DMARD		0.60(0.08,4.43)	0.61(0.08,3.83)	-0.01(-0.05,0.12)
SD ANA + DMARD		0.85(0.12,6.02)	0.85(0.12,4.95)	-0.01(-0.05,0.17)
SD CERTO SC + DMARD		0.58(0.06,5.65)	0.59(0.06,4.77)	-0.01(-0.05,0.16)
SD TOCI SC + DMARD		1.11(0.14,8.73)	1.10(0.14,6.65)	0.00(-0.04,0.23)
LD ADA SC		0.58(0.23,1.32)	0.59(0.24,1.30)	-0.02(-0.05,0.01)
HD TOFA PO		0.47(0.16,1.47)	0.49(0.16,1.44)	-0.02(-0.06,0.01)
HD ADA SC		0.90(0.41,1.99)	0.90(0.42,1.93)	0.00(-0.03,0.03)
HD TOCI IV + DMARD		1.31(0.20,8.63)	1.29(0.20,6.50)	0.01(-0.04,0.24)
SD TOC IV + PL SC	SD ETN SC	0.76(0.07,7.99)	0.77(0.10,7.32)	-0.01(-0.28,0.09)
SD TOFA PO		0.23(0.02,2.47)	0.25(0.03,2.43)	-0.04(-0.31,0.01)
SD CERTO SC		2.71(0.21,39.52)	2.44(0.27,27.00)	0.07(-0.21,0.36)
SD TOC SC + PL IV		0.66(0.05,7.95)	0.67(0.07,7.18)	-0.02(-0.28,0.10)
SD ETN SC + MTX		1.04(0.33,3.10)	1.03(0.35,2.65)	0.00(-0.07,0.16)
SD ETN SC + DMARD		0.90(0.06,11.09)	0.91(0.09,9.54)	0.00(-0.27,0.15)
SD ADA SC + DMARD		0.42(0.02,7.51)	0.44(0.03,6.63)	-0.03(-0.29,0.11)
SD ANA + DMARD		0.60(0.03,9.77)	0.62(0.04,8.48)	-0.02(-0.28,0.15)
SD CERTO SC + DMARD		0.41(0.02,9.20)	0.42(0.02,7.82)	-0.03(-0.29,0.15)
SD TOCI SC + DMARD		0.78(0.04,14.46)	0.79(0.04,11.43)	-0.01(-0.27,0.22)

(Continued)

LD ADA SC		0.39(0.04,3.55)	0.41(0.05,3.45)	-0.03(-0.30,0.03)
HD TOFA PO		0.32(0.03,3.15)	0.33(0.05,3.09)	-0.04(-0.30,0.02)
HD ADA SC		0.60(0.06,5.72)	0.62(0.09,5.48)	-0.02(-0.29,0.05)
HD TOCI IV + DMARD		0.94(0.05,14.51)	0.94(0.06,11.74)	0.00(-0.27,0.21)
SD TOFA PO	SD TOC IV + PL SC	0.31(0.07,1.32)	0.32(0.07,1.31)	-0.03(-0.11,0.01)
SD CERTO SC		3.51(0.60,25.56)	3.13(0.62,17.15)	0.09(-0.03,0.36)
SD TOC SC + PL IV		0.87(0.37,2.09)	0.88(0.38,1.98)	0.00(-0.04,0.05)
SD ETN SC + MTX		1.35(0.10,19.89)	1.33(0.10,12.73)	0.01(-0.09,0.36)
SD ETN SC + DMARD		1.14(0.20,6.39)	1.14(0.21,5.47)	0.01(-0.07,0.15)
SD ADA SC + DMARD		0.53(0.05,4.81)	0.54(0.06,4.23)	-0.02(-0.10,0.11)
SD ANA + DMARD		0.75(0.08,6.39)	0.76(0.09,5.39)	-0.01(-0.09,0.16)
SD CERTO SC + DMARD		0.51(0.04,5.99)	0.53(0.05,5.09)	-0.02(-0.10,0.15)
SD TOCI SC + DMARD		0.97(0.10,9.56)	0.98(0.11,7.46)	0.00(-0.08,0.23)
LD ADA SC		0.51(0.14,1.74)	0.52(0.15,1.71)	-0.02(-0.10,0.01)
HD TOFA PO		0.42(0.10,1.83)	0.43(0.11,1.81)	-0.02(-0.11,0.01)
HD ADA SC		0.79(0.24,2.69)	0.80(0.26,2.60)	-0.01(-0.08,0.04)
HD TOCI IV + DMARD		1.15(0.14,8.99)	1.14(0.15,7.16)	0.01(-0.08,0.23)
SD CERTO SC	SD TOFA PO	11.21(2.11,79.76)	9.71(2.05,51.52)	0.12(0.02,0.39)
SD TOC SC + PL IV		2.80(0.52,16.83)	2.72(0.52,14.73)	0.02(-0.01,0.13)
SD ETN SC + MTX		4.42(0.32,64.65)	4.20(0.33,40.39)	0.04(-0.02,0.40)
SD ETN SC + DMARD		3.74(0.58,23.89)	3.59(0.58,19.88)	0.04(-0.01,0.19)
SD ADA SC + DMARD		1.74(0.17,18.47)	1.72(0.17,15.85)	0.01(-0.02,0.15)
SD ANA + DMARD		2.46(0.25,25.78)	2.40(0.26,20.60)	0.02(-0.02,0.21)
SD CERTO SC + DMARD		1.69(0.12,22.75)	1.67(0.12,18.34)	0.01(-0.02,0.19)
SD TOCI SC + DMARD		3.20(0.29,36.23)	3.09(0.30,26.52)	0.03(-0.02,0.27)
LD ADA SC		1.65(0.45,6.49)	1.64(0.46,6.22)	0.01(-0.02,0.04)
HD TOFA PO		1.36(0.51,3.82)	1.35(0.52,3.74)	0.00(-0.01,0.03)

(Continued)

HD ADA SC		2.53(0.75,9.86)	2.47(0.75,9.32)	0.02(-0.01,0.07)
HD TOCI IV + DMARD		3.79(0.42,38.62)	3.63(0.42,28.27)	0.04(-0.01,0.27)
SD TOC SC + PL IV	SD CERTO SC	0.25(0.03,1.75)	0.28(0.04,1.65)	-0.10(-0.36,0.04)
SD ETN SC + MTX		0.38(0.02,6.87)	0.42(0.03,4.60)	-0.07(-0.35,0.30)
SD ETN SC + DMARD		0.32(0.03,2.65)	0.36(0.05,2.36)	-0.08(-0.35,0.09)
SD ADA SC + DMARD		0.15(0.01,1.89)	0.17(0.01,1.76)	-0.11(-0.37,0.06)
SD ANA + DMARD		0.21(0.01,2.69)	0.24(0.02,2.33)	-0.10(-0.37,0.10)
SD CERTO SC + DMARD		0.15(0.01,2.31)	0.17(0.01,2.09)	-0.11(-0.37,0.09)
SD TOCI SC + DMARD		0.28(0.02,3.62)	0.32(0.03,2.96)	-0.09(-0.36,0.16)
LD ADA SC		0.14(0.02,0.73)	0.17(0.03,0.74)	-0.12(-0.38,-0.01)
HD TOFA PO		0.12(0.02,0.68)	0.14(0.03,0.69)	-0.12(-0.38,-0.01)
HD ADA SC		0.22(0.03,1.18)	0.25(0.05,1.17)	-0.10(-0.37,0.01)
HD TOCI IV + DMARD		0.32(0.02,3.90)	0.36(0.03,3.14)	-0.08(-0.35,0.17)
SD ETN SC + MTX	SD TOC SC + PL IV	1.57(0.10,26.25)	1.53(0.11,17.17)	0.02(-0.10,0.37)
SD ETN SC + DMARD		1.31(0.19,8.95)	1.29(0.21,7.69)	0.01(-0.09,0.15)
SD ADA SC + DMARD		0.61(0.05,6.35)	0.62(0.06,5.57)	-0.01(-0.11,0.11)
SD ANA + DMARD		0.86(0.08,8.52)	0.87(0.09,7.35)	0.00(-0.10,0.17)
SD CERTO SC + DMARD		0.59(0.04,8.07)	0.60(0.05,6.79)	-0.01(-0.11,0.16)
SD TOCI SC + DMARD		1.11(0.10,12.81)	1.10(0.11,10.24)	0.00(-0.10,0.23)
LD ADA SC		0.58(0.12,2.68)	0.59(0.14,2.61)	-0.01(-0.12,0.02)
HD TOFA PO		0.48(0.09,2.65)	0.49(0.10,2.59)	-0.02(-0.13,0.02)
HD ADA SC		0.91(0.21,4.07)	0.91(0.23,3.91)	0.00(-0.10,0.04)
HD TOCI IV + DMARD		1.30(0.14,12.44)	1.28(0.15,9.98)	0.01(-0.09,0.23)
SD ETN SC + DMARD	SD ETN SC + MTX	0.87(0.05,14.52)	0.88(0.07,12.70)	-0.01(-0.36,0.14)
SD ADA SC + DMARD		0.40(0.02,8.85)	0.42(0.02,8.05)	-0.03(-0.38,0.11)
SD ANA + DMARD		0.58(0.02,11.97)	0.60(0.03,10.31)	-0.02(-0.37,0.15)
SD CERTO SC + DMARD		0.40(0.01,10.37)	0.42(0.02,8.96)	-0.03(-0.38,0.14)

(Continued)

SD TOCI SC + DMARD		0.75(0.03,17.16)	0.76(0.04,13.90)	-0.01(-0.36,0.21)
LD ADA SC		0.37(0.03,4.99)	0.39(0.04,4.85)	-0.03(-0.39,0.03)
HD TOFA PO		0.31(0.02,4.21)	0.33(0.04,4.10)	-0.04(-0.39,0.02)
HD ADA SC		0.60(0.04,7.95)	0.61(0.07,7.59)	-0.02(-0.38,0.05)
HD TOCI IV + DMARD		0.90(0.04,17.66)	0.91(0.05,14.64)	0.00(-0.36,0.21)
SD ADA SC + DMARD	SD ETN SC + DMARD	0.47(0.11,1.82)	0.48(0.12,1.72)	-0.02(-0.11,0.04)
SD ANA + DMARD		0.66(0.18,2.43)	0.67(0.19,2.21)	-0.01(-0.09,0.08)
SD CERTO SC + DMARD		0.46(0.08,2.47)	0.48(0.08,2.22)	-0.02(-0.12,0.08)
SD TOCI SC + DMARD		0.85(0.21,3.82)	0.86(0.22,3.21)	0.00(-0.08,0.15)
LD ADA SC		0.44(0.08,2.38)	0.46(0.10,2.34)	-0.03(-0.18,0.02)
HD TOFA PO		0.37(0.06,2.42)	0.38(0.07,2.38)	-0.03(-0.18,0.02)
HD ADA SC		0.68(0.14,3.82)	0.70(0.17,3.67)	-0.01(-0.16,0.04)
HD TOCI IV + DMARD		1.01(0.32,3.26)	1.01(0.33,2.86)	0.00(-0.06,0.14)
SD ANA + DMARD	SD ADA SC + DMARD	1.43(0.38,5.47)	1.40(0.40,5.10)	0.01(-0.05,0.11)
SD CERTO SC + DMARD		1.00(0.16,5.64)	1.00(0.17,5.15)	0.00(-0.08,0.11)
SD TOCI SC + DMARD		1.87(0.43,8.46)	1.81(0.45,7.40)	0.02(-0.04,0.18)
LD ADA SC		0.95(0.11,9.15)	0.95(0.12,8.93)	0.00(-0.14,0.04)
HD TOFA PO		0.80(0.08,8.40)	0.80(0.09,8.19)	0.00(-0.15,0.03)
HD ADA SC		1.46(0.18,14.45)	1.44(0.21,13.87)	0.01(-0.13,0.06)
HD TOCI IV + DMARD		2.18(0.68,7.44)	2.09(0.70,6.80)	0.02(-0.02,0.16)
SD CERTO SC + DMARD	SD ANA + DMARD	0.68(0.12,3.59)	0.70(0.13,3.29)	-0.01(-0.11,0.08)
SD TOCI SC + DMARD		1.30(0.33,5.29)	1.28(0.35,4.65)	0.01(-0.07,0.15)
LD ADA SC		0.68(0.08,5.77)	0.69(0.10,5.61)	-0.01(-0.19,0.03)
HD TOFA PO		0.56(0.05,5.63)	0.57(0.07,5.47)	-0.01(-0.20,0.03)
HD ADA SC		1.05(0.13,8.86)	1.05(0.16,8.49)	0.00(-0.17,0.05)
HD TOCI IV + DMARD		1.53(0.54,4.55)	1.49(0.56,4.16)	0.01(-0.04,0.13)

(Continued)

SD TOCI SC + DMARD	SD CER- TO SC + DMARD	1.90(0.33,11.57)	1.83(0.36,10.40)	0.01(-0.07,0.18)
LD ADA SC		0.98(0.08,12.31)	0.98(0.10,11.89)	0.00(-0.18,0.04)
HD TOFA PO		0.81(0.07,12.06)	0.81(0.08,11.72)	0.00(-0.19,0.03)
HD ADA SC		1.51(0.14,18.93)	1.49(0.17,18.07)	0.01(-0.16,0.06)
HD TOCI IV + DMARD		2.21(0.47,11.44)	2.10(0.51,10.48)	0.02(-0.05,0.17)
LD ADA SC	SD TOCI SC + DMARD	0.52(0.05,4.94)	0.53(0.07,4.78)	-0.02(-0.26,0.03)
HD TOFA PO		0.43(0.04,4.68)	0.44(0.06,4.56)	-0.02(-0.26,0.03)
HD ADA SC		0.81(0.09,7.72)	0.82(0.12,7.37)	-0.01(-0.24,0.05)
HD TOCI IV + DMARD		1.17(0.33,4.05)	1.16(0.37,3.75)	0.00(-0.11,0.12)
HD TOFA PO	LD ADA SC	0.82(0.24,2.89)	0.82(0.25,2.82)	0.00(-0.04,0.03)
HD ADA SC		1.54(0.64,4.18)	1.52(0.65,4.01)	0.01(-0.01,0.05)
HD TOCI IV + DMARD		2.27(0.27,18.38)	2.20(0.28,13.99)	0.03(-0.03,0.26)
HD ADA SC	HD TOFA PO	1.90(0.55,6.60)	1.86(0.56,6.22)	0.02(-0.02,0.06)
HD TOCI IV + DMARD		2.71(0.30,26.42)	2.61(0.30,19.47)	0.03(-0.02,0.27)
HD TOCI IV + DMARD	HD ADA SC	1.47(0.18,10.69)	1.45(0.19,8.12)	0.01(-0.05,0.24)
Random-effects model	Residual deviance	54.1 vs 52 data points		
	Deviance informa- tion crite- ria	294.538		
Fixed-effect model	Residual deviance	56.54 vs 52 data points		
	Deviance informa- tion crite- ria	294.2		
Note				
Total participants	11,146			
Total studies	23			

(Continued)

2-arm	19
3-arm	2
4-arm	2

Appendix 24. Serious adverse events: subgroup - trial duration (<= 6 months) network 2
SAE short, network 2: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Refer- ence	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD GOL I IV	MTX	0.95(0.08,10.49)	0.96(0.09,7.69)	0.00(-0.04,0.26)
SD RITUX IV		0.49(0.06,2.35)	0.50(0.07,2.23)	-0.02(-0.04,0.05)
SD CERTO SC + MTX		1.49(0.88,2.73)	1.46(0.88,2.55)	0.02(0.00,0.06)
SD INF IV + MTX		1.08(0.60,1.86)	1.08(0.61,1.80)	0.00(-0.02,0.03)
SD ADA SC + MTX		1.10(0.46,2.50)	1.09(0.47,2.36)	0.00(-0.02,0.05)
SD ABA SC + MTX		0.61(0.21,1.34)	0.62(0.22,1.32)	-0.02(-0.03,0.01)
SD ABA IV + MTX		0.80(0.40,1.36)	0.81(0.41,1.34)	-0.01(-0.02,0.01)
SD RITUX IV + MTX		1.36(0.69,2.65)	1.34(0.70,2.49)	0.01(-0.01,0.06)
SD GOL I SC + MTX		2.15(0.71,7.89)	2.06(0.72,6.26)	0.04(-0.01,0.20)
SD TOFA PO + MTX		2.15(0.88,5.43)	2.05(0.89,4.64)	0.04(0.00,0.14)
SD GOL I IV + MTX		2.91(0.54,24.54)	2.70(0.55,12.82)	0.07(-0.02,0.46)
SD ANA SC + MTX		1.28(0.43,4.20)	1.26(0.44,3.72)	0.01(-0.02,0.11)
LD GOL I IV		4.76(0.99,38.40)	4.12(0.99,15.69)	0.13(0.00,0.57)
LD RITUX IV + MTX		1.08(0.55,2.28)	1.07(0.56,2.18)	0.00(-0.02,0.05)
LD CERTO SC + MTX		1.58(0.27,8.35)	1.55(0.28,6.47)	0.02(-0.03,0.21)
LD GOL I IV + MTX		2.81(0.53,22.70)	2.62(0.54,12.34)	0.07(-0.02,0.44)
HD TOCI IV		1.39(0.54,3.71)	1.36(0.55,3.34)	0.01(-0.02,0.09)
HD GOL I SC		1.30(0.32,5.56)	1.28(0.33,4.73)	0.01(-0.03,0.14)
HD GOL I SC + MTX		2.90(0.99,9.95)	2.69(0.99,7.48)	0.07(0.00,0.24)
HD TOCI IV + MTX		1.48(0.50,4.45)	1.45(0.52,3.91)	0.02(-0.02,0.12)

(Continued)

HD TOFA PO + MTX		1.83(0.73,4.62)	1.77(0.74,4.07)	0.03(-0.01,0.12)
HD INF IV + MTX		1.03(0.46,2.17)	1.03(0.47,2.07)	0.00(-0.02,0.04)
HD CERTO SC + MTX		2.33(0.59,11.61)	2.21(0.60,8.17)	0.05(-0.02,0.28)
HD CERTO + MTX		1.70(0.67,4.47)	1.65(0.68,3.93)	0.03(-0.01,0.12)
SD RITUX IV	SD GOLI IV	0.50(0.02,9.39)	0.51(0.03,8.89)	-0.02(-0.28,0.06)
SD CERTO SC + MTX		1.57(0.15,20.71)	1.54(0.19,19.14)	0.02(-0.23,0.08)
SD INF IV + MTX		1.14(0.10,13.44)	1.13(0.13,12.80)	0.00(-0.25,0.05)
SD ADA SC + MTX		1.16(0.09,14.40)	1.15(0.12,13.64)	0.01(-0.26,0.07)
SD ABA SC + MTX		0.62(0.05,8.33)	0.63(0.06,8.03)	-0.01(-0.27,0.03)
SD ABA IV + MTX		0.83(0.07,10.06)	0.84(0.10,9.73)	-0.01(-0.26,0.04)
SD RITUX IV + MTX		1.46(0.12,17.67)	1.43(0.17,16.53)	0.02(-0.24,0.08)
SD GOLI SC + MTX		2.40(0.16,36.31)	2.26(0.21,32.04)	0.04(-0.22,0.20)
SD TOFA PO + MTX		2.33(0.17,30.02)	2.21(0.23,26.61)	0.04(-0.22,0.15)
SD GOLI IV + MTX		3.05(0.52,39.86)	2.71(0.55,30.57)	0.06(-0.05,0.34)
SD ANA SC + MTX		1.36(0.10,21.91)	1.34(0.13,19.64)	0.01(-0.25,0.12)
LD GOLI IV		5.03(1.01,54.83)	4.10(1.01,38.98)	0.12(0.00,0.44)
LD RITUX IV + MTX		1.17(0.10,14.55)	1.16(0.14,13.83)	0.01(-0.25,0.06)
LD CERTO SC + MTX		1.70(0.10,31.87)	1.65(0.12,26.33)	0.02(-0.23,0.21)
LD GOLI IV + MTX		3.01(0.49,33.93)	2.66(0.52,27.76)	0.06(-0.05,0.31)
HD TOCI IV		1.48(0.11,20.90)	1.45(0.14,19.03)	0.02(-0.24,0.11)
HD GOLI SC		1.41(0.09,27.43)	1.39(0.12,24.34)	0.01(-0.24,0.15)
HD GOLI SC + MTX		3.13(0.22,54.92)	2.87(0.28,44.48)	0.07(-0.20,0.24)
HD TOCI IV + MTX		1.62(0.12,22.86)	1.57(0.15,20.53)	0.02(-0.23,0.13)
HD TOFA PO + MTX		1.96(0.14,26.74)	1.88(0.19,23.80)	0.03(-0.23,0.13)
HD INF IV + MTX		1.09(0.09,13.72)	1.08(0.12,13.02)	0.00(-0.26,0.06)
HD CERTO SC + MTX		2.53(0.16,48.64)	2.36(0.20,37.83)	0.05(-0.21,0.28)
HD CERTO + MTX		1.84(0.16,27.40)	1.78(0.20,24.59)	0.03(-0.22,0.12)
SD CERTO SC + MTX	SD RITUX IV	3.08(0.59,24.72)	2.96(0.61,23.13)	0.04(-0.03,0.09)

(Continued)

SD INF IV + MTX		2.24(0.40,18.26)	2.19(0.42,17.40)	0.02(-0.05,0.06)
SD ADA SC + MTX		2.29(0.36,22.59)	2.23(0.38,21.25)	0.02(-0.05,0.08)
SD ABA SC + MTX		1.26(0.18,10.83)	1.25(0.20,10.47)	0.00(-0.07,0.04)
SD ABA IV + MTX		1.65(0.29,13.43)	1.63(0.31,12.97)	0.01(-0.06,0.04)
SD RITUX IV + MTX		2.76(0.58,22.50)	2.66(0.60,21.05)	0.03(-0.03,0.08)
SD GOL I SC + MTX		4.58(0.69,45.04)	4.25(0.70,38.73)	0.06(-0.02,0.21)
SD TOFA PO + MTX		4.53(0.71,43.46)	4.21(0.73,38.18)	0.06(-0.02,0.16)
SD GOL I IV + MTX		6.47(0.54,111.50)	5.73(0.56,67.91)	0.09(-0.03,0.48)
SD ANA SC + MTX		2.76(0.39,26.18)	2.66(0.41,23.71)	0.03(-0.04,0.13)
LD GOL I IV		10.40(1.11,164.90)	8.52(1.10,89.52)	0.14(0.00,0.59)
LD RITUX IV + MTX		2.19(0.47,17.80)	2.14(0.49,16.85)	0.02(-0.04,0.07)
LD CERTO SC + MTX		3.40(0.31,44.12)	3.21(0.32,36.77)	0.04(-0.05,0.23)
LD GOL I IV + MTX		6.24(0.58,104.50)	5.58(0.59,63.30)	0.08(-0.02,0.46)
HD TOCI IV		2.88(0.47,26.87)	2.77(0.49,24.52)	0.03(-0.04,0.12)
HD GOL I SC		2.73(0.36,30.48)	2.63(0.38,26.94)	0.03(-0.04,0.16)
HD GOL I SC + MTX		6.22(0.87,59.87)	5.57(0.87,48.16)	0.09(-0.01,0.26)
HD TOCI IV + MTX		3.10(0.46,30.30)	2.96(0.48,27.39)	0.04(-0.04,0.14)
HD TOFA PO + MTX		3.87(0.56,36.71)	3.65(0.58,32.83)	0.05(-0.03,0.14)
HD INF IV + MTX		2.13(0.35,19.07)	2.08(0.37,18.11)	0.02(-0.05,0.07)
HD CERTO SC + MTX		4.95(0.60,66.80)	4.53(0.61,51.60)	0.07(-0.02,0.30)
HD CERTO + MTX		3.50(0.56,32.87)	3.32(0.58,29.51)	0.04(-0.03,0.14)
SD INF IV + MTX	SD CERTO SC + MTX	0.72(0.30,1.54)	0.74(0.32,1.50)	-0.02(-0.06,0.02)
SD ADA SC + MTX		0.72(0.26,1.96)	0.74(0.27,1.88)	-0.02(-0.07,0.04)
SD ABA SC + MTX		0.40(0.11,1.05)	0.42(0.12,1.05)	-0.03(-0.08,0.00)
SD ABA IV + MTX		0.53(0.21,1.14)	0.55(0.22,1.13)	-0.03(-0.07,0.01)
SD RITUX IV + MTX		0.92(0.36,2.10)	0.92(0.38,2.00)	0.00(-0.06,0.05)
SD GOL I SC + MTX		1.45(0.42,5.66)	1.41(0.45,4.63)	0.02(-0.05,0.18)
SD TOFA PO + MTX		1.44(0.49,4.19)	1.40(0.51,3.65)	0.02(-0.04,0.12)

(Continued)

SD GOLI IV + MTX		1.97(0.32,16.73)	1.86(0.34,9.14)	0.05(-0.05,0.44)
SD ANA SC + MTX		0.86(0.24,3.11)	0.87(0.26,2.81)	-0.01(-0.06,0.09)
LD GOLI IV		3.21(0.57,27.22)	2.83(0.59,11.63)	0.11(-0.03,0.55)
LD RITUX IV + MTX		0.72(0.30,1.77)	0.74(0.32,1.71)	-0.02(-0.06,0.03)
LD CERTO SC + MTX		1.07(0.18,5.18)	1.06(0.19,4.18)	0.00(-0.06,0.19)
LD GOLI IV + MTX		1.91(0.32,15.94)	1.81(0.33,8.87)	0.05(-0.05,0.42)
HD TOCI IV		0.92(0.30,2.82)	0.92(0.32,2.59)	0.00(-0.06,0.08)
HD GOLI SC		0.87(0.19,4.04)	0.88(0.21,3.51)	-0.01(-0.07,0.13)
HD GOLI SC + MTX		1.97(0.57,7.23)	1.86(0.59,5.59)	0.05(-0.03,0.22)
HD TOCI IV + MTX		0.98(0.29,3.33)	0.98(0.30,2.98)	0.00(-0.06,0.10)
HD TOFA PO + MTX		1.23(0.40,3.56)	1.21(0.42,3.19)	0.01(-0.05,0.10)
HD INF IV + MTX		0.69(0.25,1.68)	0.70(0.27,1.63)	-0.02(-0.07,0.03)
HD CERTO SC + MTX		1.57(0.39,7.23)	1.51(0.41,5.32)	0.03(-0.04,0.25)
HD CERTO + MTX		1.14(0.48,2.71)	1.13(0.50,2.48)	0.01(-0.04,0.09)
SD ADA SC + MTX	SD INF IV + MTX	1.01(0.37,2.81)	1.01(0.39,2.67)	0.00(-0.04,0.05)
SD ABA SC + MTX		0.56(0.19,1.41)	0.57(0.19,1.39)	-0.02(-0.05,0.01)
SD ABA IV + MTX		0.74(0.34,1.47)	0.74(0.36,1.45)	-0.01(-0.04,0.01)
SD RITUX IV + MTX		1.25(0.53,3.11)	1.24(0.54,2.92)	0.01(-0.03,0.06)
SD GOLI SC + MTX		1.99(0.63,8.32)	1.91(0.64,6.65)	0.04(-0.02,0.20)
SD TOFA PO + MTX		2.00(0.72,5.98)	1.92(0.73,5.19)	0.04(-0.02,0.14)
SD GOLI IV + MTX		2.72(0.45,24.78)	2.52(0.47,13.37)	0.07(-0.03,0.46)
SD ANA SC + MTX		1.19(0.35,4.60)	1.18(0.37,4.10)	0.01(-0.04,0.11)
LD GOLI IV		4.46(0.85,40.18)	3.86(0.85,16.61)	0.12(-0.01,0.57)
LD RITUX IV + MTX		1.00(0.43,2.65)	1.00(0.44,2.53)	0.00(-0.04,0.05)
LD CERTO SC + MTX		1.46(0.24,8.65)	1.43(0.24,6.78)	0.02(-0.04,0.21)
LD GOLI IV + MTX		2.61(0.45,23.29)	2.44(0.47,12.83)	0.06(-0.03,0.44)
HD TOCI IV		1.27(0.43,4.06)	1.26(0.45,3.68)	0.01(-0.03,0.09)
HD GOLI SC		1.21(0.27,5.82)	1.20(0.28,4.99)	0.01(-0.04,0.14)

(Continued)

HD GOLISCRON + MTX		2.70(0.84,10.95)	2.51(0.85,8.27)	0.07(-0.01,0.24)
HD TOCICITIB + MTX		1.36(0.41,4.85)	1.34(0.43,4.27)	0.01(-0.03,0.12)
HD TOFA + MTX		1.70(0.59,5.03)	1.65(0.61,4.47)	0.03(-0.02,0.12)
HD INFILIXIMAB + MTX		0.95(0.44,2.07)	0.95(0.45,1.99)	0.00(-0.03,0.04)
HD CERTICICITIB + MTX		2.17(0.49,11.88)	2.06(0.50,8.58)	0.05(-0.03,0.28)
HD CERTICICITIB + MTX		1.57(0.54,4.97)	1.53(0.56,4.41)	0.02(-0.03,0.12)
SD ABA + MTX	SD ADA + MTX	0.54(0.15,1.76)	0.55(0.16,1.73)	-0.02(-0.07,0.02)
SD ABA + MTX		0.72(0.25,1.98)	0.73(0.26,1.94)	-0.01(-0.06,0.02)
SD RITUXIMAB + MTX		1.25(0.43,3.71)	1.23(0.45,3.49)	0.01(-0.05,0.06)
SD GOLISCRON + MTX		1.99(0.50,9.13)	1.90(0.52,7.48)	0.04(-0.04,0.19)
SD TOFA + MTX		1.98(0.77,5.34)	1.90(0.78,4.73)	0.04(-0.01,0.13)
SD GOLISCRON + MTX		2.70(0.42,27.86)	2.50(0.44,15.01)	0.07(-0.04,0.45)
SD ANA + MTX		1.18(0.29,5.25)	1.17(0.30,4.70)	0.01(-0.05,0.11)
LD GOLISCRON		4.41(0.74,40.46)	3.79(0.75,18.28)	0.12(-0.02,0.56)
LD RITUXIMAB + MTX		1.00(0.34,3.09)	1.00(0.36,2.93)	0.00(-0.05,0.05)
LD CERTICICITIB + MTX		1.49(0.21,9.09)	1.46(0.22,7.21)	0.02(-0.06,0.21)
LD GOLISCRON + MTX		2.61(0.40,24.70)	2.42(0.42,14.06)	0.06(-0.04,0.44)
HD TOCICITIB		1.26(0.36,4.73)	1.24(0.38,4.30)	0.01(-0.05,0.09)
HD GOLISCRON		1.19(0.25,6.36)	1.18(0.26,5.46)	0.01(-0.06,0.14)
HD GOLISCRON + MTX		2.67(0.70,12.09)	2.48(0.71,9.27)	0.06(-0.02,0.24)
HD TOCICITIB + MTX		1.36(0.34,5.65)	1.33(0.36,4.99)	0.01(-0.05,0.12)
HD TOFA + MTX		1.69(0.64,4.55)	1.63(0.66,4.12)	0.03(-0.02,0.11)
HD INFILIXIMAB + MTX		0.94(0.30,2.93)	0.94(0.32,2.79)	0.00(-0.05,0.05)
HD CERTICICITIB + MTX		2.16(0.44,12.68)	2.05(0.46,9.32)	0.04(-0.04,0.27)
HD CERTICICITIB + MTX		1.58(0.44,5.72)	1.54(0.46,5.05)	0.02(-0.04,0.12)
SD ABA + MTX	SD ABA + MTX	1.32(0.67,2.91)	1.31(0.68,2.85)	0.01(-0.01,0.03)
SD RITUXIMAB + MTX		2.27(0.79,7.79)	2.20(0.80,7.27)	0.03(-0.01,0.08)

(Continued)

SD GOLI SC + MTX		3.67(0.94,17.64)	3.43(0.94,14.25)	0.06(0.00,0.21)
SD TOFA PO + MTX		3.61(1.11,14.60)	3.38(1.11,12.47)	0.06(0.00,0.16)
SD GOLI IV + MTX		4.91(0.78,51.18)	4.44(0.79,28.37)	0.08(-0.01,0.48)
SD ANA SC + MTX		2.19(0.54,10.29)	2.12(0.55,9.13)	0.03(-0.02,0.13)
LD GOLI IV		8.06(1.38,80.92)	6.82(1.36,35.50)	0.14(0.01,0.59)
LD RITUX IV + MTX		1.79(0.64,6.57)	1.76(0.65,6.22)	0.02(-0.02,0.07)
LD CERTO SC + MTX		2.65(0.39,19.16)	2.54(0.40,15.15)	0.04(-0.02,0.23)
LD GOLI IV + MTX		4.78(0.76,50.17)	4.34(0.77,27.75)	0.08(-0.01,0.46)
HD TOCI IV		2.30(0.68,9.67)	2.23(0.69,8.73)	0.03(-0.01,0.11)
HD GOLI SC		2.21(0.45,12.33)	2.14(0.46,10.59)	0.03(-0.02,0.16)
HD GOLI SC + MTX		4.94(1.27,24.28)	4.49(1.25,18.21)	0.08(0.01,0.26)
HD TOCI IV + MTX		2.47(0.65,11.42)	2.38(0.66,10.08)	0.03(-0.01,0.13)
HD TOFA PO + MTX		3.07(0.88,12.42)	2.92(0.88,10.92)	0.05(-0.01,0.14)
HD INF IV + MTX		1.70(0.59,6.08)	1.67(0.60,5.73)	0.02(-0.02,0.06)
HD CERTO SC + MTX		3.99(0.81,25.92)	3.70(0.82,18.92)	0.06(-0.01,0.30)
HD CERTO + MTX		2.82(0.84,12.46)	2.69(0.85,10.93)	0.04(-0.01,0.14)
SD RITUX IV + MTX	SD ABA IV + MTX	1.70(0.73,4.42)	1.67(0.74,4.14)	0.02(-0.01,0.07)
SD GOLI SC + MTX		2.73(0.82,11.35)	2.58(0.83,9.11)	0.05(-0.01,0.21)
SD TOFA PO + MTX		2.71(0.98,8.73)	2.56(0.99,7.48)	0.05(0.00,0.15)
SD GOLI IV + MTX		3.71(0.65,33.56)	3.41(0.66,17.95)	0.08(-0.01,0.47)
SD ANA SC + MTX		1.63(0.48,6.36)	1.60(0.49,5.62)	0.02(-0.02,0.12)
LD GOLI IV		6.05(1.16,54.64)	5.18(1.15,22.43)	0.14(0.01,0.58)
LD RITUX IV + MTX		1.37(0.57,3.86)	1.35(0.59,3.63)	0.01(-0.02,0.06)
LD CERTO SC + MTX		2.01(0.32,12.28)	1.94(0.32,9.59)	0.03(-0.03,0.22)
LD GOLI IV + MTX		3.58(0.62,32.54)	3.31(0.63,17.38)	0.07(-0.01,0.45)
HD TOCI IV		1.74(0.59,5.78)	1.70(0.60,5.22)	0.02(-0.02,0.11)
HD GOLI SC		1.66(0.38,8.06)	1.62(0.39,6.83)	0.02(-0.03,0.15)
HD GOLI SC + MTX		3.69(1.11,14.81)	3.38(1.10,11.22)	0.08(0.00,0.25)

(Continued)

HD TOCI IV + MTX		1.85(0.56,6.95)	1.80(0.57,6.08)	0.03(-0.02,0.13)
HD TOFA PO + MTX		2.31(0.78,7.33)	2.22(0.79,6.48)	0.04(-0.01,0.13)
HD INF IV + MTX		1.28(0.52,3.46)	1.27(0.53,3.28)	0.01(-0.02,0.05)
HD CERTO SC + MTX		2.98(0.68,16.76)	2.80(0.69,11.93)	0.06(-0.01,0.29)
HD CERTO + MTX		2.13(0.75,7.20)	2.05(0.76,6.37)	0.03(-0.01,0.13)
SD GOLI SC + MTX	SD RITUX IV + MTX	1.60(0.44,6.74)	1.55(0.46,5.48)	0.03(-0.04,0.19)
SD TOFA PO + MTX		1.58(0.53,5.03)	1.53(0.56,4.37)	0.03(-0.04,0.13)
SD GOLI IV + MTX		2.16(0.35,19.22)	2.02(0.37,10.50)	0.05(-0.05,0.45)
SD ANA SC + MTX		0.94(0.26,3.76)	0.95(0.27,3.38)	0.00(-0.06,0.10)
LD GOLI IV		3.53(0.66,29.62)	3.09(0.68,13.17)	0.11(-0.02,0.55)
LD RITUX IV + MTX		0.80(0.41,1.62)	0.81(0.43,1.58)	-0.01(-0.05,0.02)
LD CERTO SC + MTX		1.17(0.18,7.05)	1.16(0.19,5.62)	0.01(-0.06,0.20)
LD GOLI IV + MTX		2.06(0.35,18.28)	1.94(0.37,10.36)	0.05(-0.05,0.43)
HD TOCI IV		1.02(0.32,3.32)	1.02(0.34,3.06)	0.00(-0.06,0.09)
HD GOLI SC		0.96(0.20,4.79)	0.97(0.22,4.17)	0.00(-0.06,0.13)
HD GOLI SC + MTX		2.15(0.59,9.11)	2.02(0.61,6.97)	0.05(-0.03,0.23)
HD TOCI IV + MTX		1.09(0.30,3.97)	1.09(0.32,3.54)	0.00(-0.06,0.11)
HD TOFA PO + MTX		1.35(0.43,4.24)	1.32(0.46,3.79)	0.02(-0.05,0.11)
HD INF IV + MTX		0.75(0.27,2.08)	0.76(0.29,2.00)	-0.01(-0.06,0.04)
HD CERTO SC + MTX		1.73(0.37,9.58)	1.66(0.39,7.09)	0.04(-0.05,0.27)
HD CERTO + MTX		1.24(0.41,4.12)	1.23(0.43,3.70)	0.01(-0.05,0.11)
SD TOFA PO + MTX	SD GOLI SC + MTX	0.98(0.21,4.23)	0.99(0.24,3.76)	0.00(-0.16,0.11)
SD GOLI IV + MTX		1.32(0.16,14.51)	1.28(0.19,8.33)	0.02(-0.15,0.42)
SD ANA SC + MTX		0.59(0.11,3.10)	0.61(0.14,2.83)	-0.03(-0.19,0.08)
LD GOLI IV		2.20(0.30,25.05)	1.99(0.34,11.21)	0.08(-0.13,0.53)
LD RITUX IV + MTX		0.51(0.11,1.86)	0.53(0.14,1.80)	-0.04(-0.20,0.03)
LD CERTO SC + MTX		0.70(0.09,5.67)	0.72(0.10,4.66)	-0.02(-0.18,0.18)

(Continued)

LD GOL I IV + MTX		1.29(0.16,14.85)	1.25(0.19,8.50)	0.02(-0.16,0.41)
HD TOCI IV		0.63(0.13,2.77)	0.65(0.16,2.58)	-0.03(-0.19,0.07)
HD GOL I SC		0.59(0.15,2.18)	0.62(0.17,2.03)	-0.03(-0.14,0.06)
HD GOL I SC + MTX		1.35(0.50,3.55)	1.31(0.53,3.15)	0.02(-0.07,0.14)
HD TOCI IV + MTX		0.67(0.13,3.09)	0.69(0.16,2.82)	-0.02(-0.18,0.09)
HD TOFA PO + MTX		0.84(0.16,3.56)	0.85(0.20,3.23)	-0.01(-0.17,0.09)
HD INF IV + MTX		0.47(0.11,1.70)	0.49(0.13,1.65)	-0.04(-0.20,0.03)
HD CERTO SC + MTX		1.09(0.16,7.45)	1.08(0.19,5.64)	0.01(-0.16,0.25)
HD CERTO + MTX		0.77(0.17,3.41)	0.79(0.20,3.11)	-0.02(-0.17,0.09)
SD GOL I IV + MTX	SD TOFA PO + MTX	1.35(0.19,13.94)	1.31(0.22,7.95)	0.03(-0.11,0.42)
SD ANA SC + MTX		0.60(0.14,2.62)	0.62(0.16,2.42)	-0.03(-0.13,0.08)
LD GOL I IV		2.21(0.35,20.86)	1.99(0.38,9.63)	0.08(-0.08,0.53)
LD RITUX IV + MTX		0.50(0.16,1.58)	0.52(0.19,1.54)	-0.04(-0.14,0.02)
LD CERTO SC + MTX		0.75(0.10,4.70)	0.77(0.11,3.88)	-0.02(-0.13,0.17)
LD GOL I IV + MTX		1.28(0.20,12.91)	1.25(0.22,7.62)	0.02(-0.11,0.40)
HD TOCI IV		0.64(0.17,2.42)	0.66(0.19,2.27)	-0.03(-0.13,0.06)
HD GOL I SC		0.59(0.12,3.36)	0.62(0.13,2.99)	-0.03(-0.14,0.11)
HD GOL I SC + MTX		1.36(0.34,6.29)	1.32(0.37,5.01)	0.03(-0.09,0.21)
HD TOCI IV + MTX		0.68(0.16,2.87)	0.70(0.18,2.61)	-0.02(-0.13,0.09)
HD TOFA PO + MTX		0.85(0.40,1.75)	0.86(0.43,1.68)	-0.01(-0.08,0.04)
HD INF IV + MTX		0.47(0.14,1.53)	0.50(0.16,1.49)	-0.04(-0.14,0.02)
HD CERTO SC + MTX		1.09(0.21,6.80)	1.08(0.23,5.12)	0.01(-0.11,0.24)
HD CERTO + MTX		0.80(0.21,2.92)	0.81(0.24,2.67)	-0.02(-0.12,0.09)
SD ANA SC + MTX	SD GOL I IV + MTX	0.44(0.04,3.50)	0.47(0.07,3.22)	-0.06(-0.45,0.08)
LD GOL I IV		1.62(0.46,6.80)	1.48(0.53,5.24)	0.05(-0.11,0.29)
LD RITUX IV + MTX		0.37(0.04,2.39)	0.40(0.08,2.30)	-0.06(-0.45,0.03)
LD CERTO SC + MTX		0.54(0.04,5.87)	0.58(0.06,4.88)	-0.04(-0.43,0.16)

(Continued)

LD GOL I IV + MTX		0.97(0.21,4.31)	0.98(0.25,3.62)	0.00(-0.20,0.18)
HD TOCI IV		0.47(0.05,3.34)	0.50(0.08,3.11)	-0.05(-0.44,0.07)
HD GOL I SC		0.45(0.03,4.21)	0.48(0.06,3.77)	-0.05(-0.45,0.10)
HD GOL I SC + MTX		1.03(0.09,8.26)	1.02(0.16,6.68)	0.00(-0.40,0.20)
HD TOCI IV + MTX		0.49(0.05,3.86)	0.53(0.09,3.54)	-0.05(-0.43,0.09)
HD TOFA PO + MTX		0.62(0.06,4.38)	0.65(0.11,3.99)	-0.04(-0.43,0.09)
HD INF IV + MTX		0.35(0.04,2.22)	0.38(0.07,2.15)	-0.07(-0.46,0.03)
HD CERTO SC + MTX		0.80(0.07,8.10)	0.82(0.11,6.35)	-0.02(-0.40,0.23)
HD CERTO + MTX		0.58(0.06,4.16)	0.61(0.11,3.77)	-0.04(-0.43,0.09)
LD GOL I IV	SD ANA SC + MTX	3.84(0.51,38.84)	3.30(0.54,17.85)	0.11(-0.05,0.56)
LD RITUX IV + MTX		0.83(0.22,3.22)	0.84(0.25,3.06)	-0.01(-0.11,0.05)
LD CERTO SC + MTX		1.21(0.16,9.34)	1.19(0.17,7.59)	0.01(-0.10,0.20)
LD GOL I IV + MTX		2.22(0.28,23.97)	2.07(0.31,13.81)	0.05(-0.08,0.43)
HD TOCI IV		1.08(0.23,4.68)	1.07(0.26,4.32)	0.00(-0.10,0.09)
HD GOL I SC		1.01(0.15,6.05)	1.01(0.17,5.29)	0.00(-0.11,0.13)
HD GOL I SC + MTX		2.27(0.48,11.71)	2.12(0.51,9.10)	0.06(-0.06,0.23)
HD TOCI IV + MTX		1.15(0.23,5.51)	1.14(0.25,4.89)	0.01(-0.10,0.11)
HD TOFA PO + MTX		1.43(0.31,5.87)	1.40(0.35,5.25)	0.02(-0.09,0.11)
HD INF IV + MTX		0.79(0.20,2.97)	0.80(0.22,2.84)	-0.01(-0.11,0.04)
HD CERTO SC + MTX		1.84(0.29,13.10)	1.75(0.32,9.85)	0.04(-0.08,0.27)
HD CERTO + MTX		1.32(0.30,5.81)	1.30(0.33,5.22)	0.01(-0.09,0.11)
LD RITUX IV + MTX	LD GOL I IV	0.23(0.03,1.27)	0.26(0.06,1.26)	-0.12(-0.56,0.01)
LD CERTO SC + MTX		0.32(0.02,3.22)	0.37(0.04,2.78)	-0.10(-0.54,0.12)
LD GOL I IV + MTX		0.59(0.14,2.18)	0.65(0.19,1.89)	-0.05(-0.29,0.11)
HD TOCI IV		0.28(0.03,1.90)	0.33(0.06,1.81)	-0.11(-0.55,0.04)
HD GOL I SC		0.27(0.02,2.17)	0.31(0.05,2.02)	-0.11(-0.56,0.07)
HD GOL I SC + MTX		0.62(0.06,4.45)	0.66(0.13,3.69)	-0.05(-0.51,0.17)
HD TOCI IV + MTX		0.31(0.03,2.13)	0.35(0.07,1.99)	-0.10(-0.55,0.06)

(Continued)

HD TOFA PO + MTX		0.38(0.04,2.45)	0.43(0.09,2.27)	-0.09(-0.54,0.06)
HD INF IV + MTX		0.21(0.02,1.21)	0.24(0.05,1.20)	-0.13(-0.57,0.01)
HD CERTO SC + MTX		0.48(0.04,4.63)	0.53(0.09,3.70)	-0.07(-0.52,0.19)
HD CERTO + MTX		0.35(0.04,2.39)	0.40(0.08,2.22)	-0.10(-0.54,0.06)
LD CERTO SC + MTX	LD RITUX IV + MTX	1.46(0.22,8.69)	1.43(0.24,6.92)	0.02(-0.05,0.21)
LD GOLI IV + MTX		2.59(0.42,23.11)	2.41(0.44,12.92)	0.06(-0.03,0.44)
HD TOCI IV		1.28(0.37,4.36)	1.26(0.39,3.94)	0.01(-0.04,0.09)
HD GOLI SC		1.20(0.25,6.18)	1.19(0.27,5.29)	0.01(-0.05,0.14)
HD GOLI SC + MTX		2.68(0.74,11.68)	2.49(0.76,8.92)	0.06(-0.02,0.24)
HD TOCI IV + MTX		1.37(0.35,5.10)	1.34(0.37,4.52)	0.01(-0.05,0.12)
HD TOFA PO + MTX		1.70(0.52,5.30)	1.65(0.54,4.68)	0.03(-0.03,0.12)
HD INF IV + MTX		0.95(0.31,2.62)	0.95(0.33,2.49)	0.00(-0.05,0.04)
HD CERTO SC + MTX		2.16(0.45,11.99)	2.04(0.47,8.72)	0.05(-0.03,0.28)
HD CERTO + MTX		1.57(0.48,5.00)	1.53(0.50,4.41)	0.02(-0.04,0.11)
LD GOLI IV + MTX	LD CERTO SC + MTX	1.82(0.17,25.58)	1.72(0.21,16.06)	0.04(-0.16,0.41)
HD TOCI IV		0.86(0.13,6.63)	0.87(0.17,6.13)	-0.01(-0.20,0.09)
HD GOLI SC		0.84(0.09,7.69)	0.85(0.12,6.82)	-0.01(-0.20,0.13)
HD GOLI SC + MTX		1.93(0.24,15.70)	1.81(0.29,12.44)	0.05(-0.16,0.22)
HD TOCI IV + MTX		0.93(0.13,7.66)	0.93(0.16,6.90)	0.00(-0.20,0.11)
HD TOFA PO + MTX		1.13(0.18,8.34)	1.12(0.22,7.53)	0.01(-0.18,0.11)
HD INF IV + MTX		0.65(0.10,4.22)	0.67(0.13,4.04)	-0.02(-0.21,0.05)
HD CERTO SC + MTX		1.52(0.32,8.76)	1.46(0.35,7.48)	0.03(-0.11,0.20)
HD CERTO + MTX		1.07(0.18,7.47)	1.06(0.22,6.82)	0.00(-0.18,0.10)
HD TOCI IV	LD GOLI IV + MTX	0.49(0.05,3.43)	0.52(0.09,3.16)	-0.05(-0.42,0.07)
HD GOLI SC		0.47(0.04,4.33)	0.51(0.06,3.84)	-0.05(-0.43,0.11)
HD GOLI SC + MTX		1.05(0.10,8.70)	1.05(0.16,6.87)	0.00(-0.38,0.20)
HD TOCI IV + MTX		0.52(0.05,3.97)	0.55(0.09,3.62)	-0.05(-0.41,0.09)

(Continued)

HD TOFA PO + MTX		0.67(0.07,4.37)	0.70(0.11,4.00)	-0.03(-0.41,0.09)
HD INF IV + MTX		0.36(0.04,2.29)	0.39(0.07,2.21)	-0.06(-0.44,0.03)
HD CERTO SC + MTX		0.83(0.07,8.30)	0.85(0.12,6.57)	-0.01(-0.39,0.23)
HD CERTO + MTX		0.59(0.06,4.34)	0.62(0.11,3.97)	-0.04(-0.41,0.09)
HD GOLI SC	HD TOCI IV	0.95(0.16,5.40)	0.96(0.18,4.70)	0.00(-0.09,0.13)
HD GOLI SC + MTX		2.14(0.50,10.16)	2.00(0.53,7.91)	0.05(-0.05,0.23)
HD TOCI IV + MTX		1.07(0.46,2.52)	1.07(0.48,2.35)	0.00(-0.05,0.07)
HD TOFA PO + MTX		1.34(0.34,5.09)	1.31(0.37,4.53)	0.02(-0.07,0.11)
HD INF IV + MTX		0.74(0.21,2.49)	0.76(0.23,2.39)	-0.01(-0.10,0.04)
HD CERTO SC + MTX		1.71(0.30,10.93)	1.64(0.33,8.02)	0.03(-0.07,0.27)
HD CERTO + MTX		1.24(0.31,4.81)	1.23(0.34,4.34)	0.01(-0.08,0.11)
HD GOLI SC + MTX	HD GOLI SC	2.23(0.65,8.53)	2.08(0.68,7.39)	0.05(-0.04,0.19)
HD TOCI IV + MTX		1.12(0.19,7.26)	1.11(0.22,6.47)	0.01(-0.13,0.12)
HD TOFA PO + MTX		1.42(0.25,7.47)	1.39(0.28,6.68)	0.02(-0.12,0.12)
HD INF IV + MTX		0.78(0.15,3.89)	0.79(0.17,3.71)	-0.01(-0.14,0.05)
HD CERTO SC + MTX		1.82(0.25,15.28)	1.74(0.27,11.49)	0.04(-0.11,0.27)
HD CERTO + MTX		1.30(0.23,7.11)	1.28(0.27,6.33)	0.01(-0.12,0.11)
HD TOCI IV + MTX	HD GOLI SC + MTX	0.50(0.10,2.26)	0.53(0.13,2.09)	-0.05(-0.23,0.07)
HD TOFA PO + MTX		0.63(0.12,2.48)	0.66(0.16,2.31)	-0.04(-0.22,0.07)
HD INF IV + MTX		0.35(0.08,1.27)	0.38(0.10,1.25)	-0.07(-0.24,0.01)
HD CERTO SC + MTX		0.80(0.13,5.61)	0.82(0.16,4.30)	-0.02(-0.21,0.22)
HD CERTO + MTX		0.57(0.13,2.54)	0.60(0.16,2.34)	-0.04(-0.22,0.08)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.25(0.29,5.36)	1.23(0.32,4.82)	0.01(-0.10,0.11)
HD INF IV + MTX		0.70(0.18,2.55)	0.71(0.20,2.46)	-0.02(-0.12,0.04)
HD CERTO SC + MTX		1.58(0.26,10.73)	1.52(0.29,8.08)	0.03(-0.09,0.26)
HD CERTO + MTX		1.15(0.27,4.95)	1.14(0.30,4.47)	0.01(-0.10,0.11)

(Continued)

HD INF IV + MTX	HD TOFA PO + MTX	0.56(0.17,1.89)	0.58(0.19,1.83)	-0.03(-0.12,0.03)
HD CERTO SC + MTX		1.28(0.25,8.06)	1.25(0.27,6.01)	0.02(-0.09,0.25)
HD CERTO + MTX		0.94(0.24,3.46)	0.94(0.27,3.14)	0.00(-0.10,0.09)
HD CERTO SC + MTX	HD INF IV + MTX	2.28(0.48,13.55)	2.15(0.49,9.88)	0.05(-0.03,0.28)
HD CERTO + MTX		1.66(0.51,5.89)	1.61(0.53,5.23)	0.02(-0.03,0.12)
HD CERTO + MTX	HD CERTO SC + MTX	0.72(0.13,3.65)	0.74(0.17,3.35)	-0.02(-0.25,0.08)
Random-effects model	Residual deviance	70 vs 71 data points		
	Deviance informa- tion crite- ria	380.174		
Fixed-effect model	Residual deviance	75.17 vs 71 data points		
	Deviance informa- tion crite- ria	381.124		
Note				
Total participants	12,263			
Total studies	26			
2-arm	13			
3-arm	8			
4-arm	4			
5-arm	1			

Appendix 25. Serious adverse events: subgroup - trial duration (6 to 12 months)

SAE intermediate: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model				
SD ETN SC + PL	MTX + PL	1.06(0.34,3.38)	1.06(0.37,2.68)	0.01(-0.08,0.19)
SD INF IV + MTX		0.52(0.22,1.19)	0.55(0.25,1.16)	-0.05(-0.10,0.02)

(Continued)

SD ETN SC + MTX		0.77(0.27,2.20)	0.79(0.30,1.94)	-0.02(-0.09,0.11)
SD ABA IV + MTX		0.73(0.26,1.99)	0.76(0.29,1.78)	-0.03(-0.09,0.09)
SD RITUX IV + MTX		0.74(0.27,1.96)	0.76(0.30,1.76)	-0.03(-0.09,0.09)
LD ETN SC + PL		0.72(0.22,2.50)	0.75(0.24,2.13)	-0.03(-0.10,0.13)
LD RITUX IV + MTX		0.70(0.25,1.86)	0.73(0.28,1.69)	-0.03(-0.09,0.08)
LD ABA IV + MTX		1.16(0.44,3.19)	1.14(0.47,2.55)	0.02(-0.07,0.18)
LD ETN SC + MTX		0.42(0.12,1.34)	0.46(0.14,1.29)	-0.06(-0.11,0.03)
HD INF IV + MTX		0.96(0.37,2.51)	0.96(0.40,2.14)	0.00(-0.08,0.13)
SD INF IV + MTX	SD ETN SC + PL	0.49(0.12,1.98)	0.52(0.15,1.87)	-0.06(-0.24,0.05)
SD ETN SC + MTX		0.74(0.15,3.24)	0.76(0.20,2.84)	-0.03(-0.21,0.12)
SD ABA IV + MTX		0.68(0.15,3.17)	0.72(0.20,2.78)	-0.04(-0.22,0.11)
SD RITUX IV + MTX		0.69(0.15,3.08)	0.72(0.20,2.72)	-0.03(-0.22,0.11)
LD ETN SC + PL		0.69(0.20,2.19)	0.72(0.24,1.98)	-0.03(-0.18,0.08)
LD RITUX IV + MTX		0.65(0.14,2.89)	0.68(0.19,2.56)	-0.04(-0.22,0.10)
LD ABA IV + MTX		1.10(0.25,4.94)	1.08(0.31,4.01)	0.01(-0.18,0.19)
LD ETN SC + MTX		0.40(0.08,2.05)	0.43(0.10,1.91)	-0.07(-0.25,0.05)
HD INF IV + MTX		0.90(0.20,4.07)	0.91(0.25,3.43)	-0.01(-0.20,0.15)
SD ETN SC + MTX	SD INF IV + MTX	1.46(0.40,5.88)	1.42(0.42,4.88)	0.03(-0.06,0.17)
SD ABA IV + MTX		1.42(0.38,5.13)	1.38(0.41,4.38)	0.02(-0.06,0.15)
SD RITUX IV + MTX		1.42(0.39,5.12)	1.38(0.42,4.36)	0.02(-0.06,0.15)
LD ETN SC + PL		1.40(0.31,6.27)	1.36(0.34,5.13)	0.02(-0.07,0.18)
LD RITUX IV + MTX		1.36(0.37,4.84)	1.33(0.40,4.16)	0.02(-0.07,0.14)
LD ABA IV + MTX		2.26(0.63,8.37)	2.09(0.66,6.45)	0.07(-0.03,0.23)
LD ETN SC + MTX		0.82(0.19,3.39)	0.83(0.21,3.09)	-0.01(-0.09,0.09)
HD INF IV + MTX		1.86(0.65,5.30)	1.75(0.68,4.44)	0.05(-0.03,0.17)
SD ABA IV + MTX	SD ETN SC + MTX	0.94(0.22,4.00)	0.94(0.26,3.47)	-0.01(-0.14,0.13)
SD RITUX IV + MTX		0.94(0.22,3.95)	0.95(0.26,3.44)	0.00(-0.14,0.13)

(Continued)

LD ETN SC + PL		0.93(0.20,4.50)	0.94(0.23,3.79)	-0.01(-0.15,0.16)
LD RITUX IV + MTX		0.92(0.22,3.75)	0.92(0.25,3.28)	-0.01(-0.15,0.12)
LD ABA IV + MTX		1.51(0.36,6.41)	1.43(0.41,5.12)	0.04(-0.11,0.21)
LD ETN SC + MTX		0.55(0.16,1.81)	0.58(0.18,1.72)	-0.04(-0.15,0.04)
HD INF IV + MTX		1.25(0.30,5.12)	1.22(0.34,4.29)	0.02(-0.13,0.16)
SD RITUX IV + MTX	SD ABA IV + MTX	0.99(0.25,4.19)	0.99(0.29,3.63)	0.00(-0.13,0.13)
LD ETN SC + PL		1.00(0.21,4.82)	1.00(0.24,3.99)	0.00(-0.14,0.16)
LD RITUX IV + MTX		0.94(0.24,4.00)	0.95(0.28,3.49)	0.00(-0.13,0.12)
LD ABA IV + MTX		1.61(0.60,4.49)	1.52(0.64,3.74)	0.05(-0.05,0.18)
LD ETN SC + MTX		0.58(0.12,2.77)	0.60(0.14,2.54)	-0.03(-0.16,0.08)
HD INF IV + MTX		1.30(0.33,5.25)	1.26(0.37,4.39)	0.02(-0.11,0.17)
LD ETN SC + PL	SD RITUX IV + MTX	0.98(0.21,4.73)	0.99(0.24,3.95)	0.00(-0.13,0.16)
LD RITUX IV + MTX		0.95(0.35,2.71)	0.96(0.39,2.46)	0.00(-0.09,0.09)
LD ABA IV + MTX		1.61(0.41,6.48)	1.52(0.45,5.08)	0.05(-0.09,0.22)
LD ETN SC + MTX		0.58(0.12,2.63)	0.60(0.14,2.42)	-0.03(-0.16,0.07)
HD INF IV + MTX		1.30(0.34,5.23)	1.26(0.38,4.30)	0.02(-0.11,0.17)
LD RITUX IV + MTX	LD ETN SC + PL	0.98(0.19,4.42)	0.98(0.24,3.88)	0.00(-0.17,0.12)
LD ABA IV + MTX		1.61(0.34,7.65)	1.52(0.40,6.07)	0.04(-0.12,0.22)
LD ETN SC + MTX		0.60(0.12,3.00)	0.62(0.14,2.76)	-0.03(-0.19,0.08)
HD INF IV + MTX		1.33(0.28,6.29)	1.29(0.33,5.20)	0.03(-0.14,0.17)
LD ABA IV + MTX	LD RITUX IV + MTX	1.67(0.42,6.88)	1.58(0.47,5.38)	0.05(-0.09,0.22)
LD ETN SC + MTX		0.60(0.13,2.82)	0.62(0.15,2.58)	-0.03(-0.15,0.08)
HD INF IV + MTX		1.35(0.35,5.49)	1.31(0.39,4.57)	0.03(-0.10,0.17)
LD ETN SC + MTX	LD ABA IV + MTX	0.36(0.07,1.68)	0.40(0.10,1.59)	-0.08(-0.25,0.04)
HD INF IV + MTX		0.82(0.21,3.17)	0.84(0.26,2.71)	-0.02(-0.19,0.13)

(Continued)

HD INF IV + MTX	LD ETN SC + MTX	2.26(0.52,10.49)	2.11(0.56,8.68)	0.06(-0.06,0.20)
Random-effects model	Residual deviance	16.48 vs 17 data points		
	Deviance information criteria	105.18		
Fixed-effect model	Residual deviance	16.25 vs 17 data points		
	Deviance information criteria	104.718		
Note				
Total participants	2277			
Total studies	6			
2-arm	1			
5-arm	5			

Appendix 26. Cancer: main analysis

Cancer: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
DMARD	MTX	0.11(0.01,1.07)	0.11(0.01,1.07)	-0.01(-0.01,0.00)
SD ETN SC		1.44(0.54,4.04)	1.44(0.54,3.96)	0.00(0.00,0.02)
SD ADA SC		0.19(0.01,3.31)	0.19(0.01,3.25)	-0.01(-0.01,0.02)
SD ABA IV + MTX		0.69(0.14,3.11)	0.69(0.14,3.07)	0.00(-0.01,0.01)
SD ABA SC + MTX		0.47(0.07,2.70)	0.48(0.07,2.67)	0.00(-0.01,0.01)
SD ADA SC + MTX		0.51(0.06,3.76)	0.51(0.06,3.69)	0.00(-0.01,0.02)
SD ETN SC + MTX		1.99(0.59,7.18)	1.97(0.59,6.87)	0.01(0.00,0.05)

(Continued)

SD INF IV + MTX		0.80(0.13,5.22)	0.80(0.13,5.08)	0.00(-0.01,0.03)
SD RITUX IV + MTX		0.92(0.15,5.66)	0.92(0.15,5.47)	0.00(-0.01,0.03)
SD ETN SC + DMARD		0.09(0.00,1.04)	0.09(0.00,1.04)	-0.01(-0.01,0.00)
SD ABA IV + DMARD		0.11(0.00,1.33)	0.11(0.00,1.32)	-0.01(-0.01,0.00)
LD ETN SC		0.60(0.11,2.67)	0.60(0.12,2.63)	0.00(-0.01,0.01)
LD RITUX IV + MTX		0.59(0.06,4.03)	0.59(0.06,3.95)	0.00(-0.01,0.02)
LD ETN SC + MTX		4.34(0.58,31.67)	4.23(0.58,25.72)	0.03(0.00,0.19)
HD TOCI IV		0.39(0.03,2.63)	0.39(0.04,2.60)	0.00(-0.01,0.01)
SD ETN SC	DMARD	13.86(1.28,256.80)	13.69(1.28,252.60)	0.01(0.00,0.03)
SD ADA SC		1.78(0.12,35.45)	1.78(0.12,34.93)	0.00(0.00,0.02)
SD ABA IV + MTX		6.72(0.33,176.20)	6.68(0.33,174.30)	0.00(0.00,0.02)
SD ABA SC + MTX		4.59(0.18,131.60)	4.57(0.18,130.50)	0.00(-0.01,0.02)
SD ADA SC + MTX		4.98(0.17,173.70)	4.95(0.17,170.90)	0.00(-0.01,0.02)
SD ETN SC + MTX		18.62(1.52,383.20)	18.30(1.52,370.80)	0.01(0.00,0.05)
SD INF IV + MTX		7.56(0.44,241.20)	7.51(0.44,236.90)	0.01(0.00,0.03)
SD RITUX IV + MTX		8.97(0.40,259.70)	8.89(0.40,253.70)	0.01(0.00,0.04)
SD ETN SC + DMARD		0.90(0.14,6.08)	0.90(0.14,6.06)	0.00(0.00,0.00)
SD ABA IV + DMARD		1.00(0.36,2.93)	1.00(0.36,2.92)	0.00(0.00,0.00)
LD ETN SC		5.56(0.35,127.80)	5.53(0.35,126.40)	0.00(0.00,0.02)
LD RITUX IV + MTX		5.23(0.24,189.60)	5.21(0.24,185.20)	0.00(-0.01,0.03)
LD ETN SC + MTX		40.81(1.88,1326.00)	38.78(1.88,1162.00)	0.03(0.00,0.20)
HD TOCI IV		3.43(0.51,37.98)	3.41(0.51,37.66)	0.00(0.00,0.02)
SD ADA SC	SD ETN SC	0.13(0.00,2.48)	0.13(0.00,2.44)	-0.01(-0.03,0.01)
SD ABA IV + MTX		0.48(0.07,2.75)	0.48(0.07,2.73)	-0.01(-0.03,0.01)
SD ABA SC + MTX		0.33(0.04,2.37)	0.34(0.04,2.35)	-0.01(-0.03,0.01)
SD ADA SC + MTX		0.36(0.03,3.36)	0.36(0.03,3.31)	-0.01(-0.03,0.02)
SD ETN SC + MTX		1.37(0.39,4.94)	1.36(0.40,4.78)	0.00(-0.01,0.04)
SD INF IV + MTX		0.56(0.06,4.28)	0.56(0.06,4.18)	0.00(-0.03,0.02)

(Continued)

SD RITUX IV + MTX		0.64(0.07,5.43)	0.64(0.07,5.24)	0.00(-0.03,0.03)
SD ETN SC + DMARD		0.06(0.00,0.74)	0.06(0.00,0.74)	-0.01(-0.03,0.00)
SD ABA IV + DMARD		0.07(0.00,0.97)	0.07(0.00,0.97)	-0.01(-0.03,0.00)
LD ETN SC		0.41(0.08,1.68)	0.42(0.09,1.67)	-0.01(-0.02,0.01)
LD RITUX IV + MTX		0.41(0.03,3.46)	0.42(0.03,3.39)	-0.01(-0.03,0.02)
LD ETN SC + MTX		2.99(0.36,22.54)	2.91(0.37,18.66)	0.02(-0.01,0.19)
HD TOCI IV		0.26(0.02,2.07)	0.26(0.02,2.05)	-0.01(-0.03,0.01)
SD ABA IV + MTX	SD ADA SC	3.64(0.12,133.50)	3.62(0.12,132.00)	0.00(-0.02,0.02)
SD ABA SC + MTX		2.53(0.07,111.90)	2.52(0.07,110.80)	0.00(-0.02,0.02)
SD ADA SC + MTX		2.75(0.07,141.30)	2.74(0.08,139.30)	0.00(-0.02,0.02)
SD ETN SC + MTX		10.74(0.47,343.40)	10.53(0.47,333.70)	0.01(-0.01,0.05)
SD INF IV + MTX		4.07(0.14,175.40)	4.04(0.14,171.80)	0.00(-0.02,0.03)
SD RITUX IV + MTX		4.95(0.16,210.00)	4.92(0.16,205.60)	0.00(-0.02,0.04)
SD ETN SC + DMARD		0.54(0.03,6.33)	0.54(0.03,6.32)	0.00(-0.02,0.00)
SD ABA IV + DMARD		0.58(0.03,10.26)	0.58(0.03,10.22)	0.00(-0.02,0.01)
LD ETN SC		3.22(0.12,111.50)	3.21(0.12,110.40)	0.00(-0.02,0.02)
LD RITUX IV + MTX		3.06(0.08,161.40)	3.04(0.08,158.90)	0.00(-0.02,0.03)
LD ETN SC + MTX		22.80(0.79,1116.00)	21.68(0.80,992.50)	0.03(0.00,0.20)
HD TOCI IV		2.00(0.15,27.53)	2.00(0.15,27.33)	0.00(-0.02,0.02)
SD ABA SC + MTX	SD ABA IV + MTX	0.69(0.15,3.16)	0.69(0.15,3.13)	0.00(-0.01,0.01)
SD ADA SC + MTX		0.74(0.12,5.36)	0.74(0.12,5.30)	0.00(-0.01,0.02)
SD ETN SC + MTX		2.97(0.41,22.99)	2.93(0.41,22.11)	0.01(-0.01,0.05)
SD INF IV + MTX		1.17(0.16,9.26)	1.16(0.16,9.06)	0.00(-0.01,0.03)
SD RITUX IV + MTX		1.33(0.13,14.46)	1.33(0.13,13.96)	0.00(-0.02,0.04)
SD ETN SC + DMARD		0.14(0.00,2.83)	0.14(0.00,2.82)	0.00(-0.02,0.00)
SD ABA IV + DMARD		0.15(0.00,3.67)	0.15(0.00,3.64)	0.00(-0.02,0.01)
LD ETN SC		0.86(0.09,7.50)	0.86(0.10,7.39)	0.00(-0.02,0.02)
LD RITUX IV + MTX		0.85(0.06,10.44)	0.85(0.06,10.16)	0.00(-0.02,0.02)

(Continued)

LD ETN SC + MTX		6.30(0.56,94.02)	6.08(0.57,77.80)	0.03(-0.01,0.20)
HD TOCI IV		0.55(0.03,7.57)	0.55(0.03,7.43)	0.00(-0.02,0.02)
SD ADA SC + MTX	SD ABA SC + MTX	1.08(0.31,4.13)	1.08(0.32,4.08)	0.00(-0.01,0.01)
SD ETN SC + MTX		4.19(0.51,46.24)	4.13(0.51,44.65)	0.01(-0.01,0.05)
SD INF IV + MTX		1.70(0.17,18.51)	1.69(0.17,18.06)	0.00(-0.01,0.03)
SD RITUX IV + MTX		1.93(0.16,25.05)	1.92(0.16,24.22)	0.00(-0.01,0.04)
SD ETN SC + DMARD		0.20(0.01,4.89)	0.20(0.01,4.85)	0.00(-0.02,0.01)
SD ABA IV + DMARD		0.23(0.01,6.55)	0.23(0.01,6.51)	0.00(-0.02,0.01)
LD ETN SC		1.22(0.12,15.79)	1.22(0.12,15.59)	0.00(-0.01,0.02)
LD RITUX IV + MTX		1.26(0.08,17.13)	1.26(0.08,16.78)	0.00(-0.01,0.03)
LD ETN SC + MTX		8.93(0.69,159.80)	8.61(0.70,134.80)	0.03(0.00,0.20)
HD TOCI IV		0.79(0.04,13.43)	0.79(0.04,13.21)	0.00(-0.01,0.02)
SD ETN SC + MTX	SD ADA SC + MTX	3.93(0.38,49.01)	3.88(0.38,47.02)	0.01(-0.01,0.05)
SD INF IV + MTX		1.63(0.12,17.80)	1.62(0.12,17.48)	0.00(-0.02,0.03)
SD RITUX IV + MTX		1.78(0.12,24.81)	1.77(0.13,24.14)	0.00(-0.02,0.04)
SD ETN SC + DMARD		0.18(0.00,4.97)	0.18(0.00,4.94)	0.00(-0.02,0.01)
SD ABA IV + DMARD		0.20(0.00,6.76)	0.21(0.01,6.71)	0.00(-0.02,0.01)
LD ETN SC		1.11(0.09,15.89)	1.11(0.09,15.63)	0.00(-0.02,0.02)
LD RITUX IV + MTX		1.15(0.06,16.48)	1.15(0.06,16.09)	0.00(-0.02,0.03)
LD ETN SC + MTX		8.53(0.46,164.50)	8.21(0.47,140.20)	0.03(-0.01,0.20)
HD TOCI IV		0.73(0.03,14.83)	0.73(0.03,14.60)	0.00(-0.02,0.02)
SD INF IV + MTX	SD ETN SC + MTX	0.39(0.04,3.52)	0.40(0.05,3.45)	-0.01(-0.05,0.02)
SD RITUX IV + MTX		0.46(0.05,4.10)	0.46(0.05,4.00)	-0.01(-0.05,0.03)
SD ETN SC + DMARD		0.05(0.00,0.65)	0.05(0.00,0.66)	-0.01(-0.05,0.00)
SD ABA IV + DMARD		0.05(0.00,0.83)	0.05(0.00,0.83)	-0.01(-0.05,0.00)
LD ETN SC		0.30(0.04,1.76)	0.30(0.05,1.75)	-0.01(-0.05,0.01)
LD RITUX IV + MTX		0.29(0.02,2.63)	0.30(0.02,2.59)	-0.01(-0.05,0.02)

(Continued)

LD ETN SC + MTX		2.18(0.36,13.13)	2.13(0.37,11.26)	0.02(-0.02,0.17)
HD TOCI IV		0.19(0.01,1.78)	0.19(0.01,1.77)	-0.01(-0.05,0.01)
SD RITUX IV + MTX	SD INF IV + MTX	1.13(0.08,15.99)	1.13(0.08,15.50)	0.00(-0.03,0.04)
SD ETN SC + DMARD		0.12(0.00,2.35)	0.12(0.00,2.34)	-0.01(-0.03,0.00)
SD ABA IV + DMARD		0.13(0.00,2.83)	0.13(0.00,2.81)	-0.01(-0.03,0.01)
LD ETN SC		0.73(0.07,8.35)	0.73(0.07,8.24)	0.00(-0.03,0.02)
LD RITUX IV + MTX		0.72(0.04,9.82)	0.72(0.04,9.64)	0.00(-0.03,0.02)
LD ETN SC + MTX		5.44(0.41,75.23)	5.26(0.41,63.70)	0.03(-0.01,0.20)
HD TOCI IV		0.49(0.02,6.73)	0.49(0.02,6.63)	0.00(-0.03,0.02)
SD ETN SC + DMARD	SD RITUX IV + MTX	0.10(0.00,2.43)	0.10(0.00,2.42)	-0.01(-0.04,0.00)
SD ABA IV + DMARD		0.11(0.00,2.96)	0.11(0.00,2.94)	-0.01(-0.04,0.01)
LD ETN SC		0.65(0.05,7.28)	0.66(0.06,7.18)	0.00(-0.04,0.02)
LD RITUX IV + MTX		0.63(0.06,4.55)	0.63(0.06,4.50)	0.00(-0.03,0.01)
LD ETN SC + MTX		4.74(0.31,76.08)	4.58(0.32,63.38)	0.02(-0.02,0.19)
HD TOCI IV		0.41(0.02,6.31)	0.41(0.02,6.23)	0.00(-0.04,0.01)
SD ABA IV + DMARD	SD ETN SC + DMARD	1.14(0.13,9.36)	1.14(0.13,9.33)	0.00(0.00,0.01)
LD ETN SC		6.66(0.37,163.90)	6.63(0.37,162.00)	0.00(0.00,0.02)
LD RITUX IV + MTX		6.29(0.22,240.90)	6.26(0.22,237.30)	0.00(0.00,0.03)
LD ETN SC + MTX		47.44(2.15,1487.00)	45.16(2.14,1309.00)	0.03(0.00,0.20)
HD TOCI IV		3.98(0.41,52.17)	3.97(0.41,51.60)	0.00(0.00,0.02)
LD ETN SC	SD ABA IV + DMARD	5.70(0.29,150.80)	5.67(0.30,149.00)	0.00(-0.01,0.02)
LD RITUX IV + MTX		5.12(0.20,213.20)	5.10(0.20,210.50)	0.00(-0.01,0.03)
LD ETN SC + MTX		40.87(1.75,1502.00)	38.93(1.74,1347.00)	0.03(0.00,0.20)
HD TOCI IV		3.49(0.38,46.06)	3.47(0.38,45.72)	0.00(0.00,0.02)
LD RITUX IV + MTX	LD ETN SC	1.00(0.06,12.70)	1.00(0.06,12.38)	0.00(-0.02,0.03)
LD ETN SC + MTX		7.24(0.63,85.94)	6.98(0.63,72.53)	0.03(0.00,0.20)

(Continued)

HD TOCI IV		0.63(0.04,8.20)	0.63(0.04,8.05)	0.00(-0.02,0.02)
LD ETN SC + MTX	LD RITUX IV + MTX	7.45(0.46,147.40)	7.16(0.47,125.70)	0.03(-0.01,0.20)
HD TOCI IV		0.67(0.03,12.35)	0.67(0.03,12.16)	0.00(-0.03,0.02)
HD TOCI IV	LD ETN SC + MTX	0.09(0.00,1.55)	0.09(0.00,1.54)	-0.03(-0.20,0.00)
Random-effects model	Residual deviance	43.47 vs 56 data point		
	Deviance information criteria	213.751		
Fixed-effect model	Residual deviance	43.15 vs 56 data point		
	Deviance information criteria	212.255		
Total participants	10,843			
Total Studies	24			
2-arm	16			
3-arm	8			

Appendix 27. Cancer: subgroup - established RA (2-10 years)

Cancer established RA: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	MTX	2.33(0.46,14.33)	2.31(0.47,13.27)	0.01(0.00,0.08)
SD ABA IV + MTX		0.64(0.11,3.33)	0.65(0.11,3.29)	0.00(-0.01,0.01)
SD ETN SC + MTX		2.74(0.69,15.56)	2.70(0.69,14.38)	0.01(0.00,0.08)
SD INF IV + MTX		0.86(0.15,5.23)	0.86(0.15,5.13)	0.00(-0.01,0.02)
SD ABA SC + MTX		0.40(0.04,3.16)	0.40(0.04,3.12)	0.00(-0.01,0.01)
SD RITUX IV + MTX		0.98(0.16,6.79)	0.98(0.16,6.57)	0.00(-0.01,0.03)

(Continued)

LD RITUX IV + MTX		0.63(0.06,4.29)	0.64(0.06,4.21)	0.00(-0.01,0.02)
LD ETN SC + MTX		5.55(0.81,53.48)	5.37(0.81,41.14)	0.03(0.00,0.24)
HD TOCI IV		0.24(0.01,2.58)	0.25(0.01,2.56)	0.00(-0.01,0.01)
SD ABA IV + MTX	SD ETN SC	0.27(0.02,2.86)	0.27(0.02,2.83)	-0.01(-0.08,0.01)
SD ETN SC + MTX		1.18(0.34,4.40)	1.18(0.35,4.27)	0.00(-0.03,0.04)
SD INF IV + MTX		0.37(0.03,4.06)	0.37(0.03,4.01)	-0.01(-0.08,0.02)
SD ABA SC + MTX		0.17(0.01,2.36)	0.17(0.01,2.34)	-0.01(-0.08,0.01)
SD RITUX IV + MTX		0.42(0.03,5.21)	0.42(0.03,5.08)	-0.01(-0.08,0.03)
LD RITUX IV + MTX		0.26(0.01,3.20)	0.27(0.01,3.16)	-0.01(-0.08,0.01)
LD ETN SC + MTX		2.38(0.30,22.42)	2.32(0.30,18.84)	0.02(-0.03,0.20)
HD TOCI IV		0.10(0.00,1.88)	0.10(0.00,1.87)	-0.01(-0.08,0.01)
SD ETN SC + MTX	SD ABA IV + MTX	4.45(0.50,46.49)	4.37(0.50,43.50)	0.01(-0.01,0.08)
SD INF IV + MTX		1.34(0.16,12.75)	1.34(0.17,12.51)	0.00(-0.01,0.02)
SD ABA SC + MTX		0.62(0.11,2.82)	0.62(0.11,2.80)	0.00(-0.01,0.01)
SD RITUX IV + MTX		1.54(0.13,20.39)	1.54(0.13,19.65)	0.00(-0.01,0.04)
LD RITUX IV + MTX		0.98(0.06,12.64)	0.98(0.06,12.41)	0.00(-0.01,0.02)
LD ETN SC + MTX		9.00(0.69,131.50)	8.66(0.70,105.40)	0.03(0.00,0.24)
HD TOCI IV		0.36(0.01,6.96)	0.36(0.01,6.88)	0.00(-0.02,0.01)
SD INF IV + MTX	SD ETN SC + MTX	0.31(0.03,2.90)	0.32(0.03,2.87)	-0.01(-0.08,0.01)
SD ABA SC + MTX		0.14(0.01,1.79)	0.14(0.01,1.78)	-0.02(-0.08,0.01)
SD RITUX IV + MTX		0.35(0.03,3.80)	0.35(0.03,3.70)	-0.01(-0.08,0.02)
LD RITUX IV + MTX		0.22(0.01,2.42)	0.22(0.01,2.39)	-0.01(-0.08,0.01)
LD ETN SC + MTX		1.99(0.33,13.37)	1.94(0.34,11.30)	0.02(-0.03,0.19)
HD TOCI IV		0.09(0.00,1.37)	0.09(0.00,1.37)	-0.02(-0.08,0.00)
SD ABA SC + MTX	SD INF IV + MTX	0.45(0.03,5.71)	0.45(0.03,5.63)	0.00(-0.02,0.01)
SD RITUX IV + MTX		1.13(0.09,14.61)	1.13(0.09,14.22)	0.00(-0.02,0.03)
LD RITUX IV + MTX		0.71(0.04,9.81)	0.71(0.04,9.60)	0.00(-0.02,0.02)

(Continued)

LD ETN SC + MTX		6.32(0.50,104.40)	6.09(0.51,84.16)	0.03(-0.01,0.24)
HD TOCI IV		0.26(0.01,5.97)	0.27(0.01,5.90)	0.00(-0.02,0.01)
SD RITUX IV + MTX	SD ABA SC + MTX	2.49(0.15,53.39)	2.48(0.16,51.97)	0.00(-0.01,0.04)
LD RITUX IV + MTX		1.60(0.07,32.68)	1.59(0.07,32.08)	0.00(-0.01,0.02)
LD ETN SC + MTX		14.80(0.86,336.80)	14.14(0.86,276.00)	0.03(0.00,0.24)
HD TOCI IV		0.60(0.01,16.38)	0.60(0.01,16.17)	0.00(-0.02,0.01)
LD RITUX IV + MTX	SD RITUX IV + MTX	0.63(0.06,4.34)	0.64(0.06,4.30)	0.00(-0.03,0.01)
LD ETN SC + MTX		5.70(0.38,104.80)	5.49(0.39,84.29)	0.03(-0.02,0.23)
HD TOCI IV		0.24(0.00,5.04)	0.24(0.00,4.99)	0.00(-0.04,0.01)
LD ETN SC + MTX	LD RITUX IV + MTX	9.11(0.58,216.70)	8.73(0.58,178.10)	0.03(-0.01,0.24)
HD TOCI IV		0.39(0.01,9.91)	0.39(0.01,9.78)	0.00(-0.02,0.01)
HD TOCI IV	LD ETN SC + MTX	0.04(0.00,0.97)	0.04(0.00,0.98)	-0.03(-0.24,0.00)
Random-effects model	Residual deviance	23.95 vs data points 31		
	Deviance information criteria	115.121		
Fixed-effect model	Residual deviance	23.65 vs 31 data points		
	Deviance information criteria	114.266		
Note				
Total studies	13			
2-arm	8			
3-arm	5			

Appendix 28. Cancer: subgroup - trial duration (<= 6 months)

Cancer short: odds ratios, risk ratios and risk difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ABA IV + MTX	MTX	0.72(0.11,4.57)	0.73(0.11,4.52)	0.00(-0.01,0.01)
SD ABA SC + MTX		0.44(0.04,3.99)	0.44(0.04,3.95)	0.00(-0.01,0.01)
SD INF IV + MTX		1.45(0.16,16.43)	1.44(0.16,15.69)	0.00(-0.01,0.05)
SD RITUX IV + MTX		2.39(0.19,69.59)	2.37(0.19,53.42)	0.01(-0.01,0.22)
LD RITUX IV + MTX		0.94(0.03,30.30)	0.94(0.03,26.84)	0.00(-0.01,0.12)
HD TOCI IV		0.25(0.01,2.66)	0.26(0.01,2.64)	0.00(-0.01,0.01)
SD ABA SC + MTX	SD ABA IV + MTX	0.61(0.11,2.89)	0.61(0.11,2.86)	0.00(-0.01,0.01)
SD INF IV + MTX		2.02(0.21,24.23)	2.01(0.21,23.28)	0.00(-0.01,0.05)
SD RITUX IV + MTX		3.45(0.13,139.90)	3.41(0.13,110.00)	0.01(-0.01,0.22)
LD RITUX IV + MTX		1.35(0.02,67.15)	1.35(0.02,59.70)	0.00(-0.01,0.12)
HD TOCI IV		0.34(0.01,6.62)	0.34(0.01,6.53)	0.00(-0.01,0.01)
SD INF IV + MTX	SD ABA SC + MTX	3.40(0.23,58.33)	3.38(0.23,56.39)	0.00(-0.01,0.05)
SD RITUX IV + MTX		5.71(0.18,315.00)	5.62(0.19,251.50)	0.01(-0.01,0.22)
LD RITUX IV + MTX		2.25(0.03,143.80)	2.24(0.03,126.20)	0.00(-0.01,0.12)
HD TOCI IV		0.57(0.01,16.97)	0.57(0.01,16.74)	0.00(-0.01,0.01)
SD RITUX IV + MTX	SD INF IV + MTX	1.67(0.05,92.96)	1.66(0.05,73.20)	0.00(-0.04,0.22)
LD RITUX IV + MTX		0.64(0.01,43.56)	0.64(0.01,38.58)	0.00(-0.05,0.12)
HD TOCI IV		0.16(0.00,4.88)	0.16(0.00,4.83)	-0.01(-0.05,0.01)
LD RITUX IV + MTX	SD RITUX IV + MTX	0.40(0.01,5.52)	0.41(0.02,5.32)	-0.01(-0.15,0.04)
HD TOCI IV		0.10(0.00,3.61)	0.10(0.00,3.57)	-0.01(-0.22,0.01)
HD TOCI IV	LD RITUX IV + MTX	0.26(0.00,15.60)	0.26(0.00,15.50)	0.00(-0.12,0.01)
Random-effects model	Residual deviance	13.3 vs 18 data points		

(Continued)

	Deviance information criteria	64.955
Fixed-Effect Model	Residual deviance	13.33 vs 18 data points
	Deviance information criteria	65.149
Note		
Total participants	3895	
Total studies	8	
2-arm	6	
3-arm	2	

WHAT'S NEW

Date	Event	Description
22 June 2015	New search has been performed	<p>New citation: conclusions changed, description: Original review of biologics in RA split into four by the patient populations</p> <ol style="list-style-type: none"> 1. MTX-naive; 2. biologic + MTX/other DMARDs in MTX/other DMARD failure; 3. biologic monotherapy in MTX/other DMARD failure; and 4. biologic-experienced. <p>This review presents comparisons of comparisons of biologic monotherapy (without concurrent methotrexate) versus a) placebo and b) head-to-head studies against other traditional DMARDs in a RA patient population with MTX/other DMARD failure (number 3 above).</p>
22 June 2015	New citation required and conclusions have changed	Updated, description: new search with 40 new studies included

HISTORY

Review first published: Issue 11, 2016

Date	Event	Description
1 March 2010	Amended	Odds ratios have been used in the network meta-analyses. Relative risks presented in the abstract, SoF table and PLS for ease of understanding.

Date	Event	Description
		See 'Published notes' for details.
25 February 2010	Amended	CMSG ID: C187-R

CONTRIBUTIONS OF AUTHORS

JS, GW - study concept
 JS, GW - protocol development
 JS, PT, GW, ETG - protocol editing
 JS, GW, ETG, AM - data extraction
 AH, AM, GW, JS - data analysis
 JS - first draft of the review and NMA

All authors - revision of the manuscript, and approval of the final version

DECLARATIONS OF INTEREST

JS - JS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Iroko, Merz, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, Medscape, the American College of Rheumatology and UBM, LLC. JS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501c3 entity. JS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee.

AH - none

ETG - none

RC - research grant and consultant fee (paid to his institution) from Abbott/Abbvie, MSD, Norpharma/Mundipharma, Roche

AM - none

PT - grants/honoraria from Bristol Myers, Chiltern International, and UCB

GW - research grant and consultant fee from Bristol-Myers Squibb

SOURCES OF SUPPORT

Internal sources

- The Oak Foundation, Switzerland.

Provide support for The Parker Institute: Musculoskeletal Statistics Unit.

- Birmingham VA Medical Center, Other.

JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.

External sources

- Jasvinder Singh, USA.

This work was supported in part by resources provided to the UAB Cochrane NMA Satellite by the Rheumatology Division at University of Alabama at Birmingham (UAB). JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.

NOTES

This original 2009 version was co-published in the Canadian Medical Association Journal (CMAJ 2009 DOI:10.1503/cmaj.091391) and because of separate review processes, both versions were substantively different - risk ratios were used in the network meta-analyses in the Cochrane version and odds ratios in the CMAJ version. Since the indirect comparisons approach used requires odds ratios, we have now harmonized the network meta-analyses using odds ratios in this Cochrane review while describing results as well using risk ratios in the 'Summary of findings' tables, as well as Abstract and Plain language summary.

INDEX TERMS**Medical Subject Headings (MeSH)**

Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [therapeutic use]; Antirheumatic Agents [*therapeutic use]; Arthritis, Rheumatoid [drug therapy]; Biological Products [*therapeutic use]; Certolizumab Pegol [therapeutic use]; Disease Progression; Etanercept [therapeutic use]; Interleukin 1 Receptor Antagonist Protein [therapeutic use]; Methotrexate [therapeutic use]; Network Meta-Analysis; Piperidines [*therapeutic use]; Pyrimidines [*therapeutic use]; Pyrroles [*therapeutic use]; Rituximab [therapeutic use]; Treatment Failure

MeSH check words

Humans